PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	van Hemert, MJ; Deelder, AM; Molenaar, C; Steensma, HY; van Heusden, GPH				van Hemert, MJ; Deelder, AM; Molenaar, C; Steensma, HY; van Heusden, GPH			Self-association of the spindle pole body-related intermediate filament protein Fin1p and its phosphorylation-dependent interaction with 14-3-3 proteins in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE PHOSPHORYLATION; BINDING PROTEIN; 14-3-3-PROTEINS; CELLS; IDENTIFICATION; TRANSCRIPTION; HYDROXYLASE; KINASE; DOMAIN	The Fin1 protein of the yeast Saccharomyces cerevisiae forms filaments between the spindle pole bodies of dividing cells. In the two-hybrid system it binds to 14-3-3 proteins, which are highly conserved proteins involved in many cellular processes and which are capable of binding to more than 120 different proteins. Here, we describe the interaction of the Fin1 protein with the 14-3-3 proteins Bmh1p and Bmh2p in more detail. Purified Fin1p interacts with recombinant yeast 14-3-3 proteins. This interaction is strongly reduced after dephosphorylation of Fin1p. Surface plasmon resonance analysis showed that Fin1p has a higher affinity for Bmh2p than for Bmh1p (K-D 289 versus 585 nm). Sequences in both the central and C-terminal part of Fin1p are required for the interaction with Bmh2p in the two-hybrid system. In yeast strains lacking 14-3-3 proteins Fin1 filament formation was observed, indicating that the 14-3-3 proteins are not required for this process. Fin1 also interacts with itself in the two-hybrid system. For this interaction sequences at the C terminus, containing one of two putative coiled-coil regions, are sufficient. Fin1p-Fin1p interactions were demonstrated in vivo by fluorescent resonance energy transfer between cyan fluorescent protein-labeled Fin1p and yellow fluorescent protein-labeled Fin1p.	Leiden Univ, Inst Mol Plant Sci, Sect Yeast Genet, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 ZA Leiden, Netherlands; Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Delft University of Technology	van Heusden, GPH (corresponding author), Leiden Univ, Inst Mol Plant Sci, Sect Yeast Genet, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.	Heusden@RULBIM.Leidenuniv.nl	van Heusden, Paul/S-3495-2017	van Heusden, Paul/0000-0002-6422-8034; van Hemert, Martijn/0000-0002-2617-9243				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Banik U, 1997, J BIOL CHEM, V272, P26219, DOI 10.1074/jbc.272.42.26219; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Biggins S, 2001, GENETICS, V159, P453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callejo M, 2002, J BIOL CHEM, V277, P38416, DOI 10.1074/jbc.M202050200; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; HAILEY DW, 2003, IN PRESS METHODS ENZ; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; James P, 1996, GENETICS, V144, P1425; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; Knetsch MLW, 1997, BBA-MOL CELL RES, V1357, P243, DOI 10.1016/S0167-4889(97)00060-8; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Mayordomo I, 2002, BIOCHEM J, V365, P51, DOI 10.1042/BJ20020053; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; ROTH D, 1993, FEBS LETT, V320, P207, DOI 10.1016/0014-5793(93)80587-K; Russnak R, 1996, GENE EXPRESSION, V6, P241; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; Stomski FC, 1999, BLOOD, V94, P1933; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Hemert MJ, 2002, P NATL ACAD SCI USA, V99, P5390, DOI 10.1073/pnas.072556099; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; van Heusden GPH, 2001, YEAST, V18, P1479, DOI 10.1002/yea.765; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	45	15	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15049	15055		10.1074/jbc.M212495200	http://dx.doi.org/10.1074/jbc.M212495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12551942	hybrid, Green Published			2022-12-25	WOS:000182516100062
J	Atreya, CE; Johnson, EF; Irwin, JJ; Dow, A; Massimine, KM; Coppens, I; Stempliuk, V; Beverley, S; Joiner, KA; Shoichet, BK; Anderson, KS				Atreya, CE; Johnson, EF; Irwin, JJ; Dow, A; Massimine, KM; Coppens, I; Stempliuk, V; Beverley, S; Joiner, KA; Shoichet, BK; Anderson, KS			A molecular docking strategy identifies eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DISCOVERY; STRUCTURE-BASED DESIGN; TOXOPLASMA-GONDII; LEISHMANIA-TROPICA; AUTOMATED DOCKING; METHOTREXATE; MECHANISM; BINDING; CHARGES; SHAPE	Protozoal parasites are unusual in that their thymidylate synthase (TS) and dihydrofolate reductase (DHFR) enzymes exist on a single polypeptide. In an effort to probe the possibility of substrate channeling between the TS and DHFR active sites and to identify inhibitors specific for bifunctional TS-DHFR, we used molecular docking to screen for inhibitors targeting the shallow groove connecting the two active sites. Eosin B is a 100 muM non-active site inhibitor of Leishmania major TS-DHFR identified by molecular docking. Eosin B slows both the TS and DHFR reaction rates. When Arg-283, a key residue to which eosin B is predicted to bind, is mutated to glutamate, however, eosin B only minimally inhibits the TS-DHFR reaction. Additionally, eosin B was found to be a 180 muM inhibitor of Toxoplasma gondii in both biochemical and cell culture assays.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA; Northwestern Univ, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Yale University; Yale University; Northwestern University; Washington University (WUSTL)	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.		Joiner, Keith/AAH-1059-2021	Beverley, Stephen/0000-0001-5319-0811; Irwin, John/0000-0002-1195-6417; Joiner, Keith/0000-0003-3062-823X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059953] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44630] Funding Source: Medline; NIGMS NIH HHS [GM07205, GM59953] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON KS, 1990, CHEM REV, V90, P1131, DOI 10.1021/cr00105a004; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GILSON MK, 1987, NATURE, V330, P84, DOI 10.1038/330084a0; GILSON MK, 1991, J COMPUT AID MOL DES, V5, P5; Gradler U, 2001, J MOL BIOL, V306, P455, DOI 10.1006/jmbi.2000.4256; GRUMONT R, 1986, P NATL ACAD SCI USA, V83, P5387, DOI 10.1073/pnas.83.15.5387; GRUMONT R, 1988, BIOCHEMISTRY-US, V27, P3776, DOI 10.1021/bi00410a039; GUNER OF, 1991, J CHEM INF COMP SCI, V31, P408, DOI 10.1021/ci00003a007; Jones TR, 1997, J MED CHEM, V40, P677, DOI 10.1021/jm960613f; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; Li JB, 1998, J PHYS CHEM A, V102, P1820, DOI 10.1021/jp972682r; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; Lorber DM, 1998, PROTEIN SCI, V7, P938; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MENG EC, 1993, PROTEINS, V17, P266, DOI 10.1002/prot.340170305; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; Nakaar V, 1999, J BIOL CHEM, V274, P5083, DOI 10.1074/jbc.274.8.5083; RASHIN AA, 1990, J PHYS CHEM-US, V94, P1725, DOI 10.1021/j100368a005; REICH SH, 1992, J MED CHEM, V35, P847, DOI 10.1021/jm00083a007; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; Schneider G, 2002, DRUG DISCOV TODAY, V7, P64, DOI 10.1016/S1359-6446(01)02091-8; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SHOICHET BK, 1993, PROTEIN ENG, V6, P723, DOI 10.1093/protein/6.7.723; Shoichet BK, 1999, PROTEINS, V34, P4, DOI 10.1002/(SICI)1097-0134(19990101)34:1<4::AID-PROT2>3.0.CO;2-6; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; Su AI, 2001, PROTEINS, V42, P279, DOI 10.1002/1097-0134(20010201)42:2<279::AID-PROT150>3.0.CO;2-U; Tondi D, 2001, CHEM BIOL, V8, P593, DOI 10.1016/S1074-5521(01)00034-5; Tondi D, 1999, CHEM BIOL, V6, P319, DOI 10.1016/S1074-5521(99)80077-5; Waheed AA, 2000, ANAL BIOCHEM, V287, P73, DOI 10.1006/abio.2000.4793	37	20	21	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14092	14100		10.1074/jbc.M212690200	http://dx.doi.org/10.1074/jbc.M212690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556445	hybrid			2022-12-25	WOS:000182405000070
J	Parvathenani, LK; Tertyshnikova, S; Greco, CR; Roberts, SB; Robertson, B; Posmantur, R				Parvathenani, LK; Tertyshnikova, S; Greco, CR; Roberts, SB; Robertson, B; Posmantur, R			P2X(7) mediates superoxide production in primary microglia and is up-regulated in a Transgenic mouse model of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVATION; EXTRACELLULAR ATP; RAT MICROGLIA; NITRIC-OXIDE; IN-VIVO; PURINERGIC RECEPTORS; NUCLEOTIDE RECEPTOR; P2Z PURINORECEPTOR; HUMAN NEUTROPHILS; XENOPUS-OOCYTES	Primary rat microglia stimulated with either ATP or 2'- and 3'-O-(4-benzoylbenzoyl)-ATP (BzATP) release copious amounts of superoxide (O-2(.-)). ATP and BzATP stimulate O-2(.-) production through purinergic receptors, primarily the P2X(7) receptor. O is produced through the activation of the NADPH oxidase. Although both p42/44 MAPK and p38 MAPK were activated rapidly in cells stimulated with BzATP, only pharmacological inhibition of p38 MAPK attenuated O-2(.-) production. Further more, an inhibitor of phosphatidylinositol 3-kinase attenuated O-2(.-) production to a greater extent than an inhibitor of p38 MAPK. Both ATP and BzATP stimulated microglia-induced cortical cell death indicating this pathway may contribute to neurodegeneration. Consistent with this hypothesis, P2X(7) receptor was specifically up-regulated around beta-amyloid plaques in a mouse model of Alzheimer's disease (Tg2576).	Bristol Myers Squibb Co, Pharmaceut Res Inst, Neurosci Drug Discovery, Wallingford, CT 06492 USA	Bristol-Myers Squibb	Parvathenani, LK (corresponding author), CuraGen Corp, 322 E Main St, Branford, CT 06405 USA.							Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Combs CK, 2001, J NEUROSCI, V21, P1179; Cunha RA, 2000, LIFE SCI, V68, P119, DOI 10.1016/S0024-3205(00)00923-1; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Janabi N, 1996, J IMMUNOL, V157, P2129; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; KETTENMANN H, 1993, GLIA, V7, P93, DOI 10.1002/glia.440070115; Klegeris A, 2000, J LEUKOCYTE BIOL, V67, P127, DOI 10.1002/jlb.67.1.127; Klegeris A, 1999, NEUROPHARMACOLOGY, V38, P1017, DOI 10.1016/S0028-3908(99)00014-3; Lal AS, 1999, BIOCHEM BIOPH RES CO, V259, P465, DOI 10.1006/bbrc.1999.0759; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; McDonald DR, 1997, J NEUROSCI, V17, P2284; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Norenberg W, 1997, BRIT J PHARMACOL, V121, P1087, DOI 10.1038/sj.bjp.0701241; NORENBERG W, 1994, BRIT J PHARMACOL, V111, P942; NUTTLE LC, 1993, MOL PHARMACOL, V44, P93; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; Parvathenani LK, 2000, NEUROREPORT, V11, P2293, DOI 10.1097/00001756-200007140-00045; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rane MJ, 1997, J IMMUNOL, V159, P5070; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Toescu EC, 1998, NEUROSCIENCE, V86, P925, DOI 10.1016/S0306-4522(98)00123-7; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Visentin S, 1999, J PHYSIOL-LONDON, V519, P723, DOI 10.1111/j.1469-7793.1999.0723n.x; Wang X, 2000, CELL CALCIUM, V27, P205, DOI 10.1054/ceca.2000.0110; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	50	381	413	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13309	13317		10.1074/jbc.M209478200	http://dx.doi.org/10.1074/jbc.M209478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551918	hybrid			2022-12-25	WOS:000182189500091
J	Chahdi, A; Choi, WS; Kim, YM; Beaven, MA				Chahdi, A; Choi, WS; Kim, YM; Beaven, MA			Mastoparan selectively activates phospholipase D2 in cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; RBL-2H3 CELLS; EXOCYTOSIS; RECEPTOR; D1; CALMODULIN; SECRETION	Both known isoforms of phospholipase (PL) D, PLD1 and PLD2, require phosphatidylinositol 4,5-bisphosphate for activity. However, PLD2 is fully active in the presence of this phospholipid, whereas PLD1 activation is dependent on additional factors such as ADP-ribosylation factor-1 (ARF-1) and protein kinase Calpha. We find that mastoparan, an activator of G(i) and mast cells, stimulates an intrinsic PLD activity, most likely PLD2, in fractions enriched in plasma membranes from rat basophilic leukemia 2H3 mast cells. Overexpression of PLD2, but not of PLD1, results in a large increase in the mastoparan-inducible PLD activity in membrane fractions, particularly those enriched in plasma membranes. As in previous studies, expressed PLD2 is localized primarily in the plasma membrane and PLD1 in granule membranes. Studies with pertussis toxin and other agents indicate that mastoparan stimulates PLD2 independently of G(i), ARF-1, protein kinase C, and calcium. Kinetic studies indicate that mastoparan interacts synergistically with phosphatidylinositol 4,5-bisphosphate and that oleate, itself a weak stimulant of PLD2 at low concentrations, is a competitive inhibitor of mastoparan stimulation of PLD2. Therefore, mastoparan may be useful for investigating the regulation of PLD2, particularly in view of the well studied molecular interactions of mastoparan with certain other strategic signaling proteins.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Med Coll Wisconsin, Dept Med Nephrol, Milwaukee, WI 53226 USA; Konkuk Univ, Coll Med, Dept Immunol, Chungcheongbuk Do 380701, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Medical College of Wisconsin; Konkuk University	Beaven, MA (corresponding author), NHLBI, Lab Mol Immunol, NIH, Rm 8N109,Bldg 10,9000 Rockville Pike, Bethesda, MD 20892 USA.	beavenm@nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000993, ZIAHL000993] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI H, 1990, J BIOL CHEM, V265, P745; Ali H, 1996, J PHARMACOL EXP THER, V276, P837; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Boyano-Adanez MD, 2002, NEUROCHEM INT, V40, P261, DOI 10.1016/S0197-0186(01)00067-5; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Chahdi A, 2000, J PHARMACOL EXP THER, V292, P122; Choi WS, 2002, J IMMUNOL, V168, P5682, DOI 10.4049/jimmunol.168.11.5682; Cissel DS, 1998, J PHARMACOL EXP THER, V285, P110; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Farquhar M, 2002, CHEM BIOL, V9, P63, DOI 10.1016/S1074-5521(01)00098-9; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Lee SY, 1998, FEBS LETT, V432, P50, DOI 10.1016/S0014-5793(98)00831-X; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Millar CA, 1999, BIOCHEM BIOPH RES CO, V254, P734, DOI 10.1006/bbrc.1998.0110; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Min DS, 2000, J NEUROCHEM, V75, P274, DOI 10.1046/j.1471-4159.2000.0750274.x; MIZUNO K, 1995, BRIT J PHARMACOL, V116, P2090, DOI 10.1111/j.1476-5381.1995.tb16416.x; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; Murase T, 2002, BIOCHEMISTRY-US, V41, P1618, DOI 10.1021/bi011782r; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Senyshyn J, 1998, J IMMUNOL, V160, P5136; SHAHDI A, 2002, MOL IMMUNOL, V38, P1269; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; Way G, 2000, BIOCHEM J, V346, P63, DOI 10.1042/0264-6021:3460063; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	52	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12039	12045		10.1074/jbc.M212084200	http://dx.doi.org/10.1074/jbc.M212084200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556526	hybrid			2022-12-25	WOS:000182015700043
J	Gordon, EHJ; Sjogren, T; Lofqvist, M; Richter, CD; Allen, JWA; Higham, CW; Hajdu, J; Fulop, V; Ferguson, SJ				Gordon, EHJ; Sjogren, T; Lofqvist, M; Richter, CD; Allen, JWA; Higham, CW; Hajdu, J; Fulop, V; Ferguson, SJ			Structure and kinetic properties of Paracoccus pantotrophus cytochrome cd(1) nitrite reductase with the d(1) heme active site ligand tyrosine 25 replaced by serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; THIOSPHAERA-PANTOTROPHA; PSEUDOMONAS-AERUGINOSA; C-DOMAIN; MUTAGENESIS; CATALYSIS; CLONING; PROTEIN; ENZYME; SYSTEM	The 1.4-Angstrom crystal structure of the oxidized state of a Y25S variant of cytochrome cd(1) nitrite reductase from Paracoccus pantotrophus is described. It shows that loss of Tyr(25), a ligand via its hydroxy group to the iron of the d(1) heme in the oxidized (as prepared) wild-type enzyme, does not result in a switch at the e heme of the unusual bishistidinyl coordination to the histidine/methionine coordination seen in other conformations of the enzyme. The Ser(25) side chain is seen in two positions in the d(1) heme pocket with relative occupancies of similar to7:3, but in neither case is the hydroxy group bound to the iron atom; instead, a sulfate ion from the crystallization solution is bound between the Ser(25) side chain and the heme iron. Unlike the wild-type enzyme, the Y25S mutant is active as a reductase toward nitrite, oxygen, and hydroxylamine without a reductive activation step. It is concluded that Tyr(25) is not essential for catalysis of reduction of any substrate, but that the requirement for activation by reduction of the wild-type enzyme is related to a requirement to drive the dissociation of this residue from the active site. The Y25S protein retains the d(1) heme less well than the wild-type protein, suggesting that the tyrosine residue has a role in stabilizing the binding of this cofactor.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Uppsala, Dept Biochem, S-75123 Uppsala, Sweden; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Oxford; Uppsala University; University of Warwick	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Pk Rd, Oxford OX1 3QU, England.		Hubbard, Ruth E/G-5414-2010; Fulop, Vilmos/AAZ-7720-2021	Hubbard, Ruth E/0000-0002-8688-5836; 				Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Allen JWA, 2000, BIOCHEM BIOPH RES CO, V279, P674, DOI 10.1006/bbrc.2000.4009; ALLEN JWA, 2001, HDB METALLOPROTEINS, P424; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cutruzzola F, 1997, FEBS LETT, V412, P365, DOI 10.1016/S0014-5793(97)00583-8; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; DRYDEN SC, 1990, NUCLEIC ACIDS RES, V18, P7267, DOI 10.1093/nar/18.24.7267; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Fulop V, 2001, ADV INORG CHEM, V51, P163; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; Gordon EHJ, 2001, BIOCHEM BIOPH RES CO, V281, P788, DOI 10.1006/bbrc.2001.4425; Jafferji A, 2000, J BIOL CHEM, V275, P25089, DOI 10.1074/jbc.M001377200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MICHEL LO, 1995, GENE, V152, P41, DOI 10.1016/0378-1119(94)00691-K; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nurizzo D, 1999, J BIOL CHEM, V274, P14997, DOI 10.1074/jbc.274.21.14997; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARALES RE, 1993, GENE, V133, P23, DOI 10.1016/0378-1119(93)90220-W; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; Ranghino G, 2000, BIOCHEMISTRY-US, V39, P10958, DOI 10.1021/bi000178y; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; ROBERTSON LA, 1983, J GEN MICROBIOL, V129, P2847; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Sjogren T, 2001, J BIOL CHEM, V276, P29450, DOI 10.1074/jbc.M103657200; Steensma E, 2001, J BIOL CHEM, V276, P5846, DOI 10.1074/jbc.M007345200; Van Spanning RJM, 1999, J BACTERIOL, V181, P4129, DOI 10.1128/JB.181.13.4129-4132.1999; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975	39	26	28	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11773	11781		10.1074/jbc.M211886200	http://dx.doi.org/10.1074/jbc.M211886200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556530	hybrid			2022-12-25	WOS:000182015700009
J	Kim, KS; Hong, YK; Joe, YA; Lee, Y; Shin, JY; Park, HE; Lee, IH; Lee, SY; Kang, DK; Chang, SI; Chung, SI				Kim, KS; Hong, YK; Joe, YA; Lee, Y; Shin, JY; Park, HE; Lee, IH; Lee, SY; Kang, DK; Chang, SI; Chung, SI			Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TISSUE PLASMINOGEN-ACTIVATOR; SMOOTH-MUSCLE CELLS; TUMOR-GROWTH; IN-VIVO; ESCHERICHIA-COLI; BINDING-PROTEIN; ANGIOSTATIN; MIGRATION; INHIBITION	Urokinase plasminogen activator WPM belongs to a family of proteins that contains kringle domain and plays an important role in inflammation, tissue remodeling, angiogenesis, and tumor metastasis by pericellular plasminogen activation. Kringle domains of plasminogen have been shown to demonstrate anti-angiogenic and anti-tumor activities. Here, we report our investigation of the kringle domain of uPA for anti-angiogenic activity and a possible cellular mechanism of action. The recombinant kringle domain of uPA (Asp(45)-Lys(135)) (UK1) inhibited endothelial cell proliferation stimulated by basic fibroblast growth factor, vascular endothelial growth factor (VEGF), or epidermal growth factor. It also inhibited migration of endothelial cells induced by VEGF or uPA, and in vivo angiogenesis on the chick chorioallantoic membrane. It did not block plasminogen activation by activated uPA in clot lysis and chromogenic substrate assays. Neither binding of UK1 to immobilized uPA receptor nor competitive inhibition of uPA binding were confirmed by real-time interaction analysis. However, internalization of UK1 followed by translocation from cytosol to nucleus was determined to be specific to endothelial cells. It also elicited a transient increase of Ca2+ flux of more than 2-fold within 2 min of exposure in an endothelial cell-specific manner. These results suggest that the kringle domain of uPA exhibits anti-angiogenic activity and that its anti-angiogenic activity may occur through a different mechanism from inhibition of uPA-uPA receptor interaction or uPA proteolytic activity and may be associated with endothelial-cell specific internalization not mediated by the uPA receptor.	Catholic Univ, Canc Res Inst, Catholic Res Inst Med Sci, Seocho Ku, Seoul 137701, South Korea; Catholic Univ, Coll Med, Dept Nat Sci, Seoul 137701, South Korea; Chungbuk Natl Univ, Biotechnol Res Inst, Coll Nat Sci, Dept Biochem, Cheongju 361763, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Mogam Biotechnol Res Inst, Yongin 449910, South Korea	Catholic University of Korea; Catholic University of Korea; Chungbuk National University; Yonsei University; Yonsei University Health System	Joe, YA (corresponding author), Catholic Univ, Canc Res Inst, Catholic Res Inst Med Sci, Seocho Ku, Banpo Dong 505, Seoul 137701, South Korea.		Chang, Soo-Ik/K-4079-2013	Chang, Soo-Ik/0000-0002-5620-0867				ADREASEN PA, 1997, INT J CANCER, V72, P1; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BACHMANN F, 1994, HAEMOSTASIS THROMBOS, P575; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bicknell Roy, 1996, Current Opinion in Oncology, V8, P60, DOI 10.1097/00001622-199601000-00011; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; CASTELLINO FJ, 1987, J MOL EVOL, V26, P358, DOI 10.1007/BF02101155; Chang SI, 1996, J BIOCHEM MOL BIOL, V29, P353; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1995, MOL BASIS CANC, P206; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; Husain M, 1997, AM J PHYSIOL-CELL PH, V272, pC1947, DOI 10.1152/ajpcell.1997.272.6.C1947; Husain M, 1997, CIRC RES, V80, P617, DOI 10.1161/01.RES.80.5.617; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825; Jiang LW, 2001, AM J PHYSIOL-CELL PH, V280, pC1140, DOI 10.1152/ajpcell.2001.280.5.C1140; JIANHUA H, 2002, J BIOL CHEM, V277, P10760; Kim HJ, 1999, B KOR CHEM SOC, V20, P370; Kimura C, 2001, AM J PHYSIOL-HEART C, V281, pH745, DOI 10.1152/ajpheart.2001.281.2.H745; Kirsch M, 1998, CANCER RES, V58, P4654; Kuba K, 2000, CANCER RES, V60, P6737; Lee H, 2000, ARCH BIOCHEM BIOPHYS, V375, P359, DOI 10.1006/abbi.1999.1675; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; Lou XJ, 1998, EXP MOL PATHOL, V65, P53, DOI 10.1006/exmp.1998.2230; Lucas R, 1998, BLOOD, V92, P4730; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Mohanam S, 1999, INT J ONCOL, V14, P169; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; Reuning U, 1998, INT J ONCOL, V13, P893; SCHWAB A, 1994, J CLIN INVEST, V93, P1631, DOI 10.1172/JCI117144; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Tkachuk V, 1996, CLIN EXP PHARMACOL P, V23, P759, DOI 10.1111/j.1440-1681.1996.tb01177.x; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V257, P714, DOI 10.1006/bbrc.1999.0519; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Xin L, 2000, BIOCHEM BIOPH RES CO, V277, P186, DOI 10.1006/bbrc.2000.3658; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; You WK, 1999, EXP MOL MED, V31, P197, DOI 10.1038/emm.1999.32	66	56	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11449	11456		10.1074/jbc.M212358200	http://dx.doi.org/10.1074/jbc.M212358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529357	hybrid			2022-12-25	WOS:000181855400075
J	Nikiforov, MA; Popov, N; Kotenko, I; Henriksson, M; Cole, MD				Nikiforov, MA; Popov, N; Kotenko, I; Henriksson, M; Cole, MD			The Mad and Myc basic domains are functionally equivalent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; DNA-BINDING; MYC/MAX/MAD NETWORK; TRANSCRIPTIONAL REPRESSOR; ANTAGONIST MAD1; DIFFERENTIATION; GENE; PROTEIN; CELLS; TRANSFORMATION	The Myc/Max/Mad family of transcription factors plays a fundamental role in the regulation of cell proliferation, oncogenic transformation, and cell differentiation. However, it remains unclear whether different heterodimers, such as Myc/Max and Mad/Max, recognize the same or different target genes an vivo. We show by chromatin immunoprecipitation that Myc target genes are also recognized by Mad1 in differentiated HL60 cells. We also substituted the complete basic region of Myc for the corresponding region of Mad. Wild-type cMyc was then compared with c-Myc(Mad-BR) in oncogenic transformation, regulation of cell proliferation, induction of apoptosis, activation of chromosomal gene expression, and direct binding to chromosomal sites by chromatin immunoprecipitation. We find that the wildtype c-Myc and c-Myc/MadBR proteins have indistinguishable biological activity and target gene recognition in vivo. These data are consistent with a model in which Myc and Mad regulate a common set of target genes.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Karolinska Inst, Microbiol & Tumorbiol Ctr, SE-17177 Stockholm, Sweden	Princeton University; Karolinska Institutet	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Henriksson, Marie Arsenian/F-5010-2015	Arsenian Henriksson, Marie/0000-0001-6376-7792				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS LJ, 1993, ONCOGENE, V8, P125; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Winston RL, 2000, CHEM BIOL, V7, P245, DOI 10.1016/S1074-5521(00)00099-5; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	43	20	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11094	11099		10.1074/jbc.M212298200	http://dx.doi.org/10.1074/jbc.M212298200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538578	hybrid			2022-12-25	WOS:000181855400031
J	Raffai, RL; Hasty, AH; Wang, YW; Mettler, SE; Sanan, DA; Linton, MF; Fazio, S; Weisgraber, KH				Raffai, RL; Hasty, AH; Wang, YW; Mettler, SE; Sanan, DA; Linton, MF; Fazio, S; Weisgraber, KH			Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; BONE-MARROW TRANSPLANTATION; E-DEFICIENT MICE; APOLIPOPROTEIN-E; CHYLOMICRON REMNANTS; LDL RECEPTOR; CELL-SURFACE; IN-VIVO	The importance of hepatocyte-derived apolipoprotein (apo) E in the clearance of remnant lipoproteins in the liver is controversial. To address this controversy, we compared remnant clearance in two mouse models in which apoE is primarily derived either from hepatocytes or from an extrahepatic source. Hypomorphic apoE mice universally express reduced levels of apoE in all tissues, with the liver remaining the primary source of apoE. This mouse model of hepatocyte-derived apoE was compared with Apoe(-/-) mice transplanted with mouse bone marrow as a model of primarily non-hepatocyte-derived apoE. Immunohistochemical analysis of liver sections revealed that only the hepatocyte-derived apoE model had detectable levels of apoE on hepatic sinusoidal surfaces. The non-hepatocyte-derived apoE model with plasma apoE levels similar to those in the hepatocyte-derived model had 2-fold more total plasma cholesterol, 4-fold more total plasma triglycerides, and 8-fold higher levels of apoB48, similar to Apoe(-/-) mice. Both the hepatocyte-derived and the non-hepatocyte-derived apoE models had delayed clearance of an infused bolus of I-125-labeled remnants compared with wild-type mice. However, after 3 It, plasma remnants reached wild-type levels only in the hepatocyte-derived apoE model, which had accumulated 70 +/- 5% of wildtype levels of remnants in the liver while the non-hepatocyte-derived apoE model had accumulated only 38 +/- 4%. These results demonstrate the existence of a role for both hepatically derived and localized apoE in remnant clearance. This role likely represents the enrichment of remnants sequestered on hepatocyte, with hepatocyte-derived apoE, facilitating their receptor-mediated internalization.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University	Weisgraber, KH (corresponding author), Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Hasty, Alyssa/AAA-2757-2020	Hasty, Alyssa/0000-0001-7302-8045	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660, R01HL057986] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660, R01 HL057986] Funding Source: Medline; PHS HHS [57986, 53989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Burgess JW, 2001, J LIPID RES, V42, P1413; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; Dichek HL, 2001, J LIPID RES, V42, P201; Ebara T, 2000, J CLIN INVEST, V105, P1807, DOI 10.1172/JCI8283; HAMILTON RL, 1990, J LIPID RES, V31, P1589; Hasty AH, 1999, J LIPID RES, V40, P1529; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 2001, METABOLIC MOL BASES, V2, P2835; Maugeais C, 2000, J LIPID RES, V41, P1673; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Raffai RL, 2002, J BIOL CHEM, V277, P11064, DOI 10.1074/jbc.M111222200; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; SHAFI S, 1994, J LIPID RES, V35, P709; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Windler E, 1996, HEPATOLOGY, V24, P344; Yu KCW, 2000, J LIPID RES, V41, P1715; Yu KCW, 2001, J CLIN INVEST, V107, P1387, DOI 10.1172/JCI11750; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	38	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11670	11675		10.1074/jbc.M212873200	http://dx.doi.org/10.1074/jbc.M212873200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551940	hybrid			2022-12-25	WOS:000181855400101
J	Shiraki, T; Sakai, N; Kanaya, E; Jingami, H				Shiraki, T; Sakai, N; Kanaya, E; Jingami, H			Activation of orphan nuclear constitutive androstane receptor requires subnuclear targeting by peroxisome proliferator-activated receptor gamma coactivator-1 alpha - Possible link between xenobiotic response and nutritional state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; HORMONE-RECEPTOR; SPLICING FACTOR; SR PROTEINS; CYP2B GENE; PGC-1; CAR; ALPHA	In contrast to the classical nuclear receptors, the constitutive androstane receptor (CAR) is transcriptionally active in the absence of ligand. In the course of searching for the mediator of CAR activation, we found that ligand-independent activation of CAR was achieved in cooperation with the peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha). PGC-1beta, a PGC-1alpha homologue, also activated CAR to less of an extent than PGC-1alpha. Coexpression of the ligand-binding domain of a heterodimerization partner, retinoid X receptor alpha, enhanced the PGC-1alpha-mediated activation of CAR, although it had a weak effect on the basal activity of CAR in the absence of PGC-1alpha. Both the N-terminal region, with the LXXLL motif, and the C-terminal region, with a serine/arginine-rich domain (RS domain), in PGC-1alpha were required for full activation of CAR. Pull-down experiments using recombinant proteins revealed that CAR directly interacted with both the LXXLL motif and the RS domain. Furthermore, we demonstrated that the RS domain of PGC-1alpha was required for CAR localization at nuclear speckles. These results indicate that PGC-1alpha mediates the ligand-independent activation of CAR by means of subnuclear targeting through the RS domain of PGC-1alpha.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan		Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.							Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Dussault I, 2002, MOL CELL BIOL, V22, P5270, DOI 10.1128/MCB.22.15.5270-5280.2002; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Glass CK, 2000, GENE DEV, V14, P121; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	35	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11344	11350		10.1074/jbc.M212859200	http://dx.doi.org/10.1074/jbc.M212859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551939	Green Submitted, hybrid			2022-12-25	WOS:000181855400062
J	Kim, YS; Randolph, TW; Manning, MC; Stevens, FJ; Carpenter, JF				Kim, YS; Randolph, TW; Manning, MC; Stevens, FJ; Carpenter, JF			Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; MOLECULAR-BASIS; BINDING; GLYCOSAMINOGLYCANS; CONFORMATIONS; TEMPERATURE; TRANSITION; INHIBITOR; RESIDUES; KINETICS	Congo red (CR) has been reported to inhibit or enhance amyloid fibril formation by several proteins. To gain insight into the mechanism(s) for these apparently paradoxical effects, we studied as a model amyloidogenic protein, a dimeric immunoglobulin light chain variable domain. With a range of molar ratios of CR, i.e. r = [CR]/[protein dimer], we investigated the aggregation kinetics, conformation, hydrogen-deuterium exchange, and thermal stability of the protein. In addition, we used isothermal titration calorimetry to characterize the thermodynamics of CR binding to the protein. During incubation at 37 degreesC or during thermal scanning, with CR at r = 0.3, 1.3, and 4.8, protein aggregation was greatly accelerated compared with that measured in the absence of the dye. In contrast, with CR at r = 8.8, protein unfolding was favored over aggregation. The aggregates formed with CR at r = 0 or 0.3 were typical amyloid fibrils, but mixtures of amyloid fibrils and amorphous aggregates were formed at r = 1.3 and 4.8. CR decreased the apparent thermal unfolding temperature of the protein. Furthermore, CR perturbed the tertiary structure of the protein without significantly altering its secondary structure. Consistent with this result, CR also increased the rate of hydrogen-deuterium. exchange by the protein. Isothermal titration calorimetry showed that CR binding to the protein was enthalpically driven, indicating that binding was mainly the result of electrostatic interactions. Overall, these results demonstrate that at low concentrations, CR binding to the protein favors a structurally perturbed, aggregation-competent species, resulting in acceleration of fibril formation. At high CR concentration, protein unfolding is favored over aggregation, and fibril formation is inhibited. Because low concentrations of CR can promote amyloid fibril formation, the therapeutic utility of this compound or its analogs to inhibit amyloidoses is questionable.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Ctr Pharmaceut Biotechnol,Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; United States Department of Energy (DOE); Argonne National Laboratory	Carpenter, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Ctr Pharmaceut Biotechnol,Dept Pharmaceut Sci, 4200 E 9th Ave, Denver, CO 80262 USA.	John.Carpenter@uchsc.edu		Kim, Yong-Sung/0000-0003-2673-1509				Ashburn TT, 1996, CHEM BIOL, V3, P351, DOI 10.1016/S1074-5521(96)90118-0; BENDITT EP, 1970, P NATL ACAD SCI USA, V66, P1044, DOI 10.1073/pnas.66.4.1044; Bijma K, 1998, J COLLOID INTERF SCI, V205, P245, DOI 10.1006/jcis.1998.5687; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Demaimay R, 1998, J NEUROCHEM, V71, P2534; DEYOUNG LR, 1993, BIOCHEMISTRY-US, V32, P3877, DOI 10.1021/bi00066a006; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; EDWARDS RA, 1977, BIOCHEM BIOPH RES CO, V79, P470, DOI 10.1016/0006-291X(77)90181-4; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; FRESKGARD PO, 1994, BIOCHEMISTRY-US, V33, P14281, DOI 10.1021/bi00251a041; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Inouye H, 2000, AMYLOID, V7, P179, DOI 10.3109/13506120009146832; Jiang XL, 1997, BIOCHEMISTRY-US, V36, P13187, DOI 10.1021/bi970408h; Kamen DE, 2001, PROTEIN SCI, V10, P2123, DOI 10.1110/ps.19801; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384; Khurana R, 2001, J BIOL CHEM, V276, P22715, DOI 10.1074/jbc.M011499200; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2002, J BIOL CHEM, V277, P27240, DOI 10.1074/jbc.M202492200; Kim YS, 2001, J BIOL CHEM, V276, P1626, DOI 10.1074/jbc.M007766200; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; Kisilevsky R, 2000, J STRUCT BIOL, V130, P99, DOI 10.1006/jsbi.2000.4222; KLUNK WE, 1994, NEUROBIOL AGING, V15, P691, DOI 10.1016/0197-4580(94)90050-7; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATSUURA JE, 1994, J AGR FOOD CHEM, V42, P1650, DOI 10.1021/jf00044a013; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; OONO Y, 1983, J CHEM PHYS, V78, P520, DOI 10.1063/1.444477; Piekarska B, 1996, BIOCHIMIE, V78, P183; Piekarska B, 2001, BIOPOLYMERS, V59, P446, DOI 10.1002/1097-0282(200111)59:6<446::AID-BIP1049>3.0.CO;2-X; Piekarska B, 1994, J Physiol Pharmacol, V45, P147; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Ptitsyn Oleg B., 1992, P243; Raffen R, 1999, PROTEIN SCI, V8, P509; Roterman I, 2001, Med Sci Monit, V7, P771; Rudyk H, 2000, J GEN VIROL, V81, P1155, DOI 10.1099/0022-1317-81-4-1155; Serpell LC, 1997, CELL MOL LIFE SCI, V53, P871, DOI 10.1007/s000180050107; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; STEVENS PW, 1995, PROTEIN SCI, V4, P421; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; VUILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303, DOI 10.1021/bi00090a005; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOODY AYM, 1981, BIOCHIM BIOPHYS ACTA, V655, P82, DOI 10.1016/0005-2787(81)90069-1; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Woody RW, 1996, CIRCULAR DICHROISM C, P109; WYMAN J, 1991, BINDING LINKAGE FUNC	59	105	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10842	10850		10.1074/jbc.M212540200	http://dx.doi.org/10.1074/jbc.M212540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529361	hybrid			2022-12-25	WOS:000181777500110
J	Rubenstein, NM; Guan, Y; Woo, PL; Firestone, GL				Rubenstein, NM; Guan, Y; Woo, PL; Firestone, GL			Glucocorticoid down-regulation of RhoA is required for the steroid-induced organization of the junctional complex and tight junction formation in rat mammary epithelial tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSEPITHELIAL ELECTRICAL-RESISTANCE; MOLECULAR PHYSIOLOGY; PROTEIN-KINASE; BINDING PROTEIN; MESSENGER-RNA; ACTIN; ZO-1; OCCLUDIN; ADHESION; PATHOPHYSIOLOGY	In Con8 mammary epithelial tumor cells, we have documented previously that the synthetic glucocorticoid dexamethasone induces the reorganization of the tight junction and adherens junction (apical junction) and stimulates the monolayer transepithelial electrical resistance (TER), which is a reliable in vitro measurement of tight junction sealing. Western blots demonstrated that dexamethasone treatment down-regulated the level of the RhoA small GTPase prior to the stimulation of the monolayer TER. To test the role of RhoA in the steroid regulation of apical junction dynamics functionally, RhoA levels were altered in Con8 cells by transfection of either constitutively active (RhoA.V14) or dominant negative (RhoA.DN19) forms of RhoA. Ectopic expression of constitutively active RhoA disrupted the dexamethasone-stimulated localization of zonula occludens-1 and beta-catenin to sites of cell-cell contact, inhibited tight junction sealing, and prevented the complete formation of the F-actin ring structure at the apical side of the cell monolayer. In a complementary manner, dominant negative RhoA caused a precocious organization of the tight junction, adherens junction, and the F-actin rings in the absence of steroid, whereas the monolayer TER remained glucocorticoid-responsive. Taken together, our results demonstrate that the glucocorticoid down-regulation of RhoA is a required step in the steroid signaling pathway which controls the organization of the apical junctional complex and the actin cytoskeleton in mammary epithelial cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@uclink4.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; D'Atri F, 2001, FEBS LETT, V507, P21, DOI 10.1016/S0014-5793(01)02936-2; DENISENKO N, 1994, J CELL SCI, V107, P969; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fujita H, 2000, BIOCHEM J, V346, P617, DOI 10.1042/0264-6021:3460617; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Guan Y, 2002, EXP CELL RES, V273, P1, DOI 10.1006/excr.2001.5415; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANDLER JS, 1980, AM J PHYSIOL, V238, pF1, DOI 10.1152/ajprenal.1980.238.1.F1; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Hasegawa H, 1999, J BIOL CHEM, V274, P20982, DOI 10.1074/jbc.274.30.20982; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Kamai T, 2002, BJU INT, V89, P449, DOI 10.1046/j.1464-4096.2001.01920.x; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kusama T, 2001, CANCER RES, V61, P4885; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; MEZA I, 1982, J CELL BIOCHEM, V18, P407, DOI 10.1002/jcb.1982.240180403; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1998, J INVEST DERMATOL, V110, P862, DOI 10.1046/j.1523-1747.1998.00209.x; Nguyen DAD, 1998, J MAMMARY GLAND BIOL, V3, P233, DOI 10.1023/A:1018707309361; Nusrat A, 2000, AM J PHYSIOL-GASTR L, V279, pG851, DOI 10.1152/ajpgi.2000.279.5.G851; Nusrat A, 2001, INFECT IMMUN, V69, P1329, DOI 10.1128/IAI.69.3.1329-1336.2001; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Rao JN, 2001, AM J PHYSIOL-CELL PH, V280, pC993, DOI 10.1152/ajpcell.2001.280.4.C993; Ren ZB, 1998, CARCINOGENESIS, V19, P827, DOI 10.1093/carcin/19.5.827; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Song YH, 2000, J CELL BIOCHEM, V80, P229; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thompson GE, 1996, J DAIRY RES, V63, P305, DOI 10.1017/S0022029900031794; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818; Woo PL, 2000, J BIOL CHEM, V275, P28649, DOI 10.1074/jbc.M910373199; Woo PL, 1996, J BIOL CHEM, V271, P404, DOI 10.1074/jbc.271.1.404; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	80	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10353	10360		10.1074/jbc.M213121200	http://dx.doi.org/10.1074/jbc.M213121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525486	hybrid			2022-12-25	WOS:000181777500049
J	Usui, S; Konno, D; Hori, K; Maruoka, H; Okabe, S; Fujikado, T; Tano, Y; Sobue, K				Usui, S; Konno, D; Hori, K; Maruoka, H; Okabe, S; Fujikado, T; Tano, Y; Sobue, K			Synaptic targeting of PSD-Zip45 (Homer 1c) and its involvement in the synaptic accumulation of F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; BINDING-PROTEIN; SHANK FAMILY; DIFFERENTIAL EXPRESSION; PDZ PROTEINS; NMDA; PSD-95; DOMAIN; ORGANIZATION; PLASTICITY	PSD-Zip45/Homer1c, which contains an enabled/VASP homology 1 (EVH1) domain and leucine zipper motifs, is a postsynaptic density (PSD) scaffold protein that interacts with metabotropic glutamate receptors and the shank family. We studied the molecular mechanism underlying the synaptic targeting of PSD-Zip45 in cultured hippocampal neurons. The EVH1 domain and the extreme C-terminal leucine zipper motif were molecular determinants for its synaptic targeting. The overexpression of the mutant of the EVH1 domain or deletion of the extreme C-terminal leucine zipper motif markedly suppressed the synaptic localization of endogenous shank but not PSD-95 or GKAP. In contrast, an overexpressed GKAP mutant lacking shank binding activity had no effect on the synaptic localization of shank. Actin depolymerization by latrunculin A reduced the synaptic localization of PSD-Zip45, shank, and F-actin but not of PSD-95 or GKAP. Overexpression of PSD-Zip45 enhanced the accumulation of synaptic F-actin. Additionally, overexpression. of PSD-Zip45 and an isoform of shank induced synaptic enlargement in association with the further accumulation of synaptic F-actin. The EVH1 domain and extreme C-terminal leucine zipper motif of PSD-Zip45 were also critical for these events. Thus, these data suggest that the PSD-Zip45-shank and PSD-95-GKAP complexes form different synaptic compartments, and PSD-Zip45 alone or PSD-Zip45-shank is involved in the synaptic accumulation of F-actin.	Osaka Univ, Grad Sch Med, Dept Neurosci D13, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Ophthalmol E7, Suita, Osaka 5650871, Japan; Tokyo Med & Dent Univ, Sch Med, Dept Anat & Cell Biol, Tokyo 1138519, Japan	Osaka University; Osaka University; Tokyo Medical & Dental University (TMDU)	Sobue, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Neurosci D13, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sobue@nbiochem.med.osaka-u.ac.jp		Okabe, Shigeo/0000-0003-1216-8890; Maruoka, Hisato/0000-0002-7185-3356				Allison DW, 1998, J NEUROSCI, V18, P2423; Ango F, 2000, J NEUROSCI, V20, P8710; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; CARLIN RK, 1983, P NATL ACAD SCI-BIOL, V80, P3517, DOI 10.1073/pnas.80.11.3517; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; EHLER SMD, 1999, CURR BIOL, V9, pR848; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kawashima N, 1997, FEBS LETT, V418, P301, DOI 10.1016/S0014-5793(97)01399-9; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okabe S, 2001, J NEUROSCI, V21, P9561, DOI 10.1523/JNEUROSCI.21-24-09561.2001; PALAY SL, 1958, EXP CELL RES       S, V5, P275; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2000, NAT NEUROSCI, V3, P633, DOI 10.1038/76576; Shiraishi Y, 1999, J NEUROSCI, V19, P8389; Sun J, 1998, FEBS LETT, V437, P304, DOI 10.1016/S0014-5793(98)01256-3; TADOKORO S, 1999, P NATL ACAD SCI USA, V93, P1540; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Valtschanoff JG, 2001, J NEUROSCI, V21, P1211; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463	40	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10619	10628		10.1074/jbc.M210802200	http://dx.doi.org/10.1074/jbc.M210802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524440	hybrid			2022-12-25	WOS:000181777500083
J	Yung, SL; Dela Cruz, F; Hamren, S; Zhu, J; Tsutsumi, M; Bloom, JW; Caudle, M; Roczniak, S; Todd, T; Lemoine, L; MacDougall, M; Shanafelt, AB; Pan, CQ				Yung, SL; Dela Cruz, F; Hamren, S; Zhu, J; Tsutsumi, M; Bloom, JW; Caudle, M; Roczniak, S; Todd, T; Lemoine, L; MacDougall, M; Shanafelt, AB; Pan, CQ			Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE; VIP; AFFINITY; PACAP; SPECTROSCOPIES; PHARMACOPHORE; DISCRIMINATE; ELUCIDATION; RESIDUES; H-1-NMR	Pituitary adenylate cyclase-activating peptide (PACAP) has a specific receptor PAC1 and shares two receptors VPAC1 and VPAC2 with vasoactive intestinal peptide (VIP). VPAC2 activation enhances glucose-induced insulin release while VPAC1 activation elevates glucose output. To generate a large pool of VPAC2 selective agonists for the treatment of type 2 diabetes, structure-activity relationship studies were performed on PACAP, VIP, and a VPAC2 selective VIP analog. Chemical modifications on this analog that prevent recombinant expression were sequentially removed to show that a recombinant peptide would retain VPAC2 selectivity. An efficient recombinant expression system was then developed to produce and screen hundreds of mutant peptides. The 11 mutations found on the VIP analog were systematically replaced with VIP or PACAP sequences. Three of these mutations, V19A, L27K, and N28K, were sufficient to provide most of the VPAC2 selectivity. C-terminal extension with the KRY sequence from PACAP38 led to potent VPAC2 agonists with improved selectivity (100-1000-fold). Saturation mutagenesis at positions 19, 27, 29, and 30 of VIP and charge-scanning mutagenesis of PACAP27 generated additional VPAC2 selective agonists. We have generated the first set of recombinant VPAC2 selective agonists described, which exhibit activity profiles that suggest therapeutic utility in the treatment of diabetes.	Bayer Corp, Dept Mol Technol, Berkeley, CA 94701 USA; Bayer Corp, Dept Analyt & Formulat Biotechnol, Berkeley, CA 94701 USA; Bayer Corp, Dept Metabol Disorders Res, West Haven, CT 06516 USA	Bayer AG; Bayer AG; Bayer AG	Pan, CQ (corresponding author), 800 Dwight Way,POB 1986, Berkeley, CA 94701 USA.	clark.pan.b@bayer.com	MacDougall, Mary/ABG-8212-2021					Ando E, 1996, Biomed Pept Proteins Nucleic Acids, V2, P41; BOLIN DR, 1995, BIOPOLYMERS, V37, P57, DOI 10.1002/bip.360370203; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; Gourlet P, 1996, BBA-MOL CELL RES, V1314, P267, DOI 10.1016/S0167-4889(96)00106-1; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P403, DOI 10.1016/S0196-9781(96)00322-1; Gourlet P, 1996, REGUL PEPTIDES, V62, P125, DOI 10.1016/0167-0115(96)00010-9; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; Gourlet P, 1998, EUR J PHARMACOL, V348, P95, DOI 10.1016/S0014-2999(98)00133-2; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Gozes I, 1999, CURR MED CHEM, V6, P1019; Igarashi H, 2002, J PHARMACOL EXP THER, V301, P37, DOI 10.1124/jpet.301.1.37; Igarashi H, 2002, J PHARMACOL EXP THER, V303, P445, DOI 10.1124/jpet.102.038075; INOOKA H, 1992, INT J PEPT PROT RES, V40, P456; Kashimoto K, 1996, ANN NY ACAD SCI, V805, P505; Laburthe M, 2002, REGUL PEPTIDES, V108, P165, DOI 10.1016/S0167-0115(02)00099-X; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Moreno D, 2000, PEPTIDES, V21, P1543, DOI 10.1016/S0196-9781(00)00309-0; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; ODONNELL M, 1991, J BIOL CHEM, V266, P6389; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Raingeaud J, 1996, BIOCHIMIE, V78, P14, DOI 10.1016/0300-9084(96)81324-1; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; SIMONCSITS A, 1988, EUR J BIOCHEM, V178, P343, DOI 10.1111/j.1432-1033.1988.tb14456.x; THERIAULT Y, 1991, BIOPOLYMERS, V31, P459, DOI 10.1002/bip.360310411; Tsutsumi M, 2002, DIABETES, V51, P1453, DOI 10.2337/diabetes.51.5.1453; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629	30	40	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10273	10281		10.1074/jbc.M211945200	http://dx.doi.org/10.1074/jbc.M211945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525492	hybrid			2022-12-25	WOS:000181777500039
J	Tsou, AP; Yang, CW; Huang, CYF; Yu, RCT; Lee, YCG; Chang, CW; Chen, BR; Chung, YF; Fann, MJ; Chi, CW; Chiu, JH; Chou, CK				Tsou, AP; Yang, CW; Huang, CYF; Yu, RCT; Lee, YCG; Chang, CW; Chen, BR; Chung, YF; Fann, MJ; Chi, CW; Chiu, JH; Chou, CK			Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma	ONCOGENE			English	Article						HURP; heptocellular carcinoma; liver regeneration; cell cycle regulator; bioinformatics	MITOTIC CHECKPOINT GENES; LIVER-REGENERATION; HUMAN CANCERS; HEPATITIS-B; EXPRESSION; KINASE; PROGRESSION; PATHOGENESIS; MUTATIONS; HOMOLOG	An analytic strategy was followed to identify putative regulatory genes during the development of human hepatocellular carcinoma (HCC). This strategy employed a bioinformatics analysis that used a database search to identify genes, which are differentially expressed in human HCC and are also under cell cycle regulation. A novel cell cycle regulated gene (HURP) that is overexpressed in HCC was identified. Full-length cDNAs encoding the human and mouse HURP genes were isolated. They share 72 and 61% identity at the nucleotide level and amino-acid level, respectively. Endogenous levels of HURP mRNA were found to be tightly regulated during cell cycle progression as illustrated by its elevated expression in the G(2)/M phase of synchronized HeLa cells and in regenerating mouse liver after partial hepatectomy. Immunofluorescence studies revealed that hepatoma up-regulated protein (HURP) localizes to the spindle poles during mitosis. Overexpression of HURP in 293T cells resulted in an enhanced cell growth at low serum levels and at polyhema-based, anchorage-independent growth assay. Taken together, these results strongly suggest that HURP is a potential novel cell cycle regulator that may play a role in the carcinogenesis of human cancer cells.	Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chou, CK (corresponding author), Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.		Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Boyer N, 2000, J HEPATOL, V32, P98, DOI 10.1016/S0168-8278(00)80419-5; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Ferea TL, 1999, CURR OPIN GENET DEV, V9, P715, DOI 10.1016/S0959-437X(99)00033-7; Hansen LK, 1999, J CELL SCI, V112, P2971; Higgins GM, 1931, ARCH PATHOL, V12, P186; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kawada M, 1997, BIOCHEM BIOPH RES CO, V231, P735, DOI 10.1006/bbrc.1997.6179; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Menjo M, 1998, J GASTROEN HEPATOL, V13, pS100; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Okabe H, 2001, CANCER RES, V61, P2129; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Pfleger CM, 2000, GENE DEV, V14, P655; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	29	116	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					298	307		10.1038/sj.onc.1206129	http://dx.doi.org/10.1038/sj.onc.1206129			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527899				2022-12-25	WOS:000180322400015
J	Nair, A; Venkatraman, M; Maliekall, TT; Nair, B; Karunagaran, D				Nair, A; Venkatraman, M; Maliekall, TT; Nair, B; Karunagaran, D			NF-kappa B is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix	ONCOGENE			English	Article						NF-kappa B; Re1A; I kappa B; cervical cancer; immunohistochemistry	BREAST-CANCER; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; DNA-BINDING; EXPRESSION; ALPHA; PROTEIN; INHIBITOR; DEATH; GENES	We demonstrate, for the first time, that the transcription factor NF-kappaB is constitutively activated during human cervical cancer progression. Immunohistochemical analysis was done using 106 paraffin-embedded cervical tissue specimens of different histological grades. In normal cervical tissue and low-grade squamous intraepithelial lesions, p50, RelA and IkappaB-alpha were mainly localized in the cytosol, whereas in high-grade lesions and squamous cell carcinomas, p50-RelA heterodimers translocated into the nucleus with a concurrent decrease in IkappaB-alpha protein. By Western blot analysis, p50 and RelA were detectable mainly in the cytosolic and nuclear extracts in normal and cancer tissues, respectively, and cytosolic IkappaB-alpha expression was detectable in normal but not in cancer cervical tissues. NF-kappaB DNA-binding activity increased during cervical cancer progression and the binding complex was mainly composed of the p50-RelA heterodimers as revealed by electrophoretic mobility shift assays. Semi-quantitative RT-PCR analysis, however, showed increased levels of IkappaB-alpha mRNA in cancer samples presumably because of feedback regulation as a result of enhanced NF-kappaB DNA-binding activity and a consequent functional activation of NF-kappaB. Further immunohistochemical analysis with an antibody to phospho IkappaB-alpha revealed that phosphorylation occurs mainly in squamous intraepithelial lesions, suggesting that the IkappaB-alpha gets phosphorylated initially and degraded as the tumor progressed.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India; Doctors Diagnost & Res Ctr, Dept Pathol, Thiruvananthapuram 695011, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.		Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Maliekal, Tessy/0000-0002-7311-7950				Anto RJ, 2000, J BIOL CHEM, V275, P15601, DOI 10.1074/jbc.C000105200; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Barabas E, 2001, BRAZ J MED BIOL RES, V34, P1271, DOI 10.1590/S0100-879X2001001000006; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cain JM, 2000, SCIENCE, V288, P1753, DOI 10.1126/science.288.5472.1753; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chopra V, 1998, CANCER INVEST, V16, P152, DOI 10.3109/07357909809050029; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cusack JC, 2001, CANCER RES, V61, P3535; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Fontaine V, 2000, VIROLOGY, V272, P40, DOI 10.1006/viro.2000.0363; Grendys EC, 1997, GYNECOL ONCOL, V65, P343, DOI 10.1006/gyno.1997.4649; Hazelbag S, 2001, GYNECOL ONCOL, V83, P235, DOI 10.1006/gyno.2001.6378; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hockel M, 1999, CANCER RES, V59, P4525; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Manna SK, 1999, J IMMUNOL, V162, P2095; Mori N, 1999, BLOOD, V93, P2360; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; Nair S. Asha, 1997, General and Diagnostic Pathology, V142, P297; Nair SA, 1998, TUMORI J, V84, P583, DOI 10.1177/030089169808400514; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nguyen HN, 1999, SEMIN SURG ONCOL, V16, P217, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<217::AID-SSU4>3.0.CO;2-U; Pillai MR, 1996, CANCER EPIDEM BIOMAR, V5, P329; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; VAN AD, 1996, SCIENCE, V274, P787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Yang JM, 2001, CANCER RES, V61, P4901; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	54	127	150	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					50	58		10.1038/sj.onc.1206043	http://dx.doi.org/10.1038/sj.onc.1206043			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527907				2022-12-25	WOS:000180166900006
J	Huang, ZD; Ling, J; Traugh, JA				Huang, ZD; Ling, J; Traugh, JA			Localization of p21-activated protein kinase gamma-PAK/Pak2 in the endoplasmic reticulum is required for induction of cytostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-PAK; ADAPTER PROTEIN; CELL-CYCLE; C-ABL; ACTIVATION; MECHANISM; ACTIN; AUTOPHOSPHORYLATION; PHOSPHORYLATION; CLEAVAGE	The intracellular localization and physiological functions of the p21-activated protein kinase gamma-PAK have been examined in human embryonic kidney 293T and COS-7 cells. At 1-4 days post-transfection, cell division is inhibited by the expression of wild type (WT) gamma-PAK and the mutant S490A, whereas cells expressing S490D and the inactive mutants K278R and T402A grow exponentially, indicating a role for gamma-PAK in the induction of cytostasis. WT gamma-PAK and S490A are localized in a region surrounding the nucleus identified as the endoplasmic reticulum (ER), as determined by immunofluorescence, whereas K278R, T402A, and S490D lack localization. As shown by sucrose density gradient centrifugation, WT gamma-PAK, S490A, and endogenous gamma-PAK are distributed among the high density (ER-associated), intermediate density, and low density fractions, whereas the mutants that do not inhibit cell division are present only as soluble enzyme. The amount of endogenousy-PAK associated with the particulate fractions is increased 4-fold when cell division is inhibited by ionizing radiation.,gamma-PAK in the ER and intermediate density fractions has high specific activity and is active, whereas the soluble form of gamma-PAK has low activity and is activable. The importance of localization of gamma-PAK is supported by data with the C-terminal mutants S490D and Delta488; these mutants have high levels of protein kinase activity but do not induce cytostasis and are not bound to the ER. A model for the induction of cytostasis by gamma-PAK through targeting of gamma-PAK to the ER is presented in which gamma-PAK activity and Ser-490 are implicated in the regulation of cytostasis.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; DELGRANDE RW, 1982, EUR J BIOCHEM, V123, P421; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Dutartre H, 1996, J CELL SCI, V109, P367; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; GOGA A, 1995, ONCOGENE, V11, P791; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Roig J, 2001, FEBS LETT, V507, P195, DOI 10.1016/S0014-5793(01)02965-9; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1998, J IMMUNOL, V160, P7; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SFEIR C, 1995, J BONE MINER RES, V10, P607; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733	39	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13101	13109		10.1074/jbc.M212557200	http://dx.doi.org/10.1074/jbc.M212557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560339	hybrid			2022-12-25	WOS:000182189500066
J	Kwon, O; Georgellis, D; Lin, ECC				Kwon, O; Georgellis, D; Lin, ECC			Rotational on-off switching of a hybrid membrane sensor kinase Tar-ArcB in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; SIGNAL-TRANSDUCTION SYSTEM; ASPARTATE RECEPTOR; 2-COMPONENT SYSTEM; BACTERIAL CHEMOTAXIS; ANAEROBIC REPRESSION; AEROBIC PATHWAYS; GENE-EXPRESSION; IN-VITRO; PROTEIN	Signal transduction in biological systems typically involves receptor proteins that possess an extracytosolic sensory domain connected to a cytosolic catalytic domain. Relatively little is known about the mechanism by which the signal is transmitted from the sensory site to the catalytic site. At least in the case of Tar (methyl-accepting chemotaxis protein for sensing aspartate) of Escherichia coli, vertical piston-like displacements of one transmembrane segment relative to the other within the monomer induced by ligand binding has been shown to modulate the catalytic activity of the cytosolic domain. The ArcB sensor kinase of E. coli is a transmembrane protein without a significant periplasmic domain. Here, we explore how the signal is conveyed to the catalytic site by analyzing the property of various Tar-ArcB hybrids. Our results suggest that, in contrast to the piston-like displacement that operates in Tar, the catalytic activity of ArcB is set by altering the orientation of the cytosolic domain of one monomer relative to the other in the homodimer. Thus, ArcB represents a distinct family of membrane receptor proteins whose catalytic activity is determined by rotational movements of the cytosolic domain.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Mol Genet, Mexico City 04510, DF, Mexico; Korea Res Inst Biosci & Biotechnol, Lab Met Engn, Yusong Gu, Taejon 305333, South Korea	Harvard University; Harvard Medical School; Universidad Nacional Autonoma de Mexico; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.		Georgellis, Dimitris/U-2517-2017	Georgellis, Dimitris/0000-0002-6114-795X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRONDSTED L, 1994, J BACTERIOL, V176, P5423; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; DONG JM, 1993, J BACTERIOL, V175, P6671, DOI 10.1128/jb.175.20.6671-6678.1993; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FALKE JJ, 1987, SCIENCE, V237, P1597; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1992, J BACTERIOL, V174, P3972, DOI 10.1128/jb.174.12.3972-3980.1992; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; IUCHI S, 1990, MOL MICROBIOL, V4, P715, DOI 10.1111/j.1365-2958.1990.tb00642.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; KIM SH, 1994, PROTEIN SCI, V3, P159; Kwon O, 2000, J BACTERIOL, V182, P3858, DOI 10.1128/JB.182.13.3858-3862.2000; Kwon O, 2000, J BACTERIOL, V182, P2960, DOI 10.1128/JB.182.10.2960-2966.2000; LEE GF, 1994, J BIOL CHEM, V269, P29920; Lin ECC, 1996, ESCHERICHIA COLI SAL, P1526; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Lynch A. Simon, 1996, P361; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x	29	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13192	13195		10.1074/jbc.M210647200	http://dx.doi.org/10.1074/jbc.M210647200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562763	Green Submitted, hybrid			2022-12-25	WOS:000182189500077
J	Zhang, YG; Cho, YY; Petersen, BL; Bode, AM; Zhu, F; Dong, ZG				Zhang, YG; Cho, YY; Petersen, BL; Bode, AM; Zhu, F; Dong, ZG			Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; SERINE PHOSPHORYLATION; SIGNAL TRANSDUCER; TYROSINE PHOSPHORYLATION; MAXIMAL ACTIVATION; TRANSCRIPTION; REQUIREMENT; PATHWAYS; TARGET; ATM	Phosphorylation at Ser(727) is known to be required for complete activation of STAT3 by diverse stimuli including UV irradiation, but the kinase(s) responsible for phosphorylating STAT3 (Ser(727)) is still not well discerned. In the present study, we observed that activation of ATM is required for a UVA-stimulated increase in Ser(727) phosphorylation of STAT3 as well as in activation and phosphorylation of p90 ribosomal protein S6 kinases (RSKs). Moreover, UVA-stimulated activation of upstream kinases, such as c-Jun N-terminal kinases (JNKs) and ERKs, involved in mediating phosphorylation of RSKs and STAT3 was defective or delayed in ATM-deficient cells. Furthermore, we provide evidence that RSK2-deficient cells were defective for UV-induced Ser(727) phosphorylation of STAT3, and the defect was restored after ectopic expression of transfected full-length RSK2. In vitro experiments showed that active RSK2 and JNK1 induce the phosphorylation of STAT3 precipitates from immunoprecipitation but not from glutathione S-transferase (GST) pull-down. Interestingly, the GST fusion STAT3 proteins mixed together with STAT3 immunoprecipitates can be phosphorylated by JNK. However, the in vitro phosphorylation of STAT3 was reduced by the GST-STAT3beta protein, a dominant negative form of STAT3. Taken together, our results demonstrate that the STAT3 phosphorylation at Ser(727) is triggered by active RSK2 or JNK1 in the presence of a downstream kinase or a cofactor, and thereby the intracellular phosphorylation process is stimulated through a signaling pathway involving ATM, MAPKs, RSK2, and an as yet unidentified kinase or cofactor. Additionally, RSK2-mediated phosphorylation of STAT3 (Ser(727)) was further determined to be required for basal and UVA-stimulated STAT3 transcriptional activities.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020; ZHU, Feng/G-3567-2010; ZHU, Feng/C-1303-2010	Cho, Yong-Yeon/0000-0003-1107-2651; Zhu, Feng/0000-0003-1172-0102; Zhang, Yiguo/0000-0003-3910-2779	NCI NIH HHS [CA77646, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081064, R01CA077646, R37CA081064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Frank DA, 1999, MOL MED, V5, P432; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukuzawa M, 2001, MOL CELL, V7, P779, DOI 10.1016/S1097-2765(01)00222-2; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 2000, J BIOL CHEM, V275, P27634; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	54	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12650	12659		10.1074/jbc.M210368200	http://dx.doi.org/10.1074/jbc.M210368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562765	hybrid			2022-12-25	WOS:000182189500010
J	Que-Gewirth, NLS; Lin, SH; Cotter, RJ; Raetz, CRH				Que-Gewirth, NLS; Lin, SH; Cotter, RJ; Raetz, CRH			An outer membrane enzyme that generates the 2-amino-2-deoxy-gluconate moiety of Rhizobium leguminosarum lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN GLUCOSE-DEHYDROGENASE; ACID-DEFICIENT MUTANT; ESCHERICHIA-COLI; CELLOBIOSE DEHYDROGENASE; LIPOPOLYSACCHARIDE CORE; SALMONELLA-TYPHIMURIUM; NODULE DEVELOPMENT; RESPIRATORY-CHAIN; SYMBIOTIC NODULE; CLONING	The structures of Rhizobium leguminosarum and Rhizobium etli lipid A are distinct from those found in other Gram-negative bacteria. Whereas the more typical Escherichia coli lipid A is a hexa-acylated disaccharide of glucosamine that is phosphorylated at positions 1 and 4', R. etli and R. leguminosarum lipid A consists of a mixture of structurally related species (designated A-E) that lack phosphate. A conserved distal unit, comprised of a diacylated glucosamine moiety with galacturonic acid residue at position 4' and a secondary 27-hydroxyoctacosanoyl (27-OH-C28) as part of a 2' acyloxyacyl moiety, is present in all five components. The proximal end is heterogeneous, differing in the number and lengths of acyl chains and in the identity of the sugar itself. A proximal glucosamine unit is present in B and C, but an unusual 2-amino-2-deoxy-gluconate moiety is found in D-1 and E. We now demonstrate that membranes of R. leguminosarum and R. etli can convert B to D-1 in a reaction that requires added detergent and is inhibited by EDTA. Membranes of Sinorhizobium meliloti and E. coli lack this activity. Mass spectrometry demonstrates that B is oxidized in vitro to a substance that is 16 atomic mass units larger, consistent with the formation of D-1. The oxidation of the lipid A proximal unit is also demonstrated by matrix-assisted laser desorption ionization time-of-flight mass spectrometry in the positive and negative modes using the model substrate, 1-dephospho-lipid IVA. With this material, an additional intermediate (or by product) is detected that is tentatively identified as a lactone derivative of 1-dephospho-lipid IVA. The enzyme, presumed to be an oxidase, is located exclusively in the outer membrane of R leguminosarum as judged by sucrose gradient analysis. To our knowledge, an oxidase associated with the outer membranes of Gram-negative bacteria has not been reported previously.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R37GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM-51796, GM-54882, R37 GM051796, R37 GM051796-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony C, 1996, BIOCHEM J, V320, P697, DOI 10.1042/bj3200697; ANTHONY C, 1992, INT J BIOCHEM, V24, P29, DOI 10.1016/0020-711X(92)90226-Q; BAO WJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P705, DOI 10.1006/abbi.1993.1098; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; Becker A, 2002, J MOL MICROB BIOTECH, V4, P187; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Brade H., 1999, ENDOTOXIN HLTH DIS; BREEDVELD MW, 1994, MICROBIOL REV, V58, P145, DOI 10.1128/MMBR.58.2.145-161.1994; Bright H.B., 1975, ENZYMES, V12B, P421; Broughton WJ, 2000, J BACTERIOL, V182, P5641, DOI 10.1128/JB.182.20.5641-5652.2000; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; CARLSON FW, 1992, PLANT BIOTECHNOLOGY, P33; CARLSON RW, 1989, CARBOHYD RES, V195, P101, DOI 10.1016/0008-6215(89)85092-X; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CLETONJANSEN AM, 1989, MOL GEN GENET, V217, P430, DOI 10.1007/BF02464914; COLLYER CA, 1990, J MOL BIOL, V212, P211, DOI 10.1016/0022-2836(90)90316-E; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; DOKTER P, 1988, BIOCHEM J, V254, P131, DOI 10.1042/bj2540131; Downie JA, 1999, CURR OPIN PLANT BIOL, V2, P483, DOI 10.1016/S1369-5266(99)00018-7; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; Gage DJ, 2000, CURR OPIN MICROBIOL, V3, P613, DOI 10.1016/S1369-5274(00)00149-1; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GEIGER O, 1986, BIOCHEMISTRY-US, V25, P6043, DOI 10.1021/bi00368a031; Goodwin PM, 1998, ADV MICROB PHYSIOL, V40, P1, DOI 10.1016/S0065-2911(08)60129-0; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; He XM, 2000, CHEM REV, V100, P4615, DOI 10.1021/cr9902998; Henriksson G, 2000, J BIOTECHNOL, V78, P93, DOI 10.1016/S0168-1656(00)00206-6; HIGHAM CW, 1994, FEBS LETT, V351, P128, DOI 10.1016/0014-5793(94)00847-7; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kereszt A, 1998, J BACTERIOL, V180, P5426, DOI 10.1128/JB.180.20.5426-5431.1998; KREMER SM, 1992, EUR J BIOCHEM, V205, P133, DOI 10.1111/j.1432-1033.1992.tb16760.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Li B, 1996, APPL ENVIRON MICROB, V62, P1329, DOI 10.1128/AEM.62.4.1329-1335.1996; MATSUSHITA K, 1989, BIOCHEMISTRY-US, V28, P6276, DOI 10.1021/bi00441a020; MATSUSHITA K, 1989, AGR BIOL CHEM TOKYO, V53, P2895, DOI 10.1080/00021369.1989.10869793; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Niehaus K, 1998, Subcell Biochem, V29, P73; Niner BM, 1998, SYMBIOSIS, V24, P51; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; NOEK KD, 2000, PROKARYOTIC NITROGEN, P415; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Noel KD, 2000, J BACTERIOL, V182, P5317, DOI 10.1128/JB.182.19.5317-5324.2000; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que NLS, 1998, FASEB J, V12, pA1284; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; Rotsaert FAJ, 2001, ARCH BIOCHEM BIOPHYS, V390, P206, DOI 10.1006/abbi.2001.2362; SCHRAY KJ, 1971, BIOCHEMISTRY-US, V10, P1058, DOI 10.1021/bi00782a019; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Stacey G., 1992, BIOL NITROGEN FIXATI; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Triplett E. W, 2000, PROKARYOTIC NITROGEN, V1st; VANBASTELAERE PBM, 1992, BIOCHEM J, V286, P729, DOI 10.1042/bj2860729; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; WHITLOW M, 1991, PROTEINS, V9, P153, DOI 10.1002/prot.340090302; Xu F, 2001, ENZYME MICROB TECH, V28, P744, DOI 10.1016/S0141-0229(01)00319-2; YAMADA M, 1993, J BIOL CHEM, V268, P12812; Young JPW, 1996, NEW PHYTOL, V133, P87, DOI 10.1111/j.1469-8137.1996.tb04344.x	88	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12109	12119		10.1074/jbc.M300378200	http://dx.doi.org/10.1074/jbc.M300378200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531907	Green Accepted, hybrid			2022-12-25	WOS:000182015700052
J	Cilenti, L; Lee, Y; Hess, S; Srinivasula, S; Park, KM; Junqueira, D; Davis, H; Bonventre, JV; Alnemri, ES; Zervos, AS				Cilenti, L; Lee, Y; Hess, S; Srinivasula, S; Park, KM; Junqueira, D; Davis, H; Bonventre, JV; Alnemri, ES; Zervos, AS			Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SERINE-PROTEASE; PROTEINS; DROSOPHILA; HTRA2; GENE; XIAP; IDENTIFICATION; MITOCHONDRIA; INTERACTS	Omi/HtrA2 is a mammalian serine protease with high homology to bacterial HtrA chaperones. Omi/HtrA2 is localized in mitochondria and is released to the cytoplasm in response to apoptotic stimuli. Omi/HtrA2 induces cell death in a caspase-dependent manner by interacting with the inhibitor of apoptosis protein as well as in a caspase-independent manner that relies on its protease activity. We describe the identification and characterization of a novel compound as a specific inhibitor of the proteolytic activity of Omi/HtrA2. This compound (ucf-101) was isolated in a high throughput screening of a combinatorial library using bacterially made Omi-(134-458) protease and fluorescein-casein as a generic substrate. ucf-101 showed specific activity against Omi/HtrA2 and very little activity against various other serine proteases. This compound has a natural fluorescence that was used to monitor its ability to enter mammalian cells. ucf-101, when tested in caspase-9 (-/-) null fibroblasts, was found to inhibit Omi/HtrA2-induced cell death.	Univ Cent Florida, Biomol Sci Ctr, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Morphochem AG, D-81379 Munich, Germany	State University System of Florida; University of Central Florida; Jefferson University; Harvard University; Brigham & Women's Hospital	Zervos, AS (corresponding author), Univ Cent Florida, Biomol Sci Ctr, Dept Mol Biol & Microbiol, 12722 Res Pkwy, Orlando, FL 32826 USA.		Alnemri, Emad S/B-4526-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13487] Funding Source: Medline; NIDDK NIH HHS [R01 DK55734-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Faccio L, 2000, GENOMICS, V68, P343, DOI 10.1006/geno.2000.6263; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300	21	101	111	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11489	11494		10.1074/jbc.M212819200	http://dx.doi.org/10.1074/jbc.M212819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529364	hybrid, Green Published			2022-12-25	WOS:000181855400080
J	Luttichau, HR; Clark-Lewis, I; Jensen, PO; Moser, C; Gerstoft, J; Schwartz, TW				Luttichau, HR; Clark-Lewis, I; Jensen, PO; Moser, C; Gerstoft, J; Schwartz, TW			A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SARCOMA-ASSOCIATED HERPESVIRUS; C-C CHEMOKINES; MULTIPLE-SCLEROSIS; KAPOSIS-SARCOMA; CYTOMEGALOVIRUS ENCODES; INTERNATIONAL UNION; CX3C CHEMOKINE; VMIP-II	The chemokine-like, secreted protein product of the U83 gene from human herpesvirus 6, here named vCCL4, was chemically synthesized to be characterized in a complete library of the 18 known human chemokine receptors expressed individually in stably transfected cell lines. vCCL4 was found to cause calcium mobilization as efficiently as the endogenous chemokine ligand CCL2 through the CCR2 receptor, whereas the virally encoded chemokine did not affect any of the other 17 human chemokine receptors tested. Mutual cross-desensitization between CCL2 and vCCL4 was demonstrated in the CCR2-transfected cells. The affinity of vCCL4 for the CCR2 receptor was 79 nm as determined in competition binding against radioactively labeled CCL2. In the murine pre-B lymphocyte cell line L1.2 stably transfected with the CCR2 receptor, vCCL4 acted as a relatively low potency but highly efficacious chemoattractant being equally or more efficacious in causing cell migration than CCL2 and CCL7 and considerably more efficacious than CCL8 and CCL13. It is concluded that human herpesvirus 6 encodes a highly selective and efficacious CCR2 agonist, which will attract CCR2 expressing cells, for example macrophages and monocytes, conceivably for the virus to infect and to establish latency in. It is suggested that vCCL4 during reactivation of the virus in for example monocyte-derived microglia could perhaps be involved in the pathogenesis of the CCR2-dependent disease, multiple sclerosis.	Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z4, Canada; Rigshosp, Dept Clin Microbiol, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of British Columbia; Rigshospitalet; University of Copenhagen	Luttichau, HR (corresponding author), Panum Inst, Mol Pharmacol Lab, 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.		Moser, Claus Ernst/N-5951-2017; Moser, Claus Ernst/GPK-5546-2022; Jensen, Peter Ostrup/HGD-7725-2022	Moser, Claus Ernst/0000-0002-7664-8570; Moser, Claus Ernst/0000-0002-7664-8570; Schwartz, Thue W./0000-0002-0261-6904; Jensen, Peter Ostrup/0000-0003-1648-7186; Luttichau, Hans Rudolf/0000-0002-5428-4075				Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521; Carrigan DR, 1996, NEUROLOGY, V47, P145, DOI 10.1212/WNL.47.1.145; Cha TA, 1996, J VIROL, V70, P78, DOI 10.1128/JVI.70.1.78-83.1996; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; French C, 1999, VIROLOGY, V262, P139, DOI 10.1006/viro.1999.9875; Friedman JE, 1999, MULT SCLER, V5, P355, DOI 10.1177/135245859900500509; Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Kamei A, 1997, EUR J PEDIATR, V156, P709, DOI 10.1007/s004310050695; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KONDO K, 1991, J GEN VIROL, V72, P1401, DOI 10.1099/0022-1317-72-6-1401; Liu Y, 1997, J IMMUNOL, V158, P604; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Luttichau HR, 2001, EUR J IMMUNOL, V31, P1217; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2002, PHARMACOL REV, V54, P227, DOI 10.1124/pr.54.2.227; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Osborne J, 1999, HUM IMMUNOL, V60, P921, DOI 10.1016/S0198-8859(99)00083-X; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; Tran EH, 2000, EUR J IMMUNOL, V30, P1410, DOI 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Xu L, 1997, J LEUKOCYTE BIOL, V62, P653, DOI 10.1002/jlb.62.5.653; Yamagami S, 1997, FEBS LETT, V400, P329, DOI 10.1016/S0014-5793(96)01411-1; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918; Zou P, 1999, J VIROL, V73, P5926, DOI 10.1128/JVI.73.7.5926-5933.1999	54	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10928	10933		10.1074/jbc.M211329200	http://dx.doi.org/10.1074/jbc.M211329200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12554737	hybrid			2022-12-25	WOS:000181855400009
J	Barr, SD; Gedamu, L				Barr, SD; Gedamu, L			Role of peroxidoxins in Leishmania chagasi survival - Evidence of an enzymatic defense against nitrosative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; ALKYL HYDROPEROXIDE REDUCTASE; NITRIC-OXIDE; HYDROGEN-PEROXIDE; IN-VIVO; MURINE MACROPHAGES; DONOVANI PROMASTIGOTES; ACTIVATED MACROPHAGES; REACTIVE NITROGEN; CELL-LINE	The mechanisms by which Leishmania parasites survive exposure to highly reactive oxygen (ROS) and nitrogen (RNS) species within phagosomes of macrophages are not well known. Recently it has been shown that RNS alone is sufficient and necessary to control Leishmania donovani infection in mice (Murray, H. W., and Nathan, C. F. (1999) J. Exp. Med. 189, 741-746). No enzymatic defense against RNS has been discovered in Leishmania to date. We have previously isolated two peroxidoxins (LcPxn1 and LcPxn2) from Leishmania chagasi and showed that recombinant LcPxn1 protein was capable of detoxifying hydrogen peroxide, hydroperoxide, and hydroxyl radicals (Barr, S. D., and Gedamu, L. (2001) J. Biol. Chem 276, 34279-34287). In further characterizing the physiological role of peroxidoxins in Leishmania survival, we show here that recombinant LcPxn1 protein can detoxify RNS in addition to ROS, whereas recombinant LcPxn2 protein can only detoxify hydrogen peroxide. LcPxn1 and LcPxn2 are localized to the cytoplasm, and overexpression of LcPxn1 in L chagasi parasites enhanced survival when exposed to exogenous ROS and RNS and enhanced survival within U937 macrophage cells. Site-directed mutagenesis studies revealed that the conserved Cys-52 residue is essential for detoxifying hydrogen peroxide, t-butyl hydroperoxide, and hydroxyl radicals, whereas the conserved Cys-173 residue is essential for detoxifying t-butyl hydroperoxide and peroxynitrite. This is the first report of an enzymatic defense against RNS in Leishmania.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Gedamu, L (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	lgedamu@ucalgary.ca		Barr, Stephen/0000-0002-0028-7430				Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Balavoine GGA, 1999, NITRIC OXIDE-BIOL CH, V3, P40, DOI 10.1006/niox.1999.0206; Barr SD, 2001, J BIOL CHEM, V276, P34279, DOI 10.1074/jbc.M104406200; Bhat VB, 2001, BIOCHEM BIOPH RES CO, V285, P262, DOI 10.1006/bbrc.2001.5195; Bhattacharyya S, 2002, J INFECT DIS, V185, P1704, DOI 10.1086/340820; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Butterfield LH, 1999, ANTIOXID REDOX SIGN, V1, P385, DOI 10.1089/ars.1999.1.4-385; Castro H, 2002, FREE RADICAL BIO MED, V33, P1563, DOI 10.1016/S0891-5849(02)01088-2; Castro H, 2002, FREE RADICAL BIO MED, V33, P1552, DOI 10.1016/S0891-5849(02)01089-4; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHANNON JY, 1985, PARASITOLOGY, V91, P197, DOI 10.1017/S0031182000057309; CHANNON JY, 1985, PARASITOLOGY, V91, P207, DOI 10.1017/S0031182000057310; CHANNON JY, 1984, IMMUNOLOGY, V53, P345; Chen L, 1998, MOL CELL, V1, P795, DOI 10.1016/S1097-2765(00)80079-9; CLEMENT LT, 1983, J IMMUNOL, V130, P2763; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ekman P, 1999, INFECT IMMUN, V67, P3670, DOI 10.1128/IAI.67.7.3670-3673.1999; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; EVANS TG, 1993, J IMMUNOL, V151, P907; Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893; GREEN SJ, 1990, J IMMUNOL, V144, P278; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; Jagannath C, 1998, NITRIC OXIDE-BIOL CH, V2, P174, DOI 10.1006/niox.1998.9999; JOYCE DA, 1992, AGENTS ACTIONS, V37, P305, DOI 10.1007/BF02028124; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIMURA T, 1993, FEBS LETT, V326, P232, DOI 10.1016/0014-5793(93)81797-4; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; LIEW FY, 1990, J IMMUNOL, V144, P4794; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Logan C, 2000, J BIOL CHEM, V275, P30019, DOI 10.1074/jbc.M004161200; MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73, DOI 10.1002/jlb.49.1.73; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; Miller MA, 2000, J BIOL CHEM, V275, P33883, DOI 10.1074/jbc.M003671200; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; MURRAY HW, 1982, J IMMUNOL, V129, P351; Muyombwe A, 1997, EXP PARASITOL, V85, P35, DOI 10.1006/expr.1996.4115; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nims RW, 1996, METHOD ENZYMOL, V268, P93; Paramchuk WJ, 1997, MOL BIOCHEM PARASIT, V90, P203, DOI 10.1016/S0166-6851(97)00141-2; PEARSON RD, 1982, J IMMUNOL, V129, P1282; PEARSON RD, 1983, J IMMUNOL, V131, P1994; Peshenko IV, 2001, J OCUL PHARMACOL TH, V17, P93, DOI 10.1089/108076801750125775; ROACH TIA, 1991, INFECT IMMUN, V59, P3935, DOI 10.1128/IAI.59.11.3935-3944.1991; Romao PRT, 1999, PARASITOLOGY, V118, P559, DOI 10.1017/S0031182099004278; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Streit JA, 1996, INFECT IMMUN, V64, P1810, DOI 10.1128/IAI.64.5.1810-1818.1996; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Uppu RM, 1996, METHOD ENZYMOL, V269, P322; VOULDOUKIS I, 1995, P NATL ACAD SCI USA, V92, P7804, DOI 10.1073/pnas.92.17.7804; Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998; WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	66	86	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10816	10823		10.1074/jbc.M212990200	http://dx.doi.org/10.1074/jbc.M212990200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529367	hybrid			2022-12-25	WOS:000181777500107
J	Gardner, AM; Gessner, CR; Gardner, PR				Gardner, AM; Gessner, CR; Gardner, PR			Regulation of the nitric oxide reduction operon (norRVW) in Escherichia coli - Role of norR and sigma(54) in the nitric oxide stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL CONTROL; NITROSATIVE STRESS; GENE; FLAVOHEMOGLOBIN; DIOXYGENASE; PROTEIN; FLAVORUBREDOXIN; DETOXIFICATION; HEMOGLOBIN; PROTECTION	Nitric oxide (NO) induces NO-detoxifying enzymes in Escherichia coli suggesting sensitive mechanisms for coordinate control of NO defense genes in response to NO stress. Exposure of E. coli to sub-micromolar NO levels under anaerobic conditions rapidly induced transcription of the NO reductase (NOR) structural genes, norV and norW, as monitored by lac gene fusions. Disruption of rpoN (sigma(54)) impaired the NO-mediated induction of norV and norW transcription and NOR expression, whereas disruption of the upstream regulatory gene, norR, completely ablated NOR induction. NOR inducibility was restored to NorR null mutants by expressing NorR in trans. Furthermore, an internal deletion of the N-terminal domain of NorR activated NOR expression independent of NO exposure. Neither NorR nor sigma(54) was essential for NO-mediated induction of the NO dioxygenase (flavohemoglobin) encoded by hmp. However, elevated NOR activity inhibited NO dioxygenase induction, and, in the presence of dioxygen, NO dioxygenase inhibited norV induction by NO. The results demonstrate the role of NorR as a sigma(54)-dependent regulator of norVW expression. A role for the NorR N-terminal domain as a transducer or sensor for NO is suggested.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Gardner, AM (corresponding author), Childrens Hosp Res Fdn, ML 7006,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Anne.Gardner@cchmc.org		Gardner, Paul/0000-0001-8189-0903; Gardner, Anne/0000-0001-7095-772X	NIGMS NIH HHS [GM-65090] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065090] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Barrios H, 1999, NUCLEIC ACIDS RES, V27, P4305, DOI 10.1093/nar/27.22.4305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; Demple B, 2002, MOL CELL BIOCHEM, V234, P11, DOI 10.1023/A:1015933216079; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Gardner PR, 2001, FREE RADICAL BIO MED, V31, P191, DOI 10.1016/S0891-5849(01)00569-X; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Gomes CM, 2000, BIOCHEMISTRY-US, V39, P16230, DOI 10.1021/bi001844y; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; HENDERSON N, 1989, MOL GEN GENET, V216, P484, DOI 10.1007/BF00334394; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; Hutchings MI, 2000, J BACTERIOL, V182, P6434, DOI 10.1128/JB.182.22.6434-6439.2000; Hutchings MI, 2002, J BACTERIOL, V184, P4640, DOI 10.1128/JB.184.16.4640-4643.2002; Ignarro LJ, 1996, KIDNEY INT, pS2; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kwiatkowski AV, 1996, J BIOL CHEM, V271, P24382, DOI 10.1074/jbc.271.40.24382; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pathania R, 2002, MOL MICROBIOL, V45, P1303, DOI 10.1046/j.1365-2958.2002.03095.x; Pohlmann A, 2000, MOL MICROBIOL, V38, P626, DOI 10.1046/j.1365-2958.2000.02157.x; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; RAMSEIER TM, 1994, DNA SEQUENCE, V5, P17, DOI 10.3109/10425179409039700; Reitzer L, 2001, MICROBIOL MOL BIOL R, V65, P422, DOI 10.1128/MMBR.65.3.422-444.2001; Rudd KE, 2000, NUCLEIC ACIDS RES, V28, P60, DOI 10.1093/nar/28.1.60; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; UENONISHIO S, 1983, J BACTERIOL, V153, P1247, DOI 10.1128/JB.153.3.1247-1251.1983; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; Vollack KU, 2001, J BACTERIOL, V183, P2516, DOI 10.1128/JB.183.8.2516-2526.2001; Wasserfallen A, 1998, EUR J BIOCHEM, V254, P325, DOI 10.1046/j.1432-1327.1998.2540325.x; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zumft WG, 2002, J MOL MICROB BIOTECH, V4, P277; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	50	116	120	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10081	10086		10.1074/jbc.M212462200	http://dx.doi.org/10.1074/jbc.M212462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529359	hybrid			2022-12-25	WOS:000181777500014
J	Jones, PR; Manabe, T; Awazuhara, M; Saito, K				Jones, PR; Manabe, T; Awazuhara, M; Saito, K			A new member of plant CS-lyases - A cystine lyase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE; CLONING; PURIFICATION; GENES; AUXIN; BIOSYNTHESIS; ENZYME; SULFURTRANSFERASE; ALLIINASE; MUTATION	Cystine lyases catalyze the breakdown Of L-cystine to thiocysteine, pyruvate, and ammonia. Until now there are no reports of the identification of a plant cystine lyase at a molecular level, and it is not clear what biological role this class of enzymes have in plants. A cystine lyase was isolated from Brassica oleracea (L.), and partial amino acid sequencing allowed the corresponding full-length cDNA (BOCL3) to be cloned. The deduced amino acid sequence of BOCL3 showed highest homology to the deduced amino acid sequences of several Arabidopsis thaliana genes annotated as tyrosine aminotransferase-like, including a coronatine, jasmonic acid, and salt stress-inducible gene, CORD (78.8% identity), and the unidentified rooty/superroot1 gene (44.8% identity). A full-length expressed sequence tag clone of CORM was obtained and recombinant CORI3 was synthesized in Escherichia coli. Isolated recombinant CORI3 catalyzed a cystine lyase reaction, but no aminotransferase reactions. The present study identifies, for the first time, a cystine lyase from plants at a molecular level and redefines the functional assignment of the only functionally identified member of a group of A. thaliana genes annotated as tyrosine aminotransferase-like.	Chiba Univ, CREST Japan Sci & Technol Corp, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol,Inage Ku, Chiba 2638522, Japan	Chiba University; Japan Science & Technology Agency (JST)	Saito, K (corresponding author), Chiba Univ, CREST Japan Sci & Technol Corp, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol,Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.	ksaito@p.chiba-u.ac.jp	Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				Adcock HJ, 1996, J PHARM PHARMACOL, V48, P150, DOI 10.1111/j.2042-7158.1996.tb07114.x; ANDERSON NW, 1979, PHYTOCHEMISTRY, V18, P1953, DOI 10.1016/S0031-9422(00)82710-7; Bak S, 2001, PLANT CELL, V13, P101, DOI 10.1105/tpc.13.1.101; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitinger U, 2001, PLANT PHYSIOL, V126, P631, DOI 10.1104/pp.126.2.631; Celenza JL, 2001, CURR OPIN PLANT BIOL, V4, P234, DOI 10.1016/S1369-5266(00)00166-7; Christen P, 2001, CHEM REC, V1, P436, DOI 10.1002/tcr.10005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIAMONDSTONE TI, 1966, ANAL BIOCHEM, V16, P395, DOI 10.1016/0003-2697(66)90220-X; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gong ZZ, 2001, PLANT PHYSIOL, V126, P363, DOI 10.1104/pp.126.1.363; GOPALRAJ M, 1997, 8 INT M AR RES JUN 2; HALL DI, 1983, PLANT PHYSIOL, V72, P654, DOI 10.1104/pp.72.3.654; HAMAMOTO A, 1986, PLANT PHYSIOL, V80, P702, DOI 10.1104/pp.80.3.702; Hansen CH, 2001, J BIOL CHEM, V276, P24790, DOI 10.1074/jbc.M102637200; HARGROVE JL, 1989, J BIOL CHEM, V264, P45; Hatzfeld Y, 2000, FEBS LETT, V470, P147, DOI 10.1016/S0014-5793(00)01311-9; Iciek M, 2001, POL J PHARMACOL, V53, P215; Jones PR, 1999, J BIOL CHEM, V274, P35483, DOI 10.1074/jbc.274.50.35483; Kiddle GA, 1999, PLANT CELL ENVIRON, V22, P433, DOI 10.1046/j.1365-3040.1999.00416.x; King JJ, 1995, PLANT CELL, V7, P2023, DOI 10.1105/tpc.7.12.2023; Lancaster JE, 2000, PLANT PHYSIOL, V122, P1269, DOI 10.1104/pp.122.4.1269; Lang T, 1999, J BIOL CHEM, V274, P189, DOI 10.1074/jbc.274.1.189; Lopukhina A, 2001, PLANT PHYSIOL, V126, P1678, DOI 10.1104/pp.126.4.1678; Manabe T, 1998, EUR J BIOCHEM, V257, P21, DOI 10.1046/j.1432-1327.1998.2570021.x; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Papenbrock J, 2000, EUR J BIOCHEM, V267, P145, DOI 10.1046/j.1432-1327.2000.00980.x; Ramirez EC, 1998, J FOOD BIOCHEM, V22, P427, DOI 10.1111/j.1745-4514.1998.tb00254.x; Sasaki Y, 2001, DNA RES, V8, P153, DOI 10.1093/dnares/8.4.153; SCHULTZ CJ, 1995, PLANT J, V7, P61, DOI 10.1046/j.1365-313X.1995.07010061.x; Seo M, 1998, PLANT PHYSIOL, V116, P687, DOI 10.1104/pp.116.2.687; Takahashi M, 1999, PLANT PHYSIOL, V121, P947, DOI 10.1104/pp.121.3.947; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ukai K, 1997, BIOSCI BIOTECH BIOCH, V61, P1890, DOI 10.1271/bbb.61.1890; Ukai K, 1999, PHYTOCHEMISTRY, V51, P853, DOI 10.1016/S0031-9422(99)00067-9; Urano Y, 2000, GENE, V257, P269, DOI 10.1016/S0378-1119(00)00399-1	38	31	35	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10291	10296		10.1074/jbc.M212207200	http://dx.doi.org/10.1074/jbc.M212207200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525491	hybrid			2022-12-25	WOS:000181777500041
J	Zhang, YQ; Han, H; Wang, JX; Wang, HZ; Yang, BF; Wang, ZG				Zhang, YQ; Han, H; Wang, JX; Wang, HZ; Yang, BF; Wang, ZG			Impairment of human ether-a-Go-Go-related gene (HERG) K+ channel function by hypoglycemia and hyperglycemia - Similar phenotypes but different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH GLUCOSE; OXIDATIVE STRESS; QT INTERVAL; PREFERENTIAL REGULATION; SIGNALING PATHWAYS; POTENTIAL ROLE; DYSFUNCTION; CELLS; EXPRESSION; ATP	Hyperglycemia and hypoglycemia both can cause prolongation of the Q-T interval and ventricular arrhythmias. Here we studied modulation of human ether-A-go-go-related gene (HERG) K+ channel, the major molecular component of delayed rectifier K+ current responsible for cardiac repolarization, by glucose in HEK293 cells using whole-cell patch clamp techniques. We found that both hyperglycemia (extracellular glucose concentration [Glu], = 10 or 20 mm) and hypoglycemia ([Glu], = 2.5, 1, or 0 mm) impaired HERG function by reducing HERG current (I-HERG) density, as compared with normoglycemia ([Glu], = 5 mM). Complete inhibition of glucose metabolism (glycolysis and oxidative phosphorylation) by 2-deoxy-D-glucose mimicked the effects of hypoglycemia, but inhibition of glycolysis or oxidative phosphorylation alone did not cause IHERG depression. Depletion of intracellular ATP mimicked the effects of hypoglycemia, and replacement of ATP by GTP or non-hydrolysable ATP failed to prevent the effects. Inhibition of oxidative phosphorylation by NaCN or application of antioxidants vitamin E or superoxide dismutase mimetic (Mn(III) tetrakis(4-benzoic acid) porphyrin chloride) abrogated and incubation with xanthine/xanthine oxidase mimicked the effects of hyperglycemia. Hyperglycemia or xanthine/xanthine oxidase markedly increased intracellular levels of reactive oxygen species, as measured by 5-(and-6)chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H(2)DCFDA) fluorescence dye, and this increase was prevented by NaCN, vitamin E, or Mn(III) tetrakis(4-benzoic acid) porphyrin chloride. We conclude that ATP, derived from either glycolysis or oxidative phosphorylation, is critical for normal HERG function; depression of I-HERG in hypoglycemia results from underproduction of ATP and in hyperglycemia from overproduction of reactive oxygen species. Impairment of HERG function might contribute to Q-T prolongation caused by hypoglycemia and hyperglycemia.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Harbin Med Univ, Dept Pharmacol, Harbin 150086, Heilongjiang, Peoples R China	Universite de Montreal; Universite de Montreal; Harbin Medical University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.	wangz@icm.umontreal.ca	Zhang, Yiqiang/D-9613-2012; wang, zhiguo/AAN-4182-2021; Wang, Zhiguo/GRS-4339-2022; Han, Ho Jae/M-1476-2016	Zhang, Yiqiang/0000-0003-0691-6645; Wang, Zhiguo/0000-0002-0811-2045; Han, Ho Jae/0000-0002-0657-1766; Zheng, Jie/0000-0001-6524-6800				Abo K, 1996, DIABETES CARE, V19, P1010, DOI 10.2337/diacare.19.9.1010; AIELLO EA, 1995, CIRC RES, V77, P153, DOI 10.1161/01.RES.77.1.153; BARRINGTON PL, 1988, J MOL CELL CARDIOL, V20, P1163, DOI 10.1016/0022-2828(88)90596-2; Berube J, 2001, J PHARMACOL EXP THER, V297, P96; Chelliah YR, 2000, ANAESTH INTENS CARE, V28, P698, DOI 10.1177/0310057X0002800617; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Eckert B, 1998, CLIN PHYSIOL, V18, P570, DOI 10.1046/j.1365-2281.1998.00138.x; Esposito K, 2002, J ENDOCRINOL INVEST, V25, P485, DOI 10.1007/BF03344043; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; Graier WF, 1997, HORM METAB RES, V29, P622, DOI 10.1055/s-2007-979113; Graier WF, 1999, DIABETES RES CLIN PR, V45, P153, DOI 10.1016/S0168-8227(99)00045-5; HAZEN SL, 1994, FEBS LETT, V339, P213, DOI 10.1016/0014-5793(94)80418-4; Hsieh TJ, 2002, ENDOCRINOLOGY, V143, P2975, DOI 10.1210/en.143.8.2975; KAHN JK, 1987, J CLIN ENDOCR METAB, V64, P751, DOI 10.1210/jcem-64-4-751; Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282; Koo JR, 2002, CLIN EXP HYPERTENS, V24, P333, DOI 10.1081/CEH-120004795; Landstedt-Hallin L, 1999, J INTERN MED, V246, P299, DOI 10.1046/j.1365-2796.1999.00528.x; Li PA, 1999, FREE RADICAL BIO MED, V27, P1033, DOI 10.1016/S0891-5849(99)00152-5; LINDSTROM T, 1992, DIABETIC MED, V9, P536, DOI 10.1111/j.1464-5491.1992.tb01834.x; Liu YP, 2002, CLIN EXP PHARMACOL P, V29, P305, DOI 10.1046/j.1440-1681.2002.03649.x; Liu YP, 2001, CIRC RES, V89, P146, DOI 10.1161/hh1401.093294; Losito VA, 1998, J PHYSIOL-LONDON, V511, P67, DOI 10.1111/j.1469-7793.1998.067bi.x; Ludwig B, 2001, CHEMBIOCHEM, V2, P392, DOI 10.1002/1439-7633(20010601)2:6<392::AID-CBIC392>3.3.CO;2-E; Marfella R, 2001, DIABETES NUTR METAB, V14, P63; Marfella R, 2001, J CLIN INVEST, V108, P635, DOI 10.1172/JCI13727; Marques JLB, 1997, DIABETIC MED, V14, P648, DOI 10.1002/(SICI)1096-9136(199708)14:8<648::AID-DIA418>3.3.CO;2-T; MIKI S, 1988, J MOL CELL CARDIOL, V20, P1009, DOI 10.1016/0022-2828(88)90578-0; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; ODA A, 1994, HORM METAB RES, V26, P1, DOI 10.1055/s-2007-1000762; Patane G, 2002, DIABETES, V51, P2749, DOI 10.2337/diabetes.51.9.2749; Sanguinetti MC, 1999, ANN NY ACAD SCI, V868, P406, DOI 10.1111/j.1749-6632.1999.tb11302.x; SHIMADA R, 1984, ARCH INTERN MED, V144, P1068, DOI 10.1001/archinte.144.5.1068; Siraki AG, 2002, FREE RADICAL BIO MED, V32, P2, DOI 10.1016/S0891-5849(01)00764-X; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Srivastava AK, 2002, INT J MOL MED, V9, P85; Taglialatela M, 1998, BIOCHEM PHARMACOL, V55, P1741, DOI 10.1016/S0006-2952(98)00002-1; Taglialatela M, 1997, P NATL ACAD SCI USA, V94, P11698, DOI 10.1073/pnas.94.21.11698; Takigawa T, 2000, NEUROREPORT, V11, P2547, DOI 10.1097/00001756-200008030-00040; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; vanDam PS, 1998, FREE RADICAL BIO MED, V24, P18, DOI 10.1016/S0891-5849(97)00122-6; Veglio M, 1999, DIABETOLOGIA, V42, P68, DOI 10.1007/s001250051115; Wallace D C, 2001, Novartis Found Symp, V235, P247; Wallace Douglas C, 2002, Methods Mol Biol, V197, P3, DOI 10.1385/1-59259-284-8:003; Wang HZ, 2001, J BIOL CHEM, V276, P40811, DOI 10.1074/jbc.M105572200; Wang JX, 2001, CIRCULATION, V104, P2645, DOI 10.1161/hc4701.100513; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; XU Z, 1998, AM J PHYSIOL, V271, pH2190; Yazawa K, 1997, PFLUG ARCH EUR J PHY, V433, P557, DOI 10.1007/s004240050314; YTREHUS K, 1986, CARDIOVASC RES, V20, P597, DOI 10.1093/cvr/20.8.597; Zhang YQ, 2003, FEBS LETT, V534, P125, DOI 10.1016/S0014-5793(02)03804-8; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	53	157	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10417	10426		10.1074/jbc.M211044200	http://dx.doi.org/10.1074/jbc.M211044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531891	hybrid			2022-12-25	WOS:000181777500058
J	Girardin, SE; Boneca, IG; Viala, J; Chamaillard, M; Labigne, A; Thomas, G; Philpott, DJ; Sansonetti, PJ				Girardin, SE; Boneca, IG; Viala, J; Chamaillard, M; Labigne, A; Thomas, G; Philpott, DJ; Sansonetti, PJ			Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INVASIVE SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; CROHNS-DISEASE; FAMILY MEMBER; ACTIVATION; BINDING; SUSCEPTIBILITY; RECOGNITION; MUTATIONS	Nod2 activates the NF-kappaB pathway following intracellular stimulation by bacterial products. Recently, mutations in Nod2 have been shown to be associated with Crohn's disease, suggesting a role for bacteria-host interactions in the etiology of this disorder. We show here that Nod2 is a general sensor of peptidoglycan through the recognition of muramyl dipeptide (MDP), the minimal bioactive peptidoglycan motif common to all bacteria. Moreover, the 3020insC frameshift mutation, the most frequent Nod2 variant associated with Crohn's disease patients, fully abrogates Nod2-dependent detection of peptidoglycan and MDP. Together, these results impact on the understanding of Crohn's disease development. Additionally, the characterization of Nod2 as the first pathogen-recognition molecule that detects MDP will help to unravel the well known biological activities of this immunomodulatory compound.	Inst Pasteur, Grp Immunite Innee & Signalisat, F-75724 Paris 15, France; Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; CEPH, Fdn Jean Dausset, INSERM, U434, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm)	Philpott, DJ (corresponding author), Inst Pasteur, Grp Immunite Innee & Signalisat, 28 Rue Dr Roux, F-75724 Paris 15, France.		Chamaillard, Mathias/L-6542-2013; Boneca, Ivo G/H-1677-2014	Chamaillard, Mathias/0000-0002-0243-9717; Boneca, Ivo G/0000-0001-8122-509X				ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5; Atherton D., 1989, TECHNIQUES PROTEIN C, P273; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; CHEDID L, 1983, MICROBIOL IMMUNOL, V27, P723, DOI 10.1111/j.1348-0421.1983.tb00636.x; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SUMAROKA MV, 1991, FEBS LETT, V295, P48, DOI 10.1016/0014-5793(91)81381-H; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Vidal VF, 2001, EUR J IMMUNOL, V31, P1962, DOI 10.1002/1521-4141(200107)31:7<1962::AID-IMMU1962>3.0.CO;2-V; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200	27	1771	1860	1	116	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8869	8872		10.1074/jbc.C200651200	http://dx.doi.org/10.1074/jbc.C200651200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12527755	hybrid			2022-12-25	WOS:000181524000001
J	Servant, MJ; Grandvaux, N; tenOever, BR; Duguay, D; Lin, RT; Hiscott, J				Servant, MJ; Grandvaux, N; tenOever, BR; Duguay, D; Lin, RT; Hiscott, J			Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; GENE-EXPRESSION; KAPPA-B; IRF-3; INFECTION; PHOSPHORYLATION; INDUCTION; DISTINCT; TRANSACTIVATION; LOCALIZATION	The ubiquitously expressed latent interferon regulatory factor (IRF) 3 transcription factor is activated in response to virus infection by phosphorylation events that target a cluster of Ser/Thr residues, (382)GGA<(SS)under bar>LEN-TVDLHI (S) under barN (S) under bar HPL (S) under barL<(TS)under bar>DQY(408) at the C-terminal end of the protein. To delineate the minimal phosphoacceptor sites required for IRF-3 activation, several point mutations were generated and tested for transactivation potential and cAMP-response element-binding protein-binding protein/p300 coactivator association. Expression of the IRF-3 S396D mutant alone was sufficient to induce type I IFN beta, IFNalpha1, RANTES, and the interferon-stimulated gene 561 promoters. Using SDS-PAGE and immunoblotting with a novel phosphospecific antibody, we show for the first time that, in vivo, IRF-3 is phosphorylated on Ser(396) following Sendai virus infection, expression of viral nucleocapsid, and double-stranded RNA treatment. These results demonstrate that Ser(396) within the C-terminal Ser/Thr cluster is targeted in vivo for phosphorylation following virus infection and plays an essential role in IRF-3 activation. The inability of the phosphospecific antibody to detect Ser(396) phosphorylation in lipopolysaccharide-treated cells suggests that other major pathways may be involved in IRF-3 activation following Toll-like receptor 4 stimulation.	McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University; Lady Davis Institute; McGill University	Hiscott, J (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst, 3755 Cote Ste, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; O'Neill LAJ, 2002, MOL CELL, V10, P969, DOI 10.1016/S1097-2765(02)00754-2; Orr SL, 2000, J ENDOTOXIN RES, V6, P215, DOI 10.1179/096805100101532072; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Servant MJ, 2002, J INTERF CYTOK RES, V22, P49, DOI 10.1089/107999002753452656; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Sing A, 2000, INFECT IMMUN, V68, P1600, DOI 10.1128/IAI.68.3.1600-1607.2000; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; SUBARA W, 2002, J BIOL CHEM, V277, P22304; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M., 1997, Journal of Interferon and Cytokine Research, V17, pS53	40	185	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9441	9447		10.1074/jbc.M209851200	http://dx.doi.org/10.1074/jbc.M209851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524442	hybrid			2022-12-25	WOS:000181524000076
J	Albagli-Curiel, O				Albagli-Curiel, O			Ambivalent role of BCL6 in cell survival and transformation	ONCOGENE			English	Article						BCL6; B-cell lymphoma; germinal centre; cell survival; apoptosis	ZINC-FINGER PROTEIN; TUMOR-SUPPRESSOR GENE; NON-HODGKINS-LYMPHOMA; GERMINAL-CENTER FORMATION; ACID RECEPTOR-ALPHA; CENTER B-CELLS; SOMATIC HYPERMUTATION; PROMYELOCYTIC LEUKEMIA; GAGA FACTOR; TERMINAL DIFFERENTIATION	The BCL6 gene is often structurally altered and probably 'misregulated' in two different types of human B-cell non-Hodgkin lymphomas (BNHL) thought to arise from germinal centre B cells. BCL6 encodes a BTB/POZ and zinc finger protein whose biochemical properties support a role as a DNA-binding transcriptional repressor and disclose, in part, the underlying mechanisms. In contrast, the study of the 'oncogenic' structural alterations of BCL6 in BNHL and of its cellular functions gives rise to much more heterogeneous data with no obvious unifying picture so that how and even whether BCL6 contributes to lymphomagenesis remains unclear. This review will summarize the current knowledge about the 'oncogenic' alterations and cellular functions of BCL6 and, based on some results, will propose the following hypotheses: (1) In various systems, including in memory T cells and also in germinal centre B cells and possibly in certain postmitotic cells, BCL6 may act by stabilizing a particular stage of differentiation. (2) Both its ambivalent effects on cell survival and the heterogeneous consequences of its alterations in BNHL suggest that BCL6 can be oncogenic not only upon overexpression or persistent expression, as often proposed, but also, similar to some of its relatives, upon 'accidental' downregulation.	Inst Andre Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Albagli-Curiel, O (corresponding author), Inst Andre Lwoff, CNRS, UPR 1983, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.	olivier.albagli@ujf-grenoble.fr						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Arima M, 2002, J IMMUNOL, V169, P829, DOI 10.4049/jimmunol.169.2.829; Artiga MJ, 2002, AM J PATHOL, V160, P1371, DOI 10.1016/S0002-9440(10)62564-3; Badenhorst P, 2001, DEVELOPMENT, V128, P4093; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Busturia A, 2001, DEVELOPMENT, V128, P2163; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Cattoretti G., 1997, Blood, V90, p175A; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; Chen WY, 2001, GENE CHROMOSOME CANC, V32, P281, DOI 10.1002/gcc.1191; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; DAI MS, 2002, J BIOL CHEM, V1, P1; Dalla-Favera R, 1999, CURR TOP MICROBIOL, V246, P257; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dickson BJ, 1998, CURR BIOL, V8, pR90, DOI 10.1016/S0960-9822(98)70054-5; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2001, J IMMUNOL, V166, P6104, DOI 10.4049/jimmunol.166.10.6104; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Hosokawa Y, 2001, BIOCHEM BIOPH RES CO, V283, P563, DOI 10.1006/bbrc.2001.4820; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Huynh KD, 2000, GENE DEV, V14, P1810; ICHII H, 2002, NAT IMMUNOL, V20, P20; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kojima S, 2001, DEVELOPMENT, V128, P57; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; LEMERCIER C, 2002, J BIOL CHEM, V19, P19; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Licht JD, 1996, ONCOGENE, V12, P323; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2000, BLOOD, V95, P1400, DOI 10.1182/blood.V95.4.1400.004k43_1400_1405; Lossos IS, 2001, LEUKEMIA LYMPHOMA, V42, P1343, DOI 10.1080/10428190127508; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Nakamura Y, 1996, LEUKEMIA, V10, P658; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pasqualucci L, 2000, BLOOD, V96, p703A; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Rubin H, 2002, NAT BIOTECHNOL, V20, P675, DOI 10.1038/nbt0702-675; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TANG TT, 2002, J BIOL CHEM, V2, P2; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Ueda C, 2002, ONCOGENE, V21, P368, DOI 10.1038/sj.onc.1205099; Ueda C, 2002, BLOOD, V99, P2624, DOI 10.1182/blood-2001-11-0117; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang J, 1997, CANCER RES, V57, P351; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; Yoshida T, 1999, CARDIOVASC RES, V42, P670, DOI 10.1016/S0008-6363(99)00007-3; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642; Zan H, 2000, J IMMUNOL, V165, P830, DOI 10.4049/jimmunol.165.2.830; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zhang H, 2001, BBA-MOL CELL RES, V1540, P188, DOI 10.1016/S0167-4889(01)00128-8	99	50	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					507	516		10.1038/sj.onc.1206152	http://dx.doi.org/10.1038/sj.onc.1206152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555064				2022-12-25	WOS:000180538200004
J	Ramirez, RD; Herbert, BS; Vaughan, MB; Zou, Y; Gandia, K; Morales, CP; Wright, WE; Shay, JW				Ramirez, RD; Herbert, BS; Vaughan, MB; Zou, Y; Gandia, K; Morales, CP; Wright, WE; Shay, JW			Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells	ONCOGENE			English	Article						replicative senescence; epithelial cells; cell cycle; ageing; Cdk inhibitors	HUMAN-DIPLOID FIBROBLASTS; CELLULAR SENESCENCE; DNA-REPLICATION; G(1) ARREST; LIFE-SPAN; GROWTH; P16; P53; RB; IMMORTALIZATION	Many stimuli causing 'stress' or DNA damage in cells can produce phenotypes that overlap with telomere-based replicative senescence. In epithelial systems, the p16/RB pathway may function as a stress senescence-signaling pathway independent of telomere shortening. Overexpressing cyclin-dependent kinase 4 (Cdk4) in human epidermal keratinocytes and human mammary epithelial cells not only prevents the p16(INK4a)-associated premature growth arrest due to telomere-independent stress (e.g., inadequate culture conditions), but also bypasses the ensuing telomere-dependent senescence (M1). Overexpressed Cdk4 in epithelial cells induces a dramatic upregulation of p16(INK4a) and milder upregulation of p53 and p21(WAF1), which become unresponsive to UV irradiation. Despite the high levels of these checkpoint factors, Cdk4-overexpressing cells divide in an apparently normal regulated fashion, are able to respond to changes in calcium levels, retain the stem cell phenotype, and fully differentiate and stratify. These results suggest that the differentiation pathways in Cdk4-overexpressing cells remain intact.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Dallas Vet Affairs Med Ctr, Dept Internal Med, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ramirez, RD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	ruben.ramirez@utsouthwestern.edu	Vaughan, Melville B/J-6637-2016; Shay, Jerry W/F-7878-2011	Vaughan, Melville B/0000-0003-4648-6141; Zou, Ying/0000-0003-2787-1917	NIA NIH HHS [AG01228] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG001228, R01AG001228] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jarrard DF, 1999, CANCER RES, V59, P2957; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; PARENTEAU N, 1994, KERATINOCYTE METHODS, P45; Pavey S, 1999, CANCER RES, V59, P4185; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reddel RR, 2001, J CLIN INVEST, V108, P665, DOI 10.1172/JCI200113818; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shay Jerry W., 1994, Molecular and Cellular Differentiation, V2, P1; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; Stein GH, 1999, MOL CELL BIOL, V19, P2109; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	52	73	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					433	444		10.1038/sj.onc.1206046	http://dx.doi.org/10.1038/sj.onc.1206046			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545164				2022-12-25	WOS:000180379100012
J	La, P; Morgan, TA; Sykes, SM; Mao, H; Schnepp, RW; Petersen, CD; Hua, XX				La, P; Morgan, TA; Sykes, SM; Mao, H; Schnepp, RW; Petersen, CD; Hua, XX			Fusion proteins of retinoid receptors antagonize TGF-beta-induced growth inhibition of lung epithelial cells	ONCOGENE			English	Article						TGF-beta; retinoic acid; RXR beta; PLZF-RAR alpha; p15(ink4b)	ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; TREATED HL-60 CELLS; SMAD PROTEINS; INDUCED TRANSCRIPTION; FUNCTIONAL INTERACTIONS; INDUCED PHOSPHORYLATION; MOLECULAR PATHOGENESIS; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION	Transforming growth factor-beta1 (TGF-beta) is a growth factor that has multiple functions including potent inhibition of cell growth. TGF-beta signals by binding to its cell surface serine/threonine kinase receptors, which in turn phosphorylate downstream signal transducers, Smad2 and Smad3. Phosphorylated Smad2 and Smad3, together with Smad4, enter the nucleus and associate with various transcription factors. This complex of transcription factors regulates transcription of a diverse group of genes, leading to growth arrest at G1 phase. Through a functional expression cloning approach, a gag-retinoid X receptor beta (gag-RXRbeta) fusion protein was found to antagonize TGF-beta-induced growth inhibition of mink lung epithelial cells and the fusion between gag and RXRbeta is essential for resistance to the growth inhibition. Like gag-RXRbeta, the oncogenic PLZF-RARalpha fusion protein also antagonizes TGF-beta-induced growth inhibition, and the fusion between PLZF and RARalpha is essential for resistance to TGF-beta. Moreover, TGF-beta and retinoic acid (RA) cooperatively induce growth inhibition as well as transcription of the p15(inkb) gene, while PLZF-RARalpha represses TGF-beta-induced expression of the p15(ink4b) gene. Together, these results suggest that the TGF-beta and RA pathways cooperate to inhibit cell growth and that PLZF-RARalpha -mediated resistance to TGF-beta may facilitate the development of the PLZF-RARalpha-induced leukemia.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, XX (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [K01CA078592] Funding Source: NIH RePORTER; NCI NIH HHS [1K01CA78592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BATOVA A, 1992, CELL GROWTH DIFFER, V3, P763; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Borger DR, 2000, VIROLOGY, V270, P397, DOI 10.1006/viro.2000.0282; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DICKENS TA, 1993, BIOESSAYS, V15, P71, DOI 10.1002/bies.950150111; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FALK LA, 1991, BLOOD, V77, P1248; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hayes SA, 2001, CANCER RES, V61, P2112; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kim RH, 2000, GENE DEV, V14, P1605; Kishi H, 2001, CELL BIOL INT, V25, P1125, DOI 10.1006/cbir.2001.0795; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lardon F, 1996, LEUKEMIA, V10, P1937; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MEYSKENS FL, 1995, AM J CLIN NUTR, V62, P1417, DOI 10.1093/ajcn/62.6.1417S; MORALES TI, 1992, ARCH BIOCHEM BIOPHYS, V293, P79, DOI 10.1016/0003-9861(92)90368-7; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nunes I, 1996, CANCER RES, V56, P495; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1053/jhep.1997.v26.pm0009328313; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Onishi M, 1996, EXP HEMATOL, V24, P324; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; ROBERTS AB, 1992, CANCER SURV, V14, P205; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sambrook J, 1989, MOL CLONING; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Slack James L., 1999, Current Opinion in Oncology, V11, P9, DOI 10.1097/00001622-199901000-00003; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Valette A, 1990, GROWTH FACTORS, V2, P283, DOI 10.3109/08977199009078016; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	89	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					198	210		10.1038/sj.onc.1206100	http://dx.doi.org/10.1038/sj.onc.1206100			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527889				2022-12-25	WOS:000180322400005
J	Espanel, X; Walchli, S; Ruckle, T; Harrenga, A; Huguenin-Reggiani, M; van Huijsduijnen, RH				Espanel, X; Walchli, S; Ruckle, T; Harrenga, A; Huguenin-Reggiani, M; van Huijsduijnen, RH			Mapping of synergistic components of weakly interacting protein-protein motifs using arrays of paired peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; SIGNAL-REGULATED KINASE; YES-ASSOCIATED PROTEIN; INSULIN-RECEPTOR; CATALYTIC ACTIVATION; MEMBRANE SUPPORTS; MAP KINASES; SUBSTRATE; DOMAINS; BINDING	Protein-protein recognition usually involves multiple interactions among different motifs that are scattered over protein surfaces. To identify such weak interactions, we have developed a novel double peptide synthesis (DS) method. This method allows us to map protein-protein interactions that involve two linear discontinuous components from a polypeptide by the use of spatially addressable synergistic pairs of synthetic peptides. The DS procedure is based on the "SPOT" membrane-bound peptide synthesis technique, but to synthesize a mixture of two peptides, it uses both Fmoc (N-(9-fluorenyl)methoxycarbonyl))-alanine and Alloc-alanine at the first cycle. This allows their selective deprotection by either piperidine or tributyltin/palladium treatment, respectively. Using SPOT DS, we confirmed as a proof of principle that Elk-1 Ser(383) phosphorylation by ERK-2 kinase is stimulated by the presence of the Elk-1-docking domain. SPOT DS can also be used to dissect protein-protein motifs that define phosphatase substrate affinity. Using this technique, we identified three new regions in the insulin receptor that stimulate the dephosphorylation of the receptor by protein-tyrosine phosphatase (PTP) 1B and presumably increase the selectivity of PTP for this substrate. These data demonstrate that the SPOT DS technique allows the identification of non-linear weakly interacting protein motifs, which are an important determinant of protein, kinase and phosphatase substrate specificity and of protein-protein interactions in general.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland		van Huijsduijnen, RH (corresponding author), Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland.		van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424; Walchli, Sebastien/0000-0001-5869-1746				Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Dadke SS, 2000, BIOCHEM BIOPH RES CO, V274, P583, DOI 10.1006/bbrc.2000.3188; DANGLES O, 1987, J ORG CHEM, V52, P4984, DOI 10.1021/jo00231a027; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Espanel X, 2002, PROTEIN SCI, V11, P2326, DOI 10.1110/ps.0213402; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KRAMER A, 1993, PEPTIDE RES, V6, P314; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pawson T, 2000, GENE DEV, V14, P1027; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	20	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15162	15167		10.1074/jbc.M211887200	http://dx.doi.org/10.1074/jbc.M211887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12551909	hybrid			2022-12-25	WOS:000182516100075
J	Yegneswaran, S; Deguchi, H; Griffin, JH				Yegneswaran, S; Deguchi, H; Griffin, JH			Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein C with negatively charged phospholipid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR VA; ENERGY-TRANSFER; PROTHROMBIN ACTIVATION; FACTOR-XA; BINDING; FLUORESCENCE; SURFACE; SITE; PHOSPHATIDYLSERINE; INACTIVATION	The effect of glucosylceramide (GlcCer) on activated protein C (APC)-phospholipid interactions was examined using fluorescence resonance energy transfer. Human APC, labeled with either fluorescein (F1-APC) or dansyl (DEGR-APC) donor, bound to phosphatidylcholine/phosphatidylserine (PC/PS, 9:1 w/w) vesicles containing octadecylrhodamine (OR) acceptor with a K-d app = 16 mug/ml, whereas Fl-APC (or DEGR-APC) bound to PC/ PS/GlcCer(OR) (8:1:1) vesicles with a Kd app = 3 mug/ml. This 5-fold increase in apparent affinity was not species-specific since bovine DEGR-APC also showed a similar GlcCer-dependent enhancement of binding of APC to PC/PS vesicles. From the efficiency of fluorescence resonance energy transfer, distances of closest approach of similar to63 and similar to64 Angstrom were estimated between the dansyl on DEGR-APC and rhodamine in PC/PS/Glc-Cer(OR) and PC/PS(OR), respectively, assuming K-2 = 2/3. DEGR-APC bound to short chain C8-GIcCer with an apparent K-d of 460 nm. The presence of C8-GlcCer selectively enhanced the binding of C16,6-NBD-phosphatidylserine but not C16,6-7-nitrobenz-2-oxa-1,3-diazole (N-BD)-phosphatidylcholine to coumarin-labeled APC. These data suggest that APC binds to GlcCer, that PC/ PS/GlcCer vesicles like PUPS vesicles bind to the N-terminal gamma-carboxyglutamic acid domain of APC, and that one mechanism by which GlcCer enhances the activity of APC is by increasing its affinity for membrane surfaces containing negatively charged phospholipids.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM-180, La Jolla, CA 92037 USA.	jgriffin@scripps.edu		Griffin, John/0000-0002-4302-2547; Deguchi, Hiroshi/0000-0002-7721-1207	NCRR NIH HHS [M01-RR00833] Funding Source: Medline; NHLBI NIH HHS [HL52246, HL21544] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052246, R37HL052246, R01HL021544] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Deguchi H, 2002, J BIOL CHEM, V277, P8861, DOI 10.1074/jbc.M110252200; Deguchi H, 2001, BLOOD, V97, P1907, DOI 10.1182/blood.V97.7.1907; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; Esmon CT, 2001, CRIT CARE MED, V29, pS48, DOI 10.1097/00003246-200107001-00018; Fernandez JA, 2000, BLOOD CELL MOL DIS, V26, P115, DOI 10.1006/bcmd.2000.0285; Gilbert GE, 1997, BIOCHEMISTRY-US, V36, P10768, DOI 10.1021/bi970537y; Griffin JH, 1999, J CLIN INVEST, V103, P219, DOI 10.1172/JCI5006; Hackeng TM, 2000, BIOCHEM J, V349, P757, DOI 10.1042/bj3490757; HEMKER HC, 1967, NATURE, V215, P248, DOI 10.1038/215248a0; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; Koppaka V, 1996, BIOPHYS J, V70, P2930, DOI 10.1016/S0006-3495(96)79863-6; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8193, DOI 10.1021/bi960280o; LUNDBLAD RL, 1964, BIOCHEMISTRY-US, V3, P1720, DOI 10.1021/bi00899a022; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PAPAHADJOPOULOS D, 1964, BIOCHIM BIOPHYS ACTA, V90, P436, DOI 10.1016/0304-4165(64)90220-X; PEI G, 1993, J BIOL CHEM, V268, P3226; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Srivastava A, 2002, J BIOL CHEM, V277, P1855, DOI 10.1074/jbc.M105697200; STEVENSON KJ, 1982, THROMB RES, V26, P341, DOI 10.1016/0049-3848(82)90252-3; VANDERMEER BW, 1994, RESONANCE ENERGY TRA, P159; WEBER G, 1960, BIOCHEM J, V75, P335, DOI 10.1042/bj0750335; YE J, 1991, J BIOL CHEM, V266, P23016; Yegneswaran S, 1996, FASEB J, V10, P663; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1; YEGNESWARAN S, 1997, THESIS TEXAS A M U	42	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14614	14621		10.1074/jbc.M206746200	http://dx.doi.org/10.1074/jbc.M206746200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12560338	hybrid			2022-12-25	WOS:000182516100007
J	Albertsen, M; Bellahn, I; Kramer, R; Waffenschmidt, S				Albertsen, M; Bellahn, I; Kramer, R; Waffenschmidt, S			Localization and function of the yeast multidrug transporter Tpo1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR-MEMBRANE-VESICLES; SACCHAROMYCES-CEREVISIAE; POLYAMINE TRANSPORT; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; AMINO-ACIDS; GENE; RESISTANCE; IDENTIFICATION; SYSTEMS	In Saccharomyces cerevisiae four transporters, Tpo1p-Tpo4p, all members of the major facilitator superfamily, have been shown to confer resistance to polyamines. It was suggested that they act by pumping their respective substrate into the lumen of the vacuole depending on the proton gradient generated by the VATPase. Using sucrose gradient ultracentrifugation we found that an hemagglutinin (RA)-tagged Tpo1p as well as its HA-tagged Tpo2p-4p homologues co-localize with plasma membrane markers. Because the RA-tagged Tpo1p carrier protein proved to be functional in conferring resistance to polyamines in TPO1 knockouts, a function of Tpo1p in transport of polyamines across the plasma membrane seemed to be likely. The polyamine transport activity of wild type cells was compared with the respective activity of a TPO1 knockout strain. The results obtained strongly suggest that Tpo1p is a plasma membrane-bound exporter, involved in the detoxification of excess spermidine in yeast. When studying polyamine transport of wild type cells, we furthermore found that S. cerevisiae is excreting putrescine during the fermentative growth phase.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	University of Cologne	Waffenschmidt, S (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	waff@uni-koeln.de						BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; Bianchi MM, 1999, YEAST, V15, P513, DOI 10.1002/(SICI)1097-0061(199904)15:6<513::AID-YEA370>3.3.CO;2-G; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; Buziol S, 2002, FEMS YEAST RES, V2, P283, DOI 10.1016/S1567-1356(02)00113-7; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; Desmoucelles C, 2002, J BIOL CHEM, V277, P27036, DOI 10.1074/jbc.M111433200; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; Matta MAD, 2001, GENE, V272, P111, DOI 10.1016/S0378-1119(01)00558-3; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; PRICE NPJ, 1992, J CHROMATOGR, V598, P51, DOI 10.1016/0021-9673(92)85113-8; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SATO T, 1984, J BIOL CHEM, V259, P1505; Schiller D, 2000, J BACTERIOL, V182, P6247, DOI 10.1128/JB.182.21.6247-6249.2000; Sorin A, 1997, J BIOL CHEM, V272, P9895; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Teixeira MC, 2002, BIOCHEM BIOPH RES CO, V292, P530, DOI 10.1006/bbrc.2002.6691; TJANDRAWINATA RR, 1994, J IMMUNOL, V152, P3039; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; Woolridge DP, 1997, J BIOL CHEM, V272, P8864	29	59	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12820	12825		10.1074/jbc.M210715200	http://dx.doi.org/10.1074/jbc.M210715200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562762	hybrid			2022-12-25	WOS:000182189500031
J	Lin, SS; Manchester, JK; Gordon, JI				Lin, SS; Manchester, JK; Gordon, JI			Sip2, an N-myristoylated beta subunit of Snf1 kinase, regulates aging in Saccharomyces cerevisiae by affecting cellular histone kinase activity, recombination at rDNA loci, and silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SUBCELLULAR-LOCALIZATION; GLUCOSE REPRESSION; YEAST GENE; SIR2; ACTIVATION; PHOSPHORYLATION; LONGEVITY; SUBSTRATE; BINDING	Saccharomyces cerevisiae has evolved a number of mechanisms for sensing glucose. In the present study we examine the mechanism by which one of these pathways, involving Snf1, regulates cellular aging. Snf1 is a heterotrimer composed of a catalytic alpha subunit (Snf1p) that phosphorylates target proteins at Ser/Thr residues, an activating gamma subunit (Snf4p), and a beta subunit (Sip1p, Sip2p, or Gal83). We previously showed that forced expression of Snf1p or loss of Sip2p, but not the other 13 subunits, causes accelerated aging, while removal of Snf4p extends life span (Ashrafi, K., Lin, S. S., Manchester, J. K., and Gordon, J. I. (2000) Genes Dev. 14, 18721885). We now demonstrate that in wild type cells, there is an age-associated shift in Sip2p from the plasma membrane to the cytoplasm, a prominent redistribution of Snf4p from the plasma membrane to the nucleus, a modest increase in nuclear Snflp, and a concomitant increase in cellular Snf1 histone H3 kinase activity. Covalent attachment of myristate to the N-terminal Gly of Sip2p is essential for normal cellular life span. When plasma membrane association of Sip2p is abolished by a mutation that blocks its N-myristoylation, Snf4p is shifted to the nucleus. Rapidly aging sip2Delta cells have higher levels of histone H3 kinase activity than their generation-matched isogenic wild type counterparts. Increased Snf1 activity is associated with augmented recombination at rDNA loci, plus desilencing at sites affected by Snf1-catalyzed Ser(10) phosphorylation of historic H3 (the INO1 promoter plus targets of the transcription factor Adr1p). The rapid-aging phenotype of sip2Delta cells is fully rescued by blocking recombination at rDNA loci with a fob1Delta allele; rescue is not accompanied by amelioration of an age-associated shift toward gluconeogenesis and glucose storage. Together, these findings suggest that Sip2p acts as a negative regulator of nuclear Snf1 activity in young cells by sequestering its activating gamma subunit at the plasma membrane and that loss of Sip2p from the plasma membrane to the cytoplasm in aging cells facilities Snf4p entry into the nucleus so that Snf1 can modify chromatin structure.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu			NIAID NIH HHS [AI38200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Ashrafi K, 2000, GENE DEV, V14, P1872; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; BARBEHENN EK, 1976, ANAL BIOCHEM, V70, P554, DOI 10.1016/0003-2697(76)90482-6; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Farazi TA, 2000, BIOCHEMISTRY-US, V39, P15807, DOI 10.1021/bi002074t; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1111/j.1574-6976.2001.tb00574.x; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Lodge JK, 1998, J BIOL CHEM, V273, P12482, DOI 10.1074/jbc.273.20.12482; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MULLER I, 1971, ARCH MIKROBIOL, V77, P20, DOI 10.1007/BF00407985; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PASSONEAU JV, 1993, ENZYMATIC ANAL PRACT; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Young ET, 2002, J BIOL CHEM, V277, P38095, DOI 10.1074/jbc.M206158200	41	71	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13390	13397		10.1074/jbc.M212818200	http://dx.doi.org/10.1074/jbc.M212818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562756	hybrid			2022-12-25	WOS:000182189500101
J	Fourgeaud, L; Bessis, AS; Rossignol, F; Pin, JP; Olivo-Marin, JC; Hemar, A				Fourgeaud, L; Bessis, AS; Rossignol, F; Pin, JP; Olivo-Marin, JC; Hemar, A			The metabotropic glutamate receptor mGluR5 is endocytosed by a clathrin-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-2 MUSCARINIC ACETYLCHOLINE; SPLICE VARIANTS; LIPID RAFTS; G-PROTEINS; DYNAMIN; INTERNALIZATION; AGONIST; RAT; CAVEOLAE; EXPRESSION	Metabotropic glutamate receptors 5 (mGluR5) are members of the growing group C G protein-coupled receptor family. Widely expressed in mammalian brain, they are involved in modulation of the glutamate transmission. By means of transfection of mGluR5 receptors in COS-7 cells and primary hippocampal neurons in culture followed by immunocytochemistry and quantitative image analysis and by a biochemical assay, we have studied the internalization of mGluR5 splice variants. mGluR5a and -5b were endocytosed in COS-7 cells as well as in axons and dendrites of cultured neurons. Endocytosis occurred even in the absence of receptor activity, because receptors mutated in the glutamate binding site were still internalized as well as receptors in which endogenous activity had been inhibited by an inverse agonist. We have measured a constitutive rate of endocytosis of 11.7%/min for mGluR5a. We report for the first time the endocytosis pathway of mGluR5. Internalization of mGluR5 is not mediated by clathrin-coated pits. Indeed, inhibition of this pathway by Eps15 dominant negative mutants did not disturb their endocytosis. However, the large GTPase dynamin 2 is implicated in the endocytosis of mGluR5 in COS-7. mGluR5 is the first shown member of the group C G-protein coupled receptor family internalized by a nonconventional pathway.	Univ Bordeaux 2, Inst Francois Magendie, CNRS, Physiol Cellulaire Synapse UMR 5091, F-33077 Bordeaux, France; CNRS, CCIPE, Mecan Mol Commun Cellulaires UPR 9023, F-34094 Montpellier 5, France; Inst Pasteur, CNRS, Anal Images Quantitat URA 1947, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hemar, A (corresponding author), Univ Bordeaux 2, Inst Francois Magendie, CNRS, Physiol Cellulaire Synapse UMR 5091, Rue Camille St Saens, F-33077 Bordeaux, France.	ahemar@u-bordeaux2.fr	Olivo-Marin, Jean-Christophe/K-4428-2015; Pin, Jean-Philippe/Y-6668-2019	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; Pin, Jean-Philippe/0000-0002-1423-345X				Albasanz JL, 2002, MOL BRAIN RES, V99, P54; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Ango F, 2000, J NEUROSCI, V20, P8710; Becher A, 2001, J NEUROCHEM, V79, P787, DOI 10.1046/j.1471-4159.2001.00614.x; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Cinar H, 2001, BIOCHEMISTRY-US, V40, P14030, DOI 10.1021/bi011025t; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAUTRYVARSAT A, 2001, ENDOCYTOSIS, P27; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Doherty AJ, 1999, BIOCHEM J, V341, P415, DOI 10.1042/0264-6021:3410415; Francesconi A, 2002, J NEUROSCI, V22, P2196, DOI 10.1523/JNEUROSCI.22-06-02196.2002; Garrido JJ, 2001, EMBO J, V20, P5950, DOI 10.1093/emboj/20.21.5950; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Goslin K., 1991, CULTURING NERVE CELL, P251; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Hemar A, 1997, J NEUROSCI, V17, P9026; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Hubert GW, 2001, J NEUROSCI, V21, P1838, DOI 10.1523/JNEUROSCI.21-06-01838.2001; JOLY C, 1995, J NEUROSCI, V15, P3970; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Liu MT, 2000, J NEUROSCI, V20, P3200, DOI 10.1523/JNEUROSCI.20-09-03200.2000; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Martin-Negrier ML, 2000, NEUROSCIENCE, V99, P257, DOI 10.1016/S0306-4522(00)00187-1; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mundell SJ, 2001, J NEUROCHEM, V78, P546, DOI 10.1046/j.1471-4159.2001.00421.x; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Olivo-Marin JC, 2002, PATTERN RECOGN, V35, P1989, DOI 10.1016/S0031-3203(01)00127-3; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; Romano C, 1996, J COMP NEUROL, V367, P403, DOI 10.1002/(SICI)1096-9861(19960408)367:3<403::AID-CNE6>3.0.CO;2-9; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Roseberry AG, 2001, J CELL SCI, V114, P739; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; SUBTIL A, 1994, J CELL SCI, V107, P3461; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	63	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12222	12230		10.1074/jbc.M205663200	http://dx.doi.org/10.1074/jbc.M205663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529370	hybrid			2022-12-25	WOS:000182015700066
J	Henderson, C; Mizzau, M; Paroni, G; Maestro, R; Schneider, C; Brancolini, C				Henderson, C; Mizzau, M; Paroni, G; Maestro, R; Schneider, C; Brancolini, C			Role of caspases, bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) suberoylanilide hydroxamic acid and (SAHA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-CYCLE; ACTIVATION; CANCER; PROTEINS; DIFFERENTIATION; MITOCHONDRIA; APOPTOSOME; INDUCTION; MECHANISM	Histone deacetylase activity is potently inhibited by hydroaximc acid derivatives such as suberoylanilide hydroxamic acid (SARA) and trichostatin-A (TSA). These inhibitors specifically induce differentiation/apoptosis of transformed cells in vitro and suppress tumor growth in vivo. Because of its low toxicity, SARA is currently evaluated in clinical trials for the treatment of cancer. SARA and TSA induce apoptosis, which is characterized by mitochondrial stress, but so far, the critical elements of this apoptotic program remain poorly defined. To characterize in more detail this apoptotic program, we used human cell lines containing alterations in important elements of apoptotic response such as: p53, Bcl-2, caspase-9, and caspase-3. We demonstrate that caspase-9 is critical for apoptosis induced by SARA and TSA and that efficient proteolytic activation of caspase-2, caspase-8, and caspase-7 strictly depends on caspase-9. Bcl-2 efficiently antagonizes cytochrome c release and apoptosis in response to both histone deacetylase inhibitors. We provide evidences that translocation into the mitochondria of the Bcl-2 family member Bid depends on caspase-9 and that this translocation is a late event during TSA-induced apoptosis. We also demonstrate that the susceptibility to TSA- and SARA-induced cell death is regulated by p53.	Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, I-33100 Udine, Italy; Lab Nazl Consorzio Interuniv Biotecnol AREA, I-34142 Trieste, Italy; IRCCS, CRO, MMNP Unit Expt Oncol, Natl Canc Inst, I-33081 Aviano, PN, Italy; Univ Udine, MATI Ctr Excellence, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; IRCCS Aviano (CRO); University of Udine	Brancolini, C (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, P Kolbe 4, I-33100 Udine, Italy.	cbrancolini@makek.dstb.uniud.it	Maestro, Roberta/P-9748-2019; Paroni, Gabriela/J-4848-2018; Maestro, Roberta/M-1846-2015	Maestro, Roberta/0000-0002-6642-5592; Paroni, Gabriela/0000-0003-0132-0869; Maestro, Roberta/0000-0002-6642-5592; BRANCOLINI, Claudio/0000-0002-6597-5373				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Bouillet P, 2002, J CELL SCI, V115, P1567; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuvillier O, 1999, BLOOD, V94, P3583, DOI 10.1182/blood.V94.10.3583.422k31_3583_3592; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Liu JR, 2002, CANCER RES, V62, P924; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Medina V, 1997, CANCER RES, V57, P3697; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sawa H, 2001, Brain Tumor Pathol, V18, P109, DOI 10.1007/BF02479423; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang JX, 1999, CANCER RES, V59, P2766; Wang XD, 2001, GENE DEV, V15, P2922; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhu WG, 2001, CANCER RES, V61, P1327	51	143	152	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12579	12589		10.1074/jbc.M213093200	http://dx.doi.org/10.1074/jbc.M213093200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556448	hybrid			2022-12-25	WOS:000182015700111
J	Thannickal, VJ; Lee, DY; White, ES; Cui, Z; Larios, JM; Chacon, R; Horowitz, JC; Day, RM; Thomas, PE				Thannickal, VJ; Lee, DY; White, ES; Cui, Z; Larios, JM; Chacon, R; Horowitz, JC; Day, RM; Thomas, PE			Myofibroblast differentiation by transforming growth factor-beta 1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG FIBROBLASTS; SMOOTH MUSCLE ACTIN; FACTOR-BETA; EXTRACELLULAR-MATRIX; GRANULATION-TISSUE; WOUND CONTRACTION; GENE-EXPRESSION; GROWTH-FACTOR-BETA-1; INDUCTION; FIBROSIS	Myofibroblast differentiation and activation by transforming growth factor-beta1 (TGF-beta1) is a critical event in the pathogenesis of human fibrotic diseases, but regulatory mechanisms for this effect are unclear. In this report, we demonstrate that stable expression of the myofibroblast phenotype requires both TGF-beta1 and adhesion-dependent signals. TGF-beta1-induced myofibroblast differentiation of lung fibroblasts is blocked in non-adherent cells despite the preservation of TGF-beta receptor(s)-mediated signaling of Smad2 phosphorylation. TGF-beta1 induces tyrosine phosphorylation of focal adhesion kinase (FAK) including that of its autophosphorylation site, Tyr-397, an effect that is dependent on cell adhesion and is delayed relative to early Smad signaling. Pharmacologic inhibition of FAR or expression of kinase-deficient FAK, mutated by substituting Tyr-397 with Phe, inhibit TGF-beta1-induced alpha-smooth muscle actin expression, stress fiber formation, and cellular hypertrophy. Basal expression of a-smooth muscle actin is elevated in cells grown on fibronectin-coated dishes but is decreased on laminin and poly-D-lysine, a nonintegrin binding polypeptide. TGF-beta1 up-regulates expression of integrins and fibronectin, an effect that is associated with autophosphorylation/activation of FAK. Thus, a safer and more effective therapeutic strategy for fibrotic diseases characterized by persistent myofibroblast activation may be to target this integrin/FAK pathway while not interfering with tumor-suppressive functions of TGF-beta1/Smad signaling.	Univ Michigan, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, Ann Arbor, MI 48109 USA; Tufts Univ, New England Med Ctr, Div Pulm & Crit Care, Dept Med, Boston, MA 02111 USA	University of Michigan System; University of Michigan; Tufts Medical Center; Tufts University	Thannickal, VJ (corresponding author), Univ Michigan, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.			Horowitz, Jeffrey/0000-0002-1505-2837; White, Eric/0000-0003-4060-8443	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007749, R01HL067967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67967, T32 HL007749] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dugina V, 2001, J CELL SCI, V114, P3285; Finlay GA, 2000, J BIOL CHEM, V275, P27650; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEINO J, 1989, J BIOL CHEM, V264, P380; Hubbard R, 2000, AM J RESP CRIT CARE, V161, P5, DOI 10.1164/ajrccm.161.1.9906062; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Larios JM, 2001, J BIOL CHEM, V276, P17437, DOI 10.1074/jbc.M100426200; LIKE B, 1986, J BIOL CHEM, V261, P3426; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SAPPINO AP, 1990, LAB INVEST, V63, P144; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; SKALLI O, 1989, LAB INVEST, V60, P275; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wang QJ, 1999, THORAX, V54, P805, DOI 10.1136/thx.54.9.805; ZHANG K, 1994, AM J PATHOL, V145, P114	39	464	490	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12384	12389		10.1074/jbc.M208544200	http://dx.doi.org/10.1074/jbc.M208544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531888	hybrid			2022-12-25	WOS:000182015700086
J	Ching, YP; Wong, CM; Chan, SF; Leung, THY; Ng, DCH; Jin, DY; Ng, IOL				Ching, YP; Wong, CM; Chan, SF; Leung, THY; Ng, DCH; Jin, DY; Ng, IOL			Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GENOMIC INSTABILITY; CHROMOSOME 13Q; SAM DOMAIN; GENE; MUTATIONS; HETEROZYGOSITY; PATHWAYS; EFFECTOR; CDC42HS	Hepatocellular carcinoma (HCC) is a major malignancy in many parts of the world, especially in Asia and Africa. Loss of heterozygosity (LOH) on the long arm of chromosome 13 has been reported in HCC. In search of tumor suppressor genes in this region, here we have identified DLC2 (for deleted in liver cancer 2) at 13q12.3 encoding a novel Rho family GTPase-activating protein (GAP). DLC2 mRNA is ubiquitously expressed in normal tissues but was significantly underexpressed in 18% (8/45) of human HCCs. DLC2 is homologous to DLC1, a previously identified tumor suppressor gene at 8p22-p21.3 frequently deleted in HCC. DLC2 encodes a novel protein with a RhoGAP domain, a SAM (sterile alpha motif) domain related to p73/p63, and a lipid-binding StAR-related lipid transfer (START) domain. Biochemical analysis indicates that DLC2 protein has GAP activity specific for small GTPases RhoA and Cdc42. Expression of the GAP domain of DLC2 sufficiently inhibits the Rho-mediated formation of actin stress fibers. Introduction of human DLC2 into mouse fibroblasts suppresses Ras signaling and Ras-induced cellular transformation in a GAP-dependent manner. Taken together, our findings suggest a role for DLC2 in growth suppression and hepatocarcinogenesis.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China.	dyjin@hkucc.hku.hk; iolng@hku.hk	WONG, Chun-Ming/A-6739-2009; Ching, Yick Pang/C-4244-2009	WONG, Chun-Ming/0000-0002-2497-7858; CHING, Yick Pang/0000-0002-6461-8358; Ng, Irene Oi-lin/0000-0001-7532-2029				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1995, METHOD ENZYMOL, V256, P114; ANGEL P, 1989, New Biologist, V1, P35; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bosch FX, 1997, LIVER CANCER, P13; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kawai H, 2000, HEPATOLOGY, V31, P1246, DOI 10.1053/jhep.2000.7298; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Ng IOL, 2000, CANCER RES, V60, P6581; NG IOL, 1994, ONCOGENE, V9, P985; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SCORSONE KA, 1992, CANCER RES, V52, P1635; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wong CM, 2002, CLIN CANCER RES, V8, P2266; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wong N, 2000, HEPATOLOGY, V32, P1060, DOI 10.1053/jhep.2000.19349; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhou HJ, 2001, J BIOL CHEM, V276, P28933, DOI 10.1074/jbc.M103893200; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	53	154	159	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10824	10830		10.1074/jbc.M208310200	http://dx.doi.org/10.1074/jbc.M208310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531887	hybrid			2022-12-25	WOS:000181777500108
J	de Maturana, RL; Willshaw, A; Kuntzsch, A; Rudolph, R; Donnelly, D				de Maturana, RL; Willshaw, A; Kuntzsch, A; Rudolph, R; Donnelly, D			The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT INSULINOTROPIC POLYPEPTIDE; EXTRACELLULAR DOMAIN; HORMONE RECEPTOR; GENE-EXPRESSION; IN-VITRO; INCRETIN; AGONIST; DETERMINANTS; ANTAGONIST; FRAGMENT	Two fragments of the receptor for glucagon-like peptide-1 (GLP-1), each containing the N-terminal domain, were expressed and characterized in either bacterial or mammalian cells. The first fragment, rNT-TM1, included the N-terminal domain and first transmembrane helix and was stably expressed in the membrane of human embryonic kidney 293 cells. The second, 6H-rNT, consisted of only the N-terminal domain of the receptor fused with a polyhistidine tag at its N terminus. The latter fragment was expressed in Escherichia coli in the form of inclusion bodies from which the protein was subsequently purified and refolded in vitro. Although both receptor fragments displayed negligible 125 I-labeled GLP-1(7-36)amide-specific binding, they both displayed high affinity for the radiolabeled peptide antagonist I-125-exendin-4(9-39). Competition binding studies demonstrated that the N-terminal domain of the GLP-1 receptor maintains high affinity for the agonist exendin-4 as well as the antagonists exendin-4(3-39) and exendin-4(9-39) whereas, in contrast, GLP-1 affinity was greatly reduced. This study shows that although the exendin antagonists are not dependent upon the extracellular loops and transmembrane helices for maintaining their normal high affinity binding, the endogenous agonist GLP-1 requires regions outside of the N-terminal domain. Hence, distinct structural features in exendin-4, between residues 9 and 39, provide additional affinity for the N-terminal domain of the receptor. These data are consistent with a model for the binding of peptide ligands to the GLP-1 receptor in which the central and C-terminal regions of the peptides bind to the N terminus of the receptor, whereas the N-terminal residues of peptide agonists interact with the extracellular loops and transmembrane helices.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany	University of Leeds; Martin Luther University Halle Wittenberg	Donnelly, D (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Bldg, Leeds LS2 9JT, W Yorkshire, England.	D.Donnelly@leeds.ac.uk	Donnelly, Dan/O-5374-2015	Donnelly, Dan/0000-0001-6048-6995				AKERA T, 1977, BIOCHIM BIOPHYS ACTA, V470, P412, DOI 10.1016/0005-2736(77)90132-8; Andersen NH, 2002, BIOORGAN MED CHEM, V10, P79, DOI 10.1016/S0968-0896(01)00263-2; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chang XQ, 2001, MAGN RESON CHEM, V39, P477, DOI 10.1002/mrc.880; Chow BKC, 1997, RECEPT SIGNAL TRANS, V7, P143; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; de Maturana RL, 2002, FEBS LETT, V530, P244, DOI 10.1016/S0014-5793(02)03492-0; DeAlmeida VI, 1998, MOL ENDOCRINOL, V12, P750, DOI 10.1210/me.12.5.750; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FEHMANN HC, 1992, TRENDS ENDOCRIN MET, V3, P158, DOI 10.1016/1043-2760(92)90165-W; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GOKE R, 1993, J BIOL CHEM, V268, P19650; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; Hofmann BA, 2001, PROTEIN SCI, V10, P2050, DOI 10.1110/ps.12101; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; KAWAI K, 1989, ENDOCRINOLOGY, V124, P1768, DOI 10.1210/endo-124-4-1768; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; KREYMANN B, 1987, LANCET, V2, P1300; MCINTYRE N, 1964, LANCET, V2, P20, DOI 10.1016/s0140-6736(64)90011-x; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; MontroseRafizadeh C, 1997, J BIOL CHEM, V272, P21201, DOI 10.1074/jbc.272.34.21201; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210/en.139.11.4448; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; WETTERGREN A, 1993, DIGEST DIS SCI, V38, P665, DOI 10.1007/BF01316798; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; Xiao Q, 2000, J MOL ENDOCRINOL, V25, P321, DOI 10.1677/jme.0.0250321	38	90	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10195	10200		10.1074/jbc.M212147200	http://dx.doi.org/10.1074/jbc.M212147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524435	hybrid			2022-12-25	WOS:000181777500029
J	Lah, J; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Kinne, J; Wyns, L; Loris, R				Lah, J; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Kinne, J; Wyns, L; Loris, R			Recognition of the intrinsically flexible addiction antidote MazE by a dromedary single domain antibody fragment - Structure, thermodynamics of binding, stability, and influence on interactions with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HEAT-CAPACITY CHANGES; ESCHERICHIA-COLI; F-PLASMID; PROTEIN-STRUCTURE; TOXIN-ANTITOXIN; CCD OPERON; SYSTEM; ENERGETICS; AUTOREGULATION	The Escherichia coli mazEF operon defines a chromosomal addiction module that programs cell death under various stress conditions. It encodes the toxic and long-lived MazF and the labile antidote MazE. The denaturation of MazE is a two-state reversible dimer-monomer transition. At lower concentrations the denatured state is significantly populated. This leads to a new aspect of the regulation of MazE concentration, which may decide about the life and death of the cell. Interactions of MazE with a dromedary antibody domain, cAbMaz1 (previously used as a crystallization aid), as well as with promoter DNA were studied using microcalorimetric and spectroscopic techniques. Unique features of cAbMaz1 enable a specific enthalpy-driven recognition of MazE and, thus, a significant stabilization of its dimeric native conformation. The MazE dimer and the MazE dimer-cAbMaz1 complex show very similar binding characteristics with promoter DNA, i.e. three binding sites with apparent affinities in micromolar range and highly exothermic binding accompanied by large negative entropy contributions. A working model for the MazE-DNA assembly is proposed on the basis of the structural and binding data. Both binding and stability studies lead to a picture of MazE solution structure that is significantly more unfolded than the structure observed in a crystal of the MazE-cAbMaz1 complex.	Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia; Free Univ Brussels, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biol Mol, IL-91120 Jerusalem, Israel; Cent Vet Res Labs, Dubai, U Arab Emirates	University of Ljubljana; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Lah, J (corresponding author), Univ Ljubljana, Fac Chem & Chem Technol, Askerceva 5, Ljubljana 1000, Slovenia.		Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; Brady GP, 1997, BIOPHYS J, V72, P913, DOI 10.1016/S0006-3495(97)78725-3; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Cole JL, 2001, BIOCHEMISTRY-US, V40, P5633, DOI 10.1021/bi010085w; Couturier M, 1998, TRENDS MICROBIOL, V6, P269, DOI 10.1016/S0966-842X(98)01311-0; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; EBERL L, 1992, MOL MICROBIOL, V6, P1969, DOI 10.1111/j.1365-2958.1992.tb01370.x; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Engelberg-Kulka H, 2001, ASM NEWS, V67, P617; Ewert S, 2002, BIOCHEMISTRY-US, V41, P3628, DOI 10.1021/bi011239a; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FREIRE E, 1989, COMMENTS MOL CELL BI, V6, P123; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Green MC, 2000, CANCER TREAT REV, V26, P269, DOI 10.1053/ctrv.2000.0176; Gurney R.W., 1953, IONIC PROCESSES SOLU; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hazan R, 2001, J BACTERIOL, V183, P2046, DOI 10.1128/JB.183.6.2046-2050.2001; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Lah J, 2001, J PHYS CHEM B, V105, P1670, DOI 10.1021/jp002304d; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200; MASUDA Y, 1994, J BACTERIOL, V176, P5861, DOI 10.1128/JB.176.18.5861-5863.1994; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; Press W.H., 1992, NUMERICAL RECIPES, V2, P650; Privalov P L, 1986, Methods Enzymol, V131, P4; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rawlings DE, 1999, FEMS MICROBIOL LETT, V176, P269, DOI 10.1111/j.1574-6968.1999.tb13672.x; RUIZ-ECHEVARRIA M J, 1991, Molecular and General Genetics, V225, P335; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; Sat B, 2001, J BACTERIOL, V183, P2041, DOI 10.1128/JB.183.6.2041-2045.2001; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528	67	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14101	14111		10.1074/jbc.M209855200	http://dx.doi.org/10.1074/jbc.M209855200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12533537	hybrid			2022-12-25	WOS:000182405000071
J	Cabrera, R; Fischer, H; Trapani, S; Craievich, AF; Garratt, RC; Guixe, V; Babul, J				Cabrera, R; Fischer, H; Trapani, S; Craievich, AF; Garratt, RC; Guixe, V; Babul, J			Domain motions and quaternary packing of phosphofructokinase-2 from Escherichia coli studied by small angle X-ray scattering and homology modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE KINASE; ALLOSTERIC SITE; MUTANT ENZYME; PROTEINS; BINDING; RIBOKINASE; RESOLUTION; MECHANISM; COMPLEX; FAMILY	The binding of MgATP and fructose-6-phosphate to phosphofructokinase-2 from Escherichia coli induces conformational changes that result in significant differences in the x-ray-scattering profiles compared with the unligated form of the enzyme. When fructose-6-phosphate binds to the active site of the enzyme, the pair distribution function exhibits lower values at higher distances, indicating a more compact structure. Upon binding of MgATP to the allosteric site of the enzyme, the intensity at lower angles increases as a consequence of tetramer formation, but differences along higher angles also suggest changes at the tertiary structure level. We have used homology modeling to build the native dimeric form of phosphofructokinase-2 and fitted the experimental scattering curves by using rigid body movements of the domains in the model, similar to those observed in known homologous structures. The best fit with the experimental data of the unbound protein was achieved with open conformations of the domains in the model, whereas domain closure improves the agreement with the scattering of the enzyme-fructose-6-phosphate complex. Using the same approach, we utilized the scattering curve of the phosphofructokinase-2-MgATP complex to model the arrangement and conformation of dimers in the tetramer. We observed that, along with tetramerization, binding of MgATP to the allosteric site induces domain closure. Additionally, we used the. scattering data to restore the low resolution structure of phosphofructokinase-2 (free and bound forms) by an ab initio procedure. Based on these findings, a proposal is made to account for the inhibitory effect of MgATP on the enzymatic activity.	Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Univ Sao Paulo, Inst Fis, BR-01498 Sao Paulo, SP, Brazil; Univ Sao Paulo, Inst Fis Sao Carlos, BR-13560970 Sao Carlos, SP, Brazil	Universidad de Chile; Universidade de Sao Paulo; Universidade de Sao Paulo	Babul, J (corresponding author), Univ Chile, Fac Ciencias, Dept Biol, Casilla 653, Santiago, Chile.		Guixe, Victoria/I-1126-2013; Trapani, Stefano/AAB-6145-2022; garratt, richard c/F-6921-2011; Craievich, Aldo F/A-2852-2013; Fischer, Hannes/C-2215-2012	Guixe, Victoria/0000-0001-9643-1339; Craievich, Aldo F/0000-0002-5103-0248; Fischer, Hannes/0000-0003-2984-2028; Cabrera, Ricardo/0000-0002-8896-3172; Trapani, Stefano/0000-0002-2929-6306; garratt, richard/0000-0002-2016-3179				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BABUL J, 1978, J BIOL CHEM, V253, P4350; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Bevington PR, 1969, DATA REDUCTION ERROR; BORK P, 1993, PROTEIN SCI, V2, P31; Cabrera R, 2002, ARCH BIOCHEM BIOPHYS, V406, P289, DOI 10.1016/S0003-9861(02)00435-6; CAMPOS G, 1984, J BIOL CHEM, V259, P6147; DALDAL F, 1983, J MOL BIOL, V168, P285, DOI 10.1016/S0022-2836(83)80019-9; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P118; Guixe V, 1998, BIOCHEMISTRY-US, V37, P13269, DOI 10.1021/bi980576p; GUIXE V, 1988, ARCH BIOCHEM BIOPHYS, V264, P519, DOI 10.1016/0003-9861(88)90317-7; GUIXE V, 1985, J BIOL CHEM, V260, P1001; Guixe V, 2000, ARCH BIOCHEM BIOPHYS, V376, P313, DOI 10.1006/abbi.2000.1718; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; Ronimus RS, 2001, EXTREMOPHILES, V5, P357, DOI 10.1007/s007920100215; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1	29	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12913	12919		10.1074/jbc.M212137200	http://dx.doi.org/10.1074/jbc.M212137200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12527754	hybrid			2022-12-25	WOS:000182189500042
J	Chauhan, A; Turchan, J; Pocernich, C; Bruce-Keller, A; Roth, S; Butterfield, DA; Major, EO; Nath, A				Chauhan, A; Turchan, J; Pocernich, C; Bruce-Keller, A; Roth, S; Butterfield, DA; Major, EO; Nath, A			Intracellular human immunodeficiency virus tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; REGULATORY PROTEIN TAT; OXIDATIVE STRESS; HIV-1; CELLS; ACTIVATION; TRANSACTIVATION; MECHANISMS; DAMAGE; BRAIN	The human immunodeficiency virus (HM-Tat protein has been implicated in the neuropathogenesis of HrV infection. However, its role in modulating astroglial-neuronal relationships is poorly understood. Astrocyte infection with HIV has been associated with rapid progression of dementia. We thus initially transfected astrocytes with HIV proviral. DNA and confirmed Tat production in. these cells. Subsequently, using stably Tat-producing asytocyte cell lines, we observed that Tat promoted astrocyte survival by causing a prominent antioxidant effect and resistance to cell injury in these cells. Tat was released extracellularly where it could be taken up by other cells. Tat remained functionally active following uptake and caused long terminal repeat (LTR) transactivation in lymphocytic and astrocytic cell lines. Tat released from astrocytes caused mitochondrial dysfunction, trimming of neurites, and cell death in neurons. Tat neurotoxicity was attenuated by antiTat antibodies, kynurenate or heparan sulfate. The neurotoxic effects of Tat were caused at concentrations lower than that needed to cause LTR transactivation. When Tat-expressing cells were injected into the rat dentate gyrus, Tat was taken up by granule cells and transported along neuronal pathways to the CA3 region where it caused glial cell activation and neurotoxicity. The arginine-rich domain of Tat was essential for both the LTR transactivation and the neurotoxic properties of Tat. Thus HIV-Tat is a potent neurotoxin that may act at distant sites while at the same time it assures its production by preventing cell death in astrocytes where it is produced.	Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA; Univ Kentucky, Dept Chem Anat, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Kentucky; University of Kentucky; University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Nath, A (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, 600 N Wolfe St,Pathol 509, Baltimore, MD 21287 USA.		Bruce-Keller, Annadora/N-1954-2017		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002851, ZIANS002851] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barton CH, 1996, J GEN VIROL, V77, P1643, DOI 10.1099/0022-1317-77-8-1643; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Cheng J, 1998, NEUROSCIENCE, V82, P97, DOI 10.1016/S0306-4522(97)00174-7; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Dorsky DI, 1999, J ACQ IMMUN DEF SYND, V22, P213; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Foga IO, 1997, J ACQ IMMUN DEF SYND, V16, P223, DOI 10.1097/00042560-199712010-00001; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Hudson L, 2000, J NEUROVIROL, V6, P145, DOI 10.3109/13550280009013158; Johnston JB, 2001, ANN NEUROL, V49, P230, DOI 10.1002/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O; Koller H, 2001, EUR J NEUROSCI, V14, P1793, DOI 10.1046/j.0953-816x.2001.01808.x; KOLSON DL, 1994, J GEN VIROL, V75, P1927, DOI 10.1099/0022-1317-75-8-1927; Liu W, 2000, J CELL SCI, V113, P635; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MASLIAH E, 1992, LAB INVEST, V66, P285; Mori I, 1999, J NEUROVIROL, V5, P355, DOI 10.3109/13550289909029476; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1; NATH A, 1995, J NEUROPATH EXP NEUR, V54, P320, DOI 10.1097/00005072-199505000-00005; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Nicolini A, 2001, J NEUROCHEM, V79, P713, DOI 10.1046/j.1471-4159.2001.00568.x; Picklo MJ, 1999, J NEUROCHEM, V72, P1617, DOI 10.1046/j.1471-4159.1999.721617.x; Rappaport J, 1999, J LEUKOCYTE BIOL, V65, P458, DOI 10.1002/jlb.65.4.458; RUBEN S, 1989, J VIROL, V63, P1; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Turchan J, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-3; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Wilt SG, 2000, J NEUROSCI RES, V62, P440, DOI 10.1002/1097-4547(20001101)62:3<440::AID-JNR14>3.3.CO;2-D; Wu SY, 2002, NEOPLASIA, V4, P486, DOI 10.1038/sj.neo.7900264; Yang LP, 1997, VIROLOGY, V235, P48, DOI 10.1006/viro.1997.8672	43	142	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13512	13519		10.1074/jbc.M209381200	http://dx.doi.org/10.1074/jbc.M209381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551932	hybrid			2022-12-25	WOS:000182189500115
J	Corbit, KC; Trakul, N; Eves, EM; Diaz, B; Marshall, M; Rosner, MR				Corbit, KC; Trakul, N; Eves, EM; Diaz, B; Marshall, M; Rosner, MR			Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; NF-KAPPA-B; GROWTH-FACTOR ACTIVATION; CRYSTAL-STRUCTURE; PATHWAY; ZETA; PHOSPHORYLATION; SUPPRESSION; SCAFFOLD; COMPLEX	Protein kinase C (PKC) regulates activation of the Raf-1 signaling cascade by growth factors, but the mechanism by which this occurs has not been elucidated. Here we report that one mechanism involves dissociation of Raf kinase inhibitory protein (RKIP) from Raf-1. Classic and atypical but not novel PKC isoforms phosphorylate RKIP at serine 153 (Ser-153). RKIP Ser-153 phosphorylation by PKC either in vitro or in response to 12-O-tetradecanoylphorbol-13-acetate or epidermal growth factor causes release of RKIP from Raf-1, whereas mutant RKIP (S153V or S153E) remains bound. Increased expression of PKC can rescue inhibition of the mitogen-activated protein (MAP) kinase signaling cascade by wild-type but not mutant S153V RKIP. Taken together, these results constitute the first model showing how phosphorylation by PKC relieves a key inhibitor of the Raf/MAP kinase signaling cascade and may represent a general mechanism for the regulation of MAP kinase pathways.	Univ Chicago, Ben May Canc Inst Canc Res, Chicago, IL 60637 USA; Lilly Res Labs, Indianapolis, IN 46285 USA; Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago; Eli Lilly; University of Chicago; University of Chicago	Rosner, MR (corresponding author), Univ Chicago, Ben May Canc Inst Canc Res, 5841 S Maryland Ave, Chicago, IL 60637 USA.	m-rosner@uchicago.edu			NATIONAL CANCER INSTITUTE [T32CA009594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS038846] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09594] Funding Source: Medline; NIGMS NIH HHS [T32GM07151] Funding Source: Medline; NINDS NIH HHS [NS38846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Corbit KC, 2000, MOL CELL BIOL, V20, P5392, DOI 10.1128/MCB.20.15.5392-5403.2000; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Morrison DK, 2001, J CELL SCI, V114, P1609; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ojika K, 2000, PROG NEUROBIOL, V60, P37, DOI 10.1016/S0301-0082(99)00021-0; OJIKA K, 1992, BRAIN RES, V572, P164, DOI 10.1016/0006-8993(92)90465-L; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; Serre L, 2001, J MOL BIOL, V310, P617, DOI 10.1006/jmbi.2001.4784; Simister PC, 2002, ACTA CRYSTALLOGR D, V58, P1077, DOI 10.1107/S090744490200522X; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Yuasa H, 2001, DEV BRAIN RES, V127, P1, DOI 10.1016/S0165-3806(01)00097-9; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	42	275	302	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13061	13068		10.1074/jbc.M210015200	http://dx.doi.org/10.1074/jbc.M210015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551925	hybrid			2022-12-25	WOS:000182189500061
J	Tani, K; Shibata, M; Kawase, K; Kawashima, H; Hatsuzawa, K; Nagahama, M; Tagaya, M				Tani, K; Shibata, M; Kawase, K; Kawashima, H; Hatsuzawa, K; Nagahama, M; Tagaya, M			Mapping of functional domains of gamma-SNAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; NSF ATTACHMENT PROTEINS; MEMBRANE-FUSION; ALPHA-SNAP; ATPASE ACTIVITY; VESICULAR TRANSPORT; BINDING PROTEIN; COMPLEX; FAMILY; IDENTIFICATION	gamma-Soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein (gamma-SNAP) is capable of stabilizing a 20 S complex consisting of NSF, alpha-SNAP, and SNAP receptors (SNAREs), but its function in vesicular transport is not fully understood. Our two-hybrid analysis revealed that gamma-SNAP, unlike alpha-SNAP, interacts directly with NSF, as well as Gaf-1/Rip11, but not with SNAREs. Gaf1/Rip11 is a gamma-SNAP-associated factor that belongs to the Rab11-interacting protein family. To gain insight into the molecular basis for the interactions of gamma-SNAP with NSF and Gaf-1/Rip11, we determined the regions of the three proteins involved in protein-protein interactions. gamma-SNAP bound to NSF via its extreme C-terminal region, and the full-length NSF was needed to interact with gamma-SNAP. Both the N-terminal and C-terminal regions of gamma-SNAP were required for the binding to Gaf-1/Rip11. Gaf-1/Rip11 bound to gamma-SNAP via its C-terminal domain comprising a putative coiled-coil region. Although the C-terminal domain of Gaf-1/Rip11 also interacts with Rab11, the binding of gamma-SNAP and Rab11 to Gaf-1/Rip11 was not mutually exclusive. Rather, Gaf-1/Rip11 was capable of serving a link between gamma-SNAP and Rab11. A complex comprising gamma-SNAP and Gaf-1/Rip11 was disassembled in a process coupled to NSF-mediated ATP hydrolysis, suggesting that the interaction between gamma-SNAP and Gaf-1/Rip11 is of functional significance.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Tagaya, M (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan.							Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Chen D, 2001, J BIOL CHEM, V276, P13127, DOI 10.1074/jbc.M009424200; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Cullis DN, 2002, J BIOL CHEM, V277, P49158, DOI 10.1074/jbc.M206316200; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hatsuzawa K, 2000, J BIOL CHEM, V275, P13713, DOI 10.1074/jbc.275.18.13713; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Haynes LP, 1998, FEBS LETT, V436, P1, DOI 10.1016/S0014-5793(98)01088-6; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Mayer A, 2002, ANNU REV CELL DEV BI, V18, P289, DOI 10.1146/annurev.cellbio.18.032202.114809; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Meyers JM, 2002, J BIOL CHEM, V277, P49003, DOI 10.1074/jbc.M205728200; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Peter F, 1998, J CELL SCI, V111, P2625; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	40	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13531	13538		10.1074/jbc.M213205200	http://dx.doi.org/10.1074/jbc.M213205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12554740	hybrid			2022-12-25	WOS:000182189500117
J	Carroll, SS; Tomassini, JE; Bosserman, M; Getty, K; Stahlhut, MW; Eldrup, AB; Bhat, B; Hall, D; Simcoe, AL; LaFemina, R; Rutkowski, CA; Wolanski, B; Yang, ZC; Migliaccio, G; De Francesco, R; Kuo, LC; MacCoss, M; Olsen, DB				Carroll, SS; Tomassini, JE; Bosserman, M; Getty, K; Stahlhut, MW; Eldrup, AB; Bhat, B; Hall, D; Simcoe, AL; LaFemina, R; Rutkowski, CA; Wolanski, B; Yang, ZC; Migliaccio, G; De Francesco, R; Kuo, LC; MacCoss, M; Olsen, DB			Inhibition of hepatitis C virus RNA replication by 2 '-modified nucleoside analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA-2B PLUS RIBAVIRIN; INITIAL TREATMENT; NON-A; POLYMERASE; ELONGATION; INFECTION; NS5B	The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is essential for the replication of viral RNA and thus constitutes a valid target for the chemotherapeutic intervention of HCV infection. In this report, we describe the identification of 2'-substituted nucleosides as inhibitors of HCV replication. The 5'- triphosphates of 2'-C-methyladenosine and 2'-O-methylcytidine are found to inhibit NS5B-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate. NS5B is able to incorporate either nucleotide analog into RNA as determined with gel-based incorporation assays but is impaired in its ability to extend the incorporated analog by addition of the next nucleotide. In a subgenomic replicon cell line, 2-C-methyladenosine and 2'-O-methylcytidine inhibit HCV RNA replication. The 5'-triphosphates of both nucleosides are detected intracellularly following addition of the nucleosides to the media. However, significantly higher concentrations of 2'-C-methyladenosine triphosphate than 2'-O-methylcytidine triphosphate are detected, consistent with the greater potency of 2'-C-methyladenosine in the replicon assay, despite similar inhibition of NS5B by the triphosphates in the in vitro enzyme assays. Thus, the 2'-modifications of natural substrate nucleosides transform these molecules into potent inhibitors of HCV replication.	Merck Sharp & Dohme Ltd, Res Lab, Dept Biol Chem, West Point, PA 19486 USA; Merck Sharp & Dohme Ltd, Res Lab, Dept Biol Struct, West Point, PA 19486 USA; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, Roma, Italy; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Isis Pharmaceuticals Inc	Carroll, SS (corresponding author), Merck Sharp & Dohme Ltd, Res Lab, Dept Biol Chem, WP26-265, West Point, PA 19486 USA.	steve_carroll@merck.com	De Francesco, Raffaele/J-6003-2012	De Francesco, Raffaele/0000-0001-8754-5123; olsen, david/0000-0001-5521-0206				Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; Burgess K, 2000, CHEM REV, V100, P2047, DOI 10.1021/cr990045m; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; De Clercq E, 2001, J CLIN VIROL, V22, P73, DOI 10.1016/S1386-6532(01)00167-6; DeFrancesco R, 1996, METHOD ENZYMOL, V275, P58; Franchetti P, 1998, J MED CHEM, V41, P1708, DOI 10.1021/jm9707737; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229; OHNO Y, 1989, CANCER RES, V49, P2077; OHNO Y, 1988, CANCER RES, V48, P1494; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; WALTON E, 1969, J MED CHEM, V12, P306, DOI 10.1021/jm00302a025; Wang TSF, 1995, METHOD ENZYMOL, V262, P77; Wright M, 2001, ANTIVIR CHEM CHEMOTH, V12, P201, DOI 10.1177/095632020101200401; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	30	286	337	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11979	11984		10.1074/jbc.M210914200	http://dx.doi.org/10.1074/jbc.M210914200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12554735	hybrid			2022-12-25	WOS:000182015700035
J	da Costa, CA; Mattson, MP; Ancolio, K; Checler, F				da Costa, CA; Mattson, MP; Ancolio, K; Checler, F			The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; ENDOPLASMIC-RETICULUM; PARKINSONS-DISEASE; NEURONAL CELLS; APP-ALPHA; WILD-TYPE; CLEAVAGE; BETA	Mutations on presenilins are responsible for most of familial forms of Alzheimer's disease. These holoproteins undergo rapid maturation by presenilinase mainly in the endoplasmic reticulum, leading to the production of N- and C-terminal fragments. We show first that overexpression of the presenilinase-derived maturation product of presenilin 2 (CTF-PS2) increases Abeta recovery, the production of which is almost abolished by a caspase 3 inhibitor and increased by staurosporine. This and the observation that the apoptotic inducer staurosporine enhances CTF-PS2 degradation clearly link CTF-PS2 to apoptotic cascade effectors. This prompted us to analyze the putative ability of CTF-PS2 to modulate cell death. CTF-PS2 overexpression decreases cell viability and augments both caspase 3 activity and immunoreactivity. This is accompanied by lowered bcl2-like immunoreactivity and increased poly(ADP-ribose) polymerase cleavage and cytochrome c translocation into the cytosol. Interestingly, CTF-PS2-induced caspase 3 activation is prevented by pifithrin-alpha, a selective blocker of p53 transcriptional activity. On line with the latter data, CTF-PS2 drastically increases p53 immunoreactivity and transcriptional activity. Of most interest is our observation that CTF-PS2 expression also triggers increased caspase 3 activity and immunoreactivity in fibroblasts in which presenilins had been deleted. Therefore, CTF-PS2 could modulate cell death out of the NTF/CTF heterodimeric complex thought to correspond to the biologically functional entity. This is the first direct demonstration that CTF-PS2 could exhibit some of its functions in the absence of the presenilin 2 N-terminal fragment (NTF-PS2) counterpart derived from the presenilinase cleavage.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, F-06560 Valbonne, France; NIA, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, 660 Route des Lucioles,Sophia Antipolis, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; Mattson, Mark P/F-6038-2012; da Costa, Cristine Alves/G-8075-2011	Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X	NATIONAL INSTITUTE ON AGING [Z01AG000312, ZIAAG000312, Z01AG000313, ZIAAG000317, ZIAAG000313, Z01AG000317] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Baumann K, 1997, NEUROBIOL AGING, V18, P181, DOI 10.1016/S0197-4580(97)00004-3; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Checler F, 1999, MOL NEUROBIOL, V19, P255, DOI 10.1007/BF02821716; Checler F, 1999, IUBMB LIFE, V48, P33, DOI 10.1080/152165499307396; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; da Costa CA, 1999, MOL MED, V5, P160, DOI 10.1007/BF03402059; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Marambaud P, 1998, BIOCHEM BIOPH RES CO, V252, P134, DOI 10.1006/bbrc.1998.9619; Mattson MP, 1998, J NEUROCHEM, V70, P1; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shirotani K, 1997, BIOCHEM BIOPH RES CO, V240, P728, DOI 10.1006/bbrc.1997.7730; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Ward RV, 1996, NEURODEGENERATION, V5, P293, DOI 10.1006/neur.1996.0040; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710	38	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12064	12069		10.1074/jbc.M212379200	http://dx.doi.org/10.1074/jbc.M212379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556443	hybrid			2022-12-25	WOS:000182015700046
J	Girrbach, V; Strahl, S				Girrbach, V; Strahl, S			Members of the evolutionarily conserved PMT family of protein O-mannosyltransferases form distinct protein complexes among themselves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PATHOGEN CANDIDA-ALBICANS; SACCHAROMYCES-CEREVISIAE; MANNOSYL-TRANSFERASE; ENDOPLASMIC-RETICULUM; SHUTTLE VECTORS; GENE FAMILY; YEAST; GLYCOSYLATION; PURIFICATION	Protein O-mannosyltransferases (PMTs) initiate the assembly of O-mannosyl glycans, an essential protein modification. Since PMTs are evolutionarily conserved in fungi but are absent in green plants, the PMT family is a putative target for new antifungal drugs, particularly in fighting the threat of phytopathogenic fungi. The PMT family is phylogenetically classified into PMT1, PMT2, and PMT4 subfamilies, which differ in protein substrate specificity. In the model organism Saccharomyces cerevisiae as well as in many other fungi the PMT family is highly redundant, and only the simultaneous deletion of PMT1/PMT2 and PMT4 subfamily members is lethal. In this study we analyzed the molecular organization of PMT family members in S. cerevisiae. We show that members of the PMT1 subfamily (Pmt1p and Pmt5p) interact in pairs with members of the PMT2 subfamily (Pmt2p and Pmt3p) and that Pmt1p-Pmt2p and Pmt5p-Pmt3p complexes represent the predominant forms. Under certain physiological conditions, however, Pmt1p interacts also with Pmt3p, and Pmt5p with Pmt2p, suggesting a compensatory cooperation that guarantees the maintenance of O-mannosylation. Unlike the PMT1/PMT2 subfamily members, the single member of the PMT4 subfamily (Pmt4p) acts as a homomeric complex. Using mutational analyses we demonstrate that the same conserved protein domains underlie both heteromeric and homomeric interactions, and we identify an invariant arginine residue of transmembrane domain two as essential for the formation and/or stability of PMT complexes in general. Our data suggest that protein-protein interactions between the PMT family members offer a point of attack to shut down overall protein O-mannosylation in fungi.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Strahl, S (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany.	sabine.strahlbolsinger@biologie.uni-regensburg.de						Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Ernst JF, 2001, MED MYCOL, V39, P67, DOI 10.1080/714031008; FRANK C, 2000, THESIS U REGENSBURY; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girrbach V, 2000, J BIOL CHEM, V275, P19288, DOI 10.1074/jbc.M001771200; Harlow E., 1988, ANTIBODIES LAB MANUA; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kaiser C., 1994, METHODS YEAST GENETI; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; LARRIBA G, 1976, FEBS LETT, V71, P316, DOI 10.1016/0014-5793(76)80960-X; Lodder AL, 1999, GENETICS, V152, P1487; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Mrsa V, 1997, YEAST, V13, P1145; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Ponting CP, 2000, TRENDS BIOCHEM SCI, V25, P48; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders SL, 1999, J CELL BIOL, V145, P1177, DOI 10.1083/jcb.145.6.1177; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; Timpel C, 2000, J BACTERIOL, V182, P3063, DOI 10.1128/JB.182.11.3063-3071.2000; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Truernit E, 1996, PLANT CELL, V8, P2169, DOI 10.1105/tpc.8.12.2169; Willer T, 2002, GLYCOBIOLOGY, V12, P771, DOI 10.1093/glycob/cwf086; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	53	118	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12554	12562		10.1074/jbc.M212582200	http://dx.doi.org/10.1074/jbc.M212582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551906	hybrid			2022-12-25	WOS:000182015700108
J	Ulloa, F; Real, FX				Ulloa, F; Real, FX			Benzyl-N-acetyl-alpha-D-galactosaminide induces a storage disease-like phenotype by perturbing the endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID; INTRACELLULAR-TRANSPORT; SUCRASE-ISOMALTASE; MATURE LYSOSOMES; HT-29; CELLS; GLYCOSYLATION; CANCER; GALNAC; MUCINS	The sugar analog O-benzyl-N-acetyl-alpha-D-galactosaminide (BG) is an inhibitor of glycan chain elongation and inhibits alpha2,3-sialylation in mucus-secreting HT-29 cells. Long-term exposure of these cells to BG is associated with the accumulation of apical glycoproteins in cytoplasmic vesicles. The mechanisms involved therein and the nature of the vesicles have not been elucidated. In these cells, a massive amount of BG metabolites is synthesized. Because sialic acid is mainly distributed apically in epithelial cells, it has been proposed that the BG-induced undersialylation of apical membrane glycoproteins is responsible for their intracellular accumulation due to a defect in anterograde traffic and that sialic acid may constitute an apical targeting signal. In this work, we demonstrate that the intracellular accumulation of membrane glycoproteins does not result mainly from defects in anterograde traffic. By contrast, in BG-treated cells, endocytosed membrane proteins were retained intracellularly for longer periods of time than in control cells and colocalized with accumulated MUC1 and beta(1) integrin in Rab7/lysobisphosphatidic acid(+) vesicles displaying features of late endosomes. The phenotype of BG-treated cells is reminiscent of that observed in lysosomal storage disorders. Sucrose induced a BG-like, lysosomal storage disease-like phenotype without affecting sialylation, indicating that undersialylation is not a requisite for the intracellular accumulation of membrane glycoproteins. Our findings strongly support the notion that the effects observed in BG-treated cells result from the accumulation of BG-derived metabolites and from defects in the endosomal pathway. We propose that abnormal subcellular distribution of membrane glycoproteins involved in cellular communication and/or signaling may also take place in lysosomal storage disorders and may contribute to their pathogenesis.	Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Celular & Mol, Barcelona 08003, Spain	Pompeu Fabra University	Real, FX (corresponding author), Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Celular & Mol, Barcelona 08003, Spain.	preal@imim.es	Arribas, Francisco X Real/H-5275-2015; Ulloa, Fausto/AAB-2787-2019	Arribas, Francisco X Real/0000-0001-9501-498X; 				AITSLIMANE T, 2000, EXP CELL RES, V258, P184; Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; Delannoy P, 1996, GLYCOCONJUGATE J, V13, P717, DOI 10.1007/BF00702335; DIIULIO NA, 1995, GLYCOBIOLOGY, V5, P195; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Franci C, 1996, BIOCHEM J, V314, P33, DOI 10.1042/bj3140033; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gouyer V, 2001, J CELL SCI, V114, P1455; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; HUET G, 1995, J CELL SCI, V108, P1275; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Karageorgos LE, 1997, EXP CELL RES, V234, P85, DOI 10.1006/excr.1997.3581; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LEBIVIC A, 1993, J BIOL CHEM, V268, P6909; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; MCILHINNEY RAJ, 1985, BIOCHEM J, V227, P155, DOI 10.1042/bj2270155; MERESSE S, 1995, J CELL SCI, V108, P3349; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Schmid JA, 1999, J BIOL CHEM, V274, P19063, DOI 10.1074/jbc.274.27.19063; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; TIETZE F, 1989, J BIOL CHEM, V264, P15316; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; Ulloa F, 2001, J HISTOCHEM CYTOCHEM, V49, P501, DOI 10.1177/002215540104900410; Ulloa F, 2000, J BIOL CHEM, V275, P18785, DOI 10.1074/jbc.M000510200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki A., 1999, ESSENTIALS GLYCOBIOL; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; VILA MR, 1995, LAB INVEST, V72, P395; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Zanetta JP, 2000, GLYCOBIOLOGY, V10, P565, DOI 10.1093/glycob/10.6.565	50	16	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12374	12383		10.1074/jbc.M211909200	http://dx.doi.org/10.1074/jbc.M211909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538583	hybrid			2022-12-25	WOS:000182015700085
J	Kay, CWM; Schleicher, E; Kuppig, A; Hofner, H; Rudiger, W; Schleicher, M; Fischer, M; Bacher, A; Weber, S; Richter, G				Kay, CWM; Schleicher, E; Kuppig, A; Hofner, H; Rudiger, W; Schleicher, M; Fischer, M; Bacher, A; Weber, S; Richter, G			Blue light perception in plants - Detection and characterization of a light-induced neutral flavin radical in a C450A mutant of phototropin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	13th International Symposium on Flavins and Flavoproteins	AUG 29-SEP 04, 1999	CONSTANCE, GERMANY				ELECTRON-PARAMAGNETIC-RESONANCE; NUCLEAR DOUBLE-RESONANCE; ACTIN-BINDING PROTEIN; COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; FLASH-PHOTOLYSIS; PHOTORECEPTOR PHOTOTROPIN; CHLOROPLAST RELOCATION; ARABIDOPSIS NPH1; AMINO-ACIDS	The LOV2 domain of Avena sativa phototropin and its C450A mutant were expressed as recombinant fusion proteins and were examined by optical spectroscopy, electron paramagnetic resonance, and electron-nuclear double resonance. Upon irradiation (420-480 nm), the LOV2 C450A mutant protein gave an optical absorption spectrum characteristic of a flavin radical even in the absence of exogenous electron donors, thus demonstrating that the flavin mononucleotide (FMN) cofactor in its photogenerated triplet state is a potent oxidant for redox-active amino acid residues within the LOV2 domain. The FMN radical in the LOV2 C450A mutant is N(5)-protonated, suggesting that the local pH close to the FMN is acidic enough so that the cysteine residue in the wild-type protein is likely to be also protonated. An electron paramagnetic resonance analysis of the photogenerated FMN radical gave information on the geometrical and electronic structure and the environment of the FMN cofactor. The experimentally determined hyperfine couplings of the FMN radical point to a highly restricted delocalization of the unpaired electron spin in the isoalloxazine moiety. In the light of these results a possible radical-pair mechanism for the formation of the FMN-C(4a)-cysteinyl adduct in LOV domains is discussed.	Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany; Univ Munich, Inst Zellbiol, D-80336 Munich, Germany	Free University of Berlin; Technical University of Munich; University of Munich; University of Munich	Richter, G (corresponding author), Free Univ Berlin, Inst Expt Phys, Arnimallee 14, D-14195 Berlin, Germany.		Richter, Gerald/F-3642-2011; Fischer, Markus/AFT-1856-2022; Kay, Christopher William Michael/C-2467-2008; Schleicher, Erik/C-9951-2010; Fischer, Markus/H-2870-2012; Weber, Stefan/G-6164-2010; Fischer, Markus J./G-9477-2012	Fischer, Markus/0000-0001-7243-4199; Kay, Christopher William Michael/0000-0002-5200-6004; Schleicher, Erik/0000-0003-2953-050X				BATCHELOR SN, 1993, J PHYS CHEM-US, V97, P4570, DOI 10.1021/j100120a002; Briggs WR, 2001, PLANT CELL, V13, P993, DOI 10.1105/tpc.13.5.993; Briggs WR, 2001, PLANT PHYSIOL, V125, P85, DOI 10.1104/pp.125.1.85; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARRINGTON A, 1967, INTRO MAGNETIC RESON, P103; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2002, PLANT CELL, V14, P1067, DOI 10.1105/tpc.010475; Devlin PF, 1999, TRENDS CELL BIOL, V9, P295, DOI 10.1016/S0962-8924(99)01611-6; Devlin PF, 2001, ANNU REV PHYSIOL, V63, P677, DOI 10.1146/annurev.physiol.63.1.677; EDMONDSON DE, 1983, TOP CURR CHEM, V108, P109; EDMONDSON DE, 1985, BIOCHEM SOC T, V13, P593, DOI 10.1042/bst0130593; Frisch M. J., 1998, GAUSSIAN 98 VERSION; Fuchs MR, 2002, J PHYS CHEM B, V106, P8885, DOI [10.1021/jp0259869, 10.1021/jpO259869]; Gindt YM, 1999, BIOCHEMISTRY-US, V38, P3857, DOI 10.1021/bi981191+; HEELIS PF, 1979, BIOCHIM BIOPHYS ACTA, V587, P455, DOI 10.1016/0304-4165(79)90449-5; HEELIS PF, 1979, PHOTOBIOCH PHOTOBIOP, V1, P63; HEELIS PF, 1986, BIOCHEMISTRY-US, V25, P8163, DOI 10.1021/bi00373a006; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Holzer W, 2002, PHOTOCHEM PHOTOBIOL, V75, P479, DOI 10.1562/0031-8655(2002)075<0479:SCOFMB>2.0.CO;2; HORSFIELD A, 1961, MOL PHYS, V4, P425, DOI 10.1080/00268976100100591; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Iwata T, 2002, J AM CHEM SOC, V124, P11840, DOI 10.1021/ja020834c; Jarillo JA, 2001, NATURE, V410, P952, DOI 10.1038/35073622; Kagawa T, 2001, SCIENCE, V291, P2138, DOI 10.1126/science.291.5511.2138; Kay CWM, 1999, BIOCHEMISTRY-US, V38, P16740, DOI 10.1021/bi991442u; Kinoshita T, 2001, NATURE, V414, P656, DOI 10.1038/414656a; KURRECK H, 1984, J AM CHEM SOC, V106, P737, DOI 10.1021/ja00315a048; Lin CT, 2000, TRENDS PLANT SCI, V5, P337, DOI 10.1016/S1360-1385(00)01687-3; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; Losi A, 2002, BIOPHYS J, V82, P2627, DOI 10.1016/S0006-3495(02)75604-X; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MCLAUCHLAN KA, 1991, MOL PHYS, V73, P241, DOI 10.1080/00268979100101181; MEDINA M, 1994, EUR J BIOCHEM, V222, P941, DOI 10.1111/j.1432-1033.1994.tb18943.x; MILLER SM, 1990, BIOCHEMISTRY-US, V29, P2831, DOI 10.1021/bi00463a028; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Pierre JL, 1999, BIOMETALS, V12, P195, DOI 10.1023/A:1009252919854; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; Sakai M, 1996, J MOL STRUCT, V379, P9, DOI 10.1016/0022-2860(95)09176-9; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHREINER S, 1975, PHOTOCHEM PHOTOBIOL, V21, P81, DOI 10.1111/j.1751-1097.1975.tb06632.x; SCHREINER S, 1976, FLAVINS FLAVOPROTEIN, P793; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; SONG PS, 1968, PHOTOCHEM PHOTOBIOL, V7, P311, DOI 10.1111/j.1751-1097.1968.tb08018.x; Stoeckelhuber M, 1996, J CELL SCI, V109, P1825; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; Sun JF, 2002, INORG CHIM ACTA, V336, P39, DOI 10.1016/S0020-1693(02)00876-9; Swartz TE, 2001, J BIOL CHEM, V276, P36493, DOI 10.1074/jbc.M103114200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; TOLLIN G, 1995, J BIOENERG BIOMEMBR, V27, P303, DOI 10.1007/BF02110100; TRABER R, 1982, BIOCHEMISTRY-US, V21, P1687, DOI 10.1021/bi00536a033; Weber S, 2002, P NATL ACAD SCI USA, V99, P1319, DOI 10.1073/pnas.032469399; Weber S, 2001, BIOPHYS J, V81, P1195, DOI 10.1016/S0006-3495(01)75777-3; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	63	106	111	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10973	10982		10.1074/jbc.M205509200	http://dx.doi.org/10.1074/jbc.M205509200			10	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525505	hybrid			2022-12-25	WOS:000181855400015
J	Liu, XB; Singh, BB; Ambudkar, IS				Liu, XB; Singh, BB; Ambudkar, IS			TRPC1 is required for functional store-operated Ca2+ channels - Role of acidic amino acid residues in the S5-S6 region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINUS; RELEASE; PROTEIN; CAT1; ENTRY; EXPRESSION; RETICULUM; DEPLETION; SUBUNIT; FAMILY	The exact role of TRPC1 in store-operated calcium influx channel (SOCC) function is not known. We have examined the effect of overexpression of full-length TRPC1, depletion of endogenous TRPC1, and expression of TRPC1 in which the proposed pore region (S5-S6, amino acids (aa) 557-620) was deleted or modified by site-directed mutagenesis on thapsigargin- and carbachol-stimulated SOCC activity in HSG. cells. TRPC1 overexpression induced channel activity that was indistinguishable from the endogenous SOCC activity. Transfection with antisense hTRPC1 decreased SOCC activity although characteristics of SOCC-mediated current, I-SOC, were not altered. Expression of TRPC1Delta567-793, but not TRPC1Delta664-793, induced a similar decrease in SOCC activity. Furthermore, TRPC1Delta567-793 was coimmunoprecipitated with endogenous TRPC1. Simultaneous substitutions of seven acidic as in the S5-S6 region (Asp --> Asn and Glu --> Gln) decreased SOCC-mediated Ca2+, but not Na+, current and induced a left shift in E-rev. Similar effects were induced by E576K or D581K, but not D581N or E615K, substitution. Furthermore, expressed TRPC1 proteins interacted with each other. Together, these data demonstrate that TRPC1 is required for generation of functional SOCC in HSG cells. We suggest that TRPC1 monomers co-assemble to form SOCC and that specific acidic as residues in the proposed pore region of TRPC1 contribute to Ca2+ influx.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov		Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Antoniotti S, 2002, FEBS LETT, V510, P189, DOI 10.1016/S0014-5793(01)03256-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; ENGELKE M, 2002, FEBS LETT, V17, P523; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MONTELL C, 2001, SCIENCE STKE; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; PUTNEY JW, 1990, PHARMACOL THERAPEUT, V48, P427, DOI 10.1016/0163-7258(90)90059-B; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	37	145	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11337	11343		10.1074/jbc.M213271200	http://dx.doi.org/10.1074/jbc.M213271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536150	hybrid			2022-12-25	WOS:000181855400061
J	Kunzmann, S; Wohlfahrt, JG; Itoh, S; Asao, H; Komada, M; Akdis, CA; Blaser, K; Schmidt-Weber, CB				Kunzmann, S; Wohlfahrt, JG; Itoh, S; Asao, H; Komada, M; Akdis, CA; Blaser, K; Schmidt-Weber, CB			SARA and Hgs attenuate susceptibility to TGF-beta 1-mediated T cell suppression	FASEB JOURNAL			English	Article						SARA; Hgs; TGF-beta 1; CD4(+) T cells; T cell tolerance; nucleofection	GROWTH-FACTOR-BETA; FYVE DOMAIN PROTEIN; ZINC-FINGER DOMAIN; RECEPTOR ACTIVATION; SMAD ANCHOR; TRANSFORMING GROWTH-FACTOR-BETA-1; FUNCTIONAL-CHARACTERIZATION; EARLY ENDOSOMES; HRS; IDENTIFICATION	Transforming growth factor-beta1 (TGF-beta1) is a pluripotent cytokine that controls peripheral T cell tolerance mainly in mucosal immunity. It is secreted by regulatory T cells (Tr/Th3) but also by other immununologically active cells. Smad anchor for receptor activation (SARA) and hepatic growth factor-regulated tyrosine kinase substrate (Hgs) are involved in TGF-beta1 signaling. Both molecules are known to present Smad2 and Smad3 to the TGF-beta receptor complex. The role of SARA and Hgs in TGF-beta1 susceptibility of human CD4(+) T cells is unclear. We demonstrate here that TGF-beta1 up-regulates SARA mRNA expression in CD4(+) T cells similar to that of Smad7. However, the increase in SARA expression was lower (6.1+/-0.3-fold vs. 25+/-4.1-fold) compared with Smad7 and delayed, with a maximum at 12 h compared with 2 h. Th1 and Th2 cell subsets expressed the same levels of SARA and Hgs. Compared with resting cells, significantly lower levels of the two molecules were found in antigen/allergen- or anti-CD3/CD28-stimulated cells. Down-regulation of SARA and Hgs mRNA in preactivated CD4(+) T cells was accompanied by a twofold increase in a TGF-beta1 responsive reporter gene assay. Overexpression of SARA and Hgs in T cells yielded a dose-dependent decrease in cotransfected reporter gene expression, indicating an inhibitory function of both molecules. Thus, SARA and Hgs are regulators of TGF-beta1 susceptibility in T cells and integrate regulatory signals into the influence of TGF-beta1-mediated suppression of human T cells.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 226, Japan	Swiss Institute of Allergy & Asthma Research; Netherlands Cancer Institute; Tohoku University; Tokyo Institute of Technology	Schmidt-Weber, CB (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	csweber@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020; Schmidt-Weber, Carsten B./AAU-1621-2021	Akdis, Cezmi/0000-0001-8020-019X; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Itoh, Susumu/0000-0002-7967-0730				Akdis CA, 1999, ALLERGY, V54, P31, DOI 10.1111/j.1398-9995.1999.tb04435.x; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Applied Biosystems, 1997, APPL BIOS US B; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Cottrez F, 2001, J IMMUNOL, V167, P773, DOI 10.4049/jimmunol.167.2.773; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Joss A, 2000, EUR J IMMUNOL, V30, P1683, DOI 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Song XY, 1998, J CLIN INVEST, V101, P2615, DOI 10.1172/JCI2480; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649	34	34	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					194	202		10.1096/fj.02-0550com	http://dx.doi.org/10.1096/fj.02-0550com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554698				2022-12-25	WOS:000181456900044
J	Famulski, KS; Al-Hijailan, RS; Dobler, K; Pienkowska, M; Al-Mohanna, F; Paterson, MC				Famulski, KS; Al-Hijailan, RS; Dobler, K; Pienkowska, M; Al-Mohanna, F; Paterson, MC			Aberrant sensing of extracellular Ca2+ by cultured ataxia telangiectasia fibroblasts	ONCOGENE			English	Article						ataxia telangiectasia; extracellular calcium-sensing receptor; intracellular Ca2+ mobilization; mitogen-activated protein kinase; calmodulin-dependent protein kinase II	ACTIVATED PROTEIN-KINASE; DNA-DAMAGE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; ATM; RADIATION; RECEPTOR; CELLS; EXPRESSION; GROWTH	Ataxia telangiectasia (AT) is a human hereditary syndrome whose underlying gene product, ataxia telangiectasia mutated (ATM) protein kinase, is involved in multiple intracellular signaling pathways. We demonstrated previously that AT fibroblasts are defective in intracellular Ca2+ mobilization in response to both stress-inducing and mitogenic stimuli. To extend these findings, normal and AT cells were exposed to serum in the presence of different concentrations of extracellular Ca2+ ([Ca2+](o)), and release of intracellular Ca2+, activation of calmodulin-dependent protein kinase 11 and phosphorylation of kinases ERK1 and 2 were monitored. When maintained in high [Ca2+](o) (0.42 mM), normal fibroblasts responded to serum introduction more rapidly and efficiently than did AT cells. Unexpectedly, decreasing the [Ca2+](o) in the medium had a diametrically opposite effect. Under low [Ca2+](o) (0.0022 mM) conditions, normal cells were slow and inefficient in their responses, whereas AT cells showed a substantial improvement in all three end points. These findings demonstrate that loss of ATM kinase function deregulates the extracellular calcium-sensing receptor (CaR). This malfunction presumably arises from a post-transcriptional event, since CaR mRNA proved to be normal in AT cells. Together, our data suggest that ATM may mediate cell response to mitogenic factors by tightly regulating the set point of the CaR and thereby modulating the crosstalk between this metabotropic receptor and growth factor receptors. Alternatively, the faulty sensing of extracellular calcium in AT cells may be secondary to a state of chronic oxidative stress attributable to ATM deficiency.	King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia; Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore	King Faisal Specialist Hospital & Research Center; National Cancer Centre Singapore (NCCS)	Famulski, KS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, MCB-03,POB 3354, Riyadh 11211, Saudi Arabia.	konrad@kfshrc.edu.sa	Famulski, Konrad/J-8685-2012					Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; Chattopadhyay N, 2000, INT J BIOCHEM CELL B, V32, P789, DOI 10.1016/S1357-2725(00)00031-5; Chiesa N, 2000, NEUROSCIENCE, V96, P575, DOI 10.1016/S0306-4522(99)00581-3; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Famulski KS, 1999, FEBS LETT, V453, P183, DOI 10.1016/S0014-5793(99)00664-X; Fukao T, 1999, BLOOD, V94, P1998; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Hall J, 1999, MOL MED TODAY, V5, P157, DOI 10.1016/S1357-4310(99)01435-5; Heyer BS, 2000, GENE DEV, V14, P2072; HUANG SX, 1995, BIOCHEM J, V310, P881, DOI 10.1042/bj3100881; Kamsler A, 2001, CANCER RES, V61, P1849; Keating KE, 2001, ONCOGENE, V20, P4281, DOI 10.1038/sj.onc.1204527; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; McNeil L, 1998, AM J OBSTET GYNECOL, V178, P305, DOI 10.1016/S0002-9378(98)80017-3; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; PIENKOWSKA M, 2002, CANC DETECT PREV S1, V26, pS64; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Soares HD, 1998, NEUROSCIENCE, V86, P1045, DOI 10.1016/S0306-4522(98)00117-1; Speer G, 2002, INT J COLORECTAL DIS, V17, P20, DOI 10.1007/s003840100359; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Taylor AMR, 1998, INT J RADIAT BIOL, V73, P365, DOI 10.1080/095530098142185; Yan J, 2000, INT J RADIAT BIOL, V76, P1025, DOI 10.1080/09553000050111497; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	34	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					471	475		10.1038/sj.onc.1206167	http://dx.doi.org/10.1038/sj.onc.1206167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545170				2022-12-25	WOS:000180379100018
J	Rushton, JJ; Davis, LM; Lei, WL; Mo, XM; Leutz, A; Ness, SA				Rushton, JJ; Davis, LM; Lei, WL; Mo, XM; Leutz, A; Ness, SA			Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins	ONCOGENE			English	Article						microarrays; differentiation; transcription; breast cancer; oncogenes	BREAST-CANCER; ACTIVATION; SYSTEM; FAMILY; CELLS	The c-Myb, A-Myb and B-Myb transcription factors have nearly identical DNA-binding domains, activate the same reporter gene constructs in animal cells, but have different biological roles. The Myb proteins are often coexpressed in the same cells, raising questions about whether they activate similar or distinct gene expression profiles, and whether they cooperate or compete in regulating the same promoters. Here, recombinant adenoviruses were used to express each protein in human mammary cells, and then microarray assays were used to assess global changes in gene expression. Each Myb protein induced a unique and specific set of changes, displaying activities far more complex than revealed by standard reporter gene assays. These results have important implications for the roles of various Myb proteins in normal and transformed human cells, for regulatory pathways that might modify their activities and for the importance of acquired mutations that may qualitatively alter their functions in tumors.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Keck Genom Resource, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; Exagen Corp, Albuquerque, NM USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Ness, SA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.		Leutz, Achim/K-9643-2013; Ness, Scott/AAV-4009-2020	Leutz, Achim/0000-0001-8259-927X; Ness, Scott/0000-0001-6965-8909	NCI NIH HHS [R01 CA58443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Buckhaults P, 2001, CANCER RES, V61, P6996; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GABRIELLI F, 1995, EUR J BIOCHEM, V232, P473, DOI 10.1111/j.1432-1033.1995.tb20833.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GUERIN M, 1990, ONCOGENE, V5, P131; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinz S, 2002, GENOMICS, V79, P608, DOI 10.1006/geno.2002.6743; Kamano H, 1995, ONCOGENE, V11, P2575; Kauraniemi P, 2000, CANCER RES, V60, P5323; McClowry TL, 2002, J MED VIROL, V66, P96, DOI 10.1002/jmv.2116; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Stewart H, 1999, OPHTHALMOLOGY, V106, P964, DOI 10.1016/S0161-6420(99)00539-4; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	25	78	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					308	313		10.1038/sj.onc.1206131	http://dx.doi.org/10.1038/sj.onc.1206131			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527900				2022-12-25	WOS:000180322400016
J	Hughes, E; Middleton, DA				Hughes, E; Middleton, DA			Solid-state NMR reveals structural changes in phospholamban accompanying the functional regulation of Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; DEPENDENT PROTEIN-KINASE; CA-ATPASE; TRANSMEMBRANE DOMAIN; INHIBITORY FUNCTION; INTERACTION SITE; LIPID BILAYERS; CALCIUM-PUMP; SF21 CELLS; PHOSPHORYLATION	Calcium transport across the sarcoplasmic reticulum of cardiac myocytes is regulated by a reversible inhibitory interaction between the Ca2+-ATPase and the small transmembrane protein phospholamban (PLB). A null-cysteine analogue of PLB, containing isotope labels in the transmembrane domain or cytoplasmic domain, was reconstituted into membranes in the absence and presence of the SERCA1 isoform of Ca2+-ATPase for structural investigation by cross-polarization magic-angle spinning (CP-MAS) NMR. PLB lowered the maximal hydrolytic activity of SERCA1 and its affinity for calcium in membrane preparations suitable for structural analysis by NMR. Novel backbone amide proton-deuterium exchange CP-MAS NMR experiments on the two PLB analogues co-reconstituted with SERCA1 indicated that labeled residues Leu(42) and Leu(44) were situated well within the membrane interior, whereas Pro(21) and Ala(24) lie exposed outside the membrane. Internuclear distance measurements on PLB using rotational resonance NMR indicated that the sequences Pro(21)-Ala(24) and Leu(42)-Leu(44) adopt an alpha-helical structure in pure lipid bilayers, which is unchanged in the presence of Ca2+-ATPase. By contrast, rotational echo double resonance (REDOR) NMR experiments revealed that the sequence Ala(24)-Gln(26) switches from an alpha-helix in pure lipid membranes to a more extended structure in the presence of SERCA1, which may reflect local structural distortions which change the orientations of the transmembrane and cytoplasmic domains. These results suggest that Ca2+-ATPase has a long-range effect on the structure of PLB around residue 25, which promotes the functional association of the two proteins.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Manchester	Middleton, DA (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.							Ahmed Z, 2000, BBA-BIOMEMBRANES, V1468, P187, DOI 10.1016/S0005-2736(00)00257-1; Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Asahi M, 2000, J BIOL CHEM, V275, P15034, DOI 10.1074/jbc.275.20.15034; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Chen BW, 2002, BIOCHEMISTRY-US, V41, P13965, DOI 10.1021/bi0266030; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; Ferrington DA, 2002, BIOCHEMISTRY-US, V41, P13289, DOI 10.1021/bi026407t; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; Gullion T, 2000, J MAGN RESON, V146, P220, DOI 10.1006/jmre.2000.2164; Hughes G, 1996, BIOCHEM J, V318, P973, DOI 10.1042/bj3180973; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; Kargacin ME, 1998, BIOCHEM J, V331, P245, DOI 10.1042/bj3310245; Karim CB, 2000, BIOCHEMISTRY-US, V39, P10892, DOI 10.1021/bi0003543; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Lamberth S, 2000, HELV CHIM ACTA, V83, P2141, DOI 10.1002/1522-2675(20000906)83:9<2141::AID-HLCA2141>3.0.CO;2-W; LEVITT MH, 1990, J CHEM PHYS, V92, P6347, DOI 10.1063/1.458314; Mahaney JE, 2000, BIOPHYS J, V78, P1306, DOI 10.1016/S0006-3495(00)76686-0; Mascioni A, 2002, J AM CHEM SOC, V124, P9392, DOI 10.1021/ja026507m; Middleton DA, 2000, J MAGN RESON, V147, P366, DOI 10.1006/jmre.2000.2187; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Negash S, 2000, BIOCHEM J, V351, P195, DOI 10.1042/0264-6021:3510195; Negash S, 1996, BIOCHEMISTRY-US, V35, P11247, DOI 10.1021/bi960864q; PAN Y, 1990, J MAGN RESON, V90, P330, DOI 10.1016/0022-2364(90)90138-Y; Pollesello P, 1999, BIOPHYS J, V76, P1784, DOI 10.1016/S0006-3495(99)77339-X; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; REDDY LG, 2002, BIOPH J ANN M ABSTR, V82, P263; SASAKI T, 1992, J BIOL CHEM, V267, P1674; Schmidt AG, 2001, CARDIOVASC DRUG THER, V15, P387, DOI 10.1023/A:1013381204658; SILVER B, 1985, PHYSICAL CHEM MEMBRA; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Smith SO, 2001, J MOL BIOL, V313, P1139, DOI 10.1006/jmbi.2001.5101; TADA M, 1983, J MOL CELL CARDIOL, V15, P565, DOI 10.1016/0022-2828(83)90267-5; Tatulian SA, 2002, BIOCHEMISTRY-US, V41, P741, DOI 10.1021/bi011148d; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Waterborg Jakob H., 1996, P7, DOI 10.1007/978-1-60327-259-9_2; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; Yao Q, 2001, BIOCHEMISTRY-US, V40, P6406, DOI 10.1021/bi002891t; Young HS, 2001, BIOPHYS J, V81, P884, DOI 10.1016/S0006-3495(01)75748-7; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	47	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20835	20842		10.1074/jbc.M212208200	http://dx.doi.org/10.1074/jbc.M212208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12556441	hybrid			2022-12-25	WOS:000183230500052
J	Janz, JM; Fay, JF; Farrens, DL				Janz, JM; Fay, JF; Farrens, DL			Stability of dark state rhodopsin is mediated by a conserved ion pair in intradiscal loop E-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; SCHIFF-BASE COUNTERION; HELICAL MEMBRANE-PROTEINS; CYSTEINE RESIDUE-110; DISULFIDE BOND; CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; METARHODOPSIN-III; VISUAL PIGMENTS; BOVINE	The rhodopsin crystal structure reveals that intradiscal loop E-2 covers the 11-cis-retinal, creating a "retinal plug." Recently, we noticed the ends of loop E-2 are linked by an ion pair between residues Arg-177 and Asp-190, near the highly conserved disulfide bond. This ion pair appears biologically significant; it is conserved in almost all vertebrate opsins and may occur in other G-protein-coupled receptors. We report here that the Arg-177/Asp-190 ion pair is critical for the folding and stability of dark state rhodopsin. We find ion pair mutants that regenerate with retinal are functionally and spectrally wild-type-like yet thermally unstable in their dark state because of rapid hydrolysis of the retinal Schiff base linkage. Surprisingly, Arrhenius analysis indicates that the activation energies for the hydrolysis process are similar between the ion pair mutants and wild-type rhodopsin. Furthermore, the ion pair mutants do not show increased reactivity toward hydroxylamine, suggesting that their instability is not caused by an increased exposure to bulk solvent. Our results indicate that the loop E-2 ion pair is important for rhodopsin stability and thus suggest that retinitis pigmentosa observed in patients with Asp-190 mutations may in part be the result of thermally unstable rhodopsin proteins.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Farrens, DL (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Mail Code L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	farrensd@ohsu.edu			NEI NIH HHS [EY12095-01, T32-EY07123-09] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007123, R01EY012095] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Albert AD, 2002, BBA-BIOMEMBRANES, V1565, P183, DOI 10.1016/S0005-2736(02)00568-0; Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; BAEHR W, 1982, J BIOL CHEM, V257, P6452; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; COOPER A, 1976, BIOCHEMISTRY-US, V15, P2970, DOI 10.1021/bi00659a006; COOPER A, 1987, J AM CHEM SOC, V109, P7254, DOI 10.1021/ja00258a002; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Fahmy K, 1996, BIOCHEMISTRY-US, V35, P15065, DOI 10.1021/bi961486s; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FONG TM, 1999, REC BIOCH M, P1; FUKUDA MN, 1982, METHOD ENZYMOL, V81, P214; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HAROSI FI, 1995, PHOTOCHEM PHOTOBIOL, V61, P510; HUBBARD R, 1965, COLD SPRING HARB SYM, V30, P301, DOI 10.1101/SQB.1965.030.01.032; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1999, P NATL ACAD SCI USA, V96, P1932, DOI 10.1073/pnas.96.5.1932; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; JACOBSON SG, 1991, AM J OPHTHALMOL, V112, P256, DOI 10.1016/S0002-9394(14)76726-1; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; Jung KH, 1999, BIOCHEMISTRY-US, V38, P13270, DOI 10.1021/bi991180w; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KEMP CM, 1992, AM J OPHTHALMOL, V113, P165, DOI 10.1016/S0002-9394(14)71529-6; KHORANA HG, 1992, J BIOL CHEM, V267, P1; Kochendoerfer GG, 1999, TRENDS BIOCHEM SCI, V24, P300, DOI 10.1016/S0968-0004(99)01432-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landin JS, 2001, BIOCHEMISTRY-US, V40, P11176, DOI 10.1021/bi0100539; Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1; Lewis JW, 2000, METHOD ENZYMOL, V315, P164; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; MATSUMOTO H, 1978, BIOCHIM BIOPHYS ACTA, V501, P257, DOI 10.1016/0005-2728(78)90031-2; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; REUTER T, 1976, VISION RES, V16, P909, DOI 10.1016/0042-6989(76)90220-0; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Segel I. H., 1975, ENZYME KINETICS, P931; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; SWINBOURNE ES, 1971, ANAL KINETIC DATA, P60; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3536, DOI 10.1021/bi016024f; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Yan ECY, 2002, BIOCHEMISTRY-US, V41, P3620, DOI 10.1021/bi0160011; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; Zvyaga TA, 1996, BIOCHEMISTRY-US, V35, P7536, DOI 10.1021/bi960391n	79	69	70	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16982	16991		10.1074/jbc.M210567200	http://dx.doi.org/10.1074/jbc.M210567200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12547830	hybrid			2022-12-25	WOS:000182818600073
J	Carvalho, RN; Solstad, T; Bjorgo, E; Barroso, JF; Flatmark, T				Carvalho, RN; Solstad, T; Bjorgo, E; Barroso, JF; Flatmark, T			Deamidations in recombinant human phenylalanine hydroxylase - Identification of labile asparagine residues and functional characterization of ASN -> ASP mutant forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; AMINO-ACID-SEQUENCE; PROTEIN DEAMIDATION; SUBSTRATE-BINDING; WILD-TYPE; PEPTIDES; ENZYME; DEGRADATION; GENE; PHENYLKETONURIA	Recombinant human phenylalanine hydroxylase (hPAH) expressed in Escherichia coli for 24 h at 28 degreesC has been found by two-dimensional electrophoresis to exist as a mixture of four to five molecular forms as a result of nonenzymatic deamidation of labile Asn residues. The multiple deamidations alter the functional properties of the enzyme including its affinity for L-phenylalanine and tetrahydrobiopterin, catalytic efficiency, and substrate inhibition and also result in enzyme forms more susceptible to limited tryptic proteolysis. Asn(32) in the regulatory domain deamidates very rapidly because of its nearest neighbor amino acid Gly(33) (Solstad, T., Carvalho, R. N., Andersen, O. A., Waidelich, D., and Flatmark, T. (2003) Eur. J. Biochem., in press). Matrix-assisted laser desorption/ionization time of flight-mass spectrometry of the tryptic peptides in the catalytic domain of a 24-h (28 degreesC) expressed enzyme has shown Asn(376) and Asn(133) to be labile residues. Site-directed mutagenesis of nine Asn residues revealed that the deamidations of Asn(32) and Asn(376) are the main determinants for the functional and regulatory differences observed between the 2- and 24-h-induced wild-type (wt) enzyme. The Asn(32) --> Asp, Asn(376) --> Asp, and the double mutant forms expressed for 2 h at 28 degreesC revealed qualitatively similar regulatory properties as the highly deamidated 24-h expressed wt-hPAH. Moreover, deamidation of Asn(32) in the wt-hPAH (24 h expression at 28 C) and the Asn(32) --> Asp mutation both increase the initial rate of phosphorylation of Serfs by cAMP-dependent protein kinase (p < 0.005). By contrast, the substitution of Gly(33) with Ala or Val, both preventing the deamidation of Asn(32), resulted in enzyme forms that were phosphorylated at a similar rate as nondeamidated wt-hPAH, even on 24-h expression. The other Asn --> Asp substitutions (in the catalytic domain) revealed that Asn(207) and Asn(223) have an important stabilizing structural function. Finally, two recently reported phenylketonuria mutations at Asn residues in the catalytic domain were studied, i.e. Asn(167) --> Ile and Asn(207) --> Asp, and their phenotypes were characterized.	Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Prote Unit, N-5009 Bergen, Norway; Univ Oslo, Ctr Biotechnol, N-0317 Oslo, Norway	University of Bergen; University of Bergen; University of Oslo	Flatmark, T (corresponding author), Univ Bergen, Dept Biochem & Mol Biol, Arstadveien 19, N-5009 Bergen, Norway.	torgeir.flatmark@ibmb.uib.no						BISCHOFF R, 1994, J CHROMATOGR B, V662, P261, DOI 10.1016/0378-4347(94)00203-7; Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; Bjorgo E, 2001, EUR J BIOCHEM, V268, P997, DOI 10.1046/j.1432-1327.2001.01958.x; CARVALHO RMN, 2002, CHEM BIOL PTERIDINES, P103; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Doskeland AP, 1996, BIOCHEM J, V319, P941, DOI 10.1042/bj3190941; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; Eiken HG, 1996, HUM MUTAT, V7, P228, DOI 10.1002/(SICI)1098-1004(1996)7:3<228::AID-HUMU7>3.0.CO;2-6; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; FLATMARK T, 1968, J BIOL CHEM, V243, P1623; FLATMARK T, 1967, J BIOL CHEM, V242, P2454; FLATMARK T, 1966, ACTA CHEM SCAND, V20, P1487, DOI 10.3891/acta.chem.scand.20-1487; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; Flatmark T, 2001, ANAL BIOCHEM, V294, P95, DOI 10.1006/abio.2001.5163; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; GEIGER T, 1987, J BIOL CHEM, V262, P785; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KNACK I, 1981, H-S Z PHYSIOL CHEM, V362, P1119, DOI 10.1515/bchm2.1981.362.2.1119; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Knappskog PM, 1996, HUM MUTAT, V8, P236, DOI 10.1002/(SICI)1098-1004(1996)8:3<236::AID-HUMU7>3.0.CO;2-7; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Kosky AA, 1999, PROTEIN SCI, V8, P2519; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LiCata VJ, 1997, BIOPHYS CHEM, V64, P225, DOI 10.1016/S0301-4622(96)02204-1; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Park YS, 1998, HUM MUTAT, pS121; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P4367, DOI 10.1073/pnas.071066498; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P944, DOI 10.1073/pnas.98.3.944; Robinson NE, 2001, J PEPT RES, V57, P483, DOI 10.1034/j.1399-3011.2001.00863.x; Scriver CR, 2000, HUM MUTAT, V15, P99, DOI 10.1002/(SICI)1098-1004(200001)15:1<99::AID-HUMU18>3.0.CO;2-P; SMITH SC, 1984, J BIOL CHEM, V259, P1284; Solstad T, 2000, EUR J BIOCHEM, V267, P6302, DOI 10.1046/j.1432-1327.2000.01715.x; Solstad T, 2003, EUR J BIOCHEM, V270, P929, DOI 10.1046/j.1432-1033.2003.03455.x; SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X; Tyfield LA, 1997, AM J HUM GENET, V60, P388; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; Waters PJ, 1998, HUM MUTAT, V12, P344, DOI 10.1002/(SICI)1098-1004(1998)12:5<344::AID-HUMU8>3.0.CO;2-D; Wehofsky M, 2001, EUR J MASS SPECTROM, V7, P39, DOI 10.1255/ejms.387; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	44	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15142	15152		10.1074/jbc.M212180200	http://dx.doi.org/10.1074/jbc.M212180200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12554741	hybrid			2022-12-25	WOS:000182516100073
J	Hino, S; Michiue, T; Asashima, M; Kikuchi, A				Hino, S; Michiue, T; Asashima, M; Kikuchi, A			Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; F-BOX PROTEIN; NEGATIVE REGULATOR; AXIN; PHOSPHORYLATION; DEGRADATION; INHIBITION; ACTIVATION; DOMAINS; COMPLEX	We demonstrate that Dvl-1, casein kinase Iepsilon (CKIepsilon), and Frat-1 activate the Wnt signaling pathway cooperatively. The amino acid region 228-250 of Dvl-1 was necessary for its binding to Frat-1, and the interaction of Dvl-1 with Frat-1 was enhanced by CKIepsilon. Coexpression of Dvl-1 and Frat-1 caused accumulation of beta-catenin synergistically in L cells. Both proteins also activated the transcriptional activity of T-cell factor-4 (Tcf-4) synergistically in human embryonic kidney 293 cells, but coexpression of Dvl-1-(Delta228-250), which lacks the amino acid region 228-250 from Dvl-1, and Frat-1 did not. Dvl-1, but not Dvl-1-(Delta228-250), acted synergistically with CKIepsilon to activate Tcf-4. Depletion of CKIepsilon by double-stranded RNA interference in HeLa S3 cells led to the inhibition of Wnt-3a-induced phosphorylation of Dvl and the binding of Dvl-1 to Frat-1. Furthermore, depletion of CKIepsilon reduced the Wnt-3a-induced accumulation of beta-catenin, although it did not affect the basal level of beta-catenin. These results indicate that CKIepsilon-dependent phosphorylation of Dvl enhances the formation of a complex of Dvl-1 with Frat-1 and that this complex leads to the activation of the Wnt signaling pathway.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Sorst Project, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan	Hiroshima University; University of Tokyo; University of Tokyo	Kikuchi, A (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Penton A, 2002, GENETICS, V161, P747; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	43	93	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14066	14073		10.1074/jbc.M213265200	http://dx.doi.org/10.1074/jbc.M213265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556519	hybrid			2022-12-25	WOS:000182405000066
J	Mori, H; Tsukazaki, T; Masui, R; Kuramitsu, S; Yokoyama, S; Johnson, AE; Kimura, Y; Akiyama, Y; Ito, K				Mori, H; Tsukazaki, T; Masui, R; Kuramitsu, S; Yokoyama, S; Johnson, AE; Kimura, Y; Akiyama, Y; Ito, K			Fluorescence resonance energy transfer analysis of protein translocase - SecYE from Thermus thermophilus HB8 forms a constitutive oligomer in membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PREPROTEIN TRANSLOCATION; COMPLEX; SECRETION; INSERTION; CHANNEL; SYSTEM	SecY and SecE are the two principal translocase subunits that create a channel-like pathway for the transit of preprotein across the bacterial cytoplasmic membrane. Here we report the cloning, expression, and purification of the SecYE complex (TSecYE) from a thermophilic bacterium, Thermus thermophilus HB8. Purified TSecYE can be reconstituted into proteoliposomes that function in T. thermophilus SecA (TSecA) dependent preprotein translocation. After the mixing of TSecYE derivatives labeled with either a donor or an acceptor fluorophore during reconstitution, fluorescence resonance energy transfer experiments demonstrated that 2 or more units of TSecYE in the lipid bilayer associate to form a largely non-exchangeable oligomeric structure.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; Osaka Univ, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan; Univ Tokyo, Grad Sch Sci, Tokyo 1130033, Japan; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan	Kyoto University; Osaka University; University of Tokyo; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp	Tsukazaki, Tomoya/N-2299-2019; Johnson, Arthur E/G-3457-2012; Yokoyama, Shigeyuki/N-6911-2015	Tsukazaki, Tomoya/0000-0002-6386-723X; Yokoyama, Shigeyuki/0000-0003-3133-7338; Mori, Hiroyuki/0000-0002-0429-1269	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Heuck AP, 2002, CELL BIOCHEM BIOPHYS, V36, P89, DOI 10.1385/CBB:36:1:89; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Matsuo E, 1998, J BIOL CHEM, V273, P18835, DOI 10.1074/jbc.273.30.18835; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mori H, 2001, P NATL ACAD SCI USA, V98, P5128, DOI 10.1073/pnas.081617398; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shimohata N, 2002, GENES CELLS, V7, P653, DOI 10.1046/j.1365-2443.2002.00554.x; WATSON BS, 1995, BIOCHEMISTRY-US, V34, P7904, DOI 10.1021/bi00024a015; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429	27	47	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14257	14264		10.1074/jbc.M300230200	http://dx.doi.org/10.1074/jbc.M300230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12533543	hybrid			2022-12-25	WOS:000182405000088
J	Son, M; Cloyd, CD; Rothstein, JD; Rajendran, B; Elliott, JL				Son, M; Cloyd, CD; Rothstein, JD; Rajendran, B; Elliott, JL			Aggregate formation in Cu,Zn superoxide dismutase-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; COPPER CHAPERONE; TRANSGENIC MICE; PRION PROTEIN; ALPHA-SYNUCLEIN; BINDS COPPER; DISEASE; SOD1; ZINC	Aggregation of Cu,Zn superoxide dismutase (SOD1) protein is a pathologic hallmark of familial amyotrophic lateral sclerosis linked to mutations in the SOD1 gene, although the structural motifs within mutant SOD1 that are responsible for its aggregation are unknown. Copper chaperone for SOD1 (CCS) and extracellular Cu,Zn superoxide dismutase (SOD3) have some sequence identity with SOD1, particularly in the regions of metal binding, but play no significant role in mutant SOD1-induced disease. We hypothesized that it would be possible to form CCS- or SOD3-positive aggregates by making these molecules resemble mutant SOD1 via the introduction of point mutations in codons homologous to a disease causing G85R SOD1 mutation. Using an in vitro assay system, we found that expression of wild type human CCS or a modified intracellular wild type SOD3 does not result in significant aggregate formation. In contrast, expression of G16SR CCS or G146R SOD3 produced aggregates as evidenced by the presence of high molecular weight protein complexes on Western gels or inclusion bodies on immunofluorescence. CCS- and SOD3-positive inclusions appear to be ubiquitinated and localized to aggresomes. These results suggest that proteins sharing structural similarities to mutant SOD1 are also at risk for aggregate formation.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	Elliott, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		rothstein, jeffrey d/C-9470-2013					Bartnikas TB, 2000, MAMM GENOME, V11, P409, DOI 10.1007/s003350010078; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bowler RP, 2002, J BIOL CHEM, V277, P16505, DOI 10.1074/jbc.M105409200; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Elliott JL, 2001, PROG NEURO-PSYCHOPH, V25, P1169, DOI 10.1016/S0278-5846(01)00185-3; Elliott JL, 1999, NEUROBIOL DIS, V6, P310, DOI 10.1006/nbdi.1999.0266; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FOLZ RJ, 1994, GENOMICS, V22, P162, DOI 10.1006/geno.1994.1357; Gaudette M, 2000, AMYOTROPH LATERAL SC, V1, P83, DOI 10.1080/14660820050515377; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Puttaparthi K, 2002, J NEUROSCI, V22, P8790; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Worrall BB, 2000, ARCH NEUROL-CHICAGO, V57, P33, DOI 10.1001/archneur.57.1.33	38	34	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14331	14336		10.1074/jbc.M211698200	http://dx.doi.org/10.1074/jbc.M211698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12551935	hybrid			2022-12-25	WOS:000182405000097
J	Darbandi-Tonkabon, R; Hastings, WR; Zeng, CM; Akk, G; Manion, BD; Bracamontes, JR; Steinbach, JH; Mennerick, SJ; Covey, DF; Evers, AS				Darbandi-Tonkabon, R; Hastings, WR; Zeng, CM; Akk, G; Manion, BD; Bracamontes, JR; Steinbach, JH; Mennerick, SJ; Covey, DF; Evers, AS			Photoaffinity Labeling with a neuroactive steroid analogue - 6-AZI-Pregnanolone labels voltage-dependent anion channel-1 in rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; A RECEPTOR; GABA(A) RECEPTOR; LIGAND-BINDING; ALPHA-SUBUNIT; MODULATION; ANESTHETICS; SITES; CELLS; PROTEIN	Neuroactive steroids modulate the function of gamma-aminobutyric acid, type A (GABA(A)) receptors in the central nervous system by an unknown mechanism. In this study we have used a novel neuroactive steroid analogue, 3alpha,5beta-6-azi-3-hydroxypregnan-20-one (6-AziP), as a photoaffinity labeling reagent to identify neuroactive steroid binding sites in rat brain. 6-AziP is an effective modulator of GABA(A) receptors as evidenced by its ability to inhibit binding of [S-35]t-butylbicyclophosphoro-thionate to rat brain membranes and to potentiate GABA-elicited currents in Xenopus oocytes and human endothelial kidney 293 cells expressing GABA(A) receptor subunits (alpha(1)beta(2)gamma(2)). [H-3]6-AziP produced time- and concentration-dependent photolabeling of protein bands of similar to35 and 60 kDa in rat brain membranes. The 35-kDa band was half-maximally labeled at a [H-3]6-AziP concentration of 1.9 muM, whereas the 60-kDa band was labeled at higher concentrations. The photolabeled 35-kDa protein was isolated from rat brain by two-dimensional PAGE and identified as voltage-dependent anion channel-1 (VDAC-1) by both matrix-assisted laser desorption ionization time-of-flight and ESI-tandem mass spectrometry. Monoclonal antibody directed against the N terminus of VDAC-1 immunoprecipitated labeled 35-kDa protein from a lysate of rat brain membranes, confirming that VDAC-1 is the species labeled by [H-3]6-AziP. The 132 and 133 subunits of the GABAA receptor were co-immunoprecipitated by the VDAC-1 antibody suggesting a physical association between VDAC-1 and GABAA receptors in rat brain membranes. These data suggest that neuroactive steroid effects on the GABAA receptor may be mediated by binding to an accessory protein, VDAC-1.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Evers, AS (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, 660 S Euclid Ave,Campus Box 8054, St Louis, MO 63110 USA.		Mennerick, Steven/O-2806-2017; Akk, Gustav/CAG-1703-2022	Mennerick, Steven/0000-0003-0868-0664; Evers, Alex/0000-0002-0342-0575	NIAAA NIH HHS [AA12952] Funding Source: Medline; NIGMS NIH HHS [P01 GM047969, P01-GM47969] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012952] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Anflous K, 2001, J BIOL CHEM, V276, P1954, DOI 10.1074/jbc.M006587200; ANTONUCCI R, 1952, J ORG CHEM, V17, P1369, DOI 10.1021/jo50010a014; ATKINSON RM, 1965, J MED CHEM, V8, P426, DOI 10.1021/jm00328a004; BARKER JL, 1987, J PHYSIOL-LONDON, V386, P485, DOI 10.1113/jphysiol.1987.sp016547; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; Bathori G, 2000, J BIOENERG BIOMEMBR, V32, P79, DOI 10.1023/A:1005516513313; BELLELI D, 1997, P NATL ACAD SCI USA, V94, P11031; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CALLACHAN H, 1987, PROC R SOC SER B-BIO, V231, P359, DOI 10.1098/rspb.1987.0049; Colombini M, 1996, Ion Channels, V4, P169; COTTRELL GA, 1987, BRIT J PHARMACOL, V90, P491, DOI 10.1111/j.1476-5381.1987.tb11198.x; Covey DF, 2000, J PHARMACOL EXP THER, V293, P1009; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Fountoulakis M, 1999, ELECTROPHORESIS, V20, P3572; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Greenblatt EP, 2001, ANESTHESIOLOGY, V94, P1026, DOI 10.1097/00000542-200106000-00017; HARRISON NL, 1987, J NEUROSCI, V7, P604; HARRISON NL, 1984, BRAIN RES, V323, P287, DOI 10.1016/0006-8993(84)90299-3; HARRISON NL, 1987, J PHARMACOL EXP THER, V241, P346; Hatzimanikatis V, 1999, BIOTECHNOL PROGR, V15, P312, DOI 10.1021/bp990004b; HAWKINSON JE, 1994, MOL PHARMACOL, V46, P977; Hawkinson JE, 1996, MOL PHARMACOL, V49, P897; HillVenning C, 1997, BRIT J PHARMACOL, V120, P749, DOI 10.1038/sj.bjp.0700927; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; JIMENEZ CR, 2000, CURRENT PROTOCOLS PR; KATZENELLENBOGEN JA, 1974, BIOCHEMISTRY-US, V13, P2986, DOI 10.1021/bi00711a031; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZCOLOME AM, 1990, EUR J PHARMACOL, V176, P297; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MOHLER H, 1980, P NATL ACAD SCI-BIOL, V77, P1666, DOI 10.1073/pnas.77.3.1666; Moon JI, 1999, NEUROREPORT, V10, P443, DOI 10.1097/00001756-199902250-00001; Paradiso K, 2000, MOL PHARMACOL, V58, P341, DOI 10.1124/mol.58.2.341; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Rick CE, 1998, NEUROREPORT, V9, P379, DOI 10.1097/00001756-199802160-00004; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Sabey K, 1999, MOL PHARMACOL, V55, P58, DOI 10.1124/mol.55.1.58; Sanna E, 1997, MOL PHARMACOL, V51, P484; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Steinbach JH, 2001, J PHYSIOL-LONDON, V537, P715; Tao YX, 2001, ANESTHESIOLOGY, V94, P1010, DOI 10.1097/00000542-200106000-00015; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; Ueno S, 1996, MOL PHARMACOL, V50, P931; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8; Wittmer LL, 1996, MOL PHARMACOL, V50, P1581; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23	57	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13196	13206		10.1074/jbc.M213168200	http://dx.doi.org/10.1074/jbc.M213168200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560326	hybrid			2022-12-25	WOS:000182189500078
J	Mulligan, JD; Flowers, MT; Tebon, A; Bitgood, JJ; Wellington, C; Hayden, MR; Attie, AD				Mulligan, JD; Flowers, MT; Tebon, A; Bitgood, JJ; Wellington, C; Hayden, MR; Attie, AD			ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTOR; DENSITY-LIPOPROTEIN DEFICIENCY; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; PLASMA-MEMBRANE; BINDING; TRANSPORTER; GENE; MUTATIONS; ABCG5	The ATP-binding cassette transporter A1 (ABCA1) participates in the efflux of cholesterol from cells. It remains unclear whether ABCA1 functions to efflux cholesterol across the basolateral or apical membrane of the intestine. We used. a chicken model of ABCA1 dysfunction, the Wisconsin hypoalpha mutant (WHAM) chicken, to address this issue. After an oral gavage of radioactive cholesterol, the percentage appearing in the bloodstream was reduced by 79% in the WHAM chicken along with a 97% reduction in the amount of tracer in high density lipoprotein. In contrast, the percentage of radioactive cholesterol absorbed from the lumen into the intestine was not affected by the ABCA1 mutation. Liver X receptor (LXR) agonists have been inferred to decrease cholesterol absorption through activation of ABCA1 expression. However, the LXR agonist T0901317 decreased cholesterol absorption equally in both wild type and WHAM chickens, indicating that the effect of LXR activation on cholesterol absorption is independent of ABCA1 The ABCA1 mutation resulted in accumulation of radioactive cholesterol ester in the intestine and the liver of the WHAM chicken (5.0- and 4.4-fold, respectively), whereas biliary lipid concentrations were unaltered by the WHAM mutation. In summary, ABCA1 regulates the efflux of cholesterol from the basolateral but not apical membrane in the intestine and the liver.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Anim Sci, Madison, WI 53706 USA; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V65Z 4H4, Canada; Xenon Genet, Burnaby, BC V5G 4W8, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of British Columbia	Attie, AD (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		Eckhardt, Erik/G-1567-2010; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419	NHLBI NIH HHS [HL56593] Funding Source: Medline; NIA NIH HHS [T32-AG00213] Funding Source: Medline; NIGMS NIH HHS [T32-GM07215-25] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200; Attie AD, 2001, J LIPID RES, V42, P1717; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Clee SM, 2001, CIRCULATION, V103, P1198; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Dean M, 2001, J LIPID RES, V42, P1007; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; GREEN PHR, 1978, J CLIN INVEST, V61, P528, DOI 10.1172/JCI108963; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee J, 2002, BIOCHEM J, V364, P475, DOI 10.1042/BJ20011493; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu KM, 2001, AM J HUM GENET, V69, P278, DOI 10.1086/321294; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; MARSH JB, 1974, J LIPID RES, V15, P544; MCGIBBON WH, 1981, J HERED, V72, P139, DOI 10.1093/oxfordjournals.jhered.a109450; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Neufeld EB, 2002, BIOCHEM BIOPH RES CO, V297, P974, DOI 10.1016/S0006-291X(02)02274-X; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Ohama T, 2002, BIOCHEM BIOPH RES CO, V296, P625, DOI 10.1016/S0006-291X(02)00853-7; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; POERNAMA F, 1990, J LIPID RES, V31, P955; QUINTAO E, 1971, J LIPID RES, V12, P221; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; Schmitz G, 2001, J LIPID RES, V42, P1513; SCHREYER SA, 1994, ARTERIOSCLER THROMB, V14, P2053, DOI 10.1161/01.ATV.14.12.2053; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; STURKIE PD, 1965, AVIAN PHYSL, P109; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; 2001, APPL BIOSYSTEMS USER, V2	73	94	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13356	13366		10.1074/jbc.M212377200	http://dx.doi.org/10.1074/jbc.M212377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551945	hybrid			2022-12-25	WOS:000182189500097
J	Blom, WM; de Bont, HJGM; Nagelkerke, JF				Blom, WM; de Bont, HJGM; Nagelkerke, JF			Regional loss of the mitochondrial membrane potential in the hepatocyte is rapidly followed by externalization of phosphatidylserines at that specific site during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; PERMEABILITY TRANSITION; CYTOCHROME-C; OXIDATIVE STRESS; DEATH; ATP; RECOGNITION; ACTIVATION; MECHANISM; EXPOSURE	The spatio-temporal relationship between a decrease in the mitochondrial membrane potential (MMP) and externalization of phosphatidylserines (PS) during induction of apoptosis was investigated in single freshly isolated hepatocytes. Apoptosis was induced in the hepatocytes in three different ways: attack by activated Natural Killer cells, exposure to ATP, or exposure to the inhibitor of protein synthesis cycloheximide. Fluorescence microscopy showed staining of externalized PS at those areas where the staining for MMP was lost whereas in other areas the mitochondria remained intact for longer periods of time, indicating coupling between local loss of MMP and local PS exposure. To discriminate whether the decrease in MMP itself or a decrease in ATP induced PS externalization, hepatocytes were treated with rotenone, which resulted in a rapid collapse of cellular ATP but left the MMP intact for a much longer period. Addition of fructose prevented the decrease of ATP to similar to30% and also delayed the collapse of the MMP. This indicates that ATP was needed for the maintenance of the MMP probably via reverse action of the ATP synthase. In a subsequent study hepatocytes were incubated with Natural Killer cells for induction of apoptosis followed by addition of rotenone to deplete ATP. Under these conditions the PS staining co-localized with mitochondrial MMP indicating that PS externalization does not require a collapse in AMP. Moreover, exposure of PS was evenly distributed over the whole plasma membrane. In conclusion, we propose that after an apoptotic stimulus some mitochondria start to loose their MMP, which results in cessation of ATP production and perhaps even consumption of ATP. This results in an overall decrease in cellular ATP. ATP-consuming enzyme reactions most distal from still intact mitochondria will be most sensitive to such a decrease. Apparently the translocase that keeps phosphatidylserines inward-oriented is such a sensitive enzyme.	Leiden Univ, Div Toxicol, Gorlaeus Labs, LACDR, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Nagelkerke, JF (corresponding author), Leiden Univ, Div Toxicol, Gorlaeus Labs, LACDR, POB 9502, NL-2300 RA Leiden, Netherlands.	nagelker@lacdr.Leidenuniv.nl		Blom, W.M./0000-0002-6853-0900				ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; Bernardi P, 1998, BBA-BIOENERGETICS, V1366, P1; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Blom WM, 1999, BIOCHEM PHARMACOL, V58, P1891, DOI 10.1016/S0006-2952(99)00268-3; Blom WM, 1999, HEPATOLOGY, V29, P785, DOI 10.1002/hep.510290303; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Castedo M, 1996, J IMMUNOL, V157, P512; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; FADOK VA, 1992, J IMMUNOL, V148, P2207; GiezemanSmits KM, 1997, IMMUNOBIOLOGY, V197, P429, DOI 10.1016/S0171-2985(97)80077-0; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KOOP A, 1993, BIOCHEM J, V295, P165, DOI 10.1042/bj2950165; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUMBLE KD, 1991, J CELL SCI, V99, P751; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Nagelkerke JF, 1996, J MICROSC-OXFORD, V184, P58; NAGELKERKE JF, 2001, MITOCHONDRIA PATHOGE, P449; Nicotera P, 1998, TOXICOL LETT, V103, P139; Pelassy C, 2001, BBA-MOL CELL RES, V1539, P256, DOI 10.1016/S0167-4889(01)00113-6; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Porcelli AM, 2001, METHOD CELL BIOL, V65, P353, DOI 10.1016/S0091-679X(01)65021-0; Rolstad B, 1998, SCAND J IMMUNOL, V47, P412; SMALLCOMBE A, 1996, 11 BIOR; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207	42	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12467	12474		10.1074/jbc.M201264200	http://dx.doi.org/10.1074/jbc.M201264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538597	hybrid, Green Published			2022-12-25	WOS:000182015700097
J	Ko, YH; Delannoy, M; Hullihen, J; Chiu, W; Pedersen, PL				Ko, YH; Delannoy, M; Hullihen, J; Chiu, W; Pedersen, PL			Mitochondrial ATP synthasome - Cristae-enriched membranes and a multiwell detergent screening assay yield dispersed single complexes containing the ATP synthase and carriers for P-i and ADP/ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; RESPIRATORY-CHAIN; CRYSTAL-STRUCTURE; MECHANISM; SUBUNIT; MOTOR	The terminal step of ATP synthesis in intact mitochondria is catalyzed by the ATP synthase (F0F1) that works in close synchrony with the P-i and ADP/ATP carriers. Each carrier consists of only a single polypeptide chain in dimeric form, while the ATP synthase is highly complex consisting in animals of 17 known subunit types and more than 30 total subunits. Although structures at high resolution have been obtained for the water-soluble F-1 part of the ATP synthase consisting of only five subunit types, such structures have not been obtained for either the complete ATP synthase or the P-i and ADP/ ATP carriers. Here, we report that all three proteins are localized in highly purified cristae-like vesicles obtained by extensive subfractionation of the mitochondrial inner membrane. Moreover, using a multiwell detergent screening assay, 4 nonionic detergents out of 80 tested were found to disperse these cristae-like vesicles into single soluble complexes or "ATP synthasomes" that contain the ATP synthase in association with the P-i and ADP/ATP carriers. These studies offer new mechanistic insights into the terminal steps of oxidative phosphorylation in mitochondria and set the stage for future structural efforts designed to visualize in atomic detail the entire complex involved. They also provide evidence that the cristae are a subcompartment of the inner membrane.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Natl Ctr Macromol Inaging, Houston, TX 77030 USA; Baylor Coll Med, Program Struct & COmputat Biol & Mol Biophys, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Baylor College of Medicine; Baylor College of Medicine	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	ppederse@jhmi.edu			NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10951] Funding Source: Medline; NCRR NIH HHS [P41RR02250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Belogrudov GI, 2002, J BIOL CHEM, V277, P6097, DOI 10.1074/jbc.M111256200; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; CHAN TL, 1970, J CELL BIOL, V45, P291, DOI 10.1083/jcb.45.2.291; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; Frey TG, 2002, BBA-BIOENERGETICS, V1555, P196, DOI 10.1016/S0005-2728(02)00278-5; JACOBS EE, 1956, J BIOL CHEM, V223, P147; KAGAWA Y, 1966, J BIOL CHEM, V241, P2475; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Ko YH, 2000, J BIOL CHEM, V275, P32931, DOI 10.1074/jbc.M004453200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ostermeier C, 1997, CURR OPIN STRUC BIOL, V7, P697, DOI 10.1016/S0959-440X(97)80080-2; PALADE GE, 1952, ANAT RECORD, V114, P427, DOI 10.1002/ar.1091140304; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P423, DOI 10.1023/A:1005652605340; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SOPER JW, 1976, BIOCHEMISTRY-US, V15, P2682, DOI 10.1021/bi00657a031; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; ZIEGLER M, 1993, J BIOL CHEM, V268, P25320	28	149	151	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12305	12309		10.1074/jbc.C200703200	http://dx.doi.org/10.1074/jbc.C200703200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560333	hybrid			2022-12-25	WOS:000182015700076
J	Kweon, DH; Kim, CS; Shin, YK				Kweon, DH; Kim, CS; Shin, YK			Insertion of the membrane-proximal region of the neuronal SNARE coiled coil into the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC EXOCYTOSIS; PENETRATION DEPTH; PROTEIN-STRUCTURE; SIDE-CHAINS; SPIN; COMPLEX; FUSION; BINDING; MECHANISM; SYNTAXIN	In the neuron, soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins assemble into an a-helical coiled coil that bridges the synaptic vesicle to the plasma membrane and drives membrane fusion, a required process for neurotransmitter release at the nerve terminal. How does coiled coil formation drive membrane fusion? To investigate the structural and energetic coupling between the coiled coil and membrane, the recombinant SNARE complex in the phospholipid bilayer was studied using fluorescence quenching and site-directed spin labeling EPR. Fluorescence analysis revealed that two native Trp residues at the membrane-proximal region of the coiled coil are inserted into the membrane, tightly coupling the coiled coil to the membrane. The EPR results indicate that the coiled coil penetrates into the membrane with an oblique angle, providing a favorable geometry for the basic residues to interact with negatively charged lipids. The result supports the proposition that core complex formation directly leads to the apposition of two membranes, which could facilitate lipid mixing. Trp residues and basic residues are abundant at the membrane-proximal region of transmembrane SNARE proteins, suggesting the generality of the proposed mechanism for the SNARE complex-membrane coupling.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Shin, YK (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	colishin@iastate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051290, R29GM051290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; Brunger AT, 2001, CURR OPIN STRUC BIOL, V11, P163, DOI 10.1016/S0959-440X(00)00186-X; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kim CS, 2002, BIOCHEMISTRY-US, V41, P10928, DOI 10.1021/bi026266v; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Kuzmin PI, 2001, P NATL ACAD SCI USA, V98, P7235, DOI 10.1073/pnas.121191898; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P9264, DOI 10.1021/bi025934+; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mayer A, 2001, TRENDS BIOCHEM SCI, V26, P717, DOI 10.1016/S0968-0004(01)01984-3; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Quetglas S, 2002, EMBO J, V21, P3970, DOI 10.1093/emboj/cdf404; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; RAND RP, 1986, ANNU REV PHYSIOL, V48, P201; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Russell CJ, 1999, BIOCHEMISTRY-US, V38, P337, DOI 10.1021/bi981179h; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorgeirsson TE, 1996, BIOCHEMISTRY-US, V35, P1803, DOI 10.1021/bi952300c; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200	52	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12367	12373		10.1074/jbc.M211123200	http://dx.doi.org/10.1074/jbc.M211123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529381	hybrid			2022-12-25	WOS:000182015700084
J	Li, JM; Shah, AM				Li, JM; Shah, AM			Mechanism of endothelial cell NADPH oxidase activation by angiotensin II - Role of the p47(Phox) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SUPEROXIDE PRODUCTION; NAD(P)H OXIDASE; CYTOSOLIC COMPONENT; OXIDATIVE STRESS; RENAL DISEASES; MICE; PHOSPHORYLATION; MEMBRANE; HYPERTROPHY	Endothelial cells express a constitutively active phagocyte-type NADPH oxidase whose activity is augmented by agonists such as angiotensin II. We recently reported (Li, J.-M., and Shah, A. M. (2002) J. Biol. Chem. 277, 19952-19960) that in contrast to neutrophils a substantial proportion of the NADPH oxidase in unstimulated endothelial cells exists as preassembled intracellular complexes. Here, we investigate the mechanism of angiotensin II-induced endothelial NADPH oxidase activation. Angiotensin II (100 nmol/liter)-induced reactive oxygen species production (as measured by dichloro-hydrofluorescein fluorescence or lucigenin chemiluminescence) was completely absent in coronary microvascular endothelial cells isolated from p47(phox) knockout mice. Transfection of p47(phox) cDNA into p47(phox-/-) cells restored the angiotensin II response, whereas transfection of antisense p47(phox) cDNA into wild-type cells depleted p47(phox) and inhibited the angiotensin II response. In unstimulated human microvascular endothelial cells, there was significant p47(phox)-p22(phox) complex formation but minimal detectable p47(phox) phosphorylation. Angiotensin II induced rapid serine phosphorylation of P47(phox) (within 1 min, peaking at similar to15 min), a 1.9 +/- 0.1-fold increase in p47(phox)-p22(phox) complex formation and a 1.6 +/- 0.2-fold increase in NADPH-dependent O-2(radical anion) production (p < 0.05). p47(phox) was redistributed to "nuclear" and membrane-enriched cell fractions. These data indicate that angiotensin II-stimulated endothelial NADPH oxidase activity is regulated through serine phosphorylation of p47(phox) and its enhanced binding to p22(phox).	Kings Coll London, Dept Cardiol, Guys Kings & St Thomass Sch Med, London SE5 9PJ, England	University of London; King's College London	Shah, AM (corresponding author), Kings Coll London, Dept Cardiol, Guys Kings & St Thomass Sch Med, Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk		Shah, Ajay/0000-0002-6547-0631				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Bendall JK, 2002, CIRCULATION, V105, P293, DOI 10.1161/hc0302.103712; Cifuentes ME, 2000, AM J PHYSIOL-HEART C, V279, pH2234, DOI 10.1152/ajpheart.2000.279.5.H2234; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kim S, 2000, PHARMACOL REV, V52, P11; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Lang D, 2000, CIRC RES, V86, P463, DOI 10.1161/01.RES.86.4.463; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lavigne MC, 2001, CIRCULATION, V104, P79, DOI 10.1161/01.CIR.104.1.79; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2; Li JM, 2001, J MOL CELL CARDIOL, V33, P1119, DOI 10.1006/jmcc.2001.1372; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Morozov I, 1998, J BIOL CHEM, V273, P15435, DOI 10.1074/jbc.273.25.15435; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; Pueyo ME, 1997, GEN PHARMACOL-VASC S, V29, P691, DOI 10.1016/S0306-3623(97)00021-9; Pueyo ME, 2000, ARTERIOSCL THROM VAS, V20, P645, DOI 10.1161/01.ATV.20.3.645; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Schieffer B, 2000, CIRC RES, V87, P1195, DOI 10.1161/01.RES.87.12.1195; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2	34	248	263	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12094	12100		10.1074/jbc.M209793200	http://dx.doi.org/10.1074/jbc.M209793200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560337	hybrid			2022-12-25	WOS:000182015700050
J	Burkart, EM; Sumandea, MP; Kobayashi, T; Nili, M; Martin, AF; Homsher, E; Solaro, RJ				Burkart, EM; Sumandea, MP; Kobayashi, T; Nili, M; Martin, AF; Homsher, E; Solaro, RJ			Phosphorylation or glutamic acid substitution at protein kinase C sites on cardiac troponin I differentially depress myofilament tension and shortening velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE VENTRICULAR MYOCYTES; ISOMETRIC FORCE; EXPRESSION; HEART; STIMULATION; MICE; HYPERTROPHY; ACTIVATION; MGATPASE; EPSILON	There is evidence that multi-site phosphorylation of cardiac troponin I (cTnI) by protein kinase C is important in both long- and short-term regulation of cardiac function. To determine the specific functional effects of these phosphorylation sites (Ser-43, Ser-45, and Thr-144), we measured tension and sliding speed of thin filaments in reconstituted preparations in which endogenous cTnI was replaced with cTnI phosphorylated by protein kinase C-a or mutated to cTnI-S43E/S45E/T144E, cTnI-S43E/S45E, or cTnI-T144E. We used detergent-skinned mouse cardiac fiber bundles to measure changes in Ca2+-dependence of force. Compared with controls, fibers reconstituted with phosphorylated cTnI, cTnI-S43E/S45E/T144E, or cTnI-S43E/S45E were desensitized to Ca2+, and maximum tension was as much as 27% lower, whereas fibers reconstituted with cTnI-T144E showed no change. In the in vitro motility assay actin filaments regulated by troponin complexes containing phosphorylated cTnI or cTnI-S43E/S45E/T144E showed both a decrease in Ca2+ sensitivity and maximum sliding speed compared with controls, whereas filaments regulated by cTnI-S43E/S45E showed only decreased maximum sliding speed and filaments regulated by cTnI-T144E demonstrated only desensitization to Ca2+. Our results demonstrate novel site specificity of effects of PKC phosphorylation on cTnI function and emphasize the complexity of modulation of the actin-myosin interaction by specific changes in the thin filament.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Program Cardiovasc Sci, Chicago, IL 60612 USA; Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci, Dept Physiol, Los Angeles, CA 90025 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Solaro, RJ (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, Program Cardiovasc Sci, M-C 901,835 S Wolcott Ave, Chicago, IL 60612 USA.	SolaroRJ@uic.edu			NHLBI NIH HHS [R01 HL 64035, P01 HL 62426, F32 HL 10409] Funding Source: Medline; NIAMS NIH HHS [R01 AR-30988] Funding Source: Medline; PHS HHS [T3207692] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062426, R01HL064035, F32HL010409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; Chandra M, 1999, BIOCHEM BIOPH RES CO, V263, P219, DOI 10.1006/bbrc.1999.1341; Chandra M, 2001, AM J PHYSIOL-HEART C, V280, pH705, DOI 10.1152/ajpheart.2001.280.2.H705; de Tombe PP, 2000, ANN BIOMED ENG, V28, P991, DOI 10.1114/1.1312189; EDMAN KAP, 1981, J MUSCLE RES CELL M, V2, P321, DOI 10.1007/BF00713270; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; Goekjian PG, 1999, CURR MED CHEM, V6, P877; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; GORDON AM, 1966, J PHYSIOL-LONDON, V184, P170, DOI 10.1113/jphysiol.1966.sp007909; GUO XD, 1994, J BIOL CHEM, V269, P15210; HATAKENAKA M, 1991, BIOCHEM BIOPH RES CO, V181, P1022, DOI 10.1016/0006-291X(91)92039-M; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; Huang L, 2001, AM J PHYSIOL-CELL PH, V280, pC1114, DOI 10.1152/ajpcell.2001.280.5.C1114; Jideama NM, 1996, J BIOL CHEM, V271, P23277, DOI 10.1074/jbc.271.38.23277; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Knollmann BC, 2001, J BIOL CHEM, V276, P10039, DOI 10.1074/jbc.M006745200; Knott A, 2002, J MOL CELL CARDIOL, V34, P469, DOI 10.1006/jmcc.2002.1528; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Lester JW, 2000, AM J PHYSIOL-HEART C, V279, pH2685, DOI 10.1152/ajpheart.2000.279.6.H2685; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; MacGowan GA, 2001, AM J PHYSIOL-HEART C, V280, pH835, DOI 10.1152/ajpheart.2001.280.2.H835; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Montgomery DE, 2002, AM J PHYSIOL-HEART C, V282, pH2397, DOI 10.1152/ajpheart.00714.2001; Morimoto S, 2001, BIOCHEM BIOPH RES CO, V282, P811, DOI 10.1006/bbrc.2001.4647; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; Noland TA, 1996, BIOCHEMISTRY-US, V35, P14923, DOI 10.1021/bi9616357; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; Pi YQ, 2002, CIRC RES, V90, P649, DOI 10.1161/01.RES.0000014080.82861.5F; Pyle WG, 2002, AM J PHYSIOL-HEART C, V283, pH1215, DOI 10.1152/ajpheart.00128.2002; Rarick HM, 1999, J MOL CELL CARDIOL, V31, P363, DOI 10.1006/jmcc.1998.0870; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; Solaro RJ, 2002, J MOL CELL CARDIOL, V34, P689, DOI 10.1006/jmcc.2002.2028; SOLARO RJ, 1993, CIRC RES, V73, P981, DOI 10.1161/01.RES.73.6.981; SOLARO RJ, 2001, HDB PHYSL 2, V1, P264; STRANG KT, 1995, CIRC RES, V77, P114, DOI 10.1161/01.RES.77.1.114; STRANG KT, 1994, CIRC RES, V74, P542, DOI 10.1161/01.RES.74.3.542; Takeda S, 2002, BIOPHYS J, V82, p170A; Takeishi Y, 1998, J CLIN INVEST, V102, P72, DOI 10.1172/JCI2709; Takeishi Y, 2000, CIRC RES, V86, P1218, DOI 10.1161/01.RES.86.12.1218; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; VENEMA RC, 1993, BIOCHEM J, V294, P401, DOI 10.1042/bj2940401; Wang X, 2001, J BIOL CHEM, V276, P25456, DOI 10.1074/jbc.M102418200; Wolska BM, 2002, CIRC RES, V90, P882, DOI 10.1161/01.RES.0000016962.36404.04; Wu GY, 2000, J BIOL CHEM, V275, P29927, DOI 10.1074/jbc.C000380200; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	49	133	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11265	11272		10.1074/jbc.M210712200	http://dx.doi.org/10.1074/jbc.M210712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551921	hybrid			2022-12-25	WOS:000181855400053
J	De Lean, A; McNicoll, N; Labrecque, J				De Lean, A; McNicoll, N; Labrecque, J			Natriuretic peptide receptor A activation stabilizes a membrane-distal dimer interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; FACTOR-R1 RECEPTOR; BINDING DOMAIN; ANP RECEPTOR; COMPLEX; MUTANT; IDENTIFICATION; HYPERTENSION	We have shown previously (Rondeau, J.-J., McNicoll, N., Gagnon, J., Bouchard, N., Ong, H., and De Lean, A. (1995) Biochemistry 34,2130-2136) that atrial natriuretic peptide (ANP) stabilizes a dimeric form of the natriuretic peptide receptor A (NPRA) by simultaneously interacting with both receptor subunits. However, the first crystallographic study of unliganded NPRA extracellular domain documented a V-shaped dimer involving a membrane-proximal dimer interface and separate binding sites for ANP on each monomer. We explored the possibility of an alternative A-shaped dimer involving a membrane-distal dimer interface by substituting an unpaired solvent-exposed cysteine for Trp74 in the amino-terminal lobe of full-length NPRA. The predicted spacing between Trp(74) from both subunits drastically differs, depending on whether the V-shaped (84 Angstrom) or the A-shaped (8 Angstrom) dimer model is considered. In contrast with the expected results for the reported V-shaped dimer, the NPRA(W74C) mutant was constitutively covalently dimeric. Also, the"subunits spontaneously associated following transient disulfide reduction by dithiothreitol and reoxidation. However, ANP could neither bind to nor activate NPRA(W74C). Permanent disulfide opening by reduction with dithiothreitol and alkylation with N-ethylmaleimide rescued ANP binding to NPRA(W74C). The NPRA mutant could be maintained as a covalent dimer while preserving its function by crosslinking with the bifunctional alkylating agent phenylenedimaleimides (PDM), the ortho-substituted oPDM being more efficient than mPDM or pPDM. These results indicate that the membrane-distal lobe of the NPRAM extracellular domains are dynamically interfacing in the unliganded state and that ANP binding stabilizes the receptor dimer with more stringent spacing at the dimer interface.	Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3T 1J4, Canada	Universite de Montreal	De Lean, A (corresponding author), Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3T 1J4, Canada.							CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; FETHIERE J, 1989, MOL PHARMACOL, V35, P584; Foster D C, 1999, Rev Physiol Biochem Pharmacol, V135, P1, DOI 10.1007/BFb0033668; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; Hashimoto M, 1999, BIOCHEMISTRY-US, V38, P1050, DOI 10.1021/bi9822978; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Labrecque J, 1999, J BIOL CHEM, V274, P9752, DOI 10.1074/jbc.274.14.9752; Labrecque J, 2001, J BIOL CHEM, V276, P8064, DOI 10.1074/jbc.M005550200; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; LIU B, 1989, BIOCHEMISTRY-US, V28, P5599, DOI 10.1021/bi00439a039; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Lucas KA, 2000, PHARMACOL REV, V52, P375; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Marquis M, 1999, MOL CELL BIOCHEM, V194, P23, DOI 10.1023/A:1006835808554; McNicoll N, 1996, BIOCHEMISTRY-US, V35, P12950, DOI 10.1021/bi960818q; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; RONDEAU JJ, 1995, BIOCHEMISTRY-US, V34, P2130, DOI 10.1021/bi00007a005; Suzuki T, 2001, CARDIOVASC RES, V51, P489, DOI 10.1016/S0008-6363(01)00238-3; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKASHIMA A, 1995, EUR J BIOCHEM, V227, P673, DOI 10.1111/j.1432-1033.1995.tb20187.x; van den Akker F, 2001, J MOL BIOL, V311, P923, DOI 10.1006/jmbi.2001.4922; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	34	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11159	11166		10.1074/jbc.M212862200	http://dx.doi.org/10.1074/jbc.M212862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547834	hybrid			2022-12-25	WOS:000181855400040
J	Engedal, N; Blomhoff, HK				Engedal, N; Blomhoff, HK			Combined action of ERK and NF kappa B mediates the protective effect of phorbol ester on fas-induced apoptosis in Jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN T-CELLS; CD95-MEDIATED APOPTOSIS; SIGNALING COMPLEX; UP-REGULATION; DEATH DOMAIN; ACTIVATION; CD95; INHIBITOR; RECRUITMENT	The mechanisms whereby phorbol esters antagonize Fas-induced apoptosis in Jurkat T cells are poorly defined. In the present study, we report that protection from Fas-induced apoptosis by 12-O-tetradecanoylphorbol 13-acetate (TPA) is dependent on both ERK and NFkappaB activation. First, we showed that two specific mitogen-activated protein kinase/ERK kinase-inhibitors, PD98059 and U0126, both counteracted TPA-mediated suppression of Fas-induced apoptosis. Moreover, the dose-dependence of U0126-mediated inhibition of ERK phosphorylation correlated with that of reversion of the anti-apoptotic effect of TPA. Second, we observed an excellent correlation between repression of TPA-induced NFkappaB activation by an irreversible inhibitor of IkappaBalpha phosphorylation, BAY11-7082, and its ability to abrogate TPA-induced suppression of Fas-mediated apoptosis. Furthermore, we located the anti-apoptotic effect of both ERK and NFkappaB to lie upstream of the mitochondrial membrane potential depolarization event. Finally, although each inhibitor at optimal, non-toxic concentration by itself only partly reversed TPA-mediated repression of apoptosis, the combination of U0126 and BAY11-7082 completely abolished the anti-apoptotic effect of TPA. Together these findings suggest that TPA-induced activation of ERK and NFkappaB are parallel events that are both required for maximal inhibition of Fas-induced apoptosis in Jurkat T cells.	Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway	University of Oslo	Blomhoff, HK (corresponding author), Univ Oslo, Inst Med Biochem, POB 1112,Blindern, N-0317 Oslo, Norway.	h.k.blomhoff@basalmed.uio.no	Engedal, Nikolai/AAJ-8951-2020	Engedal, Nikolai/0000-0003-3718-3464				Ahn NG, 2001, METHOD ENZYMOL, V332, P417; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; McLeod JD, 1998, J IMMUNOL, V160, P2072; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; WEISS A, 1984, J IMMUNOL, V133, P123; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	47	37	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10934	10941		10.1074/jbc.M211556200	http://dx.doi.org/10.1074/jbc.M211556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551910	hybrid			2022-12-25	WOS:000181855400010
J	Li, H; Xu, HM; Graham, DE; White, RH				Li, H; Xu, HM; Graham, DE; White, RH			The Methanococcus jannaschii dCTP deaminase is a bifunctional deaminase and diphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; CYTIDINE DEAMINASE; DEOXYURIDINE TRIPHOSPHATASE; DUTP PYROPHOSPHATASE; ADENOSINE-DEAMINASE; ESCHERICHIA-COLI; DNA-POLYMERASES; PYRIMIDINE; EVOLUTION	Most bacteria produce the dUMP precursor for thymine nucleotide biosynthesis using two enzymes: a dCTP deaminase catalyzes the formation of dUTP and a dUTP diphosphatase catalyzes pyrophosphate release. Although these two hydrolytic enzymes appear to catalyze very different reactions, they are encoded by homologous genes. The hyperthermophilic archaeon Methanococcus jannaschii has two members of this gene family. One gene, at locus MJ1102, encodes a dUTP diphosphatase, which can scavenge deoxyuridine nucleotides that inhibit archaeal DNA polymerases. The second gene, at locus MJ0430, encodes a novel dCTP deaminase that releases dUMP, ammonia, and pyrophosphate. Therefore this enzyme can singly catalyze both steps in dUMP biosynthesis, precluding the formation of free, mutagenic dUTP. Besides differing from the previously characterized Salmonella typhimurium dCTP deaminase in its reaction products, this archaeal enzyme has a higher affinity for dCTP and its steady-state turnover is faster than the bacterial enzyme. Kinetic studies suggest: 1) the archaeal enzyme specifically recognizes dCTP; 2) dCTP deamination and dUTP diphosphatase activities occur independently at the same active site, and 3) both activities depend on Mg2+. The bifunctional activity of this M. jannaschii enzyme illustrates the evolution of a suprafamily of related enzymes that catalyze mechanistically distinct reactions.	Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	White, RH (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA.	rhwhite@vt.edu	Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344				Baldo AM, 1999, J VIROL, V73, P7710, DOI 10.1128/JVI.73.9.7710-7721.1999; BECK CF, 1975, J BIOL CHEM, V250, P609; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cardenas ML, 2001, METHODS, V24, P175, DOI 10.1006/meth.2001.1178; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; DAWSON RM, 1985, DATA BIOCH RES, P103; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Graham DE, 2002, BIOCHEMISTRY-US, V41, P15074, DOI 10.1021/bi0268798; Graupner M, 2000, J BACTERIOL, V182, P3688, DOI 10.1128/JB.182.13.3688-3692.2000; Harris JM, 1999, J MOL BIOL, V288, P275, DOI 10.1006/jmbi.1999.2680; Hogrefe HH, 2002, P NATL ACAD SCI USA, V99, P596, DOI 10.1073/pnas.012372799; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MOORE JT, 1993, J BIOL CHEM, V268, P2288; NEUHARD J, 1968, J BACTERIOL, V96, P1519, DOI 10.1128/JB.96.5.1519-1527.1968; PENVERNE B, 1994, ARCH BIOCHEM BIOPHYS, V309, P85, DOI 10.1006/abbi.1994.1089; PHAM DN, 1993, BIOCHEMISTRY-US, V32, P13725, DOI 10.1021/bi00212a043; Poole A, 2001, NAT REV MOL CELL BIO, V2, P147, DOI 10.1038/35052091; Poyner RR, 2001, BIOCHEMISTRY-US, V40, P8009, DOI 10.1021/bi0103922; Prangishvili D, 1998, J BIOL CHEM, V273, P6024, DOI 10.1074/jbc.273.11.6024; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2001, CURR PROTEIN PEPT SC, V2, P301, DOI 10.2174/1389203013381017; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; Serre V, 1998, J MOL BIOL, V281, P363, DOI 10.1006/jmbi.1998.1856; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; SLUPPHAUG G, 1993, ANAL BIOCHEM, V211, P164, DOI 10.1006/abio.1993.1248; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; WILSON DK, 1993, BIOCHEMISTRY-US, V32, P1689, DOI 10.1021/bi00058a001; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Xiang SB, 1997, BIOCHEMISTRY-US, V36, P4768, DOI 10.1021/bi963091e	38	26	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11100	11106		10.1074/jbc.M212460200	http://dx.doi.org/10.1074/jbc.M212460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538648	hybrid			2022-12-25	WOS:000181855400032
J	Makino, R; Obayashi, E; Homma, N; Shiro, Y; Hori, H				Makino, R; Obayashi, E; Homma, N; Shiro, Y; Hori, H			YC-1 facilitates release of the proximal his residue in the NO and CO complexes of soluble guanylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NITRIC-OXIDE COMPLEXES; CARBON-MONOXIDE; BOVINE LUNG; LIGAND-BINDING; SMOOTH-MUSCLE; HEME-PROTEINS; CYCLIC-GMP; ACTIVATION; RAMAN	The benzylindazole compound YC-1 has been shown to activate soluble guanylate cyclase by increasing the sensitivity toward NO and CO. Here we report the action of YC-1 on the coordination of CO- and NO-hemes in the enzyme and correlate the events with the activation of enzyme catalysis. A single YC-1-binding site on the heterodimeric enzyme was identified by equilibrium dialysis. To explore the affect of YC-1 on the NO-heme coordination, the six-coordinate NO complex of the enzyme was stabilized by dibromodeuteroheme substitution. Using the dibromodeuteroheme enzyme, YC-1 converted the six-coordinate NO-heme to a five-coordinate NO-heme with a characteristic EPR signal that differed from that in the absence of YC-1. These results revealed that YC-1 facilitated cleavage of the proximal His-iron bond and caused geometrical distortion of the five-coordinate NO-heme. Resonance Raman studies demonstrated the presence of two iron-CO stretch modes at 488 and 521 cm(-1) specific to the YC-1-bound CO complex of the native enzyme. Together with the infrared C-O stretching measurements, we assigned the 488-cm(-1) band to the iron-CO stretch of a six-coordinate CO-heme and the 521-cm(-1) band to the iron-CO stretch of a five-coordinate CO-heme. These results indicate that YC-1 stimulates enzyme activity by weakening or cleaving the proximal His-iron bond in the CO complex as well as the NO complex.	Rikkyo Univ, Coll Sci, Dept Life Sci, Toshima Ku, Tokyo 1718501, Japan; RIKEN, Harima Inst, Inst Phys & Chem Res, Sayo, Hyogo 6795143, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Toyonaka, Osaka 5608531, Japan	Rikkyo University; RIKEN; Osaka University	Makino, R (corresponding author), Rikkyo Univ, Coll Sci, Dept Life Sci, Toshima Ku, Nishiikebukoro 3-34-1, Tokyo 1718501, Japan.	rmakino@rikkyo.net.jp	Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327				BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Chu GC, 2000, J BIOL CHEM, V275, P17494, DOI 10.1074/jbc.M000830200; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Kharitonov VG, 1999, BIOCHEMISTRY-US, V38, P10699, DOI 10.1021/bi990277f; Kim SY, 1996, J AM CHEM SOC, V118, P8769, DOI 10.1021/ja961411b; KON H, 1969, BIOCHEMISTRY-US, V8, P4757, DOI 10.1021/bi00840a016; KON H, 1968, J BIOL CHEM, V243, P4350; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; Makino R., 1982, OXYGENASES OXYGEN ME, P467; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEIDT WR, 1977, J AM CHEM SOC, V99, P7315, DOI 10.1021/ja00464a035; SEYBERT DW, 1977, J BIOL CHEM, V252, P4225; Sharma VS, 1999, BIOCHEM BIOPH RES CO, V254, P188, DOI 10.1006/bbrc.1998.9812; SHIRO Y, 1995, BIOCHEMISTRY-US, V34, P9052, DOI 10.1021/bi00028a014; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4535, DOI 10.1021/bi00388a055; TSUBAKI M, 1987, BIOCHEMISTRY-US, V26, P4527, DOI 10.1021/bi00388a054; UNO T, 1985, J BIOL CHEM, V260, P2023; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; WALCH A, 1989, J AM CHEM SOC, V111, P2767; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WALKER FA, 1976, J AM CHEM SOC, V98, P3484, DOI 10.1021/ja00428a016; WAYLAND BB, 1974, J AM CHEM SOC, V96, P6037, DOI 10.1021/ja00826a013; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; WU CC, 1995, BRIT J PHARMACOL, V116, P1973, DOI 10.1111/j.1476-5381.1995.tb16400.x; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P344, DOI 10.1016/0003-9861(75)90350-1; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YOSHIMURA T, 1991, B CHEM SOC JPN, V64, P2819, DOI 10.1246/bcsj.64.2819; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	55	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11130	11137		10.1074/jbc.M209026200	http://dx.doi.org/10.1074/jbc.M209026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540839	hybrid			2022-12-25	WOS:000181855400036
J	Picher, M; Boucher, RC				Picher, M; Boucher, RC			Human airway ecto-adenylate kinase - A mechanism to propagate ATP signaling on airway surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-CHANNEL EXPRESSION; NASAL EPITHELIAL-CELLS; EXTRACELLULAR ATP; NUCLEOSIDE DIPHOSPHOKINASE; RELEASE; ADENOSINE; VOLUME; METABOLISM; PHOSPHOTRANSFERASE; DIFFERENTIATION	Mechanically induced ATP release from human airway epithelial cells regulates mucociliary clearance through cell surface nucleotide receptors. Ectoenzymes detected on these cells were recently shown to terminate ATP-mediated responses by sequential dephosphorylation of extracellular ATP into ADP, AMP, and adenosine. We now demonstrate that an ecto-adenylate kinase (ecto-AK) contributes to the metabolism of adenine nucleotides on human airway epithelial surfaces by the reversible reaction: ATP + AMP reversible arrow 2ADP. This phosphotransferase exhibited a bilateral distribution on polarized primary cultures of human bronchial epithelial cells with a 4-fold higher activity on the mucosal surface. Ecto-AK presented an absolute requirement for magnesium and adenine-based nucleotides. UMP, GMP, and CMP could not substitute for AMP as gamma-phosphate acceptor, and UDP could not replace ADP. Apparent K-m and V-max values were 23 +/- 5 muM and 1.1 +/- 0.1 nmol.min(-1).cm(-2) for ATP and 43 +/- 6 muM and 0.5 +/- 0.1 nmol.min(-1).cm(-2) for ADP. Ecto-AK accounted for 20% of [gamma-P-32]ATP dephosphorylation, and the impermeant AK inhibitor, diadenosine pentaphosphate, reduced ADPase activity by more than 70% on both epithelial surfaces. Time course experiments on ATP metabolism demonstrated that ecto-AK significantly prolongs effective ATP and ADP concentrations on airway epithelial surfaces for P2 receptor signaling and reduces by 6-fold adenosine production. Our data suggest a role for this nucleotide entrapment cycle in the propagation of purine-mediated mucociliary clearance on human airway epithelial surfaces.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulmonary Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Picher, M (corresponding author), Univ N Carolina, Sch Med, 7010 Thurston Bowles Bldg, Chapel Hill, NC 27510 USA.	pichm@med.unc.edu						Beaudoin A.R, 1996, BIOMEMBRANES, V5, P369; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; CASCALHEIRA JF, 1992, EUR J PHARMACOL, V222, P49, DOI 10.1016/0014-2999(92)90462-D; CLANCY JP, 1999, AM J PHYSIOL, V267, pC361; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; DONALDSON SH, 1998, P2 NUCLEOTIDE RECEPT, P413; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUNKLEY CR, 1966, J CELL PHYSIOL, V68, P241, DOI 10.1002/jcp.1040680305; FEDDE KN, 1988, ARCH BIOCHEM BIOPHYS, V264, P400, DOI 10.1016/0003-9861(88)90305-0; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HAMADA M, 1982, J BIOL CHEM, V257, P3120; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; KUBY SA, 1978, ARCH BIOCHEM BIOPHYS, V187, P34, DOI 10.1016/0003-9861(78)90004-8; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lange K, 2000, J CELL PHYSIOL, V185, P21, DOI 10.1002/1097-4652(200010)185:1<21::AID-JCP2>3.3.CO;2-4; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; LAZAROWSKI ER, 2001, PEDIAT PULMONOLOGY S, V22, P193; LAZAROWSKI ER, 1997, BRIT J PHARMACOL, V127, P1272; Le KT, 1998, J NEUROSCI, V18, P7152; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LEHIR M, 1993, AM J PHYSIOL, V264, pF377, DOI 10.1152/ajprenal.1993.264.3.F377; LIEB T, 2001, J PHYSL, V538, P633; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485, DOI 10.1152/ajpcell.2001.280.6.C1485; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; NAGY AK, 1989, J NEUROCHEM, V53, P1166, DOI 10.1111/j.1471-4159.1989.tb07410.x; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Picher M, 2000, AM J RESP CELL MOL, V23, P255, DOI 10.1165/ajrcmb.23.2.4088; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; Picher M, 2001, DRUG DEVELOP RES, V52, P66, DOI 10.1002/ddr.1099; PICHER M, 1999, PEDIAT PULMONOLOGY S, V19, P311; Ramirez AN, 2002, AM J PHYSIOL-HEART C, V282, pH2106, DOI 10.1152/ajpheart.00892.2001; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; Van Rompay AR, 2000, PHARMACOL THERAPEUT, V87, P189, DOI 10.1016/S0163-7258(00)00048-6; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Williams M, 2000, BIOCHEM PHARMACOL, V59, P1173, DOI 10.1016/S0006-2952(99)00341-X; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; WU R, 1985, AM REV RESPIR DIS, V132, P311; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	63	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11256	11264		10.1074/jbc.M208071200	http://dx.doi.org/10.1074/jbc.M208071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551890	hybrid			2022-12-25	WOS:000181855400052
J	So, SP; Wu, JX; Huang, GX; Huang, AM; Li, DW; Ruan, KH				So, SP; Wu, JX; Huang, GX; Huang, AM; Li, DW; Ruan, KH			Identification of residues important for ligand binding of thromboxane A(2) receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; CDNA; ISOFORMS; SUBTYPE; CHAIN; SITE	The second extracellular loop (eLP2) of the thromboxane A(2) receptor (TP) had been proposed to be involved in ligand binding. Through two-dimensional H-1 NMR experiments, the overall three-dimensional structure of a constrained synthetic peptide mimicking the eLP2 had been determined by our group (Ruan, K: H., So, S.-P., Wu, J., Li, D., Huang, A., and Kung, J. (2001) Biochemistry 40, 275-280). To further identify the residues involved in ligand binding, a TP receptor antagonist, SQ29,548 was used to interact with the synthetic peptide. High resolution two-dimensional H-1 NMR experiments, NOESY, and TOCSY were performed for the peptide, SQ29,548, and peptide with SQ29,548, respectively. Through completed H-1 NMR assignment and by comparing the different spectra, extra peaks were observed on the NOESY spectrum of the peptide with SQ29,548, which implied the contacts between residues of eLP2 at Val(176), Leu(185), Thr(186), and Leu(187) with SQ29,548 at position H2, H7, and H8. Site-directed mutagenesis was used to confirm the possible ligand-binding sites on native human TP receptor. Each of the four residues was mutated to the residues either in the same group, with different structure or different charged. The mutated receptors were then tested for their ligand binding activity. The receptor with V176L mutant retained binding activity to SQ29,548. All other mutations resulted in decreased or lost binding activity to SQ29,548. These mutagenesis results supported the prediction from NMR experiments in which Val(176), Leu(185), Thr(186), and Leu(187) are the possible residues involved in ligand binding. This information facilitates the understanding of the molecular mechanism of thromboxane A(2) binding to the important receptor and its signal transduction.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Ruan, KH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.	kruan@uth.tmc.edu		Huang, Gangxiong/0000-0002-0117-5457	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056712, R29HL056712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56712] Funding Source: Medline; NINDS NIH HHS [NS 23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; FUNK CD, 1993, J BIOL CHEM, V268, P26767; FUNK CD, 1993, MOL PHARMACOL, V44, P934; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; KATSUYAMA M, 1994, FEBS LETT, V344, P74, DOI 10.1016/0014-5793(94)00355-6; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; REGAN JW, 1994, BRIT J PHARMACOL, V112, P377, DOI 10.1111/j.1476-5381.1994.tb13082.x; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Turek JW, 2002, J BIOL CHEM, V277, P16791, DOI 10.1074/jbc.M105872200; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JH, 1994, BIOCHEM BIOPH RES CO, V198, P999, DOI 10.1006/bbrc.1994.1142	28	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10922	10927		10.1074/jbc.M209337200	http://dx.doi.org/10.1074/jbc.M209337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551898	hybrid			2022-12-25	WOS:000181855400008
J	Bolsover, SR; Gomez-Fernandez, JC; Corbalan-Garcia, S				Bolsover, SR; Gomez-Fernandez, JC; Corbalan-Garcia, S			Role of the Ca2+/phosphatidylserine binding region of the C2 domain in the translocation of protein kinase C alpha to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; C(2)A DOMAIN; CALCIUM-IONS; CA2+ BINDING; BETA-II; SYNAPTOTAGMIN; DIACYLGLYCEROL; IDENTIFICATION; ACTIVATION; MECHANISM	Signal transduction. via protein kinase C (PKC) is closely regulated by its subcellular localization. To map the molecular determinants mediating the C2 domain-dependent translocation of PKCalpha to the plasma membrane, full-length native protein and several point mutants in the Ca2+/phosphatidylserine-binding site were tagged with green fluorescent protein and transiently expressed in rat basophilic leukemia cells (RBL-2H3). Substitution of several aspartate residues by asparagine completely abolished Ca2+-dependent membrane targeting of PKCalpha. Strikingly, these mutations enabled the mutant proteins to translocate in a diacylglycerol-dependent manner, suggesting that neutralization of charges in the Ca2+ binding region enables the C1 domain to bind diacylglycerol. In addition, it was demonstrated that the protein residues involved in direct interactions with acidic phospholipids play differential and pivotal roles in the membrane targeting of the enzyme. These findings provide new information on how the C2 domain-dependent membrane targeting of PKCalpha occurs in the presence of physiological stimuli.	Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol, E-30100 Murcia, Spain; UCL, Dept Physiol, London WC1E 6BT, England	University of Murcia; University of London; University College London	Corbalan-Garcia, S (corresponding author), Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol, Apartado 4021, E-30100 Murcia, Spain.	senena@um.es	Corbalan-Garcia, Senena/C-6477-2009; Gomez-Fernandez, Juan C/K-6758-2014	Corbalan-Garcia, Senena/0000-0003-1840-5578; Gomez-Fernandez, Juan C/0000-0002-5331-9029				Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; Beaven MA, 1996, CURR BIOL, V6, P798, DOI 10.1016/S0960-9822(02)00598-5; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bolsover S, 2001, BIOCHEM J, V356, P345, DOI 10.1042/0264-6021:3560345; BOSCA L, 1993, BIOCHEM J, V290, P827, DOI 10.1042/bj2900827; Chae YK, 1998, J BIOL CHEM, V273, P25659, DOI 10.1074/jbc.273.40.25659; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Conesa-Zamora P, 2000, BBA-MOL CELL BIOL L, V1487, P246, DOI 10.1016/S1388-1981(00)00099-8; Conesa-Zamora P, 2001, BIOCHEMISTRY-US, V40, P13898, DOI 10.1021/bi011303o; Corbalan-Garcia S, 1999, BIOCHEM J, V337, P513, DOI 10.1042/0264-6021:3370513; Corbalan-Garcia S, 2003, J BIOL CHEM, V278, P4972, DOI 10.1074/jbc.M209385200; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Fernandez-Chacon R, 2002, J NEUROSCI, V22, P8438; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Kohout SC, 2002, BIOCHEMISTRY-US, V41, P11411, DOI 10.1021/bi026041k; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Meyer T, 2000, METHOD ENZYMOL, V327, P500, DOI 10.1016/S0076-6879(00)27298-4; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ochoa WF, 2002, J MOL BIOL, V320, P277, DOI 10.1016/S0022-2836(02)00464-3; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SHAH J, 1992, BIOCHIM BIOPHYS ACTA, V1119, P19, DOI 10.1016/0167-4838(92)90228-6; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Swannie Helen C, 2002, Curr Oncol Rep, V4, P37, DOI 10.1007/s11912-002-0046-7; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Teruel MN, 2002, SCIENCE, V295, P1910, DOI 10.1126/science.1065028; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	40	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10282	10290		10.1074/jbc.M212145200	http://dx.doi.org/10.1074/jbc.M212145200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525479	hybrid			2022-12-25	WOS:000181777500040
J	Richter, K; Muschler, P; Hainzl, O; Reinstein, J; Buchner, J				Richter, K; Muschler, P; Hainzl, O; Reinstein, J; Buchner, J			Sti1 is a non-competitive inhibitor of the Hsp90 ATPase - Binding prevents the N-terminal dimerization reaction during the ATPase cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CHAPERONE; IMMUNOPHILINS; HYDROLYSIS; DOMAIN; P60; CO	The molecular chaperone Hsp90 is known to be involved in the activation of key regulatory proteins such as kinases, steroid hormone receptors, and transcription factors in an ATP-dependent manner. During the chaperone cycle, Hsp90 has been found associated with the partner protein Hop/Sti1, which seems to be required for the progression of the cycle. However, little is known about its specific function. Here we have investigated the interaction of Sti1 from Saccharomyces cerevisiae with Hsp90 and its influence on the ATPase activity. We show that the inhibitory mechanism of Stil on the ATPase activity of Hsp90 is non-competitive. Sti1 binds to the N- and C-terminal part of Hsp90 and prevents the N-terminal dimerization reaction that is required for efficient ATP hydrolysis. The first 24 amino acids of Hsp90, a region shown previously to be important for the association of the N-terminal domains and stimulation of ATP hydrolysis, seems to be important for this interaction.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Mayr C, 2000, J BIOL CHEM, V275, P34140, DOI 10.1074/jbc.M005251200; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	25	152	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10328	10333		10.1074/jbc.M213094200	http://dx.doi.org/10.1074/jbc.M213094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525481	hybrid, Green Published			2022-12-25	WOS:000181777500046
J	Seck, T; Baron, R; Horne, WC				Seck, T; Baron, R; Horne, WC			Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; INTRACELLULAR TRAFFICKING; TONIC INTERNALIZATION; ANGIOTENSIN-II; PROTEIN; ENDOCYTOSIS; PHOSPHORYLATION; DESENSITIZATION; MODULATION; CYTOSKELETON	Many G protein-coupled receptors undergo endocytosis, but the mechanisms involved in endocytic sorting and recycling remain to be fully elucidated. We found that the G protein-coupled calcitonin receptor (CTR) undergoes tonic internalization and accumulates within the cell. Using a fluorescence loss in photobleaching assay, we classified these vesicles functionally as recycling vesicles. In a two-hybrid screening, we found that the actin-binding protein filamin interacted with the C-terminal tail of the CTR. The degradation of the receptor was profoundly increased in the absence of filamin or the CTR-filamin interaction. The absence of filamin was also associated with a marked decrease in recycling of the receptor from the endosomes to the cell surface. In contrast, calcitonin-induced inhibition of spontaneous filamin proteolysis was associated with increased recycling of the receptor to the cell surface and decreased degradation of the CTR, suggesting an important role for filamin in the endocytic sorting and recycling of the internalized CTR.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthoped, New Haven, CT 06510 USA	Yale University; Yale University	Seck, T (corresponding author), Berufsgenossenschaftliche Klin Bergmannsheil, Burkle Camp Pl 1, D-44789 Bochum, Germany.	thomas_seck@hotmail.com			NIDCR NIH HHS [DE-0724] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Azria M., 1989, CALCITONINS PHYSL PH; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN M, 1989, J BIOL CHEM, V264, P14282; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; MARZIA M, 2002, J BONE MINER RES  S1, V17, P231; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Shyu JF, 1999, EUR J BIOCHEM, V262, P95, DOI 10.1046/j.1432-1327.1999.00346.x; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093	34	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10408	10416		10.1074/jbc.M209655200	http://dx.doi.org/10.1074/jbc.M209655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531889	hybrid			2022-12-25	WOS:000181777500057
J	Seitz, S; Lee, SJ; Pennetier, C; Boos, W; Plumbridge, J				Seitz, S; Lee, SJ; Pennetier, C; Boos, W; Plumbridge, J			Analysis of the interaction between the global regulator Mlc and EIIBGlc of the glucose-specific phosphotransferase system in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MEMBRANE SEQUESTRATION; TRANSPORTER; EXPRESSION; PTSG; DOMAIN; PURIFICATION; REPRESSOR; IICBGLC; PROTEIN	Me is a global regulator acting as a transcriptional repressor for several genes and operons of Escherichia coli encoding sugar-metabolizing enzymes and uptake systems. The repressing activity of Me is inactivated by binding to the dephosphorylated form of EIICBGlc (PtsG), which is formed during the transport of glucose. Here, we demonstrate that EIIBGlc, the cytoplasmic domain of PtsG, alone is sufficient to inactivate Me but only when EHBGlc is attached to the membrane by a protein anchor, which can be unrelated to PtsG. Several EIIBGlc mutants, which were altered in and around the phosphorylation site (Cys-421) of EIIBGlc, were tested for their ability to bind Mlc and to affect transcriptional repression by Mlc. The exchange of Cys-421 with serine or aspartate still allowed binding to Me, and in addition, derepression became constitutive, i.e. independent of phosphoenolpyruvate-dependent phosphotransferase system (PTS) phosphorylation. Mutations were made in the surface-exposed residues in the vicinity of Cys-421 and identified Arg-424 as essential for binding to Me. Binding of We to the EIIBGlc constructs in membrane preparations paralleled their ability to derepress Mlc-dependent transcription in vivo. These observations demonstrate that it is not the charge change at Cys-421, produced by PTS phosphorylation, that allows Me binding but rather the structural change in the environment surrounding Cys-421 that the phosphorylation provokes. Native Me exists as a tetramer. Deleting 18 amino acids from the C-terminal removes a putative amphipathic helix and results in dimeric We that is no longer able to repress.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Inst Biol Physicochim, UPR9073, F-75005 Paris, France	University of Konstanz	Plumbridge, J (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	plumbridge@ibpe.fr						ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1994, J BIOL CHEM, V269, P23437; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; Gorke B, 2001, J MOL BIOL, V308, P131, DOI 10.1006/jmbi.2001.4590; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 2001, EMBO J, V20, P3587, DOI 10.1093/emboj/20.13.3587; Kornberg HL, 2000, P NATL ACAD SCI USA, V97, P1808, DOI 10.1073/pnas.97.4.1808; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; Miller JH., 1972, EXPT MOL GENETICS; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Notley-McRobb L, 2000, J BACTERIOL, V182, P4437, DOI 10.1128/JB.182.16.4437-4442.2000; Oh H, 1999, J BIOL CHEM, V274, P14006, DOI 10.1074/jbc.274.20.14006; Plumbridge J, 2000, MICROBIOL-UK, V146, P2655, DOI 10.1099/00221287-146-10-2655; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; Plumbridge J, 2001, J MOL MICROB BIOTECH, V3, P371; Qin YP, 2000, EMBO J, V19, P5212, DOI 10.1093/emboj/19.19.5212; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Takahashi H, 1998, MOL GEN GENET, V259, P317, DOI 10.1007/s004380050818; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; Zeppenfeld T, 2000, J BACTERIOL, V182, P4443, DOI 10.1128/JB.182.16.4443-4452.2000; Zhuang JP, 1999, ARCH BIOCHEM BIOPHYS, V372, P89, DOI 10.1006/abbi.1999.1458	34	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10744	10751		10.1074/jbc.M212066200	http://dx.doi.org/10.1074/jbc.M212066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529317	hybrid			2022-12-25	WOS:000181777500098
J	Valverde, AM; Arribas, M; Mur, C; Navarro, P; Pons, S; Cassard-Doulcier, AM; Kahn, CR; Benito, M				Valverde, AM; Arribas, M; Mur, C; Navarro, P; Pons, S; Cassard-Doulcier, AM; Kahn, CR; Benito, M			Insulin-induced up-regulated uncoupling protein-1 expression is mediated by insulin receptor substrate 1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in fetal brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR I; GENE-EXPRESSION; PHOSPHOTYROSINE PROTEIN; GLUCOSE-TRANSPORT; IGF-I; DIFFERENTIATION; FAT; IRS-1; ASSOCIATION; ALPHA	To investigate the role of insulin receptor substrate-1 (IRS-1) and its downstream signaling in insulin-induced thermogenic differentiation of brown adipocytes, we have reconstituted IRS-1-deficient fetal brown adipocytes (IRS-1(-/-)) with wild-type IRS-1 (IRS-1(wt)). The lack of IRS-1 resulted in the inability of insulin to induce IRS-1-associated phosphatidylinositol 3-kinase (PI 3-kinase) activity and Akt phosphorylation in IRS-1(-/-) brown adipocytes. In addition, these cells showed an impairment in activating alpha-Akt, beta-Akt, and gamma-Akt isoforms upon insulin stimulation. Reconstitution of IRS-1(-/-) brown adipocytes with IRS-1(wt) restored the IRS-1/PI 3-kinase/Akt signaling pathway. Treatment of wildtype brown adipocytes with insulin for 24 h up-regulated uncoupling protein-1 (UCP-1) expression and transactivated the UCP-1 promoter; this effect was abolished in the absence of IRS-1 or in the presence of an Akt inhibitor and further recovered after IRS-1wt reconstitution. Neither UCP-2 nor UCP-3 was up-regulated by insulin in wild-type and IRS-1-deficient brown adipocytes. Insulin stimulated the expression of CCAAT/enhancer-binding protein alpha (C/EBPalpha) and its DNA binding activity in wild-type brown adipocytes but not in IRS-1(-/-) cells. However, insulin stimulation of both C/EBPalpha expression and binding activity was restored after IRS-1(wt) reconstitution of deficient cells. Retrovirus-mediated expression of C/EBPalpha and peroxisome proliferator-activated receptor gamma in IRS-1(-/-) brown adipocytes up-regulated UCP-1 protein content and transactivated UCP-1 promoter regardless of insulin stimulation. Both C/EBPalpha and peroxisome proliferator-activated receptor gamma reconstituted FAS mRNA expression, but only C/EBPalpha restored insulin sensitivity in the absence of IRS-1. Finally, reconstitution of IRS-1(-/-) brown adipocytes with the IRS-1 mutants IRS-1(Phe-895), which lacks IRS-1/growth factor receptor binding protein 2 binding but not IRS-1/p85-PI 3-kinase binding, or with IRS-1(Tyr-608/Tyr-628/Tyr-658), which only binds p85-PI 3-kinase, induced UCP-1 expression and transactivated the UCP-1 promoter. These data provide strong evidence for an essential role of IRS-1 through the PI 3-kinase/Akt signaling pathway inducing UCP-1 gene expression by insulin.				benito@farm.ucm.es	CASSARD, Anne-Marie/B-6095-2019; Kahn, Ronald/AAY-2435-2021; Pons, Sebastian/K-7794-2014; Benito, Manuel/J-5637-2014	CASSARD, Anne-Marie/0000-0002-1813-5128; Kahn, Ronald/0000-0002-7583-9228; Pons, Sebastian/0000-0003-1027-0621; Benito, Manuel/0000-0002-7218-406X				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Dalgaard LT, 2001, DIABETOLOGIA, V44, P946, DOI 10.1007/s001250100596; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Guerra C, 1996, J BIOL CHEM, V271, P2076, DOI 10.1074/jbc.271.4.2076; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLAUS S, 1994, J CELL SCI, V107, P313; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; TERUEL T, 1995, BIOCHEM J, V310, P771, DOI 10.1042/bj3100771; Teruel T, 1996, BIOCHEM J, V319, P627, DOI 10.1042/bj3190627; TRAYHURN P, 1989, CAN J PHYSIOL PHARM, V67, P811, DOI 10.1139/y89-128; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; Valverde AM, 2001, MOL CELL BIOL, V21, P2269, DOI 10.1128/MCB.21.7.2269-2280.2001; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	48	51	55	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10221	10231		10.1074/jbc.M209363200	http://dx.doi.org/10.1074/jbc.M209363200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525499	hybrid, Green Published			2022-12-25	WOS:000181777500033
J	Van Lanen, SG; Kinzie, SD; Matthieu, S; Link, T; Culp, J; Iwata-Reuyl, D				Van Lanen, SG; Kinzie, SD; Matthieu, S; Link, T; Culp, J; Iwata-Reuyl, D			tRNA modification by S-adenosylmethionine : tRNA ribosyltransferase-isomerase - Assay development and characterization of the recombinant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PREPARATIVE-SCALE PURIFICATION; ESCHERICHIA-COLI; GUANINE TRANSGLYCOSYLASE; WOBBLE BASE; HELA-CELLS; ADENINE PHOSPHORIBOSYLTRANSFERASE; MODIFYING ENZYME; NUTRIENT FACTOR; QUEUINE	The enzyme S-adenosylmethionine:tRNA ribosyltransferase-isomerase catalyzes the penultimate step in the biosynthesis of the hypermodified tRNA nucleoside queuosine (Q), an unprecedented ribosyl transfer from the cofactor S-adenosylmethionine (AdoMet) to a modified-tRNA precursor to generate epoxyqueuosine (oQ). The complexity of the reaction makes it an especially interesting mechanistic problem, and as a foundation for detailed kinetic and mechanistic studies we have carried out the basic characterization of the enzyme. Importantly, to allow for the direct measurement of oQ formation, we have developed protocols for the preparation of homogeneous substrates; specifically, an overexpression system was constructed for tRNATyr in an E. coli queA deletion mutant to allow for the isolation of large quantities of substrate tRNA, and [U-ribosyl-C-14]AdoMet was synthesized. The enzyme shows optimal activity at pH 8.7 in buffers containing various oxyanions, including acetate, carbonate, EDTA, and phosphate. Unexpectedly, the enzyme was inhibited by Mg2+ and Mn2+ in millimolar concentrations. The steady-state kinetic parameters were determined to be K-m(AdoMet) = 101.4 muM, K-m(tRNA) = 1.5 muM, and k(cat) = 2.5 min(-1). A short minihelix RNA was synthesized and modified with the precursor 7-aminomethyl-7-deazaguanine, and this served as an efficient substrate for the enzyme (K-m(RNA) = 37.7 muM and k(cat) = 14.7 min(-1)), demonstrating that the anticodon stem-loop is sufficient for recognition and catalysis by QueA.	Portland State Univ, Dept Chem, Portland, OR 97207 USA	Portland State University	Iwata-Reuyl, D (corresponding author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA.	iwatareuyld@pdx.edu		Link, Todd/0000-0003-1939-9755				AKIMOTO H, 1988, J CHEM SOC P1, V7, P1637; Alfonzo JD, 1997, BBA-PROTEIN STRUCT M, V1341, P173, DOI 10.1016/S0167-4838(97)00068-X; Alfonzo JD, 1999, J BACTERIOL, V181, P347, DOI 10.1128/JB.181.1.347-352.1999; Altman Sidney, 1995, P67; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BARANOWSKI W, 1994, CANCER RES, V54, P4468; Bjork GR, 1995, TRNA STRUCTURE BIOSY, P165; BOYLE SM, 1984, GENE, V30, P129, DOI 10.1016/0378-1119(84)90113-6; BRAVEN J, 1984, ANN CLIN BIOCHEM, V21, P366, DOI 10.1177/000456328402100505; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cunningham L, 1996, NUCLEIC ACIDS RES, V24, P3647, DOI 10.1093/nar/24.18.3647; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DAVOLL J, 1960, J CHEM SOC, P131, DOI 10.1039/jr9600000131; Deutscher Murray P., 1995, P51; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EMMERICH B, 1985, CANCER RES, V45, P4308; FRENCH BT, 1991, P NATL ACAD SCI USA, V88, P370, DOI 10.1073/pnas.88.2.370; GARCIA GA, 1998, MODIFICATION EDITING, P135; GILLAM IC, 1971, METHOD ENZYMOL, V20, P55; HATFIELD D, 1989, VIROLOGY, V173, P736, DOI 10.1016/0042-6822(89)90589-8; Hochstadt J, 1978, Methods Enzymol, V51, P558; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; HOOPS GC, 1995, BIOCHEMISTRY-US, V34, P15381, DOI 10.1021/bi00046a047; HUANG BS, 1992, CANCER RES, V52, P4696; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KERSTEN H, 1988, Biofactors, V1, P27; Kersten H., 1990, CHROMATOGRAPHY MODIF, V45, pB69; Kinzie SD, 2000, ORG LETT, V2, P1307, DOI 10.1021/ol005756h; KIRTLAND GM, 1988, J BACTERIOL, V170, P5633, DOI 10.1128/jb.170.12.5633-5641.1988; Kittendorf JD, 2001, BIOCHEMISTRY-US, V40, P14123, DOI 10.1021/bi0110589; KUCHINO Y, 1976, NUCLEIC ACIDS RES, V3, P393, DOI 10.1093/nar/3.2.393; LANGGUT W, 1990, FEBS LETT, V265, P33, DOI 10.1016/0014-5793(90)80877-L; LANGGUT W, 1993, FEBS LETT, V336, P137, DOI 10.1016/0014-5793(93)81627-C; LANGGUT W, 1995, BIOCHEM BIOPH RES CO, V207, P306, DOI 10.1006/bbrc.1995.1188; LANGGUT W, 1993, ONCOGENE, V8, P3141; LIM CK, 1989, J CHROMATOGR, V461, P259, DOI 10.1016/S0021-9673(00)94291-2; MAHR U, 1990, Biofactors, V2, P185; Maniatis T., 1982, MOL CLONING LAB MANU; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; Marks T, 1997, BIOCHEM BIOPH RES CO, V230, P233, DOI 10.1006/bbrc.1996.5768; MARTIN F, 1993, J MOL BIOL, V234, P965, DOI 10.1006/jmbi.1993.1651; MATOS JR, 1987, BIOTECHNOL APPL BIOC, V9, P39; MATOS JR, 1988, THESIS TEXAS A M U C; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Misra VK, 2000, J MOL BIOL, V299, P813, DOI 10.1006/jmbi.2000.3769; Moore JA, 1997, BIOCHEMISTRY-US, V36, P604, DOI 10.1021/bi962225l; MUELLER SO, 1995, FEBS LETT, V361, P259, DOI 10.1016/0014-5793(95)00169-A; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NISHIMURA S, 1967, BIOCHIM BIOPHYS ACTA, V142, P133, DOI 10.1016/0005-2787(67)90522-9; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P2931, DOI 10.1093/nar/4.8.2931; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; OKADA N, 1979, J BIOL CHEM, V254, P3061; Park J, 1996, BIOORGAN MED CHEM, V4, P2179, DOI 10.1016/S0968-0896(96)00228-3; PARKIN DW, 1984, J BIOL CHEM, V259, P9411; PEARSON JD, 1983, J LIQ CHROMATOGR, V6, P1441, DOI 10.1080/01483918308064863; REISSER T, 1993, BIOCHEM BIOPH RES CO, V197, P1319, DOI 10.1006/bbrc.1993.2621; REISSER T, 1994, EUR J BIOCHEM, V221, P979, DOI 10.1111/j.1432-1033.1994.tb18814.x; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; ROMER R, 1975, EUR J BIOCHEM, V55, P271, DOI 10.1111/j.1432-1033.1975.tb02160.x; Romier C, 1996, BIOCHEMISTRY-US, V35, P15734, DOI 10.1021/bi962003n; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; SCHLAX PE, 1995, BIOTECHNIQUES, V18, P94; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SLANY RK, 1994, BIOCHIMIE, V76, P389, DOI 10.1016/0300-9084(94)90113-9; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; TANNER NK, 1989, METHOD ENZYMOL, V180, P25; THOMPSON JA, 1983, METHOD ENZYMOL, V100, P368; Westaway Shawn K., 1995, P79; WHITE BN, 1973, J MOL BIOL, V74, P635, DOI 10.1016/0022-2836(73)90054-5	72	36	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10491	10499		10.1074/jbc.M207727200	http://dx.doi.org/10.1074/jbc.M207727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533518	hybrid			2022-12-25	WOS:000181777500067
J	Tian, LE; Sayer, JM; Kroth, H; Kalena, G; Jerina, DM; Shuman, S				Tian, LE; Sayer, JM; Kroth, H; Kalena, G; Jerina, DM; Shuman, S			Benzo[alpha]pyrene-dG adduct interference illuminates the interface of vaccinia topoisomerase with the DNA minor groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC INTERACTION; DIOL EPOXIDE; CLEAVAGE SITE; DUPLEX DNA; DEOXYGUANOSINE ADDUCTS; IB TOPOISOMERASE; EXONUCLEASE-III; STRAND CLEAVAGE; MECHANISM; COVALENT	Vaccinia DNA topoisomerase forms a covalent DNA(3'-phosphotyrosyl)-enzyme intermediate at a pentapyrimidine target site 5'-C+5C+4C+3 T(+2)T(+1)pdown arrow in duplex DNA. The enzyme engages the target site within a C-shaped protein clamp. Here we mapped the interface of topoisomerase with the DNA minor groove by introducing chiral C-10 R and S 7,8-diol 9,10-epoxide adducts of benzo[a]pyrene (BP) at single N-2-deoxyguanosine (dG) positions within the nonscissile DNA strand. These trans opened BPdG adducts fit into the minor groove without perturbing helix conformation or base pairing, and the R and S diastereomers are oriented in opposite directions within the minor groove. We measured the effects of the BPdG adducts on the rate and extent of single-turnover DNA transesterification. We observed a sharp margin of interference effects, whereby +5 and -2 BPdG modifications were well tolerated but +4, +3, and -1 BPdG adducts were severely deleterious. Stereo-selective effects at the -1 nucleoside (the R isomer interfered, whereas the S isomer did not) delineated at high resolution the downstream border of the minor groove interface. BPdG inhibition of transesterification is likely caused by steric exclusion of constituents of the topoisomerase from the minor groove. We also applied the BPdG interference method to probe the interactions of exonuclease III with the minor groove. DNAs containing these BPdG adducts were protected from digestion by exonuclease III, which was consistently arrested at positions 2-4 nucleotides prior to the BP-modified guanosine.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; NIDDK, Bioorgan Chem Lab, DHHS, NIH, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.			Kroth, Heiko/0000-0002-6936-3921	NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arslan T, 1998, J BIOL CHEM, V273, P12383, DOI 10.1074/jbc.273.20.12383; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P20907, DOI 10.1074/jbc.M102312200; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Kroth H, 2000, J ORG CHEM, V65, P5558, DOI 10.1021/jo000522x; Kwon K, 2002, J BIOL CHEM, V277, P353, DOI 10.1074/jbc.M109450200; LINXWEILER W, 1982, NUCLEIC ACIDS RES, V10, P4845, DOI 10.1093/nar/10.16.4845; MAO B, 1993, BIOCHEMISTRY-US, V32, P11785, DOI 10.1021/bi00095a006; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Porter KW, 1997, NUCLEIC ACIDS RES, V25, P1611, DOI 10.1093/nar/25.8.1611; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	37	19	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9905	9911		10.1074/jbc.M212468200	http://dx.doi.org/10.1074/jbc.M212468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524450	hybrid			2022-12-25	WOS:000181524000137
J	Carboni, GL; Gao, BN; Nishizaki, M; Xu, K; Minna, JD; Roth, JA; Ji, L				Carboni, GL; Gao, BN; Nishizaki, M; Xu, K; Minna, JD; Roth, JA; Ji, L			CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity	ONCOGENE			English	Article						tumor suppressor genes; apoptosis; calcium channel proteins; human chromosome 3p21.3; lung cancer	CHANNEL SUBUNIT; GABAPENTIN BINDING; CHROMOSOME 3P21.3; TUMOR-SUPPRESSOR; CA2+ HOMEOSTASIS; MULTIPLE GENES; CYTOCHROME-C; ALPHA(2)DELTA; RELEASE; DEATH	The CACNA2D2 gene, a new subunit of the Ca2+-channel complex, was identified in the homozygous deletion region of chromosome 3p21.3 in human lung and breast cancers. Expression deficiency of the CACNA2D2 in cancer cells suggests a possible link of it to Ca2+ signaling in the pathogenesis of lung cancer and other cancers. We investigated the effects of overexpression of CACNA2D2 on intracellular Ca2+ contents, mitochondria homeostasis, cell proliferation, and apoptosis by adenoviral vector-mediated wild-type CACNA2D2 gene transfer in 3p21.3-deficient nonsmall cell lung cancer cell lines. Exogenous expression of CACNA2D2 significantly inhibited tumor cell growth compared with the controls. Overexpression of CACNA2D2 induced apoptosis in H1299 (12.5%), H358 (13.7%), H460 (22.3%), and A549 (50.1%) cell lines. Levels of intracellular free Ca2+ were elevated in AdCACNA2D2-transduced cells compared with the controls. Mitochondria membrane depolarization was observed prior to apoptosis in Ad-CACNA2D2 and Adp53-transduced H460 and A549 cells. Release of cyt c into the cytosol, caspase 3 activation, and PARP cleavage were also detected in these cells. Together, these results suggest that one of the pathways in CACNA2D2-induced apoptosis is mediated through disruption of mitochondria membrane integrity, the release of cyt c, and the activation of caspases, a process that is associated with regulation of cytosolic free Ca2+ contents.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med & Pharmacol, Dallas, TX 75390 USA; Univ Hosp Bern, Div Gen Thorac Surg, Bern, Switzerland	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Bern; University Hospital of Bern	Ji, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd,Box 445, Houston, TX 77030 USA.		Carboni, Giovanni/AAA-1780-2021	Carboni, Giovanni/0000-0003-3969-1227	NCI NIH HHS [P01 CA78778-01A1, R01 CA071618, CA16672, 2P50-CA70907-04, P50 CA070907, P30 CA016672, P01 CA078778, CA71618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA071618, P50CA070907, P01CA078778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2000, MOL CELL PROBE, V14, P53, DOI 10.1006/mcpr.1999.0277; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; COSSARIZZA A, 1995, BIOCHEM BIOPH RES CO, V214, P503, DOI 10.1006/bbrc.1995.2315; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Felix R, 1999, RECEPTOR CHANNEL, V6, P351; Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Hurley JF, 2000, P NATL ACAD SCI USA, V97, P9293, DOI 10.1073/pnas.160589697; Ji L, 1999, CANCER RES, V59, P3333; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Klugbauer N, 1999, J NEUROSCI, V19, P684; Kochegarov AA, 2001, COMP BIOCHEM PHYS A, V128, P279, DOI 10.1016/S1095-6433(00)00306-8; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacinova L, 2000, GEN PHYSIOL BIOPHYS, V19, P121; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lerman MI, 2000, CANCER RES, V60, P6116; Marais E, 2001, MOL PHARMACOL, V59, P1243, DOI 10.1124/mol.59.5.1243; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nishizaki M, 2001, CLIN CANCER RES, V7, P2887; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Toyota M, 1999, CANCER RES, V59, P4535; Ueki T, 2000, CANCER RES, V60, P1835; Varadi G, 1999, CRIT REV BIOCHEM MOL, V34, P181, DOI 10.1080/10409239991209264; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang MH, 1999, BIOCHEM J, V342, P313, DOI 10.1042/0264-6021:3420313; Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	46	57	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					615	626		10.1038/sj.onc.1206134	http://dx.doi.org/10.1038/sj.onc.1206134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555074	Green Accepted			2022-12-25	WOS:000180538200014
J	Fujita, M; Ichinose, S; Kiyono, T; Tsurumi, T; Omori, A				Fujita, M; Ichinose, S; Kiyono, T; Tsurumi, T; Omori, A			Establishment of latrunculin-A resistance in HeLa cells by expression of R183A D184A mutant beta-actin	ONCOGENE			English	Article							CYTOCHALASIN; MOTILITY; YEAST	Actin plays central roles in cell motility through formation of the actin cytoskeleton. Recently, the very intriguing possibility that actin also contributes to processes in the cell nucleus has been emerging. To dissect its dynamics and functions, several actin-disrupting drugs have been widely and effectively employed. Among them, latrunculin-A has proved particularly useful, supplanting the classical drug cytochalasin-D. One reason is that latrunculin-A appears to bind only to actin monomers impairing the nucleotide exchange, the mode being simpler than with cytochalasin. This property may be especially crucial when studying actin functions as a monomer, as suggested for nuclear actin. Very importantly, actin mutations that cause cells to become resistant to the effects of latrunculin-A have been identified in budding yeast. However, it remains controversial as to whether all of the various phenotypes observed with latrunculin in mammalian cells more complicated than yeast are truly the consequence of its specific actions against actin. Here, we show that the expression of R183A D184A mutant beta-actin specifically confers resistance to the effects of latrunculin-A on actin cytoskeleton formation and cell growth in HeLa cells. The established system provides a strong tool to address the various functions of actin in mammalian cells.			Fujita, M (corresponding author), Natl Canc Ctr, Virol Div, Chuoh Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	mafujita@gan2.res.ncc.go.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; TOYAMA S, 1984, CELL, V37, P609, DOI 10.1016/0092-8674(84)90391-X; Wasser M, 2000, NAT CELL BIOL, V2, P268, DOI 10.1038/35010535; WERTMAN KF, 1992, GENETICS, V132, P337; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	14	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					627	631		10.1038/sj.onc.1206173	http://dx.doi.org/10.1038/sj.onc.1206173			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555075				2022-12-25	WOS:000180538200015
J	Vandesompele, J; Edsjo, A; De Preter, K; Axelson, H; Speleman, F; Pahlman, S				Vandesompele, J; Edsjo, A; De Preter, K; Axelson, H; Speleman, F; Pahlman, S			ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value	ONCOGENE			English	Article						ID2; MYC; MYCN; neuroblastoma; prognosis	N-MYC; GENE-EXPRESSION; PROTEINS; CELLS	The MYCN proto-oncogene is frequently amplified in a subgroup of highly aggressive neuroblastomas. The molecular mechanism(s) by which the overexpressed MYCN contributes to an aggressive tumor cell behavior is not well understood. Recently, it was reported that the ID2 gene is a direct target for the MYCN and MYC transcription factors, and that ID2 expression and MYCN amplification correlate positively in neuroblastoma. In addition, ID2 expression was proposed as a negative prognostic parameter. As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated. We found no correlation between MYCN and ID2 expression in neuroblastoma cell lines or tumor specimens. However, we did find a significant positive correlation between MYC and ID2 expressions in both MYCN-amplified and single-copy tumor specimens, and in MYCN single-copy cell lines. As previously reported, we also found an inverse correlation between MYC and MYCN expressions. Importantly, we could not confirm the reported prognostic power of ID2-expression in neuroblastoma. These data, obtained in two independent laboratories, challenge the previously proposed ID2-MYCN relation.	Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, S-20502 Malmo, Sweden; Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium	Lund University; Skane University Hospital; Ghent University; Ghent University Hospital	Pahlman, S (corresponding author), Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, Entrance 78, S-20502 Malmo, Sweden.	sven.pahlman@molmed.mas.lu.se	Edsjö, Anders/AAC-8658-2019; speleman, frank/AAR-5184-2020; De Preter, Katleen/I-7135-2013; Vandesompele, Jo/W-3411-2018	speleman, frank/0000-0002-6628-8559; De Preter, Katleen/0000-0002-7726-5096; Vandesompele, Jo/0000-0001-6274-0184				Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; De Preter K, 2002, MODERN PATHOL, V15, P159, DOI 10.1038/modpathol.3880508; Hoehner JC, 1998, LAB INVEST, V78, P29; Hoehner JC, 1996, LAB INVEST, V75, P659; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Judware R, 1995, ONCOGENE, V11, P2599; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Reiter JL, 1998, GENE CHROMOSOME CANC, V23, P134, DOI 10.1002/(SICI)1098-2264(199810)23:2<134::AID-GCC6>3.0.CO;2-3; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	20	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					456	460		10.1038/sj.onc.1206148	http://dx.doi.org/10.1038/sj.onc.1206148			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545167				2022-12-25	WOS:000180379100015
J	Demeret, C; Garcia-Carranca, A; Thierry, F				Demeret, C; Garcia-Carranca, A; Thierry, F			Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein	ONCOGENE			English	Article						HPV18 E2; apoptosis; caspases; extrinsic pathway; transactivation domain	CERVICAL-CARCINOMA; TRANSACTIVATION DOMAIN; CASPASE FAMILY; HELA-CELLS; TYPE-16; ACTIVATION; E6; PROLIFERATION; DEGRADATION; ONCOPROTEIN	Cervical carcinomas are most frequently associated with human papillomaviruses (HPV), whose E6 and E7 oncogenes products induce cellular immortalization. The papillomavirus E2 protein is a transcription factor, which represses the expression of the viral oncogenes, and activates viral DNA replication during the vegetative viral cycle. This protein is specifically inactivated in HPV18-associated carcinoma cells, suggesting that E2 functions prevent carcinogenic progression. Indeed, ectopic expression of E2 in cervical carcinoma cells strongly inhibits cell proliferation. Here we show that above a threshold level of expression, the E2 protein induces apoptosis, independently of other viral functions. The amino-terminal domain is responsible for this apoptotic activity, but surprisingly with no involvement of its transcriptional functions. The death pathway triggered by E2 relies on activation of the initiator caspase 8, specific of the extrinsic pathway of apoptosis. E2 itself is cleaved by caspases during cell death, providing an example of an apoptotic inducer that is itself a target for caspase processing. The autonomous proapoptotic activity of HPV18 E2 described here may counteract the proliferative functions of viral oncogenes, and renders the inactivation of E2 crucial for carcinogenic progression.	Inst Pasteur, Unit Gene Express & Dis, URA 1644, CNRS, F-75724 Paris 15, France; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad Nacional Autonoma de Mexico	Demeret, C (corresponding author), Inst Pasteur, Unit Gene Express & Dis, URA 1644, CNRS, Fernbach Bldg,25 Rue Dr Roux, F-75724 Paris 15, France.			Demeret, caroline/0000-0002-1103-6805				Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Corden SA, 1999, J CLIN PATHOL-MOL PA, V52, P275, DOI 10.1136/mp.52.5.275; Crouzet J, 1997, P NATL ACAD SCI USA, V94, P1414, DOI 10.1073/pnas.94.4.1414; DARZYNKIEWICZ Z, 1994, METHODS CELL BIOL; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Maitland NJ, 1998, J PATHOL, V186, P275, DOI 10.1002/(SICI)1096-9896(1998110)186:3&lt;275::AID-PATH159&gt;3.0.CO;2-E; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049	27	67	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					168	175		10.1038/sj.onc.1206108	http://dx.doi.org/10.1038/sj.onc.1206108			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527886				2022-12-25	WOS:000180322400002
J	Mitev, YA; Wolf, SS; Almeida, OFX; Patchev, VK				Mitev, YA; Wolf, SS; Almeida, OFX; Patchev, VK			Developmental expression profiles and distinct regional estrogen responsiveness suggest a novel role for the steroid receptor coactivator SRC-1 as a discriminative amplifier of estrogen signaling in the rat brain	FASEB JOURNAL			English	Article						ontogeny; regulation; hypothalamus; cortex	ELEMENT-BINDING PROTEIN; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; REPRODUCTIVE-BEHAVIOR; ER-BETA; HORMONE; ALPHA; COREGULATORS; PITUITARY; MICE	The regional distribution, developmental profiles, and gonadectomy- and estrogen-induced changes in the density of transcripts encoding the steroid receptor coactivator-1 (SRC-1) were examined in the female rat brain by semiquantitative in situ hybridization. The results demonstrate striking differences in the abundance of SRC-1 mRNA in discrete brain regions throughout ontogeny. Whereas transcript densities gradually decreased with age in the cerebral cortex, they peaked prominently during the peripubertal period in the hypothalamic medial preoptic area (MPOA) and ventromedial nucleus (VMN). Gonadectomy and estrogen substitution influenced SRC-1 mRNA levels in sexually mature animals in a region-specific fashion. Ovariectomy resulted in a down-regulation of SRC-1 mRNA levels in the VMN, a brain region richly endowed with estrogen receptors and playing a major role in neuroendocrine control of reproductive functions. In contrast, SRC-1 transcript levels were significantly upregulated after estradiol treatment. Interestingly, SRC-1 expression in the cortex was refractory to alterations of the estrogen milieu. The obtained SRC-1 mRNA expression profiles during development clearly demonstrate brain region specificity and regulation by estrogen, thus it is proposed that SRC-1 amplifies estrogen receptor-dependent transcription in a temporally and spatially coordinated manner and therefore contributes to the functional specialization of brain areas involved in the regulation of reproduction.	Schering AG Jenapharm, Gender Hlth Care Res, D-07745 Jena, Germany; Max Planck Inst Psychiat, Dept Neuroendocrinol, D-80804 Munich, Germany	Schering AG; Max Planck Society	Patchev, VK (corresponding author), Jenapharm GmbH & Co KG, Otto Schott St 15, D-07745 Jena, Germany.	Vladimir.Patchev@jenapharm.de	Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928				Apostolakis EM, 2002, MOL ENDOCRINOL, V16, P1511, DOI 10.1210/me.16.7.1511; Auger AP, 2000, P NATL ACAD SCI USA, V97, P7551, DOI 10.1073/pnas.97.13.7551; Auger AP, 2002, ENDOCRINOLOGY, V143, P3009, DOI 10.1210/en.143.8.3009; Bousios S, 2001, J STEROID BIOCHEM, V78, P401, DOI 10.1016/S0960-0760(01)00123-6; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; MADEIRA MD, 1995, PROG NEUROBIOL, V45, P275, DOI 10.1016/0301-0082(94)00052-J; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Meijer OC, 2000, ENDOCRINOLOGY, V141, P2192, DOI 10.1210/en.141.6.2192; Meijer OC, 2002, J NEUROENDOCRINOL, V14, P499, DOI 10.1046/j.1365-2826.2002.00795.x; Misiti S, 1999, ENDOCRINOLOGY, V140, P1957, DOI 10.1210/en.140.4.1957; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Molenda HA, 2002, ENDOCRINOLOGY, V143, P436, DOI 10.1210/en.143.2.436; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; Ojeda SR, 1994, PHYSL REPRODUCTION, V2, P363; ONATE SA, 1995, SCIENCE, V270, P1354; Osterlund MK, 2000, J CLIN ENDOCR METAB, V85, P3840, DOI 10.1210/jc.85.10.3840; PATCHEV VK, 1999, STEROID HORMONE DEPE, P39; PFAFF DW, 1994, PHYSL REPRODUCTION, V2, P107; PILGRIM C, 1994, NEUROSCIENCE, V60, P843, DOI 10.1016/0306-4522(94)90267-4; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Smith CL, 2002, MOL CELL BIOL, V22, P525, DOI 10.1128/MCB.22.2.525-535.2002; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swanson L. W, 1998, BRAIN MAPS STRUCTURE; ToranAllerand CD, 1996, DEV NEUROSCI-BASEL, V18, P36, DOI 10.1159/000111393; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; Xu JJ, 1998, ELECTROCHEM SOLID ST, V1, P1, DOI 10.1149/1.1390615	32	51	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					518	+		10.1096/fj.02-0513fje	http://dx.doi.org/10.1096/fj.02-0513fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551846				2022-12-25	WOS:000181453700011
J	Mohanty, AK; Singh, G; Paramasivam, M; Saravanan, K; Jabeen, T; Sharma, S; Yadav, S; Kaur, P; Kumar, P; Srinivasan, A; Singh, TP				Mohanty, AK; Singh, G; Paramasivam, M; Saravanan, K; Jabeen, T; Sharma, S; Yadav, S; Kaur, P; Kumar, P; Srinivasan, A; Singh, TP			Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONLACTATING PERIOD; SYNOVIAL-CELLS; CHITINASE; BINDING; LECTIN; RESOLUTION; IDENTIFICATION; SYSTEM; MEMBER	We have determined the crystal structure of a novel regulatory protein (MGP-40) from the mammary gland. This protein is implicated as a protective signaling factor that determines which cells are to survive the drastic tissue remodeling that occurs during involution. It has been indicated that certain cancers could surreptitiously utilize the proposed normal protective signaling by proteins of this family to extend their own survival and thereby allow them to invade the organ and metastasize. In view of this, MGP-40 could form an important target for rational structure-based drug design against breast cancer. It is a single chain, glycosylated protein with a molecular mass of 40 kDa. It was isolated from goat dry secretions and has been cloned and sequenced. It was crystallized by microdialysis from 20 mg ml(-1) solution in 0.1 m Tris-HCl, pH 8.0, and equilibrated against the same solution containing 19% ethanol. Its x-ray structure has been determined by molecular replacement and refined to a 2.9 Angstrom resolution. The protein adopts a beta/alpha domain structure with a triose-phosphate isomerase barrel conformation in the core and a small alpha+beta folding domain. A single glycosylation site containing two N-acetylglucosamine units has been observed in the structure. Compared with chitinases and chitinase-like proteins the most important mutation in this protein pertains to a change from Glu to Leu at position 119, which is part of the so-called active site sequence in the form of Asp(115), Leu(119), and ASp(186) and in this case resulting in the loss of chitinase activity. The orientations of two Trp residues Trp(78) and Trp(331) in the beta barrel reduces the free space, drastically impairing the binding of saccharides/polysaccharides. However, the site and mode of binding of this protein to cell surface receptors are not yet known.	All India Inst Med Sci, Dept Biophys, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.	tps@aiims.aiims.ac.in		Kumar, Pravindra/0000-0003-2128-7736				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aronson NN, 1997, J CHEM INF COMP SCI, V37, P999, DOI 10.1021/ci970236v; Boraston AB, 2000, BIOCHEM J, V350, P933, DOI 10.1042/0264-6021:3500933; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENNIG M, 1992, FEBS LETT, V306, P80, DOI 10.1016/0014-5793(92)80842-5; HENNIG M, 1995, J MOL BIOL, V254, P237, DOI 10.1006/jmbi.1995.0614; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MORRISON BW, 1994, ONCOGENE, V9, P3417; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; QUIOCHO FA, 1988, CURR TOP MICROBIOL, V139, P135; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; Sawicki MW, 2001, IMMUNOL REV, V181, P52, DOI 10.1034/j.1600-065X.2001.1810104.x; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; TABARY F, 1985, BIOCHEM J, V229, P687, DOI 10.1042/bj2290687; Varela PF, 2002, J BIOL CHEM, V277, P13229, DOI 10.1074/jbc.M110502200; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	29	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14451	14460		10.1074/jbc.M208967200	http://dx.doi.org/10.1074/jbc.M208967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12529329	hybrid			2022-12-25	WOS:000182405000112
J	Deng, Y; Pang, A; Wang, JH				Deng, Y; Pang, A; Wang, JH			Regulation of mammalian STE20-like kinase 2 (MST2) by protein phophorylation/dephosphorylation and proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED ACTIVATION; PHOSPHORYLATION; APOPTOSIS; MST/KRS; CLEAVAGE; CLONING	Mammalian STE20-like kinase 2 (MST2), a member of the STE20-like kinase family, has been shown in previous studies to undergo proteolytic activation by caspase-3 during cell apoptosis. A few studies have also implicated protein phosphorylation reactions in MST2 regulation. In this study, we examined the mechanism of MST2 regulation with an emphasis on the relationship between caspase-3 cleavage and protein phosphorylation. Both the full-length MST2 and the caspase-3 truncated form of MST2 overexpressed in 293T cells exist in a phosphorylated state. On the other hand, the endogenous full-length MST2 from rat thymus or from proliferating cells is mainly unphosphorylated whereas the caspase-3-truncated endogenous MST2 from apoptotic cells is highly phosphorylated. Cell transfection studies using mutant MST2 constructs indicate that MST2 depends on the autophosphorylation of a unique threonine residue, Thr(180), for kinase activity. The autophosphorylation reaction shows strong dependence on MST2 concentration suggesting that it is an intermolecular reaction. While both the full-length MST2 and the caspase-3-truncated form of MST2 undergo autophosphorylation, the two forms of the phosphorylated MST2 display marked difference in susceptibility to protein phosphatases. The full-length phospho-MST2 is rapidly dephosphorylated by protein phosphatase 1 or protein phosphatase 2A whereas the truncated MST2 is remarkably resistant to the dephosphorylation. Based on the present results, a novel molecular mechanism for MST2 regulation in apoptotic cells is postulated. In normal cells, because of the low concentration and the ready reversal of the autophosphorylation by protein phosphatases, MST2 is present mainly in the unphosphorylated and inactive state. During cell apoptosis, MST2 is cleaved by caspase-3 and undergoes irreversible autophosphorylation, thus resulting in the accumulation of active MST2.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	jerwang@ust.hk						Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Kakeya H, 1998, CANCER RES, V58, P4888; Kakeya H, 1999, ANN NY ACAD SCI, V886, P273, DOI 10.1111/j.1749-6632.1999.tb09434.x; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lian JP, 2001, J IMMUNOL, V166, P6349, DOI 10.4049/jimmunol.166.10.6349; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; Watabe M, 2000, J BIOL CHEM, V275, P8766, DOI 10.1074/jbc.275.12.8766	23	54	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11760	11767		10.1074/jbc.M211085200	http://dx.doi.org/10.1074/jbc.M211085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12554736	hybrid			2022-12-25	WOS:000182015700007
J	El Meskini, R; Culotta, VC; Mains, RE; Eipper, BA				El Meskini, R; Culotta, VC; Mains, RE; Eipper, BA			Supplying copper to the cuproenzyme peptidylglycine alpha-amidating monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; WILSON-DISEASE PROTEIN; FACTOR LEADER REGION; P-TYPE ATPASES; MENKES-DISEASE; FUNCTIONAL EXPRESSION; SECRETORY PATHWAY; HYDROXYLATING MONOOXYGENASE; TRANSPORTING ATPASE; GOLGI COMPARTMENT	We explored the role of known copper transporters and chaperones in delivering copper to peptidylglycine-alpha-hydroxylating monooxygenase (PHM), a copper-dependent enzyme that functions in the secretory pathway lumen. We examined the roles of yeast Ccc2, a P-type ATPase related to human ATP7A (Menkes disease protein) and ATP7B (Wilson disease protein), as well as yeast Atx1, a cytosolic copper chaperone. We expressed soluble PHMcc (catalytic core) in yeast using the yeast pre-pro-alpha-mating factor leader region to target the enzyme to the secretory pathway. Although the yeast genome encodes no PHM-like enzyme, PHMcc expressed in yeast is at least as active as PHMcc produced by mammalian cells. PRMcc partially co-migrated with a Golgi marker during subcellular fractionation and partially co-localized with Ccc2 based on immunofluorescence. To determine whether production of active PHM was dependent on copper trafficking pathways involving the CCC2 or ATX1 genes, we expressed PFMcc in wild-type, ccc2, and atx1 mutant yeast. Although ccc2 and atx1 mutant yeast produce normal levels of PHMcc protein, it lacks catalytic activity. Addition of exogenous copper yields fully active PHMcc. Similarly, production of active PHM in mouse fibroblasts is impaired in the presence of a mutant ATP7A gene. Although delivery of copper to lumenal cuproproteins like PAM involves ATP7A, lumenal chaperones may not be required.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	University of Connecticut; Johns Hopkins University	Eipper, BA (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	eipper@uchc.edu			NIDDK NIH HHS [DK-32949] Funding Source: Medline; NIGMS NIH HHS [GM-50016] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R37DK032949, R01DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050016, R37GM050016] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Bell J, 1997, BIOCHEMISTRY-US, V36, P16239, DOI 10.1021/bi970903d; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; El Meskini R, 2001, J BIOL CHEM, V276, P3384, DOI 10.1074/jbc.M008062200; ELLIOTT S, 1989, GENE, V79, P167, DOI 10.1016/0378-1119(89)90102-9; FELDMAN RI, 1987, J BIOL CHEM, V262, P9332; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GREEN R, 1986, J BIOL CHEM, V261, P7558; Grimes A, 1997, HUM MOL GENET, V6, P1037, DOI 10.1093/hmg/6.7.1037; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kelly EJ, 1996, NAT GENET, V13, P219, DOI 10.1038/ng0696-219; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kosonen T, 1997, BIOCHEM J, V327, P283, DOI 10.1042/bj3270283; Kulathila R, 1999, NAT PROD REP, V16, P145, DOI 10.1039/a801346b; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LINDGREN S, 1991, SCAND J GASTROENTERO, V26, P361, DOI 10.3109/00365529108996495; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P381; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Marx R, 1999, J NEUROSCI, V19, P8300; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; Meskini RE, 2000, ENDOCRINOLOGY, V141, P3020; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Murata Y, 1997, PEDIATR RES, V42, P436, DOI 10.1203/00006450-199710000-00003; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; Otterbein L, 2000, EUR J BIOCHEM, V267, P1619, DOI 10.1046/j.1432-1327.2000.01166.x; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Sayre LM, 2000, CELL MOL BIOL, V46, P731; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steveson TC, 2003, ENDOCRINOLOGY, V144, P188, DOI 10.1210/en.2002-220716; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; WATERS MG, 1988, J BIOL CHEM, V263, P6209; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	68	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12278	12284		10.1074/jbc.M211413200	http://dx.doi.org/10.1074/jbc.M211413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529325	hybrid			2022-12-25	WOS:000182015700073
J	Khoshbouei, H; Wang, HW; Lechleiter, JD; Javitch, JA; Galli, A				Khoshbouei, H; Wang, HW; Lechleiter, JD; Javitch, JA; Galli, A			Amphetamine-induced dopamine efflux - A voltage-sensitive and intracellular Na+-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; CARRIER-MEDIATED RELEASE; PROTEIN-KINASE-C; SEROTONIN TRANSPORTERS; EXCHANGE DIFFUSION; TRANSFECTED CELLS; MICE LACKING; COCAINE; NEURONS; CALCIUM	Amphetamine (AMPH) elicits its behavioral effects by acting on the dopamine (DA) transporter (DAT) to induce DA overflow into the synaptic cleft. Facilitated exchange diffusion is the classical model used to describe AMPH-induced DA efflux. This model hypothesizes that AMPH-induced DA efflux is mediated by DAT and results from the transport of AMPH into the cell followed by a counter movement of DA out to the extracellular compartment. To further characterize the action of AMPH, we used the patch clamp technique in the whole-cell configuration combined with amperometry on human embryonic kidney HEK-293 cells stably transfected with the human DAT (DAT cells). In DAT cells, AMPH-induced DAT-mediated currents were blocked by cocaine. We demonstrate that DA efflux mediated by DAT is voltage-dependent, electrogenic, and dependent on intracellular Na+ concentration in the recording electrode. Intracellular Na+ fluorescence, as measured by confocal microscopy using a Na+-sensitive dye, was enhanced by AMPH application. Furthermore, the ability of AMPH to induce DA efflux was regulated by intracellular Na+ concentration and correlated with the size of the DAT-mediated, AMPH-induced ion flux across the plasma membrane. In the absence of intracellular Na+ but the presence of high intracellular Cl-, AMPH-induced inward currents elicited DA efflux proportionally to their dimension and duration. Thus, we propose that AMPH-induced DA efflux depends on two correlated transporter processes. First, AMPH binds to the DAT and is transported, thereby causing an inward current. Second, because of this AMPH-induced inward current, Na+ becomes more available intracellularly to the DAT, thereby enhancing DAT-mediated reverse transport of DA.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Health San Antonio; Columbia University; Columbia University; Columbia University	Galli, A (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	Aurelio.Galli@Vanderbilt.edu		Javitch, Jonathan/0000-0001-7395-2967; Khoshbouei, Habibeh/0000-0002-1533-8771	NIDA NIH HHS [DA-14684, DA-13975] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013975, R01DA014684] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BONISCH H, 1986, N-S ARCH PHARMACOL, V332, P135, DOI 10.1007/BF00511403; Burnette WB, 1996, ANAL CHEM, V68, P2932, DOI 10.1021/ac960022x; Chen NH, 1998, J NEUROCHEM, V71, P653; Chen NH, 2000, MOL BRAIN RES, V75, P208, DOI 10.1016/S0169-328X(99)00288-0; Cowell RM, 2000, EUR J PHARMACOL, V389, P59, DOI 10.1016/S0014-2999(99)00828-6; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; Jones SR, 1998, J NEUROSCI, V18, P1979; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Kantor L, 2001, J PHARMACOL EXP THER, V297, P1016; LIANG NY, 1983, EUR J PHARMACOL, V89, P153, DOI 10.1016/0014-2999(83)90621-0; NELSON PJ, 1982, J BIOL CHEM, V257, P6151; Pierce RC, 1997, J NEUROSCI, V17, P3254; Pifl C, 1999, MOL PHARMACOL, V56, P1047, DOI 10.1124/mol.56.5.1047; Pifl C, 1999, NEUROPHARMACOLOGY, V38, P157, DOI 10.1016/S0028-3908(98)00155-5; POWIS DA, 1988, N-S ARCH PHARMACOL, V337, P273; Prasad BM, 2001, J NEUROSCI, V21, P7561, DOI 10.1523/JNEUROSCI.21-19-07561.2001; RAITERI M, 1979, J PHARMACOL EXP THER, V208, P195; Rees S, 1996, BIOTECHNIQUES, V20, P102; RUDNICK G, 1992, BIOCHEMISTRY-US, V31, P6710, DOI 10.1021/bi00144a010; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; SULZER D, 1995, J NEUROSCI, V15, P4102; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; SULZER D, 1992, ANN NY ACAD SCI, V654, P525, DOI 10.1111/j.1749-6632.1992.tb26020.x	31	143	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12070	12077		10.1074/jbc.M212815200	http://dx.doi.org/10.1074/jbc.M212815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556446	hybrid			2022-12-25	WOS:000182015700047
J	Shoji, H; Nishi, N; Hirashima, M; Nakamura, T				Shoji, H; Nishi, N; Hirashima, M; Nakamura, T			Characterization of the Xenopus galectin family - Three structurally different types as in mammals and regulated expression during embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; PERIPHERAL-NERVES; ANIMAL LECTINS; CDNA CLONING; LAEVIS; GENE; PEPTIDE; GROWTH; DEATH; BONES	We have isolated six novel galectin cDNAs from a Xenopus laevis kidney cDNA library. The newly identified X. laevis galectins (xgalectins) comprise one proto type (xgalectin-Vb), one chimera type (xgalectin-VIIa), and four tandem repeat types (xgalectin-IIb, -IIIb, -VIa, and -VIIIa). Thus, together with those mentioned in our previous work (Shoji, H., Nishi, N., Hirashima, M., and Nakamura, T. (2002) Glycobiology 12, 163-172), the 12 xgalectins are classified into three types based on their domain structures, as in mammals. The xgalectins whose counterparts in other species have not been identified (xgalectin-IVa, -Vb, and -VIa) were confirmed to possess lactose-binding activity by expression of their recombinant forms. This shows that they truly function as animal lectins. The protein purification study revealed that the major xgalectins in kidney are xgalectin-Ib, -IIa, -IIb, -IIIa, and -VIIa. The mRNAs of xgalectin-IIb, -IIIb, -Vb, and -VIa were localized to specific adult tissues, whereas those of xgalectin-VIIa and -VIIIa were broadly distributed. The temporal expression patterns of the mRNAs of the 12 xgalectins during embryogenesis were analyzed and categorized into three groups: 1) mRNA observed to exist throughout embryogenesis, i.e. maternal mRNA also exists (xgalectin-Ia, -IIa, -IIIa, -IIIb, -Va, -VIIa, and -VIIIa); 2) mRNA observed from the gastrula stage (xgalectin-VIa); and 3) mRNA observed from the tail bud or the tadpole stage (xgalectin-Ib, -IIb, -IVa, and -Vb). The mRNA of the most abundant xgalectin in embryos, xgalectin-VIIa, was localized to the surface layer of embryos, the epidermis, the cement gland, and various placodes. Xgalectin-VIIa protein was also observed to exist throughout embryogenesis by Western blot analysis with specific antiserum. These results show that the expression of each member is spatiotemporally regulated from eggs to adulthood, suggesting that galectins play multiple roles not only in adults, but also in development.	Kagawa Med Univ, Dept Endocrinol, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Immunol & Immunopathol, Kagawa 7610793, Japan; Galpharma Co Ltd, Kagawa 7610301, Japan	Kagawa University; Kagawa University	Nakamura, T (corresponding author), Kagawa Med Univ, Dept Endocrinol, 1750-1 Miki Cho, Kagawa 7610793, Japan.			Nishi, Nozomu/0000-0001-7050-3226				BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; Colnot C, 2001, DEV BIOL, V229, P203, DOI 10.1006/dbio.2000.9933; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; Dunphy JL, 2000, J BIOL CHEM, V275, P32106, DOI 10.1074/jbc.M003739200; Dunphy JL, 2002, J BIOL CHEM, V277, P14916, DOI 10.1074/jbc.M200214200; Evanson JE, 1996, J CRAN GENET DEV BIO, V16, P74; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; FRUNCHAK YN, 1993, ANAT EMBRYOL, V187, P299; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; Gopalkrishnan RV, 2000, ONCOGENE, V19, P4405, DOI 10.1038/sj.onc.1203767; Horie H, 1999, J NEUROSCI, V19, P9964; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Inagaki Y, 2000, EUR J BIOCHEM, V267, P2955, DOI 10.1046/j.1432-1033.2000.01311.x; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; Murphy KM, 1999, DEV DYNAM, V215, P248, DOI 10.1002/(SICI)1097-0177(199907)215:3<248::AID-AJA7>3.3.CO;2-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishi N, 1996, PROSTATE, V28, P139; Okabayashi K, 1999, BIOCHEM BIOPH RES CO, V254, P42, DOI 10.1006/bbrc.1998.9892; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; POIRIER F, 1992, DEVELOPMENT, V115, P143; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; Sato M, 2002, J BIOCHEM, V131, P255, DOI 10.1093/oxfordjournals.jbchem.a003096; Sato M, 2002, GLYCOBIOLOGY, V12, P191, DOI 10.1093/glycob/12.3.191; Shoji H, 2002, GLYCOBIOLOGY, V12, P163, DOI 10.1093/glycob/12.3.163; Visegrady B, 2001, PROTEIN ENG, V14, P875, DOI 10.1093/protein/14.11.875; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Yamada K, 1999, DEV BIOL, V214, P318, DOI 10.1006/dbio.1999.9412; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200	38	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12285	12293		10.1074/jbc.M209008200	http://dx.doi.org/10.1074/jbc.M209008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538594	hybrid			2022-12-25	WOS:000182015700074
J	Kalant, D; Cain, SA; Maslowska, M; Sniderman, AD; Cianflone, K; Monk, PN				Kalant, D; Cain, SA; Maslowska, M; Sniderman, AD; Cianflone, K; Monk, PN			The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg(77)/acylation-stimulating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLATION-STIMULATING PROTEIN; HUMAN C5A RECEPTOR; ANAPHYLATOXIN C3A; U937 CELLS; COMPLEMENT; C3A(DESARG); EXPRESSION; NEUTROPHILS; CHEMOTAXIN; ACTIVATION	The orphan receptor C5L2 has recently been described as a high affinity binding protein for complement fragments C5a and C3a that, unlike the previously described C5a receptor (CD88), couples only weakly to G; like G proteins (Cain, S. A., and Monk, P. N. (2002) J. Biol. Chem. 277, 7165-7169). Here we demonstrate that C5L2 binds the metabolites of C4a and C3a, C4a des-Arg(77), and C3a des-Arg(77) (also known as the acylation-stimulating protein or ASP) at a site distinct from the C5a binding site. The binding of these metabolites to C5L2 does not stimulate the degranulation of transfected rat basophilic leukemia cells either through endogenous rat G proteins or when co-transfected with human G(alpha16). C3a des-Arg(77)/ASP and C3a can potently stimulate triglyceride synthesis in human skin fibroblasts and 3T3-L1 preadipocytes. Here we show that both cell types and human adipose tissue express C5L2 mRNA and that the human fibroblasts express C5L2 protein at the cell surface. This is the first demonstration of the expression of C5L2 in cells that bind and respond to C3a des-Arg(77)/ASP and C3a. Thus C5L2, a promiscuous complement fragment-binding protein with a high affinity site that binds C3a des-Arg /ASP, may mediate the acylation-stimulating properties of this peptide.	Univ Sheffield, Sch Med, Dept Neurol, Sheffield S10 2RX, S Yorkshire, England; McGill Univ, Ctr Hlth, Div Med, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada	University of Sheffield; McGill University	Monk, PN (corresponding author), Univ Sheffield, Sch Med, Dept Neurol, E Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.		Monk, Peter/C-6155-2008; Cain, Stuart A/G-2836-2017	Monk, Peter/0000-0003-4637-3059; Cain, Stuart/0000-0001-8417-1058				BALDO A, 1995, J LIPID RES, V36, P1415; Bhatia M, 2000, J PATHOL, V190, P117; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; CHARRIAUT C, 1982, P NATL ACAD SCI-BIOL, V79, P6003, DOI 10.1073/pnas.79.19.6003; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; CIANFLONE K, 1989, J LIPID RES, V30, P1727; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Fischer WH, 1997, J IMMUNOL, V159, P4279; Fischer WH, 1999, J IMMUNOL, V162, P453; KLOS A, 1992, BIOCHEMISTRY-US, V31, P11274, DOI 10.1021/bi00161a003; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; MONK PN, 1994, BBA-MOL CELL RES, V1221, P323, DOI 10.1016/0167-4889(94)90257-7; MONK PN, 1995, J BIOL CHEM, V270, P16625, DOI 10.1074/jbc.270.28.16625; MOUSLI M, 1992, J IMMUNOL, V148, P2456; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Murray I, 1997, J LIPID RES, V38, P2492; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; Puschel GP, 1996, HEPATOLOGY, V24, P685, DOI 10.1053/jhep.1996.v24.pm0008781343; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; SCHUPF N, 1989, Brain Behavior and Immunity, V3, P28, DOI 10.1016/0889-1591(89)90003-2; SHETH B, 1991, BIOCHEM J, V275, P809, DOI 10.1042/bj2750809; SHUM JK, 1995, BIOCHEM BIOPH RES CO, V208, P223, DOI 10.1006/bbrc.1995.1327; Wilken HC, 1999, J IMMUNOL METHODS, V226, P139, DOI 10.1016/S0022-1759(99)00064-2; Zwirner J, 1998, EUR J IMMUNOL, V28, P1570, DOI 10.1002/(SICI)1521-4141(199805)28:05<1570::AID-IMMU1570>3.0.CO;2-6	33	151	168	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11123	11129		10.1074/jbc.M206169200	http://dx.doi.org/10.1074/jbc.M206169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540846	hybrid			2022-12-25	WOS:000181855400035
J	Silvis, MR; Picciano, JA; Bertrand, C; Weixel, K; Bridges, RJ; Bradbury, NA				Silvis, MR; Picciano, JA; Bertrand, C; Weixel, K; Bridges, RJ; Bradbury, NA			A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-TRANSPORT; CFTR; IDENTIFICATION; LOCALIZATION; TAIL; GENE	Cystic fibrosis is a common lethal genetic disease among Caucasians. The cystic fibrosis gene encodes a cyclic adenosine monophosphate-activated chloride channel (cystic fibrosis transmembrane conductance regulator (CFTR)) that mediates electrolyte transport across the luminal surfaces of a variety of epithelial cells. Mutations in CFTR fall into two broad categories; those that affect protein biosynthesis/stability and traffic to the cell surface and those that cause altered channel kinetics in proteins that reach the cell surface. Here we report a novel mechanism by which mutations in CFTR give rise to disease. N287Y, a mutation within an intracellular loop of CFTR, increases channel endocytosis from the cell surface without affecting either biosynthesis or channel gating. The sole consequence of this novel mutation is to generate a novel tyrosine-based endocytic sequence within an intracellular loop in CFTR leading to increased removal from the cell surface and a reduction in the steady-state level of CFTR at the cell surface.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bradbury, NA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, S306 BST S,3500 Terrace St, Pittsburgh, PA 15261 USA.	nabrad@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490, R01DK057583] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50DK56490, DK57583] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Bradbury Neil A., 1999, Physiological Reviews, V79, pS175; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; FEREC C, 1995, MOL CELL PROBE, V9, P135, DOI 10.1016/S0890-8508(95)80038-7; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; RIORDAN JR, 1989, SCIENCE, V245, P1066; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Seibert FS, 1997, BIOCHEMISTRY-US, V36, P11966, DOI 10.1021/bi9712652; Shrimpton AE, 1997, HUM MUTAT, V10, P436, DOI 10.1002/(SICI)1098-1004(1997)10:6<436::AID-HUMU4>3.0.CO;2-B; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WARD CL, 1994, J BIOL CHEM, V269, P25710; Weixel Kelly, 2002, Methods Mol Med, V70, P323; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; XIE JX, 1995, J BIOL CHEM, V270, P28084; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	30	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11554	11560		10.1074/jbc.M212843200	http://dx.doi.org/10.1074/jbc.M212843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529365	hybrid			2022-12-25	WOS:000181855400088
J	Aguilar, RC; Watson, HA; Wendland, B				Aguilar, RC; Watson, HA; Wendland, B			The yeast epsin Ent1 is recruited to membranes through multiple independent interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EH-DOMAIN; SACCHAROMYCES-CEREVISIAE; CLATHRIN; UBIQUITIN; PROTEIN; RECEPTOR; BINDING; PHOSPHORYLATION; DEGRADATION; ADAPTERS	In addition to its well known role in targeting proteins for proteasomal degradation, ubiquitin (Ub) is also involved in promoting internalization of cell surface proteins into the endocytic pathway. Moreover, putative Ub interaction motifs (UIMs) as well as Ub-associated (UBA) domains have been identified in key yeast endocytic proteins (the epsins Ent1 and Ent2, and the Eps15 homolog Ede1). In this study, we characterized the interaction of Ub with the Ede1 UBA domain and with the UIMs of Ent1. Our data suggest that the UIMs and the UBA are involved in binding these proteins to biological membranes. We also show that the Ent1 ENTH domain binds to phosphoinositides in vitro and that Ent1 NPF motifs interact with the EH domain-containing proteins Ede1 and Pan1. Our findings indicate that the ENTH domain interaction with membrane lipids cooperates with the binding of membrane-associated Ub moieties. These events may in turn favor the occurrence of other interactions, for instance EH-NPF recognition, thus stabilizing networks of low affinity binding partners at endocytic sites.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Wendland, B (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 35,3400 N Charles St, Baltimore, MD 21218 USA.	bwendland@jhu.edu			NIGMS NIH HHS [R01 GM60979] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060979] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gagny B, 2000, J CELL SCI, V113, P3309; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Ling R, 2000, ANAL BIOCHEM, V282, P54, DOI 10.1006/abio.2000.4586; Loayza D, 1998, MOL CELL BIOL, V18, P779, DOI 10.1128/MCB.18.2.779; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Ni L, 2001, MOL BIOL CELL, V12, P2147, DOI 10.1091/mbc.12.7.2147; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Watson HA, 2001, MOL BIOL CELL, V12, P3668, DOI 10.1091/mbc.12.11.3668; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383	27	88	92	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10737	10743		10.1074/jbc.M211622200	http://dx.doi.org/10.1074/jbc.M211622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529323	hybrid			2022-12-25	WOS:000181777500097
J	Mitoma, J; Petryniak, B; Hiraoka, N; Yeh, JC; Lowe, JB; Fukuda, M				Mitoma, J; Petryniak, B; Hiraoka, N; Yeh, JC; Lowe, JB; Fukuda, M			Extended core 1 and core 2 branched O-glycans differentially modulate sialyl Lewis x-type L-selectin ligand activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-N-ACETYLLACTOSAMINE; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ASN-LINKED OLIGOSACCHARIDES; EXPRESSION CLONING; P-SELECTIN; CELL-ADHESION; LYMPH-NODES; MOLECULAR-CLONING; HL-60 CELLS; UDP-GLCNAC	It has been established that sialyl Lewis x in core 2 branched O-glycans serves as an E- and P-selectin ligand. Recently, it was discovered that 6-sulfosialyl Lewis x in extended core 1 O-glycans, NeuNAcalpha2-->3Gal-beta1-->4(Fucalpha1-->3(sulfo-->6))GIcNAc,beta1--> 3Galbeta1-->3Gal-NAcalpha1-->Ser/Thr, functions as an L-selectin ligand in high endothelial venules. Extended core 1 O-glycans can be synthesized when a core 1 extension enzyme is present. In this study, we first show that beta1,3-N-acetylglucosaminyltransferase-3 (beta3GlcNAcT-3) is almost exclusively responsible for core 1 extension among seven different beta3GlcNAcTs and thus acts on core 1 O-glycans attached to PSGL-1. We found that transcripts encoding beta3GLcNAcT-3 were expressed in human neutrophils and lymphocytes but that their levels were lower than those of transcripts encoding core 2)beta1,6-N-acetylglucosaminyltransferase I (Core2GlcNAcT-1). Neutrophils also expressed transcripts encoding fucosyltransferase VII (FucT-VII) and Core2GlcNAcT-1, whereas lymphocytes expressed only small amounts of transcripts encoding FucT-VII. To determine the roles of sialyl Lewis x in extended core 1 O-glycans, Chinese hamster ovary (CHO) cells were stably transfected to express PSGL-1, FucT-VII, and either beta3GlcNAcT-3 or Core2GlcNAcT-1. Glycan structural analyses disclosed that PSGL-1 expressed in these transfected cells carried comparable amounts of sialyl Lewis x in extended core 1 and core 2 branched O-glycans. In a rolling assay, CHO cells expressing sialyl Lewis x in extended core 1 O-glycans supported a significant degree of shear-dependent tethering and rolling of neutrophils and lymphocytes, although less than CHO cells expressing sialyl Lewis x in core 2 branched O-glycans. These results indicate that sialyl Lewis x in extended core 1 O-glycans can function as an L-selectin ligand and is potentially involved in neutrophil adhesion on neutrophils bound to activated endothelial cells.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Pathol, Ann Arbor, MI 48104 USA; Univ Michigan, Sch Med, Inst Life Sci, Ann Arbor, MI 48104 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [R01CA428737, P01CA71932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; CLARNETTE RM, 1994, J GERIATR PSYCH NEUR, V7, P23, DOI 10.1177/089198879400700105; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; Fukuda Minoru, 2002, P114; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Henion TR, 2001, J BIOL CHEM, V276, P30261, DOI 10.1074/jbc.M102979200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Kataoka K, 2002, BIOCHEM BIOPH RES CO, V294, P843, DOI 10.1016/S0006-291X(02)00553-3; LEE N, 1990, J BIOL CHEM, V265, P20476; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Schwientek T, 2002, J BIOL CHEM, V277, P32421, DOI 10.1074/jbc.M206213200; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG WC, 1988, J BIOL CHEM, V263, P4576; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	54	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9953	9961		10.1074/jbc.M212756200	http://dx.doi.org/10.1074/jbc.M212756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12529363	hybrid			2022-12-25	WOS:000181524000143
J	Planque, S; Zhou, YX; Nishiyama, Y; Sinha, M; O'Connor-McCourt, M; Arnett, FC; Paul, S				Planque, S; Zhou, YX; Nishiyama, Y; Sinha, M; O'Connor-McCourt, M; Arnett, FC; Paul, S			Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice	FASEB JOURNAL			English	Article						Fas defects; EGFR; antibody library	EGF RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECOGNITION; HEAVY-CHAIN; EXPRESSION; BINDING; PROTEIN; TRAFFICKING; FIBROBLASTS; ACTIVATION	Autoantibodies to the recombinant extracellular domain of epidermal growth factor receptor (exEGFR) were detected by ELISA in the serum of Fas-defective old MRL/MpJ/lpr and C3H/HeJ/gld mice, but not young mice from these strains, or nonautoimmune young and old BALB/c, MRL/MpJ/++, and C3H/HeJ/MMTV mice. Compared with control human subjects without autoimmune disease, the frequency of exEGFR-binding autoantibodies was increased in scleroderma (systemic sclerosis) patients and to a lesser extent in lupus patients. Phage autoantibodies (Fv fragments) isolated from a lupus library by selection on a linear epitope of EGFR (residues 294310) displayed the ability to bind exEGFR. Treatment of EGFR-expressing A431 cells with autoantibodies purified by affinity chromatography on immobilized exEGFR resulted in specific staining of the cells. Short-lived but strong inhibition of cellular DNA synthesis was observed in the presence of the autoantibodies. We concluded that autoantibody responses to EGFR hold the potential of fulfilling a pathogenic role in autoimmune disease.	Univ Texas, Houston Med Sch, Dept Pathol, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Internal Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; National Research Council Canada	Paul, S (corresponding author), Univ Texas, Houston Med Sch, Dept Pathol, Chem Immunol & Therapeut Res Ctr, MSB 2-250,6431 Fannin, Houston, TX 77030 USA.	Sudhir.Paul@uth.tmc.edu	Sinha, Meenal/B-7158-2016	Sinha, Meenal/0000-0002-4008-4080	NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031268, R01AI031268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044888] Funding Source: NIH RePORTER; NCI NIH HHS [CA-80312] Funding Source: Medline; NHLBI NIH HHS [HL-44126] Funding Source: Medline; NIAID NIH HHS [AI-31268] Funding Source: Medline; NIAMS NIH HHS [P50AR44888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baron AT, 1997, HYBRIDOMA, V16, P259, DOI 10.1089/hyb.1997.16.259; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Ellis I, 1997, DEVELOPMENT, V124, P1593; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; GILL PJ, 1997, JAVA REP, V2, P16; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; HEINER JS, 1994, AM J REPROD IMMUNOL, V32, P152, DOI 10.1111/j.1600-0897.1994.tb01106.x; Jones M. K., 1999, Frontiers in Bioscience, V4, pD303; Jordan KC, 2000, NAT GENET, V24, P429, DOI 10.1038/74294; MODJTAHEDI H, 1993, BRIT J CANCER, V67, P254, DOI 10.1038/bjc.1993.49; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; NAKOPOULOU L, 1994, NEPHROL DIAL TRANSPL, V9, P764; Okada T, 2001, BIOL NEONATE, V79, P46, DOI 10.1159/000047065; Oyama N, 1998, J DERMATOL SCI, V16, P120, DOI 10.1016/S0923-1811(97)00040-6; PAUL S, 1991, J BIOL CHEM, V266, P16128; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; ROSENTHAL AK, 1993, ANN RHEUM DIS, V52, P531, DOI 10.1136/ard.52.7.531; Sambrook J, 1989, MOL CLONING LAB MANU, V3; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; Sivinski Connie L., 1999, P347; SOROKIN A, 1995, ONCOGENE, V11, P1531; STYREN SD, 1990, BRAIN RES, V512, P347, DOI 10.1016/0006-8993(90)90647-T; SUN M, 1994, J BIOL CHEM, V269, P734; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; TAMURA M, 1995, HUM REPROD, V10, P1891, DOI 10.1093/oxfordjournals.humrep.a136203; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tan FK, 2000, ARTHRITIS RHEUM-US, V43, P2464, DOI 10.1002/1529-0131(200011)43:11<2464::AID-ANR13>3.0.CO;2-F; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; TOKIYAMA K, 1990, J RHEUMATOL, V17, P1463; TOSI E, 1995, INT J CANCER, V62, P643, DOI 10.1002/ijc.2910620525; Walker RA, 1998, J PATHOL, V185, P234, DOI 10.1002/(SICI)1096-9896(199807)185:3<234::AID-PATH128>3.0.CO;2-8; Yang XD, 1999, CANCER RES, V59, P1236; Zhou YX, 2001, FASEB J, V15, pA1199	42	15	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					136	143		10.1096/fj.01-0847com	http://dx.doi.org/10.1096/fj.01-0847com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554692				2022-12-25	WOS:000181456900038
J	Lange, K; Uckert, W; Blankenstein, T; Nadrowitz, R; Bittner, C; Renauld, JC; van Snick, J; Feller, AC; Merz, H				Lange, K; Uckert, W; Blankenstein, T; Nadrowitz, R; Bittner, C; Renauld, JC; van Snick, J; Feller, AC; Merz, H			Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice	ONCOGENE			English	Article						t(2;5) translocation; anaplastic lymphoma kinase (ALK); IL-9 transgenic mice; retroviral-mediated gene transfer	NON-HODGKINS-LYMPHOMA; GENE-TRANSFER; TYROSINE KINASE; CELL LYMPHOMA; INTERLEUKIN-9; PROTEIN; FUSION; SUBTYPE; GROWTH; MODEL	Anaplastic large-cell lymphoma (ALCL) comprises approximately 25% of all non-Hodgkin lymphomas (NHL) in children and young adults, and up to 15% of high-grade NHL in older patients. Over 50% of these tumours carry the translocation t(2;5)(p23;q35). The result of this translocation is the fusion of the nucleophosmin (NPM) gene to the anaplastic lymphoma kinase (ALK) gene. The resulting hybrid protein contains the ALK catalytic domain that consequently confers transforming potential, which contributes to the pathogenesis of ALCL. To further analyse the transforming activity in an animal model, a cDNA encoding the protein product, NPM-ALK, was inserted into the retrovirus vector pLXSN and transduced into mouse bone marrow progenitors. These cells were subsequently used in a bone marrow transplant with the aim of reconstituting the haematopoietic compartments of lethally irradiated recipients. IL-9 transgenic mice were chosen as the animal model system, because dysregulated expression of the IL-9 gene in transgenic mice results in the sporadic development of spontaneous thymic lymphomas. Moreover, IL-9 is known to be expressed in cases of human ALCL. We used 15 IL-9 transgenic mice and eight corresponding wild-type mice (FVB/N) and transplanted them with NPM/ALK infected bone marrow cells. Eight IL-9 transgenic mice, serving as a control group, received pLXSN (vector only)-infected marrow. Reconstituted mice developed NPM-ALK-positive lymphomas, including lymphoblastic lymphomas of T-cell type (T-LB), mature and immature plasmacytoma (PC), and plasmoblastic/anaplastic diffuse large-B-cell lymphoma after about 19-20 weeks. The combined overexpression of NPM-ALK and IL-9 led to the transformation of murine lymphoid cells with accelerated and enhanced development of T-LB in 46% of the mice, which only very rarely occurs in IL-9 transgenic mice only. Of the 15 animals, five (33%) developed plasmacytic/plasmoblastic neoplasms, of which the most aggressive tumours share many features with anaplastic/plasmoblastic diffuse large-B-cell lymphoma on the basis of morphology, a characteristic growth pattern and ALK expression.	Med Univ Lubeck, Dept Pathol, D-23538 Lubeck, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Med Univ Lubeck, Inst Radiotherapy & Nucl Med, D-23538 Lubeck, Germany; Ludwig Inst Canc Res, B-1200 Brussels, Belgium	University of Lubeck; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Lubeck; Ludwig Institute for Cancer Research	Lange, K (corresponding author), Med Univ Lubeck, Dept Pathol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	lange@patho.mu-luebeck.de	Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131				Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bittner C, 2000, LAB INVEST, V80, P1523, DOI 10.1038/labinvest.3780162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Demoulin J B, 1998, Int Rev Immunol, V16, P345, DOI 10.3109/08830189809043001; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ladanyi M, 1997, CANCER SURV, V30, P59; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; LEBEAU MM, 1989, LEUKEMIA, V3, P866; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Maes B, 2001, AM J PATHOL, V158, P2185, DOI 10.1016/S0002-9440(10)64690-1; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MERZ H, 1991, BLOOD, V78, P1311; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Uckert W, 2000, METH MOLEC MED, V35, P275, DOI 10.1385/1-59259-086-1:275; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; Wellmann A, 1997, FASEB J, V11, P965, DOI 10.1096/fasebj.11.12.9337149	33	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					517	527		10.1038/sj.onc.1206076	http://dx.doi.org/10.1038/sj.onc.1206076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555065	Bronze			2022-12-25	WOS:000180538200005
J	Arsura, M; Panta, GR; Bilyeu, JD; Cavin, LG; Sovak, MA; Oliver, AA; Factor, V; Heuchel, R; MErcurio, F; Thorgeirsson, SS; Sonenshein, GE				Arsura, M; Panta, GR; Bilyeu, JD; Cavin, LG; Sovak, MA; Oliver, AA; Factor, V; Heuchel, R; MErcurio, F; Thorgeirsson, SS; Sonenshein, GE			Transient activation of NF-kappa B through a TAK1/IKK kinase pathway by TGF-beta 1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation	ONCOGENE			English	Article						NF-kappa B; IKK; TGF-beta 1; JNK; AP-1; apoptosis	GROWTH-FACTOR-BETA; MICE LACKING; IKK-ALPHA; EMBRYONIC LETHALITY; TRANSGENIC MICE; HEPATOCELLULAR CARCINOMAS; MEDIATED TRANSCRIPTION; TERMINAL KINASE; ADAPTER PROTEIN; JNK ACTIVATION	NF-kappaB has been implicated in the regulation of apoptosis, a key mechanism of normal and malignant growth control. Previously, we demonstrated that inhibition of NF-kappaB activity by TGF-beta1 leads directly to induction of apoptosis of murine B-cell lymphomas and hepatocytes. Thus, we were surprised to determine that NF-kappaB is transiently activated in response to TGF-beta1 treatment. Here we elucidate the mechanism of TGF-beta1-mediated regulation of NF-kappaB and induction of apoptosis in epithelial cells. We report that TGF-beta1 activates IKK kinase, which mediates IkappaB-alpha phosphorylation. In turn, the activation of IKK following TGF-beta1 treatment is mediated by the TAK1 kinase. As a result of NF-kappaB activation, IkappaB-alpha mRNA and protein levels are increased leading to postrepression of NF-kappaB and induction of cell death. Inhibition of NF-kappaB following TGF-beta1 treatment increased AP-1 complex transcriptional activity through sustained c-Jun phosphorylation, thereby potentiating AP-1/SMADs-mediated cell killing. Furthermore, TGF-beta1-mediated upregulation of Smad7 appeared independent of NF-kappaB. In hepatocellular carcinomas of TGF-beta1 or TGF-alpha/c-myc transgenic mice, we observed constitutive activation of NF-kappaB that led to inhibition of JNK signaling. Overall, our data illustrate an autocrine mechanism based on the ability of IKK/NF-kappaB/IkappaB-alpha signaling to negatively regulate NF-kappaB levels thereby permitting TGF-beta1-induced apoptosis through AP-1 activity.	Univ Tennessee, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; NCI, CCR, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA; Celgene Signal Res Div, San Diego, CA 92121 USA; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	University of Tennessee System; University of Tennessee Health Science Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research	Arsura, M (corresponding author), Univ Tennessee, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.		Heuchel, Rainer/P-7875-2019	Heuchel, Rainer/0000-0002-2782-585X	NATIONAL CANCER INSTITUTE [R01CA036355, R01CA078616, R01CA082742, Z01BC010036] Funding Source: NIH RePORTER; NCI NIH HHS [CA78616-S1, CA82742, CA36355, CA78616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; [Anonymous], GENOME BIOL; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Azuma M, 1999, EXP CELL RES, V250, P213, DOI 10.1006/excr.1999.4503; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chang H, 2001, MOL CELL ENDOCRINOL, V180, P39, DOI 10.1016/S0303-7207(01)00513-5; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; Factor VM, 1997, CANCER RES, V57, P2089; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; WU JC, 1994, CANCER RES, V54, P5964; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	73	119	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					412	425		10.1038/sj.onc.1206132	http://dx.doi.org/10.1038/sj.onc.1206132			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545162				2022-12-25	WOS:000180379100010
J	Wu, SQ; Cetinkaya, C; Munoz-Alonso, MJ; von der Lehr, N; Bahram, F; Beuger, V; Eilers, M; Leon, J; Larsson, LG				Wu, SQ; Cetinkaya, C; Munoz-Alonso, MJ; von der Lehr, N; Bahram, F; Beuger, V; Eilers, M; Leon, J; Larsson, LG			Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter	ONCOGENE			English	Article						Myc; Miz-1; p21Cip1; differentiation; cell cycle; transcription	C-MYC; CELL-CYCLE; MYC/MAX/MAD NETWORK; HISTONE ACETYLATION; ESSENTIAL COFACTOR; LEUKEMIA-CELLS; GENE; GROWTH; ACTIVATION; P15(INK4B)	Inhibition of cellular differentiation is one of the well-known biological activities of c-Myc-family proteins. We show here that Myc represses differentiation-induced expression of the cyclin-dependent kinase (CDK) inhibitor p21CIP1 (CDKN1A, p21), known to play an important role in cell fate decisions during growth and differentiation, in hematopoietic cells. Our results demonstrate that the c-Myc-responsive region is situated in the p21 core promoter. c-Myc binds to this region in vitro and in vivo through interaction with the initiator-binding Zn-finger transcription factor Miz-1, which associates directly with the promoter. Association of Myc with the promoter in vivo correlates inversely with p21 expression. Using mutants of c-Myc with impaired binding to Miz-1, our results further show that repression of p21 promoter/reporters as well as the endogenous p21 gene by Myc depends on interaction with Miz-1. Expression of Miz-1 increases during hematopoietic differentiation and Miz-1 activates the p21 promoter under conditions of low Myc levels, indicating a positive role for free Miz-1 in this process. In conclusion, repression of differentiation-induced p21 expression through Miz-1 may be an important mechanism by which Myc blocks differentiation.	Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, S-75007 Uppsala, Sweden; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain; Univ Cantabria, CSIC, Unidad Asociada, E-39005 Santander, Spain; Inst Mol Biol & Tumor Res, Marburg, Germany	Swedish University of Agricultural Sciences; Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria	Larsson, LG (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, Box 7080, S-75007 Uppsala, Sweden.		Larsson, Lars-Gunnar/D-9747-2012; Leon, Javier/K-4615-2014	Leon, Javier/0000-0001-5803-0112; Eilers, Martin/0000-0002-0376-6533				Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Bahram F, 1999, BLOOD, V93, P3900, DOI 10.1182/blood.V93.11.3900.411a42_3900_3912; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; JIANG HP, 1994, ONCOGENE, V9, P3397; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	41	236	244	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					351	360		10.1038/sj.onc.1206145	http://dx.doi.org/10.1038/sj.onc.1206145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545156				2022-12-25	WOS:000180379100004
J	Elez, R; Piiper, A; Kronenberger, B; Kock, M; Brendel, M; Hermann, E; Pliquett, U; Neumann, E; Zeuzem, S				Elez, R; Piiper, A; Kronenberger, B; Kock, M; Brendel, M; Hermann, E; Pliquett, U; Neumann, E; Zeuzem, S			Tumor regression by combination antisense therapy against Plk1 and Bcl-2	ONCOGENE			English	Article						polo-like kinase 1 (PLK1); BCL-2; antisense therapy; electroporation; cell cycle; mitotic catastrophe	POLO-LIKE KINASE; PROGNOSTIC-SIGNIFICANCE; DNA-DAMAGE; MITOTIC CATASTROPHE; MALIGNANT-MELANOMA; DROSOPHILA POLO; PROTEIN-KINASE; EXPRESSION; INHIBITION; CANCER	Increased expression of the cell proliferation-associated polo-like kinase 1 (PLK1) and apoptosis-associated BCL-2 genes has been observed in different human malignancies. Inhibition of cell proliferation and reactivation of apoptosis are basic principles in anticancer therapy. The efficiency of this approach is often limited by insufficient targeting and delivery of anticancer drugs into the tumors. Phosphorothioate antisense oligodeoxynucleotides (ODNs) directed against PLK1 and BCL-2 were administered systemically via the tail vein into nude mice bearing A549, MDA-MB-435, and Detroit562 xenografts. To enhance tumor-specific uptake and to reduce systemic toxicity of antisense ODNs membrane electroporation transfer was applied in vivo. Northern and Western blot analyses were used to assess PLK1 and BCL-2 expression. Tumor mass was assessed after resection of tumors. All three cell lines and corresponding xenografts expressed high levels of PLK1 and were sensitive towards antisense PLK1 treatment. Antisense BCL-2 therapy was effective in tumors expressing high levels of BCL-2, but not in A549 cells and corresponding xenografts, which express low levels of BCL-2. Administration of antisense ODNs in a dose of 5mg/kg, twice weekly during four weeks supported by the membrane electroporation transfer, eradicated 60-100% of the xenografted tumors. Antitumor effect in BCL-2 overexpressing MDA-MB-435 cells was synergistic for BCL-2 and PLK1 combination therapy. This study provides evidence that combined systemic administration of antisense ODNs against proliferation and pro- survival associated targets and in vivo electroporation of tumors represents a promising antitumor therapeutic approach.	Univ Saarland, Dept Internal Med 2, Mol Oncol Unit, D-66422 Homburg, Germany; Univ Frankfurt, Dept Internal Med, D-60590 Frankfurt, Germany; Univ Frankfurt, Anim Res Facil, Sch Med, D-6000 Frankfurt, Germany; Univ Frankfurt, Inst Microbiol, Frankfurt, Germany; Univ Bielefeld, Fac Chem, D-4800 Bielefeld, Germany	Saarland University; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; University of Bielefeld	Elez, R (corresponding author), Univ Saarland, Dept Internal Med 2, Mol Oncol Unit, D-66422 Homburg, Germany.		Neumann, Eberhard/AAU-6955-2020; Zeuzem, Stefan/AAE-7435-2019	Neumann, Eberhard/0000-0003-0861-072X; Brendel, Martin/0000-0002-7716-7576				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Donaldson MM, 2001, J CELL SCI, V114, P2357; Draghia-Akli R, 1999, NAT BIOTECHNOL, V17, P1179, DOI 10.1038/70718; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Heller R, 1998, CANCER-AM CANCER SOC, V83, P148, DOI 10.1002/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W; Heller R, 1996, CANCER-AM CANCER SOC, V77, P964, DOI 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Khaled Z, 1996, NUCLEIC ACIDS RES, V24, P737, DOI 10.1093/nar/24.4.737; Knecht R, 1999, CANCER RES, V59, P2794; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lebleu B., 1993, ANTISENSE RES APPL; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIR LM, 1991, CR ACAD SCI III-VIE, V313, P613; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; Neumann E, 1999, BIOELECTROCH BIOENER, V48, P3, DOI 10.1016/S0302-4598(99)00008-2; Neumann E, 2000, METH MOLEC MED, V37, P1, DOI 10.1385/1-59259-080-2:1; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sheehan JP, 1998, BLOOD, V92, P1617, DOI 10.1182/blood.V92.5.1617.417k13_1617_1625; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; SWANSON PE, 1995, AM J PATHOL, V146, P963; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862	46	77	88	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					69	80		10.1038/sj.onc.1206038	http://dx.doi.org/10.1038/sj.onc.1206038			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527909				2022-12-25	WOS:000180166900008
J	Kajimura, M; Shimoyama, M; Tsuyama, S; Suzuki, T; Kozaki, S; Takenaka, S; Tsubota, K; Oguchi, Y; Suematsu, M				Kajimura, M; Shimoyama, M; Tsuyama, S; Suzuki, T; Kozaki, S; Takenaka, S; Tsubota, K; Oguchi, Y; Suematsu, M			Visualization of gaseous monoxide reception by soluble guanylate cyclase in the rat retina	FASEB JOURNAL			English	Article						nitric oxide; carbon monoxide; soluble guanylate cyclase; neural transmission	NITRIC-OXIDE SYNTHASE; CARBON-MONOXIDE; HEME OXYGENASE-2; DEPENDENT ACTIVATION; ENDOGENOUS MODULATOR; MONOCLONAL-ANTIBODY; CELLS; LIVER; MICE; TRANSDUCTION	Immunohistochemistry using novel monoclonal antibodies (mAbs) allowed us to uncover tissue activities of soluble guanylate cyclase (sGC) fine tuned by NO and CO. Upon NO and CO applications in vitro, purified sGC increased the affinity to mAb3221 by 100- and 10-fold, respectively, but not to mAb28131. Immunohistochemistry for gas-generating enzymes revealed that NO occurred in amacrine, bipolar, and Muller's glia cells (MGCs), whereas CO was derived mostly from heme oxygenase (HO)-2 in MGCs. Basal sGC immunoreactivities in vivo to mAb3221 but not to mAb28131 were enhanced by injecting L-arginine and attenuated by blocking NO synthases, suggesting the ability of the former mAb to sense NO. Comparison of mAb-assisted immunohistochemistry suggested that sGC activities were enhanced by zinc protoporphyrin-IX, an HO inhibitor, and repressed completely by blocking NO. However, suggested roles of CO played in situ varied among different retinal layers. In inner plexiform and inner nuclear layers located in the proximity of the cellular NO sources, CO serves as a simple inhibitor of local sGC, while playing roles in housekeeping sGC activation in external limiting membrane standing far from them. These results suggest that CO generated in MGCs is a diffusible gas mediator regulating sGC in both autocrine and paracrine manners.	Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan; Tokyo Dent Coll, Dept Ophthalmol, Chiba, Japan; Univ Osaka Prefecture, Dept Mol Biol Life Sci & Vet Sci, Osaka, Japan	Keio University; Keio University; Tokyo Dental College; Osaka Metropolitan University	Suematsu, M (corresponding author), Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Tokyo 1608582, Japan.	msuem@sc.itc.keio.ac.jp	Suematsu, Makoto/I-8135-2013; Kajimura, Mayumi/L-1734-2013; Suematsu, Makoto/O-5762-2018	Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336				ANTONINI E, 1971, N HOLLAND RES MONOGR, V12, P13; Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; Cao LX, 2000, VISUAL NEUROSCI, V17, P319, DOI 10.1017/S0952523800173018; Chun MH, 1999, VISUAL NEUROSCI, V16, P379, DOI 10.1017/S0952523899162175; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; Friedman JM, 1998, GENET MED, V1, P54; Goda N, 1998, J CLIN INVEST, V101, P604, DOI 10.1172/JCI1324; Guidry C, 1996, INVEST OPHTH VIS SCI, V37, P740; Hangai M, 1999, INVEST OPHTH VIS SCI, V40, P450; HAUGH LM, 1990, ANN BIOMED ENG, V18, P19, DOI 10.1007/BF02368415; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; Imai T, 2001, CIRC RES, V89, P55, DOI 10.1161/hh1301.092679; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Job C, 1998, J CELL BIOL, V143, P1661, DOI 10.1083/jcb.143.6.1661; Johansson K, 2000, INVEST OPHTH VIS SCI, V41, P305; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177; Kyokane T, 2001, GASTROENTEROLOGY, V120, P1227, DOI 10.1053/gast.2001.23249; MILLS SL, 1995, NATURE, V377, P734, DOI 10.1038/377734a0; Ozawa N, 2002, J CLIN INVEST, V109, P457, DOI [10.1172/JCI0213190, 10.1172/JCI200213190]; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; SUEMATSU M, 1993, MICROVASC RES, V46, P28, DOI 10.1006/mvre.1993.1033; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; Suzuki T, 2001, FEBS LETT, V507, P49, DOI 10.1016/S0014-5793(01)02943-X; Tsuyama S, 1999, FEBS LETT, V455, P291, DOI 10.1016/S0014-5793(99)00884-4; VARDIMON L, 1986, P NATL ACAD SCI USA, V83, P9060, DOI 10.1073/pnas.83.23.9060; Wakabayaski Y, 1999, AM J PHYSIOL-GASTR L, V277, pG1088, DOI 10.1152/ajpgi.1999.277.5.G1088; Wolin MS, 1999, RESP PHYSIOL, V115, P229, DOI 10.1016/S0034-5687(99)00023-7; Yamaguchi T, 1996, BBA-GEN SUBJECTS, V1289, P110, DOI 10.1016/0304-4165(95)00128-X; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848	33	53	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					506	+		10.1096/fj.02-0359fje	http://dx.doi.org/10.1096/fj.02-0359fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551840				2022-12-25	WOS:000181453700008
J	Kosmadaki, MG; Yaar, M; Arble, BL; Gilchrest, BA				Kosmadaki, MG; Yaar, M; Arble, BL; Gilchrest, BA			UV induces VEGF through a TNF-alpha-independent pathway	FASEB JOURNAL			English	Article						skin; cytokines; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; VASCULAR-PERMEABILITY FACTOR; HUMAN KERATINOCYTES; FACTOR EXPRESSION; ULTRAVIOLET-B; FACTOR GENE; CULTURED KERATINOCYTES; FACTOR VPF/VEGF; CANCER CELLS	Vascular endothelial growth factor (VEGF) is a potent keratinocyte-derived angiogenic factor. Prior reports suggest that following UV irradiation VEGF in keratinocytes is induced primarily by tumor necrosis factor (TNF)-alpha, a cytokine synthesized and secreted by keratinocytes after UV irradiation. We investigated whether blocking TNF-alpha binding to its receptors would inhibit UV-induced VEGF expression and secretion in the keratinocyte-derived line SCC-12F. Irradiation with physiologic UV doses (30 mJ/cm(2)) substantially induced VEGF mRNA in this cell line, as expected, and mRNA induction was followed by increased VEGF in medium conditioned by UV-irradiated cells. Also as expected, TNF-alpha induced VEGF expression and secretion in a dose-dependent manner. Addition of a hexapeptide (Ac-KWIIVW-NH2), known to block TNF-alpha binding to its receptors, abrogated this TNF-alpha effect on VEGF mRNA induction. However, addition of the peptide to cells immediately after UV irradiation did not substantially affect VEGF mRNA induction or secretion into the medium. Our results suggest that VEGF induction after UV irradiation is mediated by multiple mechanisms and that blocking a single pathway does not affect the response.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St,J-Bldg, Boston, MA 02118 USA.	bgilcre@bu.edu						Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; ADASHI EY, 1989, J BIOL CHEM, V264, P11591; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; Blaudschun R, 2000, FEBS LETT, V474, P195, DOI 10.1016/S0014-5793(00)01605-7; Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793; BRENNEISEN P, 2002, BIOCH J, V2; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J IMMUNOL, V154, P2801; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clingen PH, 2001, BRIT J DERMATOL, V145, P54, DOI 10.1046/j.1365-2133.2001.04281.x; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; CORSINI E, 1995, PHOTODERMATOL PHOTO, V11, P112, DOI 10.1111/j.1600-0781.1995.tb00149.x; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GILCHREST BA, 1993, J INVEST DERMATOL, V101, P666, DOI 10.1111/1523-1747.ep12371673; GILL PJ, 1997, JAVA REP, V2, P16; Gille J, 2000, J INVEST DERMATOL, V115, P30, DOI 10.1046/j.1523-1747.2000.00020.x; Huang S, 2000, CANCER RES, V60, P5334; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; JOHNSON B, 1984, PHYSL PATHOPHYSIOLOG, P2414; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Kozlowska U, 1998, DERMATOLOGY, V196, P89, DOI 10.1159/000017878; Kruszynski M, 1999, CYTOKINE, V11, P37, DOI 10.1006/cyto.1998.0389; Leccia MT, 1998, J INVEST DERMATOL, V110, P691; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Longuet-Perret I, 1998, BRIT J DERMATOL, V138, P221; Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1562/0031-8655(1999)070<0674:UAURDR>2.3.CO;2; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Rheinwald J, 1983, HUMAN CARCINOGENESIS; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Weninger W, 1996, LAB INVEST, V75, P647; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	47	32	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					446	+		10.1096/fj.02-0379fje	http://dx.doi.org/10.1096/fj.02-0379fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551841				2022-12-25	WOS:000181453700003
J	Fischer, H; Dias, SMG; Santos, MAM; Alves, AC; Zanchin, N; Craievich, AF; Apriletti, JW; Baxter, JD; Webb, P; Neves, FAR; Ribeiro, RCJ; Polikarpov, I				Fischer, H; Dias, SMG; Santos, MAM; Alves, AC; Zanchin, N; Craievich, AF; Apriletti, JW; Baxter, JD; Webb, P; Neves, FAR; Ribeiro, RCJ; Polikarpov, I			Low resolution structures of the retinoid X receptor DNA-binding and ligand-binding domains revealed by synchrotron x-ray solution scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT SHAPE DETERMINATION; THYROID-HORMONE RECEPTORS; SMALL-ANGLE SCATTERING; NUCLEAR RECEPTORS; BIOLOGICAL MACROMOLECULES; TETRAMER FORMATION; CRYSTAL-STRUCTURE; RXR-ALPHA; ACID; HETERODIMERS	Nuclear receptors are ligand-inducible transcription factors that share structurally related DNA-binding (DBD) and ligand-binding (LBD) domains. Biochemical and structural studies have revealed the modular nature of DBD and LBD. Nevertheless, the domains function in concert in vivo. While high-resolution crystal structures of nuclear receptor DBDs and LBDs are available, there are no x-ray structural studies of nuclear receptor proteins containing multiple domains. We report the solution structures of the human retinoid X receptor DBD-LBD (hRXRalphaDeltaAB) region. We obtained ab initio shapes of hRXRalphaDeltaAB dimer and tetramer to 3.3 and 1.7 nm resolutions, respectively, and established the position and orientation of the DBD and LBD by fitting atomic coordinates of hRXRalpha DBD and LBD. The dimer is U-shaped with DBDs spaced at similar to2 nm in a head to head orientation forming an angle of about 10degrees with respect to each other and with an extensive interface area provided by the LBD. The tetramer is a more elongated X-shaped molecule formed by two dimers in head to head arrangement in which the DBDs are extended from the structure and spaced at about 6 nm. The close proximity of DBDs in dimers may facilitate homodimer formation on DNA, however, for the homodimer to bind to a DNA element containing two directly repeated half-sites, one of the DBDs would need to rotate with respect to the other element. By contrast, the separation of DBDs in the tetramers may account for their decreased ability to recognize DNA.	Univ Sao Paulo, Dept Fis & Informat, Inst Fis Sao Carlos, BR-13560970 Sao Carlos, SP, Brazil; Univ Sao Paulo, Inst Fis, BR-05508900 Sao Paulo, Brazil; Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Brasilia, Dept Ciencias Farmaceut, BR-70900910 Brasilia, DF, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Laboratorio Nacional de Luz Sincrotron (LNLS); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia	Polikarpov, I (corresponding author), Univ Sao Paulo, Dept Fis & Informat, Inst Fis Sao Carlos, Av Trabalhador Sao Carlense 400, BR-13560970 Sao Carlos, SP, Brazil.		Fischer, Hannes/C-2215-2012; Polikarpov, Igor/D-2575-2012; Craievich, Aldo F/A-2852-2013; Zanchin, Nilson Ivo Tonin/AAB-4907-2019; Dias, Sandra/AAB-7042-2019	Fischer, Hannes/0000-0003-2984-2028; Craievich, Aldo F/0000-0002-5103-0248; Zanchin, Nilson Ivo Tonin/0000-0002-1153-0694; Polikarpov, Igor/0000-0001-9496-4174	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009516, R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41842, DK 09516] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; Chen ZP, 1998, J MOL BIOL, V275, P55, DOI 10.1006/jmbi.1997.1413; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Egea PF, 2001, J MOL BIOL, V307, P557, DOI 10.1006/jmbi.2000.4409; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P839; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Guinier A., 1955, SMALL ANGLE SCATTERI; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lin BC, 1997, J BIOL CHEM, V272, P9860; Magli E, 2000, RRD PATTERN RECOGNIT, V1, P1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; Shannon C., 1964, MATH THEORY COMMUNIC; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STURMANN HB, 1970, J PHYS CHEM-US, V72, P177; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; SVERGUN DI, 1991, ACTA CRYSTALLOGR A, V47, P736, DOI 10.1107/S0108767391006414; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YEN PM, 1992, J BIOL CHEM, V267, P3565; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	49	14	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16030	16038		10.1074/jbc.M206953200	http://dx.doi.org/10.1074/jbc.M206953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12533536	Green Published, hybrid			2022-12-25	WOS:000182680000074
J	Stahelin, RV; Burian, A; Bruzik, KS; Murray, D; Cho, WW				Stahelin, RV; Burian, A; Bruzik, KS; Murray, D; Cho, WW			Membrane binding mechanisms of the PX domains of NADPH oxidase p40(phox) and p47(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; CYTOSOLIC PHOSPHOLIPASE A(2); C2 DOMAIN; MOLECULAR-BASIS; CELL MEMBRANES; ROLES; ACTIVATION; PRESSURE; RESIDUES; LOCATION	Phox (PX) domains are phosphoinositide (PI)-binding domains with broad PI specificity. Two cytosolic components of NADPH oxidase, p40(phox) and p47(phox), contain PX domains. The PX domain of p40(phox) specifically binds phosphatidylinositol 3-phosphate, whereas the PX domain of p47(phox) has two lipid binding sites, one specific for phosphatidylinositol 3,4-bisphosphate and the other with affinity for phosphatidic acid or phosphatidylserine. To delineate the mechanisms by which these PX domains interact with PI-containing membranes, we measured the membrane binding of these domains and respective mutants by surface plasmon resonance and monolayer techniques and also calculated the electrostatic potentials of the domains as a function of PI binding. Results indicate that membrane binding of both PX domains is initiated by nonspecific electrostatic interactions, which is followed by the membrane penetration of hydrophobic residues. The membrane penetration of the p40(phox) PX domain is induced by phosphatidylinositol 3-phosphate, whereas that of the p47(phox) PX domain is triggered by both phosphatidylinositol 3,4-bisphosphate and phosphatidic acid (or phosphatidylserine). Studies of enhanced green fluorescent protein-fused PX domains in HEK293 cells indicate that this specific membrane penetration is also important for subcellular localization of the two PX domains. Further studies on the full-length p40(phox) and p47(phox) proteins showed that an intramolecular interaction between the C-terminal Src homology 3 domain and the PX domain prevents the nonspecific monolayer penetration of p47(phox), whereas such an interaction is absent in p40(phox).	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University	Cho, WW (corresponding author), Univ Illinois, Dept Chem, M C 111,845 W Taylor St, Chicago, IL USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598, R01GM057568, R01GM066147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52598, GM53987, GM57568, GM66147] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200	43	122	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14469	14479		10.1074/jbc.M212579200	http://dx.doi.org/10.1074/jbc.M212579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556460	hybrid			2022-12-25	WOS:000182405000114
J	Xu, Y; Johnson, J; Kohn, H; Widger, WR				Xu, Y; Johnson, J; Kohn, H; Widger, WR			ATP binding to Rho transcription termination factor - Mutant F355W ATP-induced fluorescence quenching reveals dynamic ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICYCLOMYCIN-RESISTANT MUTANTS; ESCHERICHIA-COLI F1-ATPASE; RNA-BINDING; PROTEIN-RHO; SITES; SEQUENCE; HELICASE; MUTATIONS; AFFINITY; DOMAIN	Rho transcription termination factor mutant, F355W, showed tryptophan fluorescence intensity approximately twice that of wild-type Rho at equivalent protein concentrations and underwent a decrease in relative fluorescence intensity at 350 nm when 100 muM ATP was added in the presence or absence of RNA. Titration of this fluorescence quenching with varying concentrations of ATP (0-600 muM), where Rho is shown to exist as a hexamer (400 nm Rho), revealed tight and loose ATP-binding sites. Bicyclomycin, a specific inhibitor of Rho, increased the tight ATP binding and was used to calibrate ATP-induced fluorescence quenching by using [gamma-P-32]ATP filter binding. For the Rho mutant F355W, three tight (K-d1, = 3 +/- 0.3 muM) and three loose (K-d2 = 58 +/- 3 muM) ATP-binding sites per hexamer were seen on Scatchard analysis in the absence of bicyclomycin and poly(C). In the presence of bicyclomycin, the K-d1 changed from 3.0 to 1.4 muM, but K-d2 underwent a lesser change. The non-hydrolyzable ATP analogue, gamma-S-ATP, gave a similar profile with three tight (K-d1 = 0.2 muM) and three loose (K-d2 = 70 pm) ATP-binding sites per hexamer. Adding poly(C) to F355W did not alter the K-d1 or K-d2 for ATP or for gamma-S-ATP. ADP-induced quenching produced 5.5 loose (K-d = 92 muM) binding sites in the absence of poly(C), and the binding became weaker (K-d = 175 muM) in the presence of poly(C). The data suggest that in the presence of ADP Rho has six equivalent nucleotide-binding sites. When ATP was added these sites converted to three tight and three loose binding loci. We propose an alternating ATP site mechanism where ATP binding creates heterogeneity in the ATP binding in adjacent subunits, and we suggest that ATP binding to a neighboring loose site stimulates hydrolysis at a neighboring tight binding site such that all six subunits can be potential "active" sites for ATP hydrolysis. The dynamic nature of the ATP binding to Rho is discussed in the terms of the mechanism of RNA tracking driven by ATP hydrolysis.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA	University of Houston System; University of Houston; University of North Carolina; University of North Carolina Chapel Hill	Widger, WR (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.				NIGMS NIH HHS [GM37934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; Boyer PD, 1998, ANGEW CHEM INT EDIT, V37, P2297, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2296::AID-ANIE2296>3.0.CO;2-W; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CROSS RL, 1975, BIOCHEMISTRY-US, V14, P392, DOI 10.1021/bi00673a028; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; Kim DE, 1999, J BIOL CHEM, V274, P32667, DOI 10.1074/jbc.274.46.32667; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; Koshland DE, 2002, J BIOL CHEM, V277, P46841, DOI 10.1074/jbc.R200014200; Magyar A, 1999, J BIOL CHEM, V274, P7316, DOI 10.1074/jbc.274.11.7316; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; Moyse KA, 2001, BBA-GENE STRUCT EXPR, V1520, P223, DOI 10.1016/S0167-4781(01)00271-8; Moyse KA, 2000, J MOL BIOL, V302, P565, DOI 10.1006/jmbi.2000.4090; ODA T, 1972, J MOL BIOL, V71, P799; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; Vincent F, 2000, BIOCHEMISTRY-US, V39, P9077, DOI 10.1021/bi000504+; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Walstrom KM, 1998, J MOL BIOL, V279, P713, DOI 10.1006/jmbi.1998.1814; WANG Y, 1993, J BIOL CHEM, V268, P13940; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Wei RR, 2001, J MOL BIOL, V314, P1007, DOI 10.1006/jmbi.2000.5207; Xu Y, 2002, J BIOL CHEM, V277, P30023, DOI 10.1074/jbc.M111009200; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810	47	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13719	13727		10.1074/jbc.M212979200	http://dx.doi.org/10.1074/jbc.M212979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12551938	hybrid			2022-12-25	WOS:000182405000022
J	Chandrasekera, CP; Lytton, J				Chandrasekera, CP; Lytton, J			Inhibition of human SERCA3 by PL/IM430 - Molecular analysis of the interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM CA-ATPASE; SARCOPLASMIC-RETICULUM; MESSENGER-RNA; CALCIUM PUMPS; DEPENDENT RELAXATION; SMOOTH-MUSCLE; CA-2+ PUMP; CA2+-ATPASE; GENE; EXPRESSION	The monoclonal antibody PL/IM430 has previously been reported to uncouple Ca2+ transport from ATP hydrolysis in platelet membranes (Hack, N., Wilkinson, J. M., and Crawford, N. (1988) Biochem. J. 250,355-361). More recently, we have demonstrated that this antibody is specific for human SERCA3 (Poch, E., Leach, S., Snape, S., Cacic, T., MacLennan, D. H., and Lytton, J. (1998) Am. J. Physiol. 275, C1449-CI458). In this paper, we have extended the analysis of the PL/IM430-SERCA3 interaction. Using HEK293 cells to express human SERCA3a, we were able to measure bot ATP-mediated, oxalate-dependent Ca-45(2+) uptake and Ca2+-dependent ATP hydrolysis activities due exclusively to SERCA3. Treatment with PL/IM430 inhibited both activities almost identically, with a maximal inhibition of 81 and 73% and a half-maximal concentration of 8.3 and 5.9 mug/ml, for Ca2+ uptake and ATP hydrolysis, respectively. We conclude that PL/IM430 does inhibit SERCA3 activity but does not uncouple Ca2+ transport from ATP hydrolysis. Using a combination of partial proteolysis, GST fusion protein expression, and mutation of residues that differ between rat and human SERCA3, we have identified human SERCA3 amino acids Pros and Glu(192) as essential to forming the PL/IM430 epitope. PL/IM430 thus recognizes a linearly noncontiguous set of amino acids within the actuator domain of human SERCA3. We propose that PL/IM430 inhibits SERCA3 activity by sterically preventing movement of the actuator domain into a catalytically critical position in the E2 conformation of the enzyme.	Univ Calgary, Hlth Sci Ctr, Cardiovasc Res Grp, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Cardiovasc Res Grp, Dept Biochem & Mol Biol, Rm 2518,3330 Hosp Dr,NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Lytton, Jonathan/0000-0003-4770-2512				ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANGER M, 1993, FEBS LETT, V334, P45, DOI 10.1016/0014-5793(93)81677-R; ANGER M, 1994, J MOL CELL CARDIOL, V26, P539, DOI 10.1006/jmcc.1994.1064; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; East JM, 2000, MOL MEMBR BIOL, V17, P189, DOI 10.1080/09687680010009646; FRASSETTO SS, 1993, MOL CELL BIOCHEM, V129, P47, DOI 10.1007/BF00926575; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Martin V, 2002, J BIOL CHEM, V277, P24442, DOI 10.1074/jbc.M202011200; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; PAPP B, 1991, J BIOL CHEM, V266, P14593; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; ROE MW, 1994, J BIOL CHEM, V269, P18279; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775	33	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12482	12488		10.1074/jbc.M212745200	http://dx.doi.org/10.1074/jbc.M212745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540840	hybrid			2022-12-25	WOS:000182015700099
J	Delmas, C; Aragou, N; Poussard, S; Cottin, P; Darbon, JM; Manenti, S				Delmas, C; Aragou, N; Poussard, S; Cottin, P; Darbon, JM; Manenti, S			MAP kinase-dependent degradation of p27(Kip1) by calpains in choroidal melanoma cells - Requirement of p27(Kip1) nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; GROWTH-FACTOR; INHIBITOR P27(KIP1); S-PHASE; DOWN-REGULATION; CYTOPLASMIC LOCALIZATION; RESTRICTION POINT; EPITHELIAL-CELLS; CYCLIN E-CDK2; 3T3 CELLS	We investigated the status and the regulation of the cyclin-dependent kinases (CDK) inhibitor p27(Kip1) in a choroidal melanoma tumor-derived cell line (OCM-1). By contrast to normal choroidal melanocytes, the expression level of p27(Kip1) was low in these cells and the mitogen-activated protein (MAP) kinase pathway was constitutively activated. Genetic or chemical inhibition of this pathway induced p27(Kip1) accumulation, whereas MAP kinase reactivation triggered a down-regulation of P27(Kip1) that could be partially reversed by calpain inhibitors. In good accordance, ectopic expression of the cellular calpain inhibitor calpastatin led to an increase of endogenous p27(Kip1) expression. In vitro, p27(Kip1) was degraded by calpains, and OCM-1 cell extracts contained a calcium-dependent p27(Kip1) degradation activity. MAP kinase inhibition partially inhibited both calpain activity and calcium-dependent p27(Kip1) degradation by cellular extracts. Immunofluoreseence labeling and subcellular fractionation revealed that p27(Kip1) was in part localized in the cytoplasmic compartment of OCM-1 cells but not of melanocytes, and accumulated into the nucleus upon MAP kinase inhibition. MAP kinase activation triggered a cytoplasmic translocation of the protein, as well as a change in its phosphorylation status. This CRM-1-dependent cytoplasmic translocation was necessary for MAP kinase- and calpain-dependent degradation. Taken together, these data suggest that in tumor-derived cells, p27(Kip1) could be degraded by calpains through a MAP kinase-dependent process, and that abnormal cytoplasmic localization of the protein, probably linked to modifications of its phosphorylation state, could be involved in this alternative mechanism of degradation.	Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088,IFR 109, F-31062 Toulouse, France; Univ Bordeaux 1, Lab Biochim & Technol Aliments, USC 429, INRA, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; INRAE; UDICE-French Research Universities; Universite de Bordeaux	Manenti, S (corresponding author), Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088,IFR 109, Batiment 4R3B1,118 Route Narbonne, F-31062 Toulouse, France.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chen ZP, 2001, J VIROL, V75, P3613, DOI 10.1128/JVI.75.8.3613-3625.2001; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Ciarallo S, 2002, MOL CELL BIOL, V22, P2993, DOI 10.1128/MCB.22.9.2993-3002.2002; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Croall DE, 2002, ANAL BIOCHEM, V304, P129, DOI 10.1006/abio.2001.5606; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GARRET C, 1988, FEBS LETT, V227, P209, DOI 10.1016/0014-5793(88)80900-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kamiyama J, 1999, FEBS LETT, V455, P281, DOI 10.1016/S0014-5793(99)00899-6; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Mouriaux F, 1998, INVEST OPHTH VIS SCI, V39, P876; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Muller D, 2000, EMBO J, V19, P2168, DOI 10.1093/emboj/19.10.2168; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200	62	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12443	12451		10.1074/jbc.M209523200	http://dx.doi.org/10.1074/jbc.M209523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529328	hybrid			2022-12-25	WOS:000182015700094
J	Koizumi, H; Yamaguchi, N; Hattori, M; Ishikawa, TO; Aoki, J; Taketo, MM; Inoue, K; Arai, H				Koizumi, H; Yamaguchi, N; Hattori, M; Ishikawa, TO; Aoki, J; Taketo, MM; Inoue, K; Arai, H			Targeted disruption of intracellular type I platelet activating factor-acetylhydrolase catalytic subunits causes severe impairment in spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIEKER LISSENCEPHALY GENE; NEURONAL MIGRATION; LIS1; PROTEIN; PURIFICATION; EXPRESSION; REDUCTION; SUBSTRATE; MOUSE	Intracellular type I platelet activating factor-acetylhydrolase is a phospholipase that consists of a dimer of two homologous catalytic subunits alpha1 and alpha2 as well as LIS1, a product of the causative gene for type I lissencephaly. LIS1 plays an important role in neuronal migration during brain development, but the in vivo function of the catalytic subunits remains unclear. In this study, we generated alpha1- and alpha2-deficient mice by targeted disruption. alpha1(-/-) mice are indistinguishable from wild-type mice, whereas alpha2(-/-) male mice show a significant reduction in testis size. Double-mutant male mice are sterile because of severe impairment of spermatogenesis. Histological examination revealed marked degeneration at the spermatocyte stage and an increase of apoptotic cells in the seminiferous tubules. The catalytic subunits are expressed at high levels in testis as well as brain in mice. In wild-type mice, alpha2 is expressed in all seminiferous tubule cell types, whereas alpha1 is expressed only in the spermatogonia. This expression pattern parallels the finding that deletion of both subunits induces a marked loss of germ cells at an early spermatogenic stage. We also found that the LIS1 protein levels, but not the mRNA levels, were significantly reduced in alpha2(-/-) and double-mutant mice, suggesting that the catalytic subunits, especially alpha2, are a determinant of LIS1 expression level.	Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Lab Biomed Genet, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Banyu Tsukuba Res Inst, Merck, Tsukuba, Ibaraki 3000026, Japan	University of Tokyo; University of Tokyo; Merck & Company	Arai, H (corresponding author), Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	harai@mol.f.u-tokyo.ac.jp	Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969; Aoki, Junken/0000-0001-9435-1896				Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; Bazan NG, 1998, PROG BRAIN RES, V118, P281; Chiarini-Garcia H, 2001, BIOL REPROD, V65, P1179, DOI 10.1095/biolreprod65.4.1179; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1; Lecointe N, 1999, ONCOGENE, V18, P2852, DOI 10.1038/sj.onc.1202645; Levine AS, 2002, J ANDROL, V23, P471; Maclennan KM, 1996, PROG NEUROBIOL, V50, P585, DOI 10.1016/S0301-0082(96)00047-0; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Minhas BS, 1996, AM J REPROD IMMUNOL, V35, P267; Mori C, 1997, DEV DYNAM, V208, P125; Nagano M, 1999, BIOL REPROD, V60, P1429, DOI 10.1095/biolreprod60.6.1429; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nothwang HG, 2001, HUM MOL GENET, V10, P797, DOI 10.1093/hmg/10.8.797; Parreira GG, 1998, BIOL REPROD, V59, P1360, DOI 10.1095/biolreprod59.6.1360; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RICKER DD, 1989, FERTIL STERIL, V52, P655; Roudebush WE, 2000, FERTIL STERIL, V74, P257, DOI 10.1016/S0015-0282(00)00646-4; Roudebush WE, 2001, THERIOGENOLOGY, V55, P1633, DOI 10.1016/S0093-691X(01)00508-8; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0	34	69	72	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12489	12494		10.1074/jbc.M211836200	http://dx.doi.org/10.1074/jbc.M211836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551946	hybrid			2022-12-25	WOS:000182015700100
J	Guillard, C; Chretien, S; Pelus, AS; Porteu, F; Muller, O; Mayeux, P; Duprez, V				Guillard, C; Chretien, S; Pelus, AS; Porteu, F; Muller, O; Mayeux, P; Duprez, V			Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i) protein beta gamma-subunit-initiated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ERYTHROID-DIFFERENTIATION; TYROSINE-PHOSPHORYLATED PROTEIN; NUCLEOTIDE EXCHANGE FACTOR; RAS-DEPENDENT ACTIVATION; AIRWAY SMOOTH-MUSCLE; MAP KINASE; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO	We have recently shown that a heterotrimeric G(i) protein is coupled to the erythropoietin (Epo) receptor. The G(i) protein constitutively associates in its heterotrimeric form with the intracellular domain of Epo receptor (EpoR). After Epo stimulation G(i) is released from the receptor and activated. In the present study we have investigated the functional role of the heterotrimeric G(i) protein bound to EpoR. In Chinese hamster ovary cells expressing EpoR, the G(i) inhibitor pertussis toxin blocked mitogen-activated protein kinase (MAPK) Erk1/2 activation induced by Epo. Epo-dependent MAPK activation was also sensitive to the Gbetagamma competitive inhibitor betaARK1-ct (C-terminal fragment of the beta-adrenergic receptor kinase), to the Ras dominant negative mutant RasN17, and to the phosphoinositide 3-kinase (PI3K) inhibitor LY 294002. A region of 7 amino acids (469-475) in the C-terminal end of EpoR was shown to be required for G(i) binding to EpoR in vivo. Deletion of this region in EpoR abolished both MAPK and PI3K activation in response to Epo. We conclude that in Chinese hamster ovary cells, Epo activates MAPK via a novel pathway dependant on G(i) association to EpoR, Gbetagamma subunit, Ras, and PI3K. The tyrosine kinase Jak2 also contributes to this new pathway, more likely downstream of betagamma and upstream of Ras and PI3K. This pathway is similar to the best characterized pathway used by seven transmembrane receptors coupled to G(i) to activate MAPK and may cooperate with other described Epo-dependent MAPK activation pathways in hematopoietic cells.	Univ Paris 05, CNRS UMR 8104, INSERM U567, Inst Cochin,Dept Hematol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Duprez, V (corresponding author), Univ Paris 05, CNRS UMR 8104, INSERM U567, Inst Cochin,Dept Hematol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		PORTEU, Françoise/I-8445-2016; Chretien, Stany/M-5166-2018	PORTEU, Françoise/0000-0002-2403-4163; 				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN J, 1992, BLOOD, V80, P1923; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Devemy E, 1997, CELL SIGNAL, V9, P41, DOI 10.1016/S0898-6568(96)00095-2; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duprez V, 1998, J BIOL CHEM, V273, P33985, DOI 10.1074/jbc.273.51.33985; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Guillard C, 2001, J BIOL CHEM, V276, P2007, DOI 10.1074/jbc.M003527200; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; MILLER BA, 1991, BLOOD, V77, P486; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TORTI M, 1992, J BIOL CHEM, V267, P8293; VAN BT, 1995, NATURE, V376, P781; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Yu XB, 2002, DEVELOPMENT, V129, P505	69	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11050	11056		10.1074/jbc.M208834200	http://dx.doi.org/10.1074/jbc.M208834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538595	hybrid			2022-12-25	WOS:000181855400025
J	Hara, N; Yamada, K; Terashima, M; Osago, H; Shimoyama, M; Tsuchiya, M				Hara, N; Yamada, K; Terashima, M; Osago, H; Shimoyama, M; Tsuchiya, M			Molecular identification of human glutamine- and ammonia-dependent NAD synthetases - Carbon-nitrogen hydrolase domain confers glutamine dependency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ADP-RIBOSE; GENE; ENZYME; EXPRESSION; NITRILASE; CLONING; FAMILY; BIOSYNTHESIS	NAD synthetase catalyzes the final step in the biosynthesis of NAD. In the present study, we obtained cDNAs for two types of human NAD synthetase (referred as NADsyn1 and NADsyn2). Structural analysis revealed in both NADsyn1 and NADsyn2 a domain required for NAD synthesis from ammonia and in only NADsyn1 an additional carbon-nitrogen hydrolase domain shared with enzymes of the nitrilase family that cleave nitriles as well as amides to produce the corresponding acids and ammonia. Consistent with the domain structures, biochemical assays indicated (i) that both NADsyn1 and NADsyn2 have NAD synthetase activity, (ii) that NADsyn1 uses glutamine as well as ammonia as an amide donor, whereas NADsyn2 catalyzes only ammonia-dependent NAD synthesis, and (iii) that mutant NADsyn1 in which Cys-175 corresponding to the catalytic cysteine residue in nitrilases was replaced with Ser does not use glutamine. Kinetic studies suggested that glutamine and ammonia serve as physiological amide donors for NADsyn1 and NADsyn2, respectively. Both synthetases exerted catalytic activity in a multimeric form. In the mouse, NADsyn1 was seen to be abundantly expressed in the small intestine, liver, kidney, and testis but very weakly in the skeletal muscle and heart. In contrast, expression of NADsyn2 was observed in all tissues tested. Therefore, we conclude that humans have two types of NAD synthetase exhibiting different amide donor specificity and tissue distributions. The ammonia-dependent synthetase has not been found in eucaryotes until this study. Our results also indicate that the carbon-nitrogen hydrolase domain is the functional domain of NAD synthetase to make use of glutamine as an amide donor in NAD synthesis. Thus, glutamine-dependent NAD synthetase may be classified as a possible glutamine amidase in the nitrilase family. Our molecular identification of NAD synthetases may prove useful to learn more of mechanisms regulating cellular NAD metabolism.	Shimane Med Univ, Dept Biochem, Izumo, Shimane 6938501, Japan	Shimane University	Tsuchiya, M (corresponding author), Shimane Med Univ, Dept Biochem, 89-1, Izumo, Shimane 6938501, Japan.							Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; BORK P, 1994, PROTEIN SCI, V3, P1344, DOI 10.1002/pro.5560030821; Cantoni R, 1998, J BACTERIOL, V180, P3218, DOI 10.1128/JB.180.12.3218-3221.1998; Elgadi KM, 1999, PHYSIOL GENOMICS, V1, P51, DOI 10.1152/physiolgenomics.1999.1.2.51; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; FOSTER JW, 1980, MICROBIOL REV, V44, P83, DOI 10.1128/MMBR.44.1.83-105.1980; Fukuoka S, 1998, BBA-GENE STRUCT EXPR, V1395, P192, DOI 10.1016/S0167-4781(97)00143-7; Haag F, 1998, J BIOL REG HOMEOS AG, V12, P53; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; NESSI C, 1995, J BIOL CHEM, V270, P6181, DOI 10.1074/jbc.270.11.6181; NOVO C, 1995, FEBS LETT, V367, P275, DOI 10.1016/0014-5793(95)00585-W; Okazaki IJ, 1998, J BIOL CHEM, V273, P23617, DOI 10.1074/jbc.273.37.23617; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; SPENCER RL, 1967, J BIOL CHEM, V242, P385; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TRITZ GJ, 1987, ESCHERICHIA COLI SAL, P557; White III H. B., 1982, PYRIDINE NUCLEOTIDE, P1; WILLISON JC, 1994, J BACTERIOL, V176, P3400, DOI 10.1128/jb.176.11.3400-3402.1994; YU CK, 1972, J BIOL CHEM, V247, P4794; ZALKIN H, 1985, METHOD ENZYMOL, V113, P297; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; ZEREZ CR, 1990, BLOOD, V75, P1576	31	55	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10914	10921		10.1074/jbc.M209203200	http://dx.doi.org/10.1074/jbc.M209203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547821	hybrid			2022-12-25	WOS:000181855400007
J	Koprowski, P; Kubalski, A				Koprowski, P; Kubalski, A			C termini of the Escherichia coli mechanosensitive ion channel (MscS) move apart upon the channel opening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; CRYSTAL-STRUCTURE; GATING MECHANISM; ACTIVATION; SUBUNIT; PROTEIN; IDENTIFICATION; ADAPTATION; DOMAINS; BINDING	Heptameric YggB is a mechanosensitive ion channel (MscS) from the inner membrane of Escherichia coli. We demonstrate, using the patch clamp technique, that cross-linking of the YggB C termini led to irreversible inhibition of the channel activities. Application of Ni2+ to the YggB-His, channels with the hexahistidine tags added to the ends of their C termini also resulted in a marked but reversible decrease of activities. Western blot revealed that YggB-His, oligomers are more stable in the presence of Ni2+, providing evidence that Ni2+ is coordinated between C termini from different subunits of the channel. Intersubunit coordination of Ni2+ affecting channel activities occurred in the channel closed conformation and not in the open state. This may suggest that the C termini move apart upon channel opening and are involved in the channel activation. We propose that the as yet undefined C-terminal region may form a cytoplasmic gate of the channel. The results are discussed and interpreted based on the recently released quaternary structure of the channel.	M Nencki Inst Expt Biol, Dept Cell Biol, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kubalski, A (corresponding author), M Nencki Inst Expt Biol, Dept Cell Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	kubalski@nencki.gov.pl	Koprowski, Piotr R/R-4088-2016	Koprowski, Piotr R/0000-0002-7571-2446				Ajouz B, 1998, J BIOL CHEM, V273, P26670, DOI 10.1074/jbc.273.41.26670; Anishkin A, 2002, BIOPHYS J, V82, p269A; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Batiza AF, 2002, P NATL ACAD SCI USA, V99, P5643, DOI 10.1073/pnas.082092599; Batiza AF, 1999, STRUCTURE, V7, pR99, DOI 10.1016/S0969-2126(99)80061-6; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Bezanilla F, 2002, SCIENCE, V298, P1562, DOI 10.1126/science.1079369; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kloda A, 2001, BIOPHYS J, V80, P229, DOI 10.1016/S0006-3495(01)76009-2; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; Koprowski P, 1998, J MEMBRANE BIOL, V164, P253, DOI 10.1007/s002329900410; Koprowski P, 2001, BIOESSAYS, V23, P1148, DOI 10.1002/bies.10017; KUBALSKI A, 1995, BBA-BIOMEMBRANES, V1238, P177, DOI 10.1016/0005-2736(95)00126-N; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; McLaggan D, 2002, MOL MICROBIOL, V43, P521, DOI 10.1046/j.1365-2958.2002.02764.x; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; Okada K, 2002, J BIOL CHEM, V277, P27682, DOI 10.1074/jbc.M202497200; Paar JM, 2002, J IMMUNOL, V169, P856, DOI 10.4049/jimmunol.169.2.856; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; SILLEN LG, 1971, STABILITY CONSTAN S, V1; Sukharev S, 2002, BIOPHYS J, V83, P290, DOI 10.1016/S0006-3495(02)75169-2; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; Zhou BY, 1998, J GEN PHYSIOL, V111, P555, DOI 10.1085/jgp.111.4.555	38	59	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11237	11245		10.1074/jbc.M212073200	http://dx.doi.org/10.1074/jbc.M212073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551944	hybrid			2022-12-25	WOS:000181855400050
J	Appeldoorn, CCM; Molenaar, TJM; Bonnefoy, A; van Leeuwen, SH; Vandervoort, PAH; Hoylaerts, MF; van Berkel, TJC; Biessen, EAL				Appeldoorn, CCM; Molenaar, TJM; Bonnefoy, A; van Leeuwen, SH; Vandervoort, PAH; Hoylaerts, MF; van Berkel, TJC; Biessen, EAL			Rational optimization of a short human P-selectin-binding peptide leads to nanomolar affinity antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN LIGAND-1; CARBOHYDRATE INTERACTIONS; TYROSINE SULFATION; VENOUS THROMBOSIS; PHAGE; RECOGNITION; CONSENSUS	P-selectin plays an important role in the development of various diseases, including atherosclerosis and thrombosis. In our laboratory we recently identified a number of specific human P-selectin-binding peptides containing a Glu-Trp-Val-Asp-Val consensus motif, displaying a low micromolar affinity for P-selectin (IC50 = 2 gm). In search of more potent antagonists for P-selectin, we have optimized the EWVDV pentapeptide core motif via a two-step combinatorial chemistry approach. A dedicated library of peptide derivatives was generated by introducing seven substituents at the N and C termini of the motif. In particular, pentapeptides with gallic acid or 1,3,5-benzenetricarboxylic acid substituents at the N terminus proved to be considerably more potent inhibitors of P-selectin binding than the parental peptide. After removal of the N-terminal glutamic acid from the core sequence, which appeared to be replaceable by a carboxamide function without loss of affinity, a second library was synthesized to map the chemical moieties within the gallic acid or 1,3,5-benzenetricarboxyl acid groups responsible for the enhanced P-selectin binding. Moreover, by varying the length and rigidity of the connective spacer, we have further optimized the spatial orientation of the N-terminal substituent. The combined use of phage display and subsequent combinatorial. chemistry led to the design of a number of gallic acid-containing peptides with low nanomolar affinity for P-selectin both under static and dynamic conditions (IC50 = 15.4 nM). These small synthetic antagonists, which are equally as potent as the natural ligand P-selectin glycoprotein ligand-1, are promising leads in anti-atherothrombotic therapy.	Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Leiden University; Leiden University - Excl LUMC; KU Leuven	Biessen, EAL (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9502, NL-2300 RA Leiden, Netherlands.	biessen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021	Hoylaerts, Marc/0000-0002-6474-3933				Adda CG, 2002, COMB CHEM HIGH T SCR, V5, P1; Andre P, 2000, P NATL ACAD SCI USA, V97, P13835, DOI 10.1073/pnas.250475997; Apletalina EV, 2000, BIOCHEM BIOPH RES CO, V267, P940, DOI 10.1006/bbrc.1999.2060; BLABER M, 1995, J MOL BIOL, V246, P317, DOI 10.1006/jmbi.1994.0087; Blann AD, 2000, BRIT J HAEMATOL, V108, P191, DOI 10.1046/j.1365-2141.2000.01813.x; BYCROFT BW, 1993, J CHEM SOC CHEM COMM, P778, DOI 10.1039/c39930000778; Hoess RH, 2001, CHEM REV, V101, P3205, DOI 10.1021/cr000056b; JACOB GS, 1995, ADV EXP MED BIOL, V376, P283; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Merten M, 2000, CIRCULATION, V102, P2045, DOI 10.1161/01.CIR.102.17.2045; Molenaar TJM, 2002, BLOOD, V100, P3570, DOI 10.1182/blood-2002-02-0641; Myers DD, 2001, THROMB HAEMOSTASIS, V85, P423; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; Theilmeier G, 1999, BLOOD, V94, P2725, DOI 10.1182/blood.V94.8.2725.420k18_2725_2734; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WeitzSchmidt G, 1996, ANAL BIOCHEM, V238, P184, DOI 10.1006/abio.1996.0273; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh RH, 2001, J BIOL CHEM, V276, P12235, DOI 10.1074/jbc.M011232200	27	31	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10201	10207		10.1074/jbc.M209267200	http://dx.doi.org/10.1074/jbc.M209267200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525501	hybrid, Green Published			2022-12-25	WOS:000181777500030
J	Takahashi, S; Saito, T; Hisanaga, S; Pant, HC; Kulkarni, AB				Takahashi, S; Saito, T; Hisanaga, S; Pant, HC; Kulkarni, AB			Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK5 ACTIVATOR P35; PROTEIN-KINASE; NEURITE OUTGROWTH; ABNORMAL PHOSPHORYLATION; REGULATORY SUBUNIT; RECOMBINANT TAU; MESSENGER-RNA; FETAL-TAU; EXPRESSION; LOCALIZATION	The microtubule-associated protein tau is a developmentally regulated neuronal phosphoprotein. The phosphorylation of tau reduces its ability to bind and stabilize axonal microtubules during axonal growth. Although tau is phosphorylated by cyclin-dependent kinase 5 (Cdk5) in vitro, its in vivo roles remain unclear. Here, we show that tau is phosphorylated by Cdk5/p39 during brain development, resulting in a reduction of its affinity for microtubules. The activity of Cdk5 is tightly regulated by association with its neuronal activators, p35 or p39. The p35 and p39 expression levels were investigated in the developing mouse brain; the p39 expression level was higher in embryonic hind brain and spinal cord and in postnatal cerebral cortex, whereas that of p35 was most prominent in cerebral cortex at earlier stages of development. The ability of Cdk5 to phosphorylate tau was higher when in association with p39 than in association with p35. Tau phosphorylation at Ser-202 and Thr-205 was decreased in Cdk5-/- mouse brain but not in p35-/- mouse brain, suggesting that Cdk5/p39 is responsible for the in vivo phosphorylation of tau at these sites. Our data suggest that tau phosphorylation by Cdk5 may provide the neuronal microtubules with dynamic properties in a region-specific and developmentally regulated manner.	NIDCR, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; Tokyo Metropolitan Univ, Dept Biol Sci, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Tokyo Metropolitan University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Kulkarni, AB (corresponding author), NIDCR, Funct Genom Unit, NIH, Bldg 30,Rm 527,30 Convent Dr, Bethesda, MD 20892 USA.	ak40m@nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000698, Z01DE000698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002725, Z01NS002725] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; AVILA J, 1994, INT J DEV BIOL, V38, P13; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1994, NEUROSCIENCE, V63, P895, DOI 10.1016/0306-4522(94)90533-9; BRION JP, 1993, J NEUROCHEM, V61, P2071, DOI 10.1111/j.1471-4159.1993.tb07444.x; CACERES A, 1991, J NEUROSCI, V11, P1515; Cai XH, 1997, NEUROSCI RES, V28, P355, DOI 10.1016/S0168-0102(97)00063-1; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Humbert S, 2000, NEUROREPORT, V11, P2213, DOI 10.1097/00001756-200007140-00030; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KENESSEY A, 1993, BRAIN RES, V629, P40, DOI 10.1016/0006-8993(93)90478-6; Ko J, 2001, J NEUROSCI, V21, P6758; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ohshima T, 2002, J NEUROSCI, V22, P4036, DOI 10.1523/JNEUROSCI.22-10-04036.2002; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; Ohshima T, 1996, GENOMICS, V35, P372, DOI 10.1006/geno.1996.0370; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PIERRE M, 1983, BIOCHEM BIOPH RES CO, V115, P212, DOI 10.1016/0006-291X(83)90991-9; Pigino G, 1997, J CELL SCI, V110, P257; RIEDERER BM, 1992, HISTOCHEM J, V24, P783, DOI 10.1007/BF01046350; RIEDERER BM, 1994, BRAIN RES BULL, V33, P155, DOI 10.1016/0361-9230(94)90245-3; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; TAKEMURA R, 1991, NEUROSCIENCE, V44, P393, DOI 10.1016/0306-4522(91)90064-U; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Town T, 2002, J NEUROSCI RES, V69, P362, DOI 10.1002/jnr.10299; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wu DC, 2000, NEUROCHEM RES, V25, P923, DOI 10.1023/A:1007544106645; Wullner U, 1998, DEV BRAIN RES, V110, P1, DOI 10.1016/S0165-3806(98)00079-0; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	59	64	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10506	10515		10.1074/jbc.M211964200	http://dx.doi.org/10.1074/jbc.M211964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12536148	hybrid, Green Submitted			2022-12-25	WOS:000181777500069
J	Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM				Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM			Ajoene-induced cell death in human promyeloleukemic cells does not require JNK but is amplified by the inhibition of ERK	ONCOGENE			English	Article						ajoene; apoptosis; mitogen-activated protein kinase; c-Jun NH2-terminal kinase; extracellular signal-regulated kinases	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; INDUCED APOPTOSIS; SIGNALING PATHWAYS; CANCER CELLS; CYTOCHROME-C; HL-60 CELLS; KAPPA-B; T-CELLS	Treatment of human promyeloleukemic HL-60 cells with the experimental antileukemic drug ajoene induces the activation of the mitogen-activated protein kinases (MAPKs) c-Jun NH2-terminal kinase (JNK), p38 and extracellular signal-regulated kinases (ERK) 1/2 as well as the survival kinase Akt. JNK activation occurred in HL-60/neo, HL-60/bcl-x(L), and in HL-60 cells pretreated with the pan-caspase inhibitor zVAD-fmk, indicating that JNK activation is not dependent on ajoene-induced mitochondria perturbation and subsequent caspase activation. Cells overexpressing a dominant-negative JNK showed no altered sensitivity towards ajoene suggesting that the activation of JNK is not necessary for ajoene-induced cell death. Inhibition of p38 MAPK by SB 203580 had no influence on ajoene-mediated apoptosis. In contrast, inhibition of ERK1/2 vastly enhanced ajoene-induced cell death. The survival kinase Akt, in contrast, did not participate in ajoene-induced death signaling as shown by the use of the phosphatidylinositol-3-kinase inhibitor wortmannin. Thus in contrast to the previous findings regarding stress-induced cell death, ajoene-mediated activation of JNK and p38 has no impact on ajoene-induced apoptosis in HL-60 cells. Blockade of ERK1/2 but not Akt pathways leads to sensitization of cells against ajoene-mediated apoptosis supporting the view that inhibition of ERK1/2 is a valuable strategy to increase the sensitivity of promyeloleukemic cells towards ajoene.	Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan	University of Munich; National Taiwan University	Dirsch, VM (corresponding author), Univ Munich, Ctr Drug Res, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.		Kuo, Min-Liang/C-4872-2009	Dirsch, Verena/0000-0002-9261-5293				Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; Bamford M, 2000, EXP CELL RES, V256, P1, DOI 10.1006/excr.2000.4837; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dirsch VM, 2001, CANCER RES, V61, P5817; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; Dirsch VM, 2002, LEUKEMIA, V16, P74, DOI 10.1038/sj.leu.2402337; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/BST0290345; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ibrado AM, 1996, CANCER RES, V56, P4743; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Mandlekar S, 2000, CANCER RES, V60, P5995; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Shiah SG, 2001, MOL PHARMACOL, V59, P254, DOI 10.1124/mol.59.2.254; Shiah SG, 1999, CANCER RES, V59, P391; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	44	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					582	589		10.1038/sj.onc.1206161	http://dx.doi.org/10.1038/sj.onc.1206161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555071				2022-12-25	WOS:000180538200011
J	Bhanoori, M; Yellaturu, CR; Ghosh, SK; Hassid, A; Jennings, LK; Rao, GN				Bhanoori, M; Yellaturu, CR; Ghosh, SK; Hassid, A; Jennings, LK; Rao, GN			Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders it proapoptotic via activation of STATs and p53 and induction of expression of caspase1 and p21(waf1/cip1)	ONCOGENE			English	Article						apoptosis; cell growth; protein tyrosine phosphatases; protein tyrosine kinases; thiols; transcription factors	SMOOTH-MUSCLE CELLS; NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; DISULFIDE BOND FORMATION; NECROSIS-FACTOR-ALPHA; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTOR; REDOX REGULATION; SIGNALING PATHWAY; KINASE ACTIVATION	Thiols provide the major intracellular redox milieu and can undergo reversible oxidation and reduction. To understand the role of thiols in redox signaling events, we have studied the effect of N-ethylmaleimide, a specific thiol alkylating agent, on platelet-derived growth factor-BB (PDGF-BB)-induced mitogenesis in vascular smooth muscle cells (VSMC). Thiol alkylation inhibited PDGF-BB-induced expression of the Fos and Jun family proteins and AP-1 activity in VSMC. Thiol alkylation also inhibited PDGF-BB-induced expression of cyclin A and growth in these cells. In contrast, thiol alkylation enhanced and sustained the effect of PDGF-BB on the activation of the Jak STAT pathway, and this event was correlated with inhibition of protein tyrosine phosphatase 1B activity. Thiol alkylation via inducing the expression of p21(waf1/cip1) in a STAT1- and p53-dependent manner antagonized the downregulation of this cell cycle inhibitory molecule by PDGF-BB. The inhibition of AP-1 and activation of STATs, particularly STAT1, by thiol alkylation correlated with increased production of active caspase 1 and apoptosis in VSMC. Together, these findings suggest a role for thiols in mediating mitogenic and/or apoptotic signaling events in VSMC. These results also show that a sustained change in the intracellular thiol redox state can convert a mitogen into a death promoter.	Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.		Bhanoori, Manjula/ACH-9333-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chen B, 2000, CANCER RES, V60, P3290; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Chernoff J, 1999, J CELL PHYSIOL, V180, P173; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Clottes E, 1998, J BIOL CHEM, V273, P19391, DOI 10.1074/jbc.273.31.19391; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Ghosh SK, 2002, J BIOL CHEM, V277, P21325, DOI 10.1074/jbc.M201608200; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOSHI T, 2001, J PHYSL, V15, P1; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Kwaw I, 2001, BIOCHEMISTRY-US, V40, P10491, DOI 10.1021/bi010866x; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Preston TJ, 2001, J BIOL CHEM, V276, P9558, DOI 10.1074/jbc.M004617200; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; Rao GN, 1996, ONCOGENE, V13, P713; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Schmidt KN, 1996, ADV EXP MED BIOL, V387, P63; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wei SJ, 2000, CANCER RES, V60, P6688; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	69	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					117	130		10.1038/sj.onc.1206065	http://dx.doi.org/10.1038/sj.onc.1206065			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527914				2022-12-25	WOS:000180166900013
J	Wang, XH; Jin, DY; Wong, HL; Feng, HC; Wong, YC; Tsao, SW				Wang, XH; Jin, DY; Wong, HL; Feng, HC; Wong, YC; Tsao, SW			MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells	ONCOGENE			English	Article						MA132; Bcl-2; vincristine; Raf; nasopharyngeal carcinoma	SPINDLE ASSEMBLY CHECKPOINT; PROTEIN-KINASE; MAP KINASE; PROMOTING COMPLEX; GROWTH ARREST; HUMAN CANCERS; APOPTOSIS; BCL-2; DEATH; MAD2	Mitotic arrest deficient 2 (MAD2) is thought to be a key component of the mitotic checkpoint, which ensures accurate chromosome segregation. Reduced expression of MAD2 protein is associated with mitotic checkpoint abrogation and chromosomal instability in certain types of human cancers. To explore the possibility of developing a novel strategy for the treatment of cancer based on selective killing of mitotic checkpoint-defective or -competent cells, here we have investigated the effect of MAD2 expression on cellular sensitivity to checkpoint-targeting anticancer drugs. We reintroduced MAD2 protein in a mitotic checkpoint-defective nasopharyngeal carcinoma cell tine, CNE2, using an inducible expression vector. We found that overexpression of MAD2 led to an increased sensitivity to vincristine, which was accompanied by increased mitotic index and G2/M cell cycle arrest. In addition, increased phosphorylation of Raf, MEK1/2 and Bcl-2 was observed in MAD2-overexpressing cells in response to vincristine. Furthermore, inhibition of phosphorylation of MEK1/2 by its inhibitor PD098059 led to reduced sensitivity to vincristine, which was associated with decreased Bcl-2 phosphorylation. Our data suggest a role for MAD2 in the sensitization of cancer cells to certain mitotic checkpoint-targeting anticancer drugs.	Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Tsao, SW (corresponding author), Univ Hong Kong, Dept Anat, 21 Sassoon Rd,1st Floor,Fac Med Bldg,Lab Block, Hong Kong, Hong Kong, Peoples R China.		Feng, Huichen/F-5502-2011	Feng, Huichen/0000-0003-3069-8174				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bricker K.S., 1978, Kasetsart University Fisheries Research Bulletin, V10, P1; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Fan MY, 2000, CANCER RES, V60, P6403; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Huang STJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0852com; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jordan MA, 1996, CANCER RES, V56, P816; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lovric J, 1996, ONCOGENE, V12, P1109; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Pennisi E, 1998, SCIENCE, V279, P477, DOI 10.1126/science.279.5350.477; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Stadheim TA, 2001, CANCER RES, V61, P1533; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XH, 1999, INT J ONCOL, V15, P1097; Wang XH, 1998, CANCER RES, V58, P5019; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	39	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					109	116		10.1038/sj.onc.1206069	http://dx.doi.org/10.1038/sj.onc.1206069			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527913				2022-12-25	WOS:000180166900012
J	White, RA; Kannan, MS; Walseth, TF				White, RA; Kannan, MS; Walseth, TF			Intracellular calcium signaling through the cADPR pathway is agonist specific in porcine airway smooth muscle	FASEB JOURNAL			English	Article						CD38; cADPR; airway smooth muscle; calcium signaling	CYCLIC-ADP-RIBOSE; CA2+-INDUCED CA2+ RELEASE; RAT CARDIAC MYOCYTES; ENDOTHELIN RECEPTORS; HUMAN CD38; CELLS; HYDROLYSIS; CYCLASE; ACETYLCHOLINE; OSCILLATIONS	Cyclic ADP-ribose (cADPR) induces intracellular Ca(2+) ([Ca(2+)](i)) release in airway smooth muscle, and the cADPR antagonist, 8-amino-cADPR, abolishes [Ca(2+)](i) oscillations elicited by acetylcholine (ACh), suggesting that cADPR is involved during muscarinic receptor activation. Whether the cADPR signaling pathway is common to agonists acting through different G protein-coupled receptors is not known. Using digital video imaging of Fura2-AM loaded porcine airway smooth muscle cells, we examined the effects of the membrane-permeant cADPR antagonist, 8-bromo-cADPR (8Br-cADPR), on the [Ca(2+)](i) responses to ACh, histamine and endothelin-1 (ET-1). In cells preincubated with 100 muM 8Br-cADPR, the [Ca(2+)](i) responses to ACh and ET-1 were significantly attenuated, whereas responses to histamine were not, suggesting agonist specificity of cADPR signaling. The effects of 8Br-cADPR were concentration dependent. We further examined whether muscarinic receptor subtypes specifically couple to this pathway, because in porcine airway smooth muscle cells, ACh activates both M(2) and M(3) muscarinic receptors coupled to G(alphai) and G(alphaq), respectively. Methoctramine, an M(2)-selective antagonist, attenuated the [Ca(2+)](i) responses to Ach, and there was no further attenuation by 8Br-cADPR. In airway smooth muscle, the CD38/cADPR signaling pathway is involved in [Ca(2+)](i) responses to contractile agonists in an agonist-specific manner.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Coll Vet Med, Dept Vet Pathobiol, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Walseth, TF (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.	walseth@mail.ahc.umn.edu	Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL057498] Funding Source: Medline; NIDA NIH HHS [P50 DA011806] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BARON CB, 1984, P NATL ACAD SCI-BIOL, V81, P6899, DOI 10.1073/pnas.81.21.6899; Barone F, 2002, FASEB J, V16, DOI 10.1096/fj.01-0749com; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Chini EN, 1997, P NATL ACAD SCI USA, V94, P5872, DOI 10.1073/pnas.94.11.5872; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Esguerra M, 2002, GLIA, V39, P314, DOI 10.1002/glia.10115; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Hall IP, 2000, EUR RESPIR J, V15, P1120, DOI 10.1034/j.1399-3003.2000.01523.x; Han MK, 2000, J BIOL CHEM, V275, P20799, DOI 10.1074/jbc.M001189200; Hay DWP, 1999, N-S ARCH PHARMACOL, V359, P404, DOI 10.1007/PL00005368; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Kannan MS, 1997, AM J PHYSIOL-LUNG C, V272, pL659, DOI 10.1152/ajplung.1997.272.4.L659; Kotlikoff MI, 1998, AM J RESP CRIT CARE, V158, pS109, DOI 10.1164/ajrccm.158.supplement_2.13tac600; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LUCCHESI PA, 1990, AM J PHYSIOL, V258, pC730, DOI 10.1152/ajpcell.1990.258.4.C730; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Morel JL, 1997, BRIT J PHARMACOL, V121, P451, DOI 10.1038/sj.bjp.0701157; Morita K, 1997, J BIOL CHEM, V272, P21002, DOI 10.1074/jbc.272.34.21002; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; Prakash YS, 1997, AM J PHYSIOL-CELL PH, V272, pC966, DOI 10.1152/ajpcell.1997.272.3.C966; Roux E, 1997, BRIT J PHARMACOL, V120, P1294, DOI 10.1038/sj.bjp.0701061; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; SHIEH CC, 1991, J PHARMACOL EXP THER, V256, P141; Shieh Char-Chang, 1995, Journal of Biomedical Science, V2, P272, DOI 10.1007/BF02253388; Sims SM, 1996, AM J PHYSIOL-LUNG C, V271, pL300, DOI 10.1152/ajplung.1996.271.2.L300; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; White TA, 2000, BBA-MOL CELL RES, V1498, P64, DOI 10.1016/S0167-4889(00)00077-X; Yu JZ, 2000, AM J PHYSIOL-HEART C, V279, pH873, DOI 10.1152/ajpheart.2000.279.3.H873; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017	43	71	72	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					482	+		10.1096/fj.02-0622fje	http://dx.doi.org/10.1096/fj.02-0622fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551848				2022-12-25	WOS:000181453700005
J	Nieto, N; Cederbaum, AI				Nieto, N; Cederbaum, AI			Increased Sp1-dependent transactivation of the LAM gamma 1 promoter in hepatic stellate cells co-cultured with HepG2 cells overexpressing cytochrome P450 2E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; BASEMENT-MEMBRANES; LIPID-PEROXIDATION; OXIDATIVE STRESS; RECEPTOR LBP-32; FISH-OIL; LAMININ; EXPRESSION; LIVER; GENE	Laminin is a basement-membrane protein that increases in liver fibrosis. To study the role of oxidative stress on laminin expression, hepatic stellate cells (HSC) were co-cultured with HepG2 cells that do or do not express (E47 or C34 cells, respectively) CYP2E1, a potent generator of oxygen radicals. Co-incubation of HSC with E47 cells increased laminin beta1 and gamma1 proteins compared with co-incubation with C34 cells; this increase was prevented by antioxidants and CYP2E1 inhibitors. Similar results were observed in co-culture with primary hepatocytes from saline- or pyrazole-treated (with high levels of CYP2E1) rats. Laminin alpha1 chain was not detectable in the HSC in any of the systems; however, laminin alpha2 chain increased in HSC co-cultured with E47 cells. Synthesis but not turnover of laminin beta1 and gamma1 proteins was increased in HSC in the E47 co-culture. Laminin beta1 and gamma1 mRNAs were up-regulated in HSC in the E47. co-culture because of transcriptional activation of both genes. Transfection experiments in HSC with reporter constructs driven by the laminin gamma1 promoter showed maximal responsiveness with the -230/+106 and the -1400/+106 constructs in the E47 system. Gelshift assays demonstrated an increase in Sp1 binding to the laminin gamma1 promoter in HSC when co-incubated with E47 cells, which was blocked by an anti-Sp1 antibody. Co-transfection of a Sp1 expression vector further increased the responsiveness of the -330LAMgamma1-CAT reporter vector in HSC in the HSC/E47 system. These results show that diffusable CYP2E1-derived oxidative-stress mediators induce synthesis of laminins by a transcriptional mechanism in HSC. Such interactions between hepatocytes and HSC may be important during liver fibrosis.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Nieto, N (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	ny2000@hotmail.com			NIAAA NIH HHS [AA03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA003312, R56AA003312] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALBRECHTSEN R, 1988, HEPATOLOGY, V8, P538, DOI 10.1002/hep.1840080318; BOOTHANDFORD RP, 1987, J BIOL CHEM, V262, P12475; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1524, DOI 10.1016/S0891-5849(01)00741-9; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLEMENT B, 1988, HEPATOLOGY, V8, P794, DOI 10.1002/hep.1840080417; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Engvall E, 1996, J CELL BIOCHEM, V61, P493; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; Kedar V, 1997, MOL BRAIN RES, V47, P87, DOI 10.1016/S0169-328X(97)00062-4; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LEVAVASSEUR F, 1994, J CELL PHYSIOL, V161, P257, DOI 10.1002/jcp.1041610210; Lietard J, 1997, AM J PATHOL, V151, P1663; LIOTTA LA, 1983, LAB INVEST, V49, P636; MAHER JJ, 1994, HEPATOLOGY, V19, P764, DOI 10.1002/hep.1840190332; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; Nieto N, 2002, HEPATOLOGY, V35, P62, DOI 10.1053/jhep.2002.30362; Nieto N, 2002, J BIOL CHEM, V277, P9853, DOI 10.1074/jbc.M110506200; Nieto N, 2001, HEPATOLOGY, V33, P597, DOI 10.1053/jhep.2001.22520; Nieto N, 2000, J BIOL CHEM, V275, P20136, DOI 10.1074/jbc.M001422200; OGAWA K, 1988, J BIOL CHEM, V263, P8384; ONeill BC, 1997, AM J PHYSIOL-RENAL, V273, pF411, DOI 10.1152/ajprenal.1997.273.3.F411; RESCAN PY, 1991, HEPATOLOGY, V13, P289, DOI 10.1016/0270-9139(91)92442-B; RESCAN PY, 1990, AM J PATHOL, V137, P701; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; WEINER FR, 1992, MATRIX, V12, P36, DOI 10.1016/S0934-8832(11)80102-2; WEVER UM, 1992, VIRCHOWS ARCH A, V421, P87; Wu DF, 2001, MOL PHARMACOL, V59, P795, DOI 10.1124/mol.59.4.795; WU DF, 1993, J PHARMACOL EXP THER, V264, P1468; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; Yurchenco P. D., 1994, EXTRACELLULAR MATRIX; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15360	15372		10.1074/jbc.M206790200	http://dx.doi.org/10.1074/jbc.M206790200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12529372	hybrid			2022-12-25	WOS:000182516100101
J	Wu, WS; Xu, ZX; Hittelman, WN; Salomoni, P; Pandolfi, PP; Chang, KS				Wu, WS; Xu, ZX; Hittelman, WN; Salomoni, P; Pandolfi, PP; Chang, KS			Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappa B survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML-RAR-ALPHA; CYTOCHROME-C; FACTOR RECEPTOR; NUCLEAR-BODIES; CELL-DEATH; GROWTH; DAXX; TRANSCRIPTION; EXPRESSION; INDUCTION	The promyelocytic leukemia protein (PML) is a growth/tumor suppressor essential for induction of apoptosis by diverse apoptotic stimuli. The mechanism by which PML regulates cell death remains unclear. In this study we found that ectopic expression of PML potentiates cell death by apoptosis in the tumor necrosis factor alpha (TNFalpha)-resistant cell line U2OS and other cell lines. Treatment with TNFa significantly sensitized these cells to apoptosis in a p53-independent manner. PML/TNFalpha-induced cell death is associated with DNA fragmentation, activation of caspase-3, -7, and -8, and degradation of DNA fragmentation factor/inhibitor of CAD. PML/TNFalpha-induced cell death could be blocked by the caspase-8 inhibitors Crm-A and c-FLIP but not by Bcl-2. These findings indicate that this cell death event is initiated through the death receptor-dependent apoptosis pathway. PML is a transcriptional repressor of NF-kappaB by interacting with RelA/p65 and prevents its binding to the cognate enhancer through the C terminus. Coimmunoprecipitation and double-color immunofluorescence staining demonstrated that PML physically interacts with RelA/p65 in vivo and the two proteins colocalized at the endogenous levels. Overexpression of NF-kappaB rescued cell death induced by PML TNFalpha. Furthermore, PML-/- mouse embryo fibroblasts are more resistant to TNFalpha-induced apoptosis. Together this study defines a novel mechanism by which PML induces apoptosis through repression of the NF-kappaB survival pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holocombe Blvd,Unit 89, Houston, TX 77030 USA.	kchang@mail.mdanderson.org	Wu, Wen-Shu/I-1258-2014	Wu, Wen-Shu/0000-0002-0225-2522	NCI NIH HHS [CA 55577, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA055577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; Chan JYH, 1998, EUR J CANCER, V34, P1015, DOI 10.1016/S0959-8049(97)10138-1; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gastman BR, 2000, CANCER RES, V60, P6811; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; IRMIER M, 1997, NATURE, V388, P190; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson BW, 1999, J BIOL CHEM, V274, P18552, DOI 10.1074/jbc.274.26.18552; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Min W, 1996, MOL CELL BIOL, V16, P359; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Stadler M, 1995, ONCOGENE, V11, P2565; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wilkinson GWG, 1998, J GEN VIROL, V79, P1233, DOI 10.1099/0022-1317-79-5-1233; Wu WS, 2002, J BIOL CHEM, V277, P31734, DOI 10.1074/jbc.M201648200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	68	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12294	12304		10.1074/jbc.M211849200	http://dx.doi.org/10.1074/jbc.M211849200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540841	hybrid			2022-12-25	WOS:000182015700075
J	de Valencia, FF; Paulucci, AA; Quaggio, RB; da Silva, ACR; Farah, CS; Reinach, FD				de Valencia, FF; Paulucci, AA; Quaggio, RB; da Silva, ACR; Farah, CS; Reinach, FD			Parallel measurement of Ca2+ binding and fluorescence emission upon Ca2+ titration of recombinant skeletal muscle troponin C - Measurement of sequential calcium binding to the regulatory sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; TRYPTOPHAN ANALOGS; BIOSYNTHETIC INCORPORATION; STAPHYLOCOCCAL NUCLEASE; CA-2+-SPECIFIC SITES; DIRECTED MUTAGENESIS; MAGNESIUM BINDING; DISULFIDE BOND; RNA-POLYMERASE; HIGH-AFFINITY	Calcium binding to chicken recombinant skeletal muscle TnC (TnC) and its mutants containing tryptophan (F29W), 5-hydroxytryptophan (F29 (H) under barW), or 7-azatryptophan (F29 (Z) under barW) at position 29 was measured by flow dialysis and by fluorescence. Comparative analysis of the results allowed us to determine the influence of each amino acid on the calcium binding properties of the N-terminal regulatory domain of the protein. Compared with TnC, the Ca2+ affinity of N-terminal sites was: 1) increased 6-fold in F29W, 2) increased 3-fold in F29 (Z) under barW, and 3) decreased slightly in F29 (H) under barW. The Ca2+ titration of F29 (H) under barW monitored by fluorescence displayed a bimodal curve related to sequential Ca2+ binding to the two N-terminal Ca2+ binding sites. Single and double mutants of TnC, F29W, F29 (H) under barW, and F29 (Z) under barW were constructed by replacing aspartate by alanine at position 30 (site I) or 66 (site II) or both. Ca2+ binding data showed that the Asp --> Ala mutation at position 30 impairs calcium binding to site I only, whereas the Asp --> Ala mutation at position 66 impairs calcium binding to both sites I and II. Furthermore, the Asp --> Ala mutation at position 30 eliminates the differences in Ca2+ affinity observed for replacement of Phe at position 29 by Trp, 5-hydroxytryptophan, or 7-azatryptophan. We conclude that position 29 influences the affinity of site I and that Ca2+ binding to site I is dependent on the previous binding of metal to site II.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil	Universidade de Sao Paulo	de Valencia, FF (corresponding author), Univ Brasilia, Inst Ciencias Biol, Dept Cellular Biol, ICC SUL, Campus Univ,Asa Norte, BR-7091997 Brasilia, DF, Brazil.		Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302				BARLATI S, 1970, J BACTERIOL, V101, P166, DOI 10.1128/JB.101.1.166-172.1970; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DRAPEAU GR, 1968, J MOL BIOL, V35, P357, DOI 10.1016/S0022-2836(68)80030-0; ELLIS PD, 1988, J BIOL CHEM, V263, P10284; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Fredricksen RS, 1996, BIOCHEMISTRY-US, V35, P14012, DOI 10.1021/bi961270q; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; GRABAREK Z, 1983, J BIOL CHEM, V258, P4098; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GRIFFITHS PJ, 1984, FEBS LETT, V176, P144, DOI 10.1016/0014-5793(84)80929-1; GUSEV NB, 1991, J BIOL CHEM, V266, P16622; GUTH K, 1987, J BIOL CHEM, V262, P13627; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOGUE CWV, 1992, FEBS LETT, V310, P269, DOI 10.1016/0014-5793(92)81346-N; HOGUE CWV, 1993, BIOPHYS CHEM, V48, P159, DOI 10.1016/0301-4622(93)85007-5; IIDA S, 1988, J BIOCHEM-TOKYO, V103, P482, DOI 10.1093/oxfordjournals.jbchem.a122296; JOHNSON JD, 1978, J BIOL CHEM, V253, P6451; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P9703, DOI 10.1021/bi00155a025; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; Pearlstone JR, 2000, J BIOL CHEM, V275, P35106, DOI 10.1074/jbc.M001000200; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1981, FED PROC, V40, P2653; REINACH FC, 1988, J BIOL CHEM, V263, P2371; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; ROSS JBA, 1992, P NATL ACAD SCI USA, V89, P12023, DOI 10.1073/pnas.89.24.12023; Ross JBA, 1997, METHOD ENZYMOL, V278, P151; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TELEMAN O, 1983, EUR J BIOCHEM, V134, P453, DOI 10.1111/j.1432-1033.1983.tb07588.x; Tikunova SB, 2002, BIOCHEMISTRY-US, V41, P6697, DOI 10.1021/bi011763h; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TRIGOGONZALEZ G, 1992, BIOCHEMISTRY-US, V31, P7009, DOI 10.1021/bi00146a001; Wong CY, 1997, PROTEIN SCI, V6, P689; Wong CY, 1998, BIOCHEMISTRY-US, V37, P8947, DOI 10.1021/bi971863g; Yu A, 1999, BBA-PROTEIN STRUCT M, V1431, P53, DOI 10.1016/S0167-4838(99)00043-6; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031; ZOT AS, 1987, J BIOL CHEM, V262, P1966; ZOT HG, 1986, J BIOL CHEM, V261, P5883	57	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11007	11014		10.1074/jbc.M209943200	http://dx.doi.org/10.1074/jbc.M209943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531902	hybrid			2022-12-25	WOS:000181855400019
J	Ando, H; Mizutani, A; Matsu-ura, T; Mikoshiba, K				Ando, H; Mizutani, A; Matsu-ura, T; Mikoshiba, K			IRBIT, a novel inositol 1,4,5-trisphosphate (IP3) receptor-binding protein, is released from the IP3 receptor upon IP3 binding to the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; SITE-DIRECTED MUTAGENESIS; TRISPHOSPHATE RECEPTOR; LIGAND-BINDING; RAT-LIVER; DOWN-REGULATION; CA2+ RELEASE; FK506-BINDING PROTEIN; FUNCTIONAL LIGAND; STORAGE PROTEIN	The inositol 1,4,5-trisphosphate (IP3) receptors (IP(3)Rs) are IP3-gated Ca2+ channels on intracellular Ca2+ stores. Herein, we report a novel protein, termed IRBIT (IP3R binding protein released with inositol 1,4,5-trisphosphate), which interacts with type 1 IP3R (IP(3)R1) and was released upon IP3 binding to IP(3)R1. IRBIT was purified from a high salt extract of crude rat brain microsomes with IP3 elution using an affinity column with the huge immobilized N-terminal cytoplasmic region of IP(3)R1 (residues 1-2217). IRBIT, consisting of 530 amino acids, has a domain homologous to S-adenosylhomocysteine hydrolase in the C-terminal and in the N-terminal, a 104 amino acid appendage containing multiple potential phosphorylation sites. In vitro binding experiments showed the N-terminal region of IRBIT to be essential for interaction, and the IRBIT binding region of IP(3)R1 was mapped to the IP3 binding core. IP3 dissociated IRBIT from IP(3)R1 with an EC50 of similar to0.5 muM, i.e. it was 50 times more potent than other inositol polyphosphates. Moreover, alkaline phosphatase treatment abolished the interaction, suggesting that the interaction was dualistically regulated by IP3 and phosphorylation. Immunohistochemical studies and co-immunoprecipitation assays showed the relevance of the interaction in a physiological context. These results suggest that IRBIT is released from activated IP3R, raising the possibility that IRBIT acts as a signaling molecule downstream from IP3R.	Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Brain Sci Inst, Inst Phys & Chem Res RIKEN, Lab Dev Neurobiol, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Int Cooperat Res Project ICORP, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan	University of Tokyo; RIKEN; Japan Science & Technology Agency (JST)	Ando, H (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hando@ims.u-tokyo.ac.jp	Matsu-ura, Toru/P-3461-2017; Ando, Hideaki/D-3876-2017; Mikoshiba, Katsuhiko/N-7943-2015; Mizutani, Akihiro/GPS-4809-2022	Matsu-ura, Toru/0000-0002-9876-3086; Mizutani, Akihiro/0000-0003-4155-802X				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; AKSAMIT RR, 1994, J BIOL CHEM, V269, P4084; AULTRICHE DB, 1994, J BIOL CHEM, V269, P31472; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Bultynck G, 2000, J PHYSIOL-LONDON, V525, P681, DOI 10.1111/j.1469-7793.2000.t01-1-00681.x; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Dargan SL, 2002, BIOCHEM J, V361, P401, DOI 10.1042/0264-6021:3610401; Dekker JW, 2002, IMMUNOGENETICS, V53, P993, DOI 10.1007/s00251-001-0402-z; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GOMI T, 1990, J BIOL CHEM, V265, P16102; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Joseph SK, 2000, J BIOL CHEM, V275, P16084, DOI 10.1074/jbc.M000506200; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Laflamme K, 2002, J CELL BIOCHEM, V85, P219, DOI 10.1002/jcb.10124; Luzzi V, 1998, J BIOL CHEM, V273, P28657, DOI 10.1074/jbc.273.44.28657; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; Natsume T, 1999, BIOCHEM BIOPH RES CO, V260, P527, DOI 10.1006/bbrc.1999.0905; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shen L, 2000, J NEUROSCI, V20, P7932; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Turner MA, 1998, NAT STRUCT BIOL, V5, P369, DOI 10.1038/nsb0598-369; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Yokoyama K, 2002, EMBO J, V21, P83, DOI 10.1093/emboj/21.1.83; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498; Yuan CS, 1996, J BIOL CHEM, V271, P28009, DOI 10.1074/jbc.271.45.28009; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	76	146	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10602	10612		10.1074/jbc.M210119200	http://dx.doi.org/10.1074/jbc.M210119200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525476	hybrid			2022-12-25	WOS:000181777500081
J	Benians, A; Leaney, JL; Milligan, G; Tinker, A				Benians, A; Leaney, JL; Milligan, G; Tinker, A			The dynamics of formation and action of the ternary complex revealed in living cells using a G-protein-gated K+ channel as a biosensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CURRENT; FUNCTIONAL EXPRESSION; C-PROTEIN; RECEPTOR; ACTIVATION; BINDING; EFFICACY; NEURONS; FUSION; DETERMINANTS	Traditionally the consequences of activation of G-protein-coupled receptors (GPCRs) by an agonist are studied using biochemical assays. In this study we use live cells and take advantage of a G-protein-gated inwardly rectifying potassium channel (Kir3.1+3.2A) that is activated by the direct binding of Gbetagamma subunit to the channel complex to report, in real-time, using the patch clamp technique the activity of the "ternary complex" of agonist/receptor/G-protein. This analysis is further facilitated by the use of pertussis toxin-resistant fluorescent and non-fluorescent Galpha(i/o) subunits and a series of HEK293 cell lines stably expressing both channel and receptors (including the adenosine A(1) receptor, the adrenergic alpha(2A) receptor, the dopamine D-2S receptor, the M4 muscarinic receptor, and the dimeric GABA-B-1b/2 receptor). We systematically analyzed the contribution of the various inputs to the observed kinetic response of channel activation. Our studies indicate that the combination of agonist, GPCR, and G-protein isoform uniquely specify the behavior of these channels and thus support the importance of the whole ternary complex at a kinetic level.	UCL, Ctr Clin Pharmacol, Dept Med, BHF Labs, London WC1E 6JJ, England; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of London; University College London; University of Glasgow	Tinker, A (corresponding author), UCL, Ctr Clin Pharmacol, Dept Med, BHF Labs, Rm 420,5 Univ St, London WC1E 6JJ, England.	a.tinker@ucl.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Drici MD, 2000, BRIT J PHARMACOL, V131, P569, DOI 10.1038/sj.bjp.0703611; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Greif GJ, 2000, J NEUROPHYSIOL, V83, P1010, DOI 10.1152/jn.2000.83.2.1010; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 1996, PHARMACOL REV, V48, P413; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Leaney JL, 2000, P NATL ACAD SCI USA, V97, P5651, DOI 10.1073/pnas.080572297; Leaney JL, 2002, J BIOL CHEM, V277, P28803, DOI 10.1074/jbc.M204683200; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; NOMA A, 1978, PFLUG ARCH EUR J PHY, V377, P193, DOI 10.1007/BF00584272; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sadja R, 2002, P NATL ACAD SCI USA, V99, P10783, DOI 10.1073/pnas.162346199; Shea L, 1997, BIOCHEM PHARMACOL, V53, P519, DOI 10.1016/S0006-2952(96)00768-X; Shea LD, 2000, LIFE SCI, V68, P647, DOI 10.1016/S0024-3205(00)00977-2; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Sodickson DL, 1998, J NEUROSCI, V18, P8153; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f; Yamada M, 1998, PHARMACOL REV, V50, P723; Yang Q, 1999, MOL PHARMACOL, V56, P651, DOI 10.1124/mol.56.3.651; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	45	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10851	10858		10.1074/jbc.M212299200	http://dx.doi.org/10.1074/jbc.M212299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529316	hybrid			2022-12-25	WOS:000181777500111
J	Liu, M; Barth, A				Liu, M; Barth, A			Mapping interactions between the Ca2+-ATPase and its substrate ATP with infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONSERVED PHOSPHORYLATION LOOP; NUCLEAR-MAGNETIC-RESONANCE; NUCLEOTIDE-BINDING; STRUCTURAL-CHANGES; CATALYTIC SITE; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGE; REACTION-MECHANISM	Infrared spectroscopy has been used to map substrate-protein interactions: the conformational changes of the sarcoplasmic reticulum Ca2+-ATPase upon nucleotide binding and ATPase phosphorylation were monitored using the substrate ATP and ATP analogues (2'-deoxy-ATP, 3'-deoxy-ATP, and inosine 5'-triphosphate), which were modified at specific functional groups of the substrate. Modifications to the 2'-OH, the X-OH, and the amino group of adenine reduce the extent of binding-induced conformational change of the ATPase, with particularly strong effects observed for the latter two. This demonstrates the structural sensitivity of the nucleotide-ATPase complex to individual interactions between nucleotide and ATPase. All groups studied are important for binding and interactions of a given ligand group with the ATPase depend on interactions of other ligand groups. Phosphorylation of the ATPase was observed for ITP and 2'-deoxy-ATP, but not for 3'-deoxy-ATP. There is no direct link between the extent of conformational change upon nucleotide binding and the rate of phosphorylation showing that the full extent of the ATP-induced conformational change is not mandatory for phosphorylation. As observed for the nucleotide-ATPase complex, the conformation of the first phosphorylated ATPase intermediate E1PCa(2) also depends on the nucleotide, indicating that ATPase states have a less uniform conformation than previously anticipated.	Goethe Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Barth, A (corresponding author), Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	Andreas.Barth@dbb.su.se	Liu, Man/GXH-3184-2022; Barth, Andreas/N-8872-2013	Liu, Man/0000-0002-1390-7862; Barth, Andreas/0000-0001-5784-7673				Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1992, ACTA PHYSIOL SCAND, V146, P151; BAENZIGER JE, 1993, BIOCHEMISTRY-US, V32, P5448, DOI 10.1021/bi00071a022; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1998, BIOPHYS J, V75, P538, DOI 10.1016/S0006-3495(98)77543-5; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; Barth A, 2000, FEBS LETT, V477, P151, DOI 10.1016/S0014-5793(00)01782-8; BELASCO JG, 1980, BIOCHEMISTRY-US, V19, P472, DOI 10.1021/bi00544a012; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CAREY PR, 1995, ACCOUNTS CHEM RES, V28, P8, DOI 10.1021/ar00049a002; Cepus V, 1998, BIOCHEMISTRY-US, V37, P10263, DOI 10.1021/bi973183j; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; CLORE GM, 1982, EUR J BIOCHEM, V128, P113; COAN C, 1993, J BIOL CHEM, V268, P6917; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DAVIES DB, 1974, BIOCHEMISTRY-US, V13, P4417, DOI 10.1021/bi00718a027; Davis AM, 1999, ANGEW CHEM INT EDIT, V38, P737, DOI 10.1002/(SICI)1521-3773(19990315)38:6<736::AID-ANIE736>3.0.CO;2-R; de Meis L, 1973, J Biol Chem, V248, P3691; Deng H, 1999, METHOD ENZYMOL, V308, P176; Ettrich R, 2001, J MOL MODEL, V7, P184; FERREIRA ST, 1988, J BIOL CHEM, V263, P9973; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Hasselbach W, 1979, Top Curr Chem, V78, P1; HASSELBACH W, 1974, ENZYMES, P431; HASSELBACH W, 1981, MEMBRANE TRANSPORT, P183; HOBBS AS, 1985, J BIOL CHEM, V260, P2035; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Huang SH, 1998, BIOCHEMISTRY-US, V37, P18064, DOI 10.1021/bi981997+; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; JONA I, 1990, BIOCHIM BIOPHYS ACTA, V1028, P183, DOI 10.1016/0005-2736(90)90153-F; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; Liu M, 2002, BIOPOLYMERS, V67, P267, DOI 10.1002/bip.10113; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MacLennan DH, 2000, NATURE, V405, P633, DOI 10.1038/35015206; MATA AM, 1993, BIOCHIM BIOPHYS ACTA, V1147, P6, DOI 10.1016/0005-2736(93)90309-N; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; OUALI M, 1993, J AM CHEM SOC, V115, P4264, DOI 10.1021/ja00063a049; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETRETSKI JH, 1989, J BIOL CHEM, V264, P20339; RUBTSOV AM, 1988, FEBS LETT, V238, P240, DOI 10.1016/0014-5793(88)80487-3; SCHLEICH T, 1972, BIOCHEMISTRY-US, V11, P137, DOI 10.1021/bi00752a001; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P6095, DOI 10.1021/bi00074a022; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; TAILLANDIER E, 1987, BIOCHEMISTRY-US, V26, P3361, DOI 10.1021/bi00386a017; THE R, 1975, EUR J BIOCHEM, V53, P105, DOI 10.1111/j.1432-1033.1975.tb04047.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; von Germar F, 2000, BIOPHYS J, V78, P1531, DOI 10.1016/S0006-3495(00)76705-1; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WARTELL RM, 1986, BIOCHEMISTRY-US, V25, P2664, DOI 10.1021/bi00357a056; Wharton CW, 2000, NAT PROD REP, V17, P447, DOI 10.1039/b002066o; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	66	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10112	10118		10.1074/jbc.M212403200	http://dx.doi.org/10.1074/jbc.M212403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12538577	hybrid			2022-12-25	WOS:000181777500018
J	Muradov, KG; Boyd, KK; Martinez, SE; Beavo, JA; Artemyev, NO				Muradov, KG; Boyd, KK; Martinez, SE; Beavo, JA; Artemyev, NO			The GAFa domains of rod cGMP-phosphodiesterase 6 determine the selectivity of the enzyme dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR CGMP-PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; GENE FAMILY; BINDING; SUBUNIT; PHOSPHORYLATION; PURIFICATION; INHIBITION; EXPRESSION; PROTEINS	Retinal rod cGMP phosphodiesterase (PDE6 family) is the effector enzyme in the vertebrate visual transduction cascade. Unlike other known PDEs that form catalytic homodimers, the rod PDE6 catalytic core is a heterodimer composed of alpha and beta subunits. A system for efficient expression of rod PDE6 is not available. Therefore, to elucidate the structural basis for specific dimerization of rod PDE6, we constructed a series of chimeric proteins between PDE6alphabeta and PDE5, which contain the N-terminal GAFa/GAFb domains, or portions thereof, of the rod enzyme. These chimeras were co-expressed in Sf9 cells in various combinations as His-, myc-, or FLAG-tagged proteins. Dimerization of chimeric PDEs was assessed using gel filtration and sucrose gradient centrifugation. The composition of formed dimeric enzymes was analyzed with Western blotting and immunoprecipitation. Consistent with the selectivity of PDE6 dimerization in vivo, efficient heterodimerization was observed between the GAF regions of PDE6alpha and PDE6beta with no significant homodimerization. In addition, PDE6alpha was able to form dimers with the cone PDE6alpha' subunit. Furthermore, our analysis indicated that the PDE6 GAFa domains contain major structural determinants for the affinity and selectivity of dimerization of PDE6 catalytic subunits. The key dimerization selectivity module of PDE6 has been localized to a small segment within the GAFa domains, PDE6alpha-59-74/PDE6beta-57-72. This study provides tools for the generation of the homodimeric alphaalpha and betabeta enzymes that will allow us to address the question of functional significance of the unique heterodimerization of rod PDE6.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Iowa; University of Washington; University of Washington Seattle	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	nikolai-artemyev@uiowa.edu		Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Cook TA, 2001, J BIOL CHEM, V276, P5248, DOI 10.1074/jbc.M004690200; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; Institutionen B Universitet Uppsala S, 1963, PURE APPL CHEM, V233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Natochin M, 2000, METHOD ENZYMOL, V315, P539; Okada D, 2002, BIOCHEMISTRY-US, V41, P9672, DOI 10.1021/bi025727+; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; QIN N, 1994, J BIOL CHEM, V269, P3265; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; STROOP SD, 1991, J BIOL CHEM, V266, P23802; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	45	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10594	10601		10.1074/jbc.M208456200	http://dx.doi.org/10.1074/jbc.M208456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531898	hybrid, Green Published			2022-12-25	WOS:000181777500080
J	Sakuraba, H; Tsuge, H; Shimoya, I; Kawakami, R; Goda, S; Kawarabayasi, Y; Katunuma, N; Ago, H; Miyano, M; Ohshima, T				Sakuraba, H; Tsuge, H; Shimoya, I; Kawakami, R; Goda, S; Kawarabayasi, Y; Katunuma, N; Ago, H; Miyano, M; Ohshima, T			The first crystal structure of archaeal aldolase - Unique tetrameric structure of 2-deoxy-D-ribose-5-phosphate aldolase from the hyperthermophilic archaea Aeropyrum pernix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOTOGA-MARITIMA; DEOXYRIBOSE-5-PHOSPHATE ALDOLASE; 5-PHOSPHATE ALDOLASE; PYROCOCCUS-FURIOSUS; ORGANIC-SYNTHESIS; BACILLUS-CEREUS; MECHANISM; SEQUENCE; INSIGHTS; MUTANTS	A gene encoding a 2-deoxy-D-ribose-5-phosphate aldolase (DERA) homolog was identified in the hyperthermophilic Archaea Aeropyrum pernix. The gene was over-expressed in Escherichia coli, and the produced enzyme was purified and characterized. The enzyme is an extremely thermostable DERA, its activity was not lost after incubation at 100 degreesC for 10 min. The enzyme has a molecular mass of similar to93 kDa and consists of four subunits with an identical molecular mass of 24 kDa. This is the first report of the presence of tetrameric DERA. The three-dimensional structure of the enzyme was determined by x-ray analysis. The subunit folds into an alpha/beta-barrel. The asymmetric unit consists of two homologous subunits, and a crystallographic 2-fold axis generates the functional tetramer. The main chain coordinate of the monomer of the A. pernix enzyme is quite similar to that of the E. coli enzyme. There was no significant difference in hydrophobic interactions and the number of ion pairs between the monomeric structures of the two enzymes. However, a significant difference in the quaternary structure was observed. The area of the subunit-subunit interface in the dimer of the A. pernix enzyme is much larger compared with the E. coli enzyme. In addition, the A. pernix enzyme is 10 amino acids longer than the E. coli enzyme in the N-terminal region and has an additional N-terminal helix. The N-terminal helix produces a unique dimer-dimer interface. This promotes the formation of a functional tetramer of the A. pernix enzyme and strengthens the hydrophobic inter-subunit interactions. These structural features are considered to be responsible for the extremely high stability of the A. pernix enzyme. This is the first description of the structure of hyperthermophilic DERA and of aldolase from the Archaea domain.	Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Tokushima Bunri Univ, Inst Hlth Sci, Tokushima 7708514, Japan; Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058566, Japan	Tokushima University; Tokushima Bunri University; National Institute of Advanced Industrial Science & Technology (AIST)	Ohshima, T (corresponding author), Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan.	ohshima@bio.tokushima-u.ac.jp	Goda, Shuichiro/E-7177-2013; Miyano, Masashi/R-2785-2016; Tsuge, Hideaki/ABF-6424-2021	Goda, Shuichiro/0000-0002-0525-6887; Miyano, Masashi/0000-0003-2253-6175; Tsuge, Hideaki/0000-0003-0166-9163				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARBAS CF, 1990, J AM CHEM SOC, V112, P2013, DOI 10.1021/ja00161a064; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; BLANK J, 1972, MOL GEN GENET, V116, P291, DOI 10.1007/BF00270086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CLELAND WW, 1971, ENZYMES, V2, P1; Dams T, 2000, J MOL BIOL, V297, P659, DOI 10.1006/jmbi.2000.3570; FEINGOLD DS, 1972, ENZYMES, V7, P330; Gefflaut T, 1995, PROG BIOPHYS MOL BIO, V63, P301, DOI 10.1016/0079-6107(95)00008-9; Hashimoto H, 1999, J MOL BIOL, V292, P707, DOI 10.1006/jmbi.1999.3100; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Machajewski TD, 2000, ANGEW CHEM INT EDIT, V39, P1352, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1352::AID-ANIE1352>3.0.CO;2-J; Maeda N, 2002, J BIOL CHEM, V277, P31656, DOI 10.1074/jbc.M203117200; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORSE DE, 1968, ADV ENZYMOL RAMB, V31, P125; MORSE DE, 1972, ENZYMES, V7, P213; MUNCHPETERSEN A, 1970, EUR J BIOCHEM, V15, P191, DOI 10.1111/j.1432-1033.1970.tb00994.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RACKER E, 1952, J BIOL CHEM, V196, P347; Rice DW, 1996, FEMS MICROBIOL REV, V18, P105; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; Sako Y, 1996, INT J SYST BACTERIOL, V46, P1070, DOI 10.1099/00207713-46-4-1070; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sazuka T, 1996, DNA Res, V3, P225, DOI 10.1093/dnares/3.4.225; SGARRELLA F, 1992, BIOCHIM BIOPHYS ACTA, V1118, P130, DOI 10.1016/0167-4838(92)90139-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TOZZI MG, 1984, BIOCHEM INT, V9, P319; VALENTINHANSEN P, 1979, J MOL BIOL, V133, P1, DOI 10.1016/0022-2836(79)90248-1; VALENTINHANSEN P, 1982, EUR J BIOCHEM, V125, P561, DOI 10.1111/j.1432-1033.1982.tb06719.x; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P412, DOI 10.1002/anie.199504121; WONG CH, 1995, J AM CHEM SOC, V117, P3333, DOI 10.1021/ja00117a003	44	47	51	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10799	10806		10.1074/jbc.M212449200	http://dx.doi.org/10.1074/jbc.M212449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529358	hybrid			2022-12-25	WOS:000181777500105
J	Thiec, F; Cherel, G; Christophe, OD				Thiec, F; Cherel, G; Christophe, OD			Role of the GLa and first epidermal growth factor-like domains of factor X in the prothrombinase and tissue factor-factor VIIa complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; VON WILLEBRAND FACTOR; ACTIVATED PROTEIN-C; FACTOR-IX; FACTOR-VA; FACTOR PATHWAY; SUBSTRATE RECOGNITION; HYBRIDOMA ANTIBODIES; RESIDUES LYS(165); LIGHT-CHAIN	Factor X (FX) has high structure homology with other proteins of blood coagulation such as factor IX (FIX) and factor VII (FVII). These proteins present at their amino-terminal extremity ay-carboxyglutamic acid containing domain (Gla domain), followed by two epidermal growth factor-like (EGF1 and EGF2) domains, an activation peptide, and a serine protease domain. After vascular damage, the tissue factor-FVIIa (TF-FVIIa) complex activates both FX and FIX. FXa interacts stoichiometrically with tissue pathway inhibitor (TFPI), regulating TF-FVIIa activity by forming the TF-FVIIa-TFPI-FXa quaternary complex. Conversely, FXa boosts coagulation by its association with its cofactor, factor Va (FVa). To investigate the contribution of the Gla and EGF1 domains of FX in these complexes, FX chimeras were produced in which FIX Gla and EGF1 domains substituted the corresponding domains of FX. The affinity of the two chimeras, FX/FIX(Gla) and FX/FIX(EGF1), for the TF-FVIIa complex was markedly reduced compared with that of wild-type-FX (wt-FX) independently of the presence of phospholipids. Furthermore, the association rate constants of preformed FX/FIX(Gla)-TFPI and FX/FIX(EGF1)-TFPI complexes with TF-FVIIa were, respectively, 10- and 5-fold slower than that of wt-FXa-TFPI complex. Finally, the apparent affinity of FVa was 2-fold higher for the chimeras than for wt-FX in the presence of phospholipids and equal in their absence. These data demonstrate that FX Gla and EGF1 domains contain residues, which interact with TF-FVIIa exosites contributing to the formation of the TF-FVIIa-FX and TF-FVIIa-TFPI-FXa complexes. On the opposite, FXa Gla and EGF1 domains are not directly involved in FVa binding.	Hop Bicetre, INSERM, U143, F-94276 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Christophe, OD (corresponding author), Hop Bicetre, INSERM, U143, Batiment Claude Bernard,84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	olivier@kb.inserm.fr	christophe, olivier/W-4268-2017	christophe, olivier/0000-0002-9080-6336				APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BROZE GJ, 1987, BLOOD, V69, P150; Celie PHN, 2002, J BIOL CHEM, V277, P20214, DOI 10.1074/jbc.M108446200; Chen SWW, 2002, THROMB HAEMOSTASIS, V88, P74; Christophe OD, 2001, BLOOD, V98, P1416, DOI 10.1182/blood.V98.5.1416; Cook BC, 2000, J BIOL CHEM, V275, P38774, DOI 10.1074/jbc.M004573200; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAIR DS, 1985, BRIT J HAEMATOL, V59, P235, DOI 10.1111/j.1365-2141.1985.tb02990.x; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LINDHOUT T, 1995, THROMB HAEMOSTASIS, V74, P910; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MANN KG, 1990, BLOOD, V76, P1; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MEYER D, 1984, BRIT J HAEMATOL, V57, P597, DOI 10.1111/j.1365-2141.1984.tb02937.x; MEYER D, 1984, BRIT J HAEMATOL, V57, P609, DOI 10.1111/j.1365-2141.1984.tb08550.x; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OLSEN ENH, 2001, THROMB HAEMOSTASIS S, V86; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Persson KEM, 2002, J BIOL CHEM, V277, P35616, DOI 10.1074/jbc.M205930200; RAO LVM, 1995, BIOCHEMISTRY-US, V34, P10867, DOI 10.1021/bi00034a020; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; ROSING J, 1980, J BIOL CHEM, V255, P274; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; RUF W, 1992, J BIOL CHEM, V267, P6375; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; SANDERS NL, 1985, BLOOD, V66, P204; SMITH CM, 1976, BIOCHEMISTRY-US, V15, P1830, DOI 10.1021/bi00654a007; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TITANI K, 1972, BIOCHEMISTRY-US, V11, P4899, DOI 10.1021/bi00776a004; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WARNCRAMER BJ, 1988, THROMB HAEMOSTASIS, V60, P453; Zhong DG, 2002, J BIOL CHEM, V277, P3622, DOI 10.1074/jbc.M111202200	53	22	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10393	10399		10.1074/jbc.M212144200	http://dx.doi.org/10.1074/jbc.M212144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529356	hybrid			2022-12-25	WOS:000181777500055
J	Barry, JB; Leong, GM; Church, WB; Issa, LL; Eisman, JA; Gardiner, EM				Barry, JB; Leong, GM; Church, WB; Issa, LL; Eisman, JA; Gardiner, EM			Interactions of SKIP/NCoA-62, TFIIB, and retinoid X receptor with vitamin D receptor helix H10 residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIB; D-MEDIATED TRANSCRIPTION; CRYSTAL-STRUCTURE; NUCLEAR RECEPTORS; PROTEIN; BINDING; LIGAND; DOMAIN; SKIP; ACTIVATION	The vitamin D receptor (VDR) is a ligand-dependent transcription factor that heterodimerizes with retinoid X receptor (RXR) and interacts with the basal transcription machinery and transcriptional cofactors to regulate target gene activity. The p160 coactivator GRIP1 and the distinct coregulator Ski-interacting protein (SKIP)/NCoA-62 synergistically enhance ligand-dependent VDR transcriptional activity. Both coregulators bind directly to and form a ternary complex with VDR, with GRIP1 contacting the activation function-2 (AF-2) domain and SKIP/NCoA-62 interacting through an AF-2 independent interface. It was previously reported that SKIP/NCoA-62 interaction with VDR was independent of the heterodimerization interface (specifically, helices H10/H11). In contrast, the present study defines specific residues within a conserved and surface-exposed region of VDR helix H10 that are required for interaction with SKIP/NCoA-62 and for full ligand-dependent transactivation activity. SKIP/NCoA-62, the basal transcription factor TFIIB, and RXR all interacted with VDR helix H10 mutants at reduced levels compared with wild type in the absence of ligand and exhibited different degrees of increased interaction upon ligand addition. Thus, SKIP/NCoA-62 interacts with VDR at a highly conserved region not previously associated with coregulator binding to regulate transactivation by a molecular mechanism distinct from that of p160 coactivators.	Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia; Garvan Inst Med Res, Mol Modeling Facil, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research	Gardiner, EM (corresponding author), Garvan Inst Med Res, Bone & Mineral Res Program, 384 Victoria St,Darlinghurst, Sydney, NSW 2010, Australia.		Church, William/H-6040-2013; Eisman, John A/C-2886-2014	Church, William/0000-0002-8033-5518; 				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Glass CK, 2000, GENE DEV, V14, P121; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Issa LL, 2001, ENDOCRINOLOGY, V142, P1606, DOI 10.1210/en.142.4.1606; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leong GM, 1998, J BIOL CHEM, V273, P2296, DOI 10.1074/jbc.273.4.2296; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; LEONG GM, 1998, BONE, V23, pS256; Lu ZJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P99, DOI 10.1006/abbi.1996.9864; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; NISHIKAWA J, 1995, NUCLEIC ACIDS RES, V23, P606, DOI 10.1093/nar/23.4.606; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; Prathapam T, 2001, ONCOGENE, V20, P7677, DOI 10.1038/sj.onc.1204960; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000; Zhou SF, 2000, J VIROL, V74, P1939, DOI 10.1128/JVI.74.4.1939-1947.2000	31	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8224	8228		10.1074/jbc.C200712200	http://dx.doi.org/10.1074/jbc.C200712200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12529369	hybrid			2022-12-25	WOS:000181466800062
J	Bilsland, AE; Anderson, CJ; Fletcher-Monaghan, AJ; McGregor, F; Evans, TRJ; Ganly, I; Knox, RJ; Plumb, JA; Keith, WN				Bilsland, AE; Anderson, CJ; Fletcher-Monaghan, AJ; McGregor, F; Evans, TRJ; Ganly, I; Knox, RJ; Plumb, JA; Keith, WN			Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase	ONCOGENE			English	Article						telomerase; hTERT; hTR; gene therapy; nitroreductase; GDEPT; adenovirus	THYMIDYLATE SYNTHASE PROMOTER; REVERSE-TRANSCRIPTASE GENE; ENZYME PRODRUG THERAPY; TUMOR-CELLS; RNA GENE; TATA-LESS; HMLH1 EXPRESSION; IMMORTAL CELLS; HTERT; ACTIVATION	Reactivation of telomerase maintains telomere function and is considered critical to immortalization in most human cancer cells. Elevation of telomerase expression in cancer cells is highly specific: transcription of both RNA (hTR) and protein (hTERT) components is strongly upregulated in cancer cells relative to normal cells. Therefore, telomerase promoters may be useful in cancer gene therapy by selectively expressing suicide genes in cancer cells and not normal cells. One example of suicide gene therapy is the bacterial nitroreductase (NTR) gene, which bioactivates the prodrug CB1954 into an active cytotoxic alkylating agent. We describe construction of adenovirus vectors harbouring the bacterial NTR gene under control of the hTR or hTERT promoters. Western blot analysis of NTR expression in normal and cancer cells infected with adenoviral vectors showed cancer cell-specific nitroreductase expression. Infection with adenoviral telomerase-NTR constructs in a panel of seven cancer cell lines resulted in up to 18-fold sensitization to the prodrug CB1954, an effect that was retained in two drug-resistant ovarian lines. Importantly, no sensitization was observed with either promoter in any of the four normal cell strains. Finally, an efficacious effect was observed in cervical and ovarian xenograft models following single intratumoural injection with low doses of vector, followed by injection with CB1954.	Univ Glasgow, Canc Res UK, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Enact Pharma Plc, Salisbury SP4 0JQ, Wilts, England	Beatson Institute; Cancer Research UK; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK, Dept Med Oncol, Beatson Labs, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.		Bilsland, Alan/G-2629-2010; Cairney, Claire/H-6989-2012; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Cairney, Claire/0000-0001-6531-245X; Bilsland, Alan/0000-0003-0957-3908				Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196; Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q; ANLEZARK GM, 1992, BIOCHEM PHARMACOL, V44, P2289, DOI 10.1016/0006-2952(92)90671-5; Anthoney DA, 1996, CANCER RES, V56, P1374; Boyd M, 2001, J GENE MED, V3, P165, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM158>3.0.CO;2-C; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Chung-Faye G, 2001, CLIN CANCER RES, V7, P2662; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cui W, 1999, GENE THER, V6, P764, DOI 10.1038/sj.gt.3300873; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Dong S, 2000, J CELL BIOCHEM, V77, P50, DOI 10.1002/(SICI)1097-4644(20000401)77:1<50::AID-JCB6>3.0.CO;2-C; Downey MG, 2001, J ORAL PATHOL MED, V30, P577, DOI 10.1034/j.1600-0714.2001.301001.x; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Garrett MD, 1999, EUR J CANCER, V35, P2010, DOI 10.1016/S0959-8049(99)00280-4; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horikawa I, 1999, CANCER RES, V59, P826; Karamouzis MV, 2002, CLIN CANCER RES, V8, P949; KEITH WN, 2002, EXP REV MOL MED; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Koga S, 2001, ANTICANCER RES, V21, P1937; Komata T, 2001, CANCER RES, V61, P5796; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Naasani I, 1999, CANCER RES, V59, P4004; Pascolo E, 2002, J BIOL CHEM, V277, P15566, DOI 10.1074/jbc.M201266200; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Ring CJA, 1996, GENE THER, V3, P1094; Rudge TL, 1999, J CELL BIOCHEM, V73, P90, DOI 10.1002/(SICI)1097-4644(19990401)73:1<90::AID-JCB10>3.0.CO;2-W; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Scapin G, 2002, DRUG DISCOV TODAY, V7, P601, DOI 10.1016/S1359-6446(02)02290-0; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shi QW, 1997, HUM GENE THER, V8, P403, DOI 10.1089/hum.1997.8.4-403; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Soder AI, 1998, ONCOGENE, V16, P979, DOI 10.1038/sj.onc.1201620; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Takakura M, 1999, CANCER RES, V59, P551; Vassaux G, 1999, GENE THER, V6, P1192, DOI 10.1038/sj.gt.3300910; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wisman GBA, 2000, HUM PATHOL, V31, P1304, DOI 10.1053/hupa.2000.19299; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhao JQ, 1998, ONCOGENE, V16, P1345, DOI 10.1038/sj.onc.1201892; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	51	72	79	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					370	380		10.1038/sj.onc.1206168	http://dx.doi.org/10.1038/sj.onc.1206168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545158				2022-12-25	WOS:000180379100006
J	Sharma, GG; Gupta, A; Wang, H; Scherthan, H; Dhar, S; Gandhi, V; Iliakis, G; Shay, JW; Young, CSH; Pandita, TK				Sharma, GG; Gupta, A; Wang, H; Scherthan, H; Dhar, S; Gandhi, V; Iliakis, G; Shay, JW; Young, CSH; Pandita, TK			HTERT associates with human telomeres and enhances genomic stability and DNA repair	ONCOGENE			English	Article						hTERT; telomeres; transcription; DNA repair; ionizing radiation	ATAXIA-TELANGIECTASIA CELLS; EXTENDED-LIFE-SPAN; IONIZING-RADIATION; HUMAN FIBROBLASTS; RNA COMPONENT; IMMUNOHISTOCHEMICAL DETECTION; SACCHAROMYCES-CEREVISIAE; CHROMOSOME INSTABILITY; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT	Ectopic expression of telomerase in telomerase-silent cells is sufficient to overcome senescence and to extend cellular lifespan. We show here that the catalytic subunit of human telomerase (hTERT) crosslinks telomeres. This interaction is blocked by the telomere repeat binding factor 1, but not by a dominant negative form of this protein. It is also abolished by destruction of the RNA component of telomerase as well as by mutations in the hTERT protein. Ectopic expression of hTERT leads to transcriptional alterations of a subset of genes and changes in the interaction of the telomeres with the nuclear matrix. This is associated with reduction of spontaneous chromosome damage in G, cells, enhancement of the kinetics of DNA repair and an increase in NTP levels. The effect on DNA repair is likely indirect as TERT does not directly affect DNA end rejoining in vitro or meiotic recombination in vivo. The observed effects of hTERT occurred rapidly before any significant lengthening of telomeres was observed. Our findings establish an intimate relationship between hTERT-telomere interactions and alteration in transcription of a subset of genes that may lead to increased genomic stability and enhanced repair of genetic damage. These novel functions of telomerase are distinct from its known effect on telomere length and have potentially important biological consequences.	Washington Univ, Sch Med, Radiat & Canc Biol Div, St Louis, MO 63108 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Texas, MDACC, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	Washington University (WUSTL); Columbia University; Jefferson University; Max Planck Society; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pandita, TK (corresponding author), 4511 Forest Pk,Suite 411, St Louis, MO 63108 USA.		Pandita, Tej K/AAM-9188-2020; Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA13696, CN-15015] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Fan ZH, 2000, CANCER GENE THER, V7, P1307, DOI 10.1038/sj.cgt.0243; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Iliakis G, 1999, METH MOL B, V113, P543; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; Kawakami Y, 2000, ONCOGENE, V19, P3888, DOI 10.1038/sj.onc.1203733; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Ng P, 2000, BIOTECHNIQUES, V29, P524, DOI 10.2144/00293st04; NISHIKAWA K, 1992, CANCER RES, V52, P4758; OLOVNIKOV AM, 1992, IZV AN SSSR BIOL+, P641; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; PLUNKETT W, 1980, CANCER RES, V40, P588; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6406, DOI 10.1021/bi00344a014; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; ROBERTS JJ, 1978, ADV RADIAT BIOL, V7, P211; Rodriguez CO, 2000, J CHROMATOGR B, V745, P421, DOI 10.1016/S0378-4347(00)00303-0; RUDD GN, 1995, CANCER CHEMOTH PHARM, V35, P323, DOI 10.1007/BF00689452; Sawant SG, 1999, FASEB J, V13, P1047, DOI 10.1096/fasebj.13.9.1047; Scherthan H, 2000, MOL CELL BIOL, V20, P7773, DOI 10.1128/MCB.20.20.7773-7783.2000; Scherthan H, 2001, NAT REV MOL CELL BIO, V2, P621, DOI 10.1038/35085086; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	67	208	224	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					131	146		10.1038/sj.onc.1206063	http://dx.doi.org/10.1038/sj.onc.1206063			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527915				2022-12-25	WOS:000180166900014
J	Teixeira, CE; Ifa, DR; Corso, G; Santagada, V; Caliendo, G; Antunes, E; De Nucci, G				Teixeira, CE; Ifa, DR; Corso, G; Santagada, V; Caliendo, G; Antunes, E; De Nucci, G			Sequence and structure-activity relationship of a scorpion venom toxin with nitrergic activity in rabbit corpus cavernosum	FASEB JOURNAL			English	Article						nitric oxide; Tityus serrulatus; sodium channels; erectile tissue	AMINO-ACID-SEQUENCE; TITYUS-SERRULATUS; ERECTILE DYSFUNCTION; SODIUM-CHANNELS; NITRIC-OXIDE; RELAXATION; THIONINS; PEPTIDES; KARSCH	An alpha-toxin responsible for nitric oxide (NO) release in rabbit corpus cavernosum (RbCC) was isolated from Tityus serrulatus venom (TSV). The isolated peptide (molecular mass of 7427.66+/-0.15 Da) was identified as Ts3 after determination of Cys residues, N-terminal amino acid analysis, and proteolytic peptide mapping. Ts3 (30 nM) markedly relaxed the RbCC; this response was blocked by the NO synthesis inhibitor N-omega-nitro-L-arginine methyl ester (100 muM) and the Na+ channel blocker tetrodotoxin (100 nM). Synthetic peptides based on either Ts3 (P1-16, P17-32, P33-48, P49-64, P9-24, P25-40, P41-56, YGLPDKVPTKT) or Bukatoxin (isolated from Buthus martensi Karsch scorpion venom) sequence (Buka11, Buka11-B, PDKVP, PDSEP) were assayed. These peptides slightly relaxed the RbCC, and such an effect was independent of Na+ channel activation or NO release. Our results indicate that Ts3 exerts nitrergic actions and contributes to the relaxing activity of TSV in RbCC, thus providing a valuable tool to investigate the mechanisms underlying nerve activation in erectile tissues, because NO released from nitrergic fibers plays a key role in the erectile process. Our findings revealed the key importance of the Ts3 structure three-dimensional conformation maintenance for biological activity, because linear peptide sequences neither presented substantial relaxations nor was this effect related to nitrergic activity.	Univ Estadual Campinas, Fac Med Sci, Dept Pharmacol, BR-13081970 Campinas, SP, Brazil; Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, BR-05508900 Sao Paulo, Brazil; Univ Naples Federico II, Dept Toxicol & Pharmaceut Chem, Naples, Italy	Universidade Estadual de Campinas; Universidade de Sao Paulo; University of Naples Federico II	Teixeira, CE (corresponding author), Univ Estadual Campinas, Fac Med Sci, Dept Pharmacol, POB 6111, BR-13081970 Campinas, SP, Brazil.	cleber.teixeira@directnet.com.br	Corso, Gaetano/H-9450-2013; ANTUNES, EDSON/F-6731-2012; Ifa, Demian/D-3978-2012; De Nucci, Gilberto/ABB-7380-2021; De Nucci, Gilberto/J-5990-2012	Corso, Gaetano/0000-0003-4720-1320; ANTUNES, EDSON/0000-0003-2201-8247; De Nucci, Gilberto/0000-0002-4346-7941; De Nucci, Gilberto/0000-0002-4346-7941; Caliendo, Giuseppe/0000-0002-5098-6045				AMITAI Y, 1985, CLIN PEDIATR, V24, P136, DOI 10.1177/000992288502400303; Andersson KE, 2001, PHARMACOL REV, V53, P417; BAWASKAR HS, 1982, LANCET, V1, P552; Bivalacque TJ, 2000, TRENDS PHARMACOL SCI, V21, P484, DOI 10.1016/S0165-6147(00)01587-X; Corona M, 1996, TOXICON, V34, P251, DOI 10.1016/0041-0101(95)00129-8; COURAUD F, 1984, HDB NATURAL TOXINS, V2, P659; FREIREMAIA L, 1995, J TOXICOL-TOXIN REV, V14, P423, DOI 10.3109/15569549509019472; FURCHGOTT R F, 1988, P401; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; HERSHKOVICH Y, 1985, TOXICON, V23, P845, DOI 10.1016/0041-0101(85)90015-7; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; ISMAIL M, 1995, TOXICON, V33, P825, DOI 10.1016/0041-0101(95)00005-7; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; KIRSCH GE, 1989, J GEN PHYSIOL, V93, P67, DOI 10.1085/jgp.93.1.67; LEBRETON F, 1994, BIOCHEMISTRY-US, V33, P11135, DOI 10.1021/bi00203a010; Lue TF, 2000, NEW ENGL J MED, V342, P1802, DOI 10.1056/NEJM200006153422407; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; MARTINEAUCLAIRE MF, 1994, FEBS LETT, V342, P181, DOI 10.1016/0014-5793(94)80496-6; NITTI G, 1995, EUR J BIOCHEM, V228, P250, DOI 10.1111/j.1432-1033.1995.tb20257.x; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; Orru S, 1997, BIOL CHEM, V378, P989; POSSANI LD, 1982, TOXICON, V20, P75; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; POSSANI LD, 1991, J BIOL CHEM, V266, P3178; Possani LD, 2000, BIOCHIMIE, V82, P861, DOI 10.1016/S0300-9084(00)01167-6; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; Simard J.M., 1990, P414; Srinivasan KN, 2001, FEBS LETT, V494, P145, DOI 10.1016/S0014-5793(01)02342-0; Teixeira CE, 2001, UROLOGY, V57, P816, DOI 10.1016/S0090-4295(00)01047-5; Teixeira CE, 1998, BRIT J PHARMACOL, V123, P435, DOI 10.1038/sj.bjp.0701623; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; WHEELER KP, 1983, PFLUG ARCH EUR J PHY, V397, P164, DOI 10.1007/BF00582058	32	18	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					485	+		10.1096/fj.02-0635fje	http://dx.doi.org/10.1096/fj.02-0635fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551849				2022-12-25	WOS:000181453700006
J	Chen, R; Lee, JC				Chen, R; Lee, JC			Functional roles of loops 3 and 4 in the cyclic nucleotide binding domain of cyclic AMP receptor protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; REGULATORY SUBUNIT; FOOTPRINTING TECHNIQUE; PREDICTED STRUCTURES; CRYSTAL-STRUCTURE; CAMP; SITES; KINASE; ACTIVATION; MUTAGENESIS	Cyclic AMP is a ubiquitous secondary message that regulates a large variety of functions. The protein structural motif that binds cAMP is highly conserved with the exception of loops 3 and 4, whose structure and length are variable. The cAMP receptor protein of Escherichia coli, CRP, was employed as a model system to elucidate the functional roles of these loops. Based on the sequence differences between CRP and cyclic nucleotide gated channel, three mutants of CRP were constructed: deletion (residues 54-56 in loop 3 were deleted), insertion (loop 4 was lengthened by 5 residues between Glu-78 and Gly-79) and double mutants. The effects of these mutations on the structure and function of CRP were monitored. Results show that the deletion and insertion mutations do not significantly change the secondary structure of CRP, although the tertiary and quaternary structures are perturbed. The functional data indicate that loop 3 modulates the binding affinities of cAMP and DNA. Although the lengthened loop 4 may have some fine-tuning functions, the specific function of the original loop 4 of CRP remains uncertain. The function consequences of mutation in loop 3 of CRP are similar to that of site A and site B in the regulatory subunits of cyclic AMP-dependent protein kinases. Thus, the roles played by loop 3 in CRP may represent a more common mechanism employed by cyclic nucleotide binding domain in modulating ligand binding affinity and intramolecular communication.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lee, JC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	jelee@utmb.edu	Lee, James C/A-7849-2009		NIGMS NIH HHS [GM-45579] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baichoo N, 1999, PROTEIN SCI, V8, P518; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Cheng XD, 1998, BIOCHEMISTRY-US, V37, P51, DOI 10.1021/bi9719455; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; Chu SY, 2001, J BIOL CHEM, V276, P11230, DOI 10.1074/jbc.M010428200; COHN EJ, 1943, PROTEINS AMINO ACIDS, P372; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; DEGRAZIA H, 1990, BIOCHEMISTRY-US, V29, P3557, DOI 10.1021/bi00466a019; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; GRONENBORN AM, 1988, BIOCHEM J, V253, P801, DOI 10.1042/bj2530801; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Lee J C, 1979, Methods Enzymol, V61, P49; Lin SH, 2002, BIOCHEMISTRY-US, V41, P11857, DOI 10.1021/bi026099z; Lin SH, 2002, BIOCHEMISTRY-US, V41, P2946, DOI 10.1021/bi0119215; Malecki J, 2000, J BIOL CHEM, V275, P8480, DOI 10.1074/jbc.275.12.8480; Minard P, 2001, PROTEIN SCI, V10, P129, DOI 10.1110/ps.32401; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1982, FEBS LETT, V150, P161, DOI 10.1016/0014-5793(82)81326-4; OGREID D, 1983, J BIOL CHEM, V258, P1041; Pan H, 2000, P NATL ACAD SCI USA, V97, P12020, DOI 10.1073/pnas.220240297; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Richards MJ, 2000, BIOCHEMISTRY-US, V39, P14003, DOI 10.1021/bi001639i; ROBINSONSTEINER AM, 1983, J BIOL CHEM, V258, P1032; SAMBROOOK J, 2001, MOL CLONING LAB MANU, V2; Scott SP, 2001, BIOCHEMISTRY-US, V40, P7464, DOI 10.1021/bi002804x; Scott SP, 1996, PROTEIN ENG, V9, P333, DOI 10.1093/protein/9.4.333; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAN GS, 1991, BIOCHEMISTRY-US, V30, P5076, DOI 10.1021/bi00234a034; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Tibbs GR, 1998, J BIOL CHEM, V273, P4497, DOI 10.1074/jbc.273.8.4497; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; WASYLEWSKI M, 1995, J PROTEIN CHEM, V14, P299, DOI 10.1007/BF01886787; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; Won HS, 2002, J BIOL CHEM, V277, P11450, DOI 10.1074/jbc.M112411200; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	48	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13235	13243		10.1074/jbc.M211551200	http://dx.doi.org/10.1074/jbc.M211551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551924	hybrid			2022-12-25	WOS:000182189500082
J	Chauchereau, A; Amazit, L; Quesne, M; Guiochon-Mantel, A; Milgrom, E				Chauchereau, A; Amazit, L; Quesne, M; Guiochon-Mantel, A; Milgrom, E			Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; LIGAND-BINDING DOMAIN; SUMO-1 MODIFICATION; COVALENT MODIFICATION; ESTROGEN-RECEPTOR; ANDROGEN RECEPTOR; CRYSTAL-STRUCTURE; IN-VIVO	SUMO-1 (small ubiquitin-like modifier) conjugation regulates the subcellular localization, stability, and activity of a variety of proteins. We show here that SUMO-1 overexpression markedly enhances progesterone receptor (PR)-mediated gene transcription. PR undergoes a sumoylation at lysine 388 located in its N-terminal domain. However, sumoylation of the receptor is not responsible for enhanced transcription because substitution of its target lysine did not abolish the effect of SUMO-1 and even converted the receptor into a slightly more active transactivator. Furthermore estrogen receptor alpha (ERalpha)-driven transcription is also enhanced by SUMO-1 overexpression contrasting with the absence of sumoylation of this receptor. We thus analyzed SUMO-1 conjugation to the steroid receptor coactivator SRC-1. We showed that this protein contains two major sites of conjugation at Lys-732 and Lys-774. Sumoylation was shown to increase PR-SRC-1 interaction and to prolong SRC-1 retention in the nucleus. It did not prevent SRC-1 ubiquitinylation and did not exert a clear effect on the stability of the protein. Overexpression of SUMO-1 enhanced PR-mediated gene transcription even in the presence of non-sumoylated mutants of SRC-1. This observation suggests that among the many protein partners involved in steroid hormone-mediated gene regulation several are probably targets of SUMO-1 modification.	Hop Bicetre, INSERM, U 135, F-94275 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Milgrom, E (corresponding author), Hop Bicetre, INSERM, U 135, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.		Guiochon-Mantel, Anne S/S-8408-2018; CHAUCHEREAU, Anne/B-1074-2009; Chauchereau, Anne/N-8880-2016	Guiochon-Mantel, Anne S/0000-0003-1737-1409; Chauchereau, Anne/0000-0001-9447-3797				Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Boddy MN, 1996, ONCOGENE, V13, P971; Boudjelal M, 2000, CANCER RES, V60, P2247; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen F, 2000, CELL GROWTH DIFFER, V11, P239; Chilov D, 1999, J CELL SCI, V112, P1203; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Glass CK, 2000, GENE DEV, V14, P121; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Jensen WA, 1998, SEX PLANT REPROD, V11, P1, DOI 10.1007/s004970050113; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; LORENZO F, 1988, EUR J BIOCHEM, V176, P53, DOI 10.1111/j.1432-1033.1988.tb14250.x; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Santiago-Josefat B, 2001, MOL CELL BIOL, V21, P1700, DOI 10.1128/MCB.21.5.1700-1709.2001; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	75	113	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12335	12343		10.1074/jbc.M207148200	http://dx.doi.org/10.1074/jbc.M207148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529333	hybrid, Green Published			2022-12-25	WOS:000182015700080
J	Chavey, C; Mari, B; Monthouel, MN; Bonnafous, S; Anglard, P; Van Obberghen, E; Tartare-Deckert, S				Chavey, C; Mari, B; Monthouel, MN; Bonnafous, S; Anglard, P; Van Obberghen, E; Tartare-Deckert, S			Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; TNF-ALPHA; CELLS; MICE; ADIPOGENESIS; PROLIFERATION; INHIBITOR; LEPTIN; GENE; PREADIPOCYTES	Matrix metalloproteinases (MMPs) are essential for proper extracellular matrix remodeling, a process that takes place during obesity-mediated adipose tissue formation. Here, we examine expression profiles and the potential role of MMPs and their tissue inhibitors (TIMPs) in adipose tissue remodeling during obesity. Expression patterns are studied by Northern blot and real-time PCR in two genetic models of obesity (ob/ob and db/db mice) and in a diet-induced model of obesity (AKR mice). Of the MMPs and TIMPs studied, mRNA levels for MMP-2, MMP-3, MMP-12, MNW-14, MMP-19, and TIMP-1 are strongly induced in obese adipose tissues compared with lean tissues. In contrast, MMP-7 and TIMP-3 mRNAs are markedly decreased in obesity. Interestingly, enzymatic activities of MMP-12 and of a new identified adipocyte-derived 30-kDa metalloproteinase are enhanced in obese adipose tissue fractions, demonstrating that MMP/TIMP balance is shifted toward increased matrix degradation in obesity. Finally, we analyze the modulation of MMP-2, MMP-19, and TIMP-1 during 3T3-L1 preadipocyte differentiation, and we explore the effect of inhibition of MMP activity on in vitro adipogenesis. We find that the synthetic MMP inhibitor BB-94 (Batimastat) decreases adipose conversion of 3T3-L1 and primary rat preadipocytes. BB-94 represses differentiation without affecting mitotic clonal expansion but prevents the early expression of CCAAT/enhancer-binding protein beta, a transcription factor that is thought to play a major role in the adipogenic program. Such findings support a role for the MMP/TIMP system in the control of proteolytic events and adipogenesis during obesity-mediated fat mass development.	INSERM, U145, IFR 50, F-06107 Nice, France; INSERM, U385, Fac Med, F-06107 Nice 2, France; INSERM, U526, IFR 50, F-06107 Nice, France; UMR 7104, Inst Genet & Biol Mol, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm)	Tartare-Deckert, S (corresponding author), INSERM, U385, Fac Med, Ave Valombrose, F-06107 Nice 2, France.		Anglard, Patrick/M-6618-2019; Mari, Bernard/Q-5832-2019; Mari, Bernard P/F-8960-2013; Mari, Bernard P/GVS-3100-2022; TARTARE-DECKERT, Sophie/P-6057-2015; Mari, Bernard P/D-7445-2015	Anglard, Patrick/0000-0001-5701-441X; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Mari, Bernard P/0000-0002-0422-9182; Chavey, Carine/0000-0002-5267-5638				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Alessi MC, 2000, HORM METAB RES, V32, P504, DOI 10.1055/s-2007-978677; Alexander CM, 2001, J CELL BIOL, V152, P693, DOI 10.1083/jcb.152.4.693; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Bouloumie A, 2001, DIABETES, V50, P2080, DOI 10.2337/diabetes.50.9.2080; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown LM, 1997, AM J PHYSIOL-CELL PH, V272, pC937, DOI 10.1152/ajpcell.1997.272.3.C937; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Curci JA, 1998, J CLIN INVEST, V102, P1900, DOI 10.1172/JCI2182; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Kawaguchi N, 2002, AM J PATHOL, V160, P1895, DOI 10.1016/S0002-9440(10)61136-4; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Lijnen HR, 2002, ARTERIOSCL THROM VAS, V22, P374, DOI 10.1161/hq0302.104522; Lijnen HR, 2001, THROMB HAEMOSTASIS, V85, P1111; Lijnen HR, 2002, THROMB HAEMOSTASIS, V87, P530; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Maquoi E, 2002, DIABETES, V51, P1093, DOI 10.2337/diabetes.51.4.1093; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Pierleoni C, 1998, EUR J HISTOCHEM, V42, P183; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Selvarajan S, 2001, NAT CELL BIOL, V3, P267, DOI 10.1038/35060059; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P22231, DOI 10.1074/jbc.M010634200; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	42	340	353	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11888	11896		10.1074/jbc.M209196200	http://dx.doi.org/10.1074/jbc.M209196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529376	hybrid			2022-12-25	WOS:000182015700023
J	Golovleva, I; Bhattacharya, S; Wu, ZP; Shaw, N; Yang, YW; Andrabi, H; West, KA; Burstedt, MSI; Forsman, K; Holmgren, G; Sandgren, O; Noy, N; Qin, J; Crabb, JW				Golovleva, I; Bhattacharya, S; Wu, ZP; Shaw, N; Yang, YW; Andrabi, H; West, KA; Burstedt, MSI; Forsman, K; Holmgren, G; Sandgren, O; Noy, N; Qin, J; Crabb, JW			Disease-causing mutations in the cellular retinaldehyde binding protein tighten and abolish ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; RETINITIS-PIGMENTOSA; BOTHNIA DYSTROPHY; CYCLE; RLBP1; SPECIFICITY	Mutations in the human cellular retinaldehyde binding Protein (CRALBP) gene cause retinal pathology. To understand the molecular basis of impaired CRALBP function, we have characterized human recombinant CRALBP containing the disease causing mutations R233W or M225K Protein structures were verified by amino acid analysis and mass spectrometry, retinoid binding properties were evaluated by UV-visible and fluorescence spectroscopy and substrate carrier functions were assayed for recombinant 11-cis-retinol dehydrogenase (rRDH5). The M225K mutant was less soluble than the R233W mutant and lacked retinoid binding capability and substrate carrier function. In contrast, the R233W mutant exhibited solubility comparable to wild type rCRALBP and bound stoichiometric amounts of 11-cis- and 9-cis-retinal with at least 2-fold higher affinity than wild type rCRALBP. Holo-R233W significantly decreased the apparent affinity of rRDH5 for 11-cis-retinoid relative to wild type rCRALBP. Analyses by heteronuclear single quantum correlation NMR demonstrated that the R233W protein exhibits a different conformation than wild type rCRALBP, including a different retinoid-binding pocket conformation. The R233W mutant also undergoes less extensive structural changes upon photoisomerization of bound ligand, suggesting a more constrained structure than that of the wild type protein. Overall, the results show that the M225K mutation abolishes and the R233W mutation tightens retinoid binding and both impair CRALBP function in the visual cycle as an 11-cis-retinol acceptor and as a substrate carrier.	Umea Univ, Dept Med Biosci, S-90185 Umea, Sweden; Umea Univ, Dept Ophthalmol, S-90185 Umea, Sweden; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Umea University; Umea University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cornell University; University System of Ohio; Cleveland State University	Crabb, JW (corresponding author), Umea Univ, Norrlands Univ Hosp, S-90185 Umea, Sweden.	crabbj@ccf.org		Qin, Jun/0000-0002-2647-9270; Golovleva, Irina/0000-0001-8741-0616; andrabi, Khurshid/0000-0003-0314-5662	NCI NIH HHS [CA68150] Funding Source: Medline; NEI NIH HHS [EY6603, EY14239] Funding Source: Medline; NHLBI NIH HHS [HL58758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhattacharya SK, 2002, FASEB J, V16, pA14; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budhu A, 2001, J MOL BIOL, V305, P939, DOI 10.1006/jmbi.2000.4340; Burstedt MSI, 1999, INVEST OPHTH VIS SCI, V40, P995; Burstedt MSL, 2001, ARCH OPHTHALMOL-CHIC, V119, P260; Crabb JW, 1998, METH MOL B, V89, P91; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; Crabb JW, 2001, INVEST OPHTH VIS SCI, V42, pS655; CRABB JW, 1997, CURRENT PROTOCOLS S, V7; Crouch RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P613, DOI 10.1111/j.1751-1097.1996.tb03114.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; Eichers ER, 2002, AM J HUM GENET, V70, P955, DOI 10.1086/339688; FUTTERMAN S, 1961, J BIOL CHEM, V236, P1652; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Jang GF, 2000, J BIOL CHEM, V275, P28128; Katsanis N, 2001, CLIN GENET, V59, P424, DOI 10.1034/j.1399-0004.2001.590607.x; Kennedy B N, 1998, Mol Vis, V4, P14; Luck LA, 1997, TECH PROT CHEM, V8, P439, DOI 10.1016/S1080-8914(97)80044-0; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; NOY N, 1999, HANDB EXP PHARM, V139, P3; Phelan JK, 2000, MOL VIS, V6, P116; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; Saari John C., 1994, P351; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058; Wu ZP, 2003, J BIOL CHEM, V278, P12390, DOI 10.1074/jbc.M212775200	35	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12397	12402		10.1074/jbc.M207300200	http://dx.doi.org/10.1074/jbc.M207300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12536144	hybrid			2022-12-25	WOS:000182015700088
J	Leckie, C; Empson, R; Becchetti, A; Thomas, J; Galione, A; Whitaker, M				Leckie, C; Empson, R; Becchetti, A; Thomas, J; Galione, A; Whitaker, M			The NO pathway acts late during the fertilization response in sea urchin eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; PHOSPHOLIPASE C-GAMMA; FREE CALCIUM LEVELS; NITRIC-OXIDE; INOSITOL 1,4,5-TRISPHOSPHATE; CA2+ OSCILLATIONS; SIGNALING PATHWAY; INTRACELLULAR PH; STARFISH EGGS; ACTIVATION	Both the inositol 1,4,5-trisphosphate (InsP(3)) and ryanodine receptor pathways contribute to the Ca2+ transient at fertilization in sea urchin eggs. To date, the precise contribution of each pathway has been difficult to ascertain. Evidence has accumulated to suggest that the InsP(3) receptor pathway has a primary role in causing Ca2+ release and egg activation. However, this was recently called into question by a report implicating NO as the primary egg activator. In the present study we pursue the hypothesis that NO is a primary egg activator in sea urchin eggs and build on previous findings that an NO/cGMP/cyclic ADP-ribose (cADPR) pathway is active at fertilization in sea urchin eggs to define its role. Using a fluorescence indicator of NO levels, we have measured both NO and Ca2+ at fertilization and establish that NO levels rise after, not before, the Ca2+ wave is initiated and that this rise is Ca2+-dependent. By inhibiting the increase in NO at fertilization, we find not that the Ca2+ transient is abolished but that the duration of the transient is significantly reduced. The latency and rise time of the transient are unaffected. This effect is mirrored by the inhibition of cGMP and cADPR signaling in sea urchin eggs at fertilization. We establish that cADPR is generated at fertilization, at a time comparable to the time of the rise in NO levels. We conclude that NO is unlikely to be a primary egg activator but, rather, acts after the initiation of the Ca2+ wave to regulate the duration of the fertilization Ca2+ transient.	Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	Newcastle University - UK; University of Oxford	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Galione, Antony/E-5884-2011; Becchetti, Andrea/AAF-7821-2020	Becchetti, Andrea/0000-0002-9297-0527; Galione, Antony/0000-0002-4132-7646; Empson, Ruth/0000-0002-0415-6083				Abassi YA, 2000, DEV BIOL, V218, P206, DOI 10.1006/dbio.1999.9582; AYABE T, 1995, DEVELOPMENT, V121, P2233; Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; Carroll DJ, 1999, DEV BIOL, V206, P232, DOI 10.1006/dbio.1998.9145; Carroll J, 2001, SEMIN CELL DEV BIOL, V12, P37, DOI 10.1006/scdb.2000.0215; Ciapa B, 1996, BIOCHEM BIOPH RES CO, V223, P633, DOI 10.1006/bbrc.1996.0946; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CROSSLEY I, 1991, CELL REGUL, V2, P121, DOI 10.1091/mbc.2.2.121; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Giusti AF, 2000, J BIOL CHEM, V275, P16788, DOI 10.1074/jbc.M001091200; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; HOFMANN F, 1985, EUR J BIOCHEM, V150, P85, DOI 10.1111/j.1432-1033.1985.tb08991.x; Hyslop LA, 2001, DEV BIOL, V234, P216, DOI 10.1006/dbio.2001.0252; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Kinsey WH, 2000, DEV BIOL, V225, P253, DOI 10.1006/dbio.2000.9830; Kojima H, 2001, J NEUROCHEM, V76, P1404, DOI 10.1046/j.1471-4159.2001.00161.x; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Kuo RK, 2000, NATURE, V406, P633, DOI 10.1038/35020577; Kuroda R, 2001, DEVELOPMENT, V128, P4405; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Lee SJ, 1996, DEV BIOL, V180, P324, DOI 10.1006/dbio.1996.0304; Lee SJ, 1998, DEV BIOL, V193, P195, DOI 10.1006/dbio.1997.8792; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MILLER AL, 1993, J CELL SCI, V106, P523; MIYAZAKI S, 1993, BIOMED RES-TOKYO, V14, P35; MOHRI T, 1995, DEV BIOL, V172, P139, DOI 10.1006/dbio.1995.0011; NUCCITELLI R, 1993, DEV BIOL, V158, P200, DOI 10.1006/dbio.1993.1179; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; REES BB, 1995, DEV BIOL, V169, P683, DOI 10.1006/dbio.1995.1179; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Sethi JK, 1996, BIOCHEM J, V319, P613, DOI 10.1042/bj3190613; Shearer J, 1999, DEVELOPMENT, V126, P2273; SHEN SS, 1993, DEV BIOL, V157, P157, DOI 10.1006/dbio.1993.1120; SHEN SS, 1978, NATURE, V272, P253, DOI 10.1038/272253a0; Shiwa M, 2002, AM J PHYSIOL-REG I, V282, pR727, DOI 10.1152/ajpregu.00519.2001; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; SWANN K, 1985, NATURE, V314, P274, DOI 10.1038/314274a0; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WENNMALM A, 1992, BRIT J PHARMACOL, V106, P507, DOI 10.1111/j.1476-5381.1992.tb14365.x; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER MJ, 1982, Q REV BIOPHYS, V15, P593, DOI 10.1017/S0033583500003760; Willmott N, 1996, J BIOL CHEM, V271, P3699; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Yoshida M, 1998, DEV BIOL, V203, P122, DOI 10.1006/dbio.1998.9037; ZUCKER RS, 1978, BIOCHIM BIOPHYS ACTA, V541, P459, DOI 10.1016/0304-4165(78)90155-1	58	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12247	12254		10.1074/jbc.M210770200	http://dx.doi.org/10.1074/jbc.M210770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540836	hybrid			2022-12-25	WOS:000182015700069
J	Pudi, R; Abhiman, S; Srinivasan, N; Das, S				Pudi, R; Abhiman, S; Srinivasan, N; Das, S			Hepatitis C virus internal ribosome entry site-mediated translation is stimulated by specific interaction of independent regions of human La autoantigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TERMINATION FACTOR LA; MESSENGER-RNA; TRANSCRIPTION TERMINATION; CRYSTAL-STRUCTURE; BINDING PROTEIN; POLIOVIRUS RNA; RECOGNITION MOTIF; INITIATION CODON; LEADER RNA	The human La autoantigen has been shown to interact with the internal ribosome entry site (IRES) of hepatitis C virus (HCV) in vitro. Using a yeast three-hybrid system, we demonstrated that, in addition to full-length La protein, both N- and C-terminal halves were able to interact with HCV IRES in vivo. The exogenous addition of purified full-length and truncated La proteins in rabbit reticulocyte lysate showed dose-dependent stimulation of HCV IRES-mediated translation. However, an additive effect was achieved adding the terminal halves together in the reaction, suggesting that both might play critical roles in achieving full stimulatory activity of the full-length La protein. Using computational analysis, three-dimensional structures of the RNA recognition motifs (RRM) of the La protein were independently modeled. Of the three putative RRMs, RRM2 was predicted to have a good binding pocket for the interaction with the HCV IRES around the GCAC motif near the initiator AUG and RRM3 binds perhaps in a different location. This observation was further investigated by the filter-binding and toe-printing assays. The results presented here strongly suggest that both the N- and C-terminal halves can interact independently with the HCV IRES and are involved in stimulating internal initiation of translation.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in		Limgala, Renuka/0000-0001-6957-6284				Ali N, 2000, J BIOL CHEM, V275, P27531; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; FRANCOEUR AM, 1982, P NATL ACAD SCI-BIOL, V79, P6772, DOI 10.1073/pnas.79.22.6772; Fukushi S, 2001, VIRUS RES, V73, P67, DOI 10.1016/S0168-1702(00)00228-8; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; Hahn B, 1998, J VIROL, V72, P8782, DOI 10.1128/JVI.72.11.8782-8788.1998; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Isoyama T, 1999, J GEN VIROL, V80, P2319, DOI 10.1099/0022-1317-80-9-2319; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kim YK, 1999, J GEN VIROL, V80, P3159, DOI 10.1099/0022-1317-80-12-3159; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; Martin F, 2000, NUCLEIC ACIDS RES, V28, P1594, DOI 10.1093/nar/28.7.1594; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Ohndorf UM, 2001, J BIOL CHEM, V276, P27188, DOI 10.1074/jbc.M102891200; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; PARK YW, 1995, J BIOL CHEM, V270, P28433; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Reynolds JE, 1996, RNA, V2, P867; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; SRINIVASAN N, 1993, PROTEIN ENG, V6, P501, DOI 10.1093/protein/6.5.501; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P385, DOI 10.1093/protein/1.5.385; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TOPHAM CM, 1993, J MOL BIOL, V229, P194, DOI 10.1006/jmbi.1993.1018; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; ZHU ZY, 1992, PROTEIN ENG, V5, P43, DOI 10.1093/protein/5.1.43	61	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12231	12240		10.1074/jbc.M210287200	http://dx.doi.org/10.1074/jbc.M210287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540850	hybrid			2022-12-25	WOS:000182015700067
J	Dhar-Mascareno, M; Chen, J; Zhang, RH; Carcamo, JM; Golde, DW				Dhar-Mascareno, M; Chen, J; Zhang, RH; Carcamo, JM; Golde, DW			Granulocyte-macrophage colony-stimulating factor signals for increased glucose transport via phosphatidylinositol 3-kinase- and hydrogen peroxide-dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; HUMAN-ENDOTHELIAL CELLS; RECEPTOR-ALPHA-SUBUNIT; GM-CSF RECEPTOR; HEMATOPOIETIC-CELLS; HEXOSE-TRANSPORT; VITAMIN-C; GLUT4 TRANSLOCATION; CYTOPLASMIC DOMAIN; INSULIN ACTION	Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates cellular glucose uptake by decreasing the apparent Km for substrate transport through facilitative glucose transporters on the plasma membrane. Little is known about this signal transduction pathway and the role of the a subunit of the GM-CSF receptor (alphaGMR) in modulating transporter activity. We examined the function of phosphatidylinositol 3-kinase (PI 3-kinase) in GM-CSF-stimulated glucose uptake and found that PI 3-kinase inhibitors, wortmannin and LY294002, completely blocked the GM-CSF-dependent increase of glucose uptake in Xenopus oocytes expressing the low affinity aGMR and in human cells expressing the high affinity alphabetaGMR complex. We identified a Src homology 3 domain-binding motif in aGMR at residues 358-361 as a potential interaction site for the PI 3-kinase regulatory subunit, p85. Physical evidence for p85 binding to aGMR was obtained by co-immunoprecipitation with antibodies to aGMR and p85, and an aGMR mutant with alteration of the Src homology 3 binding domain lost the ability to bind p85. Experiments with a construct eliminating most of the intracellular portion of aGMR showed a 50% reduction in GM-CSF-stimulated glucose uptake with residual activity blocked by wortmannin. Searching for a proximally generated diffusible factor capable of activating PI 3-kinase, we identified hydrogen peroxide (H2O2), generated by ligand or antibody binding to aGMR, as the initiating factor. Catalase treatment abrogated GM-CSF- or anti-aGMR antibody-stimulated glucose uptake in alphaGMR-expressing oocytes, and H2O2 activated PI 3-kinase and led to some stimulation of glucose uptake in uninjected oocytes. Human myeloid cell lines and primary explant human lymphocytes expressing high affinity GM-CSF receptors responded to aGMR antibody with increased glucose uptake. These results identify the early events in the stimulation of glucose uptake by GM-CSF as involving local H2O2 generation and requiring PI 3-kinase activation. Our findings also provide a mechanistic explanation for signaling through the isolated a subunit of the GM-CSF receptor.	Mem Sloan Kettering Canc Ctr, Dept Clin Chem, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA; CUNY, Weill Grad Sch Med Sci, Dept Pharmacol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; City University of New York (CUNY) System; Cornell University	Golde, DW (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA.	d-golde@ski.mskcc.org	Dhar-Mascareno, Manya/S-9392-2019		NCI NIH HHS [2P30 CA08748-28, CA30388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA030388, R37CA030388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed N, 1997, BIOCHEM J, V327, P369, DOI 10.1042/bj3270369; AVALOS BR, 1990, BLOOD, V75, P851; BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; BIRD TA, 1990, J BIOL CHEM, V265, P13578; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Carcamo JM, 2002, BLOOD, V99, P3205, DOI 10.1182/blood.V99.9.3205; CORKEY RF, 1981, J CELL PHYSIOL, V106, P425, DOI 10.1002/jcp.1041060312; Cushman SW, 1998, ADV EXP MED BIOL, V441, P63; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEXTER TM, 1984, DIFFERENTIATION, V27, P163, DOI 10.1111/j.1432-0436.1984.tb01423.x; DING DXH, 1994, P NATL ACAD SCI USA, V91, P2537, DOI 10.1073/pnas.91.7.2537; DIPERSIO JF, 1990, INT J CELL CLONING, V8, P63, DOI 10.1002/stem.5530080707; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Egert S, 1997, CARDIOVASC RES, V35, P283, DOI 10.1016/S0008-6363(97)00133-8; Evans CA, 2002, BLOOD, V100, P3164, DOI 10.1182/blood-2001-12-0235; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; FREEDMAN MH, 1993, BLOOD, V81, P3068; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Geijsen N, 2001, CYTOKINE GROWTH F R, V12, P19, DOI 10.1016/S1359-6101(00)00019-8; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; GOULD GW, 1994, J BIOL CHEM, V269, P26622; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HAMILTON JA, 1988, J CELL PHYSIOL, V134, P405, DOI 10.1002/jcp.1041340311; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRSCH T, 1995, BIOCHEM BIOPH RES CO, V217, P138, DOI 10.1006/bbrc.1995.2755; Ishizuka T, 1999, AM J PHYSIOL-ENDOC M, V276, pE196, DOI 10.1152/ajpendo.1999.276.1.E196; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kozlovsky N, 1997, FREE RADICAL BIO MED, V23, P859, DOI 10.1016/S0891-5849(97)00069-5; LEE SC, 1993, J IMMUNOL, V150, P594; Lilly MB, 2001, BLOOD, V97, P1662, DOI 10.1182/blood.V97.6.1662; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; Medina RA, 2002, BIOL RES, V35, P9, DOI 10.4067/S0716-97602002000100004; MIYAJIMA A, 1993, BLOOD, V82, P1960; Moon BG, 2001, IMMUNOLOGY, V102, P289, DOI 10.1046/j.1365-2567.2001.01196.x; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Robertson SA, 2001, BIOL REPROD, V64, P1206, DOI 10.1095/biolreprod64.4.1206; Sattler M, 1999, BLOOD, V93, P2928; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Scott CL, 1998, BLOOD, V92, P4119, DOI 10.1182/blood.V92.11.4119.423k40_4119_4127; SIEGERT W, 1981, BLUT, V43, P297, DOI 10.1007/BF00320953; SPIELHOLZ C, 1995, BLOOD, V85, P973, DOI 10.1182/blood.V85.4.973.bloodjournal854973; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TAKETAZU F, 1991, J CELL PHYSIOL, V146, P251, DOI 10.1002/jcp.1041460209; Tan AS, 1998, BLOOD, V91, P649, DOI 10.1182/blood.V91.2.649.649_649_655; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TOMONAGA M, 1986, BLOOD, V67, P1433; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vera JC, 1998, BLOOD, V91, P2536, DOI 10.1182/blood.V91.7.2536.2536_2536_2546; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; Zambrano A, 2001, J CELL BIOCHEM, V80, P625, DOI 10.1002/1097-4644(20010315)80:4<625::AID-JCB1017>3.0.CO;2-9	64	29	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11107	11114		10.1074/jbc.M212541200	http://dx.doi.org/10.1074/jbc.M212541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538575	hybrid			2022-12-25	WOS:000181855400033
J	Machius, M; Declerck, N; Huber, R; Wiegand, G				Machius, M; Declerck, N; Huber, R; Wiegand, G			Kinetic stabilization of Bacillus licheniformis alpha-amylase through introduction of hydrophobic residues at the surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; ELECTRON-DENSITY MAPS; METAL-BINDING SITES; COLD-SHOCK PROTEIN; CRYSTAL-STRUCTURE; HYPERTHERMOSTABLE MUTANTS; ANGSTROM RESOLUTION; STABILITY; THERMOSTABILITY; DETERMINANTS	It is generally assumed that in proteins hydrophobic residues are not favorable at solvent-exposed sites, and that amino acid substitutions on the surface have little effect on protein thermostability. Contrary to these assumptions, we have identified hyperthermostable variants of Bacillus licheniformis alpha-amylase (BLA) that result from the incorporation of hydrophobic residues at the surface. Under highly destabilizing conditions, a variant combining five stabilizing mutations unfolds 32 times more slowly and at a temperature 13 degreesC higher than the wild-type. Crystal structure analysis at 1.7 Angstrom resolution suggests that stabilization is achieved through (a) extension of the concept of increased hydrophobic packing, usually applied to cavities, to surface indentations, (b) introduction of favorable aromatic-aromatic interactions on the surface, (c) specific stabilization of intrinsic metal binding sites, and (d) stabilization of a beta-sheet by introducing a residue with high beta-sheet forming propensity. All mutated residues are involved in forming complex, cooperative interaction networks that extend from the interior of the protein to its surface and which may therefore constitute "weak points" where BLA unfolding is initiated. This might explain the unexpectedly large effect induced by some of the substitutions on the kinetic stability of BLA. Our study shows that substantial protein stabilization can be achieved by stabilizing surface positions that participate in underlying cooperatively formed substructures. At such positions, even the apparently thermodynamically unfavorable introduction of hydrophobic residues should be explored.	Univ Texas, SW Med Ctr Dallas, Dallas, TX 75390 USA; INAP G, CNRS, URA 1925, INRA UMR 216, F-78850 Thiverval Grignon, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Centre National de la Recherche Scientifique (CNRS); INRAE; Max Planck Society	Machius, M (corresponding author), Univ Texas, SW Med Ctr Dallas, Dallas, TX 75390 USA.			Declerck, Nathalie/0000-0003-1551-1607				Bertoldo C, 2002, CURR OPIN CHEM BIOL, V6, P151, DOI 10.1016/S1367-5931(02)00311-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryan PN, 2000, BBA-PROTEIN STRUCT M, V1543, P203, DOI 10.1016/S0167-4838(00)00235-1; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; CONRAD B, 1995, EUR J BIOCHEM, V230, P481; DECLERCK M, 2002, IN PRESS BIOL BRAT S, V57; Declerck N, 1997, PROTEIN ENG, V10, P541, DOI 10.1093/protein/10.5.541; DECLERCK N, 1990, J BIOL CHEM, V265, P15481; Declerck N, 2000, J MOL BIOL, V301, P1041, DOI 10.1006/jmbi.2000.4025; Declerck N, 1995, PROTEIN ENG, V8, P1029, DOI 10.1093/protein/8.10.1029; Demirjian DC, 2001, CURR OPIN CHEM BIOL, V5, P144, DOI 10.1016/S1367-5931(00)00183-6; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fitter J, 2001, BIOCHEMISTRY-US, V40, P10723, DOI 10.1021/bi010808b; Frigerio F, 1996, PROTEIN ENG, V9, P439, DOI 10.1093/protein/9.5.439; Gu H, 1999, PROTEIN SCI, V8, P2734; Harris GW, 1997, PROTEINS, V29, P77, DOI 10.1002/(SICI)1097-0134(199709)29:1<77::AID-PROT6>3.3.CO;2-K; Hartley BS, 2000, BBA-PROTEIN STRUCT M, V1543, P294, DOI 10.1016/S0167-4838(00)00246-6; HUBBARD SJ, 1995, CURR OPIN BIOTECH, V6, P375, DOI 10.1016/0958-1669(95)80065-4; Hwang KY, 1997, MOL CELLS, V7, P251; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYET P, 1992, BIO-TECHNOL, V10, P1579, DOI 10.1038/nbt1292-1579; Knegtel RMA, 1996, J MOL BIOL, V256, P611, DOI 10.1006/jmbi.1996.0113; Kwok SC, 2002, PROTEIN SCI, V11, P1519, DOI 10.1110/ps.4170102; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee B, 1997, CURR OPIN BIOTECH, V8, P423, DOI 10.1016/S0958-1669(97)80063-8; Lu Y, 1997, CURR OPIN STRUC BIOL, V7, P495, DOI 10.1016/S0959-440X(97)80112-1; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; Machius M, 1998, STRUCTURE, V6, P281, DOI 10.1016/S0969-2126(98)00032-X; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; Munson M, 1996, PROTEIN SCI, V5, P1584, DOI 10.1002/pro.5560050813; Nielsen JE, 2000, BBA-PROTEIN STRUCT M, V1543, P253, DOI 10.1016/S0167-4838(00)00240-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Poso D, 2000, J BIOL CHEM, V275, P35723, DOI 10.1074/jbc.M001747200; Predki PF, 1996, NAT STRUCT BIOL, V3, P54, DOI 10.1038/nsb0196-54; Schindler T, 1998, PROTEINS, V30, P401, DOI 10.1002/(SICI)1097-0134(19980301)30:4<401::AID-PROT7>3.3.CO;2-G; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; Shaw A, 1999, CURR OPIN BIOTECH, V10, P349, DOI 10.1016/S0958-1669(99)80063-9; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; Suvd D, 2001, J BIOCHEM, V129, P461, DOI 10.1093/oxfordjournals.jbchem.a002878; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; Tanaka A, 2002, BIOCHEM J, V364, P635, DOI 10.1042/BJ20011436; Terashima M, 1996, ANN NY ACAD SCI, V799, P65, DOI 10.1111/j.1749-6632.1996.tb33179.x; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; VANDENBURG B, 1994, EUR J BIOCHEM, V220, P981; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	54	99	108	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11546	11553		10.1074/jbc.M212618200	http://dx.doi.org/10.1074/jbc.M212618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540849	hybrid			2022-12-25	WOS:000181855400087
J	Miyake, Y; Kakeya, H; Kataoka, T; Osada, H				Miyake, Y; Kakeya, H; Kataoka, T; Osada, H			Epoxycyclohexenone inhibits Fas-mediated apoptosis by blocking activation of pro-caspase-8 in the death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; CASPASE INHIBITOR; CD95; RECEPTOR; CELLS; FADD; NEUROPROTECTION; RECRUITMENT; MODULATION	Death receptors belong to the tumor necrosis factor receptor family. They can induce apoptosis following engagement with specific ligands and are known to play an important role in the regulation of the immune system. Here we report that epoxycyclohexenone (ECH) inhibits apoptosis induced by anti-Fas antibody, Fas ligand (FasL), or tumor necrosis factor-alpha but not by staurosporine, MG-132, C2-ceramide, or UV irradiation. These results suggest that ECH specifically blocks death receptor-mediated apoptosis. Neither the surface expression of Fas nor the Fas-FasL interaction was influenced by ECH. However, ECH did block the activation of pro-caspase-8 in the death-inducing signaling complex, although recruitment of Fas-associating death domain (FADD) and pro-caspase-8 was not affected. ECH inhibited the enzymatic activity of recombinant active caspase-8 at slightly lower concentrations than it did for active caspase-3 and active caspase-9 in vitro. However, in FasL-treated cells, ECH was only able to inhibit the activation of pro-caspase-8, and it had no effect on the already activated caspase-8 at a concentration that is effective at inhibiting Fas-induced apoptosis. ECH directly bound the large subunit of active caspase-8 that contains the active center cysteine and had a relatively higher affinity to pro-caspase-8. Moreover, compared with pro-caspase-3 and pro-caspase-9, pro-caspase-8 was predominantly depleted by biotinylated ECH with avidin beads in the cell lysates, suggesting that ECH preferentially affects pro-caspase-8. Thus, our results suggest that ECH blocks the self-activation of pro-caspase-8 in the death-inducing signaling complex and thus selectively inhibits death receptor-mediated apoptosis.	RIKEN, Discovery Res Inst, Antibiot Lab, Wako, Saitama 3510198, Japan; Tokyo Inst Technol, Res Ctr Expt Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	RIKEN; Tokyo Institute of Technology	Osada, H (corresponding author), RIKEN, Discovery Res Inst, Antibiot Lab, Wako, Saitama 3510198, Japan.	antibiot@postman.riken.go.jp	Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014; Kakeya, Hideaki/B-3527-2012	Kakeya, Hideaki/0000-0002-4293-7331				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Arakaki N, 1999, J BIOL CHEM, V274, P13541, DOI 10.1074/jbc.274.19.13541; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Osada H, 2000, BIOPROBES, P1; OSADA H, 1990, J ANTIBIOT, V43, P163, DOI 10.7164/antibiotics.43.163; Patel M, 1998, J NEUROCHEM, V71, P1068, DOI 10.1046/j.1471-4159.1998.71031068.x; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; 1999, Patent No. 11222456	38	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11213	11220		10.1074/jbc.M209610200	http://dx.doi.org/10.1074/jbc.M209610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551927	hybrid			2022-12-25	WOS:000181855400047
J	Yanofsky, C				Yanofsky, C			Using studies on tryptophan metabolism to answer basic biological questions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							OPERON LEADER REGION; BINDING ATTENUATION PROTEIN; IN-VITRO TRANSCRIPTION; ESCHERICHIA-COLI K-12; TRP REPRESSOR; TRANSFER-RNA; MESSENGER-RNA; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; GENE-EXPRESSION		Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.							Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BAKER RF, 1968, NATURE, V219, P26, DOI 10.1038/219026a0; BAUERLE RH, 1967, J MOL BIOL, V26, P423, DOI 10.1016/0022-2836(67)90313-0; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; Benzer S., 1957, Proceedings of the International Genetics Symposia, 1956. Tokyo & Kyoto, September 1956, pp; Berg P, 1973, Harvey Lect, V67, P247; BRODY S, 1963, P NATL ACAD SCI USA, V50, P9, DOI 10.1073/pnas.50.1.9; CARBON J, 1966, COLD SPRING HARB SYM, V31, P487, DOI 10.1101/SQB.1966.031.01.063; COX EC, 1967, P NATL ACAD SCI USA, V58, P1895, DOI 10.1073/pnas.58.5.1895; CRAWFORD IP, 1958, P NATL ACAD SCI USA, V44, P1161, DOI 10.1073/pnas.44.12.1161; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; DAS A, 1989, NUCLEIC ACIDS RES, V17, P9333, DOI 10.1093/nar/17.22.9333; Di Martino P, 2002, CAN J MICROBIOL, V48, P132, DOI 10.1139/W02-001; DOOLITTLE WF, 1968, J BACTERIOL, V95, P1283, DOI 10.1128/JB.95.4.1283-1294.1968; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; FISHER R, 1983, J BIOL CHEM, V258, P9208; FISHER RF, 1985, J MOL BIOL, V182, P397, DOI 10.1016/0022-2836(85)90199-8; FRANKLIN NC, 1965, BIOCHEM BIOPH RES CO, V18, P898; GOLDBERG ME, 1966, J MOL BIOL, V21, P71, DOI 10.1016/0022-2836(66)90080-5; Gollnick P., 2002, BACILLUS SUBTILIS IT, P233; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; Gong F, 2002, J BIOL CHEM, V277, P17095, DOI 10.1074/jbc.M201213200; Grundy FJ, 2002, P NATL ACAD SCI USA, V99, P11121, DOI 10.1073/pnas.162366799; GUEST JR, 1965, J MOL BIOL, V12, P793, DOI 10.1016/S0022-2836(65)80328-X; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; GUPTA NK, 1966, P NATL ACAD SCI USA, V56, P772, DOI 10.1073/pnas.56.2.772; HELINSKI DR, 1963, J BIOL CHEM, V238, P1043; Henkin TM, 2000, CURR OPIN MICROBIOL, V3, P149, DOI 10.1016/S1369-5274(00)00067-9; Henkin TM, 2002, BIOESSAYS, V24, P700, DOI 10.1002/bies.10125; Henner Dennis, 1993, P269; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; HERSHFIE.V, 1974, P NATL ACAD SCI USA, V71, P3455, DOI 10.1073/pnas.71.9.3455; HOGNESS DS, 1954, J GEN MICROBIOL, V11, P401, DOI 10.1099/00221287-11-3-401; HOROWITZ H, 1982, J MOL BIOL, V156, P257, DOI 10.1016/0022-2836(82)90327-8; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IMAMOTO F, 1967, J MOL BIOL, V28, P1, DOI 10.1016/S0022-2836(67)80073-1; IMAMOTO F, 1966, COLD SPRING HARB SYM, V31, P235, DOI 10.1101/SQB.1966.031.01.032; INGRAM VM, 1958, BIOCHIM BIOPHYS ACTA, V28, P539, DOI 10.1016/0006-3002(58)90516-X; JACKSON DA, 1969, J BIOL CHEM, V244, P4539; JACKSON EN, 1973, J MOL BIOL, V76, P89, DOI 10.1016/0022-2836(73)90082-X; JACKSON EN, 1972, J MOL BIOL, V69, P307, DOI 10.1016/0022-2836(72)90232-X; Jurgens C, 2000, P NATL ACAD SCI USA, V97, P9925, DOI 10.1073/pnas.160255397; KASAI T, 1974, NATURE, V249, P523, DOI 10.1038/249523a0; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LANDICK R, 1985, P NATL ACAD SCI USA, V82, P4663, DOI 10.1073/pnas.82.14.4663; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; LEE F, 1976, J MOL BIOL, V103, P383, DOI 10.1016/0022-2836(76)90318-1; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; MERINO E, 2002, BACILLUS SUBTILIS IT, P323; Miles E W, 1995, Subcell Biochem, V24, P207; MITCHELL HK, 1948, J BIOL CHEM, V175, P481; MORSE DE, 1976, J MOL BIOL, V103, P209, DOI 10.1016/0022-2836(76)90310-7; MORSE DE, 1969, COLD SPRING HARB SYM, V34, P725, DOI 10.1101/SQB.1969.034.01.082; NAGATA S, 1989, J BIOL CHEM, V264, P6288; OPPENHEIM DS, 1980, GENETICS, V95, P785; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; ROSE JK, 1973, NATURE-NEW BIOL, V245, P133, DOI 10.1038/newbio245133a0; ROTH JR, 1966, COLD SPRING HARB SYM, V31, P383, DOI 10.1101/SQB.1966.031.01.050; ROTHMAN FG, 1987, PHOSPHATE METABOLISM, P307; SANGER F, 1952, ADV PROTEIN CHEM, V7, P1, DOI 10.1016/S0065-3233(08)60017-0; SARABHAI AS, 1964, NATURE, V201, P13, DOI 10.1038/201013a0; Sarsero JP, 2000, P NATL ACAD SCI USA, V97, P2656, DOI 10.1073/pnas.050578997; SCHNEIDER WP, 1981, P NATL ACAD SCI-BIOL, V78, P2169, DOI 10.1073/pnas.78.4.2169; SOMERVILLE RL, 1964, J MOL BIOL, V8, P616, DOI 10.1016/S0022-2836(64)80019-X; SQUIRES CL, 1975, J MOL BIOL, V92, P93, DOI 10.1016/0022-2836(75)90093-5; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; SUSKIND Sr, 1955, P NATL ACAD SCI USA, V41, P577, DOI 10.1073/pnas.41.8.577; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; UMBREIT WW, 1946, J BIOL CHEM, V165, P731; Valbuzzi A, 2002, J BIOL CHEM, V277, P10608, DOI 10.1074/jbc.M111813200; Valbuzzi A, 2001, SCIENCE, V293, P2057, DOI 10.1126/science.1062187; Wang DD, 2001, J BACTERIOL, V183, P4210, DOI 10.1128/JB.183.14.4210-4216.2001; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WINKLER ME, 1981, BIOCHEMISTRY-US, V20, P3738, DOI 10.1021/bi00516a011; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; YANOFSKY C, 1984, MOL BIOL EVOL, V1, P143; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; YANOFSKY C, 1964, P NATL ACAD SCI USA, V51, P266, DOI 10.1073/pnas.51.2.266; YANOFSKY C, 1959, VIROLOGY, V8, P425, DOI 10.1016/0042-6822(59)90046-7; Yanofsky C, 2001, ANNU REV BIOCHEM, V70, P1, DOI 10.1146/annurev.biochem.70.1.1; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; YANOFSKY C, 1952, P NATL ACAD SCI USA, V38, P215, DOI 10.1073/pnas.38.3.215; YANOFSKY C, 1954, J BACTERIOL, V68, P577, DOI 10.1128/JB.68.5.577-584.1954; YANOFSKY C, 1977, J MOL BIOL, V113, P663, DOI 10.1016/0022-2836(77)90229-7; Yanofsky C, 2000, J BACTERIOL, V182, P1, DOI 10.1128/JB.182.1.1-8.2000; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991; YANOFSKY C, 1984, J BACTERIOL, V158, P1018, DOI 10.1128/JB.158.3.1018-1024.1984; YANOFSKY C, 1967, P NATL ACAD SCI USA, V57, P296, DOI 10.1073/pnas.57.2.296; YANOFSKY C, 1956, H FORD HOSP INT S EN, P147; YANOFSKY C, 1963, COLD SPRING HARB SYM, V28, P296; YANOFSKY C, 1969, 12TH P INT C GEN, V3, P155; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P641; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317	101	32	35	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10859	10878		10.1074/jbc.X200012200	http://dx.doi.org/10.1074/jbc.X200012200			20	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12556463	hybrid			2022-12-25	WOS:000181855400001
J	Albers, E; Laize, V; Blomberg, A; Hohmann, S; Gustafsson, L				Albers, E; Laize, V; Blomberg, A; Hohmann, S; Gustafsson, L			Ser3p (Yer081wp) and Ser33p (Yil074cp) are phosphoglycerate dehydrogenases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASES; SERINE BIOSYNTHESIS; ANAEROBIC GROWTH; GENE-EXPRESSION; NITROGEN-SOURCE; METABOLISM; GLYCINE; AMINOTRANSFERASE; COMPARTMENTATION; REPRESSION	Two genes YER081W and YIL074C, renamed SER3 and SER33, respectively, which encode phosphoglycerate dehydrogenases in Saccharomyces cerevisiae were identified. These dehydrogenases catalyze the first reaction of serine and glycine biosynthesis from the glycolytic metabolite 3-phosphoglycerate. Unlike either single mutant, the ser3Delta ser33Delta double mutant lacks detectable phosphoglycerate dehydrogenase activity an is auxotrophic for serine or glycine for growth on glucose media. However, the requirement for the SER-dependent "phosphoglycerate pathway" is conditional since the "glyoxylate" route of serine/glycine biosynthesis is glucose-repressed. Thus, in cells grown on ethanol both expression and activity of all SER-encoded proteins are low, including the remaining enzymes of the phosphoglycerate pathway, Ser1p and Ser2p. Moreover the available nitrogen source regulates the expression of SER genes. However, for only SER33, and not SER3, expression was regulated in relation to the available nitrogen source in a coordinated fashion with SER1 and SER2. Based on these mRNA data together with data on enzyme activities, Ser33p is likely to be the main isoenzyme of the phosphoglycerate pathway during growth on glucose. Moreover, since phosphoglycerate dehydrogenase activity requires NAD(+) as cofactor, deletion of SER3 and SER33 markedly affected redox metabolism as shown by substrate and product analysis.	Chalmers Univ Technol, Dept Mol Biotechnol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Cell & Mol Biol Microbiol, SE-40530 Gothenburg, Sweden	Chalmers University of Technology; University of Gothenburg	Albers, E (corresponding author), Chalmers Univ Technol, Dept Mol Biotechnol, Box 462, SE-40530 Gothenburg, Sweden.	Eva.Albers@molbiotech.chalmers.se	Hohmann, Stefan/K-9895-2013; Laizé, Vincent/B-4463-2008	Hohmann, Stefan/0000-0002-0809-1985; Laizé, Vincent/0000-0001-9565-9198; Albers, Eva/0000-0002-1921-3415				Achouri Y, 1997, BIOCHEM J, V323, P365, DOI 10.1042/bj3230365; Albers E, 1996, APPL ENVIRON MICROB, V62, P3187, DOI 10.1128/AEM.62.9.3187-3195.1996; Albers E, 1998, MICROBIOL-UK, V144, P1683, DOI 10.1099/00221287-144-6-1683; ALBERS E, 2000, THESIS CHALMERS U TE; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; BELHUMEUR P, 1994, YEAST, V10, P385, DOI 10.1002/yea.320100311; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dickinson JR, 1997, J BIOL CHEM, V272, P26871, DOI 10.1074/jbc.272.43.26871; DRYER RL, 1957, J BIOL CHEM, V225, P177; *EBC, 1987, AN EBC, pE141; Entian KD, 1998, METHOD MICROBIOL, V26, P431; Grant GA, 1996, PROTEIN SCI, V5, P34; GRENSON M, 1970, J BACTERIOL, V103, P770, DOI 10.1128/JB.103.3.770-777.1970; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HIRSCHKOLB H, 1971, METHODS ENZYMOL B, V17, P331; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; Larsson N, 1997, ELECTROPHORESIS, V18, P418, DOI 10.1002/elps.1150180316; LEWIS MJ, 1963, J I BREWING, V69, P39; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McNeil JB, 1996, GENETICS, V142, P371; MELCHER K, 1995, CURR GENET, V27, P501, DOI 10.1007/BF00314439; MELCHER K, 1992, CURR GENET, V21, P295, DOI 10.1007/BF00351686; Monschau N, 1997, FEMS MICROBIOL LETT, V150, P55, DOI 10.1016/S0378-1097(97)00096-7; Norbeck J, 1997, YEAST, V13, P1519, DOI 10.1002/(SICI)1097-0061(199712)13:16<1519::AID-YEA211>3.0.CO;2-U; OURA E, 1977, PROCESS BIOCHEM, V12, P19; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; Planta RJ, 1999, YEAST, V15, P329, DOI 10.1002/(SICI)1097-0061(19990315)15:4<329::AID-YEA360>3.0.CO;2-C; RADLER F, 1986, EXPERIENTIA, V42, P884, DOI 10.1007/BF01941765; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; Sambrook J., 1989, MOL CLONING, pA1; SINCLAIR DA, 1995, GENETICS, V140, P1213; Soussi-Boudekou S, 1999, MOL MICROBIOL, V31, P753, DOI 10.1046/j.1365-2958.1999.01187.x; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TAKADA Y, 1985, BIOCHEM J, V231, P157, DOI 10.1042/bj2310157; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; ULANE R, 1972, J BACTERIOL, V109, P34, DOI 10.1128/JB.109.1.34-43.1972; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Warringer J, 2003, YEAST, V20, P53, DOI 10.1002/yea.931; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996; [No title captured]	49	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10264	10272		10.1074/jbc.M211692200	http://dx.doi.org/10.1074/jbc.M211692200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525494	hybrid			2022-12-25	WOS:000181777500038
J	Cabral, WA; Mertts, MV; Makareeva, E; Colige, A; Tekin, M; Pandya, A; Leikin, S; Marin, JC				Cabral, WA; Mertts, MV; Makareeva, E; Colige, A; Tekin, M; Pandya, A; Leikin, S; Marin, JC			Type I collagen triplet duplication mutation in lethal osteogenesis imperfecta shifts register of alpha chains throughout the helix and disrupts incorporation of mutant helices into fibrils and extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE LABELING REAGENTS; N-PROTEINASE; PRO-ALPHA-1(I) CHAIN; POINT MUTATION; PROCOLLAGEN; CLEAVAGE; DELETION; COL1A1; HETEROGENEITY; TRANSLATION	The majority of collagen mutations causing osteogenesis imperfecta (OI) are glycine substitutions that disrupt formation of the triple helix. A rare type of collagen mutation consists of a duplication or deletion of one or two Gly-X-Y triplets. These mutations shift the register of collagen chains with respect to each other in the helix but do not interrupt the triplet sequence, yet they have severe clinical consequences. We investigated the effect of shifting the register of the collagen helix by a single Gly-X-Y triplet on collagen assembly, stability, and incorporation into fibrils and matrix. These studies utilized a triplet duplication in COL1A1 exon 44 that occurred in the cDNA and gDNA of two siblings with lethal OI. The normal allele encodes three identical Gly-Ala-Hyp triplets at aa 868-876, whereas the mutant allele encodes four. The register shift delays helix formation, causing overmodification. Differential scanning calorimetry yielded a decrease in T-m of 2 degreesC for helices with one mutant chain and a 6 degreesC decrease in helices with two mutant chains. An in vitro binary co-processing assay of N-proteinase cleavage demonstrated that procollagen with the triplet duplication has slower N-propeptide cleavage than in normal controls or procollagen with proalpha1(I) G832S, G898S, or G997S substitutions, showing that the register shift persists through the entire helix. The register shift disrupts incorporation of mutant collagen into fibrils and matrix. Proband fibrils formed inefficiently in vitro and contained only normal helices and helices with a single mutant chain. Helices with two mutant chains and a significant portion of helices with one mutant chain did not form fibrils. In matrix deposited by proband fibroblasts, mutant chains were abundant in the immaturely cross-linked fraction but constituted a minor fraction of maturely cross-linked chains. The profound effects of shifting the collagen triplet register on chain interactions in the helix and on fibril formation correlate with the severe clinical consequences.	NICHD, Sect Connect Tissue Disorders, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; NICHD, Sect Phys Biochem, NIH, Bethesda, MD 20892 USA; Univ Liege, Connect Tissue Res Labs, Liege, Belgium; Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Liege; Virginia Commonwealth University	Marin, JC (corresponding author), NICHD, Sect Connect Tissue Disorders, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241,9000 Rockville Pike, Bethesda, MD 20892 USA.	oidoc@helix.nih.gov	Leikin, Sergey/A-5518-2008; Tekin, Mustafa/ABG-7627-2020; Makareeva, Elena/F-5183-2011	Leikin, Sergey/0000-0001-7095-0739; Makareeva, Elena/0000-0002-5815-0760; Tekin, Mustafa/0000-0002-3525-7960	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000256, ZIAHD000408] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000408, Z01HD000256] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; BONADIO J, 1985, J BIOL CHEM, V260, P1734; Byers Peter H., 1993, P317; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Dalgleish R, 1998, NUCLEIC ACIDS RES, V26, P253, DOI 10.1093/nar/26.1.253; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; FIEDLERNAGY C, 1981, ARCH BIOCHEM BIOPHYS, V212, P668, DOI 10.1016/0003-9861(81)90411-2; FILIE JD, 1993, HUM MUTAT, V2, P380, DOI 10.1002/humu.1380020510; FORLINO A, 1994, HUM MOL GENET, V3, P2201, DOI 10.1093/hmg/3.12.2201; GRANGE DK, 1990, NUCLEIC ACIDS RES, V18, P4227, DOI 10.1093/nar/18.14.4227; HAWKINS JR, 1991, J BIOL CHEM, V266, P22370; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; MARINI JC, 1989, J BIOL CHEM, V264, P11893; MARINI JC, 2001, MANAGEMENT GENETIC S, P281; MCBRIDE DJ, 1992, MATRIX, V12, P256; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; Pace JM, 2001, HUM MUTAT, V18, P319, DOI 10.1002/humu.1193; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Sacca B, 2002, CHEMBIOCHEM, V3, P904, DOI 10.1002/1439-7633(20020902)3:9<904::AID-CBIC904>3.0.CO;2-I; Sacca B, 2002, J MOL BIOL, V324, P309, DOI 10.1016/S0022-2836(02)01065-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; TIFFANY ML, 1969, BIOPOLYMERS, V8, P347, DOI 10.1002/bip.1969.360080306; Van der Hoeve J., 1918, ARCH OPHTHALMOL-CHIC, V95, P81, DOI DOI 10.1007/BF01928336; VOGEL BE, 1987, J BIOL CHEM, V262, P14737; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WALLIS GA, 1992, J BIOL CHEM, V267, P25529; Ward L M, 2001, Hum Mutat, V17, P434, DOI 10.1002/humu.1124; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; WILLING MC, 1994, AM J HUM GENET, V55, P638	39	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10006	10012		10.1074/jbc.M212523200	http://dx.doi.org/10.1074/jbc.M212523200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12538651	hybrid			2022-12-25	WOS:000181777500003
J	Corcoran, EE; Joseph, JD; MacDonald, JA; Kane, CD; Haystead, TAJ; Means, AR				Corcoran, EE; Joseph, JD; MacDonald, JA; Kane, CD; Haystead, TAJ; Means, AR			Proteomic analysis of calcium/calmodulin-dependent protein kinase I and IV in vitro substrates reveals distinct catalytic preferences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MAPKAP KINASE-2; CONSTITUTIVE EXPRESSION; MEDIATED TRANSCRIPTION; CELLULAR-LOCALIZATION; PHOSPHORYLATION SITES; RECOGNITION MOTIFS; NERVOUS-SYSTEM; CALMODULIN; ACTIVATION	The multifunctional calcium/calmodulin-dependent protein kinases I and TV (CaMKI and CaMKIV) are closely related by primary sequence and predicted to have similar substrate specificities based on peptide studies. We identified a fragment of p300-(1-117) that is a substrate of both kinases, and through both mutagenesis and Edman phosphate (P-32) release sequencing, established that CaMKI and CaMKIV phosphorylate completely different sites. The CaMKI site, Ser(89) ((84)LLRSGSSPNL(93)), fits the expected consensus whereas the CaMKIV site, Ser(24) ((19)SSpALSASAS(28)) is novel. To compare kinase substrate preferences more generally, we employed a proteomic display technique that allowed comparison of complex cell extracts phosphorylated by each kinase in a rapid in vitro assay, thereby demonstrating substrate preferences that overlapped but were clearly distinct. To validate this approach, one of the proteins labeled in this assay was identified by microsequencing as HSP25, purified as a recombinant protein, and examined as a substrate for both CaMKI and CaMKIV. Again, CaMKI and CaMKIV were different, this time in kinetics and stoichiometry of the phosphorylation sites, with CaMKI preferring Ser(15) ((10)LLRTPSWGPF(19)) to Ser(85) ((80)LNRQLSSGVS(89)) 3:1, but CaMKIV phosphorylating the two sites equally. These differences in substrate specificities emphasize the need to consider these protein kinases independently despite their close homology.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.	means001@mc.duke.edu	Kane, Christopher/C-8256-2019	Kane, Christopher/0000-0002-0469-1668; MacDonald, Justin/0000-0002-9238-8473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07503-24] Funding Source: Medline; NIDDK NIH HHS [DK52378-06] Funding Source: Medline; NIGMS NIH HHS [GM33976-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed BY, 2000, NEUROSCI LETT, V290, P149, DOI 10.1016/S0304-3940(00)01347-1; ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Armstrong CL, 2000, J COMP NEUROL, V416, P383, DOI 10.1002/(SICI)1096-9861(20000117)416:3<383::AID-CNE9>3.0.CO;2-M; Armstrong CL, 2001, J COMP NEUROL, V434, P262, DOI 10.1002/cne.1176; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Geier A, 1997, IN VITRO CELL DEV-AN, V33, P129; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Guo ZY, 2000, BIOCHEM BIOPH RES CO, V270, P183, DOI 10.1006/bbrc.2000.2401; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Loones MT, 2000, CELL STRESS CHAPERON, V5, P291, DOI 10.1379/1466-1268(2000)005<0291:TDOHSP>2.0.CO;2; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; Mackey AJ, 2002, MOL CELL PROTEOMICS, V1, P139, DOI 10.1074/mcp.M100004-MCP200; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Means AR, 2000, PRINCIPLES OF MOLECULAR REGULATION, P187; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Wakayama T, 1998, CELL BIOL INT, V22, P295, DOI 10.1006/cbir.1998.0252; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	38	15	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10516	10522		10.1074/jbc.M210642200	http://dx.doi.org/10.1074/jbc.M210642200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12538590	hybrid			2022-12-25	WOS:000181777500070
J	Yin, YJ; Salah, Z; Maoz, M; Ram, SCE; Ochayon, S; Neufeld, G; Katzav, S; Bar-Shavit, R				Yin, YJ; Salah, Z; Maoz, M; Ram, SCE; Ochayon, S; Neufeld, G; Katzav, S; Bar-Shavit, R			Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation	FASEB JOURNAL			English	Article						thrombin receptor; vascular endothelial growth factor; invasion; metastasis	ENDOTHELIAL GROWTH-FACTOR; COUPLED THROMBIN RECEPTOR; PROTEIN-KINASE-C; SIGNALING PATHWAYS; TYROSINE KINASE; FACTOR VEGF; PROTHROMBIN DEFICIENCY; EXTRACELLULAR-MATRIX; EMBRYONIC LETHALITY; BLOOD-COAGULATION	The formation of new blood vessels is a critical determinant of tumor progression. We find that Par1 gene expression plays a central role in blood vessel recruitment in animal models. By in vivo injection of either Matrigel plugs containing Par1-expressing cells or of rat prostatic carcinoma cells transfected with tetracycline-inducible Par1 expression vectors, we show that Par1 significantly enhances both angiogenesis and tumor growth. Several vascular endothelial growth factor (VEGF) splice forms are induced in cells expressing Par1. Activation of PAR1 markedly augments the expression of VEGF mRNAs and of functional VEGFs as determined by in vitro assays for endothelial tube alignment and bovine aortic endothelial cell proliferation. Because neutralizing anti-VEGF antibodies potently inhibited Par1-induced endothelial cell proliferation, we conclude that Par1-induced angiogenesis requires VEGF. Specific inhibitors of protein kinase C (PKC), Src, and phosphatidylinositol 3-kinase (PI3K) inhibit Par1-induced VEGF expression, suggesting the participation of these kinases in the process. We also show that oncogenic transformation by genes known to be part of PAR1 signaling machinery is sufficient to increase VEGF expression in NIH 3T3 cells. These data support the novel notion that initiation of cell signaling either by activating PAR1 or by the activated forms of oncogenes is sufficient to induce VEGF and hence angiogenesis.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Oncol, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91010 Jerusalem, Israel; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Technion Israel Institute of Technology	Bar-Shavit, R (corresponding author), Hadassah Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	barshav@md.huji.ac.il	Neufeld, Gera/F-1524-2019					Bar-Shavit R, 2002, IMMUNOLOGY, V105, P35, DOI 10.1046/j.0019-2805.2001.01351.x; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 2001, SCIENCE, V293, P1602, DOI 10.1126/science.1064981; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fiedler W, 1997, BLOOD, V89, P1870, DOI 10.1182/blood.V89.6.1870; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Huang YQ, 2001, THROMB HAEMOSTASIS, V86, P1094; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; Itoh T, 1998, CANCER RES, V58, P1048; KATZAV S, 1995, ONCOGENE, V11, P1079; KATZAV S, 1993, ONCOGENE, V8, P1757; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Landau E, 2000, J BIOL CHEM, V275, P2281, DOI 10.1074/jbc.275.4.2281; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PASSANITI A, 1992, LAB INVEST, V67, P519; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Preissner KT, 2000, J PATHOL, V190, P360; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; RICKLES FR, 1983, BLOOD, V62, P14; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shock DD, 1997, BIOCHEM J, V321, P525, DOI 10.1042/bj3210525; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; Toomey JR, 1996, BLOOD, V88, P1583; Trousseau A., 1872, LECT CLIN MED DELIVE, P281; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xue JC, 1998, P NATL ACAD SCI USA, V95, P7603, DOI 10.1073/pnas.95.13.7603; ZACHARSKI LR, 1995, THROMB HAEMOSTASIS, V73, P793	66	100	108	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					163	174		10.1096/fj.02-0316com	http://dx.doi.org/10.1096/fj.02-0316com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554695				2022-12-25	WOS:000181456900041
J	Savarino, A; Bensi, T; Chiocchetti, A; Bottarel, F; Mesturini, R; Ferrero, E; Calosso, L; Deaglio, S; Ortolan, E; Butto, S; Cafaro, A; Katada, T; Ensoli, B; Malavasi, F; Dianzani, U				Savarino, A; Bensi, T; Chiocchetti, A; Bottarel, F; Mesturini, R; Ferrero, E; Calosso, L; Deaglio, S; Ortolan, E; Butto, S; Cafaro, A; Katada, T; Ensoli, B; Malavasi, F; Dianzani, U			Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.	FASEB JOURNAL			English	Article						CD4; leukocyte surface antigens; lentiviruses; lymphocytes; antiviral molecules	HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTE SURFACE MOLECULES; T-CELL ACTIVATION; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED CHILDREN; TYPE-1 INFECTION; LIPID RAFTS; CD4; RECEPTOR; BINDING	CD38 is a progression marker in HIV-1 infection, it displays lateral association with CD4, and down-modulates gp120/CD4 binding. The aim of this study was to elucidate the mechanism behind the interplay between CD4, CD38, and HIV-1. We used mouse cell transfectants expressing human CD4 and either CD38 or other CD4-associated molecules to show that CD38 specifically inhibits gp120/CD4 binding. Human cell transfectants expressing truncated forms of CD38 and bioinformatic analysis were used to map the anti-HIV activity and show that it is concentrated in the membrane-proximal region. This region displayed significant sequence-similarity with the V3 loop of the HIV-1 gp120 glycoprotein. In line with this similarity, synthetic soluble peptides derived from this region reproduced the anti-HIV effects of full-length CD38 and inhibited HIV-1 and HIV-2 primary isolates from different subtypes and with different coreceptor use. A multiple-branched peptide construct presenting part of the sequence of the V3-like region potently and selectively inhibited HIV-1 replication in the nanomolar range. Conversely, a deletion in the V3-like region abrogated the anti-HIV-1 activity of CD38 and its lateral association with CD4. These findings may provide new insights into the early events of HIV-1 fusion and strategies to intervene.	A Avogadro Univ Eastern Piedmont, Dept Med Sci, Immunol Lab, Interdisciplinary Res Ctr Autoimmune Dis, I-28100 Novara, Italy; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo, Japan; Ist Super Sanita, Virol Lab, Div Retrovirol, I-00161 Rome, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Turin; University of Tokyo; Istituto Superiore di Sanita (ISS)	Savarino, A (corresponding author), A Avogadro Univ Eastern Piedmont, Dept Med Sci, Immunol Lab, Interdisciplinary Res Ctr Autoimmune Dis, Via Solaroli 17, I-28100 Novara, Italy.	asavarino@medscape.com	Cafaro, Aurelio/K-5314-2016; Dianzani, Umberto/K-1952-2016; Ensoli, Barbara/J-9169-2016; Buttò, Stefano/J-9324-2018	Ensoli, Barbara/0000-0002-0545-8737; Cafaro, Aurelio/0000-0001-9675-6344; Chiocchetti, Annalisa/0000-0002-4349-1087; Butto, Stefano/0000-0002-3289-2686; Savarino, Andrea/0000-0003-0983-3693; MALAVASI, Fabio/0000-0002-1844-174X; ORTOLAN, Erika/0000-0003-2287-9020				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BENJOUAD A, 1995, VIROLOGY, V206, P457, DOI 10.1016/S0042-6822(95)80061-1; Bragardo M, 1997, J IMMUNOL, V159, P1619; Carbone J, 2000, AIDS, V14, P2823, DOI 10.1097/00002030-200012220-00003; Cesano A, 1998, J IMMUNOL, V160, P1106; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; CHOE H, 1996, CELL, V85, P135; Denisova G, 1997, J IMMUNOL, V158, P1157; Dettin M, 1997, BIOCHEM BIOPH RES CO, V241, P584, DOI 10.1006/bbrc.1997.7857; DIANZANI U, 1995, EUR J IMMUNOL, V25, P1306, DOI 10.1002/eji.1830250526; DIANZANI U, 1994, J IMMUNOL, V153, P952; Feito MJ, 1997, INT IMMUNOL, V9, P1141, DOI 10.1093/intimm/9.8.1141; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967; HaraYokoyama M, 1996, J BIOL CHEM, V271, P12951, DOI 10.1074/jbc.271.22.12951; Hoffman NG, 2002, J VIROL, V76, P3852, DOI 10.1128/JVI.76.8.3852-3864.2002; Hoshino S, 1997, J IMMUNOL, V158, P741; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Kaufmann GR, 2000, AIDS, V14, P2643, DOI 10.1097/00002030-200012010-00003; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Levy JA, 2001, TRENDS IMMUNOL, V22, P312, DOI 10.1016/S1471-4906(01)01925-1; Lichtenthaler Hartmut K., METHODS ENZYMOLOGY, P350, DOI [10.1016/0076-6879(87)48036-1, DOI 10.1016/0076-6879(90)84256-G, DOI 10.1016/0076-6879(87)48036-1]; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Moir S, 1996, J VIROL, V70, P8019, DOI 10.1128/JVI.70.11.8019-8028.1996; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Nardese V, 2001, NAT STRUCT BIOL, V8, P611, DOI 10.1038/89653; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Rabehi L, 1998, AIDS RES HUM RETROV, V14, P1605, DOI 10.1089/aid.1998.14.1605; Resino S, 2001, CLIN EXP IMMUNOL, V125, P266, DOI 10.1046/j.1365-2249.2001.01612.x; Roussanov BV, 2000, AIDS, V14, P2715, DOI 10.1097/00002030-200012010-00011; Savarino A, 1999, FASEB J, V13, P2265, DOI 10.1096/fasebj.13.15.2265; Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P47, DOI 10.1002/(SICI)1099-0844(199903)17:1<47::AID-CBF810>3.0.CO;2-V; Savarino A, 2000, AIDS, V14, P1079, DOI 10.1097/00002030-200006160-00004; Savarino A, 2001, AIDS, V15, P2221, DOI 10.1097/00002030-200111230-00002; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; Su J, 2000, AIDS RES HUM RETROV, V16, P37, DOI 10.1089/088922200309584; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tilling R, 2002, AIDS, V16, P589, DOI 10.1097/00002030-200203080-00010; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; Vigano A, 1998, LANCET, V352, P1905, DOI 10.1016/S0140-6736(05)60396-0; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; YAHI N, 1995, P NATL ACAD SCI USA, V92, P4867, DOI 10.1073/pnas.92.11.4867; ZANOTTO C, 1995, VIROLOGY, V206, P807, DOI 10.1006/viro.1995.1003; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zubiaur M, 2002, J BIOL CHEM, V277, P13, DOI 10.1074/jbc.M107474200; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	53	26	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					461	+		10.1096/fj.02-0512fje	http://dx.doi.org/10.1096/fj.02-0512fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551845				2022-12-25	WOS:000181453700001
J	Burnett, JR; Shan, J; Miskie, BA; Whitfield, AJ; Yuan, J; Tran, K; McKnight, CJ; Hegele, RA; Yao, ZM				Burnett, JR; Shan, J; Miskie, BA; Whitfield, AJ; Yuan, J; Tran, K; McKnight, CJ; Hegele, RA; Yao, ZM			A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; HUMAN APOLIPOPROTEIN-B; CARBOXYL-TERMINAL TRUNCATION; MCA-RH7777 CELLS; DECREASED PRODUCTION; LIPID RECRUITMENT; AMINO-TERMINUS; FATTY LIVER; SECRETION	Familial hypobetalipoproteinemia (FHBL), an autosomal co-dominant disorder, is associated with reduced plasma concentrations (<5th percentile for age and sex) of apolipoprotein (apo) B and beta-migrating lipoproteins. To date, only mutations in APOB encoding prematurely truncated apoB have been found in FHBL. We discovered a novel APOB gene mutation, namely R463W, in an extended Christian Lebanese FHBL kindred. Heterozygotes for R463W had the typical FHBL phenotype, whereas homozygotes had barely detectable apoB-100. The effect of the R463W mutation on apoB secretion was examined using transfected McA-RH7777 cells that expressed one of two recombinant human apoBs, namely B48 and B17. In both cases, the mutant proteins (B48RW and B17RW) were retained within the endoplasmic reticulum and were secreted poorly compared with their wild-type counterparts. Pulse-chase analysis showed that secretion efficiencies of B48RW and B17RW were, respectively, 45 and 40% lower than those of the wild-types. Substitution of Arg(463) with Ala in apoB-17 (B17RA) decreased secretion efficiency by similar to50%, but substitution with Lys (B17RK) had no effect on secretion, indicating that the positive charge was important. Molecular modeling of apoB predicted that Arg(463) was in close proximity to Glu(756) and Asp(456). Substitution of Glu(756) with Gln (B17EQ) had no effect on secretion, but substitution of Asp456 with Asn (Bl7DN) decreased secretion to the same extent as B17RW. In co-transfection experiments, the mutant B17RW showed increased binding to microsomal triglyceride transfer protein as compared with wild-type B17. Thus, the naturally occurring R463W mutant reveals a key local domain governing assembly and secretion of apoB-containing lipoproteins.	Univ Western Australia, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia; Univ Western Australia, Dept Pathol, Perth, WA 6847, Australia; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada; John P Robarts Res Inst, London, ON N6A 5K8, Canada; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; Western University (University of Western Ontario); Boston University	Burnett, JR (corresponding author), Univ Western Australia, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia.		Hegele, Robert/G-3301-2011; Hooper, Amanda J/H-7757-2014; Hegele, Robert/AAF-6482-2020	Hegele, Robert/0000-0003-2861-5325; McKnight, Christopher/0000-0002-3237-0896				AGUILARSALINAS CA, 1995, ARTERIOSCL THROM VAS, V15, P71, DOI 10.1161/01.ATV.15.1.71; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; BURGESS WH, 2000, J BIOL CHEM, V275, P16267; BURNETT JR, 1993, MED J AUSTRALIA, V159, P272, DOI 10.5694/j.1326-5377.1993.tb137834.x; Cham BE, 1999, CLIN CHIM ACTA, V287, P45, DOI 10.1016/S0009-8981(99)00117-5; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; Elias N, 1999, ARTERIOSCL THROM VAS, V19, P2714, DOI 10.1161/01.ATV.19.11.2714; ELOVSON J, 1988, J LIPID RES, V29, P1461; Gabelli C, 1996, ARTERIOSCL THROM VAS, V16, P1189, DOI 10.1161/01.ATV.16.9.1189; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hegele RA, 2001, AM J HUM GENET, V69, P1161, DOI 10.1086/324647; Herscovitz H, 2001, J LIPID RES, V42, P51; HIXSON JE, 1990, J LIPID RES, V31, P545; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Kane JP, 2001, METABOLIC MOL BASES; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LINTON MF, 1993, J LIPID RES, V34, P521; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MCCORMICK SPA, 1992, BIOCHIM BIOPHYS ACTA, V1138, P290, DOI 10.1016/0925-4439(92)90006-9; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; Ogata H, 1997, AM J GASTROENTEROL, V92, P339; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; Parhofer KG, 1996, J LIPID RES, V37, P844; Pulai JI, 1998, AM J MED GENET, V76, P79, DOI 10.1002/(SICI)1096-8628(19980226)76:1<79::AID-AJMG15>3.3.CO;2-E; RICKWOOD D, 1982, ANAL BIOCHEM, V123, P23, DOI 10.1016/0003-2697(82)90618-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARROCK WJ, 1992, J MOL BIOL, V226, P903, DOI 10.1016/0022-2836(92)90642-W; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Tarugi P, 2000, J HEPATOL, V33, P361, DOI 10.1016/S0168-8278(00)80270-6; Tarugi P, 2001, J LIPID RES, V42, P1552; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Welty FK, 1997, ARTERIOSCL THROM VAS, V17, P881, DOI 10.1161/01.ATV.17.5.881; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yao ZM, 1997, J LIPID RES, V38, P1937; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	57	66	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13442	13452		10.1074/jbc.M300235200	http://dx.doi.org/10.1074/jbc.M300235200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551903	hybrid			2022-12-25	WOS:000182189500107
J	Ju, M; Stevens, L; Leadbitter, E; Wray, D				Ju, M; Stevens, L; Leadbitter, E; Wray, D			The roles of N- and C-terminal determinants in the activation of the Kv2.1 potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; TETRAMERIZATION DOMAIN; T1 DOMAIN; RAT-BRAIN; VOLTAGE; PERSPECTIVE; EXPRESSION; RESIDUES; MOVEMENT; CLONING	The human and rat forms of the Kv2.1 channel have identical amino acids over the membrane-spanning regions and differ only in the N- and C-terminal intracellular regions. Rat Kv2.1 activates much faster than human Kv2.1. Here we have studied the role of the N- and C-terminal residues that determine this difference in activation kinetics between the two channels. For this, we constructed mutants and chimeras between the two channels, expressed them in oocytes, and recorded currents by two-electrode voltage clamping. In the N-terminal region, mutation Q67E in the rat channel displayed a slowing of activation relative to rat wild type, whereas mutation D75E in the human channel showed faster activation than human wild type. In the C-terminal region, we found that some residues within the region of amino acids 740-853 ("CTA" domain) were also involved in determining activation kinetics. The electrophysiological data also suggested interactions between the N and C termini. Such an interaction was confirmed directly by using a glutathione S-transferase (GST) fusion protein with the N terminus of Kv2.1, which we showed to bind to the C terminus of Kv2.1. Taken together, these data suggest that exposed residues in the T1 domain of the N terminus, as well as the CTA domain in the C terminus, are important in determining channel activation kinetics and that these N- and C-terminal regions interact.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Wray, D (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.							ALBRECHT B, 1993, RECEPTOR CHANNEL, V1, P99; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; Bezanilla F, 2002, J GEN PHYSIOL, V120, P465, DOI 10.1085/jgp.20028660; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; CATTERALL WA, 2002, IUPHAR COMPENDIUM VO, P86; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Elkes DA, 1997, NEURON, V19, P165, DOI 10.1016/S0896-6273(00)80356-6; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Jones PA, 2001, FEBS LETT, V508, P85, DOI 10.1016/S0014-5793(01)03023-X; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kurata HT, 2002, J BIOL CHEM, V277, P29045, DOI 10.1074/jbc.M111470200; Liu TI, 2001, J NEUROPHYSIOL, V85, P61, DOI 10.1152/jn.2001.85.1.61; Marten I, 1997, P NATL ACAD SCI USA, V94, P3448, DOI 10.1073/pnas.94.7.3448; Milligan CJ, 2000, BIOPHYS J, V78, P1852, DOI 10.1016/S0006-3495(00)76734-8; Minor DL, 2001, CURR OPIN STRUC BIOL, V11, P408, DOI 10.1016/S0959-440X(00)00225-6; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Packer Jeremy, 2000, Trends in Pharmacological Sciences, V21, P327, DOI 10.1016/S0165-6147(00)01527-3; Pascual JM, 1997, AM J PHYSIOL-CELL PH, V273, pC1849, DOI 10.1152/ajpcell.1997.273.6.C1849; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; WRAY D, 2001, PHARM NEWS, V8, P12; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797	30	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12769	12778		10.1074/jbc.M212973200	http://dx.doi.org/10.1074/jbc.M212973200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560340	hybrid			2022-12-25	WOS:000182189500025
J	Picher, M; Burch, LH; Hirsh, AJ; Spychala, J; Boucher, RC				Picher, M; Burch, LH; Hirsh, AJ; Spychala, J; Boucher, RC			Ecto 5 '-nucleotidase and nonspecific alkaline phosphatase - Two amp-hydrolyzing ectoenzymes with distinct roles in human airways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASAL EPITHELIAL-CELLS; CYSTIC-FIBROSIS; ATP RELEASE; CHLORIDE SECRETION; EXTRACELLULAR ATP; MUCIN SECRETION; APICAL MEMBRANE; ION-TRANSPORT; HUMAN-LUNG; ADENOSINE	In human airways, extracellular adenosine regulates epithelial functions supporting mucociliary clearance, an important airway defense mechanism against bacterial infection. Thus, defining the mechanisms of adenosine generation is critical for elucidating the role of this nucleoside in airway homeostasis. In this study, we identified the source of adenosine on the mucosal surface of human airway epithelia. Polarized primary cultures of human nasal or bronchial epithelial cells were assayed for transepithelial transport, cytosolic and cell surface adenosine production. Ussing chamber experiments indicated that serosal 1 muM [H-3]adenosine was not transported to the mucosal compartment. Messenger RNA for the cytosolic AMP-specific 5'-nucleotidase (CN-I) was not detected in human bronchial epithelial cells, suggesting that mucosal adenosine did not originate from intracellular pools. In contrast, extracellular 0.1 mM ATP was rapidly dephosphorylated into adenosine on the mucosal epithelial surface. We identified two ectonucleotidases that mediated the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline phosphatase (AP). Both mucosal and serosal epithelial surfaces displayed ecto 5'-NT activity (K-m = 14 muM, V-max = 0.5 nmol.min(-1) .cm(-2)), whereas AP activity was restricted to the mucosal surface (K-m,high = 36 muM, V-max = = 717 muM, V-max = 2.8 nmol.min(-1).cm(-2) K-m,K-low = min(-1).cm(-2)). In bronchial cultures and tissues, ecto 5'-NT accounted for >80% of total activity toward 0.01 mM AMP, compared with < 15% for 5 mm AMP. The proximal airway AP isoform was identified as nonspecific AP (NS AP) by levamisole sensitivity and mRNA expression. The two ectoenzymes presented opposite airway distributions, ecto 5'-NT and NS AP mRNA dominating in higher and lower airways, respectively. Collectively, these experiments support a major role for extracellular nucleotide catalysis and for ecto 5'-NT and NS AP in the regulation of adenosine concentrations on airway surfaces.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Dept Pulm & Crit Care Med, Durham, NC 27710 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University; University of North Carolina; University of North Carolina Chapel Hill	Picher, M (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, 7010 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.				PHS HHS [34322] Funding Source: Medline; ODCDC CDC HHS [CCF R026, CCF R001] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ODCDC CDC HHS		Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; BELFIELD A, 1968, NATURE, V219, P73, DOI 10.1038/219073a0; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Braun N, 1998, J COMP NEUROL, V393, P528, DOI 10.1002/(SICI)1096-9861(19980420)393:4<528::AID-CNE10>3.0.CO;2-L; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; Capelli A, 1997, AM J RESP CRIT CARE, V155, P249, DOI 10.1164/ajrccm.155.1.9001320; Cass C E, 1999, Pharm Biotechnol, V12, P313; Chandrasena G, 1997, BIOCHEM PHARMACOL, V53, P1909, DOI 10.1016/S0006-2952(97)00170-6; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; Clancy JP, 1999, AM J PHYSIOL-CELL PH, V276, pC361, DOI 10.1152/ajpcell.1999.276.2.C361; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; Davis CW, 1997, PULM PHARMACOL THER, V10, P145, DOI 10.1006/pupt.1997.0088; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; EVANS WH, 1973, BIOCHEM J, V133, P189, DOI 10.1042/bj1330189; FEDDE KN, 1988, ARCH BIOCHEM BIOPHYS, V264, P400, DOI 10.1016/0003-9861(88)90305-0; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; FORTUNA R, 1980, CALCIFIED TISSUE INT, V30, P217, DOI 10.1007/BF02408631; FYFE GK, 1994, BBA-MOL CELL RES, V1224, P355, DOI 10.1016/0167-4889(94)90268-2; GALIETTA LJV, 1992, FEBS LETT, V304, P61, DOI 10.1016/0014-5793(92)80589-9; GATZY JT, 1975, AM J PHYSIOL, V228, P1162, DOI 10.1152/ajplegacy.1975.228.4.1162; GOLDSTEIN DJ, 1982, CLIN CHIM ACTA, V125, P63, DOI 10.1016/0009-8981(82)90046-8; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; HENDERSON RF, 1984, ENVIRON HEALTH PERSP, V56, P115, DOI 10.2307/3429841; HIRSH AJ, 2001, PEDIATR PULM, V22, P241; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; LAZAROWSKI ER, 2001, PEDIATR PULM, V22, P239; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LEHIR M, 1989, ENZYME, V41, P87, DOI 10.1159/000469058; LEHIR M, 1985, RENAL PHYSIOL BIOCH, V8, P321; LEHIR M, 1993, AM J PHYSIOL, V264, pF377, DOI 10.1152/ajprenal.1993.264.3.F377; LIEB T, 2001, J PHYSL, V538, P633; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485, DOI 10.1152/ajpcell.2001.280.6.C1485; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; NOUWEN EJ, 1986, CANCER RES, V46, P866; NOUWEN EJ, 1990, CELL TISSUE RES, V260, P321, DOI 10.1007/BF00318635; Orlati S, 2000, ARCH BIOCHEM BIOPHYS, V375, P69, DOI 10.1006/abbi.1999.1589; Otero M, 2000, MOL CELL BIOCHEM, V205, P115, DOI 10.1023/A:1007018001735; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314, DOI 10.1152/ajpgi.1997.272.6.G1314; PICHER M, 2001, DRUG DEVELOP RES, V23, P255; PICHER M, 2001, PEDIATR PULM, V22, P242; PIZAURO JM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P22, DOI 10.1016/0167-4838(93)90058-Y; Poelstra K, 1997, LAB INVEST, V76, P319; Polosa R, 2002, THORAX, V57, P649, DOI 10.1136/thorax.57.7.649; Pragnacharyulu PVP, 2000, J MED CHEM, V43, P4694, DOI 10.1021/jm0002533; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; SONG CS, 1967, J BIOL CHEM, V242, P694; STEFANOVIC V, 1988, RENAL PHYSIOL BIOCH, V11, P89; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; STUTTS MJ, 1994, AM J PHYSIOL, V267, pC1444; SUGIURA M, 1975, CHEM PHARM BULL, V23, P2369; SUGIURA M, 1976, CHEM PHARM BULL, V2, P1698; SUNDERMAN FW, 1990, ANN CLIN LAB SCI, V20, P123; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; TURNAY J, 1992, MOL CELL BIOCHEM, V117, P23; VANBELLE H, 1976, CLIN CHEM, V22, P972; VANHOOF VO, 1994, CRIT REV CL LAB SCI, V31, P197, DOI 10.3109/10408369409084677; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watkins DN, 1997, BRIT J PHARMACOL, V121, P1482; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; WU R, 1985, AM REV RESPIR DIS, V132, P311; YOUNG GP, 1981, BIOCHIM BIOPHYS ACTA, V676, P257, DOI 10.1016/0304-4165(81)90194-X; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	79	147	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13468	13479		10.1074/jbc.M300569200	http://dx.doi.org/10.1074/jbc.M300569200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560324	hybrid			2022-12-25	WOS:000182189500110
J	Sarandeses, CS; Covelo, G; Diaz-Jullien, C; Freire, M				Sarandeses, CS; Covelo, G; Diaz-Jullien, C; Freire, M			Prothymosin alpha is processed to thymosin alpha(1) and thymosin alpha(11) by a lysosomal asparaginyl endopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MESSENGER-RNA; HISTONE H1; THYMOSIN; THYMUS; CLEAVAGE; PEPTIDE; IDENTIFICATION; PURIFICATION; LEGUMAIN	Thymosin alpha(1) (Talpha(1)) and thymosin Talpha(11) (Talpha(11)) are polypeptides with immunoregulatory properties first isolated from thymic extracts, corresponding to the first 28 and 35 amino acid residues, respectively, of prothymosin a (ProTalpha), a protein involved in chromatin remodeling. It has been widely supposed that these polypeptides are not natural products of the in vivo processing of ProTalpha, since neither was found in extracts in which proteolysis was prevented. Here we show that a lysosomal asparaginyl endopeptidase is able to process ProTalpha to generate Talpha(1) and Talpha(11). In view of its catalytic properties and structural and immunological analyses, this protease was identified as mammalian legumain. It selectively cleaves some of the asparaginyl-glycine residues in the ProTa sequence; specifically, Asn(28)-Gly(29) and Asn(35)-Gly(36) residues are cleaved with similar efficiency in vitro to generate Talpha(1) and Talpha(11), respectively. By contrast Talpha(1) is the main product detected in vivo, free in the cytosol, at concentrations similar to that of ProTalpha. The data here reported demonstrate that Talpha(1) is not an artifact but rather is naturally present in diverse mammalian tissues and raise the possibility that it has a functional role.	Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain	Universidade de Santiago de Compostela	Freire, M (corresponding author), Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain.	bnfreire@usc.es	Diaz-Jullien, Cristina/L-4575-2018	Diaz-Jullien, Cristina/0000-0002-4307-8129; Sarandeses da Costa, Concepcion Sofia/0000-0002-0299-7129				BARCIA MG, 1993, J BIOL CHEM, V268, P4704; CALDARELLA J, 1983, P NATL ACAD SCI-BIOL, V80, P7424, DOI 10.1073/pnas.80.24.7424; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Enkemann SA, 2000, J CELL PHYSIOL, V182, P256, DOI 10.1002/(SICI)1097-4652(200002)182:2<256::AID-JCP15>3.0.CO;2-N; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; Evstafieva AG, 2000, FEBS LETT, V467, P150, DOI 10.1016/S0014-5793(00)01139-X; FRANCO FJ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P43, DOI 10.1016/0167-4838(92)90422-A; Freire J, 2001, BIOCHEM CELL BIOL, V79, P123, DOI 10.1139/bcb-79-2-123; FREIRE M, 1985, ARCH BIOCHEM BIOPHYS, V239, P480, DOI 10.1016/0003-9861(85)90715-5; FREIRE M, 1981, P NATL ACAD SCI-BIOL, V78, P192, DOI 10.1073/pnas.78.1.192; FREIRE M, 1978, P NATL ACAD SCI USA, V75, P6007, DOI 10.1073/pnas.75.12.6007; FREIRE M, 2002, RECENT RES DEV PROTE, V1, P257; GOLDSTEIN AL, 1977, P NATL ACAD SCI USA, V74, P725, DOI 10.1073/pnas.74.2.725; GOLDSTEIN AL, 1972, P NATL ACAD SCI USA, V69, P1800, DOI 10.1073/pnas.69.7.1800; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW TLK, 1979, J BIOL CHEM, V254, P981; LOW TLK, 1985, METHOD ENZYMOL, V116, P213; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; MANROW RE, 1991, J BIOL CHEM, V266, P3916; PAN LX, 1986, ARCH BIOCHEM BIOPHYS, V250, P197, DOI 10.1016/0003-9861(86)90717-4; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Perez-Estevez A, 2000, MOL CELL BIOCHEM, V208, P111, DOI 10.1023/A:1007050206653; PerezEstevez A, 1997, J BIOL CHEM, V272, P10506; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9	37	63	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13286	13293		10.1074/jbc.M213005200	http://dx.doi.org/10.1074/jbc.M213005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12554742	hybrid			2022-12-25	WOS:000182189500088
J	Basuroy, S; Sheth, P; Kuppuswamy, D; Balasubramanian, S; Ray, RM; Rao, RK				Basuroy, S; Sheth, P; Kuppuswamy, D; Balasubramanian, S; Ray, RM; Rao, RK			Expression of kinase-inactive c-Src delays oxidative stress-induced disassembly and accelerates calcium-mediated reassembly of tight junctions in the Caco-2 cell monolayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; INDUCED DISRUPTION; HYDROGEN-PEROXIDE; BARRIER FUNCTION; GROWTH-FACTOR; ACTIVATION; OCCLUDIN; PERMEABILITY; DISSOCIATION; ORGANIZATION	The activity of Src kinases appears to play a role in both assembly and disassembly of tight junction. However, the robe of a specific isoform. of Src kinase in regulation of tight junction is not known. In the present study the role of c-Src in regulation of epithelial tight junction was investigated in Caco-2 cell monolayers. Oxidative stress (xanthine oxidase + xanthine) induced an activation and membrane translocation of c-Src. The oxidative stress-induced decrease in transepithelial electrical resistance, increase in inulin permeability, and redistribution of occludin and ZO-1 from the intercellular junctions were prevented by PP2. The rates of oxidative stress-induced activation of c-Src, tyrosine phosphorylation of ZO-1 and beta-catenin, decrease in resistance, increase in permeability to inulin, and redistribution of occludin and ZO-1 were significantly greater in cells transfected with wild type c-Src, whereas it was low in cells transfected with kinase-inactive c-SrcK297R mutant, when compared with those in empty vector-transfected cells. The rates of recovery of resistance, increase in barrier to inulin, and reorganization of occludin and ZO-1 into the intercellular junctions during the calcium-induced reassembly of tight junction were much greater in Caco-2 cells transfected with c-SrcK297R as compared with those in cells transfected with empty vector or wild type c-Src. These results show that the dominant-negative expression of kinase-inactive c-Src delays the oxidative stress-induced disruption of tight junction and accelerates calcium induced assembly of tight junction in Caco-2 cells and demonstrate that oxidative stress-induced disruption of tight junction is mediated by the activation of c-Src.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, RK (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Rm 426, Memphis, TN 38163 USA.	rkrao@physio1.utmem.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012307] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA012307, R01-AA12307] Funding Source: Medline; NIDDK NIH HHS [R01-DK55532, R01 DK055532] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Atkinson KJ, 2001, AM J PHYSIOL-GASTR L, V280, pG1280, DOI 10.1152/ajpgi.2001.280.6.G1280; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V91, P83; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Collares-Buzato CB, 1998, EUR J CELL BIOL, V76, P85, DOI 10.1016/S0171-9335(98)80020-4; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gomez S, 1999, BBA-MOL CELL RES, V1452, P121, DOI 10.1016/S0167-4889(99)00124-X; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Grisendi S, 1998, J CELL PHYSIOL, V176, P465, DOI 10.1002/(SICI)1097-4652(199809)176:3<465::AID-JCP3>3.0.CO;2-M; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Ihara Y, 2002, BIOCHEM BIOPH RES CO, V297, P353, DOI 10.1016/S0006-291X(02)02195-2; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Meyer TN, 2001, J BIOL CHEM, V276, P22048, DOI 10.1074/jbc.M011477200; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rao RK, 1997, AM J PHYSIOL-GASTR L, V273, pG812, DOI 10.1152/ajpgi.1997.273.4.G812; Rao RK, 2000, AM J PHYSIOL-GASTR L, V279, pG332, DOI 10.1152/ajpgi.2000.279.2.G332; Ries J, 1997, AM J PHYSIOL-CELL PH, V272, pC794, DOI 10.1152/ajpcell.1997.272.3.C794; Sato K, 2001, DEV GROWTH DIFFER, V43, P55; STADDON JM, 1995, J CELL SCI, V108, P609; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Trischitta F, 2001, J COMP PHYSIOL B, V171, P85, DOI 10.1007/s003600000152; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yap AS, 1997, ENDOCRINOLOGY, V138, P2315, DOI 10.1210/en.138.6.2315	41	139	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11916	11924		10.1074/jbc.M211710200	http://dx.doi.org/10.1074/jbc.M211710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547828	hybrid			2022-12-25	WOS:000182015700027
J	Lanning, CC; Ruiz-Velasco, R; Williams, CL				Lanning, CC; Ruiz-Velasco, R; Williams, CL			Novel mechanism of the co-regulation of nuclear transport of SmgGDS and rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; GTP EXCHANGE PROTEIN; RHO-FAMILY; ACTIVATION; INTERACTS; CATENIN; IDENTIFICATION; LOCALIZATION; PRENYLATION; REPEATS	The armadillo protein SmgGDS promotes guanine nucleotide exchange by small GTPases containing a C-terminal polybasic region (PBR), such as Rac1 and RhoA. Because the PBR resembles a nuclear localization signal (NLS) sequence, we investigated the nuclear transport of SmgGDS with Rac1 or RhoA. We show that the Rac1 PBR has significant NLS activity when it is fused to green fluorescent protein (GFP) or in the context of full-length Rac1. In contrast, the RhoA PBR has very poor NLS activity when it is fused to GFP or in the context of full-length RhoA. The nuclear accumulation of both Rac1 and SmgGDS is enhanced by Rac1 activation and diminished by mutation of the Rac1 PBR. Conversely, SmgGDS nuclear accumulation is diminished by interactions with RhoA. An SmgGDS nuclear export signal sequence that we identified promotes SmgGDS nuclear export. These results suggest that SmgGDS-Rac1 complexes accumulate in the nucleus because the Rac1 PBR has NLS activity and because Rac1 supplies the appropriate GTP-dependent signal. In contrast, SmgGDS(.)RhoA complexes accumulate in the cytoplasm because the RhoA PBR does not have NLS activity. This model may be applicable to other armadillo proteins in addition to SmgGDS, because we demonstrate that activated Rac1 and RhoA also provide stimulatory and inhibitory signals, respectively, for the nuclear accumulation of p120 catenin. These results indicate that small GTPases with a PBR can regulate the nuclear transport of armadillo proteins.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, 1 Guthrie Square, Sayre, PA 18840 USA.	williams_carol@guthrie.org			NHLBI NIH HHS [R01 HL063921, R01 HL63921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Goodwin DJ, 2001, J BIOL CHEM, V276, P19905, DOI 10.1074/jbc.M009513200; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P237; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; KOTANI K, 1992, ONCOGENE, V7, P1699; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; KUDO N, 1996, P NTL ACAD SCI US, V96, P9112; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; ORITA S, 1993, J BIOL CHEM, V268, P25542; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Ruiz-Velasco R, 2002, J BIOL CHEM, V277, P33081, DOI 10.1074/jbc.M202664200; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Shafer SH, 1999, EXP CELL RES, V248, P148, DOI 10.1006/excr.1998.4385; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Strassheim D, 1999, J BIOL CHEM, V274, P18675, DOI 10.1074/jbc.274.26.18675; Strassheim D, 2000, J BIOL CHEM, V275, P6699, DOI 10.1074/jbc.275.10.6699; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Vithalani KK, 1998, MOL BIOL CELL, V9, P3095, DOI 10.1091/mbc.9.11.3095; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	38	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12495	12506		10.1074/jbc.M211286200	http://dx.doi.org/10.1074/jbc.M211286200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551911	hybrid			2022-12-25	WOS:000182015700101
J	Gotte, G; Vottariello, F; Libonati, M				Gotte, G; Vottariello, F; Libonati, M			Thermal aggregation of ribonuclease A - A contribution to the understanding of the role of 3D domain swapping in protein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; RNASE; DIMER	By lyophilizing RNase A from 40% acetic acid solutions, two dimeric aggregates, the "minor" and "major" dimers (named here N-dimer and C-dimer, respectively), form by 3D domain swapping at. a ratio of 1:4. Trimeric and tetrameric aggregates are also obtained. The two dimers and the higher oligomers also form without a lyophilization step. By keeping IRNase A dissolved at a high concentration (generally 200 mg/ml) in various media at temperatures ranging from 23 to 70 degreesC for times varying from a few minutes to 2 h, various oligomers, in particular the two dimeric conformers, formed in quite different amounts, often inverting their relative quantities depending on the more or less severe unfolding conditions. When unfolding mainly concerned the N terminus of the protein, richer in hydrophilic residues, the N-dimer, formed by 3D domain swapping of the N-terminal alpha-helix of each monomer, prevailed over the C-dimer. Under more vigorous denaturing conditions, where also the C terminus of RNase A, richer in hydrophobic amino acids, unfolded, the C-dimer, formed by 3D domain swapping of the C-terminal beta-strand, prevailed over the other, possibly because of the induction to aggregation promoted by the hydrophobic residues present in the C termini of the two monomers.	Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Visione, I-87134 Verona, Italy	University of Verona	Libonati, M (corresponding author), Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Visione, Strada Grazie 8, I-87134 Verona, Italy.	massimo.libonati@univr.it		Gotte, Giovanni/0000-0003-3179-7158				BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Juminaga D, 1997, BIOCHEMISTRY-US, V36, P10131, DOI 10.1021/bi970711i; Juneja J, 2002, BIOCHEMISTRY-US, V41, P2641, DOI 10.1021/bi011480p; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; LIBONATI M, 1969, Italian Journal of Biochemistry (English Edition), V18, P407; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; MARZOTTO A, 1970, ARCH BIOCHEM BIOPHYS, V137, P373, DOI 10.1016/0003-9861(70)90451-0; Neira JL, 1999, J MOL BIOL, V285, P627, DOI 10.1006/jmbi.1998.2365; Nenci A, 2001, PROTEIN SCI, V10, P2017, DOI 10.1110/ps.14101; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; Park C, 2000, PROTEIN SCI, V9, P2026, DOI 10.1110/ps.9.10.2026; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; RICO M, 1990, P 2 INT M STRUCT MEC, P9; SHINDO H, 1976, J BIOL CHEM, V251, P2648; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; TSONG TY, 1972, P NATL ACAD SCI USA, V69, P1809, DOI 10.1073/pnas.69.7.1809; TSONG TY, 1972, J MOL BIOL, V63, P453, DOI 10.1016/0022-2836(72)90440-8	28	66	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10763	10769		10.1074/jbc.M213146200	http://dx.doi.org/10.1074/jbc.M213146200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533538	hybrid			2022-12-25	WOS:000181777500100
J	Kovacina, KS; Park, GY; Bae, SS; Guzzetta, AW; Schaefer, E; Birnbaum, MJ; Roth, RA				Kovacina, KS; Park, GY; Bae, SS; Guzzetta, AW; Schaefer, E; Birnbaum, MJ; Roth, RA			Identification of a proline-rich Akt substrate as a 14-3-3 binding partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PROTEIN; GROWTH; PHOSPHORYLATION; MAINTENANCE; 3-KINASE; TUBERIN; MICE	Akt (also called protein kinase B) is one of the major downstream targets of the phosphatidylinositol 3-kinase pathway. This protein kinase has been implicated in insulin signaling, stimulation of cellular growth, and inhibition of apoptosis as well as transformation of cells. Although a number of cellular proteins have been identified as putative targets of the enzyme, additional substrates may play a role in the varied responses elicited by this enzyme. We have used a combination of 14-3-3 binding and recognition by an antibody to the phosphorylation consensus of the enzyme to identify and isolate one of the major substrates of Akt, which is also a 14-3-3 binding protein. This 40-kDa protein, designated PRAS40, is a proline-rich Akt substrate. Demonstration that it is a substrate of Akt was accomplished by showing that 1) PRAS40 was phosphorylated in vitro by purified Akt on the same site that was phosphorylated in insulin-treated cells; 2) activation of an inducible Akt was alone sufficient to stimulate the phosphorylation of PRAS40; and 3) cells lacking Akt1 and Akt2 exhibit a diminished ability to phosphorylate this protein. Thus, PRAS40 is a novel substrate of Akt, the phosphorylation of which leads to the binding of this protein to 14-3-3.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Thermo Finnigan, San Jose, CA 95134 USA; Hopkinton Div BioSource Int, Hopkinton, MA 01748 USA	Stanford University; Howard Hughes Medical Institute; University of Pennsylvania	Roth, RA (corresponding author), Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA.	rroth@stanford.edu		Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056886] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56886, DK34976] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lizcano JM, 2002, CURR BIOL, V12, pR236, DOI 10.1016/S0960-9822(02)00777-7; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Masters SC, 2002, BIOCHEM SOC T, V30, P360, DOI 10.1042/bst0300360; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	26	257	272	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10189	10194		10.1074/jbc.M210837200	http://dx.doi.org/10.1074/jbc.M210837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524439	hybrid			2022-12-25	WOS:000181777500028
J	Le Guiner, C; Gesnel, MC; Breathnach, R				Le Guiner, C; Gesnel, MC; Breathnach, R			TIA-1 or TUR is required for DT40 cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; GENE-EXPRESSION; MESSENGER-RNA; INTRON SEQUENCES; BINDING; APOPTOSIS; CLEAVAGE; IDENTIFICATION	TIA-1 and TIAR are a pair of related RNA-binding proteins which have been implicated in apoptosis. We show that chicken DT40 cells with both tia-1 alleles and one tiar allele disrupted (tia-1(-/-)tiar(-/+) cells) are viable. However, their growth and survival in medium containing low serum levels is significantly reduced compared with DT40 cells. The remaining intact tiar allele in tia-1(-/-)tiar(-/+) cells can only be disrupted if TIA-1 expression is first restored to the cells by transfection of a TIA-1 expression vector. We conclude that DT40 cells require either TIA-1 or TIAR for viability. TIA-1 overexpression in tia-1(-/-)tiar(-/+) cells leads to a radical drop in TIAR levels, by inducing efficient splicing of two tiar alternative exons carrying in-frame stop codons. In wild-type DT40 cells, tiar transcripts including these exons can also be detected. These transcripts increase significantly in abundance in cycloheximide-treated cells, suggesting that splicing of the exons exposes mRNAs to nonsense-mediated mRNA decay. TIA-1 or TIAR depletion leads to a marked drop in splicing of the exons. The human tiar gene contains a corresponding pair of TIA-1-inducible alternative exons, and we show that there is very high sequence conservation between chickens and humans of the exon pair and parts of the flanking introns. The TIA-1/TIAR responsiveness of these alternative tiar exons is likely to be of physiological importance for controlling TIAR levels.	CHR, INSERM, U463, Inst Biol, F-44093 Nantes 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	Breathnach, R (corresponding author), CHR, INSERM, U463, Inst Biol, 9 Quai Moncousu, F-44093 Nantes 1, France.	breathna@nantes.inserm.fr	Breathnach, Richard/K-7599-2015					Anderson P, 1995, Curr Top Microbiol Immunol, V198, P131; Anderson P, 2002, CELL STRESS CHAPERON, V7, P213, DOI 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2; Anderson P, 2002, J CELL SCI, V115, P3227; Anderson P, 2000, ANN RHEUM DIS, V59, P3; Beck ARP, 1998, P NATL ACAD SCI USA, V95, P2331, DOI 10.1073/pnas.95.5.2331; Buerstedde JM, 2002, NUCLEIC ACIDS RES, V30, P230, DOI 10.1093/nar/30.1.230; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Degen WGJ, 2000, CELL DEATH DIFFER, V7, P70, DOI 10.1038/sj.cdd.4400617; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2001, RNA, V7, P1185, DOI 10.1017/S1355838201010536; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; Iseni F, 2002, EMBO J, V21, P5141, DOI 10.1093/emboj/cdf513; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Jin KL, 2001, ANN NEUROL, V50, P93, DOI 10.1002/ana.1073; KAWAKAMI A, 1994, J IMMUNOL, V152, P4937; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Li W, 2002, J VIROL, V76, P11989, DOI 10.1128/JVI.76.23.11989-12000.2002; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; Osborne NN, 1997, INVEST OPHTH VIS SCI, V38, P1390; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Saito K, 2001, ARTHRITIS RHEUM-US, V44, P2879, DOI 10.1002/1529-0131(200112)44:12<2879::AID-ART476>3.0.CO;2-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sonoda E, 2001, PHILOS T ROY SOC B, V356, P111, DOI 10.1098/rstb.2000.0755; Sureau A, 2001, EMBO J, V20, P1785, DOI 10.1093/emboj/20.7.1785; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Tsuzuki S, 2001, INSECT BIOCHEM MOLEC, V31, P321, DOI 10.1016/S0965-1748(00)00124-7; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; Yu Q, 2003, J BIOL CHEM, V278, P1579, DOI 10.1074/jbc.M203526200	46	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10465	10476		10.1074/jbc.M212378200	http://dx.doi.org/10.1074/jbc.M212378200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533540	hybrid			2022-12-25	WOS:000181777500064
J	Staudinger, R; Phogat, SK; Xiao, XD; Wang, XH; Dimitrov, DS; Zolla-Pazner, S				Staudinger, R; Phogat, SK; Xiao, XD; Wang, XH; Dimitrov, DS; Zolla-Pazner, S			Evidence for CD4-enchanced signaling through the chemokine receptor CCR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1; INFECTION; FUSION; CD4; IDENTIFICATION; CORECEPTOR; COMPONENT; DOPAMINE; ANTIGEN; BINDING	The chemokine receptor CCR5 is constitutively associated with the T cell co-receptor CD4 in plasma cell membranes, but the physiological role of this interaction has not been elucidated. Here we show that detergent-solubilized, purified CCR5 can directly associate with purified soluble fragments of the extracellular portion of CD4. We further demonstrate that the physical association of CCR5 and CD4 in membrane vesicles results in the formation of a receptor complex that exhibits macrophage inflammatory protein 1beta (MIP-1beta) binding properties that are distinct from CCR5. The affinity of the CD4-CCR5 complex for MIP-1beta was 3.5-fold lower than for CCR5, but the interaction of CD4 and CCR5 resulted in a receptor complex that exhibited enhanced G-protein signaling as compared with CCR5 alone. MIP1beta-induced G-protein activation was further increased by simultaneous stimulation of CD4 with its natural agonist, interleukin-16. Thus, the physical association of CD4 and CCR5 results in receptor cross-talk with allosteric CD4-dependent regulation of the binding and signaling properties of CCR5. Although the precise physiological role of the CD4 effects on CCR5-mediated signaling remains unknown, one can speculate that the cross-talk is a component of mechanisms involved in the fine tuning of immune system cell responses.	NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, NIH, Ft Detrick, MD 21702 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Vet Affairs New York Harbor Healthcare Syst, New York, NY 10016 USA	New York University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; New York University; New York University	Staudinger, R (corresponding author), NYU, Sch Med, Dept Neurol, 550 1st Ave,NBV 7W11, New York, NY 10016 USA.	robert.staudinger@med.nyu.edu	Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036085, P30AI027742] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59725] Funding Source: Medline; NIAID NIH HHS [AI27742, AI36085] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Beckner SK, 1997, METHOD ENZYMOL, V288, P309; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; EVANS SW, 1987, NATURE, V325, P166, DOI 10.1038/325166a0; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; Mashikian MV, 1999, J IMMUNOL, V163, P3123; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Mueller A, 2002, BRIT J PHARMACOL, V135, P1033, DOI 10.1038/sj.bjp.0704540; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Staudinger R, 2001, BIOCHEM BIOPH RES CO, V286, P41, DOI 10.1006/bbrc.2001.5345; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Willett BJ, 1997, NATURE, V385, P587, DOI 10.1038/385587a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496	29	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10389	10392		10.1074/jbc.M212013200	http://dx.doi.org/10.1074/jbc.M212013200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531905	hybrid			2022-12-25	WOS:000181777500054
J	Peng, AM; Chen, PL				Peng, AM; Chen, PL			NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY PARTICIPANT; HISTONE H2AX; PROTEIN; REPAIR; BRCT; RAD9	Signaling pathways in response to DNA double strand breaks involve molecular cascades consisting of sensors, transducers, and effector proteins that activate cell cycle checkpoints and recruit repair machinery proteins. NFBD1 (a nuclear factor with BRCT domains protein 1) contains FRA ((f) under bar ork (h) under bar ead-(a) under bar ssociated), BRCT ((br) under bar east cancer susceptibility gene 1 carboxyl terminus) domains, and internal repeats and is an early participant in nuclear foci in response to IR. To elucidate its role in the response pathways, small interfering RNA (siRNA) directed against NFDB1 in human cells demonstrated that its absence is associated with increased radio-sensitivity and delayed G(2)/M transition, but not G(1) to S. NFBD1 associates with nuclear foci within minutes following 111, a property similar to histone H2AX, 53BP1, and Chk2, which are all early participants in the DNA damage signaling cascade. Temporal studies show that H2AX is required for the foci positive for NFBD1, but NFBD1 is not needed for 53BP1- and H2AX-positive foci. NFBD1, together with 53BP1, plays a partially redundant role in regulating phosphorylation of the downstream effector protein, Chk2; since abrogation of both diminishes phosphorylated Chk2 in IR-induced foci. These results place NFBD1 parallel to 53BP1 in regulating Chk2 and downstream of H2AX in the recruitment of repair and signaling proteins to sites of DNA damage.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	chenp0@uthscsa.edu		Chen, Phang-Lang/0000-0002-0357-9017	NATIONAL CANCER INSTITUTE [R01CA085605] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	21	83	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8873	8876		10.1074/jbc.C300001200	http://dx.doi.org/10.1074/jbc.C300001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12551934	hybrid			2022-12-25	WOS:000181524000002
J	Heinrichs, S; Deppert, W				Heinrichs, S; Deppert, W			Apoptosis or growth arrest: modulation of the cellular response to p53 by proliferative signals	ONCOGENE			English	Article						p53; p21; apoptosis; growth arrest; lymphoid tumors	NF-KAPPA-B; WILD-TYPE P53; MITOCHONDRIAL PERMEABILITY TRANSITION; KINASE C-THETA; P53-MEDIATED APOPTOSIS; BCL-X; P53-DEPENDENT APOPTOSIS; CALCIUM IONOPHORES; PHORBOL ESTER; CYCLE ARREST	Activation of the tumor suppressor p53 after genotoxic insults may result in two different responses: growth arrest or apoptosis. In this study, we analysed how mitogenic stimulation of primary mouse lymphocytes influences p53 signaling upon gamma-irradiation. We found that Go lymphocytes rapidly went into p53-dependent apoptosis, whereas stimulated lymphocytes went into a p53-dependent, p21-mediated growth arrest. The switch in p53 response upon stimulation did neither result from a switch in transcriptional activation of major p53 target genes, nor from the high level of p21 expressed in stimulated, irradiated cells. Growth stimulation, however, led to the upregulation of the antiapoptotic factors Bcl-x(L) and Bfl-1. In resting cells, p53 induced apoptosis after gamma-irradiation was accompanied by a breakdown of the mitochondrial membrane potential (Psi(m)) that was counteracted by growth stimulation. We propose that growth stimulation intercepted p53 proapoptotic signaling at the level of mitochondrial integrity, most likely by upregulating the antiapoptotic factors Bcl-x(L) and Bfl-1. Upregulation of Bcl-x(L) and of Bfl-1 upon growth stimulation was mediated by the PKC-dependent activation of NF-kappaB. Consequently, blocking PKC activity restored apoptosis in stimulated, irradiated splenocytes. The inherent coupling of growth stimulation with antiapoptotic signaling in primary lymphocytes might provide hints as to how precancerous lymphocytes bypass the need for mutational inactivation of p53. Thus, our findings might explain the relatively low frequency of p53 mutations in lymphomas in comparison to other tumor entities.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BROOME HE, 1995, J IMMUNOL, V155, P2311; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Castedo M, 1996, J IMMUNOL, V157, P512; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; DOSCH HM, 1980, J IMMUNOL, V125, P827; Drexler HG, 2000, LEUKEMIA, V14, P198, DOI 10.1038/sj.leu.2401604; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAWRYLOWICZ CM, 1984, IMMUNOLOGY, V53, P703; Henry H, 2002, ONCOGENE, V21, P748, DOI 10.1038/sj.onc.1205125; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KASTAN MB, 1991, CANCER RES, V51, P6304; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; LI YS, 1989, EUR J IMMUNOL, V19, P1721, DOI 10.1002/eji.1830190929; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NOVOGRODSKY A, 1971, BIOCHIM BIOPHYS ACTA, V228, P579, DOI 10.1016/0005-2787(71)90064-5; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OPPENHEIM JJ, 1976, PROG ALLERGY, V20, P65; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; Tian H, 2000, CANCER RES, V60, P679; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; Tymms M J, 1995, Methods Mol Biol, V37, P31; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WEDNER HJ, 1976, PROG ALLERGY, V20, P195; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	73	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					555	571		10.1038/sj.onc.1206138	http://dx.doi.org/10.1038/sj.onc.1206138			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555069				2022-12-25	WOS:000180538200009
J	Freund, A; Chauveau, C; Brouillet, JP; Lucas, A; Lacroix, M; Licznar, A; Vignon, F; Lazennec, G				Freund, A; Chauveau, C; Brouillet, JP; Lucas, A; Lacroix, M; Licznar, A; Vignon, F; Lazennec, G			IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast; cancer; interleukin-8; invasion	AUTOCRINE GROWTH-FACTOR; HUMAN OVARIAN-CANCER; PROSTATE-CANCER; CARCINOMA-CELLS; ER-BETA; ENDOTHELIAL INTERLEUKIN-8; REDUCED TUMORIGENICITY; LEUKEMIC-CELLS; MESSENGER-RNA; NUDE-MICE	Estrogen-receptor (ER) status is an important parameter in breast cancer management as ER-positive breast cancers have a better prognosis than ER-negative tumors. This difference comes essentially from the lower aggressiveness and invasiveness of ER-positive tumors. Here, we demonstrate, that interleukin-8 (IL-8) was clearly over-expressed in most ER-negative breast, ovary cell lines and breast tumor samples tested, whereas no significant IL-8 level could be detected in ER-positive breast or ovarian cell tines. We have also cloned human IL-8 from ER-negative MDA-MB-231 cells, and we show that IL-8 produced by breast cancer cells is identical to monocyte-derived IL-8. Interestingly, the invasion potential of ER-negative breast cancer cells is associated at least in part with expression of IL-8, but not with IL-8 receptor levels. Moreover, IL-8 increases the invasiveness of ER-positive breast cancer cells by two fold, thus confirming the invasion-promoting role of IL-8. On the other hand, exogenous expression of estrogen receptors in ER-negative cells led to a decrease of IL-8 levels. In summary, our data show that IL-8 expression is negatively linked to ER status of breast and ovarian cancer cells. We also support the idea that IL-8 expression is associated with a higher invasiveness potential of cancer cells in vitro, which suggests that IL-8 could be a novel marker of tumor aggressiveness.	INSERM, U540, F-34090 Montpellier, France; Hop Arnaud de Villeneuve, Lab Biol Cellulaire & Hormonale, F-34295 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Lazennec, G (corresponding author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Lacroix, Matthieu/O-1928-2018	Lacroix, Matthieu/0000-0002-1268-9058; Lazennec, Gwendal/0000-0002-8522-1763				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Balbay MD, 1999, CLIN CANCER RES, V5, P783; BASOLO F, 1993, INT J CANCER, V55, P926, DOI 10.1002/ijc.2910550609; Brew R, 1997, BIOCHEM SOC T, V25, pS264, DOI 10.1042/bst025264s; Brouillet JP, 2001, INT J CANCER, V95, P205, DOI 10.1002/1097-0215(20010720)95:4<205::AID-IJC1035>3.0.CO;2-Y; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Fontanini G, 1999, BRIT J CANCER, V80, P579, DOI 10.1038/sj.bjc.6690394; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Green AR, 1997, INT J CANCER, V72, P937; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; Greene GF, 1997, AM J PATHOL, V150, P1571; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Ivarsson K, 1998, GYNECOL ONCOL, V71, P420, DOI 10.1006/gyno.1998.5198; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lee LF, 2000, J IMMUNOL, V164, P2769, DOI 10.4049/jimmunol.164.5.2769; Luca M, 1997, AM J PATHOL, V151, P1105; MADSEN MW, 1990, EUR J CANCER, V26, P793, DOI 10.1016/0277-5379(90)90154-L; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MCGUIRE WL, 1975, CANCER, V36, P638; Merogi AJ, 1997, HUM PATHOL, V28, P321, DOI 10.1016/S0046-8177(97)90131-3; Miller LJ, 1998, ANTICANCER RES, V18, P77; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakashima E, 1996, PHARMACEUT RES, V13, P1896, DOI 10.1023/A:1016057830271; Pisani Paola, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P313; Platet Nadine, 1998, Invasion and Metastasis, V18, P198, DOI 10.1159/000024513; Pujol P, 1998, CANCER RES, V58, P5367; Roger P, 2001, CANCER RES, V61, P2537; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; SKOOG L, 1987, ACTA ONCOL, V26, P95, DOI 10.3109/02841868709091747; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Speirs V, 1996, INT J CANCER, V66, P551, DOI 10.1002/(SICI)1097-0215(19960516)66:4<551::AID-IJC21>3.0.CO;2-9; SPRENGER H, 1994, J IMMUNOL, V153, P2524; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; Terui Y, 1998, BLOOD, V92, P2672, DOI 10.1182/blood.V92.8.2672.420k40_2672_2680; Terui Y, 1999, CANCER RES, V59, P5651; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5; Xu L, 2000, ONCOL RES, V12, P97, DOI 10.3727/096504001108747567; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	42	171	185	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					256	265		10.1038/sj.onc.1206113	http://dx.doi.org/10.1038/sj.onc.1206113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527894	Green Submitted, Green Accepted			2022-12-25	WOS:000180322400010
J	Bode, JG; Ludwig, S; Ehrhardt, C; Erhardt, A; Albrecht, U; Schaper, F; Heinrich, PC; Haussinger, D				Bode, JG; Ludwig, S; Ehrhardt, C; Erhardt, A; Albrecht, U; Schaper, F; Heinrich, PC; Haussinger, D			IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3	FASEB JOURNAL			English	Article						cross-talk; viral resistance; interferon therapy; viral hepatitis	VIRUS; EXPRESSION; INTERLEUKIN-6; COUNTERACTS; INHIBITION; RECEPTOR; PATHWAY; BINDING; DOMAIN; STAT1	Eighty percent of patients newly infected with the hepatitis C virus (HCV) develop chronic infection, suggesting that HCV can develop effective strategies to escape the unspecific and specific immune response of the host. Because SOCS molecules have been recognized to be powerful inhibitors of cytokine signaling via the Jak/STAT pathway, virus-induced expression of these molecules should be an efficient instrument to counteract the cellular response toward interferons (IFNs), an essential part of first line antiviral immune response. This study shows that overexpression of HCV core protein inhibits IFN-alpha-induced tyrosine phosphorylation and activation of STAT1 in hepatic cells. With the use of a STAT1-YFP fusion protein, further evidence is given that HCV core is capable to inhibit nuclear translocation of STAT1. Inhibition of STAT1-tyrosine phosphorylation was accompanied by the induction of SOCS3-mRNA expression, suggesting that the HCV core protein impairs IFN-alpha-induced signal transduction via induction of SOCS3 expression. HCV core protein was competent to partially rescue growth of a genetically engineered influenza A virus lacking its own IFN antagonist. These IFN-antagonistic properties of the HCV core protein may be part of the molecular basis of IFN-alpha unresponsiveness in about one-half of chronically infected HCV-patients.	Univ Dusseldorf, Med Klin, Klin Gastroenterol Hepatol & Infektiol, D-40225 Dusseldorf, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52074 Aachen, Germany	Heinrich Heine University Dusseldorf; University of Wurzburg; RWTH Aachen University; RWTH Aachen University Hospital	Bode, JG (corresponding author), Univ Dusseldorf, Med Klin, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 05, D-40225 Dusseldorf, Germany.	Johannes.Bode@t-online.de	Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414; Ludwig, Stephan/0000-0003-4490-3052				Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basu A, 2001, VIROLOGY, V288, P379, DOI 10.1006/viro.2001.1100; BERG T, 2001, HEPATITIS C, P229; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Didcock L, 1999, J VIROL, V73, P9928, DOI 10.1128/JVI.73.12.9928-9933.1999; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Foster GR, 1997, SEMIN LIVER DIS, V17, P287, DOI 10.1055/s-2007-1007205; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Garcia-Sastre A, 2001, VIROLOGY, V279, P375, DOI 10.1006/viro.2000.0756; Garcin D, 1999, J VIROL, V73, P6559, DOI 10.1128/JVI.73.8.6559-6565.1999; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; KURACHI S, 1998, BIOCHEMICA, V3, P43; Manns M P, 2001, Indian J Gastroenterol, V20 Suppl 1, pC47; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Shen XN, 2000, FEBS LETT, V480, P132, DOI 10.1016/S0014-5793(00)01905-0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; *WHO, 2000, HEP C FACT SHEEP	30	239	252	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					488	+		10.1096/fj.02-0664fje	http://dx.doi.org/10.1096/fj.02-0664fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551851				2022-12-25	WOS:000181453700007
J	Dussmann, H; Kogel, D; Rehm, M; Prehn, JHM				Dussmann, H; Kogel, D; Rehm, M; Prehn, JHM			Mitochondrial membrane permeabilization and superoxide production during apoptosis - A single-cell analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; RAT HIPPOCAMPAL-NEURONS; INTERMEMBRANE SPACE; DEATH; GENERATION; HYDROETHIDINE; DYSFUNCTION; BINDING; PROTEIN; CHAIN	The temporal relationship between mitochondrial membrane permeabilization and reactive oxygen species production during apoptosis remains unknown. We analyzed the rate of superoxide production of human breast carcinoma cells expressing a cytochrome c-green fluorescent protein (cyt-c-GFP) fusion protein at the single-cell level during apoptosis. In cells treated with the proapoptotic agents stattrosporine (3 mum) or tumor necrosis factor-alpha (100 ng/ml), the release of cyt-c-GFP was individually set for each cell, and the majority of the fusion protein was released in less than 10 min. Prior to the release of the fusion protein, cells demonstrated a constant rate of superoxide production determined with the probe hydroethidine. After the release was completed, the superoxide concentration increased rapidly to a level more than 3-fold above baseline. Treatment with the broad spectrum caspase inhibitor z-Val-Ala-Asp(O-methyl)-fluoromethylketone (z-VAD-fink; 200 mum) did not alter the kinetics of the cyt-c-GFP release but significantly reduced superoxide concentration after the release of cyt-c-GFP. Interestingly, treatment with z-VAD-fink also reduced the increase in superoxide concentration in response to menadione in the absence of mitochondrial cyt-c-GFP release. Mitochondrial depolarization with the protonophore carbonyl cyanide p-trifluoromethoxy-phenylhydrazone per se did not trigger cyt-c-GFP release or an increase in superoxide production. Our data suggest that mitochondria increase their superoxide production during apoptosis directly after the quantitative release of soluble intermembrane proteins and demonstrate novel antioxidative effects of the commonly used caspase inhibitor z-VAD-frnk.	Westphalian Wilhelms Univ, Interdisciplinary Ctr Clin Res, IZKF, D-48149 Munster, Germany; Westphalian Wilhelms Univ, Dept Pharmacol & Toxicol, D-48149 Munster, Germany	University of Munster; University of Munster	Prehn, JHM (corresponding author), Klinikum Johann Wolfgang Goethe Univ, Haus 25 B,4-OG,Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Prehn, Jochen HM/A-3928-2010; Rehm, Markus/C-3398-2012	Prehn, Jochen HM/0000-0003-3479-7794; Rehm, Markus/0000-0001-6149-9261; Kogel, Donat/0000-0003-1209-0210; Dussmann, Heiko/0000-0002-3582-8057				Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; Cadenas E, 1985, Adv Enzyme Regul, V23, P217, DOI 10.1016/0065-2571(85)90049-4; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CORTESE JD, 1995, BBA-BIOENERGETICS, V1228, P216, DOI 10.1016/0005-2728(94)00178-8; D'Herde K, 2000, CELL DEATH DIFFER, V7, P331, DOI 10.1038/sj.cdd.4400655; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; JORDAN J, 1995, MOL PHARMACOL, V47, P1095; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Luetjens CM, 2001, MOL PHARMACOL, V60, P1008, DOI 10.1124/mol.60.5.1008; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wang XD, 2001, GENE DEV, V15, P2922; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	34	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12645	12649		10.1074/jbc.M210826200	http://dx.doi.org/10.1074/jbc.M210826200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560329	hybrid			2022-12-25	WOS:000182189500009
J	Kawashima, H; Watanabe, N; Hirose, M; Sun, X; Atarashi, K; Kimura, T; Shikata, K; Matsuda, M; Ogawa, D; Hejasvaara, R; Rehn, M; Pihlajaniemi, T; Miyasaka, M				Kawashima, H; Watanabe, N; Hirose, M; Sun, X; Atarashi, K; Kimura, T; Shikata, K; Matsuda, M; Ogawa, D; Hejasvaara, R; Rehn, M; Pihlajaniemi, T; Miyasaka, M			Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC DIFFERENCES; CHONDROITIN SULFATE; P-SELECTIN; CORRESPONDING TRANSCRIPTS; DEFICIENT MICE; EXPRESSION; IDENTIFICATION; LIGANDS; LECAM-1; KIDNEY	Leukocyte infiltration during inflammation is mediated by the sequential actions of adhesion molecules and chemokines. By using a rat ureteral obstruction model, we showed previously that L-selectin plays an important role in leukocyte infiltration into the kidney. Here we report the purification, identification, and characterization of an L-selectin-binding heparan sulfate proteoglycan (HSPG) expressed in the rat kidney. Partial amino acid sequencing and Western blotting analyses showed that the L-selectin-binding HSPG is collagen XVIII, a basement membrane HSPG. The binding of L-selectin to isolated collagen XVIII was specifically inhibited by an anti-L-selectin monoclonal antibody, EDTA, treatment of the collagen XVIII with heparitinase or heparin but not by chemically desulfated heparin. A cell binding assay showed that the L-selectin-collagen XVIII interaction mediates cell adhesion. Interestingly, collagen XVIII also interacted with a chemokine, monocyte chemoattractant protein-1, and presented it to a monocytic cell line, THP-1, which enhanced the alpha(4)beta(1) integrin-mediated binding of the THP-1 cells to vascular cell adhesion molecule-1. Thus, collagen XVIII may provide a link between selectin-mediated cell adhesion and chemokine-induced cellular activation and accelerate the progression of leukocyte infiltration in renal inflammation.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr, FIN-90014 Oulu, Finland; Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, Okayama 7008558, Japan; Osaka Univ, Grad Sch Med, Lab MOl & Cellular Recognit, Suita, Osaka 5650871, Japan	University of Oulu; University of Oulu; Okayama University; Osaka University	Kawashima, H (corresponding author), Burnham Inst, Glycobiol Program, Canc Res Ctr, La Jolla, CA 92037 USA.	hkawashima@burnham.org	まゆみ, 廣瀬/AAK-5735-2020; Miyasaka, Masayuki/AAM-6343-2020	Pihlajaniemi, Taina/0000-0002-1664-9045; Heljasvaara, Ritva/0000-0003-4763-3844; Atarashi, Kazuyuki/0000-0002-4166-7114; Kimura, Tetsuya/0000-0001-6367-7818				ABE N, 1993, BIOCHEM BIOPH RES CO, V196, P576, DOI 10.1006/bbrc.1993.2288; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KRISKO I, 1977, KIDNEY INT, V12, P238, DOI 10.1038/ki.1977.108; LEY K, 1991, BLOOD, V77, P2553; Li YF, 1999, FEBS LETT, V444, P201, DOI 10.1016/S0014-5793(99)00046-0; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; NELSON RM, 1993, BLOOD, V82, P3253; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PRODJOSUDJADI W, 1995, CLIN NEPHROL, V44, P148; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; ROVIN BH, 1994, LAB INVEST, V71, P536; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Schlondorff D, 1997, KIDNEY INT, V51, P610, DOI 10.1038/ki.1997.90; Shikata K, 1999, J PATHOL, V188, P93, DOI 10.1002/(SICI)1096-9896(199905)188:1<93::AID-PATH305>3.0.CO;2-#; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; TAMATANI T, 1993, J IMMUNOL, V150, P1735; TAMATANI T, 1993, EUR J IMMUNOL, V23, P2181, DOI 10.1002/eji.1830230920; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; Tesch GH, 1999, J CLIN INVEST, V103, P73, DOI 10.1172/JCI4876; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Watanabe N, 1999, J BIOCHEM-TOKYO, V125, P826, DOI 10.1093/oxfordjournals.jbchem.a022355; WATANABE T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P321, DOI 10.1016/0167-4781(92)90033-V; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	40	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13069	13076		10.1074/jbc.M212244200	http://dx.doi.org/10.1074/jbc.M212244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556525	hybrid			2022-12-25	WOS:000182189500062
J	Kiba, A; Yabana, N; Shibuya, M				Kiba, A; Yabana, N; Shibuya, M			A set of loop-1 and-3 structures in the novel vascular endothelial growth factor (VEGF) family member, VEGF-ENZ-7, is essential for the activation of VEGFR-2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING SITE; TYROSINE KINASE; CRYSTAL-STRUCTURE; ORF VIRUS; EXTRACELLULAR DOMAIN; FLT-1; IDENTIFICATION; PERMEABILITY; NEUROPILIN-1; PROTEIN	The vascular endothelial growth factor (VEGF) family plays important roles in angiogenesis and vascular permeability. Novel members of the VEGF family encoded in the Orf virus genome, VEGF-E, function as potent angiogenic factors by specifically binding and activating VEGFR-2 (KDR). VEGF-E is about 45% homologous to VEGF-A at amino acid levels, however, the amino acid residues in VEGF-A crucial for the VEGFR-2-binding are not conserved in VEGF-E. To understand the molecular basis of the biological activity of VEGF-E, we have functionally mapped residues important for interaction of VEGF-E with VEGFR-2 by exchanging the domains between VEGF-ENZ-7 and PIGF, which binds only to VEGFR-1 (Flt-1). Exchange on the amino- and carboxyl-terminal regions had no suppressive effect on biological activity. However, exchange on either the loop-1 or -3 region of VEGF-ENZ-7 significantly reduced activities. On the other hand, introduction of the loop-1 and -3 of VEGF-ENZ-7 to placenta growth factor rescued the biological activities. The chimera between VEGF-A and VEGF-ENZ-7 gave essentially the same results. These findings strongly suggest that a common rule exists for VEGFR-2 ligands (VEGF-ENZ-7, and VEGF-A) that they build up the binding structure for VEGFR-2 through the appropriate interaction between loop-1 and -3 regions.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.							Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kreysing J, 1996, FEBS LETT, V385, P181, DOI 10.1016/0014-5793(96)00349-3; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wiesmann C, 1998, BIOCHEMISTRY-US, V37, P17765, DOI 10.1021/bi9819327; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	37	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13453	13461		10.1074/jbc.M210931200	http://dx.doi.org/10.1074/jbc.M210931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551914	hybrid			2022-12-25	WOS:000182189500108
J	Li, J; Gorospe, M; Barnes, J; Liu, Y				Li, J; Gorospe, M; Barnes, J; Liu, Y			Tumor promoter arsenite stimulates histone H3 phosphoacetylation of proto-oncogenes c-fos and c-jun chromatin in human diploid fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; MAP KINASE; DRINKING-WATER; CELL-PROLIFERATION; TERMINAL DOMAIN; AP-1 ACTIVITY; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; INDUCTION	Although epidemiological studies have long established that inorganic arsenic is a potent human carcinogen, the underlying mechanisms are still poorly understood. Recent studies suggest that inorganic arsenic may act as a tumor promoter by perturbing key signaling transduction pathways. We have shown previously that arsenite can potently activate the mitogen-activated protein kinase cascades and induce the expression of proliferation-associated genes, including protooncogenes c-jun and c-fos. In order to elucidate further the molecular mechanisms underlying its tumor-promoting properties, we investigated the signaling events involved in arsenite-mediated induction of c-fos and c-jun. We found that induction of both c-fos and c-jun by arsenite can be substantially inhibited by the MEK-selective inhibitor U0126, suggesting that the ERK pathway is critically involved in their up-regulation. Interestingly, arsenite dramatically induced the phosphorylation and acetylation of histone H3 preceding the induction of mRNAs encoding c-fos and c-jun. Finally, chromatin immunoprecipitation assays revealed that arsenite treatment markedly induced the phosphorylation/acetylation of histone H3 associated with the c-fos and c-jun genes through an ERK-dependent pathway. Our results strongly suggest that arsenic-triggered alterations in chromatin structure perturb specific gene transcription, including that of proto-oncogenes c-jun and c-fos, and may thereby contribute to the carcinogenic process.	NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Liu, Y (corresponding author), Ohio State Univ, Columbus Childrens Hosp, Ctr Dev Pharmacol & Toxicol, Columbus Childrens Res Inst,Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	liuy@pediatrics.ohio-state.edu	Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109	NATIONAL INSTITUTE ON AGING [ZIAAG000511, Z01AG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Calderon RL, 1999, ENVIRON HEALTH PERSP, V107, P663, DOI 10.2307/3434459; CANO E, 1995, J CELL SCI, V108, P3599; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Germolec DR, 1996, TOXICOL APPL PHARM, V141, P308, DOI 10.1016/S0041-008X(96)80037-8; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hartwig A, 1997, CARCINOGENESIS, V18, P399, DOI 10.1093/carcin/18.2.399; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Huang CS, 2001, ANTICANCER RES, V21, P261; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDOLPH JR, 1989, BIOL TRACE ELEM RES, V21, P459, DOI 10.1007/BF02917289; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; LI JH, 1989, BIOL TRACE ELEM RES, V21, P373, DOI 10.1007/BF02917278; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; *NAT RES COUNC, 2001, ARS DRINK WAT 2001 U, P217; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheth K, 2001, SURGERY, V130, P242, DOI 10.1067/msy.2001.115902; Simeonova PP, 2000, CANCER RES, V60, P3445; SMITH AH, 1992, ENVIRON HEALTH PERSP, V97, P259, DOI 10.2307/3431362; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tian DF, 2001, J TOXICOL ENV HEAL A, V64, P473, DOI 10.1080/152873901753215939; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wiencke JK, 1997, MUTAT RES-REV MUTAT, V386, P335, DOI 10.1016/S1383-5742(97)00016-1	48	71	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13183	13191		10.1074/jbc.M300269200	http://dx.doi.org/10.1074/jbc.M300269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547826	hybrid			2022-12-25	WOS:000182189500076
J	Turner, J; Nicholas, H; Bishop, D; Matthews, JM; Crossley, M				Turner, J; Nicholas, H; Bishop, D; Matthews, JM; Crossley, M			The LIM protein FHL3 binds basic Kruppel-like factor/Kruppel-like factor 3 and its co-repressor C-terminal-binding protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; FACTOR EKLF; DOMAIN PROTEIN; LEUKEMIA-CELLS; FAMILY; CTBP; ASSOCIATION; FINGER; COACTIVATOR; COREPRESSOR	The ability of DNA-binding transcription factors to recruit specific cofactors is central to the mechanism by which they regulate gene expression. BKLF/KLF3, a member of the Kruppel-like factor family of zinc finger proteins, is a potent transcriptional repressor that recruits a CtBP co-repressor. We show here that BKLF also recruits the four and a half LIM domain protein FHL3. Different but closely linked regions of BKLF mediate contact with CtBP2 and FHL3. We present evidence that CtBP2 also interacts with FHL3 and demonstrate that the three proteins co-elute in gel filtration experiments. CtBP and FHL proteins have been implicated in both nuclear and cytoplasmic functions, but expression of BKLF promotes the nuclear accumulation of both FHL3 and CtBP2. FHL proteins have been shown to act predominantly as co-activators of transcription. However, we find FHL3 can repress transcription. We suggest that LIM proteins like FHL3 are important in assembling specific repression or activation complexes, depending on conditions such as cofactor availability and promoter context.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Sydney	Crossley, M (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, G08, Sydney, NSW 2006, Australia.		Crossley, Merlin/D-7888-2011; Matthews, Jacqueline/A-7322-2013	Crossley, Merlin/0000-0003-2057-3642; Matthews, Jacqueline/0000-0001-8518-3472; Bishop, David/0000-0001-6415-1455; Nicholas, Hannah/0000-0002-2239-9249				Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P251, DOI 10.1006/bbrc.1999.0180; MORGAN MJ, 1995, BIOCHEM BIOPH RES CO, V212, P840, DOI 10.1006/bbrc.1995.2045; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Ng EKO, 2002, J CELL BIOCHEM, V84, P556, DOI 10.1002/jcb.10041.abs; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; PERKINS AC, 1997, BLOOD S, V90, P575; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Schuierer M, 2001, J BIOL CHEM, V276, P27944, DOI 10.1074/jbc.M100070200; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Turner J, 1999, INT J BIOCHEM CELL B, V31, P1169, DOI 10.1016/S1357-2725(99)00067-9; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	49	52	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12786	12795		10.1074/jbc.M300587200	http://dx.doi.org/10.1074/jbc.M300587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556451	hybrid			2022-12-25	WOS:000182189500027
J	Chreneik, JE; Burgin, AB; Pommier, Y; Stewart, L; Redinbo, MR				Chreneik, JE; Burgin, AB; Pommier, Y; Stewart, L; Redinbo, MR			Structural impact of the leukemia drug 1-beta-D-arabinofuranosyleytosine (Ara-C) on the covalent human topoisomerase I-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; CLEAVAGE COMPLEXES; ACTIVE-SITE; CAMPTOTHECIN; INDUCTION; ARABINOSYLCYTOSINE; RECOMBINATION; MOLSCRIPT	1-beta-D-Arabinofuranosylcytosine (Ara-C) is a potent antineoplastic drug used in the treatment of acute leukemia. Previous biochemical studies indicated the incorporation of Ara-C into DNA reduced the catalytic activity of human topoisomerase I by decreasing the rate of single DNA strand religation by the enzyme by 2-3-fold. We present the 3.1 Angstrom crystal structure of human topoisomerase I in covalent complex with an oligonucleotide containing Ara-C at the + 1 position of the non-scissile DNA strand. The structure reveals that a hydrogen bond formed between the 2'-hydroxyl of Ara-C and the O4' of the adjacent -1 base 5' to the damage site stabilizes a C3'-endo pucker in the Ara-C arabinose ring. The structural distortions at the site of damage are translated across the DNA double helix to the active site of human topoisomerase I. The free sulfhydryl at the 5'-end of the nicked DNA strand in this trapped covalent complex is shifted out of alignment with the 3'-phosphotyrosine linkage at the catalytic tyrosine 723 residue, producing a geometry not optimal for religation. The subtle structural changes caused by the presence of Ara-C in the DNA duplex may contribute to the cytotoxicity of this leukemia drug by prolonging the lifetime of the covalent human topoisomerase I-DNA complex.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; DeCODE Genet Inc, Biostruct Grp, Bainbridge Isl, WA 98110 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Redinbo, MR (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.	redinbo@unc.edu			NATIONAL CANCER INSTITUTE [Z01BC006161, ZIABC006161] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Burgin AB, 2000, METH MOL B, V95, P119; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; COLLINS ARS, 1977, BIOCHIM BIOPHYS ACTA, V478, P461, DOI 10.1016/0005-2787(77)90101-0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; Grant S, 1998, ADV CANCER RES, V72, P197; GRANT S, 1997, FRONT BIOSCIENCE, V2, P242; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Holden Joseph A., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P1, DOI 10.2174/1568011013354859; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Hwang Y, 1999, VIROLOGY, V262, P479, DOI 10.1006/viro.1999.9920; Kazmierczak RA, 2002, NUCLEIC ACIDS RES, V30, P5193, DOI 10.1093/nar/gkf652; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 1999, VIROLOGY, V264, P441, DOI 10.1006/viro.1999.0022; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; MASTRIANNI DM, 1992, AM J MED, V92, P286, DOI 10.1016/0002-9343(92)90079-Q; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SCHWEITZER BI, 1994, BIOCHEMISTRY-US, V33, P11460, DOI 10.1021/bi00204a008; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; THIBAUDEAU C, 1994, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39940000537; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEATES TO, 1988, ACTA CRYSTALLOGR A, V44, P142, DOI 10.1107/S0108767387009632	41	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12461	12466		10.1074/jbc.M212930200	http://dx.doi.org/10.1074/jbc.M212930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12533542	hybrid			2022-12-25	WOS:000182015700096
J	Wu, ZP; Yang, YW; Shaw, N; Bhattacharya, S; Yan, L; West, K; Roth, K; Noy, N; Qin, J; Crabb, JW				Wu, ZP; Yang, YW; Shaw, N; Bhattacharya, S; Yan, L; West, K; Roth, K; Noy, N; Qin, J; Crabb, JW			Mapping the ligand binding pocket in the cellular retinaldehyde binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE; MUTATIONS	Retinoid interactions determine the function of the cellular retinaldehyde binding protein (CRALBP) in the rod visual cycle where it serves as an 11-cis-retinol acceptor for the enzymatic isomerization of all-trans- to 11-cis-retinol and as a substrate carrier for 11-cis-retinol dehydrogenase (RDH5). Based on preliminary NMR studies suggesting retinoid interactions with Met and Trp residues, human recombinant CRALBP (rCRALBP) with altered Met or Trp were produced and analyzed for ligand interactions. The primary structures of the purified proteins were verified for mutants M20SA, M222A, M225A, W165F, and W244F, then retinoid binding properties and substrate carrier functions were evaluated. All the mutant proteins bound 11-cis- and 9-cis-retinal and therefore were not grossly misfolded. Altered UV-visible spectra and lower retinoid binding affinities were observed for the mutants, supporting modified ligand interactions. Altered kinetic parameters were observed for RDH5 oxidation of 11-cis-retinol bound to rCRALBP mutants M222A. M225A, and W244F, supporting impaired substrate carrier function. Heteronuclear single quantum correlation NMR analyses confirmed localized structural changes upon photoisomerization of rCRALBP-bound 11-cis-retinal and demonstrated ligand-dependent conformational changes for residues Met-208, Met-222, Trp-165, and Trp-244. Furthermore, residues Met-208, Met-222, Met-225, and Trp-244 are within a region exhibiting high homology to the ligand binding cavity of phosphatidylinositol transfer protein. Overall the data implicate Trp-165, Met-208, Met-222, Met-225, and Trp-244 as components of the CRALBP ligand binding cavity.	Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Cornell University	Crabb, JW (corresponding author), Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,I31, Cleveland, OH 44195 USA.	crabbj@ccf.org		Qin, Jun/0000-0002-2647-9270	NCI NIH HHS [CA68150] Funding Source: Medline; NEI NIH HHS [EY6603, EY14239] Funding Source: Medline; NHLBI NIH HHS [HL58758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhattacharya SK, 2002, FASEB J, V16, pA14; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507; CHEN Y, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P371; Crabb JW, 1998, METH MOL B, V89, P91; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; CRABB JW, 1997, CURRENT PROTOCOLS S, V7; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Golovleva I, 2003, J BIOL CHEM, V278, P12397, DOI 10.1074/jbc.M207300200; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Jang GF, 2000, J BIOL CHEM, V275, P28128; Luck LA, 1997, TECH PROT CHEM, V8, P439, DOI 10.1016/S1080-8914(97)80044-0; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; Qin J, 2001, METHOD ENZYMOL, V339, P377, DOI 10.1016/S0076-6879(01)39323-0; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; Saari John C., 1994, P351; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058; Wu Z, 2001, INVEST OPHTH VIS SCI, V42, pS358	28	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12390	12396		10.1074/jbc.M212775200	http://dx.doi.org/10.1074/jbc.M212775200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12536149	hybrid			2022-12-25	WOS:000182015700087
J	Hambrock, HO; Nitsche, DP; Hansen, U; Bruckner, P; Paulsson, M; Maurer, P; Hartmann, U				Hambrock, HO; Nitsche, DP; Hansen, U; Bruckner, P; Paulsson, M; Maurer, P; Hartmann, U			SC1/hevin - An extracellular calcium-modulated protein that binds collagen I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLYCOPROTEIN SC1/ECM2; CRYSTAL-STRUCTURE; SPARC; SC1; BRAIN; HEVIN; BM-40; LYMPHOPOIESIS; FOLLISTATIN; ASTROCYTES	SC1, a member of the BM-40 family of extracellular matrix proteins, was recombinantly expressed in a eukaryotic expression system. The full-length protein as well as truncated versions were purified to homogeneity under non-denaturing conditions. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry of full-length SC1 revealed a mass of 87.8 kDa of which 16.8 kDa is contributed by posttranslational modifications. In electron microscopy, after negative staining, SC1 was revealed as a globule attached to a thread-like structure. A calcium dependence of the SC1 conformation could be demonstrated by fluorescence spectroscopy. In the extracellular matrix of cultured osteosarcoma cells SC1 was found associated with collagen I-containing fibrils, and binding of SC1 to reconstituted collagen I fibrils could be demonstrated by immunogold labeling and electron microscopy. SC1 showed a broad expression in a variety of tissues.	Univ Cologne, Ctr Biochem, Fac Med, D-50931 Cologne, Germany; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Cologne; University of Munster	Hartmann, U (corresponding author), Univ Cologne, Ctr Biochem, Fac Med, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.		Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				Bendik I, 1998, CANCER RES, V58, P626; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Claeskens A, 2000, BRIT J CANCER, V82, P1123, DOI 10.1054/bjoc.1999.1051; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Girard JP, 1996, J BIOL CHEM, V271, P4511; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; IruelaArispe ML, 1996, DEV DYNAM, V207, P171, DOI 10.1002/(SICI)1097-0177(199610)207:2<171::AID-AJA5>3.0.CO;2-E; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; McKinnon PJ, 1996, BRAIN RES, V709, P27, DOI 10.1016/0006-8993(95)01224-9; McKinnon PJ, 2000, MOL CELL BIOL, V20, P656, DOI 10.1128/MCB.20.2.656-660.2000; MENDIS DB, 1994, BRAIN RES, V633, P197, DOI 10.1016/0006-8993(94)91540-7; Mendis DB, 1996, BRAIN RES, V713, P53, DOI 10.1016/0006-8993(95)01472-1; Mendis DB, 1996, BRAIN RES, V730, P95; Nelson PS, 1998, CANCER RES, V58, P232; Oritani K, 1997, BLOOD, V90, P3404, DOI 10.1182/blood.V90.9.3404; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Oritani K, 1998, LEUKEMIA LYMPHOMA, V32, P1; Ringuette M, 1998, DEV GENES EVOL, V208, P403, DOI 10.1007/s004270050196; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Vannahme C, 2002, J BIOL CHEM, V277, P37977, DOI 10.1074/jbc.M203830200; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200	30	71	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11351	11358		10.1074/jbc.M212291200	http://dx.doi.org/10.1074/jbc.M212291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538579	hybrid			2022-12-25	WOS:000181855400063
J	Talukder, AH; Mishra, SK; Mandal, M; Balasenthil, S; Mehta, S; Sahin, AA; Barnes, CJ; Kumar, R				Talukder, AH; Mishra, SK; Mandal, M; Balasenthil, S; Mehta, S; Sahin, AA; Barnes, CJ; Kumar, R			MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; CAK ACTIVITY; TFIIH; ALPHA; CDK7; CHROMATIN; PHOSPHORYLATION; PROTEIN; CDK7-CYCLIN-H; COREPRESSOR	The transcriptional activity of estrogen receptor-a is controlled by coregulators. MTA1 (metastasis-associated protein 1) represses estrogen receptor-a-driven transcription by recruiting histone deacetylases (HDACs) to the estrogen response element containing target gene chromatin in breast cancer cells. Using a yeast two-hybrid screen with the MTA1 C-terminal domain as bait, we identified MAT1 (menage a trois 1) as an MTA1-binding protein. MAT1 is an assembly/targeting factor for cyclin-dependent kinase-activating kinase (CAK), which has been shown to functionally interact with general transcriptional factor TFIIH, a known inducer of ER transactivation. We show that estrogen signaling promotes nuclear translocation of MAT1 and that MTA1 interacts with MAT1 both in vitro and in vivo. MAT1 binds to the C-terminal 389-441 amino acids GATA domain and N-terminal 1-164 amino acids bromo-domain of MTA1, whereas MTA1 binds to the N-terminal ring finger domain of the MAT1. In addition, MAT1 interacts with the activation function 2 domain of ER and colocalizes with ER in activated cells. MTA1 deregulation in breast cancer cells led to its interactions with the CAK complex components, ER, and HDAC2. Accordingly, MTA1 inhibited CAK stimulation of ER transactivation that was partially relieved by HDAC inhibitor trichostatin A, suggesting that MTA1 might inhibit CAK-induced transactivation function of ER by recruiting HDAC. Furthermore, MTA1 overexpression inhibited the ability of CAK complex to phosphorylate ER. Together, these findings identified MAT1 as a target of MTA1 and provided new evidence to suggest that the transactivation functions of ER might be influenced by the regulatory interactions between CAK and MTA1 in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol 108, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022; Barnes, Christopher/B-1545-2015	Mandal, Mahitosh/0000-0003-3861-3323; Mishra, Sandip/0000-0002-0776-6581; Barnes, Christopher/0000-0001-9682-0748				Barnes CJ, 2002, CANCER RES, V62, P1251; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TOH Y, 1994, J BIOL CHEM, V269, P22958; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	32	48	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11676	11685		10.1074/jbc.M209570200	http://dx.doi.org/10.1074/jbc.M209570200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12527756	hybrid			2022-12-25	WOS:000181855400102
J	Tateno, H; Winter, HC; Petryniak, J; Goldstein, IJ				Tateno, H; Winter, HC; Petryniak, J; Goldstein, IJ			Purification, characterization, molecular cloning, and expression of novel members of jacalin-related lectins from rhizomes of the true fern Phlebodium aureum (L) J. Smith (Polypodiaceae)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CARBOHYDRATE-BINDING PROPERTIES; MUSA-ACUMINATA LECTIN; ARTOCARPUS-INTEGRIFOLIA; HELIANTHUS-TUBEROSUS; OLIGOSACCHARIDES; RECOGNITION; AGGLUTININ; PROTEINS; REVEALS	A lectin was purified from rhizomes of the fern Phlebodium aureum by affinity chromatography on mannose-Sepharose. The lectin, designated P. aureum lectin (PAL), is composed of two identical subunits of similar to15 kDa associated by noncovalent bonds. From a cDNA library and synthetic oligonucleotide probes based on a partial amino acid sequence, 5'- and 3'-rapid amplification of cDNA ends allowed the generation of two similar full-length cDNAs, termed PALa and PALb, each of which had an open reading frame of 438 by encoding 146 amino acid residues. The two proteins share 88% sequence identity and showed structural similarity to jacalin-related lectins. PALa contained peptide sequences exactly matching those found in the isolated lectin. PALa and PALb were expressed in Escherichia coli using pET-22b(+) vector and purified by one-step affinity chromatography. Native and recombinant forms of PAL agglutinated rabbit erythrocytes and precipitated with yeast mannan, dextran, and the high mannose-containing glycoprotein invertase. The detailed carbohydrate-binding properties of the native and recombinant lectins were elucidated by agglutination inhibition assay, and native lectin was also studied by isothermal titration calorimetry. Based on the results of these assays, we conclude that this primitive vascular plant, like many higher plants, contains significant quantities of a mannose/glucose-binding protein in its storage tissue, whose binding specificity differs in detail from either legume mannose/glucose-binding lectins or monocot mannose-specific lectins. The identification of a jacalin-related lectin in a true fern reveals for the first time the widespread distribution and molecular evolution of this lectin family in the plant kingdom.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Goldstein, IJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	igoldste@umich.edu	Tateno, Hiroaki/M-2706-2018	Tateno, Hiroaki/0000-0003-3006-1659	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bourne Y, 1999, STRUCTURE, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; FU DT, 1995, ANAL BIOCHEM, V227, P377, DOI 10.1006/abio.1995.1294; Goldstein I.J., 1997, GLYCOPROTEINS, P403; Goldstein IJ, 2001, EUR J BIOCHEM, V268, P2616, DOI 10.1046/j.1432-1327.2001.02149.x; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; Hirano K, 2000, PLANT CELL PHYSIOL, V41, P258, DOI 10.1093/pcp/41.3.258; HUI Y, 1993, J BIOL CHEM, V268, P5905; JEANES A, 1954, J AM CHEM SOC, V76, P5041, DOI 10.1021/ja01649a011; KAKU H, 1992, CARBOHYD RES, V229, P337, DOI 10.1016/S0008-6215(00)90579-2; KIMURA M, 1969, P NATL ACAD SCI USA, V63, P1181, DOI 10.1073/pnas.63.4.1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENER IE, 1986, LECTINS, P3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mann K, 2001, EUR J BIOCHEM, V268, P4414, DOI 10.1046/j.1432-1327.2001.02368.x; MELLOR RB, 1981, BIOCHEM BIOPH RES CO, V99, P1348, DOI 10.1016/0006-291X(81)90767-1; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; Mo HQ, 2001, EUR J BIOCHEM, V268, P2609, DOI 10.1046/j.1432-1327.2001.02148.x; Nomura K, 2000, BIOCHEM BIOPH RES CO, V276, P23, DOI 10.1006/bbrc.2000.3420; Novak T.P., 1975, BIOCHIM BIOPHYS ACTA, V393, P115; Peumans WJ, 1997, GLYCOCONJUGATE J, V14, P259, DOI 10.1023/A:1018502107707; Peumans WJ, 2000, PLANTA, V211, P546, DOI 10.1007/s004250000307; PLUMMER TH, 1964, J BIOL CHEM, V239, P2530; Rosa JC, 1999, PROTEIN SCI, V8, P13; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; Van Damme EJM, 1999, EUR J BIOCHEM, V259, P135, DOI 10.1046/j.1432-1327.1999.00013.x; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; Van Damme EJM, 2002, PLANT PHYSIOL, V130, P757, DOI 10.1104/pp.005892; Vasheka O. V., 1999, Ukrainskii Biokhimicheskii Zhurnal, V71, P93; Winter HC, 2002, J BIOL CHEM, V277, P14996, DOI 10.1074/jbc.M200161200; Yagi F, 2002, EUR J BIOCHEM, V269, P4335, DOI 10.1046/j.1432-1033.2002.03127.x; YOUNG NM, 1991, FEBS LETT, V282, P382, DOI 10.1016/0014-5793(91)80518-8; Zhang WL, 2000, PLANTA, V210, P970, DOI 10.1007/s004250050705	37	35	35	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10891	10899		10.1074/jbc.M211840200	http://dx.doi.org/10.1074/jbc.M211840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538584	hybrid			2022-12-25	WOS:000181855400004
J	Toustrup-Jensen, M; Vilsen, B				Toustrup-Jensen, M; Vilsen, B			Importance of conserved Thr(214) in domain A of the Na+,K+-ATPase for stabilization of the phosphoryl transition state complex in E2P dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; 4TH TRANSMEMBRANE SEGMENT; E1-E2 CONFORMATIONAL TRANSITIONS; RAT-KIDNEY NA+,K+-ATPASE; FUNCTIONAL CONSEQUENCES; ENERGY TRANSDUCTION; ALPHA-SUBUNIT; CALCIUM-PUMP; NA,K-ATPASE; MUTATIONS	Thr(214) of the highly conserved (214)TGES sequence in domain A of the Na+,K+-ATPase was replaced with alanine, and the mutant was compared functionally with the previously characterized domain A mutant Gly(263) --> Ala. Thr(214) --> Ala displayed a conspicuous 150-fold reduction of the apparent vanadate affinity for inhibition of ATPase activity, which could not simply be explained by the observed shifts of the conformational equilibria in favor of E-1 and E1P. The intrinsic vanadate affinity of the E-2 form and the effect on the apparent vanadate affinity of displacement of the E-1-E-2 equilibrium were determined in a phosphorylation assay that allows the enzyme-vanadate complex to be formed under equilibrium conditions. When the E-2 form prevailed, Thr(214) Ala retained a reduced vanadate affinity relative to wild type, whereas the affinity of Gly(263) --> Ala became wild type-like. Thus, mutation of Thr(214) affected the intrinsic affinity of E-2 for vanadate. Furthermore, Thr(214) --> Ala showed at least a 5-fold reduced E2P dephosphorylation rate relative to wild type in the presence of saturating concentrations of K+ and Mg2+. Because vanadate is a phosphoryl transition state analog, it is proposed that defective binding of the phosphoryl transition state complex (transition state destabilization) causes the inability to catalyze E2P dephosphorylation properly. By contrast, the phosphorylation site in the E-1 form was unaffected in Thr(214) --> Ala. Replacement of the glutamate, Glu(216), of (214)TGES with alanine was incompatible with cell viability, indicating a very low transport activity or expression level. Our results support the hypothesis that domain A is isolated in the E-1 form, but contributes to make up the catalytic site in the E-2 and E2P conformations.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Toustrup-Jensen, Mads Schak/0000-0003-2064-5861; Vilsen, Bente/0000-0002-4727-9382				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P1; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; Goldshleger R, 2001, J BIOENERG BIOMEMBR, V33, P387, DOI 10.1023/A:1010615422932; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KUNKEL TA, 1985, P NATL ACAD SCI USA, V85, P3314; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; SMITH RL, 1980, J BIOL CHEM, V255, P9852; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toustrup-Jensen M, 2002, J BIOL CHEM, V277, P38607, DOI 10.1074/jbc.M203665200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Vilsen B, 1997, ANN NY ACAD SCI, V834, P297, DOI 10.1111/j.1749-6632.1997.tb52260.x; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11402	11410		10.1074/jbc.M212136200	http://dx.doi.org/10.1074/jbc.M212136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531906	hybrid			2022-12-25	WOS:000181855400069
J	Zhang, WG; Wang, YM; Long, J; Girton, J; Johansen, J; Johansen, KM				Zhang, WG; Wang, YM; Long, J; Girton, J; Johansen, J; Johansen, KM			A developmentally regulated splice variant from the complex lola locus encoding multiple different zinc finger domain proteins interacts with the chromosomal kinase JIL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BTB DOMAIN; HISTONE DEACETYLASE; CHROMATIN STRUCTURE; POZ DOMAIN; N-COR; DOSAGE COMPENSATION; INTERACTION MOTIF; BTB/POZ DOMAIN; DNA-BINDING	Using a yeast two-hybrid screen we have identified a novel isoform. of the lola locus, Lola zf5, that interacts with the chromosomal kinase JIL-1. We characterized the lola locus and provide evidence that it is a complex locus from which at least 17 different splice variants are likely to be generated. Fifteen of these each have a different zinc finger domain, whereas two are without. This potential for expression of multiple gene products suggests that they serve diverse functional roles in different developmental contexts. By Northern and Western blot analyses we demonstrate that the expression of Lola zf5 is developmentally regulated and that it is restricted to early embryogenesis. Immunocytochemical labeling with a Lola zf5-specific antibody of Drosophila embryos indicates that Lola zf5 is localized to nuclei. Furthermore, by creating double-mutant flies we show that a reduction of Lola protein levels resulting from mutations in the lola locus acts as a dominant modifier of a hypomorphic JIL-1 allele leading to an increase in embryonic viability. Thus, genetic interaction assays provide direct evidence that gene products from the lola locus function within the same pathway as the chromosomal kinase JIL-1.	Iowa State Univ, Dept Zool & Genet, Ames, IA 50011 USA	Iowa State University	Johansen, KM (corresponding author), Iowa State Univ, Dept Zool & Genet, 3154 Mol Biol Bldg, Ames, IA 50011 USA.			Wang, Yanming/0000-0002-0710-043X; Zhang, Weiguo/0000-0002-3045-0569	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Akhtar A, 2001, EMBO REP, V2, P113, DOI 10.1093/embo-reports/kve022; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Arrizabalaga G, 1999, GENETICS, V153, P1825; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Buchner K, 2000, GENETICS, V155, P141; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Cavarec L, 1997, MOL CELL BIOL, V17, P482, DOI 10.1128/MCB.17.1.482; CHEN W, 1995, MOL CELL BIOL, V15, P3424; Crowner D, 2002, DEVELOPMENT, V129, P1317; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Ghosh D, 2001, EMBO J, V20, P2518, DOI 10.1093/emboj/20.10.2518; GINIGER E, 1994, DEVELOPMENT, V120, P1385; GODT D, 1993, DEVELOPMENT, V119, P799; Gorelick RJ, 1999, J VIROL, V73, P8185, DOI 10.1128/JVI.73.10.8185-8195.1999; Harlow E., 1988, ANTIBODIES LAB MANUA; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Jin Y, 2000, J CELL BIOL, V149, P1005, DOI 10.1083/jcb.149.5.1005; Jin Y, 1999, MOL CELL, V4, P129, DOI 10.1016/S1097-2765(00)80195-1; Johansen KM, 1999, CRIT REV EUKAR GENE, V9, P267, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.110; Kanezaki R, 2001, J BIOL CHEM, V276, P7278, DOI 10.1074/jbc.M004227200; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LINDSLEY DL, 1992, GENOM E DROSOPHILA M; Madden K, 1999, DEV BIOL, V213, P301, DOI 10.1006/dbio.1999.9399; Meller VH, 2002, ADV GENET, V46, P1; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; Roberts D. B, 1986, DROSOPHILA PRACTICAL; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Ruhf ML, 2001, DEVELOPMENT, V128, P1429; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Spradling AC, 1999, GENETICS, V153, P135; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521; Usuka J, 2000, J MOL BIOL, V297, P1075, DOI 10.1006/jmbi.2000.3641; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Wang YM, 2001, CELL, V105, P433, DOI 10.1016/S0092-8674(01)00325-7; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WOLFFE AP, 1996, SCIENCE, V272, P408; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	52	22	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11696	11704		10.1074/jbc.M213269200	http://dx.doi.org/10.1074/jbc.M213269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538650	hybrid			2022-12-25	WOS:000181855400104
J	Kramar, EA; Bernard, JA; Gall, CM; Lynch, G				Kramar, EA; Bernard, JA; Gall, CM; Lynch, G			Integrins modulate fast excitatory transmission at hippocampal synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ARG-GLY-ASP; CELL-ADHESION MOLECULES; AMPA RECEPTORS; ALPHA-5 INTEGRIN; LIGAND-BINDING; NMDA RECEPTORS; RAT-BRAIN; KINASE; PHOSPHORYLATION	The present study provides the first evidence that adhesion receptors belonging to the integrin family modulate excitatory transmission in the adult rat brain. Infusion of an integrin ligand (the peptide GRGDSP) into rat hippocampal slices reversibly increased the slope and amplitude of excitatory postsynaptic potentials. This effect was not accompanied by changes in paired pulse facilitation, a test for perturbations to transmitter release, or affected by suppression of inhibitory responses, suggesting by exclusion that alterations to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)-type glutamate receptors cause the enhanced responses. A mixture of function-blocking antibodies to integrin subunits alpha(3), alpha(5), and alpha(v) blocked ligand effects on synaptic responses. The ligand-induced increases were W blocked by inhibitors of Src tyrosine kinase, antagonists of N-methyl-D-aspartate receptors, and inhibitors of calcium calmodulin-dependent protein kinase II and (ii) accompanied by phosphorylation of both the Thr(286) site on calmodulin-dependent protein kinase II and the Ser(831) site on the GluR1 subunit of the AMPA receptor. N-Methyl-D-aspartate receptor antagonists blocked the latter two phosphorylation events, but Src kinase inhibitors did not. These results point to the conclusion that synaptic integrins regulate glutamatergic transmission and suggest that they do this by activating two signaling pathways directed at AMPA receptors.	Univ Calif Irvine, Dept Psychiat & Hlth Behav, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Kramar, EA (corresponding author), 101 Theory Dr,Suite 250,Univ Res Pk, Irvine, CA 92612 USA.	ekramar@uci.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037799] Funding Source: NIH RePORTER; NIMH NIH HHS [MH61007] Funding Source: Medline; NINDS NIH HHS [NS37799] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; BAHR BA, 1992, BIOCHEM J, V281, P137, DOI 10.1042/bj2810137; Bahr BA, 1997, J NEUROSCI, V17, P1320; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BI F, 2000, P NATL ACAD SCI USA, V97, P3606, DOI DOI 10.1073/PNAS.97.7.3602; Bi XN, 2001, J COMP NEUROL, V435, P184, DOI 10.1002/cne.1201; Bouvard D, 1998, J CELL SCI, V111, P657; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Chang HP, 1999, LEARN MEMORY, V6, P448, DOI 10.1101/lm.6.5.448; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; Connolly JB, 1998, CURR BIOL, V8, pR386, DOI 10.1016/S0960-9822(98)70244-1; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Einheber S, 1996, J COMP NEUROL, V370, P105; Endo A, 1999, NEUROSCI RES, V33, P1, DOI 10.1016/S0168-0102(98)00105-9; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; GALL CM, 2003, IN PRESS RECENT ADV; GEIGER B, 2002, NAT CELL BIOL, P793; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Grooms SY, 1997, NEUROSCI LETT, V231, P139, DOI 10.1016/S0304-3940(97)00524-7; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; GROSSHANS DR, 2002, NAT NEUROSCI, V22, P4406; GROTEWIEL MS, 1998, NATURE, V18, P7847; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hernandez RV, 2001, BIOL BULL, V201, P236, DOI 10.2307/1543341; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; Hoffman KB, 1998, BRAIN RES, V811, P152, DOI 10.1016/S0006-8993(98)00907-X; Hoffman KB, 1998, BRAIN RES, V811, P29, DOI 10.1016/S0006-8993(98)00906-8; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; King VR, 2001, J NEUROCYTOL, V30, P243, DOI 10.1023/A:1012753808599; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Kramar EA, 2002, NEUROSCIENCE, V110, P29, DOI 10.1016/S0306-4522(01)00540-1; KRAMAR EA, 2003, IN PRESS NEUROSCIENC; Liang F, 2001, J NEUROCHEM, V77, P1626, DOI 10.1046/j.1471-4159.2001.00377.x; Liao DZ, 2001, J NEUROSCI, V21, P6008, DOI 10.1523/JNEUROSCI.21-16-06008.2001; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; Murase S, 1998, J COMP NEUROL, V395, P161, DOI 10.1002/(SICI)1096-9861(19980601)395:2<161::AID-CNE2>3.0.CO;2-0; Nishimura SL, 1998, BRAIN RES, V791, P271, DOI 10.1016/S0006-8993(98)00118-8; Nishizaki T, 2002, MOL BRAIN RES, V98, P130, DOI 10.1016/S0169-328X(01)00331-X; PENG X, 1991, NEUROREPORT, V2, P461, DOI 10.1097/00001756-199108000-00013; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; Platts SH, 1998, AM J PHYSIOL-HEART C, V275, pH1449; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Poncer JC, 2002, J NEUROSCI, V22, P4406, DOI 10.1523/JNEUROSCI.22-11-04406.2002; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Rodriguez MA, 2000, P NATL ACAD SCI USA, V97, P3550, DOI 10.1073/pnas.050589797; Rohrbough J, 2000, J NEUROSCI, V20, P6868, DOI 10.1523/JNEUROSCI.20-18-06868.2000; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schuster T, 2001, J NEUROBIOL, V49, P142, DOI 10.1002/neu.1071; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; Staubli U, 1998, J NEUROSCI, V18, P3460; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu X, 2001, J BIOL CHEM, V276, P30285, DOI 10.1074/jbc.M102436200; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zhang JW, 1998, EUR J NEUROSCI, V10, P3358, DOI 10.1046/j.1460-9568.1998.00347.x; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	81	57	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10722	10730		10.1074/jbc.M210225200	http://dx.doi.org/10.1074/jbc.M210225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524441	hybrid			2022-12-25	WOS:000181777500095
J	Amon, M; Menger, MD; Vollmar, B				Amon, M; Menger, MD; Vollmar, B			Heme oxygenase and nitric oxide synthase mediate cooling-associated protection against TNF-alpha-induced microcirculatory dysfunction and apoptotic cell death	FASEB JOURNAL			English	Article						cooling; inflammation; apoptosis; TNF-alpha; nitric oxide; carbon monoxide; mice; microcirculation; leukocyte-endothelial cell interaction	LEUKOCYTE ADHESION; CARBON-MONOXIDE; ENDOTHELIAL-CELLS; RELAXING FACTOR; HYPOTHERMIA; EXPRESSION; INDUCTION; ISCHEMIA; INFLAMMATION; NEUTROPHILS	Local cooling protects against TNF-alpha-induced injury by attenuating inflammation-associated microcirculatory dysfunction and leukocytic response. Mechanisms of protection, however, are not fully understood. We studied whether the metabolites of the HO and NOS pathway, exerting potent vasodilatory, antioxidant, and anti-apoptotic properties, are involved in tissue cryoprotection. In animals pretreated with L-NAME or SnPP-IX, cooling-associated abrogation of TNF-alpha-induced microcirculatory dysfunction was abolished. Combined L-NAME/SnPP-IX pretreatment did not cause greater blunting than seen when each mediator system was inhibited separately. In SnPP-IX- but not L-NAME-pretreated animals, transient hypothermia failed to reduce TNF-alpha-mediated leukocyte adherence. Vice versa, treatment of TNF-alpha-exposed animals with either the NO donor L-arginine or the HO-1 inductor hemin mimicked cooling-associated tissue protection except for failure of L-arginine to abrogate the inflammatory leukocyte response. The efficiency of cooling to inhibit TNF-alpha-induced apoptotic cell death was blunted in SnPP-IX-, L-NAME-, and SnPP-IX/L-NAME-pre-treated animals. Coadministration of Trolox in SnPPIX-treated animals partly attenuated leukocyte adherence and cell apoptosis, implying that the HO pathway metabolite biliverdin contributes to the salutary effects of cooling. Thus, our study provides evidence that metabolites of the HO and the NOS pathway mediate the cooling-associated protection of inflamed tissue. Biliverdin rather than CO and NO mediates the anti-inflammatory action, whereas a coordinated function of the gaseous monoxides prevents microcirculatory dysfunction and apoptotic cell death.	Univ Saarland, Inst Clin & Expt Surg, D-66421 Homburg, Germany	Saarland University	Vollmar, B (corresponding author), Univ Rostock, Dept Expt Surg, D-18055 Rostock, Germany.	brigitte.vollmar@med.uni-rostock.de						BREASTED JH, 1930, E SMITH SURG PAPYRUS, V1; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; Clancy RM, 1998, ARTHRITIS RHEUM-US, V41, P1141, DOI 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S; CLANCY RM, 1995, P SOC EXP BIOL MED, V210, P93; COHN BT, 1989, AM J SPORT MED, V17, P344, DOI 10.1177/036354658901700306; Cullen KE, 1997, J BIOL CHEM, V272, P1742, DOI 10.1074/jbc.272.3.1742; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEHSEL K, 1995, J IMMUNOL, V155, P2858; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GRASER T, 1990, BIOMED BIOCHIM ACTA, V49, P293; Haddix TL, 1996, J SURG RES, V64, P176, DOI 10.1006/jsre.1996.0325; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Hickey MJ, 1997, J IMMUNOL, V158, P3391; HIRASAWA M, 1994, BRIT J CANCER, V70, P466, DOI 10.1038/bjc.1994.329; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kubes P, 2000, AM J MED, V109, P150, DOI 10.1016/S0002-9343(00)00480-0; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; LAING DR, 1973, NEW ZEAL MED J, V78, P155; LEHR HA, 1993, AM J PATHOL, V143, P1055; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; LUO DS, 1994, EUR J PHARM-MOLEC PH, V267, P263, DOI 10.1016/0922-4106(94)90149-X; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matz JM, 1996, PHYSIOL BEHAV, V60, P1369, DOI 10.1016/S0031-9384(96)00220-X; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; Menger MD, 2000, MICROCIRCULATION, V7, P291, DOI 10.1038/sj.mn.7300117; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morisaki H, 2001, ANESTHESIOLOGY, V95, P192, DOI 10.1097/00000542-200107000-00030; Motoyoshi N, 2001, J THORAC CARDIOV SUR, V122, P351, DOI 10.1067/mtc.2001.113935; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; Nash GB, 2001, PFLUG ARCH EUR J PHY, V442, P762, DOI 10.1007/s004240100598; OLEARY DS, 1994, AM J PHYSIOL, V266, pR1213, DOI 10.1152/ajpregu.1994.266.4.R1213; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SWAN H, 1973, SURGERY, V73, P736; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; Thorlacius H, 1998, J TRAUMA, V45, P715, DOI 10.1097/00005373-199810000-00016; Vollmar B, 2000, AM J PHYSIOL-HEART C, V279, pH1591, DOI 10.1152/ajpheart.2000.279.4.H1591; WARD ME, 1993, J APPL PHYSIOL, V74, P1606, DOI 10.1152/jappl.1993.74.4.1606; Westermann S, 1999, SURGERY, V126, P881, DOI 10.1067/msy.2099.100474; Wyllie A H, 1992, Semin Immunol, V4, P389; Xu XP, 1995, CARDIOVASC RES, V30, P841, DOI 10.1016/S0008-6363(95)00117-4; Yamauchi J, 1999, DIGEST SURG, V16, P400, DOI 10.1159/000018755; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	48	54	56	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					175	185		10.1096/fj.02-0368com	http://dx.doi.org/10.1096/fj.02-0368com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554696				2022-12-25	WOS:000181456900042
J	Bachelier, R; Xu, XL; Wang, XY; Li, WM; Naramura, M; Gu, H; Deng, CX				Bachelier, R; Xu, XL; Wang, XY; Li, WM; Naramura, M; Gu, H; Deng, CX			Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice	ONCOGENE			English	Article						T-lymphoma; Brca1; p53; tumorigenesis	DNA-DAMAGE RESPONSE; DOUBLE-STRAND BREAKS; MAMMARY EPITHELIAL-CELLS; MURINE BRCA1; CANCER SUSCEPTIBILITY; SUBCELLULAR-LOCALIZATION; ATAXIA-TELANGIECTASIA; CHROMOSOME STABILITY; GENETIC INSTABILITY; REPAIR	Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-Delta11), which disrupts the full-length isoform, but not the short isoform of Brcal, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brcal short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30% of Brca1(Delta11/Delta11)p53(+/-) mice develop thymic lymphoma between 3 and 7 months of age. We demonstrate that p53 plays an essential role in Brca1-associated lymphoma, as all the tumors from Brca1(Delta11/Delta11)p53(+/-) mice exhibit LOH of p53 and Brca1(Delta11/Delta)11p53(-/-) mice exhibited accelerated tumorigenesis. We further demonstrate that the Brca1-Delta11 deficiency does not affect thymocyte proliferation; however, it increases genetic instability and triggers gamma-irradiation-induced apoptosis. The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-Delta11 thymocytes, eventually leading to thymic lymphoma formation.	NIDDK, Genet Dev & Dis Branch, Lab Immunol, Bethesda, MD 20892 USA; NIAID, Lab Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, Lab Immunol, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016	Naramura, Mayumi/0000-0003-3658-0767	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen YM, 1996, CANCER RES, V56, P3168; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EASTON DF, 1995, AM J HUM GENET, V56, P265; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRETZULA JC, 1987, J AM ACAD DERMATOL, V17, P479, DOI 10.1016/S0190-9622(87)70233-3; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kuschel B, 2001, GENE CHROMOSOME CANC, V31, P96, DOI 10.1002/gcc.1122; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	66	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					528	537		10.1038/sj.onc.1206208	http://dx.doi.org/10.1038/sj.onc.1206208			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555066				2022-12-25	WOS:000180538200006
J	Fu, WN; Bertoni, F; Kelsey, SM; McElwaine, SM; Cotter, FE; Newland, AC; Jia, L				Fu, WN; Bertoni, F; Kelsey, SM; McElwaine, SM; Cotter, FE; Newland, AC; Jia, L			Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia	ONCOGENE			English	Article						Apaf-1; apoptosis; methylation; CpG island; real-time polymerase chain reaction	CYTOCHROME-C; INDUCED APOPTOSIS; LEUKEMIC-CELLS; CANCER; INACTIVATION; EPIGENETICS; ACTIVATION; CASPASE-9; DEATH	Apaf-1 protein deficiency occurs in human leukaemic blasts and confers resistance to cytochrome-c-dependent apoptosis. Demethylation treatment with 5-aza-2-deoxycytidine (5aza2dc) increased the sensitivity of the K562 leukaemic cell line to UV light-induced apoptosis in association with increased Apaf-1 protein levels. There was no correlation between Apaf-1 protein expression and Apaf-1 mRNA levels after the demethylation treatment. Methylation-specific polymerase chain reaction was used to show that the methylation can occur within the Apaf-1 promoter region in leukaemic blasts. Apaf-1 DNA methylation was demonstrated in acute myeloid leukaemia, chronic myeloid leukaemia and acute lymphoid leukaemia, suggesting that it is not specific to a particular leukaemia subtype. Apaf-1 protein expression did not correlate with Apaf-1 mRNA levels in human leukaemic blasts. Some leukaemic cells expressed high levels of Apaf-1 mRNA but low levels of Apaf-1 protein. This study suggests that Apaf-1 DNA promoter methylation might contribute to the inactivation of Apaf-1 expression. However, Apaf-1 protein levels might also be controlled at post-transcription level.	St Bartholomews & Royal London Sch Med & Dent, Dept Haematol Oncol, London E1 2AD, England; Osped San Giovanni Bellinzona, Oncol Inst So Switzerland, Bellinzona, Switzerland	University of London; Queen Mary University London; Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Haematol Oncol, Turner St, London E1 2AD, England.		Bertoni, Francesco/G-6922-2014	Bertoni, Francesco/0000-0001-5637-8983; Jia, Li/0000-0002-6076-8455				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Chitnis S, 2000, ARTHRITIS RES, V2, P399, DOI 10.1186/ar118; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Fu WN, 2001, BIOCHEM BIOPH RES CO, V282, P268, DOI 10.1006/bbrc.2001.4575; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu FT, 2002, BRIT J HAEMATOL, V117, P333, DOI 10.1046/j.1365-2141.2002.03418.x; Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015; Perkins C, 1998, CANCER RES, V58, P4561; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Shinoura N, 2001, INT J CANCER, V93, P252, DOI 10.1002/ijc.1327; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; van Noesel MM, 2002, CANCER RES, V62, P2157; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	22	77	89	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					451	455		10.1038/sj.onc.1206147	http://dx.doi.org/10.1038/sj.onc.1206147			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545166				2022-12-25	WOS:000180379100014
J	Nagashima, M; Shiseki, M; Pedeux, RM; Okamura, S; Kitahama-Shiseki, M; Miura, K; Yokota, J; Harris, CC				Nagashima, M; Shiseki, M; Pedeux, RM; Okamura, S; Kitahama-Shiseki, M; Miura, K; Yokota, J; Harris, CC			A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis	ONCOGENE			English	Article						PHD-finger motif; ING1; ING3; p53	CANDIDATE TUMOR-SUPPRESSOR; ALTERNATIVE TRANSCRIPTS; DNA-BINDING; P53; ACETYLATION; P33(ING1); GENE; DEACETYLASE; EXPRESSION; MUTATIONS	A candidate tumor suppressor gene, p33ING1, was previously identified by using the genetic suppressor element methodology. p33ING1 cooperates with p53 and plays a significant role in p53-mediated cellular processes. Recently, we have identified p33ING2, which shows a sequence homology similar to p33ING1 and modulates p53 function. In the present study, we identified and characterized another 'ING family' gene. The estimated molecular weight of the encoded protein is 46.8 kDa, thus, we named it p47ING3. The p47ING3 gene is located at chromosome 7q31.3 and consists of 12 exons that encode 418 amino acids. A computational domain search revealed a C-terminal PHD-finger motif. Such motifs are common in proteins involved in chromatin remodeling. p47ING3 is highly expressed in some normal human tissues or organs, including the spleen, testis, skeletal muscle, and heart. p47ING3 expression levels varied among cancer cell lines. p47ING3 overexpression resulted in a decreased population of cells in S phase, a diminished colony-forming efficiency, and induced apoptosis in RKO cells, but not in RKO-E6 cells with inactivated p53. p47ING3 activates p53-transactivated promoters, including promoters of p21/waf1 and bax. Thus, we have isolated a novel ING family gene, p47ING3, which modulates p53-mediated transcription, cell cycle control, and apoptosis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Rm 2C05, Bethesda, MD 20892 USA.	curtis_harris@nih.gov	PEDEUX, Rémy M/I-2603-2014	PEDEUX, Rémy M/0000-0002-2553-7934; Miura, Koh/0000-0001-7303-9430	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Garkavtsev I, 1999, NAT GENET, V23, P373, DOI 10.1038/15566; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Helbing CC, 1997, CANCER RES, V57, P1255; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MIYASHITA T, 1995, CELL, V80, P293; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	26	129	136	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					343	350		10.1038/sj.onc.1206115	http://dx.doi.org/10.1038/sj.onc.1206115			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545155				2022-12-25	WOS:000180379100003
J	Wang, SN; Mori, Y; Sato, F; Yin, J; Xu, Y; Zou, TT; Olaru, A; Kimos, MC; Perry, K; Selaru, FM; Deacu, E; Sun, MH; Shi, YC; Shibata, D; Abraham, JM; Greenwald, BD; Meltzer, SJ				Wang, SN; Mori, Y; Sato, F; Yin, J; Xu, Y; Zou, TT; Olaru, A; Kimos, MC; Perry, K; Selaru, FM; Deacu, E; Sun, MH; Shi, YC; Shibata, D; Abraham, JM; Greenwald, BD; Meltzer, SJ			An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma	ONCOGENE			English	Article						esophageal cancer; ST7; 7q31; LOH; mutation; expression	TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; HETEROZYGOSITY; REGION; 7Q31.1	Frequent loss of heterozygosity (LOH) on human chromosome 7q31 has been reported in numerous malignancies. Suppressor of tumorigenicity 7 (ST7) has been identified as a candidate tumor suppressor gene in this region. To identify whether 7q31 and genetic alterations of ST7 were involved in human esophageal carcinogenesis, we performed LOH mapping of a 5.4cM region at 7q31-q35 in 43 primary esophageal carcinomas, as well as mutational analyses of the ST7 gene in tumors with LOH in this region. Of 43 tumors, 12 (28%) showed LOH at 7q31-q35. These included four (22%) of 18 squamous cell carcinomas and eight (32%) of 25 adenocarcinomas. The peak LOH locus was D7S480, lying 4.2 Mb telomeric to ST7 and showing LOH in eight of 37 informative tumors, or 22%. No mutations were found in the entire coding or flanking intronic regions of the ST7 gene among 12 tumors with 7q-LOH. In addition, quantitative RT-PCR analyses of ST7 mRNA expression levels in 11/13 normal-tumor pairs failed to show more than a 50% decrease in tumor ST7 mRNA relative to matched normal tissues. These data suggest that LOH at 7q31-q35 is involved in the origin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target gene of this somatic event.	Univ Maryland, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Baltimore VA Hosp, Sch Med,Greenbaum Canc Ctr, Div Surg Oncol,Dept Surg, Baltimore, MD 21201 USA; Fudan Univ, Coll Med, Dept Pathol, Shanghai 200433, Peoples R China	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Fudan University	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Div Gastroenterol, Dept Med, 22 S Greene St, Baltimore, MD 21201 USA.			Perry, Kellie/0000-0001-6238-8221; Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [CA77057, CA95323, CA85069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095323, U01CA085069, R01CA077057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; Hughes KA, 2001, NAT GENET, V29, P380, DOI 10.1038/ng783; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Miller BA, 1996, NIH PUB, V96-4104; Mori Y, 2001, CANCER RES, V61, P6046; Riegman PHJ, 2001, CANCER RES, V61, P3164; Roth MJ, 2001, CANCER RES, V61, P4098; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Thomas NA, 2001, NAT GENET, V29, P379, DOI 10.1038/ng784; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; van Dekken H, 1999, J PATHOL, V188, P263, DOI 10.1002/(SICI)1096-9896(199907)188:3<263::AID-PATH374>3.0.CO;2-Y; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	19	11	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					467	470		10.1038/sj.onc.1206125	http://dx.doi.org/10.1038/sj.onc.1206125			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545169				2022-12-25	WOS:000180379100017
J	Yuan, BZ; Zhou, XL; Durkin, ME; Zimonjic, DB; Gumundsdottir, K; Eyfjord, JE; Thorgeirsson, SS; Popescu, NC				Yuan, BZ; Zhou, XL; Durkin, ME; Zimonjic, DB; Gumundsdottir, K; Eyfjord, JE; Thorgeirsson, SS; Popescu, NC			DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity	ONCOGENE			English	Article						tumor suppressor gene; breast cancer; colon cancer; prostate cancer; tumorigenicity; metastasis	TUMOR-SUPPRESSOR GENE; CHROMOSOME 8P DELETION; HEPATOCELLULAR-CARCINOMA; RHO GTPASES; METASTASIS; IDENTIFICATION; ASSOCIATION; LINKAGE; PROTEIN; CLONING	The human DLC-1 (deleted in liver cancer 1) gene was cloned from a primary human hepatocellular carcinoma (HCC) and mapped to the chromosome 8p21-22 region frequently deleted in common human cancers and suspected to harbor tumor suppressor genes. DLC-1 was found to be deleted or downregulated in a significant number of HCCs. We expanded our investigations to other cancers with recurrent deletions of 8p22, and in this study examined alterations of DLC-1 in primary human breast tumors, human breast, colon, and prostate tumor cell lines. Genomic deletion of DLC-1 was observed in 40% of primary breast tumors, whereas reduced or undetectable levels of DLC-1 mRNA were seen in 70% of breast, 70% of colon, and 50% of prostate tumor cell lines To see whether DLC-1 expression affects cell growth and tumorigenicity, two breast carcinoma cell lines lacking the expression of endogenous gene were transfected with the DLC-1 cDNA. In both cell lines, DLC-1 transfection caused significant growth inhibition and reduction of colony formation. Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.	NCI, Expt Carcinogenesis Lab, Canc Res Ctr, Bethesda, MD 20892 USA; Iceland Canc Soc, Reykjavik, Iceland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Expt Carcinogenesis Lab, Canc Res Ctr, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [Z01BC010038, ZIABC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P4169, DOI 10.1038/sj.onc.1204539; Durkin ME, 2002, GENE, V288, P119, DOI 10.1016/S0378-1119(02)00462-6; Euer N, 2002, ANTICANCER RES, V22, P733; Gustafson CE, 1996, CANCER RES, V56, P5238; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ng IOL, 2000, CANCER RES, V60, P6581; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Xu JF, 2001, AM J HUM GENET, V69, P341, DOI 10.1086/321967; YAREMKO ML, 1998, GENE CHROMOSOME CANC, V21, P189; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 1999, CYTOGENET CELL GENET, V87, P189, DOI 10.1159/000015462; YUAN BZ, IN PRESS CANC GENET; YUAN BZ, 2000, P AM ASSOC CANC RES, V41, P105; Zimonjic DB, 2000, INT J ONCOL, V16, P221; Zitzelsberger H, 1997, HISTOCHEM CELL BIOL, V108, P403, DOI 10.1007/s004180050181	29	126	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					445	450		10.1038/sj.onc.1206064	http://dx.doi.org/10.1038/sj.onc.1206064			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545165				2022-12-25	WOS:000180379100013
J	Hodgson, L; Henderson, AJ; Dong, C				Hodgson, L; Henderson, AJ; Dong, C			Melanoma cell migration to type IV collagen requires activation of NF-kappa B	ONCOGENE			English	Article						chemotaxis; integrin; GTPase; transactivation; A2058	FOCAL ADHESION KINASE; ANTIINFLAMMATORY SESQUITERPENE LACTONE; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVITY; EXTRACELLULAR-MATRIX; RHO; CDC42; GTPASES; RAC	Chemotaxis is the consequence of environmental factors engaging their receptors to initiate signaling cascades. However, the biochemical mechanisms controlling this phenomenon are not clear. We employed an in vitro modified Boyden 48-well chemotaxis migration system to characterize the role of signal transducers in type IV collagen (CIV) induced A2058 human melanoma cell migration. Using specific pharmacological inhibitors and a series of dominant-negative and constitutively active signaling proteins, we show that Ras and Rac GTPases, PI-3K, and PKC participate in cell migration mediated by beta1 integrins. Collagen also induces a time-dependent degradation of IkappaB-alpha and an increase in nuclear translocation of NF-kappaB which is dependent on PKC pathway. More importantly, collagen-stimulated melanoma cell migration directly correlated with an increase in NF-kappaB transactivation. Furthermore, CIV induced an increase in beta1 integrin mRNA levels. Specific NF-kappaB inhibitors Helenalin and SN-50 inhibited melanoma cell migration to collagen, indicating a novel requirement for NF-kappaB transactivation in cell chemotaxis mediated by beta1 integrin signals. These results describe signal transduction events that are initiated by type IV collagen through beta1 integrins and demonstrate an important role for NF-kappaB in regulating melanoma chemotaxis.	Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Dong, C (corresponding author), Penn State Univ, Dept Bioengn, 229 Hallowell, University Pk, PA 16802 USA.	exd23@psu.edu		Henderson, Andrew/0000-0002-9299-5302; Hodgson, Louis/0000-0001-9188-7580	NATIONAL CANCER INSTITUTE [R29CA076434, R01CA097306] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046261] Funding Source: NIH RePORTER; NCI NIH HHS [CA76434, R01 CA097306, R01 CA097306-01A1, R01 CA097306-02] Funding Source: Medline; NCRR NIH HHS [M01 RR010732-110202, M01 RR010732-090202, M01 RR010732, M01 RR010732-080202, M01 RR010732-070202, M01 RR010732-100202, M01 RR010732-060202] Funding Source: Medline; NIAID NIH HHS [AI46261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Benoliel AM, 1997, J CELL SCI, V110, P2089; Boukerche H, 2000, CANCER RES, V60, P5848; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; Hodgson L, 2001, AM J PHYSIOL-CELL PH, V281, pC106, DOI 10.1152/ajpcell.2001.281.1.C106; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palmantier R, 2001, CANCER RES, V61, P2445; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pasco S, 2000, CANCER RES, V60, P467; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POWIS G, 1994, CANCER CHEMOTH PHARM, V34, P344, DOI 10.1007/BF00686043; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHNAPER HW, 1993, PEDIATR NEPHROL, V7, P96, DOI 10.1007/BF00861587; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Stracke M L, 1994, In Vivo, V8, P49; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; VAN AL, 1997, GENE DEV, V11, P2295; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	55	34	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					98	108		10.1038/sj.onc.1206059	http://dx.doi.org/10.1038/sj.onc.1206059			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527912	Green Accepted			2022-12-25	WOS:000180166900011
J	Hausmann, S; Shuman, S				Hausmann, S; Shuman, S			Defining the active site of Schizosaccharomyces pombe C-terminal domain phosphatase fcp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROTEIN PHOSPHATASE; PHOSPHOSERINE PHOSPHATASE; MUTATIONAL ANALYSIS; CATALYTIC DOMAIN; CTD PHOSPHATASE; TRANSCRIPTION; SUBUNIT; DEPHOSPHORYLATION; PURIFICATION	Fcp1 is an essential protein serine phosphatase that dephosphorylates the C-terminal domain (CTD) of RNA polymerase 11. By testing the effects of serial N- and C-terminal deletions of the 723-amino acid Schizosaccharomyces pombe Fcp1, we defined a minimal phosphatase domain spanning amino acids 156-580. We employed site-directed mutagenesis (introducing 24 mutations at 14 conserved positions) to locate candidate catalytic residues. We found that alanine substitutions for Arg(223), Asp(258), Lys(280), Asp(297), and Asp(298) abrogated the phosphatase activity with either p-nitrophenyl phosphate or CTD-PO4 as substrates. Structure-activity relationships were determined by introducing conservative substitutions at each essential position. Our results, together with previous mutational studies, highlight a constellation of seven amino acids (Asp(170), Asp(172), Arg(223), Asp(258), Lys(280), Asp(297), and Asp(298)) that are conserved in all Fcp1 orthologs and likely comprise the active site. Five of these residues (Asp(170), Asp(172) Lys(280), Asp(297), and Asp (298)) are conserved at the active site of T4 polynucleotide X-phosphatase, suggesting that Fcp1 and T4 phosphatase are structurally and mechanistically related members of the DXD phosphotransferase superfamily.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hirose Y, 2000, GENE DEV, V14, P1415; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; Mandal SS, 2002, MOL CELL BIOL, V22, P7543, DOI 10.1128/MCB.22.21.7543-7552.2002; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8	29	22	22	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13627	13632		10.1074/jbc.M213191200	http://dx.doi.org/10.1074/jbc.M213191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556522	hybrid			2022-12-25	WOS:000182405000010
J	Lee, M; Metso, J; Jauhiainen, M; Kovanen, PT				Lee, M; Metso, J; Jauhiainen, M; Kovanen, PT			Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; APOLIPOPROTEIN-B; HDL; ATHEROSCLEROSIS; PARTICLES; SECRETION; RESISTANT; TRANSPORT; GRANULES; ABILITY	Human atherosclerotic lesions contain mast cells filled with the neutral protease chymase. Here we studied the effect of human chymase on W phospholipid transfer protein (PLTP)-mediated phospholipid (PL) transfer activity, and (ii) the ability of PLTP to generate pre-beta-high density lipoprotein (HDL). Immunoblot analysis of PLTP after incubation with chymase for 6 h revealed, in addition to the original 80-kDa band, four specific proteolytic fragments of PLTP with approximate molecular masses of 70, 52, 48, and 31 kDa. This specific pattern of PLTP degradation remained stable for at least 24 h of incubation with chymase. Such proteolyzed PLTP had reduced ability (i) to transfer PL from liposome donor particles to acceptor HDL3 particles, and (ii) to facilitate the formation of pre-beta-HDL. However, when PLTP was incubated with chymase in the presence of HDL3 only one major cleavage product of PLTP (48 kDa) was generated, and PL, transfer activity was almost fully preserved. Moreover, chymase effectively depleted the pre-beta-HDL particles generated from HDL3 by PLTP and significantly inhibited the high affinity component of cholesterol efflux from macrophage foam cells. These results suggest that the mast cells in human atherosclerotic lesions, by secreting chymase, may prevent PLTP-dependent formation of pre-beta-HDL particles from HDL3 and so impair the anti-atherogenic function of PLTP.	Wihuri Res Inst, Helsinki 00140, Finland; Univ Havana, Fac Biol, Havana 10400, Cuba; Natl Publ Hlth Inst, Dept Mol Med, FIN-00290 Helsinki, Finland	Wihuri Research Institute; Universidad de la Habana; Finland National Institute for Health & Welfare	Kovanen, PT (corresponding author), Wihuri Res Inst, Kalliolinnatie 4, Helsinki 00140, Finland.	petri.kovanen@wri.fi						BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CAUGHEY GH, 1998, HDB PROTEOLYTIC ENZY, P66; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DAY JR, 1994, J BIOL CHEM, V269, P9388; Desrumaux C, 2001, J BIOL CHEM, V276, P5908, DOI 10.1074/jbc.M008420200; Dullaart RPF, 2001, SCAND J CLIN LAB INV, V61, P69; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Huuskonen J, 1998, J LIPID RES, V39, P2021; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2001, ATHEROSCLEROSIS, V155, P269, DOI 10.1016/S0021-9150(01)00447-6; Huuskonen J, 1998, BBA-LIPID LIPID MET, V1391, P181, DOI 10.1016/S0005-2760(98)00008-3; Jaari S, 2001, COMP BIOCHEM PHYS B, V128, P781, DOI 10.1016/S1096-4959(01)00297-4; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; Karkkainen M, 2002, J BIOL CHEM, V277, P15413, DOI 10.1074/jbc.M112247200; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee M, 1999, ARTERIOSCL THROM VAS, V19, P1066, DOI 10.1161/01.ATV.19.4.1066; Lee M, 2002, ARTERIOSCL THROM VAS, V22, P1475, DOI 10.1161/01.ATV.0000029782.84357.68; Lee M, 2000, J LIPID RES, V41, P975; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; Lindstedt L, 2001, ATHEROSCLEROSIS, V155, P87, DOI 10.1016/S0021-9150(00)00544-X; MarquesVidal P, 1997, ATHEROSCLEROSIS, V133, P87, DOI 10.1016/S0021-9150(97)00120-2; Oka T, 2000, J LIPID RES, V41, P1651; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Haperen R, 2000, ARTERIOSCL THROM VAS, V20, P1082, DOI 10.1161/01.ATV.20.4.1082; van Haperen R, 2002, J BIOL CHEM, V277, P48938, DOI 10.1074/jbc.M209128200; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; vonEckardstein A, 1996, BBA-LIPID LIPID MET, V1301, P255, DOI 10.1016/0005-2760(96)00050-1; Wolfbauer G, 1999, BBA-MOL CELL BIOL L, V1439, P65, DOI 10.1016/S1388-1981(99)00077-3; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	43	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13539	13545		10.1074/jbc.M210847200	http://dx.doi.org/10.1074/jbc.M210847200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12531890	hybrid			2022-12-25	WOS:000182189500118
J	Rai, R; Tate, JJ; Cooper, TG				Rai, R; Tate, JJ; Cooper, TG			Ure2, a prion precursor with homology to glutathione S-transferase, protects Saccharomyces cerevisiae cells from heavy metal ion and oxidant toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; GENE-EXPRESSION; YEAST; ALPHA; MKS1; TRANSCRIPTION; BIOSYNTHESIS; GENERATION; ENCODES; REGION	Ure2, the protein that negatively regulates GATA factor (GIn3, Gat1)-mediated transcription in Saccharomyces cerevisiae, possesses prion-like characteristics. Identification of metabolic and environmental factors that influence prion formation as well as any activities that prions or prion precursors may possess are important to understanding them and developing treatment strategies for the diseases in which they participate. Ure2 exhibits primary sequence and three-dimensional homologies to known glutathione S-transferases. However, multiple attempts over nearly 2 decades to demonstrate Ure2-mediated S-transferase activity have been unsuccessful, leading to the possibility that Ure2 may wen not participate in glutathionation reactions. Here we show that Ure2 is required for detoxification of glutathione S-transferase substrates and cellular oxidants. ure2Delta mutants are hypersensitive to cadmium and nickel ions and hydrogen peroxide. They are only slightly hypersensitive to diamide, which is nitrogen source-dependent, and minimally if at all hypersensitive to 1-chloro-2,4-dinitrobenzene, the most commonly used substrate for glutathione S-transferase enzyme assays. Therefore, Ure2 shares not only structural homology with various glutathione S-transferases, but ure2 mutations possess the same phenotypes as mutations in known S. cerevisiae and Schizosaccharomyces pombe glutathione S-transferase genes. These findings are consistent with Ure2 serving as a glutathione S-transferase in S. cerevisiae.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avendano A, 1997, J BACTERIOL, V179, P5594, DOI 10.1128/jb.179.17.5594-5597.1997; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cunningham TS, 2000, J BACTERIOL, V182, P6584, DOI 10.1128/JB.182.23.6584-6591.2000; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Fraser JA, 2002, APPL ENVIRON MICROB, V68, P2802, DOI 10.1128/AEM.68.6.2802-2808.2002; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LACROUTE F, 1968, J BACTERIOL, V95, P824, DOI 10.1128/JB.95.3.824-832.1968; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MAGASANIK B, 1993, MOL CELLULAR BIOL YE, P2853; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Sherratt PJ, 1997, BIOCHEM J, V326, P837, DOI 10.1042/bj3260837; Shin YH, 2002, BBA-GENE STRUCT EXPR, V1577, P164, DOI 10.1016/S0167-4781(02)00422-0; Tan KL, 1996, BIOCHEM J, V315, P727, DOI 10.1042/bj3150727; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Veal EA, 2002, J BIOL CHEM, V277, P35523, DOI 10.1074/jbc.M111548200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	39	54	54	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12826	12833		10.1074/jbc.M212186200	http://dx.doi.org/10.1074/jbc.M212186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562760	Green Accepted, hybrid			2022-12-25	WOS:000182189500032
J	Masuda, Y; Ohmae, M; Masuda, K; Kamiya, K				Masuda, Y; Ohmae, M; Masuda, K; Kamiya, K			Structure and enzymatic properties of a stable complex of the human REV1 and REV7 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ZETA; DEOXYCYTIDYL TRANSFERASE-ACTIVITY; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; DCMP TRANSFERASE; UV MUTAGENESIS; HUMAN HOMOLOG; ABASIC SITES; ERROR-PRONE; YEAST	With yeast Saccharomyces cerevisiae, results from a variety of genetic and biochemical investigations have demonstrated that the REV genes play a major role in induction of mutations through replication processes that directly copy the damaged DNA template during DNA replication. However, in higher eucaryotes functions of homologues are poorly understood and appear somewhat different from the yeast case. It has been suggested that human REV1 interacts with human REV7, this being specific to higher eucaryotes. Here we show that purified human REV1 and REV7 proteins form a heterodimer in solution, which is stable through intensive purification steps. Results from biochemical analysis of the transferase reactions of the REV1-REV7 complex demonstrated, in contrast to the case of yeast Rev3 whose polymerase activity is stimulated by assembly with yeast Rev7, that human REV7 did not influence the stability, substrate specificity, or kinetic parameters of the transferase reactions of REV1 protein. The possible role of human REV7 is discussed.	Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Kamiya, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.		Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988				Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo DY, 2001, NUCLEIC ACIDS RES, V29, P2875, DOI 10.1093/nar/29.13.2875; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; LAWRENCE CW, 1985, MOL GEN GENET, V200, P80, DOI 10.1007/BF00383316; Lawrence CW, 1996, CANCER SURV, V28, P21; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; LAWRENCE CW, 1976, GENETICS, V82, P207; LEMONTT JF, 1971, GENETICS, V68, P21; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Masuda Y, 2002, FEBS LETT, V520, P88, DOI 10.1016/S0014-5793(02)02773-4; Masuda Y, 2002, J BIOL CHEM, V277, P3040, DOI 10.1074/jbc.M110149200; Masuda Y, 2001, J BIOL CHEM, V276, P15051, DOI 10.1074/jbc.M008082200; MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Otsuka C, 2002, MUTAT RES-FUND MOL M, V502, P53, DOI 10.1016/S0027-5107(02)00023-4; Sambrook J., 2002, MOL CLONING LAB MANU; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Xiao W, 2000, GENETICS, V155, P1633; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630	33	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12356	12360		10.1074/jbc.M211765200	http://dx.doi.org/10.1074/jbc.M211765200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529368	hybrid			2022-12-25	WOS:000182015700082
J	Samaras, SE; Zhao, L; Means, A; Henderson, E; Matsuoka, T; Stein, R				Samaras, SE; Zhao, L; Means, A; Henderson, E; Matsuoka, T; Stein, R			The islet beta cell-enriched RIPE3b1/Maf transcription factor regulates pdx-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR 3-BETA; DNA-BINDING ACTIVITY; INSULIN-II GENE; C-MAF; LENS DEVELOPMENT; FACTOR IDX1/IPF1; DISTINCT ROLES; NEURAL CELLS; PAX6; DIFFERENTIATION	Pancreatic duodenal homeobox factor-1, PDX-1, is required for pancreas development, islet cell differentiation, and the maintenance of 0 cell function. Selective expression in the pancreas appears to be principally regulated by Area II, one of four conserved regulatory sequence domains found within the 5'-flanking region of the pdx-1 gene. Detailed mutagenesis studies have identified potential sites of interaction for both positive- and negative-acting factors within the conserved sequence blocks of Area II. The islet beta cell-enriched RIPE3b1 transcription factor, the activator of insulin C1 element-driven expression, was shown here to also stimulate Area II by binding to sequence blocks 4 and 5 (termed B4/5). Accordingly, B4/5 DNA-binding protein's molecular mass (i.e. 46 kDa), binding specificity, and islet beta cell-enriched distribution were identical to RIPE3b1. Area II-mediated activation was also unaffected upon replacing B4/5 with the insulin C1/RIPE3b1 binding site. In addition, the chromatin immunoprecipitation assay showed that the Area II region of the endogenous pdx-1 gene was precipitated by an antiserum that recognizes the large Maf protein that comprises the RIPE3b1 transcription factor. These results strongly suggest that RIPE3b1/Maf has an important role in generating and maintaining physiologically functional beta cells.	Vanderbilt Univ, Dept Physiol & Mol Biophys, Ctr Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Surg Oncol, Ctr Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Dept Physiol & Mol Biophys, Ctr Med, 221 Kirkland Hall, Nashville, TN 37232 USA.	Roland.Stein@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042502, R01DK050203, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK42502, R01 DK50203, P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Brink C, 2001, MECH DEVELOP, V100, P37, DOI 10.1016/S0925-4773(00)00500-1; Civil A, 2002, NUCLEIC ACIDS RES, V30, P975, DOI 10.1093/nar/30.4.975; Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DEWIT L, 1993, BIOCHEM BIOPH RES CO, V192, P840, DOI 10.1006/bbrc.1993.1491; Gannon M, 2001, DEV BIOL, V238, P185, DOI 10.1006/dbio.2001.0359; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Ishibashi S, 2001, MECH DEVELOP, V101, P155, DOI 10.1016/S0925-4773(00)00585-2; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KATO K, 1981, BIOCHIM BIOPHYS ACTA, V660, P30, DOI 10.1016/0005-2744(81)90104-2; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Lee CS, 2002, DIABETES, V51, P2546, DOI 10.2337/diabetes.51.8.2546; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; Marshak S, 2001, DIABETES, V50, pS37, DOI 10.2337/diabetes.50.2007.S37; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; Matsuoka T, 2001, J BIOL CHEM, V276, P22071, DOI 10.1074/jbc.M010321200; MOSSELMAN S, 1990, FEBS LETT, V271, P33, DOI 10.1016/0014-5793(90)80365-P; Muta M, 2002, GENES CELLS, V7, P791, DOI 10.1046/j.1365-2443.2002.00560.x; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Perez-Villamil B, 1999, ENDOCRINOLOGY, V140, P3857, DOI 10.1210/en.140.8.3857; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Reza HM, 2002, MECH DEVELOP, V116, P61, DOI 10.1016/S0925-4773(02)00137-5; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; Samaras SE, 2002, MOL CELL BIOL, V22, P4702, DOI 10.1128/MCB.22.13.4702-4713.2002; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz PT, 2000, J BIOL CHEM, V275, P19106, DOI 10.1074/jbc.M000655200; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; WEST RE, 1982, LIFE SCI, V31, P1335, DOI 10.1016/0024-3205(82)90375-7; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xu PX, 1999, DEVELOPMENT, V126, P383; Xu ZP, 1997, J BIOL CHEM, V272, P3430, DOI 10.1074/jbc.272.6.3430; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	64	51	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12263	12270		10.1074/jbc.M210801200	http://dx.doi.org/10.1074/jbc.M210801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551916	hybrid			2022-12-25	WOS:000182015700071
J	Speare, JO; Rush, TS; Bloom, ME; Caughey, B				Speare, JO; Rush, TS; Bloom, ME; Caughey, B			The role of helix 1 aspartates and salt bridges in the stability and conversion of prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; CELL-FREE CONVERSION; SECONDARY STRUCTURE; PRP 27-30; PURIFICATION; AGGREGATION; SIMULATIONS; SPECIFICITY; DISEASES; BINDING	A key event in the pathogenesis of transmissible spongiform encephalopathies is the conversion of PrP-sen to PrP-res. Morrissey and Shakhnovich (Morrissey, M. P., and Shakhnovich, E. I. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11293-11298) proposed that the conversion mechanism involves critical interactions at helix 1 (residues 144-153) and that the helix is stabilized on PrP-sen by intra-helix salt bridges between two aspartic acid-arginine ion pairs at positions 144 and 148 and at 147 and 151, respectively. Mutants of the hamster prion protein were constructed by replacing the aspartic acids with either asparagines or alanines to destabilize the proposed helix 1 salt bridges. Thermal and chemical denaturation experiments using circular dichroism spectroscopy indicated the overall structures of the mutants are not substantially destabilized but appear to unfold differently. Cell-free conversion reactions per. formed using ionic denaturants, detergents, and salts (conditions unfavorable to salt bridge formation) showed no significant differences between conversion efficiencies of mutant and wild type proteins. Using conditions more favorable to salt bridge formation, the mutant proteins converted with up to 4-fold higher efficiency than the wild type protein. Thus, although spectroscopic data indicate the salt bridges do not substantially stabilize PrP-sen, the cell-free conversion data suggest that Asp-144 and Asp-147 and their respective salt bridges stabilize PrP-sen from converting to PrP-res.	NIAID, Rocky Mt Lab, Lab Persistent Viral Dis, NIH, Hamilton, MT 59840 USA; Univ Montana, Dept Chem, Missoula, MT 59812 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Montana System; University of Montana	Caughey, B (corresponding author), NIAID, Rocky Mt Lab, Lab Persistent Viral Dis, NIH, Hamilton, MT 59840 USA.	bcaughey@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000580, ZIAAI000580, Z01AI000908] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso DOV, 2001, ADV PROTEIN CHEM, V57, P107; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Caughey B, 2001, ADV PROTEIN CHEM, V57, P139; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morrissey MP, 1999, P NATL ACAD SCI USA, V96, P11293, DOI 10.1073/pnas.96.20.11293; Nakamura H, 1996, Q REV BIOPHYS, V29, P1, DOI 10.1017/S0033583500005746; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Rezaei H, 2000, EUR J BIOCHEM, V267, P2833, DOI 10.1046/j.1432-1033.2000.01347.x; ROBERTSON MN, 1992, J VIROL, V66, P3271, DOI 10.1128/JVI.66.6.3271-3277.1992; RUBENSTEIN R, 1986, J GEN VIROL, V67, P671, DOI 10.1099/0022-1317-67-4-671; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Vorberg I, 2001, J VIROL, V75, P10024, DOI 10.1128/JVI.75.21.10024-10032.2001; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Zuegg J, 1999, BIOCHEMISTRY-US, V38, P13862, DOI 10.1021/bi991469d	46	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12522	12529		10.1074/jbc.M211599200	http://dx.doi.org/10.1074/jbc.M211599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551897	hybrid			2022-12-25	WOS:000182015700104
J	Wouters, J; Oudjama, Y; Barkley, SJ; Tricot, C; Stalon, V; Droogmans, L; Poulter, CD				Wouters, J; Oudjama, Y; Barkley, SJ; Tricot, C; Stalon, V; Droogmans, L; Poulter, CD			Catalytic mechanism of Escherichia coli isopentenyl diphosphate isomerase involves Cys-67, Glu-116, and Tyr-104 as suggested by crystal structures of complexes with transition state analogues and irreversible inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYLALLYL DIPHOSPHATE; ACTIVE-SITE; IDENTIFICATION; BIOSYNTHESIS; GENE; TRP	Isopentenyl diphosphate (IPP):dimethylallyl diphosphate (DMAPP) isomerase is a key enzyme in the biosynthesis of isoprenoids. The reaction involves protonation and deprotonation of the isoprenoid unit and proceeds through a carbocationic transition state. Analysis of the crystal structures (2 Angstrom) of complexes of Escherichia coli IPP(.)DMAPPs isomerase with a transition state analogue (N,N-dimethyl-2-amino-1-ethyl diphosphate) and a covalently attached irreversible inhibitor (3,4-epoxy-3methyl-1-butyl diphosphate) indicates that Glu-116, Tyr-104, and Cys-67 are involved in the antarafacial addition/elimination of protons during isomerization. This work provides a new perspective about the mechanism of the reaction.	Inst Rech Microbiol JM Wiame, B-1070 Brussels, Belgium; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium; Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Utah System of Higher Education; University of Utah	Wouters, J (corresponding author), Inst Rech Microbiol JM Wiame, 1 Av E Gryzon, B-1070 Brussels, Belgium.			Wouters, Johan/0000-0002-4920-6857	NIGMS NIH HHS [GM25521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025521] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonanno JB, 2001, P NATL ACAD SCI USA, V98, P12896, DOI 10.1073/pnas.181466998; CLIFFORD K, 1971, J CHEM SOC CHEM COMM, P1699; CORNFORTH RH, 1969, METHOD ENZYMOL, V15, P359; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Durbecq V, 2001, EMBO J, V20, P1530, DOI 10.1093/emboj/20.7.1530; Hahn FM, 1999, J BACTERIOL, V181, P4499, DOI 10.1128/JB.181.15.4499-4504.1999; Hoeffler JF, 2002, BIOCHEM J, V366, P573, DOI 10.1042/BJ20020337; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leyes AE, 1999, CHEM COMMUN, P717, DOI 10.1039/a900621d; LU XJ, 1992, BIOCHEMISTRY-US, V31, P9955, DOI 10.1021/bi00156a014; MUELBACHER M, 1988, BIOCHEMISTRY-US, V27, P7315; Oudjama Y, 2001, ACTA CRYSTALLOGR D, V57, P287, DOI 10.1107/S0907444900017571; POULTER CD, 1989, J AM CHEM SOC, V111, P3740, DOI 10.1021/ja00192a037; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, V1, P162; REARDON JE, 1986, BIOCHEMISTRY-US, V25, P5609, DOI 10.1021/bi00367a040; Roussel A, 1992, TURBO FRODO BIOGRAPH; SATTERWHITE DM, 1985, METHOD ENZYMOL, V110, P92; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; STREET IP, 1994, BIOCHEMISTRY-US, V33, P4212, DOI 10.1021/bi00180a014; STREET IP, 1990, J AM CHEM SOC, V112, P8577, DOI 10.1021/ja00179a049; Wouters J, 1998, PROTEIN SCI, V7, P2472, DOI 10.1002/pro.5560071127	22	67	70	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11903	11908		10.1074/jbc.M212823200	http://dx.doi.org/10.1074/jbc.M212823200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540835	hybrid			2022-12-25	WOS:000182015700025
J	Coulthard, VH; Matsuda, S; Heery, DM				Coulthard, VH; Matsuda, S; Heery, DM			An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; THYROID-HORMONE RECEPTOR; ESTROGEN-RECEPTOR; LIGAND-BINDING; COACTIVATOR COMPLEX; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; PROTEIN; ALPHA; BETA	The interaction of coactivators with the ligand-binding domain of nuclear receptors (NRs) is mediated by amphipathic a-helices containing the signature motif LXXLL. TRAP220 contains two LXXLL motifs (LXM1 and LXM2) that are required for its interaction with NRs. Here we show that the nuclear receptor interaction domain (NID) of TRAP220 interacts weakly with Class I NRs. In contrast, SRC1 NID binds strongly to both Class I and Class II NRs. Interaction assays using nine amino acid LXXLL core motifs derived from SRC1 and TRAP220 revealed no discriminatory NR binding preferences. However, an extended LXMl sequence containing amino acids -4 to +9, (where the first conserved leucine is +1) showed selective binding to thyroid hormone receptor and reduced binding to estrogen receptor. Replacement of either TRAP220 LXXLL motif with the corresponding 13 amino acids of SRC1 LXM2 strongly enhanced the interaction of the TRAP220 NID with the estrogen receptor. Mutational analysis revealed combinatorial effects of the LXMl core and flanking sequences in the determination of the NR binding specificity of the TRAP220 NID. In contrast, a mutation that increased the spacing between TRAP220 LXM1 and LXM2 had little effect on the binding properties of this domain. Thus, a 13-amino acid sequence comprising an extended LXXLL motif acts as the key determinant of the NR binding specificity of TRAP220. Finally, we show that the NR binding specificity of full-length TRAP220 can be altered by swapping extended LXM sequences.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Heery, DM (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Heery, David/0000-0002-5035-2392				Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2002, EMBO J, V21, P3464, DOI 10.1093/emboj/cdf348; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Ko L, 2002, MOL ENDOCRINOL, V16, P128, DOI 10.1210/me.16.1.128; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Le Douarin B, 2001, METH MOL B, V176, P227; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Li DS, 1999, MOL CELL BIOL, V19, P7191; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Mak HY, 1999, MOL CELL BIOL, V19, P3895; Malik S, 2002, MOL CELL BIOL, V22, P5626, DOI 10.1128/MCB.22.15.5626-5637.2002; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suzuki T, 2001, P NATL ACAD SCI USA, V98, P12403, DOI 10.1073/pnas.221552998; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	58	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10942	10951		10.1074/jbc.M212950200	http://dx.doi.org/10.1074/jbc.M212950200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12556447	hybrid			2022-12-25	WOS:000181855400011
J	Minoguchi, M; Minoguchi, S; Aki, D; Joo, A; Yamamoto, T; Yumioka, T; Matsuda, T; Yoshimura, A				Minoguchi, M; Minoguchi, S; Aki, D; Joo, A; Yamamoto, T; Yumioka, T; Matsuda, T; Yoshimura, A			STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TYROSINE KINASE; CELLULAR-TRANSFORMATION; MOLECULAR-CLONING; JAK/STAT PATHWAY; DOCKING PROTEIN; GENE-REGULATION; SH2 DOMAINS; RECEPTOR; FAMILY	As a c-fins-interacting protein, we cloned a novel adaptor molecule, signal-transducing adaptor protein-2 (STAP-2), which contains pleckstrin homology- and Src homology 2-like (PH and SRC) domains and a proline-rich region. STAP-2 is structurally related to STAP-1/BRDG1 (BCR downstream signaling-1), which we had cloned previously from hematopoietic stem cells. STAP-2 is a murine homologue of a recently identified adaptor molecule, BKS, a substrate of BRK tyrosine kinase. STAP-2 was tyrosine-phosphorylated and translocated to the plasma membrane in response to epidermal growth factor when overexpressed in fibroblastic cells. To define the function of STAP-2, we generated mice lacking the STAP-2 gene. STAP-2 mRNA was strongly induced in the liver in response to lipopolysaccharide and in isolated hepatocytes in response to interleukin-6. In the STAP-2(-/-) hepatocytes, the interleukin-6-induced expression of acute-phase (AP) genes and the tyrosine-phosphorylation level of STAT3 were reduced specifically at the late phase (6-24 h) of the response. These data indicate that STAP-2 plays a regulatory role in the AP response in systemic inflammation. STAP-2 contains a YXXQ motif in the C-terminal region that is a potential STAT3-binding site. Overexpression of wild-type STAP-2, but not of mutants lacking this motif, enhanced the AP response element reporter activity and an AP protein production. These data suggest that STAP-2 is a new class of adaptor molecule that modulates STAT3 activity through its YXXQ motif.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Sapporo, Hokkaido 0600812, Japan	Kyushu University; Hokkaido University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Yoshimura, Akihiko/K-5515-2013; Matsuda, Tadashi/A-3835-2012	Matsuda, Tadashi/0000-0002-3089-3757				Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Alonzi T, 1998, CYTOKINE, V10, P13, DOI 10.1006/cyto.1997.0250; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Burack WR, 2002, CURR OPIN IMMUNOL, V14, P312, DOI 10.1016/S0952-7915(02)00347-3; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Masuhara M, 2000, BIOCHEM BIOPH RES CO, V268, P697, DOI 10.1006/bbrc.2000.2223; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; Ohtsuka S, 2002, MOL CELL BIOL, V22, P3066, DOI 10.1128/MCB.22.9.3066-3077.2002; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; ROHRSCHNEIDER LR, 1995, GUIDEBOOK CYTOKINES, P168; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	36	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11182	11189		10.1074/jbc.M211230200	http://dx.doi.org/10.1074/jbc.M211230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540842	hybrid			2022-12-25	WOS:000181855400043
J	Anwar, A; Dehn, D; Siegel, D; Kepa, JK; Tang, LJ; Pietenpol, JA; Ross, D				Anwar, A; Dehn, D; Siegel, D; Kepa, JK; Tang, LJ; Pietenpol, JA; Ross, D			Interaction of human NAD(P)H : Quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H QUINONE OXIDOREDUCTASE; DT-DIAPHORASE; WILD-TYPE; C-JUN; POLYMORPHISM; INDUCTION; REDUCTASE; GENE; CARCINOGENESIS; SUSCEPTIBILITY	NAD(P)H:quinone oxidoreductase 1 (NQO1) has been proposed to stabilize p53 via a redox mechanism involving oxidation of NAD(P)H as a consequence of the catalytic activity of NQO1. We report that treatment of HCT-116 human colon carcinoma cells with the NQO1 inhibitor ES936 had no effect on the levels of p53 protein. ES936 is a mechanism-based inhibitor of NQO1 that irreversibly blocks the catalytic function of the enzyme. This suggests that a redox mechanism involving NQO1-mediated NAD(P)H oxidation is not responsible for the stabilization of p53. We also examined the ability of the NQO1 protein to associate with p53 using co-immunoprecipitation experiments. Results from these experiments demonstrated co-immunoprecipitation of NQO1 with p53 and vice versa. The association between p53 and NQO1 was not affected by treatment of HCT-116 cells with ES936, demonstrating that the association was not dependent on the catalytic activity of NQO1. A comparison of isogenic HCT-116 p53+/+ and HCT-116 p53-/- cells demonstrated an interaction of NQO1 and p53 only in the p53+/+ cells. Experiments performed in an in vitro transcription/translation system utilizing rabbit reticulocyte lysates confirmed the interaction of NQO1 and p53. In these experiments a full-length p53 coding region was used to express p53 in the presence of recombinant NQO1 protein. An association of p53 and NQO1 was also observed in primary human keratinocytes and mammary epithelial cells. In studies where mdm-2 co-immunoprecipitated with p53, no association of mdm-2 with NQO1 was observed. These data demonstrate an association between p53 and NQO1 that may represent an alternate mechanism of p53 stabilization by NQO1 in a wide variety of human cell types.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA; Vanderbilt Univ, Dept Biochem, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vanderbilt University; Vanderbilt University	Ross, D (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Box C-238,4200 E 9th Ave, Denver, CO 80262 USA.	david.ross@uchse.edu		Ross, David/0000-0002-8307-5942	NATIONAL CANCER INSTITUTE [R01CA070856, R01CA051210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009554] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51210, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES09554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Anwar A, 2002, J BIOL CHEM, V277, P14060, DOI 10.1074/jbc.M111576200; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; BEALL HD, 1994, CANCER RES, V54, P3196; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Clairmont A, 1999, CARCINOGENESIS, V20, P1235, DOI 10.1093/carcin/20.7.1235; Ernster, 1967, METHOD ENZYMOL, V10, P309, DOI [DOI 10.1016/0076-6879(67)10059-1, 10.1016/0076-6879(67)10059-1]; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HUGGINS C, 1964, J EXP MED, V119, P923, DOI 10.1084/jem.119.6.923; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kawai H, 2001, J BIOL CHEM, V276, P45928, DOI 10.1074/jbc.M107770200; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Krajinovic M, 2002, INT J CANCER, V97, P230, DOI 10.1002/ijc.1589; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; Larson RA, 1999, BLOOD, V94, P803, DOI 10.1182/blood.V94.2.803.414k44_803_807; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, CANCER RES, V62, P3030; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Naoe T, 2000, CLIN CANCER RES, V6, P4091; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; PREUSCH PC, 1991, FREE RADICAL BIO MED, V11, P77, DOI 10.1016/0891-5849(91)90191-5; ROSS D, 1993, CANCER METAST REV, V12, P83, DOI 10.1007/BF00689803; Ruscoe JE, 2001, J PHARMACOL EXP THER, V298, P339; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schulz WA, 1997, PHARMACOGENETICS, V7, P235, DOI 10.1097/00008571-199706000-00008; Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; Smith MT, 2001, BLOOD, V97, P1422, DOI 10.1182/blood.V97.5.1422; Steele RJC, 1998, BRIT J SURG, V85, P1460; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; TALALAY P, 1987, CHEM SCRIPTA, V27A, P61; THOR H, 1982, J BIOL CHEM, V257, P2419; Traver RD, 1997, BRIT J CANCER, V75, P69, DOI 10.1038/bjc.1997.11; TRAVER RD, 1992, CANCER RES, V52, P797; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wiemels JL, 1999, CANCER RES, V59, P4095; Winski SL, 2001, BIOCHEMISTRY-US, V40, P15135, DOI 10.1021/bi011324i; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	54	117	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10368	10373		10.1074/jbc.M211981200	http://dx.doi.org/10.1074/jbc.M211981200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529318	hybrid			2022-12-25	WOS:000181777500051
J	Rathz, DA; Gregory, KN; Fang, Y; Brown, KM; Liggett, SB				Rathz, DA; Gregory, KN; Fang, Y; Brown, KM; Liggett, SB			Hierarchy of polymorphic variation and desensitization permutations relative to beta(1)- and beta(2)-adrenergic receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EXERCISE CAPACITY; HEART; PHOSPHORYLATION; KINASES; DOMAIN	Agonist-promoted desensitization of G-protein-coupled receptors results in partial uncoupling of receptor from cognate G-protein, a process that provides for rapid adaptation to the signaling environment. This property plays important roles in physiologic and pathologic processes as well as therapeutic efficacy. However, coupling is also influenced by polymorphic variation, but the relative impact of these two mechanisms on signal transduction is not known. To determine this we utilized recombinant cells expressing the human beta(1)-adrenergic receptor (beta(1)AR) or a gain-of-function polymorphic variant (beta(1)AR-Arg(389)), and the beta(2)-adrenergic receptor (beta(2)AR) or a loss-of-function polymorphic receptor (beta(2)AR-Ile(164)). Adenylyl cyclase activities were determined with multiple permutations of the possible states of the receptor- genotype, basal, or agonist stimulated and with or without agonist pre-exposure. For the PAR, the enhanced function of the Arg(389) receptor underwent less agonist-promoted desensitization compared with its allelic counterpart. Indeed, the effect of polymorphic variation on absolute adenylyl cyclase activities was such that desensitized beta(1)AR-Arg(389) signaling was equivalent to non-desensitized wild-type beta(1)AR; that is, the genetic component had as much impact as desensitization on receptor coupling. In contrast, the enhanced signaling of wild-type beta(2)AR underwent less desensitization compared with beta(2)AR-Ile(389), thus the heterogeneity in absolute signaling was markedly broadened by this polymorphism. Inverse agonist function was not affected by polymorphisms of either subtype. A general model is proposed whereby up to 10 levels of signaling by G-protein-coupled receptors can be present based on the influences of desensitization and genetic variation on coupling.	Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol, 231 Albert Sabin Way,Rm G-062, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007463] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P50HL052318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22619, HL52318] Funding Source: Medline; NICHD NIH HHS [HD07463] Funding Source: Medline; NIGMS NIH HHS [GM61376] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; EASON MG, 1992, J BIOL CHEM, V267, P25473; Engelhardt S, 2001, MOL PHARMACOL, V60, P712; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GREEN SA, 1993, J BIOL CHEM, V268, P23116; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Liggett SB, 2001, NAT MED, V7, P281, DOI 10.1038/85411; Liggett SB, 2001, J CLIN INVEST, V107, P947, DOI 10.1172/JCI12774; Liggett SB, 2000, PHARMACOLOGY, V61, P167, DOI 10.1159/000028397; Liggett SB, 1993, REGULATION CELLULAR, P71; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; Moore MM, 1999, MUTAGENESIS, V14, P271, DOI 10.1093/mutage/14.3.271; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rana BK, 2001, ANNU REV PHARMACOL, V41, P593, DOI 10.1146/annurev.pharmtox.41.1.593; Small Kersten M, 2003, Am J Pharmacogenomics, V3, P65, DOI 10.2165/00129785-200303010-00008; Small KM, 2002, FEBS LETT, V516, P253, DOI 10.1016/S0014-5793(02)02564-4; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Wagoner LE, 2002, AM HEART J, V144, P840, DOI 10.1067/mhj.2002.125325; Wagoner LE, 2000, CIRC RES, V86, P834, DOI 10.1161/01.RES.86.8.834	25	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10784	10789		10.1074/jbc.M206054200	http://dx.doi.org/10.1074/jbc.M206054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525504	hybrid			2022-12-25	WOS:000181777500103
J	Willoughby, EA; Perkins, GR; Collins, MK; Whitmarsh, AJ				Willoughby, EA; Perkins, GR; Collins, MK; Whitmarsh, AJ			The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; DUAL-SPECIFICITY PHOSPHATASES; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ACTIVATION; FAMILY; MKP-7; M3/6; IB1	The c-Jun N-terminal kinase (JNK) group of mitogen-activated protein kinases (MAPKs) are activated by pleiotropic signals including environmental stresses, growth factors, and hormones. A subset of JNK can bind to distinct scaffold proteins that also bind upstream kinases of the JNK pathway, allowing sequential kinase activation within a signaling module. The JNK-interacting protein-1 (JIP-1) scaffold protein specifically binds JNR, MAP kinase kinase 7, and members of the MLK family and is essential for stress-mediated JNK activation in neurones. Here we report that JIP-1 also binds the dual-specificity phosphatases MKP7 and M3/6 via a region independent of its JNK binding domain. The C-terminal region of MKP7, homologous to that of M3/6 but not other DSPs, is required for interaction with JIP-1. When MKP7 is bound to JIP-1 it reduces JNK activation leading to reduced phosphorylation of the JNK target c-Jun. These results indicate that the JIP-1 scaffold protein modulates JNK signaling via association with both protein kinases and protein phosphatases that target JNK.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; UCL, Dept Immunol & Mol Pathol, London W1T 4JF, England; Royal Free Med Sch, Windeyer Inst, London W1T 4JF, England	University of Manchester; University of London; University College London; University of London; University College London	Whitmarsh, AJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	alan.j.whitmarsh@man.ac.uk		Whitmarsh, Alan/0000-0003-1184-6610				Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuda S, 2001, J NEUROSCI, V21, P6597; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tawadros T, 2002, J CELL SCI, V115, P385; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200; Zama T, 2002, J BIOL CHEM, V277, P23919, DOI 10.1074/jbc.M200838200	37	84	85	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10731	10736		10.1074/jbc.M207324200	http://dx.doi.org/10.1074/jbc.M207324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524447	hybrid			2022-12-25	WOS:000181777500096
J	Bocchetta, M; Miele, L; Pass, HI; Carbone, M				Bocchetta, M; Miele, L; Pass, HI; Carbone, M			Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells	ONCOGENE			English	Article						SV40; DNA tumor viruses; carcinogenicity; mesothelioma; notch-1	SMALL-T-ANTIGEN; SIMIAN-VIRUS-40; TRANSFORMATION; DIFFERENTIATION; EXPRESSION; ASBESTOS; PROTEIN; SEL-10; TRANSACTIVATION; PATHOGENESIS	We show that SV40 infection of human mesothelial cells directly causes overexpression of Notch-1, a key cell regulatory gene. Notch-1 induction is achieved at the transcriptional level and requires both the SV40 large T-antigen and the small t-antigen. Notch-1 upregulation is maintained in SV40-transformed human mesothelial clones and in SV40-positive mesotheliomas and derived cell lines. Activation of Notch-1 promotes cell cycle progression and it is required for the growth of SV40-transformed mesothelial cells. Our finding is relevant to the process of SV40-mediated human cell transformation, an effect that cannot be accounted for solely by SV40-Tag inhibition of Rb and p53.	Loyola Univ, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Dept Pathol, Maywood, IL 60153 USA; Univ Illinois, Dept Pharmacodynam & Pharmaceut, Chicago, IL USA; Univ Illinois, Ctr Canc, Chicago, IL USA; Wayne State Univ, Aerodigest Program, Karmanos Ctr Inst, Detroit, MI 48201 USA	Loyola University Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Wayne State University	Carbone, M (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Dept Pathol, Room 205,2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		Pass, Harvey/0000-0003-3222-3471; Miele, Lucio/0000-0002-5853-7287	NCI NIH HHS [R0-1 CA92657, R0-1 CA84065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092657, R01CA084065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Grammatikakis N, 2001, J BIOL CHEM, V276, P27840, DOI 10.1074/jbc.M101987200; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Imperiale MJ, 2001, SEMIN CANCER BIOL, V11, P81, DOI 10.1006/scbi.2000.0349; Jang MS, 2000, CURR OPIN MOL THER, V2, P55; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; KLEIN G, 2000, P NATL ACTA SCI US, V97, P10214; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; MATTHEWS BJ, 1987, J VIROL, V61, P1282, DOI 10.1128/JVI.61.4.1282-1285.1987; McLendon C, 2000, FASEB J, V14, P2383; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mossman BT, 2002, AM J RESP CELL MOL, V26, P167, DOI 10.1165/ajrcmb.26.2.f229; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Pass HI, 1996, CANCER RES, V56, P4044; Pass HI, 1998, J THORAC CARDIOV SUR, V116, P854, DOI 10.1016/S0022-5223(98)00438-3; Porras A, 1996, J VIROL, V70, P6902; Powers A, 2002, CANCER BIOL THER, V1, P348; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SCHILLING LJ, 1994, NUCLEIC ACIDS RES, V22, P3061, DOI 10.1093/nar/22.15.3061; Schrump DS, 2001, SEMIN CANCER BIOL, V11, P73, DOI 10.1006/scbi.2000.0348; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Testa JR, 2001, SEMIN CANCER BIOL, V11, P31, DOI 10.1006/scbi.2000.0344; TESTA JR, 2001, CANC PRINCIPLES PRAC, V6, P1937; Toyooka S, 2001, CANCER RES, V61, P5727; Wiman KG, 1997, NAT MED, V3, P839, DOI 10.1038/nm0897-839; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001	52	79	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					81	89		10.1038/sj.onc.1206097	http://dx.doi.org/10.1038/sj.onc.1206097			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527910				2022-12-25	WOS:000180166900009
J	Wang, ET; Yin, YL; Zhao, M; Forrester, JV; McCaig, CD				Wang, ET; Yin, YL; Zhao, M; Forrester, JV; McCaig, CD			Physiological electric fields control the G(1)/S phase cell cycle checkpoint to inhibit endothelial cell proliferation	FASEB JOURNAL			English	Article						bioelectricity; cell growth; cyclin; apoptosis	ANGIOGENESIS; NEOVASCULARIZATION; STIMULATION; MECHANISMS; CANCER; ROOTS	Vascular endothelial cell (VEC) proliferation is a key event in angiogenesis and is tightly regulated. Electric potential differences exist around the vascular endothelium and give rise to endogenous electric fields (EFs), whether these EFs influence VEC proliferation is unclear. We exposed cultured VECs to applied EFs of physiological strengths for up to 72 h. EF at 50 or 100 mV/mm did not influence cell proliferation, but at 200 mV/mm, cell density, cell growth rate, and mitosis index decreased significantly. EF-induced reduction in VEC proliferation was not due to increased apoptosis, because caspase apoptosis inhibitor Z-VAD-FMK (20 muM), had no effect on this response. Rather, EF responses were mediated via decreased entry of cells into S phase from G(1) phase, as shown by flow cytometry. Western blot showed that EFs decreased G(1)-specific cyclin E expression and increased cyclin/cyclin-dependent kinase complex inhibitor p27(kip1) expression. Thus EFs controlled VEC proliferation through induction of cell cycle arrest at G(1) by down-regulation of cyclin E expression and up-regulation of p27(kip1) expression, rather than by promoting apoptosis. If control of the cell cycle by endogenous EFs extends beyond VECs, this would be of widespread biological significance in vivo.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Sch Med, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	McCaig, CD (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	c.mccaig@abdn.ac.uk	McCaig, Colin/B-1774-2010					Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; AZADNIV M, 1993, RADIAT ENVIRON BIOPH, V32, P73, DOI 10.1007/BF01213133; BRAYMAN AA, 1986, RADIAT ENVIRON BIOPH, V25, P141, DOI 10.1007/BF01211738; Buckley CD, 1997, BRIT MED J, V315, P236, DOI 10.1136/bmj.315.7102.236; Buschmann I, 1999, NEWS PHYSIOL SCI, V14, P121; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; CHU ZW, 1991, ACTA PHARM SINIC, V12, P285; CORONEL R, 1991, CIRC RES, V68, P1241, DOI 10.1161/01.RES.68.5.1241; Cuzick J, 1998, LANCET, V352, P359, DOI 10.1016/S0140-6736(97)10002-2; FITZSIMMONS RJ, 1992, J CELL PHYSIOL, V150, P84, DOI 10.1002/jcp.1041500112; Goldman R, 1996, BIOELECTROMAGNETICS, V17, P450, DOI 10.1002/(SICI)1521-186X(1996)17:6<450::AID-BEM4>3.0.CO;2-2; HIRATA S, 1989, ARTHRITIS RHEUM, V32, P1065, DOI 10.1002/anr.1780320903; Hoshi T, 1998, ANTICANCER RES, V18, P4347; INOUE M, 1985, BIOELECTROMAGNETICS, V6, P293, DOI 10.1002/bem.2250060309; Kanno S, 1999, CIRCULATION, V99, P2682, DOI 10.1161/01.CIR.99.20.2682; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; MATSUBARA T, 1989, J CLIN INVEST, V83, P158, DOI 10.1172/JCI113853; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; McCaig CD, 2002, TRENDS NEUROSCI, V25, P354, DOI 10.1016/S0166-2236(02)02174-4; NAEGELE RJ, 1991, CANCER BIOCHEM BIOPH, V12, P95; NORDENSTROM BEW, 1994, EUR J SURG, P7; Nuccitelli R., 1988, ADV CELL BIOL, V2, P213, DOI DOI 10.1016/S1569-2558(08)60435-X; Patterson C, 1999, CIRCULATION, V99, P2614, DOI 10.1161/01.CIR.99.20.2614; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTSON D, 1981, BIOELECTROMAGNETICS, V2, P329, DOI 10.1002/bem.2250020405; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; RYABY JT, 1998, CLIN ORTHOP S, V355, P205; SAWYER PN, 1966, BIOPHYS J, V6, P641, DOI 10.1016/S0006-3495(66)86683-3; SAWYER PN, 1953, AM J PHYSIOL, V175, P103, DOI 10.1152/ajplegacy.1953.175.1.103; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spranger J, 2000, DIABETOLOGIA, V43, P1404, DOI 10.1007/s001250051546; Stupack DG, 1999, BRAZ J MED BIOL RES, V32, P573, DOI 10.1590/S0100-879X1999000500011; Szekanecz Z, 1998, J INVEST MED, V46, P27; WRIGHT HP, 1972, ATHEROSCLEROSIS, V15, P93; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942	39	50	60	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					458	+		10.1096/fj.02-0510fje	http://dx.doi.org/10.1096/fj.02-0510fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551844				2022-12-25	WOS:000181453700002
J	Huse, JT; Byant, D; Yang, YX; Pijak, DS; D'Souza, I; Lah, JJ; Lee, VMY; Doms, RW; Cook, DG				Huse, JT; Byant, D; Yang, YX; Pijak, DS; D'Souza, I; Lah, JJ; Lee, VMY; Doms, RW; Cook, DG			Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain - A potential mechanism for regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; TRANSMEMBRANE ASPARTATES; CLEAVAGE; PEPTIDE; FURIN; PHOSPHORYLATION; LOCALIZATION; DISINTEGRIN	Sequential proteolysis of the amyloid precursor protein (APP) by beta- and gamma-secretase activities yields the amyloid beta peptide that is widely deposited in the brains of individuals with Alzheimer's disease. The membrane-anchored aspartyl protease (beta) under bar- site (A) under bar PP- cleaving (e) under bar nzyme (BACE) exhibits all of the characteristics of a beta-secretase and has been shown to cleave APP at its beta-site in vitro and in vivo. We found that BACE undergoes cleavage on a surface-exposed alpha-helix between amino acid residues Leu-228 and Ala-229, generating stable N- and C-terminal fragments that remain covalently associated via a disulfide bond. The efficiency of BACE endoproteolysis was observed to depend heavily on cell and tissue type. In contrast to brain where holoprotein was predominant, BACE was found primarily as endoproteolyzed fragments in pancreas, liver, and muscle. In addition, we observed a marked up-regulation of BACE endoproteolysis in C2 myoblasts upon differentiation into multinucleated myotubes, a well established model system of muscle tissue specification. As in liver, BACE exists as endoproteolyzed fragments in the hepatic cell line, HepG2. We found that HepG2 cells are capable of generating amyloid beta peptide, suggesting that endoproteolyzed BACE retains measurable beta-secretase activity. We also found that BACE endoproteolysis occurs only after export from the endoplasmic reticulum, is enhanced in the trans-Golgi network, and is sensitive to inhibitors of vesicular acidification. The membrane-bound proteases tumor necrosis factor alpha-converting enzyme and furin were not found to be responsible for this cleavage nor was BACE observed to mediate its own endoproteolysis by an autocatalytic mechanism. Thus, we characterize a specific processing event that may serve to regulate the enzymatic activity of BACE on a post-translational level.	Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Emory University	Cook, DG (corresponding author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, 1660 S Columbian Way, Seattle, WA 98108 USA.	dgcook@u.washington.edu			NATIONAL INSTITUTE ON AGING [R01AG011762, P01AG011542] Funding Source: NIH RePORTER; NIA NIH HHS [NIA-R01 AG11762, AG05136, P01 AG11542] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bodendorf U, 2001, J BIOL CHEM, V276, P12019, DOI 10.1074/jbc.M008861200; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Drose S, 1997, J EXP BIOL, V200, P1; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; LIE SO, 1973, BIOCHEM PHARMACOL, V22, P3109, DOI 10.1016/0006-2952(73)90197-4; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; TAKAHASHI K, 1995, ADV EXP MED BIOL, V362, P53; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAMOTO K, 1995, ADV EXP MED BIOL, V362, P223; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	60	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17141	17149		10.1074/jbc.M213303200	http://dx.doi.org/10.1074/jbc.M213303200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12551920	hybrid			2022-12-25	WOS:000182818600093
J	Sarafianos, SG; Clark, AD; Tuske, S; Squire, CJ; Das, K; Sheng, DQ; Ilankumaran, P; Ramesha, AR; Kroth, H; Sayer, JM; Jerina, DM; Boyer, PL; Hughes, SH; Arnold, E				Sarafianos, SG; Clark, AD; Tuske, S; Squire, CJ; Das, K; Sheng, DQ; Ilankumaran, P; Ramesha, AR; Kroth, H; Sayer, JM; Jerina, DM; Boyer, PL; Hughes, SH; Arnold, E			Trapping HIV-1 reverse transcriptase before and after translocation on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIBODY FAB FRAGMENT; DOUBLE-STRANDED DNA; ANGSTROM RESOLUTION; SELECTIVE EXCISION; CRYSTAL-STRUCTURE; TEMPLATE-PRIMER; RESISTANCE; COMPLEX; DISULFIDES	A disulfide cross-linking strategy was used to co-valently trap as a stable complex (complex N) a short-lived, kinetic intermediate in DNA polymerization. This intermediate corresponds to the product of polymerization prior to translocation. We also prepared the trapped complex that corresponds to the product of polymerization after translocation (complex P). The cross-linking method that we used is a variation of a technique developed by the Verdine and Harrison laboratories. It involves disulfide interchange between an engineered sulfhydryl group of the protein (Q258C mutation) and a disulfide-containing tether attached at the N-2 amino group of a modified dG in either the template or the primer strand of the nucleic acid. We report here a highly efficient synthesis of the precursor, bis(3-aminopropyl)disulfide dihydrochloride, used to introduce this substituent into the oligonucleotide. Efficient cross-linking takes place when the base pair containing the substituent is positioned seven registers from the dNTP-binding site (N site) and the N site is occupied. Complex N, but not complex P, is a substrate for the ATP-based excision reaction that unblocks nucleoside reverse transcriptase inhibitor (NRTI)-terminated primers and causes resistance to several NRTIs, confirming predictions that the excision reaction takes place only when the X-end of the primer is bound at the N site. These techniques can be used for biochemical and structural studies of the mechanism of DNA polymerization, translocation, and excision-based resistance of RT to NRTIs. They may also be useful in studying other DNA or RNA polymerases or other enzymes.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Arnold, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.	arnold@cabm.rutgers.edu	Das, Kalyan/O-9224-2019; Das, Kalyan/B-2967-2018	Das, Kalyan/0000-0002-8897-324X; Das, Kalyan/0000-0002-8897-324X; Sarafianos, Stefan G/0000-0002-5840-154X; Squire, Christopher/0000-0001-9212-0461; Kroth, Heiko/0000-0002-6936-3921	NATIONAL CANCER INSTITUTE [Z01BC010481, ZIABC010481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027690, R37AI027690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056609] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27690] Funding Source: Medline; NIGMS NIH HHS [GM 56609] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; Boyer PL, 2002, J VIROL, V76, P9143, DOI 10.1128/JVI.76.18.9143-9151.2002; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Clark AD, 1995, METHOD ENZYMOL, V262, P171, DOI 10.1016/0076-6879(95)62017-6; DeCorte BL, 1996, CHEM RES TOXICOL, V9, P630, DOI 10.1021/tx9501795; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; DIRSCHERL W, 1951, LIEBIGS ANN CHEM, V574, P131; DOI JT, 1985, J ORG CHEM, V50, P1, DOI 10.1021/jo00201a001; ERLANSON DA, 1993, J AM CHEM SOC, V115, P12583, DOI 10.1021/ja00079a047; EVANS BJ, 1990, J ORG CHEM, V55, P2580, DOI 10.1021/jo00296a009; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; MATTINGLY PG, 1990, SYNTHESIS-STUTTGART, P366; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Peletskaya EN, 2001, J VIROL, V75, P9435, DOI 10.1128/JVI.75.19.9435-9445.2001; RAMESHA AR, 1992, SYNTHETIC COMMUN, V22, P3277, DOI 10.1080/00397919208021143; RAMESHA AR, 1994, J ORG CHEM, V59, P1354, DOI 10.1021/jo00085a025; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449	27	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16280	16288		10.1074/jbc.M212911200	http://dx.doi.org/10.1074/jbc.M212911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12554739	Green Published, hybrid			2022-12-25	WOS:000182680000104
J	Susan-Resiga, D; Nowak, T				Susan-Resiga, D; Nowak, T			The proton transfer step catalyzed by yeast pyruvate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED-FUNCTION-ANALYSIS; STEREOCHEMISTRY; HYDROXYLAMINE; ENOLPYRUVATE; INTERMEDIATE; MECHANISM; SUBSTRATE; ROLES; WATER	The nature of the proton donor to the C-3 of the enolate of pyruvate, the intermediate in the reaction catalyzed by yeast pyruvate kinase, was investigated by site-directed mutagenesis and physical and kinetic analyses. Thr-298 is correctly located to function as the proton donor. T298S and T298A were constructed and purified. Both mutants are catalytically active with a decrease in k(cat) and k(cat)/K-m,K-PEP. Mn2+-activated T298S and T298A do not exhibit homotropic kinetic cooperativity with phosphoenolpyruvate (PEP) in the absence of fructose 1,6-bisphosphate, although PEP binding to enzyme-Mn2+ is cooperative. The pH dependence of k(cat) for T298A indicates the loss of pK(alpha,2) = 6.4-6.9. Thr-298 affects the ionization (pK(alpha) approximate to6.5) responsible for modulation of k(cat). Fluorescence studies show altered dissociation constants of ligands to each enzyme complex upon Thr-298 mutations. The rates of the phosphoryl transfer and proton transfer steps in the pyruvate kinase-catalyzed reaction are altered; pyruvate enolization is affected to a greater extent. Proton inventory studies demonstrate solvent isotope effects on k(cat) and k(cat)/K-m,K-PEP. Fractionation factors are metal-dependent and significantly <1. The data suggest that a water molecule in a water channel is the direct proton donor to enolpyruvate and that Thr-298 affects a late step in catalysis.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Nowak, T (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.		Susan-Resiga@ircm.qc.ca, Delia/O-2548-2017	Susan-Resiga@ircm.qc.ca, Delia/0000-0002-4856-090X	NIDDK NIH HHS [DK 17049] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017049] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; Bollenbach TJ, 1999, BIOCHEMISTRY-US, V38, P9137, DOI 10.1021/bi990690n; Bollenbach TJ, 2001, BIOCHEMISTRY-US, V40, P13088, DOI 10.1021/bi010125w; BOLLENBACH TJ, 1999, THESIS U NOTRE DAME; BURKE RL, 1983, J BIOL CHEM, V258, P2193; CHABEREK S, 1952, J AM CHEM SOC, V74, P5057, DOI 10.1021/ja01140a019; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DOUGHERTY TM, 1985, BIOCHEMISTRY-US, V24, P5870, DOI 10.1021/bi00342a027; FORD SR, 1976, BIOCHIM BIOPHYS ACTA, V438, P119, DOI 10.1016/0005-2744(76)90228-X; GUPTA RK, 1976, BIOCHEMISTRY-US, V15, P2881, DOI 10.1021/bi00658a028; Hishiki T, 2000, J BIOCHEM, V128, P965, DOI 10.1093/oxfordjournals.jbchem.a022848; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KIICK DM, 1991, J AM CHEM SOC, V113, P8499, DOI 10.1021/ja00022a043; KIRSHENBAUM I, 1951, PHYSICAL PROPERTIES; KREAGE AJ, 1964, PURE APPL CHEM, V8, P243; KUO D J, 1979, Journal of the American Chemical Society, V101, P5025, DOI 10.1021/ja00511a037; KUO DJ, 1978, J AM CHEM SOC, V100, P6288, DOI 10.1021/ja00487a084; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LEBLOND DJ, 1976, BIOCHIM BIOPHYS ACTA, V438, P108, DOI 10.1016/0005-2744(76)90227-8; LORIA JP, 1997, THESIS U NOTRE DAME; LUMRY R, 1951, J AM CHEM SOC, V73, P4330, DOI 10.1021/ja01153a090; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6803, DOI 10.1021/bi962870s; MESECAR AM, 1995, THESIS U NOTRE DAME; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; Oprea TI, 1997, P NATL ACAD SCI USA, V94, P2133, DOI 10.1073/pnas.94.6.2133; Rigden DJ, 1999, J MOL BIOL, V291, P615, DOI 10.1006/jmbi.1999.2918; ROBINSON JL, 1972, J BIOL CHEM, V247, P1096; ROSE IA, 1989, BIOCHEMISTRY-US, V28, P9579, DOI 10.1021/bi00451a005; ROSE IA, 1991, BIOCHEMISTRY-US, V30, P722, DOI 10.1021/bi00217a021; ROSE IA, 1960, J BIOL CHEM, V235, P1170; ROSE IA, 1970, J BIOL CHEM, V245, P6052; SEEHOLZER SH, 1991, BIOCHEMISTRY-US, V30, P727, DOI 10.1021/bi00217a022; SHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SWINDELLS JF, 1958, C440 NAT BUR STAND, P5; TEITZ A, 1958, ARCH BIOCHEM BIOPHYS, V78, P477; WEISS PM, 1984, BIOCHEMISTRY-US, V23, P4346, DOI 10.1021/bi00314a015	39	21	22	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12660	12671		10.1074/jbc.M300257200	http://dx.doi.org/10.1074/jbc.M300257200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562754	hybrid			2022-12-25	WOS:000182189500011
J	De Sarno, P; Shestopal, SA; King, TD; Zmijewska, A; Song, L; Jope, RS				De Sarno, P; Shestopal, SA; King, TD; Zmijewska, A; Song, L; Jope, RS			Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; CYCLIN-DEPENDENT KINASES; NEURODEGENERATIVE DISEASES; BAX; DEATH; P53; NEURONS; BRAIN; NEUROTRANSMITTERS; NEUROTOXICITY	The impact of muscarinic receptor stimulation was examined on apoptotic signaling induced by DNA damage, oxidative stress, and mitochondrial impairment. Exposure of human neuroblastoma SH-SY5Y cells to the DNA-damaging agent camptothecin increased p53 levels, activated caspase-3, and caused cell death. Pretreatment with oxotremorine-M, a selective agonist of muscarinic receptors that are expressed endogenously in these cells, did not affect the accumulation of p53 but greatly attenuated caspase-3 activation and protected from cell death to nearly the same extent as treatment with a general caspase inhibitor. Treatment with 50-200 muM H2O2 caused the activation of caspase-3 beginning after 2-3 h, followed by eventual cell death. Oxotremorine-M pretreatment protected cells from H2O2-induced caspase-3 activation and death, and this was equivalent to protection afforded by a caspase inhibitor. Muscarinic receptor stimulation also protected cells from caspase-3 activation induced by exposure to rotenone, a mitochondrial complex 1 inhibitor, but no protection was evident from staurosporine-induced caspase-3 activation. The mechanism of protection afforded by muscarinic receptor activation from camptothecin-induced apoptotic signaling involved blockade of mitochondrial cytochrome c release associated with a bolstering of mitochondrial bcl-2 levels and blockade of the translocation of Bax to mitochondria. Likely the most proximal of these events to muscarinic receptor activation, mitochondrial Bax accumulation, also was attenuated by oxotremorine-M treatment after treatment with H2O2 or rotenone. These results demonstrate that stimulation of muscarinic receptors provides substantial protection from DNA damage, oxidative stress, and mitochondrial impairment, insults that may be encountered by neurons in development, aging, or neurodegenerative diseases. These findings suggest that neurotransmitter-induced signaling bolsters survival mechanisms, and inadequate neurotransmission may exacerbate neuronal loss.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama Birmingham, Dept Psychiat, 1720 7th Ave S,Sparks Ctr 1057, Birmingham, AL 35294 USA.	jope@uab.edu		Shestopal, Svetlana/0000-0003-0725-5885	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021045] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021045] Funding Source: Medline; NIMH NIH HHS [R01 MH038752] Funding Source: Medline; NINDS NIH HHS [R01 NS037768] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; Behl C, 1999, PROG NEUROBIOL, V57, P301, DOI 10.1016/S0301-0082(98)00055-0; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castagne V, 1999, PROG NEUROBIOL, V59, P397, DOI 10.1016/S0301-0082(99)00012-X; Costa LG, 1999, BIOCHEM PHARMACOL, V57, P721, DOI 10.1016/S0006-2952(98)00278-0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Gibson GE, 2002, FRONT BIOSCI, V7, pD1007, DOI 10.2741/gibson; Gottlieb RA, 2000, METHOD ENZYMOL, V322, P213; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Hohmann CF, 1998, PERSPECT DEV NEUROBI, V5, P401; Ikonomidou C, 2001, BIOCHEM PHARMACOL, V62, P401, DOI 10.1016/S0006-2952(01)00696-7; JACKSON GR, 1994, DEV NEUROSCI-BASEL, V16, P285, DOI 10.1159/000112121; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; JOPE RS, 1999, J ALZHEIMERS DIS, V1, P287; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamata H, 1996, NEUROSCI LETT, V212, P179, DOI 10.1016/0304-3940(96)12806-8; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; Krishnamurthy PK, 2000, J NEUROSCI RES, V61, P515, DOI 10.1002/1097-4547(20000901)61:5<515::AID-JNR6>3.0.CO;2-#; LAMBERT DG, 1989, EUR J PHARMACOL, V165, P71, DOI 10.1016/0014-2999(89)90771-1; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Manfredi G, 2000, BRAIN PATHOL, V10, P462; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MATTSON MP, 1997, ALZHEIMERS DIS REV, V2, P1; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nguyen L, 2001, CELL TISSUE RES, V305, P187, DOI 10.1007/s004410000343; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Nomura M, 1999, CANCER RES, V59, P5542; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Xiang H, 1998, J NEUROSCI, V18, P1363; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	60	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11086	11093		10.1074/jbc.M212157200	http://dx.doi.org/10.1074/jbc.M212157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538580	Green Accepted, hybrid			2022-12-25	WOS:000181855400030
J	He, ZW; Ma, WY; Liu, GM; Zhang, YG; Bode, AM; Dong, ZG				He, ZW; Ma, WY; Liu, GM; Zhang, YG; Bode, AM; Dong, ZG			Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-INDUCED PHOSPHORYLATION; MOLECULAR MECHANISMS; CELL-TRANSFORMATION; GENE-EXPRESSION; PROLIFERATION; REQUIREMENT; INDUCTION; MITOSIS; MODEL; MSK1	Arsenite is known to be an environmental human carcinogen. However, the mechanism of action of this compound in skin carcinogenesis is not completely clear. Here, we provide evidence that arsenite can induce phosphorylation of histone H3 at serine 10 in a time- and dose-dependent manner in JB6 Cl 41 cells. Arsenite induces phosphorylation of Akt1 at serine 473 and increases Akt1 activity. A dominant-negative mutant of Akt1 inhibits the arsenite-induced phosphorylation of histone H3 at serine 10. Additionally, active Akt1 kinase strongly phosphorylates histone H3 at serine 10 in vitro. The arsenite-induced phosphorylation of histone H3 at serine 10 was almost completely blocked by a dominant-negative mutant of extracellular signal-regulated kinase 2 and the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor PD98059. N- or C-terminal mutant mitogen- and stress-activated protein kinase I or its inhibitor H89 had no effect on arsenite-induced phosphorylation of histone H3 at serine 10 in JB6 Cl 41 cells. However, cells deficient in p90 ribosomal S6 kinase 2 (Rsk2(-/-)) totally block this phosphorylation in a dose- and time-dependent manner. Taken together, these results suggested that arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2 and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu		Zhang, Yiguo/0000-0003-3910-2779	NATIONAL CANCER INSTITUTE [R37CA081064, R01CA081064, R01CA077646, P01CA088961] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA81064, CA88961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHIN KV, 1990, J BIOL CHEM, V265, P221; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DABEVA MD, 1993, AM J PATHOL, V143, P1606; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 2002, ENVIRON HEALTH PERSP, V110, P757, DOI 10.1289/ehp.02110s5757; Falk H, 1981, Am J Ind Med, V2, P43, DOI 10.1002/ajim.4700020108; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Germolec DR, 1998, AM J PATHOL, V153, P1775, DOI 10.1016/S0002-9440(10)65692-1; Gown AM, 1996, J HISTOCHEM CYTOCHEM, V44, P221, DOI 10.1177/44.3.8648081; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 2001, ANTICANCER RES, V21, P261; Liu YC, 1997, J CELL BIOCHEM, V64, P423; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pott WA, 2001, REV ENVIRON CONTAM T, V169, P165; Rossman TG, 2001, TOXICOL APPL PHARM, V176, P64, DOI 10.1006/taap.2001.9277; Salazar AM, 1997, MUTAT RES-FUND MOL M, V381, P259, DOI 10.1016/S0027-5107(97)00207-8; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Simeonova PP, 2000, CANCER RES, V60, P3445; Strelkov IS, 2002, CANCER RES, V62, P75; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Vernhet L, 2000, TOXICOLOGY, V142, P127; Waxman S, 2001, ONCOLOGIST, V6, P3, DOI 10.1634/theoncologist.6-suppl_2-3; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Zhang P, 1999, J BIOL REG HOMEOS AG, V13, P195; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	35	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10588	10593		10.1074/jbc.M208581200	http://dx.doi.org/10.1074/jbc.M208581200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529330	hybrid			2022-12-25	WOS:000181777500079
J	Jones, SM; Luo, M; Peters-Golden, M; Brock, TG				Jones, SM; Luo, M; Peters-Golden, M; Brock, TG			Identification of two novel nuclear import sequences on the 5-lipoxygenase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNALS; ALVEOLAR MACROPHAGES; CRYSTALLOGRAPHIC ANALYSIS; IN-VITRO; EXPRESSION; TRANSLOCATION; RECOGNITION; ACTIVATION; INHIBITION; DOMAIN	The nuclear import of 5-lipoxygenase modulates its capacity to produce leukotrienes from arachidonic acid. However, the molecular determinants of its nuclear import are unknown. Recently, we used structural and functional criteria to identify a novel import sequence at Arg(518) on human 5-lipoxygenase (Jones, S. M., Luo, M.' Healy, A. M., Peters-Golden, M., and Brock, T. G. (2002) J. Biol. Chem. 277, 38550 -38556). However, this analysis also indicated that other import sequences must exist. Here, we identify two additional sites, at Arg(112) and Lys(158), as nuclear import sequences. Both sites were found to be common to 5-lipoxygenases from different species but not found on other lipoxygenases. Both sites also appeared to be a part of structures that were predominantly random loops. Peptide sequences at these sites were sufficient to direct nuclear import of green fluorescent protein. Mutation of basic residues in these sites impaired nuclear import and combinations of mutations at different sites were additive in effect. Mutations in all three sites were required to disable nuclear accumulation of 5-lipoxygenase in all cells. Significantly, mutation in these sites did not inhibit catalytic function. Taken together, these results indicate that nuclear import of 5-lipoxygenase may reflect the combined functional effects of three discrete import sequences. Mutation of individual sites can, by itself, impair nuclear import, which in turn could impact arachidonic acid metabolism.	Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA.	brocko@umich.edu			NIAID NIH HHS [R29 AI43574, R21 AI48141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043574, R21AI048141] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boden SE, 2000, INT J BIOCHEM CELL B, V32, P1069, DOI 10.1016/S1357-2725(00)00049-2; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 2001, J BIOL CHEM, V276, P35071, DOI 10.1074/jbc.M105676200; Brock TG, 1999, J IMMUNOL, V162, P1669; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Cowburn AS, 1999, J IMMUNOL, V163, P456; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; HOFFMAN T, 1991, J IMMUNOL, V146, P692; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; Liu MT, 1998, VIROLOGY, V247, P62, DOI 10.1006/viro.1998.9228; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PETERSGOLDEN M, 1991, AM J PHYSIOL, V261, pL462, DOI 10.1152/ajplung.1991.261.6.L462; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Stelz G, 2002, VIROLOGY, V295, P360, DOI 10.1006/viro.2002.1384; Sud'ina GF, 2001, BIOCHEM J, V359, P621, DOI 10.1042/0264-6021:3590621; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10257	10263		10.1074/jbc.M211021200	http://dx.doi.org/10.1074/jbc.M211021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525477	hybrid			2022-12-25	WOS:000181777500037
J	Isoda, T; Paolocci, N; Haghighi, K; Wang, CR; Wang, YB; Georgakopoulos, D; Servillo, G; Della Fazia, MA; Kranias, GF; DePaoli-Roach, AA; Sassone-Corsi, P; Kass, DA				Isoda, T; Paolocci, N; Haghighi, K; Wang, CR; Wang, YB; Georgakopoulos, D; Servillo, G; Della Fazia, MA; Kranias, GF; DePaoli-Roach, AA; Sassone-Corsi, P; Kass, DA			Novel regulation of cardiac force-frequency relation by CREM (cAMP response element modulator)	FASEB JOURNAL			English	Article						CRE-responsive transcription factor; mouse; phosphatase; phospholamban; sarcoplasmic reticulum; cardiac function	TRANSCRIPTION FACTOR CREM; ADENOVIRAL GENE-TRANSFER; HEART-FAILURE; BINDING PROTEIN; SER(16) PHOSPHORYLATION; DILATED CARDIOMYOPATHY; MICE LACKING; PHOSPHOLAMBAN; EXPRESSION; SPERMATOGENESIS	The cAMP response element modulator (CREM) plays pivotal roles in the hypothalamic-pituitary-gonadal axis. CREM mRNA is robustly expressed in human myocardium, and identified isoforms may suppress cAMP response element-mediated transcription. However, little is known about the physiological importance of CREM in intact hearts remains unknown. We studied CREM-null mice and age-matched control littermates by in vivo pressure-volume loops to analyze basal and reserve cardiac function. Basal systolic and diastolic function, echocardiographic morphology, and myocardial histology were normal in CREM-null animals. However functional reserve with increasing heart rate was markedly depressed, with less contractile augmentation (+22+/-9% CREM-/- vs. +62+/-11% controls, P<0.05) and relaxation shortening (5+/-5% CREM-/- vs. -18+/-3% controls; P<0.05) at faster rates. In contrast, isoproterenol dose-responses were similar, suggesting normal beta-adrenergic receptor-coupled signaling. Gene expression of calcium handling proteins (SERCA, phospholamban) and stress-response genes (e. g., alpha-skeletal actin, beta-myosin heavy chain, natriuretic peptides) were similar between groups. However, total and serine-phosphorylated phospholamban protein declined -38 and -64% respectively, and protein phosphatase-1 (PP1) activity increased 44% without increased protein levels (all P<0.01) in CREM-/- vs. controls. These results demonstrate novel involvement of CREM in regulation of PP1 activity and of PLB, likely resulting in a potent frequency-dependent influence on cardiac function.	Johns Hopkins Med Inst, Div Cardiol, Dept Med, Baltimore, MD 21287 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, Strasbourg, France	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; University System of Ohio; University of Cincinnati; Indiana University System; Indiana University-Purdue University Indianapolis; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kass, DA (corresponding author), Johns Hopkins Med Inst, Div Cardiol, Dept Med, Halsted 500,600 N Wolfe St, Baltimore, MD 21287 USA.	dkass@jhmi.edu	paolocci, nazareno/A-7124-2009; Sassone-Corsi, Paolo/H-6182-2011	Servillo, Giuseppe/0000-0001-7960-7689; Della Fazia, Maria Agnese/0000-0002-5373-8477; Wang, Yibin/0000-0003-0852-0767; Paolocci, Nazareno/0000-0001-7011-997X	NHLBI NIH HHS [HL-64018, P01 HL 59408, HL-52318, HL-26057, P50 HL 52307] Funding Source: Medline; NIDDK NIH HHS [DK36569] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, P01HL059408, R37HL026057, R01HL064018, P50HL052318, P50HL052307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Behr R, 2001, INT J ANDROL, V24, P126, DOI 10.1046/j.1365-2605.2001.00277.x; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Boknik P, 2001, AM J PHYSIOL-HEART C, V280, pH786, DOI 10.1152/ajpheart.2001.280.2.H786; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Brittsan AG, 2000, J BIOL CHEM, V275, P12129, DOI 10.1074/jbc.275.16.12129; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; De Cesare D, 2000, J ENDOCRINOL INVEST, V23, P592, DOI 10.1007/BF03343781; DRAKEHOLLAND AJ, 1992, CARDIOVASC RES, V26, P496, DOI 10.1093/cvr/26.5.496; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Fimia GM, 2001, MOL CELL ENDOCRINOL, V179, P17, DOI 10.1016/S0303-7207(01)00463-4; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Georgakopoulos D, 2000, AM J PHYSIOL-HEART C, V279, pH443, DOI 10.1152/ajpheart.2000.279.1.H443; Georgakopoulos D, 2001, J PHYSIOL-LONDON, V534, P535, DOI 10.1111/j.1469-7793.2001.00535.x; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; GOLDSPINK PH, 1994, CIRC RES, V74, P1042, DOI 10.1161/01.RES.74.6.1042; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hajjar RJ, 1998, J MOL MED-JMM, V76, P747, DOI 10.1007/s001090050276; Hajjar RJ, 1997, CIRC RES, V81, P145, DOI 10.1161/01.RES.81.2.145; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Huang BY, 1999, CIRC RES, V85, P848, DOI 10.1161/01.RES.85.9.848; Maldonado R, 1999, P NATL ACAD SCI USA, V96, P14094, DOI 10.1073/pnas.96.24.14094; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meyer M, 1999, AM J PHYSIOL-HEART C, V276, pH779, DOI 10.1152/ajpheart.1999.276.3.H779; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; Muller FU, 1998, FASEB J, V12, P1191; Muller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Netticadan T, 2000, CIRC RES, V86, P596, DOI 10.1161/01.RES.86.5.596; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Pfeffer M, 1998, EUR J NEUROSCI, V10, P2896, DOI 10.1111/j.1460-9568.1998.00309.x; Ross J, 1998, BASIC RES CARDIOL, V93, P95; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Sande JB, 2002, CARDIOVASC RES, V53, P382, DOI 10.1016/S0008-6363(01)00489-8; SCHWMIDT U, 1999, AM J PHYSIOL, V277, pH474; SEED WA, 1984, CIRCULATION, V70, P799, DOI 10.1161/01.CIR.70.5.799; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; SHARIR T, 1994, CIRCULATION, V89, P2045, DOI 10.1161/01.CIR.89.5.2045	47	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					144	151		10.1096/fj.01-0981com	http://dx.doi.org/10.1096/fj.01-0981com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554693				2022-12-25	WOS:000181456900039
J	Vigorito, E; Billadeu, DD; Savoy, D; McAdam, S; Doody, G; Fort, P; Turner, M				Vigorito, E; Billadeu, DD; Savoy, D; McAdam, S; Doody, G; Fort, P; Turner, M			RhoG regulates gene expression and the actin cytoskeleton in lymphocytes	ONCOGENE			English	Article						RhoG; Vav; lymphocytes; signalling; NFAT	ACTIVATED T-CELLS; VAV FAMILY; GTPASE-RHO; THYMOCYTE DEVELOPMENT; INDEPENDENT PATHWAYS; ADP-RIBOSYLATION; EXCHANGE FACTOR; WILD-TYPE; RAC; EFFECTOR	RhoG, a member of the Rho family of GTPases, has been implicated as a regulator of the actin cytoskeleton. In this study, we show a novel function for the small GTPase RhoG on the regulation of the interferon-gamma promoter and nuclear factor of activated T cells (NFAT) gene transcription in lymphocytes. Optimal function of RhoG for the expression of these genes requires a calcium signal, normally provided by the antigen receptor. In addition, RhoG potentiation of NFAT requires the indirect activity of Rac and Cdc42; however, pathways distinct from those activated by Rac and Cdc42 mediate RhoG activation of NFAT-dependent transcription. Using effector domain mutants of RhoG we found that its ability to potentiate NFAT-dependent transcription correlates with its capacity to increase actin polymerization, supporting the suggestion that NFAT-dependent transcription is an actin-dependent process. RhoG also promotes T-cell spreading on fibronectin, a property that is independent of its ability to enhance NFAT-dependent transcription. Hence, these results implicate RhoG in leukocyte trafficking and the control of gene expression induced in response to antigen encounter.	Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA; CNRS, Ctr Rech Biochim Macromol, IFR24,UPR 1086, Dept Immunol, F-34293 Montpellier, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Mayo Clinic; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Vigorito, E (corresponding author), Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England.		Turner, Martin/N-9976-2014; Doody, Gina/AAN-8246-2021; Fort, Philippe/M-9498-2015	Turner, Martin/0000-0002-3801-9896; Doody, Gina/0000-0003-0665-6759; Fort, Philippe/0000-0001-5997-8722				Angkachatchai V, 1999, J IMMUNOL, V163, P3819; Arrieumerlou C, 2000, J IMMUNOL, V165, P3182, DOI 10.4049/jimmunol.165.6.3182; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blangy A, 2000, J CELL SCI, V113, P729; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Costello PS, 2000, J EXP MED, V192, P77, DOI 10.1084/jem.192.1.77; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gomez M, 2000, NAT IMMUNOL, V1, P348, DOI 10.1038/79808; Gomez M, 2001, IMMUNITY, V15, P703, DOI 10.1016/S1074-7613(01)00235-7; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Henning SW, 1998, J EXP MED, V188, P931, DOI 10.1084/jem.188.5.931; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANG P, 1992, J BIOL CHEM, V267, P11677; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MALY FE, 1994, J BIOL CHEM, V269, P18743; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Na SQ, 1999, ONCOGENE, V18, P7966, DOI 10.1038/sj.onc.1203122; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wielowieyski PA, 2000, J BIOL CHEM, V275, P38474, DOI 10.1074/jbc.M007682200; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647	52	42	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					330	342		10.1038/sj.onc.1206116	http://dx.doi.org/10.1038/sj.onc.1206116			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545154				2022-12-25	WOS:000180379100002
J	Castellone, MD; Cirafici, AM; De Vita, G; De Falco, V; Malorni, L; Tallini, G; Fagin, JA; Fusco, A; Melillo, RM; Santoro, M				Castellone, MD; Cirafici, AM; De Vita, G; De Falco, V; Malorni, L; Tallini, G; Fagin, JA; Fusco, A; Melillo, RM; Santoro, M			Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes	ONCOGENE			English	Article						kinase; carcinoma; survival; ras; tyrosine; thyroid; oncogene; TUNEL	EPIDERMAL GROWTH-FACTOR; PAPILLARY CARCINOMAS; RET PROTOONCOGENE; PATHWAY; REARRANGEMENTS; PROLIFERATION; ONCOPROTEIN; ACTIVATION; RECEPTOR; KINASES	RET gene rearrangements, which generate chimeric RET/ PTC oncogenes, are early events in the evolution of thyroid papillary carcinomas. Expression of RET/PTC oncogenes promotes neoplastic transformation of cultured thyroid cells and of thyroid glands in transgenic mice. Notwithstanding these oncogenic effects, we have found that the expression of two RET/PTC oncogenes (H4-RET and RFG-RET) induces apoptosis of rat thyroid PC CL 3 cells. Promotion of thyroid cell death depends on the kinase activity of RET/PTC and on the phosphorylation of a tyrosine residue (tyrosine 1062) that maps in the carboxy-terminus of the RET protein. Tyrosine 1062 is essential for RET/PTC-mediated activation of the Ras/ ERK pathway. Inhibition of Ras/ERK by a dominant negative Ras or by the MEKI inhibitor, PD98059, obstructed RET/PTC-mediated apoptosis. We also show that signals transmitted by tyrosine 1062 mediate proapoptotic events like Bcl-2 down regulation and Bax upregulation, and that adoptive overexpression of Bcl-2 overcomes RET/PTC-induced apoptosis. Thus, gene rearrangements that generate RET/PTC oncogenes subvert RET function by converting it into a chronically active kinase that is constitutively phosphorylated on tyrosine 1062. In turn, Y1062 phosphorylation transmits not only mitogenic but also proapoptotic signals to thyroid cells.	Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Yale Univ, Dept Pathol, New Haven, CT 06520 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Yale University; University System of Ohio; University of Cincinnati	Santoro, M (corresponding author), Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		melillo, rosa marina/O-5255-2015; DE FALCO, VALENTINA/C-2061-2015; Tallini, Giovanni/F-7850-2013; Malorni, Luca/J-1973-2019; De Vita, Gabriella/H-4422-2011	DE FALCO, VALENTINA/0000-0002-8972-7921; Tallini, Giovanni/0000-0003-0113-6682; Malorni, Luca/0000-0002-4297-2997; De Vita, Gabriella/0000-0002-7302-1174; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275				Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Corvi R, 2001, LAB INVEST, V81, P1639, DOI 10.1038/labinvest.3780377; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; LAMY F, 1993, J BIOL CHEM, V268, P8398; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; ROGER PP, 1982, FEBS LETT, V144, P209, DOI 10.1016/0014-5793(82)80639-X; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Tong Q, 1997, J BIOL CHEM, V272, P9043; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	30	38	38	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					246	255		10.1038/sj.onc.1206112	http://dx.doi.org/10.1038/sj.onc.1206112			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527893				2022-12-25	WOS:000180322400009
J	Ma, YX; Fan, SJ; Xiong, JB; Yuan, RQ; Meng, QH; Gao, M; Goldberg, ID; Fuqua, SA; Pestell, RG; Rosen, EM				Ma, YX; Fan, SJ; Xiong, JB; Yuan, RQ; Meng, QH; Gao, M; Goldberg, ID; Fuqua, SA; Pestell, RG; Rosen, EM			Role of BRCA1 in heat shock response	ONCOGENE			English	Article						BRCA1; prostate cancer; breast cancer; DU-145; MCF-7; heat shock; HSP27; HSP70; HSP90	BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; DIFFERENTIAL REGULATION; ACTIN POLYMERIZATION; ANTISENSE INHIBITION; PROTEIN-DEGRADATION; NEGATIVE REGULATION; THERMAL PROTECTION	The heat shock response is an evolutionarily conserved response to heat and other stresses that promotes the maintenance of key metabolic functions and cell survival. We report that exposure of human prostate (DU-145) and breast (MCF-7) cancer cells to heat (42degreesC caused a rapid disappearance of the breast cancer susceptibility gene-1 (BRCA1) protein, starting at 1 h after the onset of heating and slightly lagging behind the increase in heat shock protein 70 (HSP70) levels. The heat-induced loss of BRCA1 occurred at the protein level, since: (1) BRCA1 mRNA expression was unaffected; and (2) the BRCA1 protein loss was also observed in DU-145 cells that expressed exogenous wild-type BRCA1 (wtBRCA1). In addition to heat regulation of BRCA1 protein levels, we also found that BRCA1 could modulate the heat shock response. Thus, wtBRCA1 overexpressing DU-145 cell clones showed significantly decreased sensitivity to heat-induced cytotoxicity; and Brca1 mutant mouse embryo fibroblasts showed increased sensitivity to heat. The DU-145 wtBRCA1 clones also showed increased expression of the small heat shock protein HSP27; and reporter assays revealed that wtBRCA1 stimulated a two to four-fold increase in HSP27 promoter activity, consistent with its ability to upregulate HSP27 mRNA and protein levels. In studies using epitope-tagged truncated BRCA1 proteins, the ability to stimulate the HSP27 promoter and to mediate heat-induced degradation required the amino-terminus but not the carboxyl-terminus of BRCA1 Although the heat-induced loss of BRCA1 appeared to be due to protein degradation, various protein metabolic agents (or combinations) failed to block this event, including: MG132 (a 26S proteasomal inhibitor), N-Wacetyl-leucyl-leucyl-norleucinal (a calpain inhibitor), z-VAD-fmk (a pan-caspase inhibitor), and ammonium chloride and chloroquine (which stabilize lysosomes). These findings suggest that in addition to its other functions, BRCA1 may participate in mammalian heat shock response pathways.	Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New Hyde Pk, NY 11040 USA; Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rosen, EM (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.		Meng, Q./GSI-6185-2022		NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; BATES PJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P377, DOI 10.1016/0304-4165(82)90113-1; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chen YM, 1996, CANCER RES, V56, P3168; Cornford PA, 2000, CANCER RES, V60, P7099; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014-5793(00)02430-3; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Horman S, 1999, INT J CANCER, V82, P574, DOI 10.1002/(SICI)1097-0215(19990812)82:4<574::AID-IJC17>3.0.CO;2-L; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Mairesse N, 1996, CELL BIOL INT, V20, P205, DOI 10.1006/cbir.1996.0025; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakamoto H, 2000, FEBS LETT, V483, P169, DOI 10.1016/S0014-5793(00)02097-4; Newton EM, 1996, MOL CELL BIOL, V16, P839; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Payne J, 2000, INT J HYPERTHER, V16, P492, DOI 10.1080/02656730050199340; Pfleger CM, 2000, GENE DEV, V14, P655; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; POOLE B, 1997, ACTA BIOL MED GER, V36, P1777; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trautinger F, 1997, J PHOTOCH PHOTOBIO B, V39, P90, DOI 10.1016/S1011-1344(96)00010-3; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yuan RQ, 1999, PROSTATE, V40, P37; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	76	19	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					10	27		10.1038/sj.onc.1206061	http://dx.doi.org/10.1038/sj.onc.1206061			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527903				2022-12-25	WOS:000180166900002
J	Pei, W; Liou, AKF; Chen, J				Pei, W; Liou, AKF; Chen, J			Two caspase-mediated apoptotic pathways induced by rotenone toxicity in cortical neuronal cells	FASEB JOURNAL			English	Article						cortical neurons; MPT; caspase; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; DNA FRAGMENTATION; RESPIRATORY-CHAIN; INDUCTION; EXCITOTOXICITY; SUPEROXIDE; INVOLVEMENT; ACTIVATION	Our results presented here suggest that cortical neurons degenerate via two caspase-mediated apoptotic pathways when challenged with 0.5 muM rotenone. Although these two pathways can be attributed to the loss of mitochondrial integrity, the triggers for these pathways are likely due to two separate subsequent events (the release of cytochrome c and the emergence of mitochondrial permeability transition [MPT]). Despite some reports suggesting that the release of cytochrome c is a consequence of MPT, the results of our time course experiments suggest otherwise. In fact, we observed that the release of cytochrome c occurred much earlier than MPT; hence, the former is unlikely to be a consequence of the latter. In addition, we observed that the presence of an MPT inhibitor did not attenuate the activation of caspase-3, and that caspase-1-mediated cell death did not exhibit nuclear condensation and DNA fragmentation. Taken together, these results suggest that there are two routes by which cortical neurons degenerate during ischemic injury or in neurodegenerative diseases.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15217 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chen, J (corresponding author), Univ Pittsburgh, Sch Med S526, Dept Neurol, Biomed Sci Tower 3500,Terrace St, Pittsburgh, PA 15261 USA.	Jun@med.pitt.edu		Chen, Jun/0000-0002-8077-3403				Anjum R, 2001, CELL DEATH DIFFER, V8, P1038, DOI 10.1038/sj.cdd.4400915; Anup R, 1999, INDIAN J BIOCHEM BIO, V36, P266; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Campbell VA, 2001, NEUROPHARMACOLOGY, V40, P702, DOI 10.1016/S0028-3908(00)00210-0; Cao GD, 2002, J CEREBR BLOOD F MET, V22, P534, DOI 10.1097/00004647-200205000-00005; Cao GD, 2001, J NEUROSCI, V21, P4678, DOI 10.1523/JNEUROSCI.21-13-04678.2001; Cao GD, 2002, J NEUROSCI, V22, P5423; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CHAUDHRY A, 1988, MOL PHARMACOL, V34, P543; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; COSSON P, 1993, RACHIS, V5, P5; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Fasanmade AA, 2001, ARCH PHARM RES, V24, P126, DOI 10.1007/BF02976480; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HART J, 1994, MICROCONTAMINATION, V12, P63; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; ISEKI S, 1986, EXP CELL RES, V167, P311, DOI 10.1016/0014-4827(86)90172-2; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kantrow SP, 2000, FREE RADICAL BIO MED, V28, P251, DOI 10.1016/S0891-5849(99)00238-5; Kim GW, 2002, J CEREBR BLOOD F MET, V22, P798, DOI 10.1097/00004647-200207000-00005; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lim MLR, 2001, FEBS LETT, V503, P69, DOI 10.1016/S0014-5793(01)02693-X; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LUSTIG HS, 1992, J NEUROCHEM, V59, P2193; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Schulz JB, 1996, NEUROCHEM INT, V29, P167, DOI 10.1016/0197-0186(95)00122-0; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; White MJ, 1996, J NEUROSCI METH, V70, P195, DOI 10.1016/S0165-0270(96)00118-5; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5	44	48	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					520	+		10.1096/fj.02-0653fje	http://dx.doi.org/10.1096/fj.02-0653fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551850				2022-12-25	WOS:000181453700012
J	Winklhofer, KF; Heske, J; Heller, U; Reintjes, A; Muranyi, W; Moarefi, I; Tatzelt, J				Winklhofer, KF; Heske, J; Heller, U; Reintjes, A; Muranyi, W; Moarefi, I; Tatzelt, J			Determinants of the in vivo folding of the prion protein - A bipartite function of helix 1 in folding and aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOSYLATION; CEREVISIAE GAS1 PROTEIN; PRP KNOCKOUT MICE; ENDOPLASMIC-RETICULUM; MOLECULAR ANALYSIS; SCRAPIE ISOFORM; ALKALINE-PHOSPHATASE; NEUROBLASTOMA-CELLS; STRAIN VARIATION; CULTURED-CELLS	Misfolding of the mammalian prion protein (PrP) is implicated in the pathogenesis of prion diseases. We analyzed wild type PrP in comparison with different PrP mutants and identified determinants of the in vivo folding pathway of PrP. The complete N terminus of PrP including the putative transmembrane domain and the first beta-strand could be deleted without interfering with PrP maturation. Helix 1, however, turned out to be a major determinant of PrP folding. Disruption of helix 1 prevented attachment of the glycosylphosphatidylinositol (GPI) anchor and the formation of complex N-linked glycans; instead, a high mannose PrP glycoform was secreted into the cell culture supernatant. In the absence of a C-terminal membrane anchor, however, helix 1 induced the formation of unglycosylated and partially protease-resistant PrP aggregates. Moreover, we could show that the C-terminal GPI anchor signal sequence, independent of its role in GPI anchor attachment, mediates core glycosylation of nascent PrP. Interestingly, conversion of high mannose glycans to complex type glycans only occurred when PrP was membrane-anchored. Our study indicates a bipartite function of helix 1 in the maturation and aggregation of PrP and emphasizes a critical role of a membrane anchor in the formation of complex glycosylated PrP.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Univ Munich, Max Von Pettenkofer Inst Virol, Genectr Munich, D-81377 Munich, Germany	Max Planck Society; University of Munich	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de		Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Blochberger TC, 1997, PROTEIN ENG, V10, P1465, DOI 10.1093/protein/10.12.1465; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; Korth C, 2000, J GEN VIROL, V81, P2555, DOI 10.1099/0022-1317-81-10-2555; Kretzschmar HA, 2000, ARCH VIROL, P239; Kuczius T, 1998, J INFECT DIS, V178, P693, DOI 10.1086/515337; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; LOW MG, 1980, BIOCHEMISTRY-US, V19, P3913, DOI 10.1021/bi00558a004; LOWE ME, 1992, J CELL BIOL, V116, P799, DOI 10.1083/jcb.116.3.799; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; MORAN P, 1991, J BIOL CHEM, V266, P1250; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Priola SA, 2001, EMBO J, V20, P6692, DOI 10.1093/emboj/20.23.6692; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zuegg J, 2000, GLYCOBIOLOGY, V10, P959, DOI 10.1093/glycob/10.10.959	66	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14961	14970		10.1074/jbc.M209942200	http://dx.doi.org/10.1074/jbc.M209942200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12556465	hybrid			2022-12-25	WOS:000182516100051
J	Janssen, E; de Groof, A; Wijers, M; Fransen, J; Dzeja, PP; Terzic, A; Wieringa, B				Janssen, E; de Groof, A; Wijers, M; Fransen, J; Dzeja, PP; Terzic, A; Wieringa, B			Adenylate kinase 1 deficiency induces molecular and structural adaptations to support muscle energy metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; CREATINE-KINASE; SKELETAL-MUSCLE; C-MYC; MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; KNOCKOUT HEART; RAT SKELETAL; FIBERS; MICE	Genetic ablation of adenylate kinase 1 (AK1), a member of the AK family of phosphotransfer enzymes, disturbs muscle energetic economy and decreases tolerance to metabolic stress, despite rearrangements in alternative high energy phosphoryl transfer pathways. To define the mechanisms of this adaptive response, soleus and gastrocnemius muscles from AK1(-/-) mice were characterized by cDNA array profiling, Western blot and ultrastructural analysis. We demonstrate that AK1 deficiency induces fiber-type specific variation in groups of transcripts involved in glycolysis and mitochondrial metabolism and in gene products defining structural and myogenic events. This was associated with increased phosphotransfer capacities of the glycolytic enzymes pyruvate kinase and 3-phosphoglycerate kinase. Moreover, in AK1(-/-) mice, fast-twitch gastrocnemius, but not slow-twitch soleus, had an increase in adenine nucleotide translocator (ANT) and mitochondrial creatine kinase protein, along with a doubling of the intermyofibrillar mitochondrial volume. These results provide molecular evidence for wide-scale remodeling in AK1-deficient muscles aimed at preservation of efficient energetic communication between ATP producing and utilizing cellular sites.	Univ Nijmegen, Univ Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Dept Expt Therapeut, Rochester, MN 55905 USA	Radboud University Nijmegen; Mayo Clinic; Mayo Clinic; Mayo Clinic	Wieringa, B (corresponding author), Univ Nijmegen, Univ Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands.		Wijers-Rouw, Mietske/G-4456-2016; Fransen, Jack/E-8924-2010; Wieringa, Berend/A-5346-2011	Fransen, Jack/0000-0002-0571-7639; Wieringa, Berend/0000-0001-9192-8020				Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4; de Groof AJC, 2001, MUSCLE NERVE, V24, P1188, DOI 10.1002/mus.1131; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; GERLACH G, 1986, BIOCHIM BIOPHYS ACTA, V881, P398, DOI 10.1016/0304-4165(86)90032-2; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; KORGE P, 1995, SPORTS MED, V20, P215, DOI 10.2165/00007256-199520040-00002; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Liedtke AJ, 1999, AM J PHYSIOL-HEART C, V277, pH1435, DOI 10.1152/ajpheart.1999.277.4.H1435; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; MATSUURA S, 1989, J BIOL CHEM, V264, P10148; Mazurek S, 1998, ANTICANCER RES, V18, P3275; Merkulova T, 1999, J MUSCLE RES CELL M, V20, P55, DOI 10.1023/A:1005428328913; Merkulova T, 2000, AM J PHYSIOL-ENDOC M, V278, pE330, DOI 10.1152/ajpendo.2000.278.2.E330; MOERLAND TS, 1989, AM J PHYSIOL, V257, pC810, DOI 10.1152/ajpcell.1989.257.4.C810; Murdock DG, 1999, J BIOL CHEM, V274, P14429, DOI 10.1074/jbc.274.20.14429; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pette D, 1999, MUSCLE NERVE, V22, P666, DOI 10.1002/(SICI)1097-4598(199906)22:6<666::AID-MUS3>3.0.CO;2-Z; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; SAVABI F, 1994, MOL CELL BIOCHEM, V133, P145, DOI 10.1007/BF01267953; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Scholz TD, 1998, AM J PHYSIOL-CELL PH, V274, pC780, DOI 10.1152/ajpcell.1998.274.3.C780; Schuster S, 2002, BIOPHYS CHEM, V99, P63, DOI 10.1016/S0301-4622(02)00122-9; Sears PR, 1999, BIOCHEMISTRY-US, V38, P14881, DOI 10.1021/bi991076e; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; St-Amand J, 2001, FASEB J, V15, P684, DOI 10.1096/fj.00-0150com; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; THORSTENSSON A, 1977, ACTA PHYSIOL SCAND, V99, P225, DOI 10.1111/j.1748-1716.1977.tb10373.x; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	52	37	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12937	12945		10.1074/jbc.M211465200	http://dx.doi.org/10.1074/jbc.M211465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562761	Green Published, hybrid			2022-12-25	WOS:000182189500045
J	Lin, AP; McAlister-Henn, L				Lin, AP; McAlister-Henn, L			Homologous binding sites in yeast isocitrate dehydrogenase for cofactor (NAD(+)) and allosteric activator (AMP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; KINETIC-ANALYSIS; COENZYME SITE; PHOSPHORYLATION; SPECIFICITY; SUBUNITS; PROTEIN; ENZYME	Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an allosterically regulated octameric enzyme composed of two types of homologous subunits designated IDH1and IDH2. Based on sequence comparisons and structural models, both subunits are predicted to have adenine nucleotide binding sites. This was tested by alanine replacement of residues in putative sites in each subunit. Targets included adjacent aspartate/isoleucine residues implicated as important for determining cofactor specificity in related dehydrogenases and a residue in each IDH subunit in a position occupied by histidine in other cofactor binding sites. The primary kinetic effects of D286A/I287A and of H281A replacements in IDH2 were found to be a dramatic reduction in apparent affinity of the holoenzyme for NAD(+) and a concomitant reduction in V-max. Ligand binding assays also showed that the H281A mutant enzyme fails to bind NAD(+) under conditions that are saturating for the wild-type enzyme. In contrast, the primary effect of corresponding D279A/ D280A and of R274A replacements in IDH1 is a reduction in holoenzyme binding of AMP, with concomitant alterations in kinetic and isocitrate binding properties normally associated with activation by this allosteric effector. These results suggest that the nucleotide cofactor binding site is primarily contributed by the ID112 subunit, whereas the homologous nucleotide binding site in 1131111 has evolved for regulatory binding of AMP. These results are consistent with previous studies demonstrating that the catalytic isocitrate binding sites are comprised of residues primarily contributed by IDH2, whereas sites for regulatory binding of isocitrate are contributed by analogous residues of IDH1. In this study, we also demonstrate that a prerequisite for holoenzyme binding of NAD(+) is binding of isocitrate/Mg2+ at the IDH2 catalytic site. This is comparable to the dependence of AMP binding upon binding of isocitrate at the IDH1 regulatory site.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NIGMS NIH HHS [GM51265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEAN AM, 1989, J BIOL CHEM, V264, P20482; Doyle SA, 2000, BIOCHEMISTRY-US, V39, P14348, DOI 10.1021/bi001458g; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; Huang YC, 2002, BIOCHEMISTRY-US, V41, P5637, DOI 10.1021/bi0200716; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KORNBERG A, 1951, J BIOL CHEM, V189, P123; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; Lee P, 2002, ARCH BIOCHEM BIOPHYS, V401, P81, DOI 10.1016/S0003-9861(02)00041-3; Lin AP, 2002, J BIOL CHEM, V277, P22475, DOI 10.1074/jbc.M202534200; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; NICHOLS BJ, 1995, BIOCHEM J, V310, P917, DOI 10.1042/bj3100917; NICHOLS BJ, 1993, BIOCHEM J, V295, P347, DOI 10.1042/bj2950347; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; PANISKO EA, 2000, THESIS U TEXAS HLTH; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811	33	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12864	12872		10.1074/jbc.M300154200	http://dx.doi.org/10.1074/jbc.M300154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562755	hybrid			2022-12-25	WOS:000182189500036
J	Sato, Y; Sakaguchi, M; Goshima, S; Nakamura, T; Uozumi, N				Sato, Y; Sakaguchi, M; Goshima, S; Nakamura, T; Uozumi, N			Molecular dissection of the contribution of negatively and positively charged residues in S2, S3, and S4 to the final membrane topology of the voltage sensor in the K+ channel, KAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; ARABIDOPSIS-THALIANA; FUNCTIONAL EXPRESSION; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ION CHANNELS; GUARD-CELLS; SEQUENCE	Voltage-dependent ion channels control changes in ion permeability in response to membrane potential changes. The voltage sensor in channel proteins consists of the highly positively charged segment, S4, and the negatively charged segments, S2 and S3. The process involved in the integration of the protein into the membrane remains to be elucidated. In this study, we used in vitro translation and translocation experiments to evaluate interactions between residues in the voltage sensor of a hyperpolarization-activated potassium channel, KAT1, and their effect on the final topology in the endoplasmic reticulum (ER) membrane. A D95V mutation in S2 showed less S3-S4 integration into the membrane, whereas a D105V mutation allowed S4 to be released into the ER lumen. These results indicate that Asp(95) assists in the membrane insertion of S3-S4 and that Asp(105) helps in preventing S4 from being releasing into the ER lumen. The charge reversal mutation, R171D, in S4 rescued the D105R mutation and prevented S4 release into the ER lumen. A series of constructs containing different C-terminal truncations of S4 showed that Arg 174 was required for correct integration of S3 and S4 into the membrane. Interactions between Asp(105) and Arg 171 and between negative residues in S2 or S3 and Arg 174 may be formed transiently during membrane integration. These data clarify the role of charged residues in S2, S3, and S4 and identify posttranslational electrostatic interactions between charged residues that are required to achieve the correct voltage sensor topology in the ER membrane.	Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; Niigata Univ Pharm & Appl Life Sci, Fac Pharm, Niigata 9502081, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Nagoya University; Nagoya University; Niigata University; Kyushu University	Uozumi, N (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.		Uozumi, Nobuyuki/AAG-3252-2019	Uozumi, Nobuyuki/0000-0003-4268-1126				Ache P, 2000, FEBS LETT, V486, P93, DOI 10.1016/S0014-5793(00)02248-1; Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Basset M, 1995, PLANT MOL BIOL, V29, P947, DOI 10.1007/BF00014968; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; Chin CN, 2002, TRENDS BIOCHEM SCI, V27, P231, DOI 10.1016/S0968-0004(02)02082-0; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; OGATA S, 1989, J BIOL CHEM, V264, P3596; Ota K, 2000, J BIOL CHEM, V275, P29743, DOI 10.1074/jbc.M002468200; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Papazian D M, 1999, Adv Neurol, V79, P481; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; RADRIGUEZNAVARR.A, 2000, BIOCHIM BIOPHYS ACTA, V1469, P1; RIBERA AB, 1993, J NEUROSCI, V13, P4988; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; Schachtman DP, 2000, BBA-BIOMEMBRANES, V1465, P127, DOI 10.1016/S0005-2736(00)00134-6; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; UOZUMI N, 1995, J BIOL CHEM, V270, P24276, DOI 10.1074/jbc.270.41.24276; Uozumi N, 1998, P NATL ACAD SCI USA, V95, P9773, DOI 10.1073/pnas.95.17.9773; Uozumi N, 2001, AM J PHYSIOL-CELL PH, V281, pC733, DOI 10.1152/ajpcell.2001.281.3.C733; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zimmermann S, 1998, PLANT PHYSIOL, V116, P879, DOI 10.1104/pp.116.3.879	44	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13227	13234		10.1074/jbc.M300431200	http://dx.doi.org/10.1074/jbc.M300431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556517	hybrid			2022-12-25	WOS:000182189500081
J	Bache, KG; Raiborg, C; Mehlum, A; Stenmark, H				Bache, KG; Raiborg, C; Mehlum, A; Stenmark, H			STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TRANSDUCING ADAPTER MOLECULE; SRC HOMOLOGY 3; PLASMA-MEMBRANE; MOUSE SKD1; PROTEIN; YEAST; DEGRADATION; CLATHRIN; MUTANTS	STAM1 and STAM2, which have been identified as regulators of receptor signaling and trafficking, interact directly with Hrs, which mediates the endocytic sorting of ubiquitinated membrane proteins. The STAM proteins interact with the same coiled-coil domain that is involved in the targeting of Hrs to endosomes. In this work, we show that STAM1 and STAM2, as well as an endocytic regulator protein, Eps15, can be co-immunoprecipitated with Hrs both from membrane and cytosolic fractions and that recombinant Hrs, STAM1/STAM2, and Eps15 form a ternary complex. We find that overexpression of Hrs causes a strong recruitment of STAM2 to endosome membranes. Moreover, STAM2, like Hrs and Eps15, binds ubiquitin, and Hrs, STAM2, and Eps15 colocalize with ubiquitinated proteins in clathrin-containing endosomal microdomains. The localization of Hrs, STAM2, Eps15, and clathrin to endosome membranes is controlled by the AAA ATPase mVps4, which has been implicated in multivesicular body formation. Depletion of cellular Hrs by small interfering RNA results in a strongly reduced recruitment of STAM2 to endosome membranes and an impaired degradation of endocytosed epidermal growth factor receptors. We propose that Hrs, Eps15, and STAM proteins function in a multivalent complex that sorts ubiquitinated proteins into the multivesicular body pathway.	Norwegian Radium Hosp, Dept Biochem, Inst Canc Res, N-0310 Oslo, Norway	University of Oslo	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, Inst Canc Res, N-0310 Oslo, Norway.	stenmark@ulrik.uio.no	Bache, Kristi G./AAD-9335-2020; Stenmark, Harald/B-8868-2008					Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2002, EUR J BIOCHEM, V269, P3881, DOI 10.1046/j.1432-1033.2002.03046.x; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; BENMERSH A, 2003, J BIOL CHEM, V275, P3288; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Lohi O, 2001, FEBS LETT, V508, P287, DOI 10.1016/S0014-5793(01)03079-4; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, J CELL SCI, V114, P2255; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Scheuring S, 1999, GENE, V234, P149, DOI 10.1016/S0378-1119(99)00163-8; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yamada M, 2002, MOL CELL BIOL, V22, P8648, DOI 10.1128/MCB.22.24.8648-8658.2002; Yamada M, 2001, MOL CELL BIOL, V21, P3807, DOI 10.1128/MCB.21.11.3807-3819.2001; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	64	238	252	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12513	12521		10.1074/jbc.M210843200	http://dx.doi.org/10.1074/jbc.M210843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551915	hybrid			2022-12-25	WOS:000182015700103
J	Ninio, S; Schuldiner, S				Ninio, S; Schuldiner, S			Characterization of an archaeal multidrug transporter with a unique amino acid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BINDING-SITE; ESCHERICHIA-COLI; TRANSMEMBRANE HELICES; EMRE; PROTEINS; OLIGOMER; ENZYMES; EFFLUX; H+	The Smr family of multidrug transporters consists of small membrane proteins that extrude various drugs in exchange with protons rendering cells resistant to these drugs. Smr proteins identified to date have been found only in Eubacteria. In this work we present the cloning and characterization of an Smr protein from the archaeon Halobacterium salinarum, the first Smr in the archaeal kingdom. The protein, named Hsmr, was identified through sequence similarity to the Smr family, and the DNA sequence was cloned into an Escherichia coli expression system. Hsmr is heterologously expressed in a functional form despite the difference in lipid composition of the membrane and the lower salt in the cell and its environment. Cells harboring the Hsmr plasmid transport ethidium bromide in an uncoupler-sensitive process and gain resistance to ethidium bromide and acriflavine. Hsmr binds tetraphenylphosphonium (TPP+) with a relatively low affinity (K-D similar to200 nm) at low salt concentration that increases (K-D similar to40 nm) upon the addition of 2 m of either NaCl or KCl. The Hsmr protein contains many of the signature sequence elements of the Smr family and also a high content of negative residues in the loops, characteristic of extreme halophiles. Strikingly, Hsmr is composed of over 40% valine and alanine residues. These residues are clustered at certain regions of the protein in domains that are not important for activity, as judged from lack of conservation and from previous studies with other Smr proteins. We suggest that this high content of alanine and valine residues is a reflection of a "natural" alanine and valine scanning necessitated by the high GC content of the gene. This phenomenon reveals significant sequence elements in small multidrug transporters.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers SV, 2001, EXTREMOPHILES, V5, P285, DOI 10.1007/s007920100214; Elcock AH, 1998, J MOL BIOL, V280, P731, DOI 10.1006/jmbi.1998.1904; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GUTMAN N, 2003, J BIOL CHEM; Jiang SL, 2000, PROTEINS, V40, P429, DOI 10.1002/1097-0134(20000815)40:3<429::AID-PROT80>3.0.CO;2-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBERT B, 1984, BIOCHEMISTRY-US, V23, P166, DOI 10.1021/bi00296a027; Madern D, 2000, EXTREMOPHILES, V4, P91, DOI 10.1007/s007920050142; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Mevarech M, 2000, BIOPHYS CHEM, V86, P155, DOI 10.1016/S0301-4622(00)00126-5; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Stevens TJ, 2000, PROTEIN SCI, V9, P505; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; van de Vossenberg JLCM, 1998, EXTREMOPHILES, V2, P163, DOI 10.1007/s007920050056; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WATANABE Y, 1991, J BIOCHEM, V110, P40, DOI 10.1093/oxfordjournals.jbchem.a123540; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	30	40	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12000	12005		10.1074/jbc.M213119200	http://dx.doi.org/10.1074/jbc.M213119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551892	hybrid			2022-12-25	WOS:000182015700038
J	Stortelers, C; van der Woning, SP; Jacobs-Oomen, S; Wingens, M; van Zoelen, EJJ				Stortelers, C; van der Woning, SP; Jacobs-Oomen, S; Wingens, M; van Zoelen, EJJ			Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; RECEPTOR; DOMAIN; IDENTIFICATION; REVEALS; SPECIFICITY; RESIDUES; COMPLEX	EGF-like growth factors activate their ErbB receptors by promoting receptor-mediated homodimerization or, alternatively, by the formation of heterodimers with the orphan ErbB-2 through an as yet unknown mechanism. To investigate the selectivity in dimer formation by ligands, we have applied the phage display approach to obtain ligands with modified C-terminal residues that discriminate between ErbB-2 and ErbB-3 as dimerization partners. We used the epidermal growth factor/ transforming growth factor a chimera T1E as the template molecule because it binds to ErbB-3 homodimers with low affinity and to ErbB-2/ErbB-3 heterodimers with high affinity. Many phage variants were selected with enhanced binding affinity for ErbB-3 homodimers, indicating that C-terminal residues contribute to the interaction with ErbB-3. These variants were also potent ligands for ErbB-2/ErbB-3 heterodimers despite negative selection for such heterodimers. In contrast, phage variants positively selected for binding to ErbB-2/ErbB-3 heterodimers but negatively selected for binding to ErbB-3 homodimers can be considered as "second best" ErbB-3 binders, which require ErbB-2 heterodimerization for stable complex formation. Our findings imply that epidermal growth factor-like ligands bind ErbB-3 through a multi-domain interaction involving at least both linear endings of the ligand. Apparently the ErbB-3 affinity of a ligand determines whether it can form only ErbB-2/ErbB-3 complexes or also ErbB-3 homodimers. Because no separate binding domain for ErbB-2 could be identified, our data support a model in which ErbB heterodimerization occurs through a receptor-mediated mechanism and not through bivalent ligands.	Catholic Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	van Zoelen, EJJ (corresponding author), Catholic Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	vzoelen@sci.kun.nl	van Zoelen, Everardus J./D-9192-2012					ALIMANDI M, 1995, ONCOGENE, V10, P1813; Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harris A, 1998, BIOCHEM BIOPH RES CO, V251, P220, DOI 10.1006/bbrc.1998.9436; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kim JH, 2002, EUR J BIOCHEM, V269, P2323, DOI 10.1046/j.1432-1033.2002.02877.x; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Singer E, 2001, J BIOL CHEM, V276, P44266, DOI 10.1074/jbc.M105428200; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Souriau C, 1997, NUCLEIC ACIDS RES, V25, P1585, DOI 10.1093/nar/25.8.1585; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P8732, DOI 10.1021/bi025878c; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P4292, DOI 10.1021/bi012016n; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Whoriskey JS, 1998, GROWTH FACTORS, V15, P307, DOI 10.3109/08977199809017485; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	41	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12055	12063		10.1074/jbc.M211948200	http://dx.doi.org/10.1074/jbc.M211948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556529	Green Published, hybrid			2022-12-25	WOS:000182015700045
J	Pan, L; Gurevich, EV; Gurevich, VV				Pan, L; Gurevich, EV; Gurevich, VV			The nature of the arrestin-receptor complex determines the ultimate fate of the internalized receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA-ARRESTIN; VISUAL ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; MULTIPLE PHOSPHORYLATION; CRYSTAL-STRUCTURE; RHODOPSIN; BINDING	The vast majority of G protein-coupled receptors are desensitized by a uniform two-step mechanism: phosphorylation of an active receptor followed by arrestin binding. The arrestin-receptor complex is then internalized. Internalized receptor can be recycled back to the plasma membrane (resensitization) or targeted to lysosomes for degradation (down-regulation). The intracellular compartment where this choice is made and the molecular mechanisms involved are largely unknown. Here we used two arresting mutants that bind with high affinity to phosphorylated and unphosphorylated agonist-activated beta2-adrenergic receptor to manipulate the receptor-arrestin interface. We found that mutants support rapid internalization of beta2-adrenergic receptor similar to wild type arresting. At the same time, phosphorylation-independent arresting mutants facilitate receptor recycling and sharply reduce the rate of receptor loss, effectively protecting beta2-adrenergic receptor from down-regulation even after very long (up to 24 h) agonist exposure. Phosphorylation-independent arrestin2 mutants dramatically reduce receptor phosphorylation in response to an agonist both in vitro and in cells. Interestingly, co-expression of high levels of beta-adrenergic receptor kinase restores receptor down-regulation in the presence of mutants to the levels observed with wild type arresting. Our data suggest that unphosphorylated receptor internalized in complex with mutant arrestins recycles faster than phosphoreceptor and is less likely to get degraded. Thus, targeted manipulation of the characteristics of an arrestin protein that binds to a G protein-coupled receptors can dramatically change receptor trafficking and its ultimate fate in a cell.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Gurevich, VV (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Med Ctr, RRB,Rm 454, Nashville, TN 37232 USA.	Vsevolod.Gurevich@mcmail.vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH062651] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500] Funding Source: Medline; NIGMS NIH HHS [GM63097] Funding Source: Medline; NIMH NIH HHS [MH62651] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arshavsky VY, 2002, TRENDS NEUROSCI, V25, P124, DOI 10.1016/S0166-2236(00)02094-4; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; Kim YM, 2002, J BIOL CHEM, V277, P16340, DOI 10.1074/jbc.M200678200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Moore RH, 1999, EUR J PHARMACOL, V369, P113, DOI 10.1016/S0014-2999(99)00055-2; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Price RR, 2002, J BIOL CHEM, V277, P9570, DOI 10.1074/jbc.M111762200; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	47	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11623	11632		10.1074/jbc.M209532200	http://dx.doi.org/10.1074/jbc.M209532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525498	hybrid			2022-12-25	WOS:000181855400095
J	Ungefroren, H; Lenschow, W; Chen, WB; Faendrich, F; Kalthoff, H				Ungefroren, H; Lenschow, W; Chen, WB; Faendrich, F; Kalthoff, H			Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein kinase signaling downstream of smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; TGF-BETA; MESENCHYMAL TRANSDIFFERENTIATION; PANCREATIC-CANCER; INDUCED APOPTOSIS; PATHWAY; CELLS; PROTEOGLYCANS; TRANSDUCTION; FAMILY	Several signaling pathways have been implicated in mediating TGF-beta1-induced extracellular matrix production and fibrosis. We have shown recently that induction of biglycan (BGN) expression by TGF-beta1 depended on a functional Smad pathway (Chen, W.-B., Lenschow, W., Tiede, K., Fischer, J. W., Kalthoff, H., and Ungefroren, H. (2002) J. Biol. Chem. 277,36118-36128). Here, we present evidence that the ability of TGF-beta1 to induce BGN mRNA, in addition to Smads, requires p38 MAPK signaling, because 1) pharmacological inhibitors of p38 dose-dependently inhibited the TGF-beta effect without significantly affecting the transcriptional activity of a constitutively active mutant of the TGF-beta type I receptor or Smad2 phosphorylation at concentrations up to 10 pas, 2) the up-regulation of BGN mRNA was preceded by a delayed increase in the phosphorylation of p38 and its upstream activator MKK6 in TGF-beta1-treated PANC-1 cells, 3) inhibition of the p38 pathway by stable retroviral transduction with a dominant negative mutant of either p38 or MKK6 reduced TGF-beta1-induced BGN mRNA expression, and 4) overexpression of wild-type p38 or MKK6, but not MKK3, augmented the TGF-beta1 effect on BGN mRNA. We further demonstrate that the (delayed) p38 activation by TGF-beta1 is downstream of Smads and requires a functional Smad pathway, because blocking TGF-beta-induced p38 activity with SB202190 had no effect on Smad2 phosphorylation, but blocking Smad signaling by forced expression of Smad7 abolished TGF-beta1 induction of p38 activation and, as shown earlier, BGN mRNA expression; finally, re-expression of Smad4 in Smad4-null CFPAC-1 cells restored TGF-beta-induced p38 phosphorylation and, as demonstrated previously, BGN mRNA accumulation. These results clearly show that TGF-beta1 induction of BGN expression in pancreatic cells requires activation of MKK6-p38 MAPK signaling downstream of Smad signaling and provide a mechanistic clue to the up-regulation of BGN seen in inflammatory response-related fibrosis and desmoplasia.	Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, D-24105 Kiel, Germany	University of Kiel	Ungefroren, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, Arnold-Heller Str 7, D-24105 Kiel, Germany.	hungefroren@email.uni-kiel.de	Faendrich, Fred/B-1705-2010; Kalthoff, Holger/B-1618-2010					Behr TM, 2001, CIRCULATION, V104, P1292, DOI 10.1161/hc3601.094275; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Ellenrieder V, 2001, CANCER RES, V61, P4222; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocking AM, 1998, MATRIX BIOL, V17, P1; Howard BD, 2000, CANCER GENE THER, V7, P927, DOI 10.1038/sj.cgt.7700180; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Johansson N, 2000, J CELL SCI, V113, P227; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, J CELL SCI, V112, P4557; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Simeone DM, 2001, AM J PHYSIOL-CELL PH, V281, pC311, DOI 10.1152/ajpcell.2001.281.1.C311; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	62	54	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11041	11049		10.1074/jbc.M300035200	http://dx.doi.org/10.1074/jbc.M300035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538652	hybrid			2022-12-25	WOS:000181855400024
J	Wang, ZQ; Zhang, BC; Wang, MF; Carr, BI				Wang, ZQ; Zhang, BC; Wang, MF; Carr, BI			Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90(RSK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR; PC12 CELLS; TYROSINE PHOSPHORYLATION; KINASE ACTIVATION; COMPLEX-FORMATION; K-VITAMIN; INHIBITION; PATHWAY; CBP	Compound 5 (Cpd 5) or 2-(2-mercaptoethanol)-3-methyl-1,4-naphthoquinone, is an inhibitor of protein phosphatase Cdc25A and causes persistent activation of extracellular signal-regulated kinase (ERK) and cell growth inhibition. To study the mechanism(s) by which persistent ERK phosphorylation might induce cell growth inhibition, we used Cpd 5 as a tool to examine its effects on the activity of CREB (CAMP response element-binding protein) transcription factor in Hep3B human hepatoma cells. We found that CREB activity, including its DNA binding ability and phosphorylation on residue Ser-133, was strongly inhibited by Cpd 5, followed by suppression of CRE-mediated transcription of cyclin D1 and Bcl-2 genes. Cpd 5-mediated suppression of CREB phosphorylation and transcriptional activity was antagonized by mitogen-activated protein kinase kinase inhibitors PD 98059 and U-0126, implying that this inhibition of CREB activity was regulated at least in part by the ERK pathway. The phosphorylation of ribosomal S6 kinase (pp90(RSK)), a CREB kinase in response to mitogen stimulation, was also found to be inhibited by Cpd 5 action. This inhibition of pp90RSK phosphorylation is likely the result of its increased association with CREB-binding protein (CBP), which subsequently caused inhibition of CREB phosphorylation and activity. To support the hypothesis that Cpd 5 effects on Cdc25A inhibition with subsequent ERK activation could cause CREB inhibition, we examined the effects of Cdc25A inhibition without the use of Cpd 5. Hep3B cells were transfected with C430S Cdc25A mutant, and ERK was found to be phosphorylated in a constitutively activated manner, which was accompanied by decreased CREB phosphorylation and increased recruitment of CBP to pp90RSK. These data provide evidence that CBP-RSK complex formation in response to persistent ERK phosphorylation by Cpd 5 down-regulates CREB activity, leading to inhibition of both cAMP response element-mediated gene expression and cell growth.	Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg,Liver Canc Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Carr, BI (corresponding author), Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg,Liver Canc Ctr, E 1552 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.			Carr, Brian/0000-0002-6111-5077				Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Carr BI, 2003, J MOL BIOL, V326, P721, DOI 10.1016/S0022-2836(02)01445-6; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAVIS RJ, 1993, J BIOL CHEM, V268, P14533; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ni RZ, 1998, J BIOL CHEM, V273, P9906, DOI 10.1074/jbc.273.16.9906; Osada S, 2001, J MOL BIOL, V314, P765, DOI 10.1006/jmbi.2001.5171; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Parker D, 1996, MOL CELL BIOL, V16, P694; PAWSON AJ, 1997, ADV ONCOL, V13, P3; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Vogt A, 2001, J BIOL CHEM, V276, P20544, DOI 10.1074/jbc.M100078200; Wang ZQ, 2000, J CELL PHYSIOL, V183, P338, DOI 10.1002/(SICI)1097-4652(200006)183:3<338::AID-JCP6>3.0.CO;2-X; Wang ZQ, 2002, J HEPATOL, V36, P85, DOI 10.1016/S0168-8278(01)00230-6; Xia K, 1999, MOL CELL BIOL, V19, P4819; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7	44	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11138	11144		10.1074/jbc.M209108200	http://dx.doi.org/10.1074/jbc.M209108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540838	hybrid			2022-12-25	WOS:000181855400037
J	Dinger, MC; Bader, JE; Kobor, AD; Kretzschmar, AK; Beck-Sickinger, AG				Dinger, MC; Bader, JE; Kobor, AD; Kretzschmar, AK; Beck-Sickinger, AG			Homodimerization of neuropeptide y receptors investigated by fluorescence resonance energy transfer in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MOLECULAR CHARACTERIZATION; EXTRACELLULAR DOMAIN; OPIOID RECEPTORS; REPORTER GENE; DIMERIZATION; HETERODIMERIZATION; SUBTYPES; DIMERS; FRET	Up to now neuropeptide Y (NPY) receptors, which belong to the large family of G-protein-coupled receptors and are involved in a broad range of physiological processes, are believed to act as monomers. Studies with the Y-1-receptor antagonist and Y-1-receptor agonist GR231118, which binds with a 250-fold higher affinity than its monomer, led to the first speculation that NPY receptors can form homodimers. In the present work we used the fluorescence resonance energy transfer (FRET) to study homodimerization of the hY(1)-, hY(2)-, and hY(5)-receptors in living cells. For this purpose, we generated fusion proteins of NPY receptors and green fluorescent protein or spectral variants of green fluorescent protein (cyan, yellow, and red fluorescent protein), which can be used as FRET pairs. Two different FRET techniques, fluorescence microscopy and fluorescence spectroscopy, were applied. Both techniques clearly showed that the hY(1)-, hY(2)-, and hY(5)-NPY receptor subtypes are able to form homodimers. By using transiently transfected cells, as well as a stable cell line expressing the hY(2)-GFP fusion protein, we could demonstrate that the Y-GFP fusion proteins are still functional and that dimerization varies from 26 to 44% dependent on the receptor. However, homodimerization is influenced neither by NPY nor by Got protein binding.	Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany; Univ Leipzig, Inst Clin Immunol, D-04103 Leipzig, Germany	Leipzig University; Leipzig University	Beck-Sickinger, AG (corresponding author), Univ Leipzig, Inst Biochem, Talstr 33, D-04103 Leipzig, Germany.	beck-sickinger@uni-leipzig.de						Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BeckSickinger AG, 1996, DRUG DISCOV TODAY, V1, P502, DOI 10.1016/S1359-6446(96)10042-8; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; Cabrele C, 2000, J PEPT SCI, V6, P97, DOI 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E; CALZA L, 1990, REGUL PEPTIDES, V27, P127, DOI 10.1016/0167-0115(90)90211-E; Chan FKM, 2001, CYTOMETRY, V44, P361, DOI 10.1002/1097-0320(20010801)44:4<361::AID-CYTO1128>3.0.CO;2-3; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DANIELS AJ, 1995, P NATL ACAD SCI USA, V92, P9067, DOI 10.1073/pnas.92.20.9067; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Dinger MC, 2002, MOL BIOTECHNOL, V21, P9, DOI 10.1385/MB:21:1:009; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; FLOOD JF, 1987, BRAIN RES, V421, P280, DOI 10.1016/0006-8993(87)91297-2; Gicquiaux H, 2002, J BIOL CHEM, V277, P6645, DOI 10.1074/jbc.M107224200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Harpur AG, 2001, NAT BIOTECHNOL, V19, P167, DOI 10.1038/84443; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Inui A, 1999, TRENDS PHARMACOL SCI, V20, P43, DOI 10.1016/S0165-6147(99)01303-6; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Matthews JE, 1997, REGUL PEPTIDES, V72, P113, DOI 10.1016/S0167-0115(97)01044-6; Michel MC, 1998, PHARMACOL REV, V50, P143; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Sautel M, 2000, CURR MED CHEM, V7, P889, DOI 10.2174/0929867003374570; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	54	106	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10562	10571		10.1074/jbc.M205747200	http://dx.doi.org/10.1074/jbc.M205747200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524448	hybrid			2022-12-25	WOS:000181777500076
J	He, ML; Zemkova, H; Stojilkovic, SS				He, ML; Zemkova, H; Stojilkovic, SS			Dependence of purinergic P2X receptor activity on ectodomain structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; MUTATIONAL ANALYSIS; GLUTAMATE-RECEPTOR; CRYSTAL-STRUCTURES; LIGAND-BINDING; AMINO-ACIDS; DESENSITIZATION; IDENTIFICATION; ACTIVATION; RESIDUES	Purinergic receptors (P2XRs) activate and desensitize in response to the binding of extracellular nucleotides in a receptor- and ligand-specific manner, but the structural bases of their ligand preferences and channel kinetics have been incompletely characterized. Here we tested the hypothesis that affinity of agonists for binding domain accounts for a ligand-specific desensitization pattern. We generated chimeras using receptors with variable sensitivity to ATP in order: P2X(4)R > P2X(2a)R = P2X(2b)R much greater than P2X(7)R. Chimeras having the ectodomain Ile(66) - Tyr(310) sequence of P2X(2)R and Val(61) - Phe(313) sequence of P2X(7)R in the backbone of P2X(4)R were expressed but were non-functioning channels. P2X(2a) + X4R and P2X(2b) + X4R chimeras having the Val(66) - Tyr(315) ectodomain sequence of P2X(4)R in the backbones of P2X(2a)R and P2X(2b)R were functional and exhibited increased sensitivity to ligands as compared with both parental receptors. These chimeras also desensitized faster than parental receptors and in a ligand-nonspecific manner. However, like parental P2X(2)bR and P2X(2a)R, chimeric P2X(2b) + X4R desensitized more rapidly than P2X(2a) + X4R, and the rate of desensitization of P2X(2a) + X4R increased by substituting its Arg(371) - Pro(376) intracellular C-terminal sequence with the Glu(376) - Gly(381) sequence of P2X(4)R. These results indicate the relevance of interaction between the ectodomain and flanking regions around the transmembrane domains on ligand potency and receptor activation. Furthermore, the ligand potency positively correlates with the rate of receptor desensitization but does not affect the C-terminal-specific pattern of desensitization.	NICHD, ERRB, SCS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, ERRB, SCS, NIH, Bldg 49,Rm 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.	stankos@helix.nih.gov	He, Mulan/C-4140-2009; Zemkova, Hana/C-1844-2012	Zemkova, Hana/0000-0001-5219-8563	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Chow YW, 1998, J NEUROCHEM, V70, P2606; Clyne JD, 2002, J NEUROSCI, V22, P3873, DOI 10.1523/JNEUROSCI.22-10-03873.2002; Corringer PJ, 1998, J NEUROSCI, V18, P648; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Ennion SJ, 2002, BIOCHEM BIOPH RES CO, V291, P611, DOI 10.1006/bbrc.2002.6488; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; He ML, 2002, MOL PHARMACOL, V62, P1187, DOI 10.1124/mol.62.5.1187; Hu B, 2002, J BIOL CHEM, V277, P15752, DOI 10.1074/jbc.M112097200; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jiang LH, 2001, J BIOL CHEM, V276, P14902, DOI 10.1074/jbc.M011327200; Jones CA, 2000, BRIT J PHARMACOL, V129, P388, DOI 10.1038/sj.bjp.0703059; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Khakh BS, 2001, PHARMACOL REV, V53, P107; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Koshimizu T, 2002, J BIOL CHEM, V277, P46891, DOI 10.1074/jbc.M205274200; Koshimizu T, 1998, MOL ENDOCRINOL, V12, P901, DOI 10.1210/me.12.7.901; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; Nakazawa K, 2002, NEUROSCI LETT, V324, P141, DOI 10.1016/S0304-3940(02)00234-3; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; Radford KM, 1997, J NEUROSCI, V17, P6529; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; Smith FM, 1999, J PHYSIOL-LONDON, V520, P91, DOI 10.1111/j.1469-7793.1999.00091.x; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Zhou Z, 1998, BIOCHEM BIOPH RES CO, V252, P541, DOI 10.1006/bbrc.1998.9689	44	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10182	10188		10.1074/jbc.M209094200	http://dx.doi.org/10.1074/jbc.M209094200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524445	hybrid			2022-12-25	WOS:000181777500027
J	Paitel, E; Fahraeus, R; Checler, F				Paitel, E; Fahraeus, R; Checler, F			Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; PRP; MICE; NEUROTOXICITY; ALZHEIMERS; PEPTIDE; P53; CONFORMATION; INHIBITORS; RESISTANT	We examined the influence of cellular prion protein (PrPc) in the control of cell death in stably transfected TSM1 cells. PrPc expression enhanced staurosporine-stimulated neuronal toxicity and DNA fragmentation, caspase 3-like activity and immunoreactivity, and p53 immunoreactivity and transcriptional activities. Caspase activation was reduced by the chemical inhibitor of p53, pifithrin-alpha, as well as by PrPc- or p53-antisense approaches but remained insensitive to the Fyn kinase inhibitor PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine). We establish that PrPc controls p53 at a post-transcriptional level and is reversed by Mdm2 transfection and p38 MAPK inhibitor. We propose that endogenous cellular prion protein sensitizes neurons to apoptotic stimuli through a p53-dependent caspase 3-mediated activation controlled by Mdm2 and p38 MAPK.	CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Dundee, Div Mol Physiol, Dundee, Scotland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Dundee	Checler, F (corresponding author), CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	fahraeus, robin/K-8726-2014; Checler, Frederic/C-1241-2009	Checler, Frederic/0000-0003-2098-1750; , robin/0000-0003-0402-8492				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1999, J NEUROCHEM, V73, P1105, DOI 10.1046/j.1471-4159.1999.0731105.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Checler F, 2002, TRENDS NEUROSCI, V25, P616, DOI 10.1016/S0166-2236(02)02263-4; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Schatzl HM, 1997, J VIROL, V71, P8821; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; White AR, 2001, NEUROBIOL DIS, V8, P299, DOI 10.1006/nbdi.2001.0386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YIN Y, 2002, NAT CELL BIOL; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	38	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10061	10066		10.1074/jbc.M211580200	http://dx.doi.org/10.1074/jbc.M211580200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529324	hybrid			2022-12-25	WOS:000181777500011
J	Richards, MR; Listenberger, LL; Kelly, AA; Lewis, SE; Ory, DS; Schaffer, JE				Richards, MR; Listenberger, LL; Kelly, AA; Lewis, SE; Ory, DS; Schaffer, JE			Oligomerization of the murine fatty acid transport protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; EXPRESSION CLONING; SACCHAROMYCES-CEREVISIAE; BINDING; CDNA	The 63-kDa murine fatty acid transport protein 1 (FATP1) was cloned on the basis of its ability to augment fatty acid import when overexpressed in mammalian cells. The membrane topology of this integral plasma membrane protein does not resemble that of polytopic membrane transporters for other substrates. Western blot analysis of 3T3-L1 adipocytes that natively express FATP1 demonstrate a prominent 130-kDa species as well as the expected 63-kDa FATP1, suggesting that this protein may participate in a cell surface transport protein complex. To test whether FATP1 is capable of oligomerization, we expressed functional FATP1 molecules with different amino- or carboxyl-terminal epitope tags in fibroblasts. These epitope-tagged proteins also form apparent higher molecular weight species. We show that, when expressed in the same cells, differentially tagged FATP1 proteins co-immunoprecipitate. The region between amino acid residues 191 and 475 is sufficient for association of differentially tagged truncated FATP1 constructs. When wild type FATP1 and the non-functional s250a FATP1 mutant are co-expressed in COS7 cells, mutant FATP1 has dominant inhibitory function in fatty acid uptake assays. Taken together, these results are consistent with a model in which FATP1 homodimeric complexes play an important role in cellular fatty acid import.	Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Schaffer, JE (corresponding author), Washington Univ, Sch Med, Ctr Cardiovac Res, Dept Internal Med, 660 S Euclid Ave,Box 8086, St Louis, MO 63110 USA.	jschaff@im.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07275] Funding Source: Medline; NIDDK NIH HHS [DK54268] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; Gargiulo CE, 1999, J LIPID RES, V40, P881; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Schaffer JE, 2002, AM J PHYSIOL-ENDOC M, V282, pE239, DOI 10.1152/ajpendo.00462.2001; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Stump DD, 2001, J LIPID RES, V42, P509; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	25	33	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10477	10483		10.1074/jbc.M212469200	http://dx.doi.org/10.1074/jbc.M212469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533547	hybrid			2022-12-25	WOS:000181777500065
J	Yague, E; Armesilla, AL; Harrison, G; Elliott, J; Sardini, A; Higgins, CF; Raguz, S				Yague, E; Armesilla, AL; Harrison, G; Elliott, J; Sardini, A; Higgins, CF; Raguz, S			P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; DRUG-RESISTANCE; PROMOTER REGION; HEAT-SHOCK; TRANSCRIPTION; CANCER; ACTIVATION; PROTEIN; INDUCTION; PHENOTYPE	Multidrug resistance in acute myeloid leukemia is often conferred by overexpression of P-glycoprotein, encoded by the MDR1 gene. We have characterized the key regulatory steps in the development of multidrug resistance in K562 myelogenous leukemic cells. Unexpectedly, up-regulation of MDR1 levels was not due to transcriptional activation but was achieved at two distinct post-transcriptional steps, mRNA turnover and translational regulation. The short-lived (half-life 1 h) MDR1 mRNA of naive cells (not exposed to drugs) was stabilized (half-life greater than 10 h) following short-term drug exposure. However, this stabilized mRNA was not associated with translating polyribosomes and did not direct P-glycoprotein synthesis. Selection for drug resistance, by long-term exposure to drug, led to resistant lines in which the translational block was overcome such that the stabilized mRNA was translated and P-glycoprotein expressed. The absence of a correlation between steady-state MDR1 mRNA and P-glycoprotein levels was not restricted to K562 cells but was found in other lymphoid cell lines. These findings have implications for the avoidance or reversal of multidrug resistance in the clinic.	Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Fac Med, London W12 0NN, England; Canc Res UK, Paterson Inst Canc Res, Cell Regulat Lab, Manchester M20 4BX, Lancs, England	Imperial College London; Cancer Research UK; Paterson Institute for Cancer Research; University of Manchester	Raguz, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Fac Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	s.raguz@csc.mrc.ac.uk		Armesilla, Angel/0000-0003-3546-5580				Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; BAILLY JD, 1995, LEUKEMIA, V9, P799; BONIFACINO JS, 1998, CURRENT PROTOCOLS MO; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHIN KV, 1990, J BIOL CHEM, V265, P221; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P1894, DOI 10.1074/jbc.270.4.1894; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Ivy SP, 1996, BLOOD, V88, P309; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kantharidis P, 2000, DRUG RESIST UPDATE, V3, P99, DOI 10.1054/drup.2000.0121; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KIZAKI M, 1990, LEUKEMIA RES, V14, P645, DOI 10.1016/0145-2126(90)90020-A; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Knutsen T, 1998, GENE CHROMOSOME CANC, V23, P44, DOI 10.1002/(SICI)1098-2264(199809)23:1<44::AID-GCC7>3.0.CO;2-6; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Lee CH, 1998, J CELL PHYSIOL, V177, P1; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; MARINO PA, 1990, CELL GROWTH DIFFER, V1, P57; Marthinet E, 2000, GENE THER, V7, P1224, DOI 10.1038/sj.gt.3301231; McKenna SL, 1997, BRIT J HAEMATOL, V96, P659, DOI 10.1046/j.1365-2141.1997.d01-2095.x; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Meschini S, 2000, INT J CANCER, V87, P615, DOI 10.1002/1097-0215(20000901)87:5<615::AID-IJC1>3.3.CO;2-W; Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362; MULLER C, 1995, MOL PHARMACOL, V47, P51; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Norgaard JM, 1998, BRIT J HAEMATOL, V100, P534, DOI 10.1046/j.1365-2141.1998.00593.x; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Prokipcak RD, 1999, BIOCHEM BIOPH RES CO, V261, P627, DOI 10.1006/bbrc.1999.1101; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; RITKE MK, 1993, BIOCHEM PHARMACOL, V46, P2007, DOI 10.1016/0006-2952(93)90643-B; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLUESENER HJ, 1992, IMMUNOPHARMACOLOGY, V23, P37, DOI 10.1016/0162-3109(92)90007-Y; SCHRENK D, 1994, CARCINOGENESIS, V15, P2541, DOI 10.1093/carcin/15.11.2541; SERPINSKAYA AS, 1981, BIOCHIM BIOPHYS ACTA, V673, P86, DOI 10.1016/0304-4165(81)90313-5; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1987, J BIOL CHEM, V262, P505; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; VANKALKEN CK, 1992, AM J PATHOL, V141, P1063; Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199; Wang FS, 1999, HUM GENE THER, V10, P1185, DOI 10.1089/10430349950018175; West MJ, 1995, ONCOGENE, V11, P2515; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; YAGUE E, 1994, MOL MICROBIOL, V12, P41, DOI 10.1111/j.1365-2958.1994.tb00993.x; Zhang WD, 2000, J CELL PHYSIOL, V184, P17, DOI 10.1002/(SICI)1097-4652(200007)184:1<17::AID-JCP2>3.0.CO;2-U	62	106	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10344	10352		10.1074/jbc.M211093200	http://dx.doi.org/10.1074/jbc.M211093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525496	hybrid, Green Published			2022-12-25	WOS:000181777500048
J	Eller, MS; Li, GZ; Firoozabadi, R; Puri, N; Gilchrest, BA				Eller, MS; Li, GZ; Firoozabadi, R; Puri, N; Gilchrest, BA			Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3 ' overhang specific DNA	FASEB JOURNAL			English	Article						DNA damage responses; senescence; ATM; p53 phosphorylation	NIJMEGEN BREAKAGE SYNDROME; CELL-CYCLE ARREST; LARGE-T-ANTIGEN; ATAXIA-TELANGIECTASIA; CATALYTIC SUBUNIT; FISSION YEAST; P53; DAMAGE; REPAIR; PHOSPHORYLATION	Telomere shortening induces a nonproliferative senescent phenotype, believed to reduce cancer risk, and telomeres are involved in a poorly understood manner in responses to DNA damage. Although telomere disruption induces p53 and triggers apoptosis or cell cycle arrest, the features of the disrupted telomere that trigger this response and the precise mechanism involved are poorly understood. Using human cells, we show that DNA oligonucleotides homologous to the telomere 3' overhang sequence specifically induce and activate p53 and activate an S phase checkpoint by modifying the Nijmegen breakage syndrome protein, known to mediate the S phase checkpoint after DNA damage. These responses are mediated, at least in part, by the ATM kinase and are not attributable to disruption of cellular telomeres. Based on these and earlier data, we propose that these oligonucleotides mimic a physiological signal, exposure of the telomere 3' overhang due to opening of the normal telomere loop structure, and hence evoke these protective anti-proliferative responses in the absence of DNA damage or telomere disruption.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St,J Bldg, Boston, MA 02118 USA.			Li, Guangmu/0000-0001-7115-0928				Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chamankhah M, 1999, NUCLEIC ACIDS RES, V27, P2072, DOI 10.1093/nar/27.10.2072; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Cruz PD, 2000, J INVEST DERMATOL, V114, P253, DOI 10.1046/j.1523-1747.2000.00866.x; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Eller MS, 2000, PIGM CELL RES, V13, P94, DOI 10.1034/j.1600-0749.13.s8.17.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; Gilchrest BA, 1999, J INVEST DERM SYMP P, V4, P35, DOI 10.1038/sj.jidsp.5640178; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; Goukassian DA, 2002, FASEB J, V16, P754, DOI 10.1096/fj.01-0829fje; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 2002, ONCOGENE, V21, P592, DOI 10.1038/sj.onc.1205084; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; Kobayashi N, 2001, PIGM CELL RES, V14, P94, DOI 10.1034/j.1600-0749.2001.140204.x; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Maeda T, 1999, MUTAT RES-DNA REPAIR, V433, P137, DOI 10.1016/S0921-8777(98)00071-8; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Milyavsky M, 2001, NUCLEIC ACIDS RES, V29, P5207, DOI 10.1093/nar/29.24.5207; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P86; Ritchie KB, 2000, GENETICS, V155, P475; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; SETLOW RB, 1966, J MOL BIOL, V17, P237, DOI 10.1016/S0022-2836(66)80105-5; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; Wang LH, 1998, ANTICANCER RES, V18, P321; WOLF DA, 1995, ONCOGENE, V10, P2067; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; XUDONG Z, 2000, NAT GENET, V25, P347; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	76	53	55	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					152	162		10.1096/fj.02-0197com	http://dx.doi.org/10.1096/fj.02-0197com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554694				2022-12-25	WOS:000181456900040
J	Rossow, KL; Janknecht, R				Rossow, KL; Janknecht, R			Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300	ONCOGENE			English	Article						CBP; E1A; p300; p68 RNA helicase; RNA polymerase II; transcription	ESTROGEN-RECEPTOR-ALPHA; DEAD BOX PROTEIN; COLORECTAL TUMORS; POLYMERASE-II; GENE; ACTIVATION; COAMPLIFICATION; OVEREXPRESSION; IDENTIFICATION; NEUROBLASTOMA	p68 RNA helicase has been implicated in a variety of processes, including rearrangement of RNA secondary structures, RNA splicing, gene transcription and tumor development, yet its mechanisms of action are not well understood. In this study, we show that p68 is predominantly localized to the cell nucleus, where it partially colocalizes with the transcriptional coactivator p300. Accordingly, p68 and p300, or the paralogous CREB-binding protein (CBP), coimmunoprecipitate. Similarly, p68 and RNA polymerase II (Pol II) are able to interact in vivo. GST pull-down assays confirmed these interactions in vitro, demonstrating that p68 can interact with several domains of CBP, while CBP/p300 bind to amino acids 176-388 of p68 and RNA Pol II binds to the N-terminal 80 amino acids of p68. Furthermore, p68 stimulates transcription mediated by the C-terminal transactivation domain of CBP. p68 is also able to stimulate TPA oncogene responsive unit (TORU) promoter activity, and p300 acts in synergy with p68. On the other hand, suppression of CBP/p300 function by the adenoviral protein E1A abolishes TORU promoter activation by p68. Altogether, our results suggest the existence of a multiprotein complex in which p68 RNA helicase, CBP/p300 and RNA Pol II jointly promote gene expression.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St,SW,Guggenheim Bldg 1501A, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562				AKAO Y, 1995, CANCER RES, V55, P3444; Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Eisen A, 1998, BIOESSAYS, V20, P634, DOI 10.1002/(SICI)1521-1878(199808)20:8<634::AID-BIES6>3.0.CO;2-I; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Goodman RH, 2000, GENE DEV, V14, P1553; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE CG, 1993, J BIOL CHEM, V268, P16822; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; MONTE D, 1995, ONCOGENE, V11, P771; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Rossler OG, 2001, NUCLEIC ACIDS RES, V29, P2088, DOI 10.1093/nar/29.10.2088; Rossow KL, 2001, CANCER RES, V61, P2690; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341	33	89	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					151	156		10.1038/sj.onc.1206067	http://dx.doi.org/10.1038/sj.onc.1206067			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527917				2022-12-25	WOS:000180166900016
J	Schwahn, BC; Chen, ZT; Laryea, MD; Wendel, U; Lussier-Cacan, S; Genest, J; Mar, MH; Zeisel, SH; Castro, C; Garrow, T; Rozen, R				Schwahn, BC; Chen, ZT; Laryea, MD; Wendel, U; Lussier-Cacan, S; Genest, J; Mar, MH; Zeisel, SH; Castro, C; Garrow, T; Rozen, R			Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency	FASEB JOURNAL			English	Article						homocystinuria; hyperhomocysteinemia; folate; methyl donors; choline metabolism	CORONARY-ARTERY DISEASE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; METHIONINE METABOLISM; PLASMA HOMOCYSTEINE; DIETARY METHIONINE; FOLATE-DEFICIENCY; RAT HEPATOCYTES; FOLIC-ACID; METHYLATION; CHOLINE	Hyperhomocysteinemia, a proposed risk factor for cardiovascular disease, is also observed in other common disorders. The most frequent genetic cause of hyperhomocysteinemia is a mutated methylenetetrahydrofolate reductase (MTHFR), predominantly when folate status is impaired. MTHFR synthesizes a major methyl donor for homocysteine remethylation to methionine. We administered the alternate choline-derived methyl donor, betaine, to wild-type mice and to littermates with mild or severe hyperhomocysteinemia due to hetero- or homozygosity for a disruption of the Mthfr gene. On control diets, plasma homocysteine and liver choline metabolite levels were strongly dependent on the Mthfr genotype. Betaine supplementation decreased homocysteine in all three genotypes, restored liver betaine and phosphocholine pools, and prevented severe steatosis in Mthfr-deficient mice. Increasing betaine intake did not further decrease homocysteine. In humans with cardiovascular disease, we found a significant negative correlation between plasma betaine and homocysteine concentrations. Our results emphasize the strong interrelationship between homocysteine, folate, and choline metabolism. Hyperhomocysteinemic Mthfr-compromised mice appear to be much more sensitive to changes of choline/betaine intake than do wild-type animals. Hyperhomocysteinemia, in the range of that associated with folate deficiency or with homozygosity for the 677T MTHFR variant, may be associated with disturbed choline metabolism.	McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Dept Human Genet, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Dept Biol, Montreal, PQ H3H 1P3, Canada; Univ Childrens Hosp, Metab Unit, Dusseldorf, Germany; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ, Canada; Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Nutr, Chapel Hill, NC USA; Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA	McGill University; McGill University; McGill University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Illinois System; University of Illinois Urbana-Champaign	Rozen, R (corresponding author), FCCMG Montreal Childrens Hosp, 4060 Ste Catherine W,Room 200, Montreal, PQ H3Z 2Z3, Canada.	rima.rozen@mcgill.ca	Carmen, Castro/C-7813-2009	Carmen, Castro/0000-0002-6802-0572				Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; ALLEN RH, 1993, METABOLISM, V42, P1448, DOI 10.1016/0026-0495(93)90198-W; BAKER DH, 1985, J NUTR, V115, P1291, DOI 10.1093/jn/115.10.1291; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bostom AG, 1999, J AM SOC NEPHROL, V10, P891; Bottiglieri T, 2000, J NEUROL NEUROSUR PS, V69, P228, DOI 10.1136/jnnp.69.2.228; Burns SP, 1998, BBA-MOL BASIS DIS, V1406, P274, DOI 10.1016/S0925-4439(98)00015-5; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Christensen B, 1997, ARTERIOSCL THROM VAS, V17, P569, DOI 10.1161/01.ATV.17.3.569; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; DUCE AM, 1988, HEPATOLOGY, V8, P65, DOI 10.1002/hep.1840080113; Durand P, 1996, CLIN CHIM ACTA, V252, P83, DOI 10.1016/0009-8981(96)06325-5; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; FINKELSTEIN JD, 1974, METABOLISM, V23, P387, DOI 10.1016/0026-0495(74)90057-2; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; HOFFMAN DR, 1981, LIPIDS, V16, P561, DOI 10.1007/BF02534900; HOLME E, 1989, ARCH DIS CHILD, V64, P1061, DOI 10.1136/adc.64.7.1061; KIM YI, 1994, J NUTR, V124, P2197, DOI 10.1093/jn/124.11.2197; KOC HH, ANAL BIOCH; Laryea MD, 1998, CLIN CHEM, V44, P1937; Lepage N, 1997, CLIN CHEM, V43, P2397; LEVER M, 1994, BBA-GEN SUBJECTS, V1200, P259, DOI 10.1016/0304-4165(94)90165-1; LIEBER CS, 1994, ALCOHOL CLIN EXP RES, V18, P592, DOI 10.1111/j.1530-0277.1994.tb00915.x; McGregor DO, 2001, KIDNEY INT, V59, P2267, DOI 10.1046/j.1523-1755.2001.00743.x; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P21, DOI 10.1016/S0005-2760(96)00100-2; Park EI, 1999, J BIOL CHEM, V274, P7816, DOI 10.1074/jbc.274.12.7816; Park EI, 1997, J NUTR BIOCHEM, V8, P541, DOI 10.1016/S0955-2863(97)00101-0; PASCALE R, 1982, FEBS LETT, V145, P293, DOI 10.1016/0014-5793(82)80186-5; Ray JG, 1999, PLACENTA, V20, P519, DOI 10.1053/plac.1999.0417; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; REGLAND B, 1995, J NEURAL TRANSM-GEN, V100, P165, DOI 10.1007/BF01271539; Rosenblatt DS., 1995, METABOLIC MOL BASES, P3111; SAUNDERSON CL, 1990, BRIT J NUTR, V63, P339, DOI 10.1079/BJN19900120; SCHWAHN B, 2001, CLIN CONSEQUENCES AM, V1, P189; SCHWAHN B, 2002, IN PRESS BR J CLIN P; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; STEENGE GR, 2001, 3 INT C HOM MET SORR; STORCH KJ, 1991, AM J CLIN NUTR, V54, P386, DOI 10.1093/ajcn/54.2.386; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; VARELAMOREIRAS G, 1992, J NUTR BIOCHEM, V3, P519, DOI 10.1016/0955-2863(92)90073-R; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WENDEL U, 1984, EUR J PEDIATR, V142, P147, DOI 10.1007/BF00445602; WILCKEN DEL, 1983, NEW ENGL J MED, V309, P448, DOI 10.1056/NEJM198308253090802; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	52	130	130	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					512	+		10.1096/fj.02-0456fje	http://dx.doi.org/10.1096/fj.02-0456fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551843	Green Submitted			2022-12-25	WOS:000181453700010
J	MacDiarmid, CW; Milanick, MA; Eide, DJ				MacDiarmid, CW; Milanick, MA; Eide, DJ			Induction of the ZRC1 metal tolerance gene in zinc-limited yeast confers resistance to zinc shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZAP1 TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; TRANSPORT-SYSTEM; EXPRESSION; HOMEOSTASIS; IRON; ACCUMULATION; ARABIDOPSIS; ENDOCYTOSIS; SENSITIVITY	Zinc is an essential nutrient but toxic to cells with overaccumulation. For this reason, intracellular zinc levels are tightly controlled. In the yeast Saccharomyces cerevisiae, the Zrc1 and Cot1 proteins have been implicated in the storage and detoxification of excess zinc in the vacuole. Surprisingly, transcription of ZRC1 is induced in zinc-limited cells by the zinc-responsive transcription factor Zap1. We show here that this increase in ZRC1 expression is a novel mechanism of zinc homeostasis and stress tolerance. Zinc-limited cells also express high levels of the plasma membrane zinc uptake transporters. As a consequence, when zinc-limited cells are resupplied with small amounts of zinc, large quantities quickly accumulate in the cell, a condition we refer to as "zinc shock." We show here that ZRC1 and its induction in zinc-limited cells are required for resistance to this zinc shock. Experiments using the zinc-responsive fluorophore FuraZin-1 as an indicator of vacuolar zinc levels indicated that Zrc1 is required for the rapid transport of zinc into the vacuole during zinc shock. We also present evidence that cytosolic zinc rises to higher levels in cells unable to sequester this excess zinc. Thus, the increase in ZRC1 expression occurs prior to the zinc shock stress for which this induction is important. We propose that this "proactive" strategy of homeostatic regulation, such as we document here for ZRC1, may represent a common but largely unrecognized phenomenon.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Physiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.		MacDiarmid, Colin/AAV-5920-2021	MacDiarmid, Colin/0000-0001-8578-5756	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37512] Funding Source: Medline; NIGMS NIH HHS [GM56285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Cheng CL, 1998, J NEUROCHEM, V71, P2401; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MacDiarmid CW, 2002, J BIOL CHEM, V277, P39187, DOI 10.1074/jbc.M205052200; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Ragozzino D, 2000, J PHYSIOL-LONDON, V529, P83, DOI 10.1111/j.1469-7793.2000.00083.x; Sherman F., 1986, METHODS YEAST GENETI; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; STEIN WD, 1990, CHANNELS CARRIERS PU, P199; Vagabov VM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P349; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Wunderli-Ye H, 1999, ADV EXP MED BIOL, V448, P255; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	37	134	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15065	15072		10.1074/jbc.M300568200	http://dx.doi.org/10.1074/jbc.M300568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12556516	hybrid			2022-12-25	WOS:000182516100064
J	Dehaye, JP; Nagy, A; Premkumar, A; Turner, RJ				Dehaye, JP; Nagy, A; Premkumar, A; Turner, RJ			Identification of a functionally important conformation-sensitive region of the secretory Na+-K+-2Cl(-) cotransporter (NKCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; CHLORIDE COTRANSPORT; BUMETANIDE BINDING; ION-TRANSPORT; CHANNEL; PHOSPHORYLATION; ACCESSIBILITY; TOPOLOGY; DOMAINS	The secretory Na+-K+-2Cl(-) cotransporter (NKCC1) is a member of a small gene family of electroneutral salt transporters that play essential roles in salt and water homeostasis in many mammalian tissues. We have identified a highly conserved residue (Ala-483) in the sixth membrane-spanning segment of rat NKCC1 that when mutated to cysteine renders the transporter sensitive to inhibition by the sulfhydryl reagents 2-aminoethyl methanethiosulfonate (MTSEA) and 2-(trimethylammonium)ethyl methanethiosulfonate (MTSET). The mutation of Ala-483 to cysteine (A483C) results in little or no change in the affinities of NKCC1 for substrate ions but produces a 6-fold increase in sensitivity to the inhibitor bumetanide, suggesting a specific modification of the bumetanide binding site. When residues surrounding Ala-483 were mutated to cysteine, only 1484C was sensitive to inhibition by MTSEA and MTSET. Surprisingly 1484C showed increased transport activity in the presence of low concentrations of mercury (1-10 mum), whereas A483C showed inhibition. The inhibition of A483C by MTSEA was unaffected by the presence or absence of sodium and potassium but required the presence of extracellular chloride. Taken together, our results indicate that Ala-483 lies at or near an important functional site of NKCC1 and that the exposure of this site to the extracellular medium is dependent on the conformation of the transporter. Specifically, our results indicate that the cysteine introduced at residue 483 is only available for interaction with MTSEA when chloride is bound to NKCC1 at the extracellular surface.	NIDCR, Gene Therapy & Therapeut Branch, Membrane Biol Sect, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA; Free Univ Brussels, Inst Pharm, Lab Biochim & Biol Cellulaire, B-1050 Brussels, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Turner, RJ (corresponding author), NIDCR, Gene Therapy & Therapeut Branch, Membrane Biol Sect, Dept Hlth & Human Serv,NIH, Bldg 10,Rm 1A01,10 Ctr Dr,MSC 1190, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; LYTLE C, 2002, AM J PHYSIOL, V43, pC299; Moore-Hoon ML, 1998, EUR J MORPHOL, V36, P137; Moore-Hoon ML, 2000, BIOCHEMISTRY-US, V39, P3718, DOI 10.1021/bi992301v; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252	19	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11811	11817		10.1074/jbc.M213148200	http://dx.doi.org/10.1074/jbc.M213148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556450	hybrid			2022-12-25	WOS:000182015700013
J	Dirac, AMG; Bernards, R				Dirac, AMG; Bernards, R			Reversal of senescence in mouse fibroblasts through lentiviral in suppression of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR SENESCENCE; TELOMERASE ACTIVITY; G(1) CONTROL; CELLS; IMMORTALIZATION; P16(INK4A); P19(ARF); CULTURE; MICE; RB	Senescence is generally defined as an irreversible state of G(1) cell cycle arrest in which cells are refractory to growth factor stimulation. In mouse embryo fibroblasts (MEFs), induction of senescence requires the presence of P19(ARF) and p53, as genetic ablation of either of these genes allows escape from senescence and leads to immortalization. We have developed a lentiviral vector that directs the synthesis of a p53-specific short hairpin transcript, which mediates stable suppression of p53 expression through RNA interference. We show that suppression of p53 expression in senescent MEFs leads to rapid cell cycle re-entry, is associated with loss of expression of senescence-associated genes, and leads to immortalization. These data indicate that senescence in MEFs is reversible and demonstrate that both initiation and maintenance of senescence is p53-dependent.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				Bacchetti S, 1996, SEMIN CELL DEV BIOL, V7, P31, DOI 10.1006/scdb.1996.0006; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SAITO H, 1995, EXP CELL RES, V217, P272, DOI 10.1006/excr.1995.1087; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	34	171	183	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11731	11734		10.1074/jbc.C300023200	http://dx.doi.org/10.1074/jbc.C300023200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551891	hybrid, Green Published			2022-12-25	WOS:000182015700002
J	Alvestad, RM; Grosshans, DR; Coultrap, SJ; Nakazawa, T; Yamamoto, T; Browning, MD				Alvestad, RM; Grosshans, DR; Coultrap, SJ; Nakazawa, T; Yamamoto, T; Browning, MD			Tyrosine dephosphorylation and ethanol inhibition of N-methyl-D-aspartate receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; NMDA-RECEPTOR; AMPA RECEPTORS; GLUTAMATE-RECEPTORS; HIPPOCAMPAL-NEURONS; SUBUNIT COMPOSITION; CORTICAL-NEURONS; HEK-293 CELLS; MESSENGER-RNA	The inhibitory effect of ethanol on N-methyl-D-aspartate receptors (NMDARs) is well documented in several brain regions. However, the molecular mechanisms by which ethanol affects NMDARs are not well understood. In contrast to the inhibitory effect of ethanol, phosphorylation of the NMDAR potentiates channel currents (Lu, W. Y., Xiong, Z. G., Lei, S., Orser, B. A., Dudek, E., Browning, M. D., and MacDonald, J. F. (1999) Nat. Neurosci. 2, 331-338). We have previously shown that protein kinase C activators induce tyrosine phosphorylation and potentiation of the NMDAR (Grosshans, D. R., Clayton, D. R., Coultrap, S. J., and Browning, M. D. (2002) Nat. Neurosci. 5, 27-33). We therefore hypothesized that the ethanol inhibition of NMDARs might be due to changes in tyrosine phosphorylation of NMDAR subunits. In support of this hypothesis, we found that tyrosine phosphorylation of both NR2A and NR2B subunits was significantly reduced following in situ exposure of hippocampal slices to 100 nM ethanol. Specifically, phosphorylation of tyrosine 1472 on NR2B was reduced 23.5%. These data suggest a possible mechanism by which ethanol may inhibit the NMDAR via activation of a tyrosine phosphatase. Electrophysiological studies demonstrated that ethanol inhibited NMDAR field excitatory postsynaptic potential slope and amplitude to a similar degree as previously reported by our laboratory and others (Schummers, J., Bentz, S., and Browning, M. D. (1997) Alcohol Clin. Exp. Res. 21, 404-408). Inclusion of bpV(phen), a potent phosphotyrosine phosphatase inhibitor, in the recording chamber prior to and during ethanol exposure significantly reduced the inhibitory effect of ethanol on NMDAR field excitatory postsynaptic potentials. Taken together, these data suggest that phosphatase-mediated dephosphorylation of NMDAR subunits may play an important role in mediating the inhibitory effects of ethanol on the N-methyl-D-aspartate receptor.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Tokyo	Browning, MD (corresponding author), 4200 E 9th Ave,Box C236, Denver, CO 80262 USA.		Nakazawa, Takanobu/E-1012-2014	Nakazawa, Takanobu/0000-0002-5049-9140; NAKAZAWA, Takanobu/0000-0003-4863-1277	NIAAA NIH HHS [R01 AA09675] Funding Source: Medline; NIGMS NIH HHS [GM07635] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009675] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Anders DL, 1999, J NEUROCHEM, V72, P1389, DOI 10.1046/j.1471-4159.1999.721389.x; BARBAS H, 1993, J COMP NEUROL, V334, P1, DOI 10.1002/cne.903340102; Blevins T, 1997, J NEUROCHEM, V69, P2345; BLITZER RD, 1990, BRAIN RES, V537, P203, DOI 10.1016/0006-8993(90)90359-J; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; CHU B, 1995, J NEUROCHEM, V65, P140; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gordey M, 2001, NEUROSCIENCE, V105, P987, DOI 10.1016/S0306-4522(01)00234-2; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; Grosshans DR, 2001, J NEUROCHEM, V76, P737, DOI 10.1046/j.1471-4159.2001.00034.x; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; GROSSHANS DR, 2002, SCI STKE; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; Kalluri HSG, 1999, MOL BRAIN RES, V68, P159, DOI 10.1016/S0169-328X(99)00057-1; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kumari M, 2001, J BIOL CHEM, V276, P29764, DOI 10.1074/jbc.M100317200; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Maldve RE, 2002, NAT NEUROSCI, V5, P641, DOI 10.1038/nn877; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MORRISETT RA, 1993, J NEUROSCI, V13, P2264; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Peoples RW, 2000, NEUROPHARMACOLOGY, V39, P1681, DOI 10.1016/S0028-3908(00)00067-8; PEREZ RG, 1992, J COMP NEUROL, V318, P304, DOI 10.1002/cne.903180307; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; Pickard L, 2000, J NEUROSCI, V20, P7922; Popp RL, 1998, NEUROPHARMACOLOGY, V37, P45, DOI 10.1016/S0028-3908(97)00186-X; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Ronald KM, 2001, J BIOL CHEM, V276, P44729, DOI 10.1074/jbc.M102800200; Schummers J, 1997, ALCOHOL CLIN EXP RES, V21, P404; Seiler AEM, 2000, ALCOHOL CLIN EXP RES, V24, P1869, DOI 10.1111/j.1530-0277.2000.tb01992.x; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; SINCLAIR JG, 1986, GEN PHARMACOL, V17, P231, DOI 10.1016/0306-3623(86)90144-8; Snell LD, 1996, MOL BRAIN RES, V40, P71; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhao Y, 1996, BIOCHEMISTRY-US, V35, P11797, DOI 10.1021/bi960471r	60	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11020	11025		10.1074/jbc.M210167200	http://dx.doi.org/10.1074/jbc.M210167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536146	hybrid			2022-12-25	WOS:000181855400021
J	Cartron, PF; Priault, M; Oliver, L; Meflah, K; Manon, S; Vallette, FM				Cartron, PF; Priault, M; Oliver, L; Meflah, K; Manon, S; Vallette, FM			The N-terminal end of Bax contains a mitochondrial-targeting signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINUS; OUTER-MEMBRANE; BCL-2; DOMAIN; LOCALIZATION; YEAST; APOPTOSIS; FAMILY	The translocation of Bax alpha, a pro-apoptotic member of the BCL-2 family from the cytosol to mitochondria, is a central event of the apoptotic program. We report here that the N-terminal (NT) end of Bax alpha, which contains its first alpha helix (Halpha1), is a functional mitochondrial-addressing signal both in mammals and in yeast. Similar results were obtained with a newly described variant of Bax called Bax psi, which lacks the first 20 amino acids of Bax a and is constitutively associated with mitochondria. Deletion of Halpha1 impairs the binding of Bax psi to mitochondria, whereas a fusion of the N terminus of Bax alpha, which contains Halpha1 with a cytosolic protein, results in the binding of the chimeric proteins to mitochondria both in a cell-free assay and in vitro. More importantly, the mitochondria-bound chimeric proteins inhibit the interaction of Bax psi with mitochondria as well as Bax-apoptogenic properties. The mutations of the Halpha1, which inhibit Bax alpha and Bax psi translocation to mitochondria, also block the subsequent activation of the execution phase of apoptosis. Conversely, a deletion of the C terminus does not appear to influence Bax a and Bax psi mitochondrial addressing. Taken together, our results suggest that Bax is targeted to mitochondria by its NT and thus through a pathway that is unique for a member of the BCL-2 family.	INSERM, UMR 419, F-44035 Nantes 01, France; CNRS, UMR 5095, F-33007 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Vallette, FM (corresponding author), INSERM, UMR 419, 9 Quai Moncousu, F-44035 Nantes 01, France.	fval@nantes.inserm.fr	Cartron, Pierre Francois/K-9802-2015; Manon, Stéphen/C-7088-2017; Priault, Muriel/HHT-0658-2022; Oliver, Lisa J/L-3070-2015; Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018	Priault, Muriel/0000-0001-8193-0389; Oliver, Lisa J/0000-0002-5588-7564; Vallette, Francois M/0000-0002-3296-8572; Vallette, Francois/0000-0003-0802-0519; Cartron, Pierre-Francois/0000-0002-3393-784X; Manon, Stephen/0000-0002-5792-1084				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Lazebnik Y, 2001, CURR BIOL, V11, pR767, DOI 10.1016/S0960-9822(01)00465-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wattenberg B, 2001, TRAFFIC, V2, P66, DOI 10.1034/j.1600-0854.2001.20108.x; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zha HB, 1996, MOL CELL BIOL, V16, P6494	30	95	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11633	11641		10.1074/jbc.M208955200	http://dx.doi.org/10.1074/jbc.M208955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529375	hybrid			2022-12-25	WOS:000181855400096
J	Gal, I; Lesley, J; Ko, W; Gonda, A; Stoop, R; Hyman, R; Mikecz, K				Gal, I; Lesley, J; Ko, W; Gonda, A; Stoop, R; Hyman, R; Mikecz, K			Role of the extracellular and cytoplasmic domains of CD44 in the rolling interaction of lymphoid cells with hyaluronan under physiologic flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION; TRANSMEMBRANE DOMAIN; PROTEIN FAMILY; BINDING-SITE; ACID BINDING; IN-VIVO; RECEPTOR; IDENTIFICATION; EXTRAVASATION; ACTIVATION	CD44 can function as an adhesion receptor that mediates leukocyte rolling on hyaluronan (HA). To study the contributions of different domains of the standard isoform of CD44 to cell rolling, a CD44-negative mouse T lymphoma AKR1 was transfected with wild type (WT) or mutated cDNA constructs. A parallel flow chamber was used to study the rolling behavior of CD44 transfectants on immobilized HA. For CD44WT transfectants, the fraction of cells that rolled and the rolling velocity was inversely proportional to the amount of cell surface CD44. When the cytoplasmic domain distal to Gly(305) or sequences that serve as binding sites for cytoskeletal linker proteins, were deleted or replaced with foreign sequences, no significant changes in the rolling behavior of mutant cells, compared with the transfectant expressing CD44WT, were observed. Transfectants lacking 64 amino acids of the cytoplasmic tail distal to Cys(295) adhered to HA but showed enhanced rolling at low shear forces. When 83 amino acids from the "non-conserved" membrane-proximal region of the CD44 extracellular domain were deleted, cells adhered firmly to the HA substrate and did not roll at any fluid shear force tested. Unlike wild type cells that exhibited a nearly homogenous distribution of CD44 on a smooth cell surface, cells expressing the non-conserved region deletion mutant accumulated CD44 in membrane protrusions. Disruption of the actin cytoskeleton with cytochalasin B precluded the formation of membrane protrusions, however, treated cells still adhered firmly to HA and did not roll. We conclude that interaction between the cytoplasmic domain of CD44 and the cytoskeleton is not required for cell rolling on immobilized ligand. The strong effect of deletion of the non-conserved region of the extracellular domain argues for a critical role of this region in CD44-dependent rolling and adhesion interactions with HA under flow.	Rush Univ, St Lukes Med Ctr, Dept Orthoped Surg, Sect Biochem & Mol Biol, Chicago, IL 60612 USA; Salk Inst, Mol & Cell Biol Lab, San Diego, CA 92186 USA	Rush University; Salk Institute	Mikecz, K (corresponding author), Rush Univ, St Lukes Med Ctr, Dept Orthoped Surg, Sect Biochem & Mol Biol, 1735 W Harrison St,Cohn Bldg, Chicago, IL 60612 USA.	Katalin_Mikecz@rsh.net		, Reinout/0000-0002-8773-8248; Mikecz, Katalin/0000-0003-1506-4296	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045652] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31613] Funding Source: Medline; NIAMS NIH HHS [AR-45652] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Drillenburg P, 2000, BLOOD, V95, P1900, DOI 10.1182/blood.V95.6.1900; Esford LE, 1998, J CELL SCI, V111, P1021; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; Goebeler M, 1996, J CELL SCI, V109, P1957; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; Kogerman P, 1997, P NATL ACAD SCI USA, V94, P13233, DOI 10.1073/pnas.94.24.13233; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; Lesley J, 2000, EUR J IMMUNOL, V30, P245, DOI 10.1002/1521-4141(200001)30:1<245::AID-IMMU245>3.3.CO;2-O; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Li X, 1998, J EXP MED, V188, P1385, DOI 10.1084/jem.188.7.1385; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; Liu DC, 1997, J IMMUNOL, V159, P2702; Liu DC, 1998, CELL IMMUNOL, V190, P132, DOI 10.1006/cimm.1998.1397; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Peck D, 1998, J CELL SCI, V111, P1595; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; Ponta H, 1998, INT J BIOCHEM CELL B, V30, P299, DOI 10.1016/S1357-2725(97)00152-0; Siegelman M, 2001, J CLIN INVEST, V107, P159, DOI 10.1172/JCI11919; Siegelman MH, 2000, J CLIN INVEST, V105, P683, DOI 10.1172/JCI8692; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Sy MS, 1996, CURR TOP MICROBIOL, V213, P129; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Weber GF, 2002, CANCER RES, V62, P2281; Weiss L, 2000, P NATL ACAD SCI USA, V97, P285, DOI 10.1073/pnas.97.1.285; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	65	38	40	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11150	11158		10.1074/jbc.M210661200	http://dx.doi.org/10.1074/jbc.M210661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540844	hybrid			2022-12-25	WOS:000181855400039
J	Madore, E; Harvey, N; Parent, J; Chapdelaine, P; Arosh, JA; Fortier, MA				Madore, E; Harvey, N; Parent, J; Chapdelaine, P; Arosh, JA; Fortier, MA			An aldose reductase with 20 alpha-hydroxysteroid dehydrogenase activity is most likely the enzyme responsible for the production of prostaglandin F2 alpha in the bovine endometrium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F SYNTHASE; INTERFERON-TAU; MOLECULAR-CLONING; ESTROUS-CYCLE; STROMAL CELLS; CDNA CLONING; OXYTOCIN; EXPRESSION; CYCLOOXYGENASE-2; IDENTIFICATION	Prostaglandins are important regulators of reproductive function. In particular, prostaglandin F2alpha (PGF(2alpha)) is involved in labor and is the functional mediator of luteolysis to initiate a new estrous cycle in many species. These actions have been extensively studied in, ruminants, but the enzymes involved are not clearly identified. Our objective was to identify which prostaglandin F synthase is involved and to study its regulation in the endometrium and in endometrial primary cell cultures. The expression of all previously known prostaglandin F synthases (PGFSs), two newly discovered PGFS-like genes, and a 20alpha-hydroxysteroid dehydrogenase was studied by Northern blot and reverse transcription PCR. These analyses revealed that none of the known PGFS or the PGFS-like genes were significantly expressed in the endometrium. On the other hand, the 20alpha-hydroxysteroid dehydrogenase gene was strongly expressed in the endometrium at the time of luteolysis. The corresponding recombinant enzyme has a K-m of 7 muM for PGH(2) and a PGFS activity higher than the lung PGFS. This enzyme has two different activities with the ability to terminate the estrous cycle; it metabolizes progesterone and synthesizes PGF2alpha. Taken together, these data point to this newly identified enzyme as the functional endometrial PGFS.	Univ Laval, CHU Quebec, Unite Rech Ontogenie & Reprod, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, CHU Quebec, Dept Obstet & Gynecol, Ste Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Fortier, MA (corresponding author), Univ Laval, CHU Quebec, Unite Rech Ontogenie & Reprod, 2705 Boul Laurier, Ste Foy, PQ G1V 4G2, Canada.	mafortier@crchul.ulaval.ca						Arosh JA, 2002, BIOL REPROD, V67, P161, DOI 10.1095/biolreprod67.1.161; Asselin E, 1997, ENDOCRINOLOGY, V138, P4798, DOI 10.1210/en.138.11.4798; Asselin E, 1996, BIOL REPROD, V54, P371, DOI 10.1095/biolreprod54.2.371; Asselin E, 2000, BIOL REPROD, V62, P125, DOI 10.1095/biolreprod62.1.125; BEAVER CJ, 1992, PROSTAG OTH LIPID M, V44, P37, DOI 10.1016/0090-6980(92)90105-3; Bogacki M, 2002, BIOL REPROD, V67, P184, DOI 10.1095/biolreprod67.1.184; Chapdelaine P, 2001, BIOTECHNIQUES, V31, P478, DOI 10.2144/01313bm04; CHEN LY, 1992, ARCH BIOCHEM BIOPHYS, V296, P17, DOI 10.1016/0003-9861(92)90539-9; Cracowski JL, 2001, J VASC RES, V38, P93, DOI 10.1159/000051036; CRAWFORD K, 1987, ARCH OPHTHALMOL-CHIC, V105, P1112, DOI 10.1001/archopht.1987.01060080114039; FORTIER MA, 1988, J REPROD FERTIL, V83, P239, DOI 10.1530/jrf.0.0830239; Green K, 1978, Adv Prostaglandin Thromboxane Res, V5, P15; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; Kankofer M, 1999, PROSTAG LEUKOTR ESS, V61, P29, DOI 10.1054/plef.1999.0069; Kubata BK, 2000, J EXP MED, V192, P1327, DOI 10.1084/jem.192.9.1327; KUCHINKE W, 1992, BIOCHEM BIOPH RES CO, V183, P1238, DOI 10.1016/S0006-291X(05)80323-7; LACY WR, 1993, MOL ENDOCRINOL, V7, P58, DOI 10.1210/me.7.1.58; LEAVITT WW, 1985, J STEROID BIOCHEM, V22, P687, DOI 10.1016/0022-4731(85)90272-9; LEE JS, 1994, J ENDOCRINOL, V141, P491, DOI 10.1677/joe.0.1410491; Ma YF, 1995, BONE, V17, P549, DOI 10.1016/8756-3282(95)00387-8; Madore E, 2001, BIOL REPROD, V64, P319; McCracken JA, 1999, PHYSIOL REV, V79, P263, DOI 10.1152/physrev.1999.79.2.263; Mezzetti A, 2000, CARDIOVASC RES, V47, P475, DOI 10.1016/S0008-6363(00)00118-8; POYSER NL, 1995, PROSTAG LEUKOTR ESS, V53, P147, DOI 10.1016/0952-3278(95)90115-9; Robinson RS, 2001, REPRODUCTION, V122, P965, DOI 10.1530/rep.0.1220965; SILVIA WJ, 1994, J ENDOCRINOL, V141, P481, DOI 10.1677/joe.0.1410481; Soper DL, 2001, J MED CHEM, V44, P4157, DOI 10.1021/jm010264b; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Suzuki T, 1999, J BIOL CHEM, V274, P241, DOI 10.1074/jbc.274.1.241; Suzuki-Yamamoto T, 1999, FEBS LETT, V462, P335, DOI 10.1016/S0014-5793(99)01551-3; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; URADE Y, 1990, J BIOL CHEM, V265, P12029; WARREN JC, 1993, BIOCHEMISTRY-US, V32, P1401, DOI 10.1021/bi00057a003; WATANABE K, 1986, P NATL ACAD SCI USA, V83, P1583, DOI 10.1073/pnas.83.6.1583; WATANABE K, 1985, J BIOL CHEM, V260, P7035; Weber P C, 1980, Contrib Nephrol, V23, P83; WINTERGALEN N, 1995, EUR J BIOCHEM, V234, P264, DOI 10.1111/j.1432-1033.1995.264_c.x; Wu WX, 2001, J SOC GYNECOL INVEST, V8, P69, DOI 10.1016/S1071-5576(01)00094-6; Xiao CW, 1998, ENDOCRINOLOGY, V139, P2293, DOI 10.1210/en.139.5.2293; Xiao CW, 1999, BIOL REPROD, V60, P656, DOI 10.1095/biolreprod60.3.656	41	142	148	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11205	11212		10.1074/jbc.M208318200	http://dx.doi.org/10.1074/jbc.M208318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551929	hybrid			2022-12-25	WOS:000181855400046
J	Soon, LL; Yie, TA; Shvarts, A; Levine, AJ; Su, F; Tchou-Wong, KM				Soon, LL; Yie, TA; Shvarts, A; Levine, AJ; Su, F; Tchou-Wong, KM			Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; NOV PROTOONCOGENE; TUMOR-GROWTH; CCN FAMILY; CYR61; EXPRESSION; MEMBER; MIGRATION; PRODUCT	Wnt-induced-secreted-protein-1 (WISP-1) is a cysteine-rich, secreted factor belonging to the CCN family. These proteins have been implicated in the inhibition of metastasis; however, the mechanisms involved have not been described. We demonstrated that overexpression of WISP-1 in H460 lung cancer cells inhibited lung metastasis and in vitro cell invasion and motility. We investigated the possibility that WISP-1 may regulate activation of Rac, a small GTPase important for cytoskeletal reorganizations during motility. In an indirect assay, WISP-1-expressing cells exhibited marked reduction in Rac activation compared with control cells. Blocking antibodies to alpha(v)beta(5) and alpha(1) integrins restored Rac activation in WISP-1 cells, suggesting that the inhibitory effect of WISP-1 on Rac lies downstream of integrins. Constitutively activated Rac mutant (RacG12V) was transfected into WISP-1 cells to restore Rac activation and these WISP-1/RacG12V transfectants were used for further studies. We performed microarray and real-time PCR analyses to identify genes involved in invasion that may be differentially regulated by WISP-1. Here, we showed decreased expression of metalloproteinase-1 (MMP-1) in WISP-1 cells compared with controls but increased expression in WISP-1/RacG12V cells. In an invasion assay across collagen 1, an MMP-1 target matrix, WISP-1 cells were significantly less invasive compared with controls, whereas WISP-1/RacG12V cells showed elevated invasion levels. This work illustrates a negatively regulated pathway by WISP-1 involving integrins and Rac in the down-regulation of invasion.	NYU, Div Pulm & Crit Care Med, Dept Med, New York, NY 10016 USA; NYU, Dept Environm Med, New York, NY 10016 USA; NYU, Dept Microbiol, New York, NY 10016 USA; Princeton Univ, Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	New York University; New York University; New York University; Institute for Advanced Study - USA; Princeton University; Roche Holding	Tchou-Wong, KM (corresponding author), NYU, Div Pulm & Crit Care Med, Dept Med, 550 1St Ave,MSB141, New York, NY 10016 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00096] Funding Source: Medline; NIEHS NIH HHS [R01-ES0916] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Bredin CG, 1999, INT J CANCER, V82, P338, DOI 10.1002/(SICI)1097-0215(19990730)82:3<338::AID-IJC6>3.0.CO;2-Y; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; FEI S, 2002, GENE DEV, V16, P46; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; MARTINERIE C, 1992, ONCOGENE, V7, P2529; Noel A, 1997, INVAS METAST, V17, P221; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; Scholz G, 1996, MOL CELL BIOL, V16, P481; Suzuki-Inoue K, 2001, BLOOD, V98, P3708, DOI 10.1182/blood.V98.13.3708; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xu LF, 2000, GENE DEV, V14, P585; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	33	91	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11465	11470		10.1074/jbc.M210945200	http://dx.doi.org/10.1074/jbc.M210945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529380	hybrid			2022-12-25	WOS:000181855400077
J	Zarini, S; Murphy, RC				Zarini, S; Murphy, RC			Biosynthesis of 5-oxo-6,8,11,14-eicosatetraenoic acid from 5-hydroperoxyeicosatetraenoic acid in the murine macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE C-4 SYNTHASE; HUMAN NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; ACTIN POLYMERIZATION; POTENT STIMULATOR; ARACHIDONIC-ACID; HUMAN MONOCYTES; NADPH OXIDASE; IDENTIFICATION; EXPRESSION	5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a metabolite of arachidonic acid shown to possess important biological activities within different cell types. In the neutrophil, a specific NADP+-dependent dehydrogenase utilizes 5-lipoxygenase-derived 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5(S)-HETE) as the required substrate. In the present study, 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HpETE), rather than 5-HETE, was found to be the biosynthetic precursor of 5-oxo-ETE in the murine macrophage. The macrophage was not able to convert 5-HETE into 5-oxo-ETE even when preincubated with phorbol ester or with other lipid hydroperoxides. The factor responsible for the conversion of 5-HpETE into 5-oxo-ETE was found predominantly in the cytosolic fraction of the macrophage, with an approximate molecular weight of 50,000-60,000, as assessed by size exclusion chromatography. Formation of 5-oxo-ETE was rapid and the catalytic protein was found to have an apparent K-m of 5.3 muM for the eicosanoid. Furthermore, the protein could efficiently utilize 5(R,S)-HpETE as substrate and was heat and protease labile. This novel pathway of 5-oxo-ETE biosynthesis in the murine macrophage was consistent with reduction of a 5-hydroperoxy group to an intermediate alkoxy radical that could be subsequently oxidized to the 5-oxo product. Such a mechanism would enable racemic 5-HpETE, derived from free radical oxidation of arachidonic acid, to be efficiently converted into this potent chemotactic eicosanoid.	Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, Denver, CO 80206 USA.			Zarini, Simona/0000-0002-7460-3299	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN J, 1986, AGENTS ACTIONS, V17, P392, DOI 10.1007/BF01982660; BERTON G, 1985, IMMUNOLOGY, V54, P371; Bowers RC, 2000, J BIOL CHEM, V275, P29931, DOI 10.1074/jbc.C000502200; Brown K M, 2001, Public Health Nutr, V4, P593; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DELACLOS BF, 1988, BIOCHIM BIOPHYS ACTA, V958, P424, DOI 10.1016/0005-2760(88)90228-7; DELACLOS BF, 1987, PROSTAGLANDINS, V33, P315, DOI 10.1016/0090-6980(87)90016-5; DIX TA, 1985, J BIOL CHEM, V260, P5351; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GARDNER HW, 1981, BIOCHIM BIOPHYS ACTA, V665, P100, DOI 10.1016/0005-2760(81)90238-1; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; HAMBERG M, 1975, LIPIDS, V10, P87, DOI 10.1007/BF02532161; HASLETT C, 1985, AM J PATHOL, V119, P101; Hevko JM, 2002, J BIOL CHEM, V277, P7037, DOI 10.1074/jbc.M108942200; Hevko JM, 2001, J PHARMACOL EXP THER, V296, P293; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; LABEQUE R, 1988, BIOCHEMISTRY-US, V27, P7060, DOI 10.1021/bi00418a059; Lam BK, 2000, AM J RESP CRIT CARE, V161, pS16, DOI 10.1164/ajrccm.161.supplement_1.ltta-4; MacLeod RJ, 1999, J PHARMACOL EXP THER, V291, P511; Murphy RC, 2001, CHEM RES TOXICOL, V14, P463, DOI 10.1021/tx000250t; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; POWELL WS, 1994, J BIOL CHEM, V269, P25373; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; POWELL WS, 1993, J LIPID MEDIATOR, V6, P361; Powell WS, 2001, J ALLERGY CLIN IMMUN, V107, P272, DOI 10.1067/mai.2001.112847; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; Powell WS, 1997, J IMMUNOL, V159, P2952; POWELL WS, 1995, J IMMUNOL, V154, P4123; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; Sozzani S, 1996, J IMMUNOL, V157, P4664; WILBORN J, 1995, AM J PHYSIOL-LUNG C, V268, pL294, DOI 10.1152/ajplung.1995.268.2.L294; Zhang Y, 1996, J LEUKOCYTE BIOL, V59, P847, DOI 10.1002/jlb.59.6.847	38	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11190	11196		10.1074/jbc.M208496200	http://dx.doi.org/10.1074/jbc.M208496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547823	hybrid			2022-12-25	WOS:000181855400044
J	Nagao, T; Higashitsuji, H; Nonoguchi, K; Sakurai, T; Dawson, S; Mayer, RJ; Itoh, K; Fujita, J				Nagao, T; Higashitsuji, H; Nonoguchi, K; Sakurai, T; Dawson, S; Mayer, RJ; Itoh, K; Fujita, J			MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA PROTEIN; NEUROTROPHIN RECEPTOR; GENE FAMILY; CELL-CYCLE; EXPRESSION; PROLIFERATION; ANCHORAGE; APOPTOSIS	Hepatocellular carcinoma ranks among the most common malignancies in Southeast Asia and South Africa. Although there are many modalities of treatment, the recurrence and metastasis rates are high, and the prognosis is unsatisfactory. Gankyrin, a recently found oncoprotein, is a promising target for drug therapy because it is overexpressed in all studied hepatocellular carcinomas. Gankyrin contains six ankyrin repeats and interacts with Rb, Cdk4, and the S6 ATPase of the 26 S proteasome. In this study, a yeast two-hybrid screen with gankyrin has identified MAGE-A4 as another interacting protein. The interaction, mediated by the C-terminal half of MAGE-M, was reproduced in mammalian cells. The interaction was specific to MAGE-A4, because other MAGE family proteins structurally similar to MAGE-A4, ie. MAGE-A1, MAGE-A2, and MAGE-A12, did not bind to gankyrin. MAGE-A4 partially suppressed both anchorage-independent growth in vitro and tumor formation in athymic mice of gankyrin-overexpressing cells. The ability of mutant MAGE-A4 to interact with gankyrin correlated with the ability to suppress the anchorage-independent growth. These results demonstrate that MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. So far, the major focus of studies on the MAGE proteins has been on their potential for cancer immunotherapy. Our results may also shed light on novel functions for MAGE-A proteins.	Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 6068507, Japan; Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Lab Intracellular Proteolysis, Nottingham NG7 2UH, England	Kyoto University; University of Nottingham	Fujita, J (corresponding author), Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	jfujita@virus.kyoto-u.ac.jp						BAKER PA, 2002, J NEUROSCI RES, V67, P705; Chen CH, 1999, LIVER, V19, P110, DOI 10.1111/j.1478-3231.1999.tb00019.x; Chomez P, 2001, CANCER RES, V61, P5544; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Duffour MT, 1999, EUR J IMMUNOL, V29, P3329, DOI 10.1002/(SICI)1521-4141(199910)29:10<3329::AID-IMMU3329>3.0.CO;2-7; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fu XY, 2002, WORLD J GASTROENTERO, V8, P638, DOI 10.3748/wjg.v8.i4.638; Graff-Dubois S, 2002, J IMMUNOL, V169, P575, DOI 10.4049/jimmunol.169.1.575; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hopwood D, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P221; Jinno S, 2002, ONCOGENE, V21, P1777, DOI 10.1038/sj.onc.1205249; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Mou DC, 2002, BRIT J CANCER, V86, P110, DOI 10.1038/sj.bjc.6600016; Park TJ, 2001, MOL CARCINOGEN, V30, P138, DOI 10.1002/mc.1022; Saburi S, 2001, J BIOL CHEM, V276, P49378, DOI 10.1074/jbc.M108584200; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Tahara K, 1999, CANCER, V85, P1234, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.3.CO;2-Z; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096	26	78	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10668	10674		10.1074/jbc.M206104200	http://dx.doi.org/10.1074/jbc.M206104200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525503	Green Submitted, hybrid			2022-12-25	WOS:000181777500088
J	Maejima, H; Kinoshita, E; Seyama, I; Yamaoka, K				Maejima, H; Kinoshita, E; Seyama, I; Yamaoka, K			Distinct sites regulating grayanotoxin binding and unbinding to D4S6 of Na(v)1.4 sodium channel as revealed by improved estimation of toxin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCAL-ANESTHETIC AFFINITIES; SQUID GIANT-AXON; NA+ CHANNELS; POINT-MUTATIONS; SKELETAL-MUSCLE; EXCITABLE-MEMBRANES; MOLECULAR-BASIS; ALPHA-SUBUNIT; ION CHANNELS; D-RING	Grayanotoxin (GTX) exerts selective effects on voltage-dependent sodium channels by eliminating fast sodium inactivation and causing a hyperpolarizing shift in voltage dependence of channel activation. In this study, we adopted a newly developed protocol that provides independent estimates of the binding and unbinding rate constants of GTX (k(on) and k(off)) to GTX sites on the sodium channel protein, important in the molecular analysis of channel modification. Novel GTX sites were determined in D2S6 (Asn-784) and D3S6 (Ser-1276) by means of site-directed mutagenesis; the results suggested that the GTX receptor consists of the S6 transmembrane segments of four homologous domains facing the ion-conducting pore. We systematically introduced at two sites in D4S6 (Na(v)1.4-Phe-1579 and Na(v)1.4-Tyr-1586) amino acid substituents with residues containing hydrophobic, aromatic, charged, or polar groups. Generally, substitutions at Phe-1579 increased both k(on) and k(off), resulting in no prominent change in dissociation constant (K-d). It seems that the smaller the molecular size of the residue at Na(v)1.4-Phe-1579, the larger the rates of k(on) and k(off), indicating that this site acts as a gate regulating access of toxin molecules to a receptor site. Substitutions at Tyr-1586 selectively increased k(off) but had virtually no effect on k(on), thus causing a drastic increase in K-d. At position Tyr-1586, a hydrophobic or aromatic amino acid side chain was required to maintain normal sensitivity to GTX. These results suggest that the residue at position Tyr-1586 has a more critical role in mediating GTX binding than the one at position Phe-1579. Here, we propose that the affinity of GTX to Na(v)1.4 sodium channels might be regulated by two residues (Phe and Tyr) at positions Phe-1579 and Tyr-1586, which, respectively, control access and binding of to its receptor.	Hiroshima Univ, Sch Med, Dept Physiol, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Inst Hlth Sci, Hiroshima 7348551, Japan; Hiroshima Jogakuin Univ, Fac Human Life Sci, Higashi Ku, Hiroshima 7320063, Japan	Hiroshima University; Hiroshima University	Yamaoka, K (corresponding author), Hiroshima Univ, Sch Med, Dept Physiol, Kasumi 1-2-3, Hiroshima 7348551, Japan.		Kinoshita, Eiji/H-2284-2019					Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HOLLOWAY SF, 1989, PFLUG ARCH EUR J PHY, V414, P613, DOI 10.1007/BF00582125; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Ishii H, 1999, JPN J PHYSIOL, V49, P457, DOI 10.2170/jjphysiol.49.457; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; Kimura T, 2000, FEBS LETT, V465, P18, DOI 10.1016/S0014-5793(99)01715-9; Kimura T, 2001, MOL PHARMACOL, V60, P865; Kinoshita E, 2001, MOL PHARMACOL, V59, P1457, DOI 10.1124/mol.59.6.1457; LEIBOWITZ MD, 1986, J GEN PHYSIOL, V87, P25, DOI 10.1085/jgp.87.1.25; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; Li HL, 2002, MOL PHARMACOL, V61, P905, DOI 10.1124/mol.61.4.905; Li HL, 1999, MOL PHARMACOL, V55, P134, DOI 10.1124/mol.55.1.134; Linford NJ, 1998, P NATL ACAD SCI USA, V95, P13947, DOI 10.1073/pnas.95.23.13947; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; Maejima H, 2002, BIOCHEM BIOPH RES CO, V295, P452, DOI 10.1016/S0006-291X(02)00702-7; MASUTANI T, 1981, J PHARMACOL EXP THER, V217, P812; Narahashi T, 1996, PHARMACOL TOXICOL, V79, P1, DOI 10.1111/j.1600-0773.1996.tb00234.x; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; Park Y, 1997, BIOCHEM BIOPH RES CO, V239, P688, DOI 10.1006/bbrc.1997.7511; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Rao S, 2000, PFLUG ARCH EUR J PHY, V439, P349, DOI 10.1007/s004240050949; SEYAMA I, 1988, BIOPHYS J, V53, P271, DOI 10.1016/S0006-3495(88)83088-1; SEYAMA I, 1981, J PHARMACOL EXP THER, V219, P614; TATEBAYASHI H, 1994, J PHARMACOL EXP THER, V270, P595; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TSUJI K, 1991, J PHARMACOL EXP THER, V257, P788; Wang GK, 1998, MOL PHARMACOL, V54, P389, DOI 10.1124/mol.54.2.389; Wang GK, 2000, PFLUG ARCH EUR J PHY, V439, P705, DOI 10.1007/s004240050996; Wang SY, 1999, BIOPHYS J, V76, P3141, DOI 10.1016/S0006-3495(99)77465-5; Wang SY, 1998, P NATL ACAD SCI USA, V95, P2653, DOI 10.1073/pnas.95.5.2653; Wang SY, 2001, MOL PHARMACOL, V59, P1100, DOI 10.1124/mol.59.5.1100; Wang SY, 2000, BIOPHYS J, V79, P1379, DOI 10.1016/S0006-3495(00)76390-9; Yakehiro M, 2000, MOL PHARMACOL, V58, P692, DOI 10.1124/mol.58.4.692; YAKEHIRO M, 1993, J PHARMACOL EXP THER, V265, P1328; Yuki T, 2001, J PHYSIOL-LONDON, V534, P777, DOI 10.1111/j.1469-7793.2001.00777.x	38	62	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9464	9471		10.1074/jbc.M212133200	http://dx.doi.org/10.1074/jbc.M212133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524436	hybrid, Green Submitted			2022-12-25	WOS:000181524000079
J	Isaksson, A; Berggren, M; Ricksten, A				Isaksson, A; Berggren, M; Ricksten, A			Epstein-Barr virus U leader exon contains an internal ribosome entry site	ONCOGENE			English	Article						Epstein-Barr virus; internal ribosome entry site; U leader exon; luciferase expression; chloramphenicol transferase expression	SARCOMA-ASSOCIATED HERPESVIRUS; LYMPHOMA CELL-LINES; C-MYC IRES; MESSENGER-RNA; EBNA-1 GENE; ENCEPHALOMYOCARDITIS VIRUS; 5'-UNTRANSLATED REGION; INITIATION SITE; F-PROMOTER; TRANSLATION	Eukaryotic translation can be initiated either by a cap-dependent mechanism or by internal ribosome entry, a process by which ribosomes are directly recruited to structured regions of mRNA upstream of the initiation codon. Here we report the finding of an internal ribosome entry site (IRES) in the untranslated region of the Epstein-Barr nuclear antigen 1 (EBNA1) gene. EBNA1 is the only nuclear protein expressed in all known states of Epstein-Barr virus (EBV) latency and in the virus lytic cycle, and is required for the maintenance of the EBV episome. Using cDNA reporter constructs and in vitro transfection assays, we found that sequences contained in the 5' untranslated region (UTR) of the Fp and Qp initiated EBNA1 mRNA increased the expression level 4-14- fold in different Burkitt lymphoma cell lines. The U leader exon, located within the 5' UTR, included in all known EBNA1 transcripts and also contained in the EBNA3, 4 and 6 mRNAs, was demonstrated by bicistronic expression analyses to contain an IRES. The EBNA IRES initiates translation more efficiently than the encephalomyocarditis virus IRES in EBV-positive lymphoma cells. We propose that the EBNA IRES constitute a novel mechanism, whereby EBV regulates latent gene expression.	Sahlgrens Univ Hosp, Inst Lab Med, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Ricksten, A (corresponding author), Sahlgrens Univ Hosp, Inst Lab Med, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden.	anne.ricksten@clinchem.gu.se						Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Davenport MG, 1999, J VIROL, V73, P3154, DOI 10.1128/JVI.73.4.3154-3161.1999; deQuinto SL, 1997, J VIROL, V71, P4171; Dufva M, 2002, NUCLEIC ACIDS RES, V30, P2131, DOI 10.1093/nar/30.10.2131; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Hinton TM, 2001, J GEN VIROL, V82, P2257, DOI 10.1099/0022-1317-82-9-2257; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KERR BM, 1992, VIROLOGY, V187, P189, DOI 10.1016/0042-6822(92)90307-B; KIEFF E, 2001, FIELDS VIROLOGY, P2511; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1978, INT J CANCER, V21, P552, DOI 10.1002/ijc.2910210504; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; Marechal V, 1999, J VIROL, V73, P4385, DOI 10.1128/JVI.73.5.4385-4392.1999; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nateri AS, 2000, J VIROL, V74, P6269, DOI 10.1128/JVI.74.14.6269-6277.2000; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RICKSTEN A, 1988, NUCLEIC ACIDS RES, V16, P8391, DOI 10.1093/nar/16.17.8391; Rowe David T., 1999, Frontiers in Bioscience, V4, pD346, DOI 10.2741/Rowe; Sambrook J., 2001, MOL CLONING; SAMPLE J, 1986, P NATL ACAD SCI USA, V83, P5096, DOI 10.1073/pnas.83.14.5096; SAWADA K, 1989, VIROLOGY, V168, P22, DOI 10.1016/0042-6822(89)90399-1; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SCHAEFER BC, 1995, J VIROL, V69, P5039, DOI 10.1128/JVI.69.8.5039-5047.1995; Sjoblom A, 1998, J VIROL, V72, P1365; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TSAI CN, 1995, DNA CELL BIOL, V14, P767, DOI 10.1089/dna.1995.14.767; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WOISETSCHLAEGER M, 1990, P NATL ACAD SCI USA, V87, P1725, DOI 10.1073/pnas.87.5.1725; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Zetterberg H, 1999, J GEN VIROL, V80, P457, DOI 10.1099/0022-1317-80-2-457; ZUKER M, 1989, METHOD ENZYMOL, P262	41	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					572	581		10.1038/sj.onc.1206149	http://dx.doi.org/10.1038/sj.onc.1206149			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555070				2022-12-25	WOS:000180538200010
J	Carneiro, C; Jiao, MS; Hu, M; Shaffer, D; Park, M; Pandolfi, PP; Cordon-Cardo, C; Koff, A				Carneiro, C; Jiao, MS; Hu, M; Shaffer, D; Park, M; Pandolfi, PP; Cordon-Cardo, C; Koff, A			p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development	ONCOGENE			English	Article						tumorigenesis; p27kip1; Rb; Arf	DEPENDENT KINASE INHIBITOR; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; GROWTH ARREST; MICE LACKING; P27(KIP1); CANCER; CYCLE; P53; DIFFERENTIATION	Low p27 expression in many human cancers is a prognostic indicator for poor outcome. While analysing the mechanism by which p27 deficiency contributed to tumor development in the Rb+/- mouse model, we identified a role for p27 as a proapoptotic tumor suppressor. We examined the cell cycle and apoptotic response of these pituitary tumor cells to the dopamine analog bromocriptine as well as the expression of Arf and other cell cycle and apoptotic regulators in these tumors. We also examined the expression of Arf and its function in mouse embryo fibroblasts either singly or doubly deficient for Rb and p27. From these studies, we concluded that the absence of p27 disabled the trigger for an Arf-dependent apoptotic response in Rb-/- tumor cells. This suggests a novel mechanism by which the loss of p27 may impact on tumor development.	Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Mol Biol, RRL917D,Box 207,1275 York Ave, New York, NY 10021 USA.			Koff, Andrew/0000-0003-3271-3067				Arita J, 1998, NEUROENDOCRINOLOGY, V68, P163, DOI 10.1159/000054362; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drissi H, 1999, CANCER RES, V59, P3705; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Palmqvist R, 1999, J PATHOL, V188, P18, DOI 10.1002/(SICI)1096-9896(199905)188:1<18::AID-PATH311>3.0.CO;2-T; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Swerdlow RH, 1998, DRUG AGING, V13, P263, DOI 10.2165/00002512-199813040-00002; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tsihlias J, 1999, ANNU REV MED, V50, P401; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Yin DL, 1999, J CLIN NEUROSCI, V6, P326, DOI 10.1016/S0967-5868(99)90057-7; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					361	369		10.1038/sj.onc.1206163	http://dx.doi.org/10.1038/sj.onc.1206163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545157				2022-12-25	WOS:000180379100005
J	Chandrasekar, N; Mohanam, S; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS				Chandrasekar, N; Mohanam, S; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS			Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells	ONCOGENE			English	Article						migration; invasion; glioblastoma; antisense uPA	PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; MELANOMA-CELLS; INVASION; SYSTEM; STAUROSPORINE; BIOCHEMISTRY; METASTASIS; EXPRESSION; ADHESION	The ability of glioma cells to migrate great distances from a primary tumor mass is the primary cause of tumor recurrence. The urokinase-type plasminogen activator (uPA) is a serine protease that can initiate proteolytic cascades, which result in remodeling of extracellular matrix and basement membrane, allowing cells to move across and through these barriers. The binding between uPA and its receptor uPAR also mediates several signaling events that seem to contribute to the evolution of a migratory phenotype. In this study, we determined how the downregulation of uPA affects the signaling pathways leading to cell migration. Stably transfecting human glioblastoma cells with antisense uPA decreased the amount of cell-bound uPA and disrupted actin cytoskeleton formation and cell migration. The phosphatidylinositol 3-kinase (PI3k) and Akt signaling pathway has been suggested to mediate migration in various cancer cells. The antisense-uPA clones also had less phosphorylated PI3k and Akt than control cells, a finding associated with decreased cell migration, G2/M-phase arrest, and decreased clonogenic survival. Decreased activation of PI3k and the antiapoptotic factor Akt was not sufficient to induce apoptosis in the antisense-uPA clones, but staurosporine sensitized them to apoptosis to a greater extent than control cells. These results indicate that PI3k/Akt pathway is involved in the signaling cascade required to induce cell migration and that uPA has a direct role in regulating migration.	UIC, Coll Med, Dept Biomed, Div Canc Biol, Peoria, IL 61656 USA; UIC, Coll Med, Dept Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; UIC, Coll Med, Dept Neuropathol, Peoria, IL USA; UIC, Coll Med, Dept Neurosurg, Peoria, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago	Rao, JS (corresponding author), UIC, Coll Med, Dept Biomed, Div Canc Biol, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Berens M E, 1990, Neurosurg Clin N Am, V1, P1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carriero MV, 1999, CANCER RES, V59, P5307; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; GOODMAN SL, 1985, CELL, V41, P1029, DOI 10.1016/S0092-8674(85)80083-0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; HARSH GR, 1990, NEUROLOGICAL SURGERY, P3040; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kim EJ, 2001, INT J ONCOL, V18, P187; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; MacDonald TJ, 1998, J NEURO-ONCOL, V40, P215, DOI 10.1023/A:1006150506789; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Metzner B, 1996, J INVEST DERMATOL, V107, P597, DOI 10.1111/1523-1747.ep12583096; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohanam S, 2001, CLIN CANCER RES, V7, P2519; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; PYKE C, 1991, AM J PATHOL, V138, P1059; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; STAHL A, 1994, CANCER RES, V54, P3066; Stepanova V, 1999, MOL CELL BIOCHEM, V195, P199, DOI 10.1023/A:1006936623106; Sturge J, 2002, J CELL SCI, V115, P699; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510	46	87	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					392	400		10.1038/sj.onc.1206164	http://dx.doi.org/10.1038/sj.onc.1206164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545160				2022-12-25	WOS:000180379100008
J	Wei, DY; Le, XD; Zheng, LZ; Wang, LW; Frey, JA; Gao, AC; Peng, ZH; Huang, SY; Xiong, HQ; Abbruzzese, JL; Xie, KP				Wei, DY; Le, XD; Zheng, LZ; Wang, LW; Frey, JA; Gao, AC; Peng, ZH; Huang, SY; Xiong, HQ; Abbruzzese, JL; Xie, KP			Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis	ONCOGENE			English	Article						Stat3; angiogenesis; metastasis; tumor; pancreas	FACTOR GENE-EXPRESSION; FACTOR MESSENGER-RNA; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; ENHANCED EXPRESSION; PERMEABILITY FACTOR; CARDIAC MYOCYTES; UP-REGULATION; FACTOR-I; CELLS	Expression of vascular endothelial growth factor (VEGF), a key angiogenic protein, has been linked with pancreatic cancer progression. However, the molecular basis for VEGF overexpression remains unclear. Immunohistochemical studies have indicated that VEGF overexpression coincides with elevated Stat3 activation in human pancreatic cancer specimens. In our study, more than 80% of the human pancreatic cancer cell lines used exhibited constitutively activated Stat3, with Stat3 activation correlated with the VEGF expression level. Blockade of activated Stat3 via ectopic expression of dominant-negative Stat3 significantly suppressed VEGF expression, angiogenesis, tumor growth, and metastasis in vivo. Furthermore, constitutively activated Stat3 directly activated the VEGF promoter, whereas dominant-negative Stat3 inhibited the VEGF promoter. A putative Stat3-responsive element on the VEGF promoter was identified using a protein-DNA binding assay and confirmed using a promoter mutagenesis assay. These results indicate that Stat3 directly regulates VEGF expression and hence angiogenesis, growth, and metastasis of human pancreatic cancer, suggesting that Stat3 signaling may be targeted for treatment of pancreatic cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Inst Canc, Pittsburgh, PA 15213 USA; Fudan Univ, Affiliated Shanghai Peoples Hosp 1, Dept Gen Surg, Shanghai 200080, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fudan University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Box 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	kepxie@mail.mdanderson.org			NCI NIH HHS [CA 16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BROWN LF, 1993, CANCER RES, V53, P4727; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Clarke K, 2001, BRIT J CANCER, V84, P1322, DOI 10.1054/bjoc.2001.1805; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Damert A, 1997, CANCER RES, V57, P3860; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deroanne CF, 1997, CANCER RES, V57, P5590; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Evans Douglas B., 1997, P1054; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Folkman J, 1997, EXS, V79, P1; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hishinuma S, 1999, BIOCHEM BIOPH RES CO, V264, P436, DOI 10.1006/bbrc.1999.1535; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Jiang BH, 1997, CANCER RES, V57, P5328; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; KIESER A, 1994, ONCOGENE, V9, P963; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; RAK J, 1995, CANCER RES, V55, P4575; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shi Q, 2001, ONCOGENE, V20, P3751, DOI 10.1038/sj.onc.1204500; Shi Q, 2001, CANCER RES, V61, P4143; SHI Q, 1999, CLIN CANCER RES, V5, P7234; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VEZERIDIS MP, 1990, J SURG RES, V48, P51, DOI 10.1016/0022-4804(90)90145-R; Wang BL, 2001, INT J PANCREATOL, V29, P37, DOI 10.1385/IJGC:29:1:37; Wang DG, 1999, CANCER RES, V59, P1464; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	58	438	481	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					319	329		10.1038/sj.onc.1206122	http://dx.doi.org/10.1038/sj.onc.1206122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545153				2022-12-25	WOS:000180379100001
J	Alcivar, A; Hu, SM; Tang, J; Yang, XL				Alcivar, A; Hu, SM; Tang, J; Yang, XL			DEDD and DEDD2 associate with caspase-8/10 and signal cell death	ONCOGENE			English	Article						DEDD; DEDD2; caspase-8/10; apoptosis	ACTIVATION; OLIGOMERIZATION; APOPTOSIS	An apoptotic signal triggered by cell surface death receptors is disseminated to intracellular compartments through protein-protein interactions mediated by conserved domains such as the death effector domain (DED). A unique family of single DED-containing proteins, including DEDD and DEDD2, is targeted to the nucleolus. However, the role of DEDD/DEDD2 in apoptosis remains less understood. Here we show that DEDD and DEDD2 are highly conserved in diverse species, and that they are potent inducers of apoptosis in various cell types. Deletion analysis indicates that both the N-terminal DED domain and the C-terminal region of DEDD2 can induce apoptosis. The cell death activity of this family appears to be related to their nuclear localization. DEDD and DEDD2 bind to two tandem DED-containing caspases, caspase -8 and -10, that are engaged by death receptors. Consistent with the nuclear localization of this family, caspase-8 translocates to the nucleus during CD95-induced apoptosis. DEDD and DEDD2 also readily associate with themselves and with each other. These results suggest that DEDD and DEDD2 may be important mediators for death receptors and that they may target caspases to the nucleus.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Yang, XL (corresponding author), 421 Curie Blvd,Rm 610 BRB2-3, Philadelphia, PA 19104 USA.		Hu, Shimin/H-3427-2019	Hu, Shimin/0000-0001-7110-3814	NATIONAL CANCER INSTITUTE [R01CA088868] Funding Source: NIH RePORTER; NCI NIH HHS [CA88868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Roth W, 2002, J BIOL CHEM, V277, P7501, DOI 10.1074/jbc.M110749200; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhan Y, 2002, CELL DEATH DIFFER, V9, P439, DOI 10.1038/sj.cdd.4401038; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	11	54	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					291	297		10.1038/sj.onc.1206099	http://dx.doi.org/10.1038/sj.onc.1206099			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527898				2022-12-25	WOS:000180322400014
J	Gila, L; Elena, N; Yechezkel, S; Mary, B				Gila, L; Elena, N; Yechezkel, S; Mary, B			p53-associated 3 '-> 5 ' exonuclease activity in nuclear and cytoplasmic compartments of cells	ONCOGENE			English	Article						p53; 3 ' -> 5 ' exonuclease; cytoplasmic p53; nuclear p53; DNA replication fidelity	IMMUNODEFICIENCY-VIRUS TYPE-1; P53 PROTEIN; DNA-SYNTHESIS; SUBSTRATE-SPECIFICITY; REVERSE-TRANSCRIPTASE; 3 TERMINI; FIDELITY; ACCUMULATION; EXCISION; IDENTIFICATION	The tumor suppressor protein p53 plays an important role in maintenance of the genomic integrity of cells. p53 possesses an intrinsic 3' --> 5' exonuclease activity. p53 was found in the nucleus and in the cytoplasm of the cell. In order to evaluate the subcellular location and extent of p53-associated 3'--> 5' exonuclease activity, we established an in vitro experimental system of cell lines with different nuclear/cytoplasmic distribution of p53. Nuclear and cytoplasmic extracts obtained from LCC2 cells (expressing a high level of cytoplasmic wild-type p53), MCF-7 cells (expressing a high level of wild-type nuclear p53), MDA cells (expressing mutant p53) and H1299 cells (p53-null) were subjected to the analysis of exonuclease activity. Interestingly, 3' --> 5' exonuclease was predominantly cytoplasmic; the nuclear extracts derived from all cell lines tested, exerted a low level of exonuclease activity. Cytoplasmic extracts of LCC2 cells, with a high level of wild-type p53, showed an enhanced exonuclease activity in comparison to those expressing either a low level of wild-type p53 (in MCF-7 cells) or the mutant p53 (in NIDA cells). Evidence that exonuclease function detected in cytoplasmic extracts is attributed to the p53 is supported by several facts: First, this activity closely parallels with levels and status of endogenous cytoplasmic p53. Second, immunoprecipitation of p53 from cytoplasmic extracts of LCC2 cells markedly reduced the exonuclease activity. Third, the observed 3' --> 5' exonuclease in cytoplasmic fraction of LCC2 cells displays identical biochemical properties characteristic of recombinant wild-type p53. The biochemical functions include: (a) substrate specificity; exonuclease hydrolyzes single-stranded DNA in preference to double-stranded DNA and RNA/DNA template-primers, (b) efficient excision of 3'-terminal mispairs from DNA/DNA and RNA/DNA substrates, (c) the preferential excision of purine-purine mispairs over purine-pyrimidine mispairs and (d) functional interaction with exonuclease-deficient DNA polymerase, for example, murine leukemia virus reverse transcriptase (representing a relatively low fidelity enzyme), thus enhancing the fidelity of DNA synthesis by excision of mismatched nucleotides from the nascent DNA strand. Taken together, the data demonstrate that wildtype p53 in cytoplasm, in its noninduced state, is functional; it displays intrinsic 3' --> 5' exonuclease activity. The possible role of p53-associated 3' --> 5' exonuclease activity in DNA repair in nucleus and cytoplasm is discussed.	Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med C, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Lab Expt Chemotherapy, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Mary, B (corresponding author), Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel.	bakhanus@yahoo.com						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; Bakhanashvili M, 2001, ONCOGENE, V20, P7635, DOI 10.1038/sj.onc.1204956; Ballal K, 2002, J MOL MED-JMM, V80, P25, DOI 10.1007/s00109-001-0290-6; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BOSARI S, 1995, AM J PATHOL, V147, P790; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Genini D, 2001, FASEB J, V15, P5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAY H, 1992, J BIOL CHEM, V267, P5835; HARRINGTON JA, 1993, ANTIMICROB AGENTS CH, V37, P918, DOI 10.1128/AAC.37.4.918; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lilling G, 2002, CANCER INVEST, V20, P509, DOI 10.1081/CNV-120002151; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; MILNER J, 1990, ONCOGENE, V5, P1683; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; OLSON MW, 1992, J BIOL CHEM, V267, P23136; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Prives C, 1999, J PATHOL, V187, P112; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SOUSSI T, 1995, MOL GENETICS CANC, P135; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; Wang ZJ, 2002, J BIOL CHEM, V277, P4446, DOI 10.1074/jbc.M110006200; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	59	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					233	245		10.1038/sj.onc.1206111	http://dx.doi.org/10.1038/sj.onc.1206111			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527892				2022-12-25	WOS:000180322400008
J	Starke, DW; Chock, PB; Mieyal, JJ				Starke, DW; Chock, PB; Mieyal, JJ			Glutathione-thiyl radical scavenging and transferase properties of human glutaredoxin (thioltransferase) - Potential role in redox signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; S-THIOLATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ANTIOXIDANT FUNCTION; RESPIRATORY BURST; DISULFIDES; REDUCTION; OXIDATION; PEROXYNITRITE; THIOREDOXIN	Glutaredoxin (GRx, thioltransferase) is implicated in cellular redox regulation, and it is known for specific and efficient catalysis of reduction of protein-S-S-glutathione-mixed disulfides (protein-SSG) because of its remarkably low thiol pK(a) (approximate to3.5) and its ability to stabilize a catalytic S-glutathionyl intermediate (GRx-SSG). These unique properties suggested that GRx might also react with glutathione-thiyl radicals (GS(.)) and stabilize a disulfide anion radical intermediate (GRx-SSG(.)), thereby facilitating the conversion of GS(.) to GSSG or transfer of GS(.) to form protein-SSG. We found that GRx catalyzes GSSG formation in the presence of GS-thiyl radical generating systems (Fe2+/ADP/H2O2 + GSH or horseradish peroxidase/H2O2 + GSH). Catalysis is dependent on 02 and results in concomitant superoxide formation, and it is distinguished from glutathione peroxidase-like activity. With the horseradish peroxidase system and [S-35]GSH, GRx enhanced the rate of GS-radiolabel incorporation into GAPDH. GRx also enhanced the rate of S-glutathionylation of glyceraldehyde-3-phosphate dehydrogenase with GSSG or S-nitrosoglutathione, but these glutathionyl donors were much less efficient. Both actin and protein-tyrosine phosphatase-1B were superior substrates for GRx-facilitated S-glutathionylation with GS-radical. These studies characterize GRx as a versatile catalyst, facilitating GS-radical scavenging and S-glutathionylation of redox signal mediators, consistent with a critical role in cellular regulation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; NHLBI, Biochem Sect, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Mieyal, JJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.	jjm5@po.cwru.edu			NIA NIH HHS [AG15885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000202, Z01HL000202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; de Menezes SL, 2001, J BIOL CHEM, V276, P39879, DOI 10.1074/jbc.M104012200; FLOYD RA, 1983, ARCH BIOCHEM BIOPHYS, V225, P263, DOI 10.1016/0003-9861(83)90029-2; FLOYD RA, 1983, BIOCHEMISTRY-US, V22, P2645, DOI 10.1021/bi00280a008; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GOLDMAN R, 1995, BIOCHEMISTRY-US, V34, P4765, DOI 10.1021/bi00014a034; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRAVINA SA, 1993, THESIS CASE W RESERV; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KWAK HS, 1995, P NATL ACAD SCI USA, V92, P4582, DOI 10.1073/pnas.92.10.4582; Lind C, 1998, BIOCHEM BIOPH RES CO, V247, P481, DOI 10.1006/bbrc.1998.8695; Lobysheva II, 1999, BIOCHEMISTRY-MOSCOW+, V64, P153; MASON RP, 1990, METHOD ENZYMOL, V186, P318; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; MIEYAL JJ, 2003, IN PRESS CURRENT TOP; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SCHONEICH C, 1995, ANTIOX HEALTH DIS, V2, P21; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SIES H, 1987, ADV ENZYME REGUL, V26, P175, DOI 10.1016/0065-2571(87)90013-6; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Ward Paul, 1995, P1; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WINTERBOURN CC, 1995, METHOD ENZYMOL, V251, P81, DOI 10.1016/0076-6879(95)51112-1; Winterbourn CC, 1995, BIOTHIOLS HLTH DIS, P117; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; YIM MB, 1994, J BIOL CHEM, V269, P1621; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	41	140	143	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14607	14613		10.1074/jbc.M210434200	http://dx.doi.org/10.1074/jbc.M210434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12556467	hybrid			2022-12-25	WOS:000182516100006
J	Wang, B; Nguyen, M; Breckenridge, DG; Stojanovic, M; Clemons, PA; Kuppig, S; Shore, GC				Wang, B; Nguyen, M; Breckenridge, DG; Stojanovic, M; Clemons, PA; Kuppig, S; Shore, GC			Uncleaved BAP31 in association with A4 protein at the endoplasmic reticulum is an inhibitor of Fas-initiated release of cytochrome c from mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CONFORMATIONAL CHANGE; CASPASE ACTIVATION; INDUCED APOPTOSIS; IMPORT RECEPTOR; EARLY EVENTS; II CELLS; IN-VIVO; BAX; MEMBRANE	BAP31 is a polytopic integral protein of the endoplasmic reticulum. membrane and; like BID, is a preferred substrate of caspase-8. Upon Fas/CD95 stimulation, BAP31 is cleaved within. its cytosolic domain, generating proapoptotic p20 BAP31. In human KB epithelial cells expressing the caspase-resistant mutant crBAP31, Fas stimulation resulted in cleavage of BID and insertion of BAX into mitochondrial membrane, but subsequent oligomerization of BAX and BAK, egress of cytochrome c to the cytosol, and apoptosis were impaired. Bap31-null mouse cells expressing crBAP31 cannot generate the endogenous p20 BAP31 cleavage product, yet crBAP31 conferred resistance to cellular condensation and cytochrome c release in response to activation of ectopic FKBPcasp8 by FK1012z. Full-length BAP31, therefore, is a direct inhibitor of these caspase-8-initiated events, acting independently of its ability to sequester p20, with which it interacts. Employing a novel split ubiquitin yeast two-hybrid screen for BAP31-interacting membrane proteins, the putative ion channel protein of the endoplasmic reticulum, A4, was detected and identified as a constitutive binding partner of BAP31 in human cells. Ectopic A4 that was introduced into A4-deficient cells cooperated with crBAP31 to resist Fas-induced egress of cytochrome c from mitochondria and cytoplasmic apoptosis.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Univ Freiburg, Dept Mol Immunol Biol 3, D-71908 Freiburg, Germany; Max Planck Inst Immunbiol, D-71908 Freiburg, Germany	McGill University; Harvard University; Harvard Medical School; University of Freiburg; Max Planck Society	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.			wang, bing/0000-0002-6549-8837				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bouillet P, 2002, J CELL SCI, V115, P1567; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; BRECKENRIDGE DG, 2003, GENETICS APOPTOSIS, P93; BREITWIESER GE, 1997, AM J PHYSIOL, V272, P957; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chien MM, 1999, J BIOL CHEM, V274, P7059, DOI 10.1074/jbc.274.11.7059; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Csordas G, 2001, TRENDS CARDIOVAS MED, V11, P269, DOI 10.1016/S1050-1738(01)00123-2; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diver ST, 1997, J AM CHEM SOC, V119, P5106, DOI 10.1021/ja963891c; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GOPING IS, 1995, FEBS LETT, V373, P45; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McBride HM, 1996, J CELL BIOL, V134, P307, DOI 10.1083/jcb.134.2.307; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pinton P, 2002, BIOCHIMIE, V84, P195, DOI 10.1016/S0300-9084(02)01373-1; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060	50	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14461	14468		10.1074/jbc.M209684200	http://dx.doi.org/10.1074/jbc.M209684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12529377	hybrid			2022-12-25	WOS:000182405000113
J	Agarwal-Mawal, A; Qureshi, HY; Cafferty, PW; Yuan, ZF; Han, D; Lin, RT; Paudet, HK				Agarwal-Mawal, A; Qureshi, HY; Cafferty, PW; Yuan, ZF; Han, D; Lin, RT; Paudet, HK			14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2-LIKE PROTEIN-KINASE; BETA-CATENIN; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; BINDING; 14-3-3-PROTEINS; ACTIVATION; 3-BETA; FORMS; GSK3	In a recent study, we reported that in bovine brain extract, glycogen synthase kinase-3beta and tau are parts of an similar to400-500 kDa microtubule-associated tau phosphorylation complex (Sun, W., Qureshi, H. Y., Cafferty, P. W., Sobue, K., Agarwal-Mawal, A., Neufield, K. D., and Paudel, H. K. (2002) J. Biol. Chem. 277,11933-11940). In this study, we find that when purified brain microtubules are subjected to Superose 12 gel filtration column chromatography, the dimeric scaffold protein 14-3-3xi coelutes with the tau phosphorylation complex components tau and GSK3beta. From gel filtration fractions containing the tau phosphorylation complex, 14-3-3xi, GSK3beta, and tau co-immunoprecipitate with each other. From extracts of bovine brain, COS-7 cells, and HEK-293 cells transfected with GSK3beta, 14-3-3xi co-precipitates with GSK3beta, indicating that GSK3beta binds to 14-3-3xi. From HEK-293 cells transfected with tau, GSK3beta, and 14-3-3xi in different combinations, tau co-immunoprecipitates with GSK3beta only in the presence of 14-3-3xi. In vitro, similar to10-fold more tau binds to GSK3beta in the presence of than in the absence of 14-3-3xi. In transfected HEK-293 cells, 14-3-3xi stimulates GSK3beta-catalyzed tau phosphorylation in a dose-dependent manner. These data indicate that in brain, the 14-3-3xi dimer simultaneously binds and bridges tau and GSK3beta and stimulates GSK3beta-catalyzed tau phosphorylation.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Paudet, HK (corresponding author), Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca		Cafferty, Patrick/0000-0001-5563-1158				BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lovestone S, 1996, NEUROSCIENCE, V73, P1145, DOI 10.1016/0306-4522(96)00126-1; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PEI JJ, 1999, J NEUROPATHOL EXP NE, V56, P70; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Planel E, 2002, DRUG DEVELOP RES, V56, P491, DOI 10.1002/ddr.10100; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; SHIRUBA RA, 1998, BRAIN RES, V737, P119; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Sun W, 2002, J BIOL CHEM, V277, P11933, DOI 10.1074/jbc.M107182200; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wagner U, 1996, J CELL SCI, V109, P1537; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	45	194	201	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12722	12728		10.1074/jbc.M211491200	http://dx.doi.org/10.1074/jbc.M211491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551948	hybrid			2022-12-25	WOS:000182189500019
J	Olswang, Y; Blum, B; Cassuto, H; Cohen, H; Biberman, Y; Hanson, RW; Reshef, L				Olswang, Y; Blum, B; Cassuto, H; Cohen, H; Biberman, Y; Hanson, RW; Reshef, L			Glucocorticoids repress transcription of phosphoenolpyruvate carboxykinase (GTP) gene in adipocytes by inhibiting its C/EBP-mediated activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; RECEPTOR-GAMMA; FUNCTIONAL DOMAINS; GLYCERIDE-GLYCEROL; ADIPOSE EXPRESSION; MESSENGER-RNA; RESPONSE UNIT; PROMOTER; BETA; IDENTIFICATION	ddThe cytosolic form of the phosphoenolpyruvate carboxykinase (PEPCK-C) gene is selectively expressed in several tissues, primarily in the liver, kidney, and adipose tissue. The transcription of the gene is reciprocally regulated by glucocorticoids in these tissues. It is induced in the liver and kidney but repressed in the white adipose tissue. To elucidate which adipocyte-specific transcription factors participate in the repression of the gene, DNase I footprinting analyses of nuclear proteins from 3T3-F442A adipocytes and transient transfection experiments in NIH3T3 cells were utilized. Glucocorticoid treatment slightly reduced the nuclear C/EBPalpha concentration but prominently diminished the binding of adipocyte-derived nuclear proteins to CCAAT/enhancer-binding protein (C/EBP) recognition sites, without affecting the binding to nuclear receptor sites in the PEPCK-C gene promoter. Of members of the C/EBP family of transcription factors, C/EBPa was the strongest trans-activator of the PEPCK-C gene promoter in the NIH3T3 cell line. The glucocorticoid receptor (GR), in the presence of its hormone ligand, inhibited the activation of the PEPCK-C gene promoter by C/EBPa or C/EBPbeta but not by the adipocyte-specific peroxisome proliferator-activated receptor gamma2. This inhibition effect was similar using the wild type or mutant GR and did not depend on GR binding to the DNA. The glucocorticoid response unit (GRU) in the PEPCK-C gene promoter (-2000 to +73) restrained C/EBPalpha-mediated transactivation, because mutation of each single GRU element increased this activation by 3-4-fold. This series of GRU mutations were repressed by wild type GR to the same percent as was the nonmutated PEPCK-C gene promoter. In contrast, the repression by mutant GR depended on the intact AF1 site in the gene promoter, whereby mutation of the AF1 element abolished the repression.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biochem, IL-91120 Jerusalem, Israel; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Hebrew University of Jerusalem; Case Western Reserve University	Reshef, L (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biochem, IL-91120 Jerusalem, Israel.	reshef@cc.huji.ac.il		Blum, Barak/0000-0002-5308-4194	NIDDK NIH HHS [DK22541] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Allen-Jennings AE, 2002, J BIOL CHEM, V277, P20020, DOI 10.1074/jbc.M200727200; BALLARD FJ, 1967, J BIOL CHEM, V242, P2746; BAXTER JD, 1979, GLUCOCORTICOID HORMO, P10; BEALE EG, 1985, J BIOL CHEM, V260, P748; BENVENISTY N, 1987, P NATL ACAD SCI USA, V84, P1132, DOI 10.1073/pnas.84.5.1132; BENVENISTY N, 1989, P NATL ACAD SCI USA, V86, P1118, DOI 10.1073/pnas.86.4.1118; BERNE RM, 1998, PHYSIOLOGY, P942; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Botion LM, 1998, METABOLISM, V47, P1217, DOI 10.1016/S0026-0495(98)90326-2; Cassuto H, 1997, FEBS LETT, V412, P597, DOI 10.1016/S0014-5793(97)00867-3; Cassuto H, 1999, FEBS LETT, V457, P441, DOI 10.1016/S0014-5793(99)01080-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Eubank DW, 2001, J BIOL CHEM, V276, P30561, DOI 10.1074/jbc.M103019200; FABER S, 1993, J BIOL CHEM, V268, P24976; FEIFE LE, 2002, AM J PHYSIOL, V283, pF678; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; Lechner PS, 2001, J BIOL CHEM, V276, P22675, DOI 10.1074/jbc.M102422200; Lethimonier C, 2002, ENDOCRINOLOGY, V143, P2961, DOI 10.1210/en.143.8.2961; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTINSANZ P, 1990, BIOCHEM J, V271, P575, DOI 10.1042/bj2710575; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Raitskin O, 2001, P NATL ACAD SCI USA, V98, P6571, DOI 10.1073/pnas.111153798; RESHEF L, 1967, J LIPID RES, V8, P688; RESHEF L, 1969, J BIOL CHEM, V244, P5577; RESHEF L, 1970, HORM METAB RES S2, V2, P1136; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Williams CP, 1999, MOL CELL ENDOCRINOL, V148, P67, DOI 10.1016/S0303-7207(98)00234-2; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124	61	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12929	12936		10.1074/jbc.M300263200	http://dx.doi.org/10.1074/jbc.M300263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12560325	hybrid			2022-12-25	WOS:000182189500044
J	Quadri, SK; Bhattacharjee, M; Parthasarathi, K; Tanita, T; Bhattacharya, J				Quadri, SK; Bhattacharjee, M; Parthasarathi, K; Tanita, T; Bhattacharya, J			Endothelial barrier strengthening by activation of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; E-CADHERIN; ACTIN; RAC; CATENIN; CDC42; RHO; PERMEABILITY	Endothelial cell barrier (EC) properties regulate blood tissue fluid flux. To determine the role of endothelial-matrix interactions in barrier regulation, we induced cell shrinkage by exposing confluent endothelial monolayers to hyperosmolarity. The dominant effect of a 15-min hyperosmolar exposure was an increase in the trans-endothelial electrical resistance, indicating the induction of barrier strengthening. Hyperosmolar exposure also increased activity of focal adhesion kinase and E-cadherin accumulation at the cell periphery. Concomitantly, the density of actin filaments increased markedly. In EC monolayers stably expressing constitutively active or dominant negative isoforms of Rac1, the actin response to hyperosmolar exposure was enhanced or blocked, respectively; although the response in transendothelial resistance was unaffected, indicating that the endothelial barrier enhancement occurred independently of actin. However, in monolayers expressing a kinase-deficient mutant of focal adhesion kinase, the hyperosmolarity-induced increases in activity of focal adhesion and peripheral E-cadherin enhancement were blocked and the induced increase of electrical resistance was markedly blunted. These findings indicate that in EC exposed to hyperosmolar challenge, the involvement of focal adhesion kinase was critical in establishing barrier strengthening.	Columbia Univ, St Lukes Roosevelt Hosp Ctr, Lung Biol Lab, Coll Phys & Surg, New York, NY 10019 USA; Iwate Med Univ, Sch Med, Dept Thorac Surg, Iwate 0208505, Japan	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Iwate Medical University	Bhattacharya, J (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, Lung Biol Lab, Coll Phys & Surg, 1000 10th Ave, New York, NY 10019 USA.				NHLBI NIH HHS [HL36024, HL57556, HL64896] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036024, R01HL036024, R01HL064896, R01HL057556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Ehringer WD, 1999, MICROCIRCULATION, V6, P291; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J INVEST MED, V43, P117; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Glogauer M, 1997, J CELL SCI, V110, P11; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289; Moy AB, 2000, AM J PHYSIOL-LUNG C, V278, pL888, DOI 10.1152/ajplung.2000.278.5.L888; Ory S, 2000, J CELL SCI, V113, P1177; Paemeleire K, 1999, EXP BRAIN RES, V126, P473, DOI 10.1007/s002210050755; PHILLIPS PG, 1994, SEMIN THROMB HEMOST, V20, P417, DOI 10.1055/s-2007-1001930; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Ragette R, 1997, J CLIN INVEST, V100, P685, DOI 10.1172/JCI119581; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	39	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13342	13349		10.1074/jbc.M209922200	http://dx.doi.org/10.1074/jbc.M209922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556538	hybrid			2022-12-25	WOS:000182189500095
J	Tebo, J; Der, S; Frevel, M; Khabar, KSA; Williams, BRG; Hamilton, TA				Tebo, J; Der, S; Frevel, M; Khabar, KSA; Williams, BRG; Hamilton, TA			Heterogeneity in control of mRNA stability by AU-rich elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STABILIZATION; CYTOKINE; REGION; TRANSCRIPTION; BIOSYNTHESIS; DEGRADATION; INHIBITION; SEQUENCE; ALPHA	AU-rich elements (AREs), located in the 3'-untranslated region of unstable cytokine and chemokine mRNAs, promote rapid decay of otherwise stable mRNAs and may mediate selective mRNA stabilization in response to stimulation with interleukin-1 (IL-1). AREs vary considerably, however, in both size and sequence context. To assess the heterogeneity involved in control of mRNA stability by ARE motifs, human mRNA sequences from IL-1alpha-stimulated HEK293 cells and T98G cells were screened for either instability or stability using both cDNA (950 ARE containing sequences) and Affymetrix oligonucleotide (U95Av2 GeneChip) array analysis. Although ARE-containing mRNAs exhibited a broad range of stability, IL-1alpha promoted stability in a subset of mRNAs that were unstable when transcriptionally induced by tumor necrosis factor alpha. Stabilization of granulocyte/macrophage-colony stimulating factor and IL-8 mRNAs by IL-1alpha was achieved only after 2 h of stimulation, required ongoing protein synthesis, and depended on the activation of p38 MAPK. In contrast, stabilization of Gro3 mRNA in response to IL-1alpha was achieved immediately and was insensitive to inhibitors of protein synthesis and p38 MAPK activation. In concert, these findings demonstrate that ARE sequences are functionally heterogeneous; only a subset of unstable mRNAs is sensitive to stabilization by IL-1alpha. Moreover, IL-1alpha promotes stabilization of unstable mRNAs through distinct mechanistic pathways that distinguish between specific mRNA sequences.	Cleveland Clin Fdn, Dept Immunol NB30, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Toronto; King Faisal Specialist Hospital & Research Center	Hamilton, TA (corresponding author), Cleveland Clin Fdn, Dept Immunol NB30, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hamiltt@ccf.org	Hamilton, Thomas Edward/GQB-4837-2022; Hamilton, Thomas A/A-7756-2009; Williams, Bryan R. G./A-5021-2009; Khabar, Khalid/AAG-3487-2019; Khabar, Khalid/A-4772-2011	Williams, Bryan R. G./0000-0002-4969-1151; Khabar, Khalid/0000-0003-1003-9788; Khabar, Khalid/0000-0003-1003-9788; Hamilton, Thomas/0000-0002-9817-242X	NCI NIH HHS [CA62220, CA39621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220, R01CA039621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HAMILTON TA, 2002, NATURAL IMMUNE SYSTE, V2, P73; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; NATHAN CF, 1995, TXB RHEUMATOLOGY, P144; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; Stoecklin G, 2001, RNA, V7, P1578; Tebo JM, 1998, BLOOD, V92, P4742, DOI 10.1182/blood.V92.12.4742.424k26_4742_4749; Tebo JM, 2000, J BIOL CHEM, V275, P12987, DOI 10.1074/jbc.275.17.12987; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001	27	100	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12085	12093		10.1074/jbc.M212992200	http://dx.doi.org/10.1074/jbc.M212992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556523	hybrid			2022-12-25	WOS:000182015700049
J	Baumeister, MA; Martinu, L; Rossman, KL; Sondek, J; Lemmon, MA; Chou, MM				Baumeister, MA; Martinu, L; Rossman, KL; Sondek, J; Lemmon, MA; Chou, MM			Loss of phosphatidylinositol 3-phosphate binding by the C-terminal Tiam-1 pleckstrin homology domain prevents in vivo Rac1 activation without affecting membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; CYSTEINE-RICH DOMAINS; DBL FAMILY; GUANOSINE TRIPHOSPHATASES; PHOSPHOINOSITIDE BINDING; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; DISTINCT ROLES; ONCOGENIC DBL; RHO-GTPASES	Dbl family guanine nucleotide exchange factors (GEFs) for Rho family small GTPases invariably contain a pleckstrin homology (PH) domain that immediately follows their Dbl homology (DH) domain. Although the DH domain is responsible for GEF activity, the role of the PH domain is less clear. We previously reported that PH domains from several Dbl family members bind phosphoinositides with very low affinity (K-d values in the 10 pm range). This suggests that, unlike several other PH domains, those from Dbl proteins will not function as independent membrane-targeting modules. To determine the functional relevance of low affinity phosphoinositide binding, we mutated the corresponding PH domain from Tiam-1 to abolish its weak, specific binding to phosphatidylinositol 3-phosphate. We first confirmed in vitro that phosphoinositide binding by the isolated DH/PH domain was impaired by the mutations but that intrinsic GEF activity was unaffected. We then introduced the PH domain mutations into full-length Tiam-1 and found that its ability to activate Rac1 or serum response factor in vivo was abolished. Immunofluorescence studies showed that membrane targeting of Tiam-1 was essentially unaffected by mutations in the C-terminal PH domain. Our studies therefore indicate that low affinity phosphatidylinositol 3-phosphate binding by the C-terminal PH domain may be critical for in vivo regulation and activity of Tiam-1 but that the PH domain exerts its regulatory effects without altering membrane targeting. We suggest instead that ligand binding to the PH domain induces conformational and/or orientational changes at the membrane surface that are required for maximum exchange activity of its adjacent DH domain.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Immunol Grad Grp, Philadelphia, PA 19104 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, 1011 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.			Sondek, John/0000-0002-1127-8310; Lemmon, Mark/0000-0002-3379-5319	NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056846, F31GM065066, R01GM062299] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81415] Funding Source: Medline; NIGMS NIH HHS [R01 GM056846, R01-GM56846, R01-GM62299, F31-GM65066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harris BZ, 2001, J CELL SCI, V114, P3219; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lee A, 2001, METHOD ENZYMOL, V329, P457; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Qi HW, 2001, CELL GROWTH DIFFER, V12, P603; RIDLEY AJ, 1995, CURR BIOL, V5, P710, DOI 10.1016/S0960-9822(95)00140-0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	55	46	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11457	11464		10.1074/jbc.M211901200	http://dx.doi.org/10.1074/jbc.M211901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525493	hybrid			2022-12-25	WOS:000181855400076
J	King, KE; Iyemere, VP; Weissberg, PL; Shanahan, CM				King, KE; Iyemere, VP; Weissberg, PL; Shanahan, CM			Kruppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor beta 1 in the regulation of vascular smooth muscle cell phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; IN-VIVO; OSTEOGENIC PROTEIN-1; NEGATIVE REGULATION; GENE-EXPRESSION; ARTERIAL INJURY; RAT; RECEPTORS; ELEMENT; ACTIVIN	Vascular smooth muscle cell (VSMC) differentiation and phenotypic modulation is characterized by changes in mRNA expression for smooth muscle (SM) marker contractile proteins such as alpha-SM actin and SM22alpha. Transforming growth factor beta1 (TGF-beta1) is a potent VSMC differentiation factor; however, it is not known if other TGF-beta-superfamily members, in particular the bone morphogenetic proteins (BMPs), modulate VSMC phenotype. Here we demonstrate that a large subset of TGF-beta-superfamily members and their type I receptors are differentially co-expressed as VSMC phenotype changes during fetal/neonatal development and that BMP2, -4, and -6 reciprocally regulate SM-marker mRNA and protein expression in vitro. BMP2 and BMP6 decrease expression of the SM markers alpha-SM actin, SM22alpha, and calponin in rat VSMCs, whereas BMP4 increases their expression. The effects of BMP-2, -4, and -6 on SM marker gene transcription are mediated through a consensus TGF-beta-controlling element, the TCE, which is common to regulatory regions of SM-marker genes. Moreover, co-treatment experiments revealed that BMP-2, -4, and -6 each inhibit TGF-beta1-modulated increases in SM22a reporter gene activity. Regardless of whether they positively or negatively regulate SM marker expression, TGF-beta1 and BMP-2, -4, and -6 all induced binding of the Kruppel-like transcription factor, GKLF/KLF4, to the TGF-beta control element. Induction of KLF4 was confirmed by immunocytochemistry and Western blotting, which revealed that a lower molecular weight KLF4 protein is induced after treatment with TGF-beta-superfamily members. Taken together, our results demonstrate that multiple members of the TGF-beta superfamily act in concert to modulate VSMC phenotype.	Univ Cambridge, Addenbrookes Ctr Clin Invest Level 6, Dept Med, Cambridge CB2 2QQ, England	University of Cambridge	Shanahan, CM (corresponding author), Univ Cambridge, Addenbrookes Ctr Clin Invest Level 6, Dept Med, Box 110 Addenbrookes Hosp,Hills Rd, Cambridge CB2 2QQ, England.			Shanahan, Catherine/0000-0002-8352-8171				Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Agrotis A, 1996, BIOCHEM BIOPH RES CO, V219, P613, DOI 10.1006/bbrc.1996.0282; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Chang H, 1999, DEVELOPMENT, V126, P1631; Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523-1755.2000.00081.x; Engelse MA, 1999, CIRC RES, V85, P931; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JONES CM, 1991, DEVELOPMENT, V111, P531; Jung F, 1999, ARTERIOSCL THROM VAS, V19, P2591, DOI 10.1161/01.ATV.19.11.2591; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; LYONS KM, 1990, DEVELOPMENT, V109, P833; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MCCAFFERY RE, 1994, J GEN VIROL, V75, P3047, DOI 10.1099/0022-1317-75-11-3047; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; Miyazono K, 2000, J CELL SCI, V113, P1101; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakaoka T, 1997, J CLIN INVEST, V100, P2824, DOI 10.1172/JCI119830; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALTIS J, 1992, AM J PHYSIOL, V263, pC420, DOI 10.1152/ajpcell.1992.263.2.C420; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SCHLUESENER HJ, 1995, ATHEROSCLEROSIS, V113, P153, DOI 10.1016/0021-9150(94)05438-O; SHAH M, 1995, J CELL SCI, V108, P985; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Shanahan CM, 1998, ARTERIOSCL THROM VAS, V18, P333, DOI 10.1161/01.ATV.18.3.333; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; Ward MR, 1997, ARTERIOSCL THROM VAS, V17, P2461, DOI 10.1161/01.ATV.17.11.2461; Yang X, 1999, DEVELOPMENT, V126, P1571	43	94	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11661	11669		10.1074/jbc.M211337200	http://dx.doi.org/10.1074/jbc.M211337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538588	hybrid			2022-12-25	WOS:000181855400100
J	Matsui, Y; Chansky, HA; Barahmand-Pour, F; Zielinska-Kwiatkowska, A; Tsumaki, N; Myoui, A; Yoshikawa, H; Yang, L; Eyre, DR				Matsui, Y; Chansky, HA; Barahmand-Pour, F; Zielinska-Kwiatkowska, A; Tsumaki, N; Myoui, A; Yoshikawa, H; Yang, L; Eyre, DR			COL11A2 collagen gene transcription is differentially regulated by EWS/ERG sarcoma fusion protein and wild-type ERG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR GENE; HISTONE DEACETYLASE; EWINGS-SARCOMA; CELL-LINE; MOLECULAR-CLONING; PROMOTER ACTIVITY; BINDING PROTEIN; DNA-BINDING; EWS GENE; NF-Y	A specific t(21;22) chromosomal translocation creates the chimeric EWS/ERG gene in some cases of Ewing's sarcoma. In the resultant EWS/ERG fusion protein, the N-terminal part of the ETS family protein ERG is replaced by the N terminus of the RNA-binding protein EWS. We found that both the EWS/ERG and COL11A2 genes are expressed in the Ewing's sarcoma cell line, CADO-ES1. To investigate a potential role for EWS/ERG in COL11A2 gene expression, we characterized the COL11A2 promoter and tested the ability of wild-type ERG and EWS/ERG sarcoma fusion protein to transactivate COL11A2 promoter using a luciferase assay. We found that expression of EWS/ERG, but not wild-type ERG, transactivated the COL11A2 promoter and that this transactivation required not only the N-terminal region of EWS but also an intact DNA-binding domain from ERG. Electrophoretic mobility shift assay using COL11A2 promoter sequence showed involvement of EWS/ERG in the formation of DNA-protein complexes, and chromatin immunoprecipitation assay revealed direct interaction between COL11A2 promoter and EWS/ERG fusion protein in vivo. EWS/ERG, but not wild-type ERG, bound to RNA polymerase II. Treatment of cells with the histone deacetylase inhibitor trichostatin A enabled ERG to transactivate the COL11A2 promoter, therefore abolishing the differential effects of EWS/ERG and ERG. Taken together, these findings indicate that the COL11A2 gene is regulated both by potential ERG association with a histone deacetylase complex and by direct EWS/ERG recruitment of RNA polymerase II.	Osaka Univ, Sch Med, Dept Orthoped Surg, Suita, Osaka 5650871, Japan; Univ Washington, Dept Orthoped & Sports Med, Sch Med, Seattle, WA 98195 USA	Osaka University; University of Washington; University of Washington Seattle	Yang, L (corresponding author), Univ Washington, Dept Orthoped & Sports Med, Sch Med, Box 358280, Seattle, WA 98108 USA.		Myoui, Akira/E-8296-2010	Tsumaki, Noriyuki/0000-0002-0520-3654	NCI NIH HHS [1R01CA90941] Funding Source: Medline; NIAMS NIH HHS [R37 AR037318, 5R37AR36794, 5R01AR37318, R01 AR036794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR037318, R37AR036794, R01AR037318, R01AR036794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annunen S, 1999, AM J HUM GENET, V65, P974, DOI 10.1086/302585; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Chansky HA, 2001, CANCER RES, V61, P3586; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; Ginsberg JP, 1999, J CLIN ONCOL, V17, P1809, DOI 10.1200/JCO.1999.17.6.1809; GOJI J, 1992, CANCER RES, V52, P4214; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Im YH, 2000, CANCER RES, V60, P1536; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KODAMA K, 1991, CANCER GENET CYTOGEN, V57, P19, DOI 10.1016/0165-4608(91)90185-W; KODAMA K, 1994, JPN J CANCER RES, V85, P335, DOI 10.1111/j.1349-7006.1994.tb02363.x; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; Lui VCH, 1996, GENOMICS, V32, P401, DOI 10.1006/geno.1996.0135; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Matsui Y, 1998, CANCER LETT, V124, P143, DOI 10.1016/S0304-3835(97)00468-0; MORSE RH, 1991, J MOL BIOL, V222, P133, DOI 10.1016/0022-2836(91)90198-F; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; OHNO T, 1994, ONCOGENE, V9, P3087; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; REDDY ESP, 1991, ONCOGENE, V6, P2285; Reymond A, 2002, NATURE, V420, P582, DOI 10.1038/nature01178; Rudge TL, 2002, EXP CELL RES, V274, P45, DOI 10.1006/excr.2001.5451; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Soldatenkov VA, 2002, ONCOGENE, V21, P2890, DOI 10.1038/sj.onc.1205393; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Tanaka K, 2002, MOL CELL BIOL, V22, P4256, DOI 10.1128/MCB.22.12.4256-4267.2002; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Verger A, 2001, J BIOL CHEM, V276, P17181, DOI 10.1074/jbc.M010208200; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; YANG L, 1994, J BIOL CHEM, V269, P32732; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000	49	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11369	11375		10.1074/jbc.M300164200	http://dx.doi.org/10.1074/jbc.M300164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12554743	hybrid			2022-12-25	WOS:000181855400065
J	Cui, J; Huang, L; Zhao, A; Lew, JL; Yu, JH; Sahoo, S; Meinke, PT; Royo, I; Pelaez, F; Wright, SD				Cui, J; Huang, L; Zhao, A; Lew, JL; Yu, JH; Sahoo, S; Meinke, PT; Royo, I; Pelaez, F; Wright, SD			Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; ORPHAN NUCLEAR RECEPTOR; VITAMIN-D-RECEPTOR; COMMIPHORA-MUKUL; ACID RECEPTOR; NATURAL PRODUCT; PROTEIN GENE; FXR; IDENTIFICATION; CHOLESTEROL	Guggulipid is an extract of the guggul tree Commiphora mukul and has been widely used to treat hyper-lipidemia in humans. The plant sterol guggulsterone (GS) is the active agent in this extract. Recent studies have shown that GS can act as an antagonist ligand for farnesoid X receptor (FXR) and decrease expression of bile acid-activated genes. Here we show that GS, although an FXR antagonist in coactivator association assays, enhances FXR agonist-induced transcription of bile salt export pump (BSEP), a major hepatic bile acid transporter. In HepG2 cells, in the presence of an FXR agonist such as chenodeoxycholate or GW4064, GS enhanced endogenous BSEP expression with a maximum induction of 400-500% that induced by an FXR agonist alone. This enhancement was also readily observed in FXR-dependent BSEP promoter activation using a luciferase reporter construct. In addition, GS alone slightly increased BSEP promoter activation in the absence of an FXR agonist. Consistent with the results in HepG2, guggulipid treatment in Fisher rats increased BSEP mRNA. Interestingly, in these animals expression of the orphan nuclear receptor SHP (small heterodimer partner), a known FXR target, was also significantly increased, whereas expression of other FXR targets including cholesterol 7alpha-hydroxylase (Cyp 7alpha1), sterol 12alpha-hydroxylase (Cyp 8b1), and the intestinal bile acid-binding protein (I-BABP), remained unchanged. Thus, we propose that GS is a (s) under bar elective (b) under bar ile (a) under bar cid (r) under bar eceptor modulator that regulates expression of a subset of FXR targets. Guggulipid treatment in rats lowered serum triglyceride and raised serum high density lipoprotein levels. Taken together, these data suggest that guggulsterone defines a novel class of FXR ligands characterized by antagonist activities in coactivator association assays but with the ability to enhance the action of agonists on BSEP expression in vivo.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Ctr Invest Basica, Madrid 28027, Spain	Merck & Company; Merck & Company; Merck & Company	Cui, J (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000,RY80W-107, Rahway, NJ 07065 USA.	jisong_cui@merck.com	Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Beg M., 1996, Indian Journal of Physiology and Pharmacology, V40, P237; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Chander R, 1996, PHYTOTHER RES, V10, P508, DOI 10.1002/(SICI)1099-1573(199609)10:6&lt;508::AID-PTR895&gt;3.0.CO;2-P; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; Cui J, 2002, J BIOL CHEM, V277, P25963, DOI 10.1074/jbc.M200824200; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Dev S, 1999, ENVIRON HEALTH PERSP, V107, P783, DOI 10.2307/3454574; Dixit V.P., 1980, BIOCHEMISTRY AND EXPERIMENTAL BIOLOGY, V16, P421; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Lecureur V, 2000, TOXICOLOGY, V153, P203, DOI 10.1016/S0300-483X(00)00315-2; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Monden T, 1999, MOL ENDOCRINOL, V13, P1695, DOI 10.1210/me.13.10.1695; Nityanand S, 1989, J Assoc Physicians India, V37, P323; ORTI E, 1993, J BIOL CHEM, V268, P7779; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; SATYAVATI GV, 1988, INDIAN J MED RES, V87, P327; SINGH RB, 1994, CARDIOVASC DRUG THER, V8, P659, DOI 10.1007/BF00877420; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Tu H, 2000, TRENDS CARDIOVAS MED, V10, P30, DOI 10.1016/S1050-1738(00)00043-8; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Wu J, 2002, MOL ENDOCRINOL, V16, P1590, DOI 10.1210/me.16.7.1590; Xu GR, 2002, J BIOL CHEM, V277, P50491, DOI 10.1074/jbc.M209176200; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	44	185	200	1	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10214	10220		10.1074/jbc.M209323200	http://dx.doi.org/10.1074/jbc.M209323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525500	hybrid			2022-12-25	WOS:000181777500032
J	Hu, SM; Yang, XL				Hu, SM; Yang, XL			Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE; CYTOCHROME-C; DROSOPHILA IAP1; DEGRADATION; DEATH; CASPASES; REAPER; DIAP1; HID; IDENTIFICATION	Inhibitors of apoptosis (IAPs) are crucial regulators of programmed cell death. The mechanism by which IAPs prevent apoptosis has previously been attributed to the direct inhibition of caspases. The function of mammalian IAPs is counteracted by cell death inducer second mitochondria-derived activator of caspases (Smac)/DIABLO during apoptosis. Here we show that cIAP1 and cIAP2 are E3 ubiquitin-protein isopeptide ligases (ubiquitin ligases) for Smac. cIAPs stimulate Smac ubiquitination both in vivo and in vitro, leading to Smac degradation. cIAP1 and cIAP2 associate with overlapping but distinct subsets of E2 (ubiquitin carrier protein) ubiquitin-conjugating enzymes. The substrate-dependent E3 activity of cIAPs is mediated by their RING domains and is dependent on the specific interactions between cIAPs and Smac. Similarly, Drosophila IAP1 also possesses ubiquitin ligase activity that mediates the degradation of the Drosophila apoptosis inducers Grim and HID. These results suggest a novel and conserved mechanism by which IAPs block apoptosis through the degradation of death inducers.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Yang, XL (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	xyang@mail.med.upenn.edu	Hu, Shimin/H-3427-2019	Hu, Shimin/0000-0001-7110-3814	NIGMS NIH HHS [R01 GM60911] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wang XD, 2001, GENE DEV, V15, P2922; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	40	184	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10055	10060		10.1074/jbc.M207197200	http://dx.doi.org/10.1074/jbc.M207197200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525502	hybrid			2022-12-25	WOS:000181777500010
J	Lu, YB; Pan, ZZ; Devaux, Y; Ray, P				Lu, YB; Pan, ZZ; Devaux, Y; Ray, P			p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte growth factor receptor and participates in keratinocyte growth factor-mediated inhibition of oxidant-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; BRANCHING MORPHOGENESIS; TYROSINE KINASES; HEPARAN-SULFATE; ACTIVATION; LUNG; NCK; COMPLEX; GRB2; DIFFERENTIATION	Keratinocyte growth factor (KGF), a member of the fibroblast growth factor (FGF) family (also known as FGF-7), is an important protective factor for epithelial cells. The receptor for KGF (also called FGFR2-IIIb), which has intrinsic tyrosine kinase activity, is expressed specifically on epithelial cells and in the lung epithelium. Administration of KGF has been shown to protect the lung from various insults, but the mechanism of protection is not well understood. To understand the mechanism by which KGF exerts protective functions on epithelial cells, we used the yeast two-hybrid assay to identify proteins that interact with the KGF receptor (KGFR). Here we show that the cytoplasmic domain of KGFR interacts with p21-activated protein kinase (PAK) 4, which is a new member of the PAK family. The PAKs are regulated by the Rho-family GTPases Rac and Cdc42. PAK4 is the most divergent member of the PAK family of proteins and may have distinct functions. However, stimuli that regulate PAK4 activity are not known. Our data show that PAK4 can associate with the KGFR, which is dependent on KGFR tyrosine kinase activity. We show that a dominant negative mutant of PAK4 blocks KGF-mediated inhibition of caspase-3 activation in epithelial cells subjected to oxidant stress. Our data demonstrate that PAK4 is an important mediator of the anti-apoptotic effects of KGF on epithelial cells.	Univ Pittsburgh, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, Pittsburgh, PA 15213 USA; Yale Univ, Sch Med, New Haven, CT 06510 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Fox Chase Cancer Center	Ray, P (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, 3459 5th Ave,MUH 628 NW, Pittsburgh, PA 15213 USA.	rayp@pitt.edu	Pan, Zhong-Zong/B-6964-2012; DEVAUX, Yvan/AAK-3463-2020		NHLBI NIH HHS [HL 60207, R01 HL069810, HL 69810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069810, R01HL060207] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cardoso WV, 1997, DEV DYNAM, V208, P398, DOI 10.1002/(SICI)1097-0177(199703)208:3<398::AID-AJA10>3.0.CO;2-X; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guo J, 1998, AM J PHYSIOL-LUNG C, V275, pL800, DOI 10.1152/ajplung.1998.275.4.L800; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yano T, 1996, AM J RESP CELL MOL, V15, P433, DOI 10.1165/ajrcmb.15.4.8879176; Yi ES, 1996, AM J PATHOL, V149, P1963; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	41	39	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10374	10380		10.1074/jbc.M205875200	http://dx.doi.org/10.1074/jbc.M205875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529371	hybrid			2022-12-25	WOS:000181777500052
J	Miller, DL; Schildbach, JF				Miller, DL; Schildbach, JF			Evidence for a monomeric intermediate in the reversible unfolding of F factor TraM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEDIMENTATION-VELOCITY DATA; DNA-BINDING; MATING SIGNAL; ORIT REGION; PROTEIN; PLASMID; GENE; RECOMBINATION; DENATURATION; RIBONUCLEASE	F factor TraM is essential for efficient bacterial conjugation, but its molecular function is not clear. Because the physical properties of TraM may provide clues to its role in conjugation, we have characterized the TraM oligomerization equilibrium. We show that the reversible unfolding transition is non-two-state, indicating the presence of at least one intermediate. Analytical ultracentrifugation experiments indicate that the first phase of unfolding involves dissociation of the tetramer into folded monomers, which are subsequently unfolded to the denatured state in the second phase. Furthermore, we show that a C-terminal domain isolated by limited proteolysis is tetrameric in solution, like the full-length protein, and that its loss of structure correlates with dissociation of the TraM tetramer. Unfolding of the individual domains indicates that the N- and C-terminal regions act cooperatively to stabilize the full-length protein. Together, these experiments suggest structural overlap of regions important for oligomerization and DNA binding. We propose that modulating the oligomerization equilibrium of TraM may regulate its essential activity in bacterial conjugation.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schildbach, JF (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall 235,3400 N Charles St, Baltimore, MD 21218 USA.	joel@jhu.edu		Schildbach, Joel/0000-0002-3038-9745; Miller, Dana/0000-0003-3983-0493	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO T, 1993, J BACTERIOL, V175, P4466, DOI 10.1128/JB.175.14.4466-4474.1993; ABO T, 1991, J BACTERIOL, V173, P6347, DOI 10.1128/jb.173.20.6347-6354.1991; ABO T, 1995, J BACTERIOL, V177, P4350, DOI 10.1128/jb.177.15.4350-4355.1995; BRANDTS JF, 1967, J AM CHEM SOC, V89, P4826, DOI 10.1021/ja00995a002; Chen LL, 1996, J MOL BIOL, V261, P658, DOI 10.1006/jmbi.1996.0491; COWGILL RW, 1976, BIOCHEMICAL FLUORESC, V2, P441; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; Fekete RA, 2002, J BIOL CHEM, V277, P16705, DOI 10.1074/jbc.M111682200; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU YHF, 1991, J BACTERIOL, V173, P1012, DOI 10.1128/jb.173.3.1012-1020.1991; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENE RF, 1974, J BIOL CHEM, V249, P5388; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; LEDERBERG J, 1946, NATURE, V158, P558, DOI 10.1038/158558a0; LIANG P, 1999, J BIOL CHEM, V274, P19644; OU JT, 1975, P NATL ACAD SCI USA, V72, P3721, DOI 10.1073/pnas.72.9.3721; OU JT, 1978, J BACTERIOL, V133, P442, DOI 10.1128/JB.133.1.442-445.1978; Pace C N, 1986, Methods Enzymol, V131, P266; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Polzleitner E, 1997, MOL MICROBIOL, V25, P495, DOI 10.1046/j.1365-2958.1997.4831853.x; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWAB M, 1991, MOL MICROBIOL, V5, P439, DOI 10.1111/j.1365-2958.1991.tb02127.x; SCHWAB M, 1993, MOL MICROBIOL, V7, P795, DOI 10.1111/j.1365-2958.1993.tb01170.x; Schwehm JM, 1998, METHOD ENZYMOL, V295, P150; Stafford WF, 2000, METHOD ENZYMOL, V323, P302; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STITES WE, 1995, ANAL BIOCHEM, V227, P112, DOI 10.1006/abio.1995.1259; Stockner T, 2001, BIOCHEMISTRY-US, V40, P3370, DOI 10.1021/bi002031c; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Verdino P, 1999, J BIOL CHEM, V274, P37421, DOI 10.1074/jbc.274.52.37421; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	44	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10400	10407		10.1074/jbc.M212502200	http://dx.doi.org/10.1074/jbc.M212502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529360	hybrid			2022-12-25	WOS:000181777500056
J	Clark, MJ; Harrison, C; Zhong, HL; Neubig, RR; Traynor, JR				Clark, MJ; Harrison, C; Zhong, HL; Neubig, RR; Traynor, JR			Endogenous RGS protein action modulates mu-opioid signaling through G alpha(o) - Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; C6 GLIOMA-CELLS; RECEPTOR DESENSITIZATION; EXPRESSION ANALYSIS; MOLECULAR-CLONING; BINDING; SPECIFICITY; ACTIVATION; TOLERANCE; FAMILY	RGS (regulators of G protein signaling) proteins are GTPase-activating proteins for the Galpha subunits of heterotrimeric G proteins and act to regulate signaling by rapidly cycling G protein. RGS proteins may integrate receptors and signaling pathways by physical or kinetic scaffolding mechanisms. To determine whether this results in enhancement and/or selectivity of agonist signaling, we have prepared C6 cells stably expressing the mu-opioid receptor and either pertussis toxin-insensitive or RGS- and pertussis toxin-insensitive Galpha(o). We have compared the activation of G protein, inhibition of adenylyl cyclase, stimulation of intracellular calcium release, and activation of the ERK1/2 MAPK pathway between cells expressing mutant Galpha(o) that is either RGS-insensitive or RGS-sensitive. The mu-receptor agonist [D-Ala(2), MePhe(4),Gly(5)-ol]enkephalin and partial agonist morphine were much more potent and/or had an increased maximal effect in inhibiting adenylyl cyclase and in activating MAPK in cells expressing RGS-insensitive Galpha(o). In contrast, mu-opioid agonist increases in intracellular calcium were less affected. The results are consistent with the hypothesis that the GTPase-activating protein activity of RGS proteins provides a control that limits agonist action through effector pathways and may contribute to selectivity of activation of intracellular signaling pathways.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med Hypertens, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Traynor, JR (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	jtraynor@umich.edu		Neubig, Richard/0000-0003-0501-0008	NIDA NIH HHS [DA 04087] Funding Source: Medline; NIGMS NIH HHS [GM 39561] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004087] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Borgland S, 2001, CLIN EXP PHARMACOL P, V28, P147, DOI 10.1046/j.1440-1681.2001.03418.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Garzon J, 2001, EUR J NEUROSCI, V13, P801, DOI 10.1046/j.0953-816x.2000.01444.x; Gutstein HB, 1997, ANESTHESIOLOGY, V87, P1118, DOI 10.1097/00000542-199711000-00016; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; JIN WZ, 1994, J NEUROSCI, V14, P1920; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; Li LY, 1996, MOL PHARMACOL, V50, P599; Lione AM, 2000, J NEUROCHEM, V75, P934, DOI 10.1046/j.1471-4159.2000.0750934.x; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1988, BIOCHEM J, V255, P1; Moon HE, 2001, J NEUROCHEM, V76, P1805, DOI 10.1046/j.1471-4159.2001.00196.x; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Potenza MN, 1999, J PHARMACOL EXP THER, V291, P482; Remmers AE, 2000, EUR J PHARMACOL, V396, P67, DOI 10.1016/S0014-2999(00)00212-0; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; SHARMA SK, 1987, J NEUROSCI RES, V17, P135, DOI 10.1002/jnr.490170207; Smart D, 1996, TRENDS PHARMACOL SCI, V17, P264, DOI 10.1016/S0165-6147(96)10023-7; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Snow BE, 2002, METHOD ENZYMOL, V344, P740; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200; Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0	42	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9418	9425		10.1074/jbc.M208885200	http://dx.doi.org/10.1074/jbc.M208885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524446	hybrid			2022-12-25	WOS:000181524000073
J	Li, YW; Gonzalez, MI; Meinkoth, JL; Field, J; Kazanietz, MG; Tennekoon, GI				Li, YW; Gonzalez, MI; Meinkoth, JL; Field, J; Kazanietz, MG; Tennekoon, GI			Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; BINDING PROTEIN-RHO; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; FOCAL ADHESIONS; MAMMALIAN-CELLS; PERIPHERAL-NERVE; STRESS FIBERS; GROWTH-FACTOR; KINASE	Lysophosphatidic acid (LPA; 1-acyl-sn-glycerol-3-phosphate), an abundant constituent of serum, mediates multiple biological responses via G protein-coupled serpentine receptors. Schwann cells express the LPA receptors (Edg receptors), which, once activated, have the potential to signal through G(alphai) to activate p21(ras) and phosphatidylinositol 3-kinase, through G(alphaq) to activate phospholipase C, or through G(q12/13) to activate the Rho pathway. We found that the addition of serum or LPA to serum-starved Schwann cells rapidly (10 min) induced the appearance of actin stress fibers via a Rho-mediated pathway. Furthermore, LPA was able to rescue Schwann cells from apoptosis in a G(alphai)/phosphatidylinositol 3-kinase/MEK/MAPK-dependent manner. In addition, LPA increased the expression of myelin protein P-0 in Schwann cells in a G(alphai)-independent manner but dependent on protein kinase C. By means of pharmacological and overexpression approaches, we found that the novel isozyme protein kinase Cdelta was required for myelin P-0 expression. Thus, the multiple effects of LPA in Schwann cells (actin reorganization, survival. and myelin gene expression) appear to be mediated through the different G protein-dependent pathways activated by the LPA receptor.	Univ Penn, Sch Med, Dept Neurol & Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Tennekoon, GI (corresponding author), 514 Abramson Bldg,3400 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	tennekoon@email.chop.edu	Meinkoth, Judy L/G-2900-2010		NCI NIH HHS [R01 CA89202] Funding Source: Medline; NINDS NIH HHS [R01 NS21700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGUAYO AJ, 1976, J NEUROCYTOL, V5, P137, DOI 10.1007/BF01181653; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BORGHINI I, 1994, J NEUROCHEM, V62, P686; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE MB, 1986, ANN NY ACAD SCI, V486, P241; BUNGE RP, 1986, ANNU REV NEUROSCI, V9, P305; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Cheng LL, 1996, NEURON, V16, P309, DOI 10.1016/S0896-6273(00)80049-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FernandezValle C, 1997, J NEUROSCI, V17, P241, DOI 10.1523/JNEUROSCI.17-01-00241.1997; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD RM, 1992, CELL SCHWANN UPDATE, P123; Grinspan JB, 1996, J NEUROSCI, V16, P6107; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Jessen KR, 1999, ANN NY ACAD SCI, V883, P109, DOI 10.1111/j.1749-6632.1999.tb08573.x; Kaibuchi K, 1999, Prog Mol Subcell Biol, V22, P23; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Maurel P, 2000, J NEUROSCI, V20, P4635, DOI 10.1523/JNEUROSCI.20-12-04635.2000; MEWS M, 1993, GLIA, V8, P208, DOI 10.1002/glia.440080308; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; PORTER S, 1986, J NEUROSCI, V6, P3070; SOBUE G, 1984, SCIENCE, V224, P72, DOI 10.1126/science.6322307; Swarthout JT, 2000, CELL MOL LIFE SCI, V57, P1978, DOI 10.1007/PL00000678; Syroid DE, 1999, J NEUROSCI, V19, P2059; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; VAN AL, 1997, GENE DEV, V11, P2295; WADHWANI KC, 1994, PROG NEUROBIOL, V43, P235, DOI 10.1016/0301-0082(94)90002-7; Weiner JA, 2001, J NEUROSCI, V21, P7069, DOI 10.1523/JNEUROSCI.21-18-07069.2001; Weiner JA, 1998, J COMP NEUROL, V398, P587; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898	52	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9585	9591		10.1074/jbc.M213244200	http://dx.doi.org/10.1074/jbc.M213244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524451	hybrid			2022-12-25	WOS:000181524000094
J	Segall, L; Javaid, ZZ; Carl, SL; Lane, LK; Blostein, R				Segall, L; Javaid, ZZ; Carl, SL; Lane, LK; Blostein, R			Structural basis for alpha 1 versus alpha 2 isoform-distinct behavior of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE/FUNCTION ANALYSIS; FUNCTIONAL CONSEQUENCES; NA+,K+-ATPASE ACTIVITY; CONFORMATIONAL-CHANGES; CYTOPLASMIC DOMAIN; CATALYTIC SUBUNIT; CALCIUM-PUMP; PHOSPHORYLATION; ACTIVATION; CELLS	We showed earlier that the kinetic behavior of the alpha2 isoform of the Na,K-ATPase differs from the ubiquitous alpha1 isoform primarily by a shift in the steady-state E-1/E-2, equilibrium of alpha2 in favor of E-1 form(s). The aim of the present study was to identify regions of the alpha chain that confer the alpha1/alpha2 distinct behavior using a mutagenesis and chimera approach. Criteria to assess shifts in conformational equilibrium included (i) K+ sensitivity of Na-ATPase measured at micromolar ATP, under which condition E-2(K+) --> E-1 + K+ becomes rate-limiting, (ii) changes in K'(ATP) for low affinity ATP binding, (iii) vanadate sensitivity of Na,K-ATPase activity, and (iv) the rate of the partial reaction E1P --> E(2)p. We first confirmed that interactions between the cytoplasmic domains of alpha2 that modulate conformational shifts are fundamentally similar to those of alpha1, suggesting that the predilection of alpha2 for E-1 state(s) is due to differences in primary structure of the two isoforms. Kinetic behavior of the alpha1/alpha2 chimeras indicates that the difference in E-1/E-2 poise of the two isoforms cannot be accounted for by their notably distinct N termini, but rather by the front segment extending from the cytoplasmic N terminus to the C-terminal end of the extracellular loop between transmembranes 3 and 4, with a lesser contribution of the alpha1/alpha2 divergent portion within the M4-M5 loop near the ATP binding domain. In addition, we show that the E-1 shift of alpha2 results primarily from differences in the conformational transition of the dephosphoenzyme, (E-2(K+) --> E-1 + K+), rather than phosphoenzyme (E1P --> E2P).	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	McGill University; University System of Ohio; University of Cincinnati	Blostein, R (corresponding author), Montreal Gen Hosp, Res Inst, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	rhoda.blostein@mcgill.ca			NHLBI NIH HHS [HL 49204] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049204] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Blanco G, 1998, ARCH BIOCHEM BIOPHYS, V359, P139, DOI 10.1006/abbi.1998.0904; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Coppi MV, 1999, BIOCHEMISTRY-US, V38, P2494, DOI 10.1021/bi982180j; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1997, J BIOL CHEM, V272, P6341, DOI 10.1074/jbc.272.10.6341; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Feraille E, 1999, MOL BIOL CELL, V10, P2847, DOI 10.1091/mbc.10.9.2847; FERAILLE E, 1994, AM J PHYSIOL, V267, pF55, DOI 10.1152/ajprenal.1994.267.1.F55; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KLODOS I, 1994, J BIOL CHEM, V269, P1734; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1993, J BIOL CHEM, V268, P17930; Lavoie L, 1996, AM J PHYSIOL-CELL PH, V270, pC1421, DOI 10.1152/ajpcell.1996.270.5.C1421; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; Patchornik G, 2002, BIOCHEMISTRY-US, V41, P11740, DOI 10.1021/bi026334d; Pierre SV, 2002, AM J PHYSIOL-RENAL, V283, pF1066, DOI 10.1152/ajprenal.00153.2002; POST RL, 1972, J BIOL CHEM, V247, P6530; SAMPSON SR, 1994, AM J PHYSIOL, V266, pC751, DOI 10.1152/ajpcell.1994.266.3.C751; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; Segall L, 2001, J BIOL CHEM, V276, P31535, DOI 10.1074/jbc.M103720200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	33	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9027	9034		10.1074/jbc.M211636200	http://dx.doi.org/10.1074/jbc.M211636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12529322	hybrid			2022-12-25	WOS:000181524000022
J	Millan, O; Ballester, A; Castrillo, A; de la Oliva, JL; Traves, PG; Rojas, JM; Bosca, L				Millan, O; Ballester, A; Castrillo, A; de la Oliva, JL; Traves, PG; Rojas, JM; Bosca, L			H-Ras-specific activation of NF-kappa B protects NIH 3T3 cells against stimulus-dependent apoptosis	ONCOGENE			English	Article						survival; nuclear factor kappa B; apoptosis; TNF alpha; staurosporine	NITRIC-OXIDE SYNTHASE; ONCOGENIC RAS; TRANSCRIPTIONAL ACTIVITY; KINASE; INDUCTION; EXPRESSION; TRANSFORMATION; INHIBITION; PROTEINS; SUBUNIT	Ras signaling involves the activation of several downstream pathways that exhibit isoform specificity. In this study, the basal and tumor necrosis factor alpha (TNFalpha)-induced activation. of NF-kappaB has been examined in cells overexpressing H-Ras, K-Ras or N-Ras. Cells expressing H-Ras exhibited a basal kappaB activity that correlated with sustained IkappaB kinase activation and lower steady-state levels of IkappaBalpha in the cytosol. Upon activation with TNFalpha, the cells expressing the distinct Ras. isoforms behaved similarly in terms of binding of nuclear proteins to a kappaB sequence and induction of a kappaB-dependent reporter gene. The basal activation of NF-kappaB in cells expressing H-Ras impaired staurosporine-induced apoptosis in these cells, through a mechanism that was NF-kappaB-dependent and inhibitable in the presence of z-VAD. Moreover, titration of caspase activation in response to staurosporine showed a significant resistance in cells expressing H-Ras when compared with the void vector or the N-Ras counterparts. These results indicate that the distinct Ras proteins have specific effects on the NF-kappaB pathway and that this action contributes to protect cells against apoptosis.	Univ Complutense, Fac Farm, Inst Bioquim, Ctr Mixto CSIC UCM, Madrid 28040, Spain; Univ Complutense, Fac Farm, Inst Bioquim, Ctr Nacl Invest Cardiovasc, Madrid 28040, Spain; Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biol Celular, Majadahonda, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Bosca, L (corresponding author), Univ Complutense, Fac Farm, Inst Bioquim, Ctr Mixto CSIC UCM, Madrid 28040, Spain.	boscal@farm.ucm.es	Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; G. Traves, Paqui/L-5693-2014; Bosca, Lisardo/A-2059-2008	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; G. Traves, Paqui/0000-0001-5749-8426; Bosca, Lisardo/0000-0002-0253-5469; Ballester Jareno, Alicia/0000-0002-6474-7248				Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Downward J, 1996, CANCER SURV, V27, P87; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Grana TM, 2002, CANCER RES, V62, P4142; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hortelano S, 2002, CELL DEATH DIFFER, V9, P643, DOI 10.1038/sj.cdd.4401017; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ludwig L, 2001, CANCER RES, V61, P4526; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Prior IA, 2001, J CELL SCI, V114, P1603; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yan F, 2001, CANCER RES, V61, P8668; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	44	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					477	483		10.1038/sj.onc.1206179	http://dx.doi.org/10.1038/sj.onc.1206179			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555061				2022-12-25	WOS:000180538200001
J	Loreto, MP; McGlade, CJ				Loreto, MP; McGlade, CJ			Cloning and characterization of human Src-like adaptor protein 2 and a novel splice isoform, SLAP-2-v	ONCOGENE			English	Article						adaptor protein; SLAP-2; SLAP; splice variant; TCR; myeloid; chromosome 20q	T-CELL RECEPTOR; TYROSINE KINASE; C-CBL; PHOSPHORYLATION SITE; NEGATIVE REGULATOR; MYELOID-LEUKEMIA; ZAP-70; LAT; IDENTIFICATION; THYMOCYTES	Src-like adaptor protein 2 (SLAP-2) is a recently characterized adaptor protein bearing sequence and structural similarity to the Src-like adaptor protein (SLAP). SLAP-2 expression is hematopoietic-specific, and it has been demonstrated to function as a negative regulator of T-cell antigen receptor (TCR)-mediated signalling by virtue of its interaction with c-Cbl. Here we report the cloning of a cDNA encoding the human homologue of SLAP-2, as well as the genomic structure of the human SLAP-2 gene. Similar to its murine counterpart, two human SLAP-2 protein isoforms exist because of alternative translation initiation, and SLAP-2 protein expression is observed in a variety of hernatopoietic cell tines of both lymphoid and myeloid lineages. The human SLAP-2 gene is located on chromosome 20q, and the SLAP-2 coding region consists of seven exons. Concurrent with the cloning of the full-length SLAP-2 cDNA, a unique cDNA encoding an alternatively spliced SLAP-2 isoform has been identified, and designated as SLAP-2-v. The SLAP-2-v transcript encodes a putative protein of 210 amino acids that lacks the c-Cbl interaction region, and consequently is impaired in its ability to both bind to c-Cbl, and inhibit TCR signalling relative to SLAP-2.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave,Rm 3020B, Toronto, ON M5G 1X8, Canada.							Berry DM, 2001, ONCOGENE, V20, P1203, DOI 10.1038/sj.onc.1204218; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Holland SJ, 2001, J EXP MED, V194, P1263, DOI 10.1084/jem.194.9.1263; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kratchmarova I, 2001, GENE, V262, P267, DOI 10.1016/S0378-1119(00)00516-3; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Loreto MP, 2002, MOL CELL BIOL, V22, P4241, DOI 10.1128/MCB.22.12.4241-4255.2002; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MacGrogan D, 2001, ONCOGENE, V20, P4150, DOI 10.1038/sj.onc.1204540; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Pandey A, 2002, J BIOL CHEM, V277, P19131, DOI 10.1074/jbc.M110318200; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; ROULSTON D, 1993, BLOOD, V82, P3424; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Thien CBF, 1999, J IMMUNOL, V162, P7133; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	23	10	12	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					266	273		10.1038/sj.onc.1206114	http://dx.doi.org/10.1038/sj.onc.1206114			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527895				2022-12-25	WOS:000180322400011
J	Fukuma, M; Okita, H; Hata, J; Umezawa, A				Fukuma, M; Okita, H; Hata, J; Umezawa, A			Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma	ONCOGENE			English	Article						Ewing sarcoma; Id2; EWS/ets; chimeric protein	DNA-BINDING; EWS GENE; TRANSCRIPTIONAL ACTIVATION; FUSION PROTEIN; CELL-CYCLE; ETS; EXPRESSION; FAMILY; TRANSLOCATION; EWS-FLI1	The chromosomal translocation specifically linked to the Ewing sarcoma family results in the generation of fusion proteins comprising the amino terminal portion of EWS and the DNA-binding domain of ets transcription factors. The EWS/ets chimeric proteins act as aberrant transcription factors leading to tumorigenic processes. We searched for genes specifically activated in Ewing sarcoma cells but not in other tumor cell lines using the gene array technique, and found significantly enhanced expression of the Id2 gene. High levels of Id2 transcripts were detected in Ewing sarcoma cell lines and tumor tissues. The EWS/ ets chimeric proteins activated the Id2 gene via the 5'-upstream promoter sequence. Chromatin-immunoprecipitation revealed a direct interaction of EWS/Fli-1 with the promoter regions of the 142, TGF-beta type 11 receptor, cyclin D1, and c-myc genes. Since EWS/Fti-1 transactivates c-myc, a cooperative action of the chimeric protein and c-myc leads to overexpression of Id2. In the present study, we suggest that Id2 is a target of the chimeric proteins and that the c-myc/Id2 pathway plays a pivotal role in the tumorigenic processes provoked by EWS/ets proteins.	Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Umezawa, A (corresponding author), Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	umezawa@1985.jukuin.keio.ac.jp						BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; Edelman GM, 2000, P NATL ACAD SCI USA, V97, P3038, DOI 10.1073/pnas.040569897; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Im YH, 2000, CANCER RES, V60, P1536; JEON IS, 1995, ONCOGENE, V10, P1229; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; NOGUERA R, 1992, LAB INVEST, V66, P143; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OHNO T, 1994, ONCOGENE, V9, P3087; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sugimoto T, 1997, VIRCHOWS ARCH, V430, P41, DOI 10.1007/BF01008015; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Urano F, 1998, JPN J CANCER RES, V89, P703, DOI 10.1111/j.1349-7006.1998.tb03274.x; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	37	83	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					1	9		10.1038/sj.onc.1206055	http://dx.doi.org/10.1038/sj.onc.1206055			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527902				2022-12-25	WOS:000180166900001
J	Honorio, S; Agathanggelou, A; Schuermann, M; Pankow, W; Viacava, P; Maher, ER; Latif, F				Honorio, S; Agathanggelou, A; Schuermann, M; Pankow, W; Viacava, P; Maher, ER; Latif, F			Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients	ONCOGENE			English	Article						methylation; RASSF1A; sputum; ductal carcinoma in situ	FREQUENT EPIGENETIC INACTIVATION; TUMOR-SUPPRESSOR GENE; LUNG-CANCER; CPG ISLAND; 3P21.3; REGION; METHYLATION; LOCUS	The newly identified 3p21.3 tumour suppressor gene RASSF1A is methylated in the majority of primary lung tumours, lung tumour cell lines and in a variable percentage of breast tumours. To determine the extent of RASSF1A promoter hypermethylation in early lung tumorigenesis, we analysed sputum samples from lung cancer patients and from current and former smokers using a sensitive methylation-specific PCR (MSP) technique. We also analysed RASSF1A promoter region hypermethylation in trios of normal breast/invasive ductal breast carcinoma/ductal carcinoma in situ (DCIS) from breast cancer patients and DCIS without invasive cancer. We found that 50% of small cell lung cancer (SCLC) and 21% of non-small cell lung cancer (NSCLC) patients had RASSF1A methylation, while one of two former smokers and four of 13 current smokers demonstrated RASSF1A methylation in sputum. Furthermore, two of the four current smokers and one former smoker showing RASSF1A methylation in their sputum developed cancer within 12-14 months of bronchoscopy. In our breast cancer trios, RASSF1A promoter hypermethylation was detected in 65% of invasive cancers, in 42% of corresponding DCIS but in none of the normal breast samples. In addition, we found that three out of 10 DCIS without invasive breast cancer also underwent RASSF1A promoter hypermethylation. Our findings suggest that RASSF1A promoter region hypermethylation may be a useful molecular marker for early detection of lung cancer. Furthermore, since RASSF1A promoter hypermethylation was detected in ductal carcinoma in situ, inactivation of RASSF1A may be an early event in breast tumorigenesis.	Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England; Univ Marburg, D-35033 Marburg, Germany; Krankenhaus Neukolln, Abt Innere Med 3, Schwerpunkt Pneumonol Infektiol, Berlin, Germany; Univ Pisa, Dept Oncol, Div Pathol, Pisa, Italy	University of Birmingham; Philipps University Marburg; University of Pisa	Latif, F (corresponding author), Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Caligo, Adelaide Maria/K-4289-2018; MAHER, EAMONN R/A-9507-2008	Caligo, Adelaide Maria/0000-0003-0589-1829; MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Belinsky SA, 2002, CANCER RES, V62, P2370; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Lo KW, 2001, CANCER RES, V61, P3877; Morrissey C, 2001, CANCER RES, V61, P7277; Palmisano WA, 2000, CANCER RES, V60, P5954; Vlacava P, 1999, J PATHOL, V188, P245	17	94	104	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					147	150		10.1038/sj.onc.1206057	http://dx.doi.org/10.1038/sj.onc.1206057			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527916				2022-12-25	WOS:000180166900015
J	Mzhavia, N; Pan, H; Che, FY; Fricker, LD; Devi, LA				Mzhavia, N; Pan, H; Che, FY; Fricker, LD; Devi, LA			Characterization of endothelin-converting enzyme-2 - Implication for a role in the nonclassical processing of regulatory peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; PROENKEPHALIN-A; PROPROTEIN CONVERTASES; FAMILY; GENE; PURIFICATION; EXPRESSION; PROSAAS; BRAIN; METALLOPROTEASE	Most neuroendocrine peptides are generated by proteolysis of the precursors at basic residue cleavage sites. Prohormone convertases belonging to the subtilisin family of serine proteases are primarily responsible, for processing at these "classical sites." In addition to the classical cleavages, a subset of bioactive peptides is generated by processing at "nonclassical" sites. The proteases responsible for these cleavages have not been well explored. Members of several metalloprotease families have been proposed to be involved in nonclassical processing. Among them, endothelin-converting enzyme-2 (ECE-2) is a good candidate because it exhibits a neuroendocrine distribution and an acidic pH optimum. To examine the involvement of this protease in neuropeptide processing, we purified the recombinant enzyme and characterized its catalytic activity. Purified ECE-2 efficiently processes big endothelin-1 to endothelin-1 by cleavage between Trp(21) and Val(22) at acidic pH. To characterize the substrate specificity of ECE-2, we used mass spectrometry with a panel of 42 peptides as substrates to identify the products. Only 10 of these 42 peptides were processed by ECE-2. A comparison of residues around the cleavage site revealed that ECE-2 exhibits a unique cleavage site selectivity that is related to but distinct from that of ECE-1. ECE-2 tolerates a wide range of amino acids in the P1-position and prefers aliphatic/aromatic residues in the P1'-position. However, only a small fraction of the aliphatic/aromatic amino acid-containing sites were cleaved, indicating that there are additional constraints beyond the P1- and P1'-positions. The enzyme is able to generate a number of biologically active peptides from peptide intermediates, suggesting an important role for this enzyme in the biosynthesis of regulatory peptides. Also, ECE-2 processes proenkephalin-derived bovine adrenal medulla peptides, and this processing leads to peptide products known to have differential receptor selectivity. Finally, ECE-2 processes PEN-LEN, an endogenous inhibitor of prohormone convertase 1, into products that do not inhibit the enzyme. Taken together, these results are consistent with an important role for ECE-2 in the processing of regulatory peptides at nonclassical sites.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	Lakshmi.Devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Mzhavia, Nino/0000-0001-8602-9987	NIDA NIH HHS [DA00458, DA 04494, K02 DA000458, R01 DA004494] Funding Source: Medline; NINDS NIH HHS [R01 NS026880, NS 26880] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026880, R01NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000458] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; Che FY, 2001, P NATL ACAD SCI USA, V98, P9971, DOI 10.1073/pnas.161542198; Davenport AP, 2000, J CARDIOVASC PHARM, V36, pS12, DOI 10.1097/00005344-200036051-00006; DAVIS TP, 1990, EUR J PHARMACOL, V191, P253, DOI 10.1016/0014-2999(90)94157-S; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DRAY A, 1985, J PHARMACOL EXP THER, V235, P670; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Fahnoe DC, 2000, ARCH BIOCHEM BIOPHYS, V373, P385, DOI 10.1006/abbi.1999.1586; Fahnoe DC, 2000, J CARDIOVASC PHARM, V36, pS22, DOI 10.1097/00005344-200036051-00009; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; Ikeda S, 2002, BIOCHEM BIOPH RES CO, V293, P421, DOI 10.1016/S0006-291X(02)00252-8; Johnson GD, 2000, ANAL BIOCHEM, V286, P112, DOI 10.1006/abio.2000.4772; Johnson GD, 2002, ARCH BIOCHEM BIOPHYS, V398, P240, DOI 10.1006/abbi.2001.2708; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Lembo PMC, 2002, NAT NEUROSCI, V5, P201, DOI 10.1038/nn815; Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V97, P1283, DOI 10.1016/S0006-291X(80)80005-2; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V95, P1482, DOI 10.1016/S0006-291X(80)80064-7; Molineaux C, 1991, PEPTIDE BIOSYNTHESIS, P251; Mzhavia N, 1999, DNA CELL BIOL, V18, P369, DOI 10.1089/104454999315268; Mzhavia N, 2002, BIOCHEM J, V361, P67, DOI 10.1042/0264-6021:3610067; Mzhavia N, 2001, J BIOL CHEM, V276, P6207, DOI 10.1074/jbc.M009067200; Nakagomi S, 2000, NEUROSCIENCE, V101, P441, DOI 10.1016/S0306-4522(00)00345-6; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PITTIUS CW, 1984, BRAIN RES, V304, P127, DOI 10.1016/0006-8993(84)90868-0; PITTIUS CW, 1983, LIFE SCI, V33, P41, DOI 10.1016/0024-3205(83)90439-3; Qian YM, 2000, J BIOL CHEM, V275, P23596, DOI 10.1074/jbc.M001583200; Russell FD, 1999, CIRC RES, V84, P891; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; Seidah NG, 1999, ANN NY ACAD SCI, V885, P57; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; SIGAFOOS J, 1993, J ANAT, V183, P253; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; Vilim FS, 1999, MOL PHARMACOL, V55, P804; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	43	40	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14704	14711		10.1074/jbc.M211242200	http://dx.doi.org/10.1074/jbc.M211242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12560336	Green Accepted, hybrid			2022-12-25	WOS:000182516100017
J	Ibata-Ombetta, S; Idziorek, T; Trinel, PA; Poulain, D; Jouault, T				Ibata-Ombetta, S; Idziorek, T; Trinel, PA; Poulain, D; Jouault, T			Candida albicans phospholipomannan promotes survival of phagocytosed yeasts through modulation of bad phosphorylation and macrophage apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-DEATH; BETA-1,2-LINKED OLIGOMANNOSIDES; CERAMIDE; ACTIVATION; INFECTION; INHIBITION; PATHWAY; SUPPRESSION; FAMILY	The surface of the pathogenic yeast Candida albicans is coated with phospholipomannan (PLM), a phylogenetically unique glycolipid composed of beta-1,2-oligomannosides and phytoceramide. This study compared the specific contribution of PLM to the modulation of signaling pathways linked to the survival of C. albicans in macrophages in contrast to Saccharomyces cerevisiae. C. albicans endocytosis by J774 and disregulation of the ERK1/2 signal transduction pathway was associated downstream with a reduction in Bad Ser-112 phosphorylation and disappearance of free Bcl-2. This suggested an apoptotic effect, which was confirmed by staining of phosphatidylserine in the macrophage outer membrane. The addition of PLM to macrophages incubated with S. cerevisiae mimicked each of the disregulation steps observed with C. albicans and promoted the survival of S. cerevisiae. Externalization of membranous phosphatidylserine, loss of mitochondrial integrity, and DNA fragmentation induced by PLM showed that this molecule promoted yeast survival by inducing host cell death. These findings suggest strongly that PLM is a virulence attribute of C. albicans and that elucidation of the relationship between structure and apoptotic activity is an innovative field of research.	Fac Med H Warembourg, INSERM U459, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Jouault, T (corresponding author), Univ Lille 2, Lab Mycol Fondamentale & Appl, Fac Med H Warembourg, INSERM EMI0360, Pole Rech,Pl Verdun, F-59037 Lille, France.	tjouault@univ-lille2.fr	Jouault, Thierry/I-1071-2018; Jouault, Thierry/J-7437-2012; Poulain, Daniel/I-6095-2018	Jouault, Thierry/0000-0003-1988-8647; Poulain, Daniel/0000-0002-0729-5468				Aga E, 2002, J IMMUNOL, V169, P898, DOI 10.4049/jimmunol.169.2.898; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Bourbon NA, 2001, AM J PHYSIOL-CELL PH, V280, pC1403, DOI 10.1152/ajpcell.2001.280.6.C1403; Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7; Calderone RA., 2002, CANDIDA CANDIDIASIS; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Fradin C, 1996, J LEUKOCYTE BIOL, V60, P81, DOI 10.1002/jlb.60.1.81; Freire-de-Lima CG, 1998, J IMMUNOL, V161, P4909; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; Gilmore K, 1999, CYTOMETRY, V36, P355, DOI 10.1002/(SICI)1097-0320(19990801)36:4<355::AID-CYTO11>3.0.CO;2-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hacker H, 2002, J IMMUNOL, V169, P3172, DOI 10.4049/jimmunol.169.6.3172; Heidenreich S, 1996, J LEUKOCYTE BIOL, V60, P737, DOI 10.1002/jlb.60.6.737; Heussler VT, 2001, INT J PARASITOL, V31, P1166, DOI 10.1016/S0020-7519(01)00271-5; Ibata-Ombetta S, 2001, J LEUKOCYTE BIOL, V70, P149; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Jouault T, 1998, J INFECT DIS, V178, P792, DOI 10.1086/515361; JOUAULT T, 1994, IMMUNOLOGY, V83, P268; JOUAULT T, 1995, INFECT IMMUN, V63, P2378, DOI 10.1128/IAI.63.6.2378-2381.1995; Jouault T, 2000, INFECT IMMUN, V68, P965, DOI 10.1128/IAI.68.2.965-968.2000; Kanto T, 2001, J IMMUNOL, V167, P3773, DOI 10.4049/jimmunol.167.7.3773; Kim DS, 2001, PIGM CELL RES, V14, P110, DOI 10.1034/j.1600-0749.2001.140206.x; Kitatani K, 2001, ARCH BIOCHEM BIOPHYS, V395, P208, DOI 10.1006/abbi.2001.2573; Kornfeld H, 1999, CELL DEATH DIFFER, V6, P71, DOI 10.1038/sj.cdd.4400454; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Lee JS, 2001, FEBS LETT, V499, P82, DOI 10.1016/S0014-5793(01)02527-3; Liu GL, 1999, CRIT REV CL LAB SCI, V36, P511, DOI 10.1080/10408369991239240; Luberto C, 2001, GENE DEV, V15, P201, DOI 10.1101/gad.856001; Luder CGK, 2001, TRENDS PARASITOL, V17, P480, DOI 10.1016/S1471-4922(01)02093-1; Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Monack D, 2000, INT J MED MICROBIOL, V290, P7; MOORE KJ, 1994, J IMMUNOL, V152, P2930; Navarre WW, 2000, CELL MICROBIOL, V2, P265, DOI 10.1046/j.1462-5822.2000.00056.x; Orth K, 2002, CURR OPIN MICROBIOL, V5, P38, DOI 10.1016/S1369-5274(02)00283-7; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V30, P121, DOI 10.1016/S0732-8893(97)00192-2; Poulain D, 2002, INFECT IMMUN, V70, P4323, DOI 10.1128/IAI.70.8.4323-4328.2002; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; Ropert C, 2000, CURR OPIN MICROBIOL, V3, P395, DOI 10.1016/S1369-5274(00)00111-9; Rotstein D, 2000, SHOCK, V14, P278, DOI 10.1097/00024382-200014030-00006; Ruvolo PP, 2001, LEUKEMIA, V15, P1153, DOI 10.1038/sj.leu.2402197; Santos RL, 2001, INFECT IMMUN, V69, P2293, DOI 10.1128/IAI.69.4.2293-2301.2001; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schroppel K, 2001, INT J MED MICROBIOL, V290, P659, DOI 10.1016/S1438-4221(01)80003-5; Shibayama K, 2001, INFECT IMMUN, V69, P3181, DOI 10.1128/IAI.69.5.3181-3189.2001; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; TamiyaKoizumi K, 1997, BIOCHEM MOL BIOL INT, V41, P1179; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200; TRINEL PA, 1993, INFECT IMMUN, V61, P4398, DOI 10.1128/IAI.61.10.4398-4405.1993; Trinel PA, 1999, J BIOL CHEM, V274, P30520, DOI 10.1074/jbc.274.43.30520; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497	56	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13086	13093		10.1074/jbc.M210680200	http://dx.doi.org/10.1074/jbc.M210680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551950	hybrid			2022-12-25	WOS:000182189500064
J	Pias, EK; Ekshyyan, OY; Rhoads, CA; Fuseler, J; Harrison, L; Aw, TY				Pias, EK; Ekshyyan, OY; Rhoads, CA; Fuseler, J; Harrison, L; Aw, TY			Differential effects of superoxide dismutase isoform expression on hydroperoxide-induced apoptosis in PC-12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; OXIDATIVE STRESS; DOWNS-SYNDROME; CYTOCHROME-C; MITOCHONDRIAL GENERATION; ELEVATED LEVEL; OVEREXPRESSION; CUZNSOD; DAMAGE; MOUSE	The current study examines the contribution of mitochondria-derived reactive oxygen species (ROS) in tertbutyl-hydroperoxide (TBH)-induced apoptotic signaling using clones of undifferentiated pheochromocytoma (PC-12) cells that stably overexpress the human mitochondrial or cytoplasmic forms of superoxide dismutase (SOD) (viz. Mn-SOD or CuZn-SOD, respectively). Exposure of wild type cells to TBH caused an early generation of ROS (30 min) that resulted in cell apoptosis at 24 h. These responses were attenuated with N-acetylcysteine pretreatment; however, N-acetylcysteine as ineffective in cytoprotection when added after TBH-induced ROS formation. Stable overexpression of SOD isoforms caused a 2- and 3.5-fold elevation in CuZn-SOD and Mn-SOD activities in the cytoplasm and mitochondria, respectively, and 3-fold increases in cellular GSH content. Accordingly, the stable overexpression of M-nSOD attenuated TBH-induced mitochondrial ROS generation and cell apoptosis. Whereas transient Mn-SOD expression similarly prevented PC-12 apoptosis, this was associated with increases in SOD activity but not GSH, indicating that cytoprotection by Mn-SOD overexpression is related to mitochondrial ROS elimination and not due to increases in cellular GSH content per se. Stable or transient CuZn-SOD overexpression exacerbated cell apoptosis in conjunction with accelerated caspase-3 activation, regardless of cell GSH levels. Collectively, our results support a role for mitochondrial ROS in TBH-induced PC-12 apoptosis that is attenuated by Mn-SOD overexpression and is independent of cellular GSH levels per se.	Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	taw@lsuhsc.edu		Hines, Erin Pias/0000-0002-2458-6267	NIDDK NIH HHS [DK 44510, R01 DK044510-10, R01 DK044510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON BS, 1985, ANAL BIOCHEM, V146, P164, DOI 10.1016/0003-2697(85)90411-7; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen ZY, 2000, FREE RADICAL BIO MED, V29, P589, DOI 10.1016/S0891-5849(00)00363-4; Golenser J, 1998, FREE RADICAL BIO MED, V24, P1504, DOI 10.1016/S0891-5849(98)00026-4; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRISHAM MB, 1990, INFLAMMATION, V14, P669, DOI 10.1007/BF00916370; GRONER Y, 1994, BIOMED PHARMACOTHER, V48, P231, DOI 10.1016/0753-3322(94)90138-4; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Lam EWN, 1999, FREE RADICAL BIO MED, V27, P572, DOI 10.1016/S0891-5849(99)00109-4; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Midorikawa K, 2001, FEBS LETT, V495, P187, DOI 10.1016/S0014-5793(01)02383-3; Paz-Miguel JE, 1999, J IMMUNOL, V163, P5399; PeledKamar M, 1997, P NATL ACAD SCI USA, V94, P3883, DOI 10.1073/pnas.94.8.3883; PELEDKAMAR M, 1995, EMBO J, V14, P4985, DOI 10.1002/j.1460-2075.1995.tb00181.x; Pias EK, 2002, FASEB J, V16, DOI 10.1096/fj.01-0784com; Pias EK, 2002, CELL DEATH DIFFER, V9, P1007, DOI 10.1038/sj.cdd.4401064; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Stefanis L, 1998, J NEUROSCI, V18, P9204; Turrens JF, 2001, MED HYPOTHESES, V56, P617, DOI 10.1054/mehy.2001.1327; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022	33	100	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13294	13301		10.1074/jbc.M208670200	http://dx.doi.org/10.1074/jbc.M208670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551919	hybrid			2022-12-25	WOS:000182189500089
J	Li, MG; Katsura, K; Nomiyama, H; Komaki, K; Ninomiya-Tsuji, J; Matsumoto, K; Kobayashi, T; Tamura, S				Li, MG; Katsura, K; Nomiyama, H; Komaki, K; Ninomiya-Tsuji, J; Matsumoto, K; Kobayashi, T; Tamura, S			Regulation of the interleukin-1-induced signaling pathways by a novel member of the protein phosphatase 2C family (PP2C epsilon)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SERINE-THREONINE PHOSPHATASE; MOLECULAR-CLONING; TAK1 MAPKKK; KAPPA-B; 2C; P38; TRANSDUCTION; JNK; EXPRESSION	Although TAK1 signaling plays essential roles in eliciting cellular responses to interleukin-1 (IL-1), a proinflammatory cytokine, how the IL-1-TAK1 signaling pathway is positively and negatively regulated remains poorly understood. In this study, we investigated the possible role of a novel protein phosphatase 2C (PP2C) family member, PP2Cepsilon, in the regulation of the IL-1-TAK1 signaling pathway. PP2Cepsilon was composed of 303 amino acids, and the overall similarity of amino acid sequence between PP2Cepsilon and PP2Calpha was found to be 26%. Ectopic expression of PP2Cepsilon inhibited the IL-1- and TAK1-induced activation of mitogen-activated protein kinase kinase 4 (MKK4)-c-Jun N-terminal kinase or MKK3-p38 signaling pathway. PP2Cepsilon dephosphorylated TAK1 in vitro. Co-immunoprecipitation experiments indicated that PP2Cepsilon associates stably with TAK1 and attenuates the binding of TAK1 to MKK4 or MKK6. Ectopic expression of a phosphatase-negative mutant of PP2Cepsilon, PP2Cepsilon(D/A), which acted as a dominant negative form, enhanced both the association between TAK1 and MKK4 or MKK6 and the TAK1-induced activation of an AP-1 reporter gene. The association between PP2Cepsilon and TAK1 was transiently suppressed by IL-1 treatment of the cells. Taken together, these results suggest that, in the absence of IL-1-induced signal, PP2Cepsilon contributes to keeping the TAK1 signaling pathway in an inactive state by associating with and dephosphorylating TAK1.	Tohoku Univ, Dept Biochem, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan; Japan Int Res Ctr Agr Sci, Biol Resources Div, Tsukuba, Ibaraki 3050851, Japan; Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Mol, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Tohoku University; Japan International Research Center for Agricultural Sciences; Kumamoto University; University of North Carolina; North Carolina State University; Nagoya University	Kobayashi, T (corresponding author), Tohoku Univ, Dept Biochem, Inst Dev Aging & Canc, Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.	takayasu@idac.tohoku.ac.jp; tamura@idac.tohoku.ac.jp	Nomiyama, Hisayuki/F-2840-2013	Nomiyama, Hisayuki/0000-0002-2716-4043; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KATO S, 1995, ARCH BIOCHEM BIOPHYS, V318, P387, DOI 10.1006/abbi.1995.1244; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kusuda K, 1998, BIOCHEM J, V332, P243, DOI 10.1042/bj3320243; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; Merlot S, 2001, PLANT J, V25, P295, DOI 10.1046/j.1365-313x.2001.00965.x; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; PILGRIM D, 1995, MOL BIOL CELL, V6, P1159, DOI 10.1091/mbc.6.9.1159; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; TAMURA S, 1978, BIOCHIM BIOPHYS ACTA, V524, P349, DOI 10.1016/0005-2744(78)90171-7; Tamura S, 2002, EUR J BIOCHEM, V269, P1060, DOI 10.1046/j.0014-2956.2002.02754.x; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	39	74	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12013	12021		10.1074/jbc.M211474200	http://dx.doi.org/10.1074/jbc.M211474200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556533	hybrid			2022-12-25	WOS:000182015700040
J	Muller, JR; Siebenlist, U				Muller, JR; Siebenlist, U			Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALYMPHOPLASIA ALY MICE; DEFICIENT MICE; SPLENIC MICROARCHITECTURE; TRANSCRIPTIONAL ACTIVITY; INCONTINENTIA PIGMENTI; LYMPHOID-TISSUES; CELL ACTIVATION; KINASE-ALPHA; IKK-ALPHA; ORGANOGENESIS	Lymphotoxin beta receptor (LTbetaR)-induced activation of NF-kappaB in mouse embryo fibroblasts was mediated by the classical pathway and by an alternative or second pathway. The classical pathway involved the IkappaB kinase (IKK)beta- and IKKgamma-dependent degradation of IkappaBalpha and resulted in the rapid but transient activation of primarily RelA-containing NF-kappaB dimers. The alternative or second pathway proceeded via NF-kappaB-inducing kinase (NIK)-, IKKalpha-, and protein synthesis-dependent processing of the inhibitory NF-kappaB2 p100 precursor protein to the p52 form and resulted in a delayed but sustained activation of primarily RelB-containing NF-kappaB dimers. This second pathway was independent of the classical IKK complex, which is governed by its central IKKgamma regulatory subunit. The sequential engagement of two distinct pathways, coupled with the negative feedback inhibition of RelA complexes by NF-kappaB-induced resynthesis of IkappaBalpha, resulted in a pronounced temporal change in the nature of the NF-kappaB activity during the course of stimulation. Initially dominant ReIA complexes were replaced with time by RelB complexes. Therefore, the alternative activation path mediated by processing of p100 was necessary for sustained NF-kappaB activity in mouse embryo fibroblasts in response to LTbetaR stimulation. Based on the phenotype of mice deficient in various components of the LTbetaR-induced activation of p100 processing, we conclude that this pathway is critically involved in the function of stromal cells during the generation of secondary lymphoid organ microarchitectures.	NIAID, NIH, Immunoregulat Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Siebenlist, U (corresponding author), NIAID, NIH, Immunoregulat Lab, Bldg 10,Rm 11B16, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000722, ZIAAI000722, Z01AI000723] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 2002, TARGETED THERAPIES R, P381; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Matsumoto M, 1999, J IMMUNOL, V163, P1584; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Paxian S, 2002, GASTROENTEROLOGY, V122, P1853, DOI 10.1053/gast.2002.33651; Poljak L, 1999, J IMMUNOL, V163, P6581; Scheu S, 2002, J EXP MED, V195, P1613, DOI 10.1084/jem.20020215; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Tamada K, 2002, J IMMUNOL, V168, P4832, DOI 10.4049/jimmunol.168.10.4832; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	34	143	148	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12006	12012		10.1074/jbc.M210768200	http://dx.doi.org/10.1074/jbc.M210768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556537	hybrid			2022-12-25	WOS:000182015700039
J	Snyder, H; Mensah, K; Theisler, C; Lee, J; Matouschek, A; Wolozin, B				Snyder, H; Mensah, K; Theisler, C; Lee, J; Matouschek, A; Wolozin, B			Aggregated and monomeric alpha-synuclein bind to the S6 ' proteasomal protein and inhibit proteasomal function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; PARKINSONS-DISEASE; LEWY BODIES; NEURODEGENERATIVE DISEASES; DEGRADATION SIGNAL; FIBRIL FORMATION; BETA-SYNUCLEIN; 20S PROTEASOME; UBIQUITIN; PROTEOLYSIS	The accumulation of aggregated a-synuclein is thought to contribute to the pathophysiology of Parkinson's disease, but the mechanism of toxicity is poorly understood. Recent studies suggest that aggregated proteins cause toxicity by inhibiting the ubiquitin-dependent proteasomal system. In the present study, we explore how alpha-synuclein interacts with the proteasome. The proteasome exists as a 26 S and a 20 S species. The 26 S proteasome is composed of the 19 S cap and the 20 S core. Aggregated alpha-synuclein strongly inhibited the function of the 26 S proteasome. The IC50 of aggregated a-synuclein for ubiquitin-independent 26 S proteasomal activity was 1 nm. Aggregated a-synuclein also inhibited 26 S ubiquitin-dependent proteasomal activity at a dose of 500 nm. In contrast, the IC50 of aggregated a-synuclein for 20 S proteasomal activity was > 1 mum. This suggests that aggregated a-synuclein selectively interacts with the 19 S cap. Monomeric a-synuclein also inhibited proteasomal activity but with lower affinity and less potency. Recombinant monomeric alpha-synuclein inhibited the activity of the 20 S proteasomal core with an IC50 > 10 pm, exhibited no inhibition of 26 S ubiquitin-dependent proteasomal activity at doses up to 5 mum, and exhibited only partial inhibition (50%) of the 26 S ubiquitin-independent proteasomal activity at doses up to 10 mm. Binding studies demonstrate that both aggregated and monomeric alpha-synuclein selectively bind to the proteasomal protein SW, a subunit of the 19 S cap. These studies suggest that proteasomal inhibition by aggregated alpha-synuclein could be mediated by interaction with S6'.	Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Northwestern Univ, Dept Biochem & Mol Biol, Evanston, IL 60208 USA	Loyola University Chicago; Loyola University Chicago; Northwestern University	Wolozin, B (corresponding author), Loyola Univ, Med Ctr, Dept Pharmacol, Bldg 102,Rm 3634,2160 S 1st Ave, Maywood, IL 60153 USA.		Matouschek, Andreas/L-9379-2013	Matouschek, Andreas/0000-0001-6016-2341	NINDS NIH HHS [NS41786] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Golts N, 2002, J BIOL CHEM, V277, P16116, DOI 10.1074/jbc.M107866200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; LEE HJ, 2001, J BIOL CHEM, V25, P25; LEE MK, 2002, P NATL ACAD SCI US, V99; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; PRONIN AN, 2000, J BIOL CHEM; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O	57	313	323	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11753	11759		10.1074/jbc.M208641200	http://dx.doi.org/10.1074/jbc.M208641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551928	hybrid			2022-12-25	WOS:000182015700006
J	Borge, PD; Wolf, BA				Borge, PD; Wolf, BA			Insulin receptor substrate 1 regulation of sarco-endoplasmic reticulum calcium ATPase 3 in insulin-secreting beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; CA2+ HOMEOSTASIS; PLASMA-MEMBRANE; GLUCOSE SENSOR; GROWTH-FACTOR; K+ CHANNELS	We have previously characterized an insulin receptor substrate 1 (IRS-1)-overexpressing beta-cell line. These beta-cells demonstrated cytosolic Ca2+ levels compared with wildtype and vector controls. This effect of IRS-1 may be mediated via an interaction with the sarco-endoplasmic reticulum calcium ATPase (SERCA). Here we demonstrate that IRS-1 and IRS-2 localize to an endoplasmic reticulum (ER)-enriched fraction in beta-cells using subcellular fractionation. We also observe co-localization of both IRS-1 and IRS-2 with ER marker proteins using immunofluorescent confocal microscopy. Furthermore, immuno-electron microscopy studies confirm that IRS-1 and SERCA3b localize to vesicles derived from the ER. In Chinese hamster ovary-T (CHO-T) cells transiently transfected with SERCA3b alone or together with IRS-1, SERCA3b co-immunoprecipitates with IRS-1. This interaction is enhanced with insulin treatment. SERCA3b also co-immunoprecipitates with IRS-1 in wild-type and IRS-1-overexpressing beta-cell lines. Ca2+ uptake in ER-enriched fractions prepared from wild-type and IRS-1-overexpressing cell lines shows no significant difference, indicating that the previously observed decrease in Ca2+ uptake by IRS-1-overexpressing cells is not the result of a defect in SERCA. Treatment of wild-type beta-cells with thapsigargin, an inhibitor of SERCA, resulted in an increase in glucose-stimulated fractional insulin secretion similar to that observed in IRS-1-overexpressing cells. The colocalization of IRS proteins and SERCA in the ER of beta-interact with one another. Co-immunoprecipitation of IRS-1 and SERCA in CHO-T cells and beta-cells confirms that these proteins do indeed interact directly. Pharmacological inhibition of SERCA in beta-cells results in enhanced secretion of insulin. Taken together, our data suggest that interaction between IRS proteins and SERCA is an important regulatory step in insulin secretion.	Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Wolf, BA (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab Med, 5135 Main,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK49814, DK19525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, P01DK049814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Algenstaedt PM, 1997, J BIOL CHEM, V272, P23696, DOI 10.1074/jbc.272.38.23696; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Bonner-Weir S, 1999, DIABETES, V48, pA3; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; COLCA JR, 1982, J BIOL CHEM, V257, P7223; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Henquin JC, 1998, DIABETES METAB, V24, P30; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Khan FA, 2001, DIABETES, V50, P2192, DOI 10.2337/diabetes.50.10.2192; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VanRenterghem B, 1998, J BIOL CHEM, V273, P29942, DOI 10.1074/jbc.273.45.29942; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; Wang B, 1996, BIOCHEM BIOPH RES CO, V227, P27, DOI 10.1006/bbrc.1996.1462; Westerlund J, 2002, DIABETES, V51, pS50, DOI 10.2337/diabetes.51.2007.S50; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 2000, BIOCHEMISTRY-US, V39, P14912, DOI 10.1021/bi001260w; Xu GG, 1999, J BIOL CHEM, V274, P18067, DOI 10.1074/jbc.274.25.18067; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	46	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11359	11368		10.1074/jbc.M209521200	http://dx.doi.org/10.1074/jbc.M209521200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12524443	hybrid			2022-12-25	WOS:000181855400064
J	Dion, V; Coulombe, B				Dion, V; Coulombe, B			Interactions of a DNA-bound transcriptional activator with the TBP-TFIIA-TFIIB-promoter quaternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ORDERED RECRUITMENT; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING; YEAST; INITIATION; MECHANISM; DOMAIN; GENE	Site-specific protein-DNA photo-cross-linking was used to show that, when bound to its cognate site at various distances upstream of the TATA element, the chimeric transcriptional activator GAL4-VP16 can physically interact with a TATA box-binding protein (TBP)-transcription factor IIA (TFIIA)-TFIIB complex assembled on the TATA element. This result implies DNA bending and looping of promoter DNA as a result of the physical interaction between GAL4-VP16 and an interface of the TBP-TFIIA-TFIIB complex. This protein-protein interaction on promoter DNA minimally requires the presence of one GAL4 binding site and the formation of a quaternary complex containing TBP, TFIIB, and TFIIA on the TATA element. Notably, the topology of the TBP-TFIIA-TFIIB-promoter complex is not altered Significantly by the interaction with DNA-bound activators. We also show that the ability of GAL4-VP16 to activate transcription through a single GAL4 binding site varies according to its precise location and orientation relative to the TATA element and that it can approach the efficiency obtained with multiple binding sites. Taken together, our results indicate that the spatial positioning of the DNA-bound activation domain is important for efficient activation, possibly by maximizing its interactions with the transcriptional machinery including the TBP-TFIIA-TFIIB-promoter quaternary complex.	Inst Rech Clin Montreal, Lab Gene Transcript, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Coulombe, B (corresponding author), Inst Rech Clin Montreal, Lab Gene Transcript, 110 Ave Pins Quest, Montreal, PQ H2W 1R7, Canada.	coulomb@ircm.qc.ca			Canadian Institutes of Health Research [14309-2] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Blau J, 1996, MOL CELL BIOL, V16, P2044; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Coulombe Benoit, 1992, Gene Expression, V2, P99; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Ikeda K, 1999, MOL CELL BIOL, V19, P855; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; Langelier MF, 2001, J BIOL CHEM, V276, P38652, DOI 10.1074/jbc.M106422200; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Robert F, 2000, METH MOL B, V148, P383; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; Shaw SP, 1997, P NATL ACAD SCI USA, V94, P2427, DOI 10.1073/pnas.94.6.2427; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	62	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11495	11501		10.1074/jbc.M211938200	http://dx.doi.org/10.1074/jbc.M211938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538582	Green Accepted, hybrid			2022-12-25	WOS:000181855400081
J	Hikkel, I; Lucau-Danila, A; Delaveau, T; Marc, P; Devaux, F; Jacq, C				Hikkel, I; Lucau-Danila, A; Delaveau, T; Marc, P; Devaux, F; Jacq, C			A general strategy to uncover transcription factor properties identifies a new regulator of drug resistance in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; FLR1 GENE; ACTIVATION; EXPRESSION; ADAPTATION; PROTEINS; NETWORK; COMPLEX; FAMILY	We demonstrate a genomewide approach to determine the physiological role of a putative transcription factor, Ylr266, identified through yeast genome sequencing program. We constructed activated forms of the zinc finger (Zn(2)Cys(6)) protein Ylr266, and we analyzed the corresponding transcriptomes with DNA microarrays to characterize the up-regulated genes: The direct target genes of Ylr266 were further identified by in vivo chromatin immunoprecipitation procedure. The functions of the genes directly controlled by YLR266c are in agreement with the observed drug-resistance phenotype of the cell expressing an activated form of Ylr266. These target genes code for ATP-binding cassette or major facilitator superfamily transporters such as PDR15, YOR1, or AZR1 or for other proteins such as SNG1, YJL216c, or YLL056c which are already known to be involved in the yeast pleiotropic drug resistance (PDR) phenomenon. YLR266c could thus be named PDR8. Overlaps with the other PDR networks argue in favor of a new specific role for PDRS in connection with the well known PDR regulators PDR1/PDR3 and YRR1. This strategy to identify the regulatory properties of an anonymous transcription factor is likely to be generalized to all the Zn2Cys6 transcription factors from Saccharomyces cerevisiae and related yeasts.	Ecole Normale Super, CNRS, UMR 8541, Mol Genet Lab, F-75230 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Jacq, C (corresponding author), Ecole Normale Super, CNRS, UMR 8541, Mol Genet Lab, 46 Rue Ulm, F-75230 Paris, France.		Lucau-Danila, Anca/AAE-7674-2021; DEVAUX, Frédéric/N-2288-2019; MARC, Philippe/AAB-1337-2019; MARC, Philippe/E-2896-2015	DEVAUX, Frédéric/0000-0002-0039-9096; MARC, Philippe/0000-0002-0064-0572; MARC, Philippe/0000-0002-0064-0572; LUCAU-DANILA, Anca/0000-0002-9379-6241				Adams A, 1997, METHODS YEAST GENETI; Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Brachmann CB, 1998, YEAST, V14, P115; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2001, FEBS LETT, V498, P140, DOI 10.1016/S0014-5793(01)02478-4; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; Marc P, 2002, BIOINFORMATICS, V18, P888, DOI 10.1093/bioinformatics/18.6.888; Marc P., 2001, NUCLEIC ACIDS RES, V29, pE63; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Nguyen DT, 2001, J BIOL CHEM, V276, P1138, DOI 10.1074/jbc.M008377200; RAYCHAUDHURI S, 2000, PAC S BIOCOMPUT, V1, P455; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Sambrook J., 2002, MOL CLONING LAB MANU; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tenreiro S, 2001, BIOCHEM BIOPH RES CO, V280, P216, DOI 10.1006/bbrc.2000.4100; Tenreiro S, 2000, YEAST, V16, P1469, DOI 10.1002/1097-0061(200012)16:16&lt;1469::AID-YEA640&gt;3.0.CO;2-A; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	31	42	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11427	11432		10.1074/jbc.M208549200	http://dx.doi.org/10.1074/jbc.M208549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529331	hybrid			2022-12-25	WOS:000181855400072
J	Majumdar, A; Puri, N; Cuenoud, B; Natt, F; Martin, P; Khorlin, A; Dyatkina, N; George, AJ; Miller, PS; Seidman, MM				Majumdar, A; Puri, N; Cuenoud, B; Natt, F; Martin, P; Khorlin, A; Dyatkina, N; George, AJ; Miller, PS; Seidman, MM			Cell cycle modulation of gene targeting by a triple helix-forming oligonucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTRAND CROSS-LINKS; NUCLEOTIDE EXCISION-REPAIR; NUCLEOSOME CORE PARTICLES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; IN-VIVO; STRANDED DNA; 3RD STRAND; PSORALEN; CHROMATIN	Successful gene-targeting reagents must be functional under physiological conditions and must bind chromosomal target sequences embedded in chromatin. Triple helix-forming oligonucleotides (TFOs) recognize and bind specific sequences via the major groove of duplex DNA and may have potential for gene targeting in vivo. We have constructed chemically modified, psoralen-linked TFOs that mediate site-specific mutagenesis of a chromosomal gene in living cells. Here we show that targeting efficiency is sensitive to the biology of the cell, specifically, cell cycle status. Targeted mutagenesis was variable across the cycle with the greatest activity in S phase. This was the result of differential TFO binding as measured by cross-link formation. Targeted cross-linking was low in quiescent cells but substantially enhanced in S phase cells with adducts in similar to20-30% of target sequences. 75-80% of adducts were repaired faithfully, whereas the remaining adducts were converted into mutations (>5% mutation frequency). Clones with mutations could be recovered by direct screening of colonies chosen at random. These results demonstrate high frequency target binding and target mutagenesis by TFOs in living cells. Successful protocols for TFO-mediated manipulation of chromosomal sequences are likely to reflect a combination of appropriate oligonucleotide chemistry and manipulation of the cell biology.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Novartis, Horsham RH12 4AB, W Sussex, England; Novartis Pharma Ltd, CH-4002 Basel, Switzerland; Qiagen, Alameda, CA 94501 USA; Genelabs Inc, Redwood City, CA 94063 USA; ATCC, Manassas, VA 20108 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Novartis; Novartis; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Seidman, MM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.			George, Andrew/0000-0002-2866-0241	NATIONAL INSTITUTE ON AGING [Z01AG000738, ZIAAG000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asensio JL, 1999, J AM CHEM SOC, V121, P11063, DOI 10.1021/ja991949s; Barre FX, 1999, J MOL BIOL, V286, P1379, DOI 10.1006/jmbi.1999.2550; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; Barre FX, 1999, NUCLEIC ACIDS RES, V27, P743, DOI 10.1093/nar/27.3.743; Becker NA, 1999, ANTISENSE NUCLEIC A, V9, P313, DOI 10.1089/oli.1.1999.9.313; Belousov ES, 1998, NUCLEIC ACIDS RES, V26, P1324, DOI 10.1093/nar/26.5.1324; Blume SW, 1999, NUCLEIC ACIDS RES, V27, P695, DOI 10.1093/nar/27.2.695; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Brown PM, 1998, BIOCHEMISTRY-US, V37, P16139, DOI 10.1021/bi981768n; Brown PM, 1996, BIOCHEM J, V319, P607, DOI 10.1042/bj3190607; Brown PM, 1999, EUR J BIOCHEM, V261, P301, DOI 10.1046/j.1432-1327.1999.00279.x; CARIELLO NF, 1992, ENVIRON MOL MUTAGEN, V20, P81, DOI 10.1002/em.2850200202; Carlomagno T, 2001, J AM CHEM SOC, V123, P7364, DOI 10.1021/ja002592r; CHIOU CC, 1995, CARCINOGENESIS, V16, P1357, DOI 10.1093/carcin/16.6.1357; Cole R S, 1975, Basic Life Sci, V5B, P487; Cuenoud B, 1998, ANGEW CHEM INT EDIT, V37, P1288, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1288::AID-ANIE1288>3.0.CO;2-U; Dagneaux C, 1995, BIOCHEMISTRY-US, V34, P16618, DOI 10.1021/bi00051a009; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ESCUDE C, 1992, CR ACAD SCI III-VIE, V315, P521; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; Fox KR, 2000, CURR MED CHEM, V7, P17, DOI 10.2174/0929867003375506; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; Greenberg RB, 2001, J BIOL CHEM, V276, P31551, DOI 10.1074/jbc.M103588200; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; HARTLEY JA, 1993, J CHROMATOGR-BIOMED, V618, P277, DOI 10.1016/0378-4347(93)80038-6; HEARST JE, 1989, CHEM RES TOXICOL, V2, P69, DOI 10.1021/tx00008a001; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiralerspong S, 1996, P SOC EXP BIOL MED, V212, P116; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; LAQUERBE A, 1995, J MOL BIOL, V254, P38, DOI 10.1006/jmbi.1995.0597; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; Lin FLM, 2000, J BIOL CHEM, V275, P39117, DOI 10.1074/jbc.M005404200; Lorch Y, 2001, MOL CELL, V7, P89, DOI 10.1016/S1097-2765(01)00157-5; Maher LJ, 1996, CANCER INVEST, V14, P66, DOI 10.3109/07357909609018437; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; Puri N, 2002, BIOCHEMISTRY-US, V41, P7716, DOI 10.1021/bi025734y; Puri N, 2001, J BIOL CHEM, V276, P28991, DOI 10.1074/jbc.M103409200; Raha M, 1998, PHOTOCHEM PHOTOBIOL, V67, P289, DOI 10.1111/j.1751-1097.1998.tb05201.x; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; RIDDLE JC, 1978, MUTAT RES, V52, P409, DOI 10.1016/0027-5107(78)90179-3; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; Sedelnikova OA, 2002, ANTISENSE NUCLEIC A, V12, P43, DOI 10.1089/108729002753670256; SHIMIZU M, 1992, FEBS LETT, V302, P155, DOI 10.1016/0014-5793(92)80428-J; STEEN AM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P77, DOI 10.1016/0167-4781(91)90155-F; Subramanian PS, 1997, SOMAT CELL MOLEC GEN, V23, P97, DOI 10.1007/BF02679969; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Vasquez KM, 2001, J BIOL CHEM, V276, P38536, DOI 10.1074/jbc.M101797200; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; Vasquez KM, 2000, METH MOL B, V133, P183; VOS JMH, 1987, CELL, V50, P789, DOI 10.1016/0092-8674(87)90337-0; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; WESTIN L, 1995, NUCLEIC ACIDS RES, V23, P2184, DOI 10.1093/nar/23.12.2184; Zhang XW, 2001, CELL PROLIFERAT, V34, P321, DOI 10.1046/j.0960-7722.2001.00210.x	70	65	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11072	11077		10.1074/jbc.M211837200	http://dx.doi.org/10.1074/jbc.M211837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538585	hybrid			2022-12-25	WOS:000181855400028
J	Kalus, I; Schnegelsberg, B; Seidah, NG; Kleene, R; Schachner, M				Kalus, I; Schnegelsberg, B; Seidah, NG; Kleene, R; Schachner, M			The proprotein convertase PC5A and a metalloprotease are involved in the proteolytic processing of the neural adhesion molecule L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CELL-ADHESION; NEURITE OUTGROWTH; BIOCHEMICAL-CHARACTERIZATION; EXTRACELLULAR DOMAINS; MEDIATED RELEASE; SERINE PROTEASES; SCIATIC-NERVE; RAT-BRAIN; EXPRESSION	The transmembrane and multidomain neural adhesion molecule L1 plays important functional roles in the developing and adult nervous system. L1 is proteolytically processed at two distinct sites within the extracellular domain, leading to the generation of different fragments. In this report, we present evidence that the proprotein convertase PC5A is the protease that cleaves L1 in the third fibronectin type III domain, whereas the proprotein convertases furin, PC1, PC2, PACE4, and PC7 are not effective in cleaving L1. Analysis of mutations revealed Arg(845) to be the site of cleavage generating the N-terminal 140-kDa fragment. This fragment was present in the hippocampus, which expresses PC5A, but was not detectable in the cerebellum, which does not express PC5A. The 140-kDa L1 fragment was found to be tightly associated with the full-length 200-kDa L1 molecule. The complex dissociated from the membrane upon cleavage by a protease acting at a more membrane-proximal site of full-length L1. This proteolytic cleavage was inhibited by the metalloprotease inhibitor GM 6001 and enhanced by a calmodulin inhibitor. L1-dependent neurite outgrowth of cerebellar neurons was inhibited by GM 6001, suggesting that proteolytic processing of L1 by a metalloprotease is involved in neurite outgrowth.	Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany; Clin Res Inst Montreal, Lab Biochem Neuroendocrinol, Montreal, PQ H2W 1R7, Canada	University of Hamburg; University Medical Center Hamburg-Eppendorf; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Schachner, M (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	melitta.schachner@zmnh.uni-hamburg.de	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				APPEL F, 1993, J NEUROSCI, V13, P4764; Beer S, 1999, J CELL SCI, V112, P2667; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bix GJ, 1998, J NEUROSCI, V18, P307; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dityatev A, 2000, NEURON, V26, P207, DOI 10.1016/S0896-6273(00)81151-4; DONG W, 1995, J NEUROSCI, V15, P1778, DOI 10.1523/JNEUROSCI.15-03-01778.1995; FAISSNER A, 1984, DEV BRAIN RES, V15, P69, DOI 10.1016/0165-3806(84)90141-X; FISCHER G, 1986, J NEUROSCI, V6, P605; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; HOLM J, 1995, J NEUROSCI RES, V42, P9, DOI 10.1002/jnr.490420103; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hunter I, 1996, BIOCHEM J, V320, P847, DOI 10.1042/bj3200847; Jie CF, 2000, BBA-PROTEIN STRUCT M, V1479, P1, DOI 10.1016/S0167-4838(00)00030-3; Jun CD, 2001, J BIOL CHEM, V276, P29019, DOI 10.1074/jbc.M103394200; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kleene R, 2001, J BIOL CHEM, V276, P21656, DOI 10.1074/jbc.M101790200; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Lu XY, 2001, J NEUROCHEM, V77, P1553, DOI 10.1046/j.1471-4159.2001.00359.x; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Luthi A, 1996, J NEUROSCI RES, V46, P1; Lynch GW, 1999, EUR J IMMUNOL, V29, P2590, DOI 10.1002/(SICI)1521-4141(199908)29:08<2590::AID-IMMU2590>3.0.CO;2-R; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Marcinkiewicz M, 1998, MOL BRAIN RES, V59, P229, DOI 10.1016/S0169-328X(98)00141-7; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Nakagami Y, 2000, J NEUROSCI, V20, P2003; Nayeem N, 1999, J CELL SCI, V112, P4739; Newton JP, 1999, BIOCHEM BIOPH RES CO, V261, P283, DOI 10.1006/bbrc.1999.1018; Oka T, 2002, NEUROSCI LETT, V321, P141, DOI 10.1016/S0304-3940(01)02470-3; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; RATHJEN FG, 1984, EMBO J, V3, P1; REILLY PL, 1995, J IMMUNOL, V155, P529; SADOUL K, 1988, J NEUROCHEM, V50, P510, DOI 10.1111/j.1471-4159.1988.tb02941.x; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shiosaka S, 2000, NEUROSCI RES, V37, P85, DOI 10.1016/S0168-0102(00)00115-2; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Spira ME, 2001, CELL MOL NEUROBIOL, V21, P591, DOI 10.1023/A:1015135617557; Stallcup WB, 2000, J NEUROSCI RES, V61, P33, DOI 10.1002/1097-4547(20000701)61:1<33::AID-JNR4>3.0.CO;2-Y; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Thompson AJ, 2002, J NEUROSCI RES, V67, P766, DOI 10.1002/jnr.10167; Turner AJ, 1999, BIOCHEM SOC T, V27, P255, DOI 10.1042/bst0270255; Ulloa L, 2001, J BIOL CHEM, V276, P21387, DOI 10.1074/jbc.M006933200; Villeneuve P, 1999, NEUROSCIENCE, V92, P641, DOI 10.1016/S0306-4522(98)00763-5; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yoshida S, 1999, INT J MOL MED, V3, P405; Zhang Y, 2000, MOL CELL NEUROSCI, V16, P71, DOI 10.1006/mcne.2000.0852; Zheng M, 1997, DEV BIOL, V181, P268, DOI 10.1006/dbio.1996.8402	68	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10381	10388		10.1074/jbc.M208351200	http://dx.doi.org/10.1074/jbc.M208351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529374	hybrid			2022-12-25	WOS:000181777500053
J	Lindemann, MJ; Benczik, M; Gaffen, SL				Lindemann, MJ; Benczik, M; Gaffen, SL			Anti-apoptotic signaling by the interleukin-2 receptor reveals a function for cytoplasmic tyrosine residues within the common gamma (gamma c) receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; MEMBRANE-PROXIMAL REGION; NATURAL-KILLER-CELLS; SEE VOL. 30; IL-2 RECEPTOR; BETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELLS; ALPHA-CHAIN; BCL-2 EXPRESSION	The interleukin-2 receptor (IL-2R) is composed of one affinity-modulating subunit (IL-2Ralpha) and two essential signaling subunits (IL-2Rbeta and gammac). Although most known signaling events are mediated through tyrosine residues located within IL-2Rbeta, no functions have yet been ascribed to gammac tyrosine residues. In this study, we describe a role for gammac tyrosines in anti-apoptotic signal transduction. We have shown previously that a tyrosine-deficient IL-2Rbeta chain paired with wild type gammac stimulated enhancement of bcl-2 mRNA in IL-2-dependent T cells, but it was not determined which region of the IL-2R or which pathway was activated to direct this signaling response. Here we show that up-regulation of Bcl-2 by an IL-2R lacking IL-2Rbeta tyrosine residues leads to increased cell survival after cytokine deprivation; strikingly, this survival signal does not occur in the absence of gammac tyrosine residues. These gammac-dependent signals are revealed only in the absence of IL-2Rbeta tyrosines, indicating that the IL-2R engages at least two distinct signaling pathways to regulate apoptosis and Bcl-2 expression. Mechanistically, the gammac-dependent signal requires activation of Janus kinases 1 and 3 and is sensitive to wortmannin, implicating phosphatidylinositol 3-kinase. Consistent with involvement of phosphatidylinositol 3-kinase, Akt can be activated via tyrosine residues on gammac. Thus, gammac mediates an anti-apoptotic signaling pathway through Akt which cooperates with signals from its partner chain, IL-2Rbeta.	SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute	Gaffen, SL (corresponding author), SUNY Buffalo, Dept Oral Biol, 3435 Main St, Buffalo, NY 14214 USA.	sgaffen@buffalo.edu	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049329, R21AI049329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R43DE007034] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49329] Funding Source: Medline; NIDCR NIH HHS [DE07034] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Bassiri H, 2001, J IMMUNOL, V166, P5945, DOI 10.4049/jimmunol.166.10.5945; Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Buckley RH, 2000, NEW ENGL J MED, V343, P1313, DOI 10.1056/NEJM200011023431806; Candotti F, 2002, J CLIN INVEST, V109, P1261, DOI 10.1172/JCI200215769; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x; Cipres A, 1999, EUR J IMMUNOL, V29, P1158, DOI 10.1002/(SICI)1521-4141(199904)29:04<1158::AID-IMMU1158>3.0.CO;2-L; Cipres A, 2001, FEBS LETT, V500, P99, DOI 10.1016/S0014-5793(01)02594-7; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Ernst JD, 1998, ANAL BIOCHEM, V260, P18, DOI 10.1006/abio.1998.2677; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Fujii H, 1998, EMBO J, V17, P6551, DOI 10.1093/emboj/17.22.6551; Gaffen SL, 1999, BLOOD, V94, P74, DOI 10.1182/blood.V94.1.74.413k36_74_86; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; GOLDSMITH MA, 1994, CYTOKINE HDB, P57; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HATAKEYAMA M, 1986, P NATL ACAD SCI USA, V83, P9650, DOI 10.1073/pnas.83.24.9650; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Kelly E, 2002, J IMMUNOL, V168, P597, DOI 10.4049/jimmunol.168.2.597; Khaled AR, 2001, J BIOL CHEM, V276, P6453, DOI 10.1074/jbc.M006391200; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Lai SY, 1997, J CLIN INVEST, V99, P169, DOI 10.1172/JCI119144; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; LIU KD, 1995, J BIOL CHEM, V270, P22176, DOI 10.1074/jbc.270.38.22176; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lord JD, 1998, J IMMUNOL, V161, P4627; Malek TR, 2000, J IMMUNOL, V164, P2905, DOI 10.4049/jimmunol.164.6.2905; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMOTO S, 1995, BLOOD, V86, P2281, DOI 10.1182/blood.V86.6.2281.bloodjournal8662281; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Moon JJ, 2001, J IMMUNOL, V167, P2714, DOI 10.4049/jimmunol.167.5.2714; Nakajima H, 1999, J IMMUNOL, V162, P782; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; O'Dell JR, 1999, NEW ENGL J MED, V340, P310, DOI 10.1056/NEJM199901283400411; OTANI H, 1993, J BIOL CHEM, V268, P22733; Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200; Qin JZ, 2001, BLOOD, V98, P2778, DOI 10.1182/blood.V98.9.2778; Rathmell JC, 2001, J IMMUNOL, V167, P6869, DOI 10.4049/jimmunol.167.12.6869; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Rodewald HR, 2001, J EXP MED, V193, P1431, DOI 10.1084/jem.193.12.1431; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; STROUD RM, 2001, CYTOKINE REFERENCE L, V1, P21; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; SUGAMURA K, 1990, LYMPHOKINE RES, V9, P539; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; Tsujino S, 1999, GENES CELLS, V4, P363, DOI 10.1046/j.1365-2443.1999.00266.x; Tsujino S, 2000, P NATL ACAD SCI USA, V97, P10514, DOI 10.1073/pnas.180063297; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Van Parijs L, 1998, SCIENCE, V280, P243; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vosshenrich CAJ, 2001, CURR BIOL, V11, pR175, DOI 10.1016/S0960-9822(01)00087-2; Waldmann TA, 2000, ANN ONCOL, V11, P101, DOI 10.1023/A:1008324701986; Ward SG, 2001, CURR OPIN IMMUNOL, V13, P332, DOI 10.1016/S0952-7915(00)00223-5; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	98	22	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10239	10249		10.1074/jbc.M209471200	http://dx.doi.org/10.1074/jbc.M209471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525482	hybrid, Green Accepted			2022-12-25	WOS:000181777500035
J	Mikolajczyk, J; Boatright, KM; Stennicke, HR; Nazif, T; Potempa, J; Bogyo, M; Salvesen, GS				Mikolajczyk, J; Boatright, KM; Stennicke, HR; Nazif, T; Potempa, J; Bogyo, M; Salvesen, GS			Sequential autolytic processing activates the zymogen of Arg-gingipain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHYROMONAS-GINGIVALIS; CYSTEINE PROTEINASES; CRYSTAL-STRUCTURE; PROTEASE; GENES; MECHANISM; CHAPERONE; CASPASES; CLEAVAGE; SEPARASE	Most proteases are synthesized as inactive precursors to protect the synthetic machinery of the cell and allow timing of activation. The mechanisms used to render latency are varied but tend to be conserved within protease families. Proteases belonging to the caspase family have a unique mechanism mediated by transitions of two surface loops, and on the basis of conservation of mechanism one would expect this to be preserved by caspase relatives. We have been able to express the full-length precursor of the Arg-specific caspase relative from the bacterium Porphyromonas gingivalis, Arg-gingipain-B, and we show that it contains N- and C-terminal extensions that render a low amount of latency, meaning that the zymogen is substantially active. Three sequential autolytic processing steps at the N and C terminus are required for full activity, and the N-propeptide may serve as an intramolecular chaperone rather than an inhibitory peptide. Each step in activation requires the previous step, and an affinity probe reveals that incremental activity enhancements are achieved in a stepwise manner.	Burnham Inst, La Jolla, CA 92037 USA; Novo Nordisk AS, Dept Prot Design, DK-2880 Bagsvaerd, Denmark; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94043 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Fac Biotechnol, Dept Microbiol, PL-30060 Krakow, Poland	Sanford Burnham Prebys Medical Discovery Institute; Novo Nordisk; University of California System; University of California San Francisco; University System of Georgia; University of Georgia; Jagiellonian University	Salvesen, GS (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gsalvesen@burnham.org		Bogyo, Matthew/0000-0003-3753-4412; Nazif, Tamim/0000-0003-1239-2489	NCI NIH HHS [CA69381] Funding Source: Medline; NIDCR NIH HHS [DE009761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADUSEOPOKU J, 1995, INFECT IMMUN, V63, P4744, DOI 10.1128/IAI.63.12.4744-4754.1995; Aravind L, 2002, PROTEINS, V46, P355, DOI 10.1002/prot.10060; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; Curtis MA, 2001, CRIT REV ORAL BIOL M, V12, P192, DOI 10.1177/10454411010120030101; Eichinger A, 1999, EMBO J, V18, P5453, DOI 10.1093/emboj/18.20.5453; Genco CA, 1999, CLIN INFECT DIS, V28, P456, DOI 10.1086/515156; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JOHNSTON JR, 1994, MOL GENETICS YEAST P, V141, P123; Kadowaki T, 1998, J BIOL CHEM, V273, P29072, DOI 10.1074/jbc.273.44.29072; Lee A, 1999, J AM CHEM SOC, V121, P9907, DOI 10.1021/ja992009a; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; Margetts MB, 2000, PROTEIN EXPRES PURIF, V18, P262, DOI 10.1006/prep.2000.1193; Mikolajczyk-Pawlinska J, 1998, BIOL CHEM, V379, P205, DOI 10.1515/bchm.1998.379.2.205; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NIELSEN TL, 1990, APPL MICROBIOL BIOT, V33, P307, DOI 10.1007/BF00164527; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; Potempa J, 1998, J BIOL CHEM, V273, P21648, DOI 10.1074/jbc.273.34.21648; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; ROBINSON VJ, 1992, BIOORG CHEM, V20, P42, DOI 10.1016/0045-2068(92)90024-W; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SALVESEN GS, 1999, J BIOL CHEM, V274, P8359; SIKORSKI RS, 1989, GENETICS, V122, P19; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Veith PD, 2002, BIOCHEM J, V363, P105, DOI 10.1042/0264-6021:3630105; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	43	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10458	10464		10.1074/jbc.M210564200	http://dx.doi.org/10.1074/jbc.M210564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533545	hybrid			2022-12-25	WOS:000181777500063
J	Waltner-Law, M; Duong, DT; Daniels, MC; Herzog, B; Wang, XHL; Prasad, R; Granner, DK				Waltner-Law, M; Duong, DT; Daniels, MC; Herzog, B; Wang, XHL; Prasad, R; Granner, DK			Elements of the glucocorticoid and retinoic acid response units are involved in cAMP-mediated expression of the PEPCK gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; FACTOR-BINDING PROTEIN-1; COUP-TF; ACCESSORY FACTOR; AMINOTRANSFERASE GENE; NUCLEAR FACTOR-3; GTP GENE; FACTOR-I; TRANSCRIPTION; INSULIN	Although many genes are regulated by the concerted action of several hormones, hormonal signaling to gene promoters has generally been studied one hormone at a time. The phosphoenolpyruvate carboxykinase (PEPCK) gene is a case in point. Transcription of this gene is induced by glucagon (acting by the second messenger, cAMP), glucocorticoids, and retinoic acid, and it is dominantly repressed by insulin. These hormonal responses require the presence of different hormone response units (HRUs), which consist of constellations of DNA elements and associated transcription factors. These include the glucocorticoid response unit (GRU), cAMP response unit (CRU), retinoic acid response unit (RARU), and the insulin response unit. HRUs are known to have functional overlap. In particular, the cAMP response element of the CRU is also a component of the GRU. The purpose of this study was to determine whether known GRU or RARU elements or transcription factors function as components of the CRU. We show here that the glucocorticoid accessory factor binding site 1 and glucocorticoid accessory factor binding site 3 elements, which are components of both the GRU and RARU, are an important part of the CRU. Furthermore, we find that the transcription factor, chicken ovalbumin upstream promoter-transcription factor, and two coactivators, cAMP response element-binding protein-binding protein and steroid receptor coactivator-1, participate in both the cAMP and glucocorticoid responses. This provides a further illustration of how the PEPCK gene promoter integrates different hormone responses through overlapping HRUs that utilize some of the same transcription factors and coactivators.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, 707 Light Hall, Nashville, TN 37232 USA.	daryl.granner@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R37DK035107, K01DK002887, R01DK035107, T32DK007061] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35107, DK02887, DK07061, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRANNER DK, 1986, ANN NY ACAD SCI, V478, P175, DOI 10.1111/j.1749-6632.1986.tb15530.x; GRANNER DK, 1986, RECENT PROG HORM RES, V42, P111; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lin BC, 1998, DNA CELL BIOL, V17, P967, DOI 10.1089/dna.1998.17.967; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OFIR R, 1991, GENE EXPRESSION, V1, P55; ONATE SA, 1995, SCIENCE, V270, P1354; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PARK EA, 1993, J BIOL CHEM, V268, P613; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Streeper RS, 2000, J BIOL CHEM, V275, P12108, DOI 10.1074/jbc.275.16.12108; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Streeper RS, 2001, J BIOL CHEM, V276, P19111, DOI 10.1074/jbc.M101442200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wilson HL, 2002, J BIOL CHEM, V277, P43895, DOI 10.1074/jbc.M203169200; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	55	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10427	10435		10.1074/jbc.M211846200	http://dx.doi.org/10.1074/jbc.M211846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531892	hybrid			2022-12-25	WOS:000181777500059
J	Zhou, Y; Reddy, S; Murrey, H; Fei, H; Levitan, IB				Zhou, Y; Reddy, S; Murrey, H; Fei, H; Levitan, IB			Monomeric 14-3-3 protein is sufficient to modulate the activity of the Drosophila Slowpoke calcium-dependent potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-ISOFORM; IN-VIVO; INTERACTS; FORM; ASSOCIATION; ACTIVATION; LEONARDO; RECEPTOR; COMPLEX; BINDING	Drosophila 14-3-3zeta (D14-3-3zeta) modulates the activity of the Slowpoke calcium-dependent potassium channel (dSlo) by interacting with the dSlo binding protein, Slob. We show here that D14-3-3zeta forms dimers in vitro. Site-directed mutations in its putative dimerization interface result in a dimerization-deficient form of D14-33. Both the wild-type and dimerization-deficient forms of D14-3-3zeta bind to Slob with similar affinity and form complexes with dSlo. When dSlo and Slob are expressed in mammalian cells, the dSlo channel activity is similarly modulated by co-expression of either the wild-type or the dimerization-deficient form of D14-3-3zeta. In addition, dSlo is still modulated by wild-type D14-3-3zeta in the presence of a 14-3-3 mutant, which does not itself bind to Slob but forms heterodimers with the wild-type 14-3-3. These data, taken together, suggest that monomeric D14-3-3zeta is capable of modulating dSlo channel activity in this regulatory complex.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania	Zhou, Y (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.	yizhou@mail.med.upenn.edu						Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Campbell JK, 1997, BIOCHEMISTRY-US, V36, P15363, DOI 10.1021/bi9708085; Chan HC, 2000, BIOCHEM BIOPH RES CO, V270, P581, DOI 10.1006/bbrc.2000.2454; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Craparo A, 1997, J BIOL CHEM, V272, P11663; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865; Zhou Y, 2002, J NEUROSCI, V22, P3855, DOI 10.1523/JNEUROSCI.22-10-03855.2002; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4	30	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10073	10080		10.1074/jbc.M211907200	http://dx.doi.org/10.1074/jbc.M211907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529354	hybrid			2022-12-25	WOS:000181777500013
J	Beaumont, NJ; Skinner, VO; Tan, TMM; Ramesh, BS; Byrne, DJ; MacColl, GS; Keen, JN; Bouloux, PM; Mikhailidis, DP; Bruckdorfer, KR; Vanderpump, MP; Srai, KS				Beaumont, NJ; Skinner, VO; Tan, TMM; Ramesh, BS; Byrne, DJ; MacColl, GS; Keen, JN; Bouloux, PM; Mikhailidis, DP; Bruckdorfer, KR; Vanderpump, MP; Srai, KS			Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE DEFICIENCY; ACROMEGALIC PATIENTS; HUMANS; PLASMA; PEPTIDE; TISSUE	Ghrelin is a 28-residue peptide hormone that is principally released from the stomach during fasting and prior to eating. Two forms are present in human plasma: the unmodified peptide and a less abundant acylated version, in which octanoic acid is attached to the third residue, a serine, via an ester linkage. The acylated form of ghrelin acts as a ligand for the growth hormone secretagogue receptor and can stimulate the release of growth hormone from the pituitary gland. It also initiates behavioral and metabolic adaptations to fasting. Here we show that an immobilized form of ghrelin specifically binds a species of high density lipoprotein associated with the plasma esterase, paraoxonase, and clusterin. Both free ghrelin and paraoxon, a substrate for paraoxonase, can inhibit this interaction. An endogenous species of ghrelin is found to co-purify with high density lipoprotein during density gradient centrifugation and subsequent gel filtration. This interaction links the orexigenic peptide hormone ghrelin to lipid transport and metabolism. Furthermore, the interaction of the esterified hormone ghrelin with a species of HDL containing an esterase suggests a possible mechanism for the conversion of ghrelin to des-acyl ghrelin.	UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England; UCL Royal Free Hosp NHS Trust, Dept Endocrinol, London NW3 2QG, England; UCL Royal Free Hosp NHS Trust, Dept Clin Biochem, London NW3 2QG, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; University of London; University College London; University of Leeds	Beaumont, NJ (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, Rowland Hill St, London NW3 2PF, England.	n.beaumont@rfc.ucl.ac.uk	Srai, Surjit K/C-5575-2009; Srai, Kaila/AAE-7039-2021; Tan, Tricia M.M./C-7140-2011; Mikhailidis, Dimitri P/A-1869-2013; Tan, Tricia/ABD-5502-2020	Tan, Tricia M.M./0000-0001-5873-3432; Mikhailidis, Dimitri P/0000-0002-9566-2263; MacColl, Gavin/0000-0001-5032-7018				Arosio M, 2000, ATHEROSCLEROSIS, V151, P551, DOI 10.1016/S0021-9150(99)00426-8; Caminos JE, 2002, EUR J ENDOCRINOL, V147, P159, DOI 10.1530/eje.0.1470159; Cappiello V, 2002, EUR J ENDOCRINOL, V147, P189, DOI 10.1530/eje.0.1470189; CHUNG BH, 1980, J LIPID RES, V21, P284; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; DEBOER H, 1994, METABOLISM, V43, P199, DOI 10.1016/0026-0495(94)90245-3; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Ozbey N, 2000, INT J OBESITY, V24, P619, DOI 10.1038/sj.ijo.0801206; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992	14	119	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8877	8880		10.1074/jbc.C200575200	http://dx.doi.org/10.1074/jbc.C200575200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12531885	hybrid			2022-12-25	WOS:000181524000003
J	Waga, K; Nakamura, Y; Maki, K; Arai, H; Yamagata, T; Sasaki, K; Kurokawa, M; Hirai, H; Mitani, K				Waga, K; Nakamura, Y; Maki, K; Arai, H; Yamagata, T; Sasaki, K; Kurokawa, M; Hirai, H; Mitani, K			Leukemia-related transcription factor TEL accelerates differentiation of Friend erythroleukemia cells	ONCOGENE			English	Article						erythroid differentiation; FLI-1; MEL; TEL	LONG TERMINAL REPEAT; ERYTHROID-DIFFERENTIATION; MYELOID-LEUKEMIA; FUSION PROTEIN; HISTONE DEACETYLASE; CO-REPRESSORS; GENE; FLI-1; VIRUS; ACTIVATION	TEL belongs to a member of the ETS family transcription factors that represses transcription of target genes such as FLI-1. Although TEL is essential for establishing hematopoiesis in neonatal bone marrow, its role in erythroid lineage is not understood. To investigate a role for TEL in erythroid differentiation, we introduced TEL into mouse erythroleukemia (MEL) cells. Overexpressing wild-type-TEL in MEL cells enhanced differentiation induced by hexamethylene bisacetamide or dimethylsulfoxide, as judged by the increased levels of erythroid-specific delta-aminolevulinate synthase and beta-globin mRNAs. TEL bound to a corepressor mSin3A through the helix-loop-helix domain. A TEL mutant lacking this domain still bound to the ETS binding site, but lost its transrepressional effect. This mutant completely blocked erythroid differentiation in MEL cells. Moreover, it showed dominant-negative effects over TEL-mediated transcriptional repression and acceleration of erythroid differentiation. Endogenous TEL mRNA was found to increase during the first 3 days in differentiating MEL cells and drastically decrease thereafter. All these data suggest that TEL might play some role in erythroid cell differentiation.	Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan; Univ Tokyo, Dept Hematol & Oncol, Grad Sch Med, Tokyo 1138655, Japan	Dokkyo Medical University; University of Tokyo	Mitani, K (corresponding author), Dokkyo Univ, Sch Med, Dept Hematol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.							Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; Martinez R, 2000, BLOOD, V96, p453A; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479	40	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					59	68		10.1038/sj.onc.1206072	http://dx.doi.org/10.1038/sj.onc.1206072			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527908				2022-12-25	WOS:000180166900007
J	Jairajpuri, MA; Lu, AQ; Desai, U; Olson, ST; Bjork, I; Bock, SC				Jairajpuri, MA; Lu, AQ; Desai, U; Olson, ST; Bjork, I; Bock, SC			Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITE; PENTASACCHARIDE BINDING; BETA-ANTITHROMBIN; ALPHA-THROMBIN; IDENTIFICATION; MECHANISM; INHIBITION; RESIDUES; GLYCOSYLATION; ACCELERATION	The dissociation equilibrium constant for heparin binding to antithrombin III (ATIII) is a measure of the cofactor's binding to and activation of the proteinase inhibitor, and its salt dependence indicates that ionic and non-ionic interactions contribute similar to40 and similar to60% of the binding free energy, respectively. We now report that phenylalanines 121 and 122 (Phe-121 and Phe-122) together contribute 43% of the total binding free energy and 77% of the energy of non-ionic binding interactions. The large contribution of these hydrophobic residues to the binding energy is mediated not by direct interactions with heparin, but indirectly, through contacts between their phenyl rings and the non-polar stems of positively charged heparin binding residues, whose terminal amino and guanidinium groups are thereby organized to form extensive and specific ionic and non-ionic contacts with the pentasaccharide. Investigation of the kinetics of heparin binding demonstrated that Phe-122 is critical for promoting a normal rate of conformational change and stabilizing AT*H, the high affinity-activated binary complex. Kinetic and structural considerations suggest that Phe-122 and Lys-114 act cooperatively through non-ionic interactions to promote P-helix formation and ATIII binding to the pentasaccharide. In summary, although hydrophobic residues Phe-122 and Phe-121 make minimal contact with the pentasaccharide, they play a critical role in heparin binding and activation of antithrombin by coordinating the P-helix-mediated conformational change and organizing an extensive network of ionic and non-ionic interactions between positively charged heparin binding site residues and the cofactor.	Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84132 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Swedish Univ Agr Sci, Dept Vet Med Chem, SE-75123 Uppsala, Sweden	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Virginia Commonwealth University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Swedish University of Agricultural Sciences	Bock, SC (corresponding author), Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Med, 50 N Med Dr, Salt Lake City, UT 84132 USA.	susan.bock@m.cc.utah.edu	Jairajpuri, Mohamad/AAS-2556-2020; Desai, Umesh/D-3741-2013	Desai, Umesh/0000-0002-1976-6597	NHLBI NIH HHS [HL 30712, HL 39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039888, R01HL030712, R37HL039888, R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; Arocas V, 2001, J BIOL CHEM, V276, P43809, DOI 10.1074/jbc.M105294200; Arocas V, 2000, BIOCHEMISTRY-US, V39, P8512, DOI 10.1021/bi9928243; Backovic M, 2002, J PROTEOME RES, V1, P367, DOI 10.1021/pr025515z; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; CHOWDHURY V, 1995, BRIT J HAEMATOL, V89, P602, DOI 10.1111/j.1365-2141.1995.tb08369.x; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; Hileman RE, 1998, BIOCHEMISTRY-US, V37, P15231, DOI 10.1021/bi980212x; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jairajpuri MA, 2002, J BIOL CHEM, V277, P24460, DOI 10.1074/jbc.M203127200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JORDAN RE, 1983, ARCH BIOCHEM BIOPHYS, V227, P587, DOI 10.1016/0003-9861(83)90488-5; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; Kridel SJ, 1997, J BIOL CHEM, V272, P7656, DOI 10.1074/jbc.272.12.7656; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OKAJIMA K, 1993, BLOOD, V81, P1300; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P198, DOI 10.1016/S1050-1738(02)00160-3; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; PICARD V, 1996, METHODS MOL BIOL PCR, P183; Schedin-Weiss S, 2002, BIOCHEMISTRY-US, V41, P4779, DOI 10.1021/bi012163l; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; VANBOECKEL C, 1996, NAT STRUCT BIOL, V1, P423	36	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15941	15950		10.1074/jbc.M212319200	http://dx.doi.org/10.1074/jbc.M212319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12556442	Green Submitted, hybrid			2022-12-25	WOS:000182680000063
J	Iwatani, Y; Rosen, AE; Guo, JH; Musier-Forsyth, K; Levin, JG				Iwatani, Y; Rosen, AE; Guo, JH; Musier-Forsyth, K; Levin, JG			Efficient initiation of HIV-1 reverse transcription in vitro - Requirement for RNA sequences downstream of the primer binding site abrogated by nucleocapsid protein-dependent primer-template interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACID-CHAPERONE ACTIVITY; ZINC-FINGER STRUCTURES; MURINE LEUKEMIA-VIRUS; STRAND DNA-SYNTHESIS; STRONG-STOP DNA; PSI-C LOOP; SECONDARY STRUCTURE; VIRAL-RNA; ANNEALING ACTIVITIES	Synthesis of HIV-1 (-) strong-stop DNA is initiated following annealing of the 3' IS nucleotides (nt) of tRNA(3)(Lys) to the primer binding site (PBS) near the 5' terminus of viral RNA. Here, we have investigated whether sequences downstream of the PBS play a role in promoting efficient (-) strong-stop DNA synthesis. Our findings demonstrate a template requirement for at least 24 bases downstream of the PBS when tRNA(3)(Lys) or an 18-nt RNA complementary to the PBS (1118), but not an 18-nt DNA primer, are used. Additional assays using 18-nt DNA-RNA chimeric primers, as well as melting studies and circular dichroism spectra of 18-nt primer: PBS duplexes, suggest that priming efficiency is correlated with duplex conformation and stability. Interestingly, in the presence of nucleocapsid protein (NC), the 24 downstream bases are dispensable for synthesis primed by tRNA(3)(Lys) but not by R18. We present data supporting the conclusion that NC promotes extended interactions between the anticodon stem and variable loop of tRNA(3)(Lys) and a sequence upstream of the A-rich loop in the template. Taken together, this study leads to new insights into the initiation of HIV-1 reverse transcription and the functional role of NC-facilitated tRNA-template interactions in this process.	NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Minnesota System; University of Minnesota Twin Cities	Levin, JG (corresponding author), NICHD, Mol Genet Lab, NIH, Bldg 6B,Rm 216, Bethesda, MD 20892 USA.	jlevin@mail.nih.gov	Iwatani, Yasumasa/A-8675-2016	Iwatani, Yasumasa/0000-0001-9269-4828	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008700] Funding Source: NIH RePORTER; NIAID NIH HHS [AI65056] Funding Source: Medline; NIGMS NIH HHS [T32-GM08700] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ARNOTT S, 1986, J MOL BIOL, V188, P631, DOI 10.1016/S0022-2836(86)80011-0; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Brule F, 2002, RNA, V8, P8, DOI 10.1017/S1355838202010981; Cen S, 1999, J VIROL, V73, P4485, DOI 10.1128/JVI.73.5.4485-4488.1999; Chan BD, 1999, P NATL ACAD SCI USA, V96, P459, DOI 10.1073/pnas.96.2.459; Coffin J, 1997, RETROVIRUSES; CRISTOFARI G, 2000, PROG NUCL ACIDS RES, V72, P223; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Goldschmidt V, 2002, J BIOL CHEM, V277, P43233, DOI 10.1074/jbc.M205295200; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Gyi JI, 1996, BIOCHEMISTRY-US, V35, P12538, DOI 10.1021/bi960948z; Hargittai MRS, 2001, J MOL BIOL, V312, P985, DOI 10.1006/jmbi.2001.5021; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Horton NC, 1996, J MOL BIOL, V264, P521, DOI 10.1006/jmbi.1996.0658; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; Kankia BI, 1999, J PHYS CHEM B, V103, P8759, DOI 10.1021/jp991614x; KHAN R, 1992, J BIOL CHEM, V267, P6689; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 2000, J BIOL CHEM, V275, P12306, DOI 10.1074/jbc.275.16.12306; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; Li XG, 1997, J VIROL, V71, P6003, DOI 10.1128/JVI.71.8.6003-6010.1997; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Liang C, 1998, J BIOL CHEM, V273, P21309, DOI 10.1074/jbc.273.33.21309; Liang C, 2000, J VIROL, V74, P6251, DOI 10.1128/JVI.74.14.6251-6261.2000; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Miller JT, 2001, J BIOL CHEM, V276, P27721, DOI 10.1074/jbc.M100513200; Morris S, 2002, J VIROL, V76, P7571, DOI 10.1128/JVI.76.15.7571-7577.2002; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Puglisi EV, 1998, NAT STRUCT BIOL, V5, P1033, DOI 10.1038/4141; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Rong LW, 2001, J BIOL CHEM, V276, P47725, DOI 10.1074/jbc.M105124200; Roy B, 1999, ANAL BIOCHEM, V269, P403, DOI 10.1006/abio.1999.4051; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; SPROAT B, 1995, NUCLEOS NUCLEOT, V14, P255, DOI 10.1080/15257779508014668; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Szyperski T, 1999, J BIOMOL NMR, V13, P343, DOI 10.1023/A:1008350604637; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wahl MC, 2000, NUCLEIC ACIDS RES, V28, P4356, DOI 10.1093/nar/28.21.4356; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; Yang J T, 1969, Prog Nucleic Acid Res Mol Biol, V9, P223, DOI 10.1016/S0079-6603(08)60770-9; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	79	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14185	14195		10.1074/jbc.M211618200	http://dx.doi.org/10.1074/jbc.M211618200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12560327	Green Submitted, hybrid			2022-12-25	WOS:000182405000080
J	Guo, XG; Stafford, LJ; Bryan, B; Xia, CZ; Ma, WB; Wu, XS; Liu, D; Zhou, SY; Liu, MY				Guo, XG; Stafford, LJ; Bryan, B; Xia, CZ; Ma, WB; Wu, XS; Liu, D; Zhou, SY; Liu, MY			A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; RHO-FAMILY GTPASES; PLECKSTRIN HOMOLOGY DOMAINS; ACTIN STRESS FIBERS; KAPPA-B ACTIVATION; RAS TRANSFORMATION; DBL FAMILY; TRANSCRIPTIONAL ACTIVITY; P21-ACTIVATED KINASES	The Rho family of small GTPases, including Rho, Rac, and Cdc42, play essential roles in diverse cellular functions. The ability of Rho family GTPases to participate in signaling events is determined by the ratio of inactive (GDP-bound) and active (GTP-bound) forms in the cell. The activation of Rho family proteins requires the exchange of bound GDP for GTP, a process catalyzed by the Dbl family of guanine nucleotide exchange factors (GEFs). The GEFs have high affinity for the guanine nucleotide-free state of the GTPases and are thought to promote GDP release by stabilizing an intermediate transition state. In this study, we have identified and characterized a new Rac/Cdc42-specific Dbl family guanine nucleotide exchange factor, named GEFT. GEFT is highly expressed in the excitable tissues, including brain, heart, and muscle. Low or very little expression was detected in other nonexcitable tissues. GEFT has specific exchange activity for Rac and Cdc42 in our in vitro GTPase exchange assays and glutathione S-transferase-PAK pull-down assays with GTP-bound Rac1 and Cdc42. Overexpression of GEFT leads to changes in cell morphology and actin cytoskeleton re-organization, including the formation of membrane microspikes, filopodia, and lamilliopodia. Furthermore, expression of GEFT in NIH3T3 cells promotes foci formation, cell proliferation, and cell migration, possibly through the activation of transcriptional factors involved in cell growth and proliferation. Together, our data suggest that GEFT is a Rac/Cdc42-specific GEF protein that regulates cell morphology, cell proliferation, and transformation.	Texas A&M Univ, Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China; Texas A&M Univ, Hlth Sci Ctr, Dept Biochem Med & Genet, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Hunan Normal University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc Biol & Nutr, 2121 Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamu.edu		Liu, Mingyao/0000-0001-7339-5048	NHLBI NIH HHS [5R01 HL64792] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu D, 2000, ONCOGENE, V19, P5964, DOI 10.1038/sj.onc.1203992; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Penzes P, 2001, J NEUROSCI, V21, P8426, DOI 10.1523/JNEUROSCI.21-21-08426.2001; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Stafford LJ, 2002, CANCER RES, V62, P5399; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takenawa T, 2001, J CELL SCI, V114, P1801; Thrasher AJ, 2000, IMMUNOL REV, V178, P118, DOI 10.1034/j.1600-065X.2000.17803.x; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Xia CZ, 2001, P NATL ACAD SCI USA, V98, P6174, DOI 10.1073/pnas.101137298; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	77	63	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13207	13215		10.1074/jbc.M208896200	http://dx.doi.org/10.1074/jbc.M208896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547822	hybrid			2022-12-25	WOS:000182189500079
J	Ortiz-Lombardia, M; Pompeo, F; Boitel, B; Alzari, PM				Ortiz-Lombardia, M; Pompeo, F; Boitel, B; Alzari, PM			Crystal structure of the catalytic domain of the PknB serine/threonine kinase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TYROSINE KINASE; ACTIVE-SITE; SUBUNIT; SEQUENCE; INSIGHTS; COMPLEX	With the advent of the sequencing programs of prokaryotic genomes, many examples of the presence of serine/threonine protein kinases in these organisms have been identified. Moreover, these kinases could be classified as homologues of those belonging to the well characterized superfamily of the eukaryotic serine/threonine and tyrosine kinases. Eleven such kinases were recognized in the genome of Mycobacterium tuberculosis. Here we report the crystal structure of an active form of PknB, one of the four M. tuberculosis kinases that are conserved in the downsized genome of Mycobacterium leprae and are therefore presumed to play an important role in the processes that regulate the complex life cycle of mycobacteria. Our structure confirms again the extraordinary conservation of the protein kinase fold and constitutes a landmark that extends this conservation across the evolutionary distance between high eukaryotes and eubacteria. The structure of PknB, in complex with a nucleotide triphosphate analog, reveals an enzyme in the active state with an unprecedented arrangement of the Gly-rich loop associated with a new conformation of the nucleotide gamma-phosphoryl group. It presents as well a partially disordered activation loop, suggesting an induced fit mode of binding for the so far unknown substrates of this kinase or for some modulating factor(s).	Inst Pasteur, Unite Biochim Struct, URA 2185 CNRS, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ortiz-Lombardia, M (corresponding author), Inst Pasteur, Unite Biochim Struct, URA 2185 CNRS, 25 Rue Dr Roux, F-75724 Paris 15, France.	mol@ysbl.york.ac.uk; alzari@pasteur.fr	Pompeo, Frederique/Q-5772-2017	Alzari, Pedro/0000-0002-4233-1903				Ablooglu AJ, 2001, J BIOL CHEM, V276, P46933, DOI 10.1074/jbc.M107236200; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Av-Gay Y, 1999, INFECT IMMUN, V67, P5676, DOI 10.1128/IAI.67.11.5676-5682.1999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bakal CJ, 2000, TRENDS CELL BIOL, V10, P32, DOI 10.1016/S0962-8924(99)01681-5; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; FISCHER EH, 1955, J BIOL CHEM, V216, P121; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Koul A, 2001, MICROBIOL-SGM, V147, P2307, DOI 10.1099/00221287-147-8-2307; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; Leslie A. G. W.., 1992, PROTEIN CRYSTALLOGR, V26; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ogawara H, 1999, MICROBIOL-UK, V145, P3343, DOI 10.1099/00221287-145-12-3343; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Peirs P, 1997, EUR J BIOCHEM, V244, P604, DOI 10.1111/j.1432-1033.1997.00604.x; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; WANG JYJ, 1978, J BIOL CHEM, V253, P7605; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	38	132	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13094	13100		10.1074/jbc.M300660200	http://dx.doi.org/10.1074/jbc.M300660200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551895	hybrid			2022-12-25	WOS:000182189500065
J	Katafuchi, T; Kikumoto, K; Hamano, K; Kangawa, K; Matsuo, H; Minamino, N				Katafuchi, T; Kikumoto, K; Hamano, K; Kangawa, K; Matsuo, H; Minamino, N			Calcitonin receptor-stimulating peptide, a new member of the calcitonin gene-related peptide family - Its isolation from porcine brain, structure, tissue distribution, and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; RAT-BRAIN; VASOPRESSIN RECEPTOR; NATRIURETIC PEPTIDE; ADENYLATE-CYCLASE; SALMON-CALCITONIN; EXPRESSION; ADRENOMEDULLIN; POLYPEPTIDE; AMYLIN	We isolated a novel biologically active peptide, designated calcitonin receptor-stimulating peptide (CRSP), from the acid extract of the porcine brain by monitoring cAMP production in the porcine kidney cell line LLC-PK1. Determination of the amino acid sequence and cDNA analysis encoding a CRSP precursor showed that this peptide has similar to60% identity in the amino acid sequence with human calcitonin gene-related peptide type-alpha (alphaCGRP), type-beta (betaCGRP), and porcine CGRP. Northern blot analysis and radioimmunoassay demonstrated that CRSP is expressed mainly in the thyroid gland and the central nervous system, in which the calcitonin receptor was abundantly expressed. Synthetic CRSP elicited a potent stimulatory effect on the cAMP production in LLC-PK1 cells. Although it shows significant sequence similarity with CGRPs, this peptide did not elicit cAMP elevation in cells that endogenously expressed a CGRP receptor or an adrenomedullin receptor or were transfected with either of these recombinant receptors. Administration of CRSP into anesthetized rats did not alter the blood pressure but induced a transient decrease in the plasma calcium concentration. In fact, this peptide potently increased the intracellular cAMP concentration in COS-7 cells that expressed the recombinant calcitonin receptor. These unique properties indicate that CRSP is not a porcine counterpart of betaCGRP and probably elicits its biological effects via the calcitonin receptor.	Natl Cardiovasc Ctr, Inst Res, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Minamino, N (corresponding author), Natl Cardiovasc Ctr, Inst Res, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	minamino@ri.ncvc.go.jp						ALIAPOUL.MA, 1966, SCIENCE, V151, P330, DOI 10.1126/science.151.3708.330; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; FISCHER JA, 1983, J CLIN ENDOCR METAB, V57, P1314, DOI 10.1210/jcem-57-6-1314; FREED WJ, 1979, SCIENCE, V206, P850, DOI 10.1126/science.493987; FRIEDMAN J, 1965, SCIENCE, V150, P1465, DOI 10.1126/science.150.3702.1465; FRIEDMAN PA, 1993, AM J PHYSIOL, V284, pF181; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; Hilton JM, 1998, ENDOCRINOLOGY, V139, P982, DOI 10.1210/en.139.3.982; HILTON JM, 1995, NEUROSCIENCE, V69, P1223, DOI 10.1016/0306-4522(95)00322-A; HOPPENER JWM, 1986, MOL CELL ENDOCRINOL, V47, P125, DOI 10.1016/0303-7207(86)90023-7; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; IKEGAME M, 1995, J BONE MINER RES, V10, P59; Isumi Y, 1998, ENDOCRINOLOGY, V139, P2552, DOI 10.1210/en.139.5.2552; KANGAWA K, 1984, BIOCHEM BIOPH RES CO, V118, P131, DOI 10.1016/0006-291X(84)91077-5; KIKUMOTO K, IN PRESS HYPERTENS R; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MONTEMURRO L, 1991, CALCIFIED TISSUE INT, V49, P71, DOI 10.1007/BF02565124; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORLEY JE, 1981, SCIENCE, V214, P671, DOI 10.1126/science.7292006; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SEXTON PM, 1992, BRAIN RES, V596, P279, DOI 10.1016/0006-8993(92)91558-V; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; WOHLWEND A, 1986, J CELL PHYSIOL, V128, P71, DOI 10.1002/jcp.1041280112	39	80	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12046	12054		10.1074/jbc.M207970200	http://dx.doi.org/10.1074/jbc.M207970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556539	hybrid			2022-12-25	WOS:000182015700044
J	Lebreton, S; Graciet, E; Gontero, B				Lebreton, S; Graciet, E; Gontero, B			Modulation, via protein-protein interactions, of glyceraldehyde-3-phosphate dehydrogenase activity through redox phosphoribulokinase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII CHLOROPLASTS; SITE-DIRECTED MUTAGENESIS; CALVIN CYCLE ACTIVITY; C-TERMINAL EXTENSION; MULTIENZYME COMPLEXES; INFORMATION-TRANSFER; HIGHER-PLANT; ESCHERICHIA-COLI; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; SPINACH-CHLOROPLASTS	The activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) embedded in the phosphoribulokinase (PRK)-GAPDH-CP12 complex was increased 2-3-fold by reducing agents. This occurred by interaction with PRK as the cysteinyl sulfhydryls (4 SH/subunit) of GAPDH within the complex were unchanged whatever the redox state of the complex. But isolated GAPDH was not activated. Alkylation plus mass spectrometry also showed that PRK had one disulfide bridge and three SH groups per monomer in the active oxidized complex. Reduction disrupted this disulfide bridge to give 2 more SH groups and a much more active enzyme. We assessed the kinetics and dynamics of the interactions between PRK and GAPDH/CP12 using biosensors to measure complex formation in real time. The apparent equilibrium binding constant for GAPDH/CP12 and PRK was 14 +/- 1.6 nm for oxidized PRK and 62 +/- 10 nm for reduced PRK. These interactions were neither pH- nor temperature-dependent. Thus, the dynamics of PRK-GAPDH-CP12 complex formation and GAPDH activity are modulated by the redox state of PRK.	Univ Paris 06, Inst Jacques Monod, UMR 7592, CNRS, F-75251 Paris 05, France; Univ Paris 07, Inst Jacques Monod, UMR 7592, CNRS, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Gontero, B (corresponding author), Univ Paris 06, Inst Jacques Monod, UMR 7592, CNRS, 2 Pl Jussieu, F-75251 Paris 05, France.			Graciet, Emmanuelle/0000-0003-3548-8213; lebreton, Sandrine/0000-0003-4772-9467				Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; Avilan L, 1997, EUR J BIOCHEM, V250, P296, DOI 10.1111/j.1432-1033.1997.0296a.x; Avilan L, 2000, J BIOL CHEM, V275, P9447, DOI 10.1074/jbc.275.13.9447; Baalmann E, 1996, PLANT MOL BIOL, V32, P505, DOI 10.1007/BF00019102; Balmer Y, 2002, TRENDS PLANT SCI, V7, P191, DOI 10.1016/S1360-1385(02)02263-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandes HK, 1996, J BIOL CHEM, V271, P6490, DOI 10.1074/jbc.271.11.6490; Brandes HK, 1996, J BIOL CHEM, V271, P3333; CERFF R, 1979, EUR J BIOCHEM, V94, P243, DOI 10.1111/j.1432-1033.1979.tb12891.x; CLASPER S, 1994, BBA-PROTEIN STRUCT M, V1209, P101, DOI 10.1016/0167-4838(94)90143-0; CLASPER S, 1991, EUR J BIOCHEM, V202, P1239, DOI 10.1111/j.1432-1033.1991.tb16496.x; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P489, DOI 10.1016/S0968-0004(02)02191-6; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Finerty PJ, 2002, J MOL BIOL, V322, P605, DOI 10.1016/S0022-2836(02)00803-3; Geck MK, 2000, J BIOL CHEM, V275, P18034, DOI 10.1074/jbc.M001936200; Geck RK, 1996, J BIOL CHEM, V271, P24736, DOI 10.1074/jbc.271.40.24736; GIUDICIORTICONI MT, 1992, CR ACAD SCI III-VIE, V314, P477; GONTERO B, 1993, EUR J BIOCHEM, V217, P1075, DOI 10.1111/j.1432-1033.1993.tb18339.x; GONTERO B, 1988, EUR J BIOCHEM, V173, P437, DOI 10.1111/j.1432-1033.1988.tb14018.x; GONTERO B, 1994, EUR J BIOCHEM, V226, P999, DOI 10.1111/j.1432-1033.1994.00999.x; Graciet E, 2003, EUR J BIOCHEM, V270, P129, DOI 10.1046/j.1432-1033.2003.03372.x; Graciet E, 2002, J BIOL CHEM, V277, P12697, DOI 10.1074/jbc.M111121200; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; HARRIS JI, 1976, ENZYMES, V13, P1; Harrison DHT, 1998, BIOCHEMISTRY-US, V37, P5074, DOI 10.1021/bi972805y; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Lebreton S, 1997, EUR J BIOCHEM, V246, P85, DOI 10.1111/j.1432-1033.1997.t01-2-00085.x; Lebreton S, 1997, EUR J BIOCHEM, V250, P286, DOI 10.1111/j.1432-1033.1997.0286a.x; Lebreton S, 1999, J BIOL CHEM, V274, P20879, DOI 10.1074/jbc.274.30.20879; Li AD, 1997, PHOTOSYNTH RES, V51, P167; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; Miziorko HM, 2000, ADV ENZYMOL RAMB, V74, P95; Mouche F, 2002, J BIOL CHEM, V277, P6743, DOI 10.1074/jbc.M106401200; MULLER B, 1972, Z NATURFORSCH PT B, VB 27, P925, DOI 10.1515/znb-1972-0814; NICHOLSON S, 1987, EUR J BIOCHEM, V162, P423, DOI 10.1111/j.1432-1033.1987.tb10619.x; Pohlmeyer K, 1996, PLANT MOL BIOL, V32, P969, DOI 10.1007/BF00020493; Qi JF, 2001, J BIOL CHEM, V276, P35247, DOI 10.1074/jbc.M103855200; REED LJ, 1975, P NATL ACAD SCI USA, V72, P3068, DOI 10.1073/pnas.72.8.3068; Runquist JA, 2001, BIOCHEMISTRY-US, V40, P14530, DOI 10.1021/bi010778c; SAINIS JK, 1986, BIOCHEM BIOPH RES CO, V139, P947, DOI 10.1016/S0006-291X(86)80269-8; SAINIS JK, 1994, INDIAN J BIOCHEM BIO, V31, P215; Sambrook J., 2002, MOL CLONING LAB MANU; Scheibe R, 1996, BBA-PROTEIN STRUCT M, V1296, P228, DOI 10.1016/0167-4838(96)00074-X; Sparla F, 2002, J BIOL CHEM, V277, P44946, DOI 10.1074/jbc.M206873200; SUSS KH, 1995, PLANT PHYSIOL, V107, P1387, DOI 10.1104/pp.107.4.1387; SUSS KH, 1993, P NATL ACAD SCI USA, V90, P5514, DOI 10.1073/pnas.90.12.5514; Wedel N, 1997, P NATL ACAD SCI USA, V94, P10479, DOI 10.1073/pnas.94.19.10479; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; Yu LP, 1996, BIOCHEMISTRY-US, V35, P9661, DOI 10.1021/bi960507f	49	38	41	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12078	12084		10.1074/jbc.M213096200	http://dx.doi.org/10.1074/jbc.M213096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556449	hybrid, Green Accepted			2022-12-25	WOS:000182015700048
J	Basi, DL; Ross, KF; Hodges, JS; Herzberg, MC				Basi, DL; Ross, KF; Hodges, JS; Herzberg, MC			The modulation of tissue factor by endothelial cells during heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GENE-EXPRESSION; SEPSIS; ACTIVATION; INHIBITION; ATHEROSCLEROSIS; PATHOGENESIS; COAGULATION; ASSOCIATION; HERPESVIRUS	Tissue factor (TF) initiates the extrinsic coagulation cascade on the surface of macrophages and endothelial cells. In septic patients, the extrinsic coagulation cascade is activated. When septic patients are febrile, mortality is decreased. The purpose of this study was to investigate the role of elevated temperatures on TF expression by endothelial cells during a sepsis-like challenge. Human endothelial vein cells (HUVECs) were incubated with lipopolysaccharide (LPS) or interleukin-1beta (IL-1beta) for 0, 2, 4, 6, or 8 h. At the 0-h time point, some HUVECs were heat shocked at 43 C for 2 h and then recovered at 37 C for 0, 2, 4, or 6 h. Heat-shocked and non-heat-shocked LPS-stimulated HUVECs were analyzed for TF-specific mRNA expression by ribonuclease protection assay (RPA), surface TF expression by flow cytometry, and TF activity by a two-stage clotting assay. Heat shocked LPS-stimulated HUVECs expressed significantly reduced TF-specific mRNA, TF surface protein levels, and TF surface activity when compared with non-heat-shocked, LPS-stimulated HUVECs (p < 0.0125, p < 0.0125, and p < 0.0001, respectively; repeated measures analysis of variance, ANOVA). If heat shock models elevated core temperature, these results suggest that fever may protect the host during sepsis by reducing TF activity on the surface of endothelial cells.	Univ Minnesota, Sch Dent, Dept Oral Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Herzberg, MC (corresponding author), Univ Minnesota, Sch Dent, Dept Oral Sci, 17-164 Moos Tower,515 Delaware St, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011831, K16DE000270] Funding Source: NIH RePORTER; NIDCR NIH HHS [K16 DE00270, R01 DE11831] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADERKA D, 1991, ISRAEL J MED SCI, V27, P52; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BALLA G, 1990, T ASSOC AM PHYSICIAN, V103, P174; BAUER KA, 1989, THROMB RES, V56, P425, DOI 10.1016/0049-3848(89)90255-7; BRYANT RE, 1971, ARCH INTERN MED, V127, P120, DOI 10.1001/archinte.127.1.120; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu EK, 1997, CRIT CARE MED, V25, P1727, DOI 10.1097/00003246-199710000-00025; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; DRAKE TA, 1993, AM J PATHOL, V142, P1458; Esmon CT, 1999, HAEMATOLOGICA, V84, P254; Gabrielli M, 2002, CIRCULATION, V106, pE32, DOI 10.1161/01.CIR.0000025824.66358.79; Gando S, 1998, THROMB HAEMOSTASIS, V79, P1111; Gando S, 1998, CRIT CARE MED, V26, P2005, DOI 10.1097/00003246-199812000-00030; Levi M, 1997, EUR J CLIN INVEST, V27, P3, DOI 10.1046/j.1365-2362.1997.570614.x; Mackowiak PA, 1998, ARCH INTERN MED, V158, P1870, DOI 10.1001/archinte.158.17.1870; MACKOWIAK PA, 1980, AM J MED SCI, V280, P73, DOI 10.1097/00000441-198009000-00002; MAYNARD JR, 1975, J CLIN INVEST, V55, P814, DOI 10.1172/JCI107992; MINICK CR, 1979, AM J PATHOL, V96, P673; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Nieto FJ, 1996, CIRCULATION, V94, P922, DOI 10.1161/01.CIR.94.5.922; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; Pritts TA, 2000, ARCH SURG-CHICAGO, V135, P860, DOI 10.1001/archsurg.135.7.860; REGOECZI E, 1969, BRIT J HAEMATOL, V17, P73, DOI 10.1111/j.1365-2141.1969.tb05665.x; Rugonfalvi-Kiss S, 2002, CIRCULATION, V106, P1071, DOI 10.1161/01.CIR.0000027137.96791.6A; Shi Y, 2002, PATHOL INT, V52, P31, DOI 10.1046/j.1440-1827.2002.01312.x; SNYDER YM, 1992, J LEUKOCYTE BIOL, V51, P181, DOI 10.1002/jlb.51.2.181; Weiss DJ, 1998, J VET INTERN MED, V12, P317, DOI 10.1111/j.1939-1676.1998.tb02129.x; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; Yang Rei-Cheng, 1998, Kaohsiung Journal of Medical Sciences, V14, P664; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11065	11071		10.1074/jbc.M211540200	http://dx.doi.org/10.1074/jbc.M211540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538587	hybrid			2022-12-25	WOS:000181855400027
J	Escher, G; Krozowski, Z; Croft, KD; Sviridov, D				Escher, G; Krozowski, Z; Croft, KD; Sviridov, D			Expression of sterol 27-hydroxylase (CYP27A1) enhances cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; INTRACELLULAR CHOLESTEROL; CELLULAR CHOLESTEROL; TISSUE DISTRIBUTION; MACROPHAGES; CELLS; ABCA1; ELIMINATION; HOMEOSTASIS; OXYSTEROLS	Cholesterol efflux from CHOP cells transfected with sterol 27-hydroxylase (CYP27A1) was compared with non-transfected and mock-transfected cells. Transfection caused expression of CYP27A1, formation of 27-hydroxycholesterol, and inhibition of cholesterol biosynthesis. Transfection enhanced cholesterol efflux to apolipoprotein A-I or human plasma by 2-3-fold but did not affect the efflux in the absence of acceptor. The analysis of released sterols revealed that 27-hydroxycholesterol represented only a small proportion of sterols, most of which was non-oxidized cholesterol. Time course and dose dependence studies showed that expression of CYP27A1 in CHOP cells mostly affected the efflux of the "fast" cholesterol pool, and relatively more cholesterol was released with low concentrations of an acceptor. Preincubation of non-transfected cells with exogenous 27-hydroxycholesterol (10(-9) and 10(-7) M) led to the stimulation of cholesterol efflux by 24-60%. Expression of CYP27A1 in CHOP cells did not affect ABCA1 expression and abundance of ABCA1 protein. Thus, introduction of CYP27A1 into cells stimulates cholesterol efflux and therefore may increase protection against atherosclerosis.	Baker Med Res Inst, Melbourne, Vic 8008, Australia; Univ Western Australia, Dept Med, Perth, WA 6001, Australia	Baker Heart and Diabetes Institute; University of Western Australia	Sviridov, D (corresponding author), Baker Med Res Inst, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		Sviridov, Dmitri/E-7943-2010; Croft, Kevin D/C-4675-2013	Escher, Genevieve/0000-0002-5125-2262; Croft, Kevin/0000-0003-1596-4913				ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Babiker A, 1998, BBA-LIPID LIPID MET, V1392, P333, DOI 10.1016/S0005-2760(98)00047-2; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; Edwards PA, 2002, J LIPID RES, V43, P2; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Gaus K, 2001, BIOCHEMISTRY-US, V40, P9363, DOI 10.1021/bi010323n; Gaus K, 2001, BIOCHEMISTRY-US, V40, P13002, DOI 10.1021/bi010833h; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; Meir K, 2002, J BIOL CHEM, V277, P34036, DOI 10.1074/jbc.M201122200; Mori TA, 1996, REDOX REP, V2, P25, DOI 10.1080/13510002.1996.11747023; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; von Bahr S, 2002, ARTERIOSCL THROM VAS, V22, P1129, DOI 10.1161/01.ATV.0000022600.61391.A5; Westman J, 1998, ARTERIOSCL THROM VAS, V18, P554, DOI 10.1161/01.ATV.18.4.554	29	55	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11015	11019		10.1074/jbc.M212780200	http://dx.doi.org/10.1074/jbc.M212780200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531903	hybrid			2022-12-25	WOS:000181855400020
J	Vespa, A; Darmon, AJ; Turner, CE; D'Souza, SJA; Dagnino, L				Vespa, A; Darmon, AJ; Turner, CE; D'Souza, SJA; Dagnino, L			Ca2+-dependent localization of integrin-linked kinase to cell junctions in differentiating keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDUCED CHANGES; EPIDERMAL-KERATINOCYTES; MEMBRANE RAFTS; BETA-CATENIN; ADHESION; PROTEIN; EXPRESSION; BETA-1-INTEGRINS; CYTOSKELETON; MATRIX	Integrin complexes are necessary for proper proliferation and differentiation of epidermal keratinocytes. Differentiation of these cells is accompanied by down-regulation of integrins and focal adhesions as well as formation of intercellular adherens junctions through E-cadherin homodimerization. A central component of integrin adhesion complexes is integrin-linked kinase (ILK), which can induce loss of E-cadherin expression and epithelial-mesenchymal transformation when ectopically expressed in intestinal and mammary epithelia. In cultured primary mouse keratinocytes, we find that ILK protein levels are independent of integrin expression and signaling, since they remain constant during Ca2+-induced differentiation. In contrast, keratinocyte differentiation is accompanied by marked reduction in kinase activity in ILK immunoprecipitates and altered ILK subcellular distribution. Specifically, ILK distributes in close apposition to actin fibers along intercellular junctions in differentiated but not in undifferentiated keratinocytes. ILK localization to cell-cell borders occurs independently of integrin signaling and requires Ca2+ as well as an intact actin cytoskeleton. Further, and in contrast to what is observed in other epithelial cells, ILK overexpression in differentiated keratinocytes does not promote E-cadherin down-regulation and epithelial-mesenchymal transition. Thus, novel tissue-specific mechanisms control the formation of ILK complexes associated with cell-cell junctions in differentiating murine epidermal keratinocytes.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Pediat, London, ON N6A 5C1, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada; SUNY Syracuse, Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	D'Souza, SJA (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	sjdsouza@uwo.ca; ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159	NHLBI NIH HHS [HL70244] Funding Source: Medline; NIGMS NIH HHS [R01 GM047607] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070244] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Boesze-Battaglia K, 2002, J BIOL CHEM, V277, P41843, DOI 10.1074/jbc.M207111200; BRAGA VMM, 1995, CELL ADHES COMMUN, V3, P201, DOI 10.3109/15419069509081287; Braga VMM, 1998, CELL ADHES COMMUN, V5, P137, DOI 10.3109/15419069809040287; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERTLE MD, 1991, DEVELOPMENT, V112, P193; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; JENSEN PJ, 1995, EXP CELL RES, V219, P322, DOI 10.1006/excr.1995.1235; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Li FG, 1999, J CELL SCI, V112, P4589; Li LW, 1996, J INVEST DERMATOL, V106, P254, DOI 10.1111/1523-1747.ep12340654; Lozano E, 1998, CELL ADHES COMMUN, V6, P51, DOI 10.3109/15419069809069760; MAGEE AI, 1987, EXP CELL RES, V172, P43, DOI 10.1016/0014-4827(87)90091-7; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rikimaru K, 1997, EXP DERMATOL, V6, P214, DOI 10.1111/j.1600-0625.1997.tb00165.x; Somasiri A, 2001, J CELL SCI, V114, P1125; Travis AJ, 2001, DEV BIOL, V240, P599, DOI 10.1006/dbio.2001.0475; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728; ZINKEL S, 1994, SEMIN CANCER BIOL, V5, P77	43	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11528	11535		10.1074/jbc.M208337200	http://dx.doi.org/10.1074/jbc.M208337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547824	hybrid			2022-12-25	WOS:000181855400085
J	Xiao, H; Chung, J; Kao, HY; Yang, YC				Xiao, H; Chung, J; Kao, HY; Yang, YC			Tip60 is a co-repressor for STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; RECEPTOR-ALPHA-CHAIN; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; COMPLEX CONTAINS; GENE-EXPRESSION; CLASS-I; PROTEIN; ACETYLATION; COREPRESSOR	Tip60 (Tat-interactive protein, 60 kDa), a cellular protein with intrinsic histone acetyltransferase activity, is involved in DNA damage repair and apoptosis. Recent studies have suggested that Tip60 acts either as a coactivator or a co-repressor to modulate transcription. In this study, we demonstrate that Tip60 represses reporter gene expression when it is fused to the Ga14 DNA binding domain. We also show that Tip60 associates with histone deacetylase 7 (HDAC7) through its N-terminal zinc finger-containing region and that HDAC7 activity is required for the repressive effect of Tip60. Because endogenous Tip60 interacts with STAT3, we hypothesized that Tip60 might complex with STAT3 and HDAC7 and modulate STAT3-mediated trans-activation. Consistent with this hypothesis, the overexpression of Tip60 represses STAT3-driven reporter gene expression, which can be further potentiated by the co-transfection of HDAC7. Furthermore, interleukin-9-induced c-myc expression, which depends on STAT3 activity, is abrogated by exogenous expression of Tip60. This is the first demonstration of which Tip60 represses STAT3 activity in part through the recruitment of HDAC7.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER; NCI NIH HHS [CA78433] Funding Source: Medline; NHLBI NIH HHS [HL48819] Funding Source: Medline; NIDDK NIH HHS [DK50570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DERUIJTER AJ, 2003, IN PRESS BIOCH J; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Grienenberger A, 2002, CURR BIOL, V12, P762, DOI 10.1016/S0960-9822(02)00814-X; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hlubek F, 2001, J BIOCHEM-TOKYO, V129, P635, DOI 10.1093/oxfordjournals.jbchem.a002901; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Huynh KD, 2000, GENE DEV, V14, P1810; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lejeune D, 2001, BIOCHEM J, V353, P109, DOI 10.1042/bj3530109; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lough JW, 2002, DEV DYNAM, V223, P419, DOI 10.1002/dvdy.10058; McAllister D, 2002, GENE, V289, P169, DOI 10.1016/S0378-1119(02)00546-2; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; RAN Q, 2002, GENE, V258, P169; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xiao H, 2002, J BIOL CHEM, V277, P8091, DOI 10.1074/jbc.M106650200; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	60	89	94	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11197	11204		10.1074/jbc.M210816200	http://dx.doi.org/10.1074/jbc.M210816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551922	hybrid			2022-12-25	WOS:000181855400045
J	Zhang, Y; Yu, CJ; Liu, J; Spencer, TA; Chang, CCY; Chang, TY				Zhang, Y; Yu, CJ; Liu, J; Spencer, TA; Chang, CCY; Chang, TY			Cholesterol is superior to 7-ketocholesterol or 7 alpha-hydroxycholesterol as an allosteric activator for acyl-coenzyme A : cholesterol acyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; OXYSTEROLS; CELLS; VESICLES; OXIDATION; MICELLES; LIVER; RECONSTITUTION; LOCALIZATION; QUANTITATION	We compared the abilities of cholesterol versus various oxysterols as substrate and/or as activator for the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT), by monitoring the activity of purified human ACAT1 in response to sterols solubilized in mixed micelles or in reconstituted vesicles. The results showed that 5alpha,6alpha-epoxycholesterol and 7alpha-hydroxycholesterol are comparable with cholesterol as the favored substrates, whereas 7-ketocholesterol, 7beta-hydroxycholesterol, 5beta,6beta-epoxycholesterol, and 24(S),25-epoxycholesterol are very poor substrates for the enzyme. We then tested the ability of 7-ketocholesterol as an activator when cholesterol was measured as the substrate, and vice versa. When cholesterol was measured as the substrate, the addition of 7-ketocholesterol could not activate the enzyme. In contrast, when 7-ketocholesterol was measured as the substrate, the addition of cholesterol significantly activated the enzyme and changed the shape of the substrate saturation curve from sigmoidal to essentially hyperbolic. Additional results show that, as an activator, cholesterol is much better than all the oxysterols tested. These results suggest that ACAT1 contains two types of sterol binding sites; the structural requirement for the ACAT activator site is more stringent than it is for the ACAT substrate site. Upon activation by cholesterol, ACAT1 becomes promiscuous toward various sterols as its substrate.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Chang, TY (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	Ta.Yuan.Chang@Dartmouth.edu	Yu, Chunjiang/E-9419-2012	Liu, Jay/0000-0002-4230-1843; Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjorkhem I, 2002, J CLIN INVEST, V110, P725, DOI 10.1172/JCI200216388; Brown AJ, 2000, J LIPID RES, V41, P226; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BROWN MS, 1975, J BIOL CHEM, V250, P4925; CADIGAN KM, 1988, J LIPID RES, V29, P1683; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6; ERICKSON SK, 1980, J LIPID RES, V21, P930; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; Kauffman JM, 2000, J LIPID RES, V41, P991; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LI QT, 1994, ARCH BIOCHEM BIOPHYS, V315, P473, DOI 10.1006/abbi.1994.1527; LICHTENSTEIN AH, 1980, J BIOL CHEM, V255, P9098; Lu XH, 2002, J BIOL CHEM, V277, P711, DOI 10.1074/jbc.M109427200; Moschetta A, 2001, BBA-MOL CELL BIOL L, V1532, P15, DOI 10.1016/S1388-1981(01)00110-X; Patel RP, 1996, J LIPID RES, V37, P2361; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SHI SP, 1989, BIOCHIM BIOPHYS ACTA, V982, P187, DOI 10.1016/0005-2736(89)90054-0; Spencer TA, 2000, J ORG CHEM, V65, P1919, DOI 10.1021/jo991370c; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; THEUNISSEN JJH, 1986, BIOCHIM BIOPHYS ACTA, V860, P66, DOI 10.1016/0005-2736(86)90499-2; Tomkinson NCO, 1998, J ORG CHEM, V63, P9919, DOI 10.1021/jo981753v; VENTIMIGLIA JB, 1986, ANAL BIOCHEM, V157, P323, DOI 10.1016/0003-2697(86)90633-0; Verhagen JCD, 1996, J LIPID RES, V37, P1488; White T, 1998, ANAL BIOCHEM, V258, P109, DOI 10.1006/abio.1997.2545; Yu CJ, 2002, BIOCHEMISTRY-US, V41, P3762, DOI 10.1021/bi0120188; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139	39	57	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11642	11647		10.1074/jbc.M211559200	http://dx.doi.org/10.1074/jbc.M211559200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12533546	hybrid			2022-12-25	WOS:000181855400097
J	Low, WK; Lin, QS; Hew, CL				Low, WK; Lin, QS; Hew, CL			The role of N and C termini in the antifreeze activity of winter flounder (Pleuronectes americanus) antifreeze proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN-TYPE; ICE; BINDING; POLYPEPTIDES; MECHANISM; ADSORPTION; SCULPIN; INHIBITION; PRECURSOR; PEPTIDES	Antifreeze proteins (AFPs) are found in many marine fish and have been classified into five biochemical classes: AFP types I-IV and the antifreeze glycoproteins. Type I AFPs are a-helical, partially amphipathic, Alarich polypeptides. The winter flounder (Pleuronectes americanus) produces two type I AFP subclasses, the liver-type AFPs (wflAFPs) and the skin-type AFPs (wfsAFPs), that are encoded by distinct gene families with different tissue-specific expression. wfsAFPs and wflAFPs share a high level of identity even though the wfsAFPs have approximately half the activity of the wflAFPs. Synthetic polypeptides based on two representative wflAFPs and wfsAFPs were generated to examine the role of the termini in antifreeze activity. Through systematic exchange of N and C termini between wflAFP-6 and wfsAFP-2, the termini were determined to be the major causative agents for the variation in activity levels between the two AFPs. Furthermore, the termini of wflALFP-6 possessed greater helix-stabilizing ability compared with their wfsAFP-2 counterparts. The observed 50% difference in activity between wflAFP-6 and wfsAFP-2 can be divided into similar to20% for differences at each termini and similar to10% for differences in the core. Furthermore, the N terminus was determined to be the most critical component for antifreeze activity.	Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore; Hosp Sick Children, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	National University of Singapore; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Hew, CL (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore.	dbshead@nus.edu.sg	Lin, Qingsong/H-9794-2012; Hew, Choy Leong/I-1501-2012	Lin, Qingsong/0000-0001-9117-8514; Hew, Choy Leong/0000-0002-9441-0064				Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Barrett J, 2001, INT J BIOCHEM CELL B, V33, P105, DOI 10.1016/S1357-2725(00)00083-2; CARPINO LA, 1994, TETRAHEDRON LETT, V35, P2279, DOI 10.1016/0040-4039(94)85198-0; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1988, CAN J ZOOL, V66, P403, DOI 10.1139/z88-057; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; Chao HM, 1997, BIOCHEMISTRY-US, V36, P14652, DOI 10.1021/bi970817d; CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1982, P NATL ACAD SCI-BIOL, V79, P335, DOI 10.1073/pnas.79.2.335; DEVRIES AL, 1977, BIOCHIM BIOPHYS ACTA, V495, P388, DOI 10.1016/0005-2795(77)90395-6; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Freire E, 1995, METHOD ENZYMOL, V259, P144; Gong ZY, 1996, J BIOL CHEM, V271, P4106, DOI 10.1074/jbc.271.8.4106; Graether SP, 2001, BIOPHYS J, V81, P1677, DOI 10.1016/S0006-3495(01)75821-3; Greenfield NJ, 1999, TRAC-TREND ANAL CHEM, V18, P236, DOI 10.1016/S0165-9936(98)00112-5; Gronwald W, 1996, BIOCHEMISTRY-US, V35, P16698, DOI 10.1021/bi961934w; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; Haymet ADJ, 1998, FEBS LETT, V430, P301, DOI 10.1016/S0014-5793(98)00652-8; Haymet ADJ, 1999, J AM CHEM SOC, V121, P941, DOI 10.1021/ja9801341; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; HEW CL, 1985, EUR J BIOCHEM, V151, P167, DOI 10.1111/j.1432-1033.1985.tb09081.x; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Lin GS, 1999, FEBS LETT, V453, P331, DOI 10.1016/S0014-5793(99)00752-8; Loewen MC, 1999, BIOCHEMISTRY-US, V38, P4743, DOI 10.1021/bi982602p; Low WK, 2001, J BIOL CHEM, V276, P11582, DOI 10.1074/jbc.M009293200; Lu M, 1999, J MOL BIOL, V288, P743, DOI 10.1006/jmbi.1999.2707; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SHEPPARD RC, 1983, CHEM BRIT, V19, P402; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Zhang W, 1998, J BIOL CHEM, V273, P34806, DOI 10.1074/jbc.273.52.34806	38	4	7	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10334	10343		10.1074/jbc.M300081200	http://dx.doi.org/10.1074/jbc.M300081200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525484	hybrid			2022-12-25	WOS:000181777500047
J	Mosley, AL; Lakshmanan, J; Aryal, BK; Ozcan, S				Mosley, AL; Lakshmanan, J; Aryal, BK; Ozcan, S			Glucose-mediated phosphorylation converts the transcription factor Rgt1 from a repressor to an activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST; REGULATOR; MEIOSIS; SENSORS; UME6; MTH1; INDUCTION; ENCODES	Glucose, the most abundant carbon and energy source, regulates the expression of genes required for its own efficient metabolism. In the yeast Saccharomyces cerevisiae, glucose induces the expression of the hexose transporter (HXT) genes by modulating the activity of the transcription factor Rgt1 that functions as a repressor when glucose is absent. However, in the presence of high concentrations of glucose, Rgt1 is converted from a repressor to an activator and is required for maximal induction of HXT1 gene expression. We report that Rgt1 binds to the LXT1 promoter only in the absence of glucose, suggesting that Rgt1 increases HXT1 gene expression at high levels of glucose by an indirect mechanism. It is likely that Rgt1 stimulates the expression of an activator of the HXT1 gene at high concentrations of glucose. In addition, we demonstrate that Rgt1 becomes hyperphosphorylated in response to high glucose levels and that this phosphorylation. event is required for Rgt1 to activate transcription. Furthermore, Rgt1 lacks the glucose-mediated phosphorylation in the snf3 rgt2 and grr1 mutants, which are defective in glucose induction of HXT gene expression. In these mutants, Rgt1 behaves as a constitutive repressor independent of the carbon source. We conclude that phosphorylation. of Rgt1 in response to glucose is required to abolish the Rgt1-mediated repression of the HXT genes and to convert Rgt1 from a transcriptional repressor to an activator.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, 800 Rose St,MN 608, Lexington, KY 40536 USA.	sozcan@uky.edu						Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; BOWDISH KS, 1995, MOL CELL BIOL, V15, P2955; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Hepworth SR, 1998, MOL CELL BIOL, V18, P5750, DOI 10.1128/MCB.18.10.5750; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MANDEL S, 1994, DEV GENET, V15, P139, DOI 10.1002/dvg.1020150204; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, MOL CELL BIOL, V16, P6419; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; RubinBejerano I, 1996, MOL CELL BIOL, V16, P2518; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Schulte F, 2000, J BACTERIOL, V182, P540, DOI 10.1128/JB.182.2.540-542.2000; Steber CM, 1995, P NATL ACAD SCI USA, V92, P12490, DOI 10.1073/pnas.92.26.12490; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Washburn BK, 2001, MOL CELL BIOL, V21, P2057, DOI 10.1128/MCB.21.6.2057-2069.2001; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xiao Y, 2000, MOL CELL BIOL, V20, P5447, DOI 10.1128/MCB.20.15.5447-5453.2000; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	33	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10322	10327		10.1074/jbc.M212802200	http://dx.doi.org/10.1074/jbc.M212802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12527758	hybrid			2022-12-25	WOS:000181777500045
J	Zha, XH; Gauthier, A; Genest, J; McPherson, R				Zha, XH; Gauthier, A; Genest, J; McPherson, R			Secretory vesicular transport from the golgi is altered during ATP-binding cassette protein A1 (ABCA1)-mediated cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CHOLESTEROL; CELLS; RAFTS; ABC1	Apolipoprotein AI (apoAI)-mediated cholesterol efflux is a process by which cells export excess cellular cholesterol to apoAI to form high density lipoprotein. ATP-binding cassette protein A1 (ABCA1) has recently been identified as the key regulator of this process. The pathways of intracellular cholesterol transport during efflux are largely unknown nor is the molecular mechanism by which ABCA1 governs cholesterol efflux well, understood. Here, we report that, in both macrophages and fibroblasts, the secretory vesicular transport changes in response to apoAI-mediated cholesterol efflux. Vesicular transport from the Golgi to the plasma membrane increased 2-fold during efflux. This increase in vesicular transport during efflux was observed in both raft-poor and raft-rich vesicle populations originated from the Golgi. Importantly, enhanced vesicular transport in response to apoAI is absent in Tangier fibroblasts, a cell type with deficient cholesterol efflux due to functional ABCA1 mutations. These findings are consistent with an efflux model whereby cholesterol is transported from the storage site to the plasma membrane via the Golgi. ABCA1 may influence cholesterol efflux in part by enhancing vesicular trafficking from the Golgi to the plasma membrane.	Univ Ottawa, Ottawa Hlth Res Inst, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W9, Canada; McGill Univ, Ctr Hlth, Div Cardiol, Montreal, PQ H3A 1A1, Canada	University of Ottawa; Ottawa Hospital Research Institute; McGill University	Zha, XH (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Lipoprot & Atherosclerosis Grp, 725 Parkdale Ave, Ottawa, ON K1Y 4W9, Canada.	xzha@ohri.ca; rmcpherson@ottawaheart.ca						Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Ito J, 2002, J BIOL CHEM, V277, P7929, DOI 10.1074/jbc.M103878200; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Mendez AJ, 1996, J LIPID RES, V37, P2510; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Oram JF, 1996, J LIPID RES, V37, P2473; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200	16	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10002	10005		10.1074/jbc.C300024200	http://dx.doi.org/10.1074/jbc.C300024200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12551894	hybrid			2022-12-25	WOS:000181777500002
J	Strehl, S; Borkhardt, A; Slany, R; Fuchs, UE; Konig, M; Haas, OA				Strehl, S; Borkhardt, A; Slany, R; Fuchs, UE; Konig, M; Haas, OA			The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21)	ONCOGENE			English	Article						MLL gene; LASP1 gene; fusion transcript; t(11 ; 17)(q23 ; q21); retroviral transduction	HEMATOLOGICAL MALIGNANCIES; FUSION PARTNER; HRX-ENL; PROTEIN; LEUKEMOGENESIS; LIM	The MLL gene at chromosome 11q23 is frequently rearranged in acute leukemia. Here we report the identification of a new MLL fusion partner in the case of an infant with AML-M4 and a t(11;17)(q23;q21) translocation. Fluorescence in situ hybridization (FISH) and RT-PCR analyses indicated a rearrangement of the MLL gene, but no fusion with previously identified MLL fusion partners at 17q, such as AF17 or MSF. Rapid amplification of cDNA ends (RACE) revealed an in-frame fusion of MLL to LASP1, a gene that is amplified and overexpressed in breast cancer. Retroviral transduction of myeloid progenitors demonstrated that MLL/LASP1 is the fourth known fusion of MLL with a cytoplasmic protein that has no in vitro transformation capability, thus establishing a potential subgroup among the MLL fusion proteins.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Giessen, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany; Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	Saint Anna Children's Hospital; Justus Liebig University Giessen; University of Erlangen Nuremberg	Haas, OA (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	oskar.haas@ccri.univie.ac.at	Haas, Oskar/AAM-5794-2020	Strehl, Sabine/0000-0002-0179-0628				Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Borkhardt A, 2001, GENE CHROMOSOME CANC, V32, P82, DOI 10.1002/gcc.1169; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Chew CS, 2000, J CELL SCI, V113, P2035; Chew CS, 1998, AM J PHYSIOL-CELL PH, V275, pC56, DOI 10.1152/ajpcell.1998.275.1.C56; Daheron L, 2001, GENE CHROMOSOME CANC, V31, P382, DOI 10.1002/gcc.1157; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Felix C A, 1999, Oncologist, V4, P225; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Schreiber V, 1998, GENE, V207, P171, DOI 10.1016/S0378-1119(97)00622-7; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Taki T, 1999, CANCER RES, V59, P4261; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; von Bergh A, 2000, GENE CHROMOSOME CANC, V28, P14, DOI 10.1002/(SICI)1098-2264(200005)28:1<14::AID-GCC2>3.3.CO;2-O	27	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					157	160		10.1038/sj.onc.1206042	http://dx.doi.org/10.1038/sj.onc.1206042			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527918				2022-12-25	WOS:000180166900017
J	Gu, BH; Johnston, VK; Gutshall, LL; Nguyen, TT; Gontarek, RR; Darcy, MG; Tedesco, R; Dhanak, D; Duffy, KJ; Kao, CC; Sarisky, RT				Gu, BH; Johnston, VK; Gutshall, LL; Nguyen, TT; Gontarek, RR; Darcy, MG; Tedesco, R; Dhanak, D; Duffy, KJ; Kao, CC; Sarisky, RT			Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; E2-NS2 REGION; IN-VITRO; NON-A; POLYMERASE; IDENTIFICATION; NS5B; REQUIREMENTS; TEMPLATE; REPLICATION	The hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRp), the primary catalytic enzyme of the HCV replicase complex. Recently, two benzo-1,2,4-thiadiazine compounds were shown to be potent, highly specific inhibitors of the genotype 1b HCV RdRp containing a carboxyl-terminal 21 residue truncation (Delta21 HCV RdRp) (Dhanak, D., Duffy, K., Johnston, V. K., Lin-Goerke, J., Darcy, M., Shaw, A. N. G. B., Silverman, C., Gates, A. T., Earnshaw, D. L., Casper, D. J., Kaura, A., Baker, A., Greenwood, C., Gutshall, L. L., Maley, D., DelVecchio, A., Macarron, R., Hofmann, G. A., Alnoah, Z., Cheng, H.-Y., Chan, G., Khandekar, S., Keenan, R. M., and Sarisky, R. T. (2002) J. Biol. Chem. 277, 38322-38327). Compound 4 (C21H21N3O4S) reduces viral replication by virtue of its direct interaction with the viral polymerase rather than by nonspecific titration of nucleic acid template. In this study, we present several lines of evidence to demonstrate that this inhibitor interferes with the initiation step of RNA synthesis rather than acting as an elongation inhibitor. Inhibition of initial phosphodiester bond formation occurred regardless of whether replication was initiated by primer-dependent or de novo mechanisms. Filter binding studies using increasing concentrations of compound 4 did not interfere with the ability of Delta21 HCV RdRp to interact with nucleic acid. Furthermore, varying the order of reagent addition in the primer extension assay showed no distinct differences in inhibition profile. Finally, surface plasmon resonance analyses provided evidence that a ternary complex is capable of forming between the RNA template, RdRp, and compound 4. Together, these data suggest that this heterocyclic agent interacts with the apoenzyme, as well as with the RNA-bound form of Delta21 HCV RdRp, and therefore does not directly interfere with the RdRp-RNA interaction to mediate inhibition.	GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Virol, Bloomington, IN 47405 USA; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Biochem, Bloomington, IN 47405 USA; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Med Chem, Bloomington, IN 47405 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Indiana University System; Indiana University Bloomington	Sarisky, RT (corresponding author), Centocor Inc, Dept Infect Dis, R-4-1,200 Great Valley Pkwy, Malvern, PA 19355 USA.	rsarisky@cntus.jnj.com		Duffy, Kevin/0000-0002-7184-2059; Tedesco, Rosanna/0000-0001-8489-2381				BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Irie M, 1999, PHARMACOL THERAPEUT, V81, P77, DOI 10.1016/S0163-7258(98)00035-7; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kim MJ, 2001, P NATL ACAD SCI USA, V98, P4972, DOI 10.1073/pnas.081077198; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; Shim JH, 2002, J VIROL, V76, P7030, DOI 10.1128/JVI.76.14.7030-7039.2002; Sun JH, 1997, VIROLOGY, V236, P348, DOI 10.1006/viro.1997.8742; Sun JH, 1997, VIROLOGY, V233, P63, DOI 10.1006/viro.1997.8583; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	35	76	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16602	16607		10.1074/jbc.M210891200	http://dx.doi.org/10.1074/jbc.M210891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12554734	hybrid			2022-12-25	WOS:000182818600022
J	Hu, G; Zhang, ZX; Wensel, TG				Hu, G; Zhang, ZX; Wensel, TG			Activation of RGS9-1GTPase acceleration by its membrane anchor, R9AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENT MEMBRANES; CRYO-ELECTRON MICROSCOPY; INHIBITORY GAMMA-SUBUNIT; CGMP-BINDING SITES; G-PROTEIN; GTPASE ACCELERATION; ROD PHOTORESPONSE; RETINAL RODS; PHOSPHODIESTERASE; PHOTOTRANSDUCTION	The GTPase-accelerating protein (GAP) complex RGS9-1(.)Gbeta(5) plays an important role in the kinetics of light responses by accelerating the GTP hydrolysis of Gat in vertebrate photoreceptors. Much, but not all, of this complex is tethered to disk membranes by the transmembrane protein R9AP. To determine the effect of the R9AP membrane complex on GAP activity, we purified recombinant R9AP and reconstituted it into lipid vesicles along with the photon receptor rhodopsin. Full-length RGS9-1(.)Gbeta(5) bound to R9AP-containing vesicles with high affinity (K-d < 10 nm), but constructs lacking the DEP (dishevelled/EGL-10/pleckstrin) domain bound with much lower affinity, and binding of those lacking the entire N-terminal domain (i.e. the dishevelled/EGL-10/pleekstrin domain plus intervening domain) was not detectable. Formation of the membrane-bound complex with R9AP increased RGS9-1 GAP activity by a factor of 4. Vesicle titrations revealed that on the time scale of phototransduction, the entire reaction sequence from GTP uptake to GAP-catalyzed hydrolysis is a membrane-delimited process, and exchange of Gat between membrane surfaces is much slower than hydrolysis. Because in rod cells different pools exist of RGS9-1(.)Gbeta(5) that are either associated with R9AP or not, regulation of the association between R9AP and RGS9-1(.)Gbeta(5) represents a potential mechanism for the regulation of recovery kinetics.	Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	twensel@bcm.tmc.edu	Hu, Guang/E-7474-2016	Hu, Guang/0000-0003-0437-4723; Wensel, Theodore/0000-0003-3518-9352				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; Calvert PD, 2002, J GEN PHYSIOL, V119, P129, DOI 10.1085/jgp.119.2.129; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HENSELMAN RA, 1974, BIOCHEMISTRY-US, V13, P5199, DOI 10.1021/bi00722a023; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Lyubarsky A, 2001, MOL VIS, V7, P71; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2002, J BIOL CHEM, V277, P32843, DOI 10.1074/jbc.M205170200; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Parmar MM, 1999, BBA-BIOMEMBRANES, V1421, P77, DOI 10.1016/S0005-2736(99)00118-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Quick M, 2002, P NATL ACAD SCI USA, V99, P8597, DOI 10.1073/pnas.132266599; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sokal I, 2003, J BIOL CHEM, V278, P8316, DOI 10.1074/jbc.M211782200; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zhang X, 2003, J NEUROSCI, V23, P1287, DOI 10.1523/JNEUROSCI.23-04-01287.2003	40	60	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14550	14554		10.1074/jbc.M212046200	http://dx.doi.org/10.1074/jbc.M212046200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12560335	hybrid			2022-12-25	WOS:000182405000123
J	Munoz-Pinedo, C; Ruiz-Ruiz, C; de Almodovar, CR; Palacios, C; Lopez-Rivas, A				Munoz-Pinedo, C; Ruiz-Ruiz, C; de Almodovar, CR; Palacios, C; Lopez-Rivas, A			Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRAIL-INDUCED APOPTOSIS; NECROSIS-FACTOR; CASPASE-8 ACTIVATION; MOLECULAR-CLONING; SURFACE ANTIGEN; C-FLIP; CD95; FAS; LIGAND	Tumors display a high rate of glucose uptake and glycolysis. We investigated how inhibition of glucose metabolism could affect death receptor-mediated apoptosis in human tumor cells of diverse origin. We show that both substitution of glucose for pyruvate and treatment with 2-deoxyglucose enhanced apoptosis induced by tumor necrosis factor (TNF)-alpha, CD95 agonistic antibody, and TNF-related apoptosis-inducing ligand (TRAIL). Inhibition of glucose metabolism enhanced killing of myeloid leukemia U937, cervical carcinoma HeLa, and breast carcinoma MCF-7 cells upon death receptor ligation. Caspase activation, mitochondrial depolarization, and cytochrome c release were increased under these conditions. Glucose deprivation-mediated sensitization to apoptosis was prevented in MCF-7 cells overexpressing BCL-2. Interestingly, the human B-lymphoblastoid cell line SKW6.4, a prototype for mitochondria-independent death receptor-induced apoptosis, was also sensitized to anti-CD95 and TRAIL-induced apoptosis under glucose-free conditions. Changes in c-FLIPL and cFLIPs levels were observed in some but not all the cell lines studied following glucose deprivation. Glucose deprivation enhanced death receptor-triggered formation of death-inducing signaling complex and early processing of procaspase-8. Altogether, these results suggest that the glycolytic pathway may be an important target for therapeutic intervention to sensitize tumor cells to selectively toxic soluble death ligands or death ligand-expressing cells of the immune system by facilitating the activation of initiator caspase-8.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.	alrivas@ipb.csic.es	Ruiz-Ruiz, Carmen/I-8792-2017; Palacios, Carmen/G-7422-2015; Munoz-Pinedo, Cristina/B-6118-2008; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Palacios, Carmen/0000-0002-1267-2619; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Ruiz de Almodovar, Carmen/0000-0001-5975-7815; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Berridge MV, 1996, J IMMUNOL, V156, P4092; Binder C, 1997, EXP CELL RES, V236, P223, DOI 10.1006/excr.1997.3718; BRAHMA CA, 1998, MOL CELL BIOL, V18, P6353; Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Dirks W, 1997, BRIT J HAEMATOL, V96, P584, DOI 10.1046/j.1365-2141.1997.d01-2048.x; Eguchi Y, 1997, CANCER RES, V57, P1835; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fulda S, 2000, CANCER RES, V60, P3947; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; HALICKA HD, 1995, CANCER RES, V55, P444; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; Ko YG, 1999, J IMMUNOL, V162, P7217; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Latta M, 2000, J EXP MED, V191, P1975, DOI 10.1084/jem.191.11.1975; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Linsinger G, 1999, MOL CELL BIOL, V19, P3299; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mohanti BK, 1996, INT J RADIAT ONCOL, V35, P103, DOI 10.1016/S0360-3016(96)85017-6; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; Obrador E., 2001, Current Pharmaceutical Biotechnology, V2, P119; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RACKER E, 1972, AM SCI, V60, P56; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THAKKAR NS, 1993, CANCER RES, V53, P2057; THAMS P, 1988, BIOCHEM J, V253, P229, DOI 10.1042/bj2530229; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLLAND S, 1992, INT J CANCER, V52, P384, DOI 10.1002/ijc.2910520310; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x	70	86	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12759	12768		10.1074/jbc.M212392200	http://dx.doi.org/10.1074/jbc.M212392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556444	hybrid			2022-12-25	WOS:000182189500024
J	Dai, CS; Yang, JW; Liu, YH				Dai, CS; Yang, JW; Liu, YH			Transforming growth factor-beta 1 potentiates renal tubular epithelial cell death by a mechanism independent of smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; ANGIOTENSIN-II; MYOFIBROBLAST TRANSITION; INTERSTITIAL FIBROSIS; URETERAL OBSTRUCTION; MAP KINASES; APOPTOSIS; GENE; EXPRESSION	Tubular atrophy resulting from epithelial cell loss is one of the characteristic features in the development of chronic renal interstitial fibrosis. Although the trigger(s) and mechanism for tubular cell loss remain undefined, the hyperactive transforming growth factor (TGF)-beta1 signaling has long been suspected to play an active role. Here we demonstrate that although TGF-beta1 did not induce cell death per se, it dramatically potentiated renal tubular cell apoptosis initiated by other death cues in vitro. Pre-incubation of human kidney epithelial cells (HKC) with TGF-beta1 markedly promoted staurosporine-induced cell death in a time- and dose-dependent manner. TGF-beta1 dramatically accelerated the cleavage and activation of pro-caspase-9, but not pro-caspase-8, in HKC cells. This event was followed by an accelerated activation of pro-caspase-3. To elucidate the mechanism underlying TGF-beta1 promotion of tubular cell death, we investigated the signaling pathways activated by TGF-beta1. Both Smad-2 and p38 mitogen-activated protein (MAP) kinase were rapidly activated by TGF-beta1, as demonstrated by the early induction of phosphorylated Smad-2 and p38 MAP kinase, respectively. We found that overexpression of inhibitory Smad-7 completely abolished Smad-2 phosphorylation and activation induced by TGF-beta1 but did not inhibit TGF-beta1-induced apoptosis. However, suppression of p38 MAP kinase with chemical inhibitor SC68376 not only abolished p38 MAP kinase phosphorylation but also obliterated apoptosis induced by TGF-beta1. These results suggest that hyperactive TGF-beta1 signaling potentiates renal tubular epithelial cell apoptosis by a Smad-independent, p38 MAP kinase-dependent mechanism.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, YH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, S-405 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	liuy@msx.upmc.edu		Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002611, R01DK061408, R01DK054922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-61408, DK-02611, DK-54922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Border WA, 1998, HYPERTENSION, V31, P181, DOI 10.1161/01.HYP.31.1.181; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chevalier RL, 1999, PEDIATR NEPHROL, V13, P612, DOI 10.1007/s004670050756; Chevalier RL, 2000, EXP NEPHROL, V8, P115; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Dai CS, 2002, J AM SOC NEPHROL, V13, P411, DOI 10.1681/ASN.V132411; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; Horster MF, 1999, PHYSIOL REV, V79, P1157, DOI 10.1152/physrev.1999.79.4.1157; Isaka Y, 2000, KIDNEY INT, V58, P1885, DOI 10.1046/j.1523-1755.2000.00360.x; Isaka Y, 1999, KIDNEY INT, V55, P465, DOI 10.1046/j.1523-1755.1999.00275.x; Jones EA, 2000, UROLOGY, V56, P346, DOI 10.1016/S0090-4295(00)00608-7; Klahr S, 2000, KIDNEY INT, V57, pS7, DOI 10.1046/j.1523-1755.2000.07509.x; Klahr S, 2002, AM J PHYSIOL-RENAL, V283, pF861, DOI 10.1152/ajprenal.00362.2001; Kopp JB, 1996, LAB INVEST, V74, P991; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; Liu YH, 1999, AM J PHYSIOL-RENAL, V277, pF624, DOI 10.1152/ajprenal.1999.277.4.F624; Liu YH, 1998, BIOCHEM BIOPH RES CO, V246, P821, DOI 10.1006/bbrc.1998.8676; Lorz C, 2000, J AM SOC NEPHROL, V11, P1266, DOI 10.1681/ASN.V1171266; Malik RK, 2001, AM J PHYSIOL-RENAL, V281, pF56, DOI 10.1152/ajprenal.2001.281.1.F56; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyajima A, 2000, KIDNEY INT, V58, P2301, DOI 10.1046/j.1523-1755.2000.00414.x; Mozes MM, 1999, J AM SOC NEPHROL, V10, P271; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ortiz A, 1999, NEPHROL DIAL TRANSPL, V14, P1831, DOI 10.1093/ndt/14.8.1831; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Patel P, 2000, J INVEST MED, V48, P403; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schlapbach R, 2000, EUR J IMMUNOL, V30, P3680, DOI 10.1002/1521-4141(200012)30:12<3680::AID-IMMU3680>3.0.CO;2-L; Schramek H, 2002, NEWS PHYSIOL SCI, V17, P62, DOI 10.1152/nips.01365.2001; Stahl PJ, 2001, AM J PATHOL, V159, P1187, DOI 10.1016/S0002-9440(10)62503-5; Sutaria PM, 1998, LIFE SCI, V62, P1965, DOI 10.1016/S0024-3205(98)00166-0; Wolf G, 1999, J MOL MED-JMM, V77, P556, DOI 10.1007/s001099900028; Yang J, 2001, GENE THER, V8, P1470, DOI 10.1038/sj.gt.3301545; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang G, 2001, EXP NEPHROL, V9, P71; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	58	125	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12537	12545		10.1074/jbc.M300777200	http://dx.doi.org/10.1074/jbc.M300777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560323	hybrid			2022-12-25	WOS:000182015700106
J	Hasegawa, Y; Erickson, JR; Goddard, GJ; Yu, SX; Liu, SY; Cheng, KW; Eder, A; Bandoh, K; Aoki, J; Jarosz, R; Schrier, AD; Lynch, KR; Mills, GB; Fang, XJ				Hasegawa, Y; Erickson, JR; Goddard, GJ; Yu, SX; Liu, SY; Cheng, KW; Eder, A; Bandoh, K; Aoki, J; Jarosz, R; Schrier, AD; Lynch, KR; Mills, GB; Fang, XJ			Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA(3) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; PLATELET-AGGREGATION; CELLULAR-RESPONSES; ACTIVATING-FACTOR; PHOSPHORIC-ACIDS; LIPID MEDIATOR; EDG FAMILY; PATHWAY	Lysophosphatidic acid (LPA) is a bioactive lysophospholipid mediator that acts through G protein-coupled receptors. Most cell lines in culture express one or more LPA receptors, making it difficult to assign a response to specific LPA receptors. Dissection of the signaling properties of LPA has been hampered by lack of LPA receptor subtype-specific agonists and antagonists. The present study characterizes an ester-linked thiophosphate derivative (1-oleoyl-2-O-methyl-rac-glycerophosphothionate, OMPT) of LPA. OMPT is a functional LPA analogue with potent mitogenic activity in fibroblasts. In contrast to LPA, OMPT does not couple to the pheromone response through the LPA(1) receptor in yeast cells. OMPT induces intracellular calcium increases efficiently in LPA(3) receptor-expressing Sf9 cells but poorly in LPA(2) receptor-expressing cells. Guanosine 5'-O-(3-[S-35]thio)triphosphate binding assays in mammalian cells showed that LPA exhibits agonistic activity on all three LPA receptor subtypes, whereas OMPT has a potent agonistic effect only on the LPA(3) receptor. In transiently transfected HEK293 cells, OMPT stimulates mitogen-activated protein kinases through the LPA(3) but not the LPA(1) or LPA(2) receptors. Furthermore, OMPT-induced intracellular calcium mobilization in mammalian cells is efficiently inhibited by the LPA(1)/LPA(3) receptor-selective antagonist VPC12249. These results establish that OMPT is an LPA(3)-selective agonist. OMPT binding to the LPA(3) receptor in mammalian cells is sufficient to elicit multiple responses, including activation of G proteins, calcium mobilization, and activation of mitogen-activated protein kinases. Thus OMPT offers a powerful probe for the dissection of LPA signaling events in complex mammalian systems.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; LXR Biotechnol, Richmond, CA 94804 USA; Univ Tokyo, Tokyo 1130033, Japan; Univ Virginia, Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Texas System; UTMD Anderson Cancer Center; University of Tokyo; University of Virginia	Fang, XJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 1515 Holcombe Blvd,Box 317, Houston, TX 77030 USA.			Aoki, Junken/0000-0001-9435-1896	NATIONAL CANCER INSTITUTE [R01CA088994, P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA88994, CA64602] Funding Source: Medline; NIGMS NIH HHS [GM052722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Aoki J, 2000, ANN NY ACAD SCI, V905, P263; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Erickson JR, 2000, ANN NY ACAD SCI, V905, P279; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GERRARD JM, 1979, AM J PATHOL, V96, P423; Gibbs TC, 2000, ANN NY ACAD SCI, V905, P290; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; GOETZL EJ, 2000, ANN NY ACAD SCI, V905, P11; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; Hopper DW, 1999, J MED CHEM, V42, P963, DOI 10.1021/jm970809v; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Imai A, 2000, J CLIN ENDOCR METAB, V85, P3370, DOI 10.1210/jc.85.9.3370; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Liliom K, 1996, MOL PHARMACOL, V50, P616; Lynch KR, 1997, MOL PHARMACOL, V52, P75, DOI 10.1124/mol.52.1.75; McAllister G, 2000, MOL PHARMACOL, V58, P407, DOI 10.1124/mol.58.2.407; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Mukai M, 2000, FEBS LETT, V484, P69, DOI 10.1016/S0014-5793(00)02129-3; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; Olson KA, 2002, INT J CANCER, V98, P923, DOI 10.1002/ijc.10282; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Scalia R, 2000, J LEUKOCYTE BIOL, V67, P26, DOI 10.1002/jlb.67.1.26; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Toews ML, 1997, J APPL PHYSIOL, V83, P1216, DOI 10.1152/jappl.1997.83.4.1216; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Xu J, 2000, J BIOL CHEM, V275, P27520; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223	53	101	108	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11962	11969		10.1074/jbc.M209168200	http://dx.doi.org/10.1074/jbc.M209168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12554733	hybrid			2022-12-25	WOS:000182015700033
J	Stahelin, RV; Rafter, JD; Das, S; Cho, W				Stahelin, RV; Rafter, JD; Das, S; Cho, W			The molecular basis of differential subcellular localization of C2 domains of protein kinase C-alpha and group IVa cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; MEMBRANE-BINDING RESIDUES; SURFACE-PLASMON RESONANCE; CRYSTAL-STRUCTURE; LIVING CELLS; C-2 DOMAINS; CALCIUM; TRANSLOCATION; ACTIVATION; ROLES	The C2 domain is a Ca2+-dependent membrane-targeting module found in many cellular proteins involved in signal transduction or membrane trafficking. C2 domains are unique among membrane targeting domains in that they show a wide range of lipid selectivity for the major components of cell membranes, including phosphatidylserine and phosphatidyleholine. To understand how C2 domains show diverse lipid selectivity and how this functional diversity affects their subcellular targeting behaviors, we measured the binding of the C2 domains of group IVa cytosolic phospholipase A(2) (cPLA(2)) and protein kinase C-alpha (PKC-alpha) to vesicles that model cell membranes they are targeted to, and we monitored their subcellular targeting in living cells. The surface plasmon resonance analysis indicates that the PKC-alpha C2 domain strongly prefers the cytoplasmic plasma membrane mimic to the nuclear membrane mimic due to high phosphatidylserine content in the former and that Asn(189) plays a key role in this specificity. In contrast, the cPLA(2) C2 domain has specificity for the nuclear membrane mimic over the cytoplasmic plasma membrane mimic due to high phosphatidylcholine content in the former and aromatic and hydrophobic residues in the calcium binding loops of the cPLA(2) C2 domain are important for its lipid specificity. The subcellular localization of enhanced green fluorescent protein-tagged C2 domains and mutants transfected into HEK293 cells showed that the subcellular localization of the C2 domains is consistent with their lipid specificity and could be tailored by altering their in vitro lipid specificity. The relative cell membrane translocation rate of selected C2 domains was also consistent with their relative affinity for model membranes. Together, these results suggest that biophysical principles that govern the in vitro membrane binding of C2 domains can account for most of their subcellular targeting properties.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.		Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987, GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Conesa-Zamora P, 2001, BIOCHEMISTRY-US, V40, P13898, DOI 10.1021/bi011303o; Corbalan-Garcia S, 1999, BIOCHEM J, V337, P513, DOI 10.1042/0264-6021:3370513; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Gerber SH, 2001, J BIOL CHEM, V276, P32288, DOI 10.1074/jbc.C100108200; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Haugland R., 1996, HDB FLUORESCENT PROB; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; KATES M, 1986, TECHNIQUES LIPIDOLOG, P113; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; MCMURRAY, 1973, FORM FUNCTION PHOSPH, P205; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Mochly-Rosen D, 1998, FASEB J, V12, P35; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Williams SD, 2000, J LIPID RES, V41, P1585; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	55	111	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12452	12460		10.1074/jbc.M212864200	http://dx.doi.org/10.1074/jbc.M212864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531893	hybrid			2022-12-25	WOS:000182015700095
J	Virolle, T; Krones-Herzig, A; Baron, V; De Gregorio, G; Adamson, ED; Mercola, D				Virolle, T; Krones-Herzig, A; Baron, V; De Gregorio, G; Adamson, ED; Mercola, D			Egr1 promotes growth and survival of prostate cancer cells - Identification of novel Egr1 target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; IN-VIVO; INCREASED EXPRESSION; PROTEIN INHIBITOR; CARCINOMA-CELLS; UP-REGULATION; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNALING PATHWAY; ACTIVATED STAT1	In the majority of aggressive tumorigenic prostate cancer cells, the transcription factor Egr1 is overexpressed. We provide new insights of Egr1 involvement in proliferation and survival of TRAMP C2 prostate cancer cells by the identification of several new target genes controlling growth, cell cycle progression, and apoptosis such as cyclin D2, P19ink4d, and Fas. Egr1 regulation of these genes, identified by Affymetrix microarray, was confirmed by real-time PCR, immunoblot, and chromatin immunoprecipitation assays. Furthermore we also showed that Egr1 is responsible for cyclin D2 overexpression in tumorigenic DU145 human prostate cells. The regulation of these genes by Egr1 was demonstrated using Egr1 antisense oligonucleotides that further implicated Egr1 in resistance to apoptotic signals. One mechanism was illustrated by the ability of Egr1 to inhibit CD95 (Fas/Apo) expression, leading to insensitivity to FasL. The results provide a mechanistic basis for the oncogenic role of Egr1 in TRAMP C2 prostate cancer cells.	La Jolla Canc Res Fdn, Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Neuromed, Ist Ricovero & Cura Carattere Sci, I-86077 Pozzilli, Italy	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; IRCCS Neuromed	Virolle, T (corresponding author), Fac Med Nice, INSERM, Biol & Physiopathol Peau, F-06107 Av Valombrose, France.	virolle@unice.fr; eadamson@burnham.org	calogero, antonella/U-5418-2019; Virolle, Thierry/E-5838-2016; mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NATIONAL CANCER INSTITUTE [R01CA067888, R01CA084107, U01CA084998, R01CA076173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76173, CA84107, CA 84998, CA 67888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Bartkova J, 2000, ONCOGENE, V19, P4146, DOI 10.1038/sj.onc.1203769; Bowen C, 1999, CELL DEATH DIFFER, V6, P394, DOI 10.1038/sj.cdd.4400502; Calogero A, 2001, CLIN CANCER RES, V7, P2788; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; Chatterjee D, 2001, CANCER RES, V61, P7148; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Chin MT, 1999, J MOL CELL CARDIOL, V31, P2199, DOI 10.1006/jmcc.1999.1054; Costa-Pereira AP, 1999, BRIT J CANCER, V80, P371, DOI 10.1038/sj.bjc.6690365; de Belle I, 2000, BIOTECHNIQUES, V29, P162; de la Taille A, 1999, PROSTATE, V40, P89, DOI 10.1002/(SICI)1097-0045(19990701)40:2<89::AID-PROS4>3.0.CO;2-E; Dinkel A, 1997, J IMMUNOL, V159, P2678; Drivdahl RH, 2001, ENDOCRINOLOGY, V142, P1990, DOI 10.1210/en.142.5.1990; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; Eid MA, 1998, CANCER RES, V58, P2461; Fahmy RG, 2002, J CELL BIOCHEM, V84, P575, DOI 10.1002/jcb.10057.abs; Foster BA, 1997, CANCER RES, V57, P3325; Frugis G, 1999, PLANT MOL BIOL, V40, P397, DOI 10.1023/A:1006215231492; Glynne R, 2000, IMMUNOL REV, V176, P216; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Guthridge MA, 1996, ONCOGENE, V12, P1267; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Howell SB, 2000, MOL UROL, V4, P225; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Lamharzi N, 1998, REGUL PEPTIDES, V77, P185, DOI 10.1016/S0167-0115(98)00119-0; Landesberg LJ, 2001, AM J PHYSIOL-LUNG C, V281, pL1138, DOI 10.1152/ajplung.2001.281.5.L1138; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Liu YG, 2000, ONCOGENE, V19, P1579, DOI 10.1038/sj.onc.1203442; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Marcelli M, 1999, CANCER RES, V59, P382; Marcelli M, 2000, J UROLOGY, V164, P518, DOI 10.1016/S0022-5347(05)67416-2; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; NAGLE RB, 1992, J CELL BIOCHEM, P26; Nakamoto K, 2001, AM J PATHOL, V159, P1363, DOI 10.1016/S0002-9440(10)62523-0; Paggi MG, 2001, CANCER RES, V61, P4651; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Qian JQ, 2002, MODERN PATHOL, V15, P35, DOI 10.1038/modpathol.3880487; Scharnhorst V, 2000, ONCOGENE, V19, P791, DOI 10.1038/sj.onc.1203390; Scher HI, 2000, UROLOGY, V55, P323, DOI 10.1016/S0090-4295(99)00471-9; Schmidt BA, 2001, CANCER RES, V61, P4214; Schwarz DA, 1998, IMMUNITY, V9, P657, DOI 10.1016/S1074-7613(00)80663-9; Shainkin-Kestenbaum R, 1996, Biomed Pept Proteins Nucleic Acids, V2, P79; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; Speirs V, 1999, BRIT J CANCER, V81, P690, DOI 10.1038/sj.bjc.6690749; Stewart JE, 2001, CELL BIOL INT, V25, P607, DOI 10.1006/cbir.2000.0693; Stravodimos K, 2000, ANTICANCER RES, V20, P3823; SUGIMOTO K, 1994, J STEROID BIOCHEM, V51, P167, DOI 10.1016/0960-0760(94)90090-6; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Vallabhapurapu S, 2001, EUR J IMMUNOL, V31, P2612, DOI 10.1002/1521-4141(200109)31:9<2612::AID-IMMU2612>3.0.CO;2-C; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wikstrom P, 2001, MICROSC RES TECHNIQ, V52, P411, DOI 10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124	73	129	132	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11802	11810		10.1074/jbc.M210279200	http://dx.doi.org/10.1074/jbc.M210279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556466	hybrid			2022-12-25	WOS:000182015700012
J	Yang, RC; Yutzy, WH; Viscidi, RP; Roden, RBS				Yang, RC; Yutzy, WH; Viscidi, RP; Roden, RBS			Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR CAPSID PROTEIN; VIRUS-LIKE PARTICLES; COMMON NEUTRALIZATION EPITOPE; BOVINE PAPILLOMAVIRUS; VIRAL TRANSPORT; CELL-SURFACE; L1; TYPE-16; POLYMERIZATION; IDENTIFICATION	Viruses that replicate in the nucleus, including the primary causative agent of cervical cancer, human papillomavirus type 16 (HPV16), must first cross the cytoplasm. We compared the uptake of HPV16 virus-like particles (VLPs) either with or without the minor capsid protein L2. Whereas VLPs containing only the major capsid protein L1 were diffusely distributed within the cytoplasm even 6 h post-infection, VLPs comprising both L1 and L2 exhibited a radial distribution in the cytoplasm and accumulated in the perinuclear region of BPHE-1 cells within 2 h. L2 of HPV16 or bovine papillomavirus was shown to bind to a 43-kDa cellular protein that was subsequently identified as beta-actin by matrix-assisted laser desorption ionization time-of-flight analysis. A conserved domain comprising residues 25-45 of HPV16 L2 was sufficient for interaction with beta-actin. HPV16 L2 residues 25-45 fused to green fluorescent protein, but not green fluorescent protein alone, colocalized with actin and caused cell retraction and disruption of the microfilament network. Finally, wild-type L2, but not L2 with residues 25-45 deleted, facilitated HPV16 pseudovirion infection. Thus, binding of beta-actin by L2 residues 25-45 facilitates transport of HPV16 across the cytoplasm during infection, and blockade of this novel interaction may be useful for prophylaxis.	Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Roden, RBS (corresponding author), Johns Hopkins Sch Med, Dept Pathol, Ross 512B,720 Rutland Ave, Baltimore, MD 21205 USA.	roden@jhmi.edu		Viscidi, Raphael/0000-0002-7906-8002	NATIONAL CANCER INSTITUTE [R01CA083706] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI048203] Funding Source: NIH RePORTER; NCI NIH HHS [CA83706] Funding Source: Medline; NCRR NIH HHS [1S10-RR14702] Funding Source: Medline; NIAID NIH HHS [AI48203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; CHARLTON CA, 1993, VIROLOGY, V197, P245, DOI 10.1006/viro.1993.1585; Christensen ND, 1996, VIROLOGY, V223, P174, DOI 10.1006/viro.1996.0466; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; Cudmore S, 1997, TRENDS MICROBIOL, V5, P142, DOI 10.1016/S0966-842X(97)01011-1; Da Silva DM, 2001, INT IMMUNOL, V13, P633, DOI 10.1093/intimm/13.5.633; DOORBAR J, 1987, J VIROL, V61, P2793, DOI 10.1128/JVI.61.9.2793-2799.1987; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Evander M, 1997, J VIROL, V71, P2449, DOI 10.1128/JVI.71.3.2449-2456.1997; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; HAGENSEE ME, 1994, J VIROL, V68, P4503, DOI 10.1128/JVI.68.7.4503-4505.1994; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; Kawana K, 1998, J VIROL, V72, P10298, DOI 10.1128/JVI.72.12.10298-10300.1998; Kawana K, 1999, J VIROL, V73, P6188, DOI 10.1128/JVI.73.7.6188-6190.1999; Kawana Y, 2001, J VIROL, V75, P2331, DOI 10.1128/JVI.75.5.2331-2336.2001; KIRNBAUER R, 1993, J VIROL, V67, P6929, DOI 10.1128/JVI.67.12.6929-6936.1993; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; Lanier LM, 1998, VIROLOGY, V243, P167, DOI 10.1006/viro.1998.9065; Liu WJ, 2001, VIROLOGY, V282, P237, DOI 10.1006/viro.2000.0728; Luby-Phelps K, 2000, INT REV CYTOL, V192, P189; Merle E, 1999, J CELL BIOCHEM, V74, P628, DOI 10.1002/(SICI)1097-4644(19990915)74:4<628::AID-JCB12>3.0.CO;2-I; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Moss B, 2001, NAT CELL BIOL, V3, pE245, DOI 10.1038/ncb1101-e245; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Ploubidou A, 2001, CURR OPIN CELL BIOL, V13, P97, DOI 10.1016/S0955-0674(00)00180-0; Ravkov EV, 1998, J VIROL, V72, P2865, DOI 10.1128/JVI.72.4.2865-2870.1998; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Roden RBS, 2000, VIROLOGY, V270, P254, DOI 10.1006/viro.2000.0272; RODEN RBS, 1994, J VIROL, V68, P7260, DOI 10.1128/JVI.68.11.7260-7266.1994; Roden RBS, 1997, J VIROL, V71, P6247, DOI 10.1128/JVI.71.8.6247-6252.1997; RODEN RBS, 1994, J VIROL, V68, P7570, DOI 10.1128/JVI.68.11.7570-7574.1994; Roden RBS, 2001, J VIROL, V75, P10493, DOI 10.1128/JVI.75.21.10493-10497.2001; Roden RBS, 1996, J VIROL, V70, P5875, DOI 10.1128/JVI.70.9.5875-5883.1996; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sodeik B, 2000, TRENDS MICROBIOL, V8, P465, DOI 10.1016/S0966-842X(00)01824-2; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Touze A, 1998, NUCLEIC ACIDS RES, V26, P1317, DOI 10.1093/nar/26.5.1317; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; Unckell F, 1997, J VIROL, V71, P2934, DOI 10.1128/JVI.71.4.2934-2939.1997; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; ZHANG YL, 1987, J VIROL, V61, P2924, DOI 10.1128/JVI.61.9.2924-2928.1987; ZHOU J, 1993, J GEN VIROL, V74, P763, DOI 10.1099/0022-1317-74-4-763; ZHOU J, 1995, VIROLOGY, V214, P167, DOI 10.1006/viro.1995.9943; ZHOU J, 1994, J VIROL, V68, P619, DOI 10.1128/JVI.68.2.619-625.1994; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	50	48	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12546	12553		10.1074/jbc.M208691200	http://dx.doi.org/10.1074/jbc.M208691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560332	hybrid			2022-12-25	WOS:000182015700107
J	Lopez-Camarillo, C; Luna-Arias, JP; Marchat, LA; Orozco, E				Lopez-Camarillo, C; Luna-Arias, JP; Marchat, LA; Orozco, E			EhPgp5 mRNA stability is a regulatory event in the Entamoeba histolytica multidrug resistance phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE-RICH SEQUENCE; 3' UNTRANSLATED REGION; P-GLYCOPROTEIN; TRANSCRIPTIONAL ANALYSIS; 3-UNTRANSLATED REGION; PROTEIN-SYNTHESIS; GENE; PROMOTER; BINDING; INHIBITION	The multidrug resistance (MDR) phenotype in Entamoeba histolytica is characterized by the overexpression of the EhPgp5 gene in trophozoites grown in high drug concentrations. Here we evaluated the role of EhPgp5 mRNA stability on MDR using actinomycin D. EhPgp5 mRNA from trophozoites growing without emetine had a half-life of 2.1 h, which augmented to 3.1 h in cells cultured with 90 mum and to 7.8 h with 225 mum emetine. Polyadenylation sites were detected at 118-, 156-, and 189-nucleotide (nt) positions of the EhPgp5 mRNA 3'-untranslated region. Interestingly, trophozoites grown with 225 pm emetine exhibited an extra polyadenylation site at 19 nt. The 3'-untranslated region sequence is AU-rich and has putative consensus sequences for RNA-binding proteins. We detected a RNA-protein complex in a region that contains a polypyrimidine tract (142-159 nt) and a cytoplasmic polyadenylation element (146-154 nt). A longer poly(A) tail in the EhPgp5 mRNA was seen in trophozoites grown with 225 mum emetine. Emetine stress may affect factors involved in mRNA turnover, including polyadenylation/deadenylation proteins, which could induce changes in the EhPgp5 mRNA half-life and poly(A) tail length. Novel evidence on mechanisms participating in E. histolytica MDR phenotype is provided.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Expt Pathol, Mexico City 07738, DF, Mexico; Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City 07738, DF, Mexico; Inst Politecn Nacl, Program Biomed Mol, Escuela Nacl Med & Homeopatia, Mexico City 07738, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico	Orozco, E (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Expt Pathol, Mexico City 07738, DF, Mexico.	esther@mail.cinvestav.mx	Luna-Arias, Juan Pedro/D-4395-2019; Lopez-Camarillo, Cesar/I-1946-2019; Marchat, Laurence A./S-8418-2018	Luna-Arias, Juan Pedro/0000-0002-3602-8000; Lopez-Camarillo, Cesar/0000-0002-9417-2609; Marchat, Laurence A./0000-0003-1615-8614				Belasco J. G., 1993, CONTROL MESSENGER RN, P475; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Delgadillo DM, 2002, MICROB DRUG RESIST, V8, P15, DOI 10.1089/10766290252913719; DESCOTEAUX S, 1992, MOL BIOCHEM PARASIT, V54, P201, DOI 10.1016/0166-6851(92)90112-W; DESCOTEAUX S, 1995, GENE, V164, P179, DOI 10.1016/0378-1119(95)00533-C; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; EDMAN U, 1987, P NATL ACAD SCI USA, V84, P3024, DOI 10.1073/pnas.84.9.3024; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENTNER N, 1973, J PROTOZOOL, V20, P160, DOI 10.1111/j.1550-7408.1973.tb06025.x; Gomez C, 1998, J BIOL CHEM, V273, P7277, DOI 10.1074/jbc.273.13.7277; Hake LE, 1998, MOL CELL BIOL, V18, P685, DOI 10.1128/MCB.18.2.685; Higgins C.F., 1993, CONTROL MESSENGER RN, P13; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LEE CH, 1995, CELL GROWTH DIFFER, V6, P347; Lee CH, 1998, J CELL PHYSIOL, V177, P1; Lee CH, 2001, MOL CELL BIOCHEM, V216, P103, DOI 10.1023/A:1011086716568; Lopez C, 1997, Arch Med Res, V28 Spec No, P66; Marchat LA, 2002, CELL MICROBIOL, V4, P725, DOI 10.1046/j.1462-5822.2002.00220.x; MCCLEAN S, 1993, EUR J CANCER, V29A, P2243, DOI 10.1016/0959-8049(93)90215-2; MULLER C, 1995, J CELL PHYSIOL, V163, P538, DOI 10.1002/jcp.1041630314; Orozco E, 2002, PARASITOL INT, V51, P353, DOI 10.1016/S1383-5769(02)00041-7; OROZCO E, 1985, MOL BIOCHEM PARASIT, V15, P49, DOI 10.1016/0166-6851(85)90028-3; OROZCO E, 1995, PARASITOL TODAY, V11, P473, DOI 10.1016/0169-4758(95)80067-0; Perez DG, 1998, J BIOL CHEM, V273, P7285, DOI 10.1074/jbc.273.13.7285; Prokipcak RD, 1999, BIOCHEM BIOPH RES CO, V261, P627, DOI 10.1006/bbrc.1999.1101; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SALLES FJ, 1995, PCR METH APPL, V4, P317; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; ULLMAN B, 1995, J BIOENERG BIOMEMBR, V27, P77, DOI 10.1007/BF02110334; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Zhang WD, 2000, J CELL PHYSIOL, V184, P17, DOI 10.1002/(SICI)1097-4652(200007)184:1<17::AID-JCP2>3.0.CO;2-U; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	49	34	35	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11273	11280		10.1074/jbc.M211757200	http://dx.doi.org/10.1074/jbc.M211757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12556531	hybrid			2022-12-25	WOS:000181855400054
J	Petrenko, O; Fingerle-Rowson, G; Peng, T; Mitchell, RA; Metz, CN				Petrenko, O; Fingerle-Rowson, G; Peng, T; Mitchell, RA; Metz, CN			Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; S-PHASE; RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL REPRESSION; TARGETED DISRUPTION; SELECTIVE INDUCTION; TUMOR SUPPRESSION; ONCOGENIC STRESS; MRE11 COMPLEX; MOUSE EMBRYOS	Macrophage migration inhibitory factor (MIF) has been shown to functionally inactivate the p53 tumor suppressor and to inhibit p53-responsive gene expression and apoptosis. To better understand the role of MIF in cell growth and tumor biology, we evaluated MIF-null embryonic fibroblasts with respect to their immortalization and transformation properties. Although minor deviations in the growth characteristics of MIF-/- fibroblasts were observed under normal culture conditions, MIF-deficient cells were growth-impaired following the introduction of immortalizing oncogenes. The growth retardation by the immortalized MIF-/- cultures correlated with their reduced susceptibility to Ras-mediated transformation. Our results identify E2F as part of the restraining mechanism that is activated in response to oncogenic signaling and show that the biological consequences of E2F induction in MIF-/- fibroblasts vary depending on the p53 status, inducing predominantly G(1) arrest or apoptosis in p53-positive cells. This E2F activity is independent of Rb binding, but contingent on binding DNA. Resistance to oncogenic transformation by MIF-/- cells could be overcome by concomitant interference with p53- and E2F-responsive transcriptional control. Our results demonstrate that MIF plays a role in an E2F/p53 pathway that operates downstream of Rb regulation and implicate MIF as a mediator of normal and malignant cell growth.	Picower Inst Med Res, Manhasset, NY 11030 USA	Northwell Health	Metz, CN (corresponding author), N Shore Long Isl Jewish Res Inst, 350 Community Dr, Manhasset, NY 11030 USA.			Christine, Metz/0000-0002-1013-1691				Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Bacher M, 1997, AM J PATHOL, V150, P235; Bazarov AV, 2001, CANCER RES, V61, P1178; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Huang YY, 1997, CANCER RES, V57, P3640; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Humbert PO, 2000, GENE DEV, V14, P690; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kobayashi S, 1999, MECH DEVELOP, V84, P153, DOI 10.1016/S0925-4773(99)00057-X; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin WC, 2001, GENE DEV, V15, P1833; MAESTRO R, 1995, BLOOD, V85, P3239, DOI 10.1182/blood.V85.11.3239.bloodjournal85113239; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Metz CN, 1997, ADV IMMUNOL, V66, P197, DOI 10.1016/S0065-2776(08)60598-2; METZ CN, 2000, CYTOKINE REFERENCE, V1, P703; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Suzuki H, 1996, IMMUNOL LETT, V51, P141, DOI 10.1016/0165-2478(96)02543-6; Suzuki T, 1999, BRAIN RES, V816, P457, DOI 10.1016/S0006-8993(98)01179-2; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	80	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11078	11085		10.1074/jbc.M211985200	http://dx.doi.org/10.1074/jbc.M211985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538581	hybrid			2022-12-25	WOS:000181855400029
J	Tran, NH; Frost, JA				Tran, NH; Frost, JA			Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-CASCADE ACTIVATION; B-RAF; PLASMA-MEMBRANE; PAK ACTIVATION; SERINE-338; ERK; PHOSPHATIDYLSERINE; PROTEINS; PATHWAYS; DOMAINS	Exposure of cells to mitogens or growth factors stimulates Raf-1 activity through a complex mechanism that involves binding to active Ras, phosphorylation on multiple residues, and protein-protein interactions. Recently it was shown that the amino terminus of Raf-1 contains an sutoregulatory domain that can inhibit its activity in Xenopus oocytes. In the present work we show that expression of the Raf-1 autoinhibitory domain blocks extracellular signal-regulated kinase 2 activation by the Raf-1 catalytic domain in mammalian cells. We also show that phosphorylation of Raf-1 on serine 338 by PAK1 and tyrosines 340 and 341 by Src relieves autoinhibition and that this occurs through a specific decrease in the binding of the Raf-1 regulatory domain to its catalytic domain. In addition, we demonstrate that phosphorylation of threonine 491 and serine 494, two phosphorylation sites in the catalytic domain that are required for Raf-1 activation, is unlikely to regulate autoinhibition. These results demonstrate that the autoinhibitory domain of Raf-1 is functional in mammalian cells and that its interaction with the Raf-1 catalytic domain is regulated by phosphorylation of serine 338 and tyrosines 340 and 341.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Frost, JA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.			Frost, Jeffrey/0000-0001-9722-1536				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	34	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11221	11226		10.1074/jbc.M210318200	http://dx.doi.org/10.1074/jbc.M210318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551923	hybrid			2022-12-25	WOS:000181855400048
J	Xu, HS; Zhao, HY; Tian, W; Yoshida, K; Roullet, JB; Cohen, DM				Xu, HS; Zhao, HY; Tian, W; Yoshida, K; Roullet, JB; Cohen, DM			Regulation of a transient receptor potential (TRP) channel by tyrosine phosphorylation - Src family kinase-dependent tyrosine phosphorylation of TRPV4 on Tyr-253 mediates its response to hypotonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASES TRANSCRIPTION; PROTEIN; ACTIVATION; EXPRESSION; SEQUENCE; SITES; CELLS; EGR-1	The recently identified transient receptor potential (TRP) channel family member, TRPV4 (formerly known as OTRPC4, VR-OAC, TRP12, and VRL-2) is activated by hypotonicity. It is highly expressed in the kidney as well as blood-brain barrier-deficient hypothalamic nuclei responsible for systemic osmosensing. Apart from its gating by hypotonicity, little is known about TRPV4 regulation. We observed that hypotonic stress resulted in rapid tyrosine phosphorylation of TRPV4 in a heterologous expression model and in native murine distal convoluted tubule cells in culture. This tyrosine phosphorylation was sensitive to the inhibitor of Src family tyrosine kinases, PP1, in a dose-dependent fashion. TRPV4 associated with Src family kinases by co-immunoprecipitation studies and confocal immunofluorescence microscopy, and this interaction required an intact Src family kinase SH2 domain. One of these kinases, Lyn, was activated by hypotonic stress and phosphorylated TRPV4 in an immune complex kinase assay and an in vitro kinase assay using recombinant Lyn and TRPV4. Transfection of wild-type Lyn dramatically potentiated hypotonicity-dependent TRPV4 tyrosine phosphorylation whereas dominant negative-acting Lyn modestly inhibited it. Through mutagenesis studies, the site of tonicity-dependent tyrosine phosphorylation was mapped to Tyr-253, which is conserved across all species from which TRPV4 has been cloned. Importantly, point mutation of Tyr-253 abolished hypotonicity-dependent channel activity. In aggregate, these data indicate that hypotonic stress results in Src family tyrosine kinase-dependent tyrosine phosphorylation of the tonicity sensor TRPV4 at residue Tyr-253 and that this residue is essential for channel function in this context. This is the first example of direct regulation of TRP channel function through tyrosine phosphorylation.	Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Cohen, DM (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, Mailcode PP262,3314SW US Vet Hosp Rd, Portland, OR 97201 USA.	cohend@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052494] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52494] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BUCHER P, 1994, ISMB, V2, P53; Chin H, 1998, BLOOD, V91, P3734; COHEN DM, 1994, J BIOL CHEM, V269, P25865; Colbert HA, 1997, J NEUROSCI, V17, P8259; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Crepel V, 1998, J NEUROSCI, V18, P1196; Deleuze C, 2000, J PHYSIOL-LONDON, V523, P291, DOI 10.1111/j.1469-7793.2000.t01-2-00291.x; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Harlow E, 1999, USING ANTIBODIES LAB, P321; HUNTER T, 1982, J BIOL CHEM, V257, P4843; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Musch MW, 1999, J BIOL CHEM, V274, P7923, DOI 10.1074/jbc.274.12.7923; Nilius B, 1998, J PHYSIOL-LONDON, V506, P353, DOI 10.1111/j.1469-7793.1998.353bw.x; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Roullet JB, 1997, J BIOL CHEM, V272, P32240, DOI 10.1074/jbc.272.51.32240; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shuba YM, 2000, AM J PHYSIOL-CELL PH, V279, pC1144, DOI 10.1152/ajpcell.2000.279.4.C1144; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Sorota S, 1995, PFLUG ARCH EUR J PHY, V431, P178, DOI 10.1007/BF00410189; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Voets T, 1998, J PHYSIOL-LONDON, V506, P341, DOI 10.1111/j.1469-7793.1998.341bw.x; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663; Zhang Z, 1998, AM J PHYSIOL-CELL PH, V275, pC1104, DOI 10.1152/ajpcell.1998.275.4.C1104; Zhang Z, 1997, AM J PHYSIOL-RENAL, V273, pF837, DOI 10.1152/ajprenal.1997.273.5.F837	41	144	158	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11520	11527		10.1074/jbc.M211061200	http://dx.doi.org/10.1074/jbc.M211061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538589	hybrid			2022-12-25	WOS:000181855400084
J	Schaufele, F; Wang, X; Liu, XW; Day, RN				Schaufele, F; Wang, X; Liu, XW; Day, RN			Conformation of CCAAT/enhancer-binding protein alpha dimers varies with intranuclear location in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; GENE-EXPRESSION; TRANSCRIPTION; ACTIVATION; HETEROCHROMATIN; PHOSPHORYLATION; DIFFERENTIATION; ARCHITECTURE; INHIBITION; INCLUSIONS	The structure of a protein defines its biochemical properties, but the impact of intracellular location and environment on protein structure remains poorly defined. CCAAT/enhancer-binding protein alpha (C/EBPalpha) is a master regulator of transcription and cellular proliferation that concentrates and is kept inactive at transcriptionally quiescent, pericentromeric regions in mouse cell nuclei. C/EBPalpha dimer structure was measured in living cells from the amounts of fluorescence energy transferred between derivatives of the green fluorescent protein attached to different CAEBPalpha domains. Comparing the levels of fluorescence resonance energy transfer at pericentromeric and nonpericentromeric regions of the nucleus indicated that the DNA binding domains of C/EBPalpha dimers were further apart and interacted more poorly at pericentromeric heterochromatin than in the more euchromatic regions of the nucleus. In contrast, the position and interactions of the transcriptional activation domains were similar throughout the nucleus. Phorbol ester treatment caused a shift in the position of the transcriptional activation domain relative to the DNA binding domain. Thus, C/EBPalpha conformation varies with intranuclear location and with cellular environment. These "fluorescence resonance energy transfer nanoscopy" techniques will be broadly applicable for associating conformational and kinetic variations to subcompartment-specific actions of C/EBPalpha or any protein in the dynamic intracellular environment.	Univ Calif San Francisco, Ctr Diabet, Metabol Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, Dept Med, San Francisco, CA 94143 USA; Univ Virginia, Hlth Sci Ctr, Natl Sci Fdn, Ctr Biol Timing,Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Natl Sci Fdn, Ctr Biol Timing,Dept Cell Biol, Charlottesville, VA 22908 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia	Schaufele, F (corresponding author), Univ Calif San Francisco, Ctr Diabet, Metabol Res Unit, San Francisco, CA 94143 USA.	freds@diabetes.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054345] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK054345-04A1, DK 54345] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Brown K, 1999, CRIT REV EUKAR GENE, V9, P203, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.50; CAO Z, 1992, GENE DEV, V5, P1538; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Day RN, 2003, MOL ENDOCRINOL, V17, P333, DOI 10.1210/me.2002-0136; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Enwright JF, 2003, MOL ENDOCRINOL, V17, P209, DOI 10.1210/me.2001-0222; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Forster T., 1948, ANN PHYS, V6, P54; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; Hager GL, 2002, CURR OPIN GENET DEV, V12, P137, DOI 10.1016/S0959-437X(02)00278-2; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE KAW, 1992, J CELL SCI, V103, P9; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Liu WQ, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-6; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; PARKS JS, 1993, HORM RES, V40, P54, DOI 10.1159/000183768; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radovick S, 1998, HORM RES, V49, P30, DOI 10.1159/000053065; Rubinsztein DC, 1999, J MED GENET, V36, P265; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; STEPHANOVA E, 1988, EXP CELL RES, V179, P545, DOI 10.1016/0014-4827(88)90292-3; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Weatherman RV, 2002, MOL ENDOCRINOL, V16, P487, DOI 10.1210/me.16.3.487; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1; Zhang WH, 2001, J BIOL CHEM, V276, P40373, DOI 10.1074/jbc.C100505200	53	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10578	10587		10.1074/jbc.M207466200	http://dx.doi.org/10.1074/jbc.M207466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531886	hybrid			2022-12-25	WOS:000181777500078
J	Somlyo, AV; Phelps, C; Dipierro, C; Eto, M; Read, P; Barrett, M; Gibson, JJ; Burnitz, MC; Myers, C; Somlyo, AP				Somlyo, AV; Phelps, C; Dipierro, C; Eto, M; Read, P; Barrett, M; Gibson, JJ; Burnitz, MC; Myers, C; Somlyo, AP			Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants	FASEB JOURNAL			English	Article						myosin phosphatase; G-protein; endothelium; tumor necrosis	GTP-BINDING PROTEIN; LIGHT-CHAIN PHOSPHATASE; SMOOTH-MUSCLE; IN-VITRO; TUMOR; BONE; PHOSPHORYLATION; THROMBIN; INVASION; SUBUNIT	The purpose of this study was to determine the effects of inhibitors of Rho kinase (ROK) and matrix metalloproteinases (MMPs) on angiogenesis and tumor growth and to evaluate ROK activity in human prostate cancer PC3 cells and endothelial cells (HUVECs). Vacuolation by endothelial cells and lumen formation, the earliest detectable stages of angiogenesis, were inhibited by the ROK inhibitor Wf-536. Combining Wf-536 with the MMP inhibitor Marimastat greatly enhanced in vitro inhibition of endothelial vacuolation, lumen and cord formation, and VEGF- and HGF-stimulated endothelial sprout formation from aorta. Inhibition of sprout formation by the two inhibitors was synergistic. Both agents inhibited migration of HUVECs. The regulatory subunit (MYPT1) of the myosin phosphatase was phosphorylated in PC3 cells and HUVECs, and phosphorylation of MYPT1 and the myosin regulatory light chain was reduced by Wf-536, providing direct evidence of ROK activity. Early treatment of immuno-incompetent mice bearing xenotransplants of PC3 cells with a combination of Wf-536 plus Marimastat with or without Paclitaxel, significantly inhibited tumor growth, prevented tumor growth escape after discontinuation of Paclitaxel, and increased survival.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Cellular Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Dept Radiat Oncol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA; Amer Inst Dis Prostate, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Somlyo, AP (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, 1300 Jefferson Pk Ave,POB 800736,Jordan Hall, Charlottesville, VA 22908 USA.	avs5u@virginia.edu	Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48807, P01 HL19242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Bayless KJ, 2002, J CELL SCI, V115, P1123; Bissell MJ, 2002, JNCI-J NATL CANCER I, V94, P4; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Carbajal JM, 1999, AM J PHYSIOL-CELL PH, V277, pC955, DOI 10.1152/ajpcell.1999.277.5.C955; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Choy M, 2001, CANCER INVEST, V19, P181, DOI 10.1081/CNV-100000152; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; del Peso L, 1997, ONCOGENE, V15, P3047; Diggle P. J., 1996, ANAL LONGITUDINAL DA; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Figg WD, 2002, INVEST NEW DRUG, V20, P183, DOI 10.1023/A:1015626410273; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lawless J.F, 1982, STAT MODELS METHODS; Leung SYL, 2000, PROSTATE, V44, P156, DOI 10.1002/1097-0045(20000701)44:2<156::AID-PROS8>3.0.CO;2-8; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nemeth JA, 2002, J NATL CANCER I, V94, P17; Nicholson B, 2001, CANCER METAST REV, V20, P297, DOI 10.1023/A:1015543713485; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Polin L, 1997, INVEST NEW DRUG, V15, P99, DOI 10.1023/A:1005856605726; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Richards CT, 2002, J BIOL CHEM, V277, P4422, DOI 10.1074/jbc.M111047200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Stearns ME, 1996, INVAS METAST, V16, P116; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Thalmann GN, 2000, PROSTATE, V44, P91; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wicki A, 2001, INT J CANCER, V91, P763, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1128>3.0.CO;2-B; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7; Yoshioka K, 1999, CANCER RES, V59, P2004; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; ZHANG D, 1995, J CELL SCI, V108, P2285; ZUCKER S, 2002, ANTICANCER DRUG DEV, V6, P91	61	86	93	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					223	234		10.1096/fj.02-0655com	http://dx.doi.org/10.1096/fj.02-0655com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554701				2022-12-25	WOS:000181456900047
J	Callahan, G; Denison, SR; Phillips, LA; Shridhar, V; Smith, DI				Callahan, G; Denison, SR; Phillips, LA; Shridhar, V; Smith, DI			Characterization of the common fragile site FRA9E and its potential role in ovarian cancer	ONCOGENE			English	Article						common fragile sites; FRA9E; chromosomal deletions; ovarian cancer; PAPPA	PLASMA PROTEIN-A; MOLECULAR CHARACTERIZATION; REPEAT EXPANSION; INTEGRATION SITE; BREAST-CANCER; BROAD REGION; X-SYNDROME; PREGNANCY; CELLS; GENE	Common fragile sites (CFSs) are regions of profound genomic instability that have been hypothesized to play a role in cancer. The major aim of this study was to locate a fragile region associated with ovarian cancer. Differential display (DD)-PCR analysis comparing normal ovarian epithelial cultures and ovarian cancer cell tines identified pregnancy-associated plasma protein-A (PAPPA) because of its frequent loss of expression (LOE) in ovarian cancer cell lines. PAPPA is localized to human chromosome 9q32-33.1, a region associated with significant loss of heterozygosity (LOH) in ovarian tumors (> 50%) and in close proximity to the FRA9E CFS. FISH analysis determined that PAPPA was contained within the distal end of FRA9E. Characterization of FRA9E determined that aphidicolin-induced instability extended over 9 Mb, identifying FRA9E as the largest CFS characterized to date. Comprehensive LOH analysis revealed several distinct peaks of LOH within FRA9E. Semiquantitative RT-PCR analysis of 16 genes contained within FRA9E indicated that genes showing LOE in ovarian tumors coincided with regions of high LOH. PAPPA displayed the most significant loss (72%). This study provides evidence to suggest that instability within FRA9E may play an important role in the development of ovarian cancer and lends further support for the hypothesis that CFSs may be causally related to cancer.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.		Seal, Sudipta/A-7698-2012; Lomberk, Gwen/AAL-8490-2020	Lomberk, Gwen/0000-0001-5463-789X	NCI NIH HHS [CA48031, CA 75926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075926, R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; BECKER NA, 2002, IN PRESS ONCOGENE; Bednarek AK, 2000, CANCER RES, V60, P2140; Chen BK, 2002, ENDOCRINOLOGY, V143, P1199, DOI 10.1210/en.143.4.1199; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Denison SR, 2002, GENE CHROMOSOME CANC, V34, P406, DOI 10.1002/gcc.10084; DURHAM SK, 1995, ENDOCRINOLOGY, V136, P1374, DOI 10.1210/en.136.4.1374; GABRA H, 1997, BIOL FEMALE CANC, P93; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; HAMILTON TC, 1984, SEMIN ONCOL, V11, P285; Hewett DR, 1998, MOL CELL, V1, P773, DOI 10.1016/S1097-2765(00)80077-5; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; Kirschner LS, 1999, BIOTECHNIQUES, V27, P72; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KRUK PA, 1990, LAB INVEST, V63, P132; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RITCHIE RJ, 1994, HUM MOL GENET, V3, P2115, DOI 10.1093/hmg/3.12.2115; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SILAHTAROGLU AN, 1993, CYTOGENET CELL GENET, V62, P214, DOI 10.1159/000133479; Smith DI, 1998, INT J ONCOL, V12, P187; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Stabile I, 1988, Obstet Gynecol Surv, V43, P73; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Verma R.S., 1989, HUMAN CHROMOSOMES MA, P240; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	46	59	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					590	601		10.1038/sj.onc.1206171	http://dx.doi.org/10.1038/sj.onc.1206171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555072				2022-12-25	WOS:000180538200012
J	Mamay, CL; Mingo-Sion, AM; Wolf, DM; Molina, MD; Van Den Berg, CL				Mamay, CL; Mingo-Sion, AM; Wolf, DM; Molina, MD; Van Den Berg, CL			An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer	ONCOGENE			English	Article						IGF-I; JNK; IRS-1; breast cancer; apoptosis	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; GROWTH-FACTOR; INSULIN-RECEPTOR; CELLULAR STRESSES; MAP KINASE; PHOSPHORYLATION; EXPRESSION; TRANSDUCTION; PATHWAY	Insulin-like growth factor-I receptor (IGF-IR) is frequently overexpressed in a variety of cancer types. Since many breast tumors and cancer cell lines overexpress IGF-IR, we tested IGF-I effects on chemotherapy-treated breast cancer cells. IGF-I protects from chemotherapy-induced apoptosis, suggesting that overlapping signaling pathways modulate IGF-I and chemotherapy treatment outcomes. Taxol and other chemotherapy drugs induce c-Jun N-terminal kinase (JNK), a kinase that conveys cellular stress and death signals. Notably, in this paper we show that IGF-I alone induces a potent JNK response and this activity is reversed by inhibition of phosphatidylinositol 3-kinase (PI3-kinase) with LY294002 in MCF-7 but not T47D cells. Cotreatment of cells with chemotherapy and IGF-I leads to additive JNK responses. Using cells overexpressing Akt, we confirm that IGF-I-mediated survival is Akt dependent. In contrast, overexpression of JNK significantly enhances Taxol-induced apoptosis and inhibits IGF-I survival effects. Further, JNK attenuates anchorage-independent growth of MCF-7 cells. The inhibitory effect of JNK appears to be mediated by serine phosphorylation of IRS-1 (insulin receptor substrate) since both Taxol and IGF-I treatment enhanced Ser(312) IRS-1 phosphorylation, while LY294002 blocked IGF-I-mediated phosphorylation. Taken together, these data provide a mechanism whereby stress or growth factors activate JNK to reduce proliferation and/or survival in breast cancer cells.	Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Obstet & Gynecol, Denver, CO 80262 USA	University of California System; University of California Davis; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Van Den Berg, CL (corresponding author), Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA.	carla.vandenberg@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA089288] Funding Source: NIH RePORTER; NCI NIH HHS [CA89288A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AA, 1998, CANCER RES, V58, P3021; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CULLEN KJ, 1990, CANCER RES, V50, P48; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Dunn SE, 1998, CANCER RES, V58, P3353; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PEYRAT JP, 1990, J STEROID BIOCHEM, V37, P823, DOI 10.1016/0960-0760(90)90426-L; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Resnik JL, 1998, CANCER RES, V58, P1159; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; She QB, 2002, CANCER RES, V62, P1343; SINGER C, 1995, CANCER RES, V55, P2448; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VandenBerg CL, 1997, EUR J CANCER, V33, P1108, DOI 10.1016/S0959-8049(97)00071-3; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	48	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					602	614		10.1038/sj.onc.1206186	http://dx.doi.org/10.1038/sj.onc.1206186			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555073				2022-12-25	WOS:000180538200013
J	Fan, CX; Chen, XK; Zhang, C; Wang, LX; Duan, KL; He, LL; Cao, Y; Liu, SY; Zhong, MN; Ulens, C; Tytgat, J; Chen, JS; Chi, CW; Zhou, Z				Fan, CX; Chen, XK; Zhang, C; Wang, LX; Duan, KL; He, LL; Cao, Y; Liu, SY; Zhong, MN; Ulens, C; Tytgat, J; Chen, JS; Chi, CW; Zhou, Z			A novel conotoxin from Conus betulinus, kappa-BtX, unique in cysteine pattern and in function as a specific BK channel modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CA2+-ACTIVATED K+ CHANNELS; POTASSIUM CHANNELS; MOLECULAR-BASIS; VENOM PEPTIDES; VOLTAGE; CHARYBDOTOXIN; INACTIVATION; CONDUCTANCE; DIVERSITY	A novel conotoxin, kappa-conotoxin (kappa-BtX), has been purified and characterized from the venom of a worm-hunting cone snail, Conus betulinus. The toxin, with four disulfide bonds, shares no sequence homology with any other conotoxins. Based on a partial amino acid sequence, its cDNA was cloned and sequenced. The deduced sequence consists of a 26-residue putative signal peptide, a 31-residue mature toxin, and a 13-residue extra peptide at the C terminus. The extra peptide is cleaved off by proteinase post-processing. All three Glu residues are gamma-carboxylated, one of the two Pro residues is hydroxylated at position 27, and its C-terminal residue is Pro-amidated. The monoisotopic mass of the toxin is 3569.0 Da. Electrophysiological experiments show that: 1) among voltage-gated channels;, K-BtX is a specific modulator of K+ channels; 2) among the K channels, kappa-BtX specifically up-modulates the Ca2+- and voltage-sensitive BK channels (252 47%); 3) its EC50 is 0.7 nm with a single binding site (Hill = 0.88); 4) the time constant of wash-out is 8.3 s; and 5) kappa-BtX has no effect on single channel conductance, but increases the open probability of BK channels. It is concluded that kappa-BtX is a novel specific biotoxin against BK channels.	Res Inst Pharmaceut Chem, Beijing 102205, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Katholieke Univ Leuven, Toxicol Lab, Louvain, Belgium	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; KU Leuven	Zhou, Z (corresponding author), Res Inst Pharmaceut Chem, Beijing 102205, Peoples R China.		chen, xiaoke/E-5385-2011; zhou, zhuan/A-8285-2011; Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; Chen JS, 1999, J NAT TOXINS, V8, P341; Colquhoun David, 1995, P397; Elhamdani A, 1998, J NEUROSCI, V18, P6230; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GARCIA ML, 1995, AM J PHYSIOL-CELL PH, V269, pC1, DOI 10.1152/ajpcell.1995.269.1.C1; Hille B., 1992, IONIC CHANNELS EXCIT; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOSHI T, 1988, J GEN PHYSIOL, V91, P73, DOI 10.1085/jgp.91.1.73; JOHNS MB, 1989, ANAL BIOCHEM, V180, P276, DOI 10.1016/0003-2697(89)90430-2; Latorre R, 2000, HANDB EXP PHARM, V147, P197; Lawson K, 1996, CLIN SCI, V91, P651, DOI 10.1042/cs0910651; Le Gall F, 1999, BELG J ZOOL, V129, P17; McIntosh J M, 1999, Methods Enzymol, V294, P605; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NEELY A, 1992, J PHYSIOL-LONDON, V453, P133, DOI 10.1113/jphysiol.1992.sp019221; Olivera BM, 1999, J COMP PHYSIOL A, V185, P353, DOI 10.1007/s003590050394; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; SOLARO CR, 1995, J NEUROSCI, V15, P6110; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wu JJ, 2002, BIOCHEMISTRY-US, V41, P2844, DOI 10.1021/bi011367z; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	32	68	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12624	12633		10.1074/jbc.M210200200	http://dx.doi.org/10.1074/jbc.M210200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547831	hybrid			2022-12-25	WOS:000182189500007
J	Marcus, SL; Polakowski, R; Seto, NOL; Leinala, E; Borisova, S; Blancher, A; Roubinet, F; Evans, SV; Palcic, MM				Marcus, SL; Polakowski, R; Seto, NOL; Leinala, E; Borisova, S; Blancher, A; Roubinet, F; Evans, SV; Palcic, MM			A single point mutation reverses the donor specificity of human blood group B-synthesizing galactosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A; SUBSTRATE-SPECIFICITY; GLYCOSYLTRANSFERASE; RECOMBINANT; GENE; ALLELE; TRISACCHARIDE; SYSTEM; ACID	Blood group A and B antigens are carbohydrate structures that are synthesized by glycosyltransferase enzymes. The final step in B antigen synthesis is carried out by an alpha1-3 galactosyltransferase (GTB) that transfers galactose from UDP-Gal to type 1 or type 2, alphaFuc1-2betaGal-R (H)-terminating acceptors. Similarly the A antigen is produced by an alpha1-3 N-acetylgalactosaminyltransferase that transfers N-acetylgalactosamine from UDP-GalNAc to H-acceptors. Human alpha1-3 N-acetylgalactosaminyltransferase and GTB are highly homologous enzymes differing in only four of 354 amino acids (R176G, G235S, L266M, and G268A). Single crystal x-ray diffraction studies have shown that the latter two of these amino acids are responsible for the difference in donor specificity, while the other residues have roles in acceptor binding and turnover. Recently a novel cis-AB allele was discovered that produced A and B cell surface structures. It had codons corresponding to GTB with a single point mutation that replaced the conserved amino acid proline 234 with serine. Active enzyme expressed from a synthetic gene corresponding to GTB with a P234S mutation shows a dramatic and complete reversal of donor specificity. Although this enzyme contains all four "critical" amino acids associated with the production of blood group B antigen, it preferentially utilizes the blood group A donor UDP-GalNAc and shows only marginal transfer of UDP-Gal. The crystal structure of the mutant reveals the basis for the shift in donor specificity.	Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Toulouse 3, Hop Rangueil, Immunogenet Mol Lab, F-31059 Toulouse 9, France; Estab Francais Sang, Lab Immunohematol, F-31027 Toulouse, France	University of Alberta; National Research Council Canada; University of Ottawa; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Palcic, MM (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.			Evans, Stephen/0000-0002-0366-4027				AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GOLDSTEIN J, 1989, VOX SANG, V57, P142, DOI 10.1111/j.1423-0410.1989.tb01152.x; GREENWELL P, 1986, CARBOHYD RES, V149, P149, DOI 10.1016/S0008-6215(00)90375-6; Mifsud NA, 2000, TRANSFUSION, V40, P1276, DOI 10.1046/j.1537-2995.2000.40101276.x; Ouzzine M, 2002, J BIOL CHEM, V277, P25439, DOI 10.1074/jbc.M201912200; Palcic MM, 2001, TRANSFUSION MED, V11, P315, DOI 10.1046/j.1365-3148.2001.00314.x; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Roubinet F, 2002, TRANSFUSION, V42, P239, DOI 10.1046/j.1537-2995.2002.00030.x; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Seto NOL, 2000, CARBOHYD RES, V324, P161, DOI 10.1016/S0008-6215(99)00297-9; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; SETO NOL, 1995, EUR J BIOCHEM, V234, P323, DOI 10.1111/j.1432-1033.1995.323_c.x; Watkins W.M., 1980, ADV HUM GENET, V10, P379; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Yu LC, 1999, BIOCHEM BIOPH RES CO, V262, P487, DOI 10.1006/bbrc.1999.1246	20	80	86	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12403	12405		10.1074/jbc.M212002200	http://dx.doi.org/10.1074/jbc.M212002200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529355	hybrid			2022-12-25	WOS:000182015700089
J	Mohamed, MR; Niles, EG				Mohamed, MR; Niles, EG			UUUUUNU oligonucleotide stimulation of vaccinia virus early gene transcription termination, in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA POLYMERASE; TRIPHOSPHATE PHOSPHOHYDROLASE I; TEMPERATURE-SENSITIVE MUTANTS; MESSENGER-RNA; CAPPING ENZYME; H4L SUBUNIT; EUKARYOTIC TRANSCRIPTION; ESCHERICHIA-COLI; PURIFICATION; EXPRESSION	Vaccinia virus early gene transcription termination requires the vaccinia termination factor (VTF), NPH1, a single stranded DNA-dependent ATPase, the virion form of RNA polymerase containing the Rap 94 subunit, and the signal UUUUUNU, which resides in the nascent mRNA, located 30 to 50 bases upstream from the poly(A) addition site. Evidence indicates that a required termination factor acts through binding to the UUUUUNU signal. To further investigate the function of UUUUUNU, the ability of UUUUUNU containing oligonucleotides to inhibit transcription termination was tested. A 22-mer RNA oligonucleotide containing a central U9 sequence exhibited sequence and concentration-dependent stimulation of premature transcription termination and transcript release, in trans. Activation of premature termination required VTF, NPH 1, Rap 94, and ATP, demonstrating that the normal termination machinery was employed. Premature termination was not stimulated by RNA harboring a mutant UUUUUNU, demonstrating specificity. These data are consistent with a model in which a required termination factor is converted from an inactive to an active form by binding to a UUUUUNU containing oligonucleotide. The active termination factor then interacts with the ternary complex stimulating transcription termination through the normal mechanism, independent of the nascent mRNA sequence.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Niles, EG (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, 138 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	eniles@buffalo.edu	Mohamed, Mohamed Ragaa/V-9143-2019	Mohamed, Mohamed Ragaa/0000-0002-9269-3128	NIAID NIH HHS [R01-AI 43933] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; Christen LA, 1999, BIOCHEMISTRY-US, V38, P8072, DOI 10.1021/bi9903749; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Condit RC, 1996, VIROLOGY, V220, P10, DOI 10.1006/viro.1996.0280; Condit RC, 2002, BBA-GENE STRUCT EXPR, V1577, P325, DOI 10.1016/S0167-4781(02)00461-X; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; ENSINGER MJ, 1975, P NATL ACAD SCI USA, V72, P2525, DOI 10.1073/pnas.72.7.2525; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; LUO Y, 1993, J BIOL CHEM, V268, P21253; Mohamed MR, 2000, J BIOL CHEM, V275, P25798, DOI 10.1074/jbc.M002250200; Mohamed MR, 2002, VIROLOGY, V299, P142, DOI 10.1006/viro.2002.1498; Mohamed MR, 2001, J BIOL CHEM, V276, P20758, DOI 10.1074/jbc.M101641200; MORGAN JR, 1984, J VIROL, V51, P283, DOI 10.1128/JVI.51.2.283-297.1984; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 2001, POXVIRIDAE VIRUSES T, V2, P2849; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; PAOLETTI E, 1974, J BIOL CHEM, V249, P3281; PIACENTE SC, 2002, IN PRESS VIROLOGY; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; WEI CM, 1974, P NATL ACAD SCI USA, V71, P3014, DOI 10.1073/pnas.71.8.3014; Wright CF, 2001, J BIOL CHEM, V276, P40680, DOI 10.1074/jbc.M102399200; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	41	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11794	11801		10.1074/jbc.M213263200	http://dx.doi.org/10.1074/jbc.M213263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556520	hybrid			2022-12-25	WOS:000182015700011
J	Nur-E-Kamal, A; Li, TK; Zhang, AL; Qi, HY; Hars, ES; Liu, LF				Nur-E-Kamal, A; Li, TK; Zhang, AL; Qi, HY; Hars, ES; Liu, LF			Single-stranded DNA induces ataxia telangiectasia mutant (ATM)/p53-dependent DNA damage and apoptotic signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DEPENDENT APOPTOSIS; IONIZING-RADIATION; TOPOISOMERASE-I; NERVOUS-SYSTEM; S-PHASE; ATM; P53; PROTEIN; PHOSPHORYLATION	Single-stranded DNA has been speculated to be the initial signal in the DNA damage signaling pathway. We showed that introduction of single-stranded DNA with diverse sequences into mammalian cells induced DNA damage as well as apoptosis signals. Like DNA damaging agents, single-stranded DNA up-regulated p53 and activated the nuclear kinase ataxia telangiectasia mutant (ATM) as evidenced by phosphorylation of histone 2AX, an endogenous ATM substrate. Single-stranded DNA also triggered apoptosis as evidenced by the formation of caspase-dependent chromosomal DNA strand breaks, cytochrome c release, and increase in reactive oxygen species production. Moreover, single-stranded DNA-induced apoptosis was reduced significantly in p53 null cells and in cells treated with ATM small interfering RNA. These results suggest that single-stranded DNA may act upstream of ATM/p53 in DNA damage signaling.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Nur-E-Kamal, A (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.			LI, TSAI-KUN/0000-0003-0393-2340; Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA39662] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Delia D, 2000, BRIT J CANCER, V82, P1938; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Flaherty KT, 2001, CURR OPIN ONCOL, V13, P499, DOI 10.1097/00001622-200111000-00013; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Guo CY, 2002, J BIOL CHEM, V277, P4839, DOI 10.1074/jbc.M110092200; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert G, 2000, BIOCHEM BIOPH RES CO, V279, P401, DOI 10.1006/bbrc.2000.3963; Lee SH, 2002, MOL CELLS, V13, P159; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Milyavsky M, 2001, NUCLEIC ACIDS RES, V29, P5207, DOI 10.1093/nar/29.24.5207; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Schiavone N, 2000, BIOCHEM BIOPH RES CO, V270, P406, DOI 10.1006/bbrc.2000.2433; Shen WY, 2002, ANTISENSE NUCLEIC A, V12, P155, DOI 10.1089/108729002760220752; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sureda FX, 1998, GEN PHARMACOL, V30, P507, DOI 10.1016/S0306-3623(97)00294-2; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tidd DM, 2000, NUCLEIC ACIDS RES, V28, P2242, DOI 10.1093/nar/28.11.2242; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang H, 2001, CURR CANCER DRUG TAR, V1, P177, DOI 10.2174/1568009013334133; Wei ZP, 1996, NUCLEIC ACIDS RES, V24, P655, DOI 10.1093/nar/24.4.655; Xu H, 2001, Biotechnol Annu Rev, V7, P131, DOI 10.1016/S1387-2656(01)07035-1; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	50	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12475	12481		10.1074/jbc.M212915200	http://dx.doi.org/10.1074/jbc.M212915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540848	hybrid			2022-12-25	WOS:000182015700098
J	O'Connell, BC; Cheung, AF; Simkevich, CP; Tam, W; Ren, XJ; Mateyak, MK; Sedivy, JM				O'Connell, BC; Cheung, AF; Simkevich, CP; Tam, W; Ren, XJ; Mateyak, MK; Sedivy, JM			A large scale genetic analysis of c-Myc-regulated gene expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; GROWTH; TARGET; IDENTIFICATION; APOPTOSIS; PRO-CASPASE-3; ACTIVATION; REPRESSION; REVEALS; SCREEN	The myc proto-oncogenes encode transcriptional regulators whose inappropriate expression is correlated with a wide array of human malignancies. Up-regulation of Myc enforces growth, antagonizes cell cycle withdrawal and differentiation, and in some situations promotes apoptosis. How these phenotypes are elicited is not well understood, largely because we lack a clear picture of the biologically relevant downstream effectors. We created a new biological system for the optimal profiling of Myc target genes based on a set of isogenic c-myc knockout and conditional cell lines. The ability to modulate Myc activity from essentially null to supraphysiological resulted in a significantly increased and reproducible yield of targets and revealed a large subset of genes that respond optimally to Myc in its physiological range of expression. The total extent of transcriptional changes that can be triggered by Myc is remarkable and involves thousands of genes. Although the majority of these effects are not direct, many of the indirect targets are likely to have important roles in mediating the elicited cellular phenotypes. Myc-activated functions are indicative of a physiological state geared toward the rapid utilization of carbon sources, the biosynthesis of precursors for macromolecular synthesis, and the accumulation of cellular mass. In contrast, the majority of Myc-repressed genes are involved in the interaction and communication of cells with their external environment, and several are known to possess antiproliferative or antimetastatic properties.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Brown University	Sedivy, JM (corresponding author), JW Wilson Lab, Rm 223,69 Brown St, Providence, RI 02912 USA.	john_sedivy@brown.edu		Mateyak, Maria/0000-0003-0859-1901	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041690] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-15578] Funding Source: Medline; NIGMS NIH HHS [R01 GM-41690, GM-07601] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Guo QM, 2000, CANCER RES, V60, P5922; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Harlow E., 1988, ANTIBODIES LAB MANUA; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Obaya AJ, 2002, J BIOL CHEM, V277, P31263, DOI 10.1074/jbc.M202528200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROUTY SM, 1993, ONCOGENE, V8, P899; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sambrook J, 2001, MOL CLONING LAB MANU; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049	44	169	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12563	12573		10.1074/jbc.M210462200	http://dx.doi.org/10.1074/jbc.M210462200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529326	hybrid			2022-12-25	WOS:000182015700109
J	Pluquet, O; North, S; Bhoumik, A; Dimas, K; Ronai, Z; Hainaut, P				Pluquet, O; North, S; Bhoumik, A; Dimas, K; Ronai, Z; Hainaut, P			The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; DNA-DAMAGE; PROTEIN-KINASE; P53-DEPENDENT PATHWAY; TRANSCRIPTION FACTORS; TOPOISOMERASE-II; PHOSPHORYLATION; AMIFOSTINE; WR-1065; CANCER	WR1065 is an aminothiol with selective cytoprotective effects in normal cells compared with cancer cells. In a previous study (North, S., El-Ghissassi, F., Pluquet, O., Verhaegh, G., and Hainaut, P. (2000) Oncogene 19, 1206-1214), we have shown that WR1065 activates wildtype p53 in cultured cells. Here we show that WR1065 induces p53 to accumulate through escape from proteasome-dependent degradation. This accumulation is not prevented by inhibitors of phosphatidylinositol 3-kinases and is not accompanied by phosphorylation of Ser-15, -20, or -37, which are common targets of the kinases activated in response to DNA damage. Furthermore, WR1065 activates the JNK (c-Jun N-terminal kinase), decreases complex formation between p53 and inactive JNK, and phosphorylates p53 at Thr-81, a known site of phosphorylation by JNK. A dominant negative form of JNK (JNK-APF) reduces by 50% the activation of p53 by WR1065. Thus, WR1065 activates p53 through a JNK-dependent signaling pathway. This pathway may prove useful for pharmacological modulation of p53 activity through non-genotoxic mechanisms.	Int Agcy Res Canc, Unit Mol Carcinogenesis, F-69372 Lyon 08, France; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	World Health Organization; International Agency for Research on Cancer (IARC); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012; Dimas, Konstantinos/AAU-5461-2020	Hainaut, Pierre/0000-0002-1303-1610; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER; NCI NIH HHS [CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bacus SS, 1996, ONCOGENE, V12, P2535; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; CALABROJONES PM, 1988, CANCER RES, V48, P3634; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capizzi RL, 1996, EUR J CANCER, V32A, pS5, DOI 10.1016/S0959-8049(96)00333-4; Chehab NH, 2000, GENE DEV, V14, P278; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOUAY L, 1995, EUR J CANCER, V31A, pS14, DOI 10.1016/0959-8049(95)00146-A; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOMEZ DA, 1996, J BIOL CHEM, V271, P26335; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRDINA DJ, 1995, CARCINOGENESIS, V16, P767, DOI 10.1093/carcin/16.4.767; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kataoka Y, 2000, INT J RADIAT BIOL, V76, P633; Kemp G, 1996, J CLIN ONCOL, V14, P2101, DOI 10.1200/JCO.1996.14.7.2101; Kramer DL, 1999, CANCER RES, V59, P1278; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; List AF, 1996, SEMIN ONCOL, V23, P58; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu SC, 1997, CARCINOGENESIS, V18, P2457, DOI 10.1093/carcin/18.12.2457; Lu WG, 2002, CANCER RES, V62, P1305; Maurici D, 2001, ONCOGENE, V20, P3533, DOI 10.1038/sj.onc.1204428; MEIER T, 1995, BIOCHEM PHARMACOL, V50, P489, DOI 10.1016/0006-2952(95)00164-U; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Murley JS, 1997, CELL PROLIFERAT, V30, P283, DOI 10.1046/j.1365-2184.1997.00092.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Paasinen-Sohns A, 2000, J CELL BIOL, V151, P801, DOI 10.1083/jcb.151.4.801; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; PLUQUET O, 2003, IN PRESS BIOCH PHARM; POPLIN EA, 1994, CANCER CHEMOTH PHARM, V33, P415, DOI 10.1007/s002800050074; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiller JH, 1996, J CLIN ONCOL, V14, P1913, DOI 10.1200/JCO.1996.14.6.1913; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067; Shieh SY, 2000, GENE DEV, V14, P289; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Snyder RD, 2000, CANCER RES, V60, P1186; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TRAVIS EL, 1988, INT J RADIAT ONCOL, V15, P377, DOI 10.1016/S0360-3016(98)90019-0; TRESKES M, 1992, BIOCHEM PHARMACOL, V43, P1013, DOI 10.1016/0006-2952(92)90607-K; TRESKES M, 1994, EUR J CANCER, V30A, P183, DOI 10.1016/0959-8049(94)90084-1; TRESKES M, 1992, CANCER RES, V52, P2257; Vasilevskaya IA, 1999, CANCER RES, V59, P3935; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WOLOSCHAK GE, 1995, CANCER RES, V55, P4788; YUHAS JM, 1980, CANCER RES, V40, P1519	76	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11879	11887		10.1074/jbc.M207396200	http://dx.doi.org/10.1074/jbc.M207396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531896	hybrid			2022-12-25	WOS:000182015700022
J	Rojkova, AM; Woodard, GE; Huang, TC; Combs, CA; Zhang, JH; Simonds, WF				Rojkova, AM; Woodard, GE; Huang, TC; Combs, CA; Zhang, JH; Simonds, WF			G gamma subunit-selective G protein beta(5) mutant defines regulators of G protein signaling protein binding requirement for nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RGS PROTEINS; SUBCELLULAR-LOCALIZATION; CRYSTAL-STRUCTURE; EXPRESSION; INTERACTS; G-BETA-5; BRAIN; TRANSLOCATION; COEXPRESSION; MUTAGENESIS	The signal transducing function of Gbeta(5) in brain is unknown. When studied in vitro Gbeta(5) is the only heterotrimeric Gbeta subunit known to interact with both Ggamma subunits and regulators of G protein signaling (RGS) proteins. When tested with Ggamma, Gbeta(5) interacts with other classical components of heterotrimeric G protein signaling pathways such as Galpha and phospholipase C-beta. We recently demonstrated nuclear expression of Gbeta(5) in neurons and brain (Zhang, J. H., Barr, V. A., Mo, Y., Rojkova, A M., Liu, S., and Simonds, W. F. (2001) J. Biol. Chem. 276, 10284-10289). To gain further insight into the mechanism of Gbeta(5) nuclear localization, we generated a Gbeta(5) mutant deficient in its ability to interact with RGS7 while retaining its ability to bind Ggamma, and we compared its properties to the wild-type Gbeta(5). In HEK-293 cells co-transfection of RGS7 but not Ggamma(2) supported expression in the nuclear fraction of transfected wild-type Gbeta(5). In contrast the Ggamma-preferring Gbeta(5), mutant was not expressed in the HEK-293 cell nuclear fraction with either co-transfectant. The Ggamma-selective Gbeta(5) mutant was also excluded from the cell nucleus of transfected PC12 cells analyzed by laser confocal microscopy. These results define a requirement for RGS protein binding for Gbeta(5) nuclear expression.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Confocal Microscopy Core Facil, Div Intramural Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Simonds, WF (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C-101,10 Ctr Dr,MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov	Rozhkova, Alexandra/E-5607-2014; Woodard, Geoffrey/A-8608-2009	Rozhkova, Alexandra/0000-0003-4901-4705; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043304, Z01DK043304] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1995, J NEUROCHEM, V64, P1267; Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Benzing T, 2000, J BIOL CHEM, V275, P28167; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Crouch MF, 1997, FASEB J, V11, P189, DOI 10.1096/fasebj.11.2.9039962; Dessauer CW, 1996, CLIN SCI, V91, P527, DOI 10.1042/cs0910527; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jones MB, 1999, ANAL BIOCHEM, V268, P126, DOI 10.1006/abio.1998.3064; Jones PG, 1998, BBA-MOL CELL RES, V1402, P288, DOI 10.1016/S0167-4889(98)00017-2; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Patikoglou GA, 2002, J BIOL CHEM, V277, P47004, DOI 10.1074/jbc.M208186200; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Robatzek M, 2001, CURR BIOL, V11, P288, DOI 10.1016/S0960-9822(01)00074-4; Ryan JC, 2001, MOL VIS, V7, P222; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Song L, 2001, BIOCHEM BIOPH RES CO, V283, P102, DOI 10.1006/bbrc.2001.4742; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van der Linden AM, 2001, GENETICS, V158, P221; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Yoshikawa DM, 2000, BIOCHEMISTRY-US, V39, P11340, DOI 10.1021/bi0005557; Zhang JH, 2000, J NEUROCHEM, V75, P393, DOI 10.1046/j.1471-4159.2000.0750393.x; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	48	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12507	12512		10.1074/jbc.M207302200	http://dx.doi.org/10.1074/jbc.M207302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551930	hybrid			2022-12-25	WOS:000182015700102
J	Smani, T; Zakharov, SI; Leno, E; Csutora, P; Trepakova, ES; Bolotina, VM				Smani, T; Zakharov, SI; Leno, E; Csutora, P; Trepakova, ES; Bolotina, VM			Ca2+-independent phospholipase A(2) is a novel determinant of store-operated Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; NONSELECTIVE CATION CHANNEL; ARACHIDONIC-ACID; PHOSPHATIDATE PHOSPHOHYDROLASE; INTRACELLULAR CA2+; BROMOENOL LACTONE; HUMAN PLATELETS; CALCIUM INFLUX; T-LYMPHOCYTES; DEPLETION	Store-operated cation (SOC) channels and capacitative Ca2+ entry (CCE) play very important role in cellular function, but the mechanism of their activation remains one of the most intriguing and long lasting mysteries in the field of Ca2+ signaling. Here, we present the first evidence that Ca2+-independent phospholipase A(2) (iPLA(2)) is a crucial molecular determinant in activation of SOC channels and store-operated Ca2+ entry pathway. Using molecular, imaging, and electrophysiological techniques, we show that directed molecular or pharmacological impairment of the functional activity of iPLA(2) leads to irreversible inhibition of CCE mediated by nonselective SOC channels and by Ca2+-release-activated Ca2+ (CRAC) channels. Transfection of vascular smooth muscle cells (SMC) with antisense, but not sense, oligonucleotides for iPLA(2) impaired thapsigargin (TG)-induced activation of iPLA(2) and TG-induced Ca2+ and Mn2+ influx. Identical inhibition of TG-induced Ca2+ and Mn2+ influx (but not Ca2+ release) was observed in SMC, human platelets, and Jurkat T-lymphocytes when functional activity of iPLA(2) was inhibited by its mechanism-based suicidal substrate, bromoenol lactone (BEL). Moreover, irreversible inhibition of iPLA(2) impaired TG-induced activation of single nonselective SOC channels in SMC and BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)-induced activation of whole-cell CRAC current in rat basophilic leukemia cells. Thus, functional iPLA(2) is required for activation of store-operated channels and capacitative Ca2+ influx in wide variety of cell types.	Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Pecs, H-7624 Pecs, Hungary	Boston University; University of Pecs	Bolotina, VM (corresponding author), EBRC, Vasc Biol Unit, X-704,650 Albany St, Boston, MA 02118 USA.	vbolotina@medicine.bu.edu	Hajami, Tarik Smani/D-5372-2016; IBIS, CARDIOVASCULAR/P-3910-2015	Hajami, Tarik Smani/0000-0002-1877-7438; Bolotina, Victoria/0000-0001-5862-181X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054150] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Albert AP, 2002, J PHYSIOL-LONDON, V538, P717, DOI 10.1113/jphysiol.2001.013101; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Creer MH, 1998, AM J PHYSIOL-CELL PH, V275, pC1498, DOI 10.1152/ajpcell.1998.275.6.C1498; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Glitsch MD, 2002, J PHYSIOL-LONDON, V539, P93, DOI 10.1113/jphysiol.2001.012826; Golovina VA, 2001, AM J PHYSIOL-HEART C, V280, pH746, DOI 10.1152/ajpheart.2001.280.2.H746; Hirakawa Y, 1999, AM J PHYSIOL-HEART C, V277, pH1732, DOI 10.1152/ajpheart.1999.277.5.H1732; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Iwamuro Y, 1998, BRIT J PHARMACOL, V124, P1541, DOI 10.1038/sj.bjp.0701984; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; McFadzean I, 2002, BRIT J PHARMACOL, V135, P1, DOI 10.1038/sj.bjp.0704468; Mignen O, 2001, J BIOL CHEM, V276, P21365, DOI 10.1074/jbc.M102311200; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Ng LC, 2001, CIRC RES, V89, P923, DOI 10.1161/hh2201.100315; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Parekh AB, 1995, J PHYSIOL-LONDON, V489, P377, DOI 10.1113/jphysiol.1995.sp021058; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 2001, J CELL SCI, V114, P2223; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; Trepakova ES, 2002, BIOL MEMBRANY, V19, P49; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wayman CP, 1996, BRIT J PHARMACOL, V117, P566, DOI 10.1111/j.1476-5381.1996.tb15228.x; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	114	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11909	11915		10.1074/jbc.M210878200	http://dx.doi.org/10.1074/jbc.M210878200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547829	hybrid			2022-12-25	WOS:000182015700026
J	Sun, JP; Fedorov, AA; Lee, SY; Guo, XL; Shen, K; Lawrence, DS; Almo, SC; Zhang, ZY				Sun, JP; Fedorov, AA; Lee, SY; Guo, XL; Shen, K; Lawrence, DS; Almo, SC; Zhang, ZY			Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SUBSTRATE-TRAPPING MUTANTS; STRUCTURE-BASED DESIGN; HUMAN BREAST-CANCER; MOLECULAR-BASIS; INSULIN SENSITIVITY; SIGNAL-TRANSDUCTION; IN-VIVO; 1B; SPECIFICITY	Protein-tyrosine phosphatase 1B (PTP1B) has been implicated as an important regulator in several signaling pathways including those initiated by insulin and leptin. Potent and specific PTP1B inhibitors could serve as useful tools in elucidating the physiological functions of PTP1B and may constitute valuable therapeutics in the treatment of several human diseases. We have determined the crystal structure of PTP1B in complex with compound 2, the most potent and selective PTP1B inhibitor reported to date. The structure at 2.15-Angstrom resolution reveals that compound 2 simultaneously binds to the active site and a unique proximal noncatalytic site formed by Lys-41, Arg-47, and Asp-48. The structural data are further corroborated by results from kinetic analyses of the interactions of PTP1B and its site-directed mutants with compound 2 and several of its variants. Although many of the residues important for interactions between PTP1B and compound 2 are not unique to PTP1B, the combinations of all contact residues differ between PTP isozymes, which provide a structural basis for potent and selective PTP1B inhibition. Our data further suggest that potent, yet highly selective, PTP1B inhibitory agents can be acquired by targeting the area defined by residues Lys-41, Arg-47, and Asp-48, in addition to the previously identified second aryl phosphate-binding pocket.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		sun, Jinpeng/AAR-9196-2020; SUN, JINPENG/F-9551-2013		NIGMS NIH HHS [GM55242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asante-Appiah E, 2002, BIOCHEMISTRY-US, V41, P9043, DOI 10.1021/bi0259554; Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Groves MR, 1998, BIOCHEMISTRY-US, V37, P17773, DOI 10.1021/bi9816958; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; Iversen LF, 2001, BIOCHEMISTRY-US, V40, P14812, DOI 10.1021/bi011389l; Jia ZC, 2001, J MED CHEM, V44, P4584, DOI 10.1021/jm010266w; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu Gang, 2002, Curr Opin Investig Drugs, V3, P1608; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Taylor SD, 1998, BIOORGAN MED CHEM, V6, P1457, DOI 10.1016/S0968-0896(98)00075-3; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	44	128	135	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12406	12414		10.1074/jbc.M212491200	http://dx.doi.org/10.1074/jbc.M212491200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547827	hybrid			2022-12-25	WOS:000182015700090
J	Liu, CH; Gaca, MDA; Swenson, ES; Vellucci, VF; Reiss, M; Wells, RG				Liu, CH; Gaca, MDA; Swenson, ES; Vellucci, VF; Reiss, M; Wells, RG			Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells - Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; RAT-LIVER; GENE-EXPRESSION; II RECEPTOR; SIGNALING PATHWAYS; IN-VIVO; FIBRONECTIN SYNTHESIS; CELLULAR SOURCES; CARCINOMA-CELLS; TRANSGENIC MICE	Hepatic stellate cells are the primary cell type. responsible for matrix deposition in liver fibrosis, undergoing a process of transdifferentiation into fibrogenic myofibroblasts. These cells, which undergo a similar transdifferentiation process when cultured in vitro, are a major target of the profibrogenic agent transforming growth factor-beta (TGF-beta). We have studied activation of the TGF-beta downstream signaling molecules Smads 2, 3, and 4 in hepatic stellate cells (HSC) cultured in vitro for 1, 4, and 7 days, with quiescent, intermediate, and fully transdifferentiated phenotypes, respectively. Total levels of Smad4, common to multiple TGF-beta superfamily signaling pathways, do not change as HSC transdifferentiate, and the protein is found in both nucleus and cytoplasm, independent of treatment with TGF-beta or the nuclear export inhibitor leptomycin B. TGF-beta mediates activation of Smad2 primarily in early cultured cells and that of Smad3 primarily in transdifferentiated cells. The linker protein SARA, which is required for Smad2 signaling, disappears with transdifferentiation. Additionally, day 7 cells demonstrate constitutive phosphorylation and nuclear localization of Smad 2, which is not affected by pretreatment with TGF-beta-neutralizing antibodies, a type I TGF-beta receptor kinase inhibitor, or activin-neutralizing antibodies. These results demonstrate essential differences between TGF-beta-mediated signaling pathways in quiescent and in vitro transdifferentiated hepatic stellate cells.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Wells, RG (corresponding author), Univ Penn, Sch Med, Dept Med Gastroenterol, 415 Curie Blvd,670 CRB 6140, Philadelphia, PA 19104 USA.	rgwells@mail.med.upenn.edu	Reiss, Michael/A-8314-2009	Reiss, Michael/0000-0001-8543-8092	NCI NIH HHS [CA41556] Funding Source: Medline; NIDDK NIH HHS [DK58123, DK34989] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R01DK058123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BACHEM MG, 1993, VIRCHOWS ARCH B, V63, P123, DOI 10.1007/BF02899251; BACHEM MG, 1989, FEBS LETT, V257, P134, DOI 10.1016/0014-5793(89)81804-6; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Bauer M, 2001, FEBS LETT, V502, P1, DOI 10.1016/S0014-5793(01)02655-2; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; DeBleser PJ, 1997, HEPATOLOGY, V26, P905; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; DIGIOVANNA MP, 1996, CURRENT PROTOCOLS MO, P1; Dooley S, 2001, BIOCHEM BIOPH RES CO, V283, P554, DOI 10.1006/bbrc.2001.4811; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Feldmann K, 2002, EUR J IMMUNOL, V32, P1393, DOI 10.1002/1521-4141(200205)32:5<1393::AID-IMMU1393>3.0.CO;2-M; Flanders KC, 2001, DEV DYNAM, V220, P141, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1096>3.0.CO;2-4; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; GRESSNER AM, 1994, PATHOL RES PRACT, V190, P864; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Kanzler S, 1999, AM J PHYSIOL-GASTR L, V276, pG1059, DOI 10.1152/ajpgi.1999.276.4.G1059; KNAGAKI Y, 2001, J CELL PHYSL, V187, P117; Knittel T, 1996, GASTROENTEROLOGY, V111, P745, DOI 10.1053/gast.1996.v111.pm8780581; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knittel T, 1996, HEPATOLOGY, V24, P352; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Lu SL, 1999, BIOCHEM BIOPH RES CO, V259, P385, DOI 10.1006/bbrc.1999.0788; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; MILANI S, 1995, J HEPATOL, V22, P71; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; RAMADORI G, 1992, GASTROENTEROLOGY, V103, P1313, DOI 10.1016/0016-5085(92)91522-6; Roberts AB, 2001, CHEST, V120, p43S, DOI 10.1378/chest.120.1_suppl.S43-a; Roulot D, 1999, HEPATOLOGY, V29, P1730, DOI 10.1002/hep.510290622; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; Sakou T, 1999, J BONE MINER RES, V14, P1145, DOI 10.1359/jbmr.1999.14.7.1145; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stopa M, 2000, MAMM GENOME, V11, P169, DOI 10.1007/s003350010032; Tahashi Y, 2002, HEPATOLOGY, V35, P49, DOI 10.1053/jhep.2002.30083; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ueno H, 2000, HUM GENE THER, V11, P33, DOI 10.1089/10430340050016139; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Wells RG, 2000, AM J PHYSIOL-GASTR L, V279, pG845, DOI 10.1152/ajpgi.2000.279.5.G845; WILLIAMS EJ, 2001, CELLS HEPATIC SINUSO, V8, P191; Wrana JL, 1999, HEPATOLOGY, V29, P1909, DOI 10.1002/hep.510290641; Wu DN, 2001, MOL CELL ENDOCRINOL, V175, P111, DOI 10.1016/S0303-7207(01)00397-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yan W, 2000, ONCOL RES, V12, P157; Yata Y, 2002, HEPATOLOGY, V35, P1022, DOI 10.1053/jhep.2002.32673; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	73	145	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11721	11728		10.1074/jbc.M207728200	http://dx.doi.org/10.1074/jbc.M207728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12547835	hybrid			2022-12-25	WOS:000181855400107
J	Li, JX; Ma, CL; Huang, Y; Luo, H; Huang, CS				Li, JX; Ma, CL; Huang, Y; Luo, H; Huang, CS			Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA	ONCOGENE			English	Article						EGF; TPA; AP-1; kinase and signal transduction	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; CELL-TRANSFORMATION; MECHANISMS; EXPRESSION; BINDING; FAMILY; CANCER; DOMAIN; RAF	The transcription factor activator protein-1 (AP-1) has been implicated in a large variety of biological processes including cell differentiation, proliferation, apoptosis and oncogenic transformation. It is thought that the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced AP-1 activity is because of the activation of the PKC/MAPK/AP-1 pathway, although the detailed molecular mechanism has not been fully characterized. The tyrosine kinases of epidermal growth factor receptor (EGFR) lie at the head of a complex of signal transduction cascade that modulates cell proliferation, survival, adhesion, migration and differentiation. Currently, little is known about whether EGFR or its tyrosine kinase is necessary for TPA-induced AP-1 activation. In the present study, we investigated this issue using a well-characterized mouse fibroblast B82 cell line, which is devoid of the EGFR, and its stable transfectants with either wild-type EGFR (B82L) or tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721). We demonstrated that the TPA or epidermal growth factor (EGF) induced AP-1 activation in the B82L cells that express wild-type EGFR, but not in the B82 cell, whereas autophosphorylation at tyrosine(1173) of EGFR in B82L cells was only induced by EGF, but not TPA. The expression of tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721) resulted in deficiency of AP-1 induction in cellular response to EGF, while TPA treatment led to fully AP-1 activation. Furthermore, the mutation at Lys-721 of EGFR resulted in impairing of EGFR autophosphorylation at tyrosinell(1173) induced by EGF. Based on these results, we conclude that TPA-induced AP-1 activation requires the basal level-EGFR protein, but not EGFR tyrosine kinase and EGFR autophosphorylation at tyrosine(1173), whereas both EGFR tyrosine kinase and EGFR autophosphorylation at Y-1173 play a critical role in EGF-induced AP-1 activation.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	New York University; West Virginia University	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096; Luo, Jia/0000-0002-6968-3618	NCI NIH HHS [CA 16087] Funding Source: Medline; NIEHS NIH HHS [ES 00260] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker VL, 1998, PLACENTA, V19, P475, DOI 10.1016/S0143-4004(98)91040-2; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gulliford T, 1999, CELL SIGNAL, V11, P245, DOI 10.1016/S0898-6568(98)00058-8; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; SLAGA TJ, 1982, J CELL BIOCHEM, V18, P99, DOI 10.1002/jcb.1982.240180109; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; Yarden Y, 2001, EUR J CANCER, V37, pS3; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	38	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					211	219		10.1038/sj.onc.1206102	http://dx.doi.org/10.1038/sj.onc.1206102			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527890				2022-12-25	WOS:000180322400006
J	Zeitz, U; Weber, K; Soegiarto, DW; Wolf, E; Balling, R; Erben, RG				Zeitz, U; Weber, K; Soegiarto, DW; Wolf, E; Balling, R; Erben, RG			Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor	FASEB JOURNAL			English	Article						diabetes; VDR; calcium homeostasis; glucose tolerance; islet neogenesis	GLUCOSE-TOLERANCE; SUSCEPTIBILITY; DEFICIENCY; NORMALIZATION; RICKETS	It was the aim of this study to further explore the functional role of vitamin D in the endocrine pancreas. By gene targeting, we have recently generated mice in which a lacZ reporter gene is driven by the endogenous vitamin D receptor (VDR) promoter. These mice express a functionally inactive mutant VDR. Pancreatic islets but not exocrine pancreas cells showed strong lacZ reporter gene expression in mutant mice. To rule out possible influences of hypocalcemia on pancreatic endocrine function, a rescue diet enriched with calcium, phosphorus, and lactose was fed to wild-type (WT) and VDR mutant mice. The rescue diet normalized body weight and mineral homeostasis in VDR mutants. In glucose tolerance tests, baseline blood glucose levels were unchanged in fasting VDR mutants. However, blood glucose was elevated after oral or subcutaneous glucose loading, and maximum serum insulin levels were reduced by similar to60% in VDR mutants vs. WT mice on either diet. In addition, insulin mRNA levels were decreased in VDR mutant mice on both diets, whereas pancreatic cell mass, islet architecture, and islet neogenesis were normal. These findings clearly establish a molecular role of the VDR in pancreatic insulin synthesis and secretion in vivo.	Univ Munich, Inst Anim Physiol, D-80539 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85758 Neuherberg, Germany; Univ Munich, Inst Mol Anim Breeding, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Erben, RG (corresponding author), Univ Munich, Inst Anim Physiol, Vet Str 13, D-80539 Munich, Germany.	R.Erben@lrz.uni-muenchen.de	Erben, Reinhold/AAG-8007-2020; Weber, Karin/A-6034-2016; Balling, Rudi/E-9680-2010	Erben, Reinhold/0000-0003-0801-6958; Weber, Karin/0000-0002-0541-4355; Balling, Rudi/0000-0003-2902-5650; Wolf, Eckhard/0000-0002-0430-9510				Ayesha I, 2001, DIABETES NUTR METAB, V14, P78; Ayesha I, 2000, J NUTR SCI VITAMINOL, V46, P115, DOI 10.3177/jnsv.46.115; Bonner-Weir S, 2000, ENDOCRINOLOGY, V141, P1926, DOI 10.1210/en.141.6.1926; Bourlon PM, 1999, J ENDOCRINOL, V160, P87, DOI 10.1677/joe.0.1600087; BRINGHURST FR, 1998, WILLIAMS TXB ENDOCRI, P1155; CADE C, 1987, ENDOCRINOLOGY, V120, P1490, DOI 10.1210/endo-120-4-1490; CADE C, 1986, ENDOCRINOLOGY, V119, P84, DOI 10.1210/endo-119-1-84; Chang TJ, 2000, CLIN ENDOCRINOL, V52, P575, DOI 10.1046/j.1365-2265.2000.00985.x; CREUTZFELDT W, 1992, DIABETES METAB REV, V8, P149, DOI 10.1002/dmr.5610080206; Dahlquist G, 1999, DIABETOLOGIA, V42, P51, DOI 10.1007/s001250051112; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOSSLER A, 1993, GENE TARGETING PRACT, P181; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HOCHBERG Z, 1985, J CLIN ENDOCR METAB, V60, P57, DOI 10.1210/jcem-60-1-57; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; JOHNSON JA, 1994, AM J PHYSIOL, V267, pE356, DOI 10.1152/ajpendo.1994.267.3.E356; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kato S, 2000, J BIOCHEM, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662; LEE S, 1994, ENDOCRINOLOGY, V134, P1602, DOI 10.1210/en.134.4.1602; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; McDermott MF, 1997, DIABETOLOGIA, V40, P971, DOI 10.1007/s001250050776; NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216; Pani MA, 2000, DIABETES, V49, P504, DOI 10.2337/diabetes.49.3.504; Unger R.H., 1998, WILLIAMS TXB ENDOCRI, P973; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270	27	301	323	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					509	+		10.1096/fj.02-0424fje	http://dx.doi.org/10.1096/fj.02-0424fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551842				2022-12-25	WOS:000181453700009
J	Anderson, LM; Choe, SE; Yukhananov, RY; Hopfner, RL; Church, GM; Pratt, RE; Dzau, VJ				Anderson, LM; Choe, SE; Yukhananov, RY; Hopfner, RL; Church, GM; Pratt, RE; Dzau, VJ			Identification of a novel set of genes regulated by a unique liver X receptor-alpha-mediated transcription mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENIN GENE; NUCLEAR RECEPTORS; IN-VIVO; MOLECULAR MECHANISM; TRANSGENIC MICE; HUMAN GENOME; FACTOR DECOY; LXR-ALPHA; EXPRESSION; PROTEIN	We have reported previously that liver X receptor-alpha (LXRalpha) can mediate a novel cAMP-dependent increase in renin and c-myc gene transcription by binding as a monomer to a unique regulatory element termed the cAMP-negative response element (CNRE). To determine whether this novel action of LXRalpha has global implications on gene regulation, we employed expression profiling to identify other genes regulated by this unique mechanism. Here we report the existence of a set of known and unknown transcripts regulated in parallel with renin. Querying the Celera Mouse Genome Assembly revealed that a majority of these genes contained the consensus CNRE. We have confirmed the functionality of these CNREs by competition for LXRalpha binding via electrophoretic mobility shift assays (EMSA) and by the use of CNRE decoy molecules documenting the abolishment of the cAMP-mediated gene induction. Taken together, these results demonstrate that the interaction between cAMP-activated LXRalpha and the CNRE enhancer element is responsible for widespread changes in gene expression and identify a set of LXRalpha/cAMP-regulated genes that may have important biological implications.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc Res, Lab Genet Physiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Anesthesiol, Neurogenomic Lab, Pain Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Pratt, RE (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Res, Lab Genet Physiol, 75 Francis St, Boston, MA 02115 USA.	rpratt@ries.bwh.harvard.edu; VDZAU@Partners.org		church, george/0000-0001-6232-9969; Choe, Sung/0000-0001-9140-4198	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL058516, R01HL035610, R01HL061661] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61661, HL58516, HL35610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BAXTER JD, 1991, RECENT PROG HORM RES, V47, P211; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; BURT DW, 1989, J BIOL CHEM, V264, P7357; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hamilton BA, 2001, CELL, V107, P13, DOI 10.1016/S0092-8674(01)00514-1; Harrington CA, 2000, CURR OPIN MICROBIOL, V3, P285, DOI 10.1016/S1369-5274(00)00091-6; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Murray GI, 2001, ANNU REV PHARMACOL, V41, P297, DOI 10.1146/annurev.pharmtox.41.1.297; Niesor EJ, 2001, CURR PHARM DESIGN, V7, P231, DOI 10.2174/1381612013398185; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pertea M, 2001, NUCLEIC ACIDS RES, V29, P1185, DOI 10.1093/nar/29.5.1185; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Stulnig TM, 2002, MOL PHARMACOL, V62, P1299, DOI 10.1124/mol.62.6.1299; Subramanian G, 2001, JAMA-J AM MED ASSOC, V286, P2296, DOI 10.1001/jama.286.18.2296; Takasaki N, 2001, MOL CELL BIOL, V21, P8197, DOI 10.1128/MCB.21.23.8197-8202.2001; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; TAMURA K, 2000, CIRCULATION S2, V18, P415; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tomita S, 1999, CIRC RES, V84, P1059, DOI 10.1161/01.RES.84.9.1059; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Xu GR, 1998, GENOMICS, V47, P171, DOI 10.1006/geno.1997.5072; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	36	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15252	15260		10.1074/jbc.M208644200	http://dx.doi.org/10.1074/jbc.M208644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12551904	hybrid			2022-12-25	WOS:000182516100087
J	Detarsio, E; Wheeler, MCG; Bermudez, VAC; Andreo, CS; Drincovich, MF				Detarsio, E; Wheeler, MCG; Bermudez, VAC; Andreo, CS; Drincovich, MF			Maize C(4)NADP-malic enzyme - Expression in Escherichia coli and characterization of site-directed mutants at the putative nucleotide-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADP-MALIC ENZYME; CRYSTAL-STRUCTURE; DINUCLEOTIDE; PURIFICATION; PROTEINS; ISOFORMS; DISTINCT; TISSUES; C-3; C4	Malic enzymes catalyze the oxidative decarboxylation Of L-malate to yield pyruvate, CO2, and NAD(P)H in the presence of a bivalent metal ion. In plants, different isoforms of the NADP-malic enzyme (NADP-ME) are involved in a wide range of metabolic pathways. The C-4-specific NADP-ME has evolved from C-3-type malic enzymes to represent a unique and specialized form of NADP-ME as indicated by its particular kinetic and regulatory properties. In the present study, the mature C-4- specific NADP-ME of maize was expressed in Escherichia coli. The recombinant enzyme has essentially the same physicochemical properties and K-m for the substrates as those of the naturally occurring NADP-ME previously characterized. However, the k(cat) was almost 7-fold higher, which may suggest that the previously purified enzyme from maize leaves was partially inactive. The recombinant NADP-ME also has a very low intrinsic NAD-dependent activity. Five mutants of NADP-ME at the postulated putative NADP-binding site(s) (Gsite5V, Gsite2V, A392G, A387G, and R237L) were constructed by site-directed mutagenesis and purified to homogeneity. The participation of these residues in substrate binding and/or the catalytic reaction was inferred by kinetic measurements and circular dichroism and intrinsic fluorescence spectra. The results obtained were compared with a predicted three-dimensional model of maize C-4 NADP-ME based on crystallographic studies of related animal NAD(P)-MEs. The data presented here represent the first prokaryotic expression of a plant NADP-ME and reveals valuable insight regarding the participation of the mutated amino acids in the binding of substrates and/or catalysis.	Univ Nacl Rosario, CEFOBI, CONICET, RA-2000 Rosario, Argentina	National University of Rosario	Andreo, CS (corresponding author), Univ Nacl Rosario, CEFOBI, CONICET, Fund M Lillo,Suipacha 531, RA-2000 Rosario, Argentina.	candreo@fbioyf.unr.edu.ar	Drincovich, Maria F/Q-4195-2019; Drincovich, Maria F/F-3902-2017	Drincovich, Maria F/0000-0003-4897-3285; Drincovich, Maria F/0000-0003-4897-3285; Campos Bermudez, Valeria/0000-0003-0135-6482				Ashton AR, 1997, ARCH BIOCHEM BIOPHYS, V345, P251, DOI 10.1006/abbi.1997.0260; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Coleman DE, 2002, BIOCHEMISTRY-US, V41, P6928, DOI 10.1021/bi0255120; Drincovich MF, 1995, BIOCHEM MOL BIOL INT, V36, P1287; DRINCOVICH MF, 1991, PHYSIOL PLANTARUM, V81, P462; Drincovich MF, 2001, FEBS LETT, V490, P1, DOI 10.1016/S0014-5793(00)02331-0; Edwards G., 1983, C3 C4 MECH CELLULAR; EDWARDS GE, 1992, PHYTOCHEMISTRY, V31, P1845, DOI 10.1016/0031-9422(92)80322-6; GROVER SD, 1981, ARCH BIOCHEM BIOPHYS, V209, P396, DOI 10.1016/0003-9861(81)90297-6; HANSEN EJ, 1975, BIOCHEM BIOPH RES CO, V65, P559, DOI 10.1016/S0006-291X(75)80183-5; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HATCH MD, 1977, ARCH BIOCHEM BIOPHYS, V179, P361, DOI 10.1016/0003-9861(77)90123-0; Kuo CC, 2000, BIOCHEM BIOPH RES CO, V270, P821, DOI 10.1006/bbrc.2000.2502; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai LB, 2002, PLANT PHYSIOL, V128, P125, DOI 10.1104/pp.010448; Maurino VG, 1997, J EXP BOT, V48, P799, DOI 10.1093/jxb/48.3.799; Maurino VG, 1996, BIOCHEM MOL BIOL INT, V38, P239; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO SR, 1991, PHYTOCHEMISTRY, V30, P431, DOI 10.1016/0031-9422(91)83699-L; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROTHERMEL BA, 1989, J BIOL CHEM, V264, P19587; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Sheen J, 1999, ANNU REV PLANT PHYS, V50, P187, DOI 10.1146/annurev.arplant.50.1.187; Spampinato CP, 1998, BBA-PROTEIN STRUCT M, V1383, P245, DOI 10.1016/S0167-4838(97)00214-8; SPINA J, 1970, BIOCHEMISTRY-US, V9, P3794, DOI 10.1021/bi00821a019; Takeuchi K, 2000, PLANTA, V211, P265, DOI 10.1007/s004250000282; Tausta SL, 2002, PLANT MOL BIOL, V50, P635, DOI 10.1023/A:1019998905615; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2000, NAT STRUCT BIOL, V7, P251; Yang ZR, 2002, PROTEIN SCI, V11, P332, DOI 10.1110/ps.38002	35	48	52	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13757	13764		10.1074/jbc.M212530200	http://dx.doi.org/10.1074/jbc.M212530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562758	hybrid			2022-12-25	WOS:000182405000026
J	Sugimoto, H; Hamano, Y; Charytan, D; Cosgrove, D; Kieran, M; Sudhakar, A; Kalluri, R				Sugimoto, H; Hamano, Y; Charytan, D; Cosgrove, D; Kieran, M; Sudhakar, A; Kalluri, R			Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REMNANT KIDNEY MODEL; GLOMERULAR-PERMEABILITY; SLIT DIAPHRAGM; IMPAIRED ANGIOGENESIS; AMNIOTIC-FLUID; FACTOR FAMILY; MOUSE KIDNEY; NEPHRIN; EXPRESSION; GENE	There are about 2.5 million glomeruli in the kidneys each consisting of a barrel of glomerular basement membrane surrounded by glomerular endothelial cells on the inside and glomerular epithelial cells with established foot processes (podocytes) on the outside. Defects in this filtration apparatus lead to glomerular vascular leak or proteinuria. The role of vascular endothelial growth factor (VEGF) in the regulation of glomerular vascular permeability is still unclear. Recent studies indicate that patients receiving anti-VEGF antibody therapy may have an increased incidence of proteinuria. In a different setting, pregnancies complicated by preeclampsia are associated with elevated soluble VEGF receptor 1 protein (sFIt-1), endothelial cell dysfunction and proteinuria. These studies suggest that neutralization of physiologic levels of VEGF, a key endothelial survival factor, may lead to proteinuria. In the present study, we evaluated the potential of anti-VEGF neutralizing antibodies and sFlt-1 in the induction of proteinuria. Our studies demonstrate that anti-VEGF antibodies and sFIt-1 cause rapid glomerular endothelial cell detachment and hypertrophy, in association with down-regulation of nephrin, a key epithelial protein in the glomerular filtration apparatus. These studies suggest that down-regulation or neutralization of circulating VEGF may play an important role in the induction of proteinuria in various kidney diseases, some forms of cancer therapy and also in women with preeclampsia.	Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Gastroenterol, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Nephrol, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Nephrol, Ctr Canc, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Program Matrix Biol, Div Gastroenterol, Ctr Canc, Boston, MA 02215 USA; Boys Town Natl Res Hosp, Gene Express Lab, Omaha, NE 68131 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boys Town National Research Hospital; Harvard University; Dana-Farber Cancer Institute	Kalluri, R (corresponding author), Harvard Univ, Sch Med, DANA 514,330 Brookline Ave, Boston, MA 02215 USA.	rkalluri@bidme.harvard.edu	; Kalluri, Raghu/E-2677-2015	charytan, david/0000-0002-7695-3583; Kieran, Mark/0000-0003-2184-7692; Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [T32DK07199-25, DK 55001, DK-51711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007199, R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680; Benigni A, 2001, J AM SOC NEPHROL, V12, P941, DOI 10.1681/ASN.V125941; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; BROWN LF, 1997, EXS, V79, P233; BULGER RE, 1983, J CLIN INVEST, V72, P128, DOI 10.1172/JCI110950; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CAULFIEL.JP, 1974, J CELL BIOL, V63, P883, DOI 10.1083/jcb.63.3.883; CAULFIELD JP, 1975, J EXP MED, V142, P61, DOI 10.1084/jem.142.1.61; Cosgrove D, 2000, AM J PATHOL, V157, P1649, DOI 10.1016/S0002-9440(10)64802-X; Deen WM, 2001, AM J PHYSIOL-RENAL, V281, pF579; Fan LY, 2002, NEPHRON, V90, P95, DOI 10.1159/000046320; Farquhar MG, 1999, J AM SOC NEPHROL, V10, P2645; Feng D, 2000, J HISTOCHEM CYTOCHEM, V48, P545, DOI 10.1177/002215540004800412; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; GRAHAM RC, 1966, J EXP MED, V124, P1123, DOI 10.1084/jem.124.6.1123; Hamano Y, 2002, J BIOL CHEM, V277, P31154, DOI 10.1074/jbc.M204806200; Hasumi Y, 2002, CANCER RES, V62, P2019; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Honkanen EO, 2000, KIDNEY INT, V57, P2343, DOI 10.1046/j.1523-1755.2000.00094.x; JONES DB, 1985, LAB INVEST, V52, P453; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kang DH, 2001, J AM SOC NEPHROL, V12, P1434, DOI 10.1681/ASN.V1271434; Kang DH, 2001, J AM SOC NEPHROL, V12, P1448, DOI 10.1681/ASN.V1271448; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; KRISTAL B, 1988, AM J NEPHROL, V8, P198, DOI 10.1159/000167583; Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959; Langham RG, 2002, DIABETOLOGIA, V45, P1572, DOI 10.1007/s00125-002-0946-y; OLIVER C, 1972, J EXP MED, V136, P291, DOI 10.1084/jem.136.2.291; Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740; Pridjian G, 2002, OBSTET GYNECOL SURV, V57, P598, DOI 10.1097/00006254-200209000-00023; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Rantanen M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016142.29721.22; RENNKE HG, 1977, FED PROC, V36, P2619; RENNKE HG, 1977, KIDNEY INT, V11, P44, DOI 10.1038/ki.1977.6; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SCHNEEBERGER EE, 1975, KIDNEY INT, V8, P48, DOI 10.1038/ki.1975.75; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simon M, 1998, J AM SOC NEPHROL, V9, P1032; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VENKATACHALAM MA, 1970, J EXP MED, V132, P1153, DOI 10.1084/jem.132.6.1153; Vuorela P, 2000, OBSTET GYNECOL, V95, P353, DOI 10.1016/S0029-7844(99)00565-7; Vuorela-Vepsalainen P, 1999, HUM REPROD, V14, P1346, DOI 10.1093/humrep/14.5.1346; Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583; Wong AK, 2001, P NATL ACAD SCI USA, V98, P7481, DOI 10.1073/pnas.121192298; Yang WG, 2001, CANCER RES, V61, P7840; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9	56	433	470	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12605	12608		10.1074/jbc.C300012200	http://dx.doi.org/10.1074/jbc.C300012200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12538598	hybrid			2022-12-25	WOS:000182189500003
J	Ferreira-Pereira, A; Marco, S; Decottignies, A; Nader, J; Goffeau, A; Rigaud, JL				Ferreira-Pereira, A; Marco, S; Decottignies, A; Nader, J; Goffeau, A; Rigaud, JL			Three-dimensional reconstruction of the Saccharomyces cerevisiae multidrug resistance protein Pdr5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAINS; YEAST ABC PROTEINS; P-GLYCOPROTEIN; ELECTRON-MICROSCOPY; CYSTIC-FIBROSIS; BIOLOGICAL MACROMOLECULES; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE	Pdr5p, the major multidrug exporter in Saccharomyces cerevisiae, is a member of the ATP-binding cassette (ABC) superfamily. Pdr5p shares similar mechanisms of substrate recognition and transport with the human MDR1-Pgp, despite an inverted topology of transmembrane and ATP-binding domains. The hexahistidine-tagged Pdr5p multidrug transporter was highly overexpressed in yeast strains where other ABC genes have been deleted. After solubilization and purification, the 160-kDa recombinant Pdr5p has been reconstituted into a lipid bilayer. Controlled detergent removal from Pdr5p-lipid-detergent micelles allowed the production of peculiar square-shaped particles coexisting with liposomes and proteoliposomes. These particles having 11 nm in side were well suited for single particle analysis by electron microscopy. From such analysis, a computed volume has been determined at 25-Angstrom resolution, giving insight into the structural organization of Pdr5p. Comparison with the reported structures of different bacterial ABC transporters was consistent with a dimeric organization of Pdr5p in the square particles. Each monomer was composed of three subregions corresponding to a membrane region of about 50 Angstrom in height that joins two well separated protruding stalks of about 40 Angstrom in height, ending each one with a cytoplasmic nucleotide-binding domain (NBD) lobe of about 50-60 Angstrom in diameter. The three-dimensional reconstruction of Pdr5p revealed a close arrangement and a structural asymmetric organization of the two NBDs that appeared oriented perpendicularly within a monomer. The existence of different angular positions of the NBDs, with respect to the stalks, suggest rotational movements during the catalytic cycle.	Inst Curie, CNRS, Sect Rech, Unite Mixte Rech 168, F-75231 Paris 05, France; Commissariat Energie, Lab Rech Correspondant, F-75231 Paris 05, France; Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Microbiol, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Fac Farm, Dept Anal Clin & Toxicol, BR-21949900 Rio De Janeiro, Brazil; Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universite Catholique Louvain	Marco, S (corresponding author), Inst Curie, CNRS, Sect Rech, Unite Mixte Rech 168, 11 Rue Pierre & Marie Curie, F-75231 Paris 05, France.	sergio.marco@curie.fr	Ferreira-Pereira, Antonio/A-2910-2011; marco garrido, sergio/F-5876-2013; marco, SERGIO/E-4875-2017	Ferreira-Pereira, Antonio/0000-0002-0474-8388; 				Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Conseil G, 2001, BIOCHEMISTRY-US, V40, P2564, DOI 10.1021/bi002453m; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kolaczkowski M, 1997, PHARMACOL THERAPEUT, V76, P219, DOI 10.1016/S0163-7258(97)00094-6; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; LEPPERT G, 1990, GENETICS, V125, P13; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Manciu L, 2003, J BIOL CHEM, V278, P3347, DOI 10.1074/jbc.M207963200; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; Mullick R, 1998, ANN M SOC COMP APPL; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Proff C, 2001, MOL GEN GENET, V264, P883, DOI 10.1007/s004380000378; Rao G. Subba, 2002, Functional and Integrative Genomics, V1, P357; Rogers B, 2001, J MOL MICROB BIOTECH, V3, P207; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Soszynski M, 1998, ARCH BIOCHEM BIOPHYS, V354, P311, DOI 10.1006/abbi.1998.0687; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; van Veen HW, 2001, J MOL MICROB BIOTECH, V3, P185; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; Velarde G, 2001, J BIOL CHEM, V276, P46054, DOI 10.1074/jbc.M108435200; Wang EJ, 2000, BIOCHEM BIOPH RES CO, V276, P909, DOI 10.1006/bbrc.2000.3554	61	49	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11995	11999		10.1074/jbc.M212198200	http://dx.doi.org/10.1074/jbc.M212198200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551908	hybrid			2022-12-25	WOS:000182015700037
J	Herron, SR; Scavetta, RD; Garrett, M; Legner, M; Jurnak, F				Herron, SR; Scavetta, RD; Garrett, M; Legner, M; Jurnak, F			Characterization and implications of Ca2+ binding to pectate lyase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERWINIA-CHRYSANTHEMI EC16; PLANT VIRULENCE FACTOR; ELECTRON-DENSITY MAPS; 3-DIMENSIONAL STRUCTURE; TISSUE MACERATION; CELL-WALLS; CALCIUM; PROTEINS; PATHOGENICITY; ENZYMES	Ca2+ is essential for in vitro activity of Erwinia chrysanthemi pectate lyase C (PeIC). Crystallographic analyses of 11 PelC-Ca2+ complexes, formed at pH 4.5, 9.5, and 11.2 under varying Ca2+ concentrations, have been solved and refined at a resolution of 2.2 Angstrom. The Ca2+ site represents a new motif for Ca2+, consisting primarily of beta-turns and beta-strands. The principal differences between PelC and the PelC-Ca2+ structures at all pH values are the side-chain conformations of Asp-129 and Glu-166 as well as the occupancies of four water molecules. According to calculations of pK(a) values, the presence of Ca2+ and associated structural changes lower the pK(a) of Arg-218, the amino acid responsible for proton abstraction during catalysis. The Ca2+ affinity for PelC is weak, as the K-d was estimated to be 0.132 (+/- 0.004) m(M) at pH 9.5, 1.09 (+/- 0.29) m(M) at pH 11.2, and 5.84 (+/- 0.41) m(M) at pH 4.5 from x-ray diffraction studies and 0.133 (+/- 0.045) m(M) at pH 9.5 from intrinsic tryptophan fluorescence measurements. Given the pH dependence of Ca2+ affinity, PelC activity at pH 4.5 has been reexamined. At saturating Ca2+ concentrations, PelC activity increases 10-fold at pH 4.5 but is less than 1% of maximal activity at pH 9.5. Taken together, the studies suggest that the primary Ca2+ ion in PelC has multiple functions.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92612 USA	University of California System; University of California Irvine	Jurnak, F (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, D-350 Med Sci Bldg 1, Irvine, CA 92612 USA.							Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; BOCCARA M, 1988, PHYSIOL MOL PLANT P, V33, P95, DOI 10.1016/0885-5765(88)90046-X; BOCCARA M, 1989, J BACTERIOL, V171, P4085, DOI 10.1128/jb.171.7.4085-4087.1989; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BRUNGER AT, 1996, X PLOR VERSION 3 8; CARRELL CJ, 1988, J AM CHEM SOC, V110, P8651, DOI 10.1021/ja00234a011; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; CRAWFORD MS, 1987, ARCH BIOCHEM BIOPHYS, V258, P196, DOI 10.1016/0003-9861(87)90336-5; DELORENZO G, 1991, PHYSIOL MOL PLANT P, V39, P335, DOI 10.1016/0885-5765(91)90015-A; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVENS SV, 1993, J MOL GRAPHICS, V11, P134; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; HEFFRON S, 1995, MOL PLANT MICROBE IN, V8, P331, DOI 10.1094/MPMI-8-0331; HENRISSAT B, 1995, PLANT PHYSIOL, V107, P963, DOI 10.1104/pp.107.3.963; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; HERRON SR, 2002, IN PRESS PECTINS PEC; HOTCHKISS AT, 1993, CARBOHYD RES, V247, P1, DOI 10.1016/0008-6215(93)84236-Y; Hotchkiss AT, 1996, PHYSIOL MOL PLANT P, V48, P1, DOI 10.1006/pmpp.1996.0001; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kita N, 1996, J BIOL CHEM, V271, P26529, DOI 10.1074/jbc.271.43.26529; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIETZKE SE, 1994, PLANT PHYSIOL, V106, P849, DOI 10.1104/pp.106.3.849; LIM C, 1991, J PHYS CHEM-US, V95, P5610, DOI 10.1021/j100167a045; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pidcock E, 2001, J BIOL INORG CHEM, V6, P479, DOI 10.1007/s007750100214; Ried J. L., 1988, Molecular Plant-Microbe Interactions, V1, P32, DOI 10.1094/MPMI-1-032; RIHOUEY C, 1995, PLANT PHYSIOL BIOCH, V33, P497; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; TAMAKI SJ, 1988, J BACTERIOL, V170, P3468, DOI 10.1128/jb.170.8.3468-3478.1988; Tardy F, 1997, J BACTERIOL, V179, P2503, DOI 10.1128/jb.179.8.2503-2511.1997; THURN KK, 1985, APPL ENVIRON MICROB, V50, P894, DOI 10.1128/AEM.50.4.894-898.1985; VIRK SS, 1988, PLANTA, V176, P60, DOI 10.1007/BF00392480; WILSON AJC, 1942, NATURE, V150, P90; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; YODER MD, 1995, PLANT PHYSIOL, V107, P349, DOI 10.1104/pp.107.2.349; YODER MD, 1990, J BIOL CHEM, V265, P11429; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; ZUKER M, 1970, J BACTERIOL, V104, P13; [No title captured]	48	44	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12271	12277		10.1074/jbc.M209306200	http://dx.doi.org/10.1074/jbc.M209306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12540845	hybrid			2022-12-25	WOS:000182015700072
J	Kirsch, M; Fuchs, A; de Groot, H				Kirsch, M; Fuchs, A; de Groot, H			Regiospecific nitrosation of N-terminal-blocked tryptophan derivatives by N2O3 at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; S-NITROSYLATION; CREATINE-KINASE; PEROXYNITRITE; NITROSOTHIOLS; MECHANISM; OXIDATION; KINETICS; CALCIUM; AMINES	N2O3 formed from nitric oxide in the presence of oxygen attacks thiols in proteins to yield S-nitrosothiols, which are believed to play a central role in NO signaling. In the present study we examined the N-nitrosation of N-terminal-blocked (N-blocked) tryptophan derivatives in the presence of N2O3 generating systems, such as preformed nitric oxide and nitric oxide donor compounds in the presence of oxygen at pH 7.4. Under these conditions N-nitrosation of N-acetyltryptophan and lysine-tryptophan-lysine, respectively, was proven unequivocally by UV-visible spectroscopy as well as N-15 NMR spectrometry. Competition experiments performed with the known N2O3 scavenger morpholine demonstrated that the selected tryptophan derivatives were nitrosated by N2O3 with similar rate constants. It is further shown that the addition of ascorbate (vitamin C) induced the release of nitric oxide from N-acetyl-N-nitrosotryptophan as monitored polarographically with a NO electrode. Theoretical considerations strongly suggested that the reactivity of protein-bound tryptophan would be high enough to compete effectively with protein-bound cysteine for N2O3. Our data demonstrate conclusively that N2O3 nitrosates the secondary amine function (N-indole) at the indole ring of N-blocked tryptophan with high reactivity at physiological pH values.	Univ Klinikum, Inst Physiol Chem, D-45122 Essen, Germany	University of Duisburg Essen	Kirsch, M (corresponding author), Univ Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.	michael.kirsch@uni-essen.de						ARENDT J, 1979, ANN CLIN BIOCHEM, V16, P307, DOI 10.1177/000456327901600182; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P979, DOI 10.1006/jmcc.1998.0662; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blanchard B, 2000, J PINEAL RES, V29, P184, DOI 10.1034/j.1600-079X.2000.290308.x; Blanchard-Fillion B, 2001, FREE RADICAL RES, V35, P857, DOI 10.1080/10715760100301351; BONNETT R, 1979, J CHEM SOC PERK T 1, P1969, DOI 10.1039/p19790001969; BONNETT R, 1974, J CHEM SOC P1, V1, P962; Borgs M, 1996, HEPATOLOGY, V23, P1564, DOI 10.1053/jhep.1996.v23.pm0008675178; CHALLIS BC, 1972, J CHEM SOC P1, V2, P918; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; DORIE J, 1986, J MOL STRUCT, V144, P185, DOI 10.1016/0022-2860(86)80178-8; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Garcia-Santos MD, 2002, J AM CHEM SOC, V124, P2177, DOI 10.1021/ja0119503; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P488; Harohalli K, 2002, J BIOMED SCI, V9, P47, DOI 10.1007/BF02256578; HETZER HB, 1966, J PHYS CHEM-US, V70, P2869, DOI 10.1021/j100881a024; Holmes AJ, 2000, J CHEM SOC PERK T 2, P1639, DOI 10.1039/b004028m; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; Kirsch M, 2000, CHEM RES TOXICOL, V13, P451, DOI 10.1021/tx990138z; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kirsch M, 2002, J BIOL CHEM, V277, P13379, DOI 10.1074/jbc.M108079200; Konorev EA, 2000, FREE RADICAL BIO MED, V28, P1671, DOI 10.1016/S0891-5849(00)00281-1; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LEWIS RS, 1995, J AM CHEM SOC, V117, P3933, DOI 10.1021/ja00119a006; LIJINSKY W, 1970, NATURE, V225, P21, DOI 10.1038/225021a0; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lomonosova EE, 1998, FREE RADICAL BIO MED, V24, P522, DOI 10.1016/S0891-5849(97)00295-5; MEYER T, 1982, J CHEM SOC P1, V2, P1383; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Noble DR, 2001, J CHEM SOC PERK T 2, P13, DOI 10.1039/b008112o; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Redfearn J, 1997, PHYS WORLD, V10, P14; Schmidt K, 1998, FREE RADICAL BIO MED, V24, P859, DOI 10.1016/S0891-5849(97)00366-3; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; Turjanski AG, 2000, J AM CHEM SOC, V122, P10468, DOI 10.1021/ja002006u; VENITT S, 1980, CARCINOGENESIS, V1, P523, DOI 10.1093/carcin/1.6.523; WILLIAMS DLH, 1986, NITROSATION; Witanowski M., 1993, ANN REPORTS NMR SPEC, V25; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271	55	48	48	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11931	11936		10.1074/jbc.M300237200	http://dx.doi.org/10.1074/jbc.M300237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551937	hybrid			2022-12-25	WOS:000182015700029
J	Whiteman, SC; Bianco, A; Knight, RA; Spiteri, MA				Whiteman, SC; Bianco, A; Knight, RA; Spiteri, MA			Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAINS; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; IFN-GAMMA; IN-VITRO; EXPRESSION; INHIBITION; SECRETION; CYTOKINES; SUGGESTS	Human rhinoviruses are responsible for many upper respiratory tract infections. 90% of rhinoviruses utilize intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor, which also plays a critical role in recruitment of immune effector cells. Two forms of this receptor exist; membrane-bound (mICAM-1) and soluble ICAM-1 (sICAM-1). The soluble receptor may be produced independently from the membrane-bound form or it may be the product of proteolytic cleavage of mICAM-1. The ratio of airway epithelial cell expression of mlCAM-1 to the sICAM-1 form may influence cell infectivity and outcome of rhinovirus infection. We therefore investigated the effect of rhinovirus on expression of both ICAM-1 receptors in normal human bronchial epithelial cells. We observed separate distinct messenger RNA transcripts coding for mlCAM-1 and sICAM-1 in these cells, which were modulated by virus. Rhinovirus induced mICAM-1 expression on epithelial cells while simultaneously down-regulating sICAM-1 release, with consequent increase in target cell infectivity. The role of protein tyrosine kinases was investigated as a potential mechanistic pathway. Rhinovirus infection induced rapid phosphorylation of intracellular tyrosine kinase, which may be critical in up-regulation of mICAM-1. Elucidation of the underlying molecular mechanisms involved in differential modulation of both ICAM-1 receptors may lead to novel therapeutic strategies.	N Staffordshire Hosp, Lung Injury & Inflammat Res Grp, Directorate Resp Med, Stoke On Trent ST4 6QG, Staffs, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Cyst Fibrosis, London SW3 64R, England	Keele University; University Hospital of North Staffordshire NHS Trust; Imperial College London	Whiteman, SC (corresponding author), N Staffordshire Hosp, Lung Injury & Inflammat Res Grp, Directorate Resp Med, Newcastle Rd, Stoke On Trent ST4 6QG, Staffs, England.	med16_2000@yahoo.com						ARRUDA E, 1992, ANTIMICROB AGENTS CH, V36, P1186, DOI 10.1128/AAC.36.6.1186; BECKER JC, 1991, J IMMUNOL, V147, P4398; Bella J, 1999, VIRUS RES, V62, P107, DOI 10.1016/S0168-1702(99)00038-6; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Bianco A, 1998, EUR RESPIR J, V12, P619, DOI 10.1183/09031936.98.12030619; Budnik A, 1992, Exp Dermatol, V1, P27, DOI 10.1111/j.1600-0625.1992.tb00068.x; Budnik A, 1996, EXP HEMATOL, V24, P352; BurkeGaffney A, 1996, BRIT J PHARMACOL, V119, P1149, DOI 10.1111/j.1476-5381.1996.tb16017.x; Carnes J, 2000, RNA, V6, P1468, DOI 10.1017/S1355838200001242; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Gustin KE, 2002, J VIROL, V76, P8787, DOI 10.1128/JVI.76.17.8787-8796.2002; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; HIS ED, 1995, J INTERFERON CYTOKIN, V15, P89; Huber M, 1997, J VIROL, V71, P595, DOI 10.1128/JVI.71.1.595-600.1997; Huguenel ED, 1997, AM J RESP CRIT CARE, V155, P1206, DOI 10.1164/ajrccm.155.4.9105055; JACKSON AM, 1993, INT J CANCER, V55, P921, DOI 10.1002/ijc.2910550608; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; Leung KH, 1999, BIOCHEM BIOPH RES CO, V260, P734, DOI 10.1006/bbrc.1999.0965; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; Papadopoulos NG, 1999, J VIROL METHODS, V80, P179, DOI 10.1016/S0166-0934(99)00045-2; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Schofield L, 1996, J IMMUNOL, V156, P1886; SETH R, 1991, LANCET, P338; Sethi SK, 1997, CLIN EXP IMMUNOL, V110, P362, DOI 10.1046/j.1365-2249.1997.4221440.x; Stanciu LA, 1998, EUR RESPIR J, V11, P949, DOI 10.1183/09031936.98.11040949; STRATOWA C, 1995, IMMUNOBIOLOGY, V193, P293, DOI 10.1016/S0171-2985(11)80558-9; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; Turner RB, 1999, JAMA-J AM MED ASSOC, V281, P1797, DOI 10.1001/jama.281.19.1797; van Kempen M., 1999, Rhinology (Utrecht), V37, P97; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wakatsuki T, 1995, CELL ADHES COMMUN, V3, P283, DOI 10.3109/15419069509081014; WHITEMAN SC, 1999, EUR RESPIR J, V14, pS250; Winther B, 2002, ARCH OTOLARYNGOL, V128, P131, DOI 10.1001/archotol.128.2.131; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	41	63	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11954	11961		10.1074/jbc.M205329200	http://dx.doi.org/10.1074/jbc.M205329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551926	hybrid			2022-12-25	WOS:000182015700032
J	Bahadoran, P; Busca, R; Chiaverini, C; Westbroek, W; Lambert, J; Bille, K; Valony, G; Fukuda, M; Naeyaert, JM; Ortonne, JP; Ballotti, R				Bahadoran, P; Busca, R; Chiaverini, C; Westbroek, W; Lambert, J; Bille, K; Valony, G; Fukuda, M; Naeyaert, JM; Ortonne, JP; Ballotti, R			Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN-VA; MELANOSOME TRANSPORT; C2 DOMAINS; EFFECTOR; PROTEIN; MELANOCYTES; SLAC2-A/MELANOPHILIN; DETERMINANT; DYNAMICS; CLONING	Rab27a plays a pivotal role in the transport of melanosomes to dendrite tips of melanocytes and mutations in RAB27A, which impair melanosome transport cause the pigmentary dilution and the immune deficiency found in several patients with Griscelli syndrome (GS). Interestingly, three GS patients present single homozygous missense mutations in RAB27A, leading to W73G, L130P, and A152P transitions that affect highly conserved residues among Rab proteins. However, the functional consequences of these mutations have not been studied. In the present report, we evaluated the effect of overexpression of these mutants on melanosome, melanophilin, and myosin-Va localization in B16 melanoma cells. Then we studied several key parameters for Rab27a function, including GTP binding and interaction with melanophilin/myosin-Va complex, which links melanosomes to the actin network. Our results showed that Rab27a-L130P cannot bind GTP, does not interact with melanophilin, and consequently cannot allow melanosome transport on the actin filaments. Interestingly, Rab27a-W73G binds GTP but does not interact with melanophilin. Thus, Rab27a-W73G cannot support the actin-dependent melanosome transport. Finally, Rab27a-A152P binds both GTP and melanophilin. However, Rab27a-A152P does not allow melanosome transport and acts as a dominant negative mutant, because its overexpression, in B16 melanoma cells, mimics a GS phenotype. Hence, the interaction of Rab27a with melanophilin/myosin-Va is not sufficient to ensure a correct melanosome transport. Our results pointed to an unexpected complexity of Rab27a function and open the way to the search for new Rab27a effectors or regulators that control the transport of Rab27a-dependent vesicles.	INSERM, U385, Biol & Physiopathol Peau, Fac Med, F-06107 Nice 2, France; Ghent Univ Hosp, Dept Dermatol, B-9000 Ghent, Belgium; RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Ghent University; Ghent University Hospital; RIKEN	Ballotti, R (corresponding author), INSERM, U385, Biol & Physiopathol Peau, Fac Med, Ave Valombrose, F-06107 Nice 2, France.		Jo, Lambert LW/AAG-4880-2021; BALLOTTI, Robert/F-8825-2013; Fukuda, MItsunori/I-1511-2015; Jo, Lambert LW/ABD-3264-2021	Fukuda, MItsunori/0000-0002-8620-5853; BALLOTTI, Robert/0000-0002-7322-4908; Bahadoran, Philippe/0000-0002-2481-0556; Lambert, Jo/0000-0001-5303-9310				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pastural E, 2000, GENOMICS, V63, P299, DOI 10.1006/geno.1999.6081; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; WESTBROEK W, 2002, IN PRESS J INVEST DE; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	28	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11386	11392		10.1074/jbc.M211996200	http://dx.doi.org/10.1074/jbc.M211996200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12531900	hybrid			2022-12-25	WOS:000181855400067
J	Gaziova, I; Lukes, J				Gaziova, I; Lukes, J			Mitochondrial and nuclear localization of topoisomerase II in the flagellate Bodo saltans (Kinetoplastida), a species with non-catenated kinetoplast DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; SITES; EXPRESSION; MECHANISM; EVOLUTION; PROTEINS; GENES; ALPHA; BETA	We have studied topoisomerase II (topo II) in the cells of Bodo saltans, a free-living bodonid (Kinetoplastida). Phylogenetic analysis based on the sequence of the entire topo II gene, which is a single-copy gene, confirmed that B. saltans is a predecessor of parasitic trypanosomatids. Antibodies generated against either an overexpressed unique C-terminal region of topo II or a synthetic oligopeptide derived from the same region did not cross-react with cell lysates of related trypanosomatids, while they recognized a single specific band in the B. saltans lysate. Immunolocalization experiments using both antibodies showed that topo II is evenly dispersed throughout the kinetoplast. This is in striking difference from the localization of topo II in other flagellates, where it occurs in two antipodal centers flanking the kinetoplast disk. Moreover, the same topo II has a distinct localization in multiple loci at the periphery of the nucleus of B. saltans. With a minicircle probe derived from the conserved region we have shown that all relaxed non-catenated minicircles are confined to the globular kinetoplast DNA bundle. Therefore, in the mitochondrion of this primitive eukaryote topo II does not catenate relaxed DNA circles into a network in vivo, while a decatenating activity is present in partially purified cell lysates.	Acad Sci Czech Republ, Inst Parasitol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol, CR-37005 Ceske Budejovice, Czech Republic	Czech Academy of Sciences; University of South Bohemia Ceske Budejovice	Lukes, J (corresponding author), Acad Sci Czech Republ, Inst Parasitol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	jula@paru.cas.cz	Lukes, Julius/H-6760-2012	Lukes, Julius/0000-0002-0578-6618				Blom D, 1998, NUCLEIC ACIDS RES, V26, P1205, DOI 10.1093/nar/26.5.1205; Blom D, 2000, RNA, V6, P121, DOI 10.1017/S1355838200992021; Burri C, 1996, PARASITOL TODAY, V12, P226, DOI 10.1016/0169-4758(96)10017-X; Das A, 2001, NUCLEIC ACIDS RES, V29, P1844, DOI 10.1093/nar/29.9.1844; Dolezel D, 2000, INT J SYST EVOL MICR, V50, P1943, DOI 10.1099/00207713-50-5-1943; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; Fragoso SP, 1998, MOL BIOCHEM PARASIT, V94, P197, DOI 10.1016/S0166-6851(98)00066-8; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; Guilbride DL, 1998, J CELL SCI, V111, P675; Johnson CE, 1998, J CELL BIOL, V143, P911, DOI 10.1083/jcb.143.4.911; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; Komori K, 1997, J PLANT RES, V110, P65, DOI 10.1007/BF02506844; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Lukes J, 1998, EMBO J, V17, P838, DOI 10.1093/emboj/17.3.838; LUKES J, 1994, EMBO J, V13, P5086, DOI 10.1002/j.1460-2075.1994.tb06838.x; Lukes J, 2002, EUKARYOT CELL, V1, P495, DOI 10.1128/EC.1.4.495-502.2002; Lukes J, 2001, MOL BIOCHEM PARASIT, V117, P179, DOI 10.1016/S0166-6851(01)00348-6; Mahmood R, 1999, MOL CELL BIOL, V19, P6174; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Morris JC, 2001, INT J PARASITOL, V31, P453, DOI 10.1016/S0020-7519(01)00156-4; Niimi A, 2001, CHROMOSOMA, V110, P102, DOI 10.1007/s004120100140; PASION SG, 1992, MOL BIOCHEM PARASIT, V50, P57, DOI 10.1016/0166-6851(92)90244-E; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; Sakaguchi A, 2001, BIOCHEM BIOPH RES CO, V283, P876, DOI 10.1006/bbrc.2001.4856; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SHAPIRO TA, 1993, ACTA TROP, V54, P251, DOI 10.1016/0001-706X(93)90097-U; SHLOMAI J, 1994, PARASITOL TODAY, V10, P341, DOI 10.1016/0169-4758(94)90244-5; SHLOMAI J, 1983, NUCLEIC ACIDS RES, V11, P4019, DOI 10.1093/nar/11.12.4019; Simpson AGB, 2002, MOL BIOL EVOL, V19, P2071, DOI 10.1093/oxfordjournals.molbev.a004032; Stolba P, 2001, MOL BIOCHEM PARASIT, V113, P323, DOI 10.1016/S0166-6851(01)00218-3; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; SWOFFORD DL, 1998, PAUPASTERISK VERSION; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Xu CW, 1996, MOL CELL BIOL, V16, P564; Yasuhira S, 1996, RNA, V2, P1153	42	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10900	10907		10.1074/jbc.M202347200	http://dx.doi.org/10.1074/jbc.M202347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12533517	hybrid			2022-12-25	WOS:000181855400005
J	Maynard, MA; Qi, H; Chung, J; Lee, EHL; Kondo, Y; Hara, S; Conaway, RC; Conaway, JW; Ohh, M				Maynard, MA; Qi, H; Chung, J; Lee, EHL; Kondo, Y; Hara, S; Conaway, RC; Conaway, JW; Ohh, M			Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 uhiquitin ligase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTOR; PAS DOMAIN PROTEIN; PROLYL HYDROXYLATION; GROWTH-FACTOR; FACTOR-ALPHA; GENE-EXPRESSION; MESSENGER-RNAS; REGULATE HIF; ELONGIN-B	Functional inactivation of the von Hippel-Lindau (VHL) tumor suppressor protein is the cause of familial VHL disease and sporadic kidney cancer. The VHL gene product (pVHL) is a component of an E3 ubiquitin ligase complex that targets the hypoxia-inducible factor (HIF) 1 and 2 alpha subunits for polyubiquitylation. This process is dependent on the hydroxylation of conserved proline residues on the a subunits of HIF-1/2 in the presence of oxygen. In our effort to identify orphan HIF-like proteins in the data base that are potential targets of the pVHL complex, we report multiple splice variants of the human HIF-3alpha locus as follows: hHIF-3alpha1, hHIF-3alpha2 (also referred to as hIPAS; human inhibitory PAS domain protein), hHIF-3alpha3, hHIF-3alpha4, hHIF-3alpha5, and hHIF-3alpha6. We demonstrate that the common oxygen-dependent degradation domain of hHIF-3alpha1-3 splice variants is targeted for ubiquitylation by the pVHL complex an vitro and an vivo. This activity is enhanced in the presence of prolyl hydroxylase and is dependent on a proline residue at position 490. Furthermore, the ubiquitin conjugation occurs on lysine residues at position 465 and 568 within the oxygen-dependent degradation domain. These results demonstrate additional targets of the pVHL complex and suggest a growing complexity in the regulation of hypoxia-inducible genes by the HIF family of transcription factors.	Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Nippon Med Coll, Dept Urol, Bunkyo Ku, Tokyo 1138603, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Publ Hlth, Minato Ku, Tokyo 1088641, Japan; Stowers Inst Med Res, Kansas City, MO 64110 USA	University of Toronto; Nippon Medical School; Kitasato University; Stowers Institute for Medical Research	Maynard, MA (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.			Conaway, Joan/0000-0002-2786-0663				Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Siemeister G, 1996, CANCER RES, V56, P2299; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199	42	224	236	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11032	11040		10.1074/jbc.M208681200	http://dx.doi.org/10.1074/jbc.M208681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538644	hybrid			2022-12-25	WOS:000181855400023
J	Fan, X; Roy, E; Zhu, LP; Murphy, TC; Kozlowski, M; Nanes, MS; Rubin, J				Fan, X; Roy, E; Zhu, LP; Murphy, TC; Kozlowski, M; Nanes, MS; Rubin, J			Nitric oxide donors inhibit luciferase expression in a promoter-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MESSENGER-RNA; REAL-TIME; 3'-UNTRANSLATED REGION; BINDING; STABILIZATION; VALIDATION; KINASE; TARGET; DNA	Nitric oxide (NO) is an important molecule with diverse bio-messenger functions including regulation of gene expression. Transcriptional studies using sensitive luciferase reporter systems have suggested that NO inhibits the promoter activity of a variety of genes. Here we report that NO donors (sodium nitroprusside, 2',2'(hydroxynitrosohydrazono)bis-ethanimine, and (+/-)-(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexen-1-yl-nicotinamide) decrease luciferase activity in a promoter-independent fashion in both viral and eukaryotic promoters, with a reduction to nearly 50% in the presence of 100 mum NO donor. Addition of an SV40 enhancer downstream of the luciferase coding region shifted NO donor inhibition to the right, with inhibition at similar to300 muM. In contrast, when studied in a chloramphenicol acetyltransferase reporter, two promoters indicating inhibition by NO were unaffected. The decrease in luciferase activity was not caused by NO suppression of the luciferase enzyme. Real-time PCR data showed that luciferase mRNA half-life decreased by nearly half in the presence of NO donor (from 75 to 45 min). The SV40 enhancer prolonged luciferase mRNA half-life and somewhat blunted the NO effect. Our data suggest that exogenous NO inhibits luciferase activity in a dose-dependent manner through decreasing luciferase mRNA stability. Thus, the use of luciferase reporter systems to study transcriptional regulation by NO should be attempted with caution.	Emory Univ, VA Med Ctr, Decatur, GA 30033 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Fan, X (corresponding author), Emory Univ, VA Med Ctr, 1670 Clairmont Rd,VAMC 151, Decatur, GA 30033 USA.	xfan@emory.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042360, R56AR042360] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42360] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dean DA, 1999, EXP CELL RES, V253, P713, DOI 10.1006/excr.1999.4716; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Fowler AA, 1999, BIOCHEM CELL BIOL, V77, P201, DOI 10.1139/bcb-77-3-201; Fukai T, 2000, J CLIN INVEST, V105, P1631, DOI 10.1172/JCI9551; Hara H, 2000, FREE RADICAL RES, V33, P279, DOI 10.1080/10715760000301441; Hara H, 2002, MOL PHARMACOL, V61, P194, DOI 10.1124/mol.61.1.194; HARRINGTON MA, 1991, GENE, V102, P165, DOI 10.1016/0378-1119(91)90074-L; Hertz JM, 1999, J BIOL CHEM, V274, P24232, DOI 10.1074/jbc.274.34.24232; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kroncke KD, 2000, FASEB J, V14, P166; Lane P, 1999, SEMIN NEPHROL, V19, P215; Marino M, 2001, BIOCHEM BIOPH RES CO, V286, P529, DOI 10.1006/bbrc.2001.5433; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; NAUGHTON P, 2002, J BIOL CHEM; Rubin J, 2002, J BONE MINER RES, V17, P1452, DOI 10.1359/jbmr.2002.17.8.1452; Rubin J, 2000, MOL CELL ENDOCRINOL, V160, P193, DOI 10.1016/S0303-7207(99)00212-9; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Sellak H, 2002, CIRC RES, V90, P405, DOI 10.1161/hh0402.105898; Skidgel RA, 2002, J IMMUNOL, V169, P2093, DOI 10.4049/jimmunol.169.4.2093; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Sugawara J, 2000, J CLIN ENDOCR METAB, V85, P2714, DOI 10.1210/jc.85.8.2714; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200	30	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10232	10238		10.1074/jbc.M209911200	http://dx.doi.org/10.1074/jbc.M209911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525497	hybrid			2022-12-25	WOS:000181777500034
J	Zhu, YH; Jin, KL; Mao, XO; Greenberg, DA				Zhu, YH; Jin, KL; Mao, XO; Greenberg, DA			Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression	FASEB JOURNAL			English	Article						neurogenesis; VEGF; transcription factors	NEUROGENESIS IN-VITRO; STIMULATES AXONAL OUTGROWTH; GLOBAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; CELL-GROWTH; NEUROTROPHIC FACTOR; HIPPOCAMPAL-NEURONS; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; FACTOR RECEPTOR	Neurogenesis, or the production of new neurons, is regulated by physiological and pathological processes including aging, stress, and brain injury. Many mitogenic and trophic factors that regulate proliferation of nonneuronal cells are also involved in neurogenesis. These include vascular endothelial cell growth factor (VEGF), which stimulates the incorporation of bromodeoxyuridine (BrdU) into neuronal precursor cells in vitro and in the adult rat brain in vivo. Using BrdU labeling as an index of cell proliferation, we found that the in vitro neuroproliferative effect of VEGF was associated with up-regulation of E2F family transcription factors, cyclin D1, cyclin E, and cdc25. VEGF also increased nuclear expression of E2F1, E2F2, and E2F3, consistent with regulation of the G(1)/S phase transition of the cell cycle. The proliferative effect of VEGF was inhibited by the extracellular signal-regulated kinase kinase (MEK) inhibitor PD98059, the phospholipase C (PLC) inhibitor U73122, the protein kinase C (PKC) inhibitor GF102390X, and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, indicating involvement of multiple signaling pathways. These findings help to provide a molecular basis for some of the recently identified neuronal effects of VEGF.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Greenberg, DA (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dgreenberg@buckinstitute.org			NINDS NIH HHS [NS-37695] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037695] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dolcet X, 1999, J NEUROCHEM, V73, P521, DOI 10.1046/j.1471-4159.1999.0730521.x; Gala S, 2001, BLOOD, V97, P227, DOI 10.1182/blood.V97.1.227; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Ino H, 2000, MOL BRAIN RES, V78, P163, DOI 10.1016/S0169-328X(00)00092-9; Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251; Jin KL, 2000, NEUROSCIENCE, V100, P713, DOI 10.1016/S0306-4522(00)00331-6; Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2002, J NEUROSCI, V22, P5365; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Jin KL, 2001, ANN NEUROL, V50, P93, DOI 10.1002/ana.1073; Jones SM, 2000, ONCOGENE, V19, P5558, DOI 10.1038/sj.onc.1203858; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Laird AD, 2000, CANCER RES, V60, P4152; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lee JK, 2000, DEV DYNAM, V217, P361, DOI 10.1002/(SICI)1097-0177(200004)217:4<361::AID-DVDY3>3.0.CO;2-8; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; Liu JL, 1998, J NEUROSCI, V18, P7768; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nicot A, 2001, P NATL ACAD SCI USA, V98, P4758, DOI 10.1073/pnas.071465398; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1997, J NEUROSCI, V17, P3727; PARK JE, 1994, J BIOL CHEM, V269, P25646; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Rakic P, 2002, NAT REV NEUROSCI, V3, P65, DOI 10.1038/nrn700; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xiang H, 1996, J NEUROSCI, V16, P6753; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang XJ, 1996, J NEUROSCI, V16, P6089; Yoshikawa K, 2000, NEUROSCI RES, V37, P1, DOI 10.1016/S0168-0102(00)00101-2; Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	69	142	151	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					186	193		10.1096/fj.02-0515com	http://dx.doi.org/10.1096/fj.02-0515com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554697				2022-12-25	WOS:000181456900043
J	Lee, SH; Kim, JW; Lee, HW; Cho, YS; Oh, SH; Kim, YJ; Jung, CH; Zhang, W; Lee, JH				Lee, SH; Kim, JW; Lee, HW; Cho, YS; Oh, SH; Kim, YJ; Jung, CH; Zhang, W; Lee, JH			Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression	ONCOGENE			English	Article						telomerase; hTERT; interferon-gamma (INF-gamma); IRF-1	HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; MESSENGER-RNA; DAUDI CELLS; APOPTOSIS; CANCER; DEGRADATION; PROTEIN; P53	Constitutive activation of the telomerase is a key step in the development of human cancers. Interferon-gamma (IFN-gamma) signaling induces growth arrest in many tumors through multiple regulatory mechanisms. In this study, we show that IFN-gamma signaling represses telomerase activity and human telomerase reverse transcriptase (hTERT) transcription, and suggest that this signaling is mediated by IRF-1. Ectopic expression of IRF-1 attenuated hTERT promoter activity. Murine embryonic fibroblasts (MEFs) genetically deficient in IRF-1 (IRF-1(-/-)) showed an elevated level (> 15 times) of hTERT promoter activity as compared to the hTERT promoter activity of wild-type MEFs. The telomerase activity and hTERT expression in IRF-1(-/-) MEFs were downregulated by IRF-1 transfection. Interestingly, less extent of telomerase repression was observed in HPV E6 and E7 negative, p53 mutant HT-3 cells than in HPV 18 E6 and E7 positive HeLa cells (intact p53). These findings provide evidence that IRF-1 is a potential mediator of IFN-gamma-induced attenuation of telomerase activity and hTERT expression.	Sungkyunkwan Univ, Coll Med,Mol Therapy Res Ctr, Samsung Med Ctr Annex 8F, Kangnam Gu, Seoul 130710, South Korea; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Sungkyunkwan Univ, Coll Med, Dept Mol Biol, Jangan Gu, Suwon 440746, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Sungkyunkwan University (SKKU); University of Pennsylvania; Sungkyunkwan University (SKKU); University of Texas System; UTMD Anderson Cancer Center	Lee, JH (corresponding author), Sungkyunkwan Univ, Coll Med,Mol Therapy Res Ctr, Samsung Med Ctr Annex 8F, Kangnam Gu, 50 ILwon Dong, Seoul 135710, South Korea.	jeholee@samsung.co.kr		Kim, Jung-whan/0000-0002-7829-1480				Akiyama M, 1999, CANCER LETT, V142, P23, DOI 10.1016/S0304-3835(99)00109-3; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boyer SN, 1996, CANCER RES, V56, P4620; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Crowe DL, 2001, BBA-GENE STRUCT EXPR, V1518, P1, DOI 10.1016/S0167-4781(00)00296-7; De Maeyer E, 1998, Int Rev Immunol, V17, P53, DOI 10.3109/08830189809084487; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim J, 1999, CANCER GENE THER, V6, P172, DOI 10.1038/sj.cgt.7700006; Kim KY, 2000, J GEN VIROL, V81, P695, DOI 10.1099/0022-1317-81-3-695; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiratsuchi M, 1999, LEUKEMIA LYMPHOMA, V34, P349, DOI 10.3109/10428199909050960; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; YASUI W, 1988, JPN J CANCER RES, V89, P1099; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	56	41	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					381	391		10.1038/sj.onc.1206133	http://dx.doi.org/10.1038/sj.onc.1206133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545159				2022-12-25	WOS:000180379100007
J	Wiedemeyer, R; Westermann, F; Wittke, I; Nowock, J; Schwab, M				Wiedemeyer, R; Westermann, F; Wittke, I; Nowock, J; Schwab, M			Ataxin-2 promotes apoptosis of human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; ataxin-2; apoptosis; MYCN; amplification; SCA2	DRUG-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; N-MYC; CHILDHOOD NEUROBLASTOMAS; NUCLEAR-LOCALIZATION; INTERFERON-GAMMA; PROTEIN-KINASE; IFN-GAMMA; S-PHASE; EXPRESSION	Neuroblastoma is a highly heterogeneous tumor of young children. Although many advances have been made towards understanding the molecular mechanisms dictating the phenotypic heterogeneity, the prognosis of children with neuroblastoma, particularly of progressively growing variants, has remained dire. About 10% of neuroblastomas regress spontaneously, probably by apoptosis, while another 20% have amplified the MYCN gene resulting in a poor prognosis. In pursuit of identifying cell death-associated genes in neuroblastoma, we encountered the SCA2 gene, coding for ataxin-2, as an important player. Here, we report that enforced expression of wild-type ataxin-2, but not of mutant ataxin-2, sensitizes neuroblastoma cells for apoptosis. In line with this, higher levels of ataxin-2 were detected in apoptotic cells compared to nonapoptotic cells. Neuroblastoma tumors with amplified MYCN contain significantly less ataxin-2 protein than tumors without amplified MYCN. Collectively, our data suggest that ataxin-2 has an important role in regulating the susceptibility of neuroblastoma cells to apoptotic stimuli in vitro and in vivo.	German Canc Res Ctr, Dept Cytogenet, D-69121 Heidelberg, Germany; Univ Frankfurt, Sect Mol Neurogenet, D-60590 Frankfurt, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt	Schwab, M (corresponding author), German Canc Res Ctr, Dept Cytogenet, H0400,Neuenheimer Feld 280, D-69121 Heidelberg, Germany.		Westermann, Frank/F-7509-2013					Annicchiarico-Petruzzelli M, 2001, MED PEDIATR ONCOL, V36, P115; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; BERTHOLD F, 1990, KLIN PADIATR, V202, P262, DOI 10.1055/s-2007-1025531; Berthold F, 2000, DRUGS, V59, P1261, DOI 10.2165/00003495-200059060-00006; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Catchpoole DR, 2001, EUR J CANCER, V37, P2217, DOI 10.1016/S0959-8049(01)00273-8; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Eggert A, 2001, CANCER RES, V61, P1314; Estrada R, 1999, ACTA NEUROPATHOL, V97, P306, DOI 10.1007/s004010050989; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Huynh DP, 2000, NAT GENET, V26, P44, DOI 10.1038/79162; Ikeda H, 1996, AM J SURG PATHOL, V20, P649, DOI 10.1097/00000478-199606000-00001; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakagawara A, 1997, CANCER RES, V57, P4578; Nechiporuk T, 1998, HUM MOL GENET, V7, P1301, DOI 10.1093/hmg/7.8.1301; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WITTKE I, 2002, UNPUB	38	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					401	411		10.1038/sj.onc.1206150	http://dx.doi.org/10.1038/sj.onc.1206150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545161				2022-12-25	WOS:000180379100009
J	Yawata, T; Kamino, H; Kugoh, H; Katoh, M; Nomura, N; Oishi, M; Horikawa, I; Barrett, JC; Oshimura, M				Yawata, T; Kamino, H; Kugoh, H; Katoh, M; Nomura, N; Oishi, M; Horikawa, I; Barrett, JC; Oshimura, M			Identification of a <= 600-kb region on human chromosome 1q42.3 inducing cellular senescence	ONCOGENE			English	Article						cellular senescence; chromosome transfer; chromosome 1; telomerase; mouse melanoma	TELOMERASE REPRESSOR GENE; IMMORTAL CELLS; INDEPENDENT SENESCENCE; SUPPRESSES TELOMERASE; MULTIPLE PATHWAYS; GROWTH ARREST; HETEROZYGOSITY; CARCINOMA; CANCER; ALLELOTYPE	The introduction of a human chromosome 1 via microcell-mediated chromosome transfer (MMCT) induces the cellular senescence in mouse melanoma B16-F10 cells. The senescent cells maintained still the telomerase activity, which is frequently associated with immortal growth of human cells, suggesting that a telomerase-independent mechanism is involved in the senescence observed in this mouse cell line. To map the senescence-inducing gene to a specific chromosomal region, we took two experimental approaches: identification of a minimal region with the senescence-inducing activity via MMCT of a series of subchromosomal transferrable fragments (STFs), each consisting of a different profile of human chromosome 1-derived regions, and identification of a region commonly deleted from the transferred chromosome 1 in the revertant clones that escaped cellular senescence. These approaches identified a 2.7-3.0 Mb of senescence-inducing region shared among the active STFs and a 2.4-3.0 Mb of commonly deleted region in the revertant clones. These two regions overlapped each other to map the responsible gene at the 450 to 600-kb interval between UniSTS93710 and D1S3542 on chromosome 1q42.3. This study provides essential information and materials for cloning and characterization of a novel senescence-inducing gene that functions in a telomerase-independent pathway, which is likely to be conserved between mice and humans.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Yonago, Tottori 6838503, Japan; NCI, Lab Biosyst & Canc, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Tottori Univ, Dept Human Genome Sci, Div Life Sci, Grad Sch Med, Yonago, Tottori 6838503, Japan; Kazusa DNA Res Inst, Chiba, Japan	Tottori University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tottori University; Kazusa DNA Research Institute	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, 86 Nishimachi, Yonago, Tottori 6838503, Japan.	oshimura@grape.med.tottori-u.ac.jp		KAMINO, HIROKI/0000-0002-2489-0453	DIVISION OF BASIC SCIENCES - NCI [Z01BC010417] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; Carman TA, 1998, EXP CELL RES, V244, P33, DOI 10.1006/excr.1998.4207; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Groth A, 2000, J BIOL CHEM, V275, P27473; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Horikawa I, 2000, J ANTI-AGING MED, V3, P373, DOI 10.1089/rej.1.2000.3.373; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamura Y, 2000, GENE CHROMOSOME CANC, V27, P244; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KUGOH H, 1995, GENOMICS, V27, P207, DOI 10.1006/geno.1995.1028; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LOUPART ML, 1995, GENE CHROMOSOME CANC, V12, P16, DOI 10.1002/gcc.2870120104; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; Nishimoto A, 2001, ONCOGENE, V20, P828, DOI 10.1038/sj.onc.1204165; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Polascik TJ, 1996, CANCER RES, V56, P1892; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; SANO T, 1991, CANCER RES, V51, P2926; Sasaki K, 1998, MOL CARCINOGEN, V23, P20; SASAKI M, 1994, CANCER RES, V54, P6090; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tanaka H, 1999, MOL CARCINOGEN, V25, P249, DOI 10.1002/(SICI)1098-2744(199908)25:4<249::AID-MC3>3.0.CO;2-Z; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; TSUCHIYA E, 1992, CANCER RES, V52, P2478; Uejima H, 1998, MOL CARCINOGEN, V22, P34, DOI 10.1002/(SICI)1098-2744(199805)22:1<34::AID-MC5>3.0.CO;2-L; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; YAMADA H, 1990, ONCOGENE, V5, P1141	49	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					281	290		10.1038/sj.onc.1206143	http://dx.doi.org/10.1038/sj.onc.1206143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527897				2022-12-25	WOS:000180322400013
J	Gunnarsson, C; Ahnstrom, M; Kirschner, K; Olsson, B; Nordenskjold, B; Rutqvist, LE; Skoog, L; Stal, O				Gunnarsson, C; Ahnstrom, M; Kirschner, K; Olsson, B; Nordenskjold, B; Rutqvist, LE; Skoog, L; Stal, O			Amplification of HSD17B1 and ERBB2 in primary breast cancer	ONCOGENE			English	Article						17q; 17 beta-HSD; breast cancer; ERBB2 estrogen; HSD17B1; real-time PCR	17-BETA-HYDROXYSTEROID DEHYDROGENASE; ESTRADIOL LEVELS; EXPRESSION; REGIONS; TYPE-1; TISSUE; TUMORS; CELLS; RECURRENCE; TAMOXIFEN	Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17beta-hydroxysteriod dehydrogenase (17beta-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17beta-HSD type 1 (HSD17B1) is located at 17q12-21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P = 0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P = 0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P=0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.	Linkoping Univ, Dept Biomed & Surg, Div Oncol, Fac Hlth Sci, SE-58185 Linkoping, Sweden; Huddinge Univ Hosp, Dept Oncol, SE-14186 Stockholm, Sweden; Karolinska Hosp, Div Cytol, SE-10401 Stockholm, Sweden	Linkoping University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Stal, O (corresponding author), Linkoping Univ Hosp, Dept Oncol, SE-58185 Linkoping, Sweden.		Gunnarsson, Cecilia/ABD-9170-2021	Kirschner, Kristina/0000-0001-7607-8670				Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bieche I, 1996, CANCER RES, V56, P3886; Dowsett M, 1997, J STEROID BIOCHEM, V61, P261; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Feigelson HS, 2001, CANCER RES, V61, P785; Gunnarsson C, 2001, CANCER RES, V61, P8448; Jarvinen TAH, 2000, AM J PATHOL, V156, P839, DOI 10.1016/S0002-9440(10)64952-8; Kauraniemi P, 2001, CANCER RES, V61, P8235; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Latham C, 2001, CANCER GENET CYTOGEN, V127, P16, DOI 10.1016/S0165-4608(00)00427-1; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; MANNERMAA A, 1994, HUM GENET, V93, P319, DOI 10.1007/BF00212030; Miettinen MM, 1996, BIOCHEM J, V314, P839, DOI 10.1042/bj3140839; Miyoshi Y, 2001, INT J CANCER, V94, P685, DOI 10.1002/ijc.1525; Osborne RJ, 2000, CANCER RES, V60, P3706; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; POUTANEN M, 1992, INT J CANCER, V50, P386, DOI 10.1002/ijc.2910500310; Purohit A, 2002, BREAST CANCER RES, V4, P65, DOI 10.1186/bcr425; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Sasano H, 1996, J CLIN ENDOCR METAB, V81, P4042, DOI 10.1210/jc.81.11.4042; Speirs V, 1999, BRIT J CANCER, V81, P690, DOI 10.1038/sj.bjc.6690749; Speirs V, 1998, BRIT J CANCER, V78, P1421, DOI 10.1038/bjc.1998.702; Speirs V, 1998, J STEROID BIOCHEM, V67, P267, DOI 10.1016/S0960-0760(98)00119-8; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; Stal O, 2000, ANN ONCOL, V11, P1545, DOI 10.1023/A:1008313310474; Suzuki T, 2000, BRIT J CANCER, V82, P518; Utsumi T, 1999, CANCER RES, V59, P377; Vihko P, 2001, MOL CELL ENDOCRINOL, V171, P71, DOI 10.1016/S0303-7207(00)00389-0; Yue W, 1998, CANCER RES, V58, P927	30	71	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					34	40		10.1038/sj.onc.1206078	http://dx.doi.org/10.1038/sj.onc.1206078			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527905				2022-12-25	WOS:000180166900004
J	Nakatani, F; Tanaka, K; Sakimura, R; Matsumoto, Y; Matsunobu, T; Li, X; Hanada, M; Okada, T; Iwamoto, Y				Nakatani, F; Tanaka, K; Sakimura, R; Matsumoto, Y; Matsunobu, T; Li, X; Hanada, M; Okada, T; Iwamoto, Y			Identification of p21(WAF1/CIP1) as a direct target of EWS-Fli1 oncogenic fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EWINGS-SARCOMA; SODIUM-BUTYRATE; CELL-GROWTH; TRANSCRIPTION FACTOR; BINDING-PROTEIN; GENE PROMOTER; SOFT-TISSUE; EXPRESSION; P300; P53	Translocation t(11;22) is a karyotypic abnormality detected in over 90% of Ewing's family tumors. This translocation results in the EWS-Fli1 fusion gene, which has been shown to be a potent, single-step transforming gene. We reported previously that suppression of the EWS-Fli1 fusion protein altered the expression of G(1) regulatory cyclins and cyclin-dependent kinase inhibitors both at mRNA and protein levels, resulting in G(1) growth arrest in Ewing's family tumor cell lines. These data suggest that the G(1) regulatory molecules may be targets of the EWS-Fli1 fusion protein, which functions as an aberrant transcription factor. By using electrophoretic mobility shift assays, we show here the direct association of EWS-Fli1 fusion protein with ETS consensus sequences, which are in the promoter of the p21(WAF1/CIP1) gene. Reporter gene assays revealed that the activity of the p21(WAF1/CIP1) promoter is negatively regulated by EWS-Fli1 fusion protein through at least two ETS-binding sites in the promoter. EWS-Fli1 interacted with p300 cotransactivator and suppressed its histone acetyltransferase activity, which may explain the down-regulation of p21(WAF1/CIP1) by EWS-Fli1. In the presence of a histone deacetylase inhibitor, the histone acetyltransferase activity of the Ewing's family tumor cell was recovered resulting in the induction of p21, and the cell growth was dramatically inhibited. These results demonstrated that p21(WAF1/CIP1) might be one of the direct targets of EWS-Fli1, and that p21(WAF1/CIP1) could serve as a target for a molecularly based therapy for Ewing's family tumors.	Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Tanaka, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tanaka@ortho.med.kyushu-u.ac.jp	Tanaka, Kazuhiro/Q-7387-2019	Tanaka, Kazuhiro/0000-0002-5138-8952				Ahrens S, 1999, MED PEDIATR ONCOL, V32, P186, DOI 10.1002/(SICI)1096-911X(199903)32:3<186::AID-MPO5>3.0.CO;2-D; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG QG, 1993, ANTI-CANCER DRUG, V4, P617, DOI 10.1097/00001813-199312000-00003; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Fujimura Y, 2001, ONCOGENE, V20, P6653, DOI 10.1038/sj.onc.1204684; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Goodman RH, 2000, GENE DEV, V14, P1553; GRAHAM KA, 1988, J CELL PHYSIOL, V136, P63, DOI 10.1002/jcp.1041360108; Hahm KB, 1999, NAT GENET, V23, P481, DOI 10.1038/70611; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOVAR H, 1993, ONCOGENE, V8, P2683; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Rossow KL, 2001, CANCER RES, V61, P2690; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; TANAKA K, 1995, CANCER RES, V55, P2927; TANAKA K, 1995, LAB INVEST, V72, P237; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka Kazuhiro, 2002, J Orthop Sci, V7, P477, DOI 10.1007/s007760200083; Thompson AD, 1996, ONCOGENE, V13, P2649; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	108	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15105	15115		10.1074/jbc.M211470200	http://dx.doi.org/10.1074/jbc.M211470200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12560328	hybrid			2022-12-25	WOS:000182516100068
J	Heiss, A; DuChesne, A; Denecke, B; Grotzinger, J; Yamamoto, K; Renne, T; Jahnen-Dechent, W				Heiss, A; DuChesne, A; Denecke, B; Grotzinger, J; Yamamoto, K; Renne, T; Jahnen-Dechent, W			Structural basis of calcification inhibition by alpha(2)-HS glycoprotein/fetuin-A - Formation of colloidal calciprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; SECONDARY STRUCTURE; APATITE FORMATION; FETUIN FAMILY; IN-VITRO; BONE; CALCIUM; SERUM; GROWTH; HYDROXYAPATITE	Genetic evidence from mutant mice suggests that alpha(2)-HS glycoprotein/fetuin-A (Ahsg) is a systemic inhibitor of precipitation of basic calcium phosphate preventing unwanted calcification. Using electron microscopy and dynamic light scattering, we demonstrate that precipitation inhibition by Ahsg is caused by the transient formation of soluble, colloidal spheres, containing Ahsg, calcium, and phosphate. These "calciprotein particles" of 30-150 nm in diameter are initially amorphous and soluble but turn progressively more crystalline and insoluble in a time- and temperature-dependent fashion. Solubilization in Ahsg-containing calciprotein particles provides a novel conceptual framework to explain how insoluble calcium precipitates may be transported and removed in the bodies of mammals. Mutational analysis showed that the basic calcium phosphate precipitation inhibition activity resides in the amino-terminal cystatin-like domain D1 of Ahsg. A structure-function analysis of wild type and mutant forms of cystatin-like domains from Ahsg, full-length fetuin-B, histidine-rich glycoprotein, and kininogen demonstrated that Ahsg domain D1 is most efficient in inhibiting basic calcium phosphate precipitation. The computer-modeled domain structures suggest that a dense array of acidic residues on an extended beta-sheet of the cystatin-like domain Ahsg-D1 mediates efficient inhibition.	Univ Clin, IZKF BIOMAT, RWTH Aachen, D-52074 Aachen, Germany; Max Planck Inst Polymer Res, D-55128 Mainz, Germany; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Kinki Univ, Sch Med, Dept Biochem, Osaka 5898511, Japan; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	Max Planck Society; University of Kiel; Kindai University (Kinki University); University of Wurzburg	Jahnen-Dechent, W (corresponding author), Univ Clin, IZKF BIOMAT, RWTH Aachen, Pauwelsstr 30, D-52074 Aachen, Germany.	willi.jahnen@rwth-aachen.de	Heiss, Alexander/C-9698-2009; Heiss, Alexander/AAK-4928-2020; Jahnen-Dechent, Willi/A-7608-2011	Heiss, Alexander/0000-0002-6033-6636; Jahnen-Dechent, Willi/0000-0003-1315-4407; Renne, Thomas/0000-0003-4594-5975				ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BLUMENTHAL NC, 1989, CLIN ORTHOP RELAT R, P279; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BROWN WM, 1992, EUR J BIOCHEM, V205, P321, DOI 10.1111/j.1432-1033.1992.tb16783.x; Busch E, 2000, J BIOL CHEM, V275, P25508, DOI 10.1074/jbc.M001770200; Busch S, 1999, EUR J INORG CHEM, P1643; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; Du Chesne A, 1999, MACROMOL CHEM PHYSIC, V200, P1813, DOI 10.1002/(SICI)1521-3935(19990801)200:8<1813::AID-MACP1813>3.0.CO;2-N; GILMAN H, 1994, J INORG BIOCHEM, V55, P21, DOI 10.1016/0162-0134(94)85129-8; GLIMCHER MJ, 1990, BIOMATERIALS, V11, P7; Haglund AC, 2001, BIOCHEM J, V357, P437, DOI 10.1042/0264-6021:3570437; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HAUSCHKA PV, 1982, BIOCHEMISTRY-US, V21, P2538, DOI 10.1021/bi00539a038; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; JAHNENDECHENT W, 1994, EUR J BIOCHEM, V226, P59, DOI 10.1111/j.1432-1033.1994.tb20026.x; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KETTELER M, 2003, IN PRESS LANCET; Kirschvink JL, 2001, CURR OPIN NEUROBIOL, V11, P462, DOI 10.1016/S0959-4388(00)00235-X; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Nakamura I, 1999, HUM GENET, V104, P492, DOI 10.1007/s004390050993; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Neuman W. F., 1980, FUNDAMENTAL CLIN BON, P83; Olivier E, 2000, BIOCHEM J, V350, P589, DOI 10.1042/0264-6021:3500589; Price PA, 2002, J BONE MINER RES, V17, P1171, DOI 10.1359/jbmr.2002.17.7.1171; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; RAJ PA, 1992, J BIOL CHEM, V267, P5968; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Schinke T, 1997, FEBS LETT, V412, P559, DOI 10.1016/S0014-5793(97)00827-2; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; Schinke T, 1999, NAT GENET, V21, P150, DOI 10.1038/5928; Shen XY, 1997, J BIOL CHEM, V272, P32472, DOI 10.1074/jbc.272.51.32472; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Suvorova EI, 1999, J MICROSC-OXFORD, V196, P46, DOI 10.1046/j.1365-2818.1999.00608.x; SUZUKI M, 1994, J EXP ZOOL, V270, P501, DOI 10.1002/jez.1402700603; Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; TERMINE JD, 1988, CIBA FDN S, V136, P178; Triffit J. T., 1980, FUNDAMENTAL CLIN BON, P45; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; WALSH D, 1994, SCIENCE, V264, P1576, DOI 10.1126/science.264.5165.1576; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200	51	374	394	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13333	13341		10.1074/jbc.M210868200	http://dx.doi.org/10.1074/jbc.M210868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556469	Green Submitted, hybrid			2022-12-25	WOS:000182189500094
J	Katagiri, Y; Brew, SA; Ingham, KC				Katagiri, Y; Brew, SA; Ingham, KC			All six modules of the gelatin-binding domain of fibronectin are required for full affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR	The gelatin-binding sites of fibronectin are confined to a 42-kDa region having four type I and two type II modules in the following order: I-6-II1-II2-I-7-I-8-I-9. To determine the relative importance of each module for recognition of gelatin, recombinant green fluorescent fusion proteins were prepared in which individual modules or groups of modules were deleted, and the resulting proteins were tested for binding to gelatin by analytical affinity chromatography. Deletion of both type II modules did not eliminate binding, confirming that at least some of the type I modules in this region are able to bind gelatin. It was found that deletion of type I module 6 tends to increase the affinity, whereas deletion of any other module decreases it. Deletion of module I-9 had a large effect but only if module II2 was also present, suggesting an interaction between these two noncontiguous modules. Analysis of more than 20 recombinant fusion products led to the conclusion that all modules contribute to the interaction either directly by contacting the ligand or indirectly through module-module interactions.	Amer Red Cross Holland Lab, Dept Biochem, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA	American Red Cross	Ingham, KC (corresponding author), Amer Red Cross Holland Lab, Dept Biochem, Jerome H Holland Lab Biomed Sci, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	ingham@usa.redcross.org						BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; Bocquier AA, 1999, STRUCT FOLD DES, V7, P1451, DOI 10.1016/S0969-2126(00)88336-7; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; Ingham KC, 2002, ARCH BIOCHEM BIOPHYS, V407, P217, DOI 10.1016/S0003-9861(02)00454-X; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; ISAACS BS, 1989, BIOCHEMISTRY-US, V28, P842, DOI 10.1021/bi00428a065; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Katagiri Y, 2002, BIOTECHNIQUES, V33, P24, DOI 10.2144/02331bm01; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083	12	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11897	11902		10.1074/jbc.M212512200	http://dx.doi.org/10.1074/jbc.M212512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12538576	hybrid			2022-12-25	WOS:000182015700024
J	Lundin, A; Nilsson, C; Gerhard, M; Andersson, DI; Krabbe, M; Engstrand, L				Lundin, A; Nilsson, C; Gerhard, M; Andersson, DI; Krabbe, M; Engstrand, L			The NudA protein in the gastric pathogen Helicobacter pylori is an ubiquitous and constitutively expressed dinucleoside polyphosphate hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; BARTONELLA-BACILLIFORMIS; INVASION GENE; HEAT-SHOCK; APPPPA; PYROPHOSPHATASE; IDENTIFICATION; COLONIZATION; SEQUENCE; REVEALS	The gastric pathogen Helicobacter pylori harbors one Nudix hydrolase, NudA, that belongs to the nucleoside polyphosphate hydrolase subgroup. In this work, the enzymatic activity of purified recombinant NudA protein was analyzed on a number of nucleoside polyphosphates. This predicted 18.6-kDa protein preferably hydrolyzes diadenosine tetraphosphate, AP(4)A at a k(cat) of 0.15 s(-1) and a K-m of 80 mum, resulting in an asymmetrical cleavage of the molecule into ATP and AMP. To study the biological role of this enzyme in H. pylori, an insertion mutant was constructed. There was a 2-7-fold decrease in survival of the mutant as compared with the wild type after hydrogen peroxide exposure but no difference in survival after heat shock or in spontaneous mutation frequency. Western blot analyses revealed that NudA is constitutively expressed in H. pylori at different growth stages and during stress, which would indicate that this protein has a housekeeping function. Given that H. pylori is a diverse species and that all the H. pylori strains tested in this study harbor the nudA gene and show protein expression, we consider NudA to be an important enzyme in this bacterium.	Swedish Inst Infect Dis Control, Dept Bacteriol, S-17182 Solna, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Tech Univ Munich, Dept Med 2, D-81675 Munich, Germany; Pyrosequencing AB, S-75228 Uppsala, Sweden	Swedish Institute for Infectious Disease Control; Karolinska Institutet; Technical University of Munich	Engstrand, L (corresponding author), Swedish Inst Infect Dis Control, Dept Bacteriol, S-17182 Solna, Sweden.	lars.engstrand@smi.ki.se	Gerhard, Markus/P-8996-2019; Gerhard, Markus/N-3387-2014	Gerhard, Markus/0000-0001-9110-3950; Gerhard, Markus/0000-0001-9110-3950; Andersson, Dan/0000-0001-6640-2174				Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; AMES BN, 1960, J BIOL CHEM, V235, P769; Amieva MR, 2002, CELL MICROBIOL, V4, P677, DOI 10.1046/j.1462-5822.2002.00222.x; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; Bjorkholm B, 2001, INFECT IMMUN, V69, P7832, DOI 10.1128/IAI.69.12.7832-7838.2001; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Bjorkholm BM, 2002, J BIOL CHEM, V277, P34191, DOI 10.1074/jbc.M203613200; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Conyers GB, 2000, BIOCHEMISTRY-US, V39, P2347, DOI 10.1021/bi992458n; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; FERRERO RL, 1992, J BACTERIOL, V174, P4212, DOI 10.1128/JB.174.13.4212-4217.1992; GARRISON PN, 1986, MOL CELL BIOL, V6, P1179, DOI 10.1128/MCB.6.4.1179; Gaywee J, 2002, MOL CELL PROTEOMICS, V1, P179, DOI 10.1074/mcp.M100030-MCP200; Gaywee J, 2002, INFECT IMMUN, V70, P6346, DOI 10.1128/IAI.70.11.6346-6354.2002; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; Guo BP, 2002, P NATL ACAD SCI USA, V99, P8354, DOI 10.1073/pnas.122244899; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; JOHNSTONE DB, 1991, EMBO J, V10, P3897, DOI 10.1002/j.1460-2075.1991.tb04959.x; Kwok T, 2002, INFECT IMMUN, V70, P2108, DOI 10.1128/IAI.70.4.2108-2120.2002; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; Lock RA, 2001, PATHOLOGY, V33, P365; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MITCHELL SJ, 1995, INFECT IMMUN, V63, P1552, DOI 10.1128/IAI.63.4.1552-1562.1995; Nakamura A, 2000, FREE RADICAL BIO MED, V28, P1611, DOI 10.1016/S0891-5849(00)00284-7; Nishimura A, 1997, GENES CELLS, V2, P401, DOI 10.1046/j.1365-2443.1997.1300328.x; NOACH LA, 1994, J CLIN PATHOL, V47, P699, DOI 10.1136/jcp.47.8.699; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Salama N, 2000, P NATL ACAD SCI USA, V97, P14668, DOI 10.1073/pnas.97.26.14668; Tassotto ML, 2002, J BIOL CHEM, V277, P15807, DOI 10.1074/jbc.M200965200; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Vartanian A, 1999, FEBS LETT, V456, P175, DOI 10.1016/S0014-5793(99)00956-4; Xu WL, 2002, J BIOL CHEM, V277, P23181, DOI 10.1074/jbc.M203325200	39	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12574	12578		10.1074/jbc.M212542200	http://dx.doi.org/10.1074/jbc.M212542200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551907	hybrid			2022-12-25	WOS:000182015700110
J	Biswas, K; Bandyopadhyay, U; Chattopadhyay, I; Varadaraj, A; Ali, E; Banerjee, RK				Biswas, K; Bandyopadhyay, U; Chattopadhyay, I; Varadaraj, A; Ali, E; Banerjee, RK			A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROESOPHAGEAL-REFLUX DISEASE; FIBROBLAST-GROWTH-FACTOR; PROTON-PUMP INHIBITORS; HELICOBACTER-PYLORI; ACID-SECRETION; MUCOSAL INJURY; LIPID-PEROXIDATION; NITRIC-OXIDE; C-FOS	The mechanism of the antiulcer effect of omeprazole was studied placing emphasis on its role to block oxidative damage and apoptosis during ulceration. Dose-response studies on gastroprotection in stress and indomethacin-induced ulcer and inhibition of pylorus ligation-induced acid secretion indicate that omeprazole significantly blocks gastric lesions at lower dose (2.5 mg/kg) without inhibiting acid secretion, suggesting an independent mechanism for its antiulcer effect. Time course studies on gastroprotection and acid reduction also indicate that omeprazole almost completely blocks lesions at 1 h when acid inhibition is partial. The severity of lesions correlates well with the increased level of endogenous hydroxyl radical ((OH)-O-.), which when scavenged by dimethyl sulfoxide causes around 90% reduction of the lesions, indicating that (OH)-O-. plays a major role in gastric damage. Omeprazole blocks stress-induced increased generation of (OH)-O-. and associated lipid peroxidation and protein oxidation, indicating that its antioxidant role plays a major part in preventing oxidative damage. Omeprazole also prevents stress-induced DNA fragmentation, suggesting its antiapoptotic role to block cell death during ulceration. The oxidative damage of DNA by (OH)-O-. generated in vitro is also protected by omeprazole or its analogue, lansoprazole. Lansoprazole when incubated in a (OH)-O-.-generating system scavenges (OH)-O-. to produce four oxidation products of which the major one in mass spectroscopy shows a molecular ion peak at m/z 385, which is 16 mass units higher than that of lansoprazole (m/z 369). The product shows no additional aromatic proton signal for aromatic hydroxylation in H-1 NMR. The product absorbing at 278 nm shows no alkaline shift for phenols, thereby excluding the formation of hydroxylansoprazole. The product is assigned to lansoprazole sulfone formed by the addition of one oxygen atom at the sulfur center following attack by the (OH)-O-.. Thus, omeprazole plays a significant role in gastroprotection by acting as a potent antioxidant and antiapoptotic molecule.	Indian Inst Chem Biol, Dept Physiol, Kolkata 700032, W Bengal, India; Indian Inst Chem Biol, Dept Immunol, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Banerjee, RK (corresponding author), Indian Inst Chem Biol, Dept Physiol, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	ranajitb@yahoo.com	Biswas, Kaushik/AAR-1446-2020	Biswas, Kaushik/0000-0003-2502-9515; Varadaraj, Archana/0000-0002-1868-1268				Akimoto M, 2000, J CARDIOVASC PHARM, V36, pS282, DOI 10.1097/00005344-200036051-00083; ARAI I, 1987, RES COMMUN CHEM PATH, V57, P313; BABBS CF, 1990, METHOD ENZYMOL, V186, P137; Bandyopadhyay D, 2000, J PINEAL RES, V29, P143, DOI 10.1034/j.1600-079X.2000.290303.x; Bandyopadhyay Debashis, 2001, Current Molecular Medicine (Hilversum), V1, P501, DOI 10.2174/1566524013363483; Bandyopadhyay U, 2002, LIFE SCI, V71, P2845, DOI 10.1016/S0024-3205(02)02143-4; Bhattacharjee M, 2002, FREE RADICAL BIO MED, V32, P731, DOI 10.1016/S0891-5849(02)00757-8; Buege J A, 1978, Methods Enzymol, V52, P302; BURGET DW, 1990, GASTROENTEROLOGY, V99, P345, DOI 10.1016/0016-5085(90)91015-X; CHO CH, 1979, EUR J PHARMACOL, V55, P23, DOI 10.1016/0014-2999(79)90144-4; Cho JY, 2002, BRIT J CLIN PHARMACO, V53, P393, DOI 10.1046/j.1365-2125.2002.01366.x; CURIPEDROSA R, 1993, BR J CLIN PHARM, V36, P156; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; DAS D, 1993, MOL CELL BIOCHEM, V125, P115, DOI 10.1007/BF00936440; Das D, 1998, FREE RADICAL BIO MED, V24, P460, DOI 10.1016/S0891-5849(97)00281-5; DAVIES GR, 1994, GUT, V35, P179, DOI 10.1136/gut.35.2.179; DAVIES GR, 1994, EUR J GASTROEN HEPAT, V6, P1; Esplugues JV, 1996, P NATL ACAD SCI USA, V93, P14839, DOI 10.1073/pnas.93.25.14839; Evbuomwan M I, 1993, Afr J Med Med Sci, V22, P29; FELDMAN M, 1986, GASTROENTEROLOGY, V90, P540, DOI 10.1016/0016-5085(86)91106-6; FELLENIUS E, 1981, NATURE, V290, P159, DOI 10.1038/290159a0; Fujii Y, 2000, P SOC EXP BIOL MED, V224, P102, DOI 10.1046/j.1525-1373.2000.22407.x; Garnett WR, 1996, ANN PHARMACOTHER, V30, P1425, DOI 10.1177/106002809603001212; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Guslandi M, 1999, AM J GASTROENTEROL, V94, P2797, DOI 10.1111/j.1572-0241.1999.02797.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAYASE M, 1986, DIGEST DIS SCI, V31, P166, DOI 10.1007/BF01300703; Horn J, 2000, CLIN THER, V22, P266, DOI 10.1016/S0149-2918(00)80032-6; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; ITO T, 1990, GASTROENTEROLOGY, V98, P1525, DOI 10.1016/0016-5085(90)91085-K; ITOH M, 1985, GASTROENTEROLOGY, V88, P1162, DOI 10.1016/S0016-5085(85)80075-5; Jones MK, 1999, AM J PHYSIOL-GASTR L, V276, pG1345, DOI 10.1152/ajpgi.1999.276.6.G1345; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Kanazawa H, 2002, J CHROMATOGR A, V949, P1, DOI 10.1016/S0021-9673(01)01508-4; Kobayashi T, 2002, PHARMACOL RES, V46, P75, DOI 10.1016/S1043-6618(02)00034-8; Kohda K, 1999, GUT, V44, P456, DOI 10.1136/gut.44.4.456; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P695; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P211; Kusuhara H, 1998, EUR J PHARMACOL, V360, P273, DOI 10.1016/S0014-2999(98)00679-7; Kwiecien S, 2002, J PHYSIOL PHARMACOL, V53, P39; LANGMAN MJS, 1991, J GASTROEN HEPATOL, V6, P442, DOI 10.1111/j.1440-1746.1991.tb00885.x; Langtry HD, 1998, DRUGS, V56, P447, DOI 10.2165/00003495-199856030-00012; LARSSON H, 1985, SCAND J GASTROENTERO, V20, P23, DOI 10.3109/00365528509095817; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MATTSSON H, 1983, EUR J PHARMACOL, V91, P111, DOI 10.1016/0014-2999(83)90370-9; Miller T A, 1987, Am J Med, V83, P8, DOI 10.1016/0002-9343(87)90805-9; MILNE L, 1993, ARCH BIOCHEM BIOPHYS, V304, P102, DOI 10.1006/abbi.1993.1327; MIZUI T, 1986, LIFE SCI, V38, P2163, DOI 10.1016/0024-3205(86)90216-X; MOORE D, 1998, CURRENT PROTOCOLS MO, V1; Morise Z, 1998, AM J PHYSIOL-GASTR L, V274, pG246, DOI 10.1152/ajpgi.1998.274.2.G246; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Obst B, 2000, CARCINOGENESIS, V21, P1111, DOI 10.1093/carcin/21.6.1111; PERRY MA, 1986, GASTROENTEROLOGY, V90, P362, DOI 10.1016/0016-5085(86)90933-9; PHULL PS, 1995, EUR J GASTROEN HEPAT, V7, P265; PIHAN G, 1987, DIGEST DIS SCI, V32, P1395, DOI 10.1007/BF01296666; Piotrowski J, 1997, BIOCHEM MOL BIOL INT, V42, P247; Piotrowski J, 1997, SCAND J GASTROENTERO, V32, P203, DOI 10.3109/00365529709000195; Piotrowski J, 1996, BIOCHEM MOL BIOL INT, V40, P597; Piotrowski J, 1999, SCAND J GASTROENTERO, V34, P129; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; Sachs G, 1997, PHARMACOTHERAPY, V17, P22; SACHS G, 1993, ALIMENT PHARM THER, V7, P4; SALIM AS, 1991, INTENS CARE MED, V17, P455, DOI 10.1007/BF01690766; SHAY H, 1954, GASTROENTEROLOGY, V26, P906, DOI 10.1016/s0016-5085(54)80008-4; SHIMATSU K, 1997, HEPATOLOGY, V145, P1323; Slomiany BL, 1998, J PHYSIOL PHARMACOL, V49, P489; Slomiany BL, 1997, SCAND J GASTROENTERO, V32, P638, DOI 10.3109/00365529708996511; Szabo I, 2000, J PHYSIOL PHARMACOL, V51, P3; SZABO S, 1995, SCAND J GASTROENTERO, V30, P3, DOI 10.3109/00365529509107754; SZABO S, 1994, GASTROENTEROLOGY, V106, P1106, DOI 10.1016/0016-5085(94)90773-0; Tarnawski A, 1995, J CLIN GASTROENTEROL, V21, pS93; TARNAWSKI A, 2001, AM J GASTROENTEROL, V96, pS74; Tarnawski AS, 1998, J PHYSIOL PHARMACOL, V49, P479; VAANANEN PM, 1991, AM J PHYSIOL, V261, pG470, DOI 10.1152/ajpgi.1991.261.3.G470; Wallace JL, 1996, FASEB J, V10, P731, DOI 10.1096/fasebj.10.7.8635690; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; WANG JY, 1994, AM J PHYSIOL, V266, pG878, DOI 10.1152/ajpgi.1994.266.5.G878; Watanabe S, 2000, J GASTROEN HEPATOL, V15, P168, DOI 10.1046/j.1440-1746.2000.02062.x; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; Wolfe MM, 2000, GASTROENTEROLOGY, V118, pS9, DOI 10.1016/S0016-5085(00)70004-7; YOSHIKAWA T, 1993, GUT, V34, P732, DOI 10.1136/gut.34.6.732; YOSHIKAWA T, 1986, J CLIN BIOCHEM NUTR, V1, P271; Zimmermann AE, 1997, PHARMACOTHERAPY, V17, P308	84	220	226	4	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10993	11001		10.1074/jbc.M210328200	http://dx.doi.org/10.1074/jbc.M210328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529378	hybrid			2022-12-25	WOS:000181855400017
J	Xiao, KH; Engstrom, G; Rajagukguk, S; Yu, CA; Yu, L; Durham, B; Millett, F				Xiao, KH; Engstrom, G; Rajagukguk, S; Yu, CA; Yu, L; Durham, B; Millett, F			Effect of famoxadone on photoinduced electron transfer between the iron-sulfur center and cytochrome c(1) in the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES; DOMAIN MOVEMENT; BC1 COMPLEX; ENERGY TRANSDUCTION; CRYSTAL-STRUCTURE; PROTEIN; MITOCHONDRIAL; RESOLUTION; UBIQUINOL; BINDING	Famoxadone is a new cytochrome bc(1) Q(o) site inhibitor that immobilizes the iron-sulfur protein (ISP) in the b conformation. The effects of famoxadone on electron transfer between the iron-sulfur center (2Fe-2S) and cyt c(1) were studied using a ruthenium dimer to photoinitiate the reaction. The rate constant for electron transfer in the forward direction from 2Fe-2S to cyt c(1) was found to be 16,000 s(-1) in bovine cyt bc(1). Binding famoxadone decreased this rate constant to 1,480 s(-1), consistent with a decrease in mobility of the ISP. Reverse electron transfer from cyt c(1) to 2Fe-2S was found to be biphasic in bovine cyt bc(1) with rate constants of 90,000 and 7,300 s(-1). In the presence of famoxadone, reverse electron transfer was monophasic with a rate constant of 1,420 s(-1). It appears that the rate constants for the release of the oxidized and reduced ISP from the b conformation are the same in the presence of famoxadone. The effects of famoxadone binding on electron transfer were also studied in a series of Rhodobacter sphaeroides cyt bc(1) mutants involving residues at the interface between the Rieske protein and cyt c(1) and/or cyt b.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	Oklahoma State University System; Oklahoma State University - Stillwater; University of Arkansas System; University of Arkansas Fayetteville	Millett, F (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	millett@comp.uark.edu	Xiao, Kunhong/AAG-4275-2020	Xiao, Kunhong/0000-0002-1069-1226				BEAUTEMENT K, 1991, PESTIC SCI, V31, P499, DOI 10.1002/ps.2780310406; Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; DOWNARD AJ, 1991, INORG CHEM, V30, P2259, DOI 10.1021/ic00010a007; Engstrom G, 2002, J BIOL CHEM, V277, P31072, DOI 10.1074/jbc.M202594200; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; HEACOCK DH, 1993, J BIOL CHEM, V268, P27171; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jordan DB, 1999, PESTIC SCI, V55, P105, DOI 10.1002/(SICI)1096-9063(199902)55:2&lt;105::AID-PS879&gt;3.0.CO;2-D; Joshi MM, 1996, BRIGHTON CROP PROTECTION CONFERENCE: PESTS & DISEASES - 1996, VOLS 1-3, P21; JURIS A, 1988, COORDIN CHEM REV, V84, P85, DOI 10.1016/0010-8545(88)80032-8; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MEINHARDT SW, 1982, FEBS LETT, V149, P223, DOI 10.1016/0014-5793(82)81105-8; MOELLER T, 1957, INORG SYN, V5, P185, DOI 10.1002/9780470132364.ch51; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2001, J BIOL CHEM, V276, P46125, DOI 10.1074/jbc.M107436200; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; Yu CA, 2002, BBA-BIOENERGETICS, V1555, P65, DOI 10.1016/S0005-2728(02)00256-6; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	38	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11419	11426		10.1074/jbc.M211620200	http://dx.doi.org/10.1074/jbc.M211620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525495	hybrid			2022-12-25	WOS:000181855400071
J	Janssens, V; Jordens, J; Stevens, I; Van Hooff, C; Martens, E; De Smedt, H; Engelborghs, Y; Waelkens, E; Goris, J				Janssens, V; Jordens, J; Stevens, I; Van Hooff, C; Martens, E; De Smedt, H; Engelborghs, Y; Waelkens, E; Goris, J			Identification and functional analysis of two Ca2+-binding EF-hand motifs in the B ''/PR72 subunit of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; REGULATORY SUBUNIT; SIGNALING COMPLEX; GERMINAL CENTER; DNA-PRIMASE; A-SUBUNIT; RECEPTOR; BINDING; PHOSPHORYLATION; EXPRESSION	Protein phosphatase 2A (PP2A) is a multifunctional serine/threonine phosphatase that is critical to many cellular processes including cell cycle regulation and signal transduction. PP2A is a heterotrimer containing a structural (A) and catalytic (C) subunit, associated with one variable regulatory or targeting B-type subunit, of which three families have been described to date (B/PR55, B'/PR61, and B"/PR72). We identified two functional and highly conserved Ca2+-binding EF-hand motifs in human B"/PR72 (denoted EF1 and EF2), demonstrating for the first time the ability of Ca2+ to interact directly with and regulate PP2A. EF1 and EF2 apparently bind Ca2+ with different affinities. Ca2+ induces a significant conformational change, which is dependent on the integrity of the motifs. We have further evaluated the effects of Ca2+ on subunit composition, subcellular targeting, catalytic activity, and function during the cell cycle of a PR72-containing PP2A trimer (PP2A(T72)) by site-directed mutagenesis of either or both motifs. The results suggest that integrity of EF2 is required for A/PR65 subunit interaction and proper nuclear targeting of PR72, whereas EF1 might mediate the effects of Ca2+ on PP2A(T72) activity in vitro and is at least partially required for the ability of PR72 to alter cell cycle progression upon forced expression.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Sci, Lab Biomol Dynam, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Physiol Lab, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven	Goris, J (corresponding author), Gasthuisberg O&N, Afdeling Biochem, Herestr 49, B-9000 Ghent, Belgium.	jozef.goris@med.kuleuven.ac.be	Janssens, Veerle/I-7059-2016	Janssens, Veerle/0000-0002-6772-8448				Alen P, 1999, MOL CELL BIOL, V19, P6085; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Camilleri C, 2002, PLANT CELL, V14, P833, DOI 10.1105/tpc.010402; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Chen FS, 1998, J NEUROCHEM, V71, P248; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; James P, 1996, GENETICS, V144, P1425; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kono Y, 2002, GENES CELLS, V7, P821, DOI 10.1046/j.1365-2443.2002.00562.x; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Kuwahara K, 2000, BLOOD, V95, P2321, DOI 10.1182/blood.V95.7.2321.007k33_2321_2328; Kuwahara K, 2001, P NATL ACAD SCI USA, V98, P10279, DOI 10.1073/pnas.181335698; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Sansom SC, 1997, J BIOL CHEM, V272, P9902; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; STEVENS I, 2003, EUR J BIOCHEM, V270, P1; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Tian LJ, 1998, J BIOL CHEM, V273, P13531, DOI 10.1074/jbc.273.22.13531; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	52	71	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10697	10706		10.1074/jbc.M211717200	http://dx.doi.org/10.1074/jbc.M211717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524438	hybrid, Green Published			2022-12-25	WOS:000181777500092
J	Frank, S; Boudko, S; Mizuno, K; Schulthess, T; Engel, J; Bachinger, HP				Frank, S; Boudko, S; Mizuno, K; Schulthess, T; Engel, J; Bachinger, HP			Collagen triple helix formation can be nucleated at either end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE; PROTEINS; ISOMERIZATION; STABILITY; SEQUENCE; COIL	The directional dependence of folding rates for rodlike macromolecules such as parallel a-helical coiled-coils, DNA double-helices, and collagen triple helices is largely unexplored. This is mainly due to technical difficulties in measuring rates in different directions. Folding of collagens is nucleated by trimeric non-collagenous domains. These are usually located at the COOH terminus, suggesting that triple helix folding proceeds from the COOH to the NH2 terminus. Evidence is presented here that effective nucleation is possible at both ends of the collagen-like peptide (Gly-Pro-Pro)(10), using designed proteins in which this peptide is fused either NH2- or COOH-terminal to a nucleation domain, either T4-phage foldon or the disulfide knot of type III collagen. The location of the nucleation domain influences triple-helical stability, which might be explained by differences in the linker sequences and the presence or absence of repulsive charges at the carboxyl-terminal end of the triple helix. Triple helical folding rates are found to be independent of the site of nucleation and consistent with cis-trans isomerization being the rate-limiting step.	Oregon Hlth Sci Univ, Shriners Hosp Children, Dept Res, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland	Oregon Health & Science University; Oregon Health & Science University; University of Basel	Bachinger, HP (corresponding author), Oregon Hlth Sci Univ, Shriners Hosp Children, Dept Res, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.		Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264; Boudko, Sergei/0000-0003-3856-4859				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Areida SK, 2001, J BIOL CHEM, V276, P1594, DOI 10.1074/jbc.M008709200; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; Boudko S, 2002, J MOL BIOL, V317, P459, DOI 10.1006/jmbi.2002.5439; Buevich AV, 2002, J AM CHEM SOC, V124, P7156, DOI 10.1021/ja012699u; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; DAVIS MT, 1995, ANAL CHEM, V67, P4549, DOI 10.1021/ac00120a019; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; Krantz BA, 2001, NAT STRUCT BIOL, V8, P1042, DOI 10.1038/nsb723; Ottl J, 1999, J PEPT SCI, V5, P103, DOI 10.1002/(SICI)1099-1387(199902)5:2<103::AID-PSC188>3.0.CO;2-N; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4134, DOI 10.1021/bi00823a016; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; VANHOLDE KE, 1985, PHYSICAL BIOCHEMISTR; Xu YJ, 2002, BIOCHEMISTRY-US, V41, P8143, DOI 10.1021/bi015952b	20	45	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7747	7750		10.1074/jbc.C200698200	http://dx.doi.org/10.1074/jbc.C200698200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12540847	hybrid			2022-12-25	WOS:000181466800002
J	Pollock, AS; Turck, J; Lovett, DH				Pollock, AS; Turck, J; Lovett, DH			The prodomain of interleukin 1 alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells	FASEB JOURNAL			English	Article						IL-1 alpha; nuclear localization signal; RNA processing; Bcl-X	PRE-MESSENGER-RNA; SPLICING FACTORS; SR PROTEINS; BCL-X; NUCLEAR SPECKLES; 2-HYBRID SYSTEM; PRECURSOR; SEQUENCE; GENE; TRANSCRIPTION	Interleukin 1alpha (IL-1alpha), a 33 kDa precursor, is cleaved releasing the 17 kDa carboxyl-terminal cytokine IL-1alpha to which all of the biological properties of IL-1alpha have been attributed. We investigated the potential independent properties of the remaining 16 kDa IL-1alpha amino-terminal propiece by expression in human tumor and primary human cell lines. The IL-1alpha propiece produced apoptosis in malignant but not normal cell lines. A minimal fragment comprised of amino acids 55-108 was required for apoptosis. Deletion and mutation studies identified an extended nuclear localization sequence required for nuclear localization, induction of apoptosis and concentration of the IL-1alpha propiece in interchromatin granule clusters, concentrations of proteins in the RNA splicing and processing pathways. The IL-1alpha propiece interacted with five known components of the RNA splicing/processing pathway, suggesting that the mechanism of action may involve changes in RNA splicing or processing. Expression of the IL-1alpha propiece caused a shift in the ratio of Bcl-X-1/Bcl-X-s toward the apoptotic direction. Our findings indicate that the IL-1alpha propiece induces apoptosis in a range of tumor cells and likely operates through a mechanism involving the RNA processing apparatus and the alternate splicing of apoptosis regulatory proteins.	Univ Calif San Francisco, Vet Adm Med Ctr, No Calif Inst Res & Educ, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	Northern California Institute for Research & Education; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Pollock, AS (corresponding author), San Francisco VA Med Ctr, Dept Med 111J, 4150 Clement St, San Francisco, CA 94121 USA.	pollock.allan@maelstrom.ucsf.edu			NCI NIH HHS [R55 CA91038] Funding Source: Medline; NIDDK NIH HHS [R01DK31398, R01DK39776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA091038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031398, R01DK039776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEASLEY D, 1995, AM J PHYSIOL-CELL PH, V269, pC961, DOI 10.1152/ajpcell.1995.269.4.C961; BEUSCHER HU, 1988, J BIOL CHEM, V263, P4023; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Bruzik JP, 1996, MICROB PATHOGENESIS, V21, P149, DOI 10.1006/mpat.1996.0050; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FINER MH, 1994, BLOOD, V83, P43; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FURUTANI Y, 1986, NUCLEIC ACIDS RES, V14, P3167, DOI 10.1093/nar/14.8.3167; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hanamura A, 1998, RNA, V4, P430; Honma T, 1996, VIRCHOWS ARCH, V428, P165; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; Kobayashi Y, 1997, J BIOCHEM-TOKYO, V121, P896; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kuhn AN, 1999, MOL CELL, V3, P65, DOI 10.1016/S1097-2765(00)80175-6; KUPPER TS, 1990, J INVEST DERMATOL, V94, pS146, DOI 10.1111/1523-1747.ep12876130; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Liu ML, 1996, J VIROL, V70, P2497, DOI 10.1128/JVI.70.4.2497-2502.1996; Luo HBR, 1999, RNA, V5, P893, DOI 10.1017/S1355838299990520; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Matsunaga K, 2000, PATHOL INT, V50, P206, DOI 10.1046/j.1440-1827.2000.01025.x; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; McMahon GA, 1997, J BIOL CHEM, V272, P28202, DOI 10.1074/jbc.272.45.28202; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Mintz PJ, 2000, J STRUCT BIOL, V129, P241, DOI 10.1006/jsbi.2000.4213; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Perera LP, 1998, P NATL ACAD SCI USA, V95, P14308, DOI 10.1073/pnas.95.24.14308; Pombo A, 1996, EXP CELL RES, V229, P201, DOI 10.1006/excr.1996.0360; Puvion E, 1996, EXP CELL RES, V229, P217, DOI 10.1006/excr.1996.0363; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Sharma S, 1996, P NATL ACAD SCI USA, V93, P11842, DOI 10.1073/pnas.93.21.11842; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; STEVENSON FT, 1992, J CELL PHYSIOL, V152, P223, DOI 10.1002/jcp.1041520202; STEVENSON FT, 1993, P NATL ACAD SCI USA, V90, P7245, DOI 10.1073/pnas.90.15.7245; Tacke R, 1999, P SOC EXP BIOL MED, V220, P59, DOI 10.1046/j.1525-1373.1999.d01-10.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMSON AM, 1995, CLIN EXP METASTAS, V13, P319, DOI 10.1007/BF00121908; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	62	58	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					203	213		10.1096/fj.02-0602com	http://dx.doi.org/10.1096/fj.02-0602com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554699				2022-12-25	WOS:000181456900045
J	Wong, JMS; Ionescu, D; Ingles, CJ				Wong, JMS; Ionescu, D; Ingles, CJ			Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2	ONCOGENE			English	Article						replication protein A; BRCA2; DSB repair; protein-protein interaction	NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAINS; DNA-REPLICATION; RAD51; RPA; P53; BIND; GENE; SUSCEPTIBILITY	Mutations in the BRCA1 and BRCA2 genes predispose women to familial, early-onset breast cancer. Both the BRCA1 and BRCA2 proteins appear to function in the homologous recombination pathway of DNA double-strand break repair. Both BRCA1 and BRCA2 have also been implicated in transcription by RNA polymerase II, for both proteins have domains which, when tethered adjacent to a promoter, can activate transcription. In experiments reported here, we have used protein affinity chromatography and coimmunoprecipitation techniques to show that the putative N-terminal acidic transcriptional activation domain of BRCA2 interacts with replication protein A (RPA), a protein essential for DNA repair, replication and recombination. This interaction was not mediated by DNA and was specific for human RPA but not yeast RPA. Since the cancer-predisposing mutation Y42C in BRCA2 significantly compromised the interaction between RPA and BRCA2, this interaction may be biologically important. That BRCA2 protein in HeLa cell extract also coimmunoprecipitated with RPA suggested that this interaction occurs in vivo. Therefore, the transcriptional activation domains within BRCA2, and perhaps BRCA1, may provide links to RPA and DNA repair processes rather than transcription.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Ingles, CJ (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Choudhary SK, 2002, J CELL BIOCHEM, V84, P666, DOI 10.1002/jcb.10081; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Greenblatt J, 1996, METHOD ENZYMOL, V274, P120; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Nordling M, 1998, CANCER RES, V58, P1372; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOPTA M, 1985, J BIOL CHEM, V260, P353; van Golen K, 1999, J LAB CLIN MED, V134, P11, DOI 10.1016/S0022-2143(99)90049-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	39	63	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					28	33		10.1038/sj.onc.1206071	http://dx.doi.org/10.1038/sj.onc.1206071			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527904				2022-12-25	WOS:000180166900003
J	de Belle, I; Wu, JX; Sperandio, S; Mercola, D; Adamson, ED				de Belle, I; Wu, JX; Sperandio, S; Mercola, D; Adamson, ED			In vivo cloning and characterization of a new growth suppressor protein TOE1 as a direct target gene of EGR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IN-VIVO; CELLS; BINDING; TRANSFORMATION; CHROMATIN; APOPTOSIS; INDUCTION; LOCALIZATION; FORMALDEHYDE	Egr1, an immediate early transcription factor, responds to diverse stimuli and affects gene transcription to accomplish its biological effects. One important effect of Egr1 expression is to decrease the growth and tumorigenic potential of several tumor cell types. To identify important Egr1 target genes, we have adapted a methodology involving formaldehyde-induced protein-DNA cross-linking, chromatin immunoprecipitation, and multiplex PCR. Using this approach, we report the cloning of a new Egr1 target gene that is able to account, at least in part, for the growth inhibitory activity of Egr1. We have named this new protein TOE1 for target of Egr1.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA; Buck Inst Age Res, Novato, CA 94945 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Buck Institute for Research on Aging; University of California System; University of California San Diego	de Belle, I (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NATIONAL CANCER INSTITUTE [R01CA067888] Funding Source: NIH RePORTER; NCI NIH HHS [CA67888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Cheung TH, 1999, CANCER-AM CANCER SOC, V86, P1294, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1294::AID-CNCR26>3.3.CO;2-F; de Belle I, 2000, BIOTECHNIQUES, V29, P162; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Evdokiou A, 1999, MOL ENDOCRINOL, V13, P1738, DOI 10.1210/me.13.10.1738; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Leary T, 1999, LAB INVEST, V79, P1461; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Smedley D, 2000, GENE CHROMOSOME CANC, V28, P121, DOI 10.1002/(SICI)1098-2264(200005)28:1<121::AID-GCC14>3.0.CO;2-O; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102	29	26	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14306	14312		10.1074/jbc.M210502200	http://dx.doi.org/10.1074/jbc.M210502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562764	hybrid			2022-12-25	WOS:000182405000094
J	Liu, Y; Bambara, RA				Liu, Y; Bambara, RA			Analysis of human flap endonuclease 1 mutants reveals a mechanism to prevent triplet repeat expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; MICROSATELLITE INSTABILITY; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEATS; SECONDARY STRUCTURE; GENETIC INSTABILITY; MUTATION AVOIDANCE; OKAZAKI FRAGMENTS; EXCISION-REPAIR	Flap endonuclease 1 (FEN1), involved in the joining of Okazaki fragments, has been proposed to restrain DNA repeat sequence expansion, a process associated with aging and disease. Here we analyze properties of human FEN1 having mutations at two conserved glycines (G66S and G242D) causing defects in nuclease activity. Introduction of these mutants into yeast led to sequence expansions. Reconstituting triplet repeat expansion in vitro, we previously found that DNA ligase I promotes expansion, but FEN1 prevents the ligation that forms expanded products. Here we show that among the intermediates that could generate sequence expansion, a bubble is necessary for ligation to produce the expansion product. Severe exonuclease defects in the mutant FEN1 suggested that the inability to degrade bubbles exonucleolytically leads to expansion. However, even wild type FEN1 exonuclease cannot compete with DNA ligase I to degrade a bubble structure before it can be ligated. Instead, we propose that FEN1 suppresses sequence expansion by degrading flaps that equilibrate with bubbles, thereby reducing bubble concentration. In this way FEN1 employs endonuclease rather than exonuclease to prevent expansions. A model is presented describing the roles of DNA structure, DNA Iigase 1, and FEN1 in sequence expansion.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NIGMS NIH HHS [GM24441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; BUDD ME, 2000, MUTAT RES, V459, P137; Debrauwere H, 1997, BIOCHIMIE, V79, P577, DOI 10.1016/S0300-9084(97)82006-8; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Greene AL, 1999, HUM MOL GENET, V8, P2263, DOI 10.1093/hmg/8.12.2263; Harfe BD, 1999, MOL CELL BIOL, V19, P4766; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HENDERSON ST, 1993, GENETICS, V134, P57; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lopes J, 2002, EMBO J, V21, P3201, DOI 10.1093/emboj/cdf310; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; MERLO A, 1994, CANCER RES, V54, P2098; Mirkin SM, 2002, NAT GENET, V31, P5, DOI 10.1038/ng0502-5; MIRONOV NM, 1994, CANCER RES, V54, P41; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Morel P, 1998, P NATL ACAD SCI USA, V95, P10003, DOI 10.1073/pnas.95.17.10003; Nagata Y, 2002, GENETICS, V160, P13; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; PFAFFENBERGER RC, 1981, STAT METHODS BUSINES, P665; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROSE MD, 2000, METHODS YEAST GENETI, P171; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; White PJ, 1999, MOL CELL BIOL, V19, P5675; Wierdl M, 1997, GENETICS, V146, P769; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001	64	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13728	13739		10.1074/jbc.M212061200	http://dx.doi.org/10.1074/jbc.M212061200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12554738	hybrid			2022-12-25	WOS:000182405000023
J	Pons, JL; de Lamotte, F; Gautier, MF; Delsuc, MA				Pons, JL; de Lamotte, F; Gautier, MF; Delsuc, MA			Refined solution structure of a liganded type 2 wheat nonspecific lipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PICHIA-PASTORIS; SECONDARY STRUCTURE; NMR; BINDING; PURIFICATION; ASSIGNMENT; DIFFUSION; ALLERGEN	The refined structure of a wheat type 2 nonspecific lipid transfer protein (ns-LTP2) ligapded with L-alpha-palmitoylphosphatidylglycerol has been determined by NMR. The N-15-labeled protein was produced in Pichia pastoris. Physicochemical conditions and ligandation were intensively screened to obtain the best NMR spectra quality. This ns-LTP2 is a 67-residue globular protein with a diameter of about 30 Angstrom. The structure is composed of five helices forming a right superhelix. The protein presents an inner cavity, which has been measured at 341 Angstrom(3). All of the helices display hydrophobic side chains oriented toward the cavity. The phospholipid is found in this cavity. Its fatty acid chain is completely inserted in the protein, the L-alpha-palmitoylphosphatidylglycerol glycerol moiety being located on a positively charged pocket on the surface of the protein. The superhelix structure of the protein is coiled around the fatty acid chain. The overall structure shows similarities with ns-LTP1. Nevertheless, large three-dimensional structural discrepancies are observed for the H3 and H4 alpha-helices, the C-terminal region, and the last turn of the H2 helix. The lipid is orthogonal to the orientation observed in ns-LTP1. The volume of the hydrophobic cavity appears to be in the same range as the one of ns-LTP1, despite the fact that ns-LTP2 is shorter by 24 residues.	Univ Montpellier I, INSERM, CNRS, Ctr Biochim Struct, F-34060 Montpellier, France; INRA, Unite Mixte Rech Genomique Appliquee Caracteres A, F-34060 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; INRAE	Delsuc, MA (corresponding author), Univ Montpellier I, INSERM, CNRS, Ctr Biochim Struct, 15 Ave C Flahault, F-34060 Montpellier, France.	MA.Delsuc@cbs.cnrs.fr	Delsuc, Marc-André/ABI-5400-2020; de Lamotte, Frédéric/ABD-2561-2020	Delsuc, Marc-André/0000-0002-1400-5326; de Lamotte, Frédéric/0000-0003-4234-1172				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Blein JP, 2002, TRENDS PLANT SCI, V7, P293, DOI 10.1016/S1360-1385(02)02284-7; Charvolin D, 1999, EUR J BIOCHEM, V264, P562, DOI 10.1046/j.1432-1327.1999.00667.x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; de Lamotte F, 2001, CR ACAD SCI II C, V4, P839, DOI 10.1016/S1387-1609(01)01298-1; de Lamotte F, 1999, BIOTECHNOL TECH, V13, P351, DOI 10.1023/A:1008953326639; de Lamotte F, 2001, PROTEIN EXPRES PURIF, V22, P318, DOI 10.1006/prep.2001.1435; DEMURA T, 1993, PLANT PHYSIOL, V103, P815, DOI 10.1104/pp.103.3.815; DHARMARAJ S, 2002, J BIOL CHEM, V277, P35267; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Douliez JP, 2001, EUR J BIOCHEM, V268, P1400, DOI 10.1046/j.1432-1327.2001.02007.x; Garcia-Garrido JM, 1998, FEBS LETT, V428, P193, DOI 10.1016/S0014-5793(98)00529-8; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; GINCEL E, 1994, EUR J BIOCHEM, V226, P413, DOI 10.1111/j.1432-1033.1994.tb20066.x; Gomar J, 1996, PROTEIN SCI, V5, P565; Heinemann B, 1996, PROTEIN SCI, V5, P13; Hendriks T, 1994, NATO ASI SERIES H, V81, P85; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JAKOBSEN K, 1989, PLANT MOL BIOL, V12, P285, DOI 10.1007/BF00043205; Johnson CS, 1999, PROG NUCL MAG RES SP, V34, P203, DOI 10.1016/S0079-6565(99)00003-5; KADER JC, 1984, EUR J BIOCHEM, V139, P411, DOI 10.1111/j.1432-1033.1984.tb08020.x; Kader JC, 1997, TRENDS PLANT SCI, V2, P66, DOI 10.1016/S1360-1385(97)82565-4; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Klein C, 1998, PROTEIN EXPRES PURIF, V13, P73, DOI 10.1006/prep.1998.0888; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V29, P26; KRAUSE A, 1994, MOL PLANT MICROBE IN, V7, P411, DOI 10.1094/MPMI-7-0411; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JY, 1998, J MOL BIOL, V276, P437, DOI 10.1006/jmbi.1997.1550; Lerche MH, 1997, STRUCTURE, V5, P291, DOI 10.1016/S0969-2126(97)00186-X; Lerche MH, 1998, PROTEIN SCI, V7, P2490, DOI 10.1002/pro.5560071202; LUDVIGSEN S, 1991, J MOL BIOL, V217, P731, DOI 10.1016/0022-2836(91)90529-F; Malliavin TE, 1998, BIOINFORMATICS, V14, P624, DOI 10.1093/bioinformatics/14.7.624; Monnet FP, 2001, PLANT SCI, V161, P747, DOI 10.1016/S0168-9452(01)00459-9; MONNET FP, 1990, THESIS U SCI TECHNIQ; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 2001, ALLERGY, V56, P45, DOI 10.1034/j.1398-9995.2001.00914.x; Pons JL, 1999, J BIOMOL NMR, V15, P15, DOI 10.1023/A:1008338605320; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Poznanski J, 1999, EUR J BIOCHEM, V259, P692, DOI 10.1046/j.1432-1327.1999.00093.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; Sodano P, 1997, FEBS LETT, V416, P130, DOI 10.1016/S0014-5793(97)01185-X; STERK P, 1991, PLANT CELL, V3, P907, DOI 10.1105/tpc.3.9.907; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; Tassin S, 1998, BIOCHEMISTRY-US, V37, P3623, DOI 10.1021/bi9723515; Tassin-Moindrot S, 2000, EUR J BIOCHEM, V267, P1117, DOI 10.1046/j.1432-1327.2000.01109.x; TERRAS FRG, 1992, PLANT PHYSIOL, V100, P1055, DOI 10.1104/pp.100.2.1055; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toriyama K, 1998, FEBS LETT, V424, P234, DOI 10.1016/S0014-5793(98)00174-4; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; YE ZH, 1994, P NATL ACAD SCI USA, V91, P6539, DOI 10.1073/pnas.91.14.6539	58	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14249	14256		10.1074/jbc.M211683200	http://dx.doi.org/10.1074/jbc.M211683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12525478	Green Published, hybrid			2022-12-25	WOS:000182405000087
J	Rajagopal, L; Clancy, A; Rubens, CE				Rajagopal, L; Clancy, A; Rubens, CE			A eukaryotic type serine/threonine kinase and phosphatase in Streptococcus agalactiae reversibly phosphorylate an inorganic pyrophosphatase and affect growth, cell segregation, and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SER/THR PROTEIN-KINASE; GROUP-B STREPTOCOCCUS; BACILLUS-SUBTILIS; SUBSTRATE-SPECIFICITY; ALKALINE-PHOSPHATASE; SECONDARY METABOLISM; SIGNAL-TRANSDUCTION; GENES; THREONINE; SERINE	Protein phosphorylation is essential for the regulation of cell growth, division, and differentiation in both prokaryotes and eukaryotes. Signal transduction in prokaryotes was previously thought to occur primarily by histidine kinases, involved in two-component signaling pathways. Lately, bacterial homologues of eukaryotictype serine/threonine kinases and phosphatases have been found to be necessary for cellular functions such as growth, differentiation, pathogenicity, and secondary metabolism. The Gram-positive bacteria Streptococcus agalactiae (group B streptococci, GBS) is an important human pathogen. We have identified and characterized a eukaryotic-type serine/threonine protein kinase (Stk1) and its cognate phosphatase (Stp1) in GBS. Biochemical assays revealed that Stk1 has kinase activity and localizes to the membrane and that Stp1 is a soluble protein with manganese-dependent phosphatase activity on Stk1. Mutations in these genes exhibited pleiotropic effects on growth, virulence, and cell segregation of GBS. Complementation of these mutations restored the wild type phenotype linking these genes to the regulation of various cellular processes in GBS. In vitro phosphorylation of cell extracts from wild type and mutant strains revealed that Stk1 is essential for phosphorylation of six GBS proteins. We have identified the predominant endogenous substrate of both Stk1 and Stp1 as a manganese-dependent inorganic pyrophosphatase (PpaC) by liquid chromatography/tandem mass spectrometry. These results suggest that these eukaryotictype enzymes regulate pyrophosphatase activity and other cellular functions of S. agalactiae.	Childrens Hosp & Reg Med Ctr, Dept Pediat, Div Infect Dis, Seattle, WA 98105 USA	Seattle Children's Hospital	Rubens, CE (corresponding author), Childrens Hosp & Reg Med Ctr, Dept Pediat, Div Infect Dis, Mail Stop 8G-1,4800 Sandpoint Way NE, Seattle, WA 98105 USA.	craig.rubens@seattlechildrens.org			NIAID NIH HHS [811501/N01-AI-75326] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075326] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu Kwaik Y, 1998, INFECT IMMUN, V66, P203; Adler E, 1997, MOL MICROBIOL, V23, P57, DOI 10.1046/j.1365-2958.1997.1801552.x; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Av-Gay Y., 1997, MICROB COMP GENOMICS, V2, P63, DOI DOI 10.1089/OMI.1.1997.2.63; Bakal CJ, 2000, TRENDS CELL BIOL, V10, P32, DOI 10.1016/S0962-8924(99)01681-5; Bork P, 1996, PROTEIN SCI, V5, P1421, DOI 10.1002/pro.5560050720; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Chaffin DO, 1998, GENE, V219, P91, DOI 10.1016/S0378-1119(98)00396-5; Chaffin DO, 2000, J BACTERIOL, V182, P4466, DOI 10.1128/JB.182.16.4466-4477.2000; Cieslewicz MJ, 2001, J BIOL CHEM, V276, P139, DOI 10.1074/jbc.M005702200; CLARK JM, 1977, EXPT BIOCH, P105; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanlon WA, 1997, MOL MICROBIOL, V23, P459, DOI 10.1046/j.1365-2958.1997.d01-1871.x; HENRICHSEN J, 1985, NEONATAL GROUP B STR, V35, P53; Hooper GR, 1986, PROCEDURES TRANSMISS; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; Inouye Sumiko, 2000, Microbial and Comparative Genomics, V5, P103, DOI 10.1089/10906590050179783; Jones AL, 2000, MOL MICROBIOL, V37, P1444, DOI 10.1046/j.1365-2958.2000.02099.x; Juris SJ, 2000, P NATL ACAD SCI USA, V97, P9431, DOI 10.1073/pnas.170281997; Kamei A, 2001, J BACTERIOL, V183, P1505, DOI 10.1128/JB.183.5.1505-1510.2001; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; LAHTI R, 1983, MICROBIOL REV, V47, P169, DOI 10.1128/MMBR.47.2.169-178.1983; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; Lee MH, 1999, J BACTERIOL, V181, P5790, DOI 10.1128/JB.181.18.5790-5799.1999; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; Lower BH, 2000, J BACTERIOL, V182, P3452, DOI 10.1128/JB.182.12.3452-3459.2000; Ma PS, 1997, MICROBIOL-SGM, V143, P3451, DOI 10.1099/00221287-143-11-3451; MACKINTOSH C, 1993, PROTEIN PHOSPHORYLAT, P197; Madec E, 2002, MOL MICROBIOL, V46, P571, DOI 10.1046/j.1365-2958.2002.03178.x; MADOFF LC, 1991, INFECT IMMUN, V59, P204, DOI 10.1128/IAI.59.1.204-210.1991; MATSUMOTO A, 1994, GENE, V146, P47; Mijakovic I, 2002, P NATL ACAD SCI USA, V99, P13442, DOI 10.1073/pnas.212410399; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; Nizet V, 1999, STREPTOCOCCAL INFECTIONS, P180; NotleyMcRobb L, 1997, MICROBIOL-SGM, V143, P1909, DOI 10.1099/00221287-143-6-1909; O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x; Ogawara H, 1999, MICROBIOL-UK, V145, P3343, DOI 10.1099/00221287-145-12-3343; OKADA N, 1993, MOL MICROBIOL, V7, P893, DOI 10.1111/j.1365-2958.1993.tb01180.x; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; PINCUS SH, 1992, J BACTERIOL, V174, P3739, DOI 10.1128/JB.174.11.3739-3749.1992; RANDERATH K, 1964, THIN LAYER CHROMATOG, P93; Reed L.J., 1938, SIMPLE METHOD ESTIMA, V27, P493, DOI [10.1093/oxfordjournals.aje.a118408, DOI 10.1093/OXFORDJOURNALS.AJE.A118408]; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; Rudd JJ, 2003, J EXP BOT, V54, P141, DOI 10.1093/jxb/54.380.141; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; Schuchat A, 1998, CLIN MICROBIOL REV, V11, P497, DOI 10.1128/CMR.11.3.497; SHAKHOV YA, 1981, BIOCHEM INT, V3, P139; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi L, 1998, FEMS MICROBIOL REV, V22, P229, DOI 10.1016/S0168-6445(98)00015-1; Shintani T, 1998, FEBS LETT, V439, P263, DOI 10.1016/S0014-5793(98)01381-7; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Treuner-Lange A, 2001, MOL MICROBIOL, V40, P126, DOI 10.1046/j.1365-2958.2001.02362.x; Umeyama T, 2002, APPL MICROBIOL BIOT, V59, P419, DOI 10.1007/s00253-002-1045-1; Umeyama T, 2000, GENE, V258, P55, DOI 10.1016/S0378-1119(00)00450-9; Villafranca JE, 1996, CURR OPIN BIOTECH, V7, P397; Wang JY, 1998, J BACTERIOL, V180, P6764, DOI 10.1128/JB.180.24.6764-6768.1998; Whittaker CJ, 1996, INFECT IMMUN, V64, P4137, DOI 10.1128/IAI.64.10.4137-4142.1996; WILLETT NP, 1966, J BACTERIOL, V91, P2245, DOI 10.1128/JB.91.6.2245-2250.1966; Wu JG, 1999, P NATL ACAD SCI USA, V96, P13068, DOI 10.1073/pnas.96.23.13068; Yang XF, 1996, GENE DEV, V10, P2265, DOI 10.1101/gad.10.18.2265; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; ZHANG CC, 1993, P NATL ACAD SCI USA, V90, P11840, DOI 10.1073/pnas.90.24.11840; Zhang CC, 1998, NUCLEIC ACIDS RES, V26, P3619, DOI 10.1093/nar/26.16.3619; Zhang CC, 1998, J BACTERIOL, V180, P2616, DOI 10.1128/JB.180.10.2616-2622.1998; Zhang CC, 1996, MOL MICROBIOL, V20, P9, DOI 10.1111/j.1365-2958.1996.tb02483.x	75	132	144	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14429	14441		10.1074/jbc.M212747200	http://dx.doi.org/10.1074/jbc.M212747200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562757	hybrid			2022-12-25	WOS:000182405000110
J	Cheskis, BJ; McKenna, NJ; Wong, CW; Wong, JM; Komm, B; Lyttle, CR; O'Malley, BW				Cheskis, BJ; McKenna, NJ; Wong, CW; Wong, JM; Komm, B; Lyttle, CR; O'Malley, BW			Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; CONFORMATIONAL-CHANGES; TRAP220 COMPONENT; LIGAND-BINDING; DRIP COMPLEX; ER-ALPHA; ACTIVATION; TRANSCRIPTION; COREGULATORS; BETA	Nuclear receptor (NR)-mediated transcription is driven by dynamic multiprotein coactivator complexes, the composition of which is thought to determine the biological activity of NRs at specific promoters. The extent to which NRs discriminate between a spectrum of potential binding partners is intuitively a function of the inherent affinities of these individual interactions. Using real time interaction analysis with BIAcore, we evaluated the affinities and kinetics of the interactions of full-length members of the SRC/p160 coactivator family with estrogen receptor a (ERalpha) and ERbeta bound to a variety of ligands. We substantiate that 17beta-estradiol enhances the affinity of ER-SRC/p160 interactions, whereas 4(OH)-tamoxifen, raloxifene, and ICI-182,780 inhibit these interactions. We show that a well defined, ER isoform-specific hierarchy governs the association of liganded ERs with full length SRC/p160 family members. Moreover, our data indicate that the interaction affinities of the full-length SRC/p160s with ERs are significantly higher then those of the NR interaction domains of the same coactivators, indicating that portions of coactivator molecules distinct from NR interaction domains might participate in receptor-coactivator complex formation. Finally, the interaction kinetics of SRC/p160s with ERs are consistent with a bipartite model, involving initial rapid formation of an unstable intermediate complex, and a subsequent slower reaction leading to its stabilization. We interpret our results as evidence that hierarchical coactivator interaction affinities are an important source of diversity in NR-mediated signaling and that the complexity of receptor-coactivator cross-talk might be best understood in the context of full-length molecules.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Wyeth Ayerst Res, Womens Hlth Res Inst, Collegeville, PA 19426 USA	Baylor College of Medicine; Pfizer	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Wong, Jiemin/0000-0002-5311-842X; McKenna, Neil/0000-0001-6689-0104	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19 DK62434-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHESKIS BJ, 1999, STEROID NUCL HORMONE, P95; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Graham JD, 2000, STEROIDS, V65, P579, DOI 10.1016/S0039-128X(00)00116-1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939	36	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13271	13277		10.1074/jbc.M211031200	http://dx.doi.org/10.1074/jbc.M211031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12540843	hybrid			2022-12-25	WOS:000182189500086
J	Grinberg, AV; Kerppola, T				Grinberg, AV; Kerppola, T			Both Max and TFE3 cooperate with Smad proteins to bind the plasminogen activator inhibitor-1 promoter, but they have opposite effects on transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR SMAD4; TGF-BETA; DNA-BINDING; C-MYC; FUNCTIONAL-CHARACTERIZATION; HETERO-OLIGOMERIZATION; SIGNALING PATHWAYS; GENE; REPRESSION	Transforming growth factor (TGF)-beta regulates gene expression in large part through combinatorial interactions between members of the Smad family and other transcription factors. The basic helix-loop-helix leucine zipper (bHLHZIP) protein TFE3 and Smad3 synergistically activate transcription of the plasminogen activator inhibitor-1 (PAI-1) as well as other genes. We investigated interactions among different bHLHZIP and Smad family proteins. TFE3, TFEB, and Max associated with Smad3 and Smad4 in the absence of DNA and at the PE2.1 element of the PAI-1 promoter. These interactions were mediated by the leucine zipper and MH1 regions of the respective proteins. No interactions were observed with the E47 bHLH family protein. Chimeric proteins, in which leucine zippers from bHLHZIP or bZIP proteins were fused to heterologous bHLH domains, associated with Smad proteins both in the absence of DNA and at the PE2.1 element. The kinetics of bHLHZIP and Smad protein binding at the PE2.1 element were examined using surface plasmon resonance analysis. TFE3 exhibited cooperative DNA binding with Smad proteins, whereas no cooperativity was observed between E47 and Smads. Max inhibited transcription activation by Smad3 and TGF-beta at the PAI-1 promoter, whereas TFE3 and TFEB stimulated transcription activation. These results suggest that Smad family proteins can interact with several bHLHZIP proteins, resulting in different transcriptional outcomes.	Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kerppola, T (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Kerppola, Tom/AFK-6155-2022; Kerppola, Tom/AAG-4457-2022	Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Correia JJ, 2001, BIOCHEMISTRY-US, V40, P1473, DOI 10.1021/bi0019343; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McDonnell JM, 2001, CURR OPIN CHEM BIOL, V5, P572, DOI 10.1016/S1367-5931(00)00251-9; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	63	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11227	11236		10.1074/jbc.M211734200	http://dx.doi.org/10.1074/jbc.M211734200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551947	hybrid			2022-12-25	WOS:000181855400049
J	Leskov, KS; Klokov, DY; Li, J; Kinsella, TJ; Boothman, DA				Leskov, KS; Klokov, DY; Li, J; Kinsella, TJ; Boothman, DA			Synthesis and functional analyses of nuclear clusterin, a cell death protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSED PROSTATE MESSAGE-2; RAT VENTRAL PROSTATE; STRAND BREAK REPAIR; AMINO-ACID-SEQUENCE; SULFATED GLYCOPROTEIN-2; MESSENGER-RNA; HEAT-SHOCK; GENE-EXPRESSION; APOPTOSIS; STRESS	Nuclear clusterin (nCLU) is an ionizing radiation (IR)-inducible protein that binds Ku70, and triggers apoptosis when overexpressed in MCF-7 cells. We demonstrate that endogenous nCLU synthesis is a product of alternative splicing. Reverse transcriptase-PCR analyses revealed that exon II, containing the first AUG and encoding the endoplasmic reticulum-targeting peptide, was omitted. Exons I and III are spliced together placing a downstream AUG in exon III as the first available translation start site. This shorter mRNA produces the 49-kDa precursor nCLU protein. Ku70 binding activity was localized to the C-terminal coiled-coil domain of nCLU. Leucine residues 357, 358, and 361 of nCLU were necessary for Ku70-nCLU interaction. The N- and C-terminal coiled-coil domains of nCLU interacted with each other, suggesting that the protein could dimerize or fold. Mutation analyses indicate that the C-terminal NLS was functional in nCLU with the same contribution from N-terminal NLS. The C-terminal coiled-coil domain of nCLU was the minimal region required for Ku binding and apoptosis. MCF-7 cells show nuclear as well as cytoplasmic expression of GFP-nCLU in apoptotic cells. Cytosolic aggregation of GFP-nCLU was found in viable cells. These results indicate that an inactive precursor of nCLU exists in the cytoplasm of non-irradiated MCF-7 cells, translocates into the nucleus following IR, and induces apoptosis.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr,Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr,Sch Med, BRB-326 E,10900 Euclid Ave, Cleveland, OH 44106 USA.		Leskov, Konstantin S/J-2339-2017; Klokov, Dmitry/AAM-7316-2020; Boothman, David/Q-7776-2019	Leskov, Konstantin S/0000-0001-6201-5660; Klokov, Dmitry/0000-0003-1629-1431; 	NATIONAL CANCER INSTITUTE [R01CA084578, P30CA043703, R01CA078530] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703, CA78530, CA84578, R01 CA078530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; BURSCH W, 1995, ARCH TOXICOL, V69, P253, DOI 10.1007/s002040050167; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Clark AM, 1997, J ANDROL, V18, P257; DANIK M, 1991, P NATL ACAD SCI USA, V88, P8577, DOI 10.1073/pnas.88.19.8577; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; HARMONY JAK, 1995, CLUSTERIN ROLE VERTE, P75; HARPER JW, 1993, CELL, V75, P805; HIRAI S-I, 1989, New Biologist, V1, P181; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; Kim SH, 1999, CANCER RES, V59, P4012; Kimura K, 1997, CELL BIOCHEM FUNCT, V15, P251, DOI 10.1002/(SICI)1099-0844(199712)15:4<251::AID-CBF748>3.0.CO;2-3; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; KOUZARIDES T, 1991, ONCOGENE, V6, P195; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; Leskov KS, 2001, SEMIN RADIAT ONCOL, V11, P352, DOI 10.1053/srao.2001.26912; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAY PC, 1993, ANN NY ACAD SCI, V679, P235, DOI 10.1111/j.1749-6632.1993.tb18303.x; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Miyake H, 2000, CANCER RES, V60, P2547; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SENSIBAR JA, 1995, CANCER RES, V55, P2431; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; TSURUTA JK, 1990, BIOCHEM J, V268, P571, DOI 10.1042/bj2680571; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066; WONG P, 1993, J BIOL CHEM, V268, P5021; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907	45	326	353	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11590	11600		10.1074/jbc.M209233200	http://dx.doi.org/10.1074/jbc.M209233200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12551933	hybrid			2022-12-25	WOS:000181855400092
J	Shouldice, SR; Dougan, DR; Skene, RJ; Tari, LW; McRee, DE; Yu, RH; Schryvers, AB				Shouldice, SR; Dougan, DR; Skene, RJ; Tari, LW; McRee, DE; Yu, RH; Schryvers, AB			High resolution structure of an alternate form of the ferric ion binding protein from Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING; ACTIVE-TRANSPORT; TRANSFERRIN; NEISSERIA; COORDINATION; ACQUISITION; EXPRESSION; LIMITATION; RECEPTORS; SYSTEMS	The periplasmic iron binding protein of pathogenic Gram-negative bacteria performs an essential role in iron acquisition from transferrin and other iron sources. Structural analysis of this protein from Haemophilus influenzae identified four amino acids that ligand the bound iron: His(9), Glu(57), Tyr(195), and Tyr(196). A phosphate provides an additional ligand, and the presence of a water molecule is required to complete the octahedral geometry for stable iron binding. We report the 1.14-Angstrom resolution crystal structure of the iron-loaded form of the H. influenzae periplasmic ferric ion binding protein (FbpA) mutant H9Q. This protein was produced in the periplasm of Escherichia coli and, after purification and conversion to the apo form, was iron-loaded. H9Q is able to bind ferric iron in an open conformation. A surprising finding in the present high resolution structure is the presence of EDTA located at the previously determined anion ternary binding site, where phosphate is located in the wild type holo and apo structures. EDTA contributes four of the six coordinating ligands for iron, with two Tyr residues, 195 and 196, completing the coordination. This is the first example of a metal binding protein with a bound metal.EDTA complex. The results suggest that FbpA may have the ability to bind and transport iron bound to biological chelators, in addition to bare ferric iron.	Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Syrrx Inc, San Diego, CA 92121 USA	University of Calgary; University of Calgary	Schryvers, AB (corresponding author), Univ Calgary, Dept Microbiol & Infect Dis, Rm 274,Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	schryver@ucalgary.ca	Schryvers, Anthony B./AAF-3417-2020	Skene, Robert/0000-0002-1482-6546				Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker HM, 2001, BIOCHEMISTRY-US, V40, P11670, DOI 10.1021/bi010907p; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Griffiths E, 1988, VIRULENCE MECHANISMS, P121; Guo ML, 2003, J BIOL CHEM, V278, P2490, DOI 10.1074/jbc.M208776200; He QY, 2000, BIOCHEMISTRY-US, V39, P1205, DOI 10.1021/bi9915216; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizutani K, 1999, J BIOL CHEM, V274, P10190, DOI 10.1074/jbc.274.15.10190; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; OGUNNARIWO JA, 1990, MICROB PATHOGENESIS, V9, P397, DOI 10.1016/0882-4010(90)90058-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Sebastian S, 1999, INFECT IMMUN, V67, P3141, DOI 10.1128/IAI.67.6.3141-3145.1999; SOLANS X, 1984, ACTA CRYSTALLOGR C, V40, P635, DOI 10.1107/S0108270184005151; Stojiljkovic I, 1997, J BACTERIOL, V179, P805, DOI 10.1128/jb.179.3.805-812.1997; Taboy CH, 2001, J BIOL CHEM, V276, P2719, DOI 10.1074/jbc.M004763200; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; WEINBERG ED, 1995, CURR OPIN INFECT DIS, V8, P164, DOI 10.1097/00001432-199506000-00004; WEST SEH, 1985, INFECT IMMUN, V47, P388, DOI 10.1128/IAI.47.2.388-394.1985; WILLIAMS P, 1990, J GEN MICROBIOL, V136, P2343, DOI 10.1099/00221287-136-12-2343; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W	35	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11513	11519		10.1074/jbc.M211780200	http://dx.doi.org/10.1074/jbc.M211780200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12533539	hybrid			2022-12-25	WOS:000181855400083
J	Chavez, JA; Knotts, TA; Wang, LP; Li, GB; Dobrowsky, RT; Florant, GL; Summers, SA				Chavez, JA; Knotts, TA; Wang, LP; Li, GB; Dobrowsky, RT; Florant, GL; Summers, SA			A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SKELETAL-MUSCLE CELLS; NECROSIS-FACTOR-ALPHA; GLUT4 TRANSLOCATION; RECEPTOR SUBSTRATE-1; LIPOPROTEIN-LIPASE; SER/THR KINASE; GLUCOSE-UPTAKE; AKT KINASE; B AKT	Multiple studies suggest that lipid oversupply to skeletal muscle contributes to the development of insulin resistance, perhaps by promoting the accumulation of lipid metabolites capable of inhibiting signal transduction. Herein we demonstrate that exposing muscle cells to particular saturated free fatty acids (FFAs), but not mono-unsaturated FFAs, inhibits insulin stimulation of Akt/protein kinase B, a serine/threonine kinase that is a central mediator of insulin-stimulated anabolic metabolism. These saturated FFAs concomitantly induced the accumulation of ceramide and diacylglycerol, two products of fatty acyl-CoA that have been shown to accumulate in insulin-resistant tissues and to inhibit early steps in insulin signaling. Preventing de novo ceramide synthesis negated the antagonistic effect of saturated FFAs toward Akt/protein kinase B. Moreover, inducing ceramide buildup recapitulated and augmented the inhibitory effect of saturated FFAs. By contrast, diacylglycerol proved dispensable for these FFA effects. Collectively these results identify ceramide as a necessary and sufficient intermediate linking saturated fats to the inhibition of insulin signaling.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	Colorado State University; Colorado State University; University of Kansas	Summers, SA (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	ssummers@lamar.colostate.edu	/AAE-5384-2020; Li, Guibin/E-3507-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK059749, R01DK058784, R21DK060676] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK58784, DK59749, R21-DK60676] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Charles MA, 1997, DIABETOLOGIA, V40, P1101, DOI 10.1007/s001250050793; CHEN KS, 1991, T ASSOC AM PHYSICIAN, V104, P206; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CHIN JE, 1993, J BIOL CHEM, V268, P6338; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cortright RN, 2000, AM J PHYSIOL-ENDOC M, V278, pE553, DOI 10.1152/ajpendo.2000.278.3.E553; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Gorski J, 1998, MOL CELL BIOCHEM, V178, P113, DOI 10.1023/A:1006820907955; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hansen BC, 1999, ANN NY ACAD SCI, V892, P1, DOI 10.1111/j.1749-6632.1999.tb07782.x; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Ho RC, 2002, AM J PHYSIOL-ENDOC M, V283, pE799, DOI 10.1152/ajpendo.00105.2002; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lin YS, 2001, AM J PHYSIOL-ENDOC M, V281, pE8, DOI 10.1152/ajpendo.2001.281.1.E8; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MINAMIDE LS, 2003, IN PRESS METHODS CEL; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; Motley ED, 2001, CELL MOL BIOL, V47, P1059; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Raatz SK, 2001, J NUTR, V131, P231; RANDLE PJ, 1963, LANCET, V1, P785; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schmitz-Peiffer C, 2002, ANN NY ACAD SCI, V967, P146; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHMUELI E, 1993, J INTERN MED, V234, P397, DOI 10.1111/j.1365-2796.1993.tb00761.x; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Summers SA, 1999, ANN NY ACAD SCI, V892, P169, DOI 10.1111/j.1749-6632.1999.tb07795.x; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Thompson AL, 2000, AM J PHYSIOL-ENDOC M, V279, pE577, DOI 10.1152/ajpendo.2000.279.3.E577; Turcotte LP, 2001, DIABETES, V50, P1389, DOI 10.2337/diabetes.50.6.1389; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; VESSBY B, 1994, DIABETES, V43, P1353, DOI 10.2337/diabetes.43.11.1353; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zinda MJ, 2001, BIOCHEM BIOPH RES CO, V280, P1107, DOI 10.1006/bbrc.2000.4248	69	455	465	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10297	10303		10.1074/jbc.M212307200	http://dx.doi.org/10.1074/jbc.M212307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525490	hybrid			2022-12-25	WOS:000181777500042
J	Brenner, T; Hamra-Amitay, Y; Evron, T; Boneva, N; Seidman, S; Soreq, H				Brenner, T; Hamra-Amitay, Y; Evron, T; Boneva, N; Seidman, S; Soreq, H			The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis	FASEB JOURNAL			English	Article						neuromuscular function; MG; acetylcholine	NEUROMUSCULAR-JUNCTION; MOLECULAR-FORMS; GENE-EXPRESSION; ANTISENSE; CELLS; DIFFERENTIATION; SUPPRESSION; GENERATION; DEFICIENCY; RESPONSES	Alternative splicing induces, under abnormal cholinergic neurotransmission, overproduction of the rare "readthrough" acetylcholinesterase variant AChE-R. We explored the pathophysiological relevance of this phenomenon in patients with myasthenia gravis (MG) and rats with experimental autoimmune MG (EAMG), neuromuscular junction diseases with depleted acetylcholine receptors. In MG and EAMG, we detected serum AChE-R accumulation. In EAMG, we alleviated electromyographic abnormalities by nanomolar doses of EN101, an antisense oligonucleotide that selectively lowers AChE-R in blood and muscle yet leaves unaffected the synaptic variant AChE-S. Whereas animals treated with placebo or conventional anticholinesterases continued to deteriorate, a 4 wk daily oral administration of EN101 improved survival, neuromuscular strength and clinical status in moribund EAMG rats. The efficacy of targeting only one AChE splicing variant highlights potential advantages of mRNA-targeted therapeutics for chronic cholinergic malfunctioning.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@shum.huji.ac.il		Soreq, Hermona/0000-0002-0955-526X				ANGLISTER L, 1994, J CELL BIOL, V125, P183, DOI 10.1083/jcb.125.1.183; Behra M, 2002, NAT NEUROSCI, V5, P111, DOI 10.1038/nn788; Boneva N, 2000, MUSCLE NERVE, V23, P1204, DOI 10.1002/1097-4598(200008)23:8<1204::AID-MUS7>3.0.CO;2-H; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Carlson CG, 1998, NEUROBIOL DIS, V5, P3, DOI 10.1006/nbdi.1998.0188; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; Darboux I, 1996, EMBO J, V15, P4835, DOI 10.1002/j.1460-2075.1996.tb00864.x; Dove A, 2002, NAT BIOTECHNOL, V20, P121, DOI 10.1038/nbt0202-121; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; Galyam N, 2001, ANTISENSE NUCLEIC A, V11, P51, DOI 10.1089/108729001750072128; Grifman M, 1997, ANTISENSE NUCLEIC A, V7, P351, DOI 10.1089/oli.1.1997.7.351; Haley RW, 1999, TOXICOL APPL PHARM, V157, P227, DOI 10.1006/taap.1999.8703; He FS, 1998, HUM EXP TOXICOL, V17, P40, DOI 10.1191/096032798678907810; Huang DR, 2001, EUR J IMMUNOL, V31, P225, DOI 10.1002/1521-4141(200101)31:1<225::AID-IMMU225>3.3.CO;2-S; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; Lev-Lehman E, 2000, J MOL NEUROSCI, V14, P93, DOI 10.1385/JMN:14:1-2:093; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; MILLARD CB, 1995, J NEUROCHEM, V64, P1909, DOI 10.1046/j.1471-4159.1995.64051909.x; Monia BP, 1997, CIBA F SYMP, V209, P107; Mor I, 2001, FASEB J, V15, P2039, DOI 10.1096/fj.00-0814fje; Moran D, 1996, J THERM BIOL, V21, P171, DOI 10.1016/0306-4565(95)00042-9; Ohno K, 2000, ANN NEUROL, V47, P162, DOI 10.1002/1531-8249(200002)47:2<162::AID-ANA5>3.0.CO;2-Q; Ostlie NS, 2001, J IMMUNOL, V166, P4853, DOI 10.4049/jimmunol.166.8.4853; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; PRICE DL, 1993, PROG BRAIN RES, V98, P51; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; ROTUNDO RL, 1990, J CELL BIOL, V110, P715, DOI 10.1083/jcb.110.3.715; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Tracey KJ, 2001, FASEB J, V15, P1575, DOI 10.1096/fj.01-0148hyp; Vincent A, 1999, CURR OPIN NEUROL, V12, P545, DOI 10.1097/00019052-199910000-00008; WIRGUIN I, 1994, MUSCLE NERVE, V17, P523, DOI 10.1002/mus.880170509; Zhang GX, 1999, J IMMUNOL, V162, P3775	38	100	105	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					214	222		10.1096/fj.02-0609com	http://dx.doi.org/10.1096/fj.02-0609com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554700				2022-12-25	WOS:000181456900046
J	Sprowles, A; Wisdom, R				Sprowles, A; Wisdom, R			Oncogenic effect of delta deletion in v-Jun does not result from uncoupling Jun from JNK signaling	ONCOGENE			English	Article						Jun; JNK; transformation	ACTIVATED PROTEIN-KINASES; C-JUN; TRANSCRIPTION FACTORS; MAP KINASES; EMBRYO FIBROBLASTS; DOCKING SITES; HA-RAS; PHOSPHORYLATION; DOMAIN; ONCOPROTEIN	The protein encoded by the v-Jun oncogene shows increased transforming activity compared to c-Jun, its normal cellular counterpart. One major determinant of this increased transforming activity is an in-frame deletion of a region near the amino-terminus of the protein. This region, referred to as the delta domain, functions as a docking site for Jun N-terminal kinase (JNK), the mitogen-activated protein (MAP) kinase that phosphorylates c-Jun to regulate its transcriptional properties. As a consequence of this deletion, v-Jun is unresponsive to JNK signaling, and it is widely believed that it is the uncoupling of v-Jun from JNK signaling that underlies the oncogenic effects of the delta-domain deletion; however, this idea has never been directly tested. Here we use JNK overexpression as well as alanine scanning mutagenesis to test this idea. Point mutants that are uncoupled from JNK signaling do not show enhanced transforming activity, suggesting that disruption of the Jun-JNK interaction is not the mechanism by which the delta-domain deletion enhances transforming activity. Consistent with this idea, we have generated a panel of point mutants that show markedly enhanced transforming activity, despite the fact that they do not perturb the ability of JNK to either dock with or phosphorylate c-Jun in vitro or in vivo. The fact that these mutants cluster in a small region suggests the existence of an additional regulator of Jun function whose activity is disrupted by mutations in this region.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Univ Calif Davis, Ctr Canc, UC Davis Sch Med, Sacramento, CA 95817 USA	Vanderbilt University; University of California System; University of California Davis	Wisdom, R (corresponding author), Res Bldg 3,Rm 1100 4645 2nd Ave, Sacramento, CA 95817 USA.				NCI NIH HHS [CA64118, T32CA009582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064118, T32CA009582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kilbey A, 1996, ONCOGENE, V12, P2409; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	36	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					498	506		10.1038/sj.onc.1206165	http://dx.doi.org/10.1038/sj.onc.1206165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555063				2022-12-25	WOS:000180538200003
J	Berkovich, E; Ginsberg, D				Berkovich, E; Ginsberg, D			ATM is a target for positive regulation by E2F-1	ONCOGENE			English	Article						E2F; ATM; oncogenic stress	TRANSCRIPTION FACTOR E2F-1; GENE-PRODUCT; DNA-REPLICATION; EXPRESSION; APOPTOSIS; PHOSPHORYLATION; P53; INDUCTION; FAMILY; REPAIR	The E2F-1 transcription factor is a critical downstream target of the tumor suppressor, RB. When activated, E2F-1 induces cell proliferation. In addition, deregulation of E2F-1 constitutes an oncogenic stress that can induce apoptosis. The protein kinase ATM is a pivotal mediator of the response to another type of stress, genotoxic stress. In response to ionizing radiation, ATM activates the tumor suppressor p53, a key player in the control of cell growth and viability. We show here that E2F-1 elevates ATM promoter activity and induces an increase in ATM mRNA and protein levels. This is accompanied by an E2F-nduced increase in p53 phosphorylation. Expression of the E7 protein of HPV16, which dissociates RB/E2F complexes, also induces the elevation of ATM levels and p53 phosphorylation, implicating endogenous E2F in these phenomena. These data demonstrate that ATM is transcriptionally regulated by E2F-1 and suggest that ATM serves as a novel, ARF-independent functional link between the RB/E2F pathway and p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Imai T, 1997, GENOMICS, V42, P388, DOI 10.1006/geno.1997.4769; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					161	167		10.1038/sj.onc.1206144	http://dx.doi.org/10.1038/sj.onc.1206144			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527885				2022-12-25	WOS:000180322400001
J	Theis-Febvre, N; Filhol, O; Froment, C; Cazales, M; Cochet, C; Monsarrat, B; Ducommun, B; Baldin, V				Theis-Febvre, N; Filhol, O; Froment, C; Cazales, M; Cochet, C; Monsarrat, B; Ducommun, B; Baldin, V			Protein kinase CK2 regulates CDC25B phosphatase activity	ONCOGENE			English	Article						cell cycle; CDC25B phosphatase; CK2 kinase; phosphorylation	CELL-CYCLE PROGRESSION; BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; MASS-SPECTROMETRY; CASEIN KINASE-2; FISSION YEAST; TYROSINE PHOSPHATASE; CHECKPOINT PATHWAY; G(1)/S TRANSITION	Human dual-specificity phosphatases CDC25 (A, B and C) play an important role in the control of cell cycle progression by activating the cyclin-dependent kinases (CDKs). Regulation of these phosphatases during the cell cycle involves post-translational modifications such as phosphorylation and protein-protein interactions. Given the suspected involvement of the protein kinase CK2 at the G2/M transition, we have investigated its effects on the CDC25B phosphatase. We show that in vitro CK2 phosphorylates CDC25B, but not CDC25C. Mass spectrometry analysis demonstrates that at least two serine residues, Ser-186 and Ser-187, are phosphorylated in vivo. We also report that CDC25B interacts with CK2, and this interaction, mediated by the CK2beta regulatory subunit, involves domains that are located within the first 55 amino acids of CK2beta and between amino acids 122 and 200 on CDC25B. This association was confirmed in vivo, in Sf9 insect cells and in U2OS human cells expressing an HA epitope-tagged CDC25B. Finally, we demonstrate that phosphorylation of CDC25B by protein kinase CK2 increases the catalytic activity of the phosphatase in vitro as well as in vivo. We discuss the possibility that CDC25B phosphorylation by CK2 could play a role in the regulation of the activity of CDC25B as a starter of mitosis.	Univ Toulouse 3, LBCMCP, CNRS, UMR 5088,Inst Explorat Fonct Genomes,IFR 109, F-31062 Toulouse, France; INSERM, EMI 0104, CEA, DBMS, F-38054 Grenoble 9, France; IPBS, UMR 5089, F-31070 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Baldin, V (corresponding author), Univ Toulouse 3, LBCMCP, CNRS, UMR 5088,Inst Explorat Fonct Genomes,IFR 109, 118 Route Narbonne, F-31062 Toulouse, France.		Filhol-Cochet, Odile/I-3962-2016; BALDIN, Véronique/Y-8397-2019; DUCOMMUN, Bernard/B-3208-2008	BALDIN, Véronique/0000-0001-8523-0494; Cochet, Claude/0000-0002-1772-4270; DUCOMMUN, Bernard/0000-0002-7126-8368; Filhol, Odile/0000-0003-1964-7958				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; BALDIN V, 2002, J BIOL CHEM, V9, P9; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Cans C, 1999, ANTICANCER RES, V19, P1241; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, PATHOL BIOL, V48, P182; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1994, BIOCHEM BIOPH RES CO, V198, P660, DOI 10.1006/bbrc.1994.1096; FILHOLCOCHET O, 1994, CELL MOL BIOL RES, V40, P529; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gotz C, 2000, BIOCHEM BIOPH RES CO, V268, P882, DOI 10.1006/bbrc.2000.2230; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Lammer C, 1998, J CELL SCI, V111, P2445; Leroy D, 1999, MOL CELL BIOCHEM, V191, P85, DOI 10.1023/A:1006858210835; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Lorenz P, 1999, FEBS LETT, V448, P283, DOI 10.1016/S0014-5793(99)00388-9; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAGATA A, 1991, NEW BIOL, V3, P959; Nambirajan S, 2000, J BIOSCIENCE, V25, P33, DOI 10.1007/BF02985179; NASTAINCZYK W, 1995, HYBRIDOMA, V14, P335, DOI 10.1089/hyb.1995.14.335; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; Romero-Oliva F, 2001, J CELL BIOCHEM, V81, P445, DOI 10.1002/1097-4644(20010601)81:3<445::AID-JCB1058>3.0.CO;2-2; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	71	66	69	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					220	232		10.1038/sj.onc.1206107	http://dx.doi.org/10.1038/sj.onc.1206107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527891				2022-12-25	WOS:000180322400007
J	Zhou, YQ; He, C; Chen, YQ; Wang, D; Wang, MH				Zhou, YQ; He, C; Chen, YQ; Wang, D; Wang, MH			Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential	ONCOGENE			English	Article						receptor tyrosine kinase; splicing variants; colon cancer; oncogenesis	MACROPHAGE-STIMULATING PROTEIN; POINT MUTATIONS; GROWTH-FACTOR; C-MET; GENE; OVEREXPRESSION; IDENTIFICATION; CANCER; ACTIVATION; PRODUCT	The RON receptor tyrosine kinase is a member of the MET proto-oncogene family that has been implicated in regulating motile-invasive phenotypes in certain types of epithelial cancers. The purpose of this study was to determine if RON expression is altered in primary human colorectal adenocarcinomas. Results from immuohistochemical staining showed that RON is highly expressed in the majority of colorectal adenocarcinomas (29/49 cases). Accumulated RON is also constitutively active with autophosphorylation in tyrosine residues. Moreover, three splicing, variants of RON, namely RONDelta165, RONDelta160, and RONDelta155 were detected and cloned from two primary colon cancer samples. These RON variants were generated by deletions in different regions in extracellular domains of the RON beta chain. Functional studies showed that expression of RONDelta160 or RONDelta155 in Martin-Darby canine kidney cells resulted in increased cell dissociation (scatter-like activity). RON variants, RONDelta160 and RONDelta155, also exerted the ability to induce multiple focus formation and sustain anchorage-independent growth of transfected NIH3T3 cells. Moreover, NIH3T3 cells expressing RONDelta160 or RONDelta155 formed tumors in athymic nude mice and colonized in the lungs. These data suggest that RON expression is altered in certain primary colon cancers. Abnormal accumulation of RON variants may play a role in the progression of certain colorectal cancers in vivo.	Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med, Denver, CO 80204 USA; Zhejiang Univ, Sch Med, Div Neurosurg, Affiliated Hosp 1, Hangzhou 310027, Peoples R China; Zhejiang Univ, Sch Med, Dept Surg, Sir Run Run Shaw Hosp, Hangzhou 310027, Peoples R China; Univ Colorado, Sch Med, Dept Med, Denver, CO USA; Univ Colorado, Sch Med, CU Canc Ctr, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Zhejiang University; Zhejiang University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med, 777 Bannock St,Mail 4000, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA91980] Funding Source: Medline; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allred DC, 1998, MODERN PATHOL, V11, P155; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; Crawford J., 1994, GASTROINTESTINAL TRA; Dorudi Sina, 1993, Current Opinion in Oncology, V5, P130; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Montero-Julian FA, 1998, HYBRIDOMA, V17, P541, DOI 10.1089/hyb.1998.17.541; Okino T, 1999, INT J ONCOL, V15, P709; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Portera CA, 1998, SURG ONCOL, V7, P183, DOI 10.1016/S0960-7404(99)00020-1; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P3436; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Xiao ZQ, 2000, BIOCHEM BIOPH RES CO, V267, P669, DOI 10.1006/bbrc.1999.2011; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	31	158	177	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					186	197		10.1038/sj.onc.1206075	http://dx.doi.org/10.1038/sj.onc.1206075			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527888				2022-12-25	WOS:000180322400004
J	Buchsbaum, RJ; Connolly, BA; Feig, LA				Buchsbaum, RJ; Connolly, BA; Feig, LA			Regulation of p70 S6 kinase by complex formation between the rac guanine nucleotide exchange factor (Rac-GEF) Tiam1 and the scaffold spinophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; FILAMENT-BINDING PROTEIN; N-TERMINAL PLECKSTRIN; CELL-ADHESION; NEURABIN; INVASION; RHO; FAMILY; CDC42; RAS-GRF1/CDC25(MM)	Tiam1 is a ubiquitous guanine nucleotide exchange factor (GEF) that activates the Rac GTPase. We have shown previously that the N terminus of Tiam1 contributes to the signaling specificity of its downstream target Rac via association with IB2, a scaffold that promotes Rac activation of a p38 kinase cascade. Here we show that the N terminus of Tiam1 can influence Rac signaling specificity in a different way by interaction with spinophilin, a scaffold that binds to p70 S6 kinase, another protein regulated by Rac. In particular, spinophilin binding promotes the plasma membrane localization of Tiam1 and enhances the ability of Tiam1 to activate p70 S6 kinase. In contrast, spinophilin binding suppresses the ability of Tiam to activate Pak1, a different Rac effector. Finally, a mutant spinophilin that cannot bind to Tiam1 suppresses serum-induced p70 S6 kinase activation in cells, suggesting that a Tiam1/spinophilin complex contributes to p70 S6 kinase regulation by extracellular signals. These findings add to a growing body of evidence supporting the concept that some Rac-GEFs not only activate Rac GTPases but also participate in the selection of Rac effector by binding to particular scaffolds that complex with components of specific Rac effector pathways.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA	Tufts University; Tufts Medical Center; Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK34928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kawazoe N, 1999, ONCOGENE, V18, P2413, DOI 10.1038/sj.onc.1202555; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stephens DJ, 1999, J BIOL CHEM, V274, P30080, DOI 10.1074/jbc.274.42.30080; Stephens DJ, 2000, BIOCHEM J, V345, P185, DOI 10.1042/0264-6021:3450185; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	38	95	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18833	18841		10.1074/jbc.M207876200	http://dx.doi.org/10.1074/jbc.M207876200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12531897	hybrid			2022-12-25	WOS:000182932200018
J	Hoshino, T; Tsutsumi, S; Tomisato, W; Hwang, HJ; Tsuchiya, T; Mizushima, T				Hoshino, T; Tsutsumi, S; Tomisato, W; Hwang, HJ; Tsuchiya, T; Mizushima, T			Prostaglandin E-2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-INDUCED APOPTOSIS; BICARBONATE SECRETION; SELECTIVE INHIBITOR; CASPASE ACTIVATION; EP(3) RECEPTORS; INTEGRAL-PART; RAT; KINASE; PHOSPHORYLATION; EXPRESSION	Prostaglandin E-2 (PGE(2)) has a strong protective effect on the gastric mucosa in vivo; however, the molecular mechanism of a direct cytoprotective effect of PGE(2) on gastric mucosal cells has yet to be elucidated. Although we reported previously that PGE(2) inhibited gastric irritant-induced apoptotic DNA fragmentation in primary cultures of guinea pig gastric mucosal cells, we show here that PGE(2) inhibits the ethanol-dependent release of cytochrome c from mitochondria. Of the four main subtypes of PGE(2) receptors, we also demonstrated, using subtype-specific agonists, that EP2 and EP4 receptors are involved in the PGE(2)-mediated protection of gastric mucosal cells from ethanol-induced apoptosits. Activation of EP2 and EP4 receptors is coupled with an increase in cAMP, for which a cAMP analogue was found here to inhibit the ethanol-induced apoptosis. The increase in cAMP is known to activate both protein kinase A (PKA) and phosphatidylinositol 3-kinase pathways. An inhibitor of PKA but not of phosphatidylinositol 3-kinase blocked the PGE(2)-mediated protection of cells from ethanol-induced apoptosis, suggesting that a PKA pathway is mainly responsible for the PGE(2)-mediated inhibition of apoptosis. Based on these results, we considered that PGE(2) inhibited gastric irritant-induced apoptosis in gastric mucosal cells via induction of an increase in cAMP and activation of PKA, and that this effect was involved in the PGE(2)-mediated protection of the gastric mucosa from gastric irritants in vivo.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan; Japan Sci & Technol Corp, PRESTO, Okayama 7008530, Japan	Okayama University; Japan Science & Technology Agency (JST)	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	mizushima@pharm.okayama-u.ac.jp						Araki H, 2000, ALIMENT PHARM THERAP, V14, P116, DOI 10.1046/j.1365-2036.2000.014s1116.x; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chen WS, 2001, MOL CELL BIOL, V21, P4636, DOI 10.1128/MCB.21.14.4636-4646.2001; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; GRYGLEWSKI RJ, 1987, BIOCHEM PHARMACOL, V36, P4209, DOI 10.1016/0006-2952(87)90660-5; Hassan S, 1996, DIGESTION, V57, P196, DOI 10.1159/000201339; Hoshino T, 2002, DIGEST DIS SCI, V47, P2370, DOI 10.1023/A:1020164000898; Houchen CW, 2003, AM J PHYSIOL-GASTR L, V284, pG490, DOI 10.1152/ajpgi.00240.2002; Ikari A, 1999, JPN J PHYSIOL, V49, P365, DOI 10.2170/jjphysiol.49.365; Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689; Iordanov MS, 2000, CANCER RES, V60, P1983; KAUFFMAN GL, 1980, AM J PHYSIOL, V239, pG44, DOI 10.1152/ajpgi.1980.239.1.G44; Keogh JP, 1997, CLIN EXP PHARMACOL P, V24, P844, DOI 10.1111/j.1440-1681.1997.tb02701.x; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P211; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Mizushima T, 1999, DIGEST DIS SCI, V44, P510, DOI 10.1023/A:1026692920848; Morimoto K, 1997, AM J PHYSIOL-GASTR L, V272, pG681, DOI 10.1152/ajpgi.1997.272.3.G681; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Morris GP, 1998, J CLIN GASTROENTEROL, V27, pS53, DOI 10.1097/00004836-199800001-00010; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; NARIBAYASHIINOMOTO Y, 1995, GASTROENTEROLOGY, V109, P341, DOI 10.1016/0016-5085(95)90319-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; PIHAN G, 1986, GASTROENTEROLOGY, V91, P1415, DOI 10.1016/0016-5085(86)90195-2; POWIS G, 1994, CANCER RES, V54, P2419; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Rokutan K, 1998, AM J PHYSIOL-GASTR L, V275, pG526, DOI 10.1152/ajpgi.1998.275.3.G526; Srinivasan B D, 1989, Prog Clin Biol Res, V312, P229; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Suzuki K, 2001, DIGESTION, V63, P92, DOI 10.1159/000051876; Takano T, 2002, DIGEST DIS SCI, V47, P1546, DOI 10.1023/A:1015819203084; Takeuchi K, 1997, GASTROENTEROLOGY, V113, P1553, DOI 10.1053/gast.1997.v113.pm9352857; Takeuchi K, 2001, J PHARMACOL EXP THER, V297, P1160; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomisato W, 2002, DIGEST DIS SCI, V47, P2125, DOI 10.1023/A:1019653719397; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; WATABE A, 1993, J BIOL CHEM, V268, P20175; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Webster CRL, 2002, AM J PHYSIOL-GASTR L, V283, pG727, DOI 10.1152/ajpgi.00410.2001; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yokotani K, 1996, BRIT J PHARMACOL, V117, P653, DOI 10.1111/j.1476-5381.1996.tb15240.x; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	51	117	121	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12752	12758		10.1074/jbc.M212097200	http://dx.doi.org/10.1074/jbc.M212097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556459	hybrid			2022-12-25	WOS:000182189500023
J	Pallavi, B; Nagaraj, R				Pallavi, B; Nagaraj, R			Palmitoylated peptides from the cysteine-rich domain of SNAP-23 cause membrane fusion depending on peptide length, position of cysteines, and extent of palmitoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNARE COMPLEX; PROTEIN; BINDING; STIMULATION; EXOCYTOSIS; MECHANISM; VESICLES; SYNDET	Synaptosome-associated proteins SNAP-23/25, members of a family of proteins essential for exocytosis, have a highly conserved central cysteine-rich domain that plays an important role in membrane targeting. More than one cysteine in this domain is modified by palmitic acid through a thioester linkage. In an effort to address the biological significance of acylation of this domain, we have generated synthetic peptides corresponding to the cysteine-rich region of SNAP-23 and covalently modified the cysteines with palmitic acid. The interaction of acylated and nonacylated peptides with lipid vesicles and natural membranes has been investigated. Our results indicate that palmitoylation is essential for membrane association. The palmitoylated peptides were able to fuse both model and natural membranes. The extent of fusion depended on the length of the peptides and the number and positions of covalently linked palmitic acids. Peptide-mediated fusion was suppressed by lysolipid and involved both outer and inner leaflets of the lipid bilayer, which is characteristic of natural membrane fusion. Our results suggest an important role for the cysteine-rich palmitoylated domain of SNAP-23 in promoting membrane fusion in cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Nagaraj, R (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	nraj@ccmb.res.in						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burger KNJ, 2000, TRAFFIC, V1, P605, DOI 10.1034/j.1600-0854.2000.010804.x; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1995, CURR OPIN STRUC BIOL, V5, P541, DOI 10.1016/0959-440X(95)80041-7; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Edwardson JM, 1998, METHODS, V16, P209, DOI 10.1006/meth.1998.0669; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gonelle-Gispert C, 2000, J CELL SCI, V113, P3197; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k; Harishchandran A, 2002, PROTEIN PEPTIDE LETT, V9, P411, DOI 10.2174/0929866023408571; HEBN CA, 1993, METHOD ENZYMOL, V220, P130; HENNANDEZ LD, 1996, ANN REV CELL BIOL, V12, P627; HOEKSTRA D, 1993, METHOD ENZYMOL, V220, P15, DOI 10.1016/0076-6879(93)20070-J; Hughson FM, 1999, CURR BIOL, V9, pR49, DOI 10.1016/S0960-9822(99)80008-6; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Koticha DK, 2002, J CELL SCI, V115, P3341; Koticha DK, 1999, J BIOL CHEM, V274, P9053, DOI 10.1074/jbc.274.13.9053; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lane SR, 1997, J NEUROCHEM, V69, P1864; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Langosch D, 2001, J BIOL CHEM, V276, P32016, DOI 10.1074/jbc.M102579200; Lentz BR, 2000, CURR OPIN STRUC BIOL, V10, P607, DOI 10.1016/S0959-440X(00)00138-X; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACLEAN CM, 1993, BIOCHEM J, V294, P325, DOI 10.1042/bj2940325; MAUKIN VS, 1984, GEN PHYSL BIOPHYS, V5, P361; MELDOLESI J, 1971, J CELL BIOL, V49, P109, DOI 10.1083/jcb.49.1.109; Misura KMS, 2000, CURR OPIN STRUC BIOL, V10, P662, DOI 10.1016/S0959-440X(00)00151-2; MOBLEY PW, 1995, BBA-MOL BASIS DIS, V1271, P304, DOI 10.1016/0925-4439(95)00048-9; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Peisajovich SG, 2000, J MOL BIOL, V296, P1353, DOI 10.1006/jmbi.2000.3543; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; STRUCK KD, 1981, BIOCHEMISTRY-US, V20, P4039; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamm LK, 2000, BIOSCIENCE REP, V20, P501, DOI 10.1023/A:1010406920417; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	53	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12737	12744		10.1074/jbc.M208598200	http://dx.doi.org/10.1074/jbc.M208598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551899	hybrid			2022-12-25	WOS:000182189500021
J	Zhang, N; Hodge, D; Rogers, TJ; Oppenheim, JJ				Zhang, N; Hodge, D; Rogers, TJ; Oppenheim, JJ			Ca2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHEMOATTRACTANTS; CROSS-DESENSITIZATION; CALCIUM MOBILIZATION; MORPHINE; ACTIVATION; LOCALIZATION; CELLS; PHOSPHORYLATION; CORTICOSTERONE; DEGRADATION	Heterologous desensitization of chemokine receptors by opioids has been considered to contribute to their immunosuppressive effects. Previous studies show that Met-enkephalin, an endogenous opioid, down-regulates chemotaxis of selected chemokine receptors via phosphorylation. In the present study, we further investigated the molecular mechanism of such cross-regulation. Our data showed that preincubation with Metenkephalin inhibited both MIP-1alpha-mediated chemotaxis and Ca2+ flux of monocytes in a dose-dependent manner. The inhibitory effects were maximal using nanomolar concentrations of activating chemokines, a concentration found in physiological conditions. A decrease both in chemokine receptor affinity and in coupling efficiency between receptors and G protein were observed, which directly contributed to the desensitization effects. However, comparing with chemokines such as MIP-1alpha and MCP-1, opioids did not elicit a calcium flux, failed to induce MIP-1alpha receptors internalization, and mediated a less potent heterologous desensitization. We hypothesized that these differences might originate from the involvement of different protein kinase C (PKC) isotypes. In our studies, opioid-mediated down-regulation of MIP-1alpha receptors could be blocked by the general PKC inhibitor calphostin C, but not by the calcium-dependent classic PKC inhibitor Go6976. Western blotting analysis and immunofluorescent staining further showed that only calcium-independent PKCs were activated upon opioid stimulation. Thus, opioids achieve desensitization of chemokine receptors via a unique pathway, involving only calcium-independent PKC isotypes.	Intramural Res Support Program, Mol Immunoregulat Lab, Frederick, MD 21702 USA; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Oppenheim, JJ (corresponding author), Intramural Res Support Program, Mol Immunoregulat Lab, Bldg 560,Rm 21-89A, Frederick, MD 21702 USA.				NIDA NIH HHS [DA-06550, DA-14230, DA-11130, DA-13429] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009369, ZIABC009369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014230, R01DA011130, R03DA006550, P30DA013429] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; BADOLATO R, 1995, J IMMUNOL, V155, P4004; BRYANT HU, 1991, ENDOCRINOLOGY, V128, P3253, DOI 10.1210/endo-128-6-3253; CATERINA MJ, 1995, J BIOL CHEM, V270, P4418, DOI 10.1074/jbc.270.9.4418; Ceder G, 2001, CLIN CHEM, V47, P1980; DONAHOE RM, 1988, ADV BIOCHEM PSYCHOPH, V44, P145; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Flores LR, 1996, EUR J PHARMACOL, V318, P437, DOI 10.1016/S0014-2999(96)00788-1; FREIER DO, 1994, J PHARMACOL EXP THER, V270, P1127; Fuertes G, 2000, EUR J PHARMACOL, V388, P49, DOI 10.1016/S0014-2999(99)00829-8; Grimm MC, 1998, ANN NY ACAD SCI, V840, P9, DOI 10.1111/j.1749-6632.1998.tb09544.x; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; Heemskerk MHM, 1999, CELL IMMUNOL, V195, P10, DOI 10.1006/cimm.1999.1520; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; McCarthy L, 2001, J NEUROIMMUNOL, V114, P173, DOI 10.1016/S0165-5728(01)00248-X; Meller N, 1999, CELL IMMUNOL, V193, P185, DOI 10.1006/cimm.1999.1478; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; MUELLER SG, 1995, J BIOL CHEM, V270, P10439, DOI 10.1074/jbc.270.18.10439; NOVICK DM, 1989, J PHARMACOL EXP THER, V250, P606; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; Richmond A, 1997, METHOD ENZYMOL, V288, P3; TAUB DD, 1991, P NATL ACAD SCI USA, V88, P360, DOI 10.1073/pnas.88.2.360; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; Yang D, 2001, J IMMUNOL, V166, P4092, DOI 10.4049/jimmunol.166.6.4092; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Yang W, 1997, BIOCHEMISTRY-US, V36, P15193, DOI 10.1021/bi971594u	37	50	51	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12729	12736		10.1074/jbc.M300430200	http://dx.doi.org/10.1074/jbc.M300430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551901	hybrid			2022-12-25	WOS:000182189500020
J	Kitagawa, A; Shimohama, S; Oeda, T; Uemura, K; Kohno, R; Kuzuya, A; Shibasaki, H; Ishii, N				Kitagawa, A; Shimohama, S; Oeda, T; Uemura, K; Kohno, R; Kuzuya, A; Shibasaki, H; Ishii, N			The role of the presenilin-1 homologue gene sel-12 of Caenorhabditis elegans in apoptotic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PROGRAMMED CELL-DEATH; AMYLOID BETA-PEPTIDE; C-ELEGANS; OXIDATIVE STRESS; IN-VIVO; PROTEIN; MUTATION; CALCIUM; MUTANT	Many cases of autosomal dominant early onset familial Alzheimer's disease result from mutations in presenilin-l (PSI). In this study, we examined the role of the PS1 homologue gene sel-12 of Caenorhabditis elegans under oxidative stress and clarified the sel-12-induced apoptosis. A genetic null allele mutant, sel-12(ar171), showed resistance to oxidative stress and prevented mitochondrial dysfunction-induced apoptosis. On the other hand, another allele mutant, sel-12(ar131), that carries a missense mutation showed a proapoptotic activity, which may be the result of a gain of function property. Also, sel-12 (ar131)-induced apoptosis was ced-3- and ced-4-dependent. Dantrolene, which specifically inhibits Ca2+ release from endoplasmic reticulum stores, prevents sel-12(ar131)-induced apoptosis. SEL-12, which is localized in the endoplasmic reticulum, may induce apoptosis through abnormal calcium release from the endoplasmic reticulum. Together, with the previous finding that human PSI could substitute for SEL-12, these results suggest the similar involvement of PS1-inducing apoptosis under oxidative stress and mitochondrial dysfunction in the Alzheimer's Disease brain.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Kyoto University; Tokai University	Shimohama, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogin Kawaharacho, Kyoto 6068507, Japan.							BAGLEY AC, 1986, P NATL ACAD SCI USA, V83, P3189, DOI 10.1073/pnas.83.10.3189; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRENNER S, 1974, GENETICS, V77, P71; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DRISCOLL M, 1995, METHOD CELL BIOL, V46, P323; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; HOSONO R, 1978, EXP GERONTOL, V13, P369, DOI 10.1016/0531-5565(78)90047-5; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Leissring MA, 1999, J BIOL CHEM, V274, P32535, DOI 10.1074/jbc.274.46.32535; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Lewis PA, 2000, BIOCHEM BIOPH RES CO, V277, P261, DOI 10.1006/bbrc.2000.3646; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SOHAL RS, 1988, EXP GERONTOL, V23, P211, DOI 10.1016/0531-5565(88)90008-3; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; SULSTON JE, 1974, GENETICS, V77, P95; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	35	11	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12130	12134		10.1074/jbc.M212058200	http://dx.doi.org/10.1074/jbc.M212058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556527	hybrid			2022-12-25	WOS:000182015700054
J	Lee, JM; Calkins, MJ; Chan, KM; Kan, YW; Johnson, JA				Lee, JM; Calkins, MJ; Chan, KM; Kan, YW; Johnson, JA			Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; NRF2 TRANSCRIPTION FACTOR; HUMAN NEUROBLASTOMA-CELLS; HEME OXYGENASE-1 GENE; GLUTATHIONE S-TRANSFERASES; DETOXIFYING ENZYME GENES; CREB-BINDING-PROTEIN; MEDIATED EXPRESSION; SUBUNIT GENE; QUINONE REDUCTASE	The antioxidant responsive element (ARE) mediates transcriptional regulation of phase II detoxification enzymes and antioxidant proteins such as NAD(P)H:quinone oxidoreductase (NQO1), glutathione S-transferases, and glutamate-cysteine ligase. In this study, we demonstrate that NF-E2-related factor-2 (Nrf2) plays a major role in transcriptional activation of ARE-driven genes and identify Nrf2-dependent genes by oligonucleotide microarray analysis using primary cortical astrocytes from Nrf2(+/+) and Nrf2(-/-) mice. Nrf2(-/-) astrocytes had decreased basal NQO1 activity and no induction by tert-butylhydroquinone compared with Nrf2(+/+) astrocytes. Similarly, both basal and induced levels of human NQO1-ARE-luciferase expression in Nrf2(-/-) astrocytes were significantly lower than in Nrf2(+/+) astrocytes. Furthermore, human NQO1-ARE-luciferase expression in Nrf2(-/-) astrocytes was restored by overexpression of Nrf2, whereas ARE activation in Nrf2(+/+) astrocytes was completely blocked by dominant-negative Nrf2. In addition, we observed that Nrf2-dependent genes protected primary astrocytes from H2O2-or platelet-activating factor-induced apoptosis. In support of these observations, we identified Nrf2-dependent genes encoding detoxification enzymes, glutathione-related proteins, antioxidant proteins, NADPH-producing enzymes, and anti-inflammatory genes using oligonucleotide microarrays. Proteins within these functional categories are vital to the maintenance and responsiveness of a cell defense system, suggesting that an orchestrated change in gene expression via Nrf2 and the ARE gives a synergistic protective effect against oxidative stress.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Univ Wisconsin, Ctr Neurosci, Madison, WI 53705 USA; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Hong Kong; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Johnson, JA (corresponding author), Univ Wisconsin, Sch Pharm, 6125 Rennebohm Hall,777 Highland Ave, Madison, WI 53705 USA.		Chan, Kaimin/C-4207-2009		NIDDK NIH HHS [DK16666] Funding Source: Medline; NIEHS NIH HHS [ES09090, ES10042, ES08089] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016666, R37DK016666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008089, P30ES009090, R01ES008089, R01ES010042] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Aschner M, 2000, NEUROTOXICOLOGY, V21, P1101; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Chen YH, 2000, J BIOL CHEM, V275, P27366; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; Drukarch B, 1998, FREE RADICAL BIO MED, V25, P217, DOI 10.1016/S0891-5849(98)00050-1; Duffy S, 1998, J NEUROCHEM, V71, P69; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hostettler ME, 2002, GLIA, V38, P228, DOI 10.1002/glia.10065; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Kang KW, 2001, MOL PHARMACOL, V59, P1147, DOI 10.1124/mol.59.5.1147; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; Li J, 2002, PHYSIOL GENOMICS, V9, P137, DOI 10.1152/physiolgenomics.00003.2002; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Sonnewald U, 2002, J PHARMACOL EXP THER, V301, P1, DOI 10.1124/jpet.301.1.1; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545	60	607	641	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12029	12038		10.1074/jbc.M211558200	http://dx.doi.org/10.1074/jbc.M211558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556532	hybrid			2022-12-25	WOS:000182015700042
J	Gales, L; Cardoso, I; Fayard, B; Quintanilha, A; Saraiva, MJ; Damas, AM				Gales, L; Cardoso, I; Fayard, B; Quintanilha, A; Saraiva, MJ; Damas, AM			X-ray absorption spectroscopy reveals a substantial increase of sulfur oxidation in transthyretin (TTR) upon fibrillization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRILS; IN-VITRO; SULFONATED TRANSTHYRETIN; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; K-EDGE; BETA(2)-MICROGLOBULIN; AMYLOIDOGENICITY; PROTEINS; MONOMERS	Transthyretin (TTR) amyloid fibrils are the main component of the amyloid deposits occurring in Familial Amyloidotic Polyneuropathy patients. This is 1 of 20 human proteins leading to protein aggregation disorders such as Alzheimer's and Creutzfeldt-Jakob diseases. The structural details concerning the association of the protein molecules are essential for a better understanding of the disease and consequently the design of new strategies for diagnosis and therapeutics. Disulfide bonds are frequently considered essential for the stability of protein aggregates and since in the TTR monomers there is one cysteine residue, it is important to determine unambiguously the redox state of sulfur present in the fibrils. In this work we used x-ray spectroscopy to further characterize TTR amyloid fibrils. The sulfur K-edge absorption spectra for the wild type and some amyloidogenic TTR variants in the soluble and fibrillar forms were analyzed. Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH3) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Further interpretation of the data reveals that there are no disulfide bridges in the fibrillar samples and suggest conformational changes in the TTR molecule, namely in strand A and/or in its vicinity, upon fibril formation.	Univ Porto, ICBAS, P-4099003 Oporto, Portugal; Univ Porto, Inst Mol & Cell Biol, P-4150 Oporto, Portugal; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Universidade do Porto; Universidade do Porto; European Synchrotron Radiation Facility (ESRF)	Damas, AM (corresponding author), Univ Porto, ICBAS, Largo Prof Abel Salazar N2, P-4099003 Oporto, Portugal.		Saraiva, Maria João/K-3907-2013; Gales, Luis/J-8716-2013; Quintanilha, Alexandre/L-5371-2013; Cardoso, Isabel/K-3903-2013	Saraiva, Maria João/0000-0002-3360-6899; Gales, Luis/0000-0002-8352-6539; Quintanilha, Alexandre/0000-0001-8544-0061; Cardoso, Isabel/0000-0003-2472-7055				ATLAND K, 1999, NEUROGENETICS, V2, P183; Bellacchio E, 2001, J SYNCHROTRON RADIAT, V8, P1056, DOI 10.1107/S0909049500017210; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; CAMBILLAU C, 1997, TURBO FRODO VERSION; Cardoso I, 2002, J MOL BIOL, V317, P683, DOI 10.1006/jmbi.2002.5441; DAMAS A, 1995, AMYLOID, V2, P173, DOI 10.3109/13506129509036922; Eneqvist T, 2000, MOL CELL, V6, P1207, DOI 10.1016/S1097-2765(00)00117-9; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Hammersley A. P., 1998, ESRF98HA01T; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Inouye H, 1998, AMYLOID, V5, P163, DOI 10.3109/13506129809003842; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kishikawa M, 2000, PEDIATR RES, V47, P492, DOI 10.1203/00006450-200004000-00013; Kishikawa M, 1999, AMYLOID, V6, P183, DOI 10.3109/13506129909007324; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCCUTCHEN SL, 1993, BIOCHEM BIOPH RES CO, V197, P415, DOI 10.1006/bbrc.1993.2495; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Redondo C, 2000, BIOCHEM J, V348, P167, DOI 10.1042/0264-6021:3480167; Rompel A, 1998, P NATL ACAD SCI USA, V95, P6122, DOI 10.1073/pnas.95.11.6122; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; Sarret G, 1999, J SYNCHROTRON RADIAT, V6, P670, DOI 10.1107/S0909049598014253; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; Serag AA, 2002, NAT STRUCT BIOL, V9, P734, DOI 10.1038/nsb838; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; Theberge R, 1999, ANAL CHEM, V71, P452, DOI 10.1021/ac980531u; THYLEN C, 1993, EMBO J, V12, P743, DOI 10.1002/j.1460-2075.1993.tb05708.x; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399	33	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11654	11660		10.1074/jbc.M210798200	http://dx.doi.org/10.1074/jbc.M210798200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538647	hybrid			2022-12-25	WOS:000181855400099
J	McHugh, D; Flemming, R; Xu, SZ; Perraud, AL; Beech, DJ				McHugh, D; Flemming, R; Xu, SZ; Perraud, AL; Beech, DJ			Critical intracellular Ca2+ dependence of transient receptor potential melastatin 2 (TRPM2) cation channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE; FAMILY; LTRPC2	TRPM2 is a member of the melastatin-related TRP (transient receptor potential) subfamily. It is expressed in brain and lymphocytes and forms a cation channel that is activated by intracellular ADP-ribose and associated with cell death. In this study we investigated the calcium dependence of human TRPM2 expressed under a tetracycline-dependent promoter in HEK-293 cells. TRPM2 expression was associated with enhanced hydrogen peroxide-evoked intracellular calcium signals. In whole-cell patch clamp recordings, switching from barium- to calcium-containing extracellular solution markedly activated TRPM2 as long as ADP-ribose was in the patch pipette and exogenous intracellular calcium buffering was minimal. We suggest this effect reveals a critical dependence of TRPM2 channel activity on intracellular calcium. In the absence of extracellular calcium we observed concentration-dependent activation of TRPM2 channels by calcium delivered from the patch pipette (EC50 340 nM, slope 4.9); the maximum effect was at least as large as that evoked by extracellular calcium. Intracellular dialysis of cells with high concentrations of EGTA or 1,2-bis(o-Aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) strongly reduced the amplitude of the extracellular calcium response, and the residual response was abolished by a mixture of high and low affinity calcium buffers. TRPM2 channel currents in inside-out patches showed a strong requirement for Ca2+ at the intracellular face of the membrane. We suggest that calcium entering via TRPM2 proteins acts at an intracellular calcium sensor closely associated with the channel, providing essential positive feedback for channel activation.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Leeds; National Jewish Health	Beech, DJ (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.		Xu, Shang-Zhong/P-2807-2015	Xu, Shang-Zhong/0000-0002-7295-9347; McHugh, Damian/0000-0001-9677-2934; Beech, David/0000-0002-7683-9422				BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; SMITH GA, 1983, P NATL ACAD SCI-BIOL, V80, P7178, DOI 10.1073/pnas.80.23.7178; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84	17	215	220	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11002	11006		10.1074/jbc.M210810200	http://dx.doi.org/10.1074/jbc.M210810200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529379	hybrid			2022-12-25	WOS:000181855400018
J	Jourdain, S; Acker, J; Ducrot, C; Sentenac, A; Lefebvre, O				Jourdain, S; Acker, J; Ducrot, C; Sentenac, A; Lefebvre, O			The tau 95 subunit of yeast TFIIIC influences upstream and downstream functions of TFIIIC-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; SACCHAROMYCES-CEREVISIAE; BINDING DOMAINS; GENE; PROTEIN; MUTATION; CLONING; RECRUITMENT; COMPONENTS	The yeast transcription factor IIIC (TFIIIC) is organized in two distinct multisubunit domains, tauA and tauB, that are respectively responsible for TFIIIB assembly and stable anchoring of TFIIIC on the B block of tRNA genes. Surprisingly, we found that the removal of tauA by mild proteolysis stabilizes the residual tauB(.)DNA complexes at high temperatures. Focusing on the well conserved tau95 subunit that belongs to the tauA domain, we found that the tau95-E447K mutation has long distance effects on the stability of TFIIIC-DNA complexes and start site selection. Mutant TFIIIC(.)DNA complexes presented a shift in their 5' border, generated slow-migrating TFIIIB(.)DNA complexes upon stripping TFIIIC by heparin or heat treatment, and allowed initiation at downstream sites. In addition, mutant TFIIIC(.)DNA complexes were highly unstable at high temperatures. Co-immunoprecipitation experiments indicated that tau95 participates in the interconnection of tauA with tauB via its contacts with tau138 and tau91 polypeptides. The results suggest that tau95 serves as a scaffold critical for tauA-DNA spatial configuration and tauB-DNA stability.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lefebvre, O (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 144, F-91191 Gif Sur Yvette, France.	Olivier.Lefebvre@Cea.Fr	LEFEBVRE, Olivier/C-3847-2014; Acker, Joël/F-5138-2010	LEFEBVRE, Olivier/0000-0002-3903-9450; Acker, Joël/0000-0002-0855-875X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arrebola R, 1998, MOL CELL BIOL, V18, P1; Aye M, 2001, MOL CELL BIOL, V21, P7839, DOI 10.1128/MCB.21.22.7839-7851.2001; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BRAUN BR, 1992, J BIOL CHEM, V267, P22562; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; CONESA C, 1993, J BIOL CHEM, V268, P18047; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; FABRIZIO P, 1987, P NATL ACAD SCI USA, V84, P8763, DOI 10.1073/pnas.84.24.8763; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Huang Y, 2000, J BIOL CHEM, V275, P31480, DOI 10.1074/jbc.M004635200; Huet J, 1996, METHOD ENZYMOL, V273, P249; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; Manaud N, 1998, MOL CELL BIOL, V18, P3191, DOI 10.1128/MCB.18.6.3191; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Maxam A M, 1980, Methods Enzymol, V65, P499; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2000, J BIOL CHEM, V275, P26591, DOI 10.1074/jbc.M003991200; Moir RD, 2002, MOL CELL BIOL, V22, P6131, DOI 10.1128/MCB.22.17.6131-6141.2002; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STILLMAN DJ, 1984, EMBO J, V3, P847, DOI 10.1002/j.1460-2075.1984.tb01895.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102	49	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10450	10457		10.1074/jbc.M213310200	http://dx.doi.org/10.1074/jbc.M213310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533520	hybrid			2022-12-25	WOS:000181777500062
J	Koteiche, HA; Mchaourab, HS				Koteiche, HA; Mchaourab, HS			Mechanism of chaperone function in small heat-shock proteins - Phosphorylation-induced activation of two-mode binding in alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; A-CRYSTALLIN; HUMAN HSP27; STRESS; LENS; OLIGOMERIZATION; EXPRESSION; STATE; ACCUMULATION; RESISTANCE	The consequences of alphaB-crystallin phosphorylation on its chaperone activity were investigated using a detailed analysis of the recognition and binding of destabilized T4 lysozyme (T4L) mutants by alphaB-crystallin phosphorylation mimics containing combinations of serine to aspartate substitutions. The T4L, site-directed mutants were selected to constitute an energetic ladder of progressively destabilized proteins having similar structures in the folded state. alphaB-crystallin and its variants differentially recognize the T4L mutants, binding the more destabilized ones to a larger extent. Furthermore, the aspartate substitutions result in an increase in the extent of binding to the same T4L, mutant and in the appearance of biphasic binding isotherms. The latter indicates the presence of two modes of binding characterized by different affinities and different numbers of binding sites. The transition to two-mode binding can also be induced by temperature or pH activation of the second mode. The similarity between the phosphorylation, pH, and temperature effects suggests a common structural origin. The location of the phosphorylation sites in the N-terminal domain and the hypothesized burial of this domain in the core of the oligomeric structure are consistent with a critical role for the destabilization of the quaternary structure in the process of recognition and binding by small heat-shock proteins.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 741 Light Hall, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu			NATIONAL EYE INSTITUTE [R01EY012683] Funding Source: NIH RePORTER; NEI NIH HHS [EYR0112683] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Benndorf R, 2000, METH MOL B, V99, P431; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Eaton P, 2001, J MOL CELL CARDIOL, V33, P1659, DOI 10.1006/jmcc.2001.1418; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Englander SW, 1998, TRENDS BIOCHEM SCI, V23, P378, DOI 10.1016/S0968-0004(98)01281-X; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Landry J, 1999, BIOCHEM SOC SYMP, P79; Llinas M, 1999, NAT STRUCT BIOL, V6, P1072; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; MAHAOURAB HS, 2002, J BIOL CHEM, V277, P40557; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; TARDIEU A, 1988, ANNU REV BIOPHYS BIO, V17, P47; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang KY, 2000, EXP EYE RES, V71, P385, DOI 10.1006/exer.2000.0890	46	102	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10361	10367		10.1074/jbc.M211851200	http://dx.doi.org/10.1074/jbc.M211851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529319	hybrid			2022-12-25	WOS:000181777500050
J	Lee, DH; Pfeifer, GP				Lee, DH; Pfeifer, GP			Deamination of 5-methylcytosines within cyclobutane pyrimidine dimers is an important component of UVB mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; DNA-POLYMERASE-ETA; SKIN-CANCER; P53 GENE; SEQUENCE SPECIFICITY; MUTATION HOTSPOTS; ESCHERICHIA-COLI; IRRADIATED DNA; INDUCED CC; SUNLIGHT	UVB mutagenesis is characterized by an abundance of C --> T and 5-methylcytosine --> T transitions at dipyrimidine sequences. It is not known how these mutations might arise. One hypothesis is that UV-induced mutations occur only after deamination of the cytosine or 5-methylcytosine within the pyrimidine dimer. It is not clear how methylation of cytosines at the 5-position influences deamination and how this affects mutagenesis. We have now conducted experiments with a CpG-methylated supF shuttle vector that was irradiated with UVB and then incubated at 37 degreesC to allow time for deamination before passage through a human cell line to establish mutations. This led to a significantly increased frequency of CC --> TT mutations and of transition mutations at 5'-PymCG-3' sequences. A spectrum of deaminated cis-syn cyclobutane pyrimidine dimers in the supF gene was determined using the mismatch glycosylase activities of MBD4 protein in combination with ligation-mediated PCR. Methylation at the C-5 position promoted the deamination of cytosines within cis-syn cyclobutane pyrimidine dimers, and these two events combined led to a significantly increased frequency of UVB-induced transition mutations at 5'-PymCG-3' sequences. Under these conditions, the majority of all supF mutations were transition mutations at 5'-PymCG-3', and they clustered at several mutational hot spots. Exactly these types of mutations are frequently observed in the p53 gene of nonmelanoma skin tumors. This particular mutagenic pathway may become prevalent under conditions of inefficient DNA repair and slow proliferation of cells in the human epidermis.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARAK Y, 1995, J BIOL CHEM, V270, P24174, DOI 10.1074/jbc.270.41.24174; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Burger A, 2003, MUTAT RES-FUND MOL M, V522, P145, DOI 10.1016/S0027-5107(02)00310-X; Canella KA, 2000, MUTAT RES-FUND MOL M, V450, P61, DOI 10.1016/S0027-5107(00)00016-6; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; GIBBS PEM, 1993, NUCLEIC ACIDS RES, V21, P4059, DOI 10.1093/nar/21.17.4059; Giglia G, 1998, CANCER RES, V58, P4402; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; JIANG N, 1993, BIOCHEMISTRY-US, V32, P472, DOI 10.1021/bi00053a011; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; LEMAIRE DGE, 1993, BIOCHEMISTRY-US, V32, P2525, DOI 10.1021/bi00061a009; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Maxam A M, 1980, Methods Enzymol, V65, P499; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Pfeifer GP, 2000, CURR TOP MICROBIOL, V249, P1; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sarasin A, 2002, EXP DERMATOL, V11, P44, DOI 10.1034/j.1600-0625.11.s.1.11.x; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; Tommasi S, 1997, CANCER RES, V57, P4727; TORMANEN VT, 1992, ONCOGENE, V7, P1729; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Wallin H, 2000, MUTAT RES-FUND MOL M, V447, P317, DOI 10.1016/S0027-5107(99)00214-6; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	50	80	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10314	10321		10.1074/jbc.M212696200	http://dx.doi.org/10.1074/jbc.M212696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525487	hybrid			2022-12-25	WOS:000181777500044
J	Raja, A; DeStefano, JJ				Raja, A; DeStefano, JJ			Interaction of HIV reverse transcriptase with structures mimicking recombination intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STRAND TRANSFER-REACTIONS; NUCLEOCAPSID PROTEIN; CLEAVAGE SPECIFICITY; INTERNAL REGIONS; MECHANISM; BINDING; MODEL; ENDONUCLEASE; POLYMERASE	Interactions between human immunodeficiency virus (HIV) reverse transcriptase (RT) and structures mimicking intermediates proposed to occur during recombination (strand transfer) were investigated. One mechanism proposed for strand transfer is strand exchange in which a homologous RNA (acceptor) "invades" a donor RNA-DNA duplex (replication intermediate) on which DNA synthesis is occurring. The acceptor displaces the donor of the duplex and binds to the DNA. During exchange a transient trimeric structure forms. A model structure was designed with a replication intermediate to which an acceptor RNA was bound. The acceptor was bound to the 5'-end of the DNA over a 54-base region, whereas the donor associated with the DNA 3'-end over a 28-base region. The dimeric constituents of the trimer (acceptor RNA-DNA and donor RNA-DNA) were also constructed. The acceptor RNA-DNA formed a branched structure in this case. Results showed that RT could cleave the RNA portion of all the structures examined. Association with junction substrates was less stable as determined by off-rates. On the trimer, RT cleaved both RNAs but showed a clear preference for cleaving the donor RNA region. This preference was accentuated by HIV nucleocapsid protein (NC). Results suggest that during recombination RT generally associates with the donor-RNA portion of the trimer and the acceptor RNA is protected but not immune from cleavage. The partial protection likely allows the acceptor RNA to more easily complete strand exchange and shield this RNA to provide a means to salvage replication if the DNA were to dissociate from the cleaved donor RNA.	Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	DeStefano, JJ (corresponding author), Univ Maryland, Dept Mol Genet & Cell Biol, Bldg 231, College Pk, MD 20742 USA.	jd146@umail.umd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051140, R29GM051140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51140, R01 GM051140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cristofaro JV, 2002, BIOCHEMISTRY-US, V41, P10968, DOI 10.1021/bi025871v; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Delviks KA, 1999, J VIROL, V73, P7923, DOI 10.1128/JVI.73.10.7923-7932.1999; DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1994, J MOL BIOL, V243, P558, DOI 10.1016/0022-2836(94)90030-2; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gorshkova II, 2001, ANAL BIOCHEM, V291, P198, DOI 10.1006/abio.2001.5053; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kensch O, 2000, J MOL BIOL, V301, P1029, DOI 10.1006/jmbi.2000.3998; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Sambrook J, 2001, MOL CLONING LAB MANU; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	27	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10102	10111		10.1074/jbc.M210201200	http://dx.doi.org/10.1074/jbc.M210201200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533519	hybrid			2022-12-25	WOS:000181777500017
J	Yaka, R; He, DY; Phamluong, K; Ron, D				Yaka, R; He, DY; Phamluong, K; Ron, D			Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; CULTURED HIPPOCAMPAL-NEURONS; SYNAPTIC TRANSMISSION; NMDA RECEPTORS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; CORTICAL-NEURONS; SIGNALING COMPLEX; CA1 REGION	We recently identified a novel mechanism for modulation of the phosphorylation state and function of the N-methyl-D-aspartate (NMDA) receptor via the scaffolding protein RACK1. We found that RACK1 binds both the NR2B subunit of the NMDA receptor and the nonreceptor protein-tyrosine kinase, Fyn. RACK1 inhibits Fyn phosphorylation of NR2B and decreases NMDA receptor-mediated currents in CA1 hippocampal slices (Yaka, R., Thornton, C., Vagts, A. J., Phamluong, K., Bonci, A., and Ron, D. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 5710-5715). Here, we identified the signaling cascade by which RACK1 is released from the NMDA receptor complex and identified the consequences of the dissociation. We found that activation of the cAMP/protein kinase A pathway in hippocampal slices induced the release of RACK1 from NR2B and Fyn. This resulted in the induction of NR2B phosphorylation and the enhancement of NMDA receptor-mediated activity via Fyn. We identified the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACAP(1-38)), as a ligand that induced phosphorylation of NR2B and enhanced NMDA receptor potentials. Finally, we found that activation of the cAMP/protein kinase A pathway induced the movement of RACK1 to the nuclear compartment in dissociated hippocampal neurons. Nuclear RACK1 in turn was found to regulate the expression of brain-derived neurotrophic factor induced by PACAP(1-38). Taken together our results suggest that activation of adenylate cyclase by PACAP(1-38) results in the release of RACK1 from the NMDA receptor and Fyn. This in turn leads to NMDA receptor phosphorylation, enhanced activity mediated by Fyn, and to the induction of brain-derived neurotrophic factor expression by RACK1.	Univ Calif San Francisco, Ernest Gallo Clin, Emeryville, CA 94608 USA; Univ Calif San Francisco, Res Ctr, Emeryville, CA 94608 USA; Univ Calif San Francisco, Dept Neurol, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ron, D (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	dorit@itsa.ucsf.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013438] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01AA/MH13438-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; BASILLE M, 1995, J NEUROCHEM, V65, P1318; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Gottschalk W, 1998, J NEUROSCI, V18, P6830; Hayes VY, 1997, MOL BRAIN RES, V45, P189, DOI 10.1016/S0169-328X(96)00254-9; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; Heidinger V, 2002, J NEUROSCI, V22, P5452; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1997, MOL PSYCHIATR, V2, P197, DOI 10.1038/sj.mp.4000245; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; Lai CC, 1997, BRAIN RES, V748, P189, DOI 10.1016/S0006-8993(96)01297-8; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LESSMANN V, 1994, NEUROREPORT, V6, P21; Levine ES, 2000, J NEUROSCI RES, V62, P357, DOI 10.1002/1097-4547(20001101)62:3<357::AID-JNR5>3.0.CO;2-6; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Li YX, 1998, J NEUROSCI, V18, P10231; Lin JW, 1998, J NEUROSCI, V18, P2017; Lin SY, 1998, MOL BRAIN RES, V55, P20, DOI 10.1016/S0169-328X(97)00349-5; Liu GJ, 1997, J NEUROPHYSIOL, V78, P2231, DOI 10.1152/jn.1997.78.4.2231; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nicoll RA, 1999, ANN NY ACAD SCI, V868, P515, DOI 10.1111/j.1749-6632.1999.tb11320.x; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; Pellegri G, 1998, EUR J NEUROSCI, V10, P272, DOI 10.1046/j.1460-9568.1998.00052.x; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Roberto M, 2001, LEARN MEMORY, V8, P265, DOI 10.1101/lm.40501; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ron D, 2000, FASEB J, V14, P2303, DOI 10.1096/fj.00-0143com; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Shioda S, 1997, NEUROSCI RES, V28, P345, DOI 10.1016/S0168-0102(97)00065-5; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; Suvarna NU, 2002, J PHARMACOL EXP THER, V302, P249, DOI 10.1124/jpet.302.1.249; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Telegdy G, 2000, BRAIN RES, V874, P194, DOI 10.1016/S0006-8993(00)02579-8; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 1998, ANN NY ACAD SCI, V865, P92, DOI 10.1111/j.1749-6632.1998.tb11167.x; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	59	144	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9630	9638		10.1074/jbc.M209141200	http://dx.doi.org/10.1074/jbc.M209141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524444	hybrid			2022-12-25	WOS:000181524000100
J	Ikeuchi, T; Sisodia, SS				Ikeuchi, T; Sisodia, SS			The notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent "gamma-secretase" cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; NUCLEAR ACCESS; APP; MUTATIONS; RECEPTOR; TRAFFICKING; DEFICIENCY; MEMBRANE	The evolutionary conserved Notch signaling pathway is involved in cell fate specification and mediated by molecular interactions between the Notch receptors and the Notch ligands, Delta, Serrate, and Jagged. In this report, we demonstrate that like Notch, Delta1 and Jagged2 are subject to presenilin (PS)-dependent, intramembranous "gamma-secretase" processing, resulting in the production of soluble intracellular derivatives. Moreover, and paralleling the observation that expression of familial Alzheimer's disease-linked mutant PSI compromises production of Notch S3/NICD, we show that the PS-dependent production of Delta1 cytoplasmic derivatives are also reduced in cells expressing mutant PS1. These studies led us to conclude that a similar molecular apparatus is responsible for intramembranous processing of Notch and it's ligands. To assess the potential role of the cytoplasmic derivative on nuclear transcriptional events, we expressed a Delta1-Gal4VP16 chimera and demonstrated marked transcriptional stimulation of a luciferase-based reporter. Our findings offer the proposal that Delta1 and Jagged2 play dual roles as activators of Notch receptor signaling and as receptors that mediate nuclear signaling events via gamma-secretase-generated cytoplasmic domains.	Univ Chicago, Ctr Mol Neurobiol, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Sisodia, SS (corresponding author), Univ Chicago, Ctr Mol Neurobiol, Dept Neurobiol Pharmacol & Physiol, Abbott 210,947 E 58th St, Chicago, IL 60637 USA.				NIA NIH HHS [AG021494] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GRACE GE, 1999, AM J PATHOL, V165, P785; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171	29	184	196	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7751	7754		10.1074/jbc.C200711200	http://dx.doi.org/10.1074/jbc.C200711200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12551931	hybrid			2022-12-25	WOS:000181466800003
J	Bao, XM; Thelen, JJ; Bonaventure, G; Ohlrogge, JB				Bao, XM; Thelen, JJ; Bonaventure, G; Ohlrogge, JB			Characterization of cyclopropane fatty-acid synthase from Sterculia foetida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-CHARACTERIZATION; MICROSOMAL PREPARATIONS; BIOSYNTHESIS; DESATURASE; PLANTS; DEHYDROGENASE; PURIFICATION; INHIBITION; LIPIDS; TISSUE	Cyclopropane synthase from Sterculia foetida developing seeds catalyzes the addition of a methylene group from S-adenosylmethionine to the cis double bond of oleic acid (Bao, X., Katz, S., Pollard, M., and Ohlrogge, J. (2002) Proc. NatL Aca& Sci. U. S. A. 99, 7172-7177). To understand this enzyme better, differential expression in leaf and seed tissues, protein properties, and substrate preferences of plant cyclopropane synthase were investigated. Immunoblot analysis with antibodies raised to recombinant S. foetida cyclopropane synthase (SfCPA-FAS) revealed that SfCPA-FAS is expressed in S. foetida seeds, but not in leaves, and is a membrane protein localized to microsomal fractions. Transformed tobacco cells expressing SfCPA-FAS were labeled in vivo with L-[methyl-C-14]methionine and assayed in vitro with S-adenosyl-L-[methyl-C-14]methionine. These kinetic experiments demonstrated that dihydrosterculate was synthesized from oleic acid esterified at the sn-1 position of phosphatidylcholine (PC). Furthermore, analysis of acyl chains at sn-1 and sn-2 positions that accumulated in PC from S. foetida developing seeds and from tobacco cells expressing SfCPA-FAS also demonstrated that greater than 90% of dihydrosterculate was esterified to the sn-1 position. Thus, we conclude that SfCPA-FAS is a microsomal localized membrane protein that catalyzes the addition of methylene groups derived from S-adenosyl-L-methionine across the double bond of oleic acid esterified to the sn-1 position of PC. A survey of plant and bacterial genomes for sequences related to SfCPA-FAS indicated that a peptide domain with a putative flavin-binding site is either fused to the methyltransferase domain of the plant protein or is often found encoded by a gene adjacent to a bacterial cyclopropane synthase gene.	Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University	Ohlrogge, JB (corresponding author), Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA.			Bonaventure, Gustavo/0000-0001-6120-3897; Thelen, Jay/0000-0001-5995-1562				BAFOR M, 1991, BIOCHEM J, V280, P507, DOI 10.1042/bj2800507; Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAO JM, 1993, BIOCHIM BIOPHYS ACTA, V1210, P27, DOI 10.1016/0005-2760(93)90045-B; Chapman KD, 2001, J AM OIL CHEM SOC, V78, P941, DOI 10.1007/s11746-001-0368-y; CHRISTIE W. W., 1970, Topics in Lipid Chemistry, V1, P1; Christie WW, 1982, LIPID ANAL, P155; CHUNG AE, 1964, BIOCHEMISTRY-US, V3, P967, DOI 10.1021/bi00895a021; CRAVEN B, 1960, J AM CHEM SOC, V82, P3858, DOI 10.1021/ja01500a017; ELHUSSEIN SA, 1988, BIOCHEM J, V252, P39, DOI 10.1042/bj2520039; FOGERTY AC, 1972, LIPIDS, V7, P335, DOI 10.1007/BF02532651; GAYDOU EM, 1993, J AGR FOOD CHEM, V41, P886, DOI 10.1021/jf00030a009; Grogan DW, 1997, MICROBIOL MOL BIOL R, V61, P429, DOI 10.1128/.61.4.429-441.1997; HAYES MK, 1991, PLANT PHYSIOL, V97, P1381, DOI 10.1104/pp.97.4.1381; HILDEBRAND JG, 1964, BIOCHEMISTRY-US, V3, P1304, DOI 10.1021/bi00897a020; Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200; JIE MSF, 1977, J CHEM SOC CHEM COMM, V1264, P78; KLEIMAN R, 1969, LIPIDS, V4, P317, DOI 10.1007/BF02530999; LAW JH, 1963, BIOCHIM BIOPHYS ACTA, V70, P143, DOI 10.1016/0926-6542(63)90023-4; LI RX, 1993, TETRAHEDRON LETT, V34, P1279, DOI 10.1016/S0040-4039(00)91774-X; MARINARI LA, 1978, BIOCHEMISTRY-US, V13, P1978; MEYER H, 1966, J BIOL CHEM, V241, P5000; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; OHLROGGE JB, 1976, BIOCHIM BIOPHYS ACTA, V431, P257, DOI 10.1016/0005-2760(76)90146-6; Page AM, 1997, COMP BIOCHEM PHYS B, V118, P79, DOI 10.1016/S0305-0491(97)00027-8; PASHA MK, 1992, J AGR FOOD CHEM, V40, P626, DOI 10.1021/jf00016a020; PHELPS RA, 1965, POULTRY SCI, V44, P358, DOI 10.3382/ps.0440358; RALAIMANARIVO A, 1982, LIPIDS, V17, P1, DOI 10.1007/BF02535115; ROTHFIELD L, 1966, J BIOL CHEM, V241, P1386; SCHMID KM, 1988, PHYTOCHEMISTRY, V27, P2831, DOI 10.1016/0031-9422(88)80672-1; SCHMID KM, 1988, LIPIDS, V23, P248, DOI 10.1007/BF02535466; SERGHINICAID H, 1988, PLANT SCI, V54, P93, DOI 10.1016/0168-9452(88)90086-6; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; STYMNE S, 1986, BIOCHEM J, V240, P385, DOI 10.1042/bj2400385; TAYLOR FR, 1979, BIOCHEMISTRY-US, V18, P3292, DOI 10.1021/bi00582a015; Thelen JJ, 2001, PLANT PHYSIOL, V125, P2016, DOI 10.1104/pp.125.4.2016; Thelen JJ, 1999, PLANT PHYSIOL, V119, P635, DOI 10.1104/pp.119.2.635; THOMAS PJ, 1966, J BIOL CHEM, V241, P5013; WANG AY, 1992, BIOCHEMISTRY-US, V31, P11020, DOI 10.1021/bi00160a011; YANO I, 1972, LIPIDS, V7, P30, DOI 10.1007/BF02531266; ZALKIN H, 1963, J BIOL CHEM, V238, P1242	42	42	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12846	12853		10.1074/jbc.M212464200	http://dx.doi.org/10.1074/jbc.M212464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562759	hybrid			2022-12-25	WOS:000182189500034
J	Anantharam, A; Lewis, A; Panaghie, G; Gordon, E; McCrossan, ZA; Lerner, DJ; Abbott, GW				Anantharam, A; Lewis, A; Panaghie, G; Gordon, E; McCrossan, ZA; Lerner, DJ; Abbott, GW			RNA interference reveals that endogenous Xenopus MinK-related peptides govern mammalian K+ channel function in oocyte expression studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; CARDIAC POTASSIUM CURRENT; I-KR; MOLECULAR-BASIS; HERG MUTATIONS; LANGE-NIELSEN; BETA-SUBUNIT; ISK MINK; GENE; KCNQ1	The physiological properties of most ion channels are defined experimentally by functional expression of their pore-forming alpha subunits in Xenopus laevis oocytes. Here, we cloned a family of Xenopus KCNE genes that encode MinK-related peptide K+ channel beta subunits (xMiRPs) and demonstrated their constitutive expression in oocytes. Electrophysiological analysis of xMiRP2 revealed that when overexpressed this gene modulates human cardiac K+ channel a subunits HERG (human ether-ago-go-related gene) and KCNQ1 by suppressing HERG currents and removing the voltage dependence of KCNQ1 activation. The ability of endogenous levels of xMiRP2 to contribute to the biophysical attributes of overexpressed mammalian K+ channels in oocyte studies was assessed next. Injection of an xMiRP2 sequence-specific short interfering RNA (siRNA) oligo reduced endogenous xMiRP2 expression 5-fold, whereas a control siRNA oligo had no effect, indicating the effectiveness of the RNA interference technique in Xenopus oocytes. The functional effects of endogenous xMiRP2 silencing were tested using electrophysiological analysis of heterologously expressed HERG channels. The RNA interference-mediated reduction of endogenous xMiRP2 expression increased macroscopic HERG current as much as 10-fold depending on HERG cRNA concentration. The functional effects of human MiRP1 (hMiRP1)/HERG interaction were also affected by endogenous xMiRP2. At high HERG channel density, at which the effects of endogenous xMiRP2 are minimal, hMiRP1 reduced HERG current. At low HERG current density, hMiRPI paradoxically up-regulated HERG current, a result consistent with hMiRP1 rescuing HERG from suppression by endogenous xMiRP2. Thus, endogenous Xenopus MiRP subunits contribute to the baseline properties of K+ channels like HERG in oocyte expression studies, which could explain expression level- and expression system-dependent variation in K+ channel function.	Cornell Univ, Weill Med Coll, Grad Program Pharmacol, New York, NY 10021 USA; Cornell Univ, Div Cardiol, Dept Med, New York, NY 10021 USA; Cornell Univ, Div Cardiol, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Grad Program Neurosci, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University; Cornell University	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Grad Program Pharmacol, 520 E 70th St,Starr 463, New York, NY 10021 USA.			Abbott, Geoffrey/0000-0003-4552-496X				Abbott GW, 2002, FASEB J, V16, DOI 10.1096/fj.01-0520hyp; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CIRC RES, V88, P981, DOI 10.1161/hh1001.091869; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Angelo K, 2002, BIOPHYS J, V83, P1997, DOI 10.1016/S0006-3495(02)73961-1; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Chen J, 2002, P NATL ACAD SCI USA, V99, P12461, DOI 10.1073/pnas.192367299; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Finley MR, 2002, AM J PHYSIOL-HEART C, V283, pH126, DOI 10.1152/ajpheart.00622.2001; Grunnet M, 2002, J PHYSIOL-LONDON, V542, P119, DOI 10.1113/jphysiol.2002.017301; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Mazhari R, 2001, CIRC RES, V89, P33, DOI 10.1161/hh1301.093633; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Ohyama H, 2001, PFLUG ARCH EUR J PHY, V442, P329, DOI 10.1007/s004240100547; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Seebohm G, 2001, PFLUG ARCH EUR J PHY, V442, P891; Sesti F, 2000, BIOPHYS J, V79, P1369, DOI 10.1016/S0006-3495(00)76389-2; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1997, NEW ENGL J MED, V336, P1562, DOI 10.1056/NEJM199705293362204; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Weber WM, 1999, BBA-BIOMEMBRANES, V1421, P213, DOI 10.1016/S0005-2736(99)00135-2; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; Weber WM, 1995, J MEMBRANE BIOL, V148, P263; Weerapura M, 2002, J PHYSIOL-LONDON, V540, P15, DOI 10.1113/jphysiol.2001.013296; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	44	57	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11739	11745		10.1074/jbc.M212751200	http://dx.doi.org/10.1074/jbc.M212751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529362	hybrid			2022-12-25	WOS:000182015700004
J	Banbury, AN; Oakley, JD; Sessions, RB; Banting, G				Banbury, AN; Oakley, JD; Sessions, RB; Banting, G			Tyrphostin A23 inhibits internalization of the transferrin receptor by perturbing the interaction between tyrosine motifs and the medium chain subunit of the AP-2 adaptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CYTOPLASMIC DOMAIN; CELL-PROLIFERATION; KINASE INHIBITORS; CYTOSOLIC DOMAIN; SORTING SIGNALS; MU-2 SUBUNIT; CLATHRIN; TGN38; ENDOCYTOSIS	Several intracellular membrane trafficking events are mediated by tyrosine-containing motifs within the cytosolic domains of integral membrane proteins. Many such motifs conform to the consensus YXXPhi, where Phi represents a bulky hydrophobic residue. This motif interacts with the medium chain (mu) subunits of adaptor complexes that link the cytosolic domains of integral membrane proteins to the clathrin coat involved in vesicle formation. The YXXPhi motif is similar to motifs in which the tyrosine residue is phosphorylated by tyrosine kinases. Tyrphostins (structural analogs of tyrosine) are inhibitors of tyrosine kinases and function by binding to the active sites of the enzymes. We previously showed that, in vitro and in yeast two-hybrid interaction assays, some tyrphostins can inhibit the interaction between YXXPhi motifs and the mu2 subunit of the AP-2 adaptor complex (Crump, C., Williams, J. L., Stephens, D. J., and Banting, G. (1998) J. Biol. Chem. 273, 2807328077). A23 is such a tyrphostin. We now show that molecular modeling of tyrphostin A23 into the tyrosine-binding pocket in mu2 provides a structural explanation for A23 being able to inhibit the interaction between YXXPhi motifs and mu2. Furthermore, we show that A23 inhibited the internalization of I-125-transferrin in Heb7a cells without having any discernible effect on the morphology of compartments of the endocytic pathway. Control tyrphostins, active as inhibitors of tyrosine kinase activity, but incapable of inhibiting the YXXPhi motif/mu2 interaction, did not inhibit endocytosis. These data are consistent with A23 inhibition of the YXXPhi motif/mu2 interaction in intact cells and with the possibility that different tyrphostins may be used to inhibit specific membrane trafficking events in eukaryotic cells.	Univ Bristol, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England	University of Bristol	Banting, G (corresponding author), Univ Bristol, Dept Biochem, Sch Med Sci, Univ Walk, Bristol BS8 1TD, Avon, England.			Sessions, Richard/0000-0003-0320-0895; Banting, George/0000-0001-8249-1621				Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chuang E, 1997, J IMMUNOL, V159, P144; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Crump CM, 1998, J BIOL CHEM, V273, P28073, DOI 10.1074/jbc.273.43.28073; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; LYALL RM, 1989, J BIOL CHEM, V264, P14503; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; McGraw T. E., 1999, CURRENT PROTOCOLS CE; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Stephens DJ, 1997, FEBS LETT, V416, P27, DOI 10.1016/S0014-5793(97)01165-4; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WALKER J, 1995, J CELL SCI, V108, P2433; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L; WILDE A, 1994, J BIOL CHEM, V269, P7131; WONG SH, 1993, J BIOL CHEM, V268, P22853; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	103	106	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12022	12028		10.1074/jbc.M211966200	http://dx.doi.org/10.1074/jbc.M211966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556528	hybrid			2022-12-25	WOS:000182015700041
J	Dearth, LR; DeWille, J				Dearth, LR; DeWille, J			Posttranscriptional and posttranslational regulation of C/EBP delta in G(0) growth-arrested mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; DEPENDENT KINASE INHIBITOR; BINDING-PROTEIN-EPSILON; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; MAMMALIAN-CELLS; MEDIATED DEGRADATION; GROWING CELLS; EXPRESSION; BETA	Previous work from our laboratory demonstrated that CCAAT/enhancer-binding protein delta (C/EBPdelta) functions in the initiation and maintenance of G(0) growth arrest in mouse mammary epithelial cells (MECs). In this report, we investigated the posttranscriptional and posttranslational regulation of C/EBPdelta in G(0) growth-arrested mouse MECs. The results of transcriptional inhibitor studies demonstrated that the C/EBPdelta mRNA exhibits a relatively short half-life in G(0) growth-arrested mouse MECs (t(1/2) similar to35 min). In contrast, C/EBPdelta mRNA has a longer half-life in G(0) growth-arrested mouse fibroblast cells (t(1/2) > 100 min). Oligo/RNase H cleavage analysis and rapid amplification of cDNA ends-poly(A) test both confirmed the short C/EBPdelta mRNA half-life observed in MECs and demonstrated that the C/EBPdelta mRNA poly(A) tail is relatively short (similar to100 nucleotides). In addition, the poly(A) tail length was not shortened during C/EBPdelta mRNA degradation, which suggested a deadenylation-independent pathway. The C/EBPdelta protein also exhibited a relatively short half-life in Go growth-arrested mouse MECs (t(1/2) similar to120 min). The C/EBPbeta protein was degraded in a ubiquitin-dependent manner, primarily in the nucleus, during G(0) growth arrest. In conclusion, these studies indicated that the C/EBPdelta mRNA and protein content are under tight regulation in G(0) growth-arrested mouse MECs, despite the general concept that G(0) growth arrest is associated with a decrease in cellular activity.	Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Ohio State University; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	DeWille, J (corresponding author), Ohio State Univ, Dept Vet Biosci, 1900 Coffey Rd, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [P30CA016058, R43CA057067, R44CA057067] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058, CA57067] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BAER MR, 1992, BLOOD, V79, P1319; Bosse F, 1999, J NEUROSCI RES, V55, P164, DOI 10.1002/(SICI)1097-4547(19990115)55:2<164::AID-JNR4>3.0.CO;2-9; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chuang LC, 2001, J BIOL CHEM, V276, P1610, DOI 10.1074/jbc.M008896200; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Dearth LR, 2001, J CELL BIOCHEM, V82, P357, DOI 10.1002/jcb.1167; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Dennis AP, 2001, FRONT BIOSCI, V6, pD954, DOI 10.2741/Dennis; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; Evdokiou A, 1998, EXP CELL RES, V240, P359, DOI 10.1006/excr.1998.4011; FERRERO M, 1994, J CELL PHYSIOL, V158, P263, DOI 10.1002/jcp.1041580208; Ferrini JB, 2001, J HEPATOL, V35, P170, DOI 10.1016/S0168-8278(01)00112-X; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Gigliotti AP, 1999, BREAST CANCER RES TR, V58, P57, DOI 10.1023/A:1006381906288; Gonos ES, 1998, ANN NY ACAD SCI, V851, P466, DOI 10.1111/j.1749-6632.1998.tb09024.x; Gu HD, 1999, P NATL ACAD SCI USA, V96, P8943, DOI 10.1073/pnas.96.16.8943; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; JACKMAN J, 1994, CANCER RES, V54, P5656; JOHNSON LF, 1975, CELL, V4, P69, DOI 10.1016/0092-8674(75)90135-X; JOHNSON LF, 1976, J CELL BIOL, V71, P933, DOI 10.1083/jcb.71.3.933; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; O'Rourke JP, 1999, BIOCHEM BIOPH RES CO, V262, P696, DOI 10.1006/bbrc.1999.1256; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; Touriol C, 1999, J BIOL CHEM, V274, P21402, DOI 10.1074/jbc.274.30.21402; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	76	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11246	11255		10.1074/jbc.M207930200	http://dx.doi.org/10.1074/jbc.M207930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12554732	hybrid			2022-12-25	WOS:000181855400051
J	Huo, HR; Guo, XM; Hong, SY; Jiang, MR; Liu, XY; Liao, K				Huo, HR; Guo, XM; Hong, SY; Jiang, MR; Liu, XY; Liao, K			Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-I RECEPTOR; TYROSINE PHOSPHORYLATION; CAVEOLAE MEMBRANE; ADIPOCYTE DIFFERENTIATION; CHOLESTEROL DEPLETION; GLUT4 TRANSLOCATION; PLASMA-MEMBRANE; MDCK CELLS; C-CRK	Lipid rafts/caveolae are found to be essential for insulin-like growth factor (IGF)-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. In 3T3-L1 cells, IGF-1 receptor is located in lipid rafts/caveolae of the plasma membrane and can directly interact with caveolin-1, the major protein component in caveolae. Disruption of lipid rafts/caveolae by depleting cellular cholesterol with cholesterol-binding reagent, beta-methylcyclodextrin or filipin, blocks the IGF-1 receptor signaling in 3T3-L1 preadipocyte. Both hormonal induced adipocyte differentiation and mitotic clonal expansion are inhibited by lipid rafts/caveolae disruption. However, a nonspecific lipid binding reagent, xylazine, does not affect adipocyte differentiation or mitotic clonal expansion. Further studies indicate that lipid rafts/caveolae are required only for IGF-1 receptor downstream signaling and not the activation of receptor itself by ligand. Thus, our results suggest that localization in lipid rafts/caveolae and association with caveolin enable IGF-1 receptor to have a close contact with downstream signal molecules recruited into lipid rafts/caveolae and transmit the signal through these signal molecule complexes.	Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Chinese Acad Sci, State Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Liao, K (corresponding author), Shanghai Inst Biochem & Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	kliao@sibs.ac.cn	Jiang, Manrong/E-6991-2011; Huo, Hairong/B-7700-2011					Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Czech MP, 2000, NATURE, V407, P147, DOI 10.1038/35025183; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hailstones D, 1998, J LIPID RES, V39, P369; Jin SH, 2000, J BIOL CHEM, V275, P34344, DOI 10.1074/jbc.M004927200; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Koval AP, 1998, BIOCHEM J, V330, P923; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LIAO K, 1995, J BIOL CHEM, V270, P12123, DOI 10.1074/jbc.270.20.12123; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Maggi D, 2002, BIOCHEM BIOPH RES CO, V295, P1085, DOI 10.1016/S0006-291X(02)00809-4; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Modan-Moses D, 1998, BIOCHEM J, V333, P825, DOI 10.1042/bj3330825; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tibayan FA, 2002, FASEB J, V16, pA1127; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	56	109	109	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11561	11569		10.1074/jbc.M211785200	http://dx.doi.org/10.1074/jbc.M211785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538586	hybrid			2022-12-25	WOS:000181855400089
J	Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Kobayashi, R				Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Kobayashi, R			A single amino acid difference between alpha and beta Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; REGULATORY MECHANISM; CATALYTIC SUBUNIT; CALMODULIN; CASCADE; IV; ACTIVATION; EXPRESSION; CALCIUM; CREB	We recently developed STO-609, a selective inhibitor of Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), and we demonstrated that CaM-KKbeta is more sensitive to STO-609 than the CaM-KKalpha isoform (Tokumitsu H., Inuzuka H., Ishikawa Y., Ikeda M., Saji I., and Kobayashi R. (2002) J. Biol. Chem. 277,15813-15818). By using catalytic chimera and point mutants of both isoforms, we demonstrated that Val(269) in CaM-KKbeta/Leu(233) in CaM-KKalpha confers a distinct sensitivity (similar to10fold) to STO-609 on CaM-KK isoforms. Various mutations of Val(269) in CaM-KKbeta indicate that substitution by hydrophobic residues with bulky side chains significantly decreases drug sensitivity and that the V269F mutant is the most effective drug-resistant enzyme (similar to80-fold higher IC50 value). These findings are consistent with a result obtained with a full-length mutant expressed in COS-7 cells. Furthermore, suppression of CaM-KK-mediated CaM-KIV activation in transfected HeLa cells by STO-609 treatment was completely abolished by the co-expression of the CaM-KKbeta V269F mutant. Based on the results that the distinct sensitivity of CaM-KK isoforms to STO-609 is because of a single amino acid substitution (Val/Leu) in the ATP-binding pocket, we have generated an STO-609-resistant CaM-KK mutant, which might be useful for validating the pharmacological effects and specificity of STO-609 in vivo.	Kagawa Med Univ, Dept Signal Transduct Sci, Kagawa 7610793, Japan	Kagawa University	Tokumitsu, H (corresponding author), Kagawa Med Univ, Dept Signal Transduct Sci, 1750-1 Miki Cho, Kagawa 7610793, Japan.	tokumit@kms.ac.jp	Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kostich M, 2002, GENOME BIOL, V3; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Wu JY, 2000, ENDOCRINOLOGY, V141, P4777, DOI 10.1210/en.141.12.4777; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153	35	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10908	10913		10.1074/jbc.M213183200	http://dx.doi.org/10.1074/jbc.M213183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540834	hybrid			2022-12-25	WOS:000181855400006
J	Castrillo, A; Joseph, SB; Marathe, C; Mangelsdorf, DJ; Tontonoz, P				Castrillo, A; Joseph, SB; Marathe, C; Mangelsdorf, DJ; Tontonoz, P			Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE INHIBITION; MUSCLE-CELL-MIGRATION; FACTOR-KAPPA-B; GENE-EXPRESSION; GELATINASE-B; CHOLESTEROL EFFLUX; LIPID-METABOLISM; DEFICIENT MICE; FOAM CELLS; GAMMA	Matrix metalloproteinases (MMPs) are zinc endopeptidases that degrade extracellular matrix (ECM) components during normal and pathogenic tissue remodeling. Inappropriate expression of these enzymes contributes to the development of vascular pathology, including atherosclerosis. MMP-9 is expressed in its active form in atherosclerotic lesions and is believed to play an important role in vascular remodeling, smooth muscle cell migration, and plaque instability. We demonstrate here that the liver X receptors (LXRs) LXRalpha and LXRbeta inhibit basal and cytokine-inducible expression of MMP-9. Treatment of murine peritoneal macrophages with the synthetic LXR agonists GW3965 or T1317 reduces MMP-9 mRNA expression and blunts its induction by pro-inflammatory stimuli including lipopolysaccharide, interleukin-1beta, and tumor necrosis factor a. In contrast, macrophage expression of MMP-12 and MMP-13 is not altered by LXR ligands. We further show that the ability of LXR ligands to regulate MMP-9 expression is strictly receptor-dependent and is not observed in macrophages obtained from LXRalphabeta null mice. Analysis of the 5'-flanking region of the MMP-9 gene indicates that LXR/RXR heterodimers do not bind directly to the MMP-9 promoter. Rather, activation of LXRs represses MMP-9 expression, at least in part through antagonism of the NFkappaB signaling pathway. These observations identify the regulation of macrophage MMP-9 expression as a mechanism whereby activation of LXRs may impact macrophage inflammatory responses.	Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Box 951662, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu		Joseph, Sean/0000-0002-2602-8517; Mangelsdorf, David/0000-0002-4355-0796				Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Dubois B, 2002, EUR J IMMUNOL, V32, P2163, DOI 10.1002/1521-4141(200208)32:8<2163::AID-IMMU2163>3.0.CO;2-Q; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Jeng AY, 1999, ANN NY ACAD SCI, V878, P555, DOI 10.1111/j.1749-6632.1999.tb07725.x; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; LAFFITTE BA, 2003, IN PRESS MOL CELL BI; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LIBBY P, 1995, ANN NY ACAD SCI, V748, P158; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mason DP, 1999, CIRC RES, V85, P1179; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Prescott MF, 1999, ANN NY ACAD SCI, V878, P179, DOI 10.1111/j.1749-6632.1999.tb07683.x; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; SATO H, 1993, J BIOL CHEM, V268, P23460; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schuster GU, 2002, CIRCULATION, V106, P1147, DOI 10.1161/01.CIR.0000026802.79202.96; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Woessner JF, 1999, ANN NY ACAD SCI, V878, P388, DOI 10.1111/j.1749-6632.1999.tb07697.x	47	258	275	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10443	10449		10.1074/jbc.M213071200	http://dx.doi.org/10.1074/jbc.M213071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531895	hybrid			2022-12-25	WOS:000181777500061
J	Hooks, SB; Waldo, GL; Corbitt, J; Bodor, ET; Krumins, AM; Harden, TK				Hooks, SB; Waldo, GL; Corbitt, J; Bodor, ET; Krumins, AM; Harden, TK			RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of G(i) family G-proteins with differential selectivity and maximal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; COUPLED RECEPTORS; BINDING PROTEIN; NERVOUS-SYSTEM; SIGNALING RGS; REGULATORS; SUBUNIT; DOMAIN; SPECIFICITY; INHIBITION	Regulator of G-protein signaling (RGS) proteins are GTPase activating proteins (GAPs) of heterotrimeric G-proteins that alter the amplitude and kinetics of receptor-promoted signaling. In this study we defined the G-protein alpha-subunit selectivity of purified Sf9 cell-derived R7 proteins, a subfamily of RGS proteins (RGS6,-7, -9, and -11) containing a Ggamma-like (GGL) domain that mediates dimeric interaction with Gbeta(5). Gbeta(5)/R7 dimers stimulated steady state GTPase activity of Galpha-subunits of the G(i) family, but not of Galpha(q) or Galpha(11), when added to proteoliposomes containing M2 or M1 muscarinic receptor-coupled G-protein heterotrimers. Concentration effect curves of the Gbeta(5)/R7 proteins revealed differences in potencies and efficacies toward Galpha-subunits of the G(i) family. Although all four Gbeta(5)/R7 proteins exhibited similar potencies toward Galpha(o), Gbeta(5)/RGS9 and Gbeta(5)/RGS11 were more potent GAPs of Galpha(i1), Galpha(i2), and Galpha(i3), than were Gbeta(5)/RGS6 and Gbeta(5)/RGS7. The maximal GAP activity exhibited by Gbeta(5)/RGS11 was 2- to 4-fold higher than that of Gbeta(5)/RGS7 and Gbeta(5)/RGS9, with Gbeta(5)/RGS6 exhibiting an intermediate maximal GAP activity. Moreover, the less efficacious Gbeta(5)/RGS7 and Gbeta(5)/RGS9 inhibited Gbeta(5)/RGS11-stimulated GTPase activity of Galpha(o). Therefore, R7 family RGS proteins are G(i) family-selective GAPs with potentially important differences in activities.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hooks, SB (corresponding author), Univ N Carolina, Dept Pharmacol, Campus Box 7365, Chapel Hill, NC 27599 USA.	shelleyb@med.unc.edu		Hooks, Shelley/0000-0003-4702-0490	NIGMS NIH HHS [GM66561, GM65533, GM34497, GM29536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R37GM034497, F32GM066561, P01GM065533, R01GM029536, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Capuano B, 2002, CURR MED CHEM, V9, P521, DOI 10.2174/0929867024606939; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Chidiac P, 1999, BIOCHEM PHARMACOL, V58, P39, DOI 10.1016/S0006-2952(99)00080-5; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gold SJ, 1997, J NEUROSCI, V17, P8024; Gurrath M, 2001, CURR MED CHEM, V8, P1605, DOI 10.2174/0929867013371798; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Ingi T, 1998, J NEUROSCI, V18, P7178; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LIU YF, 1994, J BIOL CHEM, V269, P13880; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2002, J BIOL CHEM, V277, P32843, DOI 10.1074/jbc.M205170200; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; OHara CM, 1996, J PHARMACOL EXP THER, V278, P354; PARKER EM, 1991, J BIOL CHEM, V266, P519; Patikoglou GA, 2002, J BIOL CHEM, V277, P47004, DOI 10.1074/jbc.M208186200; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SADEE W, 2002, AAPS PHARMSCI, V3, pE22; Sautel M, 2000, CURR MED CHEM, V7, P889, DOI 10.2174/0929867003374570; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Sierra DA, 2000, TRENDS CARDIOVAS MED, V10, P263, DOI 10.1016/S1050-1738(00)00072-4; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watts VJ, 1998, J NEUROSCI, V18, P8692; Weiner DM, 2001, J PHARMACOL EXP THER, V299, P268; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	50	121	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10087	10093		10.1074/jbc.M211382200	http://dx.doi.org/10.1074/jbc.M211382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531899	hybrid, Green Published			2022-12-25	WOS:000181777500015
J	Chen, Z; Singer, WD; Wells, CD; Sprang, SR; Sternweis, PC				Chen, Z; Singer, WD; Wells, CD; Sprang, SR; Sternweis, PC			Mapping the G alpha(13) binding interface of the rgRGS domain of p115RhoGEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; P115 RHOGEF; ALPHA-SUBUNITS; TRANSITION-STATE; RGS PROTEINS; HYDROLYSIS; MECHANISMS; REGULATOR	Structural requirements for function of the (R) under bar ho (G) under bar EF (guanine nucleotide exchange factor) (r) under bar egulator of (G) under bar protein signaling (rgRGS) domains of p115RhoGEF and homologous exchange factors differ from those of the classical RGS domains. An extensive mutagenesis analysis of the p115RhoGEF rgRGS domain was undertaken to determine its functional interface with the Galpha(13) subunit. Results indicate that there is global resemblance between the interaction surface of the rgRGS domain with Galpha(13) and the interactions of RGS4 and RGS9 with their Galpha substrates. However, there are distinct differences in the distribution of functionally critical residues between these structurally similar surfaces and an additional essential requirement for a cluster of negatively charged residues at the N terminus of rgRGS. Lack of sequence conservation within the N terminus may also explain the lack of GTPase-activating protein (GAP) activity in a subset of the rgRGS domains. For all mutations, loss of functional GAP activity is paralleled by decreases in binding to Galpha(13). The same mutations, when placed in the context of the p115RhoGEF molecule, produce deficiencies in GAP activity as observed with the rgRGS domain alone but show no attenuation of the regulation of Rho exchange activity by Galpha(13). This suggests that the rgRGS domain may serve a structural or allosteric role in the regulation of the nucleotide exchange activity of p115RhoGEF on Rho by Galpha(13.)	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Chen, Zhe/0000-0002-1668-4051	NIDDK NIH HHS [R01 DK046371, DK46371] Funding Source: Medline; NIGMS NIH HHS [GM31954, GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046371, R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM031954] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; Coleman DE, 1999, J BIOL CHEM, V274, P16669, DOI 10.1074/jbc.274.24.16669; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wells C, 2002, METHOD ENZYMOL, V345, P371; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Wieland T, 2000, J BIOL CHEM, V275, P28500, DOI 10.1074/jbc.M004187200; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	32	35	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9912	9919		10.1074/jbc.M212695200	http://dx.doi.org/10.1074/jbc.M212695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12525488	hybrid			2022-12-25	WOS:000181524000138
J	Goel, MS; Diamond, SL				Goel, MS; Diamond, SL			Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XI ACTIVATION; GLYCOPROTEIN IB-ALPHA; BLOOD-COAGULATION; TISSUE FACTOR; P-SELECTIN; PROCOAGULANT ACTIVITY; THROMBIN GENERATION; RECEPTOR; COLLAGEN; BINDING	Human neutrophil proteases cathepsin G and elastase can directly alter platelet function and/or participate in coagulation cascade reactions on the platelet or neutrophil surface to enhance fibrin formation. The clotting of recalcified platelet-free plasma (PFP) or platelet-rich plasma (PRP) supplemented with corn trypsin inhibitor (to shut down contact activation) was studied in well-plates or flow assays. Inhibitors of cathepsin G or elastase significantly delayed the burst time 450) of thrombin generation in neutrophil-supplemented PRP from 49 min to 59 and 77 min, respectively, in well-plate assays as well as reduced neutrophil-promoted fibrin deposition on fibrinogen-adherent platelets under flow conditions. In flow assays, purified cathepsin G was a far more potent activator of platelet-dependent coagulation than elastase. Anti-tissue factor had no effect on neutrophil protease-enhanced thrombin formation in PRP. The addition of cathepsin G (425 nM) or convulxin (10 nM) to PRP dramatically reduced the t(50) of thrombin generation from 53 min to 17 or 23 min, respectively. In contrast, the addition of elastase to PRP left the t50 unaltered. Whereas perfusion of PFP (gamma(w) = 62.5 s(-1)) over fibrinogen-adherent platelets did not result in fibrin formation until 50 min, massive fibrin could be observed on cathepsin G-treated platelets even at 35 min. Cathepsin G addition to corn trypsin inhibitor-treated PFP produced little thrombin unless anionic phospholipid was present. However, further activation inhibition studies indicated that cathepsin G enhances fibrin deposition under flow conditions by elevating the activation state of fibrinogen-adherent platelets rather than by cleaving coagulation factors.	Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Diamond, SL (corresponding author), Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, 3340 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007954, R01HL056621] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 56621, T32 HL 07954-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DH, 1995, J BIOL CHEM, V270, P1408, DOI 10.1074/jbc.270.3.1408; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; Briede JJ, 2001, THROMB HAEMOSTASIS, V85, P509, DOI 10.1055/s-0037-1615613; Bunescu A, 2002, CLIN SCI, V102, P279, DOI 10.1042/CS20010118; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; CHIGNARD M, 1994, BBA-MOL CELL RES, V1224, P433, DOI 10.1016/0167-4889(94)90279-8; Coakley RJ, 2001, AM J MED SCI, V321, P33, DOI 10.1097/00000441-200101000-00006; de Gaetano G, 1999, HAEMOSTASIS, V29, P41; FERRERLOPEZ P, 1992, J LAB CLIN MED, V119, P231; Furihata K, 2001, ARTERIOSCL THROM VAS, V21, P1857, DOI 10.1161/hq1001.096643; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gardiner EE, 2001, BLOOD, V98, P1440, DOI 10.1182/blood.V98.5.1440; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Goel MS, 2002, BLOOD, V100, P3797, DOI 10.1182/blood-2002-03-0712; Goel MS, 2001, ARTERIOSCL THROM VAS, V21, P2093, DOI 10.1161/hq1201.100255; Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; HIGUCHI DA, 1992, BLOOD, V79, P1712; Holmes MB, 2000, CIRCULATION, V102, P2051, DOI 10.1161/01.CIR.102.17.2051; Kinlough-Rathbone RL, 1999, THROMB RES, V95, P315, DOI 10.1016/S0049-3848(99)00051-1; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; Kuharsky AL, 2001, BIOPHYS J, V80, P1050, DOI 10.1016/S0006-3495(01)76085-7; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; McEver RP, 2002, THROMB HAEMOSTASIS, V87, P364; Monroe D, 2002, ARTERIOSCL THROM VAS, V22, P1381, DOI 10.1161/01.ATV.0000031340.68494.34; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PIDARD D, 1994, BIOCHEM J, V303, P489, DOI 10.1042/bj3030489; Plescia J, 1996, BIOCHEM J, V319, P873, DOI 10.1042/bj3190873; Quinton TM, 2002, BLOOD, V99, P3228, DOI 10.1182/blood.V99.9.3228; SAELMAN EUM, 1994, BLOOD, V83, P1244; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; Schmidtke DW, 2000, J CELL BIOL, V149, P719, DOI 10.1083/jcb.149.3.719; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Sumner WT, 1996, THROMB RES, V81, P533, DOI 10.1016/0049-3848(96)00028-X; VICENTE V, 1990, J BIOL CHEM, V265, P274; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399	38	45	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9458	9463		10.1074/jbc.M211956200	http://dx.doi.org/10.1074/jbc.M211956200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524437	hybrid			2022-12-25	WOS:000181524000078
J	Okabe, T; Nakamura, T; Nishimura, YN; Kohu, K; Ohwada, S; Morishita, Y; Akiyama, T				Okabe, T; Nakamura, T; Nishimura, YN; Kohu, K; Ohwada, S; Morishita, Y; Akiyama, T			RICS, a novel GTPase-activating protein for Cdc42 and Rac1, is involved in the beta-catenin-N-cadherin and N-methyl-D-aspartate receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CALMODULIN KINASE-II; POSTSYNAPTIC DENSITY PROTEIN; DENDRITIC SPINE MORPHOLOGY; CELL-ADHESION MOLECULES; NMDA RECEPTOR; SYNAPTIC PLASTICITY; EXCITATORY SYNAPSES; MUTANT MICE; IN-VIVO	Cadherin adhesion molecules are believed to be important for synaptic plasticity. beta-Catenin, which links cadherins and the actin cytoskeleton, is a modulator of cadherin adhesion and regulates synaptic structure and function. Here we show that)beta-catenin interacts with a novel GTPase-activating protein, named RICS, that acts on Cdc42 and Rac1. The RICS-betacatenin complex was found to be associated with N-cadherin, N-methyl-D-aspartate receptors, and postsynaptic density-95, and localized to the postsynaptic density. Furthermore, the GTPase-activating protein activity of RICS was inhibited by phosphorylation by Ca2+ /calmodulin-dependent protein kinase H. These results suggest that RICS is involved in the synaptic adhesion- and N-methyl-D-aspartate-mediated organization of cytoskeletal networks and signal transduction. Thus, RICS may regulate dendritic spine morphology and strength by modulating Rho GTPases.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Gunma Univ, Sch Med, Dept Surg 2, Maebashi, Gumma 371, Japan	University of Tokyo; Gunma University	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp						AEL DE, 2002, CELL, V108, P849; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Benson DL, 1998, J NEUROSCI, V18, P6892; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; El-Hussein AE, 2000, SCIENCE, V290, P1364; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2001, J NEUROSCI, V21, P1501, DOI 10.1523/JNEUROSCI.21-05-01501.2001; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Hinds HL, 1998, LEARN MEMORY, V5, P344; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Margo, 1998, Cancer Control, V5, P310; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Murase S, 1999, CURR OPIN CELL BIOL, V11, P549, DOI 10.1016/S0955-0674(99)00019-8; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ouyang Y, 1997, J NEUROSCI, V17, P5416; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Roy BC, 2002, GENES CELLS, V7, P607; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Sheng M, 2001, J CELL SCI, V114, P1251; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Takeichi M., 1986, P373; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Toni N, 2001, J NEUROSCI, V21, P6245, DOI 10.1523/JNEUROSCI.21-16-06245.2001; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	80	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9920	9927		10.1074/jbc.M208872200	http://dx.doi.org/10.1074/jbc.M208872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12531901	hybrid			2022-12-25	WOS:000181524000139
J	Hu, K; Davletov, B				Hu, K; Davletov, B			SNAREs and control of synaptic release probabilities	FASEB JOURNAL			English	Article						neurotransmission; synapse; exocytosis; vesicle; stochastic	TRANSMITTER RELEASE; MEMBRANE-FUSION; VESICLE FUSION; GLUTAMATERGIC SYNAPSES; HIPPOCAMPAL SYNAPSES; QUANTAL SECRETION; CALCIUM; COMPLEX; FACILITATION; SYNAPTOTAGMIN	Since quantal release was first described, it has been clear that release of neurotransmitters is a stochastic process. Modulation of neurotransmitter release probability by regulatory factors likely affects the transfer of information within the nervous system. Although many rules governing release probabilities at the synapse have been discovered, their molecular basis is still under investigation. Here we analyze stimulus-evoked probabilistic assembly of the SNARE fusion machinery and show that a simple SNARE-based mechanism can account quantitatively for the classical binomial behavior of stochastic neurotransmitter release. Our analysis highlights for the first time how the fusion machinery, which is directly responsible for neurotransmitter release, may also contribute to the rich variety of synaptic responses.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Davletov, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	baz@mrc-lmb.cam.ac.uk	Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Angleson JK, 2001, J NEUROPHYSIOL, V85, P287, DOI 10.1152/jn.2001.85.1.287; Atwood HL, 2002, NAT REV NEUROSCI, V3, P497, DOI 10.1038/nrn876; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; BELLEN H, 1999, NEUROTRANSMITTER REL; Bennett MR, 2000, BIOPHYS J, V78, P2201, DOI 10.1016/S0006-3495(00)76769-5; BENNETT MR, 1989, J PHYSIOL-LONDON, V418, P235, DOI 10.1113/jphysiol.1989.sp017837; BLISS TVP, 1990, COLD SPRING HARB SYM, V55, P119; Bollmann JH, 2000, SCIENCE, V289, P953, DOI 10.1126/science.289.5481.953; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; COOPER RL, 1995, J NEUROSCI, V15, P4209; COWAN WM, 2001, SYNAPSES; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERANDEZ I, 2001, NEURON, V32, P1057; Finley MFA, 2002, J NEUROSCI, V22, P1266, DOI 10.1523/JNEUROSCI.22-04-01266.2002; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Goda Y, 1997, CURR OPIN CELL BIOL, V9, P513, DOI 10.1016/S0955-0674(97)80027-0; Hanse E, 2001, J PHYSIOL-LONDON, V537, P141, DOI 10.1111/j.1469-7793.2001.0141k.x; Hanse E, 2001, J PHYSIOL-LONDON, V531, P481, DOI 10.1111/j.1469-7793.2001.0481i.x; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1995, CURR BIOL, V5, P257, DOI 10.1016/S0960-9822(95)00054-6; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; MATULSKY H, 1995, INTUITIVE BIOSTATIST; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Oertner TG, 2002, NAT NEUROSCI, V5, P657, DOI 10.1038/nn867; Prange O, 1999, J NEUROPHYSIOL, V81, P1810, DOI 10.1152/jn.1999.81.4.1810; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Schikorski T, 1997, J NEUROSCI, V17, P5858; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wittung-Stafshede P, 1999, P NATL ACAD SCI USA, V96, P6587, DOI 10.1073/pnas.96.12.6587; Xu JH, 2002, J NEUROSCI, V22, P53, DOI 10.1523/JNEUROSCI.22-01-00053.2002; Xu-Friedman MA, 2001, J NEUROSCI, V21, P6666, DOI 10.1523/JNEUROSCI.21-17-06666.2001; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	49	3	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					130	135		10.1096/fj.02-0595hyp	http://dx.doi.org/10.1096/fj.02-0595hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554691				2022-12-25	WOS:000181456900037
J	Kanai, M; Konda, Y; Nakajaima, T; Izumi, Y; Kanda, N; Nanakin, A; Kubohara, Y; Chiba, T				Kanai, M; Konda, Y; Nakajaima, T; Izumi, Y; Kanda, N; Nanakin, A; Kubohara, Y; Chiba, T			Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway	ONCOGENE			English	Article						DIF-1; STAT3; ERK; cell growth; gastric cancer	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; SERINE PHOSPHORYLATION; DICTYOSTELIUM-DISCOIDEUM; CONSTITUTIVE ACTIVATION; PUTATIVE MORPHOGEN; SUPPRESSES GROWTH; LEUKEMIA-CELLS; DNA-BINDING; IN-VITRO	Differentiation-inducing factor-1 (DIF-1) is a chlorinated hexaphenone isolated from Dictyostelium. DIF-1 exhibits antitumor activity in several types of mammalian tumor cells, although the underlying mechanisms remain unknown. On the other hand, recent studies indicate that constitutively activated STAT3 acts as an oncogene and could be a target for antitumor drug. In the present study, we examined the effects of DIF-1 on proliferation of gastric cancer cell lines as well as on its signal transduction pathways, focusing mainly on STAT proteins. DIF-1 inhibited proliferation of gastric cancer cells. Western blot analysis and electrophoretic mobility shift assay showed that DIF-1 inhibited STAT3 activity in an MEK-ERK-dependent manner in gastric cancer cell lines, AGS and MKN28. Moreover, blockade of STAT3 activity by ectopic expression of dominant-negative STAT3 or the Janus kinase inhibitor, tyrphostin AG490, inhibited cell growth of AGS cells. These results suggest that STAT3 activity plays an important role for cell growth in AGS cells, and raises the possibility that inhibition of STAT3 activity is one of the mechanisms responsible for the antitumor effect of DIF-1 in these cells.	Kyoto Univ, Grad Sch Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Physiol, Maebashi, Gumma 3718512, Japan	Kyoto University; Gunma University	Konda, Y (corresponding author), Kyoto Univ, Grad Sch Med, Div Gastroenterol & Hepatol, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.		Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648				ASAHI KI, 1995, BIOCHEM BIOPH RES CO, V208, P1036, DOI 10.1006/bbrc.1995.1438; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gollob JA, 1999, J IMMUNOL, V162, P4472; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ishiyama M, 1997, TALANTA, V44, P1299, DOI 10.1016/S0039-9140(97)00017-9; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KUBOHARA Y, 1995, FEBS LETT, V359, P119, DOI 10.1016/0014-5793(95)00022-2; Kubohara Y, 1999, BIOCHEM BIOPH RES CO, V263, P790, DOI 10.1006/bbrc.1999.1468; Kubohara Y, 1997, BIOCHEM BIOPH RES CO, V236, P418, DOI 10.1006/bbrc.1997.6964; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Niu GL, 2001, CANCER RES, V61, P3276; Sartor CI, 1997, CANCER RES, V57, P978; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	31	71	75	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					548	554		10.1038/sj.onc.1206109	http://dx.doi.org/10.1038/sj.onc.1206109			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555068				2022-12-25	WOS:000180538200008
J	Gimeno, RE; Ortegon, AM; Patel, S; Punreddy, S; Ge, P; Sun, Y; Lodish, HF; Stahl, A				Gimeno, RE; Ortegon, AM; Patel, S; Punreddy, S; Ge, P; Sun, Y; Lodish, HF; Stahl, A			Characterization of a heart-specific fatty acid transport protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CARDIAC MYOCYTES; BINDING-PROTEIN; ADIPOSE-TISSUE; MUSCLE; FAMILY; RAT; TRANSLOCATION	Fatty acids are a major source of energy for cardiac myocytes. Changes in fatty acid metabolism have been implicated as causal in diabetes and cardiac disease. The mechanism by which long chain fatty acids (LCFAs) enter cardiac myocytes is not well understood but appears to occur predominantly by protein-mediated transport. Here we report the cloning, expression pattern, and subcellular localization of a novel member of the fatty acid transport protein (FATP) family termed FATP6. FATP6 is principally expressed in the heart where it is the predominant FATP family member. Similar to other FATPs, transient and stable transfection of FATP6 into 293 cells enhanced uptake of LCFAs. FATP6 mRNA was localized to cardiac myocytes by in situ hybridization. Immunofluorescence microscopy of FATP6 in monkey and murine hearts revealed that the protein is exclusively located on the sarcolemma. FATP6 was restricted in its distribution to areas of the plasma membrane juxtaposed with small blood vessels. In these membrane domains FATP6 also colocalizes with another molecule involved in LCFA uptake, CD36. These findings suggest that FATP6 is involved in heart LCFA uptake, in which it may play a role in the pathogenesis of lipid-related cardiac disorders.	Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Stanford Univ, Sch Med, Palo Alto, CA 94301 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Palo Alto Medical Foundation Research Institute; Stanford University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Stahl, A (corresponding author), Palo Alto Med Fdn, Palo Alto, CA 94301 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618, R01DK047618] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41484] Funding Source: Medline; NIDDK NIH HHS [DK 47618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALLARD FB, 1960, J CLIN INVEST, V39, P717, DOI 10.1172/JCI104088; Barger PM, 1999, AM J MED SCI, V318, P36, DOI 10.1097/00000441-199907000-00006; BASSINGTHWAIGHTE JB, 1989, MOL CELL BIOCHEM, V88, P51, DOI 10.1007/BF00223423; BECKER W, 1985, PROG LIPID RES, V24, P325, DOI 10.1016/0163-7827(85)90010-4; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; BING RJ, 1955, CIRCULATION, V12, P635, DOI 10.1161/01.CIR.12.4.635; Binnert C, 2000, AM J PHYSIOL-ENDOC M, V279, pE1072, DOI 10.1152/ajpendo.2000.279.5.E1072; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DEGRELLA RF, 1985, BASIC RES CARDIOL, V80, P107; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; HENSON LC, 1977, BIOCHIM BIOPHYS ACTA, V487, P212, DOI 10.1016/0005-2760(77)90057-1; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; Pohl J, 2000, Eur J Med Res, V5, P438; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; STRAUSS AW, 1995, P NATL ACAD SCI USA, V92, P10496, DOI 10.1073/pnas.92.23.10496; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; van der Vusse GJ, 2000, CARDIOVASC RES, V45, P279, DOI 10.1016/S0008-6363(99)00263-1; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	31	147	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16039	16044		10.1074/jbc.M211412200	http://dx.doi.org/10.1074/jbc.M211412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12556534	hybrid			2022-12-25	WOS:000182680000075
J	Tamm, I; Trepel, M; Cardo-Vila, M; Sun, Y; Welsh, K; Cabezas, E; Swatterthwait, A; Arap, W; Reed, JC; Pasqualini, R				Tamm, I; Trepel, M; Cardo-Vila, M; Sun, Y; Welsh, K; Cabezas, E; Swatterthwait, A; Arap, W; Reed, JC; Pasqualini, R			Peptides targeting caspase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; BINDING CONSTANTS; IAP; XIAP; SPECIFICITIES; PROTEINS; DOMAIN	Here we report on the identification of peptides targeting the X-inhibitor of apoptosis protein (XIAP). XIAP functions as a caspase inhibitor and is a member of the inhibitors of apoptosis (IAP) family of proteins. IAPs are often overexpressed in cancers and leukemias and are associated with an unfavorable clinical prognosis. We have selected peptides from a phage library by using recombinant full-length human XIAP or a fragment containing only the baculovirus. IAP repeat 2 (BIR2) domain. A consensus motif, C(D/E/P)(W/F/Y)-acid/basic-XC, was recovered from two independent screenings by using different libraries. Phage-displaying variations of the consensus sequence bound specifically to the BIR2 domain of XIAP but not to other IAPs The interaction was specific as it could be blocked by the cognate synthetic peptides in a dose-dependent manner. Phage displaying the XIAP-binding motif CEFESC bound to the BIR2 domain of XIAP with an estimated dissociation constant of 1.8 nm as determined by surface plasmon resonance. Protein-protein interaction assays revealed that caspase-3 and caspase-7 (but not caspase-8) blocked the binding of the CEFESC phage to XIAP, indicating that this peptide targets a domain within XIAP that is related to the caspase-binding site. In fact, the sequence EFES is homologous to a loop unique to the executioner caspase-3 and caspase-7 that are targeted by XIAP. Finally, we demonstrated that an internalizing version of the XIAP-binding peptide identified in our screenings (PFKQ) can induce programmed cell death in leukemia cells. Peptides interacting with XIAP could serve as prototypes for the design of low molecular weight modulators of apoptosis.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Burnham Inst, La Jolla, CA USA; Virchow Clin, Dept Hematol & Oncol, Charite, Berlin, Germany	University of Texas System; UTMD Anderson Cancer Center; Sanford Burnham Prebys Medical Discovery Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Pasqualini, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.	jreed@burnham-inst.org; rpasqual@notes.mdace.tmc.edu			NCI NIH HHS [CA90270, CA8297601, CA9081001, CA55164] Funding Source: Medline; NIA NIH HHS [AG15402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, P50CA090270, U54CA090810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; KOINSTINEN P, 1991, LEUKEMIA, V5, P704; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i	28	60	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14401	14405		10.1074/jbc.M210133200	http://dx.doi.org/10.1074/jbc.M210133200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12538646	Green Published, hybrid			2022-12-25	WOS:000182405000106
J	Metzger, JM; Michele, DE; Rust, EM; Borton, AR; Westfall, MV				Metzger, JM; Michele, DE; Rust, EM; Borton, AR; Westfall, MV			Sarcomere thin filament regulatory isoforms - Evidence of a dominant effect of slow skeletal troponin I on cardiac contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEFT-VENTRICLE; HYPERTROPHIC CARDIOMYOPATHY; BETA-TROPOMYOSIN; STRIATED-MUSCLE; GENE-TRANSFER; COOPERATIVE ACTIVATION; DEVELOPMENTAL-CHANGES; MYOFILAMENT TENSION; MOLECULAR-CLONING; ALPHA-TROPOMYOSIN	Thin filament proteins tropomyosin (Tm), troponin T (TnT), and troponin I (TnI) form an allosteric regulatory complex that is required for normal cardiac contraction. Multiple isoforms of TnT, Tm, and TnI are differentially expressed in both cardiac development and disease, but concurrent TnI, Tin, and TnT isoform switching has hindered assignment of cellular function to these transitions. We systematically incorporated into the adult sarcomere the embryonic/fetal isoforms of Tin, TnT, and TnI by using gene transfer. In separate experiments, greater than 90% of native TnI and 40-50% of native Tin or TnT were specifically replaced. The Ca2+ sensitivity of tension development was markedly enhanced by TnI replacement but not by TnT or Tin isoform replacement. Titration of TnI replacement from >90% to <30% revealed a dominant functional effect of slow skeletal TnI to modulate regulation. Over this range of isoform replacement, TnI, but not Tin or TnT embryonic isoforms, influenced calcium regulation of contraction, and this identifies TnI as a potential target to modify contractile performance in normal and diseased myocardium.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Metzger, JM (corresponding author), Univ Michigan, Dept Physiol, 7730 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.			Westfall, Margaret/0000-0001-9491-0125				ANDERSON PAW, 1988, CIRC RES, V63, P742, DOI 10.1161/01.RES.63.4.742; ANDERSON PAW, 1992, BASIC RES CARDIOL, V87, P117; ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BRANDT PW, 1990, J MOL BIOL, V212, P473, DOI 10.1016/0022-2836(90)90326-H; Fabiato A, 1978, Ann N Y Acad Sci, V307, P491, DOI 10.1111/j.1749-6632.1978.tb41979.x; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; GREIG A, 1994, CIRC RES, V74, P41, DOI 10.1161/01.RES.74.1.41; James J, 1997, AM J PHYSIOL-HEART C, V273, pH2105, DOI 10.1152/ajpheart.1997.273.5.H2105; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; LEE JA, 1991, J CLIN INVEST, V88, P361, DOI 10.1172/JCI115311; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; MacGowan GA, 2001, AM J PHYSIOL-HEART C, V281, pH2539, DOI 10.1152/ajpheart.2001.281.6.H2539; MARTIN AF, 1981, J BIOL CHEM, V256, P964; MCAULIFFE JJ, 1991, PEDIATR RES, V29, P580, DOI 10.1203/00006450-199106010-00012; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; MesnardRouiller L, 1997, J MOL CELL CARDIOL, V29, P3043, DOI 10.1006/jmcc.1997.0519; METZGER JM, 1995, BIOPHYS J, V68, P1430, DOI 10.1016/S0006-3495(95)80316-4; METZGER JM, 1994, J CELL BIOL, V126, P701, DOI 10.1083/jcb.126.3.701; Michele DE, 1999, NAT MED, V5, P1413; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Michele DE, 2000, TRENDS CARDIOVAS MED, V10, P177, DOI 10.1016/S1050-1738(00)00067-0; Michele DE, 2000, J MOL MED, V78, P543, DOI 10.1007/s001090000161; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Muthuchamy M, 1998, J MOL CELL CARDIOL, V30, P1545, DOI 10.1006/jmcc.1998.0720; Muthuchamy M, 1999, CIRC RES, V85, P47; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; Rust EM, 1998, MOL CELL BIOCHEM, V181, P143, DOI 10.1023/A:1006802719136; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SMILLIE L, 1996, BIOCH SMOOTH MUSCLE; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 1999, J BIOL CHEM, V274, P22508, DOI 10.1074/jbc.274.32.22508; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2001, NEWS PHYSIOL SCI, V16, P278; Westfall MV, 2001, AM J PHYSIOL-CELL PH, V280, pC324, DOI 10.1152/ajpcell.2001.280.2.C324; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13118	13123		10.1074/jbc.M212601200	http://dx.doi.org/10.1074/jbc.M212601200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551900	hybrid			2022-12-25	WOS:000182189500068
J	Ramos, CRR; Figueredo, RCR; Pertinhez, TA; Vilar, MM; do Nascimento, ALTO; Tendler, M; Raw, I; Spisni, A; Ho, PL				Ramos, CRR; Figueredo, RCR; Pertinhez, TA; Vilar, MM; do Nascimento, ALTO; Tendler, M; Raw, I; Spisni, A; Ho, PL			Gene structure and M20T polymorphism of the Schistosoma mansoni Sm14 fatty acid-binding protein - Molecular, functional, and immunoprotection analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD FLUKE	The Schistosoma mansoni Sm14 antigen belongs to the fatty acid-binding protein family and is considered a vaccine candidate against at least two parasite worms, Fasciola hepatica and S. mansoni. Here the genomic sequence and the polymorphism of Sm14 have been characterized for the first time. We found that the conserved methionine at position 20 is polymorphic, being exchangeable with threonine (M20T). To evaluate the function of the amino acid residue at this position, we have also constructed the mutant Sm14-A20 besides the two native isoforms (Sm14-M20 and Sm14-T20). The three purified recombinant His(6)-tagged Sm14 proteins (rSm14-M20, rSm14-T20, and rSm14-A20) present a predominant beta-barrel structure as shown by CD spectroscopy. Thermal and urea unfolding studies evidenced a higher structural stability of rSm14-M20 over the other forms (rSm14-M20>rSm14-T20>rSm14-A20). All of the Sm14 proteins were able to bind 11-(dansylamino)undecanoic acid (DAUDA) without substantial difference in the binding affinity. However, rSm14-M20 exhibited a higher affinity for natural fatty acids than the rSm14-T20 and rSm14-A20 proteins as judged by competitive experiments against DAUDA (rSm14-M20>rSm14-T20> rSm14-A20). The rSm14-M20 or rSm14-T20 isoforms but not the rSm14-A20 mutant was able to induce significant protection against S. mansoni cercariae challenge in immunized mice. The level of protection efficacy correlates with the extent of structure stability of the recombinant Sm14 isoforms and mutant.	Ctr Biotecnol, Inst Butantan, BR-05503900 Sao Paulo, SP, Brazil; Univ Sao Paulo, Inst Quim, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Biociencias, BR-05508900 Sao Paulo, Brazil; Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Fiocruz MS, Inst Oswaldo Cruz, Dept Helmintol, BR-21045900 Rio De Janeiro, Brazil; Univ Parma, Dept Expt Med, I-43100 Parma, Italy	Instituto Butantan; Universidade de Sao Paulo; Universidade de Sao Paulo; Laboratorio Nacional de Luz Sincrotron (LNLS); Fundacao Oswaldo Cruz; University of Parma	Ho, PL (corresponding author), Ctr Biotecnol, Inst Butantan, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.	hoplee@butantan.gov.br	Ramos, Celso R. R./H-6349-2015; Spisni, Alberto/AAY-7778-2020; Nascimento, Ana L. T. O./E-8488-2012; Ho, Paulo/P-8267-2015	Ramos, Celso R. R./0000-0002-5760-8661; Nascimento, Ana L. T. O./0000-0003-4851-0870; Ho, Paulo/0000-0003-3652-241X; Magno Vilar, Monica/0000-0001-9015-8247				Balendiran GK, 2000, J BIOL CHEM, V275, P27045; BECKER MM, 1994, GENE, V148, P321, DOI 10.1016/0378-1119(94)90706-4; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brito CFA, 2000, SCAND J IMMUNOL, V51, P595; Dalessio PM, 2000, BIOCHEMISTRY-US, V39, P860, DOI 10.1021/bi991937j; DESPRES L, 1993, MOL BIOCHEM PARASIT, V60, P221, DOI 10.1016/0166-6851(93)90133-I; Esteves A, 1997, INT J PARASITOL, V27, P1013, DOI 10.1016/S0020-7519(97)00071-4; Junqueira de Azevedo ILM, 2001, J BIOL CHEM, V276, P39836; Kennedy MW, 2000, BIOCHEM J, V349, P377, DOI 10.1042/0264-6021:3490377; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; Krajewski JL, 2001, MOL PHARMACOL, V60, P725; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; MOSER D, 1991, J BIOL CHEM, V266, P8447; Plenefisch J, 2000, MOL BIOCHEM PARASIT, V105, P223, DOI 10.1016/S0166-6851(99)00179-6; Richieri GV, 1998, J BIOL CHEM, V273, P7397, DOI 10.1074/jbc.273.13.7397; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scott JC, 2000, BBA-GENE STRUCT EXPR, V1517, P53, DOI 10.1016/S0167-4781(00)00254-2; Tendler M, 1996, P NATL ACAD SCI USA, V93, P269, DOI 10.1073/pnas.93.1.269; TENDLER M, 1986, INT J PARASITOL, V16, P347, DOI 10.1016/0020-7519(86)90113-X; Wu QW, 2001, INSECT BIOCHEM MOLEC, V31, P553, DOI 10.1016/S0965-1748(00)00158-2; Zimmerman AW, 2001, INT J BIOCHEM CELL B, V33, P865, DOI 10.1016/S1357-2725(01)00070-X	25	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12745	12751		10.1074/jbc.M211268200	http://dx.doi.org/10.1074/jbc.M211268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551912	hybrid, Green Submitted			2022-12-25	WOS:000182189500022
J	Tsivkovskii, R; Efremov, RG; Lutsenko, S				Tsivkovskii, R; Efremov, RG; Lutsenko, S			The role of the invariant His-1069 in folding and function of the Wilson's disease protein, the human copper-transporting ATPase ATP7B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; CALCIUM-PUMP; SACCHAROMYCES-CEREVISIAE; REGULATED TRAFFICKING; MUTATION; CA2+-ATPASE; EXPRESSION; RETICULUM; MEMBRANE; BINDING	The copper-transporting ATPase ATP7B is essential for normal distribution of copper in human cells. Mutations in ATP7B lead to Wilson's disease, a severe disorder with neurological and hepatic manifestations. One of the most common disease mutations, a H1069Q substitution, causes intracellular mislocalization of ATP7B (the Wilson's disease protein, WNDP). His-1069 is located in the nucleotide-binding domain of WNDP and is conserved in all copper-transporting ATPases from bacteria to mammals; however, the specific role of this His in the structure and function of WNDP remains unclear. We demonstrate that substitution of His-1069 for Gln, Ala, or Cys does not significantly alter the folding of the WNDP nucleotide-binding domain or the proteolytic resistance of the full-length WNDP. In contrast, the function of WNDP is markedly affected by the mutations. The ability to form an acylphosphate intermediate in the presence of ATP is entirely lost in all three mutants, suggesting that His-1069 is important for ATP-dependent phosphorylation. Other steps of the WNDP enzymatic cycle are less dependent on His-1069. The H1069C mutant shows normal phosphorylation in the presence of inorganic phosphate; it binds an ATP analogue, beta,gamma-imidoadenosine 5'-triphosphate (AMP-PNP), and copper and undergoes nucleotide-dependent conformational transitions similar to those of the wild-type WNDP. Although binding of AMP-PNP is not disrupted by the mutation, the apparent affinity for the nucleotide is decreased by 4-fold. We conclude that His-1069 is responsible for proper orientation of ATP in the catalytic site of WNDP prior to ATP hydrolysis.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	Oregon Health & Science University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	lutsenko@ohsu.edu	Roman, Efremov/A-7460-2014	Roman, Efremov/0000-0002-5474-4721	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55719] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, GASTROENTEROLOGY, V124, P335, DOI 10.1053/gast.2003.50066; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Okkeri J, 2002, EUR J BIOCHEM, V269, P1579, DOI 10.1046/j.1432-1033.2002.02810.x; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; THOMAS GR, 1995, AM J HUM GENET, V56, P1315; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	23	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13302	13308		10.1074/jbc.M300034200	http://dx.doi.org/10.1074/jbc.M300034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551905	hybrid			2022-12-25	WOS:000182189500090
J	Valkova, N; Lepine, F; Labrie, L; Dupont, M; Beaudet, R				Valkova, N; Lepine, F; Labrie, L; Dupont, M; Beaudet, R			Purification and characterization of PrbA, a new esterase from Enterobacter cloacae hydrolyzing the esters of 4-hydroxybenzoic acid (parabens)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLPARABEN	The esterase PrbA from Enterobacter cloacae strain EM has previously been shown to confer additional resistance to the esters of 4-hydroxybenzoic acid (parabens) to two species of Enterobacter. The PrbA protein has been purified from E. cloacae strain EM using a three-step protocol resulting in a 60-fold increase in specific activity. The molecular mass of the mature enzyme was determined to be 54,619 +/- 1 Da by mass spectrometry. It is highly active against a series of parabens with alkyl groups ranging from methyl to butyl, with K-m and V-max values ranging from 0.45 to 0.88 mm and 0.031 to 0.15 mM/min, respectively. The K-m and V-max values for p-nitrophenyl acetate were 3.7 mm and 0.051 mM/min. PrbA hydrolyzed a variety of structurally analogous compounds, with activities larger than 20% relative to propyl paraben for methyl 3-hydroxybenzoate, methyl 4-aminobenzoate, or methyl vanillate. The enzyme showed optimum activity at 31 degreesC and at pH 7.0. PrbA was able to transesterify parabens with alcohols of increasing chain length from methanol to n-butanol, achieving 64% transesterification of 0.5 mm propyl paraben with 5% methanol within 2 h. PrbA was inhibited by 1-chloro-3-tosyl-amido-4-phenyl-2-butanone and 1-chloro-3-tosylamido-7-amino-2-heptanone (TLCK), with k(i) values of 0.29 and 0.20 mM, respectively, and was irreversibly inhibited by Diisopropyl fluorophosphate (DFP) or diethyl pyrocarbonate. The stoichiometry of addition of DFP to the enzyme was 1:1 and only 1 TLCK molecule was found in TLCK-modified enzyme, as measured by mass spectrometry. Analysis of the tryptic digest of the DFP-modified PrbA demonstrated that the addition of a DFP molecule occurred at Ser-189, indicating the location of the active serine.	Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada	University of Quebec; Institut national de la recherche scientifique (INRS)	Lepine, F (corresponding author), Univ Quebec, Inst Armand Frappier, INRS, 531 Blvd Prairies, Laval, PQ H7V 1B7, Canada.							CHILD JJ, 1971, CAN J MICROBIOL, V17, P1455, DOI 10.1139/m71-231; CLOSE J, 1976, APPL ENVIRON MICROB, V31, P718, DOI 10.1128/AEM.31.5.718-722.1976; GOTTFRIED NS, 1962, AM J HOSP PHARM, V19, P310; HAAG T, 1984, COSMET SCI TECHNOL S, V1, P63; HORIUCHI K, 1994, J FERMENT BIOENG, V77, P324, DOI 10.1016/0922-338X(94)90243-7; HUGO WB, 1964, J PHARM PHARMACOL, V16, P209, DOI 10.1111/j.2042-7158.1964.tb07445.x; Lobemeier C, 1996, BIOL CHEM, V377, P647, DOI 10.1515/bchm3.1996.377.10.647; RASTOGI SC, 1995, CONTACT DERMATITIS, V32, P28, DOI 10.1111/j.1600-0536.1995.tb00836.x; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; Valkova N, 2002, J BACTERIOL, V184, P5011, DOI 10.1128/JB.184.18.5011-5017.2002; Valkova N, 2001, APPL ENVIRON MICROB, V67, P2404, DOI 10.1128/AEM.67.6.2404-2409.2001; W. T. SOKOLSKI, 1962, Developments in industrial microbiology. Vol. 3., P179; WALLS AF, 1992, BIOCHEM PHARMACOL, V43, P1243, DOI 10.1016/0006-2952(92)90498-8; WILSON BW, 1974, P NATL ACAD SCI USA, V71, P3194, DOI 10.1073/pnas.71.8.3194; ZEDAN H H, 1984, Egyptian Journal of Microbiology, V19, P41	15	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12779	12785		10.1074/jbc.M213281200	http://dx.doi.org/10.1074/jbc.M213281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556461	hybrid			2022-12-25	WOS:000182189500026
J	Gauthier, A; Vassiliou, G; Benoist, F; McPherson, R				Gauthier, A; Vassiliou, G; Benoist, F; McPherson, R			Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; HUMAN ADIPOSE-TISSUE; CELL-SURFACE PROTEOGLYCANS; CETP MESSENGER-RNA; LDL-RECEPTOR; PPAR-GAMMA; ALPHA-2-MACROGLOBULIN RECEPTOR; ALZHEIMERS-DISEASE; DEPENDENT ACTIVATION; MOLECULAR CHAPERONE	The alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) is a large multifunctional receptor that interacts with a variety of molecules. It is implicated in biologically important processes such as lipoprotein metabolism, neurological function, tissue remodeling, protease complex clearance, and cell signal transduction. However, the regulation of LRP gene expression remains largely unknown. In this study, we have analyzed 2 kb of the 5'-flanking region of the LRP gene and identified a predicted peroxisome proliferator response element (PPRE) from -1185 to -1173. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation. These agents were found to increase LRP transcription. Gel shift analysis of the putative PPRE demonstrated direct binding of PPARgamma/retinoid X receptor alpha heterodimers to the PPRE in the LRP gene. Furthermore, these heterodimers could no longer interact with a mutated PPRE probe. The isolated promoter was functional in SW872 cells, and its activity was increased by 1.5-fold with the addition of rosiglitazone. Furthermore, the isolated response element was similarly responsive to rosiglitazone when placed upstream of an ideal promoter. Mutagenesis of the predicted PPRE abolished the ability of this construct to respond to rosiglitazone. These data demonstrate that fatty acids and rosiglitazone directly stimulate transcription of the LRP gene through activation of PPARgamma and increase functional LRP expression.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute	McPherson, R (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Rm H441,40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.							ADOLPH S, 1993, J CELL SCI, V105, P113; Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; Baumann CA, 2000, J BIOL CHEM, V275, P9131, DOI 10.1074/jbc.275.13.9131; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; BENOIST F, 1997, CIRCULATION, V96, P485; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Businaro R, 1997, J NEUROIMMUNOL, V72, P75, DOI 10.1016/S0165-5728(96)00157-9; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dodd F, 2000, J CELL BIOCHEM, V77, P624, DOI 10.1002/(SICI)1097-4644(20000615)77:4<624::AID-JCB10>3.0.CO;2-M; DUGAIL I, 2001, ADIPOSE TISSUE PROTO, P141; Edvardsson U, 1999, J LIPID RES, V40, P1177; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAETA BA, 1994, BBA-GENE STRUCT EXPR, V1219, P307, DOI 10.1016/0167-4781(94)90053-1; GAFVELS ME, 1992, J BIOL CHEM, V267, P21230; Gauthier B, 1999, J LIPID RES, V40, P1284; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1999, LIPOPROTEINS HLTH DI; Hill MR, 1997, ENDOCRINOLOGY, V138, P3073, DOI 10.1210/en.138.7.3073; Izem L, 2001, J BIOL CHEM, V276, P26534, DOI 10.1074/jbc.M103624200; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Krapp A, 1996, J LIPID RES, V37, P926; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Kuchenhoff A, 1997, AM J PHYSIOL-CELL PH, V272, pC369, DOI 10.1152/ajpcell.1997.272.2.C369; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Martin G, 2000, J BIOL CHEM, V275, P12612, DOI 10.1074/jbc.275.17.12612; Medh JD, 1996, J BIOL CHEM, V271, P17073, DOI 10.1074/jbc.271.29.17073; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Radeau T, 1998, BBA-LIPID LIPID MET, V1392, P245, DOI 10.1016/S0005-2760(98)00039-3; Radeau T, 1998, ATHEROSCLEROSIS, V139, P369, DOI 10.1016/S0021-9150(98)00051-3; Radeau T, 1995, J LIPID RES, V36, P2552; Reblin T, 1997, J LIPID RES, V38, P2103; Richardson MA, 1996, J LIPID RES, V37, P1162; Sambrook J., 2002, MOL CLONING LAB MANU; Savonen R, 1999, J BIOL CHEM, V274, P25877, DOI 10.1074/jbc.274.36.25877; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1996, J LIPID RES, V37, P907; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Slomiany BA, 2000, BIOTECHNIQUES, V28, P938, DOI 10.2144/00285st08; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; Ulery PG, 2000, J CLIN INVEST, V106, P1077, DOI 10.1172/JCI11455; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; VANLEUVEN F, 1994, GENOMICS, V24, P78, DOI 10.1006/geno.1994.1584; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vassiliou G, 2001, J BIOL CHEM, V276, P48823, DOI 10.1074/jbc.M103954200; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350	76	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11945	11953		10.1074/jbc.M212989200	http://dx.doi.org/10.1074/jbc.M212989200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551936	hybrid			2022-12-25	WOS:000182015700031
J	Koglin, M; Behrends, S				Koglin, M; Behrends, S			A functional domain of the alpha(1) subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BOVINE LUNG; 2 SUBUNITS; RAT LUNG; EXPRESSION; SITE	Soluble guanylyl cyclase is a heterodimeric enzyme consisting of an alpha(1) and a beta(1) subunit and is an important target for endogenous nitric oxide and the guanylyl cyclase modulator YC-1. The activation of the enzyme by both substances is dependent on the presence of a prosthetic heme group. It has been unclear whether this prosthetic heme group is sandwiched between the alpha(1) and beta(1) subunits or whether it exclusively binds to the beta(1) subunit. Here we analyze progressive amino-terminal deletion mutants of the human alpha(1) subunit after co-expression with the human beta(1) subunit in the baculovirus/Sf9 system. Spectral, biochemical, and pharmacological analysis shows that the first 259 amino acids of the alpha(1) subunit can be deleted without loss of sensitivity to nitric oxide (NO) or YC-1 or loss of heme binding of the respective enzyme complex with the beta(1) subunit. This is in contrast to previous data indicating that NO sensitivity and a functional heme binding site requires full-length amino termini of bovine alpha(1) and beta(1) subunits. Further deletion of the first 364 amino acids of the alpha(1) subunit leads to an enzyme complex with preserved heme binding but loss of sensitivity to NO or YC-1 despite induction of the typical spectral shift by NO binding to the prosthetic heme group. We conclude that 1) the amino-terminal part of the alpha(1) subunit is not involved in heme binding and 2) amino acids 259-364 of the alpha(1) subunit represent an important functional domain for the transduction of the NO activation signal and likely represent the target for NO-sensitizing substances like YC-1.	Univ Hamburg, Inst Expt & Klin Pharmakol, D-20246 Hamburg, Germany	University of Hamburg	Behrends, S (corresponding author), Univ Clin Eppendorf, Pharmakol Inst, Martinistr 52, D-20246 Hamburg, Germany.		Behrends, Sönke/A-2551-2010	Behrends, Sönke/0000-0002-9068-0729				Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Friebe A, 1999, BIOCHEMISTRY-US, V38, P15253, DOI 10.1021/bi9908944; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; Koglin M, 2000, BBA-GENE STRUCT EXPR, V1494, P286, DOI 10.1016/S0167-4781(00)00211-6; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Lucas KA, 2000, PHARMACOL REV, V52, P375; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; NAKANE M, 1990, J BIOL CHEM, V265, P16841; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	21	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12590	12597		10.1074/jbc.M212740200	http://dx.doi.org/10.1074/jbc.M212740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560334	hybrid			2022-12-25	WOS:000182015700112
J	Zhang, D; Vik, SB				Zhang, D; Vik, SB			Close proximity of a cytoplasmic loop of subunit alpha with c subunits of the ATP synthase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION SCANNING MUTAGENESIS; B-SUBUNIT; PROTON TRANSLOCATION; DELETION ANALYSIS; LACTOSE PERMEASE; CROSS-LINKING; ROTARY MOTOR; A-SUBUNIT; ROTATION; F-1-ATPASE	Interactions between subunit a and the c subunits of the Escherichia coli ATP synthase are thought to control proton translocation through the F. sector. In this study cysteine substitution mutagenesis was used to define the cytoplasmic ends of the first three transmembrane spans of subunit a, as judged by accessibility to 3-N-maleimidyl-propionyl biocytin. The cytoplasmic end of the fourth transmembrane span could not be defined in this way because of the limited extent of labeling of all residues between 186 and 206. In contrast, most of the preceding residues in that region, closer to transmembrane span 3, were labeled readily. The proximity of this region to other subunits in F. was tested by reacting mono-cysteine mutants with a photoactivated crosslinker. Residues 165, 169, 173, 174, 177, 178, and 182-184 could all be cross-linked to subunit c, but no sites were cross-linked to b subunits. Attempts using double mutants of subunit a to generate simultaneous cross-links to two different c subunits were unsuccessful. These results indicate that the cytoplasmic loop between transmembrane spans 3 and 4 of subunit a is in close proximity to at least one c subunit. It is likely that the more highly conserved, carboxyl-terminal region of this loop has limited surface accessibility due to protein-protein interactions. A model is presented for the interaction of subunit a with subunit c, and its implications for the mechanism of proton translocation are discussed.	So Methodist Univ, Dept Sci Biol, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Sci Biol, 6501 Airline Rd, Dallas, TX 75275 USA.			Vik, Steven/0000-0002-5285-015X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40508, R01 GM040508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Braun P, 1997, J BIOL CHEM, V272, P29566, DOI 10.1074/jbc.272.47.29566; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dmitriev OY, 2002, BIOCHEMISTRY-US, V41, P5537, DOI 10.1021/bi012198l; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P11355, DOI 10.1074/jbc.275.15.11355; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Long JC, 2002, J BIOL CHEM, V277, P27288, DOI 10.1074/jbc.M202118200; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Revington M, 2002, PROTEIN SCI, V11, P1227, DOI 10.1110/ps.3200102; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; WANG S, 1994, J BIOL CHEM, V269, P3095; Wolin CD, 1999, BIOCHEMISTRY-US, V38, P8590, DOI 10.1021/bi990650j; Wolin CD, 2001, BIOCHEMISTRY-US, V40, P1996, DOI 10.1021/bi0025767; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhang D, 2003, BIOCHEMISTRY-US, V42, P331, DOI 10.1021/bi026649t	47	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12319	12324		10.1074/jbc.M212413200	http://dx.doi.org/10.1074/jbc.M212413200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12525480	hybrid			2022-12-25	WOS:000182015700078
J	Angermayr, M; Bandlow, W				Angermayr, M; Bandlow, W			Permanent nucleosome exclusion from the Ga14p-inducible yeast GCY1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; POSITIONED NUCLEOSOMES; ACTIVATE TRANSCRIPTION; ADENYLATE KINASE; GENE-REGULATION; PHO5 PROMOTER; PROTEIN; DNA; POLY(DA-DT)	The promoter of the galactose-inducible yeast GCY1 gene allows high rates of basal transcription and is kept free of nucleosomes regardless of growth conditions. The general regulatory factor, Reb1p, as well as the nucleotide sequence of a single Gal4p-binding site, structurally cooperate to exclude nucleosomes from about 480 by of DNA that spans the UAS(GAL), the Reb1p-binding site, the TATA-box, and the transcriptional initiation sites. Gal4p, which induces transcription of GCY1 about 25-fold in the presence of galactose, is not required for the alteration in chromatin configuration in the promoter upstream region since the hypersensitive site is unchanged when Gal4p is inactive or absent. As soon as either the Reb1p-binding site or the UASGAL or both are mutated, nucleosomes slip into the promoter of GCY1 paralleled by a reduction of basal transcription activity to about 30% in either single mutant and to <10% in the double mutant. In the mutant of the Reb1p-binding site, induction by galactose/Gal4p restores a nucleosome-free state to an extent resembling the GCY1 wild-type promoter, showing that, in principle, activated Gal4p can exclude nucleosomes on its own. Northern blots of GCY1 transcripts confirm that Reb1p modulates basal transcription and has little influence on the galactose-induced state.	Univ Munich, Dept Biol 1, Bereich Genet, D-80638 Munich, Germany	University of Munich	Angermayr, M (corresponding author), Univ Munich, Dept Biol 1, Bereich Genet, Maria Ward Str 1A, D-80638 Munich, Germany.							ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Angermayr M, 1997, MOL GEN GENET, V256, P682, DOI 10.1007/s004380050616; Angermayr M, 2002, NUCLEIC ACIDS RES, V30, P4199, DOI 10.1093/nar/gkf551; Angermayr M, 1997, J BIOL CHEM, V272, P31630, DOI 10.1074/jbc.272.50.31630; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; Costenoble R, 2000, YEAST, V16, P1483, DOI 10.1002/1097-0061(200012)16:16<1483::AID-YEA642>3.0.CO;2-K; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; McLean M, 1995, MOL MICROBIOL, V18, P605, DOI 10.1111/j.1365-2958.1995.mmi_18040605.x; Moreira JMA, 2002, J BIOL CHEM, V277, P3202, DOI 10.1074/jbc.M108962200; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; OECHSNER U, 1988, FEBS LETT, V242, P187, DOI 10.1016/0014-5793(88)81013-5; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; Thoma F, 1996, METHOD ENZYMOL, V274, P197; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	40	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11026	11031		10.1074/jbc.M210932200	http://dx.doi.org/10.1074/jbc.M210932200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536147	hybrid			2022-12-25	WOS:000181855400022
J	Kumar, A; Lee, CM; Reddy, EP				Kumar, A; Lee, CM; Reddy, EP			c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; INDUCED TERMINAL DIFFERENTIATION; HUMAN HEMATOPOIETIC-CELLS; IMMEDIATE EARLY RESPONSE; MYELOID-LEUKEMIA; TRANSCRIPTIONAL ACTIVATION; K562 CELLS; EXPRESSION; GENE; GROWTH	The c-myb proto-oncogene plays a central role in hematopoiesis and encodes a major translational product of 75 kDa. c-Myb is highly expressed in immature hematopoietic cells, and its expression is down-regulated during terminal differentiation. Deregulated expression of c-Myb has been shown to block terminal differentiation of hematopoietic cells. Here we have studied the mechanism of action and the nature of target genes through which c-Myb mediates the block in differentiation of 32Dc13 murine myeloid cells. We show that the ectopic overexpression of c-Myb in 32Dc13 cells results in the overexpression of c-Myc. However, enforced expression of c-Myc in 32Dc13 cells did not alter the normal pattern of differentiation. In addition, expression of dominant-negative mutants of c-Myc relieved c-Myb-mediated block in differentiation. These results led us to conclude that c-myc is a target gene of c-Myb and activation of the c-myc gene is a necessary event in Myb-mediated transformation. However, c-Myc expression alone is inadequate to elicit the phenotypic effects seen with Myb-mediated block in differentiation of myeloid cells, suggesting that activation of additional transcriptional targets by c-Myb plays a critical role in this process.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, MD Ph D Program, Philadelphia, PA 19140 USA; Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Reddy, EP (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@unix.temple.edu	Reddy, E. Premkumar/F-6233-2011; Lee, Clement M./E-7104-2012	Lee, Clement M./0000-0003-3486-8492	NATIONAL CANCER INSTITUTE [R01CA079086, R24CA088261] Funding Source: NIH RePORTER; NCI NIH HHS [CA79086, R24 CA88261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Bourgeade MF, 1998, BLOOD, V91, P3333, DOI 10.1182/blood.V91.9.3333.3333_3333_3339; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DELGADO MD, 1995, ONCOGENE, V10, P1659; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAWLEY RG, 1994, GENE THER, V1, P136; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; KASTAN MB, 1989, BLOOD, V74, P1517; LAROCCA SA, 1994, ONCOGENE, V9, P3499; Lerga A, 1999, CELL GROWTH DIFFER, V10, P639; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; Patel G, 1996, ONCOGENE, V13, P1197; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; Sitzmann J, 1995, ONCOGENE, V11, P2273; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	51	9	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11480	11488		10.1074/jbc.M300080200	http://dx.doi.org/10.1074/jbc.M300080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525485	hybrid			2022-12-25	WOS:000181855400079
J	Renato, J; Cussiol, R; Alves, SV; de Oliveira, MA; Netto, LES				Renato, J; Cussiol, R; Alves, SV; de Oliveira, MA; Netto, LES			Organic hydroperoxide resistance gene encodes a thiol-dependent peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPESTRIS PV. PHASEOLI; SALMONELLA-TYPHIMURIUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; PSEUDOMONAS-AERUGINOSA; BACILLUS-SUBTILIS; GENOME SEQUENCE; OHR GENE; REDUCTASE; ANTIOXIDANT	ohr (organic hydroperoxide resistance gene) is present in several species of bacteria, and its deletion renders cells specifically sensitive to organic peroxides. The goal of this work was to determine the biochemical function of Ohr from Xylella fastidiosa. All of the Ohr homologues possess two cysteine residues, one of them located in a VCP motif, which is also present in all of the proteins from the peroxiredoxin family. Therefore, we have investigated whether Ohr possesses thiol-dependent peroxidase activity. The ohr gene from X. fastidiosa was expressed in Escherichia coli, and the recombinant Ohr decomposed hydroperoxides in a dithiothreitol-dependent manner. Ohr was about twenty times more efficient to remove. organic hydroperoxides than to remove H2O2. This result is consistent with the organic hydroperoxide sensitivity of Deltaohr strains. The dependence of Ohr on thiol compounds was ascertained by glutamine synthetase protection assays. Approximately two thiol equivalents were consumed per peroxide removed indicating that Ohr catalyzes the following reaction: 2RSH + ROOH --> RSSR + ROH + H2O. Pretreatment of Ohr with N-ethyl maleimide and substitution of cysteine residues by serines inhibited this peroxidase activity indicating that both of the Ohr cysteines are important to the decomposition of peroxides. C125S still had a residual enzymatic activity indicating that Cys-61 is directly involved in peroxide removal. Monothiol compounds do not support the peroxidase activity of Ohr as well as thioredoxin from Saccharomyces cerevisaae and from Spirulina. Interestingly, dithiothreitol and dyhydrolipoic acid, which possess two sulfhydryl groups, do support the peroxidase activity of Ohr. Taken together our results unequivocally demonstrated that Ohr is a thiol-dependent peroxidase.	Univ Sao Paulo, Inst Biociencias, Dept Biol, BR-05508900 Sao Paulo, SP, Brazil	Universidade de Sao Paulo	Netto, LES (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Biol, Rua Matao 277, BR-05508900 Sao Paulo, SP, Brazil.		Cussiol, José Renato/E-5142-2015; Netto, Luis/A-3783-2008; de Oliveira, Marcos A/K-5746-2015	Cussiol, José Renato/0000-0001-5909-8215; Netto, Luis/0000-0002-4250-9177; de Oliveira, Marcos A/0000-0002-1192-7296				AKAIKE T, 1992, ARCH BIOCHEM BIOPHYS, V294, P55, DOI 10.1016/0003-9861(92)90136-K; Atichartpongkul S, 2001, MICROBIOL-SGM, V147, P1775, DOI 10.1099/00221287-147-7-1775; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Bsat N, 1996, J BACTERIOL, V178, P6579, DOI 10.1128/jb.178.22.6579-6586.1996; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Fuangthong M, 2001, J BACTERIOL, V183, P4134, DOI 10.1128/JB.183.14.4134-4141.2001; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; KIM KW, 1988, J BIOL CHEM, V263, P4704; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; Maeng JH, 1996, J BACTERIOL, V178, P3695, DOI 10.1128/jb.178.13.3695-3700.1996; Mongkolsuk S, 1998, J BACTERIOL, V180, P2636, DOI 10.1128/JB.180.10.2636-2643.1998; MONGKOLSUK S, 2000, J BACTERIOL, V182, P2636; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Ochsner UA, 2001, J BACTERIOL, V183, P773, DOI 10.1128/JB.183.2.773-778.2001; Ochsner UA, 2000, J BACTERIOL, V182, P4533, DOI 10.1128/JB.182.16.4533-4544.2000; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; RADI R, 1991, J BIOL CHEM, V266, P4244; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rince A, 2001, J BACTERIOL, V183, P1482, DOI 10.1128/JB.183.4.1482-1488.2001; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Shea RJ, 2002, INFECT IMMUN, V70, P794, DOI 10.1128/IAI.70.2.794-802.2002; Simpson AJG, 2000, NATURE, V406, P151, DOI 10.1038/35018003; Sriprang R, 2000, APPL ENVIRON MICROB, V66, P4017, DOI 10.1128/AEM.66.9.4017-4021.2000; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Sukchawalit R, 2001, J BACTERIOL, V183, P4405, DOI 10.1128/JB.183.15.4405-4412.2001; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Vattanaviboon P, 2000, GENE, V241, P259, DOI 10.1016/S0378-1119(99)00483-7; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	43	72	76	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11570	11578		10.1074/jbc.M300252200	http://dx.doi.org/10.1074/jbc.M300252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540833	hybrid			2022-12-25	WOS:000181855400090
J	Treber, M; Dai, J; Woldegiorgis, G				Treber, M; Dai, J; Woldegiorgis, G			Identification by mutagenesis of conserved arginine and glutamate residues in the C-terminal domain of rat liver carnitine palmitoyltransferase I that are important for catalytic activity and malonyl-CoA sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PICHIA-PASTORIS; FUNCTIONAL-CHARACTERIZATION; HEART; ENZYME; ISOFORM; BINDING; TISSUE	Carnitine palmitoyltransferase I (CPTI) catalyzes the conversion of long chain fatty acyl-CoAs to acylcarnitines in the presence of L-carnitine. To determine the role of the conserved glutamate residue, Glu-603, on catalysis and malonyl-CoA sensitivity, we separately changed the residue to alanine, histidine, glutamine, and aspartate. Substitution of Glu-603 with alanine or histidine resulted in complete loss of L-CPTI activity. A change of Glu-603 to glutamine caused a significant decrease in catalytic activity and malonyl-CoA sensitivity. Substitution of Glu-603 with aspartate, a negatively charged amino acid with only one methyl group less than the glutamate residue in the wild type enzyme, resulted in partial loss in CPTI activity and a 15-fold decrease in malonyl-CoA sensitivity. The mutant L-CPTI with a replacement of the conserved Arg-601 or Arg-606 with alanine also showed over 40-fold decrease in malonyl-CoA sensitivity, suggesting that these two conserved residues may be important for substrate and inhibitor binding. Since a conservative substitution of Glu-603 to aspartate or glutamine resulted in partial loss of activity and malonyl-CoA sensitivity, it further suggests that the negative charge and the longer side chain of glutamate are essential for catalysis and malonyl-CoA sensitivity. We predict that this region of L-CPTI spanning these conserved C-terminal residues may be the region of the protein involved in binding the CoA moiety of palmitoyl-CoA and malonyl-CoA and/or the putative low affinity acyl-CoA/malonyl-CoA binding site.	Oregon Hlth & Sci Univ, Oregon Grad Inst, Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA	Oregon Health & Science University	Woldegiorgis, G (corresponding author), Oregon Hlth & Sci Univ, Oregon Grad Inst, Sch Sci & Engn, Dept Environm & Biomol Syst, 20000 NW Walker Rd, Beaverton, OR 97006 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barycki JJ, 2001, J BIOL CHEM, V276, P36718, DOI 10.1074/jbc.M104839200; BENNEFONT JP, 1996, AM J HUM GENET, V58, P971; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CORR PB, 1995, HERZ, V20, P156; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Tao Bernard Y., 1994, P69; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; Woldegiorgis G, 2000, J NUTR, V130, p310S, DOI 10.1093/jn/130.2.310S; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zheng GL, 2002, J BIOL CHEM, V277, P42219, DOI 10.1074/jbc.M202914200; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	24	11	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11145	11149		10.1074/jbc.M210566200	http://dx.doi.org/10.1074/jbc.M210566200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12540837	hybrid			2022-12-25	WOS:000181855400038
J	Wang, P; Wu, YL; Ge, X; Ma, L; Pei, G				Wang, P; Wu, YL; Ge, X; Ma, L; Pei, G			Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PROSTAGLANDIN E-2 RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CLATHRIN ADAPTER; VISUAL ARRESTIN; BINDING; BETA-ARRESTIN2	beta-Arrestinl and beta-arrestin2 play a key role in the regulation of G protein-coupled receptor-mediated signaling, whereas the subcellular distribution of beta-arrestin1 and beta-arrestin2 has been shown to be quite different. In this study, we found that although both beta-arrestin1 and beta-arrestin2 are able to interact with ubiquitin-protein isopeptide ligase (E3) Mdm2, only expression of beta-arrestin2 leads to the relocalization of Mdm2 from the nucleus to the cytoplasm. Further study reveals that beta-arrestin2 but not beta-arrestin1 shuttles between the cytoplasm and nucleus in a leptomycin B-sensitive manner. A hydrophobic amino acid-rich region (VXXX-LXL) at the C terminus of beta-arrestin2 was further demonstrated to serve as a nuclear export signal responsible for the extranuclear localization of beta-arrestin2. In the corresponding region of beta-arrestin1, there is a single amino acid difference (Glu instead of Leu. in beta-arrestin2), and mutation of Glu to Leu conferred to beta-arrestin1 similar subcellular distribution to that of beta-arrestin2. Moreover, data from a series of deletion mutations demonstrated that the N domain (residues 1-185) was indispensable for the nuclear localization of both beta-arrestins, and the results from a Val to Asp point mutation in the N domain also supported this notion. In addition, our data showed that nucleocytoplasmic shuttling of beta-arrestin2 was required, via protein/protein interaction, for the cytoplasmic relocalization of Mdm2 and JNK3, another well known beta-arrestin2-binding protein. Our study thus suggests that both the nuclear export signal motif and the N domain of beta-arrestins are critical for the regulation of their subeellular localization and that beta-arrestin2 may modulate the function of its binding partners such as Mdm2 and JNK3 by alteration of their subcellular distribution.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Fudan Univ, Med Ctr, Natl Lab Med Neurobiol, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472				Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; NISHI K, 1994, J BIOL CHEM, V269, P6320; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; WANG P, 2002, J BIOL CHEM     1217; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yu QM, 1999, ACTA BIOCH BIOPH SIN, V31, P344; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	40	118	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11648	11653		10.1074/jbc.M208109200	http://dx.doi.org/10.1074/jbc.M208109200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538596	hybrid			2022-12-25	WOS:000181855400098
J	Wu, DY; Marko, M; Claycombe, K; Paulson, KE; Meydani, SN				Wu, DY; Marko, M; Claycombe, K; Paulson, KE; Meydani, SN			Ceramide-induced and age-associated increase in macrophage COX-2 expression is mediated through up-regulation of NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; TRANSCRIPTION FACTOR; VITAMIN-E; PROSTAGLANDIN SYNTHASE; C-ZETA; INDUCIBLE CYCLOOXYGENASE; NEGATIVE REGULATION; COMPLEMENTARY-DNA; RESPONSE ELEMENT	We have shown that the age-associated increase in lipopolysaccharide (LPS)-stimulated macrophages (Mphi) prostaglandin E-2 (PGE(2)) production is because of ceramide-induced up-regulation of cyclooxygenase (COX)-2 transcription that leads to increased COX-2 expression and enzyme activity. To determine the mechanism of the age-related and ceramide-dependent increase in COX-2 transcription, we investigated the role of various transcription factors involved in COX-2 gene expression. The results showed that LPS-initiated activations of both consensus and COX-2-specific NF-kappaB, but not AP-1 and CREB, were significantly higher in Mphi from old mice than those from young mice. We further showed that the higher NF-kappaB activation in old Mphi was because of greater IkappaB degradation in the cytoplasm and p65 translocation to the nucleus. An IkappaB phosphorylation inhibitor, Bay 11-7082, inhibited NF-kappaB activation, as well as PGE(2) production, COX activity, COX-2 protein, and mRNA expression in both young and old M. Similar results were obtained by blocking NF-kappaB binding activity using a NF-kappaB decoy. Furthermore, NF-kappaB inhibition resulted in significantly greater reduction in PGE(2) production and COX activity in old compared with young Mphi. Addition of ceramide to the young Mphi, in the presence or absence of LPS, increased NF-kappaB activation in parallel with PGE(2) production. Bay 11-7082 or NF-kappaB decoy prevented this ceramide-induced increase in NF-kappaB binding activity and PGE(2) production. These findings strongly suggest that the age-associated and ceramide-induced increase in COX-2 transcription is mediated through higher NF-kappaB activation, which is, in turn, because of a greater IkappaB degradation in old Mphi.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Nutr Immunol Lab, Boston, MA 02111 USA; Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Pathol, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; Tufts University	Meydani, SN (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, Nutr Immunol Lab, Boston, MA 02111 USA.				NIA NIH HHS [R01-AG09140-09] Funding Source: Medline; NIEHS NIH HHS [ES11518] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES011518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009140] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bartocci A., 1982, PROSTAGLANDINS CANC, P725; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Beharka AA, 1997, MECH AGEING DEV, V93, P59, DOI 10.1016/S0047-6374(96)01819-2; Beharka AA, 2002, FREE RADICAL BIO MED, V32, P503, DOI 10.1016/S0891-5849(01)00817-6; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Chakravarti B, 1999, MECH AGEING DEV, V108, P183, DOI 10.1016/S0047-6374(99)00009-3; Chen LC, 1996, INFECT IMMUN, V64, P4288, DOI 10.1128/IAI.64.10.4288-4298.1996; Claycombe KJ, 2002, J BIOL CHEM, V277, P30784, DOI 10.1074/jbc.M204463200; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FU JY, 1990, J BIOL CHEM, V265, P16737; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Hayek MG, 1997, J IMMUNOL, V159, P2445; HAYEK MG, 1994, J GERONTOL, V49, P197; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kim HJ, 2000, FREE RADICAL BIO MED, V28, P683, DOI 10.1016/S0891-5849(99)00274-9; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; Mestre JR, 2001, FEBS LETT, V496, P147, DOI 10.1016/S0014-5793(01)02422-X; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; MEYDANI SN, 1986, MECH AGEING DEV, V34, P191, DOI 10.1016/0047-6374(86)90034-5; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697; ROSENSTEIN MM, 1980, J RETICULOENDOTH SOC, V27, P159; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; von Knethen A, 2000, BIOCHEMISTRY-US, V39, P1532, DOI 10.1021/bi990820s; Wu D, 1998, AM J PHYSIOL-CELL PH, V275, pC661, DOI 10.1152/ajpcell.1998.275.3.C661; Xiao ZQ, 2000, AM J PHYSIOL-GASTR L, V278, pG855, DOI 10.1152/ajpgi.2000.278.6.G855; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yan ZQ, 1999, ARTERIOSCL THROM VAS, V19, P2854, DOI 10.1161/01.ATV.19.12.2854	57	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10983	10992		10.1074/jbc.M207470200	http://dx.doi.org/10.1074/jbc.M207470200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529332	hybrid			2022-12-25	WOS:000181855400016
J	Malli, R; Frieden, M; Osibow, K; Graier, WF				Malli, R; Frieden, M; Osibow, K; Graier, WF			Mitochondria efficiently buffer subplasmalemmal Ca2+ elevation during agonist stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE CONTRIBUTES; ENTRY; STORE; ACTIVATION; CHANNELS; CELLS; INHIBITION; FREQUENCY; DYNAMICS; SIGNALS	In endothelial cells, local Ca2+ release from superficial endoplasmic reticulum (ER) activates BKCa channels. The resulting hyperpolarization promotes capacitative Ca2+ entry (CCE), which, unlike BKCa channels, is inhibited by high Ca2+. To understand how the coordinated activation of plasma membrane ion channels with opposite Ca2+ sensitivity is orchestrated, the individual contribution of mitochondria and ER in regulation of subplasmalemmal Ca2+ concentration ([Ca2+](pm)) was investigated. For organelle visualization, cells were transfected with DsRed and yellow cameleon targeted to mitochondria and ER. The patch pipette was placed far from any organelle (L1), close to ER (L3), or mitochondria (L2) and activity of BKCa. channels was used to estimate local [Ca2+](pm). Under standard patch conditions (130 mm K+ in the bath), histamine increased [Ca2+](pm) at L1 and L3 to similar to1.6 mum, whereas close to mitochondria [Ca2+](pm) remained unchanged. If mitochondria moved apart from the pipette or in the presence of carbonyl cyanide-4-trifluoromethoxyphenylhyrazone, [Ca2+](pm) at L2 increased in response to histamine. Under standard patch conditions Ca2+ entry was negligible due to cell depolarization. Using a physiological patch approach (5.6 mm K+ in the bath), changes in [Ca2+](pm) to histamine could be monitored without cell depolarization and, thus, in conditions where Ca2+ entry occurred. Here, histamine induced an initial transient Ca2+ elevation to greater than or equal to3.5 muM followed by a long lasting plateau at similar to1.2 muM in L1 and L3, whereas mitochondria kept neighboring [Ca2+](pm) low during stimulation. Thus, superficial mitochondria and ER generate local domains of low and high Ca2+ allowing simultaneous activation of BKCa. and CCE, despite their opposite Ca2+ sensitivity.	Graz Univ, Dept Med Biochem & Med Mol Biol, A-8010 Graz, Austria; Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva 4, Switzerland	University of Graz; University of Geneva	Graier, WF (corresponding author), Graz Univ, Dept Med Biochem & Med Mol Biol, Harrachgassee 21-III, A-8010 Graz, Austria.	wolfgang.graier@uni-graz.at	Graier, Wolfgang F./B-7052-2008; Malli, Roland/B-7369-2008	Graier, Wolfgang F./0000-0003-1871-3298; Malli, Roland/0000-0001-6327-8729; Frieden, Maud/0000-0001-7135-0874; Osibow, Karin/0000-0002-9703-595X				BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Frieden M, 2000, J PHYSIOL-LONDON, V524, P715, DOI 10.1111/j.1469-7793.2000.00715.x; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; GRAIER WF, 1994, ENDOTHELIUM, V1, P223; GROSCHNER K, 1992, BIOCHIM BIOPHYS ACTA, V1137, P162, DOI 10.1016/0167-4889(92)90198-K; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Kamouchi M, 1999, GEN PHYSIOL BIOPHYS, V18, P199; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; Krendel M, 1998, CELL MOTIL CYTOSKEL, V40, P368, DOI 10.1002/(SICI)1097-0169(1998)40:4<368::AID-CM5>3.3.CO;2-R; Krutetskaia Z I, 1998, Tsitologiia, V40, P93; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lipp P, 2002, J PHYSIOL-LONDON, V542, P383, DOI 10.1113/jphysiol.2001.013382; Madge L, 1997, J PHYSIOL-LONDON, V498, P351, DOI 10.1113/jphysiol.1997.sp021863; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Orlati S, 1996, CELL CALCIUM, V20, P399, DOI 10.1016/S0143-4160(96)90002-0; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; PALTAUFDOBURZYN.J, 2000, J PHYSL, V524, P501; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Park KS, 2002, PFLUG ARCH EUR J PHY, V443, P344, DOI 10.1007/s004240100703; Perez GJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1769, DOI 10.1152/ajpcell.2001.281.6.C1769; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Sedova M, 2000, J BIOL CHEM, V275, P35402, DOI 10.1074/jbc.M006058200; Thyagarajan B, 2002, BRIT J PHARMACOL, V137, P821, DOI 10.1038/sj.bjp.0704949; Yaffe MP, 1999, NAT CELL BIOL, V1, pE149, DOI 10.1038/14101; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	41	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10807	10815		10.1074/jbc.M212971200	http://dx.doi.org/10.1074/jbc.M212971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529366	hybrid			2022-12-25	WOS:000181777500106
J	Murphy, JM; Ford, SC; Wiedemann, UA; Carr, PD; Ollis, DL; Young, IG				Murphy, JM; Ford, SC; Wiedemann, UA; Carr, PD; Ollis, DL; Young, IG			A novel functional epitope formed by domains 1 and 4 of the human common beta-subunit is involved in receptor activation by granulocyte macrophage colony-stimulating factor and interleukin 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; HUMAN GM-CSF; COMPLETE EXTRACELLULAR DOMAIN; HUMAN GROWTH-HORMONE; ALPHA-CHAIN; LIGAND-BINDING; IL-5 RECEPTORS; CYTOKINE RECEPTORS; CRYSTAL-STRUCTURE; EPO RECEPTOR	The receptors for human interleukins 3 and 5 and granulocyte macrophage colony-stimulating factor are composed of ligand-specific alpha-subunits and a common beta-subunit (betac), the major signaling entity. The way in which betac interacts with ligands in the respective activation complexes has remained poorly understood. The recently determined crystal structure of the extracellular domain of betac revealed a possible ligand-binding interface composed of domain 1 of one chain of the betac dimer and the adjacent domain 4 of the symmetry-related chain. We have used site-directed mutagenesis, in conjunction with ligand binding and proliferation studies, to demonstrate the critical requirement of the domain I residues, Tyr(15) (A-B loop) and Phe(79) (E-F loop), in high affinity complex formation and receptor activation. The novel ligand-receptor interface formed between domains 1 and 4 represents the first example of a class I cytokine receptor interface to be composed of two noncontiguous fibronectin III domains.	John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research; Australian National University	Young, IG (corresponding author), John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia.	Ian.Young@anu.edu.au	Murphy, James/B-4863-2017; Ollis, David/I-5967-2014	Murphy, James/0000-0003-0195-3949; 				BARRY SC, 1994, J BIOL CHEM, V269, P8488; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cook AD, 2001, ARTHRITIS RES, V3, P293, DOI 10.1186/ar318; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; Gustin SE, 2001, EUR J BIOCHEM, V268, P2905, DOI 10.1046/j.1432-1327.2001.02178.x; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Haman A, 1999, J BIOL CHEM, V274, P34155, DOI 10.1074/jbc.274.48.34155; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; INGLEY E, 1991, BLOOD, V78, P339; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; McQualter JL, 2001, J EXP MED, V194, P873, DOI 10.1084/jem.194.7.873; Middleton SA, 1999, J BIOL CHEM, V274, P14163, DOI 10.1074/jbc.274.20.14163; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MILLER J, 1985, J IMMUNOL, V134, P4212; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLINS PO, 1995, J BIOL CHEM, V270, P23754, DOI 10.1074/jbc.270.40.23754; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Yoshida T, 1996, IMMUNITY, V4, P483, DOI 10.1016/S1074-7613(00)80414-8; Zhang JL, 2002, J MOL BIOL, V315, P399, DOI 10.1006/jmbi.2001.5243	49	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10572	10577		10.1074/jbc.M211664200	http://dx.doi.org/10.1074/jbc.M211664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525483	hybrid			2022-12-25	WOS:000181777500077
J	Silva, FPG; Morolli, B; Storlazzi, CT; Anelli, L; Wessels, H; Bezrookove, V; Kluin-Nelemans, HC; Giphart-Gassler, M				Silva, FPG; Morolli, B; Storlazzi, CT; Anelli, L; Wessels, H; Bezrookove, V; Kluin-Nelemans, HC; Giphart-Gassler, M			Identification of RUNX1/AML1 as a classical tumor suppressor gene	ONCOGENE			English	Article						RUNX1; tumor suppressor gene; AML; leukemia	ACUTE MYELOID-LEUKEMIA; PROTEIN-PROTEIN INTERACTIONS; CORE-BINDING FACTOR; RUNT DOMAIN; DNA-BINDING; TRANSCRIPTIONAL REGULATION; AML1/PEBP2-ALPHA-B GENE; POINT MUTATIONS; VIRUS ENHANCERS; C/EBP-ALPHA	Based on our previous results indicating the presence of a tumor suppressor gene (TSG), chromosome 21 was analysed for loss of heterozygosity (LOH) in 18 patients with acute myeloid leukemia (17, AML-M0; one, AML-M1). Allelotyping at polymorphic loci was performed on purified material, allowing unequivocal detection of allelic loss and homozygous deletions. Six AML-M0 patients shared a common region of LOH harboring a single gene: RUNX1 (AML1), the most frequent site of translocations in acute leukemia and a well-known fusion oncogene. Fluorescence in situ hybridization allowed the identification of deletions with breakpoints within RUNX1 in two patients as the cause of LOH. In the four others the LOH pattern and the presence of two karyotypically normal chromosomes 21 were in line with mitotic recombination. Further molecular and cytogenetic analyses showed that this caused homozygosity of primary RUNX1 mutations: two point mutations, a partial deletion and, most significantly, a complete deletion of RUNX1. These findings identify RUNX1 as a classical TSG: both alleles are mutated or absent in cancer cells from four of the 17 AML-M0 patients examined. In contrast to AML-MO, the AML-M1 patient was trisomic for chromosome 21 and has two mutated - and one normal RUNX1 allele, suggesting that the order of mutagenic events leading to leukemia may influence the predominant tumor type.	Leiden Univ, Ctr Med, Dept Radiat Genet & Chem Mutagensis, NL-2600 RA Leiden, Netherlands; Univ Bari, Dept Genet, I-70126 Bari, Italy; Leiden Univ, Ctr Med, Dept Clin Cytogenet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Hematol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Universita degli Studi di Bari Aldo Moro; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Giphart-Gassler, M (corresponding author), Leiden Univ, Ctr Med, Dept Radiat Genet & Chem Mutagensis, POB 9503, NL-2600 RA Leiden, Netherlands.		Kluin-Nelemans, Johanna C/F-8658-2018; Silva, Fernando/N-1847-2014; Anelli, Luisa/K-2661-2016	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Silva, Fernando/0000-0003-2379-9137; Anelli, Luisa/0000-0002-9185-724X; Storlazzi, Clelia Tiziana/0000-0002-1696-0028				BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; de Nooij-van Dalen AG, 1998, GENE CHROMOSOME CANC, V21, P30, DOI 10.1002/(SICI)1098-2264(199801)21:1<30::AID-GCC5>3.0.CO;2-9; de Nooij-van Dalen AG, 2001, GENE CHROMOSOME CANC, V30, P323, DOI 10.1002/gcc.1098; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; Friedman AD, 1996, LEUKEMIA RES, V20, P809, DOI 10.1016/S0145-2126(96)00035-5; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Giphart-Gassler M, 1998, MUTAT RES-FUND MOL M, V400, P409, DOI 10.1016/S0027-5107(98)00022-0; Hiebert SW, 2001, CURR OPIN HEMATOL, V8, P197, DOI 10.1097/00062752-200107000-00003; Holt D, 1999, AM J HUM GENET, V65, P1423, DOI 10.1086/302614; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mitelman F., 1995, ISCN INT SYSTEM HUMA; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Nagata T, 2001, J MOL BIOL, V308, P191, DOI 10.1006/jmbi.2001.4596; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; SUDOL M, 1994, ONCOGENE, V9, P2145; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tanaka Tomoyuki, 1997, Leukemia (Basingstoke), V11, P299; Tanke HJ, 1999, EUR J HUM GENET, V7, P2, DOI 10.1038/sj.ejhg.5200265; Uchida H, 1997, J IMMUNOL, V158, P2251; VANDAM FJ, 1992, MUTAT RES, V271, P231, DOI 10.1016/0165-1161(92)90018-H; Vrieling H, 2001, NAT GENET, V28, P101, DOI 10.1038/88794; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	48	57	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					538	547		10.1038/sj.onc.1206141	http://dx.doi.org/10.1038/sj.onc.1206141			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555067				2022-12-25	WOS:000180538200007
J	Jishage, M; Fujino, T; Yamazaki, Y; Kuroda, H; Nakamura, T				Jishage, M; Fujino, T; Yamazaki, Y; Kuroda, H; Nakamura, T			Identification of target genes for EWS/ATF-1 chimeric transcription factor	ONCOGENE			English	Article						clear cell sarcoma; EWS/ATF-1; transcription factor; target gene; POSH	RNA-POLYMERASE-II; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; HOMEOBOX GENES; SOFT PARTS; ATAXIA-TELANGIECTASIA; DNA-BINDING; FUSION; EWS; RECEPTOR	Chromatin immunoprecipitation is a useful technique to detect in vivo direct interaction between any transcription factor and its binding site on genomic DNA. We applied this skill to identify the direct target gene for EWS/ATF-1 by coupling with a GFP reporter assay. This novel approach isolated 62 of cloned DNA fragments responding upon EWS/ATF-1 expression and 16 of 62 clones included putative ATF-1 binding sites. Further analysis revealed that six of the cloned fragments included possible regulatory regions of ATM, GPP34, ARNT2, NKX6.1, NYD-SP28 and POSH. Most of these clones upregulated reporter activity by overexpression of EWS/ATF-1, suggesting that putative ATF-1 binding sites in these clones are functional elements for ATF-1 in vivo. Consistently, endogenous expression of these genes was upregulated by EWS/ATF-1. Interestingly, the clone containing the promoter region of POSH, which is known to be a strong inducer of apoptosis, repressed reporter activity by overexpression of EWS/ATF-1. Correspondingly, EWS/ATF-1 expression decreased endogenous POSH expression, suggesting that six isolated genes may be involved in direct regulation by EWS/ATF-1. Moreover, induction of POSH brought apoptotic cell death to KAS, the clear cell sarcoma (CCS) cell line, suggesting that repressed expression of POSH in CCS may be relevant to the normal signaling pathway in apoptosis.	Japanese Fdn Canc Res, Inst Canc, Dept Carcinogenesis, Toshima Ku, Tokyo 1708455, Japan; Tokyo Med & Dent Univ, Dept Orthoped, Fac Med, Tokyo 1130034, Japan	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU)	Nakamura, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Carcinogenesis, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.			Fujino, Takashi/0000-0002-0953-7379				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROWN AD, 1995, ONCOGENE, V10, P1749; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P889; Fujimura Y, 1996, ONCOGENE, V12, P159; Fujino T, 2001, EXP HEMATOL, V29, P856, DOI 10.1016/S0301-472X(01)00655-5; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hirose K, 1996, MOL CELL BIOL, V16, P1706; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KUO MH, 1996, METHODS, V3, P425; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; OHNO T, 1994, ONCOGENE, V9, P3087; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Panagopoulos I, 1996, ONCOGENE, V12, P489; Rossow KL, 2001, CANCER RES, V61, P2690; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 2000, GENE DEV, V14, P2134, DOI 10.1101/gad.820400; Schaefer KL, 2002, VIRCHOWS ARCH, V440, P476, DOI 10.1007/s00428-001-0558-9; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Watson D K, 2000, Methods Mol Biol, V130, P1; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	40	24	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					41	49		10.1038/sj.onc.1206074	http://dx.doi.org/10.1038/sj.onc.1206074			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527906				2022-12-25	WOS:000180166900005
J	Mukhopadhyay, A; Heard, TS; Wen, XH; Hammen, PK; Weiner, H				Mukhopadhyay, A; Heard, TS; Wen, XH; Hammen, PK; Weiner, H			Location of the actual signal in the negatively charged leader sequence involved in the import into the mitochondrial matrix space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ISOPROPYLMALATE SYNTHASE; LIVER ALDEHYDE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; PROCESSING PEPTIDASE; PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; RAT CHAPERONIN-10; PRECURSOR PROTEIN; INNER MEMBRANE; IDENTIFICATION	Proteins destined for the mitochondrial matrix space have leader sequences that are typically present at the most N-terminal end of the nuclear-encoded precursor protein. The leaders are rich in positive charges and usually deficient of negative charges. This observation led to the acid-chain hypothesis to explain how the leader sequences interact with negatively charged receptor proteins. Here we show using both chimeric leaders and one from isopropyl malate synthase that possesses a negative charge that the leader need not be at the very N terminus of the precursor. Experiments were performed with modified non-functioning leader sequences fused to either the native or a non-functioning leader of aldehyde dehydrogenase so that an internal leader sequence could exist. The internal leader is sufficient for the import of the modified precursor protein. It appears that this leader still needs to form an amphipathic helix just like the normal N-terminal leaders do. This internal leader could function even if the most N-terminal portion contained negative charges in the first 7-11 residues. If the first 11 residues were deleted from isopropyl malate synthase, the resulting protein was imported more successfully than the native protein. It appears that precursors that carry negatively charged leaders use an internal signal sequence to compensate for the non-functional segment at the most N-terminal portion of the protein.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weiner, H (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ St, W Lafayette, IN 47907 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010795] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10795] Funding Source: Medline; NIGMS NIH HHS [GM 53269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BELTZER JP, 1988, J BIOL CHEM, V263, P368; Bomer U, 1997, J BIOL CHEM, V272, P30439, DOI 10.1074/jbc.272.48.30439; Casalone E, 2000, YEAST, V16, P539, DOI 10.1002/(SICI)1097-0061(200004)16:6<539::AID-YEA547>3.0.CO;2-K; CHU TW, 1987, J BIOL CHEM, V262, P12806; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HAMPSEY DM, 1983, P NATL ACAD SCI-BIOL, V80, P1270, DOI 10.1073/pnas.80.5.1270; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; Heard TS, 1998, J BIOL CHEM, V273, P29389, DOI 10.1074/jbc.273.45.29389; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; Mukhopadhyay A, 2002, PROTEIN SCI, V11, P1026, DOI 10.1110/ps.3760102; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RYAN MT, 1994, FEBS LETT, V337, P152, DOI 10.1016/0014-5793(94)80263-7; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schleiff E, 1999, FEBS LETT, V461, P9, DOI 10.1016/S0014-5793(99)01415-5; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VANHEIJNE G, 1986, EMBO J, V5, P1335; Voss H, 1997, YEAST, V13, P655, DOI 10.1002/(SICI)1097-0061(19970615)13:7<655::AID-YEA120>3.0.CO;2-I; Waltner M, 1996, J BIOL CHEM, V271, P21226, DOI 10.1074/jbc.271.35.21226; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; WANG Y, 1993, J BIOL CHEM, V268, P4759; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Zhou JZ, 2001, PROTEIN SCI, V10, P1490, DOI 10.1110/ps.5301	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13712	13718		10.1074/jbc.M212743200	http://dx.doi.org/10.1074/jbc.M212743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12551941	hybrid			2022-12-25	WOS:000182405000021
J	Senn, JJ; Klover, PJ; Nowak, IA; Zimmers, TA; Koniaris, LG; Furlanetto, RW; Mooney, RA				Senn, JJ; Klover, PJ; Nowak, IA; Zimmers, TA; Koniaris, LG; Furlanetto, RW; Mooney, RA			Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; ADIPOSE-TISSUE; GROWTH-HORMONE; FACTOR-ALPHA; MICE LACKING; TNF-ALPHA; GLUCOSE-PRODUCTION; BOX MOTIF	Interleukin-6 (IL-6) is one of several pro-inflammatory cytokines implicated in insulin resistance during infection, cachexia, and obesity. We recently demonstrated that IL-6 inhibits insulin signaling in hepatocytes (Senn, J. J., Klover, P. J., Nowak, I. A., and Mooney, R. A. (2002) Diabetes 51, 3391-3399). Members of the suppressors of cytokine signaling (SOCS) family associate with the insulin receptor (IR), and their ectopic expression inhibits IR signaling. Since several SOCS proteins are induced by IL-6, a working hypothesis is that IL-6-dependent insulin resistance is mediated, at least in part, by induction of SOCS protein(s) in insulin target cells. To examine the involvement of SOCS protein(s) in IL-6-dependent inhibition of insulin receptor signaling, HepG2 cells were treated with IL-6 (20 ng/ml) for periods from 1 min to 8 h. IL-6 induced SOCS-3 transcript at 30 min with a maximum effect at 1 h. SOCS-3 protein levels were also markedly elevated at 1 h. Transcript and protein levels returned to near basal levels by 2 h. SOCS-3 induction by IL-6 paralleled IL-6-dependent inhibition of IR signal transduction. Ectopically expressed SOCS-3 associated with the IR and suppressed insulin-dependent receptor autophosphorylation, insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, association of IRS-1 with the p85 subunit of phosphatidylinositol 3-kinase, and activation of Akt. SOCS-3 was also a direct inhibitor of insulin receptor autophosphorylation in vitro. In mice exposed to IL-6 for 60-90 min, hepatic SOCS-3 expression was increased. This was associated with inhibition of hepatic insulin-dependent receptor autophosphorylation and IRS-1 tyrosine phosphorylation. These data suggest that induction of SOCS-3 in liver may be an important mechanism of IL-6-mediated insulin resistance.	Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Surg, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Mooney, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, 601 Elmwood Ave, Rochester, NY 14642 USA.		Zimmers, Teresa/AAD-5461-2019	Zimmers, Teresa/0000-0001-7872-0540	PHS HHS [R01-38138] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Boisclair YR, 2000, J BIOL CHEM, V275, P3841, DOI 10.1074/jbc.275.6.3841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Cheung AT, 1998, ENDOCRINOLOGY, V139, P4928, DOI 10.1210/en.139.12.4928; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hong F, 2001, FASEB J, V15, P1595, DOI 10.1096/fj.00-0908fje; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING PR, 1994, METABOLISM, V43, P279, DOI 10.1016/0026-0495(94)90093-0; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; RIZZA RA, 1982, DIABETES, V31, P663, DOI 10.2337/diabetes.31.8.663; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang Y, 2000, AM J PHYSIOL-ENDOC M, V279, pE196, DOI 10.1152/ajpendo.2000.279.1.E196	54	461	490	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13740	13746		10.1074/jbc.M210689200	http://dx.doi.org/10.1074/jbc.M210689200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12560330	hybrid			2022-12-25	WOS:000182405000024
J	Grimm, HS; Beher, D; Lichtenthaler, SF; Shearman, MS; Beyreuther, K; Hartmann, T				Grimm, HS; Beher, D; Lichtenthaler, SF; Shearman, MS; Beyreuther, K; Hartmann, T			gamma-secretase cleavage site specificity differs for intracellular and secretory amyloid beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PRECURSOR PROTEIN APP; ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; LATE COMPARTMENTS; NEURONAL CELLS; BREFELDIN-A; PRESENILIN-1; PEPTIDE	The final step in Abeta generation is the cleavage of the C-terminal 99 amino acid residues of the amyloid precursor protein by gamma-secretase. gamma-Secretase activity is closely linked to the multi-transmembrane-spanning proteins presenilin 1 and presenilin 2. To elucidate whether the cleavage site specificities of gamma-secretase leading to the formation of secreted and intracellular A,6 are identical, we made use of point mutations close to the gamma-cleavage site, known to have a dramatic effect on the 42/40 ratio of secreted Abeta. We found that the selected point mutations only marginally influenced the 42/40 ratio of intracellular Abeta, suggesting differences in the gamma-secretase cleavage site specificity for the generation of secreted and intracellular Abeta. The analysis of the subcellular compartments involved in the generation of intracellular Abeta revealed that Abeta is not generated in the early secretory pathway in the human SH-SY5Y neuroblastoma cell line. In this study we identified late Golgi compartments to be involved in the generation of intracellular Abeta. Moreover, we demonstrate that the presence of processed PS1 is not sufficient to obtain gamma-secretase processing of the truncated amyloid precursor protein construct C99, proposing the existence of an additional factor downstream of the endoplasmic reticulum and early Golgi required for the formation of an active gamma-secretase complex.	Heidelberg Univ, ZMBH, Ctr Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Biochem, Harlow CM20 2QR, Essex, England; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Mol Biol, Harlow CM20 2QR, Essex, England	Ruprecht Karls University Heidelberg; University of Munich; Merck & Company; Merck & Company	Grimm, HS (corresponding author), Heidelberg Univ, ZMBH, Ctr Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	h.grimm@mail.zmbh.uni-heidelberg.de; tobias.hartmann@zmbh.uni-heidelberg	Hartmann, Tobias/AAB-8297-2022; Lichtenthaler, Stefan F/B-6587-2016	Lichtenthaler, Stefan F/0000-0003-2211-2575; Beher, Dirk/0000-0001-8005-5359; Hartmann, Tobias/0000-0001-7481-6430				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Culvenor JG, 2000, EXP CELL RES, V255, P192, DOI 10.1006/excr.1999.4791; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; D'Andrea MR, 2002, NEUROSCI LETT, V333, P163, DOI 10.1016/S0304-3940(02)00875-3; De Strooper B, 2000, J CELL SCI, V113, P1857; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Grziwa B, 2003, J BIOL CHEM, V278, P6803, DOI 10.1074/jbc.M210047200; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LE AQ, 1994, J BIOL CHEM, V269, P7514; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Lichtenthaler SF, 2002, P NATL ACAD SCI USA, V99, P1365, DOI 10.1073/pnas.032395699; Lichtenthaler SF, 1999, FEBS LETT, V453, P288, DOI 10.1016/S0014-5793(99)00730-9; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Mochizuki A, 2000, LANCET, V355, P42, DOI 10.1016/S0140-6736(99)04937-5; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Peraus GC, 1997, J NEUROSCI, V17, P7714; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Petanceska SS, 2000, J NEUROCHEM, V74, P1878, DOI 10.1046/j.1471-4159.2000.0741878.x; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	86	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13077	13085		10.1074/jbc.M210380200	http://dx.doi.org/10.1074/jbc.M210380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556458	hybrid			2022-12-25	WOS:000182189500063
J	Koldamova, RP; Lefterov, LM; Ikonomovic, MD; Skoko, J; Lefterov, PI; Isanskis, BA; DeKosky, ST; Lazo, JS				Koldamova, RP; Lefterov, LM; Ikonomovic, MD; Skoko, J; Lefterov, PI; Isanskis, BA; DeKosky, ST; Lazo, JS			22R-Hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; LIVER-X RECEPTORS; PRECURSOR PROTEIN; MESSENGER-RNA; HIPPOCAMPAL-NEURONS; BLEOMYCIN HYDROLASE; CEREBROSPINAL-FLUID; ABCA1 TRANSPORTER; IN-VITRO; APOA-I	The ATP-binding cassette transporter A1 (ABCA1) is a major regulator of peripheral cholesterol efflux and plasma high density lipoprotein metabolism. In adult rat brain we found high expression of ABCA1 in neurons in the hypothalamus, thalamus, amygdala, cholinergic basal forebrain, and hippocampus. Large neurons of the cholinergic nucleus basalis together with CA1 and CA3 pyramidal neurons were among the most abundantly immunolabeled neurons. Glia cells were largely negative. Because cholesterol homeostasis may have an essential role in central nervous system function and neurodegeneration, we examined ABCA1 expression and function in different brain cell types using cultures of primary neurons, astrocytes, and microglia isolated from embryonic rat brain. The basal ABCA1 mRNA and protein levels detected in these cell types were increased markedly after exposure to oxysterols and 9-cis-retinoic acid, which are ligands for the nuclear hormone liver X receptors and retinoic X receptors, respectively. Functionally, the increased ABCA1 expression caused by these ligands was followed by elevated apoA-I- and apoE-specific cholesterol efflux in neurons and glia. In non-neuronal and neuronal cells overexpressing a human Swedish variant of amyloid precursor protein, 22R-hydroxycholesterol and 9-cis-retinoic acid induced ABCA1 expression and increased apoA-I-mediated cholesterol efflux consequently decreasing cellular cholesterol content. More importantly, we demonstrated that these ligands alone or in combination with apoA-I caused a substantial reduction in the stability of amyloid precursor protein C-terminal fragments and decreased amyloid beta production. These effects of 22R-hydroxycholesterol may provide a novel strategy to decrease amyloid beta secretion and consequently reduce the amyloid burden in the brain.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E-1358 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		Skoko, John/AAL-1885-2021	Koldamova, Radosveta/0000-0002-6761-0984; Skoko, John/0000-0002-1885-6929; DeKosky, Steven/0000-0003-3743-2758; Lefterov, Iliya/0000-0002-0249-0280	NIA NIH HHS [AG 18558] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Attie AD, 2001, J LIPID RES, V42, P1717; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; CACERES A, 1986, J NEUROSCI, V6, P714; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Clee SM, 2001, CIRCULATION, V103, P1198; Costet P, 2000, J BIOL CHEM, V275, P28240; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; De Strooper B, 2000, J CELL SCI, V113, P1857; Dean M, 2001, J LIPID RES, V42, P1007; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; GAYEN AK, 1995, ARCH BIOCHEM BIOPHYS, V322, P475, DOI 10.1006/abbi.1995.1491; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Hobbs HH, 1999, J CLIN INVEST, V104, P1015, DOI 10.1172/JCI8509; IKONOMOVIC MD, 1995, J COMP NEUROL, V359, P239, DOI 10.1002/cne.903590205; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lefterov IM, 2001, BIOCHEM BIOPH RES CO, V283, P994, DOI 10.1006/bbrc.2001.4860; Lefterov IM, 2000, FASEB J, V14, P1837, DOI 10.1096/fj.99-0938com; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Panzenboeck U, 2002, J BIOL CHEM, V277, P42781, DOI 10.1074/jbc.M207601200; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Steiner RD, 2000, J LIPID RES, V41, P1437; van Dam MJ, 2002, LANCET, V359, P37, DOI 10.1016/S0140-6736(02)07277-X; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; WOLLMER MA, 2002, NEUROBIOL AGING, V23, pS216; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992	63	211	220	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13244	13256		10.1074/jbc.M300044200	http://dx.doi.org/10.1074/jbc.M300044200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12547833	hybrid			2022-12-25	WOS:000182189500083
J	Medley, QG; Buchbinder, EG; Tachibana, K; Ngo, H; Serra-Pages, C; Streuli, M				Medley, QG; Buchbinder, EG; Tachibana, K; Ngo, H; Serra-Pages, C; Streuli, M			Signaling between focal adhesion kinase and trio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HIGH-AFFINITY BINDING; SRC FAMILY KINASES; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; PROTEIN-KINASE; SERINE/THREONINE KINASE; SERINE PHOSPHORYLATION; SUBSTRATE P130(CAS); NEURITE OUTGROWTH	The Trio guanine nucleotide exchange factor functions in neural development in Caenorhabditis elegans and Drosophila and in the development of neural tissues and skeletal muscle in mouse. The association of Trio with the Lar tyrosine phosphatase led us to study the role of tyrosine phosphorylation in Trio function using focal adhesion kinase (FAK). The Lar-interacting domain of Trio is constitutively tyrosine-phosphorylated when expressed in COS-7 cells and was highly phosphorylated when it was co-transfected with FAK. Co-precipitation. studies indicated that Trio binds to the FAK amino-terminal domain and to the FAK kinase domain via its SH3 and kinase domains, respectively. Tyrosine-phosphorylated FAK and Trio were present mainly in the detergent-insoluble fraction of cell lysates, and co-expression of Trio and FAK resulted in increased amounts of Trio present in the detergent-insoluble fraction. Immunofluorescence of cells co-transfected with FAK and Trio revealed significant co-localization. of the proteins at the cell periphery, indicating that they form a stable complex in vivo. A FAK phosphorylation site, tyrosine residue 2737, was identified in subdomain I of the Trio kinase domain. Additionally, in vitro phosphorylation assays and in vivo co-expression studies indicated that Trio enhances FAK kinase activity. These results suggest Trio may be involved in the regulation of focal adhesion dynamics in addition to effecting changes in the actin cytoskeleton. through the activation of Rho family GTPases.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Medley, QG (corresponding author), UCB Res, 840 Mem Dr, Cambridge, MA 02139 USA.				NATIONAL CANCER INSTITUTE [R01CA075091, R01CA055547] Funding Source: NIH RePORTER; NCI NIH HHS [CA75091, CA55547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blangy A, 2000, J CELL SCI, V113, P729; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chernoff J, 1999, NAT CELL BIOL, V1, pE115, DOI 10.1038/12942; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Ma A, 2001, MOL BIOL CELL, V12, P1; Medley QG, 2000, J BIOL CHEM, V275, P36116, DOI 10.1074/jbc.M003775200; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Seipel K, 2001, J CELL SCI, V114, P389; Seipel K, 1999, J CELL SCI, V112, P1825; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sieg DJ, 1999, J CELL SCI, V112, P2677; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Turner CE, 2000, J CELL SCI, V113, P4139; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	51	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13265	13270		10.1074/jbc.M300277200	http://dx.doi.org/10.1074/jbc.M300277200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12551902	hybrid			2022-12-25	WOS:000182189500085
J	Pan, Y; Zvaritch, E; Tupling, AR; Rice, WJ; de Leon, S; Rudnick, M; McKerlie, C; Banwell, BL; MacLennan, DH				Pan, Y; Zvaritch, E; Tupling, AR; Rice, WJ; de Leon, S; Rudnick, M; McKerlie, C; Banwell, BL; MacLennan, DH			Targeted disruption of the ATP2A1 gene encoding the sarco(endo)plasmic reticulum Ca2+ ATPase isoform 1 (SERCA1) impairs diaphragm function and is lethal in neonatal mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; BRODY-DISEASE; CARDIAC CONTRACTILITY; MESSENGER-RNA; CA-2+ ATPASE; CA2+-ATPASE; EXPRESSION; HEART; RAT	Mutations in the ATP2A1 gene, encoding isoform I of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA1), are one cause of Brody disease, characterized in humans by exercise-induced contraction of fast twitch (type 11) skeletal muscle fibers. In an attempt to create a model for Brody disease, the mouse ATP2A1 gene was targeted to generate a SERCA1-null mutant mouse line. In contrast to humans, term SERCA1-null mice had progressive cyanosis and gasping respiration and succumbed from respiratory failure shortly after birth. The percentage of affected homozygote SERCA1(-/-) mice was consistent with predicted Mendelian inheritance. A survey of multiple organs from 10-, 15-, and 18-day embryos reirealed no morphological abnormalities, but analysis of the lungs in term mice revealed diffuse congestion and epithelial hypercellularity and studies of the diaphragm muscle revealed prominent hypercontracted regions in scattered fibers and increased fiber size variability. The V-max of Ca2+ transport activity in mutant diaphragm and skeletal muscle was reduced by 80% compared with wild-type muscle, and the contractile response to electrical stimulation under physiological conditions was reduced dramatically in mutant diaphragm muscle. No compensatory responses were detected in analysis of mRNAs encoding other Ca2+ handling proteins or of protein levels. Expression of ATP2A1 is largely restricted to type 11 fibers, which predominate in normal mouse diaphragm. The absence of SERCA1 in type II fibers, and the absence of compensatory increases in other Ca2+ handling proteins, coupled with the marked increase in contractile function required of the diaphragm muscle to support postnatal respiration, can account for respiratory failure in term SERCA1-null mice.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Banting Inst, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Hosp Sick Children, Dept Pediat Neurol, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.			Rudnicki, Michael/0000-0002-3866-5249; McKerlie, Colin/0000-0002-2232-0967; Rice, William/0000-0002-5187-255X; Tupling, A. Russell/0000-0002-3895-6767				ARAI M, 1992, AM J PHYSIOL, V262, P614; ARMSTRONG RB, 1991, SPORTS MED, V12, P184, DOI 10.2165/00007256-199112030-00004; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BENDERS AAGM, 1994, J CLIN INVEST, V94, P741, DOI 10.1172/JCI117393; Bernhard W, 2001, AM J RESP CELL MOL, V25, P725, DOI 10.1165/ajrcmb.25.6.4616; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRODY IA, 1969, NEW ENGL J MED, V281, P187, DOI 10.1056/NEJM196907242810403; BURK SE, 1989, J BIOL CHEM, V264, P18561; DANON MJ, 1988, NEUROLOGY, V38, P812, DOI 10.1212/WNL.38.5.812; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fournier M, 2000, AM J PHYSIOL-ENDOC M, V278, pE707, DOI 10.1152/ajpendo.2000.278.4.E707; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; HOU PCL, 1989, RESP PHYSIOL, V78, P265, DOI 10.1016/0034-5687(89)90103-5; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KARPATI G, 1986, ANN NEUROL, V20, P38, DOI 10.1002/ana.410200108; KARPATI G, 1999, EXERCISE INTOLERANCE, P45; KOLBECK RC, 1994, J APPL PHYSIOL, V77, P1991, DOI 10.1152/jappl.1994.77.4.1991; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Mortola J. P., 2001, RESP PHYSL NEWBORN M; Neville C, 1997, METHOD CELL BIOL, V52, P85, DOI 10.1016/S0091-679X(08)60375-1; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Odermatt A, 2000, HUM GENET, V106, P482, DOI 10.1007/s004390000297; Ortenblad N, 2000, J APPL PHYSIOL, V89, P210; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7; Pette D, 2001, HISTOCHEM CELL BIOL, V115, P359, DOI 10.1007/s004180100268; SCHWARTZ WN, 1977, BIOCHEM J, V167, P811, DOI 10.1042/bj1670811; Takekura H, 2001, DEV BIOL, V239, P204, DOI 10.1006/dbio.2001.0437; TAYLOR DJ, 1988, J NEUROL NEUROSUR PS, V51, P1425, DOI 10.1136/jnnp.51.11.1425; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WEVERS RA, 1992, J INHERIT METAB DIS, V15, P423, DOI 10.1007/BF02435994; Williams JH, 1997, J APPL PHYSIOL, V83, P444, DOI 10.1152/jappl.1997.83.2.444; WU KD, 1993, AM J PHYSIOL, V264, P333; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	46	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13367	13375		10.1074/jbc.M213228200	http://dx.doi.org/10.1074/jbc.M213228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556521	hybrid			2022-12-25	WOS:000182189500098
J	Weber, J; Wilke-Mounts, S; Senior, AE				Weber, J; Wilke-Mounts, S; Senior, AE			Identification of the F-1-binding surface on the delta-Subunit of ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVITY CONFERRING PROTEIN; B-SUBUNIT; F1F0-ATP SYNTHASE; ALPHA-SUBUNIT; CROSS-LINKING; H+-ATPASE; BINDING; F1; DOMAIN; STATOR	The stator function in ATP synthase was studied by a combined mutagenesis and fluorescence approach. Specifically, binding of delta-subunit to delta-depleted F-1 was studied. A plausible binding surface on delta-subunit was identified from conservation of amino acid sequence and the high resolution NMR structure. Specific mutations aimed at modulating binding were introduced onto this surface. Affinity of binding of wild-type and mutant delta-subunits to delta-depleted F-1 was determined quantitatively using the fluorescence signals of natural delta-Trp-28, inserted delta-Trp-11, or inserted delta-Trp-79. The results demonstrate that helices 1 and 5 in the N-terminal domain of the delta-subunit provide the F-1-binding surface of delta. Unexpectedly, mutations that impaired binding between F-1 and delta were found to not necessarily mpair ATP synthase activity. Further investigation revealed that inclusion of the soluble cytoplasmic domain of the b subunit substantially enhanced affinity of binding of delta-subunit to F-1. The new data show that the stator is "overengineered" to resist rotor torque during catalysis.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Covell DG, 1997, J MOL BIOL, V269, P281, DOI 10.1006/jmbi.1997.1028; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; Golden TR, 1998, BIOCHEMISTRY-US, V37, P13871, DOI 10.1021/bi981120a; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; HAZARD AL, 1994, J BIOL CHEM, V269, P418; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rubinstein JL, 2002, J MOL BIOL, V321, P613, DOI 10.1016/S0022-2836(02)00671-X; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	31	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13409	13416		10.1074/jbc.M212037200	http://dx.doi.org/10.1074/jbc.M212037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556473	hybrid			2022-12-25	WOS:000182189500103
J	Kahler, RA; Westendorf, JJ				Kahler, RA; Westendorf, JJ			Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; RECEPTOR-RELATED PROTEIN-5; LEUKEMIA-VIRUS ENHANCERS; CLEIDOCRANIAL DYSPLASIA; SIGNAL-TRANSDUCTION; BONE-FORMATION; DNA-BINDING; OSTEOBLAST DIFFERENTIATION; EMBRYONIC-DEVELOPMENT; COLON-CANCER	Functional control of the transcription factor Runx2 is crucial for normal bone formation. Runx2 is detectable throughout osteoblast development and maturation and temporally regulates several bone-specific genes. In this study, we identified a novel post-translational mechanism regulating Runx2-dependent activation of the osteocalcin promoter. A functional binding site for the high mobility group protein lymphoid enhancer-binding factor 1 (LEF1) was found adjacent to the proximal Runx2-binding site in the osteocalcin promoter. In transcription assays, LEF1 repressed Runx2-induced activation of the mouse osteocalcin 2 promoter in several osteoblast lineage cell lines. Mutations in the LEF1-binding site increased the basal activity of the osteocalcin promoter; however, the LEF1 recognition site in the osteocalcin promoter was surprisingly not required for LEF1 repression. A novel interaction between the DNA-binding domains of Runx2 and LEF1 was identified and found crucial for LEF1-mediated repression of Runx2. LEF1 is a nuclear effector of the Wnt/LRP5/beta-catenin signaling pathway, which is also essential for osteoblast proliferation and normal skeletal development. A constitutively active beta-catenin enhanced LEF1-dependent repression of Runx2. These data identify a novel mechanism of regulating Runx2 activity in osteoblasts and link Runx2 transcriptional activity to beta-catenin signaling.	Univ Minnesota, Ctr Canc, Dept Orthopaed Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Grad Program Microbiol Immunol & Canc Biol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Westendorf, JJ (corresponding author), Univ Minnesota, Ctr Canc, Dept Orthopaed Surg, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	weste047@umn.edu						Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Bejsovec A, 1999, CURR BIOL, V9, pR684, DOI 10.1016/S0960-9822(99)80439-4; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Cadigan KM, 2002, DEVELOPMENT, V129, P3393; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Ezashi T, 2001, MOL CELL BIOL, V21, P7883, DOI 10.1128/MCB.21.23.7883-7891.2001; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hetman M, 2000, J NEUROSCI, V20, P2567; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Latchman DS, 1996, INT J BIOCHEM CELL B, V28, P965, DOI 10.1016/1357-2725(96)00039-8; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Peifer M, 1999, NATURE, V400, P213, DOI 10.1038/22214; Piepenburg O, 2000, MOL CELL, V6, P203, DOI 10.1016/S1097-2765(00)00022-8; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Van Hul E, 2002, J BONE MINER RES, V17, P1111, DOI 10.1359/jbmr.2002.17.6.1111; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Yang X, 2000, DEVELOPMENT, V127, P3695; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang J, 1998, DEVELOPMENT, V125, P3075; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	68	161	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11937	11944		10.1074/jbc.M211443200	http://dx.doi.org/10.1074/jbc.M211443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551949	hybrid			2022-12-25	WOS:000182015700030
J	O'Brien, KB; Argetsinger, LS; Diakonova, M; Carter-Su, C				O'Brien, KB; Argetsinger, LS; Diakonova, M; Carter-Su, C			YXXL motifs in SH2-B beta are phosphorylated by JAK2, JAK1, and platelet-derived growth factor receptor and are required for membrane ruffling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; STAT5 ACTIVATION; ADAPTER PROTEIN; SH2 DOMAIN; FACTOR-I; HORMONE; BINDING; IDENTIFICATION	SH2-Bbeta binds to the activated form of JAK2 and various receptor tyrosine kinases. It is a potent stimulator of JAK2, is required for growth hormone (GH)-induced membrane ruffling, and increases mitogenesis stimulated by platelet-derived growth factor (PDGF) and insulin-like growth factor I. Its domain structure suggests that SH2-Bbeta may act as an adapter protein to recruit downstream signaling proteins to kinase-SH2-Bbeta complexes. SH2-Bbeta is tyrosyl-phosphorylated in response to GH and interferon-gamma, stimulators of JAK2, as well as in response to PDGF and nerve growth factor. To begin to elucidate the role of tyrosyl phosphorylation in the function of SH2-Bbeta, we used phosphopeptide mapping, mutagenesis, and a phosphotyrosine-specific antibody to identify Tyr-439 and Tyr-494 in SH2-Bbeta as targets of JAK2 both in vitro and in intact cells. SH2-Bbeta lacking Tyr-439 and Tyr-494 inhibits GH-induced membrane ruffling but still activates JAK2. We provide evidence that JAK1, like JAK2, phosphorylates Tyr-439 and Tyr-494 in SH2-Bbeta and that PDGF receptor phosphorylates SH2-Bbeta on Tyr-439. Therefore, phosphorylated Tyr-439 and/or Tyr-494 in SH2-Bbeta may provide a binding site for one or more proteins linking cytokine receptor JAK2 complexes and/or receptor tyrosine kinases to the actin cytoskeleton.	Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 49109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 48109 USA.	cartersu@umich.edu		Diakonova, Maria/0000-0002-4554-2730	NCI NIH HHS [P30-CA46592] Funding Source: Medline; NIDDK NIH HHS [P60-DK20572, R01-DK54222, R37 DK034171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, R01DK054222, R37DK034171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Diakonova M, 2002, J BIOL CHEM, V277, P10669, DOI 10.1074/jbc.M111138200; Gergely J, 1999, IMMUNOL LETT, V68, P3, DOI 10.1016/S0165-2478(99)00024-3; Goh ELK, 2000, J BIOL CHEM, V275, P17683, DOI 10.1074/jbc.M001972200; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Herrington J, 2000, J BIOL CHEM, V275, P13126, DOI 10.1074/jbc.275.17.13126; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Brien KB, 2002, J BIOL CHEM, V277, P8673, DOI 10.1074/jbc.M109165200; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Pandey A, 2002, ONCOGENE, V21, P8029, DOI 10.1038/sj.onc.1205988; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Riedel H, 2000, ONCOGENE, V19, P39, DOI 10.1038/sj.onc.1203253; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1999, J BIOL CHEM, V274, P26485, DOI 10.1074/jbc.274.37.26485; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Yousaf N, 2001, J BIOL CHEM, V276, P40940, DOI 10.1074/jbc.M104191200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	38	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11970	11978		10.1074/jbc.M210765200	http://dx.doi.org/10.1074/jbc.M210765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551917	hybrid			2022-12-25	WOS:000182015700034
J	Vander Kooi, BT; Streeper, RS; Svitek, CA; Oeser, JK; Powell, DR; O'Brien, RM				Vander Kooi, BT; Streeper, RS; Svitek, CA; Oeser, JK; Powell, DR; O'Brien, RM			The three insulin response sequences in the glucose-6-phosphatase catalytic subunit gene promoter are functionally distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; TRANSCRIPTION FACTOR FKHR; NUCLEAR FACTOR-I; PHOSPHOENOLPYRUVATE CARBOXYKINASE; FORKHEAD TRANSCRIPTION; KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE; PEPCK GENE; PROXIMAL PROMOTER; MAMMALIAN TARGET	Glucose-6-phosphatase catalyzes the terminal step in the gluconeogenic and glycogenolytic pathways. In HepG2 cells, the maximum repression of basal glucose-6-phosphatase catalytic subunit (G6Pase) gene transcription by insulin requires two distinct promoter regions, designated A (located between -231 and -199) and B (located between -198 and -159), that together form an insulin response unit. Region A binds hepatocyte nuclear factor-1, which acts as an accessory factor to enhance the effect of insulin, mediated through region B, on G6Pase gene transcription. We have previously shown that region B binds the transcriptional activator FKHR (FOXO1a) in vitro. Chromatin immunoprecipitation assays demonstrate that FKHR also binds the G6Pase promoter in situ and that insulin inhibits this binding. Region B contains three insulin response sequences (IRSs), designated IRS 1, 2, and 3, that share the core sequence T(G/A)TTTT. However, detailed analyses reveal that these three G6Pase IRSs are functionally distinct. Thus, FKHR binds IRS 1 with high affinity and IRS 2 with low affinity but it does not bind IRS 3. Moreover, in the context of the G6Pase promoter, IRS I and 2, but not IRS 3, are required for the insulin response. Surprisingly, IRS 3, as well as IRS 1 and IRS 2, can each confer an inhibitory effect of insulin on the expression of a heterologous fusion gene, indicating that, in this context, a transcription factor other than FKHR, or its orthologs, can also mediate an insulin response through the T(G/A)TTTT motif.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Vanderbilt University; Baylor College of Medicine	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 761 PRB,MRB 2Hall, Nashville, TN 37232 USA.				NIDDK NIH HHS [P60 DK20593, DK56374, 5 T 32 DK07563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, T32DK007563, R01DK056374] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Band CJ, 1997, J BIOL CHEM, V272, P138; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; CONSOLI A, 1992, DIABETES CARE, V15, P430, DOI 10.2337/diacare.15.3.430; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Kaestner KH, 2000, GENE DEV, V14, P142; Khan A, 1998, METABOLISM, V47, P627, DOI 10.1016/S0026-0495(98)90021-X; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; MARTIN CC, 2003, IN PRESS BIOCH J; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBrien RM, 1995, BBA-GENE STRUCT EXPR, V1264, P284, DOI 10.1016/0167-4781(95)00194-8; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Patel S, 2002, BIOCHEM J, V365, P537, DOI 10.1042/BJ20020266; Patel S, 2002, J BIOL CHEM, V277, P9889, DOI 10.1074/jbc.M109870200; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 2000, J BIOL CHEM, V275, P12108, DOI 10.1074/jbc.275.16.12108; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200	86	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11782	11793		10.1074/jbc.M212570200	http://dx.doi.org/10.1074/jbc.M212570200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12556524	hybrid			2022-12-25	WOS:000182015700010
J	Wu, GS; Olivecrona, G; Olivecrona, T				Wu, GS; Olivecrona, G; Olivecrona, T			The distribution of lipoprotein lipase in rat adipose tissue - Changes with nutritional state engage the extracellular enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG TISSUES; ADIPOCYTES; METABOLISM; STARVATION; MECHANISMS; EXPRESSION; INSULIN; MUSCLE; CELLS; HEART	Lipoprotein lipase (LPL) acts at the vascular endothelium. Earlier studies have shown that down-regulation of adipose tissue LPL during fasting is post-translational and involves a shift from active to inactive forms of the lipase. Studies in cell systems had indicated that during fasting LPL might be retained in the endoplasmic reticulum. We have now explored the relation between active/inactive and intra/extracellular forms of the lipase. Within adipocytes, neither LPL mass nor the distribution of LPL between active and inactive forms changed on fasting. Extracellular LPL mass also did not change significantly, but shifted from predominantly active to predominantly inactive. To explore if changes in secretion were compensated by changes in turnover, synthesis of new protein was blocked by cycloheximide. The rates at which intra- and extracellular LPL mass and activity decreased did not change on fasting. To further explore how LPL is distributed in the tissue, heparin (which detaches the enzyme from the endothelial surface) was injected. Tissue LPL activity decreased by about 10% in 2 min and by 50% in 1 h. Heparin released mainly the active form of the lipase. There was no change of LPL activity or mass within adipocytes. The fraction of extracellular LPL that heparin released and the time course were the same in fed and fasted rats, indicating that active, extracellular LPL was distributed in a similar way in the two nutritional states. This study suggests that the nutritional regulation of LPL in adipose tissue determines the activity state of extracellular LPL.	Umea Univ, Dept Med Biosci, SE-90185 Umea, Sweden	Umea University	Olivecrona, T (corresponding author), Umea Univ, Dept Med Biosci, Bldg 6M,3rd Floor, SE-90185 Umea, Sweden.	Thomas.Olivecrona@medbio.umu.se						Ben-Zeev O, 2002, J BIOL CHEM, V277, P10727, DOI 10.1074/jbc.M108128200; Bergo M, 2002, J BIOL CHEM, V277, P11927, DOI 10.1074/jbc.M200325200; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BORENSZTAJN J, 1987, LIPOPROTEIN LIPASE, P133; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; CRYER A, 1975, BIOCHEM J, V146, P481, DOI 10.1042/bj1460481; CRYER A, 1973, BIOCHEM J, V132, P833, DOI 10.1042/bj1320833; CRYER A, 1976, CLIN SCI MOL MED, V50, P213, DOI 10.1042/cs0500213; CUNNINGHAM VJ, 1969, BIOCHEM J, V112, P203, DOI 10.1042/bj1120203; CUPP M, 1987, J BIOL CHEM, V262, P6383; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; ENERBACK S, 1988, GENE, V64, P97, DOI 10.1016/0378-1119(88)90484-2; ERSKINE JM, 1994, J NUTR, V124, P500, DOI 10.1093/jn/124.4.500; FRIEDMAN G, 1982, BIOCHIM BIOPHYS ACTA, V711, P114, DOI 10.1016/0005-2760(82)90016-9; GARFINKEL AS, 1976, BIOCHIM BIOPHYS ACTA, V424, P264, DOI 10.1016/0005-2760(76)90194-6; Goldberg IJ, 1996, J LIPID RES, V37, P693; HOLLENBERG CH, 1959, AM J PHYSIOL, V197, P667, DOI 10.1152/ajplegacy.1959.197.3.667; KUWAJIMA M, 1988, METABOLISM, V37, P597, DOI 10.1016/0026-0495(88)90178-3; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LASUNCION MA, 1983, BIOCHEM J, V210, P639, DOI 10.1042/bj2100639; Lee JJ, 1998, J NUTR, V128, P940, DOI 10.1093/jn/128.6.940; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; Olivecrona G, 1997, METHOD ENZYMOL, V286, P102; OLIVECRONA G, 1995, ATHEROSCLEROSIS, V10; Olivecrona T, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P223; Ong JM, 1995, METABOLISM, V44, P1596, DOI 10.1016/0026-0495(95)90081-0; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Roh C, 2001, J BIOL CHEM, V276, P35990, DOI 10.1074/jbc.M102791200; SCHOTZ MC, 1965, BIOCHIM BIOPHYS ACTA, V106, P202, DOI 10.1016/0005-2760(65)90109-8; SEMB H, 1986, BIOCHIM BIOPHYS ACTA, V878, P330, DOI 10.1016/0005-2760(86)90240-7; SEMB H, 1986, BIOCHIM BIOPHYS ACTA, V876, P249, DOI 10.1016/0005-2760(86)90281-X; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SPEAKE BK, 1985, BIOCHIM BIOPHYS ACTA, V840, P419, DOI 10.1016/0304-4165(85)90223-5; SPENCER IM, 1978, BIOCHIM BIOPHYS ACTA, V530, P375, DOI 10.1016/0005-2760(78)90157-1; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; TERRETTAZ J, 1994, INT J OBESITY, V18, P9	39	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11925	11930		10.1074/jbc.M212736200	http://dx.doi.org/10.1074/jbc.M212736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12551943	hybrid			2022-12-25	WOS:000182015700028
J	Wang, XX; Spangler, L; Dvir, A				Wang, XX; Spangler, L; Dvir, A			Promoter escape by RNA polymerase II - Downstream promoter DNA is required during multiple steps of early transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL INITIATION-FACTORS; TFIIH; ATP; COMPLEX; MUTAGENESIS; MECHANISM; HELICASE; ROLES; LIVER; XPB	Recent evidence, obtained in a reconstituted RNA polymerase II transcription system, indicated that the promoter escape stage of transcription requires template DNA located downstream of the elongating polymerase. In the absence of downstream DNA, very early elongation complexes are unable to synthesize transcripts longer than similar to10-14 nucleotides. In contrast, once transcripts longer than similar to15 nucleotides have been synthesized, an extended region of downstream DNA is no longer required (Dvir, A., Tan, S., Conaway, J. W., and Conaway, R. C. (1997) J. Biot Chem. 272,28175-28178). In this work, we sought to define precisely when, during the synthesis of the first 10-15 phosphodiester bonds, downstream DNA is required. We report that, for complete promoter escape, downstream DNA extending to position 40/42 is required. The polymerase can be forced to arrest at several points prior to the completion of promoter escape by removing downstream DNA proximally to positions 40/42. The positions at which the polymerase arrests appear to be determined by the length of available downstream DNA, with arrest occurring at a relatively fixed position of similar to28 nucleotides to the distal end of the template. A similar requirement is observed for transcription initiation, i.e. the formation of the first phosphodiester bond of nascent transcripts. In addition, we show that the requirement for a downstream region is independent of downstream DNA sequence, suggesting that the requirement reflects a general mechanism. Taken together, our results indicate (i) that downstream DNA is required continuously through the synthesis of the first 14-15 phosphodiester bonds of nascent transcripts, and (ii) that a major conformational change in the transcription complex likely occurs only after the completion of promoter escape.	Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA	Oakland University	Dvir, A (corresponding author), Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.	dvir@oakland.edu						Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; DVIR A, 2002, BIOCHIM BIOPHYS ACTA, V1577, P218; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUSE DS, 1987, J BIOL CHEM, V262, P14990; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PETERSON MG, 1991, NATURE, V354, P369; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; TAN SY, 1994, BIOTECHNIQUES, V16, P824; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668	31	4	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10250	10256		10.1074/jbc.M210848200	http://dx.doi.org/10.1074/jbc.M210848200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12527757	hybrid			2022-12-25	WOS:000181777500036
J	Le, XF; Hittelman, WN; Liu, JX; McWatters, A; Li, C; Mills, GB; Bast, RC				Le, XF; Hittelman, WN; Liu, JX; McWatters, A; Li, C; Mills, GB; Bast, RC			Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr(421) and Ser(424) via multiple signaling pathways in mitosis	ONCOGENE			English	Article						paclitaxel; p70S6K; phosphorylation; activation; mitosis	PROTEIN-KINASE; REGULATORY MECHANISM; GROWTH-REGULATION; MESSENGER-RNA; CELL-CYCLE; IN-VIVO; RAPAMYCIN; P70(S6K); ACTIVATION; INHIBITION	The 70kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration-and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorytated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca++, PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6K, paclitaxel inactivates this kinase in a concentration- and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6K(T421)/(S424) phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6K(T421)/S-424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [R01CA039930] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOONSTRA J, 1981, J CELL PHYSIOL, V107, P75, DOI 10.1002/jcp.1041070110; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Grammer TC, 1996, CANCER SURV, V27, P271; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Li C, 1998, CANCER RES, V58, P2404; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nakamura M, 2001, CURR BIOL, V11, P1512, DOI 10.1016/S0960-9822(01)00456-0; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SOUZA CPE, 2000, CELL, V102, P293; TEMPLETON DJ, 2001, CURR BIOL, V8, P69; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	48	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					484	497		10.1038/sj.onc.1206175	http://dx.doi.org/10.1038/sj.onc.1206175			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555062				2022-12-25	WOS:000180538200002
J	Honorio, S; Agathanggelou, A; Wernert, N; Rothe, M; Maher, ER; Latif, F				Honorio, S; Agathanggelou, A; Wernert, N; Rothe, M; Maher, ER; Latif, F			Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours	ONCOGENE			English	Article						methylation; 3p21.3 tumour suppressor gene; testicular tumours	HUMAN-CHROMOSOME 3P21.3; CPG ISLAND; PROMOTER HYPERMETHYLATION; LUNG CARCINOMAS; ABERRANT METHYLATION; HUMAN NEOPLASIA; CANCER; HETEROZYGOSITY; REGION; BREAST	Testicular germ cell tumours (TGCTs) are histologically heterogeneous neoplasms with variable malignant potential. Previously, we demonstrated frequent 3p allele loss in TGCTs, and recently we and others have shown that the 3p21.3 RASSF1A tumour suppressor gene (TSG) is frequently inactivated by promoter hypermethylation in a wide range of cancers including lung, breast, kidney and neuroblastoma. In order to investigate the role of epigenctic events in the pathogenesis of TGCTs, we analysed the promoter methylation status of RASSF1A and nine other genes that may be epigenetically inactivated in cancer (p16(INK4A), APC, MGMT, GSTP1, DAPK, CDH1, CDH13, RARbeta and FHIT) in 24 primary TGCTs (28 histologically distinct components). RASSF1A methylation was detected in four of 10 (40%) seminomas and 15 of 18 (83%) nonseminoma TGCT (NSTGCT) components (P = 0.0346). None of the other nine candidate genes were methylated in seminomas, but MGMT (44%), APC (29%) and FHIT (29%) were frequently methylated in NSTGCTs. Furthermore, in two mixed germ cell tumours, the NSTGCT component for one demonstrated RASSF1A, APC and CDH13 promoter methylation, but the seminoma component was unmethylated for all genes analysed. In the second mixed germ cell tumour, the NSTGCT component was methylated for RASSF1A and MGMT, while the seminoma component was methylated only for RASSF1A. In all, 61% NSTGCT components but no seminoma samples demonstrated promoter methylation at two or more genes (P = 0.0016). These findings are consistent with a multistep model for TGCT pathogenesis in which RASSF1A methylation occurs early in tumorigenesis and additional epigenetic events characterize progression from seminoma to NSTGCTs.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Bonn, Inst Pathol, D-53011 Bonn, Germany; Univ Birmingham, Sch Med, Canc Res UK Renal Mol Oncol Res Grp, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Bonn; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chaubert P, 1997, AM J PATHOL, V151, P859; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kraggerud SM, 2002, CANCER RES, V62, P512; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Lind Guro Elisabeth, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1120; Lo KW, 2001, CANCER RES, V61, P3877; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; LOOIJENGA LHJ, 1994, GENE CHROMOSOME CANC, V9, P153, DOI 10.1002/gcc.2870090302; LOTHE RA, 1995, LAB INVEST, V73, P606; Maruyama R, 2002, CLIN CANCER RES, V8, P514; MATHEW S, 1994, CANCER RES, V54, P6265; Morrissey C, 2001, CANCER RES, V61, P7277; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Murty VVVS, 1996, ONCOGENE, V12, P2719; PELTOMAKI P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P187, DOI 10.1016/0925-4439(91)90004-S; Rothe M, 1999, J PATHOL, V188, P389, DOI 10.1002/(SICI)1096-9896(199908)188:4<389::AID-PATH364>3.0.CO;2-K; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	43	93	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					461	466		10.1038/sj.onc.1206119	http://dx.doi.org/10.1038/sj.onc.1206119			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545168				2022-12-25	WOS:000180379100016
J	Belka, C; Gruber, C; Jendrossek, V; Wesselborg, S; Budach, W				Belka, C; Gruber, C; Jendrossek, V; Wesselborg, S; Budach, W			The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways	ONCOGENE			English	Article							RADIATION-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; IRRADIATION-INDUCED APOPTOSIS; NF-KAPPA-B; LYMPHOMA-CELLS; DIFFERENTIAL REQUIREMENT; CD95-INDUCED APOPTOSIS; IONIZING-RADIATION; CASPASE ACTIVATION; LEUKEMIA-CELLS	The induction of apoptosis requires the activation of a highly coordinated signaling network ultimately leading to the activation of caspases. In previous experiments we and others have shown that the tyrosine kinase Lck is required for adequate apoptosis induction in response to ionizing radiation, ceramide incubation and overexpression of the HIV-TAT protein. However, the position of Lck within given apoptotic signaling cascades remains unclear. We therefore aimed to define the role of Lck during radiation-induced apoptosis. Apoptosis induction in response to ionizing radiation, CD95 or TRAIL receptor stimulation was determined in Jurkat T-cells, the Lck-deficient Jurkat clone JCaM1.6- and Lck-retransfected JCaM1.6/Lck. No apoptosis, release of cytochrome c, breakdown of the mitochondrial potential were detectable during the first 48 h after irradiation of JCaM1.6 cells. In parallel, no activation of caspase-9, -8 and -3 was detectable. Since mitochondrial apoptosis pathways act within a feedback mechanism during death-receptor-mediated apoptosis, the influence of the Lck defect on CD95/Fas/Apo-1-L or TRAIL-induced apoptosis was also tested. Both stimuli induced apoptosis in Lck-deficient cells. However, the kinetics of apoptosis induction determined by caspase-8, -9 and -3 activation as well as DeltaPsi(m) breakdown was slowed. We conclude that the Lck deficiency influences early steps during radiation-induced mitochondrial alterations.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107; Wesselborg, Sebastian/0000-0002-5236-942X				Belka C, 2000, ANTICANCER RES, V20, P3243; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIMENEZ B, 1995, ONCOGENE, V10, P811; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pena LA, 2000, CANCER RES, V60, P321; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Tomicic MT, 2002, ONCOGENE, V21, P2141, DOI 10.1038/sj.onc.1205280; Tuosto L, 2002, J IMMUNOL, V168, P6106, DOI 10.4049/jimmunol.168.12.6106; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; WADDICK KG, 1993, RADIAT RES, V136, P313, DOI 10.2307/3578542; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	50	30	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					176	185		10.1038/sj.onc.1206103	http://dx.doi.org/10.1038/sj.onc.1206103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527887				2022-12-25	WOS:000180322400003
J	Bentires-Alj, M; Barbu, V; Fillet, M; Chariot, A; Relic, B; Jacobs, N; Gielen, J; Merville, MP; Bours, V				Bentires-Alj, M; Barbu, V; Fillet, M; Chariot, A; Relic, B; Jacobs, N; Gielen, J; Merville, MP; Bours, V			NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells	ONCOGENE			English	Article						MDR1; apoptosis; cancer; transcription factors; NF-kappa B; chemotherapy	TUMOR-NECROSIS-FACTOR; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CYCLOSPORINE-A; GLUCOCORTICOID RECEPTOR; LIVER DEGENERATION; INDUCED APOPTOSIS; BREAST-CANCER; MICE LACKING; T-CELLS	The ubiquitous NF-kappaB transcription factor has been reported to inhibit apoptosis and to induce drug resistance in cancer cells. Drug resistance is the major reason for cancer therapy failure and neoplastic cells often develop multiple mechanisms of drug resistance during tumor progression. We observed that NF-kappaB or P-glycoprotein inhibition in the HCT15 colon cancer cells led to increased apoptotic cell death in response to daunomycin treatment. Interestingly, NF-kappaB inhibition through transfection of a plasmid coding for a mutated IkappaB-alpha inhibitor increased daunomycin cell uptake. Indeed, the inhibition of NF-kappaB reduced mdr1 mRNA and P-glycoprotein expression in HCT15 cells. We identified a consensus NF-kappaB binding site in the first intron of the human mdr1 gene and demonstrated that NF-kappaB complexes could bind with this intronic site. Moreover, NF-kappaB transactivates an mdr1 promoter luciferase construct. Our data thus demonstrate a role for NF-kappaB in the regulation of the mdr1 gene expression in cancer cells and in drug resistance.	Univ Liege, Ctr Cellular & Mol Therapy, Liege, Belgium; Hop St Antoine, INSERM, Unit 402, Mol Biol Lab, F-75571 Paris, France; Univ Liege, Ctr Res Expt Cancerol, Liege, Belgium	University of Liege; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Liege	Bours, V (corresponding author), Univ Liege, Dept Genet, CHU B35, B-4000 Liege, Belgium.		Mohamed, Bentires-Alj/F-4484-2015	Mohamed, Bentires-Alj/0000-0001-6344-1127; Chariot, Alain/0000-0002-1691-4347; Jacobs, Nathalie/0000-0002-9895-8465; Fillet, Marianne/0000-0002-1453-6282				Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BIEDLER JL, 1994, CANCER RES, V54, P666; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; DEJARDIN E, 1995, ONCOGENE, V11, P1835; GALA JL, 1995, J CLIN PATHOL, V48, P679, DOI 10.1136/jcp.48.7.679; GOLDIE JH, 1992, CHEMOTHERAPY SOURCE, P54; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; Lee JI, 1999, TRANSPLANTATION, V68, P1255, DOI 10.1097/00007890-199911150-00007; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LING V, 1983, CANCER TREAT REP, V67, P869; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; OGURA M, 1992, NUCLEIC ACIDS RES, V20, P5811, DOI 10.1093/nar/20.21.5811; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Ros JE, 2001, HEPATOLOGY, V33, P1425, DOI 10.1053/jhep.2001.24667; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Sonneveld P, 1997, SEMIN HEMATOL, V34, P34; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; UEDA K, 1987, J BIOL CHEM, V262, P17432; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	56	352	394	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					90	97		10.1038/sj.onc.1206056	http://dx.doi.org/10.1038/sj.onc.1206056			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527911	Green Published			2022-12-25	WOS:000180166900010
J	Gilberger, TW; Thompson, JK; Triglia, T; Good, RT; Duraisingh, MT; Cowman, AF				Gilberger, TW; Thompson, JK; Triglia, T; Good, RT; Duraisingh, MT; Cowman, AF			A novel erythrocyte binding antigen-175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; GLYCOPHORIN-B; INVASION; RECOMBINATION; PROTEIN; MEROZOITES; EBA-175; GENOME; SEQUENCES; FAMILY	The recognition and invasion of human erythrocytes by the most lethal malaria parasite Plasmodium falciparum is dependent on multiple ligand-receptor interactions. Members of the erythrocyte binding-like (ebl) family, including the erythrocyte binding antigen-175 (EBA-175), are responsible for high affinity binding to glycoproteins on the surface of the erythrocyte. Here we describe a paralogue of EBA-175 and show that this protein (EBA-181/JESEBL) binds in a sialic acid-dependent manner to erythrocytes. EBA-181 is expressed at the same time as EBA-175 and co-localizes with this protein in the microneme organelles of asexual stage parasites. The receptor binding specificity of EBA-181 to erythrocytes differs from other members of the ebl family and is trypsin-resistant and chymotrypsin-sensitive. Furthermore, using glycophorin B-deficient erythrocytes we show that binding of EBA-181 is not dependent on this sialoglycoprotein. The level of expression of EBA-181 differs among parasite lines, and the importance of this ligand for invasion appears to be strain-dependent as the EBA-181 gene can be disrupted in W2mef parasites, without affecting the invasion phenotype, but cannot be targeted in 3D7 parasites.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.		Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004; Gilberger, Tim-Wolf/0000-0002-7965-8272				Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1; ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; Barnwell John W., 1998, P93; BIANCO AE, 1986, P NATL ACAD SCI USA, V83, P8713, DOI 10.1073/pnas.83.22.8713; Butler D, 2002, NATURE, V419, P426, DOI 10.1038/419426a; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; Chitnis CE, 2000, PARASITOL TODAY, V16, P411, DOI 10.1016/S0169-4758(00)01756-7; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; Cowman AF, 2002, SCIENCE, V298, P126, DOI 10.1126/science.1078169; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Duraisingh MT, 2002, INT J PARASITOL, V32, P81, DOI 10.1016/S0020-7519(01)00345-9; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; KAIN KC, 1993, J EXP MED, V178, P1497, DOI 10.1084/jem.178.5.1497; Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; Michon P, 2002, MOL BIOL EVOL, V19, P1128, DOI 10.1093/oxfordjournals.molbev.a004171; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Narum DL, 2002, MOL BIOCHEM PARASIT, V119, P159, DOI 10.1016/S0166-6851(01)00428-5; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SIM BKL, 1990, MOL BIOCHEM PARASIT, V41, P293, DOI 10.1016/0166-6851(90)90193-P; SIM BKL, 1994, EXP PARASITOL, V78, P259, DOI 10.1006/expr.1994.1027; SIM BKL, 1992, MOL BIOCHEM PARASIT, V51, P157, DOI 10.1016/0166-6851(92)90211-2; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Triglia T, 2001, MOL BIOCHEM PARASIT, V116, P55, DOI 10.1016/S0166-6851(01)00303-6; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	35	149	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14480	14486		10.1074/jbc.M211446200	http://dx.doi.org/10.1074/jbc.M211446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556470	hybrid			2022-12-25	WOS:000182405000115
J	Galvan, V; Logvinova, A; Sperandio, S; Ichijo, H; Bredesen, DE				Galvan, V; Logvinova, A; Sperandio, S; Ichijo, H; Bredesen, DE			Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASES; INDUCED ACTIVATION; DEATH; CELL; PATHWAY; AKT; TRANSDUCTION; REQUIREMENT; THIOREDOXIN; LIGAND	The type 1 insulin-like growth factor receptor (IGF-IR) is a receptor-tyrosine kinase that plays a critical role in signaling cell survival and proliferation. IGF-IR binding to its ligand, insulin-like growth factor (IGF-1) activates phosphoinositide 3-kinase (PI3K), promotes cell proliferation by activating the mitogen-activated protein kinase (MAPK) cascade, and blocks apoptosis by inducing the phosphorylation and inhibition of proapoptotic proteins such as BAD. Apoptosis signal-regulating kinase 1 (ASK1) is a MAP kinase kinase kinase (MAPKKK) that is required for c-Jun N-terminal kinase (JNK) and p38 activation in response to Fas and tumor necrosis factor (TNF) receptor stimulation, and for oxidative stress- and TNFalpha-induced apoptosis. The results presented here indicate that ASK1 forms a complex with the IGF-IR and becomes phosphorylated on tyrosine residue(s) in a manner dependent on IGF-IR activity. IGF-IR signaling inhibited ASK1 irrespective of TNFalpha-induced ASK1 activation and resulted in decreasedASKIdependent JNK1 stimulation. Signaling through IGF-IR rescued cells from ASK1-induced apoptotic cell death in a manner independent of PI3K activity. These results indicate that IGF-IR signaling suppresses the ASK-1-mediated stimulation of JNK/p38 and the induction of programmed cell death. The simultaneous activation of MAP kinases and the inhibition of the stress-activated arm of the cascade by IGF-IR may constitute a potent proliferative signaling system and is possibly a mechanism by which IGF-I can stimulate growth and inhibit cell death in a wide variety of cell types and biological settings.	Buck Inst Age Res, Novato, CA 94945 USA; Tokyo Med & Dent Univ, Lab Cell Signaling, Grad Sch, Tokyo 1138549, Japan	Buck Institute for Research on Aging; Tokyo Medical & Dental University (TMDU)	Bredesen, DE (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.			Ichijo, Hidenori/0000-0002-5005-6438				Abe K, 2000, ANN NY ACAD SCI, V926, P52; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Gatzka M, 2000, CANCER RES, V60, P4222; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Holzenberger M, 2001, ENDOCRINOLOGY, V142, P4469, DOI 10.1210/en.142.10.4469; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Nicholas RS, 2002, J NEUROIMMUNOL, V124, P36, DOI 10.1016/S0165-5728(02)00011-5; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Parrizas M, 1997, J BIOL CHEM, V272, P154; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200	32	68	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13325	13332		10.1074/jbc.M211398200	http://dx.doi.org/10.1074/jbc.M211398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556535	hybrid			2022-12-25	WOS:000182189500093
J	Lee, K; Neigeborn, L; Kaufman, RJ				Lee, K; Neigeborn, L; Kaufman, RJ			The unfolded protein response is required for haploid tolerance in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; GLUCOSE-REGULATED PROTEINS; KAR2 BIP GENE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; DNA-REPLICATION; CELL-CYCLE; TRANSCRIPTION FACTOR; CENTROSOME DUPLICATION; TRANSMEMBRANE PROTEIN	HAC1 encodes a transcription factor that mediates the unfolded protein response (UPR) in Saccharomyces cerevisiae. We characterized hac1Delta mutants in the sporulation-proficient SK1 genetic background and found a novel function for HAC1 in haploid tolerance. hac1Delta spore clones contain a diploid DNA content as determined by fluorescence-activated cell sorting and genetic analyses. Autodiploidization of hac1 spore clones occurred after germination; hac1 spores were born haploid, but efficiently generated diploid progeny during the subsequent mitotic division. Once the hac1 mutant acquired a diploid DNA content, no further ploidy increase was observed. Interestingly, the increase in genome content following meiosis was not a general property associated with hac1 spore clones; instead, it was restricted to an inability to tolerate the haploid state. Genetic analyses involving the UPR target gene KAR2 and the UPR regulator IRE1 revealed that autodiploidization associated with hac1 mutants is a consequence of its role in the UPR pathway. Inhibition of the UPR pathway induces autodiploidization, and constitutive activation of UPR target genes suppresses this response.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA; Rutgers Coll, New Brunswick, NJ 08901 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Rutgers State University New Brunswick	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, MSRB 2,Rm 4570,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Longo, Kenneth A/A-5631-2010					Archambault J, 1996, GENETICS, V142, P737; Bloom K, 2001, CURR BIOL, V11, pR326, DOI 10.1016/S0960-9822(01)00176-2; BRIZA P, 1986, J BIOL CHEM, V261, P4288; CHAN CSM, 1993, GENETICS, V135, P677; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Chevalier S, 1996, CURR OPIN CELL BIOL, V8, P815, DOI 10.1016/S0955-0674(96)80082-2; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; Detweiler CS, 1997, J CELL SCI, V110, P753; DeZwaan TM, 1997, J CELL BIOL, V138, P1023, DOI 10.1083/jcb.138.5.1023; Dricu A, 1997, CANCER RES, V57, P543; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Guthrie C, 1991, METHODS ENZYMOL, V194; Hamilton TG, 1996, J BIOL CHEM, V271, P30610, DOI 10.1074/jbc.271.48.30610; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Higashio H, 2002, BIOCHEM BIOPH RES CO, V296, P568, DOI 10.1016/S0006-291X(02)00923-3; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HOSAKA K, 1994, J BIOCHEM-TOKYO, V116, P1317, DOI 10.1093/oxfordjournals.jbchem.a124681; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kagiwada S, 1996, GENETICS, V143, P685; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1998, J BIOL CHEM, V273, P1802, DOI 10.1074/jbc.273.3.1802; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LARSSON O, 1993, J CELL SCI, V106, P299; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOIDL J, 1995, GENETICS, V139, P1511; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nikawa J, 1997, GENE, V201, P5, DOI 10.1016/S0378-1119(97)00418-6; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NOJIMA H, 1994, NUCLEIC ACIDS RES, V22, P5279, DOI 10.1093/nar/22.24.5279; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; POLAINA J, 1993, CURR GENET, V24, P369, DOI 10.1007/BF00351842; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Sato M, 2002, BIOCHEM BIOPH RES CO, V296, P560, DOI 10.1016/S0006-291X(02)00922-1; Schroder M, 2000, GENE DEV, V14, P2962, DOI 10.1101/gad.852300; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sherman F, 1986, LAB COURSE MANUAL ME; Shirra MK, 2001, MOL CELL BIOL, V21, P5710, DOI 10.1128/MCB.21.17.5710-5722.2001; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearns T, 2001, CELL, V105, P417, DOI 10.1016/S0092-8674(01)00366-X; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sugiyama M, 2001, J BACTERIOL, V183, P4985, DOI 10.1128/JB.183.17.4985-4993.2001; VALLEN EA, 1994, GENETICS, V137, P407; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; WEISS RL, 1975, P NATL ACAD SCI USA, V72, P794, DOI 10.1073/pnas.72.3.794; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	83	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11818	11827		10.1074/jbc.M210475200	http://dx.doi.org/10.1074/jbc.M210475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560331	hybrid			2022-12-25	WOS:000182015700014
J	Mueller, SO; Hall, JM; Swope, DL; Pedersen, LC; Korach, KS				Mueller, SO; Hall, JM; Swope, DL; Pedersen, LC; Korach, KS			Molecular determinants of the stereoselectivity of agonist activity of estrogen receptors (ER) alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; DIETHYLSTILBESTROL METABOLITES; CONFORMATIONAL-CHANGES; TISSUE DISTRIBUTION; CELL-LINES; WILD-TYPE; TRANSACTIVATION; ANTIESTROGENS; ANALOGS; IDENTIFICATION	The two known estrogen receptors, ERalpha and ERbeta, are hormone-inducible transcription factors that have distinct roles in regulating cell proliferation and differentiation. Previously, our laboratory demonstrated that ERalpha exhibits stereoselective ligand binding and transactivation for several structural derivatives and metabolites of the synthetic estrogen diethylstilbestrol. We have previously described the properties of indenestrol A (IA) enantiomers on ERalpha. In the study presented here, the estrogenic properties of the S and R enantiomers of IA, IA-S and IA-R, respectively, were expanded to exam. ine the activity in different cell and promoter contexts using ERalpha and ERbeta. Using human cell lines stably expressing either ERalpha or ERbeta, we found that IA-S was a more potent activator of transcription than IA-R through ERalpha in human endometrial Ishikawa and breast MDA-MB 231 (MDA) cells. Interestingly, IA-R was more potent on ERbeta when compared with ERalpha in MDA, but not in Ishikawa cells, and IA-R exhibited equally low binding affinities to ERalpha and ERbeta in vitro in contrast to its cell line-dependent preferential activation of ERG. Alignment of the protein structures of the ligand-binding domains of ERalpha and ERbeta revealed one mismatched residue, Leu-384 in ERalpha and Met-283 in ERbeta, which may be responsible for making contact with the methyl substituent at the chiral carbon of IA-S and IA-R. Mutagenesis and exchange of this one residue showed that the binding of IA-R and IA-S was not affected by this mutation in ERalpha and ERbeta. However, in transactivation studies, IA-R showed higher potency in activating L384M-mutated ERalpha and wild-type ERbeta compared with wild-type ERalpha and M283L-mutated ERbeta in all cell and promoter contexts examined. Furthermore, IA-R-bound ERalpha L384M and wild-type ERbeta displayed enhanced interactions with the nuclear receptor interaction domains of the coactivators SRC-1 and GRIP1. These data demonstrate that a single residue in the ligand-binding domain determines the stereoselectivity of ERalpha and ERbeta for indenestrol ligands and that IA-R shows cell type selectivity through ERbeta.	NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Korach, KS (corresponding author), Merck KGaA, Inst Toxicol, POB 64271, Darmstadt, Germany.		Pedersen, Lars/C-6173-2019	Pedersen, Lars/0000-0002-4488-4077; Korach, Kenneth/0000-0002-7765-418X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES070065, Z01ES070065] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; BUCCHINFUSO WP, 1997, MOL ENDOCRINOL, V11, P587; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chaidarun SS, 1998, MOL ENDOCRINOL, V12, P1355, DOI 10.1210/me.12.9.1355; Chang WY, 1999, PROSTATE, V40, P115; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kohno H, 1996, J MOL ENDOCRINOL, V16, P277, DOI 10.1677/jme.0.0160277; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; KORACH KS, 1989, J BIOL CHEM, V264, P5642; KORACH KS, 1979, J BIOL CHEM, V254, P8963; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Mueller SO, 2001, J ANDROL, V22, P652; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; SCHROEDER J, 1989, SIGNAL PROCESS, V17, P19, DOI 10.1016/0165-1684(89)90069-8; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SOULE HD, 1990, CANCER RES, V50, P6075; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; Tyulmenkov VV, 2000, ARCH BIOCHEM BIOPHYS, V381, P135, DOI 10.1006/abbi.2000.1974; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200	36	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12255	12262		10.1074/jbc.M203578200	http://dx.doi.org/10.1074/jbc.M203578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12547836	hybrid			2022-12-25	WOS:000182015700070
J	Que-Gewirth, NLS; Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH				Que-Gewirth, NLS; Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH			Origin of the 2-amino-2-deoxy-gluconate unit in Rhizobium leguminosarum lipid A - Expression cloning of the outer membrane oxidase LpxQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACYL CHAINS; BIOSYNTHESIS; PROTEIN; LIPOPOLYSACCHARIDE; SALMONELLA; ENZYME; GENE; PRECURSORS	An unusual feature of the lipid A from the plant endosymbionts Rhizobium etli and Rhizobium leguminosarum is the presence of a proximal sugar unit consisting of a 2-amino-2-deoxy-gluconate moiety in place of glucosamine. An outer membrane oxidase that generates the 2-amino-2-deoxy-gluconate unit from a glucosamine-containing precursor is present in membranes of R. leguminosarum and R. etli but not in S. meliloti or Escherichia coli. We now report the identification of a hybrid cosmid that directs the overexpression of this activity by screening 1800 lysates of individual colonies of a R. leguminosarum 3841 genomic DNA library in the host strain R. etli CE3. Two cosmids (p1S11D and p1U12G) were identified in this manner and transferred into S. meliloti, in which they also directed the expression of oxidase activity in the absence of any chromosomal background. Subcloning and sequencing of the oxidase gene on a 6.5-kb fragment derived from the similar to20-kb insert in p1S11D revealed that the enzyme is encoded by a gene (lpxQ) that specifies a protein of 224 amino acid residues with a putative signal sequence cleavage site at position 28. Heterologous expression of lpxQ using the T7lac promoter system in E. coli resulted in the production of catalytically active oxidase that was localized in the outer membrane. A new outer membrane protein of the size expected for LpxQ was present in this construct and was subjected to microsequencing to confirm its identity and the site of signal peptide cleavage. LpxQ expressed in E. coli generates the same products as seen in R. leguminosarum membranes. LpxQ is dependent on O-2 for activity, as demonstrated by inhibition of the reaction under strictly anaerobic conditions. An ortholog of LpxQ is present in the genome of Agrobacterium tumefaciens, as shown by heterologous expression of oxidase activity in E. coli.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R37GM051796, T32GM008558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fernandez C, 2001, FEBS LETT, V504, P173, DOI 10.1016/S0014-5793(01)02742-9; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GLAZEBROOK J, 1991, METHOD ENZYMOL, V204, P398; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Miller JH., 1972, EXPT MOL GENETICS; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; RUSSA R, 1985, ARCH MICROBIOL, V141, P284, DOI 10.1007/BF00428838; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14186, DOI 10.1074/jbc.M200408200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	60	28	31	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12120	12129		10.1074/jbc.M300379200	http://dx.doi.org/10.1074/jbc.M300379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12531908	hybrid, Green Accepted			2022-12-25	WOS:000182015700053
J	Zhou, Y; Ching, YP; Chun, ACS; Jin, DY				Zhou, Y; Ching, YP; Chun, ACS; Jin, DY			Nuclear localization of the cell cycle regulator CDH1 and its regulation by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CHECKPOINT PROTEIN MAD2; MITOTIC CHECKPOINT; SPINDLE CHECKPOINT; KEN BOX; INHIBITOR PDS1; DIRECT BINDING; AURORA-A; CDC20; YEAST	The anaphase-promoting complex activated by CDC20 and CDH1 is a major ubiquitination system that controls the destruction of cell cycle regulators. Exactly how ubiquitination is regulated in time and space is incompletely understood. Here we report on the cell cycle-dependent localization of CDH1 and its regulation by phosphorylation. CDH1 localizes dynamically to the nucleus during interphase and to the centrosome during metaphase and anaphase. The nuclear accumulation of CDH1 correlates with a reduction in the steady-state amount of cyclin A, but not of cyclin E. A nuclear localization signal conserved in various species was identified in CDH1, and it sufficiently targets green fluorescent protein to the nucleus. Interestingly, a CDH1-4D mutant mimicking the hyperphosphorylated form was constitutively found in the cytoplasm. In further support of the notion that phosphorylation inhibits nuclear import, the nuclear localization signal of CDH1 with two phospho-accepting serine/threonine residues changed into aspartates was unable to drive heterologous protein into the nucleus. On the other hand, abolition of the cyclin-binding ability of CDH1 has no influence on its nuclear localization. Taken together, our findings document the phosphorylation-dependent localization of CDH1 in vertebrate cells.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Dept Biochem, 3rd Floor,Lab Block,Fac Med Bldg 21,Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	dyjin@hkucc.hku.hk	Ching, Yick Pang/C-4244-2009	CHING, Yick Pang/0000-0002-6461-8358	FIC NIH HHS [D43 TW06186] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006186] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Ching YP, 2002, GENOMICS, V79, P2, DOI 10.1006/geno.2001.6670; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hendrickson C, 2001, CURR BIOL, V11, P1781, DOI 10.1016/S0960-9822(01)00564-4; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Huang JY, 2002, J CELL SCI, V115, P2847; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Inbal N, 1999, FEBS LETT, V463, P350, DOI 10.1016/S0014-5793(99)01640-3; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; Jorgensen PM, 1998, MOL CELL BIOL, V18, P468; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V268, P530, DOI 10.1006/bbrc.2000.2167; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	79	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12530	12536		10.1074/jbc.M212853200	http://dx.doi.org/10.1074/jbc.M212853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12560341	hybrid			2022-12-25	WOS:000182015700105
J	Hojlund, K; Wrzesinski, K; Larsen, PM; Fey, SJ; Roepstorff, P; Handberg, A; Dela, F; Vinten, J; McCormack, JG; Reynet, C; Beck-Nielsen, H				Hojlund, K; Wrzesinski, K; Larsen, PM; Fey, SJ; Roepstorff, P; Handberg, A; Dela, F; Vinten, J; McCormack, JG; Reynet, C; Beck-Nielsen, H			Proteome analysis reveals phosphorylation of ATP synthase beta-subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BINDING-PROTEIN; INSULIN-RESISTANCE; CREATINE-KINASE; GENE-EXPRESSION; GLYCOGEN-SYNTHASE; STRESS-PROTEINS; OKADAIC ACID; VI COLLAGEN; MITOCHONDRIAL; ACTIVATION	Insulin resistance in skeletal muscle is a hallmark feature of type 2 diabetes. An increasing number of enzymes and metabolic pathways have been implicated in the development of insulin resistance. However, the primary cellular cause of insulin resistance remains uncertain. Proteome analysis can quantitate a large number of proteins and their post-translational modifications simultaneously and is a powerful tool to study polygenic diseases like type 2 diabetes. Using this approach on human skeletal muscle biopsies, we have identified eight potential protein markers for type 2 diabetes in the fasting state. The observed changes in protein expression indicate increased cellular stress, e.g. up-regulation of two heat shock proteins, and perturbations in ATP (re)synthesis and mitochondrial metabolism, e.g. down-regulation of ATP synthase 6-subunit and creatine kinase B, in skeletal muscle of patients with type 2 diabetes. Phosphorylation appears to play a key, potentially coordinating role for most of the proteins identified in this study. In particular, we demonstrated that the catalytic beta-subunit of ATP synthase is phosphorylated in vivo and that the levels of a down-regulated ATP synthase beta-subunit phosphoisoform in diabetic muscle correlated inversely with fasting plasma glucose levels. These data suggest a role for phosphorylation of ATP synthase beta-subunit in the regulation of ATP synthesis and that alterations in the regulation of ATP synthesis and cellular stress proteins may contribute to the pathogenesis of type 2 diabetes.	Odense Univ Hosp, Diabet Res Ctr, Dept Endocrinol, DK-5000 Odense C, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Univ Copenhagen, Panum Inst, Dept Med Physiol, Copenhagen Muscle Res Ctr, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Physiol, DK-2200 Copenhagen N, Denmark; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Copenhagen; University of Copenhagen; Novo Nordisk	Beck-Nielsen, H (corresponding author), Odense Univ Hosp, Diabet Res Ctr, Dept Endocrinol, Kloevervaenget 6, DK-5000 Odense C, Denmark.	henning.beck-nielsen@ouh.fyns-amt.dk	Wrzesinski, Krzysztof/B-1464-2013; Dela, Flemming/AAU-1691-2021; Dela, Flemming/B-3239-2008; Fey, Stephen/G-3677-2012; Fey, Stephen/B-5253-2015; Handberg, Aase/G-6744-2011	Wrzesinski, Krzysztof/0000-0002-0381-4523; Dela, Flemming/0000-0001-9970-9535; Dela, Flemming/0000-0001-9970-9535; Fey, Stephen/0000-0001-6463-9477; Fey, Stephen/0000-0001-6463-9477; Handberg, Aase/0000-0001-5719-203X				Anderson CM, 1999, DRUG DEVELOP RES, V46, P67, DOI 10.1002/(SICI)1098-2299(199901)46:1<67::AID-DDR10>3.0.CO;2-V; ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790; APPLE FS, 1989, J APPL PHYSIOL, V66, P2717, DOI 10.1152/jappl.1989.66.6.2717; BASHAN N, 1993, AM J PHYSIOL, V264, pC430, DOI 10.1152/ajpcell.1993.264.2.C430; Beck-Nielsen Henning, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P255; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; Chen KD, 2000, J CELL BIOCHEM, V76, P585, DOI 10.1002/(SICI)1097-4644(20000315)76:4<585::AID-JCB7>3.0.CO;2-U; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; Fey SJ, 1997, ELECTROPHORESIS, V18, P1361, DOI 10.1002/elps.1150180811; Fey SJ, 2001, CURR OPIN CHEM BIOL, V5, P26, DOI 10.1016/S1367-5931(00)00167-8; Fredericks S, 2001, CLIN CHIM ACTA, V304, P65, DOI 10.1016/S0009-8981(00)00409-5; Gaster M, 2001, DIABETES, V50, P1324, DOI 10.2337/diabetes.50.6.1324; Gebhart SSP, 1996, METABOLISM, V45, P526, DOI 10.1016/S0026-0495(96)90231-0; Gonzalez B, 2000, PFLUG ARCH EUR J PHY, V440, P42, DOI 10.1007/s004240051020; He J, 2001, DIABETES, V50, P817, DOI 10.2337/diabetes.50.4.817; HEMMER W, 1993, FEBS LETT, V327, P35, DOI 10.1016/0014-5793(93)81034-W; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HICKSON RC, 1976, J APPL PHYSIOL, V40, P868, DOI 10.1152/jappl.1976.40.6.868; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Jensen ON, 1998, PROTEINS, P74; JOSHI JG, 1988, TOXICOLOGY, V48, P21, DOI 10.1016/0300-483X(88)90055-8; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KATZ A, 1995, BBA-GEN SUBJECTS, V1244, P229, DOI 10.1016/0304-4165(95)00050-L; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; LENNY N, 1991, J BIOL CHEM, V266, P20532; MANNING DR, 1982, AM J PHYSIOL, V242, pC234, DOI 10.1152/ajpcell.1982.242.3.C234; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Mote PL, 1998, MECH AGEING DEV, V104, P149, DOI 10.1016/S0047-6374(98)00064-5; MUONA P, 1993, AM J PATHOL, V142, P1586; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nishizawa J, 1999, CIRCULATION, V99, P934, DOI 10.1161/01.CIR.99.7.934; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sawa T, 1996, BIOCHEM BIOPH RES CO, V218, P449, DOI 10.1006/bbrc.1996.0080; SPIRO MJ, 1993, DIABETOLOGIA, V36, P93, DOI 10.1007/BF00400687; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; THOMAS F, 1994, DIABETES, V43, P63, DOI 10.2337/diabetes.43.1.63; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200	49	176	189	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10436	10442		10.1074/jbc.M212881200	http://dx.doi.org/10.1074/jbc.M212881200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531894	hybrid			2022-12-25	WOS:000181777500060
J	Kim, SJ; Woo, JR; Hwang, YS; Jeong, DG; Shin, DH; Kim, K; Ryu, SE				Kim, SJ; Woo, JR; Hwang, YS; Jeong, DG; Shin, DH; Kim, K; Ryu, SE			The tetrameric structure of Haemophilus influenza hybrid Prx5 reveals interactions between electron donor and acceptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; CRYSTAL-STRUCTURE; MAMMALIAN PEROXIREDOXIN; 2-CYS PEROXIREDOXIN; HUMAN THIOREDOXIN; PEROXIDASE; DISULFIDE; COMPLEX; OLIGOMERIZATION; IDENTIFICATION	Cellular redox control is often mediated by oxidation and reduction of cysteine residues in the redox-sensitive proteins, where thioredoxin and glutaredoxin (Grx) play as electron donors for the oxidized proteins. Despite the importance of protein-protein interactions between the electron donor and acceptor proteins, there has been no structural information for the interaction of thioredoxin or Grx with natural target proteins. Here, we present the crystal structure of a novel Haemophilus influenza peroxiredoxin (Prx) hybrid Prx5 determined at 2.8-Angstrom resolution. The structure reveals that hybrid Prx5 forms a tightly associated tetramer where active sites of Prx and Grx domains of different monomers interact with each other. The Prx-Grx interface comprises specific charge interactions surrounded by weak interactions, providing insight into the target recognition mechanism of Grx. The tetrameric structure also exhibits a flexible active site and alternative Prx-Grx interactions, which appear to facilitate the electron transfer from Grx to Prx domain. Differences of electron donor binding surfaces in Prx proteins revealed by an analysis based on the structural information explain the electron donor specificities of various Prx proteins.	Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yusong Gu, Taejon 305806, South Korea; Chonnam Natl Univ, Coll Human Ecol, Inst Home Econ, Dept Food & Nutr, Gwangju 507757, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chonnam National University	Ryu, SE (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yusong Gu, 52 Euheun Dong, Taejon 305806, South Korea.	ryuse@mail.kribb.re.kr						Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chauhan R, 2001, BIOCHEM J, V354, P209, DOI 10.1042/0264-6021:3540209; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUANG CY, 1982, ANNU REV BIOCHEM, V51, P935, DOI 10.1146/annurev.bi.51.070182.004443; Hwang YS, 2000, J BIOCHEM MOL BIOL, V33, P514; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kelley JJ, 1997, BIOCHEMISTRY-US, V36, P5029, DOI 10.1021/bi962181g; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kristensen P, 1999, BIOCHEM BIOPH RES CO, V262, P127, DOI 10.1006/bbrc.1999.1107; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231	42	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10790	10798		10.1074/jbc.M209553200	http://dx.doi.org/10.1074/jbc.M209553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529327	hybrid			2022-12-25	WOS:000181777500104
J	Kiss, RS; McManus, DC; Franklin, V; Tan, WL; McKenzie, A; Chimini, G; Marcel, YL				Kiss, RS; McManus, DC; Franklin, V; Tan, WL; McKenzie, A; Chimini, G; Marcel, YL			The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; APOA-I; TANGIER-DISEASE; CELL-LINE; ABCA1 TRANSPORTER; APOPTOTIC CELLS; GENE-EXPRESSION; CHICKEN LIVER; STEROL EFFLUX	The pathways of hepatic intra- and peri-cellular lipidation of apolipoprotein A-I (apoA-I) were studied by infecting primary mouse hepatocytes from either apoAI-deficient or ABCA1-deficient mice with a recombinant adenovirus expressing the human apoA-I (hapoA-I) cDNA (endo apoA-I) or incubating the hepatocytes with exogenously added hapoA-I (exo apoA-I) and examining the hapoA-1-containing lipoproteins formed. The cells, maintained in serum-free medium, were labeled with [H-3]choline, and the cell medium was separated by fast protein liquid chromatography or immunoprecipitated to quantify labeled choline phospholipids specifically associated with hapoA-I. With the apoA-I-deficient hepatocytes, the high density lipoprotein fraction formed with endo apoA-I contained proportionally more phospholipids than that formed with exo apoA-I. However, the lipoprotein size and electrophoretic mobility and phospholipid profiles were similar for exo apoA-I and endo apoA-I. Taken together, these data demonstrate that a significant proportion of hapoA-I is secreted from hepatocytes in a phospholipidated state but that hapoA-I is also phospholipidated peri-cellularly. With primary hepatocytes from ABCA1-deficient mice, the expression and net secretion of adenoviral-generated endogenous apoA-I was unchanged compared with control mice, but H-3-phospholipids associated with endo apoA-I and exo apoA-I decreased by 63 and 25%, respectively. The lipoprotein size and electrophoretic migration and their phospholipid profiles remained unchanged. In conclusion, we demonstrated that intracellular and peri-cellular lipidation of apoA-I represent distinct and additive pathways that may be regulated independently. Hepatocyte expression of ABCA1 is central to the lipidation of newly synthesized apoA-I but also contributes to the lipidation of exogenous apoA-I. However, a significant basal level of phospholipidation occurs in the absence of ABCA1.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Microbiol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Immunol, Ottawa, ON K1Y 4W7, Canada; CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille, France	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Pathol & Lab Med, Rm H460,40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ymarcel@ottawaheart.ca						Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; BANERJEE D, 1984, J CELL BIOL, V99, P1917, DOI 10.1083/jcb.99.6.1917; BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; CASTLE CK, 1991, J LIPID RES, V32, P439; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Chisholm JW, 2002, J LIPID RES, V43, P36; Costet P, 2000, J BIOL CHEM, V275, P28240; EISENBERG S, 1984, J LIPID RES, V25, P1017; EMMERICH J, 1993, ARTERIOSCLER THROMB, V13, P1299, DOI 10.1161/01.ATV.13.9.1299; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FORTE TM, 1987, BIOCHIM BIOPHYS ACTA, V920, P185, DOI 10.1016/0005-2760(87)90094-4; Fungwe TV, 1998, J NUTR, V128, P1270, DOI 10.1093/jn/128.8.1270; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; HAMILTON RL, 1991, J LIPID RES, V32, P529; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hayden MR, 2000, CURR OPIN LIPIDOL, V11, P117, DOI 10.1097/00041433-200004000-00003; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; Huang ZH, 2002, J LIPID RES, V43, P375; Huang ZH, 2001, ARTERIOSCL THROM VAS, V21, P2019, DOI 10.1161/hq1201.100242; HUSSAIN MM, 1991, ELECTROPHORESIS, V12, P273, DOI 10.1002/elps.1150120408; LAMONFAVA S, 1987, J BIOL CHEM, V262, P8944; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MCCALL MR, 1988, J LIPID RES, V29, P1127; McManus DC, 2001, J BIOL CHEM, V276, P21292, DOI 10.1074/jbc.M100463200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; Neufeld EB, 2002, BIOCHEM BIOPH RES CO, V297, P974, DOI 10.1016/S0006-291X(02)02274-X; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Nobusawa A, 2000, J CARDIOVASC PHARM, V36, P101, DOI 10.1097/00005344-200007000-00014; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PATSCH JR, 1978, P NATL ACAD SCI USA, V75, P4519, DOI 10.1073/pnas.75.9.4519; REMALEY AT, 1995, J LIPID RES, V36, P407; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1981, J LIPID RES, V22, P217; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; SCHREYER SA, 1994, ARTERIOSCLER THROMB, V14, P2053, DOI 10.1161/01.ATV.14.12.2053; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SIMON J B, 1970, Biochimica et Biophysica Acta, V218, P549, DOI 10.1016/0005-2760(70)90020-2; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SUBRAHMANYAN L, 1988, SCAND J IMMUNOL, V27, P251, DOI 10.1111/j.1365-3083.1988.tb02345.x; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TALL AR, 1978, NEW ENGL J MED, V299, P1232, DOI 10.1056/NEJM197811302992207; TAM SP, 1983, J LIPID RES, V24, P1343; THOMAS SS, 1995, BBA-MOL BASIS DIS, V1272, P37, DOI 10.1016/0925-4439(95)00065-C; THRIFT RN, 1986, J LIPID RES, V27, P236; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; ZANNIS VI, 1992, CURR OPIN LIPIDOL, V3, P96	67	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10119	10127		10.1074/jbc.M300137200	http://dx.doi.org/10.1074/jbc.M300137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12547832	hybrid			2022-12-25	WOS:000181777500019
J	Yellaturu, CR; Rao, GN				Yellaturu, CR; Rao, GN			Cytosolic phospholipase A(2) is an effector of Jak/STAT signaling and is involved in platelet-derived growth factor BB-induced growth in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RAT MESANGIAL CELLS; SRC TYROSINE KINASE; ARACHIDONIC-ACID; P388D(1) MACROPHAGES; ENDOTHELIAL-CELLS; FACTOR EXPRESSION; ACTIVATION; APOPTOSIS; PHOSPHORYLATION	Platelet-derived growth factor-BB (PDGF-BB) is a potent mitogen and chemoattractant for vascular smooth muscle cells (VSMC). To understand its mitogenic and chemotactic signaling events, we studied the role of cytosolic phospholipase A(2) (cPLA(2)) and the Jak/STAT pathway. PDGF-BB induced the expression and activity of cPLA(2) in a time-dependent manner in VSMC. Arachidonyl trifluoromethyl ketone, a potent and specific inhibitor of cPLA2, significantly reduced PDGF-BB-induced arachidonic acid release and DNA synthesis. PDGF-BB stimulated tyrosine phosphorylation of Jak-2 in a time-dependent manner. In addition, PDGF-BB activated STAT-3 as determined by its tyrosine phosphorylation, DNA-binding activity, and reporter gene expression, and these responses were suppressed by AG490, a selective inhibitor of Jak-2. AG490 and a dominant-negative mutant of STAT-3 also attenuated PDGF-BB-induced expression of cPLA2, arachidonic acid release, and DNA synthesis in VSMC. Together, these results suggest that induction of expression of cPLA2 and arachidonic acid release are involved in VSMC growth in response to PDGF-BB and that these events are mediated by Jak-2-dependent STAT-3 activation.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu			NHLBI NIH HHS [R01 HL65165] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; BACHHUBER BG, 1995, AM J PHYSIOL-CELL PH, V268, pC1141, DOI 10.1152/ajpcell.1995.268.5.C1141; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Denson DD, 1999, AM J PHYSIOL-CELL PH, V276, pC201, DOI 10.1152/ajpcell.1999.276.1.C201; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mallat Z, 1999, J CLIN INVEST, V103, P421, DOI 10.1172/JCI3985; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mezentsev A, 2002, J BIOL CHEM, V277, P18670, DOI 10.1074/jbc.M201143200; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Panini SR, 2001, J LIPID RES, V42, P1678; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1994, J BIOL CHEM, V269, P32586; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	53	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9986	9992		10.1074/jbc.M211276200	http://dx.doi.org/10.1074/jbc.M211276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12529382	hybrid			2022-12-25	WOS:000181524000147
J	Choi, KS; Fogg, KD; Yoon, CS; Waisman, DM				Choi, KS; Fogg, KD; Yoon, CS; Waisman, DM			p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells	FASEB JOURNAL			English	Article						annexin; S100A10; p11; plasminogen; plasmin; urokinase; cancer	ANNEXIN-II TETRAMER; BREAST-CANCER CELLS; T-PA; BOUND REACTANTS; HUMAN LEUKEMIA; PRO-UROKINASE; SARCOMA-CELLS; ALPHA-ENOLASE; ACTIVATION; RECEPTOR	The defining characteristic of a tumor cell is its ability to escape the constraints imposed by neighboring cells, invade the surrounding tissue, and metastasize to distant sites. This invasive property of tumor cells is dependent on activation of proteases at the cell surface. Most cancer cells secrete the urokinase-type plasminogen activator, which converts cell-bound plasminogen to plasmin. Here we address the issue of whether the plasminogen binding protein, p11, plays a significant role in this process. Transfection of human HT1080 fibrosarcoma cells with the human p11 gene in the antisense orientation resulted in a loss of p11 protein from the cell surface and concomitant decreases in cellular plasmin production, ECM degradation, and cellular invasiveness. The transfected cells demonstrated reduced development of lung metastatic foci in SCID mice. In contrast, HT1080 cells transfected with the p11 gene in the sense orientation displayed increased cell surface p11 protein and concomitant increases in cellular plasmin production, as well as enhanced ECM degradation and enhanced cellular invasiveness. The p11 overexpressing cells showed enhanced development of lung metastatic foci. These data establish that changes in the extracellular expression of the plasminogen receptor protein, p11, dramatically affect tumor cell-mediated pericellular proteolysis.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Med Sci, Calgary, AB T2N 4N1, Canada; Univ Calgary, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662	NCI NIH HHS [CA78639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andronicos NM, 2001, BRIT J CANCER, V85, P909, DOI 10.1054/bjoc.2001.2022; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHOI KS, 2002, IN PRESS ANNEXINS BI; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Felez J, 1998, FIBRINOLYSIS PROTEOL, V12, P183, DOI 10.1016/S0268-9499(98)80012-X; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; Fogg DK, 2002, BIOCHEMISTRY-US, V41, P4953, DOI 10.1021/bi012045y; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kralovich KR, 1998, J PROTEIN CHEM, V17, P845, DOI 10.1023/A:1020738620817; LAUG WE, 1992, INT J CANCER, V52, P298, DOI 10.1002/ijc.2910520224; Lijnen HR, 1998, THROMB HAEMOSTASIS, V79, P1171; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Mustjoki S, 1999, APMIS, V107, P144, DOI 10.1111/j.1699-0463.1999.tb01537.x; NAMIRANIAN S, 1995, BIOCHEM J, V309, P977, DOI 10.1042/bj3090977; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; REDLITZ A, 1995, BAILLIERE CLIN HAEM, V8, P313, DOI 10.1016/S0950-3536(05)80270-7; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; Tapiovaara H, 1996, ADV CANCER RES, V69, P101, DOI 10.1016/S0065-230X(08)60861-1; Tibbles LA, 2002, J VIROL, V76, P1559, DOI 10.1128/JVI.76.4.1559-1568.2002; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	39	59	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					235	246		10.1096/fj.02-0697com	http://dx.doi.org/10.1096/fj.02-0697com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554702				2022-12-25	WOS:000181456900048
J	Maria, DA; Manenti, G; Galbiati, F; Ribeiro, OG; Cabrera, WHK; Barrera, RG; Pettinicchio, A; De Franco, M; Starobinas, N; Siqueira, M; Dragani, TA; Ibanez, OM				Maria, DA; Manenti, G; Galbiati, F; Ribeiro, OG; Cabrera, WHK; Barrera, RG; Pettinicchio, A; De Franco, M; Starobinas, N; Siqueira, M; Dragani, TA; Ibanez, OM			Pulmonary adenoma susceptibility 1 (Pas1) locus affects inflammatory response	ONCOGENE			English	Article						Pas1; cancer modifier loci; linkage disequilibrium; genetic polymorphisms	PREVIOUS LUNG-DISEASE; LINKAGE DISEQUILIBRIUM; RESISTANCE LOCUS; OUTBRED MICE; CANCER; MOUSE; RISK; GENE; RESPONSIVENESS; CHROMOSOME-6	Two outbred mouse lines, phenotypically selected for differential subcutaneous (s.c.) acute inflammatory response (AIR), were analysed for urethane-induced lung inflammatory response and susceptibility to lung tumorigenesis. AIR(min) Mice, which show a low response to s.c. acute inflammation, developed a persistent subacute lung inflammatory response and a 40-fold higher lung tumor multiplicity than did AIR(max) mice, which are selected for high response to s.c. acute inflammation and showed a transient lung inflammatory response. A highly significant linkage disequilibrium pattern was observed in AIR(max) and AIR(min) mice at marker alleles located within a 452-kb pulmonary adenoma susceptibility 1 (Pas1) locus region, thus defining the location of gene candidacy for inflammatory response and for the biological effects of Pas1 in this region. AIRmin and AIRmax mice segregated by descent the Pas1(s) and Pas1(r) alleles, respectively, providing evidence for the involvement of the Pas1 locus in the inflammatory response. The 452-kb region contains Kras2 and four additional genes, including the lymphoid-restricted membrane protein (Lrmp) gene, whose Pro --> Leu nonconservative variation was linked with inflammatory response and Pas1 allelotype. These results provide a model to explore the mechanism underlying inherited predisposition to lung cancer in the context of a link to inflammation.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Inst Butantan, Lab Imunogenet, Sao Paulo, Brazil	Fondazione IRCCS Istituto Nazionale Tumori Milan; Instituto Butantan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Starobinas, Nancy/B-9178-2015; Ibañez, Olga CM/B-9627-2015; Dragani, Tommaso A./K-4493-2016; Gianni-Barrera, Roberto/ACU-4280-2022; Manenti, Giacomo/J-3339-2017; DE FRANCO, MARCELO/S-5870-2019; Ribeiro, Orlando Garcia/B-5241-2016; Cabrera, Wafa HK/F-7189-2016	Starobinas, Nancy/0000-0001-5716-3394; Ibañez, Olga CM/0000-0002-2672-4758; Dragani, Tommaso A./0000-0001-5915-4598; Gianni-Barrera, Roberto/0000-0001-6303-4513; Manenti, Giacomo/0000-0002-4887-4482; DE FRANCO, MARCELO/0000-0002-0417-8215; 				Askling J, 1999, AM J RESP CRIT CARE, V160, P1668, DOI 10.1164/ajrccm.160.5.9904045; Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; Biozzi G, 1998, CARCINOGENESIS, V19, P337, DOI 10.1093/carcin/19.2.337; Brownson RC, 2000, CANCER CAUSE CONTROL, V11, P853, DOI 10.1023/A:1008999202040; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118, DOI 10.1152/ajplung.1999.277.6.L1118; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; Eden A, 1999, FEBS LETT, V457, P255, DOI 10.1016/S0014-5793(99)01054-6; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; JORDE LB, 1995, AM J HUM GENET, V56, P11; Lang SM, 1999, GUT, V44, P822, DOI 10.1136/gut.44.6.822; Malkinson AM, 2002, CARCINOGENESIS, V23, P411, DOI 10.1093/carcin/23.3.411; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Manenti G, 1999, GENOME RES, V9, P639; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; Moody TW, 2001, ANTICANCER RES, V21, P1749; Obata M, 1996, ONCOGENE, V13, P1599; Pataer A, 1997, CANCER RES, V57, P2904; Peissel B, 2000, MAMM GENOME, V11, P979, DOI 10.1007/s003350010184; Prows DR, 1999, AM J PHYSIOL-LUNG C, V277, pL372, DOI 10.1152/ajplung.1999.277.2.L372; Snyder HL, 1997, J EXP MED, V186, P1087, DOI 10.1084/jem.186.7.1087; *STAT SAS I, 1988, SAS US GUID STAT; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Tsunematsu S, 1997, J GASTROEN HEPATOL, V12, P319, DOI 10.1111/j.1440-1746.1997.tb00428.x; YANAGISAWA A, 1993, CANCER RES, V53, P953	25	41	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					426	432		10.1038/sj.onc.1206157	http://dx.doi.org/10.1038/sj.onc.1206157			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545163				2022-12-25	WOS:000180379100011
J	Li, WJ; Hu, N; Su, F; Wang, CY; Goldstein, AM; Wang, Y; Emmert-Buck, MR; Roth, MJ; Guo, WJ; Taylor, PR				Li, WJ; Hu, N; Su, F; Wang, CY; Goldstein, AM; Wang, Y; Emmert-Buck, MR; Roth, MJ; Guo, WJ; Taylor, PR			Allelic loss on chromosome 13q14 and mutation in deleted in cancer 1 gene in esophageal squamous cell carcinoma	ONCOGENE			English	Article						DICE1; LOH; SSCP; mutation; polymorphism; esophagus	TUMOR-SUPPRESSOR GENES; SUSCEPTIBILITY GENE; HETEROZYGOSITY; IDENTIFICATION; CHINA; POPULATION; REGIONS	Previous studies have shown frequent allelic loss on chromosome 13 in esophageal squamous cell carcinoma (ESCC). We assessed the frequency of allelic loss on chromosome 13q14 and mutations of deleted in cancer 1 (DICE1) (also found on 13q14) in ESCC patients to determine if this candidate tumor suppressor gene has a role in the development of ESCC, and whether this gene was an inactivation target for allelic loss on chromosome 13q14. Initially, we examined allelic loss at five markers flanking DICE1 in 56 ESCC patients from Shanxi Province, China, and then examined the entire coding sequence of this gene for mutations using polymerase chain reaction-single-strand confirmation polymorphism (PCR-SSCP) analysis and DNA sequencing. Subsequently, we extended our evaluation to an additional 80 ESCC patients and 232 healthy individuals to confirm the germline variant found in the initial 56 ESCC patients. The frequencies of allelic loss were 71, 58, and 75% for D13S325, D13S757, and D13S887, respectively, in the initial 56 ESCC patients studied. Overall, 73% of informative patients had loss of heterozygosity (LOH) for at least one of these three markers. Somatic mutations were identified in three patients (3/56, 5%), and one novel polymorphism was identified in 3% of ESCC patients (4/ 136) and 3% of healthy individuals (6/232). We conclude that DICE1 mutations occur in ESCC but are infrequent. The candidate tumor suppressor gene corresponding to the frequent allelic loss on chromosome 13q14 in ESCC remains unknown.	NCI, Canc Prevent Studies Branch, Ctr Canc Res, Bethesda, MD 20892 USA; Shanxi Canc Hosp & Inst, Taiyuan 030013, Shanxi, Peoples R China; NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Taylor, PR (corresponding author), NCI, Canc Prevent Studies Branch, Ctr Canc Res, 6116 Execut Blvd,Suite 705, Bethesda, MD 20892 USA.							BOYNTON RF, 1991, CANCER RES, V51, P5766; Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Hu N, 1999, CLIN CANCER RES, V5, P3476; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2001, CLIN CANCER RES, V7, P883; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Huang J, 2000, CARCINOGENESIS, V21, P2019, DOI 10.1093/carcin/21.11.2019; HUANG Y, 1992, CANCER RES, V52, P6525; Hyytinen ER, 1999, GENE CHROMOSOME CANC, V25, P108, DOI 10.1002/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; MACGEE TL, 1989, GENE, V80, P119; MAESAWA C, 1994, INT J CANCER, V57, P21, DOI 10.1002/ijc.2910570105; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wieland I, 2001, ONCOL RES, V12, P491, DOI 10.3727/096504001108747503; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	20	24	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					314	318		10.1038/sj.onc.1206098	http://dx.doi.org/10.1038/sj.onc.1206098			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527901				2022-12-25	WOS:000180322400017
J	Miyamoto, K; Asada, K; Fukutomi, T; Okochi, E; Yagi, Y; Hasegawa, T; Asahara, T; Sugimura, T; Ushijima, T				Miyamoto, K; Asada, K; Fukutomi, T; Okochi, E; Yagi, Y; Hasegawa, T; Asahara, T; Sugimura, T; Ushijima, T			Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers	ONCOGENE			English	Article						DNA methylation; silencing; 3-OST-2; breast cancer	REPRESENTATIONAL DIFFERENCE ANALYSIS; DNA METHYLATION; EXPRESSION; GENE; PLASMA; HYPERMETHYLATION; IDENTIFICATION; PATTERNS; ASSAY	Aberrant CpG methylations play important roles in cancer development and progression. In this study, aberrant methylations in human breast cancer were searched for using methylation-sensitive representational difference analysis (MS-RDA). A CpG island (CGI) in the 5' region of the heparan sulfate D-glucosaminyl 3-O-suffiotransferase-2 (3-OST-2) gene was found to be hypermethylated, while its exon 2 was hypomethylated. In seven breast cancer cell lines, hypermethylation of the 5' region and loss of 3-OST-2 expression were observed. Treatment with a demethylating agent, 5-aza-2'-deoxycyfidine, removed the methylation of the CGI in the 5' region and restored its expression, demonstrating silencing of the 3-OST-2 gene. Methylation-specific PCR (MSP) analysis in 85 primary breast cancers showed that the hypermethylation of the CGI in the 5' region was present in 75 (88%) of them. Quantitative reverse transcriptase-PCR (RTPCR) analysis in 37 primary breast cancers showed that the average expression level was decreased in them. Further, MSP analysis in primary colon, lung and pancreatic cancers showed that hypermethylation of the CGI in the 5' region was present in the colon (8/10, 80%), lung (7/10, 70%) and pancreatic (10/10, 100%) cancers. These results showed that silencing of 3-OST-2 was present in a wide range of human cancers. The 3-OST-2 gene encodes an enzyme involved in the final modification step of heparan sulfate proteoglycans (HSPGs), and its silencing is expected to result in abnormal modification of HSPGs and abnormal signal transduction. From the high incidence, silencing of the 3-OST-2 gene is expected to have high diagnostic, and potentially therapeutic, values.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Dept Surg, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Hiroshima University	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Asada, Kiyoshi/GPW-7758-2022; Asada, Kiyoshi/AFL-8696-2022; Ushijima, Toshikazu/AAP-5742-2021	Asada, Kiyoshi/0000-0002-4515-6047; Ushijima, Toshikazu/0000-0003-3405-7817				ASADA K, IN PRESS ONCOLOGY; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; Feinberg AP, 2001, NAT GENET, V27, P9, DOI 10.1038/83825; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; KANEDA A, IN PRESS CANC RES; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Matsuda K, 2001, CANCER RES, V61, P5562; Muller K, 2001, J BIOL CHEM, V276, P14271; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; SAMBROOK J, 1989, MOL CLONING, V2, P1914; SHAPIRO B, 1983, CANCER, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; STROUN M, 1989, ONCOLOGY, V46, P318; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284	35	111	119	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					274	280		10.1038/sj.onc.1206146	http://dx.doi.org/10.1038/sj.onc.1206146			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527896				2022-12-25	WOS:000180322400012
J	Rachmilewitz, J; Borovsky, Z; Riely, GJ; Miller, R; Tykocinski, ML				Rachmilewitz, J; Borovsky, Z; Riely, GJ; Miller, R; Tykocinski, ML			Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; THYMIC EPITHELIAL-CELLS; IMMUNOSUPPRESSIVE FACTOR; MEMBRANE MICRODOMAINS; SIGNAL-TRANSDUCTION; ENDOGENOUS LECTIN; HUMAN THYMOCYTES; RAT MACROPHAGES; PHOSPHORYLATION; GALECTIN-1	CD45 is the major protein tyrosine phosphatase receptor on T cell surfaces that functions as both a positive and a negative regulator of T cell receptor (TCR) signaling. Although CD45 is required for the activation of TCR-associated Src family kinases, it also dephosphorylates phosphoproteins involved in the TCR-signaling cascade. This study links CD45 to the inhibitory activity of placental protein 14 (PP14), a major soluble protein of pregnancy that is now known to be a direct modulator of T cells and to function by desensitizing TCR signaling. PP14 and CD45 co-capped with each other, pointing to a physical linkage between the two. Interestingly, however, the binding of PP,14 to T cell surfaces was not restricted to CD45 alone, with evidence showing that PP14 binds to other surface molecules in a carbohydrate-dependent fashion. Notwithstanding the broader molecular binding potential of PP14, its interaction with CD45 appeared to have special functional significance. Using transfected derivatives of the HPB.ALL mutant T cell line that differ in CD45 expression, we established that the inhibitory effects of PP14 are dependent upon the expression of intact CD45 on T cell surfaces. Based upon these findings, we propose a new immunoregulatory model for PP14, wherein. one of its surface molecular targets, CD45, mediates its T cell inhibitory activity, accounting for the intriguing capacity of PP14 to elevate TCR activation thresholds and thereby down-regulate T cell activation.	Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Hebrew University of Jerusalem; Case Western Reserve University; University of Pennsylvania	Rachmilewitz, J (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, POB 12000, IL-91120 Jerusalem, Israel.				NIAID NIH HHS [R01 AI-38960] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038960] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Blank N, 2001, J IMMUNOL, V166, P6034, DOI 10.4049/jimmunol.166.10.6034; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; BOLTON AE, 1987, LANCET, V1, P593; BRUNSCHWIG EB, 1995, J IMMUNOL, V155, P5498; Clark GF, 2001, CELLS TISSUES ORGANS, V168, P113, DOI 10.1159/000016812; D'Oro U, 1999, J IMMUNOL, V162, P1879; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Flower DR, 1996, BIOCHEM J, V318, P1; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; HALL LR, 1988, J IMMUNOL, V141, P2781; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Johnson KG, 2000, P NATL ACAD SCI USA, V97, P10138, DOI 10.1073/pnas.97.18.10138; JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; MORROW DM, 1994, AM J PATHOL, V145, P1485; Motoya S, 1999, J BIOL CHEM, V274, P1407, DOI 10.1074/jbc.274.3.1407; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Pace KE, 1999, J IMMUNOL, V163, P3801; Paz FL, 2001, EUR J IMMUNOL, V31, P777; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; POCKLEY AG, 1989, CLIN EXP IMMUNOL, V77, P252; POCKLEY AG, 1990, IMMUNOLOGY, V69, P277; Rabinovich G, 1996, J LEUKOCYTE BIOL, V59, P363, DOI 10.1002/jlb.59.3.363; Rabinovich GA, 1998, J IMMUNOL, V160, P4831; Rachmilewitz J, 1999, CELL IMMUNOL, V191, P26, DOI 10.1006/cimm.1998.1408; Rachmilewitz J, 2002, J IMMUNOL, V168, P2745, DOI 10.4049/jimmunol.168.6.2745; Rachmilewitz J, 2001, BLOOD, V98, P3727, DOI 10.1182/blood.V98.13.3727; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; Riely GJ, 2000, BIOCHEM J, V351, P503, DOI 10.1042/0264-6021:3510503; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEPPALA M, 1985, ANN NY ACAD SCI, V442, P212, DOI 10.1111/j.1749-6632.1985.tb37522.x; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Shivnan E, 1996, J IMMUNOL, V157, P101; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Thomas ML, 1999, CURR OPIN IMMUNOL, V11, P270, DOI 10.1016/S0952-7915(99)80044-2; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TURKA LA, 1992, EUR J IMMUNOL, V22, P551, DOI 10.1002/eji.1830220238; Veillette A, 1999, J BIOL CHEM, V274, P14392, DOI 10.1074/jbc.274.20.14392; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Walzel H, 1999, IMMUNOL LETT, V67, P193, DOI 10.1016/S0165-2478(99)00012-7; YAKURA H, 1994, CRIT REV IMMUNOL, V14, P311, DOI 10.1615/CritRevImmunol.v14.i3-4.50	59	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14059	14065		10.1074/jbc.M211716200	http://dx.doi.org/10.1074/jbc.M211716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12556471	hybrid			2022-12-25	WOS:000182405000065
J	Fraunberg, MV; Nyronen, T; Kauppinen, R				Fraunberg, MV; Nyronen, T; Kauppinen, R			Mitochondrial targeting of normal and mutant protoporphyrinogen oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT RECEPTORS TOM20; VARIEGATE PORPHYRIA; STRUCTURAL BASIS; PRESEQUENCE; MUTATIONS; YEAST; GENE; IDENTIFICATION; MEMBRANE; FAMILIES	We have investigated the signal sequence for mitochondrial transport of mutants (I12T, 78insC, IVS2-2a-->c, 338G-->C, R152C, 470A-->C, and L401F) and the wild type protoporphyrinogen oxidase (PPOX), which is the penultimate enzyme in the heme biosynthesis. We constructed the corresponding green fluorescent protein fusion proteins and studied their intracellular localization in COS-1 cells. We showed that 28 amino acids in the amino terminus of PPOX contain an independently functioning signal for mitochondrial targeting. The experiments with amino-terminally truncated green fluorescent protein fusion proteins revealed that amino acids 25-477 of PPOX contained an additional mitochondrial targeting signal(s). We constructed a structural model for the interaction between the amino-terminal end of PPOX and the putative mitochondrial receptor protein Tom20. The model suggests that leucine and isoleucine residues Leu-8, Ile-12, and Leu-15 forming an a-helical hydrophobic motif, LXXXIXXL, were crucial for the recognition of the targeting signal. The validity of the model was tested using mutants L8Q, I12T, and L15Q disrupting the hydrophobic surface of the LXXXIXXL helix. The results from in vitro expression studies and molecular modeling were in accordance supporting the hypothesis that the recognition of the mitochondrial targeting signal is dependent on hydrophobic interactions between the targeting signal and the mitochondrial receptor.	Univ Helsinki, Biomedicum Helsinki, Dept Med, Div Endocrinol, Helsinki 00029, Finland; CSC Sci Comp Ltd, Espoo 02101, Finland	University of Helsinki; Finnish IT center for science	Fraunberg, MV (corresponding author), Univ Helsinki, Cent Hosp, Dept Med, Porphyria Res Ctr,Biomedicum Helsinki, POB 700, Helsinki 00029, Finland.		Nyrönen, Tommi H./A-3612-2010	von und zu Fraunberg, Mikael/0000-0002-8457-4639; Kauppinen, Raili/0000-0002-8799-3425; Nyronen, Tommi/0000-0002-5569-5183				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Arnould S, 1999, P NATL ACAD SCI USA, V96, P14825, DOI 10.1073/pnas.96.26.14825; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAY RS, 1986, SEMIN DERMATOL, V5, P138; DeLabre ML, 1999, FEBS LETT, V449, P201, DOI 10.1016/S0014-5793(99)00415-9; DEYBACH JC, 1985, EUR J BIOCHEM, V149, P431, DOI 10.1111/j.1432-1033.1985.tb08943.x; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; Folsch H, 1998, EMBO J, V17, P6508, DOI 10.1093/emboj/17.22.6508; Frank J, 2001, J INVEST DERMATOL, V116, P821, DOI 10.1046/j.1523-1747.2001.01308.x; Fraunberg MVZ, 2001, MOL MED, V7, P320, DOI 10.1007/BF03402215; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAPPAS A, 1905, METABOLIC MOL BASES, P2116; Kauppinen R, 2001, J INVEST DERMATOL, V116, P610, DOI 10.1046/j.1523-1747.2001.01293.x; Krause-Buchholz U, 2000, YEAST, V16, P353, DOI 10.1002/1097-0061(20000315)16:4<353::AID-YEA539>3.0.CO;2-#; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MUSTAJOKI P, 1980, Q J MED, V49, P191; NISHIMURA K, 1995, J BIOL CHEM, V270, P8076, DOI 10.1074/jbc.270.14.8076; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Tzschoppe K, 2000, BIOL CHEM, V381, P1175, DOI 10.1515/BC.2000.145; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Warnich L, 1996, HUM MOL GENET, V5, P981, DOI 10.1093/hmg/5.7.981; Whatley SD, 1999, AM J HUM GENET, V65, P984, DOI 10.1086/302586; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZARA V, 1992, J BIOL CHEM, V267, P12077; [No title captured]	36	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13376	13381		10.1074/jbc.M300151200	http://dx.doi.org/10.1074/jbc.M300151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556518	hybrid			2022-12-25	WOS:000182189500099
J	Newell, JG; Czajkowski, C				Newell, JG; Czajkowski, C			The GABA(A) receptor alpha(1) subunit Pro(174)-Asp(191) segment is involved in GABA binding and channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CYSTEINE SCANNING MUTAGENESIS; AGONIST-BINDING; BENZODIAZEPINE BINDING; SUBSTITUTED CYSTEINES; SECONDARY STRUCTURE; DELTA-SUBUNIT; ACH-BINDING; SITE; RESIDUES	The GABA-binding site undergoes structural rearrangements during the transition from agonist binding to channel opening. To define possible roles of the GABA(A) receptor a, subunit Pro(174)-Asp(191) segment in these processes, we used the substituted cysteine accessibility method to characterize this region. Each residue was individually mutated to cysteine, expressed with wild-type beta(2) subunits in Xenopus laevis oocytes, and examined using two-electrode voltage clamp. Most mutations did not alter GABA EC50 values. The D183C mutation produced a 7-fold reduction in GABA sensitivity. There were no significant changes in the K, values for the competitive antagonist, SR-95531. N-Biotinylaminoethyl methanethiosulfonate modified P174C-, R176C-, S177C-, V178C-, V180C-, A181C-, D183C-, R186C- and N188C-containing receptors. The pattern of accessibility suggests that this protein segment is aqueous-exposed and adopts a random coil conformation. Both GABA and SR-95531 slowed covalent modification of V178C, V180C, and D183C, indicating that these residues may line the GABA-binding site. Further, pentobarbital-induced channel activation accelerated modification of V180C and A181C and slowed the modification of R186C, suggesting that this region of the a, subunit may act as a dynamic element during channel-gating transitions.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Czajkowski, C (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave,Rm 197 MSC, Madison, WI 53706 USA.	czajkowski@physiology.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034727] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34727] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akk G, 2000, BRIT J PHARMACOL, V130, P249, DOI 10.1038/sj.bjp.0703335; Akk G, 1999, BIOPHYS J, V76, P207, DOI 10.1016/S0006-3495(99)77190-0; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Fisher JL, 2002, NEUROPHARMACOLOGY, V42, P922, DOI 10.1016/S0028-3908(02)00050-3; GALZI JL, 1990, J BIOL CHEM, V265, P10430; Holden JH, 2002, J BIOL CHEM, V277, P18785, DOI 10.1074/jbc.M111778200; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kucken AM, 2000, MOL PHARMACOL, V57, P932; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; MCLAUGHLIN JT, 1995, BIOCHEMISTRY-US, V757, P222; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; PRESS WH, 1988, NUMERICAL RECIPES, P301; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; Sine SM, 2002, J GEN PHYSIOL, V120, P483, DOI 10.1085/jgp.20028568; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Spura A, 1999, BIOCHEMISTRY-US, V38, P4912, DOI 10.1021/bi982656z; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; Sullivan D, 2002, MOL PHARMACOL, V61, P463, DOI 10.1124/mol.61.2.463; Sullivan DA, 2000, J BIOL CHEM, V275, P12651, DOI 10.1074/jbc.275.17.12651; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Torres VI, 2002, J BIOL CHEM, V277, P43741, DOI 10.1074/jbc.M202007200; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129; Williams DB, 2002, J NEUROSCI, V22, P7417	46	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13166	13172		10.1074/jbc.M211905200	http://dx.doi.org/10.1074/jbc.M211905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12556472	hybrid			2022-12-25	WOS:000182189500074
J	Yang, HB; Cooley, D; Legakis, JE; Ge, QY; Andrade, R; Mattingly, RR				Yang, HB; Cooley, D; Legakis, JE; Ge, QY; Andrade, R; Mattingly, RR			Phosphorylation of the Ras-GRF1 exchange factor at Ser(916/898) reveals activation of ras signaling in the cerebral cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; PROTEIN-MEDIATED SIGNALS; MAP KINASE; MUSCARINIC RECEPTORS; TYROSINE KINASE; NEUROFIBROMATOSIS TYPE-1; DEPENDENT ACTIVATION; FACTOR CDC25(MM); PC12 CELLS; HA-RAS	The Ras-GRF1 exchange factor, which is regulated by increases in intracellular calcium and the release of Gbetagamma subunits from heterotrimeric G proteins, plays a critical role in the activation of neuronal Ras. Activation of G protein-coupled receptors stimulates an increase in the phosphorylation of Ras-GRF1 at certain serine residues. The first of these sites to be identified, Ser(916) in the mouse sequence (equivalent to Ser(898) in the rat sequence), is required for full activation of the Ras exchange factor activity of Ras-GRF1 by muscarinic receptors. We demonstrate here that Ras-GRF1 is highly expressed in rat brain compared with the Sos exchange factor and that there is an increase in incorporation of P-32 into Ser(898) of brain Ras-GRF1 following activation of protein kinase A. Phosphorylation of Ras-GRF1 at Ser(916) is also required for maximal induction of Ras-dependent neurite outgrowth in PC12 cells. A novel antibody (termed 2152) that selectively recognizes Ras-GRF1 when it is phosphorylated at Ser(916/898) confirmed the regulated phosphorylation of Ras-GRF1 by Western blotting in both model systems of transfected COS-7 and PC12 cells and also of the endogenous protein in rat forebrain slices. Indirect confocal immunofluorescence of transfected PC12 cells using antibody 2152 demonstrated reactivity only under conditions in which Ras-GRF1 was phosphorylated at Ser(916/898). Confocal immunofluorescence of cortical slices of rat brain revealed widespread and selective phosphorylation of Ras-GRF1 at Ser(898). In the prefrontal cortex, there was striking phosphorylation of Ras-GRF1 in the dendritic tree, supporting a role for Ras activation and signal transduction in neurotransmission in this area.	Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Barbara Ann Karmanos Canc Inst, Program Mol Biol & Genet, Detroit, MI 48201 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Mattingly, RR (corresponding author), Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Pharmacol, 640 E Canfield Ave, Detroit, MI 48201 USA.	r.mattingly@wayne.edu			NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043985] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA22453, R01 CA381150] Funding Source: Medline; NIEHS NIH HHS [P30 ES06639] Funding Source: Medline; NIMH NIH HHS [R01 MH43985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Arozarena I, 2001, J BIOL CHEM, V276, P21878, DOI 10.1074/jbc.M011383200; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Baouz S, 2001, J BIOL CHEM, V276, P1742, DOI 10.1074/jbc.M005770200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Coccetti P, 1998, BBA-PROTEIN STRUCT M, V1383, P292, DOI 10.1016/S0167-4838(97)00212-4; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fernandez-Medarde A, 2002, MOL CELL BIOL, V22, P2498, DOI 10.1128/MCB.22.8.2498-2504.2002; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; Finkbeiner S, 1998, BIOESSAYS, V20, P691, DOI 10.1002/(SICI)1521-1878(199809)20:9<691::AID-BIES1>3.3.CO;2-H; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Giese KP, 2001, NEUROPHARMACOLOGY, V41, P791, DOI 10.1016/S0028-3908(01)00096-X; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Innocenti M, 1999, FEBS LETT, V460, P357, DOI 10.1016/S0014-5793(99)01374-5; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; Mattingly RR, 2001, CELL SIGNAL, V13, P499, DOI 10.1016/S0898-6568(01)00173-5; Mattingly RR, 2001, TOXICOL APPL PHARM, V176, P162, DOI 10.1006/taap.2001.9272; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Mattingly RR, 1999, CELL SIGNAL, V11, P603, DOI 10.1016/S0898-6568(99)00034-0; Mattingly RR, 1998, IN VITRO MOL TOXICOL, V11, P57; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Mattingly RR, 1999, J BIOL CHEM, V274, P37379, DOI 10.1074/jbc.274.52.37379; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; Messer William S. Jr., 2002, Current Topics in Medicinal Chemistry, V2, P353, DOI 10.2174/1568026024607553; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Pak Y, 2002, MOL CELL BIOL, V22, P7942, DOI 10.1128/MCB.22.22.7942-7952.2002; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tonini R, 2001, MOL CELL NEUROSCI, V18, P691, DOI 10.1006/mcne.2001.1050; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Weeber EJ, 2002, NEURON, V33, P845, DOI 10.1016/S0896-6273(02)00634-7; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; Yang HB, 1999, J NEUROSCI RES, V55, P687, DOI 10.1002/(SICI)1097-4547(19990315)55:6<687::AID-JNR4>3.0.CO;2-6; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zippel R, 1997, MOL BRAIN RES, V48, P140; Zippel R, 1996, ONCOGENE, V12, P2697	69	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13278	13285		10.1074/jbc.M209805200	http://dx.doi.org/10.1074/jbc.M209805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12538592	hybrid			2022-12-25	WOS:000182189500087
J	Bianchi, L; Kwok, SM; Driscoll, M; Sesti, F				Bianchi, L; Kwok, SM; Driscoll, M; Sesti, F			A potassium channel-MiRP complex controls neurosensory function in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINK-RELATED PEPTIDE-1; I-KS; BETA-SUBUNIT; K+ CHANNEL; GENE; KCNQ1; HERG; EXPRESSION; NEURONS; IDENTIFICATION	MinK-related peptides (MiRPs) are single transmembrane proteins that associate with mammalian voltage-gated K+ subunits. Here we report the cloning and functional characterization of a MiRP beta-subunit, MPS-1, and of a voltage-gated pore-forming potassium subunit, KVS-1, from the nematode Caenorhabditis elegans. mps-1 is expressed in chemosensory and mechanosensory neurons and co-localizes with kvs-1 in a subset of these. Inactivation of either mps-1 or kvs-1 by RNA interference (RNAi) causes partially overlapping neuronal defects and results in broad-spectrum neuronal dysfunction, including defective chemotaxis, disrupted mechanotransduction, and impaired locomotion. Inactivation of one subunit by RNAi dramatically suppresses the expression of the partner subunit only in cells where the two proteins co-localize. Co-expression of MPS-1 and KVS-1 in mammalian cells gives rise to a potassium current distinct from the KVS-1 current. Taken together these data indicate that potassium currents constitute a basic determinant for C. elegans neuronal function and unravel a unifying principle of evolutionary significance: that potassium channels in various organisms use MiRPs to generate uniqueness of function with rich variation in the details.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln, Piscataway, NJ 08854 USA.	sestife@umdnj.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037955] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 37955] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; Cowley EA, 2002, J PHYSIOL-LONDON, V538, P747, DOI 10.1113/jphysiol.2001.013300; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Finley MR, 2002, AM J PHYSIOL-HEART C, V283, pH126, DOI 10.1152/ajpheart.00622.2001; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Hart AC, 1999, J NEUROSCI, V19, P1952; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Piccini M, 1999, GENOMICS, V60, P251, DOI 10.1006/geno.1999.5904; Pierce-Shimomura JT, 2001, NATURE, V410, P694, DOI 10.1038/35070575; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Song WJ, 2002, NEUROSCI RES, V42, P7, DOI 10.1016/S0168-0102(01)00305-4; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Thomas JH, 1999, PRACT APPROACH SER, V213, P143; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tseng GN, 1996, J PHARMACOL EXP THER, V279, P865; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	35	54	56	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12415	12424		10.1074/jbc.M212788200	http://dx.doi.org/10.1074/jbc.M212788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12533541	hybrid			2022-12-25	WOS:000182015700091
J	Gurung, R; Tan, A; Ooms, LM; McGrath, MJ; Huysmans, RD; Munday, AD; Prescott, M; Whisstock, JC; Mitchell, CA				Gurung, R; Tan, A; Ooms, LM; McGrath, MJ; Huysmans, RD; Munday, AD; Prescott, M; Whisstock, JC; Mitchell, CA			Identification of a novel domain in two mammalian inositol-polyphosphate 5-phosphatases that mediates membrane ruffle localization - The inositol 5-phosphatase skip localizes to the endoplasmic reticulum and translocates to membrane ruffles following epidermal growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; LIPID PHOSPHATASE; PROTEIN; INSULIN; 3-KINASE; ACTIVATION; MOVEMENT; GAMMA; SHIP	SKIP (skeletal muscle and kidney enriched inositol phosphatase) is a recently identified phosphatidylinositol 3,4,5-trisphosphate- and phosphatidylinositol 4,5-bisphosphate-specific 5-phosphatase. In this study, we investigated the intracellular localization of SKIP. Indirect immunofluorescence and subcellular fractionation showed that, in serum-starved cells, both endogenous and recombinant SKIP colocalized with markers of the endoplasmic reticulum (ER). Following epidermal growth factor (EGF) stimulation, SKIP transiently translocated to plasma membrane ruffles and colocalized with submembranous actin. Data base searching demonstrated a novel 128-amino acid domain in the C terminus of SKIP, designated SKICH for SKIP carboxyl homology, which is also found in the 107-kDa 5-phosphatase PIPP and in members of the TRAF6-binding protein family. Recombinant SKIP lacking the SKICH domain localized to the ER, but did not translocate to membrane ruffles following EGF stimulation. The SKIP SKICH domain showed perinuclear localization and mediated EGF-stimulated plasma membrane ruffle localization. The SKICH domain of the 5-phosphatase PIPP also mediated plasma membrane ruffle localization. Mutational analysis identified the core sequence within the SKICH domain that mediated constitutive membrane association and C-terminal sequences unique to SKIP that contributed to ER localization. Collectively, these studies demonstrate a novel membrane-targeting domain that serves to recruit SKIP and PIPP to membrane ruffles.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	christina.mitchell@med.monash.edu.au	Ooms, Lisa/AGZ-7420-2022	McGrath, Meagan/0000-0002-9414-6558; Whisstock, James/0000-0003-4200-5611; Mitchell, Christina A/0000-0001-9372-3192; Ooms, Lisa Michelle/0000-0002-8918-9932				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hellsten E, 2001, DEV BIOL, V240, P641, DOI 10.1006/dbio.2001.0476; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Ikonomov OC, 2002, J BIOL CHEM, V277, P9206, DOI 10.1074/jbc.M108750200; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; Janne PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Kong AM, 2000, J BIOL CHEM, V275, P24052, DOI 10.1074/jbc.M000874200; Konrad G, 2002, J BIOL CHEM, V277, P10547, DOI 10.1074/jbc.M200090200; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sternsdorf T, 1997, J CELL BIOL, V138, P435, DOI 10.1083/jcb.138.2.435; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Uyeda A, 2000, NEUROSCI LETT, V284, P61, DOI 10.1016/S0304-3940(00)00959-9; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Whisstock JC, 2000, J BIOL CHEM, V275, P37055, DOI 10.1074/jbc.M006244200; Wiradjaja F, 2001, J BIOL CHEM, V276, P7643, DOI 10.1074/jbc.M010471200; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	47	73	81	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11376	11385		10.1074/jbc.M209991200	http://dx.doi.org/10.1074/jbc.M209991200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12536145	hybrid			2022-12-25	WOS:000181855400066
J	Mitchell, KJ; Lai, FA; Rutter, GA				Mitchell, KJ; Lai, FA; Rutter, GA			Ryanodine receptor type I and nicotinic acid adenine dinucleotide phosphate receptors mediate Ca2+ release from insulin-containing vesicles in living pancreatic beta-cells (MIN6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRANSMEMBRANE GLYCOPROTEIN CD38; CALCIUM-RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; SECRETORY GRANULES; SARCOPLASMIC-RETICULUM; DANTROLENE INHIBITION; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; CYTOSOLIC CA2+	We have demonstrated recently (Mitchell, K. J., Pinton, P., Varadi, A., Tacchetti, C., Ainscow, E. K., Pozzan, T., Rizzuto, R., and Rutter, G. A. (2001) J. Cell Biol. 155, 41-51) that ryanodine receptors (RyR) are present on insulin-containing secretory vesicles. Here we show that pancreatic islets and derived beta-cell lines express type I and II, but not type III, RyRs. Purified by subcellular fractionation and membrane immuno-isolation, dense core secretory vesicles were found to possess a similar level of type I RyR immunoreactivity as Golgi/endoplasmic reticulum (ER) membranes but substantially less RyR II than the latter. Monitored in cells expressing appropriately targeted aequorins, dantrolene, an inhibitor of RyR I channels, elevated free Ca2+ concentrations in the secretory vesicle compartment from 40.1 +/- 6.7 to 90.4 +/- 14.8 muM (n = 4, p < 0.01), while having no effect on ER Ca2+ concentrations. Furthermore, nicotinic acid adenine dinucleotide phosphate (NAADP), a novel Ca2+-mobilizing agent, decreased dense core secretory vesicle but not ER free Ca2+ concentrations in permeabilized MIN6 beta-cells, and flash photolysis of caged NAADP released Ca2+ from a thapsigargin-insensitive Ca2+ store in single MIN6 cells. Because dantrolene strongly inhibited glucose-stimulated insulin secretion (from 3.07 +/- 0.51-fold stimulation to no significant glucose effect; n = 3, p < 0.01), we conclude that RyR I-mediated Ca2+-induced Ca2+ release from secretory vesicles, possibly potentiated by NAADP, is essential for the activation of insulin secretion.	Univ Bristol, Sch Med Sci, Henry Wellcome Labs Integrated Cell Signalling, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Cardiff Univ, Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, S Glam, Wales	University of Bristol; University of Bristol; Cardiff University	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Henry Wellcome Labs Integrated Cell Signalling, Univ Walk, Bristol BS8 1TD, Avon, England.	g.a.rutter@bris.ac.uk		Rutter, Guy/0000-0001-6360-0343; Lai, Tony/0000-0003-2852-8547				Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Ainscow EK, 2001, BIOCHEM J, V353, P175, DOI 10.1042/0264-6021:3530175; AIREY JA, 1990, J BIOL CHEM, V265, P14187; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Brailoiu E, 2001, MOL PHARMACOL, V60, P718; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; DEAN PM, 1975, J THEOR BIOL, V54, P309, DOI 10.1016/S0022-5193(75)80133-0; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Fitzsimmons TJ, 2000, BIOCHEM J, V351, P265, DOI 10.1042/0264-6021:3510265; Franco L, 1998, FASEB J, V12, P1507; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; Gamberucci A, 1999, FEBS LETT, V446, P309, DOI 10.1016/S0014-5793(99)00220-3; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JANJIC D, 1982, AM J PHYSIOL, V243, pE59, DOI 10.1152/ajpendo.1982.243.1.E59; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; Mears D, 1999, DIABETES, V48, pA443; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mojzisova A, 2001, PFLUG ARCH EUR J PHY, V441, P674, DOI 10.1007/s004240000465; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Paul-Pletzer K, 2001, BIOCHEMISTRY-US, V40, P531, DOI 10.1021/bi001502s; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; Rutter GA, 1998, CHEM BIOL, V5, pR285, DOI 10.1016/S1074-5521(98)90287-3; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; SHIMOMURA O, 1993, BIOCHEM J, V296, P549, DOI 10.1042/bj2960549; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TANIGUCHI T, 1996, ENDOCRINOL METAB, V3, P135; Tengholm A, 2000, CELL CALCIUM, V27, P43, DOI 10.1054/ceca.1999.0087; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; Varadi A, 2002, DIABETES, V51, pS190, DOI 10.2337/diabetes.51.2007.S190; Varadi A, 2002, J CELL SCI, V115, P4177, DOI 10.1242/jcs.00083; WOLLHEIM CB, 1975, J BIOL CHEM, V250, P1354; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; Yusufi ANK, 2002, EXP BIOL MED, V227, P36, DOI 10.1177/153537020222700107; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8	77	151	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11057	11064		10.1074/jbc.M210257200	http://dx.doi.org/10.1074/jbc.M210257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538591	hybrid			2022-12-25	WOS:000181855400026
J	Ouyang, YS; Tu, YP; Barker, SA; Yang, FY				Ouyang, YS; Tu, YP; Barker, SA; Yang, FY			Regulators of G-protein signaling (RGS) 4, insertion into model membranes and inhibition of activity by phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D; RGS PROTEINS; DIACYLGLYCEROL KINASES; APOCYTOCHROME-C; RECEPTOR; BINDING; DOMAIN; TRANSLOCATION; LOCALIZATION; ASSOCIATION	Regulators of G-protein signaling (RGS) proteins are critical for attenuating G protein-coupled signaling pathways. The membrane association of RGS4 has been reported to be crucial for its regulatory activity in reconstituted vesicles and physiological roles in vivo. In this study, we report that RGS4 initially binds onto the surface of anionic phospholipid vesicles and subsequently inserts into, but not through, the membrane bilayer. Phosphatidic acid, one of anionic phospholipids, could dramatically inhibit the ability of RGS4 to accelerate GTPase activity in vitro. Phosphatidic acid is an effective and potent inhibitor of RGS4 in a Ga-i1-[gamma-P-32]GTP single turnover assay with an IC50 similar to 4 pm and maximum inhibition of over 90%. Furthermore, phosphatidic acid was the only phospholipid tested that inhibited RGS4 activity in a receptor-mediated, steady-state GTP hydrolysis assay. When phosphatidic acid (10 mol %) was incorporated into m1 acetylcholine receptor-Galpha(q). vesicles, RGS4 GAP activity was markedly inhibited by more than 70% and the EC50 of RGS4 was increased from 1.5 to 7 nM. Phosphatidic acid also induced a conformational change in the RGS domain of RGS4 measured by acrylamide-quenching experiments. Truncation of the N terminus of RGS4 (residues 1-57) resulted in the loss of both phosphatidic acid binding and lipid-mediated functional inhibition. A single point mutation in RGS4 (Lys(20) to Glu) permitted its binding to phosphatidic acid-containing vesicles but prevented lipid-induced conformational changes in the RGS domain and abolished the inhibition of its GAP activity. We speculate that the activation of phospholipase D or diacylglycerol kinase via G protein-mediated signaling cascades will increase the local concentration of phosphatidic acid, which in turn block RGS4 GAP activity in vivo. Thus, RGS4 may represent a novel effector of phosphatidic acid, and this phospholipid may function as a feedback regulator in G protein-mediated signaling pathways.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yang, FY (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	yangfy@sun5.ibp.ac.cn						ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Cui Y, 1997, CELL SIGNAL, V9, P257, DOI 10.1016/S0898-6568(96)00177-5; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Fahimi-Vahid M, 2002, J MOL CELL CARDIOL, V34, P441, DOI 10.1006/jmcc.2002.1525; GENNIS RB, 1988, BIOMEMBRANES MOL STR, P21; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Han XH, 1996, THIN SOLID FILMS, V284, P789, DOI 10.1016/S0040-6090(95)08447-9; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; MacDonald R., 1996, VESICLES, P3; Miao Q, 2001, BIOCHEM J, V354, P681, DOI 10.1042/0264-6021:3540681; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; PARKER EM, 1991, J BIOL CHEM, V266, P519; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RIETVELD A, 1986, J BIOL CHEM, V261, P3846; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	51	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11115	11122		10.1074/jbc.M212606200	http://dx.doi.org/10.1074/jbc.M212606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12538649	hybrid			2022-12-25	WOS:000181855400034
J	Artigiani, S; Barberis, D; Fazzari, P; Longati, P; Angelini, P; van de Loo, JW; Comoglio, PM; Tamagnone, L				Artigiani, S; Barberis, D; Fazzari, P; Longati, P; Angelini, P; van de Loo, JW; Comoglio, PM; Tamagnone, L			Functional regulation of semaphorin receptors by proprotein convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE RAC; FURIN; PLEXIN; GROWTH; GUIDANCE; LIGAND; TRANSMEMBRANE; INHIBITION; ACTIVATION; INTERACTS	PLEXIN genes encode receptors for secreted and membrane-bound semaphorins. It was proposed that the extracellular domain of plexins acts as an inhibitory moiety, preventing receptor activation. Here we show that plexin-B1 and plexin-B2 undergo proteolytic processing in their extracellular portion, thereby converting single-chain precursors into non-disulfide-linked, heterodimeric receptors. We demonstrate that plexin processing is mediated by subtilisin-like proprotein convertases, by inhibition with alpha1-antitrypsin Portland, and by mutagenesis of the substrate-cleavage sites. We provide evidence indicating that proprotein convertases cleave plexins in a post-Golgi compartment and, likely, at the cell surface. In addition, we find that both cell surface targeting and proteolytic processing of plexin-B1 depend on protein-protein interaction motifs in the cytoplasmic domain of the receptor. We then show that proteolytic conversion of plexin-B1 into a heterodimeric receptor greatly increases the binding and the functional response to its specific ligand semaphorin 4D/CD100. Thus, we conclude that cleavage by proprotein convertases is a novel regulatory step for semaphorin receptors localized at the cell surface.	Univ Turin, Inst Canc Res & Treatment, Sch Med, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Tamagnone, L (corresponding author), Univ Turin, Inst Canc Res & Treatment, Sch Med, SP 142, I-10060 Candiolo, Italy.	luca.tamagnone@ircc.it	Fazzari, Pietro/ABE-9368-2020; Tamagnone, Luca/J-8948-2018	Fazzari, Pietro/0000-0003-3457-9201; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328	Telethon [E.1129] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Artigiani S, 1999, IUBMB LIFE, V48, P477, DOI 10.1080/713803563; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Constam DB, 2000, DEVELOPMENT, V127, P245; DIRENZO MF, 1995, CANCER RES, V55, P1129; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GIORDANO S, 1989, ONCOGENE, V4, P1383; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; RHOM B, 2000, FEBS LETT, V486, P68; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	39	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10094	10101		10.1074/jbc.M210156200	http://dx.doi.org/10.1074/jbc.M210156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12533544	hybrid			2022-12-25	WOS:000181777500016
J	Okamura-Ikeda, K; Kameoka, N; Fujiwara, K; Motokawa, Y				Okamura-Ikeda, K; Kameoka, N; Fujiwara, K; Motokawa, Y			Probing the H-protein-induced conformational change and the function of the N-terminal region of Escherichia coli T-protein of the glycine cleavage system by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; DECARBOXYLASE COMPLEX; MOLECULAR-CLONING; MECHANISM; GENE; IDENTIFICATION; EXPRESSION	T-protein, a component of the glycine cleavage system, catalyzes a tetrahydrofolate-dependent reaction. Previously, we reported a conformational change of Escherichia coli T-protein upon interacting with E. coli H-protein (EH), showing an important role for the N-terminal region of the T-protein in the interaction. To further investigate the T-protein catalysis, the wild type (ET) and mutants were subjected to limited proteolysis. ET was favorably cleaved at Lys(81), Lys(154), Lys(288), and Lys(360) by lysylendopeptidase and the cleavages at Lys(81) and Lys(288) were strongly prevented by EH. Although ET was highly resistant to trypsinolysis, the mutant with an N-terminal 7-residue deletion (ETDelta7) was quite susceptible and instantly cleaved at Arg(16) accompanied by the rapid degradation of the resulting C-terminal fragment, indicating that the cleavage at Arg(16) is the trigger for the C-terminal fragmentation. EH showed no protection from the N-terminal cleavage, although substantial protection from the C-terminal fragmentation was observed. The replacement of Leu(6) of ET with alanine resulted in a similar sensitivity to trypsin as ETDelta7. These results suggest that the N-terminal region of ET functions as a molecular "hasp" to hold ET in the compact form required for the proper association with EH. Leu(6) seems to play a central role in the hasp function. Interestingly, Lys(360) of ET was susceptible to proteolysis even after the stabilization of the entire molecule of ET by EH, indicating its location at the surface of the ET-EH complex. Together with the buried position of Lys(81) in the complex and previous results on folate binding sites, these results suggest the formation of a folate-binding cavity via the interaction of ET with EH. The polyglutamyl tail of the folate substrate may be inserted into the bosom of the cavity leaving the pteridine ring near the entrance of the cavity in the context of the catalytic reaction.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	Tokushima University	Okamura-Ikeda, K (corresponding author), Univ Tokushima, Inst Enzyme Res, Kuramotocho 3 Chome, Tokushima 7708503, Japan.	ikeda@ier.tokushima-u.ac.jp						BOURGUIGNON J, 1993, EUR J BIOCHEM, V217, P377, DOI 10.1111/j.1432-1033.1993.tb18256.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHENADDAD C, 1995, NAT STRUCT BIOL, V2, P63, DOI 10.1038/nsb0195-63; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; Guilhaudis L, 2000, BIOCHEMISTRY-US, V39, P4259, DOI 10.1021/bi992674w; HAYASAKA K, 1993, BIOCHEM BIOPH RES CO, V192, P766, DOI 10.1006/bbrc.1993.1480; KISLIUK RL, 1957, J BIOL CHEM, V227, P805; KOPRIVA S, 1995, PLANT MOL BIOL, V27, P1215, DOI 10.1007/BF00020895; Kure S, 1998, HUM GENET, V102, P430, DOI 10.1007/s004390050716; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; MOTOKAWA Y, 1995, BIOTHIOLS HLTH DIS, P389; NANAO K, 1994, HUM GENET, V93, P655; Okamura-Ikeda K, 1999, EUR J BIOCHEM, V264, P446, DOI 10.1046/j.1432-1327.1999.00637.x; Okamura-Ikeda K, 1999, J BIOL CHEM, V274, P17471, DOI 10.1074/jbc.274.25.17471; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; OKAMURAIKEDA K, 1992, J BIOL CHEM, V267, P18284; OKAMURAIKEDA K, 1991, J BIOL CHEM, V266, P4917; OSBORN MJ, 1960, J AM CHEM SOC, V82, P4921, DOI 10.1021/ja01503a043; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	22	9	9	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10067	10072		10.1074/jbc.M210853200	http://dx.doi.org/10.1074/jbc.M210853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12531904	hybrid			2022-12-25	WOS:000181777500012
J	Xu, JG; He, JQ; Castleberry, AM; Balasubramanian, S; Lau, AG; Hall, RA				Xu, JG; He, JQ; Castleberry, AM; Balasubramanian, S; Lau, AG; Hall, RA			Heterodimerization of alpha(2A)- and beta(1)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL CORTICAL MEMBRANES; RESONANCE ENERGY-TRANSFER; OPIOID RECEPTORS; ALPHA-2-ADRENERGIC RECEPTORS; ADRENERGIC-RECEPTORS; PROTEIN; INTERNALIZATION; GLYCOSYLATION; SOMATOSTATIN; AGONIST	beta- and alpha(2)-adrenergic receptors are known to exhibit substantial cross-talk and mutual regulation in tissues where they are expressed together. We have found that the beta(1)-adrenergic receptor (beta(1)AR) and alpha(2A)-adrenergic receptor (alpha(2A)AR) heterodimerize when coexpressed in cells. Immunoprecipitation studies with differentially tagged beta(1)AR and alpha(2A)AR expressed in HEK-293 cells revealed robust co-immunoprecipitation of the two receptors. Moreover, agonist stimulation Of alpha(2A)AR was found to induce substantial internalization of coexpressed beta(1)AR, providing further evidence for a physica association between the two receptors in a cellular environment. Ligand binding assays examining displacement of [H-3]dihydroalprenolol binding to the beta(1)AR by various ligands revealed that beta(1)AR pharmacological properties were significantly altered when the receptor was coexpressed with alpha(2A)AR. Finally, beta(1)AR/alpha(2A)AR heterodimerization was found to be markedly enhanced by a beta(1)AR point mutation (N15A) that blocks N-linked glycosylation of the beta(1)AR as well as by point mutations (N10A/N14A) that block N-linked glycosylation of the alpha(2A)AR. These data reveal an interaction between beta(1)AR and alpha(2A)AR that is regulated by glycosylation and that may play a key role in cross-talk and mutual regulation between these receptors.	Emory Univ, Sch Med, Rollins Res Ctr 5113, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hall, RA (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr 5113, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060982] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL64713] Funding Source: Medline; NIGMS NIH HHS [R01-GM60982] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Anderson Joe R., 2001, Cardiology Clinics, V19, P215, DOI 10.1016/S0733-8651(05)70209-5; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; ATKINSON BN, 1992, MOL PHARMACOL, V41, P688; BIRNBAUM AK, 1995, MOL BRAIN RES, V28, P72, DOI 10.1016/0169-328X(94)00185-H; BYLUND DB, 1994, PHARMACOL REV, V46, P121; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; He JQ, 2002, BIOCHEM BIOPH RES CO, V297, P565, DOI 10.1016/S0006-291X(02)02259-3; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; HEIDENREICH KA, 1986, ENDOCRINOLOGY, V118, P1835, DOI 10.1210/endo-118-5-1835; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; LI X, 2002, P NATL ACAD SCI USA, V96, P9992; LILJA M, 1980, ACTA MED SCAND, V207, P173; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MAGGI A, 1980, SCIENCE, V207, P645, DOI 10.1126/science.6101510; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Muller D, 2002, ENDOCRINOLOGY, V143, P23, DOI 10.1210/en.143.1.23; NAKAMURA T, 1991, BRAIN RES, V542, P181, DOI 10.1016/0006-8993(91)91564-H; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; NOMURA Y, 1984, BRAIN RES, V302, P101, DOI 10.1016/0006-8993(84)91289-7; NOTHAM WJ, 1985, EUR J PHARMACOL, V113, P153; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; Rathz DA, 2002, J CARDIOVASC PHARM, V39, P155, DOI 10.1097/00005344-200202000-00001; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Saunders C, 1999, PHARMACOL THERAPEUT, V84, P193, DOI 10.1016/S0163-7258(99)00032-7; Wheatley M, 1999, HUM REPROD UPDATE, V5, P356, DOI 10.1093/humupd/5.4.356; WOODCOCK EA, 1980, NATURE, V286, P159, DOI 10.1038/286159a0; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200	49	84	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10770	10777		10.1074/jbc.M207968200	http://dx.doi.org/10.1074/jbc.M207968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529373	hybrid			2022-12-25	WOS:000181777500101
J	Yang, LK; Rezaie, AR				Yang, LK; Rezaie, AR			The fourth epidermal growth factor-like domain of thrombomodulin interacts with the basic exosite of protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING SITE; CRYSTAL-STRUCTURE; ACTIVE-SITE; THROMBIN; ACTIVATION; RESIDUES; PROCOAGULANT; INACTIVATION; INHIBITION; EXPRESSION	Thrombomodulin (TM) functions as a cofactor to enhance the rate of protein C activation by thrombin similar to1000-fold. The molecular mechanism by which TM improves the catalytic efficiency of thrombin toward protein C is not known. Molecular modeling of the protein C activation based on the crystal structure of thrombin in complex with the epidermal growth factor-like domains 4, 5, and 6 of TM (TM456) predicts that the binding of TM56 to exosite 1 of thrombin positions TM4 so that a negatively charged region on this domain juxtaposes a positively charged region of protein C. It has been hypothesized that electrostatic interactions between these oppositely charged residues of TM4 and protein C facilitate a proper docking of the substrate into the catalytic pocket of thrombin. To test this hypothesis, we have constructed several mutants of TM456 and protein C in which charges of the putative interacting residues on both TM4 (Asp/Glu) and protein C (Lys/Arg) have been reversed. Results of TM-dependent protein C activation studies by such a compensatory mutagenesis approach support the molecular model that TM4 interacts with the basic exosite of protein C.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NHLBI NIH HHS [HL 68571, HL 62565] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R01HL068571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gerlitz B, 1996, J BIOL CHEM, V271, P22285, DOI 10.1074/jbc.271.37.22285; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LENTZ SR, 1993, J BIOL CHEM, V268, P15312; LIU LW, 1991, J BIOL CHEM, V266, P16977; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MEININGER DP, 1995, PROTEIN SCI, V4, P1683, DOI 10.1002/pro.5560040904; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P693, DOI 10.1021/bi971271y; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; REZAIE AR, 1995, BIOCHEMISTRY-US, V34, P12221, DOI 10.1021/bi00038a016; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; TSIANG M, 1992, J BIOL CHEM, V267, P6164; VINCENOT A, 1995, FEBS LETT, V367, P153, DOI 10.1016/0014-5793(95)00552-K; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	38	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10484	10490		10.1074/jbc.M211797200	http://dx.doi.org/10.1074/jbc.M211797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529320	hybrid			2022-12-25	WOS:000181777500066
J	Fiorotto, M; Khan, A; Cummings, K; Draghia, R				Fiorotto, M; Khan, A; Cummings, K; Draghia, R			Administration of a plasmid expressing growth hormone-releasing hormone (GHRH) augments lean mass gain in pigs	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2003 Meeting	APR 11-15, 2003	SAN DIEGO, CALIFORNIA						Baylor Coll Med, Houston, TX 77030 USA; ADViSYS Inc, Pediat, The Woodlands, TX USA	Baylor College of Medicine; Advisys									0	52	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 14	2003	17	4	1	S			A700	A700		10.1096/fj.02-0289fje	http://dx.doi.org/10.1096/fj.02-0289fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	658QZ	12528713				2022-12-25	WOS:000181733103295
J	Siepmann, TJ; Bohnsack, RN; Tokgoz, Z; Baboshina, OV; Haas, AL				Siepmann, TJ; Bohnsack, RN; Tokgoz, Z; Baboshina, OV; Haas, AL			Protein interactions within the N-end rule ubiquitin ligation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING ENZYME E1; CONJUGATING ENZYME; CARRIER PROTEIN; DEPENDENT PROTEOLYSIS; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; DESTRUCTION BOX; BINDING-SITES	Rate studies have been employed as a reporter function to probe protein-protein interactions within a biochemically defined reconstituted N-end rule ubiquitin ligation pathway. The concentration dependence for E1-catalyzed HsUbc2b/E2(14kb) transthiolation is hyperbolic and yields K. values of 102 +/- 13 nM and 123 +/- 19 nM for high affinity binding to rabbit and human E1/Uba1 orthologs. Competitive inhibition by the inactive substrate and product analogs HsUbc2bC88A (K-i = 104 +/- 15 nM) and HsUbc2bC88S-ubiquitin oxyester (K-i = 169 +/- 17 nM), respectively, indicates that the ubiquitin moiety contributes little to E1 binding. Under conditions of rate-limiting E3alpha-catalyzed conjugation to human a-lactalbumin, HsUbc2b-ubiquitin thiolester exhibits a K-i of 54 +/- 18 nM and is competitively inhibited by the substrate analog HsUbc2bC88S-ubiquitin oxyester (K-i = 66 +/- 29 nM). In contrast, the ligase product analog HsUbc2bC88A exhibits a Ki of 440 +/- 55 nM with respect to the wild type HsUbc2b-ubiquitin thiolester, demonstrating that ubiquitin binding contributes to the ability of E3alpha to discriminate between substrate and product E2. A survey of E1 and E2 isoform distribution in selected cell lines demonstrates that Ubc2 isoforms are the predominant intracellular ubiquitin carrier protein. Intracellular levels of E1 and Ubc2 are micromolar and approximately equal based on in vitro quantitation by stoichiometric I-125-ubiquitin thiolester formation. Comparison of intracellular E1 and Ubc2 pools with the corresponding ubiquitin pools reveals that most of the free ubiquitin in cells is present as thiolesters to the components of the conjugation pathways. The present data represent the first comprehensive analysis of protein interactions within a ubiquitin ligation pathway.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Haas, AL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	arthaas@mcw.edu	Gromley, Zeynep/AEG-5353-2022; Gromley, Zeynep/AAG-3958-2022		NIGMS NIH HHS [GM34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Baboshina OV, 2001, J BIOL CHEM, V276, P39428, DOI 10.1074/jbc.M106967200; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; DELEMOSCHIARANDINI C, 1992, EUR J CELL BIOL, V58, P187; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1991, J BIOL CHEM, V266, P5104; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, UBIQUITIN, P173; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; KABASCH W, 1999, BIOPOLYMERS, V22, P2577; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; Lawson TG, 2001, J BIOL CHEM, V276, P39629, DOI 10.1074/jbc.M102659200; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; LIU Z, 1992, J BIOL CHEM, V267, P15829; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mitruka BM, 1981, CLIN BIOCH HEMATOLOG, V2nd; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; PENDERGRASS WR, 1991, EXP CELL RES, V192, P426, DOI 10.1016/0014-4827(91)90061-X; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1990, J BIOL CHEM, V265, P3685; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEGAL IH, 1975, ENZYME KINETICS; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; SULLIVAN ML, 1993, J BIOL CHEM, V268, P8777; Sun BG, 1997, GENE, V196, P19, DOI 10.1016/S0378-1119(97)00154-6; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wee KE, 2000, J PROTEIN CHEM, V19, P489, DOI 10.1023/A:1026501515450; WEFES I, 1995, GENE, V163, P321, DOI 10.1016/0378-1119(95)00374-F; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WING SS, 1992, J BIOL CHEM, V267, P6495; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; WUNSCH AM, 1995, DEV DYNAM, V204, P118, DOI 10.1002/aja.1002040203; Yamano H, 1998, EMBO J, V17, P5670, DOI 10.1093/emboj/17.19.5670	62	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9448	9457		10.1074/jbc.M211240200	http://dx.doi.org/10.1074/jbc.M211240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524449	hybrid			2022-12-25	WOS:000181524000077
J	Gump, J; Stokoe, D; McCormick, F				Gump, J; Stokoe, D; McCormick, F			Phosphorylation of p16(INK4A) correlates with Cdk4 association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; INK4 FAMILY; INHIBITORS; MUTATIONS; MELANOMA; GENE; CANCER	Progression through the eukaryotic cell cycle is driven by the activity of cyclin-dependent kinases. The cyclin D-dependent kinase Cdk4 promotes progression through the G, phase of the cell cycle and is deregulated in many human tumors. The tumor suppressor protein p16(INK4A) (p16) forms a complex with Cdk4 and inhibits kinase activity. Here we report that p16 is phosphorylated, and the phosphorylated form of p16 is preferentially associated with Cdk4 in normal human fibroblasts. We mapped phosphorylation sites on exogenously overexpressed p16 to serines 7, 8, 140, and 152 and found that endogenous p16 associated with Cdk4 is phosphorylated at serine 152. All mapped phosphorylation sites lie outside of the conserved kinase-binding domain of p16 but in regions of the protein affected by mutations in familial and sporadic cancer. Our results suggest a novel regulation of p16 activity.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Gump, J (corresponding author), Univ Calif San Francisco, Inst Canc Res, Box 0128, San Francisco, CA 94143 USA.	jgump@cc.ucsf.edu						BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Castellano M, 1997, CANCER RES, V57, P4868; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOMIYA A, 1995, JPN J CANCER RES, V86, P622, DOI 10.1111/j.1349-7006.1995.tb02443.x; Kumar R, 1998, INT J CANCER, V75, P193, DOI 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.3.CO;2-5; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Parry D, 1999, MOL CELL BIOL, V19, P1775; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845	25	37	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6619	6622		10.1074/jbc.C200622200	http://dx.doi.org/10.1074/jbc.C200622200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12529334	hybrid			2022-12-25	WOS:000181195100001
J	Ou, BX; Huang, DJ; Hampschl-Woodill, M; Flanagan, JA				Ou, BX; Huang, DJ; Hampschl-Woodill, M; Flanagan, JA			When east meets west: the relationship between yin-yang and antioxidation-oxidation	FASEB JOURNAL			English	Article						traditional Chinese medicine; herbs; polyphenolics; oxygen radical absorbance capacity	CAPACITY; FLAVONOIDS; STRESS	Ancient traditional Chinese medicine (TCM) has effectively relied on the theory of yin-yang balance in diagnoses and treatments of diseases and disorders for more than 2000 years. However, in eastern society, yin-yang is regarded as an incomprehensible ideology without definite physical meaning. Consequently, the yin-yang balance in medicine has not been studied by modern scientific means. In the western world, yin-yang balance is often misunderstood as a religious belief or a principle of lifestyle. Herein, we attempted to define the physical meaning of yin-yang in TCM by correlating it with biochemical processes. We propose that yin-yang balance is antioxidation-oxidation balance with yin representing antioxidation and yang as oxidation. Our proposal is partially supported by the fact that the yin-tonic traditional Chinese herbs have, on average, about six times more antioxidant activity and polyphenolic contents than the yang-tonic herbs. Our hypothesis opens an avenue to systematically study the yin-yang balance and its health implications with the use of modern biochemical tools.	Brunswick Labs, Wareham, MA 02571 USA		Huang, DJ (corresponding author), Brunswick Labs, 6 Thatcher Lane, Wareham, MA 02571 USA.	dejian@brunswicklabs.com	Huang, Dejian/A-7439-2010	Huang, Dejian/0000-0002-2305-3960				Chau PL, 2000, NATURE, V404, P431, DOI 10.1038/35006734; *COMM ZHONGH BENC, 1998, ZHONGHUA BENCAO, V1; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Huang DJ, 2002, J AGR FOOD CHEM, V50, P1815, DOI 10.1021/jf0113732; LEHNINGER AL, 1990, PRINCIPLES BIOCH, P359; Ni M., 1995, YELLOW EMPERORS CLAS; Ou BX, 2001, J AGR FOOD CHEM, V49, P4619, DOI 10.1021/jf010586o; Ou BX, 2002, J AGR FOOD CHEM, V50, P3122, DOI 10.1021/jf0116606; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Prior RL, 2000, J AOAC INT, V83, P950; SIES H, 1982, OXIDATIVE STRESS, P1; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Theoharides TC, 2001, INT J IMMUNOPATH PH, V14, P119	14	88	95	3	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					127	129		10.1096/fj.02-0527hyp	http://dx.doi.org/10.1096/fj.02-0527hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554690				2022-12-25	WOS:000181456900036
J	Baeza, N; Masuoka, J; Kleihues, P; Ohgaki, H				Baeza, N; Masuoka, J; Kleihues, P; Ohgaki, H			AXIN1 mutations but not deletions in cerebellar medulloblastomas	ONCOGENE			English	Article						AXIN1; medulloblastoma; mutation; polymorphism; deletion	PRIMITIVE NEUROECTODERMAL TUMORS; ADENOMATOUS POLYPOSIS-COLI; CENTRAL-NERVOUS-SYSTEM; WNT SIGNALING PATHWAY; COMPARATIVE GENOMIC HYBRIDIZATION; GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA-CATENIN; SPORADIC MEDULLOBLASTOMAS; NEGATIVE REGULATOR; GENE-MUTATIONS	Medulloblastoma is a malignant, invasive embryonal tumour of the cerebellum which manifests preferentially in children. A subset of cases is associated with colon cancer and APC germline mutations (Turcot syndrome), and APC and beta-catenin point mutations occur in up to 10% of sporadic cases, indicating the involvement of the Wnt pathway in the development of medulloblastoma. In 39 sporadic cerebellar medulloblastomas screeened for alterations in the AXIN1 gene, another component of the Wnt pathway, we found missense AXIN1 mutations in two tumours, CCC --> TCC at codon 255 (exon 1, Pro --> Ser) and TCT --> TGT at codon 263 (exon 1, Ser --> Cys). Furthermore, the A allele at the G/A polymorphism at nucleotide 16 in intron 4 was significantly over-represented in medulloblastomas (39 cases; G 0.76 vs-A 0.24) compared to healthy individuals (86 cases; G 0.91 vs A 0.09; P = 0.0027). RT-PCR revealed large deletions in the AXIN1 gene in 5/12 (42%) medulloblastomas, consistent with a previous report. However, we observed such deletions at a similar frequency also in normal brain tissue (6/12, 50%). Since there are multiple complementary, inverted sequences present in the AXIN1 gene, these large deletions may represent RT-PCR errors due to stem-loop secondary structures.										Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; BADIALI M, 1993, DIAGN MOL PATHOL, V2, P23, DOI 10.1097/00019606-199303000-00004; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; CAVENEE WK, 2000, PATHOLOGY GENETICS T, P238; Cogen PH, 1996, J NEURO-ONCOL, V29, P103, DOI 10.1007/BF00165523; Dahmen RP, 2001, CANCER RES, V61, P7039; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; GRIFFIN CA, 1988, CANCER RES, V48, P175; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JAMES CD, 1990, GENE CHROMOSOME CANC, V2, P94, DOI 10.1002/gcc.2870020204; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KUMAR R, 1990, CHILD NERV SYST, V6, P371, DOI 10.1007/BF00302220; Lantos PL, 2002, GREENFIELDS NEUROPAT, P767; Lee YJ, 1999, J BIOL CHEM, V274, P1566, DOI 10.1074/jbc.274.3.1566; Lin YM, 2000, J HUM GENET, V45, P254, DOI 10.1007/s100380070036; Mader RM, 2001, J LAB CLIN MED, V137, P422, DOI 10.1067/mlc.2001.115452; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Pietsch T, 1997, CANCER RES, V57, P2085; Raffel C, 1997, CANCER RES, V57, P842; Reardon DA, 1997, CANCER RES, V57, P4042; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schutz BR, 1996, GENE CHROMOSOME CANC, V16, P196; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Watanabe K, 1998, ACTA NEUROPATHOL, V95, P559, DOI 10.1007/s004010050840; Wolter M, 1997, CANCER RES, V57, P2581; Wu R, 2001, CANCER RES, V61, P8247; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zurawel RH, 1998, CANCER RES, V58, P896; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	45	117	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					632	636		10.1038/sj.onc.1206156	http://dx.doi.org/10.1038/sj.onc.1206156			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555076				2022-12-25	WOS:000180538200016
